,Label,Text,Tokens
0,1.0,"53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease.","['_num_', 'patients', 'were', 'evaluated', 'for', 'efficacy', '_num_', 'patients', 'achieved', 'a', 'pr', 'and', '_num_', 'patients', 'had', 'stable', 'disease']"
1,1.0,KIT(V559D) were expressed in HEK-293 cells (in vitro).,"['kit', '_mutation_', 'were', 'expressed', 'in', '_abbrev_', 'cells', 'in', 'vitro']"
2,1.0,In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.,"['in', '3t3', 'fibroblasts', 'expressing', 'the', '_mutation_', 'mutation', 'have', 'to', 'be', 'sensitive', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_chemical_']"
3,1.0,An in-vivo assay of xenograft transplantation showed higher tumorigenicity of DU145-TxR cells.,"['an', 'in', 'vivo', 'assay', 'of', 'xenograft', 'transplantation', 'showed', 'higher', '_disease_', 'of', '_abbrev_', 'cells']"
4,1.0,24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections.,"['_num_', 'cultures', 'of', '_disease_', 'lymphocytes', 'were', 'expanded', 'from', '_num_', 'lung', 'metastasis', 'resections']"
5,1.0,"In this study we screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib, showing that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK inhibition.","['in', 'this', 'study', 'we', 'screened', 'for', 'growth', 'factors', 'that', 'elicited', 'resistance', 'in', 'newly', 'characterized', 'metastatic', 'uveal', 'melanoma', 'cell', 'lines', 'to', 'clinical', 'grade', 'mek', 'inhibitors', '_chemical_', 'and', '_chemical_', 'showing', 'that', '_gene_', '_num_', '_gene_', 'and', 'hepatocyte', 'growth', 'factor', '_gene_', 'provide', 'resistance', 'to', 'mek', 'inhibition']"
6,1.0,"In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.","['in', '_gene_', 'cells', 'with', '_gene_', '_mutation_', 'mutation', 'that', 'have', 'shown', '_chemical_', 'resistance', '_chemical_', 'was', 'significantly', 'more', 'potent', 'at', 'inhibiting', 'kinase', 'activity', 'than', '_chemical_']"
7,1.0,"In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild type tumors.","['in', 'this', 'preclinical', 'study', '_abbrev_', 'mammary', 'tumors', 'with', 'mutant', '_gene_', 'showed', 'a', 'better', 'clinical', 'response', 'to', 'chemotherapy', 'doxorubicin', 'than', '_gene_', 'wild', 'type', 'tumors']"
8,1.0,"Median progression free survival (PFS) was 9.2 months, and median overall survival (OS) was 21.8 months.","['median', 'progression', 'free', 'survival', '_disease_', 'was', '_num_', 'months', 'and', 'median', 'overall', 'survival', 'os', 'was', '_num_', 'months']"
9,1.0,"Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511).","['correlation', 'to', '_disease_', 'was', 'also', 'found', 'after', 'multivariate', 'analysis', '_p_val_', 'hr', '_num_']"
10,1.0,"Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively).","['cell', 'lines', 'with', '_gene_', 'and', '_gene_', 'losses', 'were', 'significantly', 'more', 'likely', 'to', 'be', 'classified', 'as', 'responders', 'defined', 'by', 'pharmacokinetic', 'data', 'based', 'concentration', 'of', '_ineq_', 'to', '_disease_', '_p_val_', 'relative', 'risk', '_gene_', '_ineq_', 'and', '_p_val_', '_ineq_', 'respectively']"
11,1.0,"Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT.","['again', 'the', 'test', 'for', 'interaction', '_p_val_', 'demonstrated', 'no', 'significant', 'difference', 'in', '_disease_', 'benefit', 'for', 'anti', '_gene_', 'mab', 'therapy', 'between', '_gene_', '_mutation_', 'and', 'other', '_gene_', 'mt']"
12,1.0,"Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study.","['_chemical_', 'was', 'evaluated', 'in', 'vitro', 'in', 'xenograft', 'and', 'in', 'a', 'phase', '_num_', 'study']"
13,1.0,"The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11.","['the', '_gene_', 'amplification', 'positive', 'relapsed', 'neuroblastoma', 'derived', 'cell', 'line', '_gene_', 'bar', 'contains', 'the', 'driver', '_gene_', '_gene_', '_range_', 'mutation', 'which', 'removes', 'extracellular', 'domain', 'exons', '_num_', 'through', '_num_']"
14,1.0,"Of these genes, upregulation of proteasome subunit beta type 8 PSMB8 and PDZ binding kinase PBK was confirmed by real-time reverse transcription-PCR Analysis.","['of', 'these', 'genes', 'upregulation', 'of', 'proteasome', 'subunit', 'beta', 'type', '_num_', '_gene_', 'and', '_gene_', 'binding', 'kinase', '_gene_', 'was', 'confirmed', 'by', 'real', 'time', 'reverse', 'transcription', 'pcr', 'analysis']"
15,1.0,Cell line modelling of baseline and relapse JAK2 mutational status revealed a loss of response to interferon gamma and  loss of JAK2 protein.,"['cell', 'line', 'modelling', 'of', 'baseline', 'and', 'relapse', '_gene_', 'mutational', 'status', 'revealed', 'a', 'loss', 'of', 'response', 'to', 'interferon', 'gamma', 'and', 'loss', 'of', '_gene_', 'protein']"
16,1.0,This is in a TP53 wild type context.,"['this', 'is', 'in', 'a', '_gene_', 'wild', 'type', 'context']"
17,1.0,Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor.,"['expression', 'was', 'evaluated', 'in', 'both', 'the', 'cancer', 'cells', 'and', 'fibroblasts', 'at', 'the', 'invasive', 'front', 'of', 'each', 'tumor']"
18,1.0,Another three mutations in exon 4 were retrospectively identified in the wild type population and one had a major response.,"['another', '_num_', 'mutations', 'in', 'exon', '_num_', 'were', 'retrospectively', 'identified', 'in', 'the', 'wild', 'type', 'population', 'and', '_num_', 'had', 'a', 'major', 'response']"
19,1.0,73 % of cases expressed high level of EGFRvIII.,"['_num_', 'of', 'cases', 'expressed', 'high', 'level', 'of', 'egfrviii']"
20,1.0,"In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound.","['in', 'a', '_chemical_', 'positive', 'eosinophil', 'cell', 'line', 'growth', 'inhibitory', 'effects', 'were', 'seen', 'with', 'all', '_gene_', 'blocking', 'agents', '_chemical_', '_chemical_', '_chemical_', '_chemical_', '_chemical_', '_chemical_', '_chemical_', 'with', '_chemical_', 'found', 'to', 'be', 'the', 'most', 'potent', 'compound']"
21,1.0,Targeted sequencing of 70 aCML patients identified SETBP1 mutations between codons 858 and 871 in 24.3% of the patients.,"['targeted', 'sequencing', 'of', '_num_', '_disease_', 'patients', 'identified', '_gene_', 'mutations', 'between', 'codons', '_num_', 'and', '_num_', 'in', '_num_', 'of', 'the', 'patients']"
22,1.0,This mutation was not found in the pre-crizotinib biopsy.,"['this', 'mutation', 'was', 'not', 'found', 'in', 'the', '_gene_', '_chemical_', 'biopsy']"
23,1.0,"In a subgroup of patients with wild type EGFR, phospho-Y1068 expression positive patients had a significantly prolonged PFS (4.2 months vs.1.2 months P < 0.001) compared with those without phospho-Y1068 expression.","['in', 'a', 'subgroup', 'of', 'patients', 'with', 'wild', 'type', '_gene_', '_abbrev_', 'expression', 'positive', 'patients', 'had', 'a', 'significantly', 'prolonged', '_disease_', '_num_', 'months', 'vs', '_num_', '_num_', 'months', 'p', '_num_', 'compared', 'with', 'those', 'without', '_abbrev_', 'expression']"
24,1.0,"The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6).","['the', 'overall', 'response', 'rate', 'was', '_ratio_', '_num_', '_num_', 'ci', '_range_', 'and', 'the', 'median', 'progression', 'free', 'survival', 'was', '_num_', 'months', '_num_', 'ci', '_range_']"
25,1.0,A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion.,"['a', '_num_', 'year', 'old', 'heavily', 'pretreated', 'patient', 'with', 'equivocal', '_gene_', 'overexpression', '_abbrev_', 'and', 'no', 'amplification', 'in', 'fish', 'was', 'found', 'to', 'have', 'the', '_gene_', 'ymva', 'kinase', 'domain', 'insertion']"
26,1.0,"This splice mutation was found in a Croatian, VHL type 1 family of 3.","['this', 'splice', 'mutation', 'was', 'found', 'in', 'a', 'croatian', '_gene_', 'type', '_num_', 'family', 'of', '_num_']"
27,1.0,663 patients were tested.,"['_num_', 'patients', 'were', 'tested']"
28,1.0,One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks.,"['_num_', 'patient', 'with', 'a', '_gene_', 'mutation', 'identified', 'by', 'illumina', 'genotyping', 'stayed', 'on', 'study', 'treatment', 'for', '_num_', 'weeks']"
29,1.0,"In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis.","['in', '_num_', 'patients', 'that', 'have', 'undergone', 'a', 'pancreaticoduodenectomy', 'whipple', 'for', 'the', 'resection', 'of', 'pancreatic', 'ductal', 'adenocarcinoma', 'expression', 'of', '_gene_', 'is', 'associated', 'with', 'favorable', 'prognosis']"
30,1.0,ACMG codes as follows: A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1).,"['acmg', 'codes', 'as', 'follows', 'a', 'nonsense', 'mutation', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', '_abbrev_']"
31,1.0,There was no significant difference in overall survival between wild type patients and patients with any type of exon-12 mutation.,"['there', 'was', 'no', 'significant', 'difference', 'in', 'overall', 'survival', 'between', 'wild', 'type', 'patients', 'and', 'patients', 'with', 'any', 'type', 'of', '_abbrev_', 'mutation']"
32,1.0,In multivariate Cox proportional analysis the T393C polymorphism was an independent prognostic factor for survival.,"['in', 'multivariate', 'cox', 'proportional', 'analysis', 'the', '_mutation_', 'polymorphism', 'was', 'an', 'independent', 'prognostic', 'factor', 'for', 'survival']"
33,1.0,"In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53.","['in', 'breast', 'cancer', 'patients', 'harboring', '_mutation_', 'mutation', 'the', 'prognosis', 'is', 'worse', 'than', 'any', 'other', 'hotspot', '_gene_', 'mutation', 'as', 'well', 'as', 'worse', 'than', 'patients', 'with', 'wild', 'type', '_gene_']"
34,1.0,A cell line model also showed resistance against ALK inhibition.,"['a', 'cell', 'line', 'model', 'also', 'showed', 'resistance', 'against', '_gene_', 'inhibition']"
35,1.0,"In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse.","['in', 'children', 'with', 'acute', 'myeloid', 'leukemia', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'better', 'overall', 'and', 'event', 'free', 'survival', 'and', 'decreased', 'cummulative', 'incidence', 'of', 'relapse']"
36,1.0,"In the pancreatic cell lines PL11 (FANCC homozygous deletion) and Hs766T (FANCG-mutated), sensitivity to DNA cross-linking agents was observed.","['in', 'the', 'pancreatic', 'cell', 'lines', '_abbrev_', '_gene_', 'homozygous', 'deletion', 'and', '_abbrev_', '_gene_', 'mutated', 'sensitivity', 'to', 'dna', 'cross', 'linking', 'agents', 'was', 'observed']"
37,1.0,CKIT focal amplification by FISH was also observed.,"['_gene_', 'focal', 'amplification', 'by', 'fish', 'was', 'also', 'observed']"
38,1.0,"In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).","['in', 'the', 'subgroup', 'of', 'patients', 'treated', 'with', '_chemical_', '_num_', 'of', 'the', '_num_', 'those', 'patients', 'expressing', 'topoisomerase', 'i', 'had', 'a', 'better', 'overall', 'survival', 'according', 'to', 'multivariate', 'analysis', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
39,1.0,"In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells.","['in', 'further', 'tests', 'using', '_num_', 'of', 'the', '_num_', 'nras', 'mutant', 'cell', 'lines', 'yudoso', '_abbrev_', 'and', 'yukim', '_mutation_', 'colony', 'forming', 'capacity', 'was', 'reduced', 'with', 'increased', '_chemical_', 'treatment', 'and', '_chemical_', 'induced', 'apoptotic', 'markers', 'in', 'these', 'cells']"
40,1.0,"CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma.","['_abbrev_', 'mediated', 'modelling', 'of', 'the', '_gene_', 'mutation', 'in', 'a', 'melanoma', 'cell', 'line', 'led', 'to', 'a', 'loss', 'of', 'response', 'to', 'interferon', 'alpha', 'beta', 'and', 'gamma']"
41,1.0,"In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those without deletions.","['in', 'a', 'study', 'of', '_num_', 'prostate', 'adenocarcinomas', 'those', 'with', 'either', 'hemi', '', 'or', 'homozygous', 'deletions', 'of', '_gene_', 'as', 'determined', 'by', 'interphase', 'fish', 'have', 'shorter', 'biochemical', 'recurence', 'free', 'survival', 'than', 'those', 'without', 'deletions']"
42,1.0,The median overall survival for patients whose tumors showed intact MGMT expression was 19.1 months; the median overall survival for patients with MGMT deficient tumors was not reached.,"['the', 'median', 'overall', 'survival', 'for', 'patients', 'whose', 'tumors', 'showed', 'intact', '_gene_', 'expression', 'was', '_num_', 'months', 'the', 'median', 'overall', 'survival', 'for', 'patients', 'with', '_gene_', 'deficient', 'tumors', 'was', 'not', 'reached']"
43,1.0,The proband's 8-year-old had no clinical manifestations of VHL disease.,"['the', 'proband', ""'s"", '_age_', 'had', 'no', 'clinical', 'manifestations', 'of', '_gene_', 'disease']"
44,1.0,"All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal.","['all', 'treatments', 'caused', 'tumor', 'regression', 'but', 'tumors', 'recurred', 'within', '_num_', 'days', 'after', '_chemical_', 'treatment', 'withdrawal']"
45,1.0,"In an in vitro study, a SW48 cell line expressing KRAS G12R mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 181.77 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'decreased', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'p', '_num_', 'compared', 'to', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
46,1.0,A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance (P < 0.001).,"['a', 'study', 'of', '_num_', 'patients', 'with', 'high', 'grade', 'ovarian', 'serous', 'carcinoma', 'found', 'that', 'high', 'expression', 'levels', 'of', '_gene_', 'correlated', 'with', 'poorer', 'overall', 'survival', 'p', '_num_', 'hr', '_num_', 'and', 'platinum', 'therapy', 'resistance', 'p', '_num_']"
47,1.0,OSCC patients were found to be associated with a significantly higher level of GAS6 in serum ( P = .05 ).,"['_disease_', 'patients', 'were', 'found', 'to', 'be', 'associated', 'with', 'a', 'significantly', 'higher', 'level', 'of', '_gene_', 'in', 'serum', 'p', '_num_']"
48,1.0,"After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS.","['after', 'adjusting', 'for', 'age', 'and', 'cancer', 'stage', 'the', 'presence', 'of', '_gene_', 'mutations', 'such', 'as', '_abbrev_', 'are', 'prognostic', 'for', 'poorer', 'survival', 'outcomes', 'in', 'patients', 'with', 'mds']"
49,1.0,"Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.","['_num_', 'of', '_num_', 'patients', 'with', '_gene_', 'somatic', 'mutations', '_mutation_', '_mutation_', 'and', '_mutation_', 'achieved', '_abbrev_']"
50,1.0,This study showed that GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression in patients with malignant melanoma.,"['this', 'study', 'showed', 'that', '_gene_', '_mutation_', 'snp', 'represents', 'a', 'genetic', 'host', 'factor', 'for', 'predicting', 'tumor', 'progression', 'in', 'patients', 'with', 'malignant', 'melanoma']"
51,1.0,"After a multivariate analysis using Cox proportional hazards, it was found that ARID1A expression levels are an independent predictor of progression-free survival in patients with CCRCC, although no significant correlation was found between the expression levels and cancer-specific survival.","['after', 'a', 'multivariate', 'analysis', 'using', 'cox', 'proportional', 'hazards', 'it', 'was', 'found', 'that', '_gene_', 'expression', 'levels', 'are', 'an', 'independent', 'predictor', 'of', 'progression', 'free', 'survival', 'in', 'patients', 'with', '_disease_', 'although', 'no', 'significant', 'correlation', 'was', 'found', 'between', 'the', 'expression', 'levels', 'and', '_disease_', 'survival']"
52,1.0,Human GISTs with different KIT mutations were grafted in 136 nude muce.,"['human', 'gists', 'with', 'different', 'kit', 'mutations', 'were', 'grafted', 'in', '_num_', 'nude', 'muce']"
53,1.0,"Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued YMVA HER2 induction by doxycycline.","['induction', 'of', 'mutant', '_gene_', 'in', 'these', 'mice', 'drove', 'rapid', 'development', 'of', '_disease_', 'lung', 'tumors', 'where', 'tumor', 'maintenance', 'was', 'dependent', 'on', 'continued', 'ymva', '_gene_', 'induction', 'by', 'doxycycline']"
54,0.0,Afatinib is an irreversible covalent inhibitor of EGFR (second generation).,"['_chemical_', 'is', 'an', 'irreversible', 'covalent', 'inhibitor', 'of', '_gene_', '_num_', 'generation']"
55,1.0,"In a multivariate analysis of 774 CLL patients, NOTCH1 mutations were not significantly correlated with shorter time to first treatment (HR=1.305; 95% CI=0.923-1.847).","['in', 'a', 'multivariate', 'analysis', 'of', '_num_', '_disease_', 'patients', '_gene_', 'mutations', 'were', 'not', 'significantly', 'correlated', 'with', 'shorter', 'time', 'to', '_num_', 'treatment', '_ineq_', '_num_', '_ineq_']"
56,1.0,This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent.,"['this', 'effect', 'was', 'shown', 'to', 'influence', 'survival', 'in', 'predominantly', 'white', 'patient', 'populations', 'but', 'not', 'patients', 'of', 'asian', 'descent']"
57,1.0,"In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations.","['in', 'an', 'exploratory', '_chemical_', 'analysis', 'imbalance', 'of', 'the', '_gene_', '_abbrev_', 'allele', 'most', 'frequently', 'caused', 'by', 'copy', 'neutral', 'loss', 'of', 'heterozygosity', 'targeting', 'the', 'wild', 'type', 'allele', 'was', 'associated', 'with', 'longer', '_disease_', 'as', 'was', 'the', 'presence', 'of', 'coincident', '_gene_', 'pathway', 'hotspot', 'mutations']"
58,1.0,"Seven had retinal angiomas, 7 had hemangioblastomas of the central nervous system, 5 had renal cell carcinoma, one had pancreatic cysts, and one had  pancreatic islet cell tumors (family VHL 39).","['_num_', 'had', 'retinal', 'angiomas', '_num_', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'had', 'renal', 'cell', 'carcinoma', '_num_', 'had', 'pancreatic', 'cysts', 'and', '_num_', 'had', 'pancreatic', 'islet', 'cell', 'tumors', 'family', '_gene_', '_num_']"
59,1.0,"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the N538G ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.","['using', 'an', 'estrogen', 'response', 'element', '_disease_', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_abbrev_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_chemical_', 'cell', 'lines']"
60,1.0,"Of those patients, 261 had tissue available for RRM1 evaluation.","['of', 'those', 'patients', '_num_', 'had', 'tissue', 'available', 'for', '_gene_', 'evaluation']"
61,1.0,Sensitivity was determined by assessing cell viability.,"['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'viability']"
62,1.0,"10 FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression (IHC) in marrow stromal cells, which peaked prior to overt clinical relapse and detection of resistance mutations","['_num_', '_gene_', '_disease_', 'patients', 'treated', 'with', '_abbrev_', 'developed', 'increased', '_gene_', 'expression', '_gene_', 'in', 'marrow', 'stromal', 'cells', 'which', 'peaked', 'prior', 'to', 'overt', 'clinical', 'relapse', 'and', 'detection', 'of', 'resistance', 'mutations']"
63,1.0,A gastric cancer patient derived xenograft (PDX) was transplanted into two athymic mice and one was treated with BYL719.,"['a', 'gastric', 'cancer', 'patient', 'derived', 'xenograft', '_gene_', 'was', 'transplanted', 'into', '_num_', 'athymic', 'mice', 'and', '_num_', 'was', 'treated', 'with', '_chemical_']"
64,1.0,were plotted relative to wild type TSC1.,"['were', 'plotted', 'relative', 'to', 'wild', 'type', '_gene_']"
65,1.0,IGF1R expression was also higher in patients with disease progression after gefitinib therapy in a clinical cohort (n=98).,"['_gene_', 'expression', 'was', 'also', 'higher', 'in', 'patients', 'with', 'disease', 'progression', 'after', '_chemical_', 'therapy', 'in', 'a', 'clinical', 'cohort', '_ineq_']"
66,1.0,mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with resistance to mTOR inhibitors in one analyzed cell line (SW620).,"['_gene_', 'independent', '_disease_', 'of', '_gene_', '_gene_', 'was', 'associated', 'with', 'resistance', 'to', '_gene_', 'inhibitors', 'in', '_num_', 'analyzed', 'cell', 'line', '_abbrev_']"
67,1.0,In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin.,"['in', 'vitro', 'data', 'confirmed', 'these', 'results', 'and', 'overexpression', 'or', 'knockdown', 'of', '_gene_', 'decreased', 'or', 'increased', 'in', 'vitro', 'sensitivity', 'to', '_disease_']"
68,1.0,A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1).,"['a', 'clinical', 'trial', 'of', '_num_', 'patients', 'evaluated', 'concurrent', '_ineq_', 'or', 'sequential', '_gene_', 'treatment', 'of', 'ipilimumab', '_abbrev_', 'and', 'nivolumab', '_abbrev_']"
69,1.0,"we used whole exome sequencing on 39 midline pediatric high-grade astrocytomas (pHGAs) and identified 5 with mutations in ACVR1, with 2 occurring at G328 (G328V and G328E).","['we', 'used', 'whole', 'exome', 'sequencing', 'on', '_num_', 'midline', 'pediatric', 'high', 'grade', '_disease_', 'phgas', 'and', 'identified', '_num_', 'with', 'mutations', 'in', '_gene_', 'with', '_num_', 'occurring', 'at', '_abbrev_', '_mutation_', 'and', '_mutation_']"
70,1.0,"However, the segregation data and mRNA results in this study were conflicting or inconclusive.","['however', 'the', 'segregation', 'data', 'and', 'mrna', 'results', 'in', 'this', 'study', 'were', 'conflicting', 'or', 'inconclusive']"
71,1.0,Treatment of crizotinib progressed tumors with ceritinib resulted in tumor growth which did not differ appreciably from crizotinib or vehicle treatment of these tumors.,"['treatment', 'of', '_chemical_', 'progressed', 'tumors', 'with', '_chemical_', 'resulted', 'in', 'tumor', 'growth', 'which', 'did', 'not', 'differ', 'appreciably', 'from', '_chemical_', 'or', 'vehicle', 'treatment', 'of', 'these', 'tumors']"
72,1.0,This mutation causes a stop codon at amino acid 158.,"['this', 'mutation', 'causes', 'a', 'stop', 'codon', 'at', 'amino', 'acid', '_num_']"
73,1.0,"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung.","['a', 'case', 'study', 'of', 'a', 'patient', 'with', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', 'and', 'met', 'negative', 'adenocarcinoma', 'of', 'the', 'lung']"
74,1.0,49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed.,"['_num_', '_gene_', 'mutant', 'melanoma', 'cell', 'lines', 'from', 'patients', 'not', 'previously', 'treated', 'with', '_gene_', 'inhibition', 'were', 'analyzed']"
75,1.0,"A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month.","['a', '_num_', 'year', 'old', 'patient', 'relapsed', 'after', '_num_', 'month', 'of', 'chop', 'and', 'was', 'treated', 'with', 'further', 'chemotherapy', 'and', 'autologous', 'bone', 'marrow', 'transplantation', 'resulting', 'in', 'partial', 'response', 'of', '_num_', 'month']"
76,1.0,"Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses.","['analysis', 'in', 'patients', 'with', 'uveal', 'melanoma', 'identified', '_gene_', 'and', '_gene_', 'mutations', 'in', '_num_', 'patients', 'in', 'which', '_num_', 'sd', 'and', '_num_', 'pd', 'were', 'the', 'best', 'responses']"
77,1.0,"It was also demonstrated that crizotinib inhibits ROS1 phosphorylation in HEK 293 cells transfected with a CD14-ROS1 fusion gene, and crizotinib inhibited growth in the HCC78 cell line containing a ROS1 rearrangement to a similar degree as ALK-fusion positive cell lines.","['it', 'was', 'also', 'demonstrated', 'that', '_chemical_', 'inhibits', '_gene_', '_disease_', 'in', '_gene_', '_num_', 'cells', 'transfected', 'with', 'a', '_abbrev_', 'fusion', 'gene', 'and', '_chemical_', 'inhibited', 'growth', 'in', 'the', '_abbrev_', 'cell', 'line', 'containing', 'a', '_gene_', 'rearrangement', 'to', 'a', 'similar', 'degree', 'as', '_gene_', 'fusion', 'positive', 'cell', 'lines']"
78,1.0,"After 6 months, progressive disease was seen and crizotinib withdrawn.","['after', '_num_', 'months', 'progressive', 'disease', 'was', 'seen', 'and', '_chemical_', 'withdrawn']"
79,1.0,"There was a difference in disease-free survival for FCGR2B I232T, with I/I patients deriving benefit from trastuzumab (p<0.001) compared to the T carriers who did not (p=0.81).","['there', 'was', 'a', 'difference', 'in', '_disease_', 'survival', 'for', '_gene_', '_mutation_', 'with', '_disease_', 'patients', 'deriving', 'benefit', 'from', '_chemical_', 'p', '_num_', 'compared', 'to', 'the', 't', 'carriers', 'who', 'did', 'not', '_p_val_']"
80,1.0,Cell line and structural models revealed that this mutation conferred relative resistance to entrectinib.,"['cell', 'line', 'and', 'structural', 'models', 'revealed', 'that', 'this', 'mutation', 'conferred', 'relative', 'resistance', 'to', 'entrectinib']"
81,1.0,These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.,"['these', 'trends', 'were', 'independently', 'confirmed', 'in', 'both', 'trials', 'but', 'only', 'pooled', 'results', 'showed', 'consistent', 'statistical', 'significance']"
82,1.0,2 patients were tested for NF2 mutations.,"['_num_', 'patients', 'were', 'tested', 'for', '_gene_', 'mutations']"
83,1.0,"Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions.","['_chemical_', 'was', 'initialized', 'and', 'after', '_num_', 'days', 'pet', 'scan', 'showed', 'complete', 'regression', 'of', 'all', 'lesions']"
84,1.0,"mRNA expression of ABCB1 in 17 NSCLC cell lines was associated with decreased response to paclitaxel (correlation of mRNA expression and paclitaxel IC50: r=0.5322, P=0.0279).","['mrna', 'expression', 'of', '_gene_', 'in', '_num_', '_disease_', 'cell', 'lines', 'was', 'associated', 'with', 'decreased', 'response', 'to', '_chemical_', 'correlation', 'of', 'mrna', 'expression', 'and', '_chemical_', '_abbrev_', '_ineq_', '_p_val_']"
85,1.0,418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel.,"['_num_', 'patients', 'with', 'advanced', 'cancer', 'were', 'screened', 'for', '_gene_', 'mutations', 'using', 'a', 'multiplex', 'gene', 'panel']"
86,1.0,"Treatment of mice with monotherapy of AZD5363 or lapatinib alone induced growth inhibition (37%, not significant; 65%, P = 0.004), but treatment with AZD5363 and lapatinib together induced significant tumor regression (109%, P < 0.0001) as well as delayed tumor regrowth after removal of therapy.","['treatment', 'of', 'mice', 'with', 'monotherapy', 'of', '_chemical_', 'or', '_chemical_', 'alone', 'induced', 'growth', 'inhibition', '_num_', 'not', 'significant', '_num_', 'p', '_num_', 'but', 'treatment', 'with', '_chemical_', 'and', '_chemical_', 'together', 'induced', 'significant', 'tumor', 'regression', '_num_', 'p', '_num_', 'as', 'well', 'as', 'delayed', 'tumor', 'regrowth', 'after', 'removal', 'of', 'therapy']"
87,1.0,On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive).,"['on', 'day', '_num_', 'bone', 'marrow', 'aspirates', 'were', '_disease_', 'pretreatment', 'evaluation', 'showed', '_num_', '_disease_']"
88,1.0,"Six (33.3%) patients had PR and 7 (38.9%) SD, as their best Choi responses, corresponding to RECIST SD in all cases.","['_num_', '_num_', 'patients', 'had', 'pr', 'and', '_num_', '_num_', 'sd', 'as', 'their', 'best', 'choi', 'responses', 'corresponding', 'to', '_disease_', 'sd', 'in', 'all', 'cases']"
89,1.0,"Median PFS was 5·3 months (4·6-6·4) in selumetinib group and 2·1 months (95% CI 1·4-3·7) in placebo group (HR for progression 0·58, 80% CI 0·42-0·79; one-sided p=0·014).","['median', '_disease_', 'was', '_num_', 'months', '_range_', 'in', '_chemical_', 'group', 'and', '_num_', 'months', '_num_', 'ci', '_range_', 'in', 'placebo', 'group', 'hr', 'for', 'progression', '_num_', '_num_', 'ci', '_range_', '_num_', 'sided', '_p_val_']"
90,1.0,Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8).,"['genomewide', 'analysis', 'of', '_num_', 'low', 'grade', 'adult', 'gliomas', 'revealed', 'that', 'patients', 'with', 'a', 'wildtype', '_gene_', 'had', 'significantly', 'shorter', 'overall', 'survival', 'than', 'those', 'with', 'a', 'mutated', '_gene_', 'gene', 'hr', '_num_', '_num_', 'ci', '_range_']"
91,1.0,Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation.,"['follow', 'up', 'sequencing', 'analysis', 'of', 'dna', 'from', 'the', 'patient', ""'s"", 'tumor', 'revealed', 'a', 'somatic', '_gene_', '_mutation_', 'mutation']"
92,1.0,Preclinical study in uveal melanoma.,"['preclinical', 'study', 'in', 'uveal', 'melanoma']"
93,1.0,This mutation was found in a VHL patient with retinal angiomas and hemangioblastomas of the central nervous system.,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'patient', 'with', 'retinal', 'angiomas', 'and', '_disease_', 'of', 'the', 'central', 'nervous', 'system']"
94,1.0,"In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations.","['in', 'patients', 'with', '_disease_', 'syndromes', 'those', 'with', '_gene_', 'mutations', 'have', 'been', 'shown', 'to', 'have', 'better', 'overall', 'survival', 'than', 'patients', 'without', '_gene_', 'mutations']"
95,1.0,A second biopsy at the time of progression revealed an acquired MET D1228N mutation.,"['a', '_num_', 'biopsy', 'at', 'the', 'time', 'of', 'progression', 'revealed', 'an', 'acquired', 'met', '_mutation_', 'mutation']"
96,1.0,"Due to slow progression and low tumor burden crizotinib was maintained for additional 8 months, and then he was transitioned onto ceritinib at 750 mg daily.","['due', 'to', 'slow', 'progression', 'and', 'low', 'tumor', 'burden', '_chemical_', 'was', 'maintained', 'for', 'additional', '_num_', 'months', 'and', 'then', 'he', 'was', 'transitioned', 'onto', '_chemical_', 'at', '_num_', '_unit_', 'daily']"
97,1.0,"For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).","['for', '_num_', 'patients', '_num_', 'in', 'each', 'arm', 'median', '_disease_', 'of', '_num_', 'weeks', 'for', '_chemical_', 'and', '_num_', 'for', 'combination', 'therapy', 'was', 'observed', '_p_val_']"
98,1.0,"WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.","['_gene_', 'mutations', 'were', 'associated', 'with', 'shorter', 'overall', 'and', 'disease', 'free', 'survival', 'in', 'a', 'cohort', 'of', 'cytogenetically', 'normal', 'young', '_num_', '_disease_', 'patients']"
99,1.0,Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30).,"['phase', '_num_', 'trial', 'of', '_gene_', 'inhibitor', '_chemical_', 'in', 'stage', 'iiib', 'iv', 'lung', 'cancers', 'with', '_gene_', 'mutations', 'or', 'amplification', '_ineq_']"
100,0.0,we supported this conclusion with pre-clinical studies that showed that knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel.,"['we', 'supported', 'this', 'conclusion', 'with', '_gene_', 'clinical', 'studies', 'that', 'showed', 'that', 'knock', 'down', 'of', '_gene_', 'improved', 'sensitivity', 'to', '_chemical_', 'in', 'endometrial', 'carcinoma', 'cell', 'lines', 'with', 'both', 'naturally', 'higher', 'and', 'lower', 'sensitivity', 'to', '_chemical_']"
101,1.0,"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring BRAF, KRAS, NRAS or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization.","['in', '_num_', 'out', 'of', '_num_', '_num_', 'metastatic', 'colorectal', 'cancer', 'tumors', 'harboring', '_gene_', '_gene_', 'nras', 'or', '_gene_', 'mutations', 'and', 'implanted', 'into', 'mice', 'the', 'therapeutic', 'combination', 'of', 'the', 'mek', 'inhibitor', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'disease', 'stabilization']"
102,1.0,"In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for  p53 alteration (p53 mutation or p53 overexpression by immunostaining >10% positive).","['in', 'a', 'group', 'of', 'patients', 'with', 'invasive', 'ovarian', 'carcinoma', 'who', 'had', 'undergone', 'surgery', 'a', 'subset', 'of', '_num_', 'patients', 'treated', 'with', 'platinum', 'based', 'chemotherapy', 'were', 'assessed', 'for', '_gene_', 'alteration', '_gene_', 'mutation', 'or', '_gene_', 'overexpression', 'by', 'immunostaining', '_num_', 'positive']"
103,1.0,we comment that this indicates a potential role for sunitinib in growth inhibition of acral melanomas.,"['we', 'comment', 'that', 'this', 'indicates', 'a', 'potential', 'role', 'for', '_chemical_', 'in', 'growth', 'inhibition', 'of', 'acral', 'melanomas']"
104,1.0,866 were enrolled and 510 randomized.,"['_num_', 'were', 'enrolled', 'and', '_num_', 'randomized']"
105,1.0,The patient also harbored an MLH1 c.453+1G > A mutation.,"['the', 'patient', 'also', 'harbored', 'an', '_gene_', 'c', '453+1g', 'a', 'mutation']"
106,1.0,Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13).,"['multivariate', 'analysis', 'showed', 'a', 'trend', 'towards', 'better', '_disease_', 'among', 'patients', 'with', 'a', '_mutation_', 'mutation', '_disease_', '_ineq_', '_num_', 'ci', '_range_', '_p_val_', 'os', '_ineq_', '_num_', 'ci', '_range_', '_p_val_']"
107,1.0,"The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 μmol/L).","['the', '_disease_', 'cell', 'line', '_abbrev_', 'carrying', 'the', '_gene_', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_', 'but', 'showed', 'increased', 'sensitivity', 'to', '_chemical_', '_chemical_', '_abbrev_', '_num_', 'μmol', '_unit_']"
108,1.0,The patients mother showed mile thrombocytopenia.,"['the', 'patients', 'mother', 'showed', 'mile', 'thrombocytopenia']"
109,1.0,A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.,"['a', 'case', 'report', 'of', 'a', 'patient', 'with', '_gene_', '_mutation_', 'mutation', 'and', 'clinical', 'response', 'to', '_gene_', 'inhibition', '_chemical_', 'that', 'correlated', 'to', 'in', 'vitro', 'models']"
110,1.0,"In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease.","['in', '_num_', 'patients', 'with', 'measurable', 'disease', 'responses', 'included', '_num_', 'with', 'partial', 'response', 'and', '_num_', 'with', 'stable', 'disease']"
111,1.0,A screen for fusion genes in Ph- AYA-ALL (Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and young adults) was performed using RNA-seq from multiple cohorts of ALL patients.,"['a', 'screen', 'for', 'fusion', 'genes', 'in', 'ph', '', 'aya', 'all', 'philadelphia', 'chromosome', 'negative', 'acute', '_disease_', 'leukemia', 'in', 'adolescents', 'and', 'young', 'adults', 'was', 'performed', 'using', 'rna', 'seq', 'from', 'multiple', 'cohorts', 'of', 'all', 'patients']"
112,1.0,No response was observed after cetuximab was given as a third line therapy.,"['no', 'response', 'was', 'observed', 'after', '_chemical_', 'was', 'given', 'as', 'a', '_num_', 'line', 'therapy']"
113,1.0,"A retrospective study of 178 glioblastoma patients found that LRP1B deletion (complete transcript, N=4 or focal transcript deletion of >150kb, N=13) was associated with a lower progress free survival (6.4 months vs. 10.1 months; P = 0.004) and overall free survival (13.4 months vs. 17.8 months; P = 0.001).","['a', 'retrospective', 'study', 'of', '_num_', 'glioblastoma', 'patients', 'found', 'that', '_gene_', 'deletion', 'complete', 'transcript', '_ineq_', 'or', 'focal', 'transcript', 'deletion', 'of', '150kb', '_ineq_', 'was', 'associated', 'with', 'a', 'lower', 'progress', 'free', 'survival', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_', 'and', 'overall', 'free', 'survival', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_']"
114,1.0,The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS at 6 months) and median OS was 12.6 months.,"['the', 'median', '_disease_', 'for', 'the', '_num_', 'patients', 'with', 'uveal', 'melanoma', 'was', '_num_', 'months', '_num_', '_disease_', 'at', '_num_', 'months', 'and', 'median', 'os', 'was', '_num_', 'months']"
115,1.0,In this study the genomic breakpoints of 5 cases were characterized.,"['in', 'this', 'study', 'the', 'genomic', 'breakpoints', 'of', '_num_', 'cases', 'were', 'characterized']"
116,1.0,KIT was amplified in the tumor and harbored the K642E mutation.,"['kit', 'was', 'amplified', 'in', 'the', 'tumor', 'and', 'harbored', 'the', '_mutation_', 'mutation']"
117,1.0,In a phase 1 trial belinostat (400-800mg/m2/24h) was administered to 25 patients in combination with cisplatin and etoposide.,"['in', 'a', 'phase', '_num_', 'trial', '_chemical_', '_num_', '_unit_', '_abbrev_', '24h', 'was', 'administered', 'to', '_num_', 'patients', 'in', 'combination', 'with', '_disease_', 'and', '_chemical_']"
118,1.0,"Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.","['median', '_disease_', 'and', 'os', 'months', 'for', 'the', '_num_', 'groups', '_num_', 'and', '_num_', 'uncommon', '_num_', 'and', '_num_', 'common', '_num_', 'and', '_num_', 'wild', 'type']"
119,1.0,"Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro.","['_num_', 'head', 'and', 'neck', 'cancer', 'cell', 'lines', 'with', '_gene_', '_mutation_', 'mutation', 'were', 'more', 'sensitive', 'to', '_abbrev_', 'inhibition', 'with', '_chemical_', '_chemical_', '_chemical_', 'than', '_num_', 'wild', 'type', 'cell', 'lines', 'in', 'vitro']"
120,1.0,Results showed that a low ARID1A expression was significantly related to advanced FIGO stages and high CAI25 levels (P=0.02).,"['results', 'showed', 'that', 'a', 'low', '_gene_', 'expression', 'was', 'significantly', 'related', 'to', 'advanced', '_disease_', 'stages', 'and', 'high', '_abbrev_', 'levels', '_p_val_']"
121,1.0,49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes.,"['_num_', 'tumor', 'specimens', 'from', '_num_', '_disease_', 'patients', 'treated', 'with', '_chemical_', 'were', 'evaluated', 'for', 'expression', 'of', '_gene_', 'and', '_gene_', 'by', '_gene_', 'and', 'compared', 'to', 'treatment', 'outcomes']"
122,1.0,Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.,"['sensitivity', 'was', 'defined', 'by', 'maintenance', 'of', 'complete', 'response', 'greater', 'than', '_num_', 'months', 'post', 'platinum', 'based', 'therapy']"
123,1.0,"The 60 year-old proband had CNS hemangioblastomas, retinal angiomas, renal cell carcinoma, and pancreatic cysts.","['the', '_num_', '_age_', 'proband', 'had', 'cns', '_disease_', 'retinal', 'angiomas', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts']"
124,0.0,"In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients.","['in', 'this', 'study', 'in', 'surgically', 'resected', '_disease_', 'cell', 'lung', 'cancer', '_gene_', 'amplification', 'has', 'been', 'shown', 'as', 'an', 'independent', 'negative', 'prognostic', 'factor', 'in', 'asian', 'patients']"
125,1.0,"VHL Type 1 disease is reported: CNS tumors, retinal angioma, renal cell carcinoma but no pheochromocytoma","['_gene_', 'type', '_num_', 'disease', 'is', 'reported', 'cns', 'tumors', 'retinal', 'angioma', 'renal', 'cell', 'carcinoma', 'but', 'no', 'pheochromocytoma']"
126,1.0,FGFR1 expression was mainly associated with luminal cancer subtypes.,"['_gene_', 'expression', 'was', 'mainly', 'associated', 'with', 'luminal', 'cancer', '_disease_']"
127,1.0,"The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway.","['the', 'same', 'was', 'found', 'when', '_gene_', 'mutations', '_gene_', 'loss', 'and', '_gene_', '_mutation_', 'mutations', 'were', 'combined', 'and', 'analyzed', 'as', 'hyperactive', '_gene_', 'pathway']"
128,1.0,FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas.,"['fish', 'was', 'tested', 'in', '_num_', 'fibrolamellar', 'carcinomas', 'and', 'in', '_num_', '_disease_', '_disease_', 'carcinomas']"
129,1.0,EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.,"['_gene_', 'expression', 'level', 'was', 'not', 'predicitive', 'of', 'response', 'to', '_chemical_', 'containing', '_num_', 'line', 'regimens', 'in', 'recurrent', 'or', 'metastatic', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'and', '_gene_', 'wild', 'type', 'colorectal', 'carcinoma']"
130,1.0,One patient with ALK-rearranged non-small cell lung cancer and an acquired resistance to crizotinib showed new ALK amplification (4.1 fold increase compared to pre-crizotinib specimen as measured by FISH) and harbored an EGFR L858R mutation.,"['_num_', 'patient', 'with', '_gene_', 'rearranged', 'non', 'small', 'cell', 'lung', 'cancer', 'and', 'an', 'acquired', 'resistance', 'to', '_chemical_', 'showed', 'new', '_gene_', 'amplification', '_num_', 'fold', 'increase', 'compared', 'to', '_gene_', '_chemical_', 'specimen', 'as', 'measured', 'by', 'fish', 'and', 'harbored', 'an', '_gene_', '_mutation_', 'mutation']"
131,1.0,"PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015).","['_gene_', 'mutations', 'were', 'significantly', 'associated', 'with', 'shorter', '_disease_', 'and', 'os', 'following', 'therapy', 'with', 'anti', '_gene_', 'monoclonal', 'antibodies', '_disease_', '_num_', 'studies', '_num_', 'patients', 'hr', '_num_', '_num_', 'confidence', 'interval', 'ci', '_range_', 'p', '_num_', 'os', '_num_', 'studies', '_num_', 'patients', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
132,1.0,Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'patient', 'with', 'low', 'grade', 'endometrial', 'stromal', 'sarcoma']"
133,1.0,Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4).,"['patient', ""'s"", 'phenotype', 'is', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'a', 'single', 'genetic', 'etiology', '_gene_']"
134,1.0,The I1171T ALK kinase domain mutaion was found in the MGH056-1 cell line which was derived from an ALK rearranged NSCLC patient who had progressed on crizotinib and then on alectinib given at lower dose (300mg twice daily).,"['the', '_mutation_', '_gene_', 'kinase', 'domain', 'mutaion', 'was', 'found', 'in', 'the', '_abbrev_', 'cell', 'line', 'which', 'was', 'derived', 'from', 'an', '_gene_', 'rearranged', '_disease_', 'patient', 'who', 'had', 'progressed', 'on', '_chemical_', 'and', 'then', 'on', '_chemical_', 'given', 'at', 'lower', 'dose', '_unit_', 'twice', 'daily']"
135,1.0,No association was found between methylation status and clinical factors.,"['no', 'association', 'was', 'found', 'between', 'methylation', 'status', 'and', 'clinical', 'factors']"
136,1.0,"In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival).","['in', 'patients', 'suffering', 'from', 'mds', 'the', 'presence', 'of', '_gene_', 'mutations', 'such', 'as', '_mutation_', 'do', 'not', 'confer', 'prognostic', 'value', 'overall', 'survival']"
137,1.0,In-vitro studies found this mutation to confer resistance to cetuximab.,"['in', 'vitro', 'studies', 'found', 'this', 'mutation', 'to', 'confer', 'resistance', 'to', '_chemical_']"
138,1.0,"A Ba/F3 cell line expressing EML4-ALK variant 1 was created, and then exposed to the DNA modifying agent ENU.","['a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_chemical_', 'variant', '_num_', 'was', 'created', 'and', 'then', 'exposed', 'to', 'the', 'dna', 'modifying', 'agent', '_gene_']"
139,1.0,"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001).","['a', 'phase', 'iii', 'clinical', 'trial', '_abbrev_', 'found', 'that', 'median', 'progression', 'free', 'survival', 'among', 'patients', 'with', '_gene_', 'exon', '_num_', 'deletion', 'was', '_num_', 'months', 'for', '_chemical_', 'and', '_num_', 'months', 'for', 'chemotherapy', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
140,1.0,Ten patients with Neurofibromatosis 2 were enrolled for treatment with Everolimus.,"['_num_', 'patients', 'with', 'neurofibromatosis', '_num_', 'were', 'enrolled', 'for', 'treatment', 'with', '_chemical_']"
141,1.0,"The second patient (M, 39, nonsmoker) was treated with erlotinib and had progressive disease as response, PFS of 2.3 months, OS of 7.2 months and was alive at study end.","['the', '_num_', 'patient', '_unit_', '_num_', 'nonsmoker', 'was', 'treated', 'with', '_chemical_', 'and', 'had', 'progressive', 'disease', 'as', 'response', '_disease_', 'of', '_num_', 'months', 'os', 'of', '_num_', 'months', 'and', 'was', 'alive', 'at', 'study', 'end']"
142,1.0,"There was a significant relationship (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic.","['there', 'was', 'a', 'significant', 'relationship', '_p_val_', 'between', 'histologic', 'subtype', 'monophasic', 'vs', 'biphasic', 'and', '_gene_', 'or', '_gene_', 'involvement', 'in', 'the', 'fusion', 'transcript', 'all', '_num_', 'biphasic', 'synovial', 'sarcomas', 'had', 'a', '_abbrev_', 'fusion', 'transcript', 'and', 'all', '_num_', 'tumors', 'that', 'were', 'positive', 'for', '_abbrev_', 'were', 'monophasic']"
143,1.0,AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3.,"['_disease_', 'patients', 'with', '_abbrev_', 'mutation', 'of', '_gene_', 'did', 'not', 'have', 'worse', 'overall', 'survival', 'than', 'patients', 'with', 'wild', 'type', '_gene_']"
144,1.0,Patient was given crizotinib and exhibited a partial response after 5 months with brain metastasis occurring at 21 months.,"['patient', 'was', 'given', '_chemical_', 'and', 'exhibited', 'a', 'partial', 'response', 'after', '_num_', 'months', 'with', 'brain', 'metastasis', 'occurring', 'at', '_num_', 'months']"
145,1.0,Sequencing revealed a number of abnormalities including P753S mutation in EGFR.,"['sequencing', 'revealed', 'a', 'number', 'of', 'abnormalities', 'including', '_mutation_', 'mutation', 'in', '_gene_']"
146,1.0,In patients with primary myelofibrosis CALR mutations were associated with improved median survival.,"['in', 'patients', 'with', 'primary', 'myelofibrosis', '_gene_', 'mutations', 'were', 'associated', 'with', 'improved', 'median', 'survival']"
147,1.0,"A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse.","['a', '_num_', 'year', 'old', 'heavily', 'pretreated', 'including', 'thalidomide', 'and', '_chemical_', 'patient', 'with', 'igg', 'kappa', 'multiple', 'myeloma', 'was', 'sequenced', 'following', 'extramedullary', 'relapse']"
148,1.0,"(IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 888nM)","['_abbrev_', 'for', 'proliferation', '_unit_', '_abbrev_', 'for', 'induction', 'of', 'apoptosis', '_unit_']"
149,1.0,The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.,"['the', '_abbrev_', 'fusion', 'was', 'detected', 'in', '_num_', '_ratio_', 'of', 'fibrolamellar', '_disease_', 'carcinomas', 'assayed']"
150,1.0,Best overall response rate was statistically significantly different by mutation status: 7 of 13 or 54% KIT mutated v 0% KIT amplified only.,"['best', 'overall', 'response', 'rate', 'was', 'statistically', 'significantly', 'different', 'by', 'mutation', 'status', '_num_', 'of', '_num_', 'or', '_num_', 'kit', 'mutated', 'v', '_num_', 'kit', 'amplified', 'only']"
151,1.0,"In a study of 97 patients with AML  treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', '_disease_', 'treated', 'with', '_disease_', '_num_', 'had', '_gene_', 'mutations', 'comprising', 'a', 'total', 'of', '_num_', 'mutations']"
152,1.0,we conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.,"['we', 'conclude', 'that', 'this', 'effect', 'should', 'be', 'surmountable', 'with', 'higher', 'doses', 'of', '_chemical_', 'and', 'or', 'with', 'higher', 'affinity', 'inhibitors']"
153,1.0,Clinical manifestations included: pheochromocytoma and pancreatic cysts.,"['clinical', 'manifestations', 'included', 'pheochromocytoma', 'and', 'pancreatic', 'cysts']"
154,1.0,"Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation.","['preclinical', 'study', 'to', 'investigate', 'mechanisms', 'of', '_gene_', '_mutation_', 'activity', 'and', 'inhibition', 'with', '_abbrev_', 'a', 'covalent', 'irreversible', 'inhibitor', 'which', 'binds', '_gene_', '_mutation_', 'in', 'the', 'gdp', 'bound', 'state', 'to', 'prevent', 'activation']"
155,1.0,"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002).","['in', 'a', 'phase', '_num_', 'clinical', 'trial', 'of', 'korean', 'never', 'smoker', 'lung', 'adenocarcinoma', 'patients', 'a', 'subset', 'of', 'patients', 'with', '_gene_', 'mutations', '_ineq_', 'treated', 'with', '_chemical_', 'were', 'associated', 'with', 'improved', 'overall', 'response', 'rate', 'compared', 'to', '_chemical_', 'plus', '_disease_', 'treatment', '_num_', '_ratio_', 'vs', '_num_', '_ratio_', '_p_val_']"
156,1.0,Case report of a patient with metastatic lung adenocarcinoma.,"['case', 'report', 'of', 'a', 'patient', 'with', 'metastatic', 'lung', 'adenocarcinoma']"
157,1.0,"Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002).","['patients', 'with', 'low', 'expression', 'exhibited', 'a', 'benefit', 'in', 'time', 'to', 'progression', 'average', '_gene_', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'and', 'in', 'overall', 'survival', 'average', 'os', '_num_', 'vs', '_num_', 'months', 'p', '_num_']"
158,1.0,"17-AAG also reduced survival of the parental IL3-dependent Ba/F3 cells (183.7 nM), indicating increased nonspecific effects of 17_AAG treatment.","['_chemical_', 'also', 'reduced', 'survival', 'of', 'the', 'parental', '_abbrev_', 'ba', '_abbrev_', 'cells', '_num_', '_unit_', 'indicating', 'increased', 'nonspecific', 'effects', 'of', '17_aag', 'treatment']"
159,1.0,The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival.,"['the', '_gene_', '_mutation_', 'variant', 'was', 'significantly', 'correlated', 'with', 'a', 'lower', 'response', 'to', '_disease_', 'chemotherapy', 'in', 'osteosarcoma', 'patients', 'and', 'shorter', 'event', 'free', 'survival']"
160,1.0,"Furthermore, MLL2 mutations were as frequently observed as t(14;18) Igh-BCL2 translocations, which are the most common clinically significant genetic event observed in follicular lymphoma.","['furthermore', '_gene_', 'mutations', 'were', 'as', 'frequently', 'observed', 'as', 't', '_num_', '_num_', '_abbrev_', 'translocations', 'which', 'are', 'the', 'most', 'common', 'clinically', 'significant', 'genetic', 'event', 'observed', 'in', 'follicular', 'lymphoma']"
161,1.0,dPCR and qPCR results were correlated to PFS and OS.,"['dpcr', 'and', 'qpcr', 'results', 'were', 'correlated', 'to', '_disease_', 'and', 'os']"
162,1.0,"Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib.","['case', 'report', 'of', 'a', 'patient', 'with', 'met', 'amplification', 'without', 'high', 'level', 'met', '_abbrev_', 'ratio', 'met', 'exon', '_num_', 'mutation', 'or', 'overexpression', 'who', 'achieved', 'rapid', 'response', 'to', '_chemical_']"
163,1.0,Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.,"['identified', '_num_', 'cases', 'of', '_disease_', 'liposarcoma', 'with', 'translocations', 'between', '12q13', 'and', '22q12', 'giving', 'rise', 'to', '_abbrev_', 'ews', 'chop', 'fusions', 'instead', 'of', 'the', 'more', 'common', '_abbrev_']"
164,1.0,"Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal).","['phase', '_num_', 'trial', 'in', '_num_', 'patients', 'with', 'melanoma', '_num_', 'cutaneous', 'or', 'unknown', '_num_', 'uveal']"
165,0.0,Trametinib enhances the responsiveness to NRG1 and sustained HGF-mediated activation of AKT.,"['_chemical_', 'enhances', 'the', 'responsiveness', 'to', '_gene_', 'and', 'sustained', '_gene_', 'mediated', 'activation', 'of', '_gene_']"
166,1.0,"Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six).","['patients', 'were', 'heavily', 'pretreated', 'with', 'a', 'median', 'of', '_num_', 'lines', 'of', 'previous', 'therapy', 'range', '_num_', 'to', '_num_']"
167,1.0,"In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94).","['in', 'this', '_disease_', 'analysis', 'of', '_num_', 'studies', 'with', '_num_', 'patients', 'the', 'immunotherapy', 'response', 'rate', 'was', 'higher', 'among', '_gene_', 'patients', '_gene_', '_num_', '_num_', 'ci', '_range_']"
168,1.0,"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays.","['preclinical', 'study', 'of', '_chemical_', 'in', '_disease_', 'in', 'vitro', 'in', 'vivo', 'and', 'in', 'enzyme', 'assays']"
169,1.0,"A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC.","['a', 'phase', '_num_', 'study', 'of', '_chemical_', 'and', '_chemical_', 'in', '_gene_', 'mutant', 'previously', 'treated', '_disease_']"
170,1.0,"The MGH056-1 cell line was derived from this patient, and this cell line was resistant to alectinib.","['the', '_abbrev_', 'cell', 'line', 'was', 'derived', 'from', 'this', 'patient', 'and', 'this', 'cell', 'line', 'was', 'resistant', 'to', '_chemical_']"
171,1.0,Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation.,"['preclinical', 'study', 'analyzing', 'the', 'efficacy', 'of', 'dual', '_abbrev_', 'and', 'more', 'specific', '_gene_', 'inhibitors', 'on', 'cell', 'lines', 'ba', '_abbrev_', 'expressing', '_abbrev_', 'with', 'and', 'without', 'the', '_mutation_', 'mutation']"
172,1.0,"After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy.","['after', '_num_', 'years', 'complete', 'radiological', 'response', 'was', 'seen', 'while', 'treatment', 'was', 'discontinued', 'due', 'to', 'cardiomyopathy']"
173,0.0,Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo.,"['functional', 'studies', 'show', 'that', 'met', 'activation', 'confers', 'resistance', 'to', 'anti', '_gene_', 'therapy', 'both', 'in', 'vitro', 'and', 'in', 'vivo']"
174,1.0,2 out of 7 patients with an acquired resistance to crizotinib had a G1269A mutation.,"['_num_', 'out', 'of', '_num_', 'patients', 'with', 'an', 'acquired', 'resistance', 'to', '_chemical_', 'had', 'a', '_mutation_', 'mutation']"
175,1.0,"In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules.","['in', 'vitro', 'this', 'mutation', 'was', 'shown', 'to', 'be', '_disease_', 'and', 'sensitive', 'to', '_chemical_', 'yet', 'relatively', 'insensitive', 'towards', 'small', 'molecules']"
176,1.0,MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.,"['_gene_', 'promoter', 'methylation', 'was', 'associated', 'with', 'increased', 'overall', 'and', '_disease_', 'survival', 'as', 'well', 'as', 'tumor', 'regression', 'in', 'patients', 'with', 'gliomas']"
177,1.0,This mutation ultimately causes a downstream premature stop codon and truncated BRCA1.,"['this', 'mutation', 'ultimately', 'causes', 'a', 'downstream', 'premature', 'stop', 'codon', 'and', 'truncated', '_gene_']"
178,1.0,"In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richter’s transformation).","['in', 'a', 'trial', 'of', '_num_', 'patients', 'with', 'chronic', 'lymphocytic', 'leukemia', 'treated', 'with', '_chemical_', '_num_', 'discontinued', 'treatment', 'due', 'to', 'disease', 'progression', '_num_', '_disease_', 'progression', '_num_', 'richter', '’', 's', 'transformation']"
179,1.0,"The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).","['the', 'patient', 'was', 'treated', 'with', '_chemical_', '_gene_', '_disease_', 'combined', 'with', '_chemical_', 'a', 'type', 'ii', 'met', 'inhibitor', 'and', 'had', 'a', 'response', 'which', 'continued', 'at', 'the', 'time', 'of', 'report', '_num_', 'months']"
180,1.0,Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2).,"['mutations', 'predicted', 'to', 'inactivate', 'the', '_gene_', 'protein', 'were', 'associated', 'with', 'renal', 'cell', 'carcinoma', 'and', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_gene_', 'type', '_num_', 'mutations', 'predicted', 'to', 'produce', 'full', 'length', '_gene_', 'proteins', 'were', 'associated', 'with', 'pheochromocytoma', '_gene_', 'type', '_num_']"
181,1.0,we explored the viability of PAX8 expression as a biomarker for differentiating mullerian from non-mullerian tumors.,"['we', 'explored', 'the', 'viability', 'of', '_gene_', 'expression', 'as', 'a', '_chemical_', 'for', 'differentiating', 'mullerian', 'from', 'non', 'mullerian', 'tumors']"
182,1.0,"Evidence of wild type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment.","['evidence', 'of', 'wild', 'type', 'allele', 'mediated', 'resistance', 'a', 'novel', 'concept', 'of', 'acquired', 'resistance', 'in', 'response', 'to', 'mutation', 'selective', 'inhibitor', 'therapy', 'in', 'cancer', 'treatment']"
183,1.0,"All 12 family members identified with cerebellar hemangioblastomas, 2 of 12 family members with angiomas, one with renal cell carcinoma and another with pheochromocytoma.","['all', '_num_', 'family', 'members', 'identified', 'with', 'cerebellar', '_disease_', '_num_', 'of', '_num_', 'family', 'members', 'with', 'angiomas', '_num_', 'with', 'renal', 'cell', 'carcinoma', 'and', 'another', 'with', 'pheochromocytoma']"
184,1.0,HPO terms: hemangioblastoma.,"['_disease_', 'terms', '_disease_']"
185,1.0,Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability,"['ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'mutants', 'were', 'resistant', 'to', '_chemical_', 'dependent', 'inhibition', 'of', 'cell', 'viability']"
186,1.0,CD72-ROS1 was identified in sequencing after progression on chemotherapy.,"['_abbrev_', 'was', 'identified', 'in', 'sequencing', 'after', 'progression', 'on', 'chemotherapy']"
187,1.0,A randomized phase II trial assessing the efficacy of Cabozantinib in metastatic melanoma.,"['a', 'randomized', 'phase', 'ii', 'trial', 'assessing', 'the', 'efficacy', 'of', '_chemical_', 'in', 'metastatic', 'melanoma']"
188,1.0,I1171T was found as one of 6 ALK resistance mutations from 80 sequenced tumors.,"['_mutation_', 'was', 'found', 'as', '_num_', 'of', '_num_', '_gene_', 'resistance', 'mutations', 'from', '_num_', 'sequenced', 'tumors']"
189,1.0,Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab.,"['patients', 'with', 'merkel', 'cell', 'carcinoma', '_ineq_', 'were', 'enrolled', 'to', 'receive', 'pembrolizumab']"
190,1.0,"Ba/F3 cells harboring the KIT L576P mutation were sensitive to dasatinib, nilotinib and imatinib.","['ba', '_abbrev_', 'cells', 'harboring', 'the', 'kit', '_mutation_', 'mutation', 'were', 'sensitive', 'to', '_chemical_', '_chemical_', 'and', '_chemical_']"
191,1.0,"Patients with the polymorphism, compared to those without, were more likely to be resistant without BCR-ABL mutations than resistant with BCR-ABL mutation or sensitive (odds ratio = 1.90, 95% CI 1.08–4.35).","['patients', 'with', 'the', 'polymorphism', 'compared', 'to', 'those', 'without', 'were', 'more', 'likely', 'to', 'be', 'resistant', 'without', '_gene_', 'mutations', 'than', 'resistant', 'with', '_gene_', 'mutation', 'or', 'sensitive', 'odds', 'ratio', '_num_', '_num_', 'ci', '_num_', '08–4', '_num_']"
192,1.0,Simulations indicated that the V1180L mutation interfered with alectinib binding.,"['simulations', 'indicated', 'that', 'the', '_mutation_', 'mutation', 'interfered', 'with', '_chemical_', 'binding']"
193,1.0,"After multivariate Analysis, CC-HIF1A and HIF-1α expression were still significantly associated with OS (P<0.0001).","['after', 'multivariate', 'analysis', '_abbrev_', 'and', '_abbrev_', 'expression', 'were', 'still', 'significantly', 'associated', 'with', 'os', 'p', '_num_']"
194,1.0,"In total, 10 of 32 patients with breast cancer treated at doses >100mg had a best response of SD.","['in', 'total', '_num_', 'of', '_num_', 'patients', 'with', 'breast', 'cancer', 'treated', 'at', 'doses', '_unit_', 'had', 'a', 'best', 'response', 'of', 'sd']"
195,1.0,"In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compared to the wildtype PIK3CA cell line A549.","['in', '_abbrev_', 'a', '_chemical_', 'resistant', '_disease_', 'cell', 'line', 'that', 'harbors', '_gene_', 'mutations', 'the', 'dual', '_abbrev_', 'inhibitor', '_chemical_', 'reduced', 'cell', 'growth', 'and', 'increased', 'the', 'expression', 'of', 'the', 'tumor', 'suppressor', '_gene_', 'compared', 'to', 'the', 'wildtype', '_gene_', 'cell', 'line', '_abbrev_']"
196,1.0,Resistance to WZ4002 was induced in cell lines.,"['resistance', 'to', '_chemical_', 'was', 'induced', 'in', 'cell', 'lines']"
197,1.0,Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib.,"['_num_', 'children', 'with', 'relapsed', 'or', 'refractory', '_abbrev_', '_disease_', 'were', 'treated', 'with', '_chemical_']"
198,1.0,The patient remained almost asymptomatic and without disease progression after 39 weeks.,"['the', 'patient', 'remained', 'almost', 'asymptomatic', 'and', 'without', 'disease', 'progression', 'after', '_num_', 'weeks']"
199,1.0,"The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.","['the', '_mutation_', 'mutation', 'in', '_gene_', 'has', 'been', 'shown', 'to', 'confer', 'resistance', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_chemical_', 'and', 'patients', 'harboring', 'this', 'mutation', 'that', 'are', 'placed', 'on', 'the', 'drug', 'are', 'likely', 'to', 'relapse']"
200,1.0,c-MET amplification was detected by FISH.,"['_gene_', 'amplification', 'was', 'detected', 'by', 'fish']"
201,1.0,These cells were more sensitive than other neuroblastoma cell lines containing wild type ALK.,"['these', 'cells', 'were', 'more', 'sensitive', 'than', 'other', 'neuroblastoma', 'cell', 'lines', 'containing', 'wild', 'type', '_gene_']"
202,1.0,"In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A.","['in', 'cytogenetically', 'normal', '_disease_', 'patients', '_gene_', '_abbrev_', 'mutations', 'are', 'associated', 'with', 'lower', 'overall', 'and', 'disease', 'free', 'survival', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
203,1.0,"In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivariate analysis.","['in', 'a', 'retrospective', 'analysis', 'of', '_num_', 'non', '_disease_', 'non', 'small', 'cell', 'lung', 'cancer', 'patients', 'exon', '_range_', 'mutations', 'in', '_gene_', 'were', 'significantly', 'associated', 'with', 'shorter', 'os', '_num_', 'vs', '_num_', 'months', 'also', 'after', 'multivariate', 'analysis']"
204,1.0,"TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort.","['_gene_', 'expression', 'was', 'assessed', 'by', '_gene_', 'in', '_num_', 'patients', '_num_', 'patients', 'were', 'identified', 'for', 'the', 'validation', 'cohort']"
205,1.0,Knockdown of SGK1 in resistant HCC1954 cells increased alpelisib sensitivity and reduced p-S6K and p-4EBP levels with alpelisib treatment.,"['knockdown', 'of', '_gene_', 'in', 'resistant', '_abbrev_', 'cells', 'increased', 'alpelisib', 'sensitivity', 'and', 'reduced', '_mutation_', 'and', '_abbrev_', 'levels', 'with', 'alpelisib', 'treatment']"
206,1.0,"Patients with TP53wt had significantly better PFS and OS with ACT vs. OBS (p=0.005, p=0.02, respectively) whereas patients with TP53 mutations did not show significant differences in PFS and OS between ACT and OBS (p=0.86, p=0.63).","['patients', 'with', '_abbrev_', 'had', 'significantly', 'better', '_disease_', 'and', 'os', 'with', 'act', 'vs', 'obs', '_p_val_', '_p_val_', 'respectively', 'whereas', 'patients', 'with', '_gene_', 'mutations', 'did', 'not', 'show', 'significant', 'differences', 'in', '_disease_', 'and', 'os', 'between', 'act', 'and', 'obs', '_p_val_', '_p_val_']"
207,1.0,"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring NRAS, KRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization.","['in', '_num_', 'out', 'of', '_num_', '_num_', 'metastatic', 'colorectal', 'cancer', 'tumors', 'harboring', 'nras', '_gene_', '_gene_', 'or', '_gene_', 'mutations', 'and', 'implanted', 'into', 'mice', 'the', 'therapeutic', 'combination', 'of', 'the', 'mek', 'inhibitor', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'disease', 'stabilization']"
208,1.0,The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy.,"['the', 'presence', 'of', 'the', '_gene_', 'polymorphism', '_mutation_', 'correlated', 'with', 'os', 'and', '_disease_', 'of', '_disease_', 'patients', 'treated', 'with', 'platinum', 'based', 'chemotherapy']"
209,1.0,Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009).,"['overall', 'and', 'event', 'free', 'survival', 'were', 'worse', 'for', '_gene_', 'mutant', 'patients', 'although', 'transplantation', 'status', 'was', 'not', 'considered', 'log', 'rank', '_p_val_', 'and', '_p_val_']"
210,1.0,"Because of their low frequency, patients with S45P mutations were excluded from these analyses but showed a recurrence course similar to T41A or wild type patients.","['because', 'of', 'their', 'low', 'frequency', 'patients', 'with', '_mutation_', 'mutations', 'were', 'excluded', 'from', 'these', 'analyses', 'but', 'showed', 'a', 'recurrence', 'course', 'similar', 'to', '_mutation_', 'or', 'wild', 'type', 'patients']"
211,1.0,"In this group, 92 (44.9%) were EGFR mutant.","['in', 'this', 'group', '_num_', '_num_', 'were', '_gene_', 'mutant']"
212,1.0,"In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection).","['in', 'this', 'study', 'response', 'to', '_gene_', 'inhibition', 'by', '_chemical_', 'was', 'independent', 'of', 'hpv', 'status', 'represented', 'by', 'expression', 'of', '_gene_', '_gene_', 'an', 'established', '_chemical_', 'of', '_disease_', 'infection']"
213,1.0,The D276G mutation was moderately resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
214,1.0,One carried pheochromocytoma and both carried angiomas.,"['_num_', 'carried', 'pheochromocytoma', 'and', 'both', 'carried', 'angiomas']"
215,1.0,Tumor-specific promoter hypermethylation of NAPRT1 led to loss of NAPRT1 expression in most tumor types sensitive to treatment with Nampt inhibitor GNE-617 and nicotinic acid.,"['tumor', 'specific', 'promoter', 'hypermethylation', 'of', '_gene_', 'led', 'to', 'loss', 'of', '_gene_', 'expression', 'in', 'most', 'tumor', 'types', 'sensitive', 'to', 'treatment', 'with', '_gene_', 'inhibitor', '_chemical_', 'and', '_disease_', 'acid']"
216,1.0,"Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).","['sensitivity', 'to', 'the', '_gene_', 'inhibitor', '_chemical_', 'was', 'assessed', 'and', '_ratio_', '_gene_', 'positive', 'cell', 'lines', 'were', 'reported', 'to', 'be', 'sensitive', '_abbrev_', '_num_', 'micro', 'molar', '_chemical_']"
217,1.0,In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.,"['in', '3t3', 'fibroblasts', 'expressing', 'the', '_mutation_', 'mutation', 'have', 'to', 'be', 'sensitive', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_chemical_']"
218,1.0,"The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma.","['the', '_abbrev_', 'fusion', 'gene', 'was', 'found', 'in', '_ratio_', 'tumor', 'samples', 'of', 'radiation', 'associated', 'papillary', 'thyroid', 'carcinoma', 'and', 'no', 'samples', 'of', 'non', 'radiation', 'associated', 'papillary', 'thyroid', 'carcinoma']"
219,1.0,"Further Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater.","['further', '_disease_', 'survival', 'analysis', 'revealed', 'that', 'in', 'groups', 'with', 'higher', '_gene_', 'expression', 'overall', 'survival', 'was', 'significantly', 'greater']"
220,1.0,1 patient was identified with 2 nonsynonymous coding mutations.,"['_num_', 'patient', 'was', 'identified', 'with', '_num_', 'nonsynonymous', 'coding', 'mutations']"
221,1.0,"2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC.","['_num_', 'patient', ""'s"", 'samples', 'underwent', 'whole', 'genome', 'sequencing', 'tumor', 'samples', 'from', '_num_', 'patients', 'underwent', 'exome', 'sequencing', 'and', 'expression', 'analysis', '_num_', 'samples', 'underwent', '_gene_', 'copy', 'number', 'analysis', 'mrna', 'analysis', 'and', '_gene_']"
222,1.0,"In a multivariate analysis of 774 CLL patients, SF3B1 mutations were significantly correlated with shorter time to first treatment (HR=1.644; 95% CI=1.134-2.383).","['in', 'a', 'multivariate', 'analysis', 'of', '_num_', '_disease_', 'patients', '_gene_', 'mutations', 'were', 'significantly', 'correlated', 'with', 'shorter', 'time', 'to', '_num_', 'treatment', '_ineq_', '_num_', '_ineq_']"
223,1.0,Western blots showed clear elevation of protein levels in 3/5 resistant cell lines.,"['western', 'blots', 'showed', 'clear', 'elevation', 'of', 'protein', 'levels', 'in', '_ratio_', 'resistant', 'cell', 'lines']"
224,1.0,"Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.17–0.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.19–0.46; P < 0.0001).","['significantly', 'longer', 'overall', 'survival', 'was', 'observed', 'in', 'the', '_chemical_', 'continuing', 'group', 'from', 'time', 'of', 'pd', '_num_', 'vs', '_num_', 'months', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_num_', '17–0', '_num_', 'p', '_num_', 'and', 'from', 'the', 'time', 'of', 'initial', '_chemical_', '_num_', 'vs', '_num_', 'months', 'hr', '_num_', '_num_', 'ci', '_num_', '19–0', '_num_', 'p', '_num_']"
225,1.0,"In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs.","['in', 'an', 'in', 'vitro', 'study', 'using', '_abbrev_', 'cells', 'wildtype', '_gene_', 'and', '_abbrev_', 'cells', '_abbrev_', 'inhibition', 'of', 'cell', 'growth', 'was', 'used', 'as', 'an', 'assay', 'to', 'determine', 'sensitivity', 'to', 'tyrosine', 'kinase', 'inhibitor', 'drugs']"
226,1.0,ERK inhibitor resistance was demonstrated as a result of a GNAQ Q209P mutation also identified in the patient.,"['_gene_', 'inhibitor', 'resistance', 'was', 'demonstrated', 'as', 'a', 'result', 'of', 'a', '_gene_', '_mutation_', 'mutation', 'also', 'identified', 'in', 'the', 'patient']"
227,1.0,"In an analysis of 138 desmoid fibromatosis tumors, which is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence, 117 tumors (85%) had CTNNB1 mutations.","['in', 'an', 'analysis', 'of', '_num_', '_disease_', '_disease_', 'tumors', 'which', 'is', 'a', 'rare', 'nonmetastatic', 'neoplasm', 'marked', 'by', 'local', '_disease_', 'and', 'relentless', 'recurrence', '_num_', 'tumors', '_num_', 'had', '_gene_', 'mutations']"
228,0.0,63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DPC4) via immunolabeling.,"['_num_', '_ratio_', 'of', 'carcinomas', 'analyzed', 'showed', 'inactivation', 'of', '_gene_', '_gene_', 'via', 'immunolabeling']"
229,1.0,"Derivative cell lines showed some sensitivity to CDK4/6 inhibitor palbociclib, and increased growth inhibition when treated with fulvestrant and palbociclib together.","['derivative', 'cell', 'lines', 'showed', 'some', 'sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_', 'and', 'increased', 'growth', 'inhibition', 'when', 'treated', 'with', '_chemical_', 'and', '_chemical_', 'together']"
230,1.0,"HPO terms: hemangioblastoma, retinal hemangioblastoma.","['_disease_', 'terms', '_disease_', 'retinal', '_disease_']"
231,1.0,Relevant HPO terms: Neuroendocrine neoplasm.,"['relevant', '_disease_', 'terms', 'neuroendocrine', 'neoplasm']"
232,1.0,This missense mutation was found in a VHL type 1 patient (patient no V81).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
233,1.0,"ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included.","['_gene_', 'rearrangement', 'was', 'assessed', 'via', 'approved', 'break', 'apart', 'fish', 'kit', 'and', 'patients', 'with', 'asymptomatic', 'cns', 'metastases', 'were', 'also', 'included']"
234,1.0,"CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035).","['cps', 'therapy', 'was', 'associated', 'with', 'improved', 'progression', 'free', 'survival', '_disease_', 'compared', 'with', '_gene_', 'in', 'patients', 'with', 'tumors', 'with', '_gene_', 'gene', 'copy', 'gains', 'hr', '_num_', 'p', '_num_']"
235,1.0,402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133).,"['_num_', 'patients', 'that', 'were', 'previously', 'untreated', 'or', 'progressed', 'on', 'or', 'after', 'previous', 'immunotherapy', 'were', 'randomised', 'to', 'receive', 'either', '_chemical_', '_num_', 'or', '_chemical_', '_num_']"
236,1.0,The meta-analysis showed no association between the VHL gene alteration and overall response rate or progression free survival.,"['the', '_disease_', 'analysis', 'showed', 'no', 'association', 'between', 'the', '_gene_', 'gene', 'alteration', 'and', 'overall', 'response', 'rate', 'or', 'progression', 'free', 'survival']"
237,1.0,"In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212.","['in', 'this', 'screen', 'of', '_num_', 'solid', 'cancer', 'cell', 'lines', '_gene_', 'mutations', 'were', 'predictive', 'of', 'response', 'to', 'the', 'mek', 'inhibitor', '_chemical_']"
238,1.0,"In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3.","['in', '_disease_', 'patients', '_gene_', 'mutation', 'was', 'associated', 'with', 'poorer', 'disease', 'free', 'survival', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
239,1.0,"78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.","['_num_', 'patients', 'were', 'assigned', 'to', 'each', 'group', 'with', 'median', 'time', 'to', 'progression', 'of', '_num_', 'months', 'in', '_chemical_', 'group', 'and', '_num_', 'months', 'in', '_chemical_', 'plus', '_chemical_', 'group']"
240,1.0,"In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone.","['in', 'the', '_chemical_', 'sensitive', 'cell', 'line', '_abbrev_', '_chemical_', 'synergized', 'with', '_chemical_', 'in', 'growth', 'inhibition', 'while', 'in', '_num_', '_chemical_', 'resistant', 'cell', 'lines', 'addition', 'of', '_chemical_', 'to', '_chemical_', 'treatment', 'resulted', 'in', 'increased', 'growth', 'inhibition', 'over', '_chemical_', 'alone']"
241,1.0,"Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor, GDC-0941 (pictilisib), as compared to wildtype PIK3CA cell lines.","['breast', 'cancer', 'cell', 'lines', 'with', '_disease_', '_gene_', 'mutations', 'had', 'an', 'increased', 'sensitivity', 'to', 'treatment', 'with', 'class', 'i', '_gene_', 'inhibitor', '_chemical_', 'pictilisib', 'as', 'compared', 'to', 'wildtype', '_gene_', 'cell', 'lines']"
242,1.0,The H396R mutation was resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
243,1.0,"In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months.","['in', 'a', 'melanoma', 'patient', 'with', 'nras', '_mutation_', 'mutation', 'treatment', 'with', '_chemical_', 'resulted', 'in', 'disease', 'free', 'survival', 'of', '_num_', 'months']"
244,1.0,EML4-ALK variant 3 NSCLC cell line H2228 was used in SCID mouse xenografts which were exposed to increasing crizotinib up to 100 mg/kg.,"['_chemical_', 'variant', '_num_', '_disease_', 'cell', 'line', '_abbrev_', 'was', 'used', 'in', 'scid', 'mouse', 'xenografts', 'which', 'were', 'exposed', 'to', 'increasing', '_chemical_', 'up', 'to', '_num_', '_disease_']"
245,1.0,"A missense mutation, affecting residue within the pVHL protein core, was found in 3 VHL families of 7 patients altogether.","['a', 'missense', 'mutation', 'affecting', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', '_num_', '_gene_', 'families', 'of', '_num_', 'patients', 'altogether']"
246,1.0,A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242.,"['a', 'panel', 'of', '_num_', 'breast', 'cancer', 'cell', 'lines', 'was', 'tested', 'for', 'sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_', 'and', '_abbrev_', 'inhibitor', '_chemical_']"
247,1.0,"In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.","['in', 'young', '_disease_', 'patients', '_num_', 'years', 'old', '_gene_', 'mutation', 'status', '_num_', 'of', 'which', 'were', '_abbrev_', 'was', 'not', 'predictive', 'of', 'overall', 'and', 'relapse', 'free', 'survival', 'in', 'patients', 'with', '_gene_', 'mutations', 'and', 'wildtype', '_gene_', 'or', 'wildtype', '_gene_', 'and', '_gene_']"
248,1.0,"Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient.","['_num_', '_gene_', 'carriers', 'had', 'a', 'response', 'according', 'to', '_disease_', 'with', 'the', 'response', 'sustained', 'for', 'more', 'than', '_num_', 'weeks', 'in', '_num_', 'patient']"
249,1.0,"This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291).","['this', 'phase', 'i', 'ii', 'trial', '_abbrev_', 'involved', '_num_', 'non', 'small', 'cell', 'lung', 'cancer', 'patients', 'with', 'activating', '_gene_', 'mutations', 'who', 'had', 'progressed', 'on', '_num_', 'generation', 'tyrosine', 'kinase', 'inhibitor', 'treatment', 'and', 'were', 'subsequently', 'treated', 'with', 'osimertinib', '_chemical_']"
250,1.0,Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.,"['_num_', 'dimensional', 'visualization', 'showed', 'the', '_num_', 'position', 'to', 'be', 'outside', 'of', 'the', '_chemical_', 'binding', 'position']"
251,1.0,"Missense mutation, affecting an amino acid within pVHL protein core, was found in 6 VHL type 1 families with 12 affected individuals altogether.","['missense', 'mutation', 'affecting', 'an', 'amino', 'acid', 'within', '_gene_', 'protein', 'core', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'with', '_num_', 'affected', 'individuals', 'altogether']"
252,1.0,2 PR and 8 SD among 18 patients with KRAS Mutant NSCLC.,"['_num_', 'pr', 'and', '_num_', 'sd', 'among', '_num_', 'patients', 'with', '_gene_', 'mutant', '_disease_']"
253,1.0,Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants.,"['screening', 'of', '_num_', 'unrelated', 'patients', 'with', '_gene_', 'disease', 'revealed', '_num_', 'dna', 'variants']"
254,1.0,All patients had ECOG status 0 or 1 and confirmed progression after first line therapy with oxaliplatin-based chemotherapy and bevacizumab.,"['all', 'patients', 'had', 'ecog', 'status', '_num_', 'or', '_num_', 'and', 'confirmed', 'progression', 'after', '_num_', 'line', 'therapy', 'with', '_chemical_', 'based', 'chemotherapy', 'and', '_chemical_']"
255,1.0,"In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment.","['in', '_num_', '_chemical_', 'resistant', 'cell', 'lines', 'tested', 'colony', 'formation', 'in', 'matrigel', 'was', 'markedly', 'inhibited', 'by', 'combination', 'treatment']"
256,1.0,"In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.","['in', 'subsequent', 'experiments', 'using', '_chemical_', 'or', 'altered', 'versions', 'the', 'transforming', 'potential', 'of', '_chemical_', 'was', 'found', 'to', 'be', 'dependent', 'on', 'a', 'functional', '_gene_', 'kinase', 'activity', 'as', 'well', 'as', 'the', '_gene_', 'basic', 'domain', 'which', 'was', 'shown', 'to', 'have', 'an', 'important', 'role', 'in', '_chemical_', 'dimer', 'formation']"
257,1.0,KIT V654A results in imatinib resistance in GIST patient-derived cell lines.,"['kit', '_mutation_', 'results', 'in', '_chemical_', 'resistance', 'in', 'gist', '_disease_', 'cell', 'lines']"
258,1.0,"In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.","['in', 'er', 'positive', 'breast', 'cancer', 'patients', '_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'shorter', 'overall', 'survival', 'and', 'increased', 'metastasis']"
259,1.0,"When resistance developed, a new MET kinase domain mutation, D1228V, was detected.","['when', 'resistance', 'developed', 'a', 'new', 'met', 'kinase', 'domain', 'mutation', '_mutation_', 'was', 'detected']"
260,0.0,This fusion is believed to activate MAPK pathway signaling.,"['this', 'fusion', 'is', 'believed', 'to', 'activate', '_gene_', 'pathway', 'signaling']"
261,1.0,This mutation was found in a VHL type 1 patient (patient no V41).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_gene_']"
262,1.0,"In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.","['in', '_gene_', 'clinical', 'studies', 'an', '_gene_', 'inhibitor', '_abbrev_', 'impaired', 'growth', 'of', 'glioma', 'anaplastic', '_disease_', 'cell', 'lines', 'with', '_gene_', '_mutation_', 'mutations']"
263,1.0,Study describes a phase 1 clinical trial of ponatinib in treatment of 81 refractory Philadelphia chromosome-positive leukemias.,"['study', 'describes', 'a', 'phase', '_num_', 'clinical', 'trial', 'of', '_chemical_', 'in', 'treatment', 'of', '_num_', 'refractory', 'philadelphia', 'chromosome', 'positive', 'leukemias']"
264,1.0,"In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts.","['in', 'an', 'in', 'vivo', 'mouse', 'xenograft', 'study', 'the', 'growth', 'of', 'cells', 'with', 'an', '_abbrev_', 'mutation', 'were', 'more', 'sensitive', 'to', 'treatment', 'of', '_chemical_', 'concentration', '_num_', '_unit_', '_unit_', 'median', 'tumor', 'volume', '_num_', '150mm^3', 'vs', '1000mm^3', 'compared', 'to', 'reversible', '_disease_', '_chemical_', 'treated', 'xenografts']"
265,1.0,BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.,"['_gene_', 'fusions', 'have', 'been', 'found', 'to', 'contribute', 'to', '_chemical_', 'resistance', 'in', '_disease_', 'cell', 'lines']"
266,1.0,No variants were found in 96 control cases.,"['no', 'variants', 'were', 'found', 'in', '_num_', 'control', 'cases']"
267,1.0,"However, triple therapy of MDV300, BYL719, and AZD8186 resulted in tumor regression of 113% (n=5 mice).","['however', 'triple', 'therapy', 'of', '_abbrev_', '_chemical_', 'and', '_chemical_', 'resulted', 'in', 'tumor', 'regression', 'of', '_num_', '_gene_', 'mice']"
268,1.0,9/10 partial responses were in patients with exon 11 or 13 KIT mutations.,"['_ratio_', 'partial', 'responses', 'were', 'in', 'patients', 'with', 'exon', '_num_', 'or', '_num_', 'kit', 'mutations']"
269,1.0,"Among the alterations, One cell line harbored a PIK3CA H1047R mutation.","['among', 'the', 'alterations', '_num_', 'cell', 'line', 'harbored', 'a', '_gene_', '_mutation_', 'mutation']"
270,1.0,ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease.,"['acmg', 'evidence', 'codes', ""'pvs1"", 'because', 'they', 'observe', 'a', 'frameshift', 'variant', 'in', 'a', 'gene', 'where', 'loss', 'of', 'function', 'is', 'a', 'known', 'mechanism', 'of', 'disease']"
271,1.0,"1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E.","['_num_', 'case', 'was', 'verified', 'by', '_disease_', 'to', 'be', 'a', '_abbrev_', 'fusion', 'but', 'this', 'case', 'was', 'also', 'positive', 'for', '_gene_', '_mutation_']"
272,1.0,"Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor).","['treatment', 'of', '_num_', '_gene_', 'mutant', 'cell', 'lines', 'pancreatic', 'and', 'endometrial', 'with', '_abbrev_', 'and', '_abbrev_', 'mutation', 'respectively', 'and', '_num_', 'wild', 'type', 'controls', 'showed', 'that', 'mutant', 'cell', 'lines', 'were', 'significantly', 'more', 'sensitive', 'to', '_chemical_', 'a', '_abbrev_', 'complex', 'inhibitor']"
273,1.0,Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance.,"['emergence', 'of', '_abbrev_', 'mutation', 'in', '_disease_', 'patients', 'with', '_gene_', 'tandem', 'repeat', 'is', 'associated', 'with', '_chemical_', 'resistance']"
274,1.0,"In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate.","['in', 'the', 'absence', 'of', 'a', '_gene_', '_gene_', 'mutation', 'a', 'co', 'mutation', 'of', '_gene_', 'and', '_gene_', 'had', 'a', '_num_', '_num_', 'year', 'survival', 'rate', 'whereas', 'triple', 'mutation', 'of', '_gene_', '_gene_', 'and', '_gene_', '_gene_', 'had', 'a', '_num_', '_num_', 'year', 'survival', 'rate']"
275,1.0,720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status.,"['_num_', 'patients', 'with', 'stage', 'iii', 'iv', 'oropharyngeal', 'cancer', 'were', 'retrospectively', 'analyzed', 'for', '_gene_', 'and', '_disease_', 'status']"
276,1.0,This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 79).,"['this', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
277,1.0,Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.,"['treatment', 'of', 'philadelphia', 'chromosome', 'positive', 'leukemias', 'with', '_chemical_', 'results', 'in', 'high', 'rates', 'of', 'complete', 'remission', 'in', 'patients', 'with', '_gene_']"
278,1.0,HER2 overexpression in USPC is more common in African American women.,"['_gene_', 'overexpression', 'in', '_disease_', 'is', 'more', 'common', 'in', 'african', 'american', 'women']"
279,1.0,This missense mutation was found in 4 VHL family members (proband no 6).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'family', 'members', 'proband', 'no', '_num_']"
280,1.0,"6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition.","['_ratio_', 'mice', 'responded', 'with', 'strong', 'tumor', 'growth', 'inhibition', 'or', 'regression', 'while', '_num_', '_mutation_', 'responded', 'with', 'weak', 'growth', 'inhibition']"
281,1.0,"NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer.","['_gene_', '_disease_', 'mutations', 'including', '_abbrev_', 'called', '_abbrev_', 'in', 'publication', 'have', 'shown', 'to', 'be', 'correlated', 'with', 'poor', 'prognosis', 'in', 'lung', 'cancer']"
282,1.0,This missense mutation was found in a VHL type 2B family of 12 individuals (Family ID 3682 in publication).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_', 'in', 'publication']"
283,1.0,Nine patients achieved stable disease for at least 6 months (35%).,"['_num_', 'patients', 'achieved', 'stable', 'disease', 'for', 'at', 'least', '_num_', 'months', '_num_']"
284,1.0,"Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).","['patients', 'with', 'mutations', 'in', '_gene_', 'had', 'an', 'increased', 'median', 'survival', 'compared', 'to', 'patients', 'with', 'wildtype', '_gene_', '_num_', '_unit_', 'vs', '_num_', '_unit_', '_p_val_']"
285,1.0,"Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib.","['patients', 'with', 'metastatic', 'melanoma', '_ineq_', '_num_', 'cutaneous', '_num_', 'uveal', '_num_', 'mucosal', 'were', 'enrolled', 'in', 'a', 'phase', 'ii', 'randomised', 'discontinuation', 'trial', 'assessing', '_chemical_']"
286,1.0,"In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%).","['in', '_disease_', 'screening', 'the', '_gene_', 'fusion', 'was', 'detected', 'in', '_num_', 'patients', 'with', '_disease_', '_ratio_', 'exclusively', 'in', 'the', '_disease_', 'subtype', '_ratio_', '_num_']"
287,1.0,"A t(X;18) translocation resulting in the fusion SYT-SSX (SS18-SSX1 or SS18-SSX2) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype.","['a', 't', 'x', '_num_', 'translocation', 'resulting', 'in', 'the', 'fusion', '_gene_', 'ssx', '_abbrev_', 'or', '_abbrev_', 'is', 'detected', 'cytogenetically', 'in', 'over', '_num_', 'of', 'synovial', 'sarcomas', 'regardless', 'of', 'histologic', 'subtype']"
288,1.0,"Objective response for the cohort was 11.5%, disease control rate was 50%.","['objective', 'response', 'for', 'the', 'cohort', 'was', '_num_', 'disease', 'control', 'rate', 'was', '_num_']"
289,1.0,Previous analyses in the same study identify hypermethylation of ALDH1A2 as the underlying mechanism of differential protein expression.,"['previous', 'analyses', 'in', 'the', 'same', 'study', 'identify', 'hypermethylation', 'of', '_gene_', 'as', 'the', 'underlying', 'mechanism', 'of', 'differential', 'protein', 'expression']"
290,1.0,"This nonsense mutation was found in 3 Italian, VHL type 1 family members.","['this', 'nonsense', 'mutation', 'was', 'found', 'in', '_num_', 'italian', '_gene_', 'type', '_num_', 'family', 'members']"
291,1.0,"In Western blots, ablation of pALK with brigatinib treatment above 100 nM was seen in Ba/F3 cells expressing NPM-ALK wildtype, but remained apparent at 1000 nM brigatinib in NPM-ALK G1202R cells, despite dose-dependent reduction.","['in', 'western', 'blots', 'ablation', 'of', 'palk', 'with', 'brigatinib', 'treatment', 'above', '_num_', '_unit_', 'was', 'seen', 'in', 'ba', '_abbrev_', 'cells', 'expressing', '_chemical_', 'wildtype', 'but', 'remained', 'apparent', 'at', '_num_', '_unit_', 'brigatinib', 'in', '_chemical_', '_mutation_', 'cells', 'despite', '_disease_', 'reduction']"
292,1.0,"Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25).","['unsupervised', 'transcriptomic', 'analysis', 'in', '_num_', 'meningiomas', 'revealed', 'a', 'large', 'set', 'of', 'differentially', 'expressed', 'genes', 'in', 'aggressive', 'subgroups', 'r+m', 'tumors', 'and', 'who', 'grade', 'iii', '_ineq_', 'p', '_num_', '_gene_', '_num_']"
293,1.0,The M244V mutation was  sensitive to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'sensitive', 'to', '_chemical_']"
294,1.0,"Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors.","['notably', 'in', '_disease_', 'colorectal', 'cancer', 'xenografts', 'met', 'amplification', 'correlated', 'with', 'resistance', 'to', '_gene_', 'blockade', 'which', 'could', 'be', 'overcome', 'by', 'met', 'kinase', 'inhibitors']"
295,1.0,"4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response.","['_num_', 'patients', 'with', '_gene_', 'amplified', '_disease_', 'were', 'enrolled', 'in', 'the', 'trial', 'no', '_num_', 'among', 'them', 'had', 'a', 'response']"
296,1.0,14/15 patients evaluated also harbored KRAS exon 2 mutations but no NRAS or BRAF mutations.,"['_ratio_', 'patients', 'evaluated', 'also', 'harbored', '_gene_', 'exon', '_num_', 'mutations', 'but', 'no', 'nras', 'or', '_gene_', 'mutations']"
297,1.0,Median progression free survival was 2.1 months and median overall survival was 7.7 months.,"['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'and', 'median', 'overall', 'survival', 'was', '_num_', 'months']"
298,1.0,Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia.,"['homozygous', '_gene_', '_mutation_', 'mutations', 'result', 'in', 'a', 'rare', 'congenital', 'polycythemia', 'known', 'as', 'chuvash', 'polycythemia']"
299,1.0,"In a phase 3 clinical trial of East Asian pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR:0.48, 95% CI:0.36-0.64, P<0.001), compared to carboplatin plus paclitaxel treatment.","['in', 'a', 'phase', '_num_', 'clinical', 'trial', 'of', 'east', 'asian', 'pulmonary', 'adenocarcinoma', 'patients', 'a', 'subset', 'of', 'patients', 'with', '_gene_', 'mutations', '_ineq_', 'treated', 'with', '_chemical_', 'were', 'associated', 'with', 'improved', 'response', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'compared', 'to', '_chemical_', 'plus', '_chemical_', 'treatment']"
300,1.0,"Of 7 tumors with EGFR mutations, 1 was L858R.","['of', '_num_', 'tumors', 'with', '_gene_', 'mutations', '_num_', 'was', '_mutation_']"
301,0.0,We performed a multihistology basket study of AZD5363.,"['we', 'performed', 'a', 'multihistology', 'basket', 'study', 'of', '_chemical_']"
302,1.0,"In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5).","['in', 'the', 'pooled', 'analysis', 'of', 'both', 'trials', 'patients', 'with', '_gene_', 'mutations', 'had', 'longer', 'progression', 'free', 'survival', 'with', '_chemical_', 'compared', 'to', 'placebo', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_', 'whereas', 'patients', 'with', '_gene_', 'wild', 'type', 'status', 'did', 'not', 'benefit', 'significantly', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_gene_']"
303,1.0,Rapid symptom improvement was seen.,"['rapid', 'symptom', 'improvement', 'was', 'seen']"
304,1.0,In the subgroup of patients without EGFR mutation (defined as all patients without the specific EGFR exon 19 deletion or L858R mutation) a difference in median PFS was not seen between the chemotherapy versus chemotherapy with gefitinib treatment groups.,"['in', 'the', 'subgroup', 'of', 'patients', 'without', '_gene_', 'mutation', 'defined', 'as', 'all', 'patients', 'without', 'the', 'specific', '_gene_', 'exon', '_num_', 'deletion', 'or', '_mutation_', 'mutation', 'a', 'difference', 'in', 'median', '_disease_', 'was', 'not', 'seen', 'between', 'the', 'chemotherapy', 'vs', 'chemotherapy', 'with', '_chemical_', 'treatment', 'groups']"
305,1.0,Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR.,"['_num_', 'synovial', 'sarcomas', 'were', 'assayed', 'for', '_gene_', 'ssx', 'fusion', 'messenger', 'rna', 'by', 'nested', '_disease_']"
306,1.0,"Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence.","['mutations', 'in', '_gene_', 'were', 'associated', 'with', 'a', 'worse', 'overall', 'prognosis', 'than', 'patients', 'wildtype', 'for', '_gene_', 'in', 'young', 'patients', '_range_', 'primarily', 'because', 'of', 'increased', 'risk', 'of', 'disease', 'recurrence']"
307,1.0,"Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.","['multivariate', 'cox', 'regression', 'indicated', 'that', 'shorter', 'survival', 'was', 'associated', 'with', 'higher', '_gene_', 'expression', 'and', 'not', 'with', 'age', 'or', 'ethnicity', 'and', 'that', 'observed', 'differences', 'in', 'survival', 'rates', 'between', 'ethnicities', 'can', 'be', 'ascribed', 'to', 'higher', 'rates', 'of', '_gene_', 'overexpression', 'in', 'african', 'american', 'patients']"
308,1.0,Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression.,"['_num_', 'ovarian', 'cancer', 'cell', 'lines', 'with', 'elevated', '_gene_', 'expression', 'were', '40x', 'more', 'sensitive', 'to', '_gene_', 'inhibitor', '_chemical_', 'than', '_num_', 'cell', 'lines', 'without', '_gene_', 'overexpression']"
309,1.0,"Regardless of BRCA status, none showed objective response when treated with olaparib.","['regardless', 'of', '_gene_', 'status', 'none', 'showed', 'objective', 'response', 'when', 'treated', 'with', '_chemical_']"
310,1.0,"Also, the tumors grew to a larger size at earlier time points.","['also', 'the', 'tumors', 'grew', 'to', 'a', 'larger', 'size', 'at', 'earlier', 'time', 'points']"
311,1.0,"Genetic ablation of ERBB4 (not ERBB1-3) led to apoptosis in trastuzumab- and lapatinib resistant cells, probably through a decrease in the PI3K/Akt pathway.","['genetic', 'ablation', 'of', '_gene_', 'not', '_abbrev_', 'led', 'to', 'apoptosis', 'in', '_chemical_', '', 'and', '_chemical_', 'resistant', 'cells', 'probably', 'through', 'a', 'decrease', 'in', 'the', '_gene_', 'pathway']"
312,1.0,"Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival.","['coexistence', 'of', 'exon', '_num_', '_mutation_', 'or', '_mutation_', 'and', 'exon', '_num_', 'mutations', 'but', 'not', 'either', 'alone', 'is', 'prognostic', 'for', 'worse', 'overall', 'survival', 'and', 'cancer', 'specific', 'survival']"
313,1.0,"This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension).","['this', 'patient', 'responded', 'to', 'treatment', 'with', 'the', 'pan', 'kinase', 'inhibitor', '_chemical_', 'in', 'combination', 'with', '_chemical_', 'and', '_chemical_', 'achieving', 'stable', 'disease', 'after', '_num_', 'cycles', 'extending', 'into', '_num_', 'cycles', 'at', 'which', 'time', 'she', 'expired', 'due', 'to', '_disease_', 'acute', 'myocardial', 'infarction', 'hypotension']"
314,1.0,This nonsense mutation was found in a VHL type 1 family (lineage 48).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
315,1.0,Depletion of AKT3 in TNBC sensitizes cells to the pan-Akt inhibitor GSK690693.,"['depletion', 'of', '_gene_', 'in', '_disease_', 'sensitizes', 'cells', 'to', 'the', 'pan', '_gene_', 'inhibitor', '_chemical_']"
316,1.0,"EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells.","['_gene_', '_mutation_', 'was', 'expressed', 'in', 'ba', '_abbrev_', 'cells', 'which', 'do', 'not', 'contain', 'endogenous', '_gene_', 'and', 'conferred', 'growth', 'factor', 'independance', 'to', 'the', 'cells']"
317,1.0,The patient was treated with crizotinib and had stable disease but disease progression after 18 weeks.,"['the', 'patient', 'was', 'treated', 'with', '_chemical_', 'and', 'had', 'stable', 'disease', 'but', 'disease', 'progression', 'after', '_num_', 'weeks']"
318,1.0,The G250E mutation was resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
319,1.0,This study compared in vitro EPZ-6438 treatment of four SMARCB1-deleted MRT cell lines to three control (wild type) cell lines.,"['this', 'study', 'compared', 'in', 'vitro', '_chemical_', 'treatment', 'of', '_num_', '_abbrev_', '_disease_', 'cell', 'lines', 'to', '_num_', 'control', 'wild', 'type', 'cell', 'lines']"
320,1.0,This missense mutation was found in a VHL type 1 patient (patient no V259).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
321,1.0,This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab.,"['this', 'study', 'involved', 'treatment', 'of', 'mice', 'bearing', '_mutation_', '_gene_', 'xenografts', 'treated', 'with', '_chemical_', 'or', '_chemical_']"
322,1.0,"Recurrent mutational hot spots included Y640F, D661V, D661Y, and N647I.","['recurrent', 'mutational', 'hot', 'spots', 'included', '_mutation_', '_mutation_', '_mutation_', 'and', '_mutation_']"
323,1.0,"255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months).","['_num_', 'patients', 'were', 'enrolled', 'and', 'received', 'at', 'least', '_num_', 'dose', 'of', '_chemical_', '_num_', '_disease_', 'of', 'whom', '_num_', 'had', '_gene_', 'rearranged', '_disease_', 'median', 'follow', 'up', '_num_', 'months']"
324,1.0,3 of whom still received study treatment at the cutoff date used for the final data analysis.,"['_num_', 'of', 'whom', 'still', 'received', 'study', 'treatment', 'at', 'the', 'cutoff', 'date', 'used', 'for', 'the', 'final', 'data', 'analysis']"
325,1.0,"HDAC inhibitors VPA, TSA, LBH-589, and SAHA (vorinostat) were tested in-vitro and led to decreased proliferation (all inhibitors) decreased viability and cytotoxicity (TSA, SAHA, LBH-589) in-vitro and in-vivo (VPA).","['_gene_', 'inhibitors', '_disease_', 'tsa', '_chemical_', 'and', '_disease_', '_chemical_', 'were', 'tested', 'in', 'vitro', 'and', 'led', 'to', 'decreased', 'proliferation', 'all', 'inhibitors', 'decreased', 'viability', 'and', 'cytotoxicity', 'tsa', '_disease_', '_chemical_', 'in', 'vitro', 'and', 'in', 'vivo', '_disease_']"
326,1.0,There is supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).,"['there', 'is', 'supporting', 'evidence', 'for', 'pathogenicity', 'because', 'the', 'patient', ""'s"", 'phenotype', 'is', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'a', 'single', 'genetic', 'etiology', 'acmg', 'code', '_gene_']"
327,1.0,A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels.,"['_abbrev_', 'treatment', 'of', 'cells', 'from', 'mmtv', '_disease_', 'mouse', 'tumors', 'resulted', 'in', 'decreased', 'lipid', 'kinase', 'activity', 'and', '_chemical_', '_gene_', 'levels']"
328,1.0,Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors.,"['patients', 'had', 'cohort', '_num_', 'or', 'had', 'not', 'cohort', '_num_', 'previously', 'been', 'treated', 'with', '_gene_', 'inhibitors']"
329,1.0,"HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, pheochromocytoma.","['_disease_', 'terms', '_disease_', 'retinal', '_disease_', 'renal', 'cell', 'carcinoma', 'pheochromocytoma']"
330,1.0,The time to progression of this single agent was four months.,"['the', 'time', 'to', 'progression', 'of', 'this', 'single', 'agent', 'was', '_num_', 'months']"
331,1.0,A dihydrotestosterone (DHT) and NVP-BEZ235 combination achieved tumor regression and complete response in AR/ER expressing tumors (xenografts).,"['a', '_disease_', '_disease_', 'and', '_chemical_', 'combination', 'achieved', 'tumor', 'regression', 'and', 'complete', 'response', 'in', 'ar', 'er', 'expressing', 'tumors', 'xenografts']"
332,1.0,The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib.,"['the', 'patient', 'treated', 'in', 'a', 'clinical', 'trial', 'with', 'pan', '_gene_', 'kinase', 'inhibitor', 'entrectinib']"
333,1.0,"Cell growth occurred in all wells at 250 nM, and was absent at 2000 nM.","['cell', 'growth', 'occurred', 'in', 'all', 'wells', 'at', '_num_', '_unit_', 'and', 'was', 'absent', 'at', '_year_', '_unit_']"
334,1.0,"In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001).","['in', 'multivariate', 'analysis', 'exon', '_num_', 'deletion', 'was', 'a', 'significant', 'predictive', 'factor', 'for', '_gene_', 'hr', '_num_', 'p', '_num_']"
335,1.0,The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.,"['the', 'median', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'in', '_gene_', '_abbrev_', 'patients', 'and', '_num_', 'months', 'in', '_gene_', '_abbrev_', 'patients']"
336,1.0,Breast tumors in a mouse model with R175H mutation are more responsive to doxorubicin than breast tumors with wild type TP53.,"['breast', 'tumors', 'in', 'a', 'mouse', 'model', 'with', '_mutation_', 'mutation', 'are', 'more', 'responsive', 'to', 'doxorubicin', 'than', 'breast', 'tumors', 'with', 'wild', 'type', '_gene_']"
337,1.0,"Eight years after complete remission, DUX4 fusion positive patients had over 0.8 disease free survival probability.","['_num_', 'years', 'after', 'complete', 'remission', '_gene_', 'fusion', 'positive', 'patients', 'had', 'over', '_num_', 'disease', 'free', 'survival', 'probability']"
338,1.0,Mutation analysis performed using SSCP.,"['mutation', 'analysis', 'performed', 'using', 'sscp']"
339,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
340,1.0,"In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', '_gene_', 'lung', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_abbrev_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
341,1.0,This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'nonsense', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
342,1.0,"Approximately 14%–20% of UM carry a mutation in EIF1AX, with most mutations found in exons 1 and 2.","['approximately', '_num_', '–20', 'of', '_disease_', 'carry', 'a', 'mutation', 'in', '_gene_', 'with', 'most', 'mutations', 'found', 'in', 'exons', '_num_', 'and', '_num_']"
343,1.0,Preclinical studies linking the efficacy of mTOR inhibitor CCI-779 to VHL loss in vitro and in mouse models of kidney cancer.,"['preclinical', 'studies', 'linking', 'the', 'efficacy', 'of', '_gene_', 'inhibitor', '_chemical_', 'to', '_gene_', 'loss', 'in', 'vitro', 'and', 'in', 'mouse', 'models', 'of', 'kidney', 'cancer']"
344,1.0,EML4-ALK variant 1 with G1202R mutation was expressed in Ba/F3 and subject to 17-AAG.,"['_chemical_', 'variant', '_num_', 'with', '_mutation_', 'mutation', 'was', 'expressed', 'in', 'ba', '_abbrev_', 'and', 'subject', 'to', '_chemical_']"
345,1.0,Amplification of REL is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas.,"['amplification', 'of', '_gene_', 'is', 'shown', 'to', 'be', 'associated', 'with', 'germinal', 'center', 'b', 'cell–like', 'diffuse', 'large', 'b', 'cell', 'lymphomas']"
346,1.0,LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.,"['_gene_', 'cells', 'formed', 'tumors', 'in', '_ratio_', 'scid', 'and', '_ratio_', '_disease_', 'mice']"
347,1.0,"Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib.","['phase', '_num_', 'study', 'in', '_num_', 'patients', 'with', '_gene_', 'positive', '_gene_', 'fish', '_gene_', '_gene_', 'metastatic', 'colorectal', 'cancer', 'refractory', 'to', 'standard', 'of', 'care', 'received', '_chemical_', 'and', '_chemical_']"
348,1.0,A 65-year-old man presented with stage II myeloma.,"['a', '_age_', 'man', 'presented', 'with', 'stage', 'ii', 'myeloma']"
349,1.0,"Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007).","['multivariate', 'analysis', 'of', 'factors', 'including', 'smoking', 'history', 'performance', 'status', 'score', 'histology', '_gene_', '_mutation_', 'polymorphism', 'demonstrated', 'that', '_gene_', '_mutation_', 'polymorphism', 'was', 'correlated', 'independently', 'with', '_disease_', '_p_val_']"
350,1.0,In the subpopulation free of RAS mutation (N=19) the correlation was increased.,"['in', 'the', 'subpopulation', 'free', 'of', 'ras', 'mutation', '_ineq_', 'the', 'correlation', 'was', 'increased']"
351,0.0,The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA-NTRK1 gene fusion encoding a functional LMNA-TRKA fusion oncoprotein.,"['the', 'tumor', 'of', 'a', '_age_', 'woman', 'with', 'soft', 'tissue', 'sarcoma', 'metastatic', 'to', 'the', 'lung', 'was', 'found', 'to', 'harbor', 'an', '_abbrev_', 'gene', 'fusion', 'encoding', 'a', 'functional', '_gene_', '_gene_', 'fusion', 'oncoprotein']"
352,1.0,"Among 95 patients with NSCLC in this study, 15 had an ALK translocation.","['among', '_num_', 'patients', 'with', '_disease_', 'in', 'this', 'study', '_num_', 'had', 'an', '_gene_', 'translocation']"
353,1.0,This study contains very strong evidence of pathogenicity in the form of a canonical -1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'canonical', '_num_', 'splice', 'site', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
354,1.0,"144 cases (discovery set: N=62 discovery; Independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing or WHO grade III).","['_num_', 'cases', 'discovery', 'set', '_ineq_', 'discovery', 'independent', 'validation', 'set', 'n', '_num_', 'of', 'meningiomas', 'were', 'analyzed', 'for', 'transcriptional', 'features', 'defining', 'aggressive', 'clinical', 'course', 'recurrent', 'malignantly', 'progressing', 'or', 'who', 'grade', 'iii']"
355,1.0,In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time.,"['in', 'mice', 'xenografts', 'expressing', '_gene_', '_gene_', 'the', 'combination', 'of', '_gene_', '_gene_', 'and', '_gene_', 'inhibitors', 'pertuzumab', 'and', '9f7', '_abbrev_', 'tumor', 'inhibition', 'and', 'the', 'median', 'survival', 'time']"
356,1.0,TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients.,"['_gene_', 'expression', 'was', 'associated', 'with', 'a', 'higher', 'probability', 'of', 'response', 'in', 'doxorubicin', 'treated', 'but', 'not', 'in', '_chemical_', 'treated', 'breast', 'cancer', 'patients']"
357,1.0,"In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048).","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'lung', 'adenocarcinoma', 'patients', 'with', '_gene_', 'mutations', '_ineq_', 'showed', 'worse', 'prognosis', 'os', '_num_', 'months', 'vs', '_num_', 'months', '_ineq_', '_p_val_']"
358,1.0,Ba/F3 cells expressing EML4-ALK variant 1 with ALK G1202R mutation were assessed for ceritinib sensitivity.,"['ba', '_abbrev_', 'cells', 'expressing', '_chemical_', 'variant', '_num_', 'with', '_gene_', '_mutation_', 'mutation', 'were', 'assessed', 'for', '_chemical_', 'sensitivity']"
359,1.0,This missense mutation was found in a VHL type 1 family (lineage 132).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
360,1.0,RT-PCR revealed exon 3 was excluded from the spliced transcript in this patient.,"['_disease_', 'revealed', 'exon', '_num_', 'was', 'excluded', 'from', 'the', 'spliced', 'transcript', 'in', 'this', 'patient']"
361,1.0,"This patient had two pathogenic mutations in MSH2 (E28fs, K172*).","['this', 'patient', 'had', '_num_', 'pathogenic', 'mutations', 'in', '_gene_', '_abbrev_', '_chemical_']"
362,1.0,"FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations.","['_gene_', 'mutations', 'did', 'not', 'alter', 'overall', 'survival', 'or', 'remission', 'duration', 'in', 'younger', '_range_', 'cytogenetically', 'normal', '_disease_', 'patients', 'with', '_gene_', 'mutations']"
363,1.0,"Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative).","['case', 'report', 'of', 'a', '47year', 'old', 'female', 'patient', 'with', 'metastatic', 'melanoma', '_gene_', 'nras', 'kit', 'negative']"
364,1.0,Rapamycin inhibits transformation induced by mutation in PIK3CA.,"['_gene_', 'inhibits', 'transformation', 'induced', 'by', 'mutation', 'in', '_gene_']"
365,1.0,"In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild type.","['in', 'patients', 'with', 'clear', 'cell', 'renal', 'cell', 'carcinoma', 'in', 'a', 'multivariate', 'analysis', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'worse', 'overall', 'survival', 'than', 'wild', 'type']"
366,1.0,Mutations at three of these amino acid positions conferred high degrees of in vitro AC220 resistance (based on proliferation and cell-based biochemical assays).,"['mutations', 'at', '_num_', 'of', 'these', 'amino', 'acid', 'positions', 'conferred', 'high', 'degrees', 'of', 'in', 'vitro', '_abbrev_', 'resistance', 'based', 'on', 'proliferation', 'and', 'cell', 'based', 'biochemical', 'assays']"
367,1.0,"However, this response did not meet criteria for RECIST partial response.","['however', 'this', 'response', 'did', 'not', 'meet', 'criteria', 'for', '_disease_', 'partial', 'response']"
368,1.0,"After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed.","['after', '_num_', 'months', '_disease_', '_abbrev_', 'partial', 'response', 'evidenced', 'by', 'a', 'decrease', 'of', '_num_', 'in', 'the', 'sum', 'of', 'largest', 'diameters', 'was', 'observed']"
369,1.0,This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 92).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
370,0.0,Reintroduction of AR expression resensitized nonresponsive AR-negative cells to NVP-BEZ235.,"['reintroduction', 'of', 'ar', 'expression', 'resensitized', 'nonresponsive', 'ar', 'negative', 'cells', 'to', '_chemical_']"
371,1.0,"These results suggest that neoadjuvant chemotherapy may be feasible for inoperable glioblastoma patients expressing low levels of MGMT without compromising subsequent treatment with radiotherapy, whereas patients with high MGMT expression are less likely to respond and more likely to experience progression before or during radiotherapy.","['these', 'results', 'suggest', 'that', 'neoadjuvant', 'chemotherapy', 'may', 'be', 'feasible', 'for', 'inoperable', 'glioblastoma', 'patients', 'expressing', 'low', 'levels', 'of', '_gene_', 'without', 'compromising', 'subsequent', 'treatment', 'with', 'radiotherapy', 'whereas', 'patients', 'with', 'high', '_gene_', 'expression', 'are', 'less', 'likely', 'to', 'respond', 'and', 'more', 'likely', 'to', 'experience', 'progression', 'before', 'or', 'during', 'radiotherapy']"
372,1.0,"In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.","['in', 'a', 'set', 'of', '_num_', 'patients', 'with', '_disease_', '_disease_', 'was', 'performed', 'to', 'test', 'for', 'known', '_chemical_', 'variants']"
373,1.0,Expression of CD74–ROS1 G2032R in Ba/F3 cells conferred resistance to crizotinib combared to CD74–ROS1 (IC50=353.62+/-20.15 vs. 2.76+/-0.82).,"['expression', 'of', '_abbrev_', '_mutation_', 'in', 'ba', '_abbrev_', 'cells', 'conferred', 'resistance', 'to', '_chemical_', 'combared', 'to', '_abbrev_', '_ineq_', 'vs', '_num_']"
374,1.0,"Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively.","['histologically', '_num_', '_num_', 'were', 'classified', 'as', 'biphasic', 'type', 'and', '_num_', '_num_', 'as', 'monophasic', 'type', 'based', 'on', 'the', 'presence', 'or', 'absence', 'of', 'areas', 'of', 'glandular', 'epithelial', 'differentiation', 'respectively']"
375,1.0,"Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant.","['_num_', 'of', 'the', 'patients', 'initially', 'achieved', 'morphological', 'complete', 'remission', 'bone', 'marrow', 'blasts', '_num_', 'however', '_num_', 'patients', 'developed', 'resistance', 'within', '_range_', 'weeks', 'and', 'and', '_num_', 'required', 'a', 'bone', 'marrow', 'transplant']"
376,1.0,Vandetanib was tested in 4 murine models of patient-derived xenografts.,"['_chemical_', 'was', 'tested', 'in', '_num_', 'murine', 'models', 'of', '_disease_', 'xenografts']"
377,1.0,There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.,"['there', 'is', 'no', 'significant', 'association', 'between', 'wildtype', 'kit', 'or', 'kit', 'mutations', 'in', 'exon', '_num_', 'or', '_num_', 'in', 'survival', 'among', 'gist', 'patients']"
378,1.0,Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).,"['cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']"
379,1.0,"18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals.","['_num_', 'novel', 'variants', 'were', 'identified', 'in', '_gene_', 'patients', 'but', 'none', 'were', 'present', 'in', '_num_', 'unaffected', 'control', 'individuals']"
380,1.0,"In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.","['in', 'mouse', 'xenograft', 'studies', 'of', '_gene_', 'mutant', 'breast', 'cancers', 'the', 'combination', 'of', '_gene_', 'and', '_gene_', 'inhibitors', 'overcomes', 'intrinsic', 'and', 'adaptive', 'resistance', 'leading', 'to', 'tumor', 'regressions']"
381,1.0,"MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started.","['met', 'amplification', 'was', 'found', 'by', 'fish', 'and', '_gene_', 'and', 'met', 'inhibitor', '_chemical_', 'treatment', 'was', 'started']"
382,1.0,"A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate).","['a', '_age_', 'boy', 'with', '_disease_', 'acute', '_disease_', 'leukemia', 'refractory', 'to', 'conventional', 'chemotherapy', 'and', 'harboring', 'an', '_abbrev_', 'fusion', 'responded', 'to', '_chemical_', 'plus', 'induction', 'chemotherapy', 'vincristine', '_chemical_', 'prednisone', 'and', 'intrathecal', 'methotrexate']"
383,1.0,Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.,"['treatment', 'of', 'notch', 'driven', '_disease_', 'leukemia', 'in', '_gene_', 'knockout', 'mice', 'with', '_chemical_', '_disease_', 'significantly', 'increased', 'median', 'survival']"
384,1.0,This expression was absent in the normal tissues of these patients for this isoform.,"['this', 'expression', 'was', 'absent', 'in', 'the', 'normal', 'tissues', 'of', 'these', 'patients', 'for', 'this', '_chemical_']"
385,1.0,This mutation displayed elevated levels of Ser118 phosphorylation compared to wild type ERα and appeared to possess estrogen-independent activity.,"['this', 'mutation', 'displayed', 'elevated', 'levels', 'of', '_abbrev_', '_disease_', 'compared', 'to', 'wild', 'type', 'erα', 'and', 'appeared', 'to', 'possess', 'estrogen', 'independent', 'activity']"
386,1.0,11/13 patients were deep sequenced for BTK and PLCG2.,"['_ratio_', 'patients', 'were', 'deep', 'sequenced', 'for', '_gene_', 'and', '_gene_']"
387,1.0,"This missense mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 23).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'family', '_gene_', '_num_']"
388,1.0,A phase I study  to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab with an expanded cohort in KRAS-mutant CRC.,"['a', 'phase', 'i', 'study', 'to', 'determine', 'the', 'tolerability', 'and', 'pharmacokinetics', 'of', '_chemical_', 'and', '_chemical_', 'with', 'an', 'expanded', 'cohort', 'in', '_gene_', 'mutant', '_gene_']"
389,1.0,Molecular analysis at this time identified two missense mutations in ALK C1156Y and L1196M.,"['molecular', 'analysis', 'at', 'this', 'time', 'identified', '_num_', 'missense', 'mutations', 'in', '_gene_', '_mutation_', 'and', '_mutation_']"
390,1.0,"In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival.","['in', 'patients', 'with', 'stage', 'iii', 'colorectal', 'cancer', 'undergoing', 'chemotherapy', '_gene_', '_gene_', 'mutation', 'did', 'not', 'impact', 'overall', 'or', 'disease', 'free', 'survival']"
391,1.0,Blood samples from 24 family members were collected and the Alu element was identified in the 3 with ovarian or breast cancer that had evaluable samples.,"['blood', 'samples', 'from', '_num_', 'family', 'members', 'were', 'collected', 'and', 'the', 'alu', 'element', 'was', 'identified', 'in', 'the', '_num_', 'with', 'ovarian', 'or', 'breast', 'cancer', 'that', 'had', 'evaluable', 'samples']"
392,1.0,Liver tumor biopsy was taken and estimated to be 15% tumor.,"['liver', 'tumor', 'biopsy', 'was', 'taken', 'and', 'estimated', 'to', 'be', '_num_', 'tumor']"
393,1.0,"In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild type HRAS.","['in', 'an', 'in', 'vitro', 'study', '_abbrev_', '_abbrev_', 'and', '_chemical_', 'cell', 'lines', 'expressing', '_gene_', '_mutation_', 'mutation', 'were', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', 'as', 'compared', 'to', '_abbrev_', '_abbrev_', 'and', '_chemical_', 'cells', 'expressing', 'wild', 'type', '_gene_']"
394,1.0,"Treatment included radiation, temozolomide and cediranib.","['treatment', 'included', 'radiation', '_chemical_', 'and', '_chemical_']"
395,1.0,Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK.,"['analysis', 'of', 'the', 'mutation', 'in', '_abbrev_', 'cell', 'lines', 'found', 'that', 'the', '_mutation_', 'mutant', 'alone', 'or', 'with', '_abbrev_', 'had', 'greater', 'kinase', 'activity', 'and', 'increased', 'the', 'levels', 'of', '_chemical_', 'mek']"
396,1.0,"Missense mutation at codon 273 (C>A), resulting in the same amino acid change, was also found.","['missense', 'mutation', 'at', 'codon', '_num_', 'c', 'a', 'resulting', 'in', 'the', 'same', 'amino', 'acid', 'change', 'was', 'also', 'found']"
397,1.0,"In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII mutation).","['in', 'this', 'preclinical', 'study', 'the', '_gene_', 'inhibitor', '_chemical_', 'had', 'an', 'effect', 'on', 'cell', 'viability', 'self', 'renewal', 'and', 'proliferation', 'in', '_gene_', 'amplified', '_disease_', 'cells', 'in', 'vitro', 'and', 'in', 'vivo', 'with', 'or', 'without', 'the', 'egfrviii', 'mutation']"
398,1.0,"Ba/F3 cells expressing EML4-ALK with 1151 Tins treated with alectinib had an IC50 of 165.7 nM, 16x higher than those expressing EML4-ALK wildtype variant 1.","['ba', '_abbrev_', 'cells', 'expressing', '_chemical_', 'with', '_num_', 'tins', 'treated', 'with', '_chemical_', 'had', 'an', '_abbrev_', 'of', '_num_', '_unit_', '16x', 'higher', 'than', 'those', 'expressing', '_chemical_', 'wildtype', 'variant', '_num_']"
399,1.0,"In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab.","['in', 'this', 'study', '_gene_', 'underexpression', 'was', 'associated', 'with', 'an', 'epithelial', 'to', '_disease_', 'transition', 'and', 'resistance', 'to', '_gene_', 'directed', 'treatment', 'with', '_chemical_']"
400,1.0,"SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicating a sensitivity to gemcitabine.","['_abbrev_', 'cells', 'with', '_gene_', 'expression', 'knocked', 'down', 'displayed', 'lower', '_abbrev_', 'p=', '_num_', 'indicating', 'a', 'sensitivity', 'to', '_chemical_']"
401,1.0,In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.,"['in', '3t3', 'fibroblasts', 'expressing', 'the', '_abbrev_', 'mutation', 'have', 'to', 'be', 'sensitive', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_chemical_']"
402,1.0,These cells remained sensitive to rapamycin and RapaLink-1 in vitro and in mouse xenografts.,"['these', 'cells', 'remained', 'sensitive', 'to', '_gene_', 'and', '_abbrev_', 'in', 'vitro', 'and', 'in', 'mouse', 'xenografts']"
403,1.0,"In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild type.","['in', '_num_', '_disease_', 'patients', 'with', '_disease_', '_range_', 'years', 'those', 'who', 'had', 'mutations', 'in', '_gene_', '_ineq_', 'had', 'shorter', 'event', 'free', 'survival', '_num_', 'vs', '_num_', 'p', '_num_', 'and', 'relapse', 'free', 'survival', '_num_', 'vs', '_num_', '_p_val_', 'relative', 'to', 'wild', 'type']"
404,1.0,Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK.,"['histopathological', 'analysis', 'showed', 'diffuse', 'tumor', 'cell', 'infiltrate', '_abbrev_', 'negative', 'with', 'cytoplasmic', '_gene_']"
405,1.0,"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', '_abbrev_', '_gene_', 'cell', 'line', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment']"
406,1.0,"FCGR3A V158F carriers did not have a significantly different response rate, progression-free survival, or overall survival.","['_gene_', '_mutation_', 'carriers', 'did', 'not', 'have', 'a', 'significantly', 'different', 'response', 'rate', 'progression', 'free', 'survival', 'or', 'overall', 'survival']"
407,1.0,A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).,"['a', 'total', 'of', '_num_', 'unrelated', 'cases', 'of', 'ewing', ""'s"", 'sarcoma', 'were', 'examined', 'and', '_num_', 'we', 'found', 'to', 'harbor', 'the', 't', '_num_', '_num_', '_abbrev_', '_gene_', 'chromosomal', 'abnormality', 'ews', '_gene_']"
408,1.0,Thus a total of 19 (46% of 41) achieved clinical benefit.,"['thus', 'a', 'total', 'of', '_num_', '_num_', 'of', '_num_', 'achieved', 'clinical', 'benefit']"
409,1.0,"In vitro, the double mutation was resistant to lorlatinib but sensitive to crizotinib.","['in', 'vitro', 'the', 'double', 'mutation', 'was', 'resistant', 'to', 'lorlatinib', 'but', 'sensitive', 'to', '_chemical_']"
410,1.0,"One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response.","['_num_', 'response', 'was', 'observed', 'however', 'approximately', 'half', 'the', 'patients', 'had', 'tumor', 'regression', 'that', 'did', 'not', 'meet', 'the', 'standard', 'criteria', 'for', 'a', 'partial', 'response']"
411,1.0,"TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin).","['_gene_', 'mutations', 'were', 'associated', 'with', 'an', 'improved', 'response', 'to', 'preoperative', 'treatment', 'of', 'a', 'modified', '_gene_', 'protocol', 'combination', 'of', 'doxorubicin', '_chemical_', 'and', '_disease_']"
412,1.0,Increased CCND1 expression was not correlated with sensitivity to palbociclib (p=0.671).,"['increased', '_gene_', 'expression', 'was', 'not', 'correlated', 'with', 'sensitivity', 'to', '_chemical_', '_p_val_']"
413,1.0,COS7 cell lines transfected with BCR-ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity.,"['_abbrev_', 'cell', 'lines', 'transfected', 'with', '_gene_', 'constructs', 'harboring', '_mutation_', 'mutations', 'were', 'shown', 'to', 'be', 'resistant', 'to', '_chemical_', 'and', 'exhibited', 'increased', 'kinase', 'activity']"
414,1.0,"ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.","['_gene_', 'kinase', 'inhibitor', '_chemical_', 'induced', 'cell', 'death', 'in', '_gene_', 'cells', 'at', 'low', 'nanomolar', 'concentrations', 'while', 'it', 'did', 'not', 'significantly', 'effect', 'the', '_gene_', 'rearrangement', 'negative', '_disease_', 'cell', 'line', '_abbrev_']"
415,1.0,"The resulting cell line H3122 CR2 had IC50 10x greater to crizotinib than parental H3122, and was found to contain 1151 insT mutation.","['the', 'resulting', 'cell', 'line', '_abbrev_', '_gene_', 'had', '_abbrev_', '10x', 'greater', 'to', '_chemical_', 'than', 'parental', '_abbrev_', 'and', 'was', 'found', 'to', 'contain', '_num_', 'inst', 'mutation']"
416,0.0,Crystal structure predicted ROS1 L2155S mutation to be highly destabilizating and cause protein structural modification.,"['crystal', 'structure', 'predicted', '_gene_', '_mutation_', 'mutation', 'to', 'be', 'highly', 'destabilizating', 'and', 'cause', 'protein', 'structural', 'modification']"
417,1.0,Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248.,"['murine', 'ba', '_abbrev_', 'cells', 'with', '_gene_', '_mutation_', 'mutation', 'were', 'assessed', 'as', 'not', 'sensitive', 'to', '_chemical_']"
418,1.0,"Two of the other six cell lines had stop codons leading to a truncated protein, and three had missense mutations with evidence of protein expression on western blot (two cell lines with a P114L mutation and one with an E88K mutation).","['_num_', 'of', 'the', 'other', '_num_', 'cell', 'lines', 'had', 'stop', 'codons', 'leading', 'to', 'a', 'truncated', 'protein', 'and', '_num_', 'had', 'missense', 'mutations', 'with', 'evidence', 'of', 'protein', 'expression', 'on', 'western', 'blot', '_num_', 'cell', 'lines', 'with', 'a', '_mutation_', 'mutation', 'and', '_num_', 'with', 'an', '_mutation_', 'mutation']"
419,1.0,IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild type IDH1.,"['_gene_', '_abbrev_', 'mutation', 'in', 'patients', 'with', '_disease_', 'is', 'not', 'associated', 'with', 'any', 'prognostic', 'value', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
420,1.0,"Loss of functional p16INK4A (CDKN2A) due to gene deletion (49% of cells), methylation (4% of cells), or mutation (19% of cells) was the most prevalent alteration occurring in 71% of cell lines, and significantly correlated with PD0332991 sensitivity (Fisher's exact test P < 0.02).","['loss', 'of', 'functional', '_gene_', '_gene_', 'due', 'to', 'gene', 'deletion', '_num_', 'of', 'cells', 'methylation', '_num_', 'of', 'cells', 'or', 'mutation', '_num_', 'of', 'cells', 'was', 'the', 'most', 'prevalent', 'alteration', 'occurring', 'in', '_num_', 'of', 'cell', 'lines', 'and', 'significantly', 'correlated', 'with', '_chemical_', 'sensitivity', 'fisher', ""'s"", 'exact', 'test', 'p', '_num_']"
421,1.0,"43 B-CLL patients with LoH or reduced protein levels (<50% normal expression, radioimmunoassay, western blot) of ATM were found to have significantly shorter overall survival (35.6 vs. 97.3 months; P=0.003) when compared to 108 patients with normal expression levels.","['_num_', '_disease_', 'patients', 'with', 'loh', 'or', 'reduced', 'protein', 'levels', '_num_', 'normal', 'expression', 'radioimmunoassay', 'western', 'blot', 'of', 'atm', 'were', 'found', 'to', 'have', 'significantly', 'shorter', 'overall', 'survival', '_num_', 'vs', '_num_', 'months', '_p_val_', 'when', 'compared', 'to', '_num_', 'patients', 'with', 'normal', 'expression', 'levels']"
422,1.0,Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).,"['cytoplasmic', 'localization', 'of', '_gene_', 'in', '_disease_', 'patients', 'was', 'an', 'independent', 'prognositic', 'factor', 'associated', 'with', 'complete', 'remission', 'in', 'response', 'to', 'induction', 'therapy', 'in', 'a', 'multivariate', 'analysis', '_p_val_', 'but', 'not', 'in', 'a', 'univariate', 'analysis', '_p_val_']"
423,1.0,Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.,"['primary', 'chemotherapy', 'resistant', '_disease_', 'cell', 'lines', 'harbouring', '_gene_', 'gene', 'amplification', 'were', 'sensitive', 'to', '_chemical_', 'exposure', 'and', 'significantly', 'more', 'sensitive', 'than', 'non', 'amplified', 'cell', 'lines']"
424,1.0,"WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML.","['_gene_', 'mutations', 'were', 'a', 'negative', 'prognostic', 'factor', 'for', 'overall', 'survival', 'in', 'young', '_num_', '60+', 'median', '_num_', 'patients', 'with', 'cytogenetically', 'normal', '_disease_']"
425,1.0,"These results were based on three KRAS mutant cell lines (LS180, LoVo and HCT116) and two KRAS wild type cell lines (SW48 and CaCo2).","['these', 'results', 'were', 'based', 'on', '_num_', '_gene_', 'mutant', 'cell', 'lines', '_abbrev_', '_chemical_', 'and', '_abbrev_', 'and', '_num_', '_gene_', 'wild', 'type', 'cell', 'lines', '_abbrev_', 'and', '_chemical_']"
426,1.0,"Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations.","['breast', 'cancer', 'cell', 'lines', 'with', 'the', '_gene_', '_mutation_', 'mutation', 'did', 'not', 'show', 'sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_', 'unlike', 'cell', 'lines', 'with', '_gene_', 'mutations']"
427,1.0,SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation.,"['_gene_', 'cell', 'line', 'was', 'lentivirally', 'transduced', 'with', '_gene_', '_mutation_', 'or', '_mutation_', 'mutation']"
428,1.0,"The patient was treated with 22 days of sunitinib, permitting the patient to undergo a bone marrow transplant.","['the', 'patient', 'was', 'treated', 'with', '_num_', 'days', 'of', '_chemical_', 'permitting', 'the', 'patient', 'to', 'undergo', 'a', 'bone', 'marrow', 'transplant']"
429,1.0,"In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis.","['in', 'a', 'study', 'of', '_num_', 'ewing', 'sarcoma', 'tumors', '_num_', 'showed', 'heterogenous', 'loss', 'of', '_gene_', 'expression', 'in', '_gene_', 'analysis']"
430,1.0,"Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strongly inhibited by the BET inhibitors.","['proliferation', 'of', '_num_', 'cell', 'lines', '_abbrev_', '_abbrev_', 'and', '_abbrev_', 'but', 'not', '_chemical_', 'only', 'partial', 'inhibition', 'was', 'strongly', 'inhibited', 'by', 'the', 'bet', 'inhibitors']"
431,1.0,"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222).","['_num_', 'patients', 'with', 'advanced', 'unresectable', 'gists', 'were', 'enrolled', 'onto', 'a', 'randomized', 'phase', 'ii', 'clinical', 'study', 'of', '_chemical_', '_abbrev_']"
432,1.0,"High pretreatment p21 (CDKN1A) expression was significantly associated with non-pCR (p = 0.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p = 0.002).","['high', 'pretreatment', '_gene_', '_gene_', 'expression', 'was', 'significantly', 'associated', 'with', 'non', 'pcr', 'p', '_num_', 'and', 'poor', 'disease', 'free', 'survival', 'median', '_disease_', 'low', 'vs', 'high', '_gene_', '_num_', 'vs', '_num_', 'months', 'p', '_num_']"
433,1.0,"Mice treated with single therapy of either MDV3100, BYL719, or AZD8186 resulted in mild tumor growth inhibition of 90%, 36%, and 40% respectively (n=5 mice/group).","['mice', 'treated', 'with', 'single', 'therapy', 'of', 'either', '_chemical_', '_chemical_', 'or', '_chemical_', 'resulted', 'in', 'mild', 'tumor', 'growth', 'inhibition', 'of', '_num_', '_num_', 'and', '_num_', 'respectively', '_gene_', 'mice', 'group']"
434,1.0,"In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation.","['in', 'a', 'study', 'of', '_num_', 'anaplastic', 'oligodendroglial', 'tumors', '_num_', 'samples', 'had', '_gene_', 'promoter', 'methylation']"
435,1.0,Patients with stable disease (SD; RECIST; n=26) were randomly assigned to cabozantinib (n=13) or placebo (n=13).,"['patients', 'with', 'stable', 'disease', 'sd', '_disease_', '_ineq_', 'were', 'randomly', 'assigned', 'to', '_chemical_', '_ineq_', 'or', 'placebo', '_ineq_']"
436,1.0,"Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements.","['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'patient', 'with', 'advanced', '_disease_', 'cell', 'carcinoma', 'of', 'the', 'lung', 'that', 'tested', 'negative', 'for', '_gene_', '_gene_', 'and', '_gene_', 'mutations', 'and', '_gene_', 'and', '_gene_', 'rearrangements']"
437,1.0,"In regimen B, survival increased significantly in patients with low RRM1 expression as compared to those with a high expression (P=0.046).","['in', 'regimen', 'b', 'survival', 'increased', 'significantly', 'in', 'patients', 'with', 'low', '_gene_', 'expression', 'as', 'compared', 'to', 'those', 'with', 'a', 'high', 'expression', '_p_val_']"
438,1.0,"ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology, 'PP1' because of segregation results, and 'PS3' because in-vitro studies demonstrated this variant was unable to perform normal cellular functions (downregulate JunB).","['acmg', 'evidence', 'codes', ""'pp4"", 'because', 'the', 'patients', 'phenotypes', 'and', 'family', 'history', 'are', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'single', 'genetic', 'etiology', ""'pp1"", 'because', 'of', 'segregation', 'results', 'and', ""'ps3"", 'because', 'in', 'vitro', 'studies', 'demonstrated', 'this', 'variant', 'was', 'unable', 'to', 'perform', 'normal', 'cellular', 'functions', 'downregulate', '_gene_']"
439,1.0,Researchers studied the effect of CIP2A expression in relation to  gemcitabine sensitivity via SW1990 cell lines.,"['researchers', 'studied', 'the', 'effect', 'of', '_gene_', 'expression', 'in', 'relation', 'to', '_chemical_', 'sensitivity', 'via', '_abbrev_', 'cell', 'lines']"
440,1.0,MET amplification was also present in a subset of tumor cells in the pretreatment sample.,"['met', 'amplification', 'was', 'also', 'present', 'in', 'a', 'subset', 'of', 'tumor', 'cells', 'in', 'the', 'pretreatment', 'sample']"
441,1.0,41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate.,"['_num_', 'patients', 'received', '_num_', '_unit_', '_chemical_', '_disease_', 'until', 'disease', 'progression', 'and', 'the', 'primary', 'endpoint', 'was', 'objective', 'response', 'rate']"
442,1.0,74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC).,"['_num_', 'patients', 'with', 'stage', 'iii', '_disease_', 'treated', 'with', 'concurrent', 'chemoradiotherapy', 'were', 'retrospectively', 'analyzed', 'for', '_gene_', 'expression', 'and', '_gene_', '_disease_', 'lymphocytes', '_disease_', 'density', '_gene_']"
443,1.0,There was 1 complete response.,"['there', 'was', '_num_', 'complete', 'response']"
444,1.0,"Break apart FISH assay, which does not distinguish ROS1-fusion partner, was used on the tissue microarray to determine ROS1 fusion status.","['break', 'apart', 'fish', 'assay', 'which', 'does', 'not', 'distinguish', '_abbrev_', 'partner', 'was', 'used', 'on', 'the', 'tissue', 'microarray', 'to', 'determine', '_gene_', 'fusion', 'status']"
445,1.0,"In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor ponatinib (AP24534) than the FGFR2 wild type cell line (Ishikawa) and human embryonic kidney cell line (HEK293).","['in', 'cell', 'proliferation', 'assays', 'the', '_num_', '_gene_', 'mutant', 'cell', 'lines', 'were', 'more', 'sensitive', 'to', 'the', 'pan', 'fgfr', 'inhibitor', '_chemical_', '_chemical_', 'than', 'the', '_gene_', 'wild', 'type', 'cell', 'line', 'ishikawa', 'and', 'human', 'embryonic', 'kidney', 'cell', 'line', '_abbrev_']"
446,1.0,Patient then received alectinib and exhibited partial response however liver metastasis presented after 12 months on alectinib.,"['patient', 'then', 'received', '_chemical_', 'and', 'exhibited', 'partial', 'response', 'however', 'liver', 'metastasis', 'presented', 'after', '_num_', 'months', 'on', '_chemical_']"
447,1.0,ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line.,"['_gene_', 'kinase', 'domain', 'mutations', 'were', 'assessed', 'in', '_num_', 'patients', 'with', 'stage', 'iiia', 'iv', 'pulmonary', 'adenocarcinoma', 'and', 'a', 'cell', 'line']"
448,1.0,"After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response with the third generation ALK-inhibitor lorlatinib.","['after', 'developing', 'resistance', 'to', '_num_', 'and', '_num_', 'line', '_gene_', 'inhibitors', 'mediated', 'by', 'a', '_mutation_', 'mutation', 'the', 'patient', 'had', 'a', 'partial', 'response', 'with', 'the', '_num_', 'generation', '_gene_', 'inhibitor', 'lorlatinib']"
449,1.0,"In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated.","['in', 'all', 'cases', 'samples', 'from', 'both', 'parents', 'were', 'not', 'available', 'and', 'evidence', 'of', 'de', 'novo', 'mutations', 'could', 'not', 'further', 'be', 'evaluated']"
450,1.0,"Of 65 VHL families from central Europe, 53 were identified with germline mutations.","['of', '_num_', '_gene_', 'families', 'from', 'central', 'europe', '_num_', 'were', 'identified', 'with', 'germline', 'mutations']"
451,1.0,One of these patients also harbored a L1196M mutation.,"['_num_', 'of', 'these', 'patients', 'also', 'harbored', 'a', '_mutation_', 'mutation']"
452,1.0,"This missense mutation was found in 2 unrelated, German families.","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'unrelated', 'german', 'families']"
453,1.0,A 28 year old patient with T4N3M1 stage lung adenocarcinoma harboring an EML4-ALK variant 1 fusion was treated with crizotinib after failing conventional therapy.,"['a', '_num_', 'year', 'old', 'patient', 'with', '_abbrev_', 'stage', 'lung', 'adenocarcinoma', 'harboring', 'an', '_chemical_', 'variant', '_num_', 'fusion', 'was', 'treated', 'with', '_chemical_', 'after', 'failing', 'conventional', 'therapy']"
454,1.0,"Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status), no responses were observed and overall survival was 9.3 months with a median progression-free survival of 4.5 months.","['of', 'the', '_num_', 'patients', 'with', 'colorectal', 'cancer', '_num_', '_gene_', '_mutation_', '_num_', '_abbrev_', 'unknown', 'status', 'no', 'responses', 'were', 'observed', 'and', 'overall', 'survival', 'was', '_num_', 'months', 'with', 'a', 'median', 'progression', 'free', 'survival', 'of', '_num_', 'months']"
455,1.0,"Right upper extremity (RUE), scalp, and multiple lung lesions were apparent.","['right', 'upper', 'extremity', 'rue', 'scalp', 'and', 'multiple', 'lung', 'lesions', 'were', 'apparent']"
456,1.0,In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.,"['in', '_disease_', 'cells', 'er', 'positive', 'breast', 'cancer', 'cells', 'with', 'amplified', '_gene_', '_chemical_', 'potently', 'inhibited', 'cell', 'growth', 'with', 'a', '_gene_', 'value', 'of', '_num_', '_unit_', '_unit_', 'and', 'inhibited', '_gene_', '_disease_', 'with', 'an', '_abbrev_', 'value', 'of', '_num_', '_unit_', '_unit_']"
457,1.0,"In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt.","['in', 'a', 'randomized', '_disease_', 'phase', '_num_', 'trial', '_num_', 'patients', 'with', '_disease_', 'previously', 'untreated', '_disease_', 'including', 'asympt']"
458,1.0,Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.,"['ectopic', 'expression', 'of', 'engineered', 'cdna', 'in', '293h', 'cells', 'showed', 'that', '_chemical_', 'led', 'to', 'reduced', '_gene_', '_disease_', 'in', 'fusion', 'positive', 'cells', 'whereas', '_chemical_', 'was', 'not', 'effective']"
459,0.0,The combination of MEK and CDK4/6 inhibition inhibited cancer cell growth and caused cell regression in a synergistic manner Combination therapy markedly decreased levels of phosphorylated ribosomal protein S6 both in vitro and in vivo and decreased Ki67 staining in vivo.,"['the', 'combination', 'of', 'mek', 'and', '_gene_', 'inhibition', 'inhibited', 'cancer', 'cell', 'growth', 'and', 'caused', 'cell', 'regression', 'in', 'a', 'synergistic', 'manner', 'combination', 'therapy', 'markedly', 'decreased', 'levels', 'of', 'phosphorylated', 'ribosomal', 'protein', '_gene_', 'both', 'in', 'vitro', 'and', 'in', 'vivo', 'and', 'decreased', '_gene_', 'staining', 'in', 'vivo']"
460,1.0,IDH2 R172 mutations were frequently observed in patients with the angioimmunoblastic T-cell lymphoma subtype of peripheral T-cell lymphomas but not observed in other subtypes.,"['_gene_', '_abbrev_', 'mutations', 'were', 'frequently', 'observed', 'in', 'patients', 'with', 'the', '_disease_', '_disease_', 'lymphoma', 'subtype', 'of', 'peripheral', '_disease_', 'lymphomas', 'but', 'not', 'observed', 'in', 'other', '_disease_']"
461,1.0,This missense mutation was found in two VHL type 1 family members (patient no V252).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'family', 'members', 'patient', 'no', '_abbrev_']"
462,1.0,"A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas).","['a', 'total', 'of', '_num_', 'primary', 'liver', 'tumors', 'were', 'studied', 'by', '_disease_', '_num_', 'fibrolamellar', 'carcinomas', '_num_', 'conventional', '_disease_', 'carcinomas', '_num_', '_disease_', '_num_', 'hepatic', 'adenomas', 'and', '_num_', '_disease_']"
463,1.0,Trastuzumab monotheraby was then administered.,"['_chemical_', 'monotheraby', 'was', 'then', 'administered']"
464,1.0,"In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established.","['in', 'the', 'phase', 'i', 'study', 'profile', '_num_', '_abbrev_', 'a', 'recommended', '_chemical_', 'dose', 'of', '_num_', '_unit_', 'twice', 'daily', 'for', '_num_', 'day', 'cycles', 'was', 'established']"
465,1.0,Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).,"['xenografts', 'established', 'from', 'breast', 'cancer', 'cell', 'lines', 'with', '_gene_', 'amplification', 'and', '_gene_', 'mutation', '_abbrev_', 'or', '_gene_', 'mutation', 'alone', '_chemical_', 'were', 'effectively', 'inhibited', 'in', 'vivo', 'with', 'an', '_abbrev_', '_abbrev_', 'naphthyridinone']"
466,1.0,Progression free survival (PFS) was the primary endpoint.,"['progression', 'free', 'survival', '_disease_', 'was', 'the', 'primary', 'endpoint']"
467,1.0,This finding was independent of IGHV mutation status.,"['this', 'finding', 'was', 'independent', 'of', '_gene_', 'mutation', 'status']"
468,1.0,4 patients with mutant alleles of NF1 were identified among patients relapsed after vemurafenib.,"['_num_', 'patients', 'with', 'mutant', 'alleles', 'of', '_gene_', 'were', 'identified', 'among', 'patients', 'relapsed', 'after', '_chemical_']"
469,1.0,"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were  treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild type EGFR(median 9.1 versus 2.1).","['_num_', '_disease_', 'patients', 'with', 'stage', 'iiib', 'iv', 'chemotherapy', 'resistant', 'tumors', 'were', 'treated', 'with', '_chemical_', 'and', 'the', '_mutation_', '_gene_', 'mutation', 'was', 'associated', 'with', 'longer', 'time', 'to', 'treatment', 'failure', 'than', 'those', 'with', 'wild', 'type', '_gene_', 'median', '_num_', 'vs', '_num_']"
470,1.0,The MYD88 L265P mutation was present in 56 patients (89%).,"['the', '_gene_', '_mutation_', 'mutation', 'was', 'present', 'in', '_num_', 'patients', '_num_']"
471,1.0,Partial response with erlotinib was achieved for 15 months after initial chemotherapy.,"['partial', 'response', 'with', '_chemical_', 'was', 'achieved', 'for', '_num_', 'months', 'after', 'initial', 'chemotherapy']"
472,1.0,A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer.,"['a', 'quantitative', '_disease_', 'analysis', 'was', 'performed', 'to', 'assess', 'optimal', 'ihc', 'calculated', 'cutoff', 'values', 'for', 'the', 'prognostic', 'use', 'of', '_disease_', '_chemical_', '_gene_', 'in', 'breast', 'cancer']"
473,1.0,CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2.,"['_chemical_', 'and', 'to', 'a', 'lesser', 'extent', '_abbrev_', '_disease_', 'cell', 'lines', 'expressing', 'the', '_gene_', '_mutation_', 'mutation', 'had', 'increased', 'resistance', 'to', '_disease_', 'and', '_disease_', 'treatment', 'than', 'cells', 'expressing', 'wildtype', '_gene_']"
474,1.0,"In one of these patients, they identified the L505H mutation.","['in', '_num_', 'of', 'these', 'patients', 'they', 'identified', 'the', '_mutation_', 'mutation']"
475,0.0,"Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4.","['specifically', 'the', 'phial', 'algorithm', 'nominated', 'this', 'variant', 'as', 'actionable', 'on', 'the', 'basis', 'of', 'a', 'predicted', 'synthetic', 'lethal', 'relationship', 'between', 'activated', '_gene_', 'and', '_gene_']"
476,1.0,Those with amplification had worse overall and disease-free survival.,"['those', 'with', 'amplification', 'had', 'worse', 'overall', 'and', '_disease_', 'survival']"
477,1.0,Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene.,"['whole', 'genome', 'sequencing', 'of', 'a', 'case', 'of', 'colon', 'carcinoma', 'revealed', 'a', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'gene']"
478,1.0,"In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 μM; SNU-1041, 20.65 μM; FaDu, 19.67 μM; SCC25, 49.30 μM).","['in', 'a', 'panel', 'of', 'head', 'and', 'neck', 'cancer', 'cell', 'lines', '_num_', 'lines', 'containing', 'the', '_gene_', 'mutation', '_mutation_', '_abbrev_', 'and', '_abbrev_', 'were', 'more', 'sensitive', 'to', 'growth', 'inhibition', '_abbrev_', '_num_', 'and', '_num_', 'by', 'the', '_gene_', 'specific', 'inhibitor', '_chemical_', 'alepelisib', 'than', '_num_', 'of', '_num_', 'lines', 'with', 'wild', 'type', '_gene_', '_abbrev_', '_abbrev_', '_num_', 'μm', '_abbrev_', '_num_', 'μm', '_chemical_', '_num_', 'μm', '_gene_', '_num_', 'μm']"
479,1.0,A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients.,"['a', '_disease_', 'analysis', 'of', 'the', 'role', 'of', '_gene_', 'expression', 'in', 'breast', 'cancer', 'found', '_num_', 'relevant', 'studies', 'with', 'a', 'total', '_num_', 'patients']"
480,1.0,"Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML.","['rates', 'of', 'complete', 'remission', 'and', 'refractory', 'disease', 'are', 'not', 'different', 'in', 'patients', 'with', '_gene_', 'mutations', '_num_', 'exon', '_num_', '_num_', 'exon', '_num_', 'than', 'those', 'without', 'in', 'young', '_range_', 'patients', 'with', 'cytogenetically', 'normal', '_disease_']"
481,1.0,"In patients with wild type K-ras tumors, treatment with cetuximab as compared with supportive care alone significantly improved overall survival.","['in', 'patients', 'with', 'wild', 'type', '_gene_', 'tumors', 'treatment', 'with', '_chemical_', 'as', 'compared', 'with', 'supportive', 'care', 'alone', 'significantly', 'improved', 'overall', 'survival']"
482,1.0,"Alectinib was generally well tolerated, and we conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC.","['_chemical_', 'was', 'generally', 'well', 'tolerated', 'and', 'we', 'conclude', 'that', '_chemical_', 'compared', 'favorably', 'to', '_chemical_', 'and', 'could', 'be', 'an', 'effective', 'and', 'safe', 'option', 'in', '_gene_', 'rearranged', '_disease_']"
483,1.0,"GNAS 393C homozygous patients of pT2-4 stages displayed a significantly lower risk for death than T393 homozygous patients, with heterozygous patients being at intermediate risk.","['_gene_', '393c', 'homozygous', 'patients', 'of', '_abbrev_', 'stages', 'displayed', 'a', 'significantly', 'lower', 'risk', 'for', 'death', 'than', '_abbrev_', 'homozygous', 'patients', 'with', 'heterozygous', 'patients', 'being', 'at', 'intermediate', 'risk']"
484,1.0,"In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors).","['in', 'this', 'retrospective', 'analysis', 'of', 'the', 'spectrum', 'trial', '_gene_', '_gene_', 'expression', 'and', '_disease_', 'was', 'not', 'predictive', 'of', 'response', 'to', '_gene_', 'targeted', 'therapy', 'in', 'combination', 'with', 'chemotherapy', 'n', '_num_', 'patient', 'tumors']"
485,1.0,Two patients were identified with retinal angiomas and hemangioblastomas of the central nervous system.,"['_num_', 'patients', 'were', 'identified', 'with', 'retinal', 'angiomas', 'and', '_disease_', 'of', 'the', 'central', 'nervous', 'system']"
486,1.0,This subset of patients had median progression free survival of 4.2 months.,"['this', 'subset', 'of', 'patients', 'had', 'median', 'progression', 'free', 'survival', 'of', '_num_', 'months']"
487,1.0,"This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).","['this', 'patient', 'population', 'has', 'not', 'seen', 'many', 'studies', 'responds', 'poorly', 'to', 'late', 'line', 'treatment', 'with', '_chemical_', 'and', 'in', 'this', 'study', 'was', 'treated', 'with', '_chemical_', '_chemical_', '_disease_', '_ineq_', 'vs', 'physician', ""'s"", 'choice', 'usually', '_chemical_', 'plus', 'chemotherapy', '_ineq_']"
488,1.0,STAG2-negativity was associated with lower histological grade (p = 0.009).,"['_abbrev_', 'was', 'associated', 'with', 'lower', 'histological', 'grade', 'p', '_num_']"
489,1.0,"In a pedigree with familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) spanning three generations, five members of generation II were sequenced at exons 3, 4 and 5 of the RUNX1 (or CBFA2) gene and the D198Y mutation (in the DNA binding RUNT domain) was found in 3/5 of the individuals with FPD/AML but not in 2/5 without FPD/AML.","['in', 'a', 'pedigree', 'with', 'familial', 'platelet', 'disorder', 'with', 'predisposition', 'to', 'acute', 'myeloid', 'leukemia', '_disease_', 'spanning', '_num_', 'generations', '_num_', 'members', 'of', 'generation', 'ii', 'were', 'sequenced', 'at', 'exons', '_num_', '_num_', 'and', '_num_', 'of', 'the', '_gene_', 'or', '_gene_', 'gene', 'and', 'the', '_mutation_', 'mutation', 'in', 'the', 'dna', 'binding', 'runt', 'domain', 'was', 'found', 'in', '_ratio_', 'of', 'the', 'individuals', 'with', '_disease_', 'but', 'not', 'in', '_ratio_', 'without', '_disease_']"
490,1.0,"When FGFR1, FGF3 and FGFR2 amplifications were combined, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.","['when', '_gene_', '_gene_', 'and', '_gene_', 'amplifications', 'were', 'combined', 'a', 'combined', '_gene_', 'pathway', 'amplified', 'patient', 'group', 'had', 'a', 'higher', 'mean', 'reduction', 'in', 'target', 'lesion', 'size', 'than', 'patients', 'with', '_gene_', 'non', 'amplified', 'tumors']"
491,1.0,This mutation was found in 2 family members with VHL disease (family ID 4402).,"['this', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'disease', 'family', 'id', '_num_']"
492,1.0,Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.,"['_chemical_', 'chemotherapy', 'group', 'compositions', '_num_', '_num_', '_num_', '_num_', 'del', '_num_', '_num_', '_num_', '_num_', '_mutation_', '_num_', '_num_', '_num_', '_num_', 'uncommon']"
493,1.0,Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.,"['_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'poor', 'prognosis', 'in', 'gastric', 'cancers']"
494,1.0,"Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma.","['based', 'on', 'a', '_disease_', 'analysis', 'of', '_num_', 'trials', '_num_', 'patients', 'of', 'which', '_num_', 'studies', '_num_', 'patients', 'included', 'melanoma', '_gene_', 'expression', 'was', 'associated', 'with', 'a', 'higher', 'orr', 'rate', 'in', 'patients', 'with', 'melanoma']"
495,1.0,"A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was ""pan-negative"" for driver mutations.","['a', '_abbrev_', 'fusion', 'was', 'identified', 'in', 'a', 'single', 'patient', 'with', 'metastatic', 'melanoma', 'that', 'was', 'pan', 'negative', 'for', 'driver', 'mutations']"
496,1.0,The primary end point was objective response rate.,"['the', 'primary', 'end', 'point', 'was', 'objective', 'response', 'rate']"
497,1.0,8381 women were randomized to one of four treatment arms.,"['_num_', 'women', 'were', 'randomized', 'to', '_num_', 'of', '_num_', 'treatment', 'arms']"
498,1.0,"Further, in an in vivo study, MCF7 xenografts expressing PIK3CA E545K were reportedly sensitive to ado-trastuzumab emtansine, as assessed by tumor growth.","['further', 'in', 'an', 'in', 'vivo', 'study', '_chemical_', 'xenografts', 'expressing', '_gene_', '_mutation_', 'were', 'reportedly', 'sensitive', 'to', 'ado', '_chemical_', '_chemical_', 'as', 'assessed', 'by', 'tumor', 'growth']"
499,0.0,"The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.","['the', 'investigators', 'note', 'that', 'in', 'other', '_gene_', 'cancers', 'such', 'as', 'breast', 'and', 'gastrointestinal', '_chemical_', 'in', 'combination', 'with', 'chemotherapy', 'has', 'been', 'found', 'most', 'effective', 'and', 'could', 'warrant', 'more', 'study']"
500,1.0,EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.,"['_gene_', 'overexpression', 'was', 'correlated', 'with', 'longer', 'overall', 'survival', 'in', 'patients', 'with', 'advanced', '_disease_', 'treated', 'with', '_num_', 'line', 'chemotherapy', 'and', '_chemical_', 'than', 'those', 'treated', 'with', '_num_', 'line', 'chemotherapy', 'alone']"
501,1.0,"The V1180L mutation in the kinase domain of rearranged ALK was found in an alectinib resistant cell line named H3122 CHR-A1, which was derived from the alectinib sensitive EML4-ALK variant 1 containing NSCLC cell line H3122 by passaging into higher concentrations of alectinib.","['the', '_mutation_', 'mutation', 'in', 'the', 'kinase', 'domain', 'of', 'rearranged', '_gene_', 'was', 'found', 'in', 'an', '_chemical_', 'resistant', 'cell', 'line', 'named', '_abbrev_', '_abbrev_', 'which', 'was', 'derived', 'from', 'the', '_chemical_', 'sensitive', '_chemical_', 'variant', '_num_', 'containing', '_disease_', 'cell', 'line', '_abbrev_', 'by', 'passaging', 'into', 'higher', 'concentrations', 'of', '_chemical_']"
502,1.0,"Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation.","['prior', 'to', 'the', 'development', 'of', 'the', '_gene_', '_mutation_', 'mutation', 'the', 'patient', 'was', 'treated', 'with', '_chemical_', 'and', 'achieved', 'a', 'partial', 'response', 'but', 'subsequently', 'tumor', 'progression', 'occurred', 'however', 'osimertinib', 'treatment', 'resulted', 'a', 'favorable', 'tumor', 'response', 'with', 'the', 'extinguishment', 'of', 'the', '_gene_', '_mutation_', 'mutation']"
503,1.0,"The second patient (M, 76, smoker) was treated with erlotinib and had stable disease as response, PFS of 2.6 months, OS of 2.6 months and was alive at study end.","['the', '_num_', 'patient', '_unit_', '_num_', 'smoker', 'was', 'treated', 'with', '_chemical_', 'and', 'had', 'stable', 'disease', 'as', 'response', '_disease_', 'of', '_num_', 'months', 'os', 'of', '_num_', 'months', 'and', 'was', 'alive', 'at', 'study', 'end']"
504,1.0,"In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS.","['in', 'patients', 'with', 'stage', 'iv', 'melanoma', 'nras', 'mutation', 'was', 'associated', 'with', 'reduced', 'median', 'survival', 'compared', 'to', 'patients', 'with', 'wildtype', 'nras']"
505,1.0,IHC was performed in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues for protein expression of HEF1 (NEDD9).,"['_gene_', 'was', 'performed', 'in', '_num_', '_disease_', 'carcinoma', 'tissues', 'and', 'their', 'adjacent', 'normal', 'liver', 'tissues', 'for', 'protein', 'expression', 'of', '_gene_', '_gene_']"
506,1.0,The patient was switched to pembrolizumab and major disease progression was noted.,"['the', 'patient', 'was', 'switched', 'to', 'pembrolizumab', 'and', 'major', 'disease', 'progression', 'was', 'noted']"
507,1.0,VHL mutated clear cell carcinoma is associated with Von Hippel-Lindau Disease.,"['_gene_', 'mutated', 'clear', 'cell', 'carcinoma', 'is', 'associated', 'with', '_disease_', 'hippel', 'lindau', 'disease']"
508,1.0,"Treatment of melanoma cells with UNC1062, a novel MERTK-selective small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells.","['treatment', 'of', 'melanoma', 'cells', 'with', '_chemical_', 'a', 'novel', '_gene_', 'selective', 'small', 'molecule', 'tyrosine', 'kinase', 'inhibitor', 'reduced', 'activation', 'of', '_gene_', 'mediated', 'downstream', 'signaling', 'induced', 'apoptosis', 'in', 'culture', 'reduced', 'colony', 'formation', 'in', 'soft', 'agar', 'and', 'inhibited', 'invasion', 'of', 'melanoma', 'cells']"
509,1.0,6 of 89 patients with lung adenocarcinoma had amplification of TTF1.,"['_num_', 'of', '_num_', 'patients', 'with', 'lung', 'adenocarcinoma', 'had', 'amplification', 'of', '_gene_']"
510,1.0,AKT3 was found to be preferentially required for the proliferation and tumor growth of TNBC.,"['_gene_', 'was', 'found', 'to', 'be', 'preferentially', 'required', 'for', 'the', 'proliferation', 'and', 'tumor', 'growth', 'of', '_disease_']"
511,1.0,"1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC.","['_num_', 'patients', 'with', 'breast', 'cancer', 'were', 'evaluated', 'for', '_gene_', 'expression', 'by', '_gene_']"
512,1.0,"In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival (χ (2)=4.775, P=0.029) in patients receiving sorafenib or sunitinib.","['in', '_num_', 'patients', 'with', 'advanced', 'renal', 'cell', 'carcinoma', 'high', 'expression', 'of', 'heme', '_abbrev_', '_gene_', 'was', 'associated', 'with', 'poor', 'overall', 'response', 'rate', '_num_', 'vs', '_num_', 'p', '_num_', 'clinical', 'benefit', 'rate', '_num_', 'vs', '_num_', 'p', '_num_', 'shorter', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', '_p_val_', 'and', 'poor', 'overall', 'survival', 'χ', '_num_', '_ineq_', '_p_val_', 'in', 'patients', 'receiving', '_chemical_', 'or', '_chemical_']"
513,1.0,"Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation.","['using', 'a', 'ratio', 'of', '_gene_', 'wildtype', 'levels', 'as', 'a', 'continuous', 'variable', 'a', 'higher', 'ratio', 'was', 'associated', 'with', 'reduced', 'event', 'free', 'survival', 'in', 'patients', 'with', 'an', '_gene_', 'mutation']"
514,1.0,Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation.,"['cell', 'lines', 'expressing', 'the', '_gene_', '_mutation_', 'mutation', 'responded', 'better', 'to', '_chemical_', 'treatment', 'than', 'cells', 'wildtype', 'for', '_gene_', 'as', 'measured', 'by', 'reduced', 'cellular', 'proliferation', 'and', 'inhibition', 'of', 'met', 'and', '_gene_', '_disease_']"
515,1.0,"On crizotinib, 24 of the patients achieved objective responses including 5 complete responses.","['on', '_chemical_', '_num_', 'of', 'the', 'patients', 'achieved', 'objective', 'responses', 'including', '_num_', 'complete', 'responses']"
516,1.0,"HPO terms: hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts.","['_disease_', 'terms', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts']"
517,1.0,KRAS mutations were identified in 103 patients using cfDNA.,"['_gene_', 'mutations', 'were', 'identified', 'in', '_num_', 'patients', 'using', 'cfdna']"
518,1.0,Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies.,"['_disease_', 'analysis', 'of', '_gene_', '_gene_', 'expression', 'status', 'in', '_num_', 'patients', '_num_', 'studies', 'and', 'response', 'to', '_gene_', 'monoclonal', 'antibodies']"
519,1.0,"Patients with G12C or G12V mutations had a trend towards longer OS, PFS and ORR compared to other KRAS mutations.","['patients', 'with', '_mutation_', 'or', '_mutation_', 'mutations', 'had', 'a', 'trend', 'towards', 'longer', 'os', '_disease_', 'and', 'orr', 'compared', 'to', 'other', '_gene_', 'mutations']"
520,1.0,"During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients.","['during', 'the', 'initiation', 'of', 'the', 'treatment', 'all', '_num_', 'patients', 'had', 'undetectable', 'levels', 'of', '_gene_', '_mutation_', 'mutations', 'however', 'after', 'resistance', 'developed', 'the', 'mutation', 'frequency', 'rose', 'to', '_num_', '_num_', 'and', '_num_', 'in', 'the', '_num_', 'patients']"
521,1.0,The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.,"['the', 'sms', 'kcnr', 'cell', 'line', 'harboring', 'the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
522,1.0,Evaluation of 39 aggressive cutaneous squamous cell carcinomas revealed that tumors with a KMT2C mutation were 5x more likely to invade the bone (53% versus 10%; p=0.008).,"['evaluation', 'of', '_num_', 'aggressive', 'cutaneous', '_disease_', 'cell', 'carcinomas', 'revealed', 'that', 'tumors', 'with', 'a', '_gene_', 'mutation', 'were', '5x', 'more', 'likely', 'to', 'invade', 'the', 'bone', '_num_', 'vs', '_num_', '_p_val_']"
523,1.0,"Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection.","['multivariate', 'analysis', 'identified', '_gene_', 'and', '_gene_', 'mrna', 'expression', 'independent', 'of', 'gender', 'who', 'grade', 'and', 'extent', 'of', 'resection']"
524,1.0,A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.,"['a', 'significant', 'difference', 'in', '_disease_', 'survival', 'was', 'seen', 'with', '_num_', '_disease_', 'events', 'out', 'of', '_num_', 'in', 'the', 'observation', 'arm', 'vs', '_num_', '_disease_', 'events', 'out', 'of', '_num_', 'in', 'the', '_num_', 'year', '_chemical_', 'arm']"
525,1.0,"Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance mutations.","['removing', 'fl', 'or', '_gene_', 'from', 'ligand', 'dependent', 'resistant', 'cultures', 'transiently', 'restored', 'sensitivity', 'to', '_abbrev_', 'but', 'accelerated', 'acquisition', 'of', 'secondary', 'resistance', 'mutations']"
526,1.0,Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants.,"['exon', 'array', 'and', '_disease_', 'was', 'used', 'to', 'screen', 'a', 'panel', 'of', '_num_', '_disease_', 'cell', 'lines', 'for', '_chemical_', 'variants']"
527,1.0,IHC in 36 tumors validated these results at the protein level.,"['_gene_', 'in', '_num_', 'tumors', 'validated', 'these', 'results', 'at', 'the', 'protein', 'level']"
528,1.0,LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab.,"['lux', 'breast', '_num_', 'is', 'a', 'phase', '_num_', 'trial', '_abbrev_', 'which', 'enrolled', '_num_', 'patients', 'with', 'metastatic', '_gene_', 'positive', 'bc', 'who', 'had', 'progressed', 'after', 'adjuvant', 'or', '_num_', 'line', '_chemical_']"
529,1.0,"BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts","['_gene_', 'inhibition', 'supressess', 'growth', 'and', '_disease_', 'of', '_abbrev_', '_abbrev_', '_disease_', 'cells', 'in', 'mouse', 'xenografts']"
530,1.0,"Of those 60, 9 patients had a loss of ARID1A expression.","['of', 'those', '_num_', '_num_', 'patients', 'had', 'a', 'loss', 'of', '_gene_', 'expression']"
531,1.0,Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052).,"['sequencing', 'of', '_num_', '_gene_', 'breast', 'cancer', 'samples', 'revealed', '_num_', '_gene_', 'mutation', 'rate', 'and', 'kaplan', 'meier', 'curves', 'showed', 'decreased', 'time', 'to', 'progression', 'for', 'mutant', '_gene_', 'at', 'borderline', 'statistical', 'significance', '_p_val_']"
532,1.0,72-year old male patient presents with SCC with a mutation profile consistent with UV exposure.,"['_num_', 'year', 'old', 'male', 'patient', 'presents', 'with', '_gene_', 'with', 'a', 'mutation', 'profile', 'consistent', 'with', 'uv', 'exposure']"
533,1.0,Preclinical study in 5 NSCLC cell lines.,"['preclinical', 'study', 'in', '_num_', '_disease_', 'cell', 'lines']"
534,1.0,"Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level.","['progression', 'free', 'survival', 'was', 'also', 'significantly', 'improved', 'with', '_chemical_', 'over', 'chemotherapy', 'in', 'the', 'tbm', 'subgroup', '_num_', 'vs', '_num_', 'months', 'hr', '_num_', 'p', '_num_', 'where', 'in', 'the', 'intent', 'to', 'treat', 'population', 'it', 'was', '_num_', 'vs', '_num_', 'months', 'hr', '_num_', 'p', '_num_', 'indicating', 'that', 'the', 'difficult', 'to', 'treat', 'bm', 'population', 'obtained', 'benefit', 'from', '_chemical_', 'at', 'both', 'the', 'brain', 'and', 'systemic', 'level']"
535,1.0,This mutation causes an early stop codon at amino acid 200 and was found in a VHL type 1 family (lineage 25).,"['this', 'mutation', 'causes', 'an', 'early', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
536,1.0,"Germline presence of the T allele increased the risk of glioblastoma development (adjusted odds ratio, 1.96; P = .013).","['germline', 'presence', 'of', 'the', 't', 'allele', 'increased', 'the', 'risk', 'of', 'glioblastoma', 'development', 'adjusted', 'odds', 'ratio', '_num_', 'p', '_num_']"
537,1.0,Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2.,"['intermediate', 'risk', 'patients', 'with', 'mutant', '_gene_', 'had', 'improved', 'overall', 'survival', 'with', 'the', 'presence', 'of', 'either', '_gene_', 'or', '_gene_', 'mutations', 'than', 'those', 'wildtype', 'for', 'both', '_gene_', 'and', '_gene_']"
538,1.0,Case shows CNS hemangioblastoma.,"['case', 'shows', 'cns', '_disease_']"
539,1.0,A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss.,"['a', 'patient', 'derived', 'mouse', 'xenograft', 'model', 'was', 'established', 'with', 'gastric', 'cancer', 'cells', 'having', '_gene_', 'loss']"
540,1.0,"The patient (M, 83, nonsmoker) had a partial response, progression free survival (PFS) of 37.5 months, overall survival (OS) of 53.3 months and was alive at study end.","['the', 'patient', '_unit_', '_num_', 'nonsmoker', 'had', 'a', 'partial', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'alive', 'at', 'study', 'end']"
541,1.0,"The current study investigated potential genomic markers associated with ""hyper-progression"".","['the', 'current', 'study', 'investigated', 'potential', 'genomic', 'markers', 'associated', 'with', '_disease_', 'progression']"
542,0.0,"we speculated that since this polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, it might influence cancer risk through its role in the immune response.","['we', 'speculated', 'that', 'since', 'this', 'polymorphism', 'a', 'missense', 'variant', 'in', 'the', 'gene', '_gene_', 'is', 'also', 'associated', 'with', 'haematological', 'and', 'autoimmune', 'disorders', 'it', 'might', 'influence', 'cancer', 'risk', 'through', 'its', 'role', 'in', 'the', 'immune', 'response']"
543,1.0,"In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression free survival and overall survival compared to patients with Kit exon 11 mutations.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'gastrointestinal', 'stromal', 'tumors', 'treated', 'with', '_chemical_', 'patients', 'with', 'kit', 'exon', '_num_', 'mutations', 'or', 'wildtype', 'lacking', 'kit', 'or', '_gene_', 'mutations', 'showed', 'increased', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'compared', 'to', 'patients', 'with', 'kit', 'exon', '_num_', 'mutations']"
544,1.0,EZH2 expression was higher in EZH2 mutant (N=3) and wild type melanoma cell lines (N=12) than untransformed cells (human epithelial melanocytes and human dermal fibroblasts).,"['_gene_', 'expression', 'was', 'higher', 'in', '_gene_', 'mutant', '_ineq_', 'and', 'wild', 'type', 'melanoma', 'cell', 'lines', '_ineq_', 'than', 'untransformed', 'cells', 'human', 'epithelial', 'melanocytes', 'and', 'human', 'dermal', 'fibroblasts']"
545,1.0,siRNA knockdown of Livin rendered the cells more sensitive to cisplatin.,"['sirna', 'knockdown', 'of', '_gene_', 'rendered', 'the', 'cells', 'more', 'sensitive', 'to', '_disease_']"
546,1.0,Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples.,"['expression', 'levels', 'by', 'qtpcr', 'were', 'also', 'higher', 'in', 'resistant', 'tumors', 'among', '_num_', 'patient', 'samples']"
547,1.0,MEK Inhibitors alone or the combination with gefitinib (EGFRi) or CP724714 (ERBB2i) showed strong synergy.,"['mek', 'inhibitors', 'alone', 'or', 'the', 'combination', 'with', '_chemical_', 'egfri', 'or', '_chemical_', '_abbrev_', 'showed', 'strong', 'synergy']"
548,1.0,"A pedigree of 3 generations and 8 individuals with familial platelet disease with propensity to acute myeloid leukemia (FPD/AML) was assessed for mutation in RUNX1 exons 3, 4, 5 and 6.","['a', 'pedigree', 'of', '_num_', 'generations', 'and', '_num_', 'individuals', 'with', 'familial', 'platelet', 'disease', 'with', 'propensity', 'to', 'acute', 'myeloid', 'leukemia', '_disease_', 'was', 'assessed', 'for', 'mutation', 'in', '_gene_', 'exons', '_num_', '_num_', '_num_', 'and', '_num_']"
549,1.0,"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line expressing the F359C mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', '_abbrev_', '_gene_', 'cell', 'line', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment']"
550,1.0,8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242).,"['_ratio_', 'without', '_gene_', 'amplification', 'were', 'reported', 'as', 'resistant', '_abbrev_', '_num_', 'micro', 'molar', '_chemical_']"
551,1.0,"Of these 2 germline patients, 1 showed stable disease (SD) and 1 complete response (CR).","['of', 'these', '_num_', 'germline', 'patients', '_num_', 'showed', 'stable', 'disease', 'sd', 'and', '_num_', 'complete', 'response', 'cr']"
552,1.0,"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML.","['the', 'presence', 'of', 'the', '_disease_', 'fusion', 'protein', 'is', 'a', 'diagnostic', 'marker', 'of', 'acute', 'promyelocytic', 'leukemia', 'or', '_abbrev_', '_disease_']"
553,1.0,"In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1–low expression group (P = 0.01, 1.9 × 10−3, and 9 × 10−4, respectively).","['in', '_num_', 'cohorts', 'of', '_disease_', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'patient', 'samples', 'evaluated', 'with', 'different', 'methods', 'reverse', 'phase', 'protein', 'array', '_ineq_', 'mrna', 'expression', 'array', '_ineq_', 'or', 'immunohistochemistry', '_ineq_', 'respectively', 'increased', 'expression', 'of', '_gene_', 'was', 'also', 'correlated', 'with', 'local', 'failure', 'following', 'radiotherapy', 'as', 'compared', 'to', 'the', '_abbrev_', 'expression', 'group', 'p', '_num_', '_num_', '×', '10−3', 'and', '_num_', '×', '10−4', 'respectively']"
554,1.0,Resistance was determined by assessing cell viability.,"['resistance', 'was', 'determined', 'by', 'assessing', 'cell', 'viability']"
555,1.0,"The responsiveness of these cell lines correlated with their levels of CDK4 mRNA as well as in vivo PDX, but not against sarcomas displaying low levels of CDK4 and high levels of p16ink4a (CDKN2A).","['the', 'responsiveness', 'of', 'these', 'cell', 'lines', 'correlated', 'with', 'their', 'levels', 'of', '_gene_', 'mrna', 'as', 'well', 'as', 'in', 'vivo', '_gene_', 'but', 'not', 'against', 'sarcomas', 'displaying', 'low', 'levels', 'of', '_gene_', 'and', 'high', 'levels', 'of', '_gene_', '_gene_']"
556,1.0,This missense mutation was found in a VHL type 1 family (lineage 86).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
557,1.0,Multivariate regression analysis identified expression of nuclear HSP110 as an independent prognostic factor for gastric cancer outcome (P = 0.0068).,"['multivariate', 'regression', 'analysis', 'identified', 'expression', 'of', 'nuclear', '_gene_', 'as', 'an', 'independent', 'prognostic', 'factor', 'for', 'gastric', 'cancer', 'outcome', 'p', '_num_']"
558,1.0,CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.,"['_gene_', 'hypomethylation', 'is', 'seen', 'to', 'be', 'more', 'common', 'in', 'stage', 'iii', 'and', 'iv', 'gastric', 'tumors', 'than', 'stage', 'i', 'and', 'ii']"
559,1.0,"In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation.","['in', 'patients', 'with', '_disease_', 'the', 'presence', 'of', '_gene_', '_abbrev_', 'mutation', 'is', 'prognostic', 'for', 'better', 'survival', 'compared', 'to', 'patients', 'who', 'harbor', 'wild', 'type', 'mutation']"
560,1.0,"Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006).","['patients', 'with', '_gene_', 'mutations', 'had', 'shorter', '_disease_', 'younger', 'p', '_num_', 'older', 'p', '_num_', 'event', 'free', 'both', 'p', '_num_', 'and', 'overall', 'survival', 'younger', 'p', '_num_', 'older', 'p', '_num_', 'as', 'well', 'as', 'lower', 'complete', 'remission', 'rates', 'younger', 'p', '_num_', 'older', 'p', '_num_']"
561,1.0,"In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively.","['in', '_abbrev_', 'and', '_chemical_', 'neuroblastoma', 'cell', 'lines', 'containing', '_mutation_', 'mutation', '_chemical_', 'showed', '_num_', 'and', '_num_', 'fold', 'greater', 'effect', 'on', 'cell', 'viability', 'over', '_chemical_', 'treatment', 'respectively']"
562,0.0,"Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC).","['where', 'most', 'clinical', 'trials', 'only', 'admit', 'patients', 'with', 'eastern', 'cooperative', 'oncology', 'performance', 'status', 'ps', 'of', '_num_', 'or', '_num_', 'this', 'patient', 'had', 'ps', '_num_', 'due', 'to', 'respiratory', 'failure', 'multiple', 'bone', 'metastases', 'and', 'complications', 'from', 'disseminated', 'intravascular', 'coagulation', '_gene_']"
563,1.0,12-month event-free survival rate 68.4% with alectinib vs. 48.7% with crizotinib.,"['_num_', 'month', 'event', 'free', 'survival', 'rate', '_num_', 'with', '_chemical_', 'vs', '_num_', 'with', '_chemical_']"
564,1.0,"This report identified 36 MEK1-mutated cases among 6,024 Lung adecarcinomas.","['this', 'report', 'identified', '_num_', '_abbrev_', 'cases', 'among', '_num_', 'lung', 'adecarcinomas']"
565,1.0,Responses were reported in mutational patients.,"['responses', 'were', 'reported', 'in', 'mutational', 'patients']"
566,1.0,"There was no significant difference in overall survival (median; 14.1 versus 12.8 months, HR=0.40; 95% CI: 0.06-2.0, P-value=0.24).","['there', 'was', 'no', 'significant', 'difference', 'in', 'overall', 'survival', 'median', '_num_', 'vs', '_num_', 'months', '_ineq_', '_num_', 'ci', '_range_', '_ineq_']"
567,1.0,This difference in overall survival between wild type and G12D patients persisted in the subset of patients who underwent chemotherapy at any point after enrollment.,"['this', 'difference', 'in', 'overall', 'survival', 'between', 'wild', 'type', 'and', '_mutation_', 'patients', 'persisted', 'in', 'the', 'subset', 'of', 'patients', 'who', 'underwent', 'chemotherapy', 'at', 'any', 'point', 'after', 'enrollment']"
568,1.0,R140Q mutation in IDH2 does not have prognostic value in patients with MDS.,"['_mutation_', 'mutation', 'in', '_gene_', 'does', 'not', 'have', 'prognostic', 'value', 'in', 'patients', 'with', 'mds']"
569,1.0,Preclinical evidence led to administration of CDK4 inhibitor LY2835219.,"['preclinical', 'evidence', 'led', 'to', 'administration', 'of', '_gene_', 'inhibitor', '_chemical_']"
570,1.0,"In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.","['in', 'a', 'cell', 'line', '_chemical_', 'with', 'expression', 'of', '_mutation_', 'or', '_mutation_', '_gene_', 'mutations', '_gene_', 'and', '_chemical_', 'were', 'more', 'effective', 'than', '_chemical_', 'or', '_chemical_', 'in', 'suppressing', 'cell', 'growth']"
571,1.0,"In this retrospective analysis, CCND1 amplification was analyzed in 442 patients.","['in', 'this', 'retrospective', 'analysis', '_gene_', 'amplification', 'was', 'analyzed', 'in', '_num_', 'patients']"
572,1.0,"In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.","['in', 'this', 'phase', 'iii', 'trial', '_chemical_', 'based', 'treatment', 'was', 'assessed', 'in', 'women', 'with', 'locally', 'advanced', 'or', 'metastatic', '_gene_', 'positive', 'breast', 'cancer', 'who', 'had', 'progressed', 'on', '_chemical_']"
573,1.0,"Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.","['patients', 'were', 'required', 'to', 'have', 'progressed', 'on', 'or', 'after', 'treatments', 'involving', '_chemical_', 'and', 'a', '_chemical_', 'and', 'no', 'prior', 'exposure', 'to', '_chemical_', 'or', '_disease_']"
574,1.0,26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.,"['_num_', 'colorectal', 'adenocarcinoma', 'samples', 'were', 'run', 'on', 'affymetrix', 'human', 'exon', '_num_', 'arrays', 'and', 'a', 'computational', 'method', 'that', 'assessed', 'differential', '_num_', 'and', '_num_', 'gene', 'expression', 'for', 'each', 'gene', 'was', 'used', 'to', 'find', 'potential', 'rearrangements']"
575,1.0,This mutation also causes an early stop codon at amino acid 66.,"['this', 'mutation', 'also', 'causes', 'an', 'early', 'stop', 'codon', 'at', 'amino', 'acid', '_num_']"
576,1.0,CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2.,"['_chemical_', 'and', 'to', 'a', 'lesser', 'extent', '_abbrev_', '_disease_', 'cell', 'lines', 'expressing', 'the', '_gene_', '_abbrev_', 'mutation', 'had', 'increased', 'resistance', 'to', '_disease_', 'and', '_disease_', 'treatment', 'than', 'cells', 'expressing', 'wildtype', '_gene_']"
577,1.0,Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T  (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai.,"['study', 'of', '_num_', '_disease_', 'cases', 'and', '_year_', 'cancer', 'free', 'controls', 'to', 'clarify', 'the', 'association', 'of', '_gene_', 'c', '677c', 't', 'and', 'c', '1298a', 'c', 'of', 'pancreatic', 'cancer', 'risk', 'in', 'a', 'population', 'of', 'han', 'chinese', 'in', 'shanghai']"
578,1.0,Cells harboring an exon 19 deletion were sensitive to afatinib.,"['cells', 'harboring', 'an', 'exon', '_num_', 'deletion', 'were', 'sensitive', 'to', '_chemical_']"
579,1.0,ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease .,"['acmg', 'evidence', 'codes', ""'pp2"", 'because', 'they', 'observe', 'a', 'missense', 'variant', 'in', 'a', 'gene', 'where', 'missense', 'variants', 'are', 'a', 'common', 'mechanism', 'of', 'disease']"
580,1.0,"A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance.","['a', '_num_', 'biopsy', 'identified', 'a', '_chemical_', 'fusion', 'which', 'may', 'explain', 'the', 'therapeutic', 'resistance']"
581,1.0,Crizotinib was maintained for 8 additional months due to low tumor burden and slow progression.,"['_chemical_', 'was', 'maintained', 'for', '_num_', 'additional', 'months', 'due', 'to', 'low', 'tumor', 'burden', 'and', 'slow', 'progression']"
582,1.0,The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.,"['the', 'clinical', 'use', 'of', '_chemical_', 'in', 'patients', 'with', '_gene_', 'fusion', 'has', 'resulted', 'in', 'drastic', 'prognostic', 'improvements', 'in', 'patients', 'with', '_gene_']"
583,1.0,Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors.,"['sensitivity', 'to', 'pan', '_gene_', 'inhibitor', '_chemical_', 'was', 'assessed', 'in', 'a', 'panel', 'of', '_num_', 'cell', 'lines', '_num_', 'with', '_gene_', 'evaluated', 'derived', 'from', 'solid', 'and', 'hematological', 'tumors']"
584,1.0,Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285).,"['patients', 'with', 'refractory', 'colorectal', 'cancer', 'expressing', 'immunohistochemically', 'detectable', '_gene_', 'were', 'randomly', 'assigned', 'to', 'receive', 'treatment', 'with', '_chemical_', '_ineq_', 'or', 'receive', 'supportive', 'care', 'alone', '_ineq_']"
585,1.0,Palbociclib-resistant xenografts from one cell line (PDX244) were developed in-vivo.,"['_chemical_', 'resistant', 'xenografts', 'from', '_num_', 'cell', 'line', '_abbrev_', 'were', 'developed', 'in', 'vivo']"
586,1.0,This nonsense mutation was found in a 22 year old Korean female with hemangioblastomas of the central nervous system (patient no 3).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_num_', 'year', 'old', 'korean', 'female', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'patient', 'no', '_num_']"
587,1.0,Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074.,"['mouse', 'xenografts', 'using', 'the', 'bladder', 'cell', 'line', '_abbrev_', 'which', 'harbors', 'an', '_abbrev_', 'fusion', 'showed', 'reduced', 'tumor', 'burden', 'when', 'treated', 'with', 'the', '_gene_', 'inhibitor', '_chemical_']"
588,1.0,Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib.,"['preclinical', 'study', 'in', 'breast', 'cancer', 'cell', 'lines', 'treated', 'with', '_gene_', 'inhibitor', '_chemical_']"
589,1.0,"In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation.","['in', '_abbrev_', 'amplified', 'cell', 'lines', 'sensitivity', 'to', '_gene_', 'kinase', 'inhibitor', '_chemical_', 'was', 'found', 'mainly', 'in', 'cell', 'lines', 'with', 'elevated', '_gene_', 'expression', 'and', '_gene_', 'activation']"
590,1.0,"Confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1).","['confirmed', 'overall', 'response', 'rate', 'was', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', '_num_', 'with', 'a', 'complete', 'response', 'and', '_num_', 'with', 'a', 'partial', 'response', 'median', 'duration', 'of', 'response', 'was', '_num_', 'months', '_num_', 'ci', '_num_', 'to', '_num_', 'and', 'median', 'progression', 'free', 'survival', 'was', '_num_', 'months', '_num_', 'ci', '_num_', 'to', '_num_']"
591,1.0,"However, based on this study we can infer that the variant would predispose to LS in a germline setting.","['however', 'based', 'on', 'this', 'study', 'we', 'can', 'infer', 'that', 'the', 'variant', 'would', 'predispose', 'to', 'ls', 'in', 'a', 'germline', 'setting']"
592,1.0,The most prominently enriched gene in trastuzumab resistant populations was PTEN.,"['the', 'most', 'prominently', 'enriched', 'gene', 'in', '_chemical_', 'resistant', 'populations', 'was', '_gene_']"
593,1.0,"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole.","['a', 'patient', 'with', 'metastatic', 'er', 'positive', '_abbrev_', 'breast', 'cancer', 'with', '_gene_', 'loss', 'experienced', 'a', 'short', 'lived', '_num_', 'month', 'clinical', 'response', 'to', '_chemical_', 'when', 'given', 'in', 'combination', 'with', '_chemical_']"
594,1.0,"10 melanoma patients were evaluated after sunitinib treatment, among which 3 out of the 4 patients with KIT exon 11 mutations showed either complete or partial response.","['_num_', 'melanoma', 'patients', 'were', 'evaluated', 'after', '_chemical_', 'treatment', 'among', 'which', '_num_', 'out', 'of', 'the', '_num_', 'patients', 'with', 'kit', 'exon', '_num_', 'mutations', 'showed', 'either', 'complete', 'or', 'partial', 'response']"
595,1.0,The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one of the patients harboring the CD74–ROS1 fusion.,"['the', '_gene_', '_mutation_', 'mutation', 'was', 'identified', 'in', 'a', '_chemical_', 'resistant', 'tumor', 'from', '_num_', 'of', 'the', 'patients', 'harboring', 'the', '_abbrev_', 'fusion']"
596,1.0,Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).,"['_disease_', 'analysis', 'linking', '_gene_', '_mutation_', 'to', 'a', 'higher', 'risk', 'of', 'prostate', 'cancer', 'or', '_num_', '_num_', 'confidence', 'interval', '_range_', 'p', '_num_']"
597,1.0,"A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs).","['a', 'preclinical', 'study', 'to', 'explore', 'the', 'efficacy', 'of', '_gene_', 'inhibition', 'with', '_chemical_', 'in', 'a', 'panel', 'of', 'sarcoma', 'cell', 'lines', 'and', 'sarcoma', 'tumor', 'xenografts', '_disease_']"
598,1.0,"Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115).","['correlation', 'to', '_disease_', 'was', 'also', 'found', 'after', 'multivariate', 'analysis', '_p_val_', 'hazard', 'ratio', 'hr', '_num_']"
599,0.0,"However, larger studies are warranted for confirmation.","['however', 'larger', 'studies', 'are', 'warranted', 'for', 'confirmation']"
600,1.0,Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines.,"['_chemical_', 'inhibited', 'proliferation', 'in', '_num_', '_abbrev_', 'and', '_num_', '_abbrev_', 'breast', 'cancer', 'cell', 'lines', 'at', 'higher', '_abbrev_', 'values', 'than', 'in', '_num_', 'nonamplified', 'cell', 'lines']"
601,1.0,"In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'prostate', 'cancer', '_num_', 'had', 'germ', 'line', '_gene_', 'mutations', '_num_', 'had', 'germ', 'line', '_gene_', 'mutations', 'and', '_num_', 'were', '_disease_']"
602,1.0,"In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively).","['in', 'this', 'study', 'loss', 'of', 'chromosome', '1p', 'and', 'low', '_gene_', 'protein', 'expression', 'were', 'associated', 'with', 'objective', 'response', 'p', '_num_', 'and', 'p', '_num_', 'respectively']"
603,1.0,"26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A mutation, one had G596R mutation and one had an unspecified mutation.","['_num_', 'of', 'these', 'cell', 'lines', 'had', 'the', '_gene_', '_mutation_', 'mutation', '_num_', 'cell', 'line', 'had', 'a', '_mutation_', 'mutation', '_num_', 'had', '_mutation_', 'mutation', 'and', '_num_', 'had', 'an', 'unspecified', 'mutation']"
604,1.0,BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.,"['_gene_', 'status', 'does', 'not', 'predict', 'outcome', 'in', 'patients', 'treated', 'with', '_chemical_', 'or', '_chemical_']"
605,1.0,"NOTCH1 mutations were found to be associated with worse overall survival (3.77-fold increase in the hazard of death, P < .001) in a series of 309 newly diagnosed CLL and confirmed in an additional set of 230 patients.","['_gene_', 'mutations', 'were', 'found', 'to', 'be', 'associated', 'with', 'worse', 'overall', 'survival', '_num_', '_num_', 'fold', 'increase', 'in', 'the', 'hazard', 'of', 'death', 'p', '_num_', 'in', 'a', 'series', 'of', '_num_', 'newly', 'diagnosed', '_disease_', 'and', 'confirmed', 'in', 'an', 'additional', 'set', 'of', '_num_', 'patients']"
606,1.0,"Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D)  resulted in strong autophosphorylation of PDGFRA.","['_num_', '_gene_', 'mutations', '_mutation_', '_mutation_', '_mutation_', '_mutation_', 'and', '_mutation_', 'resulted', 'in', 'strong', 'autophosphorylation', 'of', '_gene_']"
607,1.0,"Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured.","['cells', 'were', 'plated', 'and', 'treated', 'with', '_num_', 'generation', '_gene_', 'inhibitors', '_chemical_', '_chemical_', 'or', 'the', 'the', 'tool', 'compound', '_chemical_', 'and', '_abbrev_', 'values', 'were', 'measured']"
608,1.0,In-vitro and in-vivo sensitivity to DR5 antibody conatumumab was correlated with expression of caspase-8.,"['in', 'vitro', 'and', 'in', 'vivo', 'sensitivity', 'to', '_gene_', 'antibody', 'conatumumab', 'was', 'correlated', 'with', 'expression', 'of', '_gene_']"
609,1.0,Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.,"['_num_', 'line', '_chemical_', 'plus', '_chemical_', 'brought', 'about', 'some', 'symptom', 'improvement', 'and', '_disease_', 'of', '_num_', 'months']"
610,1.0,U2AF1 mutations were significantly associated with shorter overall survival in univariate analysis (P < 0.0001) but not in multivariate analysis with adjustment for age and anemia (P=0.24).,"['_gene_', 'mutations', 'were', 'significantly', 'associated', 'with', 'shorter', 'overall', 'survival', 'in', 'univariate', 'analysis', 'p', '_num_', 'but', 'not', 'in', 'multivariate', 'analysis', 'with', 'adjustment', 'for', 'age', 'and', 'anemia', '_p_val_']"
611,1.0,"Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of death (HR = 2.09 ; P = 0.028), and increased risk of distant metastasis (OR = 3.96 ; P = 0.029).","['immunohistochemical', 'analysis', 'of', 'tumors', 'from', '_num_', 'esophageal', '_disease_', 'cell', 'carcinoma', 'found', 'that', 'expression', 'of', '_gene_', 'was', 'associated', 'with', 'increased', 'progression', 'of', 'the', 'tumor', 'p', '_num_', 'increased', 'risk', 'of', 'death', 'hr', '_num_', 'p', '_num_', 'and', 'increased', 'risk', 'of', 'distant', 'metastasis', 'or', '_num_', 'p', '_num_']"
612,1.0,Significant risk of bias was reported for the included studies.,"['significant', 'risk', 'of', 'bias', 'was', 'reported', 'for', 'the', 'included', 'studies']"
613,1.0,"She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis.","['she', 'continued', 'to', 'receive', 'therapy', 'for', '_num_', 'months', 'until', 'discontinuation', 'because', 'of', 'the', 'development', 'of', 'pneumonitis']"
614,1.0,"It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance.","['it', 'was', 'thought', 'that', 'the', 'wider', 'range', 'of', '_gene_', 'family', 'blocking', 'and', 'irreversible', 'properties', 'of', '_chemical_', 'could', 'be', 'beneficial', 'in', '_chemical_', 'resistant', 'cancer', 'cells', 'since', '_gene_', 'family', 'members', 'are', 'thought', 'to', 'play', 'a', 'role', 'in', '_chemical_', 'resistance']"
615,1.0,Crizotinib treatment led to a decrease in cell growth and migration.,"['_chemical_', 'treatment', 'led', 'to', 'a', 'decrease', 'in', 'cell', 'growth', 'and', 'migration']"
616,1.0,"In 38 EGFR wildtype patients treated with erlotinib or gefitinib, those with KRAS G12C mutations (n=24) had shorter progression free survival rates compared to patients with non-G12C KRAS mutations (n=14; 4.3 vs 9 weeks; P = 0.009; HR=2.7).","['in', '_num_', '_gene_', 'wildtype', 'patients', 'treated', 'with', '_chemical_', 'or', '_chemical_', 'those', 'with', '_gene_', '_mutation_', 'mutations', '_chemical_', 'had', 'shorter', 'progression', 'free', 'survival', 'rates', 'compared', 'to', 'patients', 'with', '_abbrev_', '_gene_', 'mutations', '_gene_', '_num_', 'vs', '_num_', 'weeks', 'p', '_num_', '_ineq_']"
617,1.0,"In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression.","['in', 'patients', 'with', 'breast', 'cancer', 'those', 'with', 'expression', 'of', '_gene_', 'determined', 'by', 'immunohistochemical', 'staining', 'had', 'better', 'relapse', 'free', 'survival', 'than', 'those', 'without', 'expression']"
618,1.0,Overexpression of DDX43 mediated RAS-induced selumetinib resistance as demonstrated by depletion of DDX43 decreasing RAS proteins and ectopic expression of DDX43 induced RAS protein levels.,"['overexpression', 'of', '_gene_', 'mediated', 'ras', 'induced', '_chemical_', 'resistance', 'as', 'demonstrated', 'by', 'depletion', 'of', '_gene_', 'decreasing', 'ras', 'proteins', 'and', 'ectopic', 'expression', 'of', '_gene_', 'induced', 'ras', 'protein', 'levels']"
619,1.0,MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.,"['_chemical_', 'cell', 'lines', 'harboring', 'the', '_mutation_', 'mutation', 'in', 'the', '_disease_', 'domain', 'of', '_gene_', 'have', 'shown', 'resistance', 'to', 'hormone', 'therapy']"
620,1.0,Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs.,"['drug', 'binding', 'predictions', 'and', 'in', 'vitro', 'studies', 'demonstrated', 'that', 'the', '_mutation_', 'mutation', 'induces', 'resistance', 'to', 'type', 'i', 'but', 'not', 'type', 'ii', 'met', '_disease_']"
621,1.0,The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs.,"['the', 'mutation', 'was', 'shown', 'to', 'occur', 'at', 'a', 'hotspot', '_abbrev_', 'of', 'previously', 'reported', 'secondary', 'kit', 'mutations', 'in', '_chemical_', 'resistant', 'gists']"
622,0.0,BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.,"['_gene_', 'mutations', 'are', 'associated', 'with', 'melanoma', 'arising', 'in', 'non', 'chronic', 'sun', 'damaged', 'skin', 'and', 'with', 'superficial', 'spreading', 'melanoma']"
623,1.0,"Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.","['breast', 'cancer', 'patients', 'who', 'harbor', '_mutation_', 'mutation', 'have', 'worse', 'overall', 'survival', 'than', 'those', 'with', 'wild', 'type', '_gene_', 'but', 'have', 'better', 'prognosis', 'than', 'those', 'with', '_mutation_', 'mutation']"
624,1.0,"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization.","['in', '_num_', 'out', 'of', '_num_', '_num_', 'metastatic', 'colorectal', 'cancer', 'tumors', 'harboring', '_gene_', 'nras', '_gene_', 'or', '_gene_', 'mutations', 'and', 'implanted', 'into', 'mice', 'the', 'therapeutic', 'combination', 'of', 'the', 'mek', 'inhibitor', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'disease', 'stabilization']"
625,1.0,"From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit.","['from', '_num_', 'treated', 'patients', '_num_', 'had', 'partial', 'response', '_num_', 'had', 'stable', 'disease', 'as', 'best', 'response', 'and', '_num_', 'achieved', 'clinical', 'benefit']"
626,1.0,"In an in vitro study, a Ba/F3  cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 2.00-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'as', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein', 'reported', 'to', 'be', 'sensitizing', 'to', '_chemical_']"
627,1.0,Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone.,"['combined', 'treatment', 'with', '_gene_', 'inhibitor', '_chemical_', 'was', 'more', 'effective', 'than', 'either', 'agent', 'alone']"
628,1.0,Cytoplasmic staining of PSMB8 and PBK were not statistically significant.,"['cytoplasmic', 'staining', 'of', '_gene_', 'and', '_gene_', 'were', 'not', 'statistically', 'significant']"
629,1.0,The p110alpha-specific PI3K inhibitor BYL719 was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines.,"['the', '_abbrev_', '_gene_', 'inhibitor', '_chemical_', 'was', 'used', 'on', 'a', 'panel', 'of', '_num_', '_gene_', 'inhibitor', 'sensitive', 'and', '_num_', 'resistant', 'breast', 'cancer', 'cell', 'lines']"
630,1.0,"Of these patients, 4 with a SMO mutation displayed progressive disease and 1 stable disease for 58 weeks according to RECIST v1.1 criteria.","['of', 'these', 'patients', '_num_', 'with', 'a', '_gene_', 'mutation', 'displayed', 'progressive', 'disease', 'and', '_num_', 'stable', 'disease', 'for', '_num_', 'weeks', 'according', 'to', '_disease_', '_abbrev_', 'criteria']"
631,1.0,Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.,"['treatment', 'with', 'mek', 'inhibitor', '_chemical_', 'led', 'to', 'a', 'more', 'dramatic', 'decrease', 'in', '_gene_', 'signaling']"
632,1.0,Cytogenetic studies have repeatedly demonstrated the t(X;18)(p11;q11) translocation in approximately 90% of both monophasic and biphasic synovial sarcomas.,"['cytogenetic', 'studies', 'have', 'repeatedly', 'demonstrated', 'the', 't', 'x', '_num_', '_gene_', '_gene_', 'translocation', 'in', 'approximately', '_num_', 'of', 'both', 'monophasic', 'and', 'biphasic', 'synovial', 'sarcomas']"
633,1.0,"KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT.","['kit', 'mutation', 'is', 'associated', 'with', 'larger', 'more', 'invasive', 'tumors', 'greater', 'pathologic', 'histology', 'and', 'older', 'patients', 'compared', 'to', 'tumors', 'with', 'wildtype', 'kit']"
634,1.0,This variant was most strongly correlated with acral lentigious melanoma.,"['this', 'variant', 'was', 'most', 'strongly', 'correlated', 'with', 'acral', 'lentigious', 'melanoma']"
635,1.0,"IC50 for cell number in response to 17-AAG was 33.4 nM, in contrast to IC50 for EML4-ALK wild type, which was 98.9 nM, suggesting sensitization of this variant to HSP90 inhibition.","['_abbrev_', 'for', 'cell', 'number', 'in', 'response', 'to', '_chemical_', 'was', '_num_', '_unit_', 'in', 'contrast', 'to', '_abbrev_', 'for', '_chemical_', 'wild', 'type', 'which', 'was', '_num_', '_unit_', 'suggesting', 'sensitization', 'of', 'this', 'variant', 'to', '_gene_', 'inhibition']"
636,1.0,A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases.,"['a', '_num_', 'year', 'old', 'female', 'never', 'smoker', 'was', 'diagnosed', 'with', 'stage', 'iv', '_disease_', 'with', 'liver', 'metastases']"
637,1.0,"Subsequently, a patient-derived tumor cell line (designated 22 092) was suspended in a solution of PD18352/MK2206 combination therapy and cell growth inhibition confirmed tumor sensitivity to MEK/AKT inhibitors compared to the BRAF V600E-containing A375P cell line.","['subsequently', 'a', '_disease_', 'tumor', 'cell', 'line', 'designated', '_num_', '_num_', 'was', 'suspended', 'in', 'a', 'solution', 'of', '_abbrev_', 'combination', 'therapy', 'and', 'cell', 'growth', 'inhibition', 'confirmed', 'tumor', 'sensitivity', 'to', 'mek', '_gene_', 'inhibitors', 'compared', 'to', 'the', '_gene_', '_abbrev_', '_abbrev_', 'cell', 'line']"
638,1.0,ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.,"['_disease_', 'treatment', 'did', 'not', 'effect', 'overall', 'survival', 'in', 'patients', '_num_', 'years', 'old', 'with', '_gene_', 'mutation']"
639,1.0,"However, there was not a significant correlation between the mutation and overall survival.","['however', 'there', 'was', 'not', 'a', 'significant', 'correlation', 'between', 'the', 'mutation', 'and', 'overall', 'survival']"
640,1.0,"Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001–0.08), P<0.0001).","['risk', 'of', 'recurrence', 'was', 'significantly', 'lower', 'for', 'non', '_gene_', '_mutation_', 'hr', '_num_', '_num_', '001–0', '_num_', 'p', '_num_']"
641,1.0,"Her family history was notable for multiple relatives on her maternal side with breast cancer, including a distant male relative with breast cancer.","['her', 'family', 'history', 'was', 'notable', 'for', 'multiple', 'relatives', 'on', 'her', 'maternal', 'side', 'with', 'breast', 'cancer', 'including', 'a', 'distant', 'male', 'relative', 'with', 'breast', 'cancer']"
642,1.0,"102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR.","['_num_', '_disease_', 'patients', 'treated', 'with', 'anti', '_gene_', 'therapy', 'were', 'analyzed', 'for', '_num_', 'hotspot', 'mutations', 'in', '_gene_', 'nras', 'and', '_gene_', 'with', 'nanofluidic', 'digital', '_disease_', 'and', 'quantitative', '_disease_']"
643,1.0,"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing.","['archival', 'tumor', 'samples', 'from', '_num_', 'patients', 'from', 'the', '_abbrev_', 'and', '_num_', 'trials', 'were', 'analyzed', 'for', 'alterations', 'in', 'the', '_gene_', 'pathway', 'using', 'next', 'generation', 'sequencing', 'immunohistochemistry', '_gene_', 'and', 'sanger', 'sequencing']"
644,1.0,"After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared.","['after', '_num_', 'days', 'post', 'administration', 'the', 'lung', 'metastases', 'decreased', 'in', 'size', 'by', '_num_', '_unit_', 'to', '_unit_', 'and', 'no', 'new', 'metastatic', 'lesions', 'had', 'appeared']"
645,1.0,"There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine.","['there', 'were', '_num_', 'patients', 'enrolled', 'in', 'this', 'study', '_num_', 'of', 'which', 'were', 'treated', 'with', '_chemical_']"
646,1.0,Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC.,"['retrospective', 'analysis', 'of', 'data', 'from', '_num_', 'patients', 'who', 'underwent', 'surgery', 'and', 'molecular', 'testing', 'for', '_disease_']"
647,1.0,"Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell line.","['cell', 'lines', '_gene_', 'with', '_gene_', 'mutation', '_num_', '_abbrev_', '_abbrev_', '_abbrev_', 'were', 'more', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_abbrev_', 'than', '_gene_', '_gene_', 'wild', 'type', '_ineq_', 'cell', 'line']"
648,1.0,"In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months.","['in', 'a', 'single', 'arm', 'open', 'label', 'phase', '_num_', 'trial', 'in', '_gene_', 'amplified', 'mutated', 'and', 'or', '_gene_', 'loss', 'encompassing', '_num_', 'patients', 'no', 'objective', 'responses', 'were', 'observed', 'but', 'a', 'stable', 'disease', 'response', 'in', '_num_', 'patients', 'resulting', 'in', 'a', 'median', '_disease_', 'of', '_num_', 'months']"
649,1.0,These samples were then divided according to ARID1A expression after immunohistochemical staining.,"['these', 'samples', 'were', 'then', 'divided', 'according', 'to', '_gene_', 'expression', 'after', 'immunohistochemical', 'staining']"
650,1.0,"Multivariate Cox regression analysis showed FGFR1 to be an independent poor prognostic marker in luminal A cancers for disease free survival (hazard ratio = 3.341, p = 0.008).","['multivariate', 'cox', 'regression', 'analysis', 'showed', '_gene_', 'to', 'be', 'an', 'independent', 'poor', 'prognostic', 'marker', 'in', 'luminal', 'a', 'cancers', 'for', 'disease', 'free', 'survival', 'hazard', 'ratio', '_num_', 'p', '_num_']"
651,1.0,This pattern was seen to a lesser degree over a period of 3 years (p=.1604).,"['this', 'pattern', 'was', 'seen', 'to', 'a', 'lesser', 'degree', 'over', 'a', 'period', 'of', '_num_', 'years', 'p=', '_num_']"
652,1.0,The study was terminated before full accrual due to non-protocol considerations.,"['the', 'study', 'was', 'terminated', 'before', 'full', 'accrual', 'due', 'to', 'non', 'protocol', 'considerations']"
653,1.0,10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity.,"['_num_', 'biliary', 'tract', 'carcinoma', 'cell', 'lines', 'were', 'sorted', 'based', 'on', 'their', '_chemical_', 'sensitivity']"
654,1.0,"Expression of an alternative ALK transcript (ATI), encompassing exons 20–29 preceded by ~400 base pairs (bp) of intron 19, but not exons 1–19 was identified in three samples of thyroid cancer and melanoma.","['expression', 'of', 'an', 'alternative', '_gene_', 'transcript', '_gene_', 'encompassing', 'exons', '20–29', 'preceded', 'by', '_num_', 'base', 'pairs', '_gene_', 'of', 'intron', '_num_', 'but', 'not', 'exons', '1–19', 'was', 'identified', 'in', '_num_', 'samples', 'of', 'thyroid', 'cancer', 'and', 'melanoma']"
655,1.0,Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).,"['_num_', '_num_', 'of', '_num_', 'patients', 'with', 'nras', 'mutated', 'melanoma', 'had', 'a', 'partial', 'response', '_num_', 'confirmed']"
656,1.0,"COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.","['cog', 'n', '453x', 'and', '_abbrev_', 'xenografts', 'showed', 'some', 'inhibition', 'when', 'treated', 'with', '_chemical_', 'but', 'showed', 'complete', 'growth', 'inhibition', 'with', '_chemical_', 'treatment']"
657,1.0,Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt).,"['prospectively', 'planned', 'retrospective', '_chemical_', 'study', 'in', 'archived', 'tumor', 'tissue', 'from', '_num_', 'patients', 'from', 'the', 'piccolo', 'trial', 'panitumumab', 'plus', '_chemical_', 'in', '_gene_', 'patients', 'with', '_gene_', '_gene_']"
658,1.0,No genotype effect could be observed for UICC stages III to IV.,"['no', 'genotype', 'effect', 'could', 'be', 'observed', 'for', '_disease_', 'stages', 'iii', 'to', 'iv']"
659,1.0,"High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032).","['high', '_abbrev_', 'was', 'correlated', 'with', 'better', '_disease_', 'survival', '_disease_', '_p_val_', 'and', 'overall', 'survival', 'os', '_p_val_']"
660,0.0,"Noticeable side effects in the combination therapy group included neutropenia (54%) leucopenia (19%), fatigue (4%) back pain (2%), diarrhea (2%) and pulmonary embolism (4%).","['noticeable', 'side', 'effects', 'in', 'the', 'combination', 'therapy', 'group', 'included', 'neutropenia', '_num_', 'leucopenia', '_num_', 'fatigue', '_num_', 'back', 'pain', '_num_', 'diarrhea', '_num_', 'and', 'pulmonary', 'embolism', '_num_']"
661,1.0,"Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100).","['castrated', 'mice', 'bearing', '_disease_', 'human', 'prostate', 'adenocarcinomas', '_disease_', 'tumors', 'were', 'treated', 'with', '_gene_', 'inhibitors', '_chemical_', '_chemical_', 'and', 'an', 'androgen', 'receptor', 'inhibitor', '_chemical_']"
662,1.0,"Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT exon 9 mutations or with wild type KIT compared those with KIT exon 11 or PDGFRA mutations.","['primary', 'tumor', 'genotyping', 'of', '_num_', 'patients', 'with', 'metastatic', 'gist', 'given', '_num_', 'line', '_chemical_', 'treatment', 'after', 'prior', '_chemical_', 'therapy', 'failure', 'revealed', 'an', 'improved', 'response', 'to', '_chemical_', 'in', 'patients', 'with', 'kit', 'exon', '_num_', 'mutations', 'or', 'with', 'wild', 'type', 'kit', 'compared', 'those', 'with', 'kit', 'exon', '_num_', 'or', '_gene_', 'mutations']"
663,1.0,Ectopic SGK1 expression in sensitive MDA-MB-361 cells resulted in alpelisib resistance and preservation of phopho-S6K and phospho-4EBP with alpelisib treatment.,"['ectopic', '_gene_', 'expression', 'in', 'sensitive', '_chemical_', 'cells', 'resulted', 'in', 'alpelisib', 'resistance', 'and', 'preservation', 'of', '_abbrev_', 'and', '_abbrev_', 'with', 'alpelisib', 'treatment']"
664,1.0,DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib.,"['dna', 'sequencing', 'was', 'performed', 'in', '_num_', 'ph+', '_gene_', 'samples', 'with', 'sensitivity', 'or', 'resistance', 'to', '_chemical_']"
665,1.0,"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs.","['in', 'an', 'in', 'vitro', 'study', 'using', '_abbrev_', 'cells', 'wildtype', '_gene_', 'and', '_abbrev_', 'cells', '_abbrev_', 'inhibition', 'of', 'cell', 'growth', 'was', 'used', 'as', 'an', 'assay', 'to', 'determine', 'sensitivity', 'to', 'tyrosine', 'kinase', 'inhibitor', '_disease_', 'drugs']"
666,1.0,"Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen.","['among', '_num_', 'patients', 'with', '_gene_', 'pathway', 'aberrations', '_num_', 'partial', 'responses', 'pr', 'and', '_num_', 'with', 'stable', 'disease', 'were', 'seen']"
667,1.0,A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proliferation.,"['a', 'panel', 'of', '_num_', 'ovarian', 'cancer', 'cell', 'lines', 'with', 'varied', 'mutation', 'profiles', 'was', 'assayed', 'for', 'sensitivity', 'to', 'the', '_gene_', 'inhibitor', '_chemical_', '_chemical_', 'via', 'measurement', 'of', '_abbrev_', 'values', 'for', 'inhibition', 'of', 'proliferation']"
668,1.0,17 FBXW7 mutations were detected (isolated mutation in 2 patients).,"['_num_', '_gene_', 'mutations', 'were', 'detected', 'isolated', 'mutation', 'in', '_num_', 'patients']"
669,1.0,This mutation segregated with FDP/AML and was not found in 184 unrelated control chromosomes.,"['this', 'mutation', 'segregated', 'with', '_gene_', '_disease_', 'and', 'was', 'not', 'found', 'in', '_num_', 'unrelated', 'control', 'chromosomes']"
670,1.0,This missense mutation was found in two VHL type 1 family members (patient no V19).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'family', 'members', 'patient', 'no', '_gene_']"
671,1.0,"Mutational profiling of a large cohort of lung adenocarcinomas  identified in 2 of 207 primary lung tumors a somatic activating mutation in exon 2 of MEK1 (i.e., mitogen-activated protein kinase kinase 1 or MAP2K1) that substitutes asparagine for lysine at amino acid 57 (K57N) in the nonkinase portion of the kinase.","['mutational', 'profiling', 'of', 'a', 'large', 'cohort', 'of', 'lung', 'adenocarcinomas', 'identified', 'in', '_num_', 'of', '_num_', 'primary', 'lung', 'tumors', 'a', 'somatic', 'activating', 'mutation', 'in', 'exon', '_num_', 'of', '_gene_', '_disease_', 'mitogen', 'activated', 'protein', 'kinase', 'kinase', '_num_', 'or', '_gene_', 'that', 'substitutes', 'asparagine', 'for', 'lysine', 'at', 'amino', 'acid', '_num_', '_mutation_', 'in', 'the', 'nonkinase', 'portion', 'of', 'the', 'kinase']"
672,1.0,"While the efficacy of trastuzumab against NSCLC with elevated levels of wild type HER2 expression remains unclear, we conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC.","['while', 'the', 'efficacy', 'of', '_chemical_', 'against', '_disease_', 'with', 'elevated', 'levels', 'of', 'wild', 'type', '_gene_', 'expression', 'remains', 'unclear', 'we', 'conclude', 'that', '_chemical_', 'based', 'therapy', 'is', 'a', 'promising', 'strategy', 'for', 'chemo', 'resistant', '_gene_']"
673,0.0,Patients with these mutations presented more often with neutropenia and rheumatoid arthritis than did patients without.,"['patients', 'with', 'these', 'mutations', 'presented', 'more', 'often', 'with', 'neutropenia', 'and', 'rheumatoid', 'arthritis', 'than', 'did', 'patients', 'without']"
674,1.0,Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine.,"['open', 'label', 'non', 'randomised', 'phase', '_num_', 'trial', 'in', 'patients', 'with', 'recurrent', 'or', 'metastatic', '_gene_', '_mutation_', 'mutant', 'papillary', 'thyroid', 'cancer', 'refractory', 'to', 'radioactive', 'iodine']"
675,1.0,"M541L mutation was not associated with CML in caucasian patients, and was common among healthy controls (8.1%), in contrast to a previous study in a Japanese CML patient population in which M541L was strongly associated with CML disease.","['_mutation_', 'mutation', 'was', 'not', 'associated', 'with', '_gene_', 'in', 'caucasian', 'patients', 'and', 'was', 'common', 'among', 'healthy', 'controls', '_num_', 'in', 'contrast', 'to', 'a', 'previous', 'study', 'in', 'a', 'japanese', '_gene_', 'patient', 'population', 'in', 'which', '_mutation_', 'was', 'strongly', 'associated', 'with', '_gene_', 'disease']"
676,1.0,"we cite findings that HER2 activity in cancer may be highly dependent on its Akt/mTOR signaling arm as a possible explanation for this effect, and conclude that their results give rationale for testing of afatinib/rapamycin treatment in lung cancer.","['we', 'cite', 'findings', 'that', '_gene_', 'activity', 'in', 'cancer', 'may', 'be', 'highly', 'dependent', 'on', 'its', '_gene_', '_gene_', 'signaling', 'arm', 'as', 'a', 'possible', 'explanation', 'for', 'this', 'effect', 'and', 'conclude', 'that', 'their', 'results', 'give', 'rationale', 'for', 'testing', 'of', '_chemical_', '_gene_', 'treatment', 'in', 'lung', 'cancer']"
677,1.0,Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00).,"['_disease_', 'analysis', 'of', '_num_', 'retrospective', 'studies', 'linked', '_gene_', '_mutation_', 'to', 'a', 'higher', 'risk', 'of', 'prostate', 'cancer', 'or', '_num_', '_num_', 'confidence', 'interval', '_range_', 'p', '_num_']"
678,1.0,"In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild type patients.","['in', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'in', 'a', 'multivariate', 'analysis', 'those', 'with', 'truncating', 'mutations', 'in', '_gene_', 'had', 'worse', 'progression', 'free', 'and', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
679,1.0,"Increased expression of ETV4 was associated with greater Gleason score (P = 0.045) , pathological tumor stage (P = 0.041),  and an unfavorable prognosis (P = 0.040).","['increased', 'expression', 'of', '_gene_', 'was', 'associated', 'with', 'greater', 'gleason', 'score', 'p', '_num_', 'pathological', 'tumor', 'stage', 'p', '_num_', 'and', 'an', 'unfavorable', 'prognosis', 'p', '_num_']"
680,1.0,Median follow-up was 1.7 months (IQR 1.4-4.1).,"['median', 'follow', 'up', 'was', '_num_', 'months', 'iqr', '_range_']"
681,1.0,The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months.,"['the', 'median', 'survival', 'in', 'these', 'previously', 'treated', 'patients', 'with', 'chemotherapy', 'refractory', 'colorectal', 'cancer', 'was', '_num_', 'months']"
682,1.0,"31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen.","['_num_', 'patients', 'were', 'tested', 'via', '_disease_', 'for', 'known', '_chemical_', 'fusions', 'and', '_num_', 'were', 'shown', 'to', 'have', '_chemical_', 'variant', '_num_', '_num_', 'cases', 'had', 'variant', '_num_', 'and', '_num_', 'instance', 'of', 'variants', '_num_', '_chemical_', 'and', '_num_', 'were', 'seen']"
683,1.0,Analysis of clones from one transformed focus yielded a novel fusion.,"['analysis', 'of', 'clones', 'from', '_num_', 'transformed', 'focus', 'yielded', 'a', 'novel', 'fusion']"
684,1.0,This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203.,"['this', 'screening', 'study', 'in', 'various', 'tumor', 'xenografts', 'identified', '_gene_', 'expression', 'to', 'correlate', 'with', 'sensivity', 'to', '_gene_', 'inhibitory', 'antibody', '_abbrev_']"
685,1.0,MET amplification was also identified in 3/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues.,"['met', 'amplification', 'was', 'also', 'identified', 'in', '_ratio_', '_num_', 'chemonaive', '_gene_', '_mutation_', 'colorectal', 'cancer', 'tumor', 'tissues']"
686,1.0,"Conversely, unmethylated tumors with low MGMT mRNA expression (N = 6) did better than their counterparts.","['conversely', 'unmethylated', 'tumors', 'with', 'low', '_gene_', 'mrna', 'expression', 'n', '_num_', 'did', 'better', 'than', 'their', 'counterparts']"
687,1.0,"p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.","['_gene_', 'positivity', 'as', 'a', 'surrogate', 'marker', 'for', 'hpv', 'associated', '_disease_', 'was', 'a', 'favorable', 'prognostic', 'marker', 'in', 'recurrent', 'or', 'metastatic', 'carcinoma']"
688,1.0,GIST cancer with D842V mutation is resistant to imatinib.,"['gist', 'cancer', 'with', '_mutation_', 'mutation', 'is', 'resistant', 'to', '_chemical_']"
689,1.0,Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.,"['cells', 'harboring', '_gene_', '_mutation_', 'mutation', 'were', 'sensitive', 'to', '_chemical_', 'treatment', 'in', 'isogenic', '_abbrev_', 'cells', 'and', 'in', 'a', 'mouse', 'xenograft', 'model']"
690,1.0,182 patients were evaluated.,"['_num_', 'patients', 'were', 'evaluated']"
691,1.0,"In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12)  treated with crizotinib monotherapy, was  associated with a response as evident by the reduced size of tumors.","['in', 'a', 'never', 'smoking', 'metastatic', 'lung', 'adenocarcinoma', 'patient', 'harboring', 'a', 'met', 'splice', 'site', 'mutation', 'c', '_num_', '18_2887', '7del12', 'treated', 'with', '_chemical_', 'monotherapy', 'was', 'associated', 'with', 'a', 'response', 'as', 'evident', 'by', 'the', 'reduced', 'size', 'of', 'tumors']"
692,1.0,One patient acquired a novel GNAS1 R201C mutation at disease progression.,"['_num_', 'patient', 'acquired', 'a', 'novel', '_gene_', '_abbrev_', 'mutation', 'at', 'disease', 'progression']"
693,1.0,She was treated with AZD9291 for 9 months until disease progression.,"['she', 'was', 'treated', 'with', '_chemical_', 'for', '_num_', 'months', 'until', 'disease', 'progression']"
694,1.0,There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).,"['there', 'is', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'nonsense', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
695,1.0,Possibly benign but appears to have fairly low global mutation allele frequency.,"['possibly', 'benign', 'but', 'appears', 'to', 'have', 'fairly', 'low', 'global', 'mutation', 'allele', 'frequency']"
696,1.0,"SYT (aka SS18) pairs with various 3' partners know as SSX (especially SSX1, and SSX2).","['_gene_', 'aka', '_gene_', 'pairs', 'with', 'various', '_num_', 'partners', 'know', 'as', '_gene_', 'especially', '_gene_', 'and', '_gene_']"
697,1.0,"High SPHK1 expression was also associated with larger tumor size (p < 0.001), deeper invasion depth (p < 0.001), presence of lymph node metastasis (p = 0.029), higher FIGO stage (p = 0.029), presence of lymphovascular invasion (p = 0.045), and higher preoperative squamous cell carcinoma (SCC) antigen level (p = 0.009).","['high', '_gene_', 'expression', 'was', 'also', 'associated', 'with', 'larger', 'tumor', 'size', 'p', '_num_', 'deeper', 'invasion', 'depth', 'p', '_num_', 'presence', 'of', 'lymph', 'node', 'metastasis', 'p', '_num_', 'higher', '_disease_', 'stage', 'p', '_num_', 'presence', 'of', 'lymphovascular', 'invasion', 'p', '_num_', 'and', 'higher', 'preoperative', '_disease_', 'cell', 'carcinoma', '_gene_', 'antigen', 'level', 'p', '_num_']"
698,1.0,JQ1 also inhibited growth of a GNAQ mutant cell line (92.1) in a mouse xenograft model compared to vehicle (N=5 mice/group).,"['_abbrev_', 'also', 'inhibited', 'growth', 'of', 'a', '_gene_', 'mutant', 'cell', 'line', '_num_', 'in', 'a', 'mouse', 'xenograft', 'model', 'compared', 'to', 'vehicle', '_ineq_', 'mice', 'group']"
699,1.0,"FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors.","['_gene_', '_abbrev_', 'mutation', 'was', 'found', 'in', '_num_', '_num_', 'adult', '_disease_', 'cell', 'tumors', 'and', 'is', 'absent', 'in', 'other', 'types', 'of', 'sex', 'cord', 'stromal', 'tumors', 'and', 'juvenile', '_disease_', 'tumors']"
700,1.0,"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo, and in enzyme assays.","['preclinical', 'study', 'of', '_chemical_', 'in', '_disease_', 'in', 'vitro', 'in', 'vivo', 'and', 'in', 'enzyme', 'assays']"
701,1.0,HIF-2A (EPAS1) staining was conducted on 66 tumors.,"['_gene_', '_gene_', 'staining', 'was', 'conducted', 'on', '_num_', 'tumors']"
702,1.0,He responded well to therapy (Karnofsky index 90%).,"['he', 'responded', 'well', 'to', 'therapy', 'karnofsky', 'index', '_num_']"
703,1.0,It was found that EGFR Mutant status was a significant positive prognostic factor for overall survival.,"['it', 'was', 'found', 'that', '_gene_', 'mutant', 'status', 'was', 'a', 'significant', 'positive', 'prognostic', 'factor', 'for', 'overall', 'survival']"
704,1.0,Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks.,"['median', 'progression', 'free', 'survival', '_disease_', 'was', '_num_', 'weeks', 'and', 'median', 'overall', 'survival', 'os', 'was', '_num_', 'weeks']"
705,1.0,SNS-032 greatly prolonged the survival of mice with CCNE1 overexpressing xenografts.,"['_chemical_', 'greatly', 'prolonged', 'the', 'survival', 'of', 'mice', 'with', '_gene_', 'overexpressing', 'xenografts']"
706,1.0,"DUX4 fusions were found only in AYA cases (age 15-39) and this was significant, p=0.016.","['_gene_', 'fusions', 'were', 'found', 'only', 'in', '_disease_', 'cases', 'age', '_range_', 'and', 'this', 'was', 'significant', '_p_val_']"
707,1.0,"In a phase 3 clinical trial (NCT00829166), metastatic breast cancer patients with PIK3CA mutation (n=40), including patients with PIK3CA E545K, treated with ado-trastuzumab were associated with improved median progression free survival (10.9 vs. 9.8 months), as compared to patients with wild type PIK3CA (n=93).","['in', 'a', 'phase', '_num_', 'clinical', 'trial', '_abbrev_', 'metastatic', 'breast', 'cancer', 'patients', 'with', '_gene_', 'mutation', '_ineq_', 'including', 'patients', 'with', '_gene_', '_mutation_', 'treated', 'with', 'ado', '_chemical_', 'were', 'associated', 'with', 'improved', 'median', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', '_ineq_']"
708,1.0,"PD-L1 expression was found to be associated with several poor prognostic indicators, such as ductal cancer, high tumor grade, ER negativity, PR negativity, HER2 positivity and aggressive molecular subtypes.","['_gene_', 'expression', 'was', 'found', 'to', 'be', 'associated', 'with', 'several', 'poor', 'prognostic', 'indicators', 'such', 'as', 'ductal', 'cancer', 'high', 'tumor', 'grade', 'er', 'negativity', 'pr', 'negativity', '_gene_', 'positivity', 'and', 'aggressive', 'molecular', '_disease_']"
709,1.0,"243 primary PCa, 37 metastatic PCa, and  20  castration-resistant  PCa  (CRPC) specimens underwent IHC and microarray analysis.","['_num_', 'primary', '_disease_', '_num_', 'metastatic', '_disease_', 'and', '_num_', 'castration', 'resistant', '_disease_', '_disease_', 'specimens', 'underwent', '_gene_', 'and', 'microarray', 'analysis']"
710,1.0,"Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion.","['of', 'these', '_num_', 'patients', '_num_', 'were', 'found', 'to', 'have', 'a', '_chemical_', 'fusion']"
711,1.0,"On the basis of this and a Phase II study, accelerated approval for crizotinib in ALK-positive advanced NSCLC was granted.","['on', 'the', 'basis', 'of', 'this', 'and', 'a', 'phase', 'ii', 'study', 'accelerated', 'approval', 'for', '_chemical_', 'in', '_disease_', 'advanced', '_disease_', 'was', 'granted']"
712,1.0,This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.,"['this', 'phase', 'ii', 'single', 'arm', 'study', 'assessed', '_chemical_', 'monotherapy', 'in', '_gene_', 'positive', 'endometrial', 'cancers', 'with', 'tumor', 'response', 'as', 'primary', 'endpoint']"
713,1.0,Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.,"['downstream', 'signalling', 'was', 'independent', 'of', 'inhibitor', 'presence', 'in', 'these', 'clones', 'and', 'expression', 'of', 'the', 'mutations', 'in', '_disease_', 'cells', 'led', 'to', 'resistance']"
714,1.0,"Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.","['other', 'identified', 'aberrations', 'include', '_gene_', 'amplification', '_num_', 'copies', '_gene_', 'amplification', '_num_', 'copies', 'as', 'well', 'as', '_gene_', '_mutation_', '_gene_', '_mutation_', 'and', '_gene_', '_mutation_']"
715,1.0,66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years.,"['_num_', '_disease_', 'patients', 'treated', 'with', 'chemoradiation', 'were', 'assessed', 'for', 'survival', 'after', 'a', 'follow', 'up', 'time', 'of', '_num_', 'years']"
716,1.0,"9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006).","['_num_', 'of', '_num_', '_gene_', 'expressing', 'patients', 'showed', 'objective', 'response', 'and', '_num_', 'of', '_num_', '_gene_', 'negative', 'patients', 'showed', 'objective', 'response', '_p_val_']"
717,1.0,"This study demostrated that the progression-free survival, metastasis-free survival, and cancer-specific survival was significantly increased in patients with T393 homozygosity ie TT genotypes (56%, 84%, 82%) compared with CC genotypes (35%, 53%, 58%).","['this', 'study', 'demostrated', 'that', 'the', 'progression', 'free', 'survival', 'metastasis', 'free', 'survival', 'and', '_disease_', 'survival', 'was', 'significantly', 'increased', 'in', 'patients', 'with', '_abbrev_', 'homozygosity', 'ie', 'tt', 'genotypes', '_num_', '_num_', '_num_', 'compared', 'with', 'cc', 'genotypes', '_num_', '_num_', '_num_']"
718,1.0,NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).,"['_disease_', 'patients', 'with', 'exon', '_num_', 'deletions', 'in', '_gene_', 'had', 'longer', 'overall', 'survival', 'than', 'patients', 'with', 'an', '_mutation_', 'mutation', 'when', 'treated', 'with', '_chemical_', 'or', '_chemical_', '_num_', 'vs', '_num_', 'months', 'p', '_num_']"
719,1.0,"Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia.","['responses', 'were', 'associated', 'with', 'cellular', 'differentiation', 'and', 'maturation', 'typically', 'without', 'evidence', 'of', 'aplasia']"
720,1.0,"Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses.","['rb', 'proficient', 'cell', 'lines', 'with', 'low', '_gene_', 'expression', 'were', 'significantly', 'more', 'sensitive', 'to', '_disease_', 'as', 'defined', 'by', '_abbrev_', 'mean', 'in', 'mrna', 'expression', 'agilent', 'protein', 'level', 'western', 'blot', 'and', 'copy', 'number', 'array', '_gene_', 'analyses']"
721,1.0,12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells.,"['_num_', 'patients', 'showed', 'clearance', 'or', 'near', 'clearance', 'of', 'bone', 'marrow', 'myeloblasts', 'after', '_num_', 'range', '_range_', 'days', 'with', 'evidence', 'of', 'differentiation', 'of', 'leukemia', 'cells']"
722,1.0,"In other words, expression of CBLC is predicted to confer resistance to olaparib.","['in', 'other', 'words', 'expression', 'of', '_gene_', 'is', 'predicted', 'to', 'confer', 'resistance', 'to', '_chemical_']"
723,1.0,438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC.,"['_num_', 'patients', 'with', '_disease_', 'clear', 'cell', 'renal', 'carcinoma', 'were', 'were', 'retrospectively', 'analysed', 'for', '_gene_', 'expression', 'via', '_gene_']"
724,1.0,"Xengraft treatment with trastuzumab and AZD5363 monotherapy induced moderate growth inhibition which was significant for AZD5363, but co-treatment with trastuzumab and AZD5363 induced significant tumor regression and enhanced growth delay upon removal of treatment.","['xengraft', 'treatment', 'with', '_chemical_', 'and', '_chemical_', 'monotherapy', 'induced', 'moderate', 'growth', 'inhibition', 'which', 'was', 'significant', 'for', '_chemical_', 'but', 'co', 'treatment', 'with', '_chemical_', 'and', '_chemical_', 'induced', 'significant', 'tumor', 'regression', 'and', 'enhanced', 'growth', 'delay', 'upon', 'removal', 'of', 'treatment']"
725,1.0,"NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer.","['_gene_', '_disease_', 'mutations', 'including', '_abbrev_', 'called', '_abbrev_', 'in', 'publication', 'have', 'shown', 'to', 'be', 'correlated', 'to', 'poor', 'prognosis', 'in', 'lung', 'cancer']"
726,1.0,Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months.,"['combined', '_gene_', 'and', '_gene_', 'inhibition', 'panitumumab', 'and', '_chemical_', 'showed', 'an', 'initial', 'partial', 'response', 'for', '_num_', 'months']"
727,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_mutation_', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
728,1.0,"Three patients had retinal angiomas, 7 hand hemangioblastomas of the central nervous system, 7 had renal cell carcinoma, and 6 had pancreatic cysts (family VHL 3).","['_num_', 'patients', 'had', 'retinal', 'angiomas', '_num_', 'hand', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'had', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'had', 'pancreatic', 'cysts', 'family', '_gene_', '_num_']"
729,1.0,"In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589 patients were BRAF wild type.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'colorectal', 'cancer', '_gene_', '_num_', 'patients', 'had', '_gene_', '_abbrev_', 'mutations', 'and', '_num_', 'patients', 'were', '_gene_', 'wild', 'type']"
730,1.0,"In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations.","['in', 'children', 'with', 'bone', 'marrow', 'relapsed', '_disease_', 'precursor', 'acute', '_disease_', 'leukemia', 'in', 'multivariate', 'analysis', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'worse', 'event', 'free', 'survival', 'than', 'patients', 'without', 'mutations']"
731,1.0,Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.,"['_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'vascular', 'invasion', 'by', 'cancer', 'cells', 'in', 'gastric', 'cancers']"
732,0.0,"FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1.","['_abbrev_', 'breast', 'cancer', 'cell', 'lines', 'show', 'resistance', 'to', '_disease_', 'which', 'is', 'reversed', 'by', 'small', 'interfering', 'rna', 'silencing', 'of', '_gene_']"
733,1.0,329 consecutive patients with stage II–III colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR.,"['_num_', 'consecutive', 'patients', 'with', 'stage', 'ii–iii', 'colorectal', 'tumors', 'with', '_gene_', 'after', 'surgical', 'resection', 'at', 'tertiary', 'medical', 'centers', 'were', 'screened', 'for', '_gene_', 't', '_num_', 'by', '_disease_']"
734,1.0,Preclinical study in thyroid cancer cell lines.,"['preclinical', 'study', 'in', 'thyroid', 'cancer', 'cell', 'lines']"
735,1.0,"One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment).","['_num_', 'patient', 'in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'metastatic', 'prostate', 'cancer', 'had', 'a', 'frameshift', 'mutation', 'in', 'the', '_gene_', 'atm', '_gene_', 'and', '_gene_', 'genes', 'and', 'showed', 'clinical', 'response', 'to', '_gene_', 'inhibitor', '_chemical_', '_num_', 'weeks', 'on', 'treatment']"
736,1.0,57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms.,"['_num_', 'from', '_num_', 'patients', 'in', 'the', 'ago', '_gene_', '_num_', 'trial', 'were', 'retrospectively', 'genotyped', 'for', '_gene_', 'polymorphisms']"
737,1.0,The SM3 cell line harboring a D820Y mutation showed significant growth inhibition with sunitinib exposures of 1uM and 10uM.,"['the', '_chemical_', 'cell', 'line', 'harboring', 'a', '_mutation_', 'mutation', 'showed', 'significant', 'growth', 'inhibition', 'with', '_chemical_', 'exposures', 'of', '_unit_', 'and', '_unit_']"
738,1.0,Case-report of a patient with an acquired ALK L1152R mutation and resistance to crizotinib treatment.,"['case', 'report', 'of', 'a', 'patient', 'with', 'an', 'acquired', '_gene_', '_mutation_', 'mutation', 'and', 'resistance', 'to', '_chemical_', 'treatment']"
739,1.0,"Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001).","['among', 'the', '_num_', 'tumors', '_num_', 'of', '_num_', 'patients', '_num_', 'with', '_gene_', '_gene_', 'and', 'or', '_gene_', 'alterations', 'achieved', '_num_', 'month', 'progression', 'free', 'survival', '_abbrev_', 'vs', 'none', 'of', '_num_', 'patients', 'without', 'alterations', 'p', '_num_']"
740,1.0,"FDG-PET imaging on day 7 showed FDG uptake (mean SUV max) of 0.219 and 0.500 in HCT116 xenografts expressing the reference allele (G) and substitution allele (C) of PPP1R15A rs557806, respectively (P = 0.032).","['_chemical_', 'imaging', 'on', 'day', '_num_', 'showed', '_gene_', 'uptake', 'mean', 'suv', 'max', 'of', '_num_', 'and', '_num_', 'in', '_abbrev_', 'xenografts', 'expressing', 'the', 'reference', 'allele', '_unit_', 'and', 'substitution', 'allele', 'c', 'of', '_gene_', '_mutation_', 'respectively', 'p', '_num_']"
741,1.0,This mutation causes a premature stop codon at amino acid 173 and was found in a VHL type 1 patient (patient no V235).,"['this', 'mutation', 'causes', 'a', 'premature', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
742,0.0,MEK1 mutations define a distinct subset of lung cancers (∼1%) with potential sensitivity to MEK inhibitors.,"['_gene_', 'mutations', 'define', 'a', 'distinct', 'subset', 'of', 'lung', 'cancers', '∼1', 'with', 'potential', 'sensitivity', 'to', 'mek', 'inhibitors']"
743,1.0,"This missense mutation was found in a German, VHL type 1 family of 2.","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'family', 'of', '_num_']"
744,1.0,"This nonsense mutation was found in a VHL family with retinal angiomas, cerebellar hemangioblastomas, renal cell carcinoma, and pheochromocytoma.","['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'family', 'with', 'retinal', 'angiomas', 'cerebellar', '_disease_', 'renal', 'cell', 'carcinoma', 'and', 'pheochromocytoma']"
745,1.0,"Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.","['thus', '_chemical_', 'was', 'studied', 'in', 'this', 'phase', 'i', 'trial', 'of', '_chemical_', 'progressed', '_gene_', 'positive', 'metastatic', 'bc', '_gene_', 'in', 'combination', 'with', 'continued', '_chemical_', 'treatment', 'where', '_chemical_', 'is', 'still', 'the', 'perferred', 'treatment', 'for', '_chemical_', 'progressed', '_gene_']"
746,1.0,Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.,"['preclinical', 'study', 'showing', '_gene_', 'amplification', 'in', '_disease_', 'and', 'efficacy', 'of', '_gene_', 'inhibition', 'in', '_num_', 'amplified', 'cell', 'line']"
747,1.0,"Compatible with a gene-dose effect, homozygous CC patients were at highest risk for death (hazard ratio, 12.1; P = 0.006) compared with TT genotypes and heterozygous patients had an intermediate risk.","['compatible', 'with', 'a', 'gene', 'dose', 'effect', 'homozygous', 'cc', 'patients', 'were', 'at', 'highest', 'risk', 'for', 'death', 'hazard', 'ratio', '_num_', 'p', '_num_', 'compared', 'with', 'tt', 'genotypes', 'and', 'heterozygous', 'patients', 'had', 'an', 'intermediate', 'risk']"
748,1.0,Molecular characterization of H3122 CHR-A1 revealed a V1180L ALK kinase domain mutation.,"['molecular', 'characterization', 'of', '_abbrev_', '_abbrev_', 'revealed', 'a', '_mutation_', '_gene_', 'kinase', 'domain', 'mutation']"
749,1.0,"Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survival yrs: CALR 15.9, JAK2 5.9)","['study', 'of', '_num_', 'patients', 'with', 'primary', 'myelofibrosis', 'found', 'that', 'those', 'patients', 'harboring', '_gene_', 'exon', '_num_', 'mutations', 'displayed', 'significantly', 'longer', 'survival', 'than', 'those', 'with', '_gene_', 'mutations', 'hr', '_num_', 'median', 'survival', 'yrs', '_gene_', '_num_', '_gene_', '_num_']"
750,1.0,Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications.,"['clinical', 'trial', 'studied', 'the', 'efficacy', 'of', '_chemical_', 'on', '_num_', 'patients', 'with', '_gene_', 'amplifications']"
751,1.0,"In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively.","['in', 'total', '_num_', '_num_', 'patients', '_num_', 'with', 'increased', 'gene', 'copy', 'number', '_num_', '_num_', 'patients', '_num_', 'with', 'increased', 'gene', 'copy', 'number', 'and', '_num_', 'studies', '_num_', 'patients', '_num_', 'with', 'increased', 'gene', 'copy', 'number', 'were', 'analyzed', 'for', 'overall', 'survival', 'os', 'progression', 'free', 'survival', '_disease_', 'and', '_disease_', '_gene_', '_disease_', 'analyses', 'respectively']"
752,1.0,"Progressive disease at 4 months led to the addition of paclitaxel, resulting in partial response.","['progressive', 'disease', 'at', '_num_', 'months', 'led', 'to', 'the', 'addition', 'of', '_chemical_', 'resulting', 'in', 'partial', 'response']"
753,1.0,Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compared with the TT genotype (p = 0.002).,"['median', 'os', 'was', 'significantly', 'shorter', 'in', 'patients', 'with', '_gene_', '_chemical_', '_disease_', 'or', '_gene_', 'genotypes', 'compared', 'with', 'the', 'tt', 'genotype', 'p', '_num_']"
754,1.0,"Taken together, WRD5 inhibition is a potential therapeutic method for patients harboring N-terminal CEBPA mutations.","['taken', 'together', '_abbrev_', 'inhibition', 'is', 'a', 'potential', 'therapeutic', 'method', 'for', 'patients', 'harboring', '_chemical_', '_gene_', 'mutations']"
755,1.0,p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients).,"['_gene_', 'was', 'the', 'only', 'protein', 'that', 'served', 'as', 'a', 'predictive', '_chemical_', 'of', 'response', 'after', 'multivariate', 'analysis', '_p_val_', '_ineq_', 'patients']"
756,1.0,Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.,"['gefinitib', 'has', 'been', 'shown', 'to', 'be', 'effective', 'in', 'treating', 'cell', 'lines', 'with', '_mutation_', 'missense', 'mutations']"
757,1.0,"In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment.","['in', 'this', 'phase', 'i', 'trial', '_abbrev_', 'in', '_num_', 'patients', '_chemical_', 'was', 'assessed', 'for', 'its', 'effectiveness', 'in', 'treating', 'locally', 'advanced', 'or', 'metastatic', '_disease_', '_disease_', 'that', 'had', 'progressed', 'or', 'been', 'resistant', 'to', '_chemical_', 'treatment']"
758,1.0,"Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression.","['prior', 'to', 'the', 'development', 'of', 'the', '_gene_', '_mutation_', 'mutation', 'the', 'patient', 'was', 'treated', 'with', '_chemical_', 'followed', 'by', '_chemical_', 'for', '_num_', 'months', 'and', 'achieved', 'stable', 'disease', 'but', 'subsequently', 'metastasis', 'occurred', 'the', '_gene_', '_mutation_', 'was', 'then', 'identified', 'and', 'subsequent', '_num_', 'month', 'treatment', 'with', 'osimertinib', 'monotherapy', 'resulted', 'in', 'a', '_num_', 'disease', 'regression']"
759,1.0,"Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib.","['also', '_num_', 'of', '_num_', 'patients', 'throughout', 'the', 'cohorts', 'with', 'measurable', 'baseline', 'cns', 'lesions', 'showed', 'partial', 'response', 'to', '_chemical_']"
760,1.0,All six had retinal angiomas and 2 had cerebellar hemangioblastomas.,"['all', '_num_', 'had', 'retinal', 'angiomas', 'and', '_num_', 'had', 'cerebellar', '_disease_']"
761,1.0,"The C1156Y mutation was confirmed in a sample prior to initial crizotinib (<7% of cells), following crizotinib treatment (~50% of cells) and following lorlatinib resistance (100% of cells).","['the', '_mutation_', 'mutation', 'was', 'confirmed', 'in', 'a', 'sample', 'prior', 'to', 'initial', '_chemical_', '_num_', 'of', 'cells', 'following', '_chemical_', 'treatment', '_num_', 'of', 'cells', 'and', 'following', 'lorlatinib', 'resistance', '_num_', 'of', 'cells']"
762,1.0,"In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib.","['in', 'this', 'phase', '_num_', 'trial', '_num_', 'patients', 'with', 'advanced', 'solid', 'tumors', 'ovarian', 'breast', 'colorectal', 'melanoma', 'sarcoma', 'prostate', 'were', 'treated', 'with', '_gene_', 'inhibitor', '_chemical_']"
763,1.0,"After 9 and 5 months of therapy, respectively, the patient and her brother resumed normal schooling and daily activities.","['after', '_num_', 'and', '_num_', 'months', 'of', 'therapy', 'respectively', 'the', 'patient', 'and', 'her', 'brother', 'resumed', 'normal', 'schooling', 'and', 'daily', 'activities']"
764,1.0,A bone marrow biopsy showed complete clearance by variant allele frequency and the patient remains in remission 4-years post matched-unrelated donor allograft.,"['a', 'bone', 'marrow', 'biopsy', 'showed', 'complete', 'clearance', 'by', 'variant', 'allele', 'frequency', 'and', 'the', 'patient', 'remains', 'in', 'remission', '_num_', 'years', 'post', 'matched', 'unrelated', 'donor', 'allograft']"
765,1.0,"Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patients (19.3%) with complete response was 19.7 months.","['median', 'overall', 'survival', 'among', 'relapsed', 'refractory', 'patients', 'was', '_num_', 'months', 'and', 'for', 'the', '_num_', 'patients', '_num_', 'with', 'complete', 'response', 'was', '_num_', 'months']"
766,1.0,KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer.,"['_gene_', 'exon', '_num_', 'was', 'mutated', 'in', '_num_', 'of', '_num_', 'patients', 'with', 'advanced', 'pancreatic', 'cancer']"
767,1.0,"HPO terms: hemangioblastoma, papillary cystadenomas of the broad ligament.","['_disease_', 'terms', '_disease_', 'papillary', '_disease_', 'of', 'the', 'broad', 'ligament']"
768,1.0,The 65-year-old father had renal cell carcinoma; The 37-year old sister had pancreatic cysts and the 33-year old sister had retinal angiomas.,"['the', '_age_', 'father', 'had', 'renal', 'cell', 'carcinoma', 'the', '_num_', 'year', 'old', 'sister', 'had', 'pancreatic', 'cysts', 'and', 'the', '_num_', 'year', 'old', 'sister', 'had', 'retinal', 'angiomas']"
769,1.0,"Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68).","['patients', 'with', '_gene_', 'positive', 'tumors', '_gene_', 'tumor', 'cell', 'staining', '_ineq_', 'had', 'a', 'significantly', 'higher', 'orr', 'compared', 'to', 'patients', 'with', '_gene_', 'negative', 'tumors', 'or', '_num_', '_num_', 'cis', '_range_']"
770,1.0,"In an in vitro study, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.34-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein']"
771,1.0,Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement.,"['case', 'report', 'of', 'a', 'pediatric', 'patient', 'with', 'treatment', 'refactory', 'inflammatory', 'myofibroblastic', 'tumor', 'negative', 'for', '_gene_', 'expression', 'and', 'rearrangement']"
772,1.0,These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.,"['these', 'results', 'indicate', 'the', '_gene_', '_mutation_', 'variant', 'as', 'a', 'growth', 'pathway', 'driver', 'targetable', 'by', '_chemical_']"
773,1.0,"Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.","['breast', 'cancer', 'patients', 'who', 'harbor', '_mutation_', 'mutation', 'have', 'worse', 'overall', 'survival', 'than', 'those', 'with', 'wild', 'type', '_gene_', 'but', 'have', 'better', 'prognosis', 'than', 'those', 'with', '_mutation_', 'mutation']"
774,1.0,Median PFS in the KRAS wild type arm was 2.4 months for erlotinib alone and 2.1 months for the combination.,"['median', '_disease_', 'in', 'the', '_gene_', 'wild', 'type', 'arm', 'was', '_num_', 'months', 'for', '_chemical_', 'alone', 'and', '_num_', 'months', 'for', 'the', 'combination']"
775,1.0,The patient group with the longest progression free survival was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression.,"['the', 'patient', 'group', 'with', 'the', 'longest', 'progression', 'free', 'survival', 'was', 'characterized', 'by', 'co', 'occurrence', 'of', 'low', '_gene_', 'and', 'high', '_gene_', 'mrna', 'expression']"
776,1.0,"mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC.","['mrna', 'levels', 'of', '_gene_', '_gene_', 'and', '_gene_', 'were', 'assessed', 'rt', 'pcr', 'in', '_num_', 'patient', 'samples', 'of', '_disease_']"
777,1.0,Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR.,"['_num_', 'potential', 'fusions', 'were', 'found', 'and', 'assessed', 'using', 'rna', 'ligase', 'mediated', 'rapid', 'amplifiation', 'of', 'cdna', 'ends', 'and', '_disease_']"
778,1.0,"One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months.","['_num_', 'of', 'them', 'had', 'already', 'died', 'the', 'other', 'received', 'treatment', 'with', 'panitumumab', 'and', 'had', 'a', 'partial', 'response', '_num_', 'tumor', 'reduction', 'in', 'all', 'liver', 'lesions', 'for', '_num_', 'months']"
779,1.0,"JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL).","['_gene_', '_mutation_', 'is', 'not', 'associated', 'with', 'lymphoid', 'leukemia', 'b', 'lineage', 'all', '_disease_', 'or', '_disease_']"
780,1.0,A locally recurrent tumor was excised (and found HER2-negative) and the patient continued on lapatinib (for 2 years) as well as 5 cycles 5-FU and irinotecan.,"['a', 'locally', 'recurrent', 'tumor', 'was', 'excised', 'and', 'found', '_gene_', 'and', 'the', 'patient', 'continued', 'on', '_chemical_', 'for', '_num_', 'years', 'as', 'well', 'as', '_num_', 'cycles', '_chemical_', 'and', '_chemical_']"
781,1.0,"Addition of SGK1 reduced viability over alpelisib alone, and phospho-S6K as well as phospho-4EBP1 levels decreased with combination treatment.","['addition', 'of', '_gene_', 'reduced', 'viability', 'over', 'alpelisib', 'alone', 'and', '_gene_', 'as', 'well', 'as', '_abbrev_', 'levels', 'decreased', 'with', 'combination', 'treatment']"
782,1.0,SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO.,"['_gene_', '', '', '', 'mouse', 'embryonic', 'fibroblasts', 'expressing', 'the', '_gene_', '_abbrev_', 'mutant', 'maintained', 'hedgehog', 'signaling', 'in', 'the', 'presence', 'of', 'the', 'drug', 'and', 'had', '_abbrev_', 'values', '_num_', 'fold', 'higher', 'than', 'cells', 'expressing', 'wildtype', '_gene_']"
783,1.0,The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage.,"['the', 'combination', 'of', '_gene_', 'inhibition', '_chemical_', 'with', '_gene_', 'mutation', 'results', 'in', 'irreparable', 'and', 'lethal', 'dna', 'damage']"
784,1.0,Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.,"['increasing', 'level', 'of', '_gene_', 'mutant', 'correlated', 'with', 'reduced', '_disease_', 'and', 'overall', 'survival', 'as', 'well', 'as', 'increased', 'relapse', 'rate']"
785,1.0,"In patients with nonacral cutaneous melanoma, those with mutations in the TERT promoter had shorter overall survival than wild type patients.","['in', 'patients', 'with', 'nonacral', 'cutaneous', 'melanoma', 'those', 'with', 'mutations', 'in', 'the', '_gene_', 'promoter', 'had', 'shorter', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
786,1.0,"A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells.","['a', 'marked', 'synergistic', 'apoptotic', 'effect', 'under', '_chemical_', 'and', '_chemical_', 'co', 'treatment', 'was', 'observed', 'in', '_abbrev_', 'cells', 'and', 'a', 'milder', 'synergistic', 'effect', 'was', 'observed', 'in', '_abbrev_', 'cells']"
787,1.0,"However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later.","['however', 'during', 'the', '_num_', 'week', 'of', 'therapy', 'the', 'patient', 'rapidly', 'developed', 'skin', 'tumors', 'and', 'died', '_num_', 'months', 'later']"
788,1.0,"In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib.","['in', 'the', '_num_', 'part', 'of', 'this', 'phase', 'i', 'study', '_abbrev_', '_num_', 'patients', 'between', 'the', 'ages', 'of', '_num_', 'months', 'and', '_num_', 'years', 'with', 'anaplastic', 'large', 'cell', 'lymphoma', '_disease_', 'who', 'were', 'refractory', 'to', 'treatment', 'and', 'for', 'whom', 'no', 'further', 'known', 'treatments', 'were', 'available', 'were', 'treated', 'with', '_chemical_']"
789,1.0,Retrospective analysis of the Danish tumor bank.,"['retrospective', 'analysis', 'of', 'the', 'danish', 'tumor', 'bank']"
790,1.0,"This confirmed results from univariate analysis of patients not stratified by ELN category, but cytogenetically normal and older (38/220 patients).","['this', 'confirmed', 'results', 'from', 'univariate', 'analysis', 'of', 'patients', 'not', 'stratified', 'by', 'eln', 'category', 'but', 'cytogenetically', 'normal', 'and', 'older', '_ratio_', 'patients']"
791,1.0,This variant was detected in a single case with clear-cell renal cell carcinoma.,"['this', 'variant', 'was', 'detected', 'in', 'a', 'single', 'case', 'with', 'clear', 'cell', 'renal', 'cell', 'carcinoma']"
792,1.0,Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.,"['canonical', '_gene_', 'signaling', 'in', 'colon', 'carcinoma', 'cells', 'with', 'apc', 'mutation', 'was', 'inhibited', 'by', '_abbrev_', 'treatment']"
793,1.0,"In this cohort, aspirin use was associated with a lower relative risk of colorectal cancer (RR=0.73; 95% CI 0.69-0.87; p<0.001).","['in', 'this', 'cohort', 'aspirin', 'use', 'was', 'associated', 'with', 'a', 'lower', 'relative', 'risk', 'of', 'colorectal', 'cancer', '_ineq_', '_num_', 'ci', '_range_', 'p', '_num_']"
794,1.0,phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation.,"['_gene_', 'ribosomal', 'protein', 'staining', 'was', 'observed', 'in', 'the', 'tumor', 'indicating', '_gene_', 'pathway', 'activation']"
795,1.0,Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy.,"['treatment', 'response', 'to', 'mutant', '_gene_', 'inhibitor', '_chemical_', 'and', '_gene_', 'inhibitor', 'panitumumab', 'was', 'assayed', 'in', '_num_', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', '_gene_', 'who', 'had', 'progressed', 'on', 'chemotherapy']"
796,1.0,Median PFS was 8.9 months and median OS was 14.4. months.,"['median', '_disease_', 'was', '_num_', 'months', 'and', 'median', 'os', 'was', '_num_', 'months']"
797,1.0,HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab.,"['_gene_', 'amplification', 'fish', 'was', 'assessed', 'in', '_num_', '_gene_', '_gene_', '_disease_', 'patients', 'treated', 'with', '_chemical_', 'or', 'panitumumab']"
798,1.0,"Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression.","['of', 'those', '_num_', '_num_', 'patients', 'had', 'a', 'low', '_gene_', 'expression', 'and', '_num_', 'had', 'a', 'high', '_gene_', 'expression']"
799,1.0,"Each individual had retinal angiomas, one had hemangioblastomas of the central nervous system, one had renal cell carcinoma, and one had pancreatic cysts.","['each', 'individual', 'had', 'retinal', 'angiomas', '_num_', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'had', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'had', 'pancreatic', 'cysts']"
800,1.0,Patients who were homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rates and a tendency toward greater overall response rate than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073) when treated with bevacizumab-containing regimens.,"['patients', 'who', 'were', 'homozygous', 'for', 'the', 'reference', 'alleles', '_disease_', 'of', '_gene_', '_mutation_', 'exhibited', 'greater', 'disease', 'control', 'rates', 'and', 'a', 'tendency', 'toward', 'greater', 'overall', 'response', 'rate', 'than', 'those', 'with', 'homozygous', 'or', 'heterozygous', 'substitution', 'alleles', 'gc', 'and', 'cc', 'p', '_num_', 'and', '_num_', 'when', 'treated', 'with', '_chemical_', 'containing', 'regimens']"
801,1.0,"OICR-9429, a small molecule inhibitor of WRD5, and anti-WRD5 siRNAs selectively inhibited colony formation of mouse fetal liver cells homozygous for N-terminal CEBPA mutations but not wildtype colony formation.","['_abbrev_', 'a', 'small', 'molecule', 'inhibitor', 'of', '_abbrev_', 'and', '_abbrev_', 'sirnas', 'selectively', 'inhibited', 'colony', 'formation', 'of', 'mouse', 'fetal', 'liver', 'cells', 'homozygous', 'for', '_chemical_', '_gene_', 'mutations', 'but', 'not', 'wildtype', 'colony', 'formation']"
802,1.0,Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins.,"['subsequent', 'robotic', 'assisted', 'lobectomy', 'was', 'able', 'to', 'remove', 'the', 'previously', 'unresectable', 'tumor', 'with', 'clean', 'surgical', 'margins']"
803,0.0,"Endpoints were associations between genotype of UGT1A1 and pharmacokinetics, toxicities and proteine lysine acetylation.","['endpoints', 'were', 'associations', 'between', 'genotype', 'of', '_gene_', 'and', 'pharmacokinetics', 'toxicities', 'and', 'proteine', 'lysine', 'acetylation']"
804,1.0,"This study showed that low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001).","['this', 'study', 'showed', 'that', 'low', '_gene_', 'mrna', 'expression', 'was', 'strongly', 'predictive', 'for', 'prolonged', 'time', 'to', 'progression', 'treatment', 'response', 'and', 'length', 'of', 'survival', 'in', 'univariate', 'and', 'multivariate', 'models', 'p', '_num_']"
805,1.0,"In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684.","['in', 'a', 'panel', 'of', '_num_', 'cancer', 'cell', 'lines', '_ratio_', '_disease_', 'cell', 'lines', 'showed', '_num_', 'cell', 'viability', 'following', 'treatment', 'with', 'the', '_gene_', 'inhibitor', '_chemical_']"
806,1.0,This missense mutation was found in a VHL type 2 family (lineage 174).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
807,0.0,"Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3≥50%, TC2≥5% and <50%, TC1≥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3≥10%, IC2≥5% and <10%, IC1≥1% and <5%, and IC0<1%).","['baseline', '_gene_', 'expression', '_gene_', 'was', 'assessed', 'in', 'tumour', 'cells', 'as', 'percentage', 'of', '_abbrev_', 'tumour', 'cells', '_ineq_', '_ineq_', 'and', '_num_', '_ineq_', 'and', '_num_', 'and', '_abbrev_', '_num_', 'and', '_disease_', 'immune', 'cells', 'as', 'percentage', 'of', 'tumour', 'area', '_ineq_', '_ineq_', 'and', '_num_', '_ineq_', 'and', '_num_', 'and', '_abbrev_', '_num_']"
808,1.0,The response rates were highest among patients with MYD88(L265P) and CXCR4(WT).,"['the', 'response', 'rates', 'were', 'highest', 'among', 'patients', 'with', '_gene_', '_mutation_', 'and', '_gene_', '_gene_']"
809,1.0,Multivariate regression analysis indicated that high cytoplasmic FGF13 staining was associated with BCR.,"['multivariate', 'regression', 'analysis', 'indicated', 'that', 'high', 'cytoplasmic', '_gene_', 'staining', 'was', 'associated', 'with', '_gene_']"
810,1.0,"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1.","['massively', 'parallel', 'whole', 'transcriptome', 'sequencing', 'in', '_num_', 'specimens', 'from', '_disease_', 'patients', 'identified', '_num_', 'fusion', 'kinase', 'genes', '_abbrev_', 'and', '_abbrev_']"
811,1.0,"In a study of 413 patients with colorectal cancer who were taking aspirin since diagnosis, the frequency of PIK3CA mutations was 17% (70/413).","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'colorectal', 'cancer', 'who', 'were', 'taking', 'aspirin', 'since', 'diagnosis', 'the', 'frequency', 'of', '_gene_', 'mutations', 'was', '_num_', '_ratio_']"
812,1.0,Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone.,"['mouse', 'xenografts', 'of', '_num_', 'different', '_gene_', 'mutant', 'breast', 'cancer', 'cells', 'resistant', 'to', '_gene_', 'inhibitor', 'showed', 'stronger', 'regression', 'under', 'dual', '_gene_', 'inhibitor', 'and', 'ribociclib', 'treatment', 'than', 'with', 'either', 'treatment', 'alone']"
813,1.0,Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.,"['cells', 'harboring', '_gene_', '_mutation_', 'mutation', 'were', 'insensitive', 'to', '_chemical_', 'treatment', 'in', 'isogenic', '_abbrev_', 'cells', 'and', 'in', 'a', 'mouse', 'xenograft', 'model']"
814,1.0,"In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified.","['in', 'an', 'in', 'vitro', 'study', 'using', 'an', 'in', 'vitro', 'saturation', 'mutagenesis', 'assay', '_num_', 'residues', 'with', '_abbrev_', '_chemical_', 'resistance', 'conferring', 'mutations', 'in', 'the', 'kinase', 'domain', 'of', '_gene_', 'were', 'identified']"
815,1.0,"The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L).","['the', 'cell', 'line', '_abbrev_', 'with', '_gene_', 'mutation', '_abbrev_', 'was', 'hypersensitive', 'to', '_gene_', 'treatment', '_abbrev_', 'of', '_num_', '_unit_', '_unit_']"
816,1.0,The tumor also harbored a silent THR157THR (471T>A) somatic variant.,"['the', 'tumor', 'also', 'harbored', 'a', 'silent', '_abbrev_', '471t', 'a', 'somatic', 'variant']"
817,1.0,The patient group with the longest PFS was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression.,"['the', 'patient', 'group', 'with', 'the', 'longest', '_disease_', 'was', 'characterized', 'by', 'co', 'occurrence', 'of', 'low', '_gene_', 'and', 'high', '_gene_', 'mrna', 'expression']"
818,1.0,15 patients were enrolled (14 BRAF wt).,"['_num_', 'patients', 'were', 'enrolled', '_num_', '_gene_', '_gene_']"
819,1.0,Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells.,"['increased', '_gene_', 'stain', 'was', 'seen', 'with', 'ectopic', 'mutant', '_gene_', 'over', 'wildtype', 'cells']"
820,1.0,A 79 year old patient with prior history of graves' disease presented with follicular thyroid carcinoma.,"['a', '_num_', 'year', 'old', 'patient', 'with', 'prior', 'history', 'of', 'graves', 'disease', 'presented', 'with', 'follicular', 'thyroid', 'carcinoma']"
821,1.0,The ORR in the KRAS mutant group was 0% for selumetinib alone and 10% for the combination.,"['the', 'orr', 'in', 'the', '_gene_', 'mutant', 'group', 'was', '_num_', 'for', '_chemical_', 'alone', 'and', '_num_', 'for', 'the', 'combination']"
822,1.0,we state this is a first report of response to prospective MET targeted therapy in GBM.,"['we', 'state', 'this', 'is', 'a', '_num_', 'report', 'of', 'response', 'to', 'prospective', 'met', 'targeted', 'therapy', 'in', '_disease_']"
823,1.0,Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy.,"['complete', 'molecular', 'remission', 'of', '_chemical_', 'was', 'observed', 'in', '_num_', 'of', '_num_', 'patients', 'tested', 'post', 'therapy']"
824,1.0,"Upon a lowered dosage to 200mg of imatinib, the nodules returned and subsequently the dosage was increased to 600mg/day.","['upon', 'a', 'lowered', 'dosage', 'to', '_unit_', 'of', '_chemical_', 'the', 'nodules', 'returned', 'and', 'subsequently', 'the', 'dosage', 'was', 'increased', 'to', '_unit_', 'day']"
825,1.0,"One patient had stable disease, PFS 6.5 months, OS 15.2 months, and was not alive at study end.","['_num_', 'patient', 'had', 'stable', 'disease', '_disease_', '_num_', 'months', 'os', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
826,1.0,"In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'endogenously', 'expressing', '_gene_', '_mutation_', 'mutation', 'a', 'known', '_chemical_', 'sensitizing', 'mutation', 'and', 'overexpressing', '_gene_', '_mutation_', 'mutation', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', 'as', 'compared', 'to', 'cells', 'expressing', '_gene_', '_mutation_', 'mutation', 'and', 'wildtype', '_gene_']"
827,1.0,This work showed that TERT promoter mutations were significantly more prevalent in the tall cell papillary thyroid carcinoma (PTC) samples than in the conventional PTC and follicular variant PTC samples.,"['this', 'work', 'showed', 'that', '_gene_', 'promoter', 'mutations', 'were', 'significantly', 'more', 'prevalent', 'in', 'the', 'tall', 'cell', 'papillary', 'thyroid', 'carcinoma', '_gene_', 'samples', 'than', 'in', 'the', 'conventional', '_gene_', 'and', 'follicular', 'variant', '_gene_', 'samples']"
828,1.0,"This mutation was found in a 30-year-old VHL patient with hemangioblastomas of the central nervous system, retinal angiomas, renal cell carcinoma, and pancreatic cysts (proband no 16).","['this', 'mutation', 'was', 'found', 'in', 'a', '_age_', '_gene_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'retinal', 'angiomas', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'proband', 'no', '_num_']"
829,1.0,This fusion is also shown to be recurrent in multiple other cancer types.,"['this', 'fusion', 'is', 'also', 'shown', 'to', 'be', 'recurrent', 'in', 'multiple', 'other', 'cancer', 'types']"
830,1.0,"Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease.","['due', 'to', 'slow', 'tumor', 'growth', '_chemical_', 'was', 'continued', 'despite', '_mutation_', 'with', 're', 'addition', 'of', 'premetrexed', 'and', 'this', 'reduced', 'tumor', 'size', 'and', 'resulted', 'in', 'stable', 'disease']"
831,1.0,"Patients receiving cetuximab had increased overall survival (HR=0.77, 95%CI 0.64-0.92; p=0.005), increased progression-free survival (HR=0.68, 95%CI 0.57-0.80; p<0.001), and improved quality of life at 4 months measured by survey on physical deterioration (-5.9 vs -12.5; p=0.03) and global health status (-3.6 vs. -15.2; p<0.001).","['patients', 'receiving', '_chemical_', 'had', 'increased', 'overall', 'survival', '_ineq_', '_num_', 'ci', '_range_', '_p_val_', 'increased', 'progression', 'free', 'survival', '_ineq_', '_num_', 'ci', '_range_', 'p', '_num_', 'and', 'improved', 'quality', 'of', 'life', 'at', '_num_', 'months', 'measured', 'by', 'survey', 'on', 'physical', 'deterioration', '_num_', 'vs', '_num_', '_p_val_', 'and', 'global', 'health', 'status', '_num_', 'vs', '_num_', 'p', '_num_']"
832,1.0,"Additionally, DICER1 E1705K mutations were identified in 5/8 (63%) Sertoli cell tumors and 2/5 (40%) gynandroblastomas.","['additionally', '_gene_', '_abbrev_', 'mutations', 'were', 'identified', 'in', '_ratio_', '_num_', '_disease_', 'cell', 'tumors', 'and', '_ratio_', '_num_', '_disease_']"
833,1.0,Immunohistochemical staining was performed on 65 patients for HIF1A such that 23 were considered responders and 42 were considered non-responders.,"['immunohistochemical', 'staining', 'was', 'performed', 'on', '_num_', 'patients', 'for', '_gene_', 'such', 'that', '_num_', 'were', 'considered', 'responders', 'and', '_num_', 'were', 'considered', 'non', 'responders']"
834,1.0,The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months.,"['the', 'patient', 'was', 'treated', 'with', '_chemical_', 'and', 'experienced', 'a', 'complete', 'normalization', 'of', 'tumor', 'metabolic', 'activity', 'for', 'more', 'than', '_num_', 'months']"
835,1.0,A 54-year-old man presented with stage II myeloma.,"['a', '_age_', 'man', 'presented', 'with', 'stage', 'ii', 'myeloma']"
836,1.0,"Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild type KRAS.","['additionally', 'endogenously', 'expressing', '_gene_', '_mutation_', 'knock', 'in', 'mutation', 'demonstrated', 'resistance', 'to', '_chemical_', 'treatment', 'compared', 'to', '_abbrev_', 'parental', 'cells', 'expressing', 'wild', 'type', '_gene_']"
837,1.0,"Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease.","['among', 'the', '_gene_', 'wild', 'type', 'population', 'a', '_num_', 'response', 'rate', 'was', 'reported', 'where', 'response', 'was', 'considered', 'as', 'complete', 'response', 'partial', 'response', 'or', 'stable', 'disease']"
838,1.0,The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months).,"['the', 'trial', 'observed', 'significantly', 'longer', 'median', 'progression', 'free', 'survival', 'with', '_chemical_', 'vs', '_chemical_', 'and', '_disease_', 'treatment', '_num_', 'vs', '_num_', 'months']"
839,1.0,DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).,"['_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_abbrev_', 'were', 'associated', 'with', 'intermediate', 'risk', 'cytogenetics', 'including', 'normal', 'karyotype']"
840,1.0,"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA).","['pooled', 'analysis', 'of', '_gene_', 'mutations', 'exons', '_chemical_', 'from', '_num_', 'randomized', 'trials', 'ialt', '_abbrev_', '_abbrev_', 'and', '_disease_']"
841,1.0,Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163).,"['patients', 'were', 'given', '_chemical_', '_ineq_', 'or', '_chemical_', 'plus', '_chemical_', '_ineq_']"
842,1.0,The patient remained disease-free for 13 months when a CT-scan showed a relapse with two nodules in the right lower lobe.,"['the', 'patient', 'remained', '_disease_', 'for', '_num_', 'months', 'when', 'a', '_disease_', 'showed', 'a', 'relapse', 'with', '_num_', 'nodules', 'in', 'the', 'right', 'lower', 'lobe']"
843,1.0,Preclinical study in melanoma cell lines.,"['preclinical', 'study', 'in', 'melanoma', 'cell', 'lines']"
844,1.0,Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas.,"['plasma', 'levels', 'of', '_num_', 'potential', '_chemical_', 'were', 'tested', 'at', 'baseline', 'and', '_num_', 'weeks', 'after', '_chemical_', 'initiation', 'in', 'a', 'prospective', 'cohort', 'of', '_num_', 'patients', 'with', 'recurrent', 'high', 'grade', 'gliomas']"
845,1.0,"In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably higher antiproliferative IC50 than taselisib sensitized cell lines.","['in', 'a', 'panel', 'of', '_num_', '_disease_', 'cell', 'lines', 'tested', 'for', 'sensitivity', 'to', 'taselisib', 'an', 'alpha', 'delta', 'and', 'gamma', '_chemical_', 'specific', '_gene_', 'inhibitor', 'the', 'ud', '_gene_', '_num_', 'cell', 'line', 'with', 'homozygous', '_gene_', 'deletion', 'had', 'considerably', 'higher', 'antiproliferative', '_abbrev_', 'than', 'taselisib', 'sensitized', 'cell', 'lines']"
846,1.0,"300-gene targeted sequencing of the patient’s genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission.","['_num_', 'gene', 'targeted', 'sequencing', 'of', 'the', 'patient', '’', 's', 'genome', 'revealed', 'activating', 'subclonal', '_gene_', 'mutations', '_gene_', '_mutation_', '_num_', 'allele', 'frequency', '_gene_', '_mutation_', '_num_', 'as', 'well', 'as', 'a', '_gene_', '_abbrev_', 'mutation', '_num_', 'that', 'had', 'not', 'been', 'seen', 'prior', 'to', '_chemical_', 'treatment', 'or', 'at', 'remission']"
847,1.0,"46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations.","['_num_', 'patients', 'with', 'poorly', 'cohesive', 'signet', 'cell', 'ring', 'gastric', 'carcinoma', 'were', 'evaluated', 'for', 'genetic', 'mutations']"
848,1.0,we do not provide further details on patient outcome.,"['we', 'do', 'not', 'provide', 'further', 'details', 'on', 'patient', 'outcome']"
849,1.0,"In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild type IDH2.","['in', 'this', '_disease_', 'analysis', 'of', 'adult', 'non', 'promyelocytic', '_disease_', '_num_', 'studies', 'patients', 'with', '_gene_', '_chemical_', 'or', '_abbrev_', 'mutations', 'had', 'event', 'free', 'survival', 'and', 'overall', 'survival', 'similar', 'to', 'those', 'with', 'wild', 'type', '_gene_']"
850,1.0,PIK3CA mutations were observed in 4/5 of the most responsive tumors.,"['_gene_', 'mutations', 'were', 'observed', 'in', '_ratio_', 'of', 'the', 'most', 'responsive', 'tumors']"
851,1.0,"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, NPM1 mutation without FLT3-ITD was significantly associated with complete remission in multivariate analysis (odds ratio, 1.48; 95% CI, 1.21 to 1.80).","['in', 'young', 'patients', 'age', '_range_', 'with', 'previously', 'untreated', 'cytogenetically', 'normal', 'acute', 'myeloid', 'leukemia', '_gene_', 'mutation', 'without', '_gene_', 'was', 'significantly', 'associated', 'with', 'complete', 'remission', 'in', 'multivariate', 'analysis', 'odds', 'ratio', '_num_', '_num_', 'ci', '_num_', 'to', '_num_']"
852,1.0,116 Ewing's sarcoma tumor samples were analyzed in this study.,"['_num_', 'ewing', ""'s"", 'sarcoma', 'tumor', 'samples', 'were', 'analyzed', 'in', 'this', 'study']"
853,1.0,"In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR.","['in', 'this', 'study', '_num_', 'spindle', 'cell', 'sarcomas', 'were', 'evaluated', 'for', 'the', 'presence', 'of', 't', 'x', '_num_', 'by', '_disease_']"
854,1.0,we performed extensive in vitro and in vivo experiments to demonstrate that DUX4 fusions are likely early initiating/events and that DUX4 fusion and not DUX4 wild type are tumorigenic.,"['we', 'performed', 'extensive', 'in', 'vitro', 'and', 'in', 'vivo', 'experiments', 'to', 'demonstrate', 'that', '_gene_', 'fusions', 'are', 'likely', 'early', 'initiating', 'events', 'and', 'that', '_gene_', 'fusion', 'and', 'not', '_gene_', 'wild', 'type', 'are', '_disease_']"
855,0.0,"we show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models.","['we', 'show', 'that', 'in', 'the', '_chemical_', 'and', '_chemical_', '_chemical_', 'stabilizing', 'agents', 'demonstrate', 'specific', 'toxicity', 'against', '_gene_', 'deficient', 'breast', 'cancer', 'derived', 'cells', 'and', 'polyclonal', '_disease_', 'xenograft', 'models']"
856,1.0,A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without.,"['a', 'study', 'of', '_num_', 'patients', 'with', '_disease_', 'found', 'a', 'significant', 'resistance', 'to', 'chemotherapy', 'and', 'corresponding', 'poor', 'clinical', 'outcomes', 'among', 'the', '_num_', 'treated', 'patients', 'with', '_gene_', 'mutations', 'compared', 'to', 'the', '_num_', 'treated', 'patients', 'without']"
857,1.0,"Five patients experienced stable disease, nine had progressive disease.","['_num_', 'patients', 'experienced', 'stable', 'disease', '_num_', 'had', 'progressive', 'disease']"
858,1.0,"After randomisation, median PFS for cabozantinib patients was 4.1 months and 2.8 months for placebo (HR 0.59, p=0.284).","['after', 'randomisation', 'median', '_disease_', 'for', '_chemical_', 'patients', 'was', '_num_', 'months', 'and', '_num_', 'months', 'for', 'placebo', 'hr', '_num_', '_p_val_']"
859,1.0,CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.025).,"['cps', 'therapy', 'was', 'associated', 'with', 'improved', 'progression', 'free', 'survival', '_disease_', 'compared', 'with', '_gene_', 'in', 'patients', 'with', 'tumors', 'that', 'were', 'positive', 'for', '_gene_', 'gene', 'copy', 'gains', 'hr', '_num_', 'p', '_num_']"
860,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_abbrev_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
861,1.0,Biopsies from 520 DLBCL patients treated with R-CHOP were evaluated for PRDM1 mutations or protein (BLIMP-1) expression.,"['biopsies', 'from', '_num_', '_disease_', 'patients', 'treated', 'with', '_gene_', 'were', 'evaluated', 'for', '_gene_', 'mutations', 'or', 'protein', '_gene_', 'expression']"
862,1.0,Approximately 70% of PIK3CA wild type lines were not sensitive to PP242.,"['approximately', '_num_', 'of', '_gene_', 'wild', 'type', 'lines', 'were', 'not', 'sensitive', 'to', '_chemical_']"
863,1.0,Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF.,"['chemotherapy', 'refractory', 'patients', 'with', 'colorectal', 'cancer', 'harboring', '_gene_', 'mutations', 'had', 'lower', 'response', 'and', 'disease', 'control', 'rates', 'as', 'well', 'as', 'shorter', 'progression', 'free', 'and', 'overall', 'survival', 'following', '_chemical_', 'plus', 'chemotherapy', 'than', 'those', 'with', 'wildtype', '_gene_']"
864,1.0,Computer simulation studies indicated that the I1171T mutation interfered with alectinib binding at the ALK active site.,"['computer', 'simulation', 'studies', 'indicated', 'that', 'the', '_mutation_', 'mutation', 'interfered', 'with', '_chemical_', 'binding', 'at', 'the', '_gene_', 'active', 'site']"
865,1.0,"ORR of these patients compared to EGFR mutated or wild type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001).","['orr', 'of', 'these', 'patients', 'compared', 'to', '_gene_', 'mutated', 'or', 'wild', 'type', 'tumors', 'was', 'superior', '_num_', 'vs', '_num_', 'vs', '_num_', 'p', '_num_']"
866,1.0,"11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation.","['_num_', 'patients', 'in', 'this', 'cohort', 'had', 'characterized', '_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_mutation_', 'mutation']"
867,1.0,"In preclinical studies of transgenic mice and xenografts, continuous expression of mutant ERBB2 (M774insAYVM or the equivalent A775insYVMA) was found to be essential for tumor maintenance.","['in', 'preclinical', 'studies', 'of', 'transgenic', 'mice', 'and', 'xenografts', 'continuous', 'expression', 'of', 'mutant', '_gene_', '_abbrev_', 'or', 'the', 'equivalent', '_mutation_', 'was', 'found', 'to', 'be', 'essential', 'for', 'tumor', 'maintenance']"
868,1.0,The crizotinib-resistant MGH045 cell line with EML4-ALK L1196M was treated with crizotinib or ceritinib.,"['the', '_chemical_', 'resistant', '_abbrev_', 'cell', 'line', 'with', '_chemical_', '_mutation_', 'was', 'treated', 'with', '_chemical_', 'or', '_chemical_']"
869,1.0,"One family is described with this allele segregating with disease; 10 affected individuals: 2  patients with renal cell carcinoma, 3 with pheochromocytoma, 7 with retinal angioma, 3 with central nervous system hemangioma.","['_num_', 'family', 'is', 'described', 'with', 'this', 'allele', 'segregating', 'with', 'disease', '_num_', 'affected', 'individuals', '_num_', 'patients', 'with', 'renal', 'cell', 'carcinoma', '_num_', 'with', 'pheochromocytoma', '_num_', 'with', 'retinal', 'angioma', '_num_', 'with', 'central', 'nervous', 'system', 'hemangioma']"
870,1.0,"In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97).","['in', 'the', 'pooled', 'analysis', 'of', 'both', 'trials', 'patients', 'with', '_gene_', 'loss', 'as', 'defined', 'by', '_gene_', 'staining', 'intensity', 'and', 'proportion', 'of', 'positive', 'tumor', 'cells', 'had', 'a', 'longer', 'progression', 'free', 'survival', 'with', '_chemical_', 'compared', 'to', 'placebo', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_', 'whereas', 'patients', 'with', '_gene_', 'normal', 'status', 'had', 'a', 'hazard', 'ration', 'of', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_']"
871,1.0,Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region (AMCG code: PM4).,"['only', 'moderate', 'evidence', 'of', 'pathogenicity', 'since', 'the', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'an', 'in', 'frame', 'deletion', 'in', 'a', 'nonrepeat', 'region', 'amcg', 'code', '_abbrev_']"
872,1.0,"In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone.","['in', 'this', 'retrospective', 'analysis', 'of', '_gene_', 'status', 'as', 'surrogate', 'marker', 'for', '_disease_', 'in', 'the', 'spectrum', 'trial', '_gene_', '_gene_', 'expression', 'was', 'not', 'associated', 'with', 'improved', 'response', 'to', '_gene_', 'directed', 'therapy', 'panitumumab', 'in', 'combination', 'with', 'chemotherapy', 'compared', 'to', 'chemotherapy', 'alone']"
873,1.0,"The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2.","['the', '_year_', 'world', 'health', 'organization', 'guidelines', 'for', 'the', 'classification', 'of', 'myeloid', 'malignancies', 'and', 'acute', 'leukemia', 'describes', 'a', 'new', 'class', 'of', 'disease', 'defined', 'by', 'myeloid', 'or', 'lymphoid', 'neoplasms', 'associated', 'with', 'eosinophilia', 'and', 'rearrangement', 'of', '_gene_', '_gene_', 'or', '_gene_', 'or', 'with', '_abbrev_']"
874,0.0,These data suggest that trametinib is associated with similar PFS and response rates as docetaxel.,"['these', 'data', 'suggest', 'that', '_chemical_', 'is', 'associated', 'with', 'similar', '_disease_', 'and', 'response', 'rates', 'as', '_chemical_']"
875,1.0,BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%).,"['_gene_', '_mutation_', 'allele', 'frequency', 'was', 'detectable', '_num_', 'at', 'the', 'time', 'of', 'remission', 'but', 'dramatically', 'increased', 'at', 'relapse', '_num_']"
876,1.0,She enrolled in a clinical trial with a dose of 400mg imatinib per day (Nov 2006).,"['she', 'enrolled', 'in', 'a', 'clinical', 'trial', 'with', 'a', 'dose', 'of', '_unit_', '_chemical_', 'per', 'day', 'nov', '_year_']"
877,1.0,CT showed regression of liver lesions and primary lung lesion and ongoing response was seen at 3 months.,"['ct', 'showed', 'regression', 'of', 'liver', 'lesions', 'and', 'primary', 'lung', 'lesion', 'and', 'ongoing', 'response', 'was', 'seen', 'at', '_num_', 'months']"
878,1.0,Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC).,"['patients', 'with', 'stage', 'ii', 'iii', 'colorectal', 'cancer', 'were', 'analyzed', 'for', 'expression', 'of', '_gene_', 'by', 'microarray', 'and', '_gene_']"
879,1.0,Those with mutations had worse overall and progression free survival than those without mutations.,"['those', 'with', 'mutations', 'had', 'worse', 'overall', 'and', 'progression', 'free', 'survival', 'than', 'those', 'without', 'mutations']"
880,1.0,"Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA.","['whole', 'genome', 'sequencing', 'elucidated', 'a', '_gene_', '_gene_', 'fusion', 'which', 'can', 'be', 'successfully', 'treated', 'with', '_disease_']"
881,1.0,"BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers.","['_gene_', 'fusions', 'were', 'identified', 'in', '_num_', '_num_', 'patients', 'and', 'enriched', 'in', 'spitzoid', 'melanoma', '_disease_', '_disease_', 'pancreatic', 'acinar', 'and', 'papillary', 'thyroid', 'cancers']"
882,1.0,"Each patient had retinal angiomas, 2 had hemangioblastomas of the central nervous system, and 2 had renal cell carcinoma.","['each', 'patient', 'had', 'retinal', 'angiomas', '_num_', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', '_num_', 'had', 'renal', 'cell', 'carcinoma']"
883,1.0,"In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild type KRAS (3.35 and 1.95 months).","['in', 'a', 'study', 'of', '_num_', '_disease_', 'patients', 'those', 'with', '_mutation_', 'or', '_mutation_', 'mutant', '_gene_', 'were', 'associated', 'with', 'decreased', 'progression', 'free', 'survival', '_num_', 'months', 'compared', 'with', 'other', '_gene_', 'mutants', 'or', 'with', 'wild', 'type', '_gene_', '_num_', 'and', '_num_', 'months']"
884,1.0,"The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression.","['the', 'use', 'of', '_chemical_', 'in', 'conjunction', 'with', '_chemical_', 'but', 'not', 'as', 'monotherapy', 'in', 'a', 'lung', 'cancer', 'model', 'with', '_gene_', '_mutation_', 'mutation', 'led', 'to', 'marked', 'tumor', 'regression']"
885,1.0,"TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples.","['_gene_', 'gene', 'fusion', 'was', 'observed', 'in', '_num_', 'of', '_num_', '_num_', 'of', 'prostate', 'carcinoma', 'samples', 'and', '_num_', 'of', 'erg', 'expression', 'positive', 'prostate', 'carcinoma', 'samples']"
886,1.0,Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer.,"['_disease_', 'analysis', 'encompassing', '_num_', 'randomized', 'controlled', 'trials', 'n', '_num_', 'for', 'assessment', 'of', 'both', 'overall', 'survival', 'os', 'and', 'progression', 'free', 'survival', '_disease_', 'of', 'patients', 'with', '_gene_', 'mutant', 'metastatic', 'colorectal', 'cancer']"
887,1.0,31 patients with KRAS exon 2 mutation (codons 12 and 13) were treated with selumetinib and irinotecan.,"['_num_', 'patients', 'with', '_gene_', 'exon', '_num_', 'mutation', 'codons', '_num_', 'and', '_num_', 'were', 'treated', 'with', '_chemical_', 'and', '_chemical_']"
888,1.0,"However, FGFR1 amplification is significantly correlated with lymph node metastasis.","['however', '_gene_', 'amplification', 'is', 'significantly', 'correlated', 'with', 'lymph', 'node', 'metastasis']"
889,1.0,"In patients with de novo AML who received intensive chemotherapy, ASXL1 mutations (N=51) were associated with shorter overall (P<0.001) and event free survival (P=0.012) compared to ASXL1 wild type (N=430).","['in', 'patients', 'with', 'de', 'novo', '_disease_', 'who', 'received', 'intensive', 'chemotherapy', '_gene_', 'mutations', '_ineq_', 'were', 'associated', 'with', 'shorter', 'overall', 'p', '_num_', 'and', 'event', 'free', 'survival', '_p_val_', 'compared', 'to', '_gene_', 'wild', 'type', '_ineq_']"
890,1.0,"In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors.","['in', 'vehicle', 'treated', 'mice', 'area', 'of', 'colon', 'covered', 'by', 'tumor', 'increased', 'while', 'treatment', 'with', 'single', 'agent', 'inhibitors', 'caused', 'growth', 'inhibition', 'resulting', 'in', 'no', 'change', 'in', 'colon', 'area', 'covered', 'by', 'tumors']"
891,1.0,Cells with single FLT3 (D835H/Y) mutants were resistant to sorafenib (IC50 81 nm/210 nM) whereas cells with FLT3 (ITD) mutants were not resistant to sorafenib (IC50 1.1 nM).,"['cells', 'with', 'single', '_gene_', '_abbrev_', 'mutants', 'were', 'resistant', 'to', '_chemical_', '_abbrev_', '_num_', '_unit_', '_num_', '_unit_', 'whereas', 'cells', 'with', '_gene_', '_gene_', 'mutants', 'were', 'not', 'resistant', 'to', '_chemical_', '_abbrev_', '_num_', '_unit_']"
892,1.0,"The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.","['the', 'patient', 'was', 'treated', 'with', '_chemical_', 'and', 'after', '_num_', 'weeks', 'of', 'therapy', 'the', '_gene_', 'value', 'decreased', 'from', '_num_', 'to', '_num_', 'and', 'there', 'was', 'radiological', 'resolution', 'of', 'the', 'disease']"
893,1.0,"Tumors were classified as ""high expressor"" (either EREG or AREG mRNA level) or ""low expressor"" (neither EREG nor AREG in top tertile).","['tumors', 'were', 'classified', 'as', 'high', 'expressor', 'either', '_gene_', 'or', '_gene_', 'mrna', 'level', 'or', 'low', 'expressor', 'neither', '_gene_', 'nor', '_gene_', 'in', 'top', 'tertile']"
894,1.0,"In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'the', '_mutation_', 'mutation', 'was', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
895,1.0,43 patients with Peutz-Jeghers Syndrome were identified (clinical criteria + STK11 mutations).,"['_num_', 'patients', 'with', '_disease_', 'syndrome', 'were', 'identified', 'clinical', 'criteria', '_gene_', 'mutations']"
896,1.0,Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.,"['patients', 'with', 'other', '_gene_', '_abbrev_', 'mutations', 'also', 'respond', 'well', 'to', 'the', '_mutation_', 'drug', '_chemical_']"
897,1.0,A general tendency for taselisib sensitivity to PI3K activation (mutation/amplification) was also seen in a panel of 26 HNSCC cell lines,"['a', 'general', 'tendency', 'for', 'taselisib', 'sensitivity', 'to', '_gene_', 'activation', 'mutation', 'amplification', 'was', 'also', 'seen', 'in', 'a', 'panel', 'of', '_num_', '_disease_', 'cell', 'lines']"
898,1.0,"Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway.","['patients', 'with', '_gene_', 'hyperactive', 'pathway', 'had', 'a', 'hazard', 'ratio', 'of', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_', 'compared', 'to', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_', 'in', 'patients', 'with', '_gene_', 'normal', 'pathway']"
899,1.0,"The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61).","['the', 'response', 'rate', 'to', 'pembrolizumab', 'was', '_num_', '_num_', 'ci', '_range_', 'however', 'there', 'was', 'no', 'correlation', 'between', '_gene_', 'expression', 'cutoff', '_num_', 'on', 'tumor', 'cells', 'or', 'on', 'infiltrating', 'immune', 'cells', 'and', 'clinical', 'response', 'to', 'pembrolizumab', '_p_val_']"
900,1.0,A 58-year-old male family member had retinal angiomas and renal cell carcinoma.,"['a', '_age_', 'male', 'family', 'member', 'had', 'retinal', 'angiomas', 'and', 'renal', 'cell', 'carcinoma']"
901,1.0,(IC50 = 110nm),"['_abbrev_', '_unit_']"
902,1.0,Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme.,"['_num_', 'siblings', '_num_', 'and', '_num_', 'years', 'from', 'nonconsanguineous', 'parents', 'were', 'diagnosed', 'with', 'glioblastoma', 'multiforme']"
903,1.0,This is in contrast to the increased resistance to crizotinib associated with this mutation in the same assay.,"['this', 'is', 'in', 'contrast', 'to', 'the', 'increased', 'resistance', 'to', '_chemical_', 'associated', 'with', 'this', 'mutation', 'in', 'the', 'same', 'assay']"
904,1.0,Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation.,"['_num_', 'of', 'his', 'metastases', 'evaluated', 'using', 'whole', 'genome', 'sequencing', 'contained', 'a', '_gene_', '_mutation_', 'mutation']"
905,1.0,"The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib treatment and CD74–ROS1 rearrangment.","['the', '_mutation_', 'mutation', 'in', '_gene_', 'was', 'identified', 'in', 'the', '_abbrev_', '_num_', 'and', '_num_', 'cell', 'lines', 'which', 'harbor', 'the', '_abbrev_', 'rearrangement', 'and', 'in', '_num_', 'patients', 'with', '_disease_', 'with', 'progressive', 'disease', 'following', '_chemical_', 'treatment', 'and', '_abbrev_', 'rearrangment']"
906,1.0,"Clinical manifestations associated with this mutation include: CNS hemangioblastomas, pancreatic cysts, and retinal hemangioblastomas.","['clinical', 'manifestations', 'associated', 'with', 'this', 'mutation', 'include', 'cns', '_disease_', 'pancreatic', 'cysts', 'and', 'retinal', '_disease_']"
907,1.0,CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.,"['_gene_', 'high', 'expression', 'was', 'identified', 'as', 'a', 'potential', 'marker', 'of', 'improved', '_disease_', 'from', '_chemical_', 'treatment', 'in', 'patients', 'with', 'metastatic', '_gene_']"
908,1.0,"Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19.2 months for patients with MGMT-deficient tumors (P = 0.11).","['among', 'those', 'patients', 'who', 'received', '_chemical_', 'based', 'therapy', 'in', 'this', 'study', 'the', 'median', 'progression', 'free', 'survival', 'for', 'patients', 'whose', 'tumors', 'showed', 'intact', '_gene_', 'expression', 'was', '_num_', 'months', 'compared', 'with', '_num_', 'months', 'for', 'patients', 'with', '_disease_', 'tumors', 'p', '_num_']"
909,0.0,we conclude that MAPK targeting in CRC is a valid approach that can produce meaningful responses but additional work is required to more effectively inhibit the pathway.,"['we', 'conclude', 'that', '_gene_', 'targeting', 'in', '_gene_', 'is', 'a', 'valid', 'approach', 'that', 'can', 'produce', 'meaningful', 'responses', 'but', 'additional', 'work', 'is', 'required', 'to', 'more', 'effectively', 'inhibit', 'the', 'pathway']"
910,1.0,Primary endpoint was Overall Survival (OS).,"['primary', 'endpoint', 'was', 'overall', 'survival', 'os']"
911,1.0,"In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.","['in', '_disease_', 'patients', 'treated', 'with', '_gene_', 'tyrosine', 'kinase', 'inhibitors', 'the', 'presence', 'of', '_mutation_', 'mutation', 'is', 'prognostic', 'for', 'better', 'progression', 'free', 'survival']"
912,1.0,The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab.,"['the', '_mutation_', 'mutation', 'was', 'sensitive', 'to', '_abbrev_', 'and', 'panitumumab', 'treatment', 'but', 'resistant', 'to', '_chemical_']"
913,1.0,This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations.,"['this', 'phase', 'i', 'ib', '_num_', 'part', 'study', 'evaluated', '_chemical_', 'in', 'combination', 'with', 'anticancer', 'agents', '_chemical_', 'or', '_chemical_', 'in', '_disease_', 'with', 'and', 'without', '_gene_', 'mutations']"
914,1.0,"Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients.","['overall', 'response', 'rate', 'was', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'in', 'patients', 'with', 'confirmed', '_gene_', 'tumors', 'and', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'in', '_gene_', 'normal', 'patients']"
915,0.0,Strong inhibitory effects on both mutants were seen only with ponatinib.,"['strong', 'inhibitory', 'effects', 'on', 'both', 'mutants', 'were', 'seen', 'only', 'with', '_chemical_']"
916,1.0,These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib.,"['these', 'results', 'suggest', 'that', '_chemical_', 'variant', '_num_', 'is', 'a', 'driver', 'mutation', 'in', 'lung', 'adenocarcinoma', 'targetable', 'by', '_gene_', 'inhibitors', 'like', '_chemical_']"
917,1.0,"In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was a 6 fold increase over IC50 for EML4-ALK wild type.","['in', 'ba', '_abbrev_', 'cells', 'with', 'ectopic', '_chemical_', 'variant', '_num_', '_mutation_', '_abbrev_', 'of', '_num_', '_unit_', 'was', 'reported', 'with', '_chemical_', 'which', 'was', 'a', '_num_', 'fold', 'increase', 'over', '_abbrev_', 'for', '_chemical_', 'wild', 'type']"
918,1.0,"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS).","['pooled', 'analysis', 'of', '_gene_', 'mutations', 'exons', '_chemical_', 'from', '_num_', 'randomized', 'trials', 'ialt', '_abbrev_', '_abbrev_', 'and', '_disease_', 'of', 'platinum', 'based', 'adjuvant', 'chemotherapy', 'act', 'vs', 'observation', 'obs']"
919,1.0,"NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells).","['_gene_', 'mutation', 'type', 'a', '_abbrev_', 'causes', 'cytoplasmic', 'localization', 'of', '_gene_', 'when', 'transfected', 'into', 'a', 'non', 'hematopoietic', 'cell', 'line', '_chemical_', 'cells']"
920,1.0,"bFGF and FGFR1 were expressed in all tumor specimens, whereas expression of these proteins in cancer-associated fibroblasts was associated with lymph node metastasis (P < 0.05) and worse patient survival.","['_gene_', 'and', '_gene_', 'were', 'expressed', 'in', 'all', 'tumor', 'specimens', 'whereas', 'expression', 'of', 'these', 'proteins', 'in', 'cancer', 'associated', 'fibroblasts', 'was', 'associated', 'with', 'lymph', 'node', 'metastasis', 'p', '_num_', 'and', 'worse', 'patient', 'survival']"
921,1.0,IKZF1 deletions are associated with poor outcome in patients with childhood BCR-ABL–positive B-cell precursor acute lymphoblastic leukemia even when treated with imatinib.,"['_gene_', 'deletions', 'are', 'associated', 'with', 'poor', 'outcome', 'in', 'patients', 'with', 'childhood', '_gene_', 'abl–positive', '_disease_', 'precursor', 'acute', '_disease_', 'leukemia', 'even', 'when', 'treated', 'with', '_chemical_']"
922,1.0,"Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations.","['genomic', '_disease_', 'verified', 'the', 'existence', 'of', 'the', 'fusion', 'breakpoint', 'in', 'intronic', 'space', 'indicating', 'that', 'some', 'colorectal', 'adenocarcinoma', 'may', 'have', 'targetable', '_gene_', 'fusion', 'driver', 'mutations']"
923,1.0,Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo.,"['newly', 'developed', 'allosteric', 'inhibitors', '_abbrev_', 'of', '_gene_', 'led', 'to', 'granulocytic', 'differentiation', 'in', 'vitro', 'and', 'in', 'vivo']"
924,1.0,"A subcategory of patients taking combination therapy, who lacked mutations in p16 or CCND1 (n=34), had an even higher median free survival of 26.1 months.","['a', 'subcategory', 'of', 'patients', 'taking', 'combination', 'therapy', 'who', 'lacked', 'mutations', 'in', '_gene_', 'or', '_gene_', '_ineq_', 'had', 'an', 'even', 'higher', 'median', 'free', 'survival', 'of', '_num_', 'months']"
925,1.0,A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.,"['a', 'case', 'report', 'of', 'an', '_num_', 'year', 'old', 'patient', 'with', 'metastasized', 'merkel', 'cell', 'carcinoma', 'who', 'achieved', 'a', 'complete', 'clinical', 'response', 'under', 'therapy', 'with', 'the', '_abbrev_', '_chemical_']"
926,1.0,Knockdown of NF1 led to PLX4720 resistance in-vitro.,"['knockdown', 'of', '_gene_', 'led', 'to', '_chemical_', 'resistance', 'in', 'vitro']"
927,1.0,"In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts.","['in', 'this', 'multicenter', 'phase', 'i', 'study', 'of', '_chemical_', 'a', 'total', 'of', '_num_', 'patients', 'were', 'enrolled', '_num_', 'in', 'dose', 'escalation', 'and', '_num_', 'in', 'tumor', 'specific', 'cohorts']"
928,1.0,"Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery.","['tumors', 'from', '_num_', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'were', 'analyzed', 'for', '_gene_', 'mutations', '_num_', 'of', 'which', 'were', 'treated', 'with', 'surgery']"
929,1.0,The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified.,"['the', 'cell', 'lines', '_abbrev_', 'containing', '_chemical_', 'variant', '_num_', 'and', '_abbrev_', 'containing', 'the', '_gene_', 'exon', '_num_', 'and', '_gene_', 'exon', '_num_', 'fusion', 'variant', '3a', '_chemical_', 'were', 'identified']"
930,1.0,Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice.,"['tumors', 'were', 'induced', 'in', 'lung', 'epithelium', 'by', 'nasal', 'instillation', 'of', '_gene_', 'bearing', 'adenovirus', 'in', 'conditionally', 'targeted', 'mice']"
931,1.0,Molecular dynamics simulations and calculated solvated interaction energies indicate BCR-ABL F317L mutations are Ponatinib sensitive.,"['molecular', 'dynamics', 'simulations', 'and', 'calculated', 'solvated', 'interaction', 'energies', 'indicate', '_gene_', '_mutation_', 'mutations', 'are', '_chemical_', 'sensitive']"
932,1.0,Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171).,"['patients', 'were', 'assigned', 'in', 'a', '_ratio_', 'ratio', 'to', '_chemical_', '_ineq_', 'or', '_chemical_', 'with', '_disease_', 'or', '_chemical_', '_ineq_']"
933,1.0,Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established.,"['mouse', 'xenografts', 'with', '_range_', '_gene_', 'null', 'renal', 'cancer', 'cells', 'were', 'established']"
934,1.0,"All 7 metastatic lung lesions regressed 40 days after therapy, and the patient had a 9-month partial response.","['all', '_num_', 'metastatic', 'lung', 'lesions', 'regressed', '_num_', 'days', 'after', 'therapy', 'and', 'the', 'patient', 'had', 'a', '_num_', 'month', 'partial', 'response']"
935,0.0,Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC.,"['updated', 'results', 'from', '_abbrev_', 'trial', 'assessing', 'safety', 'and', 'activity', 'of', '_chemical_', 'in', '_gene_', 'rearranged', 'locally', 'advanced', 'or', 'metastatic', '_disease_']"
936,1.0,"As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%.","['as', 'a', 'whole', 'patients', 'with', 'uncommon', '_gene_', 'mutations', 'had', 'a', 'response', 'rate', 'of', '_num_', 'which', 'was', 'between', 'common', '_mutation_', 'and', '_mutation_', 'at', '_num_', 'and', 'wild', 'type', '_gene_', 'at', '_num_']"
937,1.0,"HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.","['_gene_', 'positivity', 'was', 'broadly', 'defined', 'as', '_abbrev_', 'positive', 'by', 'fish', 'or', 'increased', 'circulating', '_gene_', 'extracellular', 'domain']"
938,1.0,A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.,"['a', '_age_', 'female', 'presents', 'with', 'recurrent', 'metastatic', 'colonic', 'adenocarcinoma']"
939,1.0,These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines.,"['these', 'results', 'potentially', 'mirror', 'findings', 'in', 'the', '_abbrev_', '3a', '_chemical_', 'containing', '_disease_', 'cell', 'line', 'where', 'some', 'literature', 'indicates', 'it', 'does', 'respond', 'as', 'strongly', 'to', '_gene_', 'inhibition', 'as', 'other', '_chemical_', '_disease_', 'cell', 'lines']"
940,1.0,This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 80).,"['this', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
941,1.0,She was negative for BRCA1/2 mutations using standard methods but a Southern blot identified a ~350bp Alu element (AluYa5 subtype) insertion in exon 3.,"['she', 'was', 'negative', 'for', '_gene_', 'mutations', 'using', 'standard', 'methods', 'but', 'a', 'southern', 'blot', 'identified', 'a', '~350bp', 'alu', 'element', '_abbrev_', 'subtype', 'insertion', 'in', 'exon', '_num_']"
942,1.0,These variants were associated with improved progression-free and overall survival.,"['these', 'variants', 'were', 'associated', 'with', 'improved', 'progression', 'free', 'and', 'overall', 'survival']"
943,0.0,Lung cancers can accumulate activating mutations in oncogenes such as EGFR.,"['lung', 'cancers', 'can', 'accumulate', 'activating', 'mutations', 'in', 'oncogenes', 'such', 'as', '_gene_']"
944,1.0,"A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer.","['a', 'phase', 'ii', 'study', 'involving', 'adult', 'female', 'patients', '_ineq_', 'years', 'with', 'stage', '_gene_', 'or', 'iv', '_gene_', 'by', '_gene_', 'and', 'or', 'in', '_disease_', 'fluorescence', 'metastatic', 'breast', 'cancer']"
945,1.0,Treatment of mice with a heterozygous loss of Lkb1 (STK11) with rapamycin led to reduction in polyp size (p < 0.0001) and number of polyps (p=0.00022).,"['treatment', 'of', 'mice', 'with', 'a', 'heterozygous', 'loss', 'of', '_gene_', '_gene_', 'with', '_gene_', 'led', 'to', 'reduction', 'in', 'polyp', 'size', 'p', '_num_', 'and', 'number', 'of', 'polyps', '_p_val_']"
946,1.0,"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated that aberrations (N=44; mixed pathogenic germline and somatic) in exons 2-63 of ATM were significantly associated with shorter time to first treatment (HR: 1.36; 95% CI: 1.05-1.76; P = 0.021).","['in', 'a', 'study', 'of', '_num_', 'previously', 'untreated', '_disease_', 'cases', 'a', 'multivariate', 'analysis', 'indicated', 'that', 'aberrations', '_ineq_', 'mixed', 'pathogenic', 'germline', 'and', 'somatic', 'in', 'exons', '_range_', 'of', 'atm', 'were', 'significantly', 'associated', 'with', 'shorter', 'time', 'to', '_num_', 'treatment', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
947,1.0,"In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.","['in', 'light', 'of', 'results', 'showing', 'increased', '_disease_', 'using', '_disease_', 'plus', '_disease_', 'in', 'heavily', 'pretreated', 'patients', 'the', 'efficacy', 'of', '_chemical_', 'plus', '_chemical_', 'in', 'a', 'neoadjuvant', 'setting', 'with', 'untreated', 'stage', 'ii', 'or', '_disease_', '_gene_', 'positive', 'breast', 'cancer', 'was', 'assessed']"
948,1.0,A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib.,"['a', 'case', 'study', 'of', 'a', 'patient', 'with', 'urothelial', 'carcinoma', 'reported', 'exceptional', 'response', '_num_', 'months', 'in', 'a', 'phase', '_num_', 'study', 'of', '_chemical_', 'and', '_chemical_']"
949,1.0,"EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fisher’s exact test, two-tailed, P=0.038).","['eec', 'cell', 'lines', 'with', '_gene_', 'mutations', 'were', 'significantly', 'more', 'sensitive', 'to', '_chemical_', 'fisher', '’', 's', 'exact', 'test', '_num_', 'tailed', '_p_val_']"
950,1.0,Patients with T393 homozygosity exhibit a decreased survival time regardless of their resection status and show earlier tumor recurrence.,"['patients', 'with', '_abbrev_', 'homozygosity', 'exhibit', 'a', 'decreased', 'survival', 'time', 'regardless', 'of', 'their', 'resection', 'status', 'and', 'show', 'earlier', 'tumor', 'recurrence']"
951,1.0,A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice.,"['a', 'clinical', 'trial', 'comparing', '_chemical_', 'and', '_chemical_', 'vs', '_chemical_', 'and', 'placebo', 'in', '_gene_', 'mutant', '_disease_', 'was', 'recapitulated', 'in', 'mice']"
952,1.0,"In two human BRAF V600E mutant cell lines, BRAFi treatment led to progressive methylation-expression changes akin to observations across MAPKi-sensitive versus resistant tumors.","['in', '_num_', 'human', '_gene_', '_mutation_', 'mutant', 'cell', 'lines', 'brafi', 'treatment', 'led', 'to', 'progressive', 'methylation', 'expression', 'changes', 'akin', 'to', 'observations', 'across', 'mapki', 'sensitive', 'vs', 'resistant', 'tumors']"
953,1.0,"The most common mutations were K57N (64%, 23/36) followed by Q56P (19%, 7/36), all mutually exclusive with other driver mutations in the targeted panel.","['the', 'most', 'common', 'mutations', 'were', '_mutation_', '_num_', '_ratio_', 'followed', 'by', '_mutation_', '_num_', '_ratio_', 'all', 'mutually', 'exclusive', 'with', 'other', 'driver', 'mutations', 'in', 'the', 'targeted', 'panel']"
954,1.0,The patient showed progressive disease as best response after two 28-day cycles on crizotinib.,"['the', 'patient', 'showed', 'progressive', 'disease', 'as', 'best', 'response', 'after', '_num_', '_num_', 'day', 'cycles', 'on', '_chemical_']"
955,1.0,The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.,"['the', 'results', 'are', 'interpreted', 'as', 'showing', 'no', 'added', 'benefit', 'for', 'labatinib', 'addition', 'to', '_chemical_', 'in', 'the', 'adjuvant', 'treatment', 'context']"
956,1.0,FACS-assisted shRNA genetic screen identified SOX10 as a determinant of vemurafenib resistance.,"['facs', 'assisted', 'shrna', 'genetic', 'screen', 'identified', '_gene_', 'as', 'a', 'determinant', 'of', '_chemical_', 'resistance']"
957,1.0,"The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC).","['the', 'pooled', 'odds', 'ratios', 'ors', 'indicated', 'that', '_gene_', 'expression', 'was', 'associated', 'with', 'positive', 'lymph', 'node', 'metastasis', 'higher', 'histological', 'grades', 'estrogen', 'receptor', 'er', '', 'negativity', 'and', '_disease_', 'breast', 'cancer', '_disease_']"
958,1.0,One tumor showed 592-end deletion of MEN1 and the other showed a 521 frameshift mutation.,"['_num_', 'tumor', 'showed', '_num_', 'end', 'deletion', 'of', '_gene_', 'and', 'the', 'other', 'showed', 'a', '_num_', 'frameshift', 'mutation']"
959,1.0,Results were validated in public datasets.,"['results', 'were', 'validated', 'in', 'public', 'datasets']"
960,1.0,HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.,"['_gene_', '_gene_', 'expression', 'in', 'pancreatic', 'adenocarcinoma', 'cell', 'lines', 'was', 'associated', 'with', 'sensitivity', 'to', 'treatment', 'with', '_chemical_']"
961,1.0,"Nine of 12 patients had retinal angioma, 5 had cerebellar hemangioblastoma, and 2 had renal cell carcinoma.","['_num_', 'of', '_num_', 'patients', 'had', 'retinal', 'angioma', '_num_', 'had', 'cerebellar', '_disease_', 'and', '_num_', 'had', 'renal', 'cell', 'carcinoma']"
962,1.0,2 cases of ROS1 fusions were found.,"['_num_', 'cases', 'of', '_gene_', 'fusions', 'were', 'found']"
963,1.0,"After 4 months, the patient grew resistant to treatment.","['after', '_num_', 'months', 'the', 'patient', 'grew', 'resistant', 'to', 'treatment']"
964,1.0,"In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines.","['in', 'vitro', '_abbrev_', 'inhibited', 'growth', 'of', '_mutation_', 'and', '_mutation_', '_gene_', 'mutant', 'cell', 'lines']"
965,1.0,Overall survival was not different between groups.,"['overall', 'survival', 'was', 'not', 'different', 'between', 'groups']"
966,1.0,This study showed that the carriers of the T allele had a significantly less favourable course of the disease when compared to carriers of the homozygous CC genotype.,"['this', 'study', 'showed', 'that', 'the', 'carriers', 'of', 'the', 't', 'allele', 'had', 'a', 'significantly', 'less', 'favourable', 'course', 'of', 'the', 'disease', 'when', 'compared', 'to', 'carriers', 'of', 'the', 'homozygous', 'cc', 'genotype']"
967,1.0,"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.","['toga', 'a', 'phase', 'iii', 'study', '_abbrev_', 'addressed', 'use', 'of', '_chemical_', 'in', '_gene_', 'positive', 'overexpression', 'or', 'amplification', 'advanced', 'gastric', 'cancer', 'where', 'chemotherapy', 'using', 'fluoropyrimidine', 'based', 'and', 'platinum', 'based', 'combinations', 'had', 'been', 'common', 'practice']"
968,1.0,"Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected.","['moreover', 'in', 'this', '_disease_', 'cell', 'line', 'focal', 'amplification', 'of', 'the', 'gene', 'encoding', 'the', '_gene_', 'ligand', '_gene_', 'was', 'also', 'detected']"
969,1.0,This nonsense mutation was found in a VHL type 1 family (lineage 50).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
970,1.0,D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation.,"['_mutation_', 'as', 'a', 'secondary', 'mutation', 'was', 'reported', 'to', 'be', 'associated', 'with', 'resistance', 'to', '_chemical_', 'and', '_chemical_', 'in', '_disease_', 'cells', 'that', 'contain', 'the', '_abbrev_', 'mutation']"
971,0.0,"Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours.","['inhibition', 'of', 'active', 'phosphorylated', 'mek', 'by', '_chemical_', '_chemical_', 'is', 'required', 'for', 'strong', 'inhibition', 'of', 'the', '_gene_', 'pathway', 'in', '_gene_', 'mutant', 'tumours']"
972,1.0,"A response was observed in 5 of 10 (50%) vs. 5 of 57 (8.8%) patients with and without germline MET mutations, respectively.","['a', 'response', 'was', 'observed', 'in', '_num_', 'of', '_num_', '_num_', 'vs', '_num_', 'of', '_num_', '_num_', 'patients', 'with', 'and', 'without', 'germline', 'met', 'mutations', 'respectively']"
973,1.0,"Two mutations altering CRBN (Q99* and R283K), a gene previously described as being necessary for immunomodulatory drug response, were observed and thought to be responsible for resistance to the pomalidomide and dexamethasone treatment she received but failed to respond to following sequencing.","['_num_', 'mutations', 'altering', '_gene_', '_abbrev_', 'and', '_mutation_', 'a', 'gene', 'previously', 'described', 'as', 'being', 'necessary', 'for', 'immunomodulatory', 'drug', 'response', 'were', 'observed', 'and', 'thought', 'to', 'be', 'responsible', 'for', 'resistance', 'to', 'the', '_chemical_', 'and', 'dexamethasone', 'treatment', 'she', 'received', 'but', 'failed', 'to', 'respond', 'to', 'following', 'sequencing']"
974,1.0,Exon 14 skipping was detected using qRT-PCR.,"['exon', '_num_', 'skipping', 'was', 'detected', 'using', 'qrt', 'pcr']"
975,1.0,"Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)].","['_disease_', 'survival', '_disease_', 'of', 'patients', 'with', '_gene_', 'mutations', 'all', 'predicted', 'to', 'be', 'loss', 'of', 'function', 'was', 'significantly', 'greater', 'than', '_gene_', 'wild', 'type', 'tumors', 'with', 'the', 'median', '_disease_', 'of', '_num_', 'vs', '_num_', 'days', 'respectively', 'p', '_num_', 'hazards', 'ratio', '_num_', '_num_', 'confidence', 'interval', '_range_']"
976,1.0,"16 SNPs were significantly associated with the clinical outcomes after chemotherapy with paclitaxel-cisplatin: ETS2 SNP: OR = 1.34, 95% CI = 1.00–1.81, P = 0.05; aHR = 0.80, 95% CI = 0.69–0.94, P = 0.006, under additive model.","['_num_', 'snps', 'were', 'significantly', 'associated', 'with', 'the', 'clinical', 'outcomes', 'after', 'chemotherapy', 'with', '_disease_', '_gene_', 'snp', 'or', '_num_', '_num_', 'ci', '_num_', '00–1', '_num_', 'p', '_num_', '_gene_', '_num_', '_num_', 'ci', '_num_', '69–0', '_num_', 'p', '_num_', 'under', 'additive', 'model']"
977,1.0,"The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point.","['the', 'primary', 'endpoint', 'of', 'the', 'trial', 'was', '_num_', 'month', 'progression', 'free', 'survival', 'with', 'a', 'benefit', 'to', 'treatment', 'evaluated', 'to', 'be', '_num_', 'of', 'patients', 'were', 'progression', 'free', 'at', 'this', 'point']"
978,1.0,"Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed.","['patient', '_num_', '_num_', 'yrs', 'old', 'had', 'been', 'treated', 'with', 'the', '_abbrev_', 'chemotherapy', 'regimen', 'then', 'salvage', 'chemotherapy', 'to', 'prepare', 'for', 'autologous', 'bone', 'marrow', 'transplant', 'but', 'ultimately', 'relapsed']"
979,1.0,"In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.","['in', 'the', 'absence', 'of', 'results', 'the', 'trial', 'entered', 'phase', 'b', 'where', 'only', 'patients', 'with', '_gene_', 'amplification', 'by', 'fish', 'were', 'admitted']"
980,1.0,"After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later.","['after', 'further', 'chemotherapy', 'along', 'with', 'maintenance', '_chemical_', '_chemical_', 'was', 'started', 'at', '_unit_', 'twice', 'daily', 'and', 'a', 'maximal', 'partial', 'response', 'was', 'achieved', '_num_', 'months', 'later', 'with', 'regrowth', 'occurring', '_num_', 'months', 'later']"
981,1.0,"Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRAF V600G and one with BRAF V600 unknown status), 19 were evaluable and the response rate to vemurafenib was 42%, tumor regression was observed in 14/19 patients, progression-free survival was 7.3 months, and 12-month overall survival was 66%.","['of', 'the', '_num_', 'patients', 'with', 'non', 'small', 'cell', 'lung', 'cancer', '_num_', 'with', '_gene_', '_mutation_', '_num_', 'with', '_gene_', '_mutation_', 'and', '_num_', 'with', '_gene_', '_abbrev_', 'unknown', 'status', '_num_', 'were', 'evaluable', 'and', 'the', 'response', 'rate', 'to', '_chemical_', 'was', '_num_', 'tumor', 'regression', 'was', 'observed', 'in', '_ratio_', 'patients', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'and', '_num_', 'month', 'overall', 'survival', 'was', '_num_']"
982,0.0,"It was found that depletion of Akt3 potentially inhibits the growth of TNBC cell lines in three-dimensional (3D) spheroid cultures and in mouse xenograft models, which imply that therapeutic targeting of AKT3 may provide a new treatment option for TNBCs.","['it', 'was', 'found', 'that', 'depletion', 'of', '_gene_', 'potentially', 'inhibits', 'the', 'growth', 'of', '_disease_', 'cell', 'lines', 'in', '_num_', 'dimensional', '3d', 'spheroid', 'cultures', 'and', 'in', 'mouse', 'xenograft', 'models', 'which', 'imply', 'that', 'therapeutic', 'targeting', 'of', '_gene_', 'may', 'provide', 'a', 'new', 'treatment', 'option', 'for', '_disease_']"
983,1.0,CRC samples from patients who received first-line 5-FU-based adjuvant chemotherapy were stratified into two groups (complete/partial response and stable/progressive disease) based on RECIST criteria.,"['_gene_', 'samples', 'from', 'patients', 'who', 'received', '_num_', 'line', '_num_', '_gene_', 'based', 'adjuvant', 'chemotherapy', 'were', 'stratified', 'into', '_num_', 'groups', 'complete', 'partial', 'response', 'and', 'stable', 'progressive', 'disease', 'based', 'on', '_disease_', 'criteria']"
984,1.0,"Early results from the 21 evaluable patients were very promising, with 7 patients achieving a partial response (33%) and 11 patients with stable disease (52%)","['early', 'results', 'from', 'the', '_num_', 'evaluable', 'patients', 'were', 'very', 'promising', 'with', '_num_', 'patients', 'achieving', 'a', 'partial', 'response', '_num_', 'and', '_num_', 'patients', 'with', 'stable', 'disease', '_num_']"
985,1.0,Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.,"['treatment', 'with', 'the', '_gene_', 'inhibitor', '_chemical_', 'in', 'patients', 'whose', 'prostate', 'cancers', 'were', 'no', 'longer', 'responding', 'to', 'standard', 'treatments', 'and', 'who', 'had', 'defects', 'in', 'dna', 'repair', 'genes', 'led', 'to', 'a', 'high', 'response', 'rate']"
986,1.0,c.164insG causes a framehift and truncation allele.,"['c', '164insg', 'causes', 'a', 'framehift', 'and', 'truncation', 'allele']"
987,1.0,These results were confirmed in a xenograft model.,"['these', 'results', 'were', 'confirmed', 'in', 'a', 'xenograft', 'model']"
988,1.0,"In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival.","['in', 'a', 'large', 'cohort', '_ineq_', 'of', '_disease_', 'patients', '_range_', 'years', 'old', '_gene_', 'mutation', 'status', '_num_', 'of', 'which', 'were', '_abbrev_', 'had', 'no', 'prognostic', 'value', 'for', 'overall', 'relapse', 'free', 'and', 'event', 'free', 'survival']"
989,1.0,"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene.","['in', 'a', 'study', 'of', '_num_', 'unrelated', '_gene_', 'patients', '_num_', 'were', 'discovered', 'to', 'have', 'alterations', 'in', 'the', '_gene_', 'gene']"
990,1.0,EZH2 mutant cell lines were the most sensitive to GSK126 compared to wild type and untransformed.,"['_gene_', 'mutant', 'cell', 'lines', 'were', 'the', 'most', 'sensitive', 'to', '_chemical_', 'compared', 'to', 'wild', 'type', 'and', 'untransformed']"
991,1.0,Western blot evaluation of 9 NSCLC and 12 CRC cell lines showed ERBB3 expression correlated with the synergy score for combination afatinib and trametinib treatment.,"['western', 'blot', 'evaluation', 'of', '_num_', '_disease_', 'and', '_num_', '_gene_', 'cell', 'lines', 'showed', '_gene_', 'expression', 'correlated', 'with', 'the', 'synergy', 'score', 'for', 'combination', '_chemical_', 'and', '_chemical_', 'treatment']"
992,1.0,"we conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable.","['we', 'conclude', 'that', 'although', 'some', 'efficacy', 'is', 'seen', 'only', 'a', 'small', 'subset', 'of', 'patients', 'respond', 'to', 'this', 'treatment', 'and', 'the', 'responses', 'are', 'not', 'durable']"
993,1.0,Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.,"['treatment', 'of', '_num_', 'patients', 'with', 'this', 'disease', 'with', 'the', '_gene_', 'inhibitor', '_chemical_', 'led', 'to', 'symptomatic', 'and', 'hematologic', 'improvements', 'in', 'all', 'patients', 'through', '_range_', 'weeks', 'of', 'treatment']"
994,1.0,43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening.,"['_num_', 'unrelated', '_gene_', 'patients', 'with', 'previously', 'sequenced', '_gene_', 'germline', 'mutations', 'and', '_num_', 'suspected', '_gene_', 'mutation', 'carriers', 'were', 'subject', 'to', 'denaturing', 'high', 'performance', 'liquid', 'chromatography', '_disease_', 'mutation', 'screening']"
995,1.0,This missense mutation was found in 4 family members with VHL type 1 phenotype (Family ID 3820 in publication).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_', 'in', 'publication']"
996,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
997,1.0,"Highest MERTK expression was observed in metastatic melanomas, followed by primary melanomas, and lowest in benign nevi.","['highest', '_gene_', 'expression', 'was', 'observed', 'in', 'metastatic', 'melanomas', 'followed', 'by', 'primary', 'melanomas', 'and', 'lowest', 'in', 'benign', 'nevi']"
998,1.0,"GI50 values were similar in Ba/F3 cells expressing either EML4-ALK wild type or EML4-ALK G1269A (1.6nM and 2.2nM, respectively).","['_gene_', 'values', 'were', 'similar', 'in', 'ba', '_abbrev_', 'cells', 'expressing', 'either', '_chemical_', 'wild', 'type', 'or', '_chemical_', '_mutation_', '_num_', '_unit_', 'and', '_num_', '_unit_', 'respectively']"
999,1.0,"However, a second ALK mutation (C1156Y & L1198F) was detected in the lorlatinib resistant tumor.","['however', 'a', '_num_', '_gene_', 'mutation', '_mutation_', '_mutation_', 'was', 'detected', 'in', 'the', 'lorlatinib', 'resistant', 'tumor']"
1000,1.0,p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors.,"['_gene_', 'and', '_disease_', 'correlated', 'well', 'and', 'both', 'showed', 'improved', '_disease_', 'compared', 'to', 'patients', 'with', 'hpv', 'negative', '_gene_', 'negative', 'tumors']"
1001,1.0,Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival.,"['microarray', 'expression', 'data', 'from', '_num_', 'patients', 'with', 'gastric', 'adenocarcinoma', 'were', 'analyzed', 'for', 'genes', 'differentially', 'expressed', 'with', 'regard', 'to', 'overall', 'survival']"
1002,1.0,Two patient responsed and potential biomarkers were explored.,"['_num_', 'patient', 'responsed', 'and', 'potential', '_chemical_', 'were', 'explored']"
1003,1.0,"25 studies that employed multivariate analysis were used, and a hazard ratio of 2.05 for overall survival was obtained when Ki67 cutoff value was set at greater or equal to 25%.","['_num_', 'studies', 'that', 'employed', 'multivariate', 'analysis', 'were', 'used', 'and', 'a', 'hazard', 'ratio', 'of', '_num_', 'for', 'overall', 'survival', 'was', 'obtained', 'when', '_gene_', 'cutoff', 'value', 'was', 'set', 'at', 'greater', 'or', 'equal', 'to', '_num_']"
1004,1.0,MAGEH1 protein expression was negatively correlated with sensitivity.,"['_gene_', 'protein', 'expression', 'was', 'negatively', 'correlated', 'with', 'sensitivity']"
1005,1.0,"In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months.","['in', '_num_', 'patients', 'with', 'kit', '_mutation_', 'mutation', 'positive', 'chronic', 'eosinophilic', 'leukemia', '_num_', 'somatic', 'and', '_num_', 'germline', 'mutation', 'treatment', 'with', 'low', 'dose', '_chemical_', 'resulted', 'in', 'complete', 'and', 'lasting', 'remission', 'with', 'a', 'median', 'follow', 'up', 'of', '_num_', 'months', 'and', '_num_', 'patient', 'relapse', 'at', '_num_', 'months']"
1006,0.0,"Epidermal growth factor receptor (EGFR) expression and activation were evaluated by immunohistochemistry and/or phospho-arrays, real-time polimerase chain reaction, fluorescence immunostaining.","['epidermal', 'growth', 'factor', 'receptor', '_gene_', 'expression', 'and', 'activation', 'were', 'evaluated', 'by', 'immunohistochemistry', 'and', 'or', '_chemical_', 'arrays', 'real', 'time', 'polimerase', 'chain', 'reaction', 'fluorescence', 'immunostaining']"
1007,1.0,Resistance was determined by assessing cell survival.,"['resistance', 'was', 'determined', 'by', 'assessing', 'cell', 'survival']"
1008,1.0,"In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation.","['in', 'patients', 'with', 'glioblastoma', 'those', 'harboring', '_gene_', '_abbrev_', 'mutation', 'has', 'higher', 'overall', 'survival', 'compared', 'to', 'those', 'who', 'do', 'not', 'have', '_gene_', 'mutation']"
1009,1.0,"Ba/F3 cells expressing CD74–ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild type CD74–ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (only ~6 fold higher IC50 than WT).","['ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', '_mutation_', 'showed', 'resistance', 'to', '_chemical_', 'compared', 'with', 'those', 'expressing', 'wild', 'type', '_abbrev_', '_num_', 'fold', 'higher', '_abbrev_', 'however', 'showed', 'relative', 'sensitivity', 'to', '_chemical_', 'only', '_num_', 'fold', 'higher', '_abbrev_', 'than', '_gene_']"
1010,1.0,Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib.,"['molecular', 'modeling', 'indicated', 'the', '_mutation_', 'mutation', 'alters', 'the', 'conformation', 'of', 'kit', 'and', 'reduces', 'the', 'binding', 'affinity', 'of', '_chemical_']"
1011,1.0,ACMG codes as follows: A nonsense variant in a gene where loss-of-function is a known mechanism of disease (PSV1).,"['acmg', 'codes', 'as', 'follows', 'a', 'nonsense', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', '_abbrev_']"
1012,1.0,"In subgroup analysis, high expression of HEF1 correlated with a poorer prognosis in advanced (TNM III+IV) stages (P<0.05).","['in', 'subgroup', 'analysis', 'high', 'expression', 'of', '_gene_', 'correlated', 'with', 'a', 'poorer', 'prognosis', 'in', 'advanced', '_gene_', 'iii+iv', 'stages', 'p', '_num_']"
1013,1.0,Relevant ACMG codes from this paper are 'PVS1' (frameshift/null variant) and 'PP1' (limited segregation data).,"['relevant', 'acmg', 'codes', 'from', 'this', 'paper', 'are', ""'pvs1"", 'frameshift', 'null', 'variant', 'and', ""'pp1"", 'limited', 'segregation', 'data']"
1014,1.0,All 3 individuals carried cerebellar hemangioblastomas and angiomas.,"['all', '_num_', 'individuals', 'carried', 'cerebellar', '_disease_', 'and', 'angiomas']"
1015,1.0,"This nonsense mutation was found in 2 unrelated, German families.","['this', 'nonsense', 'mutation', 'was', 'found', 'in', '_num_', 'unrelated', 'german', 'families']"
1016,1.0,The F359V mutation was  moderately resistant to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
1017,1.0,"Cancerogenesis with chemical initiators/promoters (3-methylcholanthrene or control, butylated hydroxytoluene) was assessed in mice lacking Ereg (Ereg-/-) and wildtype controls (BALB/ByJ; Ereg+/+) at multiple time points and endpoints (bronchoalveolar lavage analysis, tumor analysis, mRNA expression, ELISA, wound assay).","['cancerogenesis', 'with', 'chemical', 'initiators', 'promoters', '_disease_', 'or', 'control', 'butylated', '_chemical_', 'was', 'assessed', 'in', 'mice', 'lacking', '_gene_', 'ereg', '', '', '', 'and', 'wildtype', 'controls', 'balb', 'byj', 'ereg+', '+', 'at', 'multiple', 'time', 'points', 'and', 'endpoints', 'bronchoalveolar', 'lavage', 'analysis', 'tumor', 'analysis', 'mrna', 'expression', 'elisa', 'wound', 'assay']"
1018,1.0,"Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib(AC220), a second generation class II tyrosine kinase inhibitor.","['murine', 'ba', '_abbrev_', 'cell', 'line', 'has', 'a', 'restrictive', 'sensitivity', 'to', '_chemical_', '_abbrev_', 'a', '_num_', 'generation', 'class', 'ii', 'tyrosine', 'kinase', 'inhibitor']"
1019,1.0,"19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more).","['_num_', '_gene_', 'carriers', 'had', 'ovarian', 'breast', 'or', 'prostate', 'cancers', '_num_', 'of', 'these', '_num_', 'had', 'a', 'clinical', 'benefit', 'from', 'treatment', 'with', '_chemical_', 'radiologic', 'or', 'tumor', 'marker', 'responses', 'or', 'meaningful', 'disease', 'stabilization', 'stable', 'disease', 'for', 'a', 'period', 'of', '_num_', 'months', 'or', 'more']"
1020,1.0,Twenty-one additional patients had stable disease or minor responses.,"['twenty', '_num_', 'additional', 'patients', 'had', 'stable', 'disease', 'or', 'minor', 'responses']"
1021,1.0,Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test.,"['both', '_gene_', 'and', '_gene_', 'loss', '_gene_', 'were', 'tested', 'for', 'association', 'with', 'response', 'to', '_disease_', 'using', 'fisher', ""'s"", 'exact', 'test']"
1022,1.0,"A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated with increased clinical response to chemoradiation therapy consisting of cisplatin, 5-fluorouracil, and 40 gy radiation (P = 0.0003).","['a', 'retrospective', 'study', 'examining', 'the', 'expression', 'of', '_gene_', 'in', 'tumor', 'samples', 'of', '_num_', 'esophageal', '_disease_', 'cell', 'carcinoma', 'patients', 'found', 'that', 'positive', 'expression', 'of', '_gene_', '_num_', 'of', 'cells', 'by', '_gene_', 'was', 'correlated', 'with', 'increased', 'clinical', 'response', 'to', 'chemoradiation', 'therapy', 'consisting', 'of', '_disease_', '_disease_', 'and', '_num_', 'gy', 'radiation', 'p', '_num_']"
1023,1.0,"In mice, human HER2 with YVMA insertion was placed under a doxycycline-inducible, clara cell specific promoter.","['in', 'mice', 'human', '_gene_', 'with', '_gene_', 'insertion', 'was', 'placed', 'under', 'a', 'doxycycline', 'inducible', 'clara', 'cell', 'specific', 'promoter']"
1024,1.0,No gross imbalances in clinicopathologic features of the two groups were evident.,"['no', 'gross', 'imbalances', 'in', 'clinicopathologic', 'features', 'of', 'the', '_num_', 'groups', 'were', 'evident']"
1025,1.0,"In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027).","['in', 'univariate', 'analysis', 'mutations', 'in', '_gene_', 'were', 'significantly', 'associated', 'with', 'shorter', 'overall', 'survival', 'compared', 'to', 'wildtype', '_gene_', 'in', 'adult', '_range_', 'years', 'old', '_disease_', 'acute', '_disease_', 'leukemia', '_chemical_', 'mutated', '_num_', 'wild', 'type', 'patients', '_p_val_', 'and', 'the', 'early', 'subtype', '_ineq_', 'mutated', '_num_', 'wild', 'type', 'patients', '_p_val_']"
1026,1.0,"ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue.","['_gene_', 'rearrangement', 'was', 'determined', 'by', 'fish', 'but', 'the', '_gene_', 'fusion', 'partner', 'was', 'not', 'determined', 'due', 'to', 'limited', 'tissue']"
1027,1.0,Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin.,"['patients', 'underwent', 'adjuvant', 'chemotherapy', 'with', '_disease_', 'and', '_chemical_']"
1028,1.0,"Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T/T).","['patients', 'with', 'the', 'wild', 'type', 'c', 'c', '_gene_', 'gene', 'are', '_num_', 'times', '_num_', 'ci', '_num_', '_num_', 'more', 'likely', 'to', 'have', 'a', 'positive', 'response', 'to', 'neoadjuvant', 'crt', 'and', '_num_', 'times', 'more', 'likely', 'not', 'to', 'experience', 'relapse', '_num_', 'ci', '_num_', '_num_', 'than', 'patients', 'with', 'the', 'heterozygous', '_gene_', '_mutation_', 'c', 't', 'mutation', 'or', 'the', 'homzygous', '_disease_']"
1029,1.0,Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET.,"['case', 'report', 'of', 'a', 'patient', 'with', 'lung', 'adenocarcinoma', 'harboring', 'both', 'a', 'mutation', 'in', '_gene_', 'and', 'an', 'amplification', 'of', 'met']"
1030,1.0,"Further, the patients harboring PIK3CA mutations (n=79) were associated with a decrease in disease progression (ado-trastuzumab relative to standard chemotherapy; HR:0.45; 95% CI:0.25-0.82), as compared to patients with wild type PIK3CA (n=180; HR:0.74; 95% CI:0.50-1.10).","['further', 'the', 'patients', 'harboring', '_gene_', 'mutations', '_ineq_', 'were', 'associated', 'with', 'a', 'decrease', 'in', 'disease', 'progression', 'ado', '_chemical_', 'relative', 'to', 'standard', 'chemotherapy', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', '_ineq_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_']"
1031,1.0,"This missense mutation was found in a German, VHL type 2 family with 5 affected individuals (family VHL 43).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'family', 'with', '_num_', 'affected', 'individuals', 'family', '_gene_', '_num_']"
1032,1.0,Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655).,"['phase', 'i', 'expansion', 'and', 'pharmacodynamic', 'study', 'of', 'the', 'oral', 'mek', 'inhibitor', '_abbrev_', '_chemical_']"
1033,0.0,This phase II study showed a modest antitumor activity of lapatinib in chordoma,"['this', 'phase', 'ii', 'study', 'showed', 'a', 'modest', 'antitumor', 'activity', 'of', '_chemical_', 'in', '_gene_']"
1034,1.0,In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.,"['in', 'vitro', 'studies', 'using', '_gene_', 'over', 'expressing', 'breast', 'cancer', 'cell', 'lines', '_abbrev_', 'and', '_abbrev_', 'with', '_gene_', 'amplification', 'showed', 'apoptosis', 'under', 'either', 'labatinib', 'or', '_chemical_', 'treatment']"
1035,1.0,"In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer.","['in', 'this', 'preclinical', 'study', 'of', '_chemical_', 'panitumumab', 'or', '_abbrev_', 'on', 'various', '_gene_', 'mutations', 'in', 'colorectal', 'cancer']"
1036,1.0,"In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, those with deletions of IKZF1 had worse event-free and overall survival than patients without deletions.","['in', 'children', 'with', 'bone', 'marrow', 'relapsed', '_disease_', 'precursor', 'acute', '_disease_', 'leukemia', 'those', 'with', 'deletions', 'of', '_gene_', 'had', 'worse', 'event', 'free', 'and', 'overall', 'survival', 'than', 'patients', 'without', 'deletions']"
1037,1.0,"FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide.","['_chemical_', 'a', 'high', '_gene_', 'expression', 'cell', 'line', 'and', '_abbrev_', 'a', 'low', 'expression', 'cell', 'line', 'were', 'treated', 'with', '_gene_', 'retinoic', 'acid', '_disease_', '_chemical_', 'or', '_chemical_']"
1038,1.0,A targeted copy number screen of 131 precursor B-ALL cases revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates.,"['a', 'targeted', 'copy', 'number', 'screen', 'of', '_num_', 'precursor', '_disease_', 'cases', 'revealed', 'that', '_gene_', 'deletions', 'are', 'significantly', 'associated', 'with', 'poor', 'relapse', 'free', 'and', 'overall', 'survival', 'rates']"
1039,1.0,Additional data was obtained from xenografts.,"['additional', 'data', 'was', 'obtained', 'from', 'xenografts']"
1040,1.0,The other family had a 39-year-old with renal cell carcinoma and pancreatic cysts and their 81-year-old mother with CNS hemangioblastomas (proband no 9).,"['the', 'other', 'family', 'had', 'a', '_age_', 'with', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'and', 'their', '_age_', 'mother', 'with', 'cns', '_disease_', 'proband', 'no', '_num_']"
1041,1.0,"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day).","['in', 'this', 'phase', 'ii', 'trial', 'patients', 'with', 'metastatic', 'platinum', 'refractory', 'urothelial', 'carcinoma', '_gene_', 'received', '_chemical_', '_num_', '_disease_']"
1042,1.0,A single lesion that progressed after 9 months still expressed the KRAS G12D mutation.,"['a', 'single', 'lesion', 'that', 'progressed', 'after', '_num_', 'months', 'still', 'expressed', 'the', '_gene_', '_mutation_', 'mutation']"
1043,1.0,"In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'patients', 'with', '_gene_', '_abbrev_', 'mutation', 'a', 'known', '_chemical_', 'sensitizing', 'mutation', 'that', 'developed', 'cutaneous', '_disease_', 'carcinoma', 'upon', 'treatment', 'with', '_chemical_', 'monotherapy', 'a', 'patient', 'harboring', '_gene_', '_mutation_', 'co', 'mutation', '_ineq_', 'was', 'reported', 'to', 'be', 'resistant', 'to', '_chemical_', 'treatment']"
1044,0.0,"In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.","['in', 'models', 'of', 'high', 'grade', 'serous', 'ovarian', 'cancer', 'hgs', '_disease_', '_gene_', 'attenuation', 'was', 'sufficient', 'to', 'confer', 'sensitivity', 'to', '_gene_', 'inhibition', 'suppression', 'of', 'dna', 'repair', 'via', 'homologous', 'recombination', 'and', 'reduced', 'expression', 'of', '_gene_']"
1045,1.0,U2AF1 mutations were significantly associated with anemia in univariate and multivariate analysis (72 mutated vs 385 wildtype; P<0.0001).,"['_gene_', 'mutations', 'were', 'significantly', 'associated', 'with', 'anemia', 'in', 'univariate', 'and', 'multivariate', 'analysis', '_num_', 'mutated', 'vs', '_num_', 'wildtype', 'p', '_num_']"
1046,1.0,"In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD.","['in', 'general', 'patients', 'with', 'germline', 'or', 'somatic', '_mutation_', 'mutations', 'or', '_mutation_', 'mutations', 'had', '_num_', 'complete', 'response', '_num_', 'sd', 'and', '_num_', 'pd', 'while', 'patients', 'with', 'other', '_gene_', 'mutations', 'had', '_num_', 'pd']"
1047,1.0,Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B.,"['most', '_gene_', 'mutant', 'cell', 'lines', 'mostly', '_mutation_', 'with', '_gene_', 'mutation', 'or', 'loss', 'of', 'expression', 'were', 'among', 'those', 'sensitive', 'to', 'inhibition', 'with', '_gene_', 'inhibitor', '_abbrev_']"
1048,1.0,High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy.,"['high', 'levels', 'of', '_gene_', 'expression', 'retrospectively', 'assessed', 'by', '_gene_', 'in', '_num_', '_disease_', 'patients', 'predicted', 'poorer', 'overall', 'survival', 'and', 'progression', 'free', 'survival', 'in', 'a', 'population', 'treated', 'with', 'surgery', 'and', '_disease_', 'based', 'chemotherapy']"
1049,1.0,"We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild type exons 2, 3, and 4 in KRAS and NRAS, and wild type exon 15 in BRAF.","['we', 'identified', '_num_', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', 'whose', 'tumors', 'harbored', 'both', 'wild', 'type', 'exons', '_num_', '_num_', 'and', '_num_', 'in', '_gene_', 'and', 'nras', 'and', 'wild', 'type', 'exon', '_num_', 'in', '_gene_']"
1050,1.0,Chemotherapy-refractory patients with colorectal cancer harboring KRAS mutations (primarily G12/G13) had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS.,"['chemotherapy', 'refractory', 'patients', 'with', 'colorectal', 'cancer', 'harboring', '_gene_', 'mutations', 'primarily', '_abbrev_', 'had', 'lower', 'response', 'and', 'disease', 'control', 'rates', 'and', 'shorter', 'progression', 'free', 'and', 'overall', 'survival', 'following', '_chemical_', 'plus', 'chemotherapy', 'than', 'those', 'with', 'wildtype', '_gene_']"
1051,1.0,"In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.","['in', 'lung', 'cancer', 'patients', 'with', 'acquired', 'resistance', 'to', '_chemical_', '_chemical_', 'met', 'amplification', 'and', '_gene_', '_mutation_', 'were', 'found', 'to', 'be', 'the', 'primary', 'drivers', 'of', 'resistance']"
1052,1.0,"72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients.","['_num_', 'patients', 'with', 'malignant', 'pleural', 'mesothelioma', 'were', 'analyzed', '_gene_', 'immunoexpression', 'was', 'assessed', 'in', '_num_', 'patients']"
1053,1.0,"This patient also harbored a TP53 mutation, MCL1 amplification and CDKN2A deletion.","['this', 'patient', 'also', 'harbored', 'a', '_gene_', 'mutation', '_gene_', 'amplification', 'and', '_gene_', 'deletion']"
1054,1.0,Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071).,"['low', '_abbrev_', 'was', 'correlated', 'with', 'better', 'os', '_p_val_', 'and', 'non', 'significantly', 'associated', 'with', 'longer', '_disease_', '_p_val_']"
1055,1.0,After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded.,"['after', 'progression', 'on', '_chemical_', 'the', 'patient', 'was', 'treated', 'with', 'combined', 'type', 'i', 'met', 'savolitinib', 'and', '_gene_', 'osimertinib', 'inhibition', 'and', 'responded']"
1056,1.0,"However, no complete responses were observed with afatinib alone.","['however', 'no', 'complete', 'responses', 'were', 'observed', 'with', '_chemical_', 'alone']"
1057,1.0,"3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4/15 having disease progression as best response.","['_num_', 'out', 'of', '_num_', 'patients', 'expressing', 'high', 'tumor', '_gene_', 'mrna', 'had', 'disease', 'progression', 'as', 'best', 'response', 'with', 'median', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'days', 'while', '_num_', 'patients', 'classified', 'with', 'low', 'to', 'medium', '_gene_', 'mrna', 'had', 'median', '_disease_', '_num_', 'days', 'with', '_ratio_', 'having', 'disease', 'progression', 'as', 'best', 'response']"
1058,1.0,The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC).,"['the', 'functional', 'variant', '_mutation_', 'in', 'the', '_gene_', 'gene', '_num_', '_gene_', '_gene_', 'variant', 'was', 'found', 'to', 'be', 'correlated', 'with', 'platinum', 'based', 'chemotherapy', 'resistance', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'cancer', '_disease_']"
1059,1.0,High MYCN expression was found to sensitize neuroblastoma cells to CBL0137.,"['high', '_gene_', 'expression', 'was', 'found', 'to', 'sensitize', 'neuroblastoma', 'cells', 'to', '_chemical_']"
1060,1.0,4 melanoma patients had NRAS Q61 mutations.,"['_num_', 'melanoma', 'patients', 'had', 'nras', '_abbrev_', 'mutations']"
1061,1.0,"In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment.","['in', 'a', 'case', 'study', 'a', 'patient', 'with', 'anal', 'melanoma', 'harboring', 'a', '_num_', 'codon', 'duplication', 'in', 'the', 'juxtamambrane', 'region', 'exon', '_num_', 'of', 'kit', 'showed', 'marked', 'response', '_num_', 'months', 'after', '_chemical_', 'treatment']"
1062,1.0,"In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation.","['in', 'an', 'in', 'vitro', 'study', 'to', 'identify', '_chemical_', 'resistant', 'clones', 'following', 'continuous', 'drug', 'treatment', 'a', 'resistant', 'clone', 'of', 'the', '_abbrev_', 'colorectal', 'cancer', 'cell', 'line', 'was', 'identified', 'to', 'have', 'the', '_gene_', '_mutation_', 'mutation']"
1063,0.0,This suggests that mutations in the PI3K holoenzyme may be targetable by mTORC1/2 inhibition.,"['this', 'suggests', 'that', 'mutations', 'in', 'the', '_gene_', 'holoenzyme', 'may', 'be', 'targetable', 'by', '_gene_', 'inhibition']"
1064,1.0,"In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants.","['in', 'vitro', 'analysis', 'in', 'the', 'murine', 'fibroblast', 'cell', 'line', '_chemical_', 'with', 'ectopic', 'expression', 'of', '_gene_', 'mutations', '_mutation_', '_mutation_', '_mutation_', 'and', '_mutation_', 'showed', 'that', '_abbrev_', 'effectively', 'bound', 'to', 'all', 'mutants', 'whereas', '_chemical_', 'and', 'panitumumab', 'did', 'not', 'effectively', 'bind', 'to', 'all', 'mutants']"
1065,1.0,Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds.,"['sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_', 'was', 'assessed', 'in', 'a', 'panel', 'of', 'breast', 'cancer', 'cell', 'lines', 'with', 'various', 'mutation', 'backgrounds']"
1066,1.0,"In a series of 33 patients with Peutz-Jeghers Syndrome, 17 mutations in STK11/LKB1 were observed in exons 1-8 (none in exon 9).","['in', 'a', 'series', 'of', '_num_', 'patients', 'with', '_disease_', 'syndrome', '_num_', 'mutations', 'in', '_abbrev_', 'were', 'observed', 'in', 'exons', '_range_', 'none', 'in', 'exon', '_num_']"
1067,1.0,"HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts.","['_disease_', 'terms', 'retinal', '_disease_', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts']"
1068,1.0,"Patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study of selumetinib and analyzed for mutations in KIT, NRAS, KRAS and FLT3.","['patients', 'with', 'relapsed', 'refractory', '_disease_', 'or', '_num_', 'years', 'old', 'or', 'more', 'with', 'untreated', '_disease_', 'were', 'enrolled', 'on', 'a', 'phase', 'ii', 'study', 'of', '_chemical_', 'and', 'analyzed', 'for', 'mutations', 'in', 'kit', 'nras', '_gene_', 'and', '_gene_']"
1069,1.0,The proband also had retinal angiomas.,"['the', 'proband', 'also', 'had', 'retinal', 'angiomas']"
1070,1.0,"Crizotinib was initiated and a sustained near complete response for 27 months was observed, after which an FDG-avid cervical lymph node appeared along with pleural effusions and pleural nodules.","['_chemical_', 'was', 'initiated', 'and', 'a', 'sustained', 'near', 'complete', 'response', 'for', '_num_', 'months', 'was', 'observed', 'after', 'which', 'an', 'fdg', 'avid', 'cervical', 'lymph', 'node', 'appeared', 'along', 'with', 'pleural', 'effusions', 'and', 'pleural', 'nodules']"
1071,1.0,32/40 mice harbored KRAS mutations including 5 G13D mutations where disease stabilization was achieved in 2/5 mice treated with AZD6244 or combination therapy and 0/5 mice treated with BEZ235 alone.,"['_ratio_', 'mice', 'harbored', '_gene_', 'mutations', 'including', '_num_', '_mutation_', 'mutations', 'where', 'disease', 'stabilization', 'was', 'achieved', 'in', '_ratio_', 'mice', 'treated', 'with', '_chemical_', 'or', 'combination', 'therapy', 'and', '_ratio_', 'mice', 'treated', 'with', '_chemical_', 'alone']"
1072,1.0,"In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily).","['in', '_abbrev_', 'xenografts', '_num_', 'dosing', 'schedules', 'of', '_chemical_', 'caused', 'significant', 'tumor', 'inhibition', '_num_', '_disease_', 'twice', 'daily', '_num_', '_disease_', 'once', 'daily', '_num_', '_disease_', 'once', 'daily']"
1073,1.0,"EML4-ALK V1180L and EML4-ALK wild type were ectopically expressed in Ba/F3 cells, and brigatinib showed strong activity against both variants.","['_chemical_', '_mutation_', 'and', '_chemical_', 'wild', 'type', 'were', 'ectopically', 'expressed', 'in', 'ba', '_abbrev_', 'cells', 'and', 'brigatinib', 'showed', 'strong', 'activity', 'against', 'both', 'variants']"
1074,1.0,One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study.,"['_num_', 'patient', 'with', '_abbrev_', 'was', 'treated', 'with', 'entrectinib', 'in', 'a', 'phase', '_num_', 'study']"
1075,1.0,When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance.,"['when', 'co', 'expressed', 'with', '_mutation_', '_chemical_', 'sensitive', 'in', 'vitro', '_mutation_', 'showed', 'moderate', '_chemical_', 'resistance']"
1076,1.0,This missense mutation was found in 4 VHL families of 11 patients altogether.,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'families', 'of', '_num_', 'patients', 'altogether']"
1077,1.0,In the KRAS-mutant CRC dose expansion cohort 14 patients were evaluable for response.,"['in', 'the', '_gene_', 'mutant', '_gene_', 'dose', 'expansion', 'cohort', '_num_', 'patients', 'were', 'evaluable', 'for', 'response']"
1078,1.0,EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival).,"['_gene_', 'amplification', 'was', 'associated', 'with', '_gene_', 'mutation', 'but', 'not', 'independently', 'with', 'patient', 'benefit', 'from', '_gene_', '_disease_', 'overall', 'and', 'progression', 'free', 'survival']"
1079,1.0,This missense mutation was found in a VHL type 1 patient (patient no V265).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
1080,1.0,This missense mutation was found in a VHL type 2A patient (patient no V49).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_abbrev_']"
1081,1.0,"Western blots of alectinib treated NPM-ALK G1269A were performed and reduced pALK Y1604 was seen at 300 nM alectinib, and no pALK at 1000 nM.","['western', 'blots', 'of', '_chemical_', 'treated', '_chemical_', '_mutation_', 'were', 'performed', 'and', 'reduced', 'palk', '_gene_', 'was', 'seen', 'at', '_num_', '_unit_', '_chemical_', 'and', 'no', 'palk', 'at', '_num_', '_unit_']"
1082,1.0,"Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study.","['multivariate', 'analysis', 'was', 'performed', 'on', 'all', 'patients', 'that', 'were', 'evaluated', 'for', 'a', 'mutation', 'in', 'at', 'least', '_num_', 'gene', '_gene_', '_gene_', 'or', '_gene_', 'totaling', '_ratio_', 'patients', 'in', 'the', 'study']"
1083,1.0,A total of 16 cell lines were used in this study.,"['a', 'total', 'of', '_num_', 'cell', 'lines', 'were', 'used', 'in', 'this', 'study']"
1084,1.0,"Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels.","['ectopic', 'expression', 'of', '_mutation_', '_abbrev_', 'and', '_mutation_', 'mutants', 'elevated', '_chemical_', 'mek', 'and', '_gene_', 'levels']"
1085,1.0,Genome wide amplification was assessed by Affymetrix SNP arrays and expression was assessed by Affymetrix gene expression arrays.,"['genome', 'wide', 'amplification', 'was', 'assessed', 'by', 'affymetrix', 'snp', 'arrays', 'and', 'expression', 'was', 'assessed', 'by', 'affymetrix', 'gene', 'expression', 'arrays']"
1086,1.0,"In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival.","['in', 'patients', 'with', 'breast', 'cancer', 'those', 'with', 'amplification', 'of', '_gene_', 'had', 'shorter', '_disease_', 'survival']"
1087,1.0,Expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas.,"['expression', 'of', '_gene_', 'was', 'a', 'strong', 'positive', 'predictive', 'factor', 'for', 'survival', 'in', 'both', 'stage', 'ii', 'and', 'stage', 'iii', 'colorectal', 'carcinomas']"
1088,1.0,SPHK1 expression did not directly predict OS.,"['_gene_', 'expression', 'did', 'not', 'directly', 'predict', 'os']"
1089,1.0,Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.,"['rates', 'of', 'adverse', 'events', 'of', 'grade', '_num_', 'or', 'higher', 'were', 'greater', 'with', '_chemical_', 'plus', '_chemical_']"
1090,1.0,IHC in 36 tumors validated these results on protein level.,"['_gene_', 'in', '_num_', 'tumors', 'validated', 'these', 'results', 'on', 'protein', 'level']"
1091,1.0,Ponatinib also inhibited FGFR2 kinase activity and phosphorylation (MFE-296 and MFE-280) as well as cell migration and invasion (MFE-296 and AN3CA) of FGFR2 mutated cancer cell lines.,"['_chemical_', 'also', 'inhibited', '_gene_', 'kinase', 'activity', 'and', '_disease_', '_abbrev_', 'and', '_abbrev_', 'as', 'well', 'as', 'cell', 'migration', 'and', 'invasion', '_abbrev_', 'and', '_abbrev_', 'of', '_gene_', 'mutated', 'cancer', 'cell', 'lines']"
1092,1.0,Addition of recombinant human EGF led to increased cetuximab resistance.,"['addition', 'of', 'recombinant', 'human', '_gene_', 'led', 'to', 'increased', '_chemical_', 'resistance']"
1093,1.0,"45 out of 123 patients (37%; 95% CI, 29%-45%) showed hypermethylation of the bidirectional promoter of PTEN and KILLIN.","['_num_', 'out', 'of', '_num_', 'patients', '_num_', '_num_', 'ci', '_num_', '_num_', 'showed', 'hypermethylation', 'of', 'the', 'bidirectional', 'promoter', 'of', '_gene_', 'and', '_gene_']"
1094,1.0,"The disease-associated PDGFB-COL1A1 fusion was consistent with the most common form, a supernumerary ring chromosome.","['the', 'disease', 'associated', '_abbrev_', 'fusion', 'was', 'consistent', 'with', 'the', 'most', 'common', 'form', 'a', 'supernumerary', 'ring', 'chromosome']"
1095,1.0,"Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations).","['preclinical', 'study', 'in', '_num_', 'nras', 'mutant', 'cell', 'lines', 'melanoma', 'lung', 'carcinoma', 'neuroblastoma', 'with', 'various', '_abbrev_', '_gene_', '_gene_', 'mutations']"
1096,1.0,Study explored the known PALB2 variant c.1592delT (p.L531C) in the context of breast cancer.,"['study', 'explored', 'the', 'known', '_gene_', 'variant', '_mutation_', 'p', '_abbrev_', 'in', 'the', 'context', 'of', 'breast', 'cancer']"
1097,1.0,"Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive.","['ba', '_abbrev_', 'cells', 'transduced', 'with', '_chemical_', 'variants', '_abbrev_', '_gene_', '_gene_', '_abbrev_', '_chemical_', '_gene_', '_abbrev_', '_gene_', '_gene_', 'and', '_abbrev_', '_abbrev_', '_gene_', 'showed', 'differential', 'sensitivity', 'to', 'both', '_chemical_', 'and', '_chemical_', 'with', 'variant', '3a', '_gene_', '_gene_', 'being', 'the', 'least', 'sensitive']"
1098,0.0,"we report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.","['we', 'report', 'that', 'due', 'to', 'the', 'limited', 'clinical', 'activity', 'of', '_chemical_', 'based', 'therapy', 'in', 'this', 'cohort', 'as', 'well', 'as', 'similar', 'results', 'in', 'other', '_chemical_', 'studies', 'that', 'targets', 'other', 'than', '_gene_', 'in', '_disease_', 'should', 'be', 'considered', 'for', 'future', 'study']"
1099,1.0,"These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days.","['these', '_num_', 'patients', 'had', 'achieved', 'confirmed', 'pr', 'with', 'duration', 'responses', 'ranging', 'from', '_num_', 'to', '_num_', 'days']"
1100,1.0,This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 82).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
1101,1.0,The data was obtained from Berlin Frankfurt Münster Clinical Trials.,"['the', 'data', 'was', 'obtained', 'from', 'berlin', 'frankfurt', 'münster', 'clinical', 'trials']"
1102,1.0,Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines.,"['cytoplasmic', 'localization', 'of', '_gene_', '_gene_', 'leads', 'to', '_chemical_', 'resistance', 'in', '_abbrev_', 'breast', 'cancer', 'cell', 'lines']"
1103,1.0,"Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort.","['although', 'these', 'numbers', 'are', 'not', 'sufficient', 'for', 'statistical', 'comparison', 'they', 'compare', 'unfavorably', 'to', '_num_', 'year', 'overall', 'survival', 'and', '_num_', '_num_', 'year', 'survival', 'of', 'chop', 'treated', '_disease_', 'patients', 'and', 'even', 'less', 'favorably', 'to', '_gene_', 'standard', 'of', 'care', 'for', '_gene_', 'positive', '_disease_', 'suggesting', 'poor', 'prognosis', 'for', '_gene_', '_disease_', 'and', 'need', 'for', 'updated', 'treatment', 'in', 'this', 'cohort']"
1104,1.0,This study shows an association of FGFR1 amplification with shorter overall and disease-free survival.,"['this', 'study', 'shows', 'an', 'association', 'of', '_gene_', 'amplification', 'with', 'shorter', 'overall', 'and', '_disease_', 'survival']"
1105,1.0,"Cancer diagnosis was more common in G84E carriers than in non-carriers (51.5% vs 30.6%, P = 0.004).","['cancer', 'diagnosis', 'was', 'more', 'common', 'in', '_mutation_', 'carriers', 'than', 'in', '_disease_', '_num_', 'vs', '_num_', 'p', '_num_']"
1106,1.0,"Moreover, gemcitabine response of MiaPaCa2 also became more sensitive.","['moreover', '_chemical_', 'response', 'of', '_abbrev_', 'also', 'became', 'more', 'sensitive']"
1107,1.0,Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone.,"['co', 'treatment', 'of', '_gene_', 'as', 'tumor', 'mice', 'with', '_gene_', 'and', '_chemical_', 'inhibited', 'tumor', 'growth', 'in', 'comparison', 'to', '_gene_', 'as', 'tumors', 'treated', 'with', '_chemical_', 'or', '_gene_', 'alone']"
1108,1.0,"Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding.","['characterization', 'of', 'this', 'mutation', 'showed', 'that', 'is', 'was', 'located', 'on', 'the', '_gene_', 'domain', 'not', 'associated', 'with', '_chemical_', 'binding']"
1109,1.0,Only 6 (4.3%) were ERBB2 positive.,"['only', '_num_', '_num_', 'were', '_gene_', 'positive']"
1110,1.0,"LY3009120, but not vemurafenib, also inhibited tumor growth of both H2405 and BxPC-3 cells xenografted into mice.","['_chemical_', 'but', 'not', '_chemical_', 'also', 'inhibited', 'tumor', 'growth', 'of', 'both', '_abbrev_', 'and', '_chemical_', 'cells', 'xenografted', 'into', 'mice']"
1111,1.0,PF-06463922 was well tolerated in the animal models.,"['_chemical_', 'was', 'well', 'tolerated', 'in', 'the', 'animal', 'models']"
1112,1.0,Patients received cabozantinib 100 mg/d during a 12-week lead-in.,"['patients', 'received', '_chemical_', '_num_', '_chemical_', 'during', 'a', '_num_', 'week', 'lead', 'in']"
1113,1.0,"In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib.","['in', 'a', 'patient', 'with', 'thymic', 'carcinoma', 'the', 'tumor', 'expressing', 'an', 'activating', 'mutation', 'in', 'exon', '_num_', 'of', 'kit', '_mutation_', 'was', 'sensitive', 'to', '_chemical_']"
1114,1.0,"In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment.","['in', 'an', '_disease_', 'patient', 'initially', 'with', '_mutation_', 'mutation', '_chemical_', 'and', '_disease_', 'combination', 'treatment', 'was', 'followed', 'by', '_chemical_', 'treatment']"
1115,1.0,In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006).,"['in', 'this', '_disease_', 'analysis', 'of', '_num_', 'studies', '_num_', 'patients', '_gene_', 'positivity', 'as', 'defined', 'by', 'high', 'protein', 'expression', 'and', 'or', '_gene_', 'mutation', 'was', 'associated', 'with', 'improved', 'response', 'to', 'chemotherapy', 'risk', 'ratio', '_gene_', '_num_', '_num_', 'confidence', 'intervals', 'ci', '_range_', 'p', '_num_']"
1116,1.0,"Missense mutation found in two VHL type 2A families of 55 individuals altogether (family IDs 3476, 3127).","['missense', 'mutation', 'found', 'in', '_num_', '_gene_', 'type', '_gene_', 'families', 'of', '_num_', 'individuals', 'altogether', 'family', 'ids', '_num_', '_num_']"
1117,1.0,"Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).","['median', 'time', 'to', 'progression', 'was', '_num_', 'months', 'in', 'the', '_chemical_', 'group', 'and', '_num_', 'months', 'in', '_chemical_', 'plus', '_chemical_', 'group', 'hazard', 'ratio', 'was', '_num_', '_num_', 'confidence', 'interval', '_num_', 'to', '_num_', 'p', '_num_']"
1118,1.0,there was one partial response in the docetaxel group and none in the trastuzumab group.,"['there', 'was', '_num_', 'partial', 'response', 'in', 'the', '_chemical_', 'group', 'and', 'none', 'in', 'the', '_chemical_', 'group']"
1119,1.0,"In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group.","['in', 'a', 'randomized', 'phase', '_num_', 'study', 'previously', 'untreated', 'advanced', 'or', 'metastatic', '_gene_', '_abbrev_', 'mutation', 'positive', 'melanoma', 'patients', 'treated', 'with', 'combination', '_chemical_', 'and', '_chemical_', 'showed', 'improved', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', 'increased', 'rate', 'of', 'complete', 'or', 'partial', 'response', '_num_', 'vs', '_num_', 'and', 'improved', 'overall', 'survival', 'at', '_num_', 'months', '_num_', 'vs', '_num_', 'compared', 'to', 'the', '_chemical_', 'and', 'placebo', 'control', 'group']"
1120,1.0,Temozolomide treatment led to better survival in patients with the rs16906252 T genotype irrespective of methylation status.,"['_chemical_', 'treatment', 'led', 'to', 'better', 'survival', 'in', 'patients', 'with', 'the', '_mutation_', 't', 'genotype', 'irrespective', 'of', 'methylation', 'status']"
1121,1.0,Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib.,"['cell', 'lines', 'with', '_abbrev_', 'fusion', 'were', 'resistant', 'to', 'treatment', 'with', '_chemical_']"
1122,1.0,Brigatinib treatment of CLB-BAR cells reduced MYCN protein levels and ALK phosphorylation (Y1604) similar to crizotnib.,"['brigatinib', 'treatment', 'of', '_gene_', 'bar', 'cells', 'reduced', '_gene_', 'protein', 'levels', 'and', '_gene_', '_disease_', '_gene_', 'similar', 'to', 'crizotnib']"
1123,1.0,"In an in vitro study, a SW48 cell line expressing KRAS G12A mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 3301.13 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'decreased', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'p', '_num_', 'compared', 'to', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
1124,1.0,Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives.,"['gene', 'expression', 'profiling', 'showed', 'upregulation', 'of', '_gene_', 'in', 'the', '_chemical_', 'resistant', 'derivatives']"
1125,1.0,"In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029).","['in', 'metastatic', 'colorectal', 'cancer', 'patients', 'with', 'wildtype', '_gene_', 'status', 'those', 'with', 'a', '_gene_', '_mutation_', 'mutation', 'were', 'less', 'likely', 'to', 'respond', 'to', 'treatment', 'with', '_chemical_', 'or', 'panitumumab', 'than', 'those', 'with', 'wildtype', '_gene_', '_num_', 'vs', '_num_', '_p_val_']"
1126,1.0,"Among patients with AML, those with mutations in ASXL1 were more likely to have the AML with myelodysplasia-related changes (AML-MRC) subtype.","['among', 'patients', 'with', '_disease_', 'those', 'with', 'mutations', 'in', '_gene_', 'were', 'more', 'likely', 'to', 'have', 'the', '_disease_', 'with', '_disease_', 'related', 'changes', '_disease_', 'subtype']"
1127,1.0,2/3 patients with CD44s had SD as best response.,"['_ratio_', 'patients', 'with', '_gene_', 'had', 'sd', 'as', 'best', 'response']"
1128,1.0,we conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course.,"['we', 'conclude', 'that', 'partial', 'response', 'to', '_chemical_', 'was', 'observed', 'and', 'that', 'in', 'future', 'trials', '_gene_', 'rearranged', '_disease_', 'patients', 'might', 'see', 'increased', 'benefit', 'with', 'earlier', 'application', 'of', 'targeted', 'therapy', 'during', 'the', 'treatment', 'course']"
1129,1.0,"BRAF V600E/NF1 mutant cell lines were sensitive to ERK inhibition with VTX-11e, modest resistance was observed against RAF inhibitor AZ628.","['_gene_', '_abbrev_', 'mutant', 'cell', 'lines', 'were', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_abbrev_', 'modest', 'resistance', 'was', 'observed', 'against', 'raf', 'inhibitor', '_chemical_']"
1130,1.0,Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation.,"['molecular', 'profiling', 'identified', 'both', 'met', 'amplification', '_num_', 'copies', 'and', 'a', '_gene_', '_mutation_', 'mutation']"
1131,1.0,"PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells.","['_gene_', 'null', 'cells', 'treated', 'with', '_gene_', 'inhibitor', '_gene_', 'also', 'did', 'not', 'show', 'substantial', 'inhibition', 'but', 'co', 'treatment', 'with', '_chemical_', 'and', '_gene_', 'induced', 'growth', 'inhibition', 'comparable', 'to', '_chemical_', 'alone', 'in', 'normal', '_abbrev_', 'cells']"
1132,1.0,One patient had retinal angiomas and two had cerebellar hemangioblastomas.,"['_num_', 'patient', 'had', 'retinal', 'angiomas', 'and', '_num_', 'had', 'cerebellar', '_disease_']"
1133,1.0,"In an in vitro study, HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R mutation was associated with increased sensitivity to ado-trastuzumab emtansine treatment compared to trastuzumab treated HCC1954 and KPL-4 cells.","['in', 'an', 'in', 'vitro', 'study', '_abbrev_', 'and', '_abbrev_', 'cell', 'lines', 'expressing', '_gene_', '_mutation_', 'mutation', 'was', 'associated', 'with', 'increased', 'sensitivity', 'to', 'ado', '_chemical_', '_chemical_', 'treatment', 'compared', 'to', '_chemical_', 'treated', '_abbrev_', 'and', '_abbrev_', 'cells']"
1134,1.0,"In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate.","['in', 'this', 'study', 'heavily', 'pretreated', 'advanced', '_disease_', 'patients', 'with', 'various', 'molecular', 'tumor', 'makeup', 'were', 'treated', 'with', '_gene_', 'inhibitor', '_chemical_', 'to', 'assess', 'overall', 'response', 'rate']"
1135,0.0,Clinical data were available for two patients.,"['clinical', 'data', 'were', 'available', 'for', '_num_', 'patients']"
1136,1.0,"Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib.","['using', 'a', 'mutation', 'screen', 'in', 'the', '_gene_', 'melanoma', 'cell', 'line', '_abbrev_', 'the', '_mutation_', 'variant', 'was', 'identified', 'as', 'conferring', 'resistance', 'to', '_chemical_']"
1137,1.0,High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy.,"['high', 'expression', 'of', '_gene_', 'was', 'assessed', 'by', '_gene_', 'in', '_num_', 'primary', 'breast', 'cancers', 'that', 'had', 'not', 'spread', 'beyond', 'the', 'breast', 'after', '_num_', 'postoperative', 'courses', 'of', '_chemical_', 'based', 'chemotherapy']"
1138,1.0,It was found to be upregulated in a set of TNBC cell lines compared to other breast cancer types.,"['it', 'was', 'found', 'to', 'be', 'upregulated', 'in', 'a', 'set', 'of', '_disease_', 'cell', 'lines', 'compared', 'to', 'other', 'breast', 'cancer', 'types']"
1139,1.0,Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation were more resistant to brigatinib treatment (IC50 325 nM) than cells expressing wildtype EML4-ALK variant 3 (IC50 6 nM).,"['cells', 'expressing', 'the', '_chemical_', 'variant', '_num_', 'with', '_mutation_', '_gene_', 'mutation', 'were', 'more', 'resistant', 'to', 'brigatinib', 'treatment', '_abbrev_', '_num_', '_unit_', 'than', 'cells', 'expressing', 'wildtype', '_chemical_', 'variant', '_num_', '_abbrev_', '_num_', '_unit_']"
1140,1.0,A phase 1 clinical trial identified a patient with chemotherapy-refractory urothelial carcinoma who had complete radiographic response lasting 14 months after combined everolimus and pazopanib treatment.,"['a', 'phase', '_num_', 'clinical', 'trial', 'identified', 'a', 'patient', 'with', 'chemotherapy', 'refractory', 'urothelial', 'carcinoma', 'who', 'had', 'complete', 'radiographic', 'response', 'lasting', '_num_', 'months', 'after', 'combined', '_chemical_', 'and', '_chemical_', 'treatment']"
1141,1.0,2 patients with prior vemurafenib treatment progressed under treatment.,"['_num_', 'patients', 'with', 'prior', '_chemical_', 'treatment', 'progressed', 'under', 'treatment']"
1142,1.0,"13 tumors displayed strong KIT expression and KIT exons 11, 13,17, and 18 were examined for mutations.","['_num_', 'tumors', 'displayed', 'strong', 'kit', 'expression', 'and', 'kit', 'exons', '_num_', '_num_', 'and', '_num_', 'were', 'examined', 'for', 'mutations']"
1143,1.0,"In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival.","['in', 'a', 'retrospective', 'study', 'comparing', 'survival', 'outcomes', 'in', 'a', 'subgroup', 'of', '_num_', '_disease_', '_chemical_', 'treated', 'patients', 'enrolled', 'in', 'a', 'phase', '_num_', 'clinical', 'trial', '_abbrev_', '_chemical_', 'therapy', 'was', 'associated', 'with', 'improved', 'survival']"
1144,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_abbrev_', 's', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
1145,1.0,Effect of the combined treatment was also observed in xenograft and cell line studies.,"['effect', 'of', 'the', 'combined', 'treatment', 'was', 'also', 'observed', 'in', 'xenograft', 'and', 'cell', 'line', 'studies']"
1146,1.0,It was less effective in one cell-line with PTEN deletion.,"['it', 'was', 'less', 'effective', 'in', '_num_', 'cell', 'line', 'with', '_gene_', 'deletion']"
1147,1.0,The primary endpoint was disease free survival.,"['the', 'primary', 'endpoint', 'was', 'disease', 'free', 'survival']"
1148,1.0,This mutation was found in a VHL type 2 family of 7 individuals.,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals']"
1149,1.0,"Cell viability was evaluated following knockdown of 834 genes in isogenic LIM1215 colorectal cancer cell lines harboring wildtype (parental), G12S, G12D or G12V KRAS.","['cell', 'viability', 'was', 'evaluated', 'following', 'knockdown', 'of', '_num_', 'genes', 'in', 'isogenic', '_abbrev_', 'colorectal', 'cancer', 'cell', 'lines', 'harboring', 'wildtype', 'parental', '_mutation_', '_mutation_', 'or', '_mutation_', '_gene_']"
1150,1.0,"In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib.","['in', 'basal', 'cell', 'carcinoma', '_mutation_', '_abbrev_', '_abbrev_', 'and', '_abbrev_', 'mutations', 'conferred', 'resistance', 'to', '_gene_', 'inhibitor', '_chemical_']"
1151,1.0,"Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235.","['_num_', '_disease_', 'xenografts', 'with', '_gene_', 'mutations', '_mutation_', '_mutation_', 'showed', 'sensitivity', 'to', '_chemical_']"
1152,1.0,"Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001).","['breast', 'cancer', 'patients', 'with', '_gene_', 'mutations', 'also', 'had', 'a', 'decrease', 'in', 'progression', 'free', 'survival', 'hr:2', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', 'p', '_num_']"
1153,1.0,"Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control.","['modest', 'response', 'was', 'seen', 'with', '_chemical_', 'treatment', 'while', 'combination', 'treatment', 'showed', 'considerable', 'tumor', 'growth', 'inhibition', 'as', 'compared', 'to', 'control']"
1154,1.0,Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.,"['thyroid', 'nodule', 'with', '_gene_', '_mutation_', 'mutation', 'is', 'highly', 'correlated', 'with', 'papillary', 'thyroid', 'cancer']"
1155,1.0,The mutation was not present in 188 unrelated control chromosomes.,"['the', 'mutation', 'was', 'not', 'present', 'in', '_num_', 'unrelated', 'control', 'chromosomes']"
1156,1.0,Screening of individuals with Li-Fraumeni syndrome but lacking TP53 mutations identified 1/4 classical and 2/18 LFS variant presentation.,"['screening', 'of', 'individuals', 'with', '_disease_', 'syndrome', 'but', 'lacking', '_gene_', 'mutations', 'identified', '_ratio_', 'classical', 'and', '_ratio_', 'lfs', 'variant', 'presentation']"
1157,1.0,"The patient (F, 66, nonsmoker) had a partial response, progression free survival (PFS) of 15.2 months, overall survival (OS) of 29.3 months and was not alive at study end.","['the', 'patient', 'f', '_num_', 'nonsmoker', 'had', 'a', 'partial', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
1158,1.0,"Relevant HPO terms: Pheochromocytoma, Multiple pancreatic cysts.","['relevant', '_disease_', 'terms', 'pheochromocytoma', 'multiple', 'pancreatic', 'cysts']"
1159,1.0,Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13).,"['whole', 'exome', 'sequencing', 'of', 'the', '_gene_', 'treatment', 'tumor', 'revealed', 'a', '_gene_', '_mutation_', 'mutation', 'allelic', 'fraction', '_num_']"
1160,1.0,"Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy.","['treatment', 'with', '_chemical_', 'was', 'associated', 'with', 'favorable', 'progression', 'free', 'survival', 'rates', '_num_', '_disease_', 'rate', 'primary', 'end', 'point', 'being', 'greater', 'than', '_num_', 'suggesting', 'that', '_gene_', 'amplification', 'is', 'predictive', 'of', 'sensitivity', 'to', '_gene_', 'inhibitor', 'therapy']"
1161,1.0,"This nonsense mutation was found in 3 VHL type 1 families and one VHL type 2 family (lineages 184, 93, 22, 92).","['this', 'nonsense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'and', '_num_', '_gene_', 'type', '_num_', 'family', 'lineages', '_num_', '_num_', '_num_', '_num_']"
1162,1.0,In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected.,"['in', 'a', 'single', 'case', 'an', '_abbrev_', '_abbrev_', 'fusion', 'was', 'detected']"
1163,1.0,Increased nuclear staining was also identified in xenograft and patient samples after trastuzumab treatment.,"['increased', 'nuclear', 'staining', 'was', 'also', 'identified', 'in', 'xenograft', 'and', 'patient', 'samples', 'after', '_chemical_', 'treatment']"
1164,1.0,Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells.,"['_chemical_', 'caused', 'rb', 'dephosphorylation', 'in', '_gene_', 'cell', 'lines', 'and', 'patient', 'derived', 'tumor', 'cells']"
1165,1.0,Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).,"['cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', '_gene_']"
1166,1.0,EML4-ALK may be a client protein of Hsp90.,"['_chemical_', 'may', 'be', 'a', 'client', 'protein', 'of', '_gene_']"
1167,1.0,Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.,"['melanoma', 'patients', 'with', 'kit', 'mutation', 'but', 'not', 'kit', 'amplification', 'showed', 'response', 'to', '_chemical_', 'treatment', 'in', 'a', 'small', 'cohort', 'of', 'patients']"
1168,1.0,ACMG evidence codes:  'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease.,"['acmg', 'evidence', 'codes', ""'pp2"", 'because', 'they', 'observe', 'a', 'missense', 'variant', 'in', 'gene', 'where', 'missense', 'variants', 'are', 'common', 'mechanism', 'of', 'disease']"
1169,1.0,"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.","['in', 'patients', 'with', 'invasive', 'epithelial', 'ovarian', 'cancer', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'better', '_num_', 'year', 'overall', 'survival']"
1170,1.0,"41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2.","['_num_', '_disease_', 'were', 'analyzed', 'by', '_gene_', 'for', 'expression', 'of', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', 'caspase', '_num_', 'and', '_gene_']"
1171,1.0,"Of these, one was a nonsense mutation (p.R2450*) present in both pretreatment and postrelapse biopsies.","['of', 'these', '_num_', 'was', 'a', 'nonsense', 'mutation', 'p', '_abbrev_', 'present', 'in', 'both', 'pretreatment', 'and', 'postrelapse', 'biopsies']"
1172,1.0,The T allele of the rs16906252 SNP was associated with MGMT methylation and low protein expression.,"['the', 't', 'allele', 'of', 'the', '_mutation_', 'snp', 'was', 'associated', 'with', '_gene_', 'methylation', 'and', 'low', 'protein', 'expression']"
1173,1.0,Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines.,"['apoptotic', 'indicators', 'and', 'cell', 'cycle', 'analysis', 'indicated', 'that', 'the', '_gene_', 'inhibitors', 'induced', '_gene_', 'arrest', 'instead', 'of', 'apoptosis', 'in', 'the', 'cell', 'lines']"
1174,1.0,"Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium).","['preclinical', 'study', 'of', '_gene_', 'inhibitor', '_disease_', 'in', '_num_', 'renal', 'carcinoma', 'cell', 'lines', '_num_', 'malignant', '_gene_', 'and', '_num_', 'non', 'malignant', 'transformed', 'cell', 'lines', 'derived', 'from', 'kidney', 'epithelium']"
1175,1.0,"A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET).","['a', 'case', 'study', 'describing', 'a', 'patient', 'with', 'met', 'polysomy', 'met', 'over', 'expression', 'and', 'evidence', 'of', '_chemical_', '_gene_', 'production', 'the', 'growth', 'factor', 'ligand', 'of', 'met']"
1176,1.0,"HPO terms: retinal hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts, pheochromocytoma.","['_disease_', 'terms', 'retinal', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts', 'pheochromocytoma']"
1177,1.0,"Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control.","['serum', 'and', 'tissue', 'levels', 'of', '_gene_', '_gene_', 'were', 'analyzed', 'in', '_num_', 'breast', 'cancer', 'patients', 'treated', 'with', '_chemical_', 'or', 'control']"
1178,1.0,After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q.,"['after', '_num_', 'treatments', 'of', '_abbrev_', 'a', 'comprehensive', 'tumor', 'profile', 'revealed', '_gene_', '_mutation_', 'as', 'the', 'only', 'genetic', 'alteration', 'on', 'a', 'near', 'diploid', 'genome', 'with', 'trisomy', '1q']"
1179,0.0,"A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined.","['a', 'fish', 'positional', 'cloning', 'strategy', 'and', '_disease_', 'analysis', 'identified', '_abbrev_', 'in', 'all', '_disease_', 'cases', 'and', 'none', 'of', 'the', 'other', 'benign', 'or', 'malignant', '_disease_', 'vascular', 'tumors', 'examined']"
1180,1.0,Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines.,"['higher', 'expression', 'of', '_gene_', 'was', 'correlated', 'with', 'decreased', 'cytotoxicity', 'of', '_chemical_', '_chemical_', 'is', 'the', 'active', 'metabolite', 'in', '_num_', '_disease_', 'and', '_gene_', 'cell', 'lines']"
1181,1.0,FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC).,"['_disease_', 'tumours', 'from', 'patients', 'enrolled', 'in', 'the', '_abbrev_', 'n', '_num_', 'and', '_abbrev_', 'n', '_num_', 'trials', 'of', '_chemical_', 'in', 'advanced', '_gene_', 'mutant', '_abbrev_', 'melanoma', 'were', 'analyzed', 'for', 'met', 'expression', '_gene_']"
1182,1.0,"The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively.","['the', 'frequency', 'of', 'mutation', 'in', 'exon', '_num_', 'deletion', 'and', '_mutation_', 'was', '_num_', '_ratio_', 'and', '_num_', '_ratio_', 'respectively']"
1183,1.0,A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR.,"['a', 'patient', 'with', 'endometrial', 'cancer', 'with', 'synchronous', '_abbrev_', 'and', '_abbrev_', 'fusions', 'had', 'a', 'pr']"
1184,1.0,"The 38-year-old proband had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma.","['the', '_age_', 'proband', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'pancreatic', 'cysts', 'and', '_disease_', '_disease_']"
1185,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_abbrev_', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
1186,1.0,"This nonsense mutation was found in 2 German, VHL type 1 family members with retinal angiomas and hemangioblastomas of the central nervous system (family VHL 56).","['this', 'nonsense', 'mutation', 'was', 'found', 'in', '_num_', 'german', '_gene_', 'type', '_num_', 'family', 'members', 'with', 'retinal', 'angiomas', 'and', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'family', '_gene_', '_num_']"
1187,1.0,"In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had either of these mutations.","['in', '_num_', 'thyroid', 'fine', 'needle', 'aspiration', 'biopsies', '_num_', 'of', 'the', '_num_', 'benign', 'tumors', 'displayed', 'either', 'the', '_mutation_', 'or', 'the', '_mutation_', '_gene_', 'promoter', 'mutation', 'however', '_num_', 'of', 'the', '_num_', 'differentiated', 'thyroid', 'cancers', 'had', 'either', 'of', 'these', 'mutations']"
1188,1.0,Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment.,"['_num_', '_disease_', 'cell', 'lines', 'with', 'activating', '_gene_', 'alterations', 'showed', 'synergistic', 'cell', 'death', 'response', 'to', 'the', 'combination', 'of', 'drug', 'with', 'radiation', 'treatment']"
1189,1.0,"In contrast, c-MYC but not MYCL was expressed in the other cell lines and I-BET151 induced downregulation of c-MYC.","['in', 'contrast', '_gene_', 'but', 'not', '_gene_', 'was', 'expressed', 'in', 'the', 'other', 'cell', 'lines', 'and', '_chemical_', 'induced', 'downregulation', 'of', '_gene_']"
1190,1.0,Median OS was 29.9m vs. 25.9m.,"['median', 'os', 'was', '_num_', '_unit_', 'vs', '_num_', '_unit_']"
1191,1.0,This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'provides', 'strong', 'evidence', 'of', 'pathogenicity', 'as', 'it', 'is', 'a', 'null', 'variant', 'in', 'a', 'gene', 'where', 'loss', 'of', 'function', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
1192,1.0,"The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2).","['the', 'endometrial', 'cancer', 'cell', 'lines', '_abbrev_', 'and', '_abbrev_', 'which', 'carry', 'the', '_mutation_', '_gene_', 'mutation', 'were', 'found', 'to', 'be', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_abbrev_', '_num_', 'to', '40x', 'more', 'sensitive', 'than', 'cell', 'lines', 'with', 'wild', 'type', '_gene_']"
1193,1.0,"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537C ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.","['using', 'an', 'estrogen', 'response', 'element', '_disease_', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_mutation_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_chemical_', 'cell', 'lines']"
1194,1.0,The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463.,"['the', '_abbrev_', 'neuroblastoma', 'cell', 'line', 'containing', 'the', '_mutation_', '_gene_', 'mutation', 'was', 'found', 'to', 'undergo', 'cell', 'death', 'when', 'treated', 'with', 'the', '_gene_', '_gene_', 'inhibitor', '_abbrev_']"
1195,1.0,"Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression.","['of', 'these', 'patients', '_num_', 'were', 'evaluated', 'for', 'response', 'rate', 'to', 'pembrolizumab', 'and', '_gene_', '_gene_', 'expression']"
1196,1.0,"DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients.","['_gene_', 'mutations', '_num_', '_abbrev_', 'were', 'associated', 'with', 'older', 'age', 'higher', 'white', 'blood', 'cell', 'count', 'and', 'cytogenetically', 'normal', '_disease_', 'in', 'a', 'large', 'cohort', 'of', 'younger', '_range_', '_disease_', 'patients']"
1197,1.0,"Sequencing revealed that 5 of these patients harbored SMO mutations known to confer resistance to the Smoothened inhibitors (D473G, D473H, Q477E, S533N, W535L) an additional patient harbored a SMO mutation of unknown consequence (R168H).","['sequencing', 'revealed', 'that', '_num_', 'of', 'these', 'patients', 'harbored', '_gene_', 'mutations', 'known', 'to', 'confer', 'resistance', 'to', 'the', 'smoothened', 'inhibitors', '_abbrev_', '_mutation_', '_abbrev_', '_abbrev_', '_mutation_', 'an', 'additional', 'patient', 'harbored', 'a', '_gene_', 'mutation', 'of', 'unknown', 'consequence', '_mutation_']"
1198,1.0,"Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both.","['of', 'the', '_num_', 'informative', 'ews', '_disease_', '_num_', 'cases', '_num_', 'were', 'positive', 'by', 'fish', 'break', 'apart', 'fish', 'fusion', 'or', 'both']"
1199,1.0,62 patients with either Stage IIIB or Stage IV NSCLC were used for this study.,"['_num_', 'patients', 'with', 'either', 'stage', '_gene_', 'or', 'stage', 'iv', '_disease_', 'were', 'used', 'for', 'this', 'study']"
1200,1.0,"21 SNPs were analyzed using qRT-PCR genotyping assays in 500 Neuroblastoma tumor samples, and the CASP8 D302H missense variant was found to be associated with worse overall survival (P = 0.0006; Q = 0.049) and worse event-free survival (P = 0.0002; Q = 0.042) in those samples that had MYCN amplification (N = 94).","['_num_', 'snps', 'were', 'analyzed', 'using', 'qrt', 'pcr', 'genotyping', 'assays', 'in', '_num_', 'neuroblastoma', 'tumor', 'samples', 'and', 'the', '_gene_', '_mutation_', 'missense', 'variant', 'was', 'found', 'to', 'be', 'associated', 'with', 'worse', 'overall', 'survival', 'p', '_num_', 'q', '_num_', 'and', 'worse', 'event', 'free', 'survival', 'p', '_num_', 'q', '_num_', 'in', 'those', 'samples', 'that', 'had', '_gene_', 'amplification', 'n', '_num_']"
1201,1.0,Study explored the response to the SMO inhibitor sonidegib (LDE225) in a cohort of 9 patients with advanced basal cell carcinoma  that exhibited treatment resistance with vismodegib (GDC0449).,"['study', 'explored', 'the', 'response', 'to', 'the', '_gene_', 'inhibitor', '_chemical_', '_chemical_', 'in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'advanced', 'basal', 'cell', 'carcinoma', 'that', 'exhibited', 'treatment', 'resistance', 'with', '_chemical_', '_chemical_']"
1202,1.0,"Rare but recurring germline truncating mutations of the 3’ end of EPCAM, were reported for 27 independent families, shown to lead to epigenetic silencing of a neighbouring gene, MSH2, and suggested to cause Lynch syndrome.","['rare', 'but', 'recurring', 'germline', 'truncating', 'mutations', 'of', 'the', '_num_', '’', 'end', 'of', '_gene_', 'were', 'reported', 'for', '_num_', 'independent', 'families', 'shown', 'to', 'lead', 'to', 'epigenetic', 'silencing', 'of', 'a', 'neighbouring', 'gene', '_gene_', 'and', 'suggested', 'to', 'cause', 'lynch', 'syndrome']"
1203,1.0,"In an experimental study of acute myeloid leukemia (AML) cell lines expressing IDH1 R132C, IDH1 R132G, or IDH1 R132H mutations were associated with increased sensitivity to small molecule glutaminase inhibitor, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) as compared to AML cell lines expressing wild type IDH1.","['in', 'an', 'experimental', 'study', 'of', 'acute', 'myeloid', 'leukemia', '_disease_', 'cell', 'lines', 'expressing', '_gene_', '_mutation_', '_gene_', '_mutation_', 'or', '_gene_', '_mutation_', 'mutations', 'were', 'associated', 'with', 'increased', 'sensitivity', 'to', 'small', 'molecule', '_gene_', 'inhibitor', '_abbrev_', '_num_', '_chemical_', '_num_', '_num_', '_num_', 'thiadiazol', '_num_', 'yl', 'ethyl', 'sulfide', 'bptes', 'as', 'compared', 'to', '_disease_', 'cell', 'lines', 'expressing', 'wild', 'type', '_gene_']"
1204,1.0,"PIK3CA (H1047R) mutation positive cell lines used were ""CAL-33"" and ""Detroit 562"".","['_gene_', '_mutation_', 'mutation', 'positive', 'cell', 'lines', 'used', 'were', '_abbrev_', 'and', 'detroit', '_num_']"
1205,1.0,"A missense mutation, affecting residue with pVHL protein core, was detected in a VHL type 1 family with 3 affected individuals.","['a', 'missense', 'mutation', 'affecting', 'residue', 'with', '_gene_', 'protein', 'core', 'was', 'detected', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'with', '_num_', 'affected', 'individuals']"
1206,1.0,Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo.,"['cell', 'lines', 'carrying', '_disease_', 'mutations', 'were', 'more', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_chemical_', 'and', '_abbrev_', 'in', 'vitro', 'and', 'in', 'vivo']"
1207,1.0,HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.,"['hera', 'was', 'a', 'phase', 'iii', 'trial', 'assessing', 'application', 'of', '_chemical_', 'in', 'an', 'extended', 'adjuvant', 'setting']"
1208,1.0,The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies.,"['the', '_gene_', '_mutation_', 'variant', 'was', 'associated', 'with', 'significantly', 'lower', 'relapse', 'free', 'survival', 'and', 'overall', 'survival', 'in', 'stomach', 'cancer', 'patients', 'treated', 'with', '_num_', 'fluorouracil', 'based', 'therapies']"
1209,1.0,Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007).,"['transformation', 'to', '_disease_', 'was', 'increased', 'for', 'mutant', '_ratio_', '_num_', 'vs', 'wildtype', '_ratio_', '_num_', 'patients', '_p_val_']"
1210,1.0,Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001).,"['response', 'rates', 'were', '_num_', 'for', '_chemical_', 'treatment', 'and', '_num_', 'for', 'chemotherapy', 'p', '_num_']"
1211,0.0,Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples.,"['immunohistochemical', 'methods', 'were', 'used', 'to', 'evaluate', 'the', 'expression', 'levels', 'of', '_gene_', 'in', 'prostate', 'cancer', '_disease_', 'tumor', 'samples']"
1212,1.0,The same applied for patients with PD-L1 positive immune cells (p<0.001 each).,"['the', 'same', 'applied', 'for', 'patients', 'with', '_gene_', 'positive', 'immune', 'cells', 'p', '_num_', 'each']"
1213,1.0,The fusions were EML4-ALK variants 1 and 2.,"['the', 'fusions', 'were', '_chemical_', 'variants', '_num_', 'and', '_num_']"
1214,1.0,CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS).,"['_gene_', 'was', 'found', 'to', 'be', 'a', 'negative', 'prognostic', '_chemical_', 'for', 'disease', 'free', 'survival', '_disease_']"
1215,1.0,VHL-deficient tumors were more sensitive to mTOR inhibition than VHL-proficient tumors.,"['_disease_', 'tumors', 'were', 'more', 'sensitive', 'to', '_gene_', 'inhibition', 'than', '_gene_', 'proficient', 'tumors']"
1216,1.0,A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefits of immune checkpoint inhibition (ICI) in patients with advanced NSCLC.,"['a', '_disease_', 'analysis', 'of', 'randomized', 'trials', 'to', 'investigate', 'if', '_gene_', 'mutation', 'status', 'affects', 'survival', 'benefits', 'of', 'immune', 'checkpoint', 'inhibition', '_disease_', 'in', 'patients', 'with', 'advanced', '_disease_']"
1217,1.0,"This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK.","['this', '_disease_', 'randomized', '_abbrev_', 'clinical', 'trial', 'compared', 'pembrolizumab', 'to', 'chemotherapy', 'in', 'treating', '_disease_', 'patients', 'with', '_gene_', 'expression', 'on', 'at', 'least', '_num_', 'of', 'tumor', 'cells', 'and', 'no', 'sensitizing', 'mutation', 'of', '_gene_', 'or', 'translocation', 'of', '_gene_']"
1218,1.0,"A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53.","['a', 'study', 'of', 'ovarian', 'carcinoma', 'patients', '_ineq_', 'reported', 'a', 'reduced', 'overall', 'survival', 'hr:1', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'for', 'patients', 'with', 'mutations', 'in', '_gene_']"
1219,1.0,133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES).,"['_num_', 'sonic', 'hedghog', 'driven', '_disease_', 'were', 'sequenced', 'for', 'alterations', '_disease_', 'or', '_disease_']"
1220,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_abbrev_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
1221,1.0,Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types.,"['trial', '_abbrev_', 'tested', 'monoclonal', 'antibody', 'nivolumab', 'against', 'the', '_gene_', 'immune', 'checkpoint', 'receptor', 'in', 'pretreated', 'patients', 'with', 'various', 'cancer', 'types']"
1222,1.0,"Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib).","['_num_', 'cell', 'lines', 'had', 'an', '_mutation_', 'activating', 'mutation', 'in', '_gene_', '_num_', 'of', 'these', 'were', 'sensitive', 'to', '_chemical_', '_chemical_']"
1223,1.0,Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).,"['increased', 'expression', 'of', '_gene_', 'in', '_num_', '_disease_', 'cell', 'lines', 'was', 'inversely', 'correlated', 'with', '_chemical_', 'sensitivity', 'r', '_num_', 'p', '_num_']"
1224,1.0,"40% of these were intrinsically resistant to mTOR inhibition with  BEZ235, PP242 or WYE354.","['_num_', 'of', 'these', 'were', 'intrinsically', 'resistant', 'to', '_gene_', 'inhibition', 'with', '_chemical_', '_chemical_', 'or', '_abbrev_']"
1225,1.0,"In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib).","['in', 'this', 'case', 'report', 'the', '_mutation_', 'mutation', 'was', 'reported', 'as', 'an', 'acquired', 'mechanism', 'of', 'resistance', 'to', 'the', 'hedgehog', 'pathway', 'inhibitor', '_chemical_', '_chemical_']"
1226,1.0,The prevalence of this fusion in synovial sarcoma approaches 100% when there is adequate tumor RNA for RT-PCR.,"['the', 'prevalence', 'of', 'this', 'fusion', 'in', 'synovial', 'sarcoma', 'approaches', '_num_', 'when', 'there', 'is', 'adequate', 'tumor', 'rna', 'for', '_disease_']"
1227,1.0,D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance.,"['_mutation_', 'was', 'observed', 'as', 'a', 'secondary', 'kit', 'mutation', 'in', '_num_', 'patients', 'with', 'secondary', '_chemical_', 'resistance']"
1228,1.0,"Like PIK3CA mutant cell lines, the PIK3R1 mutant HS578T line was also determined to be sensitive to PP242.","['like', '_gene_', 'mutant', 'cell', 'lines', 'the', '_gene_', 'mutant', '_abbrev_', 'line', 'was', 'also', 'determined', 'to', 'be', 'sensitive', 'to', '_chemical_']"
1229,1.0,"However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression.","['however', 'there', 'were', 'no', 'differences', 'of', 'response', 'to', '_chemical_', 'and', '_chemical_', 'in', 'regards', 'to', '_gene_', 'expression']"
1230,1.0,A survival advantage was observed with the addition of a TIM-3 blocking antibody.,"['a', 'survival', 'advantage', 'was', 'observed', 'with', 'the', 'addition', 'of', 'a', '_gene_', 'blocking', 'antibody']"
1231,1.0,483 patients were randomized to either afatinib (n=322) or methotrexate (n=161).,"['_num_', 'patients', 'were', 'randomized', 'to', 'either', '_chemical_', '_ineq_', 'or', 'methotrexate', '_ineq_']"
1232,1.0,"Crizotinib did not lead to a reduction in tumor volume of two cell lines in vivo but reduced the formation of macrometastases (luciferase activity, p=0.03).","['_chemical_', 'did', 'not', 'lead', 'to', 'a', 'reduction', 'in', 'tumor', 'volume', 'of', '_num_', 'cell', 'lines', 'in', 'vivo', 'but', 'reduced', 'the', 'formation', 'of', 'macrometastases', '_gene_', 'activity', '_p_val_']"
1233,1.0,"we conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma.","['we', 'conclude', 'that', 'single', 'agent', '_chemical_', 'did', 'not', 'show', 'meaningful', 'activity', 'in', '_mutation_', '_gene_', 'in', 'contrast', 'to', 'the', 'significant', '_chemical_', 'activity', 'against', '_abbrev_', 'in', 'melanoma']"
1234,1.0,BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance.,"['_abbrev_', 'mouse', 'xenograft', 'tumors', 'were', 'injected', 'with', '_gene_', 'antisense', 'as', '_chemical_', 'and', 'this', 'resulted', 'in', '_chemical_', 'resitance']"
1235,1.0,"Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome compared to wildtype however, rs2305035 A genotype  (A/A or A/G) had better local recurrence-free survival, metastasis-free survival and overall survival when compared to GG genotype (n=186).","['genotypes', '_mutation_', 'and', '_mutation_', 'were', 'not', 'associated', 'with', 'a', 'change', 'in', 'clinical', 'outcome', 'compared', 'to', 'wildtype', 'however', '_mutation_', 'a', 'genotype', 'a', 'a', 'or', '_mutation_', 'had', 'better', 'local', '_disease_', 'survival', 'metastasis', 'free', 'survival', 'and', 'overall', 'survival', 'when', 'compared', 'to', '_disease_', 'genotype', '_ineq_']"
1236,1.0,"Maxwell et al identified R173C in 1 subject (of 51 endometrial hyperplasias assayed for mutations in PTEN), and identified 10 mutations of 51 in PTEN overall (20%).","['maxwell', 'et', 'al', 'identified', '_mutation_', 'in', '_num_', 'subject', 'of', '_num_', 'endometrial', 'hyperplasias', 'assayed', 'for', 'mutations', 'in', '_gene_', 'and', 'identified', '_num_', 'mutations', 'of', '_num_', 'in', '_gene_', 'overall', '_num_']"
1237,1.0,"In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion).","['in', 'patients', 'harboring', '_abbrev_', 'there', 'were', '_num_', 'urothelial', 'cancer', 'patients', 'with', 'prs', '_num_', 'endometrial', 'cancer', 'patient', 'with', 'pr', 'also', 'had', '_abbrev_', 'fusions', 'and', 'tumor', 'shrinkage', 'in', 'a', 'patient', 'with', 'adrenal', 'carcinoma', 'also', 'had', '_abbrev_', 'fusion']"
1238,1.0,In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas.,"['in', 'vitro', 'treament', 'of', '_gene_', 'mutant', 'melanomas', 'were', '_n_fold_', 'more', 'sensitive', 'to', 'vermurafenib', '_chemical_', 'treatment', 'than', '_gene_', '_gene_', 'mutant', 'melanomas']"
1239,1.0,"Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2.","['another', 'mutation', '_abbrev_', 'also', 'remained', 'sensitive', 'to', '_chemical_', 'with', 'a', 'cellular', '_abbrev_', 'value', 'similar', 'to', 'that', 'of', 'wild', 'type', '_gene_']"
1240,1.0,This missense mutation was found in a VHL type 1 patient (patient no V266).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
1241,1.0,1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed.,"['_num_', '_gene_', 'breast', 'cancer', 'patients', 'treated', 'with', '_chemical_', 'and', 'chemotherapy', 'from', 'the', '_abbrev_', 'clinical', 'trial', 'were', 'analyzed']"
1242,1.0,"In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%).","['in', 'a', 'study', 'of', '_num_', 'low', 'grade', 'gliomas', '_gene_', '_gene_', 'or', '_gene_', 'mutations', 'were', 'found', 'in', '_num_', 'patients', '_num_']"
1243,1.0,This missense mutation was found in VHL type 1 family (lineage 208).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
1244,1.0,"ACMG codes as follows: A null, nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1).","['acmg', 'codes', 'as', 'follows', 'a', 'null', 'nonsense', 'mutation', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', '_abbrev_']"
1245,1.0,Patients received 100 mg cabozantinib daily for 12 weeks.,"['patients', 'received', '_num_', '_unit_', '_chemical_', 'daily', 'for', '_num_', 'weeks']"
1246,1.0,siRNA knockdown of LRP1B4 in JHOS3 and Kuramochi ovarian cancer cell lines decreased sensitivity to liposomal doxorubicin but not doxorubicin.,"['sirna', 'knockdown', 'of', '_abbrev_', 'in', '_abbrev_', 'and', 'kuramochi', 'ovarian', 'cancer', 'cell', 'lines', 'decreased', 'sensitivity', 'to', '_disease_', 'doxorubicin', 'but', 'not', 'doxorubicin']"
1247,1.0,"Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0.","['administration', 'of', '_chemical_', 'at', '_num_', '_unit_', 'twice', 'daily', 'was', 'followed', 'by', 'marked', 'improvement', 'seen', 'in', 'tests', 'associated', 'with', '_gene_', 'pulmonary', 'metastasis', 'and', 'change', 'in', 'ps', 'from', '_num_', 'to', '_num_']"
1248,1.0,miR-218 expression levels were found to be significantly higher in the complete/partial response group.,"['_gene_', 'expression', 'levels', 'were', 'found', 'to', 'be', 'significantly', 'higher', 'in', 'the', 'complete', 'partial', 'response', 'group']"
1249,1.0,"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs.","['in', 'an', 'in', 'vitro', 'study', 'using', '_abbrev_', 'cells', 'wildtype', '_gene_', 'and', '_abbrev_', 'cells', '_abbrev_', 'inhibition', 'of', 'cell', 'growth', 'was', 'used', 'as', 'an', 'assay', 'to', 'determine', 'sensitivity', 'to', 'reversible', 'tyrosine', 'kinase', 'inhibitor', 'drugs']"
1250,1.0,Both pazopanib and ponatinib separately resulted in minor tumor shrinkage.,"['both', '_chemical_', 'and', '_chemical_', 'separately', 'resulted', 'in', 'minor', 'tumor', 'shrinkage']"
1251,1.0,Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone.,"['deep', 'sequencing', 'revealed', 'an', '_gene_', '_abbrev_', 'mutation', 'in', 'the', '_abbrev_', 'clone']"
1252,1.0,"One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response.","['_num_', 'patient', 'was', 'found', 'to', 'harbor', 'a', 'unique', 'exon', '_num_', 'indel', 'p', '_abbrev_', 'c', '2320a', 'tggct', '_disease_', 'p', '_abbrev_', 'c', '2320delins', 'tggctgg', 'and', 'was', 'among', 'the', '_num_', 'patients', 'that', 'had', 'a', 'partial', 'response']"
1253,1.0,The disease control rate was found to be 54.4% and 51.4% for the two groups.,"['the', 'disease', 'control', 'rate', 'was', 'found', 'to', 'be', '_num_', 'and', '_num_', 'for', 'the', '_num_', 'groups']"
1254,1.0,"These mutations were also significantly associated with locoregional failure, cervical lymph node metastasis and distant metastasis, likely contributing to this finding.","['these', 'mutations', 'were', 'also', 'significantly', 'associated', 'with', 'locoregional', 'failure', 'cervical', 'lymph', 'node', 'metastasis', 'and', 'distant', 'metastasis', 'likely', 'contributing', 'to', 'this', 'finding']"
1255,1.0,This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 94).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
1256,1.0,KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer.,"['_gene_', 'mutations', 'were', 'significantly', 'associated', 'with', 'lack', 'of', 'response', 'to', '_chemical_', 'in', 'patients', 'with', 'advanced', 'colorectal', 'cancer']"
1257,1.0,"Of the 14 patients with Langerhans’-cell histiocytosis, 43% of patients had a response to vemurafenib (1 complete and 5 partial responses), disease regression was observed in 12/14 patients, all patients detailed improvement in disease-related symptoms, 0 patients had progressive disease during treatment, 12-month progression free survival was 91%, and overall survival rate was 100%.","['of', 'the', '_num_', 'patients', 'with', '_disease_', '’', '', 'cell', 'histiocytosis', '_num_', 'of', 'patients', 'had', 'a', 'response', 'to', '_chemical_', '_num_', 'complete', 'and', '_num_', 'partial', 'responses', 'disease', 'regression', 'was', 'observed', 'in', '_ratio_', 'patients', 'all', 'patients', 'detailed', 'improvement', 'in', 'disease', 'related', 'symptoms', '_num_', 'patients', 'had', 'progressive', 'disease', 'during', 'treatment', '_num_', 'month', 'progression', 'free', 'survival', 'was', '_num_', 'and', 'overall', 'survival', 'rate', 'was', '_num_']"
1258,1.0,"At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.","['at', 'the', '_num_', 'planned', 'interim', 'analysis', '_chemical_', 'treatment', 'for', '_num_', 'year', 'was', 'compared', 'with', 'observation', 'alone']"
1259,1.0,"Relative resistance to ARS-853 developed after epidermal growth factor (50 ng/mL) administration and the combination of erlotinib or afatinib (EGFR-inhibitors) with ARS-853 greatly potentiated growth arrest, apoptosis and decrease of PI3K and MAPK-signaling over single-agent ARS-853 treatment, even in the presence of added EGF.","['relative', 'resistance', 'to', '_abbrev_', 'developed', 'after', 'epidermal', 'growth', 'factor', '_num_', '_unit_', '_unit_', 'administration', 'and', 'the', 'combination', 'of', '_chemical_', 'or', '_chemical_', '_gene_', 'inhibitors', 'with', '_abbrev_', 'greatly', 'potentiated', 'growth', 'arrest', 'apoptosis', 'and', 'decrease', 'of', '_gene_', 'and', '_gene_', 'signaling', 'over', 'single', 'agent', '_abbrev_', 'treatment', 'even', 'in', 'the', 'presence', 'of', 'added', '_gene_']"
1260,1.0,"In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'the', '_mutation_', 'mutation', 'was', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
1261,1.0,"In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).","['in', '_num_', 'gastric', 'tumors', 'plasma', 'and', 'tissue', 'mrna', 'levels', 'of', '_gene_', 'were', 'lower', 'in', 'the', '_chemical_', 'sensitive', 'group', 'compared', 'to', 'the', 'resistant', 'group', 'p', '_num_', 'and', '_num_', 'respectively']"
1262,1.0,Progression-free survival at 12 weeks was 57.2% and overall median PFS was 17.9 weeks.,"['_disease_', 'survival', 'at', '_num_', 'weeks', 'was', '_num_', 'and', 'overall', 'median', '_disease_', 'was', '_num_', 'weeks']"
1263,1.0,"20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor.","['_num_', '_disease_', 'colorectal', 'cancer', 'xenografts', 'were', 'treated', 'with', '_chemical_', 'a', '_gene_', 'and', '_gene_', 'inhibitor']"
1264,1.0,Knockdown of UGT1A sensitized HT29 cells to HSP90 inhibition.,"['knockdown', 'of', '_mutation_', 'sensitized', '_abbrev_', 'cells', 'to', '_gene_', 'inhibition']"
1265,0.0,"Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines.","['preclinical', 'study', 'of', 'the', 'effects', 'of', '_disease_', 'on', 'proliferation', 'cell', 'cycle', 'apoptosis', 'and', 'rb', '_disease_', 'in', 'a', 'panel', 'of', '_num_', 'human', 'ovarian', 'cancer', 'cell', 'lines']"
1266,1.0,"2HG is considered to be an oncometabolite, or a metabolite that promotes carcinogenesis, and inhibitors of mutant isocitrate dehydrogenase are in development to target this process.","['2hg', 'is', 'considered', 'to', 'be', 'an', 'oncometabolite', 'or', 'a', 'metabolite', 'that', 'promotes', '_disease_', 'and', 'inhibitors', 'of', 'mutant', '_chemical_', '_gene_', 'are', 'in', 'development', 'to', 'target', 'this', 'process']"
1267,1.0,"IC50 of 33 nM was seen, which was 1.5 times the IC50 for EML4-ALK wild type, indicating sensitivity of the G1269A mutation to ceritinib in the context of EML4-ALK.","['_abbrev_', 'of', '_num_', '_unit_', 'was', 'seen', 'which', 'was', '_num_', 'times', 'the', '_abbrev_', 'for', '_chemical_', 'wild', 'type', 'indicating', 'sensitivity', 'of', 'the', '_mutation_', 'mutation', 'to', '_chemical_', 'in', 'the', 'context', 'of', '_chemical_']"
1268,1.0,"In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild type NRAS (p=0.36).","['in', 'patients', 'with', 'follicular', 'thyroid', 'carcinoma', 'those', 'with', 'mutations', 'in', 'nras', 'at', 'codon', '_num_', 'did', 'not', 'have', 'significantly', 'different', 'overall', 'survival', 'than', 'patients', 'with', 'wild', 'type', 'nras', '_p_val_']"
1269,1.0,The presence of p110α E545K also protected HCC827 cells from gefitinib-mediated apoptosis.,"['the', 'presence', 'of', '_abbrev_', '_mutation_', 'also', 'protected', '_chemical_', 'cells', 'from', '_chemical_', 'mediated', 'apoptosis']"
1270,1.0,This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease.,"['this', '_num_', 'arm', 'phase', 'iii', 'study', 'named', 'profile', '_num_', '_abbrev_', 'was', 'performed', 'to', 'assess', '_chemical_', 'vs', 'established', 'chemotherapy', 'in', 'non', 'small', 'cell', 'lung', 'cancer', 'patients', 'positive', 'for', '_gene_', 'rearrangement', 'assessed', 'by', 'break', 'apart', 'fish', 'with', 'locally', 'advanced', 'or', 'metastatic', 'disease']"
1271,1.0,Exogenous HFG led to an increase in MET activity (except in one cell line with high endogenous HGF levels) which was abrogated by MET inhibitor SGX523.,"['exogenous', '_disease_', 'led', 'to', 'an', 'increase', 'in', 'met', 'activity', 'except', 'in', '_num_', 'cell', 'line', 'with', 'high', 'endogenous', '_gene_', 'levels', 'which', 'was', 'abrogated', 'by', 'met', 'inhibitor', '_chemical_']"
1272,1.0,"Meta-analysis of 10 studies (9,411 patients, 13,708 controls) showed that TERT polymorphisms (rs2736100) were associated with an increased glioma risk (RR=1.28, 95% CI 1.23-1.33).","['_disease_', 'analysis', 'of', '_num_', 'studies', '_num_', 'patients', '_num_', 'controls', 'showed', 'that', '_gene_', 'polymorphisms', '_mutation_', 'were', 'associated', 'with', 'an', 'increased', 'glioma', 'risk', '_ineq_', '_num_', 'ci', '_range_']"
1273,1.0,These patients were therefore negative for LS.,"['these', 'patients', 'were', 'therefore', 'negative', 'for', 'ls']"
1274,1.0,A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial.,"['a', '_age_', 'caucasian', 'female', 'with', 'stage', 'iva', 'sezary', 'syndrome', 'presented', 'refractory', 'to', 'traditional', 'therapy', 'and', 'was', 'enrolled', 'in', 'a', 'whole', 'genome', 'study', 'trial']"
1275,1.0,T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance.,"['_mutation_', 'was', 'observed', 'as', 'a', 'secondary', 'kit', 'mutation', 'in', '_num_', 'patient', 'with', 'secondary', '_chemical_', 'resistance']"
1276,1.0,"OSI-906, an IGF1R/INSR inhibitor, does not have a significant effect on chemotherapy resistant castration-resistant prostate cancer cell lines.","['_chemical_', 'an', '_abbrev_', 'inhibitor', 'does', 'not', 'have', 'a', 'significant', 'effect', 'on', 'chemotherapy', 'resistant', 'castration', 'resistant', 'prostate', 'cancer', 'cell', 'lines']"
1277,1.0,Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients.,"['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', '_num_', 'ci', '_num_', '_num_', 'ne', 'in', '_gene_', 'inhibitor', 'naive', 'patients', 'and', '_num_', 'months', '_range_', 'in', '_gene_', 'inhibitor', 'pretreated', 'patients']"
1278,1.0,A 52 year old with a non-smoking history was diagnosed with stage IV NSCLC-adenocarcinoma and treated with chemotherapy.,"['a', '_num_', 'year', 'old', 'with', 'a', '_disease_', 'history', 'was', 'diagnosed', 'with', 'stage', 'iv', '_disease_', 'and', 'treated', 'with', 'chemotherapy']"
1279,1.0,49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study.,"['_num_', 'patients', '_num_', 'pretreatment', 'tissues', 'available', 'for', 'analysis', 'with', 'recurrent', 'glioblastomas', 'who', 'were', 'treated', 'with', '_gene_', '_disease_', 'were', 'analyzed', 'in', 'this', 'study']"
1280,1.0,"Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH).","['patients', 'from', '_num_', 'studies', '_disease_', '_num_', '_num_', 'and', '_num_', '_num_', '_num_', 'and', '_num_', 'patients', 'respectively', 'were', 'retrospectively', 'analyzed', 'for', '_gene_', '_gene_', 'expression', '_gene_', 'and', 'hpv', 'high', 'risk', 'status', '_disease_']"
1281,1.0,MTAP and CDKN2A gene (RT-qPCR) and protein (western-blotting) expresison as well as promoter methylation status  was analyzed in breast cancer patients and seven breast cancer cell lines.,"['_gene_', 'and', '_gene_', 'gene', '_disease_', 'and', 'protein', 'western', 'blotting', 'expresison', 'as', 'well', 'as', 'promoter', 'methylation', 'status', 'was', 'analyzed', 'in', 'breast', 'cancer', 'patients', 'and', '_num_', 'breast', 'cancer', 'cell', 'lines']"
1282,1.0,"Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo.","['xenografts', 'from', '_num_', 'head', 'and', 'neck', 'cancer', 'cell', 'line', '_abbrev_', 'with', 'a', '_gene_', '_mutation_', 'mutation', 'were', 'more', 'sensitive', 'to', 'the', 'combined', 'inhibition', 'of', '_abbrev_', 'and', '_gene_', 'with', '_chemical_', 'and', '_chemical_', '_chemical_', 'than', '_chemical_', '_chemical_', '_p_val_', 'or', '_chemical_', 'alone', '_chemical_', '_p_val_', 'in', 'vivo']"
1283,1.0,SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.,"['snp', 'analysis', 'of', 'patient', 'bone', 'marrow', 'mononuclear', 'cells', 'and', '_gene_', 'showed', 'chromosomal', 'changes', 'associated', 'with', 'the', 'cell', 'line', 'but', '_num_', 'of', 'snps', 'were', 'identically', 'called']"
1284,1.0,"PD-L1 positivity in TIICs related to a lower risk of death (HR = 0.784, p=0.047), and TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, p=0.002).","['_gene_', 'positivity', 'in', 'tiics', 'related', 'to', 'a', 'lower', 'risk', 'of', 'death', 'hr', '_num_', '_p_val_', 'and', 'tiics', 'indicated', 'a', 'better', 'prognosis', 'especially', 'in', 'breast', 'cancer', 'patients', 'hr', '_num_', '_p_val_']"
1285,1.0,"7 of 10 sensitive patients had mutations in EGFR, while none of the 8 gefitinib refractory patients showed EGFR mutation in these exons (p=0.004)","['_num_', 'of', '_num_', 'sensitive', 'patients', 'had', 'mutations', 'in', '_gene_', 'while', 'none', 'of', 'the', '_num_', '_chemical_', 'refractory', 'patients', 'showed', '_gene_', 'mutation', 'in', 'these', 'exons', '_p_val_']"
1286,1.0,"The primary end point was progression-free survival; secondary end points included overall survival, overall response rate, duration of response, and safety.","['the', 'primary', 'end', 'point', 'was', 'progression', 'free', 'survival', 'secondary', 'end', 'points', 'included', 'overall', 'survival', 'overall', 'response', 'rate', 'duration', 'of', 'response', 'and', 'safety']"
1287,1.0,"None of the patients had mutations in BRAF, NRAS, or GNAQ.","['none', 'of', 'the', 'patients', 'had', 'mutations', 'in', '_gene_', 'nras', 'or', '_gene_']"
1288,1.0,The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression).,"['the', 'in', 'vitro', 'data', 'consisted', 'of', 'testing', 'the', 'sensitivity', 'of', 'various', 'breast', 'cancer', 'cell', 'lines', 'to', '_chemical_', 'after', 'treatment', 'with', 'valproic', 'acid', 'which', 'increases', '_gene_', 'expression']"
1289,1.0,Metformin-induced PI3K pathway suppression was identified as a potential mechanism.,"['metformin', 'induced', '_gene_', 'pathway', 'suppression', 'was', 'identified', 'as', 'a', 'potential', 'mechanism']"
1290,1.0,The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).,"['the', 'mutation', 'at', 'codon', '_num_', 'c', 't', 'correlated', 'with', 'a', 'significantly', 'higher', 'response', 'rate', 'to', 'platinum', 'based', 'chemotherapy', 'in', 'patients', 'with', 'advanced', 'non', 'small', 'cell', 'lung', 'cancer', '_disease_']"
1291,1.0,"Considering all RAS and BRAF mutations, the patients with more than 1% mutant allele fraction (n = 37/65) had a hazard ratio of 4.52 for PFS (95% CI, 2.25–9.07; P<0.001) and 2.5 for OS (95% CI, 1.57–4.02; P<0.001).","['considering', 'all', 'ras', 'and', '_gene_', 'mutations', 'the', 'patients', 'with', 'more', 'than', '_num_', 'mutant', 'allele', 'fraction', 'n', '_ratio_', 'had', 'a', 'hazard', 'ratio', 'of', '_num_', 'for', '_disease_', '_num_', 'ci', '_num_', '25–9', '_num_', 'p', '_num_', 'and', '_num_', 'for', 'os', '_num_', 'ci', '_num_', '57–4', '_num_', 'p', '_num_']"
1292,1.0,All patients were previously treated with trastuzumab and a median of three chemotherapy lines.,"['all', 'patients', 'were', 'previously', 'treated', 'with', '_chemical_', 'and', 'a', 'median', 'of', '_num_', 'chemotherapy', 'lines']"
1293,1.0,Only moderate evidence for pathogenicity because protein length changes as a result of deletions in a nonrepeat region and stop-loss variant (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'deletions', 'in', 'a', 'nonrepeat', 'region', 'and', 'stop', 'loss', 'variant', 'acmg', 'code', '_abbrev_']"
1294,1.0,This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor.,"['this', 'mutation', 'was', '_num_', 'of', '_num_', 'new', 'homozygous', 'mutations', 'in', 'this', 'patient', '_num_', 'new', 'mutations', 'total', 'and', 'the', 'tumor', 'was', 'described', 'to', 'be', 'genetically', 'similar', 'to', 'the', '_gene_', 'treatment', 'tumor']"
1295,1.0,BIRC3 mutations were identified in 23 of 919 screened  CLLs.,"['_gene_', 'mutations', 'were', 'identified', 'in', '_num_', 'of', '_num_', 'screened', '_disease_']"
1296,1.0,Primary endpoint was death due to prostate cancer.,"['primary', 'endpoint', 'was', 'death', 'due', 'to', 'prostate', 'cancer']"
1297,1.0,Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.,"['sensitivity', 'to', 'platinum', 'was', 'defined', 'by', 'maintenance', 'of', 'complete', 'response', 'greater', 'than', '_num_', 'months', 'post', 'platinum', 'therapy']"
1298,1.0,"Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib.","['crystal', 'structure', 'indicated', 'this', 'mutation', 'interacts', 'with', 'a', 'water', 'molecule', 'in', 'the', 'ligand', 'binding', 'pocket', 'putatively', 'altering', 'its', 'interaction', 'with', 'the', '_gene_', 'inhibitor', '_chemical_']"
1299,1.0,"HPO terms: retinal hemangioblastoma, hemangioblastoma, pheochromocytoma.","['_disease_', 'terms', 'retinal', '_disease_', '_disease_', 'pheochromocytoma']"
1300,1.0,"Two had retinal angiomas, 2 had hemangioblastomas of the central nervous system, 2 hand renal cell carcinoma, and all three had pancreatic cysts.","['_num_', 'had', 'retinal', 'angiomas', '_num_', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'hand', 'renal', 'cell', 'carcinoma', 'and', 'all', '_num_', 'had', 'pancreatic', 'cysts']"
1301,1.0,"A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts.","['a', 'preclinical', 'study', 'to', 'investigate', 'the', 'efficacy', 'of', '_chemical_', '_chemical_', 'and', 'the', 'combination', 'on', '_gene_', 'mutant', 'colorectal', 'cancer', 'cell', 'lines', 'cell', 'line', 'derived', 'and', '_disease_', 'xenografts']"
1302,1.0,"A 71-year old male with metastatic extramammary Paget’s disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response.","['a', '_num_', 'year', 'old', 'male', 'with', 'metastatic', 'extramammary', 'paget', '’', 's', 'disease', 'of', 'the', 'scrotum', 'overexpressing', '_gene_', 'was', 'treated', 'with', '_chemical_', 'achieving', 'a', 'complete', 'response']"
1303,1.0,"Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology.","['subsequent', 'analysis', 'revealed', 'the', 'presence', 'of', 'this', 'fusion', 'in', 'all', 'primary', 'and', 'metastatic', 'samples', 'including', 'those', 'with', 'mixed', 'or', 'conventional', '_gene_', 'pathology']"
1304,1.0,"PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation.","['_chemical_', 'inhibited', 'the', 'growth', 'of', 'ba', '_abbrev_', 'cell', 'lines', 'containing', 'the', '_gene_', '_mutation_', 'resistance', 'mutation', 'as', 'well', 'as', '_abbrev_', 'and', '_abbrev_', 'cell', 'lines', 'that', 'contain', 'both', '_gene_', '_mutation_', 'and', '_mutation_', 'mutations', 'and', '_abbrev_', 'containing', 'an', '_gene_', 'exon', '_num_', 'deletion', '_disease_', '747_l751', 'ins', 's', 'and', 'a', '_mutation_', 'mutation']"
1305,1.0,H3122 CR2 cells treated with TAE684 produced IC50 values 20-30 times that of the parental H3122 cells.,"['_abbrev_', '_gene_', 'cells', 'treated', 'with', '_chemical_', 'produced', '_abbrev_', 'values', '_range_', 'times', 'that', 'of', 'the', 'parental', '_abbrev_', 'cells']"
1306,1.0,"IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival duration, months according to nuclear PBK Expression: -, 72.3 ± 1.2; +, 66.2 ± 3.4; ++, 53.1 ± 9.2; P = 0.002).","['_gene_', 'in', '_num_', 'gastric', 'cancer', 'patients', 'showed', 'that', 'increased', 'nuclear', 'expression', 'of', '_gene_', 'and', '_gene_', 'was', 'correlated', 'with', 'depth', 'of', 'invasion', 'lymph', 'node', 'metastasis', 'and', 'lower', 'survival', 'rates', 'survival', 'duration', 'months', 'according', 'to', 'nuclear', '_gene_', 'expression', '_num_', '±', '_num_', '_num_', '±', '_num_', '_num_', '±', '_num_', 'p', '_num_']"
1307,1.0,median duration of CNS response was 11.1 months.,"['median', 'duration', 'of', 'cns', 'response', 'was', '_num_', 'months']"
1308,1.0,"After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.","['after', '_num_', 'months', 'of', 'treatment', 'the', 'patient', 'showed', 'no', 'sign', 'of', 'disease', 'progression', 'and', '_gene_', 'had', 'dropped', 'from', '_num_', 'to', '_num_', 'u', '_unit_']"
1309,1.0,ALK positivity was assessed via IHC and verified with FISH or RT-PCR.,"['_gene_', 'positivity', 'was', 'assessed', 'via', '_gene_', 'and', 'verified', 'with', 'fish', 'or', '_disease_']"
1310,1.0,Median overall survival of patients with nonsynonymous mutations in mTOR was shorter.,"['median', 'overall', 'survival', 'of', 'patients', 'with', 'nonsynonymous', 'mutations', 'in', '_gene_', 'was', 'shorter']"
1311,1.0,EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922.,"['_chemical_', 'variant', '_num_', 'containing', '_abbrev_', '_disease_', 'cells', 'were', 'treated', 'with', '_num_', 'generation', '_gene_', 'inhibitor', '_chemical_']"
1312,1.0,"The R451C mutation showed moderate drug-receptor binding with sym004, cetuximab and panitumumab treatment and inhibition of EGFR phosphorylation.","['the', '_mutation_', 'mutation', 'showed', 'moderate', 'drug', 'receptor', 'binding', 'with', '_abbrev_', '_chemical_', 'and', 'panitumumab', 'treatment', 'and', 'inhibition', 'of', '_gene_', '_disease_']"
1313,1.0,"A genome wide association study (GWAS) meta-analysis of 13,265 cancer cases (colorectal cancer and endometrial cancer) and 40,245 controls found this variant to be associated with colorectal cancer (OR = 1.10, P = 7.23 × 10−9).","['a', 'genome', 'wide', 'association', 'study', '_gene_', '_disease_', 'analysis', 'of', '_num_', 'cancer', 'cases', 'colorectal', 'cancer', 'and', 'endometrial', 'cancer', 'and', '_num_', 'controls', 'found', 'this', 'variant', 'to', 'be', 'associated', 'with', 'colorectal', 'cancer', 'or', '_num_', 'p', '_num_', '×', '10−9']"
1314,1.0,The MGH056-1 cell line was derived from an NSCLC patient with ALK-rearrangement who had progressed on crizotinib and then on alectinib.,"['the', '_abbrev_', 'cell', 'line', 'was', 'derived', 'from', 'an', '_disease_', 'patient', 'with', '_gene_', 'rearrangement', 'who', 'had', 'progressed', 'on', '_chemical_', 'and', 'then', 'on', '_chemical_']"
1315,1.0,The interaction between FCGR2B genotype and treatment was statistically significant (p=0.03).,"['the', 'interaction', 'between', '_gene_', 'genotype', 'and', 'treatment', 'was', 'statistically', 'significant', '_p_val_']"
1316,1.0,"Furthermore loss of expression of nuclear phosphorylated Ser1981-ATM (IHC) was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001).","['furthermore', 'loss', 'of', 'expression', 'of', 'nuclear', 'phosphorylated', '_abbrev_', '_gene_', 'was', 'indicative', 'of', 'the', 'worst', 'prognosis', 'median', 'survival', '_num_', 'vs', '_num_', 'months', 'low', 'expression', 'vs', '_num_', 'months', 'high', 'expression', 'p', '_num_']"
1317,1.0,"However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months.","['however', 'of', '_ratio_', 'patients', 'found', 'to', 'be', '_gene_', 'rearranged', 'via', 'break', 'apart', 'fish', 'assay', '_num_', 'showed', 'a', 'partial', 'response', 'and', 'the', '_num_', 'stable', 'disease', 'which', 'was', 'durable', 'for', '_num_', 'months']"
1318,1.0,At approximately 40 days tumors progressed.,"['at', 'approximately', '_num_', 'days', 'tumors', 'progressed']"
1319,1.0,"However, IC50s were intermediate compared to a more potent pan-HER inhibitor.","['however', '_abbrev_', 'were', 'intermediate', 'compared', 'to', 'a', 'more', 'potent', 'pan', 'her', 'inhibitor']"
1320,1.0,"Nine of 12 individuals were identified with cerebellar hemangioblastomas, 6 with angiomas, and 6 with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'cerebellar', '_disease_', '_num_', 'with', 'angiomas', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
1321,1.0,"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS).","['pooled', 'analysis', 'of', '_gene_', 'mutations', 'exons', '_chemical_', 'from', '_num_', 'randomized', 'trials', 'ialt', '_abbrev_', '_abbrev_', 'and', '_disease_', '_num_', 'patients', 'median', 'follow', 'up', '_num_', 'years', 'of', 'platinum', 'based', 'adjuvant', 'chemotherapy', 'act', 'vs', 'observation', 'obs']"
1322,1.0,CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values.,"['_abbrev_', 'chemotherapy', 'regimen', 'was', 'administered', 'with', 'improvement', 'in', 'abdominal', 'lymph', 'nodes', 'but', 'worsening', 'in', '_disease_', 'lymph', 'nodes', 'assessed', 'via', 'standardized', 'uptake', 'values']"
1323,1.0,"Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively).","['patients', 'with', 'concurrent', '_abbrev_', '_ineq_', 'had', 'a', 'trend', 'of', 'higher', 'response', 'rates', '_num_', 'than', '_abbrev_', 'patients', '_ineq_', '_ineq_', '_p_val_', 'as', 'well', 'as', 'a', 'trend', 'of', 'higher', 'percentage', 'of', 'patients', 'on', 'study', 'at', 'week', '_num_', 'or', 'at', '_num_', 'year', '_num_', 'vs', '_num_', '_p_val_', 'and', '_num_', 'vs', '_num_', '_p_val_', 'respectively']"
1324,1.0,"Furthermore, preclinical in vivo studies assessing erlotinib, trastuzumab, afatinib (aka BIBW2992), and/or sirolimus (aka rapamycin) revealed that the combination of afatinib and sirolimus was most effective in shrinking tumors harboring this insertion.","['furthermore', 'preclinical', 'in', 'vivo', 'studies', 'assessing', '_chemical_', '_chemical_', '_chemical_', 'aka', '_chemical_', 'and', 'or', '_chemical_', 'aka', '_gene_', 'revealed', 'that', 'the', 'combination', 'of', '_chemical_', 'and', '_chemical_', 'was', 'most', 'effective', 'in', 'shrinking', 'tumors', 'harboring', 'this', 'insertion']"
1325,1.0,"A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HR = 1.58, P <.001) and poor disease free/progression free survival (DFS/PFS) (HR = 1.72, P =0 .001).","['a', '_disease_', 'analysis', 'of', '_num_', 'research', 'studies', 'involving', '_num_', 'solid', 'tumors', 'indicated', 'that', '_gene_', 'over', 'expression', 'results', 'in', 'poor', 'overall', 'survival', 'hr', '_num_', 'p', '_num_', 'and', 'poor', 'disease', 'free', 'progression', 'free', 'survival', 'dfs', 'pfs', 'hr', '_num_', 'p', '_ineq_', '_num_']"
1326,1.0,"Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone.","['melanoma', 'patients', 'with', '_gene_', '_abbrev_', 'mutations', 'had', 'longer', 'progression', 'free', 'survival', 'increased', 'tumor', 'regression', 'and', 'increased', 'duration', 'of', 'response', 'to', 'combined', '_chemical_', 'and', '_chemical_', 'treatment', 'compared', 'to', '_chemical_', 'alone']"
1327,1.0,"A subset of patients receiving PD1/PD-L1 inhibition appear to be ""hyper-progressors,"" with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy.","['a', 'subset', 'of', 'patients', 'receiving', '_abbrev_', 'inhibition', 'appear', 'to', 'be', '_disease_', 'progressors', 'with', 'a', 'greatly', 'accelerated', 'rate', 'of', 'tumor', 'growth', 'and', 'clinical', 'deterioration', 'compared', 'to', '_gene_', 'therapy']"
1328,1.0,Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild type counterparts.,"['tumors', 'expressing', '_gene_', 'or', '_gene_', 'mutations', 'show', 'notably', 'more', 'sensitivity', 'to', '_chemical_', 'than', 'their', 'wild', 'type', 'counterparts']"
1329,1.0,Complete loss of STAG2 expression was associated with a lower risk of recurrence (P = 0.023) and diminished risk of death (P = 0.034) in log-rank analysis and was a beneficial factor in uni- and multivariate analysis.,"['complete', 'loss', 'of', '_gene_', 'expression', 'was', 'associated', 'with', 'a', 'lower', 'risk', 'of', 'recurrence', 'p', '_num_', 'and', 'diminished', 'risk', 'of', 'death', 'p', '_num_', 'in', 'log', 'rank', 'analysis', 'and', 'was', 'a', 'beneficial', 'factor', 'in', 'uni', '', 'and', 'multivariate', 'analysis']"
1330,1.0,"In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status.","['in', 'multivariate', 'analysis', '_gene_', 'amplification', 'predicted', 'response', 'and', 'overall', 'survival', 'independent', 'of', '_gene_', 'status']"
1331,1.0,The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond.,"['the', 'patient', 'underwent', 'treatment', 'with', 'chop', 'chemotherapy', 'regimen', 'and', 'radiation', 'but', 'did', 'not', 'respond']"
1332,1.0,No interaction with treatment was observed.,"['no', 'interaction', 'with', 'treatment', 'was', 'observed']"
1333,1.0,A 25-year-old Caucasian male presented with a second relapse of B-ALL.,"['a', '_age_', 'caucasian', 'male', 'presented', 'with', 'a', '_num_', 'relapse', 'of', '_disease_']"
1334,1.0,"HDAC2 or BAP1 depletion sensitized a mesothelioma cell line (MSTO-211H) to HDAC inhibitors MC1568, vorinostat or mocetinostat.","['_gene_', 'or', '_gene_', 'depletion', 'sensitized', 'a', 'mesothelioma', 'cell', 'line', '_chemical_', 'to', '_gene_', 'inhibitors', '_chemical_', '_chemical_', 'or', '_chemical_']"
1335,1.0,23 (23.5%) had KRAS p.G13D-mutated tumors.,"['_num_', '_num_', 'had', '_gene_', 'p', '_abbrev_', 'mutated', 'tumors']"
1336,1.0,Loss of heterozygosity of the wildtype allele was confirmed.,"['loss', 'of', 'heterozygosity', 'of', 'the', 'wildtype', 'allele', 'was', 'confirmed']"
1337,1.0,"In HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation was associated with an increased risk of progression (HR:2.50, 95% CI:1.35-4.61, P=0.003, univariate analysis; HR:1.86, 95% CI:1.13-3.05, P=0.014, multivariate analysis) and reduced time to progression (HR:2.50, 95% CI:1.35-4.61, P=0.003) compared to wildtype PIK3CA.","['in', '_gene_', 'metastic', 'breast', 'cancer', 'patients', 'treated', 'with', '_chemical_', 'based', 'therapy', 'the', 'presence', 'of', 'a', '_gene_', 'mutation', 'was', 'associated', 'with', 'an', 'increased', 'risk', 'of', 'progression', 'hr:2', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'univariate', 'analysis', 'hr:1', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'multivariate', 'analysis', 'and', 'reduced', 'time', 'to', 'progression', 'hr:2', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'compared', 'to', 'wildtype', '_gene_']"
1338,1.0,This missense mutation was found in a VHL type 1 patient (patient no V269).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
1339,1.0,"No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN.","['no', 'other', 'alterations', 'in', 'atm', 'were', 'observed', 'however', 'this', 'patient', 'also', 'had', 'frameshift', 'mutations', 'in', '_gene_', '_gene_', 'and', '_gene_']"
1340,1.0,"In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 0·69 [95% CI 0·50–0·96], p=0.022) than in p16-positive disease (HR 0·95 [CI 0·51–1·75], p=0.67, interaction test p=0·32).","['in', 'the', 'post', '_gene_', 'analysis', 'benefit', 'of', '_chemical_', 'compared', 'with', 'methotrexate', 'was', 'more', 'pronounced', 'in', '_abbrev_', 'disease', 'hr', '_num_', '_num_', 'ci', '0·50–0·96', '_p_val_', 'than', 'in', '_abbrev_', 'disease', 'hr', '_num_', 'ci', '0·51–1·75', '_p_val_', 'interaction', 'test', '_p_val_']"
1341,1.0,"Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.","['breast', 'cancer', 'patients', 'who', 'harbor', '_mutation_', 'mutation', 'have', 'worse', 'overall', 'survival', 'than', 'those', 'with', 'wild', 'type', '_gene_', 'but', 'have', 'better', 'prognosis', 'than', 'those', 'with', '_mutation_', 'mutation']"
1342,1.0,"There was no association with age, sex, race, or stage.","['there', 'was', 'no', 'association', 'with', 'age', 'sex', 'race', 'or', 'stage']"
1343,1.0,No major objective tumor responses were observed in the study.,"['no', 'major', 'objective', 'tumor', 'responses', 'were', 'observed', 'in', 'the', 'study']"
1344,1.0,Treatment of this cell line with CDK4/6 inhibitor palbociclib led to growth inhibition and reduced RB1 phosphorylation in vitro and in-vivo.,"['treatment', 'of', 'this', 'cell', 'line', 'with', '_gene_', 'inhibitor', '_chemical_', 'led', 'to', 'growth', 'inhibition', 'and', 'reduced', '_gene_', '_disease_', 'in', 'vitro', 'and', 'in', 'vivo']"
1345,0.0,This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC.,"['this', 'review', 'identified', '_num_', 'studies', 'that', 'addressed', 'the', 'prognostic', 'role', 'of', 'fgfrs', 'in', '_disease_']"
1346,1.0,Analysis of drug response data from the Sanger center cell line screen.,"['analysis', 'of', 'drug', 'response', 'data', 'from', 'the', 'sanger', 'center', 'cell', 'line', 'screen']"
1347,1.0,"Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial.","['retrospective', 'analysis', 'of', 'somatic', 'mutations', 'and', 'copy', 'number', 'changes', 'in', '_num_', 'patient', 'treated', 'with', '_chemical_', '_chemical_', '±', '_chemical_', 'cps', 'in', 'the', '_abbrev_', 'trial']"
1348,1.0,NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab.,"['_disease_', 'guidelines', 'indicate', 'colorectal', 'cancer', 'patients', 'with', 'nras', 'mutations', 'should', 'not', 'be', 'treated', 'with', '_gene_', 'inhibitors', '_chemical_', 'or', 'panitumumab']"
1349,1.0,This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632).,"['this', 'study', 'summarized', '_num_', '_gene_', 'mutant', 'patients', 'from', '_num_', 'clinical', 'trials', 'involving', '_chemical_', '_abbrev_', 'and', 'subsequent', 'osimertinib', '_abbrev_']"
1350,1.0,AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3.,"['_disease_', 'patients', 'with', 'internal', 'tandem', 'repeat', 'of', '_gene_', 'has', 'worse', 'overall', 'survival', 'than', 'patients', 'with', 'wild', 'type', '_gene_']"
1351,1.0,The SLCO1B1 RS2306283 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.,"['the', '_gene_', '_abbrev_', 'variant', 'was', 'significantly', 'associated', 'with', '_gene_', '_abbrev_', 'and', 'as', 'such', 'associated', 'with', 'increased', 'toxicity']"
1352,1.0,"Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor GDC-0941 compared to wildtype PIK3CA cell lines (n=54, P=0.005).","['breast', 'cancer', 'cell', 'lines', 'with', '_disease_', '_gene_', 'mutations', 'had', 'an', 'increased', 'sensitivity', 'to', 'treatment', 'with', 'class', 'i', '_gene_', 'inhibitor', '_chemical_', 'compared', 'to', 'wildtype', '_gene_', 'cell', 'lines', '_ineq_', '_p_val_']"
1353,1.0,Reduced overall survival was observed in patients with low SMARCA4 expression compared to intermediate (P<0 .001) or high expression (P=0.009).,"['reduced', 'overall', 'survival', 'was', 'observed', 'in', 'patients', 'with', 'low', '_gene_', 'expression', 'compared', 'to', 'intermediate', 'p', '_num_', '_num_', 'or', 'high', 'expression', '_p_val_']"
1354,1.0,"MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity.","['_disease_', 'cells', 'were', 'transduced', 'with', '_gene_', 'tagged', '_gene_', 'with', '_abbrev_', 'mutation', 'or', '_gene_', '_gene_', 'wildtype', 'and', 'stained', 'for', 'ectopic', '_gene_', '_gene_', 'and', '_chemical_', 'as', 'a', 'readout', 'for', '_gene_', 'pathway', 'activity']"
1355,1.0,High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.,"['high', 'levels', 'of', '_chemical_', 'can', 'overcome', 'drug', 'resistance', 'of', 'ba', '_abbrev_', 'cells', 'expressing', 'the', '_chemical_', 'fusion', 'containing', 'the', '_mutation_', 'mutation']"
1356,1.0,The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie.,"['the', 'common', '_mutation_', '_gene_', 'mutation', 'has', 'been', 'shown', 'previously', 'to', 'be', 'sensitive', 'to', 'small', 'molecular', 'tyrosine', 'kinase', 'inhibitors', 'ie']"
1357,1.0,"HPO terms: retinal hemangioblastoma, hemangioblastoma, multiple pancreatic cysts.","['_disease_', 'terms', 'retinal', '_disease_', '_disease_', 'multiple', 'pancreatic', 'cysts']"
1358,1.0,Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15).,"['monitoring', '_gene_', 'mutation', 'by', 'cdna', 'based', '_disease_', 'effectively', 'predicted', 'relapse', 'in', '_ratio_', 'patients', 'by', '_num_', 'log', 'increase', 'in', '_gene_', 'levels', '_ineq_', 'or', 'lack', 'of', 'reduction', 'in', '_gene_', 'levels', 'following', '_num_', 'line', 'therapy', '_ineq_']"
1359,1.0,"IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival durations of the (-), (+), and (++) groups, classified according to nuclear PSMB8 expression, were 77.2, 70.6, and 62.2 months, respectively; P = 0.004).","['_gene_', 'in', '_num_', 'gastric', 'cancer', 'patients', 'showed', 'that', 'increased', 'nuclear', 'expression', 'of', '_gene_', 'and', '_gene_', 'was', 'correlated', 'with', 'depth', 'of', 'invasion', 'lymph', 'node', 'metastasis', 'and', 'lower', 'survival', 'rates', 'survival', 'durations', 'of', 'the', 'and', 'groups', 'classified', 'according', 'to', 'nuclear', '_gene_', 'expression', 'were', '_num_', '_num_', 'and', '_num_', 'months', 'respectively', 'p', '_num_']"
1360,1.0,64-year old female (non-smoker) was diagnosed with NSCLC.,"['_num_', 'year', 'old', 'female', 'non', 'smoker', 'was', 'diagnosed', 'with', '_disease_']"
1361,1.0,This mutation causes a premature stop codon at amino acid 170 and was found in a VHL type 1 family (lineage 16).,"['this', 'mutation', 'causes', 'a', 'premature', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
1362,1.0,"Of 142 RAS and BRAF wild type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH.","['of', '_num_', 'ras', 'and', '_gene_', 'wild', 'type', 'tumors', 'we', 'observed', '_num_', 'cases', '_num_', 'of', '_gene_', 'amplification', 'by', 'sish']"
1363,1.0,"Multivariate analysis was also significant (p = 0.001, HR 6.14; 95% CI 2.03, 18.55).","['multivariate', 'analysis', 'was', 'also', 'significant', 'p', '_num_', 'hr', '_num_', '_num_', 'ci', '_num_', '_num_']"
1364,1.0,No differences were observed in toxicity or response rate between the two doses of midostaurin.,"['no', 'differences', 'were', 'observed', 'in', 'toxicity', 'or', 'response', 'rate', 'between', 'the', '_num_', 'doses', 'of', '_chemical_']"
1365,1.0,The V1180L mutation was found to be more resistant to alectinib than the I1171T mutation found in an ALK-positive NSCLC patient who developed alectinib resistance on lower dose alectinib  (300mg twice daily).,"['the', '_mutation_', 'mutation', 'was', 'found', 'to', 'be', 'more', 'resistant', 'to', '_chemical_', 'than', 'the', '_mutation_', 'mutation', 'found', 'in', 'an', '_disease_', '_disease_', 'patient', 'who', 'developed', '_chemical_', 'resistance', 'on', 'lower', 'dose', '_chemical_', '_unit_', 'twice', 'daily']"
1366,1.0,"Copy number profiling from exome sequencing of MCF-7 and MCF-7pR, confirmed relative amplification of CCNE1.","['copy', 'number', 'profiling', 'from', 'exome', 'sequencing', 'of', '_disease_', 'and', '_abbrev_', 'confirmed', 'relative', 'amplification', 'of', '_gene_']"
1367,1.0,NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.,"['_gene_', 'mutations', 'were', 'not', 'associated', 'with', 'the', '_abbrev_', 'fab', 'subtype', 'of', 'acute', 'myeloid', 'leukemia']"
1368,1.0,Overexpression of JAK1 (lentiviral mediated) led to sensitivity to enzastaurin.,"['overexpression', 'of', '_gene_', 'lentiviral', 'mediated', 'led', 'to', 'sensitivity', 'to', '_chemical_']"
1369,1.0,"Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.","['benefit', 'was', 'seen', 'in', '_num_', 'of', '_num_', 'patients', 'assigned', 'to', '_chemical_', 'alone', '_num_', 'of', '_num_', 'assigned', 'to', '_chemical_', 'plus', '_chemical_', 'and', '_num_', 'of', '_num_', 'assigned', 'to', 'investigator', ""'s"", 'treatment', 'choice']"
1370,1.0,The patients with a low RRM1 expression had a significantly better outcome after gemcitabine treatment than those patients with high RRM1 expression (P=0.016).,"['the', 'patients', 'with', 'a', 'low', '_gene_', 'expression', 'had', 'a', 'significantly', 'better', 'outcome', 'after', '_chemical_', 'treatment', 'than', 'those', 'patients', 'with', 'high', '_gene_', 'expression', '_p_val_']"
1371,1.0,"At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died.","['at', 'data', 'cutoff', '_num_', 'months', 'of', 'follow', 'up', '_ratio_', '_num_', 'confirmed', 'responses', 'were', 'ongoing', 'and', '_ratio_', '_num_', 'of', 'patients', 'had', 'died']"
1372,1.0,ACMG codes as follows: A single exon deletion variant in a gene where loss-of-function is known mechanism of disease (PSV1).,"['acmg', 'codes', 'as', 'follows', 'a', 'single', 'exon', 'deletion', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'known', 'mechanism', 'of', 'disease', '_abbrev_']"
1373,1.0,The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation.,"['the', '_abbrev_', 'phase', 'iii', 'trial', '_abbrev_', 'assessed', '_gene_', 'inhibitor', '_chemical_', 'vs', '_chemical_', 'in', '_num_', 'patients', 'with', 'treatment', 'naive', 'metastatic', 'melanoma', 'and', 'confirmed', '_mutation_', 'mutation']"
1374,1.0,Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition.,"['inhibition', 'of', '_gene_', 'in', '_num_', '_gene_', 'mutant', 'pancreatic', 'cancer', 'cell', 'lines', 'with', '_chemical_', 'was', 'more', 'effective', 'than', 'mek', 'inhibition']"
1375,1.0,Two of these R1275Q mutations were germline and two were somatic.,"['_num_', 'of', 'these', '_mutation_', 'mutations', 'were', 'germline', 'and', '_num_', 'were', 'somatic']"
1376,1.0,Patients with stable disease (SD; RECIST) at week 12 were randomised to cabozantinib or placebo.,"['patients', 'with', 'stable', 'disease', 'sd', '_disease_', 'at', 'week', '_num_', 'were', 'randomised', 'to', '_chemical_', 'or', 'placebo']"
1377,1.0,"HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, epididymal cysts.","['_disease_', 'terms', '_disease_', 'retinal', '_disease_', 'renal', 'cell', 'carcinoma', '_disease_', 'cysts']"
1378,1.0,Co-expression of wildtype HER2 and HER3-V855A in Ba/F3 cells led to sensitivity to afatinib and pertuzumab.,"['co', 'expression', 'of', 'wildtype', '_gene_', 'and', '_abbrev_', 'in', 'ba', '_abbrev_', 'cells', 'led', 'to', 'sensitivity', 'to', '_chemical_', 'and', 'pertuzumab']"
1379,1.0,EML4-ALK containing H3122 NSCLC cells were incubated in increasing levels of crizotinib inducing resistance.,"['_chemical_', 'containing', '_abbrev_', '_disease_', 'cells', 'were', 'incubated', 'in', 'increasing', 'levels', 'of', '_chemical_', 'inducing', 'resistance']"
1380,1.0,"One of 2 individuals were identified with angiomas, one with cerebellar hemangioblastomas, and one with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
1381,1.0,"In advanced stage follicular lymphoma patients receiving rituximab + chemotherapy (R-CHOP or R-CVP), EZH2 mutations were associated with better failure free survival in patients with high-risk FLIPI scores compared to patients that were EZH2 wildtype with high-risk FLIPI scores.","['in', 'advanced', 'stage', 'follicular', 'lymphoma', 'patients', 'receiving', '_chemical_', 'chemotherapy', '_gene_', 'or', 'r', 'cvp', '_gene_', 'mutations', 'were', 'associated', 'with', 'better', 'failure', 'free', 'survival', 'in', 'patients', 'with', 'high', 'risk', '_disease_', 'scores', 'compared', 'to', 'patients', 'that', 'were', '_gene_', 'wildtype', 'with', 'high', 'risk', '_disease_', 'scores']"
1382,1.0,KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment.,"['_gene_', 'exon', '_num_', 'was', 'mutated', 'in', '_num_', 'of', '_num_', '_num_', 'patients', 'with', 'advanced', 'pancreatic', 'cancer', 'and', 'did', 'not', 'show', 'an', 'association', 'with', 'response', 'to', '_chemical_', 'treatment']"
1383,1.0,"Finally, administration of ceritinib to the crizotinib and alectinib resistant patient let to tumor regression and partial response lasting 7 months.","['finally', 'administration', 'of', '_chemical_', 'to', 'the', '_chemical_', 'and', '_chemical_', 'resistant', 'patient', 'let', 'to', 'tumor', 'regression', 'and', 'partial', 'response', 'lasting', '_num_', 'months']"
1384,1.0,"In FLT3 wild type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33–273 days).","['in', '_gene_', 'wild', 'type', 'patients', '_num_', 'out', 'of', '_num_', '_num_', 'had', 'a', 'response', '_num_', 'pr', '_num_', 'mr', '_num_', 'umr', 'that', 'lasted', 'a', 'median', 'of', '_num_', 'days', 'range', '33–273', 'days']"
1385,1.0,"A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells.","['a', 'selective', 'mek', 'inhibitor', '_chemical_', 'inhibits', 'mutant', 'induced', '_gene_', 'activity', 'in', '_chemical_', 'cells', 'and', 'growth', 'of', 'mutant', 'bearing', 'ba', '_abbrev_', 'cells']"
1386,1.0,"In the entire cohort, median overall PFS was 3.8 months (33% PFS at 6 months).","['in', 'the', 'entire', 'cohort', 'median', 'overall', '_disease_', 'was', '_num_', 'months', '_num_', '_disease_', 'at', '_num_', 'months']"
1387,1.0,NPM1 mutations were evaluated in 570 patients (310 mutated).,"['_gene_', 'mutations', 'were', 'evaluated', 'in', '_num_', 'patients', '_num_', 'mutated']"
1388,1.0,"Liver metastasis biopsy samples (3 R and 3 NR) were immunoblotted for DDX43, pERK and RAS proteins with consistent results.","['liver', 'metastasis', 'biopsy', 'samples', '_num_', 'r', 'and', '_num_', '_gene_', 'were', 'immunoblotted', 'for', '_gene_', 'perk', 'and', 'ras', 'proteins', 'with', 'consistent', 'results']"
1389,1.0,H3122 CR2 was found to contain the 1151 Tins variant as well as elevated EML4-ALK expression.,"['_abbrev_', '_gene_', 'was', 'found', 'to', 'contain', 'the', '_num_', 'tins', 'variant', 'as', 'well', 'as', 'elevated', '_chemical_', 'expression']"
1390,1.0,"Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate.","['mice', 'subsequently', 'treated', 'with', '_chemical_', 'or', '_chemical_', 'showed', 'continued', 'tumor', 'growth', 'without', 'marked', 'difference', 'from', 'control', 'while', 'combination', 'treatment', 'essentially', 'halted', 'tumor', 'growth', 'rate']"
1391,1.0,"While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild type also respond.","['while', '_gene_', 'mutation', 'is', 'a', 'strong', 'predictive', 'factor', 'for', '_gene_', 'inhibition', 'some', 'patients', 'with', '_gene_', 'wild', 'type', 'also', 'respond']"
1392,1.0,The primary end points were progression-free survival (PFS) for the KRAS wild type cohort and objective response rate (ORR) for the KRAS mutant cohort.,"['the', 'primary', 'end', 'points', 'were', 'progression', 'free', 'survival', '_disease_', 'for', 'the', '_gene_', 'wild', 'type', 'cohort', 'and', 'objective', 'response', 'rate', 'orr', 'for', 'the', '_gene_', 'mutant', 'cohort']"
1393,1.0,"Ten had retinal angiomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma.","['_num_', 'had', 'retinal', 'angiomas', '_num_', 'had', 'cerebellar', '_disease_', 'and', '_num_', 'had', 'renal', 'cell', 'carcinoma']"
1394,1.0,"Patients with a homozygous deletion of PRDM1 (7%, N=19) had a significantly shorter overall survival and poorer progression free survival compared to heterozygous or wildtype PRDM1.","['patients', 'with', 'a', 'homozygous', 'deletion', 'of', '_gene_', '_num_', '_ineq_', 'had', 'a', 'significantly', 'shorter', 'overall', 'survival', 'and', 'poorer', 'progression', 'free', 'survival', 'compared', 'to', 'heterozygous', 'or', 'wildtype', '_gene_']"
1395,1.0,16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age.,"['_num_', 'out', 'of', '_num_', '_num_', 'of', '_abbrev_', 'homozygous', 'mice', 'developed', 'cancer', 'between', '_num_', 'and', '_num_', 'months', 'of', 'age']"
1396,1.0,"In a study of 30 patients with Waldenström’s macroglobulinemia, 87% had MYD88(L265P) mutations.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'waldenström', '’', 's', '_disease_', '_num_', 'had', '_gene_', '_mutation_', 'mutations']"
1397,0.0,Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes.,"['study', 'employed', 'a', 'rapid', 'autopsy', 'technique', 'on', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'pancreatic', 'cancer', 'and', 'explored', 'the', 'status', 'of', 'several', 'genes']"
1398,1.0,Further there is weak evidence to conclude that breast cancer risk for this variant decreases with age (p=.06).,"['further', 'there', 'is', 'weak', 'evidence', 'to', 'conclude', 'that', 'breast', 'cancer', 'risk', 'for', 'this', 'variant', 'decreases', 'with', 'age', '_gene_']"
1399,1.0,The JAK2 mutation was the only homozygous mutation (allele frequency >85%) of 76 new nonsynonymous mutations in patient 2.,"['the', '_gene_', 'mutation', 'was', 'the', 'only', 'homozygous', 'mutation', 'allele', 'frequency', '_num_', 'of', '_num_', 'new', 'nonsynonymous', 'mutations', 'in', 'patient', '_num_']"
1400,1.0,In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression.,"['in', 'vivo', 'studies', 'of', 'residual', '_disease_', 'tumors', 'xenografts', 'of', '_num_', 'cell', 'lines', 'after', 'chemotherapy', 'found', 'increased', '_gene_', 'family', 'signaling', 'and', '_gene_', 'expression']"
1401,1.0,"However, based on this study, we can infer that the variant would predispose to LS in a germline setting.","['however', 'based', 'on', 'this', 'study', 'we', 'can', 'infer', 'that', 'the', 'variant', 'would', 'predispose', 'to', 'ls', 'in', 'a', 'germline', 'setting']"
1402,1.0,"HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts, papillary cystadenomas of the broad ligament.","['_disease_', 'terms', 'retinal', '_disease_', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts', 'papillary', '_disease_', 'of', 'the', 'broad', 'ligament']"
1403,1.0,A 52 year old male never smoker was diagnosed with stage IV NSCLC adenocarcinoma and was treated with chemotherapy with eventual disease progression.,"['a', '_num_', 'year', 'old', 'male', 'never', 'smoker', 'was', 'diagnosed', 'with', 'stage', 'iv', '_disease_', 'adenocarcinoma', 'and', 'was', 'treated', 'with', 'chemotherapy', 'with', 'eventual', 'disease', 'progression']"
1404,1.0,Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'woman', 'with', '_gene_', 'and', '_disease_', 'lung', 'adenocarcinoma']"
1405,1.0,"In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild type TP53.","['in', 'breast', 'cancer', 'patients', 'harboring', '_gene_', 'mutation', 'mutations', 'in', 'conserved', 'regions', 'such', 'as', '_abbrev_', 'are', 'prognostic', 'for', 'a', 'worse', 'overall', 'survival', 'compared', 'to', 'those', 'harboring', 'wild', 'type', '_gene_']"
1406,1.0,"There was not a significant difference in sensitivity to other chemotherapy drugs such as gemcitabine, topotecan, and doxorubicin.","['there', 'was', 'not', 'a', 'significant', 'difference', 'in', 'sensitivity', 'to', 'other', 'chemotherapy', 'drugs', 'such', 'as', '_chemical_', '_chemical_', 'and', 'doxorubicin']"
1407,1.0,11 patients with crizotinib-resistant NSCLC were analyzed for this study.,"['_num_', 'patients', 'with', '_chemical_', 'resistant', '_disease_', 'were', 'analyzed', 'for', 'this', 'study']"
1408,1.0,Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth.,"['transduction', 'of', 'ba', '_abbrev_', 'cells', 'with', '_chemical_', 'variant', '_num_', 'causes', '_gene_', 'independent', 'growth']"
1409,1.0,Suppression of SOX10 in melanoma cells confers resistance to BRAF and MEK inhibitors through activation of TGF-β signalling and upregulation of EGFR and PDGFRB.,"['suppression', 'of', '_gene_', 'in', 'melanoma', 'cells', 'confers', 'resistance', 'to', '_gene_', 'and', 'mek', 'inhibitors', 'through', 'activation', 'of', 'tgf', 'β', 'signalling', 'and', 'upregulation', 'of', '_gene_', 'and', '_gene_']"
1410,1.0,TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25).,"['_gene_', 'copy', 'number', 'was', 'lower', 'in', 'clinical', 'samples', 'responding', 'to', '_chemical_', 'in', 'combination', 'with', 'platinum', '_ineq_']"
1411,1.0,"High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with advanced clinical stage (p<0.001) and poor pathologic differentiation (P = 0.004) and was an independent unfavorable prognostic factors for overall and disease-free survival (OS, P=0.009; DFS, P=0.034).","['high', 'nuclear', 'expression', 'of', '_gene_', 'was', 'detected', 'in', '_num_', 'of', 'cases', 'and', 'was', 'significantly', 'correlated', 'with', 'advanced', 'clinical', 'stage', 'p', '_num_', 'and', 'poor', 'pathologic', 'differentiation', 'p', '_num_', 'and', 'was', 'an', 'independent', 'unfavorable', 'prognostic', 'factors', 'for', 'overall', 'and', '_disease_', 'survival', 'os', '_p_val_', '_disease_', '_p_val_']"
1412,1.0,G84E was highly prevalent in patients with prostate cancer than those without cancer (P < 0.0001).,"['_mutation_', 'was', 'highly', 'prevalent', 'in', 'patients', 'with', 'prostate', 'cancer', 'than', 'those', 'without', 'cancer', 'p', '_num_']"
1413,1.0,"Han et al functionally tested the R173C mutation in PTEN using an expression vector construct, assessing phosphatase activity of the mutant construct with two phosphoinositide substrates (""with[ PtdIns(3,4,5)P3] or without[ Ins(1,3,4,5)P4] a diacylglycerol chain"").","['han', 'et', 'al', 'functionally', 'tested', 'the', '_mutation_', 'mutation', 'in', '_gene_', 'using', 'an', 'expression', 'vector', 'construct', 'assessing', 'phosphatase', 'activity', 'of', 'the', 'mutant', 'construct', 'with', '_num_', '_chemical_', 'substrates', 'with', '_chemical_', '_num_', '_num_', '_num_', '_gene_', 'or', 'without', 'ins', '_num_', '_num_', '_num_', '_num_', '_gene_', 'a', '_chemical_', 'chain']"
1414,1.0,One had renal cell carcinoma.,"['_num_', 'had', 'renal', 'cell', 'carcinoma']"
1415,1.0,"Both patients had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and cystadenomas of the epididymis (family VHL 60).","['both', 'patients', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'pancreatic', 'cysts', 'and', '_disease_', 'of', 'the', 'epididymis', 'family', '_gene_', '_num_']"
1416,1.0,"Neoantigen load was assessed in 37 bMMRD patients and all malignant tumors had high numbers of predicted neoantigens (7-16x as high as in melanoma, lung or other immunoresponsive cancers).","['neoantigen', 'load', 'was', 'assessed', 'in', '_num_', 'bmmrd', 'patients', 'and', 'all', 'malignant', 'tumors', 'had', 'high', 'numbers', 'of', 'predicted', 'neoantigens', '_num_', '16x', 'as', 'high', 'as', 'in', 'melanoma', 'lung', 'or', 'other', 'immunoresponsive', 'cancers']"
1417,1.0,The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy.,"['the', 'patient', 'achieved', 'stable', 'disease', 'and', 'was', 'on', 'treatment', 'for', '_num_', 'weeks', 'which', 'was', 'the', 'patients', 'best', 'and', 'only', 'clinical', 'response', 'to', 'any', '_disease_', 'therapy']"
1418,1.0,"Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001).","['patients', 'with', 'mutations', 'in', 'codon', '_num_', 'or', '_num_', 'of', '_gene_', 'were', 'associated', 'with', 'reduced', 'response', 'to', 'panitumumab', 'compared', 'to', 'wildtype', '_gene_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'vs', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_']"
1419,1.0,"ACMG evidence codes: 'PVS1' for a single exon deletion, 'PP1' based on segregation results, 'PP4' because patients phenotypes are highly specific for a disease with single genetic etiology.","['acmg', 'evidence', 'codes', ""'pvs1"", 'for', 'a', 'single', 'exon', 'deletion', ""'pp1"", 'based', 'on', 'segregation', 'results', ""'pp4"", 'because', 'patients', 'phenotypes', 'are', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'single', 'genetic', 'etiology']"
1420,1.0,Two mutations NRAS p.Q61K and GNAS p.R201H were detected.,"['_num_', 'mutations', 'nras', '_mutation_', 'and', '_gene_', '_mutation_', 'were', 'detected']"
1421,1.0,"Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild type PI3K or PTEN mutant cell lines.","['among', 'a', 'panel', 'of', '_num_', '_disease_', 'cell', 'lines', 'activating', '_gene_', 'mutations', 'were', 'associated', 'with', 'taselisib', 'sensitivity', 'in', 'comparison', 'to', 'wild', 'type', '_gene_', 'or', '_gene_', 'mutant', 'cell', 'lines']"
1422,1.0,"Lastly, tumors with low expression were significantly more likely to be resistant to primary adjuvant chemotherapy than tumors with a higher expression (P=0.04).","['lastly', 'tumors', 'with', 'low', 'expression', 'were', 'significantly', 'more', 'likely', 'to', 'be', 'resistant', 'to', 'primary', 'adjuvant', 'chemotherapy', 'than', 'tumors', 'with', 'a', 'higher', 'expression', '_p_val_']"
1423,1.0,Sensitivity to vorinostat correlated significantly with HR23b protein expression.,"['sensitivity', 'to', '_chemical_', 'correlated', 'significantly', 'with', '_gene_', 'protein', 'expression']"
1424,1.0,"Germline homozygous c.2117delA, p. Lys706SerfsX19 mutation in PMS2, loss of PMS2 staining in the tumor and normal tissue confirmed a diagnosis of biallelic mismatch repair deficiency (bMMRD).","['germline', 'homozygous', 'c', '2117dela', 'p', '_abbrev_', 'mutation', 'in', '_gene_', 'loss', 'of', '_gene_', 'staining', 'in', 'the', 'tumor', 'and', 'normal', 'tissue', 'confirmed', 'a', 'diagnosis', 'of', 'biallelic', 'mismatch', 'repair', 'deficiency', 'bmmrd']"
1425,1.0,A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance.,"['a', 'large', 'scale', '_gene_', 'genetic', 'sereen', 'in', '_gene_', 'overexpressing', 'breast', 'cancer', 'cell', 'line', '_chemical_', 'was', 'performed', 'to', 'discover', 'genes', 'whose', 'loss', 'induced', '_chemical_', 'resistance']"
1426,1.0,FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation.,"['_gene_', 'duplication', 'length', 'did', 'not', 'effect', 'prognosis', 'in', 'patients', 'with', 'an', '_gene_', 'mutation']"
1427,1.0,"SU5614 resistance mutations were limited to exchanges in the second part of the kinase domain (TK2), with exchanges of D835 predominating (D835E were most common).","['_chemical_', 'resistance', 'mutations', 'were', 'limited', 'to', 'exchanges', 'in', 'the', '_num_', 'part', 'of', 'the', 'kinase', 'domain', '_gene_', 'with', 'exchanges', 'of', '_abbrev_', 'predominating', '_mutation_', 'were', 'most', 'common']"
1428,1.0,The E255K mutation was resistant to imatinib (20-fold IC50 increase for the proliferation assay).,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_', '_n_fold_', '_abbrev_', 'increase', 'for', 'the', 'proliferation', 'assay']"
1429,1.0,"Mean IC50s of flavopiridol were significantly lower in cell lines with a mutated or non-expressed p16 (p16-) (mean 50% inhibitory concentration [IC(50)] = 12.5 nM), than in cell lines with intact p16 (p16+) (mean IC(50) = 25 nM).","['mean', '_abbrev_', 'of', '_chemical_', 'were', 'significantly', 'lower', 'in', 'cell', 'lines', 'with', 'a', 'mutated', 'or', 'non', 'expressed', '_gene_', '_abbrev_', 'mean', '_num_', 'inhibitory', 'concentration', 'ic', '_num_', '_num_', '_unit_', 'than', 'in', 'cell', 'lines', 'with', 'intact', '_gene_', '_abbrev_', 'mean', 'ic', '_num_', '_num_', '_unit_']"
1430,1.0,Total Afatinib treatment was 15 months (11 in combination) at which time the patient developed a brain metastasis but no other progressive disease.,"['total', '_chemical_', 'treatment', 'was', '_num_', 'months', '_num_', 'in', 'combination', 'at', 'which', 'time', 'the', 'patient', 'developed', 'a', 'brain', 'metastasis', 'but', 'no', 'other', 'progressive', 'disease']"
1431,1.0,"Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed.","['pretreatment', 'biopsies', 'and', 'post', 'treatment', 'surgical', 'samples', 'were', 'obtained', 'and', 'microarray', 'performed']"
1432,0.0,Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.,"['osimertinib', 'has', 'been', 'approved', 'for', 'the', 'treatment', 'of', '_gene_', '_mutation_', 'mutant', '_disease_']"
1433,1.0,MYD88 mutations were identified in 24 of 1080 screened  CLLs.,"['_gene_', 'mutations', 'were', 'identified', 'in', '_num_', 'of', '_num_', 'screened', '_disease_']"
1434,0.0,This trial is ongoing but not recruiting patients (NCT00490139).,"['this', 'trial', 'is', 'ongoing', 'but', 'not', 'recruiting', 'patients', '_abbrev_']"
1435,1.0,The patient then received chemotheraoy (vinorelbine) and showed stable disease.,"['the', 'patient', 'then', 'received', 'chemotheraoy', '_chemical_', 'and', 'showed', 'stable', 'disease']"
1436,1.0,"In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib.","['in', 'clinical', 'trial', '_abbrev_', '_num_', 'patients', 'with', '_gene_', '_abbrev_', 'metastatic', 'colorectal', 'cancer', '_gene_', 'received', 'mutant', '_gene_', 'inhibitor', '_chemical_', 'and', 'mek', 'inhibitor', '_chemical_']"
1437,1.0,Exome sequencing revealed the C1156Y mutation was present in <7% of the pretreatment tumor and in ~50% of the crizotinib tumor prior to ceritinib therapy.,"['exome', 'sequencing', 'revealed', 'the', '_mutation_', 'mutation', 'was', 'present', 'in', '_num_', 'of', 'the', 'pretreatment', 'tumor', 'and', 'in', '_num_', 'of', 'the', '_chemical_', 'tumor', 'prior', 'to', '_chemical_', 'therapy']"
1438,1.0,"In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.","['in', 'patients', 'with', 'barrett', ""'s"", 'adenocarcinoma', 'those', 'with', 'amplification', 'of', '_gene_', 'had', 'shorter', '_disease_', 'survial']"
1439,1.0,"In total, 129 patients were treated with afatinib.","['in', 'total', '_num_', 'patients', 'were', 'treated', 'with', '_chemical_']"
1440,1.0,The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival.,"['the', 'presence', 'of', '_gene_', 'mutations', 'in', '_unit_', 'patients', 'is', 'prognostic', 'for', 'shorter', 'overall', 'and', 'progression', 'free', 'survival']"
1441,1.0,"Among these residues, two within the activation loop were found (D835, Y842).","['among', 'these', 'residues', '_num_', 'within', 'the', 'activation', 'loop', 'were', 'found', '_abbrev_', '_abbrev_']"
1442,1.0,Sorafenib response was lost in most patients after 72 (range 54-287) days.,"['_chemical_', 'response', 'was', 'lost', 'in', 'most', 'patients', 'after', '_num_', 'range', '_range_', 'days']"
1443,1.0,2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study).,"['_num_', 'of', '_num_', 'patients', 'with', '_gene_', 'mutant', 'melanoma', 'had', 'moderate', 'progressive', 'disease', 'despite', 'receiving', 'the', 'highest', 'doses', 'administered', 'in', 'the', 'study']"
1444,1.0,29 (64%) had a SYT–SSX1 (SS18-SSX1) fusion transcript.,"['_num_', '_num_', 'had', 'a', 'syt–ssx1', '_abbrev_', 'fusion', 'transcript']"
1445,1.0,"7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719.","['_num_', 'patient', 'derived', 'xenografts', 'with', '_gene_', 'mutations', '_mutation_', '_mutation_', '_mutation_', '_mutation_', '_mutation_', 'were', 'transplanted', 'into', 'mice', 'and', 'treated', 'with', '_chemical_']"
1446,1.0,Retroviral transduction of FGFR1 wild type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation.,"['retroviral', 'transduction', 'of', '_gene_', 'wild', 'type', 'or', 'the', '_gene_', '_mutation_', 'mutant', 'into', '_chemical_', 'cells', 'led', 'to', 'enhanced', 'proliferation', 'especially', 'for', 'cells', 'harboring', 'the', '_gene_', 'mutation']"
1447,1.0,A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment.,"['a', '_age_', 'man', 'presented', 'with', 'oral', 'papillary', 'adenocarcinoma', 'and', 'lung', 'metastases', 'that', 'were', 'refractory', 'to', 'standard', 'treatment']"
1448,1.0,Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.,"['_disease_', 'analysis', 'of', 'studies', 'involving', 'cytogentically', 'normal', 'younger', '_num_', 'patients', 'showed', 'reduced', 'overall', 'and', 'relapse', 'free', 'survival', 'for', 'patients', 'with', '_gene_']"
1449,1.0,Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'patient', 'with', 'recurrent', 'low', 'grade', 'serous', 'ovarian', 'cancer']"
1450,1.0,"After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.","['after', 'adjusting', 'for', 'age', 'and', 'cancer', 'stage', 'presence', 'of', '_gene_', 'mutation', 'such', 'as', '_abbrev_', 'is', 'prognostic', 'for', 'poorer', 'survival', 'outcomes', 'in', 'patients', 'with', 'mds']"
1451,1.0,This paper identified run-on mutations in 5 members of 4 distinct families.,"['this', 'paper', 'identified', 'run', 'on', 'mutations', 'in', '_num_', 'members', 'of', '_num_', 'distinct', 'families']"
1452,1.0,"Median overall survival was 15.9 months (95% CI, 11.6 to 18.3).","['median', 'overall', 'survival', 'was', '_num_', 'months', '_num_', 'ci', '_num_', 'to', '_num_']"
1453,1.0,"HER2 copy number status was significantly correlated with respoinse rate, PFS and OS.","['_gene_', 'copy', 'number', 'status', 'was', 'significantly', 'correlated', 'with', 'respoinse', 'rate', '_disease_', 'and', 'os']"
1454,1.0,This mutation was detected in a previously diagnosed VHL patient by DHPLC (VHL 73).,"['this', 'mutation', 'was', 'detected', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', '_gene_', '_num_']"
1455,1.0,"Prior to identification of the MET splice site mutation, the patient was treated with stereotactic radiotherapy, palliative radiation, and a single cycle of pemetrexed; subsequently, the patient was treated with crizotinib, but progressed at 8 weeks of treatment.","['prior', 'to', 'identification', 'of', 'the', 'met', 'splice', 'site', 'mutation', 'the', 'patient', 'was', 'treated', 'with', 'stereotactic', 'radiotherapy', 'palliative', 'radiation', 'and', 'a', 'single', 'cycle', 'of', '_chemical_', 'subsequently', 'the', 'patient', 'was', 'treated', 'with', '_chemical_', 'but', 'progressed', 'at', '_num_', 'weeks', 'of', 'treatment']"
1456,0.0,TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models.,"['_gene_', '_gene_', 'silencing', 'sensitized', 'lung', 'cancer', 'cells', 'to', '_chemical_', 'in', 'preclinical', 'xenograft', 'models']"
1457,1.0,The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had prior chemotherapy for metastatic disease (although adjuvant or neoadjuvant chemotherapy was permitted) and included 160 patients with lung adenocarcinoma subtype.,"['the', 'phase', '_num_', 'eurtac', 'study', 'consisted', 'of', 'of', '_num_', 'non', 'small', 'cell', 'lung', 'cancer', 'patients', 'who', 'had', 'not', 'had', 'prior', 'chemotherapy', 'for', 'metastatic', 'disease', 'although', 'adjuvant', 'or', 'neoadjuvant', 'chemotherapy', 'was', 'permitted', 'and', 'included', '_num_', 'patients', 'with', 'lung', 'adenocarcinoma', 'subtype']"
1458,1.0,Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML.,"['mutations', 'in', '_gene_', 'were', 'associated', 'with', 'increased', 'risk', 'of', 'recurrence', 'in', 'young', 'patients', '_range_', 'with', 'cytogenetically', 'normal', '_disease_']"
1459,1.0,The same dose dependent responses were not observed with KIT exon 11 mutations (N=130 vs 118; P=0.25; HR 0.821; 95% CI 0.585–1.151) or with wild type KIT (N=25 vs 27; P=0.07; HR 1.823; 95% CI 0.938–3.543).,"['the', 'same', 'dose', 'dependent', 'responses', 'were', 'not', 'observed', 'with', 'kit', 'exon', '_num_', 'mutations', '_ineq_', 'vs', '_num_', '_p_val_', 'hr', '_num_', '_num_', 'ci', '_num_', '585–1', '_num_', 'or', 'with', 'wild', 'type', 'kit', '_ineq_', 'vs', '_num_', '_p_val_', 'hr', '_num_', '_num_', 'ci', '_num_', '938–3', '_num_']"
1460,1.0,The patient was started on crizotinib again and had a clinical response that lasted for 6 months.,"['the', 'patient', 'was', 'started', 'on', '_chemical_', 'again', 'and', 'had', 'a', 'clinical', 'response', 'that', 'lasted', 'for', '_num_', 'months']"
1461,1.0,"In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.","['in', 'a', 'study', 'of', '_num_', 'african', 'american', 'and', 'caucasian', 'patients', 'endometrial', 'adenocarcinoma', 'samples', 'were', 'assessed', 'for', '_gene_', 'via', '_gene_', 'staining', 'and', 'association', 'studies', 'were', 'performed', 'using', 'corresponding', 'patient', 'information']"
1462,1.0,"In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab.","['in', '_gene_', 'positive', '_chemical_', 'sensitive', '_abbrev_', 'cells', 'overexpression', 'of', '_gene_', 'blunted', 'sensitivity', 'to', '_chemical_']"
1463,1.0,MEK inhibition with AZD6244 (selumetinib) had some efficacy but was also less active than in NF1 proficient cells.,"['mek', 'inhibition', 'with', '_chemical_', '_chemical_', 'had', 'some', 'efficacy', 'but', 'was', 'also', 'less', 'active', 'than', 'in', '_gene_', 'proficient', 'cells']"
1464,1.0,High protein expression was correlated with poor response to paclitaxel but not other chemotherapy.,"['high', 'protein', 'expression', 'was', 'correlated', 'with', 'poor', 'response', 'to', '_chemical_', 'but', 'not', 'other', 'chemotherapy']"
1465,1.0,No responses were seen 36 patients without known FGFR pathway aberrations.,"['no', 'responses', 'were', 'seen', '_num_', 'patients', 'without', 'known', '_gene_', 'pathway', 'aberrations']"
1466,1.0,Amphiregulin (AREG) production was identified as a potential mediator of EGFR-activation (no other alterations detectable).,"['_gene_', '_gene_', 'production', 'was', 'identified', 'as', 'a', 'potential', 'mediator', 'of', '_gene_', 'activation', 'no', 'other', 'alterations', 'detectable']"
1467,1.0,An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals.,"['an', 'investigation', 'of', '_num_', '_gene_', 'patients', 'without', 'large', 'deletions', 'for', 'intragenic', 'mutations', 'revealed', '_num_', 'different', 'mutations', 'in', '_num_', 'unrelated', 'individuals']"
1468,1.0,"A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.","['a', 'missense', 'mutation', 'affecting', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'with', 'retinal', 'angiomas', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
1469,1.0,Median PFS in KRAS wild type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02).,"['median', '_disease_', 'in', '_gene_', 'wild', 'type', 'patients', 'was', 'significantly', 'longer', 'than', 'in', '_gene_', '_gene_', 'patients', 'hr', '_num_', '_num_', 'confidence', 'interval', 'ci', '_range_', 'p', '_num_']"
1470,1.0,"Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations.","['those', 'with', '_gene_', 'but', 'not', 'nras', 'mutations', 'had', 'worse', 'overall', 'median', '_num_', 'vs', '_num_', 'months', '_p_val_', 'and', 'progression', 'free', 'survival', 'median', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'than', 'those', 'without', 'mutations']"
1471,1.0,"While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.","['while', 'cancer', 'with', '_gene_', '_mutation_', 'mutation', 'is', 'known', 'to', 'be', 'sensitive', 'to', '_chemical_', 'double', 'mutation', 'of', '_mutation_', 'and', '_mutation_', 'mutants', 'are', 'resistant', 'to', '_chemical_']"
1472,1.0,142 (19%) tumors showed HIF1A overexpression.,"['_num_', '_num_', 'tumors', 'showed', '_gene_', 'overexpression']"
1473,1.0,A reciprocal relationship between FBXW7 or PTEN loss was identified in breast cancer tumors and cell lines (mutual exclusivity of these two events).,"['a', 'reciprocal', 'relationship', 'between', '_gene_', 'or', '_gene_', 'loss', 'was', 'identified', 'in', 'breast', 'cancer', 'tumors', 'and', 'cell', 'lines', 'mutual', 'exclusivity', 'of', 'these', '_num_', 'events']"
1474,1.0,"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib.","['in', 'patients', 'with', 'non', 'small', 'cell', 'lung', 'cancer', 'harboring', '_chemical_', 'fusion', 'the', '_mutation_', 'variant', 'has', 'been', 'shown', 'to', 'confer', 'resistance', 'to', '_chemical_']"
1475,1.0,"IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01).","['_gene_', 'mutations', 'were', 'associated', 'with', 'improved', 'rate', 'of', 'response', 'to', '_chemical_', 'as', 'compared', 'to', 'patients', 'with', 'wildtype', '_gene_', '_num_', 'vs', '_num_', '_p_val_']"
1476,1.0,Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells).,"['deep', 'sequencing', 'revealed', 'an', '_gene_', '_abbrev_', 'mutation', 'in', '_gene_', 'resistant', 'clones', '_gene_', 'cells']"
1477,1.0,Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC.,"['case', 'report', 'on', 'a', 'novel', '_mutation_', 'mutation', 'located', 'in', 'exon', '_num_', 'of', 'the', '_gene_', 'tyrosine', 'kinase', 'domain', 'and', 'found', 'in', 'the', 'tumor', 'specimen', 'of', 'an', 'adolescent', 'patient', 'with', 'a', 'chemotherapy', 'resistant', 'advanced', '_disease_']"
1478,1.0,"In the uveal melanoma cohort, 61% of patients (14/23, 61%) had SD at week 12.","['in', 'the', 'uveal', 'melanoma', 'cohort', '_num_', 'of', 'patients', '_ratio_', '_num_', 'had', 'sd', 'at', 'week', '_num_']"
1479,1.0,The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%).,"['the', '_gene_', 'mutation', 'spectra', 'concerned', 'mainly', '_num_', 'point', 'mutations', 'in', '_num_', 'codons', '_num_', 'and', '_num_', '_mutation_', 'was', 'identified', 'in', '_num_', 'cases', '_num_', '_mutation_', 'was', 'identified', 'in', '_num_', 'samples', '_num_', 'and', '_mutation_', 'was', 'identified', 'in', '_num_', 'samples', '_num_']"
1480,1.0,A FGFR1 N546K mutation was detected in one patient.,"['a', '_gene_', '_mutation_', 'mutation', 'was', 'detected', 'in', '_num_', 'patient']"
1481,1.0,"In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival.","['in', 'a', 'large', 'cohort', 'of', '_disease_', 'patients', 'mean', '_num_', 'years', '_gene_', 'mutation', '_num_', 'of', 'which', 'were', '_abbrev_', 'had', 'no', 'prognostic', 'value', 'on', 'overall', 'relapse', 'free', 'and', 'event', 'free', 'survival']"
1482,1.0,Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.,"['mutation', 'status', 'of', '_gene_', 'did', 'not', 'change', 'event', 'free', 'survival', 'of', 'patients', 'with', 'an', '_gene_', 'mutation']"
1483,1.0,"Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing.","['tissue', 'samples', 'were', 'divided', 'into', 'high', 'grade', 'and', 'low', 'grade', 'for', '_chemical_', '_gene_', '_gene_', 'expression', 'and', 'tested', 'for', '_gene_', '_disease_', 'by', 'sequencing']"
1484,1.0,"This missense mutation (p.C162R) was found in a 30 year old Korean female with hemangioblastomas of the central nervous system, retinal hemangioblastomas, and renal cell carcinoma (patient no 7).","['this', 'missense', 'mutation', 'p', '_abbrev_', 'was', 'found', 'in', 'a', '_num_', 'year', 'old', 'korean', 'female', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'retinal', '_disease_', 'and', 'renal', 'cell', 'carcinoma', 'patient', 'no', '_num_']"
1485,1.0,CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts.,"['_gene_', 'and', '_gene_', 'immmunostaining', 'were', 'maintained', 'between', 'original', 'tumor', 'and', '_gene_', 'xenografts']"
1486,1.0,The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines.,"['the', '_gene_', 'inhibitor', 'ribociclib', '_chemical_', 'acted', 'synergistically', 'with', '_gene_', 'inhibitor', 'to', 'reduce', 'viability', 'in', 'all', '_num_', 'resistant', 'cell', 'lines']"
1487,1.0,"In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991).","['in', 'mantle', 'cell', 'lymphoma', '_gene_', 't', '_ratio_', '', 'induced', 'overexpression', 'of', '_gene_', '_gene_', 'was', 'targeted', 'by', '_gene_', 'inhibitor', '_chemical_', '_chemical_']"
1488,1.0,Sensitivity was determined by assessing cell growth.,"['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'growth']"
1489,1.0,"The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3.","['the', 'patient', 'was', 'diagnosed', 'with', 'splenic', '_gene_', 'diffuse', 'large', 'b', 'cell', 'lymphoma', '_disease_', 'stage', 'iii', 'group', 'a', 'with', 'an', '_gene_', 'of', '_num_']"
1490,1.0,"The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L).","['the', 'cell', 'line', '_abbrev_', 'with', '_gene_', 'mutation', '_abbrev_', 'was', 'hypersensitive', 'to', '_gene_', 'treatment', '_abbrev_', 'of', '_num_', '_unit_', '_unit_']"
1491,1.0,AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.,"['_disease_', 'patients', 'with', '_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_abbrev_', 'showed', 'worse', 'survival', 'event', 'free', 'and', 'overall', 'outcome', 'than', 'those', 'without', '_gene_', 'mutation']"
1492,1.0,31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE).,"['_num_', 'breast', 'cancer', 'cell', 'lines', 'for', 'in', 'vitro', 'sensitivity', 'to', '_chemical_', 'and', 'monomethyl', '_chemical_', 'e', 'mmae']"
1493,1.0,"In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy.","['in', 'stage', 'iv', 'lung', 'adenocarcinoma', 'patients', '_gene_', 'harboring', '_gene_', '_mutation_', 'mutation', '_gene_', '_mutation_', 'was', 'associated', 'with', 'progressive', 'disease', 'after', '_num_', 'month', 'of', '_chemical_', 'monotherapy', 'the', 'patient', 'was', 'previously', 'treated', 'with', 'standard', 'chemotherapy']"
1494,1.0,A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples.,"['a', 'subgroup', 'of', '_gene_', 'breast', 'cancer', 'patients', 'that', 'received', '_num_', 'line', '_chemical_', 'treatment', 'were', 'assessed', 'for', '_gene_', 'loss', 'via', '_gene_', 'of', '_disease_', 'samples']"
1495,1.0,9 patients had either a GNAQ (n=5) or GNA11 (n=4) mutation; only 10 patients were analyzed.,"['_num_', 'patients', 'had', 'either', 'a', '_gene_', '_gene_', 'or', '_gene_', '_gene_', 'mutation', 'only', '_num_', 'patients', 'were', 'analyzed']"
1496,1.0,This missense mutation was detected in VHL type 1 patient (Family ID 3618 in publication) with cerebellar hemangioblastomas.,"['this', 'missense', 'mutation', 'was', 'detected', 'in', '_gene_', 'type', '_num_', 'patient', 'family', 'id', '_num_', 'in', 'publication', 'with', 'cerebellar', '_disease_']"
1497,1.0,The study found mir-218 was significantly under-expressed when compared to matched adjacent normal tissue in 107 samples via qPCR.,"['the', 'study', 'found', '_abbrev_', 'was', 'significantly', 'under', 'expressed', 'when', 'compared', 'to', 'matched', 'adjacent', 'normal', 'tissue', 'in', '_num_', 'samples', 'via', 'qpcr']"
1498,1.0,"Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation.","['_chemical_', 'is', 'effective', 'in', 'patients', 'with', '_gene_', 'internal', 'tandem', 'repeats', 'but', 'not', 'in', 'wild', 'type', 'or', '_abbrev_', 'mutation']"
1499,0.0,"Eleven had prompt responses, 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase-polymerase chain reaction (RT-PCR).","['_num_', 'had', 'prompt', 'responses', '_num_', 'had', 'complete', 'resolution', 'of', 'cytogenetic', 'abnormalities', 'and', 'decrease', 'or', 'disappearance', 'of', 'fusion', 'transcripts', 'as', 'measured', 'by', 'reverse', 'transcriptase', 'polymerase', 'chain', 'reaction', '_disease_']"
1500,1.0,"In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.","['in', 'a', 'retrospective', 'study', 'of', 'patients', 'with', 'esophageal', 'carcinoma', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'worse', 'overall', 'survival']"
1501,1.0,The second patient received panitumumab with FOLFOX and showed no signs of progression for 8 months with reduction of the size of metastases.,"['the', '_num_', 'patient', 'received', 'panitumumab', 'with', '_chemical_', 'and', 'showed', 'no', 'signs', 'of', 'progression', 'for', '_num_', 'months', 'with', 'reduction', 'of', 'the', 'size', 'of', 'metastases']"
1502,1.0,"HCC1954 xenografts showed increased tumor volume with treatment of alpelisib or SGK1-Inh alone, but only combination treatment resulted in lack of volume increase and decreased phospho-S6K levels in tumors by IHC.","['_abbrev_', 'xenografts', 'showed', 'increased', 'tumor', 'volume', 'with', 'treatment', 'of', 'alpelisib', 'or', '_abbrev_', 'alone', 'but', 'only', 'combination', 'treatment', 'resulted', 'in', 'lack', 'of', 'volume', 'increase', 'and', 'decreased', '_gene_', 'levels', 'in', 'tumors', 'by', '_gene_']"
1503,1.0,There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.,"['there', 'was', 'no', 'significant', 'difference', 'in', 'the', 'median', 'post', 'progression', 'or', 'overall', 'survival', 'between', 'patients', 'with', '_mutation_', 'mutation', 'and', 'without', '_mutation_', 'mutation', 'for', 'initial', '_disease_', 'treatment']"
1504,1.0,This nonsense mutation was found in 2 unrelated families.,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', '_num_', 'unrelated', 'families']"
1505,1.0,"In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS.","['in', 'patients', 'with', 'diffuse', 'large', 'b', 'cell', 'lymphoma', 'those', 'with', 'increased', 'levels', 'of', '_gene_', 'were', 'shown', 'to', 'have', 'decreased', 'os', '_disease_', 'and', 'rfs']"
1506,1.0,"Patients with PIK3CA somatic mutations on aspirin treatment were associated with an improved response (cancer-specific survival : HR:0.18, 95%CI:0.06-0.61, P<0.001, multivariate analysis for cancer-related death) and an improved overall survival (HR:0.54, 95%CI:0.31-0.94, P=0.01, multivariate analysis for death from any cause) when compared to those patients with PIK3CA mutations that did not use aspirin after diagnosis.","['patients', 'with', '_gene_', 'somatic', 'mutations', 'on', 'aspirin', 'treatment', 'were', 'associated', 'with', 'an', 'improved', 'response', '_disease_', 'survival', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'multivariate', 'analysis', 'for', '_disease_', 'death', 'and', 'an', 'improved', 'overall', 'survival', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'multivariate', 'analysis', 'for', 'death', 'from', 'any', 'cause', 'when', 'compared', 'to', 'those', 'patients', 'with', '_gene_', 'mutations', 'that', 'did', 'not', 'use', 'aspirin', 'after', 'diagnosis']"
1507,1.0,49 out of 9012 male patients in the Mayo Clinic Biobank were carriers.,"['_num_', 'out', 'of', '_num_', 'male', 'patients', 'in', 'the', 'mayo', 'clinic', 'biobank', 'were', 'carriers']"
1508,1.0,"The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients.","['the', '_gene_', '_mutation_', '_abbrev_', '_mutation_', 'homozygous', 'variant', 'was', 'positively', 'correlated', 'with', 'response', 'to', '_chemical_', 'treatment', 'in', 'ovarian', 'cancer', 'patients']"
1509,1.0,43 of these patients were considered to have chronic-phase CML.,"['_num_', 'of', 'these', 'patients', 'were', 'considered', 'to', 'have', '_disease_', '_gene_']"
1510,1.0,Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization inhibitor or an IRAK 1/4 kinase inhibitor.,"['_disease_', '_disease_', 'cells', 'expressing', '_gene_', '_mutation_', 'were', 'treated', 'with', 'an', '_gene_', 'homodimerization', 'inhibitor', 'or', 'an', 'irak', '_ratio_', 'kinase', 'inhibitor']"
1511,1.0,"In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive).","['in', 'a', 'study', 'of', 'invasive', 'ovarian', 'carcinoma', 'patients', 'who', 'had', 'undergone', 'surgery', 'the', '_gene_', 'alteration', 'variant', 'was', 'defined', 'as', '_gene_', 'mutation', 'or', '_gene_', 'overexpression', 'by', 'immunostain', '_num_', 'positive']"
1512,1.0,"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild type PDGFRA.","['in', 'an', 'in', 'vitro', 'study', 'chinese', 'hamster', 'ovary', 'cells', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'reduced', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', 'vs', '_abbrev_', '_num_', 'compared', 'to', 'chinese', 'hamster', 'ovary', 'cells', 'expressing', 'wild', 'type', '_gene_']"
1513,1.0,"Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL.","['administration', 'of', '_unit_', '_unit_', 'd', '_chemical_', 'resulted', 'in', 'complete', 'regression', 'of', 'all', 'tumors', 'indicating', 'that', '_chemical_', 'could', 'be', 'an', 'effective', 'target', 'for', '_chemical_', 'in', '_disease_']"
1514,1.0,"Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1.","['radiation', 'resistant', 'cell', 'lines', 'exhibited', 'upregulation', 'and', 'increased', 'activation', 'of', '_gene_', '_gene_', 'kinase', 'signalling', 'as', 'well', 'as', 'increased', 'expression', 'of', '_gene_']"
1515,1.0,"Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion.","['atypical', 'chronic', 'myeloid', 'leukemia', 'has', 'the', 'same', 'symptoms', 'as', '_gene_', 'but', 'it', 'lacks', 'the', '_abbrev_', 'fusion']"
1516,0.0,Crizotinib was well tolerated in this group of pediatric patients.,"['_chemical_', 'was', 'well', 'tolerated', 'in', 'this', 'group', 'of', 'pediatric', 'patients']"
1517,1.0,"High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser240/4) was associated with higher disease control rate and progression free survival (P=0.043, P=0.001 respectively; N=28).","['high', '_gene_', 'treatment', 'expression', 'of', 'phosphorylated', '_gene_', '_gene_', 'at', '_abbrev_', 'was', 'associated', 'with', 'higher', 'disease', 'control', 'rate', 'and', 'progression', 'free', 'survival', '_p_val_', '_p_val_', 'respectively', '_ineq_']"
1518,1.0,"A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targeted inhibitors.","['a', 'quantitative', 'synthesis', 'was', 'performed', 'on', '_num_', 'studies', 'comparing', 'treatment', 'of', 'metastatic', 'colorectal', 'cancer', 'with', '_chemical_', 'or', 'panitumumab', 'and', 'chemotherapy', 'vs', 'chemotherapy', 'alone', 'or', 'with', 'other', 'targeted', 'inhibitors']"
1519,1.0,"In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.","['in', 'contrast', 'of', 'the', '_num_', 'testing', 'positive', 'for', '_chemical_', 'variant', '_num_', '_num_', 'showed', 'pr', 'and', '_num_', 'showed', 'stable', 'disease']"
1520,1.0,70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment.,"['_num_', 'patients', 'received', 'refametinib', 'bay', '_range_', 'plus', '_chemical_', 'as', 'study', 'treatment']"
1521,1.0,"This missense mutation was found in a VHL type 2B family of 7 individuals (Family ID 4414 in publication).Two of seven individuals were identified with angiomas, 3 with cereballar hemangioblastomas, one with renal cell carcinoma, and one with pheochromocytomas.Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_', 'in', 'publication', '_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cereballar', '_disease_', '_num_', 'with', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'with', 'pheochromocytomas', 'supporting', 'evidence', 'of', 'pathogenicity', 'because', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']"
1522,1.0,ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along with a tendency toward a longer overall survival (p = 0.057).,"['_gene_', '_mutation_', 'carriers', 'had', 'a', 'longer', 'progression', 'free', 'survival', 'p', '_num_', 'along', 'with', 'a', 'tendency', 'toward', 'a', 'longer', 'overall', 'survival', 'p', '_num_']"
1523,1.0,The L248V mutation was moderately resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
1524,1.0,"In cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months.","['in', 'cohort', '_num_', '_num_', 'patients', '_num_', 'achieved', 'a', 'partial', 'response', 'and', 'another', '_num_', 'patients', 'achieved', 'stable', 'disease', 'for', 'at', 'least', '_num_', 'months']"
1525,1.0,"In a 54 year old male patient with sporadic renal cell carcinoma, a c.163_164delGA causing a p.Glu55 Stop at 130 frameshift mutation was observed.","['in', 'a', '_num_', 'year', 'old', 'male', 'patient', 'with', 'sporadic', 'renal', 'cell', 'carcinoma', 'a', 'c', '163_164delga', 'causing', 'a', 'p', '_abbrev_', 'stop', 'at', '_num_', 'frameshift', 'mutation', 'was', 'observed']"
1526,1.0,"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF.","['age', 'sex', 'fab', 'subtype', 'and', 'karyotypes', 'were', 'not', 'statistically', 'significant', 'between', '_disease_', 'patients', 'with', '_gene_', '_abbrev_', 'mutations', 'and', 'those', 'who', 'harbor', 'wild', 'type', '_gene_']"
1527,1.0,"we conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that ""HER2-positive lung cancers"" is not an adequate term to describe this group of distinguishable illnesses.","['we', 'conclude', 'that', 'in', 'the', 'set', 'of', 'activating', '_gene_', 'mutations', 'benefits', 'of', 'an', 'individual', 'agent', 'may', 'be', 'specific', 'to', 'certain', 'mutations', 'and', 'that', '_gene_', 'lung', 'cancers', 'is', 'not', 'an', 'adequate', 'term', 'to', 'describe', 'this', 'group', 'of', 'distinguishable', 'illnesses']"
1528,1.0,"The G1202R ALK mutation was found in a crizotinib-resistant ALK-rearranged NSCLC, and the mutant ALK fusion was further characterized in Ba/F3 cells.","['the', '_mutation_', '_gene_', 'mutation', 'was', 'found', 'in', 'a', '_chemical_', 'resistant', '_gene_', 'rearranged', '_disease_', 'and', 'the', 'mutant', '_gene_', 'fusion', 'was', 'further', 'characterized', 'in', 'ba', '_abbrev_', 'cells']"
1529,1.0,"Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone.","['mean', 'tumor', 'growth', 'was', 'lower', 'in', 'the', 'tumors', 'treated', 'with', '_abbrev_', '_chemical_', '+77', 'vs', '+267', '_p_val_', 'compared', 'to', '_chemical_', 'alone', 'and', '+77', 'vs', '+222', '_p_val_', '_chemical_', 'alone']"
1530,1.0,KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone.,"['_gene_', 'mutation', 'status', 'was', 'assessed', 'in', '_num_', 'tumor', 'samples', 'from', 'colorectal', 'cancer', 'patients', 'who', 'were', 'randomly', 'assigned', 'to', 'receive', '_chemical_', 'plus', 'best', 'supportive', 'care', 'or', 'best', 'supportive', 'care', 'alone']"
1531,1.0,"Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued mutant HER2 induction by doxycycline.","['induction', 'of', 'mutant', '_gene_', 'in', 'these', 'mice', 'drove', 'rapid', 'development', 'of', '_disease_', 'lung', 'tumors', 'where', 'tumor', 'maintenance', 'was', 'dependent', 'on', 'continued', 'mutant', '_gene_', 'induction', 'by', 'doxycycline']"
1532,1.0,Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months.,"['_chemical_', 'treatement', 'led', 'to', 'partial', 'response', 'but', 'no', 'change', 'in', '_gene_', 'ribosomal', 'protein', 'staining', 'for', '_num_', 'months']"
1533,1.0,13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily).,"['_num_', 'patients', 'with', 'relapsed', 'or', 'chemo', 'refractory', '_abbrev_', '_disease_', 'were', 'treated', 'with', '_chemical_', '_range_', '_unit_', 'twice', 'daily']"
1534,1.0,One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study.,"['_num_', 'platinum', 'refractory', 'epithelial', 'ovarian', 'cancer', 'patient', 'with', '_gene_', 'loss', 'and', '_gene_', 'amplification', 'had', 'a', 'partial', 'response', 'on', 'treatment', 'with', '_gene_', 'inhibitor', 'pictilisib', '_chemical_', 'in', 'this', 'phase', '_num_', 'study']"
1535,1.0,p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.,"['_abbrev_', 'patients', '_disease_', 'negative', 'have', 'a', 'longer', 'overall', 'survival', 'under', 'panitumumab', 'chemotherapy', 'in', 'comparison', 'to', 'chemotherapy', 'alone']"
1536,1.0,"None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%.","['none', 'of', '_num_', 'patients', 'achieved', 'response', 'by', '_disease_', '_num_', 'criteria', 'and', '_num_', 'patients', '_num_', 'were', 'progression', 'free', 'at', '_num_', 'months', 'with', 'disease', 'control', 'rate', 'at', '_num_', 'months', 'reaching', '_num_']"
1537,1.0,The data suggests the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor.,"['the', 'data', 'suggests', 'the', 'role', 'of', '_gene_', '_mutation_', 'cc', 'genotype', 'as', 'a', 'poor', 'predictive', 'marker', 'both', 'of', '_gene_', 'and', '_disease_', 'in', 'advanced', '_disease_', 'patients', 'treated', 'with', 'tyrosine', 'kinase', 'inhibitor']"
1538,1.0,"In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047).","['in', '_num_', '_disease_', 'patients', 'with', '_disease_', 'those', 'who', 'had', 'mutations', 'in', '_gene_', '_ineq_', 'had', 'higher', 'rates', 'of', 'refractory', 'disease', 'than', 'those', 'without', '_num_', 'vs', '_num_', 'p', '_num_']"
1539,1.0,"in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease.","['in', '_num_', 'phase', 'i', 'studies', 'in', 'patients', 'with', 'advanced', 'or', 'metastatic', 'solid', 'tumors', 'including', 'patients', 'with', 'active', 'central', 'nervous', 'system', 'cns', 'disease']"
1540,1.0,"In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower among patients with CDX2 negative tumors (discovery set:hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002; validation set: hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003).","['in', 'the', 'discovery', '_num_', 'patients', 'and', 'validation', 'sets', '_num_', 'patients', '_num_', 'year', '_disease_', 'was', 'lower', 'among', 'patients', 'with', '_gene_', 'negative', 'tumors', 'discovery', 'set', 'hazard', 'ratio', 'for', 'disease', 'recurrence', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', '_p_val_', 'validation', 'set', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_']"
1541,1.0,"In this case report, a patient with metastatic, ALK-rearranged NSCLC with C1156Y mutation had tumor progression under sequential treatment with first crizotinib, then ceritinib and finally AUY922.","['in', 'this', 'case', 'report', 'a', 'patient', 'with', 'metastatic', '_gene_', 'rearranged', '_disease_', 'with', '_mutation_', 'mutation', 'had', 'tumor', 'progression', 'under', 'sequential', 'treatment', 'with', '_num_', '_chemical_', 'then', '_chemical_', 'and', 'finally', '_chemical_']"
1542,1.0,Overexpression of HEF1 protein was observed in HCC tissue when compared with their adjacent non-malignant liver tissue.,"['overexpression', 'of', '_gene_', 'protein', 'was', 'observed', 'in', '_gene_', 'tissue', 'when', 'compared', 'with', 'their', 'adjacent', 'non', 'malignant', 'liver', 'tissue']"
1543,1.0,Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib.,"['non', 'small', 'cell', 'cancer', 'patients', 'from', '_num_', 'studies', 'the', 'archer', '_num_', '_abbrev_', 'and', '_abbrev_', '_abbrev_', 'with', 'exon', '_num_', 'deletion', 'and', '_mutation_', '_gene_', 'exon', '_num_', 'mutations', 'were', 'pooled', 'to', 'compare', 'the', 'efficacy', 'of', '_chemical_', 'to', '_chemical_']"
1544,1.0,S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations.,"['_mutation_', 'mutations', 'in', 'exon', '_num_', 'of', 'the', '_gene_', 'gene', 'are', 'rare', 'and', 'are', 'typically', 'seen', 'in', 'conjunction', 'with', 'sensitizing', '_gene_', 'mutations']"
1545,1.0,The loss was more frequent in clear cell ovarian carcinoma than in the high-grade serous adenocarcinoma.,"['the', 'loss', 'was', 'more', 'frequent', 'in', 'clear', 'cell', 'ovarian', 'carcinoma', 'than', 'in', 'the', 'high', 'grade', 'serous', 'adenocarcinoma']"
1546,1.0,124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.,"['_chemical_', 'esophageal', '_disease_', 'cell', 'carcinoma', 'patients', 'with', 'radical', 'resection', 'were', 'genotyped', 'using', 'massarray']"
1547,0.0,"In conclusion, CTNNB1 mutations are highly common in desmoid tumors.","['in', 'conclusion', '_gene_', 'mutations', 'are', 'highly', 'common', 'in', '_disease_', 'tumors']"
1548,1.0,"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, KRAS mutation was assessed.","['in', 'the', 'placebo', 'controlled', 'phase', 'iii', 'study', 'saturn', 'using', '_chemical_', 'maintenance', 'therapy', 'for', 'patients', 'with', 'advanced', '_disease_', 'who', 'were', 'selected', 'for', 'response', 'or', 'stable', 'disease', 'after', '_num_', 'line', 'chemotherapy', '_gene_', 'mutation', 'was', 'assessed']"
1549,1.0,Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells.,"['cells', 'with', 'an', '_gene_', '_abbrev_', 'mutation', 'demonstrated', 'a', 'reduced', 'response', 'to', '_chemical_', '_abbrev_', '_unit_', 'vs', '_unit_', 'compared', 'to', 'wildtype', '_gene_', 'cells']"
1550,0.0,AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML).,"['_disease_', 'with', 'mutated', '_gene_', 'is', 'a', 'provisional', 'entity', 'in', 'the', 'world', 'health', 'organization', 'who', 'classification', 'of', 'acute', 'myeloid', 'leukemia', '_disease_']"
1551,1.0,An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines.,"['an', 'shdna', 'screen', 'identified', 'synergy', 'between', '_gene_', 'inhibition', 'and', 'mek', 'inhibition', 'in', '_gene_', 'mutated', 'cell', 'lines']"
1552,1.0,The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation.,"['the', 'complete', 'remission', 'and', 'overall', 'survival', 'rates', 'in', 'patients', 'with', '_gene_', '_abbrev_', 'mutation', 'is', 'not', 'significantly', 'different', 'from', 'those', 'who', 'do', 'not', 'have', 'this', 'mutation']"
1553,0.0,Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K.,"['resistance', 'was', 'conferred', 'by', 'the', 'met', 'amplification', 'driving', '_gene_', '_gene_', '', 'dependent', 'activation', 'of', '_gene_']"
1554,1.0,"Upon disease progression, the initial diagnostic biopsy tested positive for ALK-rearrangement using break apart FISH, but the ALK fusion was not sequenced for mutations.","['upon', 'disease', 'progression', 'the', 'initial', 'diagnostic', 'biopsy', 'tested', 'positive', 'for', '_gene_', 'rearrangement', 'using', 'break', 'apart', 'fish', 'but', 'the', '_gene_', 'fusion', 'was', 'not', 'sequenced', 'for', 'mutations']"
1555,1.0,"Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449).","['loss', 'of', 'heterozygosity', 'in', '_gene_', 'driven', '_disease_', 'was', 'associated', 'with', 'increased', '_disease_', 'under', 'therapy', 'with', '_chemical_', '_gene_', '_abbrev_', '_chemical_', '_chemical_']"
1556,1.0,"In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative).","['in', 'the', 'sequential', 'regimen', 'cohort', '_num_', 'of', 'patients', 'had', 'an', 'objective', 'response', 'with', 'a', 'potential', 'correlation', 'between', '_gene_', 'expression', 'and', 'response', '_num_', 'of', '_num_', 'patients', 'were', '_gene_', 'positive', 'vs', '_num_', 'of', '_num_', 'patients', 'were', '_gene_', 'negative']"
1557,0.0,"NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622).","['_gene_', 'copy', 'number', 'gain', 'in', 'a', '_disease_', 'tumor', 'xenograft', 'model', 'of', 'colorectal', 'cancer', 'was', 'associated', 'with', 'increased', '_gene_', 'and', '_gene_', 'activity', 'and', 'response', 'to', 'a', '_abbrev_', 'antibody', '_abbrev_']"
1558,1.0,"All 4 family members carried cerebellar hemangioblastomas, 2 of 4 carried angiomas and one carried renal cell carcinoma.","['all', '_num_', 'family', 'members', 'carried', 'cerebellar', '_disease_', '_num_', 'of', '_num_', 'carried', 'angiomas', 'and', '_num_', 'carried', 'renal', 'cell', 'carcinoma']"
1559,1.0,This was mediated by wild type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21.,"['this', 'was', 'mediated', 'by', 'wild', 'type', '_abbrev_', 'cell', 'arrest', 'under', 'chemotherapy', 'even', 'in', 'the', 'context', 'of', 'heterozygous', '_gene_', 'point', 'mutations', 'or', 'absence', 'of', '_gene_']"
1560,1.0,Objective response and disease control rates were 11% and 39%.,"['objective', 'response', 'and', 'disease', 'control', 'rates', 'were', '_num_', 'and', '_num_']"
1561,1.0,A majority of the mutations are in the C-terminal domain with the most frequent location being K700E (50% of reported cases).,"['a', 'majority', 'of', 'the', 'mutations', 'are', 'in', 'the', '_disease_', 'domain', 'with', 'the', 'most', 'frequent', 'location', 'being', '_mutation_', '_num_', 'of', 'reported', 'cases']"
1562,1.0,"Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.","['of', 'these', '_num_', 'had', 'partial', 'response', 'pr', 'and', '_num_', 'had', 'disease', 'progression', 'dp', 'and', 'this', 'was', 'the', 'only', 'dp', 'in', 'the', 'group', 'of', '_num_']"
1563,1.0,"She then started alectinib at 600 mg twice daily with partial response, but new liver metastases then formed at 5 months.","['she', 'then', 'started', '_chemical_', 'at', '_num_', '_unit_', 'twice', 'daily', 'with', 'partial', 'response', 'but', 'new', 'liver', 'metastases', 'then', 'formed', 'at', '_num_', 'months']"
1564,1.0,"DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients.","['_gene_', '_abbrev_', 'mutations', 'were', 'associated', 'with', 'older', 'age', 'higher', 'white', 'blood', 'cell', 'count', 'and', 'fab', '_gene_', 'and', '_gene_', '_disease_', 'compared', 'to', 'wildtype', '_gene_', 'in', 'a', 'cohort', 'of', 'cytogenetically', 'normal', '_disease_', 'patients']"
1565,1.0,we considered a fold difference of 4 to 10 between the alectinib-sensitized wild type and mutant variant to indicate a resistant mutant variant.,"['we', 'considered', 'a', 'fold', 'difference', 'of', '_num_', 'to', '_num_', 'between', 'the', '_chemical_', 'sensitized', 'wild', 'type', 'and', 'mutant', 'variant', 'to', 'indicate', 'a', 'resistant', 'mutant', 'variant']"
1566,1.0,KRAS G12C occur more frequently in women than men.,"['_gene_', '_mutation_', 'occur', 'more', 'frequently', 'in', 'women', 'than', 'men']"
1567,1.0,"NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer.","['_gene_', '_disease_', 'mutations', 'including', '_abbrev_', 'have', 'shown', 'to', 'be', 'correlated', 'to', 'poor', 'prognosis', 'in', 'lung', 'cancer']"
1568,1.0,"No difference was observed in OS (HR, 1.00; 95% CI, 0.82 to 1.22), but 76% of BSC patients entered the cross-over study.","['no', 'difference', 'was', 'observed', 'in', 'os', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'but', '_num_', 'of', '_gene_', 'patients', 'entered', 'the', '_disease_', 'study']"
1569,1.0,"In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', '_gene_', 'lung', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_abbrev_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
1570,1.0,Stable disease lasting ≥24 weeks was achieved for 31% (9/29) with KRAS-mutant disease vs 12% (4/33) with KRAS wild type disease.,"['stable', 'disease', 'lasting', '_ineq_', 'weeks', 'was', 'achieved', 'for', '_num_', '_ratio_', 'with', '_gene_', 'mutant', 'disease', 'vs', '_num_', '_ratio_', 'with', '_gene_', 'wild', 'type', 'disease']"
1571,1.0,Over-expression was also associated with resistance in various lung cancer cell lines.,"['over', 'expression', 'was', 'also', 'associated', 'with', 'resistance', 'in', 'various', 'lung', 'cancer', 'cell', 'lines']"
1572,1.0,"In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs. 82%), as well as higher CR achievement failure and early death.","['in', 'a', 'study', 'of', '_num_', '_gene_', 'patients', 'treated', 'with', 'combination', 'atra', '_chemical_', 'chemotherapy', '_gene_', '_gene_', 'mutations', '_ineq_', 'were', 'associated', 'with', 'lower', '_num_', 'year', 'os', 'compared', 'to', 'the', '_gene_', 'itd', 'negative', 'group', '_num_', 'vs', '_num_', 'as', 'well', 'as', 'higher', 'cr', 'achievement', 'failure', 'and', 'early', 'death']"
1573,1.0,"In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3.","['in', 'young', '_disease_', 'patients', '_num_', 'years', 'old', '_gene_', 'mutations', 'were', 'associated', 'with', 'significantly', 'reduced', 'overall', 'survival', 'and', 'relapse', 'free', 'survival', 'in', 'patients', 'wildtype', 'for', '_gene_', 'and', '_gene_']"
1574,1.0,Peripheral blood from NPM1 mutated AMLs was assessed for NPM1 mutation status at multiple time points using RT-qPCR with primers designed to amplify different mutant NPM1 transcripts.,"['peripheral', 'blood', 'from', '_gene_', 'mutated', '_disease_', 'was', 'assessed', 'for', '_gene_', 'mutation', 'status', 'at', 'multiple', 'time', 'points', 'using', '_disease_', 'with', 'primers', 'designed', 'to', 'amplify', 'different', 'mutant', '_gene_', 'transcripts']"
1575,1.0,"In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expression.","['in', 'patients', 'with', 'ovarian', 'carcinomas', 'those', 'with', 'aurora', 'kinase', 'a', 'expression', 'as', 'measured', 'by', 'immunohistochemistry', 'had', 'increased', 'progression', 'free', 'and', 'overall', 'survival', 'compared', 'to', 'those', 'without', 'expression']"
1576,1.0,This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'for', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'frameshift', 'mutation', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
1577,1.0,"More specifically, genetic testing demonstrated the above mutation (X214LextX15) in 3 individuals in 2 separate families.","['more', 'specifically', 'genetic', 'testing', 'demonstrated', 'the', 'above', 'mutation', '_abbrev_', 'in', '_num_', 'individuals', 'in', '_num_', 'separate', 'families']"
1578,1.0,This mutation was found in 3 family members and an unrelated patient.,"['this', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'and', 'an', 'unrelated', 'patient']"
1579,1.0,"The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib.","['the', 'melanoma', 'cell', 'line', '_abbrev_', 'which', 'harbors', 'the', '_mutation_', 'mutation', 'is', 'sensitive', 'to', '_chemical_']"
1580,1.0,FLT3-ITD was evaluated in 531 patients (164 mutated).,"['_gene_', 'was', 'evaluated', 'in', '_num_', 'patients', '_num_', 'mutated']"
1581,1.0,This difference was largely driven by the subgroup of patients with reduced response to gemcitabine-erlotinib combination therapy (7.5% vs 23.3%) with overall survival of 5.2 vs 9.7 months (N=40 vs 30) compared to those that received other therapies with an overall survival of 7.0 months for both KRAS mutated (N=31) and KRAS wildtype (N=35) patients.,"['this', 'difference', 'was', 'largely', 'driven', 'by', 'the', 'subgroup', 'of', 'patients', 'with', 'reduced', 'response', 'to', '_chemical_', 'combination', 'therapy', '_num_', 'vs', '_num_', 'with', 'overall', 'survival', 'of', '_num_', 'vs', '_num_', 'months', '_ineq_', 'vs', '_num_', 'compared', 'to', 'those', 'that', 'received', 'other', 'therapies', 'with', 'an', 'overall', 'survival', 'of', '_num_', 'months', 'for', 'both', '_gene_', 'mutated', '_ineq_', 'and', '_gene_', 'wildtype', '_ineq_', 'patients']"
1582,1.0,"In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel.","['in', 'a', 'randomized', 'phase', '_num_', 'trial', '_gene_', 'positive', 'metastatic', 'breast', 'cancer', 'patients', 'given', '_num_', 'line', 'treatment', 'of', 'pertuzumab', 'plus', 'trastuzumb', 'plus', '_chemical_', 'experienced', 'improved', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'and', 'increased', 'objective', 'response', 'rate', '_num_', 'vs', '_num_', '_p_val_', 'than', 'the', 'control', 'group', 'given', 'placebo', 'plus', '_chemical_', 'plus', '_chemical_']"
1583,1.0,"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line expressing the Y253H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', '_abbrev_', '_gene_', 'cell', 'line', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment']"
1584,1.0,"In patients with FGFR2-BICC1 fusions, 1 patient with urothelial cancer harboring FGFR2-BICC1/FGFR2-CASP7 fusions had a PR.","['in', 'patients', 'with', '_abbrev_', 'fusions', '_num_', 'patient', 'with', 'urothelial', 'cancer', 'harboring', '_abbrev_', 'fusions', 'had', 'a', 'pr']"
1585,1.0,G84E (rs138213197) substitution in HOXB13 is associated with an increased risk for prostate cancer.,"['_mutation_', '_mutation_', 'substitution', 'in', '_gene_', 'is', 'associated', 'with', 'an', 'increased', 'risk', 'for', 'prostate', 'cancer']"
1586,1.0,Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.,"['participants', 'had', 'progressed', 'under', 'previous', 'treatment', 'and', 'only', 'a', 'small', 'percentage', 'had', 'seen', '_num_', 'line', '_chemical_']"
1587,1.0,This mutation causes stop codon at amino acid 131 and was found in VHL type 1 patient (kindred no 110).,"['this', 'mutation', 'causes', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', '_gene_', 'type', '_num_', 'patient', 'kindred', 'no', '_num_']"
1588,1.0,Mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs.,"['mutational', 'analysis', 'of', '_gene_', 'and', '_gene_', 'and', 'evaluation', 'of', 'the', '_gene_', 'protein', 'status', 'in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', '_disease_', 'treated', 'with', 'anti', '_gene_', 'moabs']"
1589,1.0,Heterozygotes had an OR of 1.02 (95% CI 0.86-1.20).,"['heterozygotes', 'had', 'an', 'or', 'of', '_num_', '_num_', 'ci', '_range_']"
1590,1.0,"In contrast, the frequently used tool compound TAE684 was equally effective against EML4-ALK wild type and I1171T, causing cell death at 1000x lower concentration then in unaltered Ba/F3 cells supplemented with IL3.","['in', 'contrast', 'the', 'frequently', 'used', 'tool', 'compound', '_chemical_', 'was', 'equally', 'effective', 'against', '_chemical_', 'wild', 'type', 'and', '_mutation_', 'causing', 'cell', 'death', 'at', '1000x', 'lower', 'concentration', 'then', 'in', 'unaltered', 'ba', '_abbrev_', 'cells', 'supplemented', 'with', '_gene_']"
1591,1.0,15 (13.6%) PIK3CA mutations were observed.,"['_num_', '_num_', '_gene_', 'mutations', 'were', 'observed']"
1592,1.0,"In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis.","['in', 'patients', 'classified', 'as', 'intermediate', 'risk', 'via', 'cytogenetics', '_gene_', 'mutations', 'have', 'been', 'shown', 'to', 'be', 'correlated', 'with', 'poor', 'prognosis']"
1593,1.0,"In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.","['in', 'the', '_num_', 'case', 'a', '_num_', 'pack', 'year', 'patient', 'showed', 'intense', 'non', 'mutant', '_gene_', 'expression', 'by', '_gene_', 'without', 'dna', 'amplification', 'and', 'had', 'undergone', 'multiple', 'prior', 'lines', 'of', 'treatment']"
1594,0.0,"The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC.","['the', 'investigators', 'conclude', 'there', 'is', 'promise', 'in', '_chemical_', 'based', 'therapies', 'in', 'advanced', 'endometrial', 'cancers', 'including', '_disease_']"
1595,1.0,"Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild type CD74–ROS1; however, showed similar sensitivity to foretinib.","['ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', '_mutation_', 'mutation', 'showed', 'resistance', 'to', '_chemical_', '_num_', 'fold', 'higher', '_abbrev_', 'value', 'compared', 'with', 'those', 'expressing', 'wild', 'type', '_abbrev_', 'however', 'showed', 'similar', 'sensitivity', 'to', '_chemical_']"
1596,1.0,"Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC.","['genomic', '_disease_', 'identified', 'fusion', 'breakpoints', 'and', 'these', 'differed', 'from', 'breakpoints', 'for', 'these', '_chemical_', 'variants', 'reported', 'in', '_disease_']"
1597,1.0,A pedigree (Pedigree number 2) with familial platelet disorder and acute myeloid leukemia (FPD/AML) was studied and a one-base deletion was found in RUNX1 splice donor site.,"['a', 'pedigree', 'pedigree', 'number', '_num_', 'with', 'familial', 'platelet', 'disorder', 'and', 'acute', 'myeloid', 'leukemia', '_disease_', 'was', 'studied', 'and', 'a', '_num_', 'base', 'deletion', 'was', 'found', 'in', '_gene_', 'splice', 'donor', 'site']"
1598,1.0,"NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer.","['_gene_', '_disease_', 'mutations', 'including', '_abbrev_', 'have', 'shown', 'to', 'be', 'correlated', 'to', 'poor', 'prognosis', 'in', 'lung', 'cancer']"
1599,1.0,"In early 2016, alectinib was approved by the FDA partly based on this study for treatment of crizotinib-progressed ALK positive NSCLC","['in', 'early', '_year_', '_chemical_', 'was', 'approved', 'by', 'the', 'fda', 'partly', 'based', 'on', 'this', 'study', 'for', 'treatment', 'of', '_chemical_', 'progressed', '_gene_', 'positive', '_disease_']"
1600,1.0,"Since levels of up to 1 µM of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib.","['since', 'levels', 'of', 'up', 'to', '_num_', 'µm', 'of', '_chemical_', 'may', 'be', 'achieved', 'in', 'patients', '_abbrev_', '_abbrev_', 'and', '_abbrev_', 'mutations', 'might', 'respond', 'to', 'higher', 'doses', 'of', '_chemical_']"
1601,1.0,"Three of 8 individuals were identified with angiomas, 5 with cerebellar hemangioblastomas, and 2 with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
1602,1.0,"In TCGA samples, ALK ATI was expressed in approx 11% of melanoma samples.","['in', '_disease_', 'samples', '_gene_', '_gene_', 'was', 'expressed', 'in', 'approx', '_num_', 'of', 'melanoma', 'samples']"
1603,1.0,"Of the 290 patients, 213 had a low ARID1A expression and 77 patients had a high expression.","['of', 'the', '_num_', 'patients', '_num_', 'had', 'a', 'low', '_gene_', 'expression', 'and', '_num_', 'patients', 'had', 'a', 'high', 'expression']"
1604,1.0,"121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose.","['_num_', 'patients', 'with', '_gene_', 'overexpressing', 'breast', 'cancer', 'with', 'cns', 'recurrence', 'or', 'regression', 'who', 'had', 'previously', 'progressed', 'on', '_chemical_', 'or', '_chemical_', 'were', 'assigned', 'to', '_num_', 'arms', 'with', 'endpoint', 'in', 'the', '_disease_', 'population', 'being', 'patient', 'benefit', 'at', '_num_', 'weeks', 'defined', 'as', 'absence', 'of', 'cns', 'or', 'extra', 'cns', 'progression', 'no', 'tumor', 'related', 'worsening', 'of', 'neurological', 'symptoms', 'and', 'no', 'increase', 'in', 'corticosteroid', 'dose']"
1605,1.0,"Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.","['notably', 'a', 'complete', 'cns', 'response', 'was', 'achieved', 'in', 'a', 'patient', 'with', '_abbrev_', 'lung', 'cancer']"
1606,1.0,"L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.","['_mutation_', '_gene_', 'cells', 'had', 'very', 'low', '_abbrev_', '_unit_', '_unit_', 'values', 'for', 'all', '_num_', 'inhibitors', 'in', 'comparison', 'to', 'other', 'constructs', '_ineq_', '_ineq_', '_ineq_', 'indicating', 'sensitivity', 'to', 'all', '_num_', 'constructs']"
1607,1.0,"Two patients had confirmed partial responses, and 2 showed stable disease over 6 months.","['_num_', 'patients', 'had', 'confirmed', 'partial', 'responses', 'and', '_num_', 'showed', 'stable', 'disease', 'over', '_num_', 'months']"
1608,1.0,Glioblastoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.,"['glioblastoma', 'cell', 'lines', 'were', 'shown', 'to', 'have', 'increased', 'sensitivity', 'to', '_chemical_', 'when', 'sirna', 'induced', 'atm', 'knockdown', 'was', 'applied']"
1609,1.0,"EML4-ALK F1245C clones from the selection assay had IC50 viability value of 425 +/- 100 nM, while Ba/F3 cells expressing reintroduced EML4-ALK F1245C had IC50 value of 269 +/- 194 nM.","['_chemical_', '_mutation_', 'clones', 'from', 'the', 'selection', 'assay', 'had', '_abbrev_', 'viability', 'value', 'of', '_num_', '_num_', '_unit_', 'while', 'ba', '_abbrev_', 'cells', 'expressing', 'reintroduced', '_chemical_', '_mutation_', 'had', '_abbrev_', 'value', 'of', '_num_', '_num_', '_unit_']"
1610,1.0,"He tested positive for ALK rearrangement via break apart FISH assay, and started crizotinib with near complete response for 27 months.","['he', 'tested', 'positive', 'for', '_gene_', 'rearrangement', 'via', 'break', 'apart', 'fish', 'assay', 'and', 'started', '_chemical_', 'with', 'near', 'complete', 'response', 'for', '_num_', 'months']"
1611,1.0,SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib in comparison to five sensitive cell lines.,"['_gene_', 'mrna', 'expression', 'was', 'elevated', 'in', '_num_', 'breast', 'cancer', 'cell', 'lines', 'which', 'were', 'resistant', 'to', '_gene_', 'inhibitor', 'alpelisib', 'in', 'comparison', 'to', '_num_', 'sensitive', 'cell', 'lines']"
1612,1.0,De novo Alu element insertions were identified within the BRCA2 coding sequences in 3 out of 50 Portuguese families.,"['de', 'novo', 'alu', 'element', 'insertions', 'were', 'identified', 'within', 'the', '_gene_', 'coding', 'sequences', 'in', '_num_', 'out', 'of', '_num_', 'portuguese', 'families']"
1613,0.0,FGFR inhibitor PD173074 (and FGFR1 siRNA) was able to attenuate the protective effect of FGF2.,"['_gene_', 'inhibitor', '_chemical_', 'and', '_gene_', 'sirna', 'was', 'able', 'to', 'attenuate', 'the', 'protective', 'effect', 'of', '_gene_']"
1614,0.0,we conclude that the effect of these alleles on prognosis in lung cancer is inconclusive at best.,"['we', 'conclude', 'that', 'the', 'effect', 'of', 'these', 'alleles', 'on', 'prognosis', 'in', 'lung', 'cancer', 'is', 'inconclusive', 'at', 'best']"
1615,1.0,"Kaplan-Meier survival analysis revealed patients with RB1 mutations exhibited better overall survival (p = .04, 11.7 versus 9.1 months, CI = 1.1-28.2).","['_disease_', 'survival', 'analysis', 'revealed', 'patients', 'with', '_gene_', 'mutations', 'exhibited', 'better', 'overall', 'survival', 'p', '_num_', '_num_', 'vs', '_num_', 'months', 'ci', '_range_']"
1616,1.0,The median survival for patients with low grade gliomas was 1.7 years for patients with wild type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).,"['the', 'median', 'survival', 'for', 'patients', 'with', 'low', 'grade', 'gliomas', 'was', '_num_', 'years', 'for', 'patients', 'with', 'wild', 'type', '_gene_', '_ineq_', '_num_', 'years', 'for', 'patients', 'with', 'mutated', '_gene_', 'and', 'no', '1p', '19q', 'co', 'deletion', '_ineq_', 'and', '_num_', 'years', 'for', 'patients', 'with', '_gene_', 'mutation', 'and', 'a', '1p', '19q', 'co', 'deletion', '_ineq_']"
1617,1.0,This frameshift mutation causes an early stop codon at amino acid 130 and was found in a VHL type 1 family of 16 patients.,"['this', 'frameshift', 'mutation', 'causes', 'an', 'early', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'patients']"
1618,1.0,Only moderate evidence for pathogenicity because protein length changes as a result of insertion in a nonrepeat region (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'insertion', 'in', 'a', 'nonrepeat', 'region', 'acmg', 'code', '_abbrev_']"
1619,1.0,"Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity.","['cell', 'lines', 'were', 'assessed', 'for', 'sensitivity', 'to', '_gene_', 'allosteric', 'inhibitor', '_chemical_', 'and', 'it', 'was', 'reported', 'that', '_gene_', 'loss', 'had', 'significant', 'association', 'with', '_chemical_', 'sensitivity']"
1620,1.0,"In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival.","['in', 'japanese', 'invasive', 'breast', 'cancer', 'patients', '_gene_', 'mutation', 'was', 'associated', 'with', 'improved', 'relapse', 'free', 'survival']"
1621,1.0,"11.5% of patients exhibited partial response, 38.5% exhibited stable disease.","['_num_', 'of', 'patients', 'exhibited', 'partial', 'response', '_num_', 'exhibited', 'stable', 'disease']"
1622,1.0,Expression of these mutations in HEK293T cells demonstrated these were activating mutations.,"['expression', 'of', 'these', 'mutations', 'in', '_chemical_', 'cells', 'demonstrated', 'these', 'were', 'activating', 'mutations']"
1623,1.0,"A meta-analysis of 26 published studies including 8097 prostate cancer patients showed that, compared to patients with normal PTEN, patients with PTEN deletion exhibited a greater aggressive Gleason score (OR: 1.284, 95% CI = 1.145–1.439), pathological stage (OR: 1.628, 95% CI = 1.270–2.087), and risk for recurrence of prostate cancer (HR: 1.738, 95% CI = 1.264–2.390).","['a', '_disease_', 'analysis', 'of', '_num_', 'published', 'studies', 'including', '_num_', 'prostate', 'cancer', 'patients', 'showed', 'that', 'compared', 'to', 'patients', 'with', 'normal', '_gene_', 'patients', 'with', '_gene_', 'deletion', 'exhibited', 'a', 'greater', 'aggressive', 'gleason', 'score', 'or', '_num_', '_num_', 'ci', '_num_', '145–1', '_num_', 'pathological', 'stage', 'or', '_num_', '_num_', 'ci', '_num_', '270–2', '_num_', 'and', 'risk', 'for', 'recurrence', 'of', 'prostate', 'cancer', 'hr', '_num_', '_num_', 'ci', '_num_', '264–2', '_num_']"
1624,1.0,"In this study, tissue sampling began with 77 ovarian cancer patients.","['in', 'this', 'study', 'tissue', 'sampling', 'began', 'with', '_num_', 'ovarian', 'cancer', 'patients']"
1625,1.0,There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.,"['there', 'is', 'no', 'strong', 'association', 'between', '_gene_', 'mutation', 'status', 'and', 'overall', 'or', 'progression', 'free', 'survival', 'in', 'patients', 'with', '_disease_']"
1626,1.0,"Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines.","['co', 'treatment', 'of', 'all', '_num_', 'cell', 'lines', 'with', '_gene_', 'inhibitor', 'and', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'synergistic', 'reductions', 'in', 'cell', 'viability', 'which', 'were', 'not', 'seen', 'with', 'treatment', 'of', 'either', 'compound', 'alone', 'and', 'resulted', 'in', 'similar', 'suppression', 'to', 'viability', 'as', 'seen', 'in', 'the', 'respective', '_gene_', 'inhibitor', 'sensitive', 'parental', 'cell', 'lines']"
1627,1.0,5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture.,"['5a', 'and', '_chemical_', 'showed', 'in', 'vitro', 'kinase', 'activity', 'and', 'transformed', '3t3', 'cells', 'in', 'cell', 'culture']"
1628,1.0,"This nonsense mutation was found in a German, VHL type 1 family (family VHL 55).","['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'family', 'family', '_gene_', '_num_']"
1629,1.0,"A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.","['a', 'missense', 'mutation', 'affecting', 'residue', 'on', 'the', 'surface', 'of', '_gene_', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
1630,1.0,"Furthermore, 91% of these patients were estimated to  remain in response at 1 year (95% CI, Kaplan-Meier analysis).","['furthermore', '_num_', 'of', 'these', 'patients', 'were', 'estimated', 'to', 'remain', 'in', 'response', 'at', '_num_', 'year', '_num_', 'ci', '_disease_', 'analysis']"
1631,1.0,"HCC827 cell lines harboring activated PI3K (HCC827 p110α E545K cells) were more resistant to gefitinib in vitro (IC50, 1 μM) compared with those harboring GFP alone (IC50, 0.01 μM).","['_chemical_', 'cell', 'lines', 'harboring', 'activated', '_gene_', '_chemical_', '_abbrev_', '_mutation_', 'cells', 'were', 'more', 'resistant', 'to', '_chemical_', 'in', 'vitro', '_abbrev_', '_num_', 'μm', 'compared', 'with', 'those', 'harboring', '_gene_', 'alone', '_abbrev_', '_num_', 'μm']"
1632,0.0,"This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib.","['this', 'small', 'clinical', '_ineq_', 'study', 'suggests', 'that', 'patients', 'with', 'minor', 'mutations', 'of', '_gene_', 'like', '_mutation_', 'are', 'likely', 'to', 'have', 'a', 'moderate', 'response', 'to', 'tyrosine', 'kinase', 'inhibitors', 'like', '_chemical_', 'and', '_chemical_']"
1633,1.0,c.165G>A results in synonymous change Glu55Glu.,"['c', '_unit_', 'a', 'results', 'in', 'synonymous', 'change', '_abbrev_']"
1634,1.0,Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild type PIK3CA gene.,"['breast', 'cancer', 'cell', 'lines', 'with', '_abbrev_', 'mutations', 'showed', 'increased', 'sensitivity', 'to', '_chemical_', 'than', 'cells', 'with', 'wild', 'type', '_gene_', 'gene']"
1635,1.0,Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).,"['supporting', 'evidence', 'of', 'pathogenicity', 'because', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']"
1636,1.0,Multivariate Cox proportional analysis of a 10-year follow-up confirmed the T393C polymorphism as an independent prognostic factor in clear cell renal cell carcinoma.,"['multivariate', 'cox', 'proportional', 'analysis', 'of', 'a', '_num_', 'year', 'follow', 'up', 'confirmed', 'the', '_mutation_', 'polymorphism', 'as', 'an', 'independent', 'prognostic', 'factor', 'in', 'clear', 'cell', 'renal', 'cell', 'carcinoma']"
1637,1.0,The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.,"['the', '_mutation_', 'mutation', 'was', 'shown', 'to', 'confer', 'resistance', 'to', '_chemical_', 'in', '_abbrev_', 'cell', 'lines', 'retrovirally', 'transduced', 'with', 'wildtype', 'or', 'mutant', '_gene_']"
1638,1.0,"Patients with p53 wild type (as defined by low expression and/or wild type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases).","['patients', 'with', '_gene_', 'wild', 'type', 'as', 'defined', 'by', 'low', 'expression', 'and', 'or', 'wild', 'type', '_gene_', 'gene', 'had', 'a', 'higher', 'response', 'rate', 'to', 'chemotherapy', 'based', 'treatment', 'total', 'major', 'response', 'mr', 'risk', 'ratio', '_gene_', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'pathological', 'mr', '_gene_', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'total', 'complete', 'response', 'cr', '_gene_', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'in', 'this', '_disease_', 'analysis', '_num_', 'studies', '_num_', 'cases']"
1639,1.0,"The patient (F, 79, nonsmoker) had a partial response, progression free survival (PFS) of 5.0 months, overall survival (OS) of 15.0 months and was not alive at study end.","['the', 'patient', 'f', '_num_', 'nonsmoker', 'had', 'a', 'partial', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
1640,1.0,Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1).,"['_num_', 'myeloma', 'cell', 'lines', 'were', 'treated', 'with', '_num_', 'different', 'bet', 'inhibitors', '_chemical_', 'or', '_abbrev_']"
1641,1.0,"KIF23 V1 expression was independent of gender, age, tumor size, or TNM stage (multivariate cox regression).","['_gene_', '_gene_', 'expression', 'was', 'independent', 'of', 'gender', 'age', 'tumor', 'size', 'or', '_gene_', 'stage', 'multivariate', 'cox', 'regression']"
1642,1.0,"Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated.","['tumor', 'sequencing', 'showed', 'increased', '_gene_', 'activity', 'due', 'to', 'ret', 'over', 'expression', 'and', '_gene_', 'deletion', 'therefore', '_chemical_', 'ret', 'inhibitor', 'was', 'initiated']"
1643,1.0,The T315I mutation was resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
1644,1.0,we also summarize prior functional work that suggests that C609Y has transforming activity that is significant but not as strong as some other variants.,"['we', 'also', 'summarize', 'prior', 'functional', 'work', 'that', 'suggests', 'that', '_mutation_', 'has', 'transforming', 'activity', 'that', 'is', 'significant', 'but', 'not', 'as', 'strong', 'as', 'some', 'other', 'variants']"
1645,1.0,This missense mutation was found in a VHL type 1 family (lineage 76).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
1646,1.0,1 patient was found to have the above mutation.,"['_num_', 'patient', 'was', 'found', 'to', 'have', 'the', 'above', 'mutation']"
1647,1.0,"Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response or stable disease.","['among', '_num_', 'patients', 'with', 'melanoma', '_gene_', 'wild', 'type', 'and', 'non', 'nras', 'or', 'nras', 'unknown', 'status', '_num_', 'patients', 'experienced', 'partial', 'response', 'or', 'stable', 'disease']"
1648,1.0,"Furthermore, a statistically significant decrease in overall survival was discovered between positive and negative CIP2A expression.","['furthermore', 'a', 'statistically', 'significant', 'decrease', 'in', 'overall', 'survival', 'was', 'discovered', 'between', 'positive', 'and', 'negative', '_gene_', 'expression']"
1649,1.0,RNA sequencing revealed an in-frame stop codon after exon 12.,"['rna', 'sequencing', 'revealed', 'an', 'in', 'frame', 'stop', 'codon', 'after', 'exon', '_num_']"
1650,1.0,"In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study.","['in', 'a', '_disease_', 'analysis', 'of', '_num_', 'clinical', 'trials', 'evaluating', 'the', 'efficacy', 'of', '_chemical_', '_num_', 'patient', 'was', 'described', 'with', 'the', 'exon', '_num_', 'mutation', '_mutation_', 'from', 'the', 'beta', 'study']"
1651,1.0,In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive.,"['in', '_abbrev_', 'xenografts', '_num_', 'doses', 'of', '_chemical_', 'induced', 'significant', 'tumor', 'inhibition', '_num_', '_disease_', 'twice', 'daily', '_num_', '_disease_', 'twice', 'daily', 'while', '_num_', '_disease_', 'twice', 'weekly', '_chemical_', 'was', 'inactive']"
1652,1.0,Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.,"['median', '_disease_', 'in', 'the', 'placebo', 'arm', 'was', '_num_', 'months', 'while', 'in', 'the', 'petuzumab', 'arm', '_num_', 'months', 'was', 'achieved']"
1653,1.0,"In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient).","['in', 'vitro', '_mutation_', 'showed', '_chemical_', 'resistance', 'both', 'in', 'isolation', 'and', 'when', 'coexpressed', 'with', '_mutation_', '_abbrev_', 'the', 'primary', 'kit', 'mutations', 'found', 'on', 'the', 'same', 'allele', 'for', 'this', 'patient']"
1654,0.0,This study highlighted Livin as a potential player in colon cancer therapy.,"['this', 'study', 'highlighted', '_gene_', 'as', 'a', 'potential', 'player', 'in', 'colon', 'cancer', 'therapy']"
1655,1.0,"The three cell lines were infected with lentivirus for either EGFR or de4 EGFR, and lentivirus-infected cells were used to perform transwell migration assays, invasion assays, and cisplatin sensitivity assays.","['the', '_num_', 'cell', 'lines', 'were', 'infected', 'with', 'lentivirus', 'for', 'either', '_gene_', 'or', '_abbrev_', '_gene_', 'and', '_disease_', 'cells', 'were', 'used', 'to', 'perform', 'transwell', 'migration', 'assays', 'invasion', 'assays', 'and', '_disease_', 'sensitivity', 'assays']"
1656,1.0,"High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines.","['high', 'expression', 'of', 'class', '_num_', '_gene_', 'led', 'to', 'decreased', 'effect', 'of', '_chemical_', 'on', 'cell', 'motility', 'in', 'hela', '_disease_', 'and', '_gene_', 'cell', 'lines']"
1657,1.0,"Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease.","['_num_', 'phase', 'i', 'studies', 'in', 'patients', 'with', 'advanced', 'or', 'metastatic', 'solid', 'tumors', 'including', 'patients', 'with', 'active', 'central', 'nervous', 'system', 'cns', 'disease']"
1658,1.0,"Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without.","['partial', 'or', 'complete', 'response', 'was', 'achieved', 'in', '_num_', 'of', '_num_', 'patients', 'with', '_gene_', 'mutations', 'compared', 'to', '_num_', 'of', '_num_', 'without']"
1659,1.0,"Identified EGFR aberrations included EGFRvIII positivity, EGFR gene amplification and three somatic EGFR mutations.","['identified', '_gene_', 'aberrations', 'included', 'egfrviii', 'positivity', '_gene_', 'gene', 'amplification', 'and', '_num_', 'somatic', '_gene_', 'mutations']"
1660,1.0,Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.,"['efficacy', 'of', 'the', '_num_', 'generation', '_gene_', 'inhibitor', '_chemical_', 'was', 'tested', 'on', '_gene_', 'mutation', '_mutation_', 'containing', 'neuroblastoma', 'derived', 'cells']"
1661,1.0,Case study describes a caucasian male (age 38) never smoker presenting with stage IV non-small cell lung cancer with an ALK rearrangement.,"['case', 'study', 'describes', 'a', 'caucasian', 'male', 'age', '_num_', 'never', 'smoker', 'presenting', 'with', 'stage', 'iv', 'non', 'small', 'cell', 'lung', 'cancer', 'with', 'an', '_gene_', 'rearrangement']"
1662,1.0,All HDACi were able to regulate proliferation and apoptosis in vitro.,"['all', '_chemical_', 'were', 'able', 'to', 'regulate', 'proliferation', 'and', 'apoptosis', 'in', 'vitro']"
1663,1.0,"In a study of 114 unrelated VHL families, 85 germline mutations were found.","['in', 'a', 'study', 'of', '_num_', 'unrelated', '_gene_', 'families', '_num_', 'germline', 'mutations', 'were', 'found']"
1664,1.0,"In patients with renal clear cell carcinoma, patients with VHL mutations had longer cancer-specific survival.","['in', 'patients', 'with', 'renal', 'clear', 'cell', 'carcinoma', 'patients', 'with', '_gene_', 'mutations', 'had', 'longer', '_disease_', 'survival']"
1665,1.0,A patient harbouring a novel TNKS2–PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.,"['a', 'patient', 'harbouring', 'a', 'novel', '_abbrev_', 'fusion', 'in', 'a', 'myeloid', 'neoplasm', 'with', 'eosinophilia', 'demonstrated', 'a', 'dramatic', 'and', 'durable', 'response', 'upon', 'treatment', 'with', '_chemical_', 'mono', 'therapy']"
1666,1.0,This somatic mutation was detected in two samples from a single case with chromophobe renal cell carcinoma (a 74 year old male).,"['this', 'somatic', 'mutation', 'was', 'detected', 'in', '_num_', 'samples', 'from', 'a', 'single', 'case', 'with', '_disease_', 'renal', 'cell', 'carcinoma', 'a', '_num_', 'year', 'old', 'male']"
1667,1.0,"Only 12% of patients showed  partial response or better, with one complete response lasting 36 months and ongoing after data cutoff.","['only', '_num_', 'of', 'patients', 'showed', 'partial', 'response', 'or', 'better', 'with', '_num_', 'complete', 'response', 'lasting', '_num_', 'months', 'and', 'ongoing', 'after', 'data', 'cutoff']"
1668,1.0,Patients with GNAQ mutations remained on the study treatment from 1.4-10.3 months.,"['patients', 'with', '_gene_', 'mutations', 'remained', 'on', 'the', 'study', 'treatment', 'from', '_range_', 'months']"
1669,1.0,"Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation.","['doxycycline', 'dependent', 'expression', 'of', 'the', '_gene_', '_mutation_', 'mutation', 'in', 'mouse', 'type', 'ii', 'alveolar', 'epithelial', 'cells', 'drove', 'lung', 'cancer', 'in', 'a', 'reversible', 'fashion', 'indicating', 'the', 'driver', 'properties', 'of', 'this', '_gene_', 'catalytic', 'domain', 'mutation']"
1670,1.0,Immunohistochemical analysis was employed on a subset of 636 cases to evaluate COX2 overexpression.,"['immunohistochemical', 'analysis', 'was', 'employed', 'on', 'a', 'subset', 'of', '_num_', 'cases', 'to', 'evaluate', '_gene_', 'overexpression']"
1671,1.0,"The drug CBL0137 (a drug that interacts with SSRP1 aka FACT) exhibited a synergistic effect with standard chemotherapy (cyclophosphamide, etoposide, cisplatin, vincristine, etc).by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells.","['the', 'drug', '_chemical_', 'a', 'drug', 'that', 'interacts', 'with', '_gene_', 'aka', 'fact', 'exhibited', 'a', 'synergistic', 'effect', 'with', 'standard', 'chemotherapy', '_chemical_', '_chemical_', '_disease_', 'vincristine', 'etc', 'by', 'blocking', 'repair', 'of', 'dna', 'damage', 'caused', 'by', 'genotoxic', 'drugs', 'thus', 'creating', 'a', 'synthetic', 'lethal', 'environment', 'in', '_gene_', 'amplified', 'neuroblastoma', 'cells']"
1672,1.0,The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh.,"['the', 'alpelisib', '_gene_', 'inhibitor', 'resistant', 'breast', 'cancer', 'cell', 'line', '_abbrev_', 'was', 'treated', 'with', 'alpelsisb', 'alone', 'or', 'in', 'combination', 'with', 'the', '_gene_', 'kinase', 'inhibitor', '_abbrev_']"
1673,1.0,The FUS-DDIT3 fusion is pathognomonic of myxoid liposarcomas.,"['the', '_abbrev_', 'fusion', 'is', 'pathognomonic', 'of', '_disease_', 'liposarcomas']"
1674,1.0,"Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037).","['ovarian', 'cancer', 'patients', 'with', '_gene_', 'missense', 'mutations', 'were', 'refractory', 'to', 'platinum', 'based', 'chemotherapy', '_num_', 'vs', '_num_', 'in', 'wildtype', '_p_val_', 'and', 'had', 'a', 'shorter', 'time', 'to', 'disease', 'progression', '_ineq_', '_p_val_']"
1675,1.0,"In RAS wild type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P = .73; interaction test results were significant [P = .01]).","['in', 'ras', 'wild', 'type', 'patients', 'with', 'low', 'ligand', 'expression', 'median', '_disease_', 'was', '_num_', '_range_', 'months', '_chemical_', 'with', 'panitumumab', 'vs', '_num_', '_range_', 'months', '_chemical_', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'interaction', 'test', 'results', 'were', 'significant', 'p', '_num_']"
1676,1.0,The dual EGFR-ERBB2 (both forming heterodimers with ERBB3) inhibitors afatinib and dacomitinib each showed strong synergy with MEK Inhibition (trametinib or selumetinib) in several KRAS mutant cell lines.,"['the', 'dual', '_abbrev_', 'both', 'forming', 'heterodimers', 'with', '_gene_', 'inhibitors', '_chemical_', 'and', '_chemical_', 'each', 'showed', 'strong', 'synergy', 'with', 'mek', 'inhibition', '_chemical_', 'or', '_chemical_', 'in', 'several', '_gene_', 'mutant', 'cell', 'lines']"
1677,1.0,Both individuals were identified with renal cell carcinoma and one who also carried cerebellar hemangioblastomas.,"['both', 'individuals', 'were', 'identified', 'with', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'who', 'also', 'carried', 'cerebellar', '_disease_']"
1678,1.0,TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.,"['_gene_', 'agonist', 'immunomodulatory', '_chemical_', 'imo', 'led', 'to', 'inhibited', 'survival', 'of', '_abbrev_', 'colorectal', 'cancer', 'and', '_abbrev_', 'pancreatic', 'cancer', 'cell', 'lines', 'with', '_gene_', 'mutations']"
1679,1.0,"36 of 51 individuals had angiomas, 17 had cerebellar hemangioblastomas, 16 with renal cell carcinoma, and 36 with pheochromocytomas.","['_num_', 'of', '_num_', 'individuals', 'had', 'angiomas', '_num_', 'had', 'cerebellar', '_disease_', '_num_', 'with', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'with', 'pheochromocytomas']"
1680,1.0,A single patient with this fusion showed durable response to sorafenib.,"['a', 'single', 'patient', 'with', 'this', 'fusion', 'showed', 'durable', 'response', 'to', '_chemical_']"
1681,1.0,A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer.,"['a', 'clinical', 'trial', '_abbrev_', 'is', 'currently', 'underway', 'to', 'asses', '_abbrev_', 'in', '_gene_', 'overexpressing', 'lung', 'cancer']"
1682,1.0,A siRNA screen identified BAP1 associated with HDAC1 and HDAC2 expression.,"['a', 'sirna', 'screen', 'identified', '_gene_', 'associated', 'with', '_gene_', 'and', '_gene_', 'expression']"
1683,1.0,Crizotinib at 250 mg orally twice daily led to resolution of metastatic disease.,"['_chemical_', 'at', '_num_', '_unit_', 'orally', 'twice', 'daily', 'led', 'to', 'resolution', 'of', 'metastatic', 'disease']"
1684,1.0,Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.,"['induction', 'of', '_gene_', 'signalling', 'was', 'also', 'identified', 'in', 'a', 'patient', 'with', '_gene_', 'mutation', 'after', 'mek', 'inhibition', 'with', '_chemical_']"
1685,1.0,A 53 year old male presented with a scalp lesion which was incompletely excised.,"['a', '_num_', 'year', 'old', 'male', 'presented', 'with', 'a', 'scalp', 'lesion', 'which', 'was', 'incompletely', 'excised']"
1686,1.0,"In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders.","['in', 'the', '_gene_', 'wild', 'type', 'subroup', 'of', 'cell', 'lines', '_num_', 'were', 'assessed', 'as', 'responsive', 'while', 'in', 'the', 'subgroup', 'of', 'cell', 'lines', 'with', '_gene_', 'mutations', '_num_', 'were', 'labeled', 'as', 'responders']"
1687,1.0,A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy.,"['a', 'cohort', 'of', '_num_', 'male', 'patients', 'with', '_disease_', '_disease_', 'syndrome', 'and', 'elevated', 'serum', '_gene_', 'levels', 'were', 'enrolled', 'in', 'a', 'study', 'of', '_chemical_', '_chemical_', 'therapy']"
1688,1.0,8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus.,"['_num_', 'gastric', 'cancer', 'cell', 'lines', 'were', 'treated', 'with', 'the', '_gene_', 'inhibitor', '_chemical_']"
1689,1.0,Next generation sequencing of the patient revealed a TFG-ROS1 fusion.,"['next', 'generation', 'sequencing', 'of', 'the', 'patient', 'revealed', 'a', '_abbrev_', 'fusion']"
1690,1.0,"Among the alterations, one cell line harbored a PTEN allele deletion and R130* mutation.","['among', 'the', 'alterations', '_num_', 'cell', 'line', 'harbored', 'a', '_gene_', 'allele', 'deletion', 'and', '_abbrev_', 'mutation']"
1691,1.0,The author’s assessment of the factors predicts a pathogenicity probability of 0.73 and an Odds Ratio of 2.7.,"['the', 'author', '’', 's', 'assessment', 'of', 'the', 'factors', 'predicts', 'a', 'pathogenicity', 'probability', 'of', '_num_', 'and', 'an', 'odds', 'ratio', 'of', '_num_']"
1692,1.0,Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response.,"['persistent', 'declines', 'in', '_gene_', '_mutation_', 'in', 'cfdna', 'were', 'associated', 'with', 'improved', '_disease_', 'and', 'response']"
1693,1.0,Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib.,"['phase', '_num_', 'study', 'with', 'the', 'dual', '_abbrev_', 'inhibitor', 'apitolisib']"
1694,1.0,There was no difference betweeen overall survival of KRAS Mutation-positive and -negative patients.,"['there', 'was', 'no', 'difference', 'betweeen', 'overall', 'survival', 'of', '_gene_', 'mutation', 'positive', 'and', '', 'negative', 'patients']"
1695,1.0,Protein alignments indicated this mutation was analogous to EGFR-L858R and BRAF-L597V.,"['protein', 'alignments', 'indicated', 'this', 'mutation', 'was', 'analogous', 'to', '_abbrev_', 'and', '_abbrev_']"
1696,1.0,These results were confirmed using biopsies from liver metastases in 14 patients with uveal melanoma harboring GNAQ or GNA11 mutations who were treated on a phase II study of selumetinib.,"['these', 'results', 'were', 'confirmed', 'using', 'biopsies', 'from', 'liver', 'metastases', 'in', '_num_', 'patients', 'with', 'uveal', 'melanoma', 'harboring', '_gene_', 'or', '_gene_', 'mutations', 'who', 'were', 'treated', 'on', 'a', 'phase', 'ii', 'study', 'of', '_chemical_']"
1697,1.0,The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine).,"['the', 'study', 'began', 'with', 'a', 'total', 'of', '_num_', 'patients', 'that', 'were', 'randomly', 'assigned', 'to', 'either', 'regimen', 'a', '_chemical_', 'and', '_disease_', 'with', '_chemical_', 'or', 'regimen', 'b', '_disease_', 'and', '_chemical_']"
1698,1.0,Mouse Ba/F3 cells with FLT3 mutations were evaluated for sorafenib resistance.,"['mouse', 'ba', '_abbrev_', 'cells', 'with', '_gene_', 'mutations', 'were', 'evaluated', 'for', '_chemical_', 'resistance']"
1699,1.0,Immunohistochemistry showed that CK18 expression in PCa tissues was statistically significant inversely correlated with tumor grade.,"['immunohistochemistry', 'showed', 'that', '_gene_', 'expression', 'in', '_disease_', 'tissues', 'was', 'statistically', 'significant', 'inversely', 'correlated', 'with', 'tumor', 'grade']"
1700,1.0,"No predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss.","['no', 'predictive', '_chemical_', 'were', 'identified', 'including', '_gene_', 'mutations', '_ineq_', '_gene_', 'mutations', '_ratio_', 'or', '_gene_', 'loss']"
1701,1.0,"A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation.","['a', 'patient', 'with', 'metastatic', 'bladder', 'cancer', 'that', 'responded', 'well', 'to', 'the', '_gene_', 'inhibitor', '_chemical_', 'was', 'shown', 'to', 'harbor', 'a', '_gene_', 'frameshift', 'truncation', 'mutation', 'c', '1907_1908del', 'p', '_abbrev_', 'and', 'a', 'nonsense', '_gene_', 'mutation']"
1702,0.0,"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.","['on', 'may', '_num_', '_year_', 'the', 'u', 's', 'food', 'and', 'drug', 'administration', 'approved', '_chemical_', '_chemical_', 'for', 'the', '_num_', 'line', 'treatment', 'of', 'patients', 'with', 'metastatic', 'non', 'small', 'cell', 'lung', 'cancer', '_disease_', 'whose', 'tumors', 'have', 'epidermal', 'growth', 'factor', 'receptor', '_gene_', 'exon', '_num_', 'deletions', 'or', 'exon', '_num_', '_mutation_', 'substitution', 'mutations']"
1703,1.0,"Of note, evaluation of KRAS mutations from archival tissue from 71/143 patients identified 8 patients with mutant KRAS (wildtype by cfDNA) and 3 patients with wildtype KRAS (mutant by cfDNA).","['of', 'note', 'evaluation', 'of', '_gene_', 'mutations', 'from', 'archival', 'tissue', 'from', '_ratio_', 'patients', 'identified', '_num_', 'patients', 'with', 'mutant', '_gene_', 'wildtype', 'by', 'cfdna', 'and', '_num_', 'patients', 'with', 'wildtype', '_gene_', 'mutant', 'by', 'cfdna']"
1704,1.0,"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.","['in', 'the', 'setting', 'of', '_gene_', '_mutation_', '_gene_', 'loss', 'resulted', 'in', 'elevated', 'activation', 'of', 'ras', '_chemical_', 'but', 'does', 'not', 'show', 'resistance', 'to', 'mek', 'inhibitors']"
1705,1.0,"Overall, 5 patients had an OR.","['overall', '_num_', 'patients', 'had', 'an', 'or']"
1706,1.0,An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples.,"['an', 'expanded', 'screen', 'of', '_num_', 'additional', '_gene_', 'samples', 'and', '_num_', 'adjacent', '_disease_', 'liver', 'samples', 'was', 'positive', 'for', 'a', '_num_', 'case', 'of', '_gene_', 'with', 'both', 'conventional', 'and', 'fibrolamellar', 'features', 'but', 'negative', 'for', 'all', 'conventional', '_gene_', 'and', 'adjacent', '_disease_', 'liver', 'samples']"
1707,1.0,SU11248 + Daunorubicin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation.,"['_chemical_', '_chemical_', 'has', 'a', 'synergic', 'effect', 'on', 'murine', 'ba', '_abbrev_', 'cells', 'with', '_gene_', '_mutation_', 'mutation']"
1708,1.0,"In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF.","['in', 'patients', 'with', 'mds', 'those', 'who', 'harbor', '_abbrev_', 'mutation', 'of', '_gene_', 'do', 'not', 'show', 'statistical', 'significance', 'in', 'complete', 'remission', 'rate', 'compared', 'to', 'those', 'who', 'harbor', 'wild', 'type', '_gene_']"
1709,1.0,H3122 CR2 was found to contain the EML4-ALK InsT variant.,"['_abbrev_', '_gene_', 'was', 'found', 'to', 'contain', 'the', '_chemical_', 'inst', 'variant']"
1710,1.0,"In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival.","['in', 'patients', 'with', 'acral', 'lentiginous', 'melanoma', 'those', 'with', 'amplification', 'of', '_gene_', 'had', 'shorter', 'overall', 'survival']"
1711,1.0,Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases.,"['treatment', 'was', 'well', 'tolerated', 'and', 'led', 'to', 'a', 'partial', 'response', 'pr', 'with', '_num_', 'tumor', 'shrinkage', 'of', 'multiple', 'liver', 'metastases']"
1712,0.0,The clinical trial associated with this study is NCT00870337.,"['the', 'clinical', 'trial', 'associated', 'with', 'this', 'study', 'is', '_abbrev_']"
1713,1.0,"3 with SD, 1 with PD.","['_num_', 'with', 'sd', '_num_', 'with', 'pd']"
1714,1.0,"Low to moderate ALDH1A2 protein levels (combined as ALDH1A2low) were identified in keratinocytes of healthy mucosa as well as 73 (63.5%) primary tumors, and high ALDH1A2 protein levels in 42 (36.5%) primary tumors.","['low', 'to', 'moderate', '_gene_', 'protein', 'levels', 'combined', 'as', '_abbrev_', 'were', 'identified', 'in', '_disease_', 'of', 'healthy', 'mucosa', 'as', 'well', 'as', '_num_', '_num_', 'primary', 'tumors', 'and', 'high', '_gene_', 'protein', 'levels', 'in', '_num_', '_num_', 'primary', 'tumors']"
1715,1.0,"Uncommon mutations also had greater median PFS (5.0 vs. 2.0 months, P < 0.001) and median overall survival (15.0 vs. 10.4 months, P = 0.030) than in patients with the wild type EGFR.","['uncommon', 'mutations', 'also', 'had', 'greater', 'median', '_disease_', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'and', 'median', 'overall', 'survival', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'than', 'in', 'patients', 'with', 'the', 'wild', 'type', '_gene_']"
1716,1.0,This mutation was found in a VHL type 1 family retinal angiomas and renal cell carcinoma.,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'retinal', 'angiomas', 'and', 'renal', 'cell', 'carcinoma']"
1717,1.0,"Erlotinib also significantly improved PFS in EGFR wildtype patients, but EGFR mutant tumors treated with erlotinib had significant better PFS than EGFR wildtype.","['_chemical_', 'also', 'significantly', 'improved', '_disease_', 'in', '_gene_', 'wildtype', 'patients', 'but', '_gene_', 'mutant', 'tumors', 'treated', 'with', '_chemical_', 'had', 'significant', 'better', '_disease_', 'than', '_gene_', 'wildtype']"
1718,1.0,The R1062W variant does not display a significant functional impact relative to the wildtype.,"['the', '_abbrev_', 'variant', 'does', 'not', 'display', 'a', 'significant', 'functional', 'impact', 'relative', 'to', 'the', 'wildtype']"
1719,1.0,This missense mutation was found in a VHL type 2B patient (patient no.V87).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_abbrev_']"
1720,1.0,This finding was independent from other genomic and clinical factors explored by we.,"['this', 'finding', 'was', 'independent', 'from', 'other', 'genomic', 'and', 'clinical', 'factors', 'explored', 'by', 'we']"
1721,1.0,1 patient from a single family was confirmed to have the above mutation.,"['_num_', 'patient', 'from', 'a', 'single', 'family', 'was', 'confirmed', 'to', 'have', 'the', 'above', 'mutation']"
1722,1.0,Brigatinib reduced CLB-BAR cellular proliferation more effectively than crizotinib (IC50 75.2 vs 186.4nM).,"['brigatinib', 'reduced', '_gene_', 'bar', 'cellular', 'proliferation', 'more', 'effectively', 'than', '_chemical_', '_abbrev_', '_num_', 'vs', '_num_', '_unit_']"
1723,1.0,CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity.,"['_gene_', '_gene_', 'expression', 'in', '_num_', 'samples', 'of', '_disease_', 'carcinomas', 'was', 'correlated', 'with', '_gene_', 'activity']"
1724,1.0,"However, most of the Prognostic value of TERT mutations is thought to be derived from their inverse coorelation with IDH1 mutations.","['however', 'most', 'of', 'the', 'prognostic', 'value', 'of', '_gene_', 'mutations', 'is', 'thought', 'to', 'be', 'derived', 'from', 'their', 'inverse', 'coorelation', 'with', '_gene_', 'mutations']"
1725,1.0,Combined PLX4720 and AZD6244 (selumetinib) achieved greater efficacy than either agent alone but NF1 knockdown was still associated with residual resistance to combined RAF/MEK inhibition in vitro.,"['combined', '_chemical_', 'and', '_chemical_', '_chemical_', 'achieved', 'greater', 'efficacy', 'than', 'either', 'agent', 'alone', 'but', '_gene_', 'knockdown', 'was', 'still', 'associated', 'with', 'residual', 'resistance', 'to', 'combined', '_gene_', 'inhibition', 'in', 'vitro']"
1726,1.0,POLE mutations V411L (exonuclease domain) and R114* were identified in the primary tumor as well as a resected lymph node metastasis.,"['pole', 'mutations', '_mutation_', 'exonuclease', 'domain', 'and', '_abbrev_', 'were', 'identified', 'in', 'the', 'primary', 'tumor', 'as', 'well', 'as', 'a', 'resected', 'lymph', 'node', 'metastasis']"
1727,1.0,"Homozygous CC patients were at highest risk for progression (hazard ratio, 2.48; P = 0.009) or tumor-related death (hazard ratio, 3.15; P = 0.018) compared with T-allele carriers.","['homozygous', 'cc', 'patients', 'were', 'at', 'highest', 'risk', 'for', 'progression', 'hazard', 'ratio', '_num_', 'p', '_num_', 'or', 'tumor', 'related', 'death', 'hazard', 'ratio', '_num_', 'p', '_num_', 'compared', 'with', 't', 'allele', 'carriers']"
1728,1.0,"Serum HER2 levels were Independent predictors of lapatinib progression free survival benefit (HR per 10-ng/mL increase in serum HER2: lapatinib-containing therapies, 1.009 v nonlapatinib-containing therapies, 1.044; P interaction < .001).","['serum', '_gene_', 'levels', 'were', 'independent', 'predictors', 'of', '_chemical_', 'progression', 'free', 'survival', 'benefit', 'hr', 'per', '_num_', '_unit_', '_unit_', 'increase', 'in', 'serum', '_gene_', '_chemical_', 'containing', 'therapies', '_num_', 'v', 'nonlapatinib', 'containing', 'therapies', '_num_', 'p', 'interaction', '_num_']"
1729,1.0,One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo.,"['_num_', 'cell', 'line', 'with', '_mutation_', 'mutation', 'was', 'also', 'found', 'to', 'be', 'sensitive', 'to', '_chemical_', 'in', 'vivo']"
1730,1.0,"In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein we had encountered.","['in', 'preclinical', 'work', 'using', '_abbrev_', '_disease_', 'cells', 'which', 'contain', 'the', '_chemical_', 'variant', '_num_', 'administration', 'of', 'the', '_gene_', 'inhibitor', '_chemical_', 'caused', 'marked', 'decrease', 'of', '_chemical_', 'protein', 'levels', 'at', 'concentrations', 'lower', 'than', 'those', 'used', 'to', 'knock', 'down', 'protein', 'levels', 'of', 'drivers', 'such', 'as', '_gene_', 'or', '_gene_', 'in', 'other', 'cell', 'lines', 'making', 'it', 'the', 'most', 'sensitive', '_gene_', 'client', 'protein', 'we', 'had', 'encountered']"
1731,1.0,Large variation in palbociclib sensitivity was observed and cell lines (N=40) were classified as above (resistant) or below (sensitive) the mean log of all IC50 values.,"['large', 'variation', 'in', '_chemical_', 'sensitivity', 'was', 'observed', 'and', 'cell', 'lines', '_ineq_', 'were', 'classified', 'as', 'above', 'resistant', 'or', 'below', 'sensitive', 'the', 'mean', 'log', 'of', 'all', '_abbrev_', 'values']"
1732,1.0,Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.,"['_num_', 'clinical', 'trials', 'evaluated', 'the', 'effects', 'of', '_chemical_', 'in', '_num_', 'patients', 'with', '_gene_', '_mutation_', 'positive', 'hairy', 'cell', 'leukemia']"
1733,1.0,"This missense mutation was found in a 34 yr old VHL patient with pancreatic cysts, pheochromocytoma, renal cyst lesions, and hemangioblastomas of the central nervous system and retina (index case 74).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_num_', 'yr', 'old', '_gene_', 'patient', 'with', 'pancreatic', 'cysts', 'pheochromocytoma', 'renal', 'cyst', 'lesions', 'and', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', 'retina', 'index', 'case', '_num_']"
1734,1.0,Tumors from mice with EML4-ALK variant 3 H2228 NSCLC cell xenografts which had progressed after approximately 40 days of crizotinib treatment were sequenced for ALK mutations.,"['tumors', 'from', 'mice', 'with', '_chemical_', 'variant', '_num_', '_abbrev_', '_disease_', 'cell', 'xenografts', 'which', 'had', 'progressed', 'after', 'approximately', '_num_', 'days', 'of', '_chemical_', 'treatment', 'were', 'sequenced', 'for', '_gene_', 'mutations']"
1735,1.0,Mutation was found in DNA binding RUNT domain at amino acid 107 from alanine to proline.,"['mutation', 'was', 'found', 'in', 'dna', 'binding', 'runt', 'domain', 'at', 'amino', 'acid', '_num_', 'from', 'alanine', 'to', 'proline']"
1736,1.0,"In a phase II trial on castration-resistant prostate cancer patients, FISH detection of PTEN deletion was associated with increased progression free survival (p=0.07) and with improved PSA response (p=0.02) in response to everolimus, an mTOR pathway inhibitor.","['in', 'a', 'phase', 'ii', 'trial', 'on', 'castration', 'resistant', 'prostate', 'cancer', 'patients', 'fish', 'detection', 'of', '_gene_', 'deletion', 'was', 'associated', 'with', 'increased', 'progression', 'free', 'survival', '_p_val_', 'and', 'with', 'improved', 'psa', 'response', '_p_val_', 'in', 'response', 'to', '_chemical_', 'an', '_gene_', 'pathway', 'inhibitor']"
1737,1.0,A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment.,"['a', 'retrospective', 'study', 'with', '_num_', 'colorectal', 'cancer', 'patients', 'found', 'that', '_gene_', 'deletion', 'was', 'associated', 'with', 'worse', 'outcomes', 'during', '_disease_', 'treatment']"
1738,1.0,"In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.","['in', 'an', 'evaluation', 'of', '_num_', 'patients', 'those', 'who', 'had', '_gene_', 'germline', 'mutations', '_ineq_', 'had', 'an', 'increase', 'response', 'rate', 'to', '_disease_', 'when', 'compared', 'to', 'those', 'without', 'germline', 'mutations', '_num_', 'vs', '_num_', '_p_val_', 'although', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'was', 'not', 'significantly', 'different']"
1739,1.0,This missense mutation was found in a 2 VHL family members (proband no 2).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_num_', '_gene_', 'family', 'members', 'proband', 'no', '_num_']"
1740,1.0,The thyroid cancer manifested as a 13.5 cm mass.,"['the', 'thyroid', 'cancer', 'manifested', 'as', 'a', '_num_', '_unit_', 'mass']"
1741,1.0,14 out of 121 patient samples contained mutations in NOTCH1.,"['_num_', 'out', 'of', '_num_', 'patient', 'samples', 'contained', 'mutations', 'in', '_gene_']"
1742,1.0,Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.,"['treatment', 'with', 'pacitaxel', '_chemical_', 'with', '_chemical_', 'showed', 'clear', 'clinical', 'improvement', 'assessed', 'by', 'ct', 'scan', 'and', 'drop', 'in', '_gene_', 'levels', 'from', '_num_', 'to', '_num_', 'u', '_unit_']"
1743,1.0,A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib.,"['a', 'panel', 'of', '_num_', 'glioblastoma', 'cell', 'lines', 'harboring', 'various', 'mutations', 'was', 'treated', 'with', '_chemical_']"
1744,1.0,"In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23).","['in', 'retrospective', 'analysis', 'of', 'trials', '_chemical_', 'conferred', 'limited', 'clinical', 'benefit', 'to', 'patients', 'with', '_gene_', 'exon', '_num_', 'insertion', 'mutations', '_ineq_']"
1745,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_abbrev_', 'demonstrated', 'reduced', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
1746,1.0,"Eight of 18 individuals had angiomas, 9 carried cerebellar hemangioblastomas, 6 carried renal cell carcinoma and 10 carried pheochromocytomas.","['_num_', 'of', '_num_', 'individuals', 'had', 'angiomas', '_num_', 'carried', 'cerebellar', '_disease_', '_num_', 'carried', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'carried', 'pheochromocytomas']"
1747,1.0,we conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study.,"['we', 'conclude', 'that', 'proof', 'of', 'concept', 'for', 'lapatanib', 'addition', 'to', 'chemotherapy', 'for', 'certain', 'subgroups', 'is', 'provided', 'in', 'this', 'study']"
1748,1.0,The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy.,"['the', '_gene_', 'mutation', 'was', 'identified', 'only', 'in', 'the', 'postdose', 'biopsy', 'and', 'not', 'in', 'the', 'predose', 'biopsy']"
1749,1.0,"This variant, identified in two cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', '_num_', 'cases', 'of', '_disease_', 'colorectal', 'cancer', 'was', 'confirmed', 'to', 'be', 'somatic', 'in', 'a', 'patient', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
1750,1.0,This nonsense mutation was found in a VHL with retinal angiomas and cerebellar hemangioblastomas.,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'with', 'retinal', 'angiomas', 'and', 'cerebellar', '_disease_']"
1751,1.0,"In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization.","['in', 'comparison', '_gene_', 'cells', '_gene_', '_gene_', 'expressing', 'low', 'levels', 'of', '_gene_', 'family', 'receptors', 'were', 'resistant', 'to', '_chemical_', 'induced', '_disease_']"
1752,1.0,"In this study, 45 synovial sarcomas were assayed for SYT-SSX by RT-PCR using tumor cDNA as template.","['in', 'this', 'study', '_num_', 'synovial', 'sarcomas', 'were', 'assayed', 'for', '_gene_', 'ssx', 'by', '_disease_', 'using', 'tumor', 'cdna', 'as', 'template']"
1753,1.0,A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created.,"['a', 'cohort', 'of', '_disease_', 'xenografts', '_gene_', 'from', '_num_', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', 'was', 'created']"
1754,1.0,ALK mutation V1180L was found in an H3122 derivative cell line that had become alectinib resistant after being passaged in increasing levels of alectinib.,"['_gene_', 'mutation', '_mutation_', 'was', 'found', 'in', 'an', '_abbrev_', 'derivative', 'cell', 'line', 'that', 'had', 'become', '_chemical_', 'resistant', 'after', 'being', 'passaged', 'in', 'increasing', 'levels', 'of', '_chemical_']"
1755,1.0,Those with high expression had worse overall and disease-specific survival.,"['those', 'with', 'high', 'expression', 'had', 'worse', 'overall', 'and', '_disease_', 'survival']"
1756,1.0,Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive.,"['inhibitor', 'concentrations', 'for', '_num_', 'survival', 'fraction', '_abbrev_', 'were', 'measured', 'and', '_abbrev_', 'less', 'than', '_num_', 'micro', 'molar', 'was', 'considered', 'sensitive']"
1757,1.0,"At 12 months, he maintains stable disease.","['at', '_num_', 'months', 'he', 'maintains', 'stable', 'disease']"
1758,1.0,"4 patients had partial response with progression free survival (PFS) of 4.3, 19.3, 10.0, 8.7 months; overall survival (OS) of 4.3, 34.9, 15.7, 15.7 months; and all 4 were alive at study end.","['_num_', 'patients', 'had', 'partial', 'response', 'with', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', '_num_', '_num_', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', '_num_', '_num_', '_num_', 'months', 'and', 'all', '_num_', 'were', 'alive', 'at', 'study', 'end']"
1759,1.0,Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect.,"['progressive', 'disease', 'was', 'noted', 'after', '_num_', 'cycles', 'of', 'pembrolizumab', 'but', 're', 'introduction', 'of', '_chemical_', 'did', 'not', 'show', 'an', 'effect']"
1760,0.0,"NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma.","['_gene_', 'is', 'an', 'ongoing', 'randomised', '_disease_', 'phase', '_num_', 'study', 'of', 'patients', 'with', 'advanced', 'unresectable', '_disease_', 'iiic', 'iv', 'nras', 'mutant', 'melanoma']"
1761,1.0,Two patients had the del L858R mutation.,"['_num_', 'patients', 'had', 'the', 'del', '_mutation_', 'mutation']"
1762,1.0,"This missense mutation was found in 2 German, VHL type 2 family members with retinal angiomas, hemangioblastomas of the central nervous system, and pheochromocytomas (family VHL 29).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'german', '_gene_', 'type', '_num_', 'family', 'members', 'with', 'retinal', 'angiomas', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', 'pheochromocytomas', 'family', '_gene_', '_num_']"
1763,1.0,"In regards to molecular response, before treatment the CALR mutant allele displayed a median frequency of 41% across the cohort, during treatment a significant decrease was observed in comparison to controls treated with hydroxyurea and aspirin.","['in', 'regards', 'to', 'molecular', 'response', 'before', 'treatment', 'the', '_gene_', 'mutant', 'allele', 'displayed', 'a', 'median', 'frequency', 'of', '_num_', 'across', 'the', 'cohort', 'during', 'treatment', 'a', 'significant', 'decrease', 'was', 'observed', 'in', 'comparison', 'to', 'controls', 'treated', 'with', '_chemical_', 'and', 'aspirin']"
1764,1.0,"In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status.","['in', 'this', '_disease_', 'analysis', '_num_', 'studies', '_num_', 'patients', '_gene_', 'gene', 'copy', 'number', '_gene_', 'was', 'predictive', 'of', 'improved', 'progression', 'free', 'survival', '_disease_', 'and', 'overall', 'survival', 'os', 'with', '_chemical_', 'or', 'panitumumab', 'regardless', 'of', '_gene_', 'status']"
1765,1.0,"Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations.","['of', 'the', '_num_', 'patients', '_num_', 'patients', 'received', '_chemical_', 'of', 'these', '_num_', '_num_', 'had', '_gene_', '_mutation_', 'mutations']"
1766,0.0,Activation of melanoma-cell-intrinsic WNT/β-catenin signalling pathway contributes to a lack of T-cell infiltration in melanoma.,"['activation', 'of', 'melanoma', 'cell', 'intrinsic', '_gene_', 'β', '_gene_', 'signalling', 'pathway', 'contributes', 'to', 'a', 'lack', 'of', '_disease_', 'infiltration', 'in', 'melanoma']"
1767,1.0,"In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 patients had BRAF (V600E) mutations.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'colorectal', 'cancer', '_num_', 'patients', 'had', '_gene_', '_mutation_', 'mutations', 'and', '_num_', 'patients', 'had', '_gene_', '_mutation_', 'mutations']"
1768,1.0,This nonsense mutation was found in a VHL type 2 family (lineage 65).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
1769,1.0,we conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab.,"['we', 'conclude', 'that', '_chemical_', 'monotherapy', 'shows', 'promise', 'in', 'treatment', 'of', 'metastatic', '_gene_', 'positive', 'breast', 'cancer', 'that', 'has', 'progressed', 'under', '_chemical_']"
1770,1.0,"There were no differences between treatments in OS, PFS, or response rates according to KRAS mutation status, and no evidence that KRAS mutation is a predictive factor for a differential survival effect between gefitinib and docetaxel.","['there', 'were', 'no', 'differences', 'between', 'treatments', 'in', 'os', '_disease_', 'or', 'response', 'rates', 'according', 'to', '_gene_', 'mutation', 'status', 'and', 'no', 'evidence', 'that', '_gene_', 'mutation', 'is', 'a', 'predictive', 'factor', 'for', 'a', 'differential', 'survival', 'effect', 'between', '_chemical_', 'and', '_chemical_']"
1771,1.0,"In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data.","['in', 'this', 'preclinical', 'study', '_disease_', 'of', '_gene_', 'was', 'mainly', 'caused', 'by', 'mutation', 'in', 'head', 'and', 'neck', 'cancer', 'as', 'identified', 'in', '_disease_', 'data']"
1772,1.0,This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 66).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
1773,1.0,Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025).,"['response', 'rate', 'with', 'low', '_gene_', 'expression', 'was', '_num_', 'compared', 'with', '_num_', 'in', 'patients', 'with', 'overexpression', 'p', '_num_']"
1774,1.0,"Within 40 days tumors progressed, and progressed tumors were assayed for ALK mutation.","['within', '_num_', 'days', 'tumors', 'progressed', 'and', 'progressed', 'tumors', 'were', 'assayed', 'for', '_gene_', 'mutation']"
1775,1.0,Prior treatment involved surgery and chemotherapy.,"['prior', 'treatment', 'involved', 'surgery', 'and', 'chemotherapy']"
1776,1.0,The rs3757441 variant in Intron 6 of EZH2 (C/C versus C/T or T/T) was significantly correlated with lower progression free survival and overall survival in patients with metastatic Colorectal Cancer (mCRC).,"['the', '_mutation_', 'variant', 'in', 'intron', '_num_', 'of', '_gene_', 'c', 'c', 'vs', '_mutation_', 'or', '_disease_', 'was', 'significantly', 'correlated', 'with', 'lower', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'in', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', '_disease_']"
1777,1.0,This patient had adenocarcinoma and a 9 pack year smoking history.,"['this', 'patient', 'had', 'adenocarcinoma', 'and', 'a', '_num_', 'pack', 'year', 'smoking', 'history']"
1778,0.0,A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence.,"['a', 'tumor', 'with', 'a', 'functional', 'nerve', 'growth', 'factor', 'receptor', 'may', 'be', 'dependent', 'on', 'the', '_gene_', 'nerve', 'growth', 'factor', 'for', 'survival', 'and', 'may', 'regress', 'in', 'its', 'absence']"
1779,1.0,"In an independent study, c-MET was overexpressed in 8 of 35 (23%) MAPKi-resistant tumors from 7 of 26 (27%) patients.","['in', 'an', 'independent', 'study', '_gene_', 'was', 'overexpressed', 'in', '_num_', 'of', '_num_', '_num_', 'mapki', 'resistant', 'tumors', 'from', '_num_', 'of', '_num_', '_num_', 'patients']"
1780,1.0,"A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors","['a', 'high', 'throughput', 'compound', 'screen', 'identified', 'synergistic', 'combinations', 'in', '_gene_', 'amplified', 'high', 'grade', 'serous', 'ovarian', 'carcinoma', 'including', '_chemical_', 'and', '_gene_', 'inhibitors']"
1781,1.0,"In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'endogenously', 'expressing', '_gene_', '_mutation_', 'mutation', 'a', 'known', '_chemical_', 'sensitizing', 'mutation', 'and', 'overexpressing', '_gene_', '_mutation_', 'mutation', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', 'as', 'compared', 'to', 'cells', 'expressing', '_gene_', '_mutation_', 'mutation', 'and', 'wildtype', '_gene_']"
1782,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', 'viii', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
1783,1.0,43 patients total were enrolled for this study.,"['_num_', 'patients', 'total', 'were', 'enrolled', 'for', 'this', 'study']"
1784,1.0,"Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.","['cancer', 'morphology', 'suggested', 'papillary', 'renal', 'cell', 'carcinoma', '_gene_', 'type', '_gene_']"
1785,1.0,"In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival.","['in', 'patients', 'with', 'multiple', 'myeloma', 'the', 'presence', 'of', 'a', 'mutation', 'in', 'nras', 'was', 'not', 'significantly', 'associated', 'with', 'progression', 'free', 'or', 'overall', 'survival']"
1786,1.0,"Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively.","['_num_', 'of', 'these', 'patients', 'had', '_gene_', 'amplifications', 'qpcr', 'and', 'showed', 'tumor', 'reductions', 'of', '_num_', '_num_', '_num_', 'and', '_num_', 'respectively']"
1787,1.0,"The fusion partners were not recurrent, respectively MBNL1, VIM and a lincRNA.","['the', 'fusion', 'partners', 'were', 'not', 'recurrent', 'respectively', '_gene_', 'vim', 'and', 'a', 'lincrna']"
1788,1.0,qRT-PCR results were also shown to correlate with protein expression measured by IHC.,"['qrt', 'pcr', 'results', 'were', 'also', 'shown', 'to', 'correlate', 'with', 'protein', 'expression', 'measured', 'by', '_gene_']"
1789,1.0,DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).,"['_gene_', '_abbrev_', 'mutations', 'occur', 'most', 'often', 'in', 'de', 'novo', '_disease_', 'patients', 'with', 'intermediate', 'risk', 'cytogenetics', '_ratio_', 'intermediate', 'risk', 'patients', 'vs', '_ratio_', 'low', 'and', 'high', 'risk']"
1790,1.0,"In multivariate analysis, compared to low, high SMARCA4 expression predicted a decrease in risk of death (HR=0.6, 95% CI: 0.4-0.8, P=0.002).","['in', 'multivariate', 'analysis', 'compared', 'to', 'low', 'high', '_gene_', 'expression', 'predicted', 'a', 'decrease', 'in', 'risk', 'of', 'death', '_ineq_', '_num_', 'ci', '_range_', '_p_val_']"
1791,1.0,"Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.","['immunoprecipitation', 'and', 'western', 'blot', 'analyses', 'confirmed', 'that', 'the', 'chimeric', 'protein', 'is', 'expressed', 'in', 'tumor', 'tissue', 'and', 'a', 'cell', 'culture', 'assay', 'indicated', 'that', 'it', 'retains', 'kinase', 'activity']"
1792,1.0,"OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.","['os', 'was', 'not', 'significantly', 'different', 'in', 'the', '_disease_', 'population', 'but', 'certain', 'subpopulations', 'showed', 'significant', 'differences']"
1793,1.0,"Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and we report one compete response in a MaMel301 cell line xenograft mouse.","['effects', 'of', 'single', 'agent', 'treatment', 'with', '_chemical_', 'or', '_chemical_', 'ranged', 'from', 'minor', 'inhibition', 'to', 'tumor', 'stasis', 'while', 'dual', 'inhibitor', 'treatment', 'showed', 'synergistic', 'effects', 'in', 'each', 'case', 'with', 'marked', 'tumor', 'reductions', 'in', '_ratio_', 'cases', 'and', 'we', 'report', '_num_', 'compete', 'response', 'in', 'a', '_abbrev_', 'cell', 'line', 'xenograft', 'mouse']"
1794,1.0,8 patients exhibited neither mutation nor methylation of VHL.,"['_num_', 'patients', 'exhibited', 'neither', 'mutation', 'nor', 'methylation', 'of', '_gene_']"
1795,1.0,"The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation.","['the', 'patient', 'was', 'treated', 'with', '_chemical_', 'and', '_chemical_', 'for', '_num_', 'months', 'had', 'a', 'partial', 'response', 'to', 'therapy', 'and', 'then', 'experienced', 'progressive', 'disease', 'with', 'a', 're', 'biopsy', 'of', 'the', 'tumor', 'identifying', 'a', '_gene_', '_mutation_', 'mutation']"
1796,1.0,we suggested that FGFR1 expression is a better predictive marker than FGFR1 amplification and proposes a connection between KRAS and PIK3CA mutations.,"['we', 'suggested', 'that', '_gene_', 'expression', 'is', 'a', 'better', 'predictive', 'marker', 'than', '_gene_', 'amplification', 'and', 'proposes', 'a', 'connection', 'between', '_gene_', 'and', '_gene_', 'mutations']"
1797,1.0,"6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L).","['_num_', 'were', '_gene_', 'wild', 'type', 'and', '_num_', 'harbored', 'various', '_gene_', 'mutations', '_mutation_', '_mutation_', '_mutation_', '_mutation_', 'and', '_mutation_']"
1798,1.0,This nonsense mutation was found in a VHL type 1 family (lineage 141).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
1799,1.0,"In a Portuguese family with 6 cases of breast cancer and 1 of ovarian cancer, a 46 year old woman was diagnosed with breast cancer.","['in', 'a', 'portuguese', 'family', 'with', '_num_', 'cases', 'of', 'breast', 'cancer', 'and', '_num_', 'of', 'ovarian', 'cancer', 'a', '_num_', 'year', 'old', 'woman', 'was', 'diagnosed', 'with', 'breast', 'cancer']"
1800,1.0,A patient treated with imatinib for a FIP1L1-PDGFRA mutation relapsed during treatment.,"['a', 'patient', 'treated', 'with', '_chemical_', 'for', 'a', '_chemical_', 'mutation', 'relapsed', 'during', 'treatment']"
1801,1.0,Cyclin D1 had higher expression levels in sensitive cell lines.,"['_gene_', '_gene_', 'had', 'higher', 'expression', 'levels', 'in', 'sensitive', 'cell', 'lines']"
1802,0.0,These mutations are similar to the ones seen in MEN1 syndrome inducing endocrine gland tumors.,"['these', 'mutations', 'are', 'similar', 'to', 'the', 'ones', 'seen', 'in', '_gene_', 'syndrome', 'inducing', 'endocrine', 'gland', 'tumors']"
1803,1.0,"Relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04).","['relative', 'hazard', 'of', 'mortality', 'for', 'cancers', 'lacking', '_gene_', 'after', 'adjusting', 'for', 'other', 'prognostic', 'factors', 'was', '_num_', '_num_', 'confidence', 'interval', '_range_', 'p', '_num_']"
1804,1.0,Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts.,"['preclinical', 'study', 'analyzing', 'the', 'differential', 'response', 'to', 'mek', 'inhibitors', 'in', '_gene_', 'and', '_gene_', 'mutant', 'cancer', 'cell', 'lines', 'and', 'mouse', 'xenografts']"
1805,1.0,CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS).,"['_gene_', '_gene_', 'density', 'was', 'an', 'independent', 'predictor', 'of', 'progression', 'free', 'survival', '_disease_', 'and', 'overall', 'survival', 'os']"
1806,1.0,"Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody).","['immunohistochemical', 'analyses', 'of', '_gene_', 'protein', 'was', 'retrospectively', 'performed', 'on', '_num_', 'archived', '_disease_', 'surgical', 'tissues', '_num_', 'benign', 'thyroid', 'nodules', 'and', '_num_', 'papillary', 'thyroid', 'carcinomas', '_gene_', '_abbrev_', 'antibody']"
1807,1.0,"Loss or mutation of PTEN  eg PTEN deletion, T319fsX1/Y155C, etc).was significantly associated with ipatasertib sensitivity (p=0.000071).","['loss', 'or', 'mutation', 'of', '_gene_', 'eg', '_gene_', 'deletion', '_abbrev_', 'etc', 'was', 'significantly', 'associated', 'with', 'ipatasertib', 'sensitivity', '_p_val_']"
1808,1.0,The patient was treated with erlotinib 150 mg orally/daily.,"['the', 'patient', 'was', 'treated', 'with', '_chemical_', '_num_', '_unit_', 'orally', 'daily']"
1809,1.0,The stable disease patient had an R1275L mutation in ALK.,"['the', 'stable', 'disease', 'patient', 'had', 'an', '_mutation_', 'mutation', 'in', '_gene_']"
1810,1.0,"Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study.","['patients', 'who', 'had', 'histologically', 'confirmed', 'unresectable', 'stage', 'iiic', 'or', 'iv', 'cutaneous', 'melanoma', 'with', 'a', '_mutation_', 'or', '_mutation_', '_gene_', 'mutation', 'were', 'eligible', 'for', 'the', 'study']"
1811,1.0,"In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild type patients.","['in', 'patients', 'with', '_disease_', 'syndrome', 'in', 'a', 'multivariate', 'analysis', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'shorter', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
1812,1.0,"Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition.","['cells', 'were', 'tested', 'for', 'sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_', 'and', '_gene_', 'inhibitor', '_chemical_', 'and', 'no', 'significant', 'correlation', 'was', 'found', 'between', '_gene_', 'status', 'and', 'sensitivity', 'to', 'mtorc', 'inhibition']"
1813,1.0,"shRb treated cells showed restoration of cell proliferation (BrdU incorporation) under palbociclib treatment, indicating resistance.","['shrb', 'treated', 'cells', 'showed', 'restoration', 'of', 'cell', 'proliferation', '_disease_', 'incorporation', 'under', '_chemical_', 'treatment', 'indicating', 'resistance']"
1814,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR S768I and EGFR L858R expressing cells were 250 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_mutation_', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
1815,1.0,"High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples.","['high', 'expression', 'determined', 'by', 'immunohistochemistry', 'of', '_gene_', 'was', 'found', 'in', '_num_', 'out', 'of', '_num_', 'breast', 'cancer', 'samples']"
1816,1.0,Dose was reduced to 600 mg ceritinib daily due to gastrointestinal side effects.,"['dose', 'was', 'reduced', 'to', '_num_', '_unit_', '_chemical_', 'daily', 'due', 'to', 'gastrointestinal', 'side', 'effects']"
1817,1.0,Cell proliferation was effectively inhibited in 3 cell lines by everolimus.,"['cell', 'proliferation', 'was', 'effectively', 'inhibited', 'in', '_num_', 'cell', 'lines', 'by', '_chemical_']"
1818,1.0,These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.,"['these', 'results', 'were', 'confirmed', 'using', '_gene_', 'in', 'an', 'independent', 'cohort', 'of', '_num_', 'patients', '_num_', 'responders', 'treated', 'with', '_chemical_', 'at', 'another', 'institution']"
1819,1.0,"In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'the', '_mutation_', 'mutation', 'was', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
1820,1.0,This was potentially explained by presence of PTEN loss in wild type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007).,"['this', 'was', 'potentially', 'explained', 'by', 'presence', 'of', '_gene_', 'loss', 'in', 'wild', 'type', '_gene_', 'sample', 'and', 'combining', '_gene_', 'loss', 'with', '_gene_', 'mutation', 'resulted', 'in', 'significant', 'differences', 'in', 'time', 'to', 'progression', '_p_val_']"
1821,1.0,This EML4-ALK variant is different from those commonly found in NSCLC.,"['this', '_chemical_', 'variant', 'is', 'different', 'from', 'those', 'commonly', 'found', 'in', '_disease_']"
1822,1.0,MGH056-1 cells were resistant to crizotinib (IC50 236nmol/L; aproximately 50x higher than for ceritinib).,"['_abbrev_', 'cells', 'were', 'resistant', 'to', '_chemical_', '_abbrev_', '_unit_', '_unit_', 'aproximately', '50x', 'higher', 'than', 'for', '_chemical_']"
1823,1.0,"The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplifications.","['the', 'endothelial', 'phosphatase', '_gene_', 'a', 'negative', 'regulator', 'of', 'vascular', 'growth', 'factor', 'tyrosine', 'kinases', 'harbored', 'truncating', 'mutations', 'in', '_num_', 'of', '_num_', 'angiosarcomas', '_num_', 'which', 'correlated', 'with', '_gene_', 'amplifications']"
1824,1.0,81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib.,"['_num_', 'patients', 'were', 'enrolled', 'in', 'a', 'clinical', 'trial', 'with', 'the', '_gene_', 'inhibitor', '_chemical_']"
1825,1.0,The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model.,"['the', 'combination', 'of', 'metformin', 'and', '_chemical_', 'shown', 'synergistic', 'effects', 'in', 'most', 'tested', 'cell', 'lines', 'no', 'antagonistic', 'effects', 'observed', 'and', 'a', 'melanoma', 'xenograft', 'model']"
1826,1.0,This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status.,"['this', 'study', 'shows', 'that', 'benefit', 'of', '_gene_', 'inhibition', 'in', 'addition', 'to', 'radiotherapy', 'was', 'independent', 'of', '_abbrev_', 'status']"
1827,1.0,123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KILLIN.,"['_num_', 'patients', 'with', '_disease_', 'or', 'cowden', 'like', 'syndrome', 'from', 'the', '_abbrev_', 'series', 'and', '_num_', 'unaffected', 'individuals', 'without', '_gene_', 'variants', 'were', 'analyzed', 'for', 'germline', 'methylation', 'and', 'expression', 'of', '_gene_', 'and', '_gene_']"
1828,1.0,EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers.,"['_chemical_', 'variant', '_num_', 'was', 'discovered', 'in', 'tumor', 'tissue', 'using', '_disease_', 'with', '_gene_', 'and', '_gene_', 'specific', 'primers']"
1829,1.0,Literature analysis did not identify additional reports of patients harboring this mutation.,"['literature', 'analysis', 'did', 'not', 'identify', 'additional', 'reports', 'of', 'patients', 'harboring', 'this', 'mutation']"
1830,1.0,"Expression of HIF1A was analyzed by IHC in 49 soft-tissue sarcomas (29 malignant fibrous histiocytomas, 12 synovial sarcomas, 4 leiomyosarcomas and 4 malignant peripheral nerve sheath tumors).","['expression', 'of', '_gene_', 'was', 'analyzed', 'by', '_gene_', 'in', '_num_', 'soft', 'tissue', 'sarcomas', '_num_', 'malignant', 'fibrous', '_disease_', '_num_', 'synovial', 'sarcomas', '_num_', 'leiomyosarcomas', 'and', '_num_', 'malignant', 'peripheral', 'nerve', 'sheath', 'tumors']"
1831,1.0,"EML4-ALK F1245C was found at 500 nM crizotinib, and was among the 10 most frequently observed mutations.","['_chemical_', '_mutation_', 'was', 'found', 'at', '_num_', '_unit_', '_chemical_', 'and', 'was', 'among', 'the', '_num_', 'most', 'frequently', 'observed', 'mutations']"
1832,1.0,"Mutation also found in 8 individuals with VHL type 1 phenotype (family IDs 3314, 4419, 4403, 3708).","['mutation', 'also', 'found', 'in', '_num_', 'individuals', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'ids', '_num_', '_num_', '_num_', '_num_']"
1833,1.0,Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.,"['whole', 'exome', 'sequencing', 'of', '_num_', 'chronic', 'lymphocytic', 'leukemia', 'patients', 'with', 'acquired', 'resistance', 'to', '_chemical_', 'determined', '_ratio_', 'patients', 'harbored', 'a', '_mutation_', 'mutation', 'in', '_gene_']"
1834,1.0,HER2 positivity was assessed via FISH.,"['_gene_', 'positivity', 'was', 'assessed', 'via', 'fish']"
1835,1.0,"In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.","['in', 'patients', 'with', 'medullary', 'carcinoma', 'the', 'presence', 'of', 'ret', '_mutation_', 'mutation', 'is', 'associated', 'with', 'increased', 'probability', 'of', 'lymph', 'node', 'metastases']"
1836,1.0,"A synthetic lethal screen using a total of 3,530 shRNAs to target 518 human kinases identified ERBB3 knockdown to confer sensitivity of selumetinib-resistant H358 cells (NSCLC cell line) to the MEK inhibitor selumetinib.","['a', 'synthetic', 'lethal', 'screen', 'using', 'a', 'total', 'of', '_num_', 'shrnas', 'to', 'target', '_num_', 'human', 'kinases', 'identified', '_gene_', 'knockdown', 'to', 'confer', 'sensitivity', 'of', '_chemical_', 'resistant', '_abbrev_', 'cells', '_disease_', 'cell', 'line', 'to', 'the', 'mek', 'inhibitor', '_chemical_']"
1837,1.0,Overexpression of Sirt1 in pancreas cancer cell lines MiaPaCa-2 and PANC-1 led to increased cell viability.,"['overexpression', 'of', '_gene_', 'in', 'pancreas', 'cancer', 'cell', 'lines', '_disease_', 'and', '_gene_', 'led', 'to', 'increased', 'cell', 'viability']"
1838,1.0,"In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had  EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2).","['in', 'a', 'study', 'of', '_num_', 'non', 'small', 'cell', 'lung', 'cancer', 'patients', '_num_', 'of', 'the', 'analyzed', 'tumors', 'had', '_gene_', 'mutations', 'including', 'deletions', 'in', 'exon', '_num_', '_ineq_', '_mutation_', '_ineq_', 'and', '_mutation_', '_gene_']"
1839,1.0,"Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27% of patients who expressed STAG2 on IHC (P=0.002).","['of', 'those', 'with', '_gene_', 'expression', 'loss', '_num_', 'presented', 'with', 'metastatic', 'disease', 'compared', 'to', 'only', '_num_', 'of', 'patients', 'who', 'expressed', '_gene_', 'on', '_gene_', '_p_val_']"
1840,0.0,NF2 loss promotes oncogenic RAS-signaling via YAP-dependent transactivation of RAS and sensitizes to MEK inhibition.,"['_gene_', 'loss', 'promotes', '_disease_', 'ras', 'signaling', 'via', 'yap', 'dependent', 'transactivation', 'of', 'ras', 'and', 'sensitizes', 'to', 'mek', 'inhibition']"
1841,1.0,"This nonsense mutation was found in a Filipino, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 50).","['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', 'filipino', '_gene_', 'type', '_num_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'family', '_gene_', '_num_']"
1842,0.0,"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test","['_chemical_', 'an', 'irreversible', 'inhibitor', 'of', 'the', '_gene_', 'family', 'of', 'tyrosine', 'kinases', 'has', 'been', 'approved', 'in', 'the', 'us', 'for', 'the', '_num_', 'line', 'treatment', 'of', 'patients', 'with', 'metastatic', 'non', 'small', 'cell', 'lung', 'cancer', '_disease_', 'who', 'have', 'tumours', 'with', '_gene_', 'exon', '_num_', 'deletions', 'or', 'exon', '_num_', '_mutation_', 'substitution', 'mutations', 'as', 'detected', 'by', 'a', 'us', 'fda', 'approved', 'test']"
1843,1.0,Panitumumab was still active in-vitro and in one patient.,"['panitumumab', 'was', 'still', 'active', 'in', 'vitro', 'and', 'in', '_num_', 'patient']"
1844,1.0,This missense mutation was found in a VHL type 1 family (lineage 53).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
1845,1.0,"EML4-ALK T1151insT was expressed In Ba/F3 cells and an IC50 of 431.8 nM was obtained, which was 16 times higher than for EML4-ALK wild type, indicating strong crizotinib resistance.","['_chemical_', '_abbrev_', 'was', 'expressed', 'in', 'ba', '_abbrev_', 'cells', 'and', 'an', '_abbrev_', 'of', '_num_', '_unit_', 'was', 'obtained', 'which', 'was', '_num_', 'times', 'higher', 'than', 'for', '_chemical_', 'wild', 'type', 'indicating', 'strong', '_chemical_', 'resistance']"
1846,1.0,"For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361).","['for', 'the', 'pooled', 'analysis', 'the', 'objective', 'response', 'rate', 'orr', 'was', '_num_', '_ratio_', 'in', 'patients', 'with', 'high', '_gene_', '_gene_', 'while', 'in', 'patients', 'with', 'low', '_gene_', '_gene_', 'the', 'pooled', 'orr', 'was', '_num_', '_ratio_']"
1847,1.0,Overall survival rate in the high expression group (2+ moderate/3+ strong staining) was significantly lower compared with the low expression group (0 no/1+ weak staining) (P = 0.0364).,"['overall', 'survival', 'rate', 'in', 'the', 'high', 'expression', 'group', '2+', 'moderate', '3+', 'strong', 'staining', 'was', 'significantly', 'lower', 'compared', 'with', 'the', 'low', 'expression', 'group', '_num_', 'no', '1+', 'weak', 'staining', 'p', '_num_']"
1848,1.0,"While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.","['while', 'full', 'study', 'results', 'have', 'not', 'yet', 'been', 'published', 'this', 'paper', 'highlights', 'in', 'vitro', 'results', 'that', 'further', 'confirm', 'the', 'role', 'of', '_gene_', '_mutation_', 'mutation']"
1849,1.0,"In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib.","['in', 'a', 'phase', 'ii', 'trial', 'for', '_disease_', 'carcinoma', '_disease_', 'or', 'in', '_disease_', 'pulmonary', 'adenocarcinoma', '_gene_', 'exons', '_range_', 'were', 'analyzed', 'in', '_num_', 'patients', 'who', 'had', 'shown', 'a', 'partial', 'response', 'to', '_chemical_']"
1850,0.0,"Furthermore, cabozantinib could overcome all the resistance by all newly identified secondary mutations.","['furthermore', '_chemical_', 'could', 'overcome', 'all', 'the', 'resistance', 'by', 'all', 'newly', 'identified', 'secondary', 'mutations']"
1851,1.0,A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma.,"['a', 'phase', 'ii', 'study', 'for', 'use', 'of', '_chemical_', 'in', 'non', '', 'or', 'light', 'smokers', 'with', 'lung', 'adenocarcinoma']"
1852,1.0,"CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001).","['_gene_', 'mutations', 'are', 'associated', 'with', 'diffuse', 'type', 'mucinous', 'gastric', 'carcinoma', 'which', 'indicate', 'worse', 'prognosis', 'when', 'compared', 'to', 'intestinal', 'type', 'p', '_num_']"
1853,1.0,EGFR expression or exposure to TGF-β becomes beneficial for proliferation of melanoma cells in the presence of BRAF or MEK inhibitors.,"['_gene_', 'expression', 'or', 'exposure', 'to', 'tgf', 'β', 'becomes', 'beneficial', 'for', 'proliferation', 'of', 'melanoma', 'cells', 'in', 'the', 'presence', 'of', '_gene_', 'or', 'mek', 'inhibitors']"
1854,1.0,"The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel.","['the', 'xenograft', 'was', 'resistant', 'to', 'monotherapy', 'with', 'both', 'the', 'pan', '_gene_', 'inhibitor', '_chemical_', 'and', 'also', 'to', 'the', 'commonly', 'used', 'gastric', 'cancer', 'chemotheraputic', '_chemical_']"
1855,1.0,"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537S ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.","['using', 'an', 'estrogen', 'response', 'element', '_disease_', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_mutation_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_chemical_', 'cell', 'lines']"
1856,1.0,15 of the 28 cell lines had high levels of Cyclin D1 (CCND1) expression which did not correlate significantly with palbociclib sensitivity (p=0.348).,"['_num_', 'of', 'the', '_num_', 'cell', 'lines', 'had', 'high', 'levels', 'of', '_gene_', '_gene_', '_gene_', 'expression', 'which', 'did', 'not', 'correlate', 'significantly', 'with', '_chemical_', 'sensitivity', '_p_val_']"
1857,1.0,MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.,"['_chemical_', 'cell', 'lines', 'harboring', 'the', '_mutation_', 'mutation', 'in', 'the', '_disease_', 'domain', 'of', '_gene_', 'have', 'shown', 'resistance', 'to', 'hormone', 'therapy']"
1858,1.0,A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma.,"['a', '_gene_', '_abbrev_', 'mutation', 'was', 'found', 'to', 'activate', 'the', 'jak', '_gene_', 'signaling', 'pathway', 'in', 'vitro', 'and', 'in', 'vivo', 'in', '_disease_', 'carcinoma']"
1859,1.0,This nonsense mutation was found in 3 VHL families with 9 patients altogether.,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'families', 'with', '_num_', 'patients', 'altogether']"
1860,1.0,Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer.,"['expression', 'of', '_gene_', '_gene_', 'in', '_num_', 'prostate', 'specimens', 'assessed', 'by', '_gene_', 'was', 'increased', 'in', 'castrate', 'resistant', 'prostate', 'cancer']"
1861,1.0,Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis.,"['young', 'patients', '_range_', 'with', '_gene_', 'mutations', 'had', 'improved', 'overall', 'survival', 'following', '_disease_', 'vs', 'standard', 'dose', '_chemical_', '_p_val_', 'in', 'univariate', 'analysis']"
1862,1.0,"Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric cancer  (P=0.03/P=0.008, P(log-rank)=0.001, respectively).","['low', '_gene_', 'expression', 'was', 'associated', 'with', 'improved', 'histopathological', 'and', 'clinical', 'response', 'and', 'os', 'in', 'patients', 'with', 'gastric', 'cancer', '_p_val_', 'p', 'log', 'rank', '_ineq_', 'respectively']"
1863,1.0,TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene fusion.,"['_gene_', '_gene_', 'protein', 'expression', 'was', 'associated', 'with', 'presence', 'of', '_gene_', 'gene', 'fusion']"
1864,1.0,"In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.","['in', '_gene_', 'cells', 'with', '_gene_', '_mutation_', 'mutation', 'that', 'have', 'shown', '_chemical_', 'resistance', '_chemical_', 'was', 'significantly', 'more', 'potent', 'at', 'inhibiting', 'kinase', 'activity', 'than', '_chemical_']"
1865,1.0,"Both crizotinib treatment and siRNA against MET increased apoptotic markers in MET amplified cells but not controls, indicating that crizotinib targeting of amplified MET was inducing the apoptotic effects.","['both', '_chemical_', 'treatment', 'and', 'sirna', 'against', 'met', 'increased', 'apoptotic', 'markers', 'in', 'met', 'amplified', 'cells', 'but', 'not', 'controls', 'indicating', 'that', '_chemical_', 'targeting', 'of', 'amplified', 'met', 'was', 'inducing', 'the', 'apoptotic', 'effects']"
1866,1.0,In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy.,"['in', 'vitro', 'experiments', 'confirmed', 'that', '_gene_', 'expression', 'enhance', '_chemical_', 'efficacy']"
1867,1.0,"Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.","['of', 'the', '_num_', 'patients', '_num_', 'had', 'an', 'exon', '_num_', 'deletion', '_num_', 'had', 'an', '_mutation_', 'mutation', '_num_', 'patient', 'had', 'an', 'exon', '_num_', '_mutation_', 'mutation', '_num_', 'had', 'an', 'exon', '_mutation_', 'mutation', 'and', '_num_', 'had', 'other', 'mutations']"
1868,1.0,"Additional manifestations aside from pheochromocytoma are possible, but were not discussed.","['additional', 'manifestations', 'aside', 'from', 'pheochromocytoma', 'are', 'possible', 'but', 'were', 'not', 'discussed']"
1869,1.0,"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival.","['in', 'patients', 'with', 'cytogenetically', 'normal', 'acute', 'myeloid', 'leukemia', 'those', 'in', 'the', 'intermediate', 'i', 'risk', 'group', 'with', '_gene_', 'mutations', 'did', 'not', 'have', 'significantly', 'different', 'rates', 'of', 'event', 'free', 'survival', 'complete', 'remission', '_disease_', 'survival', 'or', 'overall', 'survival']"
1870,1.0,Response rates did not differ between groups.,"['response', 'rates', 'did', 'not', 'differ', 'between', 'groups']"
1871,1.0,MMTV-NeuT mice were crossed with floxed p110alpha mice.,"['mmtv', '_disease_', 'mice', 'were', 'crossed', 'with', 'floxed', '_gene_', 'mice']"
1872,0.0,Expression levels of RRM2 progressively increased during the development of gemcitabine resistance.,"['expression', 'levels', 'of', '_gene_', 'progressively', 'increased', 'during', 'the', 'development', 'of', '_chemical_', 'resistance']"
1873,1.0,we conclude this finding is promising and merits further study.,"['we', 'conclude', 'this', 'finding', 'is', 'promising', 'and', 'merits', 'further', 'study']"
1874,1.0,Sequencing of RUNX1 exons 3-6 revealed an 8 bp deletion which was hypothesized to result in a null allele.,"['sequencing', 'of', '_gene_', 'exons', '_range_', 'revealed', 'an', '_num_', '_gene_', 'deletion', 'which', 'was', 'hypothesized', 'to', 'result', 'in', 'a', 'null', 'allele']"
1875,1.0,NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.,"['_chemical_', 'induced', 'apoptosis', 'in', '_abbrev_', 'cells', 'harboring', 'an', '_gene_', 'mutation']"
1876,1.0,"Further, low expression of mir-218 was revealed to be associated with lower overall survival (p < .001), and multivariate analysis revealed that low expression of mir-218 as an independent predictor of poor prognosis (p < .007).","['further', 'low', 'expression', 'of', '_abbrev_', 'was', 'revealed', 'to', 'be', 'associated', 'with', 'lower', 'overall', 'survival', 'p', '_num_', 'and', 'multivariate', 'analysis', 'revealed', 'that', 'low', 'expression', 'of', '_abbrev_', 'as', 'an', 'independent', 'predictor', 'of', 'poor', 'prognosis', 'p', '_num_']"
1877,1.0,A total of 220 patients with RCC were evaluated for 341 genes at 540x coverage.,"['a', 'total', 'of', '_num_', 'patients', 'with', '_gene_', 'were', 'evaluated', 'for', '_num_', 'genes', 'at', '540x', 'coverage']"
1878,0.0,"In contrast, only 48% displayed a concordant differential expression pattern of at least one c-MET transcription factor.","['in', 'contrast', 'only', '_num_', 'displayed', 'a', 'concordant', 'differential', 'expression', 'pattern', 'of', 'at', 'least', '_num_', '_gene_', 'transcription', 'factor']"
1879,1.0,"116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.","['_num_', 'chinese', 'patients', 'with', 'histologically', 'confirmed', 'gastric', 'cancer', 'were', 'used', 'in', 'this', 'study', 'and', 'all', 'patients', 'had', 'radical', 'surgery', 'before', 'treatment']"
1880,0.0,Growth of tumors ensued after discontinuation of Everolimus.,"['growth', 'of', 'tumors', 'ensued', 'after', 'discontinuation', 'of', '_chemical_']"
1881,1.0,"When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.","['when', '_gene_', 'and', '_gene_', 'amplifications', 'were', 'also', 'assessed', 'a', 'combined', '_gene_', 'pathway', 'amplified', 'patient', 'group', 'had', 'a', 'higher', 'mean', 'reduction', 'in', 'target', 'lesion', 'size', 'than', 'patients', 'with', '_gene_', 'non', 'amplified', 'tumors']"
1882,1.0,"Compared to other dose scheme in PMID 23569312 with 200mg/d: 12week PFS 66%, overall median PFS 18 weeks.","['compared', 'to', 'other', 'dose', 'scheme', 'in', '_disease_', '_num_', 'with', '_unit_', 'd', '12week', '_disease_', '_num_', 'overall', 'median', '_disease_', '_num_', 'weeks']"
1883,1.0,"In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212.","['in', 'this', 'screen', 'of', '_num_', 'solid', 'cancer', 'cell', 'lines', '_gene_', 'and', '_gene_', 'mutations', 'were', 'predictive', 'of', 'response', 'to', 'mek', 'inhibitor', '_chemical_']"
1884,1.0,"HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma.","['_disease_', 'terms', 'retinal', '_disease_', '_disease_', 'renal', 'cell', 'carcinoma']"
1885,1.0,IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival.,"['_gene_', '_abbrev_', 'mutation', 'in', 'patients', 'suffering', 'from', '_disease_', 'syndromes', 'is', 'associated', 'with', 'worse', 'overall', 'survival']"
1886,0.0,"Its specificity for synovial sarcoma, has been confirmed by molecular screening of other morphologically similar sarcomas.","['its', 'specificity', 'for', 'synovial', 'sarcoma', 'has', 'been', 'confirmed', 'by', 'molecular', 'screening', 'of', 'other', 'morphologically', 'similar', 'sarcomas']"
1887,1.0,Pre-treatment and relapse samples of 8 patients (treated with AC220) with FLT3-ITD+ acute myeloid leukemia were analyzed.,"['_gene_', 'treatment', 'and', 'relapse', 'samples', 'of', '_num_', 'patients', 'treated', 'with', '_abbrev_', 'with', '_abbrev_', 'acute', 'myeloid', 'leukemia', 'were', 'analyzed']"
1888,1.0,In a cohort of 1596 neuroblastoma patients.,"['in', 'a', 'cohort', 'of', '_num_', 'neuroblastoma', 'patients']"
1889,1.0,A 69 year-old woman presented with metastatic mucuosal melanoma of the anus.,"['a', '_num_', '_age_', 'woman', 'presented', 'with', 'metastatic', 'mucuosal', 'melanoma', 'of', 'the', 'anus']"
1890,1.0,Results were validated in 5 KRAS mutant (BRAF WT) and 10 KRAS WT colorectal cancer cell lines.,"['results', 'were', 'validated', 'in', '_num_', '_gene_', 'mutant', '_gene_', '_gene_', 'and', '_num_', '_gene_', '_gene_', 'colorectal', 'cancer', 'cell', 'lines']"
1891,1.0,"79%, or 31 out of the 39 patients,  had the T790M EGFR mutation present, indicating its importance in the development of resistance.","['_num_', 'or', '_num_', 'out', 'of', 'the', '_num_', 'patients', 'had', 'the', '_mutation_', '_gene_', 'mutation', 'present', 'indicating', 'its', 'importance', 'in', 'the', 'development', 'of', 'resistance']"
1892,1.0,"Patients were treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and tumors harboring an EGFR mutation had an increased frequency of partial response (PR) and a lower rate of progressive disease (PD) (PR:22, PD:2 vs. PR:2, PD:17; P<0.0001) compared to wildtype EGFR patients.","['patients', 'were', 'treated', 'with', 'the', 'epidermal', 'growth', 'factor', 'receptor', 'tyrosine', 'kinase', 'inhibitor', '_chemical_', 'and', 'tumors', 'harboring', 'an', '_gene_', 'mutation', 'had', 'an', 'increased', 'frequency', 'of', 'partial', 'response', 'pr', 'and', 'a', 'lower', 'rate', 'of', 'progressive', 'disease', 'pd', 'pr:22', 'pd:2', 'vs', 'pr:2', 'pd:17', 'p', '_num_', 'compared', 'to', 'wildtype', '_gene_', 'patients']"
1893,1.0,"Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib.","['consolidation', 'therapy', 'with', '_chemical_', '_chemical_', 'mercaptopurine', 'and', '_chemical_', 'followed', 'and', 'the', 'patient', 'was', 'still', 'in', 'remission', '_num_', 'months', 'after', 'beginning', '_chemical_']"
1894,1.0,"Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration.","['whole', 'exome', 'sequencing', 'of', 'the', 'metastatic', 'tumor', 'revealed', '_gene_', '_mutation_', '_gene_', 'frameshift', 'deletion', 'and', 'atm', 'alteration']"
1895,1.0,Expression of the mutation in MDA-MB-468 cells led to AZD8055 resistance and these cells were also rapamycin and RapaLink-1 sensitive.,"['expression', 'of', 'the', 'mutation', 'in', '_disease_', 'cells', 'led', 'to', '_chemical_', 'resistance', 'and', 'these', 'cells', 'were', 'also', '_gene_', 'and', '_abbrev_', 'sensitive']"
1896,1.0,"In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K).","['in', 'a', 'panel', 'of', '_num_', 'gastric', 'cancer', 'cell', 'lines', '_num_', 'of', '_num_', 'cell', 'lines', 'having', 'the', 'highest', 'sensitivity', 'to', '_chemical_', 'contained', 'a', '_gene_', 'mutation', '_mutation_', '_mutation_', '_mutation_']"
1897,1.0,ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along with a tendency toward a longer overall survival (p = 0.093).,"['_gene_', '_mutation_', 'carriers', 'had', 'a', 'longer', 'progression', 'free', 'survival', 'p', '_num_', 'along', 'with', 'a', 'tendency', 'toward', 'a', 'longer', 'overall', 'survival', 'p', '_num_']"
1898,1.0,"Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells.","['treatment', 'of', '_chemical_', 'positive', '_disease_', 'cell', 'lines', '_abbrev_', 'and', 'su', 'dhl', '_num_', 'potently', 'inhibited', 'growth', 'and', 'this', 'was', 'seen', 'to', 'occur', 'at', 'concentrations', 'which', 'also', 'inhibited', '_chemical_', '_disease_', 'in', 'these', 'cells']"
1899,1.0,"Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer.","['exploratory', '_chemical_', 'analysis', 'from', 'a', 'phase', 'ii', 'randomized', 'trial', 'comparing', 'atezolizumab', '_gene_', 'and', '_chemical_', 'in', 'previously', 'treated', 'advanced', 'or', 'metastatic', 'non', 'small', 'cell', 'lung', 'cancer']"
1900,1.0,"Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901.","['preclinical', 'data', 'supporting', 'resistance', 'of', 'exon', '_num_', 'mutations', 'in', 'particular', '_mutation_', 'to', '_chemical_', 'and', 'sensitivity', 'to', '_chemical_']"
1901,1.0,The same in-vitro results could be reproduced for the G719S mutation.,"['the', 'same', 'in', 'vitro', 'results', 'could', 'be', 'reproduced', 'for', 'the', '_mutation_', 'mutation']"
1902,1.0,Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment.,"['resistance', 'to', '_chemical_', 'developed', 'in', 'a', 'patient', 'with', 'metastatic', 'lung', 'adenocarcinoma', 'harboring', 'a', '_abbrev_', 'rearrangement', 'who', 'had', 'initially', 'shown', 'a', 'dramatic', 'response', 'to', 'treatment']"
1903,1.0,"After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D and HLA-C*08:02.","['after', 'cultures', 'were', 'tested', 'for', 'reactivity', 'the', 'patient', 'was', 'infused', 'with', '_num_', 'x', '10^11', '_disease_', 'lymphocytes', '_num_', '_gene_', 't', 'cells', 'that', 'were', 'specifically', 'reactive', 'to', '_gene_', '_mutation_', 'and', 'hla', 'c*08:02']"
1904,1.0,"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, EGFR mutation was assessed.","['in', 'the', 'placebo', 'controlled', 'phase', 'iii', 'study', 'saturn', 'using', '_chemical_', 'maintenance', 'therapy', 'for', 'patients', 'with', 'advanced', '_disease_', 'who', 'were', 'selected', 'for', 'response', 'or', 'stable', 'disease', 'after', '_num_', 'line', 'chemotherapy', '_gene_', 'mutation', 'was', 'assessed']"
1905,1.0,Significant difference in PFS between erlotinib treated KRAS WT and MUT patients was not seen.,"['significant', 'difference', 'in', '_disease_', 'between', '_chemical_', 'treated', '_gene_', '_gene_', 'and', '_gene_', 'patients', 'was', 'not', 'seen']"
1906,1.0,"For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).","['for', '_gene_', 'patients', 'specifically', 'the', 'hazard', 'ratio', 'was', '_num_', '_num_', 'ci', '_range_']"
1907,1.0,Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells.,"['reduced', 'lipid', 'kinase', 'activity', 'and', 'reduced', '_chemical_', 'levels', 'were', 'seen', 'in', 'these', 'cells']"
1908,1.0,"Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors).","['pharmacologic', '_abbrev_', '_gene_', 'specific', 'inhibitor', 'or', 'genetic', '_gene_', 'mediated', 'knockout', 'ablation', 'of', 'the', '_gene_', '_gene_', '_chemical_', 'reduced', 'tumor', 'growth', 'and', 'tumor', 'formation', 'respectively', 'in', 'athymic', 'mice', 'transplanted', 'with', 'cells', 'transduced', 'by', 'mmtv', '_disease_', 'mammary', 'specific', 'overexpression', 'of', '_gene_', 'that', 'effectively', 'induces', 'tumors']"
1909,1.0,"In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059).","['in', 'a', 'panel', 'of', '_num_', 'cell', 'lines', '_num_', 'with', '_gene_', 'mutation', 'status', 'known', 'from', 'solid', 'and', 'hematological', 'tumors', 'significant', 'correlation', 'was', 'found', 'between', '_chemical_', 'pan', '_gene_', 'inhibitor', 'sensitivity', 'and', '_gene_', 'mutation', 'status', '_ineq_', '_p_val_']"
1910,0.0,"In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen.","['in', 'patients', 'with', 'er', 'positive', 'breast', 'cancer', 'expression', 'of', '_gene_', 'does', 'not', 'effect', 'the', 'outcome', 'of', 'treatment', 'with', 'tamoxifen']"
1911,1.0,"None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.","['none', 'of', 'the', 'xenografts', 'harboring', '_gene_', '_ineq_', 'nras', '_ineq_', 'or', '_gene_', '_ineq_', 'mutations', 'showed', 'a', 'response', 'to', '_chemical_', 'whereas', '_num_', 'out', 'of', '_num_', 'xenografts', 'with', 'a', '_gene_', 'mutation', 'responded', 'to', '_chemical_']"
1912,1.0,1 patient with a complete response >3 years had a K159fs*16 mutation in NF2.,"['_num_', 'patient', 'with', 'a', 'complete', 'response', '_num_', 'years', 'had', 'a', '_abbrev_', 'mutation', 'in', '_gene_']"
1913,1.0,"Confirmed objective response was seen in 79% of the BRCA1 mutant subgroup, and 74% confirmed objective response was seen in the somatic BRCA mutant subgroup.","['confirmed', 'objective', 'response', 'was', 'seen', 'in', '_num_', 'of', 'the', '_gene_', 'mutant', 'subgroup', 'and', '_num_', 'confirmed', 'objective', 'response', 'was', 'seen', 'in', 'the', 'somatic', '_gene_', 'mutant', 'subgroup']"
1914,1.0,"In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry.","['in', '_abbrev_', 'metastatic', 'breast', 'cancer', 'treated', 'with', '_chemical_', 'n', '_num_', 'patients', 'the', 'expression', 'of', '_gene_', 'and', '_abbrev_', 'and', 'or', '_abbrev_', 'localized', 'in', 'nucleus+cytoplasm', 'was', 'associated', 'with', 'an', 'improved', 'time', 'to', 'progression', '_gene_', 'and', 'overall', 'survival', 'os', 'compared', 'to', '_gene_', 'negative', 'tumors', 'as', 'measured', 'by', 'immunohistochemistry']"
1915,0.0,"In other words, we believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF.","['in', 'other', 'words', 'we', 'believe', 'that', 'there', 'is', 'insufficient', 'data', 'to', 'justify', 'the', 'exclusion', 'of', 'anti', '_gene_', 'monoclonal', 'antibody', 'therapy', 'for', 'patients', 'with', 'mutant', '_gene_']"
1916,1.0,28 acral or mucosal melanomas from Shinshu University Hospital in Japan were examined for KIT expression and mutations.,"['_num_', 'acral', 'or', 'mucosal', 'melanomas', 'from', 'shinshu', 'university', 'hospital', 'in', 'japan', 'were', 'examined', 'for', 'kit', 'expression', 'and', 'mutations']"
1917,1.0,High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay).,"['high', '_gene_', 'expression', 'was', 'found', 'in', '_ratio_', '_num_', 'or', 'patients', 'by', 'qpcr', 'assay']"
1918,1.0,Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.,"['_chemical_', 'can', 'inhibit', '_gene_', 'mediated', '_gene_', '_disease_', 'and', 'soft', 'agar', 'colony', 'formation', 'of', 'aale', 'cells', 'expressing', '_gene_', '_mutation_', 'in', 'vitro']"
1919,1.0,"In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'patients', 'with', '_gene_', 'rearranged', '_disease_', '_num_', 'were', '_gene_', 'positive']"
1920,1.0,This report details 2 case studies in relapsed HER2 positive SCLC.,"['this', 'report', 'details', '_num_', 'case', 'studies', 'in', 'relapsed', '_gene_', 'positive', '_gene_']"
1921,1.0,"SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively.","['_abbrev_', 'and', '_abbrev_', 'fusions', 'were', 'detected', 'in', '_num_', 'tumors', '_num_', 'and', '_num_', 'tumors', '_num_', 'respectively']"
1922,1.0,Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL).,"['genotype', 'phenotype', 'correlations', 'of', '_num_', '_gene_', 'patients', 'were', 'analyzed', 'and', 'confirmed', 'that', 'higher', 'risk', 'of', 'pheochromocytoma', 'is', 'associated', 'with', 'missense', 'mutations', 'that', 'result', 'in', 'substitution', 'of', 'a', 'surface', 'amino', 'acid', 'or', 'that', 'disrupt', 'the', 'structural', 'integrity', 'of', 'the', '_gene_', 'gene', 'product', '_gene_']"
1923,0.0,"This cell line is a model for gain of alectinib resistance, and also shows resistance to crizotinib.","['this', 'cell', 'line', 'is', 'a', 'model', 'for', 'gain', 'of', '_chemical_', 'resistance', 'and', 'also', 'shows', 'resistance', 'to', '_chemical_']"
1924,1.0,"2 deaths were observed, and 1 was judged related to study treatment.","['_num_', 'deaths', 'were', 'observed', 'and', '_num_', 'was', 'judged', 'related', 'to', 'study', 'treatment']"
1925,1.0,"In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001).","['in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', '_disease_', 'those', 'patients', 'with', 'clonal', 'or', 'sub', 'clonal', 'mutations', 'in', '_gene_', 'had', 'significantly', 'shorter', 'overall', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
1926,1.0,"27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status).","['_num_', 'patients', 'with', 'colorectal', 'cancer', 'were', 'treated', 'with', '_chemical_', 'and', '_chemical_', '_ineq_', 'with', '_gene_', '_mutation_', 'mutation', '_ineq_', 'with', '_abbrev_', 'unknown', 'status']"
1927,1.0,"Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype protein.","['consistent', 'with', 'this', 'isolated', 'mutant', 'proteins', 'also', 'showed', 'increased', 'enzyme', 'activity', 'compared', 'to', 'wildtype', 'protein']"
1928,1.0,FOS was found fused  with 3 different genes in 3 cases of bone epithelioid hemangioma.,"['fos', 'was', 'found', 'fused', 'with', '_num_', 'different', 'genes', 'in', '_num_', 'cases', 'of', 'bone', '_disease_', 'hemangioma']"
1929,1.0,"This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch syndrome (LS).","['this', 'variant', 'identified', 'in', 'a', 'case', 'of', '_disease_', 'colorectal', 'cancer', 'was', 'confirmed', 'to', 'be', 'a', 'somatic', 'mutation', 'in', 'a', 'patient', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
1930,1.0,t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.,"['t', '_num_', '_num_', 'rearrangements', 'of', '_abbrev_', 'are', 'associated', 'with', 'a', 'diagnosis', 'of', 'ewing', 'sarcoma', 'and', 'are', 'the', '_num_', 'most', 'common', 'gene', 'fusion', 'reported', 'in', 'this', 'disease']"
1931,1.0,15/127 patients with metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations.,"['_ratio_', 'patients', 'with', 'metastatic', 'gastrointestinal', 'stromal', 'tumors', 'were', 'tested', 'for', '_gene_', 'mutations']"
1932,1.0,There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).,"['there', 'is', 'very', 'strong', 'evidence', 'for', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'frameshift', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
1933,1.0,The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20).,"['the', 'tumor', 'had', '_num_', 'somatic', 'variants', 'c', '_num_', '1_20del21', 'and', 'c', '291_310del20']"
1934,1.0,Functional validation of its role in drug sensitivity was examined in cell lines (293T and Ba/F3 cells).,"['functional', 'validation', 'of', 'its', 'role', 'in', 'drug', 'sensitivity', 'was', 'examined', 'in', 'cell', 'lines', '_chemical_', 'and', 'ba', '_abbrev_', 'cells']"
1935,1.0,"The EML4 ALK variant 1 containing NSCLC cell line H3122 is highly sensitive to alectinib, and an alectinib resistant derivative cell line H3122 CHR-A1 was generated by incubation of H3122 in increasing levels of alectinib culminating in 1 micro-molar, over a course of 7 months.","['the', '_gene_', '_gene_', 'variant', '_num_', 'containing', '_disease_', 'cell', 'line', '_abbrev_', 'is', 'highly', 'sensitive', 'to', '_chemical_', 'and', 'an', '_chemical_', 'resistant', 'derivative', 'cell', 'line', '_abbrev_', '_abbrev_', 'was', 'generated', 'by', 'incubation', 'of', '_abbrev_', 'in', 'increasing', 'levels', 'of', '_chemical_', 'culminating', 'in', '_num_', 'micro', 'molar', 'over', 'a', 'course', 'of', '_num_', 'months']"
1936,1.0,Ponatinib has shown to be effective in patients with BCR-ABL kinase domain mutations like F317L.,"['_chemical_', 'has', 'shown', 'to', 'be', 'effective', 'in', 'patients', 'with', '_gene_', 'kinase', 'domain', 'mutations', 'like', '_mutation_']"
1937,1.0,A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created.,"['a', '_disease_', 'xenograft', '_gene_', 'from', 'a', 'patient', 'with', '_gene_', 'dependent', 'kinase', 'inhibitor', '2a', 'b', '_gene_', 'loss', 'and', '_gene_', 'erg', 'fusion', 'positive', 'ewing', ""'s"", 'sarcoma', 'was', 'created']"
1938,1.0,"In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization.","['in', '_num_', 'out', 'of', '_num_', '_num_', 'metastatic', 'colorectal', 'cancer', 'tumors', 'implanted', 'into', 'mice', 'the', 'therapeutic', 'combination', 'of', 'the', 'mek', 'inhibitor', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'disease', 'stabilization']"
1939,1.0,The combined hazard ratio (HR) for PD-L1 overexpression was 1.76 (OS).,"['the', 'combined', 'hazard', 'ratio', 'hr', 'for', '_gene_', 'overexpression', 'was', '_num_', 'os']"
1940,1.0,"In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine).","['in', 'this', 'subgroup', 'of', '_disease_', 'patients', 'significant', 'differences', 'were', 'seen', 'in', 'overall', 'survival', '_num_', 'months', 'with', '_chemical_', 'vs', '_num_', 'months', 'with', '_chemical_', 'as', 'well', 'as', 'median', 'progression', 'free', 'survival', '_num_', 'months', 'with', '_chemical_', 'vs', '_num_', 'months', 'with', '_chemical_']"
1941,1.0,The presence of exon 9 (such as E545K) or exon 20 mutation may result in poorer survival compared to those with wild type PIK3CA Mutation (progression-free survival P = 0.035).,"['the', 'presence', 'of', 'exon', '_num_', 'such', 'as', '_mutation_', 'or', 'exon', '_num_', 'mutation', 'may', 'result', 'in', 'poorer', 'survival', 'compared', 'to', 'those', 'with', 'wild', 'type', '_gene_', 'mutation', 'progression', 'free', 'survival', 'p', '_num_']"
1942,0.0,The truncation of the FOS gene would result in the loss of the transactivation domain (TAD) in all three cases.,"['the', 'truncation', 'of', 'the', 'fos', 'gene', 'would', 'result', 'in', 'the', 'loss', 'of', 'the', 'transactivation', 'domain', 'tad', 'in', 'all', '_num_', 'cases']"
1943,1.0,"Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance.","['western', 'blot', 'showed', 'decreased', '_gene_', 'level', 'in', 'the', 'resistant', 'cell', 'line', 'and', 'sirna', 'against', '_gene_', 'in', 'parent', '_abbrev_', 'cells', 'induced', '_disease_', 'resistance']"
1944,1.0,The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course.,"['the', '_abbrev_', 'somatic', 'mutation', 'was', 'significantly', 'correlated', 'with', 'early', 'disease', 'recurrence', 'and', 'relapse', 'in', '_num_', '_disease_', 'all', 'regardless', 'of', 'treatment', 'course']"
1945,1.0,WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type.,"['wbc', 'counts', 'were', 'not', 'significantly', 'different', 'in', '_disease_', 'patients', 'with', '_gene_', '_abbrev_', 'mutations', 'compared', 'to', 'wild', 'type']"
1946,1.0,The patient was given crizotinib and CT scans showed a positive response after 8 weeks of treatment.,"['the', 'patient', 'was', 'given', '_chemical_', 'and', 'ct', 'scans', 'showed', 'a', 'positive', 'response', 'after', '_num_', 'weeks', 'of', 'treatment']"
1947,1.0,"Of 114 NSCLC patients treated with at least 400 mg/daily ceritinib, 1 had a complete response, 65 had a partial response, 25 had stable disease, 12 had progressive disease, and 11 withdrew from the study early.","['of', '_num_', '_disease_', 'patients', 'treated', 'with', 'at', 'least', '_num_', '_unit_', 'daily', '_chemical_', '_num_', 'had', 'a', 'complete', 'response', '_num_', 'had', 'a', 'partial', 'response', '_num_', 'had', 'stable', 'disease', '_num_', 'had', 'progressive', 'disease', 'and', '_num_', 'withdrew', 'from', 'the', 'study', 'early']"
1948,1.0,Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.,"['_chemical_', 'resistance', 'is', 'thought', 'to', 'consist', 'of', 'multiple', 'compensatory', 'mechanisms', 'involving', '_gene_', 'family', 'members', 'such', 'as', 'increased', 'signaling', 'through', '_gene_', 'family', 'heterodimers']"
1949,1.0,"Among all 18 patients with Erdheim-Chester disease or Langerhans histiocytosis, 94% had BRAF V600E mutations and the remaining 6 percent (1 patient) had an unknown V600 mutation.","['among', 'all', '_num_', 'patients', 'with', '_disease_', 'disease', 'or', '_disease_', 'histiocytosis', '_num_', 'had', '_gene_', '_mutation_', 'mutations', 'and', 'the', 'remaining', '_num_', 'percent', '_num_', 'patient', 'had', 'an', 'unknown', '_abbrev_', 'mutation']"
1950,1.0,The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.,"['the', 'use', 'of', '_chemical_', 'on', 'ret', 'mutated', 'rearranged', 'cell', 'lines', 'in', 'vitro', 'led', 'to', 'strong', 'repression', 'of', 'tyroid', 'cancer', 'cell', 'growth']"
1951,1.0,"When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.","['when', '_chemical_', 'cells', 'stably', 'transduced', 'with', '_gene_', '_abbrev_', 'were', 'treated', 'with', '_chemical_', 'tyrosine', '_disease_', 'was', 'maintained', 'at', '_num_', 'and', '10umol', '_unit_', 'concentrations', 'that', 'inhibited', '_disease_', 'of', 'wildtype', '_gene_', 'consistent', 'with', 'resistance', 'to', 'this', 'inhibitor']"
1952,1.0,"In HUVEC cell line model, silencing of PTPRB  induced features of angiogenesis which were abolished in the presence of sunitinib or vatalinib, inhibitors of VEGFR.","['in', '_disease_', 'cell', 'line', 'model', 'silencing', 'of', '_gene_', 'induced', 'features', 'of', 'angiogenesis', 'which', 'were', 'abolished', 'in', 'the', 'presence', 'of', '_chemical_', 'or', 'vatalinib', 'inhibitors', 'of', '_gene_']"
1953,1.0,The publication describes a patient with a somatic RAD50 L1237F mutation in combination with LOH and a TP53 A161T mutation that showed a complete response to a combination treatment with Irinotecan and the CHK1 inhibitor AZD7762.,"['the', 'publication', 'describes', 'a', 'patient', 'with', 'a', 'somatic', '_gene_', '_abbrev_', 'mutation', 'in', 'combination', 'with', '_disease_', 'and', 'a', '_gene_', '_mutation_', 'mutation', 'that', 'showed', 'a', 'complete', 'response', 'to', 'a', 'combination', 'treatment', 'with', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_']"
1954,1.0,Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance.,"['knockdown', 'of', '_gene_', 'in', '_chemical_', 'sensitive', '_gene_', 'breast', 'cancer', '_abbrev_', 'cells', 'induced', '_chemical_', 'resistance']"
1955,1.0,"(PFS: P = 0.0015, OS: P = 0.0384).","['_disease_', 'p', '_num_', 'os', 'p', '_num_']"
1956,1.0,"Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (CK18) as downregulated in DU145-TxR cells (validated at mRNA, NMP and total cellular protein levels).","['comparison', 'of', 'nuclear', 'matrix', 'protein', '_gene_', 'patterns', 'of', '_chemical_', 'resistant', '_disease_', 'cells', '_abbrev_', 'with', 'that', 'of', 'parental', 'cell', '_chemical_', 'using', '_num_', 'dimensional', 'electrophoresis', 'identified', '_gene_', '_num_', '_gene_', 'as', 'downregulated', 'in', '_abbrev_', 'cells', 'validated', 'at', 'mrna', '_gene_', 'and', 'total', 'cellular', 'protein', 'levels']"
1957,1.0,Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variants (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'of', 'pathogenicity', 'since', 'the', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'a', 'stop', 'loss', 'variants', 'acmg', 'code', '_abbrev_']"
1958,1.0,Crizotinib treatment duration was over 16 weeks.,"['_chemical_', 'treatment', 'duration', 'was', 'over', '_num_', 'weeks']"
1959,1.0,Improvement in quality of life was also reported.,"['improvement', 'in', 'quality', 'of', 'life', 'was', 'also', 'reported']"
1960,1.0,A JAK2 F547 splice site mutation was observed at the time of relapse in patient 2.,"['a', '_gene_', '_abbrev_', 'splice', 'site', 'mutation', 'was', 'observed', 'at', 'the', 'time', 'of', 'relapse', 'in', 'patient', '_num_']"
1961,1.0,The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild type PIK3CA mutation (P = 0.035).,"['the', 'presence', 'of', 'exon', '_num_', 'such', 'as', '_mutation_', 'or', 'exon', '_num_', 'mutations', 'were', 'associated', 'with', 'poorer', 'survival', 'compared', 'to', 'those', 'with', 'wild', 'type', '_gene_', 'mutation', 'p', '_num_']"
1962,1.0,The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation.,"['the', 'patient', 'was', 'also', 'noted', 'to', 'have', 'a', '_gene_', 'kinase', 'domain', 'exon', '_num_', 'p', '_abbrev_', 'mutation']"
1963,1.0,Y375C mutation results in activation of FGFR3 and is associated with bladder carcinoma.,"['_mutation_', 'mutation', 'results', 'in', 'activation', 'of', '_gene_', 'and', 'is', 'associated', 'with', 'bladder', 'carcinoma']"
1964,1.0,12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma.,"['_num_', 'months', 'after', 'stopping', '_chemical_', 'patient', 'did', 'not', 'show', 'evidence', 'of', 'metastatic', 'melanoma']"
1965,1.0,"This mutation was found in 2 VHL type 1 families (lineages 136, 183).","['this', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'lineages', '_num_', '_num_']"
1966,1.0,"In patients with AML, those who harbor Q157P/R mutation of U2AF1 do not show a statistically significant difference in complete remission rate compared to those who harbor wild type U2AF1.","['in', 'patients', 'with', '_disease_', 'those', 'who', 'harbor', '_abbrev_', 'mutation', 'of', '_gene_', 'do', 'not', 'show', 'a', 'statistically', 'significant', 'difference', 'in', 'complete', 'remission', 'rate', 'compared', 'to', 'those', 'who', 'harbor', 'wild', 'type', '_gene_']"
1967,1.0,The patient has continued treatment for over 6 months with ongoing PR.,"['the', 'patient', 'has', 'continued', 'treatment', 'for', 'over', '_num_', 'months', 'with', 'ongoing', 'pr']"
1968,1.0,"Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488).","['overall', 'survival', 'os', 'was', 'not', 'significantly', 'different', 'between', 'groups', 'although', 'there', 'was', 'a', 'tendency', 'towards', 'shorter', 'os', 'in', 'patients', 'with', '_abbrev_', 'tumors', 'hr', '_num_', '_num_', 'ci', '_range_', '_num_', 'vs', '_num_', 'months', 'p', '_num_']"
1969,1.0,"This benefit was also methylation status dependent, as those without methylation did not see increased survival.","['this', 'benefit', 'was', 'also', 'methylation', 'status', 'dependent', 'as', 'those', 'without', 'methylation', 'did', 'not', 'see', 'increased', 'survival']"
1970,1.0,Resistance was determined by assessing GLI1 mRNA expression levels.,"['resistance', 'was', 'determined', 'by', 'assessing', '_gene_', 'mrna', 'expression', 'levels']"
1971,1.0,Thirty-six patients with CLL were treated with alemtuzumab.,"['thirty', '_num_', 'patients', 'with', '_disease_', 'were', 'treated', 'with', 'alemtuzumab']"
1972,1.0,"The overall log-rank was p < 0.001 when all three groups were calculated simultaneously; p < 0.0001 comparing BRAF wild type and BRAF V600E survival, p = 0.015 comparing BRAF wild type and BRAF D594G survival, and p = 0.98 comparing BRAF V600E and BRAF D594G.","['the', 'overall', 'log', 'rank', 'was', 'p', '_num_', 'when', 'all', '_num_', 'groups', 'were', 'calculated', 'simultaneously', 'p', '_num_', 'comparing', '_gene_', 'wild', 'type', 'and', '_gene_', '_mutation_', 'survival', 'p', '_num_', 'comparing', '_gene_', 'wild', 'type', 'and', '_gene_', '_mutation_', 'survival', 'and', 'p', '_num_', 'comparing', '_gene_', '_mutation_', 'and', '_gene_', '_mutation_']"
1973,1.0,"In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old.","['in', 'multivariate', 'analysis', '_gene_', 'mutation', 'alone', '_gene_', 'wildtype', 'was', 'associated', 'with', 'improved', 'overall', 'survival', 'but', 'not', '_disease_', 'in', 'the', 'entire', 'cohort', 'and', 'in', 'normal', 'karyotype', 'patients', '_num_', 'years', 'old']"
1974,1.0,"In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin.","['in', 'a', 'phase', 'ii', 'clinical', 'trial', '_num_', 'of', 'patients', '_ineq_', 'with', 'advanced', 'systemic', '_disease_', 'responded', 'to', 'treatment', 'with', '_chemical_']"
1975,1.0,87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH.,"['_num_', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', 'treated', 'with', '_chemical_', 'were', 'retrospectively', 'analyzed', 'for', '_gene_', 'amplifications', 'by', 'fish']"
1976,1.0,16 (36%) contained a SYT–SSX2 (SS18-SSX2) fusion transcript.,"['_num_', '_num_', 'contained', 'a', 'syt–ssx2', '_abbrev_', 'fusion', 'transcript']"
1977,1.0,Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7/SO.5.,"['_num_', '_chemical_', 'resistant', 'cell', 'lines', 'were', 'derived', 'from', 'estrogen', 'responsive', 'and', '_chemical_', 'sensitive', 'parental', 'breast', 'cancer', 'cell', 'line', '_abbrev_']"
1978,1.0,28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991).,"['_num_', 'renal', 'cell', 'carcinoma', 'cell', 'lines', 'were', 'tested', 'for', 'sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_', '_chemical_']"
1979,1.0,"In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form.","['in', 'athymic', 'mice', '_chemical_', 'resistant', 'cell', 'line', '_gene_', 'was', 'used', 'in', 'tumor', 'xenografts', 'and', 'tumors', 'were', 'allowed', 'to', 'form']"
1980,1.0,Cell lines with various putative activating mutations were tested for sensitivity to rapamycin.,"['cell', 'lines', 'with', 'various', 'putative', 'activating', 'mutations', 'were', 'tested', 'for', 'sensitivity', 'to', '_gene_']"
1981,1.0,"71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9 Patients, Gln61Arg 15 Patients).","['_num_', 'patients', 'were', 'enrolled', '_ratio_', 'patients', 'with', 'nras', 'mutation', 'had', 'a', 'partial', 'response', '_mutation_', '_num_', 'patient', '_mutation_', '_num_', 'patients', '_mutation_', '_num_', 'patients']"
1982,1.0,D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance.,"['_mutation_', 'was', 'observed', 'as', 'a', 'secondary', 'kit', 'mutation', 'in', '_num_', 'patient', 'with', 'secondary', '_chemical_', 'resistance']"
1983,1.0,Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues.,"['expression', 'of', 'the', 'protein', '_gene_', 'was', 'investigated', 'in', '_num_', 'cases', 'of', 'pancreatic', 'ductal', 'adenocarcinoma', 'and', '_num_', 'cases', 'of', 'adjacent', 'tissues']"
1984,1.0,"Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks.","['_chemical_', 'therapy', 'was', 'subsequently', 'restarted', 'with', 'peripheral', 'blood', 'and', 'bm', 'analyses', 'returning', 'to', 'normal', 'after', '_num_', 'weeks']"
1985,1.0,"The patient had a second in-frame deletion of 5 amino acids (41-45), but the author speculate that it could be an inherited polymorphism.","['the', 'patient', 'had', 'a', '_num_', 'in', 'frame', 'deletion', 'of', '_num_', 'amino', 'acids', '_range_', 'but', 'the', 'author', 'speculate', 'that', 'it', 'could', 'be', 'an', 'inherited', 'polymorphism']"
1986,1.0,"In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment.","['in', 'this', 'case', 'study', 'of', 'a', 'critically', 'ill', '_num_', 'year', 'old', 'male', 'nonsmoker', 'with', 'advanced', 'metastatic', '_disease_', '_disease_', '_chemical_', '_chemical_', 'was', 'administered', 'as', '_num_', 'line', 'treatment']"
1987,1.0,"In an in vitro study, a SW48 cell line expressing KRAS G12D mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 195.01nmol vs. 114.28 nmol P<0.01) compared to SW48 cells expressing KRAS wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'decreased', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'p', '_num_', 'compared', 'to', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
1988,1.0,"Median PFS for all patients was 105 days, median OS was 267 days.","['median', '_disease_', 'for', 'all', 'patients', 'was', '_num_', 'days', 'median', 'os', 'was', '_num_', 'days']"
1989,1.0,"EGFR L861 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.","['_gene_', '_abbrev_', 'mutations', 'have', 'been', 'associated', 'with', 'increased', 'sensitivity', 'to', '_num_', 'generation', '_gene_', 'tyrosine', 'kinase', 'inhibitors', 'including', '_chemical_', 'and', '_chemical_']"
1990,1.0,"This splice mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 48).","['this', 'splice', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'family', '_gene_', '_num_']"
1991,1.0,"In an in vitro study, a SW48 cell line expressing KRAS G12C mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 386.22 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'decreased', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'p', '_num_', 'compared', 'to', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
1992,1.0,"Within the AR mutation cohort, 78 patients had AR amplification mutations, 16 patients had AR missense mutations, and 13 patients had mutations in ZBTB16, NCOR1, FOXA1, and SPOP, which are all AR regulators or downstream effectors.","['within', 'the', 'ar', 'mutation', 'cohort', '_num_', 'patients', 'had', 'ar', 'amplification', 'mutations', '_num_', 'patients', 'had', 'ar', 'missense', 'mutations', 'and', '_num_', 'patients', 'had', 'mutations', 'in', '_gene_', '_gene_', '_gene_', 'and', '_gene_', 'which', 'are', 'all', 'ar', 'regulators', 'or', 'downstream', 'effectors']"
1993,1.0,The T315I mutation was  resistant to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
1994,1.0,Trametinib was introduced and anemia and ECOG status improved.,"['_chemical_', 'was', 'introduced', 'and', 'anemia', 'and', 'ecog', 'status', 'improved']"
1995,0.0,"Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial sarcomas.","['treatment', 'with', 'tazemetostat', 'a', 'small', 'molecule', 'inhibitor', 'of', '_gene_', 'results', 'in', 'concentration', 'dependent', 'cell', 'growth', 'inhibition', 'and', 'cell', 'death', 'specifically', 'in', '_abbrev_', '_abbrev_', 'synovial', 'sarcomas']"
1996,1.0,12 patients from 4 families were confirmed to have the above mutation.,"['_num_', 'patients', 'from', '_num_', 'families', 'were', 'confirmed', 'to', 'have', 'the', 'above', 'mutation']"
1997,1.0,"In a meta-analysis of six studies totalling 3311 patients with non-M3 acute myeloid leukemia, those with mutations in ASXL1 had worse overall survival than wild type patients (Hazard ratio 1.86, 95% CI 1.49-2.33).","['in', 'a', '_disease_', 'analysis', 'of', '_num_', 'studies', 'totalling', '_num_', 'patients', 'with', '_abbrev_', 'acute', 'myeloid', 'leukemia', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'worse', 'overall', 'survival', 'than', 'wild', 'type', 'patients', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_range_']"
1998,1.0,GDC-0941 impaired tumor growth of NCI-H2110 (RIT1 M90I mutated) xenografts in nude mice.,"['_chemical_', 'impaired', 'tumor', 'growth', 'of', '_abbrev_', '_gene_', '_abbrev_', 'mutated', 'xenografts', 'in', 'nude', 'mice']"
1999,1.0,"Subclonal mutations (VAF <12%) were not associated with reduced OS (N=29, P=0.94, univariate analysis).","['subclonal', 'mutations', '_disease_', '_num_', 'were', 'not', 'associated', 'with', 'reduced', 'os', '_ineq_', '_p_val_', 'univariate', 'analysis']"
2000,1.0,"Another VHL type 1 family of 3 affected individuals had 3 patients with retinal angiomas, one with hemangioblastomas of the central nervous system, 2 with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 49).","['another', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'affected', 'individuals', 'had', '_num_', 'patients', 'with', 'retinal', 'angiomas', '_num_', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'with', 'renal', 'cell', 'carcinoma', '_num_', 'with', 'pancreatic', 'cysts', 'and', '_num_', 'with', '_disease_', 'of', 'the', 'epididymis', 'family', '_gene_', '_num_']"
2001,1.0,"Wild-type CD74-ROS1, CD74-ROS1 G2032R, and CD74-ROS1 L2026M all showed sensitivity to PF-06463922 in these assays.","['_disease_', '_abbrev_', '_abbrev_', '_mutation_', 'and', '_abbrev_', '_mutation_', 'all', 'showed', 'sensitivity', 'to', '_chemical_', 'in', 'these', 'assays']"
2002,1.0,"In the KRAS wildtype group, erlotinib showed a significant benefit for progression free survival (PFS) over placebo (HR, 0.70; 95% CI, 0.57 to 0.87, P<0.001).","['in', 'the', '_gene_', 'wildtype', 'group', '_chemical_', 'showed', 'a', 'significant', 'benefit', 'for', 'progression', 'free', 'survival', '_disease_', 'over', 'placebo', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
2003,1.0,"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission.","['in', 'patients', 'with', 'cytogenetically', 'normal', 'acute', 'myeloid', 'leukemia', 'those', 'in', 'the', 'intermediate', 'i', 'risk', 'group', 'with', '_gene_', 'mutations', 'had', 'higher', 'rates', 'of', 'complete', 'remission']"
2004,1.0,"TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.","['tytan', 'a', 'phase', 'iii', 'study', 'in', 'asian', 'patients', 'looked', 'at', 'addition', 'of', 'tyrosine', 'kinase', 'inhibitor', '_chemical_', 'to', 'chemptherapy', 'in', 'advanced', '_gene_', 'positive', 'gastric', 'cancer']"
2005,1.0,"High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response.","['high', 'expression', 'of', '_gene_', 'as', 'assessed', 'in', '_num_', 'breast', 'cancers', 'by', '_gene_', 'was', 'associated', 'with', 'better', 'pathological', 'response']"
2006,1.0,Sensitivity was determined by assessing cell proliferation.,"['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation']"
2007,1.0,A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy.,"['a', 'patient', 'with', 'monoblastic', 'myeloid', 'sarcoma', 'harbouring', 'a', '_disease_', 'confirmed', '_chemical_', 'rearrangement', 'was', 'treated', 'with', '_chemical_', 'monotherapy']"
2008,1.0,Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).,"['median', '_disease_', 'was', 'increased', 'in', 'combination', 'therapy', '_num_', 'months', 'vs', '_num_', 'months', '_ineq_', '_num_', 'ci', '_range_', '_p_val_', 'overall', 'response', 'rate', 'was', 'increased', 'in', 'the', 'combination', 'therapy', '_num_', 'vs', '_num_', '_p_val_', 'and', 'total', 'deaths', 'were', 'reduced', 'in', 'combination', 'therapy', '_num_', 'patients', 'vs', '_num_', 'patients']"
2009,1.0,57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study.,"['_num_', 'patients', 'with', 'chemorefractory', 'colorectal', 'cancer', 'expressing', '_gene_', '_gene_', 'staining', 'were', 'treated', 'with', 'single', 'agent', '_chemical_', 'in', 'this', 'phase', '_num_', 'study']"
2010,1.0,1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.,"['_ratio_', 'patients', 'with', '_gene_', 'homozygous', 'deletion', 'had', 'a', 'response', 'to', '_chemical_', 'in', 'this', 'phase', '_num_', 'study']"
2011,1.0,Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.,"['among', '_num_', 'patients', 'who', 'transitioned', 'directly', 'from', '_chemical_', 'to', 'osimertinib', 'all', 'derived', 'clinical', 'benefit', 'from', 'osimertinib', 'with', 'either', 'prolonged', 'sd', 'or', 'pr']"
2012,1.0,"Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of loco-regional control and shorter disease-free, disease-specific, and overall survival.","['of', 'the', '_num_', 'patients', 'treated', 'with', 'radiotherapy', 'patients', 'with', 'mutations', 'in', '_gene_', 'had', 'lower', 'rates', 'of', 'loco', 'regional', 'control', 'and', 'shorter', '_disease_', '_disease_', 'and', 'overall', 'survival']"
2013,1.0,The patient received a sustained response to everolimus for 18 months.,"['the', 'patient', 'received', 'a', 'sustained', 'response', 'to', '_chemical_', 'for', '_num_', 'months']"
2014,1.0,This study finds evidence for SOX10 loss (N=2) and/or activation of TGF-β signalling (N=2) in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples.,"['this', 'study', 'finds', 'evidence', 'for', '_gene_', 'loss', '_ineq_', 'and', 'or', 'activation', 'of', 'tgf', 'β', 'signalling', '_ineq_', 'in', '_num_', 'of', 'the', '_num_', '_gene_', 'positive', '_disease_', 'melanoma', 'patient', 'samples']"
2015,1.0,LOH of the WT allele was demonstrated.,"['_disease_', 'of', 'the', '_gene_', 'allele', 'was', 'demonstrated']"
2016,1.0,"In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21.","['in', 'a', 'study', '_num_', 'participants', 'with', 'stage', 'iv', 'adenocarcinoma', 'were', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_']"
2017,1.0,No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients).,"['no', '_gene_', 'mutations', 'were', 'identified', 'in', 'patients', 'with', 'favorable', 'risk', 'cytogenetics', '_ratio_', 'patients']"
2018,1.0,"In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG.","['in', 'this', 'study', 'human', 'pancreatic', 'carcinoma', 'cell', 'line', '_abbrev_', 'which', 'is', 'a', '_chemical_', 'sensitive', 'cell', 'line', 'was', 'used', 'for', 'the', 'establishment', 'of', 'chemoresistant', 'cells', '_abbrev_']"
2019,1.0,Functional models also showed PTCH1 mutant xenografts to be sensitive to SHH inhibition with vismodegib.,"['functional', 'models', 'also', 'showed', '_gene_', 'mutant', 'xenografts', 'to', 'be', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_chemical_']"
2020,1.0,After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedanib-docetaxel trial.,"['after', 'negative', 'testing', 'for', '_gene_', 'mutations', 'and', '_gene_', 'translocations', 'and', 'failure', 'of', 'platinum', 'based', 'chemotherapy', 'she', 'was', 'enrolled', 'on', 'a', '_chemical_', '_chemical_', 'trial']"
2021,1.0,"A high number of alterations were observed including 38 rearrangements, 35 translocations, 4 indels, and 271 nonsynonymous point mutations.","['a', 'high', 'number', 'of', 'alterations', 'were', 'observed', 'including', '_num_', 'rearrangements', '_num_', 'translocations', '_num_', 'indels', 'and', '_num_', 'nonsynonymous', 'point', 'mutations']"
2022,1.0,"In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older.","['in', 'a', 'study', 'of', 'patients', 'with', 'cytogenically', 'normal', 'acute', 'myeloid', 'leukemia', '_gene_', 'mutations', 'were', 'more', 'frequent', 'in', 'patients', '_num_', 'years', 'old', 'or', 'older']"
2023,1.0,The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer.,"['the', 'snp', '_mutation_', 'in', 'the', '_gene_', 'locus', 'is', 'associated', 'with', 'increased', 'predisposition', 'for', '_gene_', '_mutation_', 'mutation', 'and', 'its', 'associated', 'cancer']"
2024,1.0,KIT mutation analysis (N=41) revealed the presence of a synonymous SNP rs3733542 (known population frequency of 20%) in exon 18 of the KIT gene in six of ten (60%) patients assessed as having a response or disease stabilization to selumetinib.,"['kit', 'mutation', 'analysis', '_ineq_', 'revealed', 'the', 'presence', 'of', 'a', 'synonymous', 'snp', '_mutation_', 'known', 'population', 'frequency', 'of', '_num_', 'in', 'exon', '_num_', 'of', 'the', 'kit', 'gene', 'in', '_num_', 'of', '_num_', '_num_', 'patients', 'assessed', 'as', 'having', 'a', 'response', 'or', 'disease', 'stabilization', 'to', '_chemical_']"
2025,1.0,"TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.","['_chemical_', 'inhibits', 'growth', 'of', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'mutations', 'however', 'cells', 'with', 'the', '_mutation_', 'mutation', 'were', 'inhibited', 'at', 'a', 'higher', '_abbrev_', 'than', 'those', 'expressing', '_mutation_']"
2026,1.0,"Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005).","['patients', 'with', '_gene_', 'mutations', 'had', 'a', '_n_fold_', 'higher', 'incidence', 'of', 'poorly', 'differentiated', 'cancer', 'gleason', 'score', '_num_', 'a', 'higher', 'incidence', 'of', 'advanced', 'stage', '_num_', 'vs', '_num_', '_p_val_', 'a', 'higher', 'incidence', 'of', '_gene_', 'involvement', '_num_', 'vs', '_num_', '_p_val_', 'and', 'a', 'higher', 'incidence', 'of', 'metastatic', 'spread', '_num_', 'vs', '_num_', '_p_val_']"
2027,1.0,"46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.","['_num_', 'women', 'with', 'platinum', 'sensitive', 'high', 'grade', '_abbrev_', 'ovarian', 'cancer', 'received', 'either', '_chemical_', 'monotherapy', 'or', '_chemical_', '_chemical_', 'combination', 'therapy']"
2028,1.0,"In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'the', '_mutation_', 'mutation', 'was', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
2029,1.0,"This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.","['this', 'phase', 'ii', 'trial', 'lux', 'breast', '_num_', '_abbrev_', 'compared', '_chemical_', '_chemical_', 'plus', '_chemical_', 'or', 'investigator', ""'s"", 'choice', 'of', 'treatment']"
2030,1.0,In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation).,"['in', 'vitro', 'study', 'in', '_num_', 'neuroblastoma', 'cell', 'lines', '_num_', 'with', 'nras', '_mutation_', 'mutation']"
2031,1.0,The patient was subsequently given trastuzumab with no response.,"['the', 'patient', 'was', 'subsequently', 'given', '_chemical_', 'with', 'no', 'response']"
2032,1.0,HER2 positivity in NSCLC is fairly common at 2-20%.,"['_gene_', 'positivity', 'in', '_disease_', 'is', 'fairly', 'common', 'at', '_range_']"
2033,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
2034,1.0,"LADC patients with high serum or plasma ActA levels had significantly shorter OS than those with low circulating ActA concentrations (p < 0.0001 in both) and were identified as an independent prognostic factor (p=0.004 and p=0.002, respectively).","['_disease_', 'patients', 'with', 'high', 'serum', 'or', 'plasma', '_gene_', 'levels', 'had', 'significantly', 'shorter', 'os', 'than', 'those', 'with', 'low', 'circulating', '_gene_', 'concentrations', 'p', '_num_', 'in', 'both', 'and', 'were', 'identified', 'as', 'an', 'independent', 'prognostic', 'factor', '_p_val_', 'and', '_p_val_', 'respectively']"
2035,1.0,On two separate treatments with dual mTOR1/2 inhibitors patient exhibited stable disease for more than 18 months.,"['on', '_num_', 'separate', 'treatments', 'with', 'dual', '_abbrev_', 'inhibitors', 'patient', 'exhibited', 'stable', 'disease', 'for', 'more', 'than', '_num_', 'months']"
2036,1.0,SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patients.,"['_gene_', 'mutations', 'were', 'identified', 'in', '_num_', 'of', '_num_', 'resistant', 'basal', 'cell', 'carcinomas', 'in', '_num_', 'patients']"
2037,1.0,"Of 20 patients studied, 5 had coding mutation in TP53.","['of', '_num_', 'patients', 'studied', '_num_', 'had', 'coding', 'mutation', 'in', '_gene_']"
2038,1.0,"The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again after 4 months of alectinib.","['the', '_mutation_', 'mutation', 'in', '_gene_', 'fusions', 'was', 'found', 'in', 'a', '_disease_', 'patient', 'shown', 'positive', 'for', '_gene_', 'rearrangement', 'via', 'break', 'apart', 'fish', 'assay', 'who', 'progressed', 'after', '_num_', 'months', 'of', '_chemical_', 'and', 'then', 'progressed', 'again', 'after', '_num_', 'months', 'of', '_chemical_']"
2039,1.0,These results were also validated in an independent cohort of 293 patients.,"['these', 'results', 'were', 'also', 'validated', 'in', 'an', 'independent', 'cohort', 'of', '_num_', 'patients']"
2040,1.0,The cell line maintained the tumor immunophenotype.,"['the', 'cell', 'line', 'maintained', 'the', 'tumor', 'immunophenotype']"
2041,1.0,ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft.,"['shrna', 'mediated', 'knockdown', 'of', '_gene_', 'inhibited', 'growth', 'of', 'ewing', 'sarcoma', 'and', 'other', 'cancer', 'cells', '_abbrev_', 'lung', 'carcinoma', 'cell', 'line', 'or', 'leukemia', 'cell', 'lines', '_abbrev_', 'and', 'kasumi', 'with', 'almost', 'complete', 'growth', 'suppression', 'only', 'in', 'the', 'ewing', 'sarcoma', 'cell', 'lines', 'and', 'knockdown', 'of', '_gene_', 'abrogated', 'growth', 'of', 'cell', 'lines', 'in', 'xenograft']"
2042,1.0,"Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.","['phase', '_num_', 'randomized', 'clinical', 'trial', 'comparing', '_chemical_', 'with', '_chemical_', 'in', '_num_', 'patients', 'with', 'previously', 'untreated', 'metastatic', 'melanoma', 'with', 'the', '_gene_', '_mutation_', 'mutation']"
2043,1.0,At last assessment 63 treatment cycles had been completed and the patient had survived for about 5 years since recurrence.,"['at', 'last', 'assessment', '_num_', 'treatment', 'cycles', 'had', 'been', 'completed', 'and', 'the', 'patient', 'had', 'survived', 'for', 'about', '_num_', 'years', 'since', 'recurrence']"
2044,1.0,"Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls.","['_disease_', 'analysis', 'of', 'prostate', 'cancer', 'with', 'sixteen', '_disease_', 'studies', 'including', '_num_', 'cases', 'and', '_num_', 'controls']"
2045,1.0,A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons).,"['a', 'relative', 'reduction', 'of', '_num_', 'in', 'the', 'risk', 'of', 'death', 'and', 'of', '_num_', 'in', 'the', 'risk', 'of', 'either', 'death', 'or', 'disease', 'progression', 'was', 'observed', 'with', '_chemical_', 'as', 'compared', 'with', '_chemical_', 'p', '_num_', 'for', 'both', 'comparisons']"
2046,1.0,"A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine was associated with a greater time to treatment failure (55.6 months vs. 31.8 months; P = .0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = .038).","['a', 'retrospective', 'tumor', 'sample', 'study', 'found', 'that', 'the', 'loss', 'of', '_gene_', 'expression', 'less', 'than', '_num_', 'of', 'nuclei', 'in', '_gene_', 'mutant', '_disease_', 'treated', 'with', '_chemical_', 'or', 'a', 'combination', 'of', 'procarbazine', 'lomustine', 'and', 'vincristine', 'was', 'associated', 'with', 'a', 'greater', 'time', 'to', 'treatment', 'failure', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_', 'and', 'a', 'greater', 'progression', 'free', 'survival', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_']"
2047,1.0,"83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation.","['_num_', 'patients', 'from', 'a', 'phase', 'ii', 'trial', '_chemical_', 'placebo', 'or', '_chemical_', 'with', '_gene_', 'mutant', 'tumors', 'were', 'retrospectively', 'assessed', 'for', 'differences', 'in', 'os', '_disease_', 'orr', 'and', 'change', 'in', 'tumor', 'size', 'at', 'week', '_num_', 'according', 'to', 'type', 'of', '_gene_', 'mutation']"
2048,1.0,Progression free survival was significantly longer with gefitinib treatment with a median of 9.2 months vs. 6.3 with cisplatin/docetaxel (HR 0.48; 95% CI 0.336-0.710; p<0.0001).,"['progression', 'free', 'survival', 'was', 'significantly', 'longer', 'with', '_chemical_', 'treatment', 'with', 'a', 'median', 'of', '_num_', 'months', 'vs', '_num_', 'with', '_disease_', '_chemical_', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
2049,1.0,"In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and two of these were germline mutations.","['in', '_num_', 'patients', 'with', 'characterized', '_gene_', 'mutations', '_num_', 'had', '_mutation_', 'mutations', 'and', '_num_', 'of', 'these', 'were', 'germline', 'mutations']"
2050,1.0,Those patients with a low expression experienced shorter progression free survival than those with no loss of expression (P<0.01).,"['those', 'patients', 'with', 'a', 'low', 'expression', 'experienced', 'shorter', 'progression', 'free', 'survival', 'than', 'those', 'with', 'no', 'loss', 'of', 'expression', 'p', '_num_']"
2051,1.0,"Furthermore, the researchers tested a KRAS-variant EOC cell line (BG1) and found it has much greater platinum-based chemotherapy resistance than a non-KRAS-variant cell line (CAOV3).","['furthermore', 'the', 'researchers', 'tested', 'a', '_gene_', 'variant', '_disease_', 'cell', 'line', '_gene_', 'and', 'found', 'it', 'has', 'much', 'greater', 'platinum', 'based', 'chemotherapy', 'resistance', 'than', 'a', 'non', '_gene_', 'variant', 'cell', 'line', '_abbrev_']"
2052,1.0,"Additionally, tumors with EGFR mutations in L858R or deletions in exon 19 were associated with increased overall survival (19.6mo vs. 10.4mo) compared to wildtype (all patients were treated with either erlotinib or gefitinib).","['additionally', 'tumors', 'with', '_gene_', 'mutations', 'in', '_mutation_', 'or', 'deletions', 'in', 'exon', '_num_', 'were', 'associated', 'with', 'increased', 'overall', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'compared', 'to', 'wildtype', 'all', 'patients', 'were', 'treated', 'with', 'either', '_chemical_', 'or', '_chemical_']"
2053,1.0,"The three cases without the mutation that appeared unaffected were aged 18, 54, and 69.","['the', '_num_', 'cases', 'without', 'the', 'mutation', 'that', 'appeared', 'unaffected', 'were', 'aged', '_num_', '_num_', 'and', '_num_']"
2054,1.0,"1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate.","['_num_', 'patient', 'demonstrated', 'complete', 'response', 'and', '_num_', 'showed', 'partial', 'response', 'for', 'an', '_num_', 'overall', 'response', 'rate']"
2055,1.0,"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 4.56-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'as', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein', 'reported', 'to', 'be', 'sensitizing', 'to', '_chemical_']"
2056,1.0,This frameshift mutation was found in a VHL type 1 family of 8 individuals (family ID 3563).,"['this', 'frameshift', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_']"
2057,1.0,"Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","['of', 'patients', 'with', '_gene_', 'mutation', 'associated', 'breast', 'and', 'ovarian', 'cancers', 'confirmed', 'responses', 'were', 'observed', 'in', '_num_', 'of', '_num_', '_num_', 'and', '_num_', 'of', '_num_', '_num_', 'patients', 'respectively']"
2058,1.0,"The study was not powered for prognostic tests, but it was still found that KRAS Mutant status was a significant negative prognostic factor on progression free survival.","['the', 'study', 'was', 'not', 'powered', 'for', 'prognostic', 'tests', 'but', 'it', 'was', 'still', 'found', 'that', '_gene_', 'mutant', 'status', 'was', 'a', 'significant', 'negative', 'prognostic', 'factor', 'on', 'progression', 'free', 'survival']"
2059,1.0,A c.3028 G->A mutation was identified in exon 14 resulting in exon 14 skipping.,"['a', 'c', '_num_', '_unit_', '', 'a', 'mutation', 'was', 'identified', 'in', 'exon', '_num_', 'resulting', 'in', 'exon', '_num_', 'skipping']"
2060,1.0,"In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients.","['in', 'a', 'study', 'of', '_num_', 'lung', 'adenocarcinoma', 'patients', 'with', 'documented', '_gene_', 'mutations', 'farnesylthiosalicylic', 'acid', '_chemical_', 'mono', 'therapy', 'resulted', 'in', 'no', 'partial', 'responses', 'and', 'did', 'not', 'improve', 'overall', 'survival', 'rates', 'compared', 'to', 'previously', 'untreated', 'patients']"
2061,1.0,Deep sequencing of TSC1 and TSC2 was performed on blood from a group of 38 sporadic Tuberous Sclerosis patients who had been previously studied with no mutation identified in TSC1 or TSC2.,"['deep', 'sequencing', 'of', '_gene_', 'and', '_gene_', 'was', 'performed', 'on', 'blood', 'from', 'a', 'group', 'of', '_num_', 'sporadic', 'tuberous', 'sclerosis', 'patients', 'who', 'had', 'been', 'previously', 'studied', 'with', 'no', 'mutation', 'identified', 'in', '_gene_', 'or', '_gene_']"
2062,1.0,"A mutation c.490C>T or R164W was found in 5/5 members with Non Hodkin's lymphoma, Hodgkin lymphoma, or multiple myeloma but not in 3/3 unaffected individuals.","['a', 'mutation', 'c', '490c', 't', 'or', '_mutation_', 'was', 'found', 'in', '_ratio_', 'members', 'with', 'non', 'hodkin', ""'s"", 'lymphoma', 'hodgkin', 'lymphoma', 'or', 'multiple', 'myeloma', 'but', 'not', 'in', '_ratio_', 'unaffected', 'individuals']"
2063,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_mutation_', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
2064,1.0,"Of the six patients with disease control, the time on treatment ranged from 15.1 to ≥ 101 weeks, with one ongoing at data cutoff.","['of', 'the', '_num_', 'patients', 'with', 'disease', 'control', 'the', 'time', 'on', 'treatment', 'ranged', 'from', '_num_', 'to', '≥', '_num_', 'weeks', 'with', '_num_', 'ongoing', 'at', 'data', 'cutoff']"
2065,1.0,In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutations of unknown clinical significance (UMUCS).,"['in', 'a', 'cohort', 'of', '_disease_', 'patients', 'tested', 'for', 'mutation', 'in', '_gene_', 'exons', '_range_', 'a', 'subset', 'had', 'uncommon', 'mutations', 'of', 'unknown', 'clinical', 'significance', 'umucs']"
2066,1.0,"Nonsense mutations in SMARCA4 were associated with small cell carcinoma of the ovary, hypercalcemic type in 10/10 tumor samples, and were rarely found in other solid tumor types catalogued by TCGA.","['nonsense', 'mutations', 'in', '_gene_', 'were', 'associated', 'with', 'small', 'cell', 'carcinoma', 'of', 'the', 'ovary', '_disease_', 'type', 'in', '_ratio_', 'tumor', 'samples', 'and', 'were', 'rarely', 'found', 'in', 'other', 'solid', 'tumor', 'types', 'catalogued', 'by', '_disease_']"
2067,1.0,ERBB3 expression was not predictive of response.,"['_gene_', 'expression', 'was', 'not', 'predictive', 'of', 'response']"
2068,1.0,"In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models.","['in', 'this', 'study', 'targeted', 'activity', 'against', '_chemical_', 'by', 'the', '_gene_', 'and', 'met', 'inhibitor', '_chemical_', 'was', 'assessed', 'in', 'cell', 'lines', 'and', 'tumor', 'xenograft', 'models']"
2069,1.0,Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib.,"['cells', 'with', 'an', '_gene_', '_abbrev_', 'mutation', 'demonstrated', 'an', 'improved', 'response', 'to', '_chemical_', '_gene_', '_num_', '_unit_', 'vs', '_unit_', 'compared', 'to', 'the', 'same', 'cells', 'treated', 'with', '_chemical_']"
2070,1.0,"JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML).","['_gene_', '_mutation_', 'is', 'associated', 'with', 'myeloid', 'malignanices', '_disease_', 'mds', '_disease_', 'atypical', '_gene_']"
2071,1.0,This study contains very strong evidence of pathogenicity in the form of a canonical -2 splice variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'canonical', '_num_', 'splice', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
2072,1.0,"In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival (3.23 months vs. 1.37 months, p=0.05), as compared to patients with wild type IDH1.","['in', 'a', 'clinical', 'study', 'of', '_num_', 'recurrent', 'glioma', 'patients', 'patients', 'treated', 'with', '_chemical_', 'monotherapy', '_ineq_', 'and', 'harboring', '_gene_', 'codon', '_num_', 'mutation', 'were', 'associated', 'with', 'improved', 'progression', 'free', 'survival', '_num_', 'months', 'vs', '_num_', 'months', '_p_val_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
2073,1.0,"Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine.","['downregulation', 'of', '_gene_', 'expression', 'in', 'mantle', 'cell', 'lymphoma', 'cell', 'lines', 'and', 'mouse', 'xenografts', 'led', 'to', 'enhanced', 'sensitivity', 'towards', 'treatment', 'with', 'doxorubicin', 'cytarabin', 'and', '_chemical_']"
2074,1.0,"Three cell lines (SNU-C1, HDC9, HCT116) were analyzed.","['_num_', 'cell', 'lines', '_abbrev_', '_abbrev_', '_abbrev_', 'were', 'analyzed']"
2075,1.0,"In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with first line reversible EGFR inhibitor gefitinib or irreversible pan-ErbB family inhibitor afatinib in order to obtain a direct comparison of these two approved first line treatments.","['in', 'the', 'lux', 'lung', '_num_', 'trial', '_abbrev_', 'stage', '_gene_', 'or', 'iv', '_disease_', 'patients', 'with', '_gene_', 'exon', '_num_', 'deletion', '_ineq_', '_mutation_', 'mutation', '_ineq_', 'or', 'both', '_ineq_', 'were', 'divided', 'into', 'equal', 'groups', 'and', 'treated', 'with', '_num_', 'line', 'reversible', '_gene_', 'inhibitor', '_chemical_', 'or', 'irreversible', 'pan', '_gene_', 'family', 'inhibitor', '_chemical_', 'in', 'order', 'to', 'obtain', 'a', 'direct', 'comparison', 'of', 'these', '_num_', 'approved', '_num_', 'line', 'treatments']"
2076,1.0,"Two patients with p.S270P, and one patient with p.S720F were observed to have poor survival outcomes.","['_num_', 'patients', 'with', 'p', '_abbrev_', 'and', '_num_', 'patient', 'with', 'p', '_abbrev_', 'were', 'observed', 'to', 'have', 'poor', 'survival', 'outcomes']"
2077,1.0,"Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation.","['likely', 'due', 'to', 'increased', 'reliance', 'of', 'mutant', 'nras', 'on', '_gene_', 'for', 'stabilization', 'inhibition', 'of', '_gene_', 'by', '_chemical_', 'was', 'shown', 'to', 'be', 'effective', 'in', 'a', 'patient', 'with', 'metastatic', 'malignant', 'melanoma', 'with', 'an', 'nras', '_mutation_', 'mutation']"
2078,1.0,Of these 29/37 Mullerian and 1/37 non-Mullerian tumors exhibited PAX8 expression.,"['of', 'these', '_ratio_', 'mullerian', 'and', '_ratio_', 'non', 'mullerian', 'tumors', 'exhibited', '_gene_', 'expression']"
2079,1.0,This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm.,"['this', 'case', 'study', 'presented', 'a', '_age_', 'never', 'smoker', 'with', 'a', 'poorly', 'differentiated', 'malignant', 'neoplasm']"
2080,1.0,Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib.,"['_num_', 'uterine', 'cancer', 'cell', 'lines', '_num_', 'with', '_gene_', 'amplification', 'and', '_num_', 'without', 'were', 'treated', 'with', 'scalar', 'concentrations', 'of', '_chemical_']"
2081,1.0,Kras(G12D) and Lkb1 (STK11) knockout mutant mice showed only mild response to combined treatment and very low response rates to docetaxel monotherapy compared to mice with Kras(G12D) alone or Kras(G12D) and Trp53 knockout.,"['_gene_', '_mutation_', 'and', '_gene_', '_gene_', 'knockout', 'mutant', 'mice', 'showed', 'only', 'mild', 'response', 'to', 'combined', 'treatment', 'and', 'very', 'low', 'response', 'rates', 'to', '_chemical_', 'monotherapy', 'compared', 'to', 'mice', 'with', '_gene_', '_mutation_', 'alone', 'or', '_gene_', '_mutation_', 'and', '_gene_', 'knockout']"
2082,1.0,"61,8% had a VHL mutation.","['_num_', 'had', 'a', '_gene_', 'mutation']"
2083,1.0,"During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.","['during', 'the', 'trial', ""'s"", 'initial', 'phase', '_num_', 'of', '_num_', 'patients', 'screened', 'met', 'the', 'criteria', 'of', '_abbrev_', 'or', '3+', 'or', 'fish', 'positivity', 'for', '_gene_', 'status']"
2084,1.0,A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.,"['a', '_num_', 'year', 'old', 'woman', 'who', 'presented', 'with', 'acute', 'myeloid', 'leukemia', 'revealed', 'a', 'complicated', 'genetic', 'profile', 'using', 'conventional', 'metaphase', 'cytogenetics', 'and', 'fish', 'analysis']"
2085,1.0,"In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases.","['in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'primary', 'invasive', 'melanoma', 'copy', 'number', 'gain', 'of', '_gene_', 'was', 'observed', 'fish', 'in', '_num_', 'of', 'cases']"
2086,1.0,Since this is a frameshift occurring early in the protein sequence we can assign an ACMG evidence code of 'PVS1'.,"['since', 'this', 'is', 'a', 'frameshift', 'occurring', 'early', 'in', 'the', 'protein', 'sequence', 'we', 'can', 'assign', 'an', 'acmg', 'evidence', 'code', 'of', ""'pvs1""]"
2087,1.0,This nonsense mutation found in VHL type 1 family (lineage 80).,"['this', 'nonsense', 'mutation', 'found', 'in', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
2088,1.0,"The effect was asserted to be specific to pRB depletion because, in two separate cell lines, also transfected with p16, that retained high pRB expression, chemotherapy resistance was still observed.","['the', 'effect', 'was', 'asserted', 'to', 'be', 'specific', 'to', '_gene_', 'depletion', 'because', 'in', '_num_', 'separate', 'cell', 'lines', 'also', 'transfected', 'with', '_gene_', 'that', 'retained', 'high', '_gene_', 'expression', 'chemotherapy', 'resistance', 'was', 'still', 'observed']"
2089,1.0,CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.,"['_chemical_', 'also', 'more', 'effectively', 'reduced', 'tumor', 'volume', 'of', 'mouse', 'xenografts', 'harboring', 'the', '_mutation_', 'than', 'those', 'with', 'wildtype', '_gene_']"
2090,1.0,"Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial.","['retrospective', 'analysis', 'of', 'somatic', 'mutations', 'and', 'copy', 'number', 'changes', 'in', '_num_', 'patients', 'treated', 'with', '_chemical_', '_chemical_', '±', '_chemical_', 'cps', 'in', 'the', '_abbrev_', 'trial']"
2091,1.0,Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.,"['transduction', 'of', 'ba', '_abbrev_', 'cells', 'with', '_chemical_', 'variant', '3a', 'caused', 'the', 'cells', 'to', 'grow', 'independently', 'of', '_gene_', 'addition']"
2092,1.0,In vivo studies confirmed oncogenic activity of ALK ATI similar to other ALK mutations or fusions and sensitivity to crizotinib.,"['in', 'vivo', 'studies', 'confirmed', '_disease_', 'activity', 'of', '_gene_', '_gene_', 'similar', 'to', 'other', '_gene_', 'mutations', 'or', 'fusions', 'and', 'sensitivity', 'to', '_chemical_']"
2093,0.0,"Toxic effects were primarily hematologic and included neutropenia (grade 3, n = 20 [33%]; grade 4, n = 2 [3%]) but no neutropenic fever.","['toxic', 'effects', 'were', 'primarily', 'hematologic', 'and', 'included', 'neutropenia', 'grade', '_num_', 'n', '_num_', '_num_', 'grade', '_num_', 'n', '_num_', '_num_', 'but', 'no', '_disease_', 'fever']"
2094,1.0,Disease burden was not measurable by Response Evaluation Criteria in Solid Tumors.,"['disease', 'burden', 'was', 'not', 'measurable', 'by', 'response', 'evaluation', 'criteria', 'in', 'solid', 'tumors']"
2095,1.0,MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines.,"['mek', 'inhibitor', '_chemical_', 'and', '_abbrev_', 'inhibitor', '_chemical_', 'together', 'induced', 'synergistic', 'increase', 'in', 'apoptotic', '_gene_', 'v+', 'pi+', 'cells', 'in', 'these', 'cell', 'lines']"
2096,1.0,The mice in which STAG2 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).,"['the', 'mice', 'in', 'which', '_gene_', 'was', 'silenced', 'had', 'tumors', 'that', 'were', 'more', 'sensitive', 'to', '_chemical_', 'induced', 'tumor', 'shrinkage', 'than', 'the', 'tumors', 'of', 'the', 'control', 'mice', 'p', '_num_']"
2097,1.0,"The results were externally validated on a previous series of 11 peritoneal pseudomyxoma patients (5.1 vs 13 months; HR for progression 11.26, 95 % CI 3.62–35.06; log-rank test p < 0.0001).","['the', 'results', 'were', 'externally', 'validated', 'on', 'a', 'previous', 'series', 'of', '_num_', 'peritoneal', '_disease_', 'patients', '_num_', 'vs', '_num_', 'months', 'hr', 'for', 'progression', '_num_', '_num_', 'ci', '_num_', '62–35', '_num_', 'log', 'rank', 'test', 'p', '_num_']"
2098,1.0,Only moderate support for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).,"['only', 'moderate', 'support', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'stop', 'loss', 'variant', 'acmg', 'code', '_abbrev_']"
2099,0.0,Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian Sertoli–Leydig cell tumors.,"['sanger', 'sequencing', 'identified', '_gene_', 'hotspot', 'mutations', 'in', '_num_', 'of', '_num_', '_num_', 'ovarian', 'sertoli–leydig', 'cell', 'tumors']"
2100,1.0,"In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival.","['in', 'renal', 'clear', 'cell', 'carcinoma', 'patients', 'with', '_gene_', 'mutations', 'did', 'not', 'have', 'a', 'significantly', 'different', 'cancer', 'specific', 'survival']"
2101,1.0,"Cell lines were developed for 6 of these mutations (one harboring Q61L, two Q61R, and three Q61K mutations) and 5/6 were sensitive to MEK inhibitors selumetinib and trametinib.","['cell', 'lines', 'were', 'developed', 'for', '_num_', 'of', 'these', 'mutations', '_num_', 'harboring', '_mutation_', '_num_', '_mutation_', 'and', '_num_', '_mutation_', 'mutations', 'and', '_ratio_', 'were', 'sensitive', 'to', 'mek', 'inhibitors', '_chemical_', 'and', '_chemical_']"
2102,1.0,"The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC.","['the', 'patient', 'was', 'identified', 'to', 'harbor', 'mutations', 'in', '_gene_', '_abbrev_', '_abbrev_', '_abbrev_', 'and', 'in', '_gene_', '_abbrev_', 'by', 'panel', 'sequencing', 'as', 'well', 'as', 'loss', 'of', 'expression', 'of', 'these', 'genes', 'as', 'confirmed', 'by', '_gene_']"
2103,1.0,"The 33-year-old proband had retinal angiomas, renal cell carcinoma, pancreatic cysts, and pheochromocytoma.","['the', '_age_', 'proband', 'had', 'retinal', 'angiomas', 'renal', 'cell', 'carcinoma', 'pancreatic', 'cysts', 'and', 'pheochromocytoma']"
2104,1.0,The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC).,"['the', '_gene_', '_mutation_', 'variant', 'is', 'significantly', 'correlated', 'with', 'increased', 'response', 'to', '_chemical_', 'and', '_chemical_', 'therapies', 'in', 'non', 'small', 'cell', 'lung', 'cancer', '_disease_']"
2105,1.0,"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALDH1.","['_num_', 'patients', 'with', 'rectal', 'cancer', 'who', 'received', '_chemical_', 'based', 'chemotherapy', 'and', 'surgery', 'were', 'retrospectively', 'analyzed', 'for', 'expression', 'of', '_gene_', 'ts', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_abbrev_', 'and', '_gene_']"
2106,1.0,Liver tumor biopsy was performed and was estimated to be 15% tumor tissue.,"['liver', 'tumor', 'biopsy', 'was', 'performed', 'and', 'was', 'estimated', 'to', 'be', '_num_', 'tumor', 'tissue']"
2107,1.0,Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors).,"['mutation', 'was', 'recurrent', '_mutation_', 'in', '_num_', 'or', '_abbrev_', 'or', '_mutation_', 'in', 'another', '_num_', 'of', 'tumors']"
2108,1.0,"In-vitro, silencing of CFLAR led to sensitization of two cell lines to bicalutamide.","['in', 'vitro', 'silencing', 'of', '_gene_', 'led', 'to', 'sensitization', 'of', '_num_', 'cell', 'lines', 'to', '_chemical_']"
2109,1.0,"(Combination Index = 0.82 for ED50, Combination Index = 0.72 for ED75, Combination Index = 0.64 for ED90)","['combination', 'index', '_num_', 'for', '_abbrev_', 'combination', 'index', '_num_', 'for', '_abbrev_', 'combination', 'index', '_num_', 'for', '_abbrev_']"
2110,1.0,"Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild type RET.","['medullary', 'thyroid', 'cancer', 'cells', 'with', 'ret', '_abbrev_', 'mutation', 'are', 'insensitive', 'to', '_chemical_', 'compared', 'to', 'wild', 'type', 'ret']"
2111,1.0,Crizotinib was also less effective at inhibiting kinase activity in ROS1 with L2026M mutation than wildtype.,"['_chemical_', 'was', 'also', 'less', 'effective', 'at', 'inhibiting', 'kinase', 'activity', 'in', '_gene_', 'with', '_mutation_', 'mutation', 'than', 'wildtype']"
2112,1.0,He was initially treated with chemotherapy and received an autologous stem cell transplant.,"['he', 'was', 'initially', 'treated', 'with', 'chemotherapy', 'and', 'received', 'an', 'autologous', 'stem', 'cell', 'transplant']"
2113,1.0,"Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement  causing Cyclin D overexpression in MCL.","['patients', 'were', 'verified', 'by', '_gene_', 'fish', 'or', 'molecular', 'testing', 'for', 'the', 't', '_ratio_', 'rearrangement', 'causing', '_gene_', 'd', 'overexpression', 'in', '_gene_']"
2114,1.0,Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0–10 uM).,"['sensitivity', 'was', 'assessed', 'by', 'cell', 'viability', 'assay', 'using', 'stable', 'transfection', 'of', 'each', 'variant', 'and', 'increasing', 'concentrations', 'of', '_chemical_', '0–10', '_unit_']"
2115,1.0,Analysis for identifying genetic alterations relating to gemcitabine resistance revealed that RRM1 was the most upregulated gene with a 4.5 fold expression.,"['analysis', 'for', 'identifying', 'genetic', 'alterations', 'relating', 'to', '_chemical_', 'resistance', 'revealed', 'that', '_gene_', 'was', 'the', 'most', 'upregulated', 'gene', 'with', 'a', '_num_', 'fold', 'expression']"
2116,1.0,A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene.,"['a', 'computational', 'method', 'was', 'used', 'to', 'find', 'potential', 'gene', 'fusions', 'which', 'assessed', 'differential', 'exon', 'expression', 'between', 'the', '_num_', 'and', '_num_', 'ends', 'of', 'each', 'gene']"
2117,1.0,"The unrelated, 45-year-old VHL patient had hemangioblastomas of the central nervous system and retina, renal cell carcinoma, and pancreatic cysts (proband no 14).","['the', 'unrelated', '_age_', '_gene_', 'patient', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', 'retina', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'proband', 'no', '_num_']"
2118,1.0,"In a phase 3 clinical trial (NCT00829166), metastatic breast cancer patients with PIK3CA mutation (n=40), including patients with PIK3CA H1047R, treated with ado-trastuzumab were associated with improved median progression free survival (10.9 vs. 9.8 months), as compared to patients with wild type PIK3CA (n=93).","['in', 'a', 'phase', '_num_', 'clinical', 'trial', '_abbrev_', 'metastatic', 'breast', 'cancer', 'patients', 'with', '_gene_', 'mutation', '_ineq_', 'including', 'patients', 'with', '_gene_', '_mutation_', 'treated', 'with', 'ado', '_chemical_', 'were', 'associated', 'with', 'improved', 'median', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', '_ineq_']"
2119,0.0,PF-06463922 was well tolerated in the in-vivo models.,"['_chemical_', 'was', 'well', 'tolerated', 'in', 'the', 'in', 'vivo', 'models']"
2120,1.0,"The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.","['the', 'patient', 'was', 'a', 'female', 'former', 'smoker', 'who', 'had', 'lung', 'adenocarcinoma', 'histology', 'and', 'demonstrated', 'response', 'for', '_num_', 'months', 'with', 'overall', 'survival', '_num_', 'months']"
2121,1.0,"This missense mutation was found in a 45-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no 4).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_age_', '_gene_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'proband', 'no', '_num_']"
2122,1.0,"In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations).","['in', 'a', 'phase', '_num_', 'clinical', 'study', 'of', '_num_', '_disease_', 'high', 'risk', 'mds', 'patients', 'treated', 'with', 'either', '_num_', 'or', '_num_', '_unit_', '_chemical_', '_num_', 'harbored', '_gene_', 'mutations', '_num_', 'had', '_gene_', '_gene_', '_num_', 'had', '_gene_', '_mutation_', 'mutations']"
2123,1.0,Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.,"['melanoma', 'cell', 'lines', 'were', 'shown', 'to', 'have', 'increased', 'sensitivity', 'to', '_chemical_', 'when', 'sirna', 'induced', 'atm', 'knockdown', 'was', 'applied']"
2124,1.0,"In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild type SMO.","['in', 'an', 'in', 'vitro', 'study', 'mouse', 'embryonic', 'fibroblasts', '_disease_', 'null', 'for', 'the', '_gene_', 'mouse', 'gene', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'resistance', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', '_unit_', 'vs', '_num_', '_unit_', '_unit_', 'compared', 'to', '_disease_', 'expressing', 'wild', 'type', '_gene_']"
2125,1.0,"Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026).","['expression', 'of', '_gene_', '_gene_', 'in', 'colorectal', 'cancer', 'patients', '_ineq_', 'by', '_gene_', 'showed', 'improved', 'benefit', 'from', 'adjuvant', 'chemotherapy', 'in', 'stage', 'iii', 'patients', '_num_', 'vs', '_num_', 'p', '_num_']"
2126,1.0,"The median PFS was 208 days (95% CI, 41-208 days).","['the', 'median', '_disease_', 'was', '_num_', 'days', '_num_', 'ci', '_range_', 'days']"
2127,1.0,Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.,"['transduction', 'of', 'ba', '_abbrev_', 'cells', 'with', '_chemical_', 'variant', '_num_', '_gene_', 'exon', '_num_', 'fused', 'to', '_gene_', 'exon', '_num_', 'caused', 'the', 'cells', 'to', 'grow', 'independently', 'of', '_gene_', 'addition']"
2128,1.0,Apoptotic markers were apparent with combination treatment.,"['apoptotic', 'markers', 'were', 'apparent', 'with', 'combination', 'treatment']"
2129,1.0,226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands.,"['_num_', '_chemical_', 'treated', 'patients', 'with', '_gene_', 'were', 'analyzed', 'for', 'mrna', 'expression', 'of', '_gene_', 'and', 'its', 'ligands']"
2130,1.0,"Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab.","['subsequent', 'knockdown', 'of', '_gene_', 'in', '_chemical_', 'cells', 'increased', 'cell', 'survival', 'when', 'treated', 'with', '_chemical_', 'and', 'growth', 'curves', 'showed', 'partial', 'restoration', 'of', 'proliferation', 'in', '_gene_', 'knockdown', '_chemical_', 'cells', 'treated', 'with', '_chemical_']"
2131,1.0,"we propose that these two activating mutations are the reason for the dramatic response to mTOR inhibition and considered them as ""biologically plausible"" to confer sensitivity to everolimus.","['we', 'propose', 'that', 'these', '_num_', 'activating', 'mutations', 'are', 'the', 'reason', 'for', 'the', 'dramatic', 'response', 'to', '_gene_', 'inhibition', 'and', 'considered', 'them', 'as', 'biologically', 'plausible', 'to', 'confer', 'sensitivity', 'to', '_chemical_']"
2132,1.0,"Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991.","['_num_', 'cell', 'lines', 'had', 'homozygous', 'deletions', 'of', '_gene_', 'but', 'not', '_gene_', 'and', '_num_', 'of', 'these', 'lines', 'were', 'classified', 'as', 'being', 'sensitive', 'to', '_disease_']"
2133,1.0,EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed.,"['_gene_', 'amplification', 'multiplex', 'ligation', 'dependent', 'probe', 'amplification', '_disease_', 'and', 'mutation', '_disease_', 'were', 'analzed']"
2134,1.0,"Treatment with selumetinib (NCT01362803) resulted in confirmed partial, long term responses in 17 of the 24 children with NF1 associated plexiform fibromas (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%).","['treatment', 'with', '_chemical_', '_abbrev_', 'resulted', 'in', 'confirmed', 'partial', 'long', 'term', 'responses', 'in', '_num_', 'of', 'the', '_num_', 'children', 'with', '_gene_', 'associated', 'plexiform', 'fibromas', '_num_', 'and', 'decreases', 'from', 'baseline', 'in', 'neurofibroma', 'volume', 'in', '_num_', 'of', '_num_', 'mice', '_num_']"
2135,1.0,MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy.,"['_gene_', 'serum', 'levels', 'were', 'assessed', 'elisa', 'at', 'baseline', 'b', 'and', 'before', 'surgery', 'in', '_num_', 'available', 'samples', 'from', 'patients', 'with', 'inflammatory', 'breast', 'cancer', 'treated', 'with', '_chemical_', 'based', 'neoadjuvant', 'therapy']"
2136,1.0,Patients with KMT2C mutations also had significantly shorter recurrent free survival (21.6 versus 167.5; p=0.003) and an increased hazards ratio for death (HR=5.16; 95%CI:1.55 to 17.18).,"['patients', 'with', '_gene_', 'mutations', 'also', 'had', 'significantly', 'shorter', 'recurrent', 'free', 'survival', '_num_', 'vs', '_num_', '_p_val_', 'and', 'an', 'increased', 'hazards', 'ratio', 'for', 'death', '_ineq_', '_num_', 'ci:1', '_num_', 'to', '_num_']"
2137,1.0,"No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies.","['no', 'statistical', 'analysis', 'was', 'reported', 'for', 'this', 'variant', 'and', '_disease_', 'or', 'os', 'citing', 'small', 'sample', 'size', 'across', 'the', 'studies']"
2138,1.0,Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.,"['median', 'survival', 'of', 'patients', 'with', '_gene_', '_mutation_', 'mutation', 'is', 'better', 'than', 'those', 'with', 'wild', 'type', '_gene_']"
2139,1.0,A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors.,"['a', 'slow', 'progression', 'developed', 'which', 'was', 'found', 'to', 'be', 'positive', 'for', '_mutation_', 'as', 'well', 'as', '_mutation_', 'mutation', 'which', 'confers', 'resistance', 'to', 'tyrosine', 'kinase', 'inhibitors']"
2140,1.0,"1-year progression free survival rates for exon 9 mutants and wild type were 68% and 57%, compared with 34% and 15% for exon 11 and PDGFRA mutants.","['_num_', 'year', 'progression', 'free', 'survival', 'rates', 'for', 'exon', '_num_', 'mutants', 'and', 'wild', 'type', 'were', '_num_', 'and', '_num_', 'compared', 'with', '_num_', 'and', '_num_', 'for', 'exon', '_num_', 'and', '_gene_', 'mutants']"
2141,1.0,"Also, 17 high-grade serous adenocarcinomas were also analyzed and none of them showed a loss of ARID1A expression.","['also', '_num_', 'high', 'grade', 'serous', 'adenocarcinomas', 'were', 'also', 'analyzed', 'and', 'none', 'of', 'them', 'showed', 'a', 'loss', 'of', '_gene_', 'expression']"
2142,1.0,The patient also harbored a second MLH1 mutation (p.D667fs) which demonstrated loss of heterozygosity.,"['the', 'patient', 'also', 'harbored', 'a', '_num_', '_gene_', 'mutation', 'p', '_abbrev_', 'which', 'demonstrated', 'loss', 'of', 'heterozygosity']"
2143,1.0,"Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A.","['young', '_disease_', 'patients', '_num_', 'years', 'old', 'with', '_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_abbrev_', 'were', 'older', 'in', 'age', 'had', 'higher', 'white', 'blood', 'cell', 'counts', 'and', 'had', 'higher', 'platelet', 'counts', 'than', 'patients', 'wildtype', 'for', '_gene_']"
2144,1.0,"Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion.","['assays', 'with', 'a', 'panel', 'of', 'mutated', '_chemical_', 'variants', 'of', 'varied', 'length', 'suggested', 'that', 'longer', '_chemical_', 'variants', 'are', 'less', 'stable', 'in', 'cells', 'although', 'this', 'tendency', 'was', 'not', 'observed', 'across', 'other', 'types', 'of', '_gene_', 'fusion']"
2145,1.0,SMAD4 was assessed by IHC in 56 of 249 (22%).,"['_gene_', 'was', 'assessed', 'by', '_gene_', 'in', '_num_', 'of', '_num_', '_num_']"
2146,1.0,pS6 staining was also reduced after rapamycin treatment.,"['_gene_', 'staining', 'was', 'also', 'reduced', 'after', '_gene_', 'treatment']"
2147,1.0,"In vivo treatment of mice with Braf/Nf1-mutant allografts showed less sensitivity to vemurafenib (PLX4032) than the MEK inhibitor, PD0325901.","['in', 'vivo', 'treatment', 'of', 'mice', 'with', '_gene_', '_gene_', 'mutant', 'allografts', 'showed', 'less', 'sensitivity', 'to', '_chemical_', '_chemical_', 'than', 'the', 'mek', 'inhibitor', '_chemical_']"
2148,1.0,"Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer.","['blood', 'mrna', 'levels', 'of', '_gene_', '_gene_', 'and', '_gene_', 'were', 'associated', 'with', 'response', 'to', '_chemical_', 'treatment', 'in', 'castration', 'resistant', 'prostate', 'cancer']"
2149,1.0,No difference in survival is seen between amplified and non-amplified patients in general.,"['no', 'difference', 'in', 'survival', 'is', 'seen', 'between', 'amplified', 'and', 'non', 'amplified', 'patients', 'in', 'general']"
2150,1.0,A phase 2 clinical trial evaluated 165 patients with oestrogen receptor positive and HER2-negative breast cancer such that 84 patients received combination therapy of palbociclib plus letrozole and 81 patients received letrozole alone.,"['a', 'phase', '_num_', 'clinical', 'trial', 'evaluated', '_num_', 'patients', 'with', 'oestrogen', 'receptor', 'positive', 'and', '_gene_', 'breast', 'cancer', 'such', 'that', '_num_', 'patients', 'received', 'combination', 'therapy', 'of', '_chemical_', 'plus', '_chemical_', 'and', '_num_', 'patients', 'received', '_chemical_', 'alone']"
2151,1.0,"Seven had retinal angiomas, 3 had cerebellar hemangioblastomas, and 5 had renal cell carcinoma.","['_num_', 'had', 'retinal', 'angiomas', '_num_', 'had', 'cerebellar', '_disease_', 'and', '_num_', 'had', 'renal', 'cell', 'carcinoma']"
2152,1.0,Relevant HPO terms: Pheochromocytoma.,"['relevant', '_disease_', 'terms', 'pheochromocytoma']"
2153,1.0,"Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs.","['ba', '_abbrev_', 'cells', 'expressing', '_num_', 'clinically', 'relevant', '_chemical_', 'resistant', 'mutant', 'forms', 'of', '_chemical_', 'namely', '_mutation_', 'and', '_mutation_', 'were', 'tested', 'for', 'growth', 'inhibition', 'by', '_num_', '_gene_', 'blocking', '_disease_']"
2154,1.0,Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells.,"['testing', 'also', 'revealed', 'a', 'high', 'mutational', 'load', 'as', 'well', 'as', '2+', '_gene_', 'expression', 'in', '_num_', 'of', 'the', 'cells']"
2155,0.0,One such example is BRAF mutations that occur outside of codon 600 (non-V600 BRAF mutations).,"['_num_', 'such', 'example', 'is', '_gene_', 'mutations', 'that', 'occur', 'outside', 'of', 'codon', '_num_', '_abbrev_', '_gene_', 'mutations']"
2156,1.0,"In a BRCA wild type subgroup, with low levels of Loss of Heterozygosity, confirmed objective response was observed in 10% of the patients.","['in', 'a', '_gene_', 'wild', 'type', 'subgroup', 'with', 'low', 'levels', 'of', 'loss', 'of', 'heterozygosity', 'confirmed', 'objective', 'response', 'was', 'observed', 'in', '_num_', 'of', 'the', 'patients']"
2157,0.0,Either of these variants is predicted to be quite deleterious.,"['either', 'of', 'these', 'variants', 'is', 'predicted', 'to', 'be', 'quite', 'deleterious']"
2158,1.0,Evidence also supported a possible link between G84E with bladder cancer (P = 0.06) and leukemia (P = 0.01).,"['evidence', 'also', 'supported', 'a', 'possible', 'link', 'between', '_mutation_', 'with', 'bladder', 'cancer', 'p', '_num_', 'and', 'leukemia', 'p', '_num_']"
2159,1.0,"Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice.","['following', '_gene_', 'treatment', 'of', 'mice', 'with', '_abbrev_', 'lung', 'tumors', 'mice', 'with', '_gene_', 'deletion', '_abbrev_', 'deletion', 'resulting', 'in', 'frameshift', 'in', 'the', 'lung', 'exhibit', 'increased', 'overall', 'survival', 'increased', 'apoptosis', 'reduced', 'proliferation', 'and', 'reduced', 'tumor', 'burden', 'compared', 'to', '_gene_', 'wildtype', 'mice']"
2160,1.0,"MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+.","['met', 'gene', 'copy', 'number', 'was', '_num_', 'met', 'fish', '_num_', 'copy', 'number', 'and', '_gene_', '3+']"
2161,1.0,Mutation detected in 4 separate cases.,"['mutation', 'detected', 'in', '_num_', 'separate', 'cases']"
2162,1.0,"Homozygous CC patients were at highest risk for progression [odds ratio (OR), 1.94; P = 0.020], metastasis (OR, 3.49; P = 0.005), and tumor-related death (OR, 2.49; P = 0.031) compared with TT genotypes.","['homozygous', 'cc', 'patients', 'were', 'at', 'highest', 'risk', 'for', 'progression', 'odds', 'ratio', 'or', '_num_', 'p', '_num_', 'metastasis', 'or', '_num_', 'p', '_num_', 'and', 'tumor', 'related', 'death', 'or', '_num_', 'p', '_num_', 'compared', 'with', 'tt', 'genotypes']"
2163,1.0,"Additionally, this patient harbored a heterozygous MLH1 p.K618del mutation.","['additionally', 'this', 'patient', 'harbored', 'a', 'heterozygous', '_gene_', '_mutation_', 'mutation']"
2164,1.0,p27 knockout resensitiuzed cells to lapatinib.,"['_gene_', 'knockout', 'resensitiuzed', 'cells', 'to', '_chemical_']"
2165,1.0,The patient had resolution of prior dyspnea and pain within 3 weeks.,"['the', 'patient', 'had', 'resolution', 'of', 'prior', 'dyspnea', 'and', 'pain', 'within', '_num_', 'weeks']"
2166,1.0,Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion.,"['case', 'report', 'of', 'a', 'patient', 'with', 'mammary', 'analogue', 'secretory', 'carcinoma', '_disease_', 'harboring', 'an', '_gene_', 'fusion']"
2167,1.0,ACMG evidence codes supported by this paper are possibly PVS1 and PP1.,"['acmg', 'evidence', 'codes', 'supported', 'by', 'this', 'paper', 'are', 'possibly', '_abbrev_', 'and', '_gene_']"
2168,1.0,TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.,"['_chemical_', 'effectively', 'inhibits', '_gene_', 'signaling', 'in', '_gene_', '_mutation_', 'cells']"
2169,1.0,Patients with low-grade tumors were more likely to have FGFR3 mutations than those with high-grade tumors.,"['patients', 'with', 'low', 'grade', 'tumors', 'were', 'more', 'likely', 'to', 'have', '_gene_', 'mutations', 'than', 'those', 'with', 'high', 'grade', 'tumors']"
2170,1.0,Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib.,"['treating', 'xenografts', 'derived', 'from', 'isogenic', '_gene_', 'wildtype', 'or', 'mutant', 'cell', 'lines', 'corroborated', 'this', 'finding', 'with', '_gene_', 'mutant', 'xenografts', 'showing', 'greater', 'sensitivity', 'to', '_chemical_']"
2171,1.0,Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both.,"['xenografts', 'harbored', 'both', 'a', 'germline', '_gene_', 'and', 'a', 'somatic', '_gene_', 'mutation', 'leading', 'to', 'disruption', 'of', 'both']"
2172,1.0,"17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment.","['_num_', '_ratio_', 'of', 'mice', 'treated', 'with', '_chemical_', 'developed', 'detectable', 'lesions', 'whereas', '_num_', 'of', 'mice', '_ratio_', 'treated', 'with', 'vehicle', 'developed', 'lesions', 'at', 'the', 'end', 'of', 'the', 'treatment']"
2173,1.0,"H3122 CR2 and H3122 cells were similarly sensitized to 17-AAG death with an IC50 value of approximately 5 nM, while control cells without EML4-ALK had IC50 values approximately 10x higher.","['_abbrev_', '_gene_', 'and', '_abbrev_', 'cells', 'were', 'similarly', 'sensitized', 'to', '_chemical_', 'death', 'with', 'an', '_abbrev_', 'value', 'of', 'approximately', '_num_', '_unit_', 'while', 'control', 'cells', 'without', '_chemical_', 'had', '_abbrev_', 'values', 'approximately', '10x', 'higher']"
2174,1.0,Break-apart signal was positive in 66% of tumor cells.,"['break', 'apart', 'signal', 'was', 'positive', 'in', '_num_', 'of', 'tumor', 'cells']"
2175,1.0,"Relevant HPO terms: Hemangioblastoma, Retinal hemangioblastoma, Multiple pancreatic cysts.","['relevant', '_disease_', 'terms', '_disease_', 'retinal', '_disease_', 'multiple', 'pancreatic', 'cysts']"
2176,1.0,This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 75).,"['this', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
2177,1.0,In this study 44 of 56 patients were treated with either gefitinib or erlotinib.,"['in', 'this', 'study', '_num_', 'of', '_num_', 'patients', 'were', 'treated', 'with', 'either', '_chemical_', 'or', '_chemical_']"
2178,1.0,There was a significant correlation between low ARID1A expression and large tumors as well as shorter survival.,"['there', 'was', 'a', 'significant', 'correlation', 'between', 'low', '_gene_', 'expression', 'and', 'large', 'tumors', 'as', 'well', 'as', 'shorter', 'survival']"
2179,1.0,"In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint.","['in', 'this', '_num_', 'arm', 'phase', 'iii', 'study', '_abbrev_', 'of', 'the', 'efficacy', 'of', 'a', '_num_', 'month', 'course', 'of', 'the', '_disease_', '_chemical_', 'after', '_chemical_', 'based', 'adjuvant', 'therapy', 'of', 'early', 'stage', '_gene_', 'breast', 'cancer', 'was', 'assessed', 'using', 'invasive', '_disease_', 'survival', 'as', 'primary', 'endpoint']"
2180,1.0,This study contains supporting evidence of pathogenicity for this variant due to cosegregation of disease with multiple family members in a gene definitively known to cause disease (ACMG code: PP1).,"['this', 'study', 'contains', 'supporting', 'evidence', 'of', 'pathogenicity', 'for', 'this', 'variant', 'due', 'to', 'cosegregation', 'of', 'disease', 'with', 'multiple', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'disease', 'acmg', 'code', '_gene_']"
2181,1.0,"In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification.","['in', 'patients', 'with', 'gastric', 'cancer', 'those', 'with', 'amplification', 'of', '_gene_', 'had', 'shorter', 'overall', 'survival', 'than', 'those', 'without', 'amplification']"
2182,1.0,"In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%).","['in', '_num_', 'cases', 'of', '_disease_', 'screened', 'for', '_gene_', 'rearrangements', '_num_', 'were', 'identified', 'frequency', '_num_']"
2183,1.0,In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.,"['in', '3t3', 'fibroblasts', 'expressing', 'the', '_mutation_', 'mutation', 'have', 'to', 'be', 'sensitive', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_chemical_']"
2184,1.0,Variant function was assessed by EGFR auto-phosphorylation.,"['variant', 'function', 'was', 'assessed', 'by', '_gene_', 'auto', '_disease_']"
2185,1.0,"Finally, AZD5438 reduced tumor growth induced by SW620 (KRAS p.G12V) colorectal tumour cells xenografted into immunodeficient mice.","['finally', '_chemical_', 'reduced', 'tumor', 'growth', 'induced', 'by', '_abbrev_', '_gene_', '_mutation_', 'colorectal', 'tumour', 'cells', 'xenografted', 'into', 'immunodeficient', 'mice']"
2186,1.0,Patients with a TP53 mutation had a reduced three year probability of overall survival and event-free survival compared to patients with the wild type TP53.,"['patients', 'with', 'a', '_gene_', 'mutation', 'had', 'a', 'reduced', '_num_', 'year', 'probability', 'of', 'overall', 'survival', 'and', 'event', 'free', 'survival', 'compared', 'to', 'patients', 'with', 'the', 'wild', 'type', '_gene_']"
2187,1.0,A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma.,"['a', '_num_', 'year', 'old', 'patient', 'presented', 'with', '_chemical_', 'resistant', '_gene_', '_abbrev_', 'cutaneous', 'melanoma']"
2188,1.0,High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004).,"['high', '_gene_', 'levels', 'were', 'also', 'associated', 'with', 'worse', '_num_', 'year', 'overall', 'survival', '_num_', 'than', 'low', 'levels', '_num_', 'p', '_num_']"
2189,1.0,"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622).","['_num_', 'patients', '_num_', 'with', 'progression', 'events', 'with', '_gene_', 'metastatic', 'breast', 'cancer', 'and', 'with', 'a', 'confirmed', 'deleterious', 'or', 'suspected', 'deleterious', 'germline', '_gene_', 'mutation', '_num_', '_gene_', '_num_', '_gene_', 'had', 'significantly', 'improved', 'progression', 'free', 'survival', 'and', 'better', 'response', 'rate', 'to', '_chemical_', '_gene_', 'inhibitor', 'than', 'standard', 'therapy', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_range_', 'in', 'this', 'randomized', 'phase', '_num_', 'trial', '_abbrev_']"
2190,1.0,A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC.,"['a', '_disease_', 'analysis', 'showed', '_gene_', 'mutation', 'is', 'associated', 'with', 'worse', 'outcome', 'in', 'patients', 'with', '_disease_']"
2191,1.0,ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.,"['atra', 'arsenic', 'combined', 'with', 'standard', 'chemotherapy', 'has', 'been', 'shown', 'to', 'induce', 'a', 'complete', 'remission', 'rate', 'of', 'greater', 'than', '_num_', 'of', 'patients', 'with', 'acute', 'promyelocytic', 'leukemia', 'harboring', 'the', '_disease_', 'fusion']"
2192,1.0,"MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.","['_gene_', 'promoter', 'methylation', 'has', 'been', 'shown', 'to', 'confer', 'sensitivity', 'to', '_chemical_', 'agents', 'such', 'as', '_chemical_', 'in', 'glioblastoma', 'cells']"
2193,1.0,"Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment.","['among', '_num_', 'advanced', '_disease_', 'patients', 'who', 'were', 'screened', 'for', '_gene_', 'rearrangement', 'using', 'a', 'break', 'apart', 'fish', 'assay', '_num_', 'patients', 'were', 'eligible', 'for', '_chemical_', 'treatment']"
2194,1.0,"In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib.","['in', 'this', 'phase', 'ii', 'trial', 'of', '_num_', 'patients', '_abbrev_', '_chemical_', 'was', 'assayed', 'for', 'safety', 'and', 'efficacy', 'in', '_gene_', 'positive', '_disease_', 'that', 'had', 'progressed', 'on', '_chemical_']"
2195,0.0,This SNP is expected to reduce MiR-199a induced repression of HIF-1α Expression.,"['this', 'snp', 'is', 'expected', 'to', 'reduce', '_gene_', 'induced', 'repression', 'of', '_abbrev_', 'expression']"
2196,1.0,One patient also had retinal angiomas.,"['_num_', 'patient', 'also', 'had', 'retinal', 'angiomas']"
2197,1.0,CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically.,"['_gene_', '_chemical_', 'expression', 'especially', '_gene_', 'was', 'identified', 'to', 'predict', 'response', 'to', '_gene_', 'antibody', '_abbrev_', 'preclinically']"
2198,1.0,High (18.4%) or moderate (35.4%) expression of HIF-1alpha was significatnly associated with shorter overall survival rate in comparison with those with a weak or negative expression in univariate analysis (P = 0.029; log-rank test) and multivariate analysis (P = 0.018).,"['high', '_num_', 'or', 'moderate', '_num_', 'expression', 'of', '_gene_', 'was', 'significatnly', 'associated', 'with', 'shorter', 'overall', 'survival', 'rate', 'in', 'comparison', 'with', 'those', 'with', 'a', 'weak', 'or', 'negative', 'expression', 'in', 'univariate', 'analysis', 'p', '_num_', 'log', 'rank', 'test', 'and', 'multivariate', 'analysis', 'p', '_num_']"
2199,1.0,"Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa).","['preclinical', 'study', 'in', 'endometrial', 'cancer', 'cell', 'lines', '_abbrev_', '_abbrev_', '_abbrev_', 'and', 'ishikawa']"
2200,1.0,Mutations were predicted to be loss-of-function.,"['mutations', 'were', 'predicted', 'to', 'be', '_disease_']"
2201,1.0,ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases.,"['_gene_', 'rearrangements', 'are', 'seen', 'in', '_num_', 'of', 'inflammatory', 'myofibroblastic', 'tumor', '_disease_', 'cases']"
2202,1.0,"RIT1 mutations were identified in approx 2% of lung adenocarcinomas (5/87 in the ""oncogene negative"" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation).","['_gene_', 'mutations', 'were', 'identified', 'in', 'approx', '_num_', 'of', 'lung', 'adenocarcinomas', '_ratio_', 'in', 'the', 'oncogene', 'negative', 'samples', 'of', '_disease_', 'no', '_gene_', 'mutations', 'were', 'observed', 'in', '_num_', 'samples', 'with', 'a', 'known', 'driver', 'mutation']"
2203,1.0,Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.,"['complete', 'remission', 'rates', 'did', 'not', 'differ', 'between', 'patients', 'with', 'wildtype', 'or', 'mutant', '_gene_', '_num_', 'of', 'which', 'affected', '_abbrev_', 'and', 'cytogenetically', 'normal', '_disease_']"
2204,1.0,"Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines.","['concentration', 'dependent', 'antiproliferative', 'effects', 'of', '_disease_', 'were', 'seen', 'in', 'all', 'ovarian', 'cancer', 'cell', 'lines', 'but', 'varied', 'significantly', 'between', 'individual', 'lines']"
2205,1.0,"Median OS was 9·4 months (6·8-13·6) in selumetinib group and 5·2 months (95% CI 3·8-non-calculable) in placebo group (hazard ratio [HR] for death 0·80, 80% CI 0·56-1·14; one-sided p=0·21).","['median', 'os', 'was', '_num_', 'months', '_range_', 'in', '_chemical_', 'group', 'and', '_num_', 'months', '_num_', 'ci', '_num_', 'non', 'calculable', 'in', 'placebo', 'group', 'hazard', 'ratio', 'hr', 'for', 'death', '_num_', '_num_', 'ci', '_range_', '_num_', 'sided', '_p_val_']"
2206,1.0,"4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074.","['_num_', 'of', '_num_', 'cell', 'lines', 'exhibited', '_gene_', 'amplification', 'and', '_num_', 'of', 'these', 'were', 'highly', 'sensitive', 'to', '_chemical_']"
2207,1.0,"During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients.","['during', 'treatment', 'a', 'significant', 'decrease', 'in', '_gene_', 'levels', 'p', '_num_', 'was', 'observed', 'in', '_num_', 'of', 'patients']"
2208,1.0,48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients).,"['_num_', 'tumor', 'samples', 'from', '_num_', 'patients', 'with', '_gene_', 'mutant', 'lung', 'adenocarcinoma', 'that', 'were', 'resistant', 'to', 'tyrosine', 'kinase', 'inhibition', 'underwent', 'next', 'generation', 'sequencing', 'ampliseq', 'cancer', 'hotspot', 'panel', '_abbrev_', 'failed', 'in', '_num_', 'samples', 'leading', 'to', 'a', 'remaining', '_num_', 'specimens', 'from', '_num_', 'patients']"
2209,1.0,No difference was observed in a control group without bevacizumab treatment.,"['no', 'difference', 'was', 'observed', 'in', 'a', 'control', 'group', 'without', '_chemical_', 'treatment']"
2210,1.0,"In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling.","['in', 'an', 'evaluation', 'of', 'a', 'patient', 'and', 'never', 'smoker', 'with', '_chemical_', 'sensitive', 'lung', 'adenocarcinoma', 'an', '_abbrev_', 'rearrangement', 'was', 'identified', 'using', 'comprehensive', 'genomic', 'profiling']"
2211,1.0,Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations.,"['_num_', 'patients', 'diagnosed', 'with', '_disease_', 'thyroid', 'carcinoma', 'hurthle', 'cell', 'thyroid', 'carcinoma', 'were', 'evaluated', 'for', '_gene_', 'mutations']"
2212,1.0,"Since this is a somatic variant, albeit with likely functional effect, we can only infer that if observed in a germline context, it might predispose for VHL.","['since', 'this', 'is', 'a', 'somatic', 'variant', 'albeit', 'with', 'likely', 'functional', 'effect', 'we', 'can', 'only', 'infer', 'that', 'if', 'observed', 'in', 'a', 'germline', 'context', 'it', 'might', 'predispose', 'for', '_gene_']"
2213,1.0,"A significant difference in genotype distribution was observed between cases and controls  (TT vs. TC vs. CC, P = 0.0021).","['a', 'significant', 'difference', 'in', 'genotype', 'distribution', 'was', 'observed', 'between', 'cases', 'and', 'controls', 'tt', 'vs', 'tc', 'vs', 'cc', 'p', '_num_']"
2214,1.0,"Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen.","['among', '_num_', 'patients', 'with', '_gene_', 'pathway', 'aberrations', '_num_', 'partial', 'responses', 'as', 'well', 'as', '_num_', 'with', 'stable', 'disease', 'were', 'seen']"
2215,1.0,Durable antitumor activity was only observed in BRCA1/2 mutation carriers.,"['durable', 'antitumor', 'activity', 'was', 'only', 'observed', 'in', '_gene_', 'mutation', 'carriers']"
2216,0.0,"IHC in 523 patient samples revealed high HR23b expression in 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST.","['_gene_', 'in', '_num_', 'patient', 'samples', 'revealed', 'high', '_gene_', 'expression', 'in', '_num_', 'of', 'sarcomas', 'among', 'them', 'malignant', 'peripheral', 'nerve', 'sheath', 'tumours', 'pleomorphic', 'liposarcomas', 'leiomyosarcomas', 'dedifferentiated', 'liposarcomas', 'synovial', 'sarcomas', 'and', 'angiosarcomas', 'and', '_num_', 'of', 'gist']"
2217,1.0,Two patients had loss of heterozygosity effecting the wildtype allele while one patient harbored a second MLH1 mutation (p.I68S).,"['_num_', 'patients', 'had', 'loss', 'of', 'heterozygosity', 'effecting', 'the', 'wildtype', 'allele', 'while', '_num_', 'patient', 'harbored', 'a', '_num_', '_gene_', 'mutation', 'p', '_abbrev_']"
2218,1.0,COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant.,"['_abbrev_', 'and', '_abbrev_', 'cells', 'harboring', '_gene_', '_mutation_', 'mutations', 'were', 'cloned', 'to', 'be', 'mek', 'inhibitor', '_chemical_', '_chemical_', 'resistant']"
2219,1.0,All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity.,"['all', 'mutations', 'were', 'compared', 'with', 'non', 'mutated', '_gene_', 'protein', 'and', 'were', 'grouped', 'according', 'to', 'their', 'anti', '_disease_', 'activity']"
2220,1.0,KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line.,"['_abbrev_', 'or', '_abbrev_', 'mutations', 'were', 'introduced', 'into', '_gene_', '_gene_', '_abbrev_', 'cell', 'line']"
2221,1.0,The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).,"['the', 'study', 'compared', '_chemical_', 'treatment', '_ineq_', 'with', 'chemotherapy', 'treatment', 'of', 'either', '_chemical_', 'or', '_chemical_', '_ineq_']"
2222,1.0,A 2 year old male presented with easy bruising and bleeding.,"['a', '_num_', 'year', 'old', 'male', 'presented', 'with', 'easy', 'bruising', 'and', 'bleeding']"
2223,1.0,"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients.","['phase', '1b', 'study', 'of', '_chemical_', '_chemical_', 'and', '_chemical_', 'in', '_num_', '_gene_', '_mutation_', 'mutant', 'colorectal', 'cancer', 'patients']"
2224,1.0,"In addition to this large family, we also provide an extensive review of prior reports of C609 variants, identifying a total of 111 patients from 19 publications, representing 21 affected kindreds and 15 sporadic cases.","['in', 'addition', 'to', 'this', 'large', 'family', 'we', 'also', 'provide', 'an', 'extensive', 'review', 'of', 'prior', 'reports', 'of', '_abbrev_', 'variants', 'identifying', 'a', 'total', 'of', '_num_', 'patients', 'from', '_num_', 'publications', 'representing', '_num_', 'affected', 'kindreds', 'and', '_num_', 'sporadic', 'cases']"
2225,1.0,"Elevated expression of RIT1 was correlated with poorer overall survival, pathological type, clinical stage, grade and vascular invasion.","['elevated', 'expression', 'of', '_gene_', 'was', 'correlated', 'with', 'poorer', 'overall', 'survival', 'pathological', 'type', 'clinical', 'stage', 'grade', 'and', 'vascular', 'invasion']"
2226,1.0,9 patients were identified with BTK mutations (C481S in 8 patients).,"['_num_', 'patients', 'were', 'identified', 'with', '_gene_', 'mutations', '_mutation_', 'in', '_num_', 'patients']"
2227,1.0,A B2M frame-shift deletion in exon 1 was identified as the only new homozygous mutation among 24 new relapse-specific mutations.,"['a', '_gene_', 'frame', 'shift', 'deletion', 'in', 'exon', '_num_', 'was', 'identified', 'as', 'the', 'only', 'new', 'homozygous', 'mutation', 'among', '_num_', 'new', 'relapse', 'specific', 'mutations']"
2228,1.0,"In a meta-analysis of 7 clinical trials of erlotinib, 10/24 patients with Exon 18 mutations harbored a G719 variant.","['in', 'a', '_disease_', 'analysis', 'of', '_num_', 'clinical', 'trials', 'of', '_chemical_', '_ratio_', 'patients', 'with', 'exon', '_num_', 'mutations', 'harbored', 'a', '_abbrev_', 'variant']"
2229,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_abbrev_', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
2230,1.0,A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.,"['a', 'cell', 'line', 'with', '_gene_', '_mutation_', 'mutation', 'was', 'found', 'to', 'be', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_abbrev_', 'in', 'this', 'study']"
2231,1.0,"The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia.","['the', '_year_', 'world', 'health', 'organization', 'guidelines', 'for', 'the', 'classification', 'of', 'myeloid', 'malignancies', 'uses', 'the', 'detection', 'of', '_abbrev_', 'or', 'rearrangements', 'involving', '_gene_', '_gene_', 'or', '_gene_', 'as', 'recommended', 'exclusion', 'criteria', 'for', 'a', 'diagnosis', 'of', 'chronic', 'myelomonocytic', 'leukemia', 'particularly', 'in', 'patients', 'with', 'evidence', 'of', 'eosinophilia']"
2232,1.0,"Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival (HR = 0.27, 95% CI: 0.13–0.56, P = 4.7×10−4, Pc = 0.003) and increased disease free survival (HR = 0.22, 95% CI: 0.11–0.43, P < .0001) when compared to patients without this mutation.","['patients', 'with', 'the', 'del', 'a', '+aa', 'genotype', 'of', '_gene_', '_mutation_', 'had', 'a', 'notably', 'increased', 'overall', 'survival', 'hr', '_num_', '_num_', 'ci', '_num_', '13–0', '_num_', 'p', '_num_', '7×10−4', 'pc', '_num_', 'and', 'increased', 'disease', 'free', 'survival', 'hr', '_num_', '_num_', 'ci', '_num_', '11–0', '_num_', 'p', '_num_', 'when', 'compared', 'to', 'patients', 'without', 'this', 'mutation']"
2233,1.0,"Median PFS was 2.8 months and 1.9 months for the KRAS-mutant and KRAS wild type populations, respectively.","['median', '_disease_', 'was', '_num_', 'months', 'and', '_num_', 'months', 'for', 'the', '_gene_', 'mutant', 'and', '_gene_', 'wild', 'type', 'populations', 'respectively']"
2234,1.0,The third patient had stable disease (T781A mutant).,"['the', '_num_', 'patient', 'had', 'stable', 'disease', '_abbrev_', 'mutant']"
2235,1.0,"Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent.","['ba', '_abbrev_', 'cells', 'require', '_gene_', 'in', 'order', 'to', 'proliferate', 'but', 'cells', 'transfected', 'with', 'an', 'activated', 'oncogene', 'are', '_gene_', 'independent']"
2236,1.0,"Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1.","['complete', 'remission', 'rates', 'were', 'higher', 'p', '_num_', 'and', 'both', '_disease_', 'survival', '_ineq_', 'vs', '_num_', '_p_val_', 'and', 'overall', 'survival', '_ineq_', 'vs', '_num_', '_p_val_', 'were', 'longer', 'for', '_disease_', 'patients', 'with', 'exon', '_num_', '_gene_', 'mutations', 'irrespective', 'of', '_gene_', 'status', 'than', 'those', 'with', 'wildtype', '_gene_']"
2237,1.0,"The CC genotype was significantly correlated with PDAC risk (OR = 1.719, 95% CI: 1.293-2.286) and shorter overall survival (OS, P<0.0001), compared with the CT/TT alleles Group.","['the', 'cc', 'genotype', 'was', 'significantly', 'correlated', 'with', '_disease_', 'risk', 'or', '_num_', '_num_', 'ci', '_range_', 'and', 'shorter', 'overall', 'survival', 'os', 'p', '_num_', 'compared', 'with', 'the', '_mutation_', 'alleles', 'group']"
2238,1.0,"The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.","['the', '_gene_', 'inhibitor', '_num_', '_num_', 'pyrimidinediamine', 'inhibited', 'growth', 'of', 'the', '3a', 'b', 'containing', '_abbrev_', '_disease_', 'cell', 'line']"
2239,1.0,A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib).,"['a', 'patient', 'with', '_gene_', 'mutant', 'melanoma', 'relapsed', 'after', 'treatment', 'with', '_chemical_', '_chemical_']"
2240,1.0,Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer.,"['case', 'study', 'of', 'a', '_num_', 'year', 'old', 'male', 'patient', 'with', '_disease_', 'syndrome', 'and', 'pancreatic', 'cancer']"
2241,1.0,In total only 4 out of 450 tumor and cell line samples had concomitant loss of both genes (p=4.9x10^-7).,"['in', 'total', 'only', '_num_', 'out', 'of', '_num_', 'tumor', 'and', 'cell', 'line', 'samples', 'had', 'concomitant', 'loss', 'of', 'both', 'genes', '_p_val_']"
2242,1.0,FBXW7 was shown to target mTOR for ubiquitination and degradation.,"['_gene_', 'was', 'shown', 'to', 'target', '_gene_', 'for', '_disease_', 'and', 'degradation']"
2243,1.0,"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF, or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization.","['in', '_num_', 'out', 'of', '_num_', '_num_', 'metastatic', 'colorectal', 'cancer', 'tumors', 'harboring', '_gene_', 'nras', '_gene_', 'or', '_gene_', 'mutations', 'and', 'implanted', 'into', 'mice', 'the', 'therapeutic', 'combination', 'of', 'the', 'mek', 'inhibitor', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'disease', 'stabilization']"
2244,1.0,"GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA.","['_gene_', 'treated', 'cells', 'formed', 'new', 'tumors', 'while', '_gene_', 'deletion', 'blocked', 'tumor', 'formation', 'indicating', 'tumor', 'dependence', 'on', '_gene_']"
2245,1.0,"Crizotinib resistant clones were produced from the parental EML4-ALK variant 1 containing cell line H3122 (CR1, CR2, CR3).","['_chemical_', 'resistant', 'clones', 'were', 'produced', 'from', 'the', 'parental', '_chemical_', 'variant', '_num_', 'containing', 'cell', 'line', '_abbrev_', '_gene_', '_gene_', '_gene_']"
2246,1.0,Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years.,"['_chemical_', 'treatment', 'in', 'a', 'phase', 'ii', 'trial', 'led', 'to', 'a', 'complete', 'and', 'durable', 'response', '_num_', 'years']"
2247,1.0,Seven of 10 individuals were identified with cerebellar hemangioblastomas and renal cell carcinoma.,"['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
2248,1.0,"When split into sub groups by cancer type overall survival  was poor for breast (HR = 1.98, P =0 .014), urothelial (HR = 2.24, P <0.001), renal (HR = 3.30,  P <0.001), and gastric cancers (HR = 1.56, P =0 .040).","['when', 'split', 'into', 'sub', 'groups', 'by', 'cancer', 'type', 'overall', 'survival', 'was', 'poor', 'for', 'breast', 'hr', '_num_', 'p', '_ineq_', '_num_', 'urothelial', 'hr', '_num_', 'p', '_num_', 'renal', 'hr', '_num_', 'p', '_num_', 'and', 'gastric', 'cancers', 'hr', '_num_', 'p', '_ineq_', '_num_']"
2249,1.0,Expression was also associated with poor survival (p=.02) and in vitro models showed SHP2 expression promoted tumor growth.,"['expression', 'was', 'also', 'associated', 'with', 'poor', 'survival', '_gene_', 'and', 'in', 'vitro', 'models', 'showed', '_gene_', 'expression', 'promoted', 'tumor', 'growth']"
2250,1.0,Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations.,"['phase', '_num_', 'trial', 'of', '_chemical_', 'and', '_chemical_', 'in', 'patients', 'with', 'advanced', 'melanoma', 'lacking', '_gene_', '_abbrev_', 'mutations']"
2251,1.0,KPL4 has suboptimal responses to trastuzumab and lapatinib.,"['_abbrev_', 'has', 'suboptimal', 'responses', 'to', '_chemical_', 'and', '_chemical_']"
2252,1.0,Patients were divided into different cohorts receiving different doses of alectinib.,"['patients', 'were', 'divided', 'into', 'different', 'cohorts', 'receiving', 'different', 'doses', 'of', '_chemical_']"
2253,1.0,120 patients were treated at doses between 2 and 70mg.,"['_num_', 'patients', 'were', 'treated', 'at', 'doses', 'between', '_num_', 'and', '_unit_']"
2254,1.0,BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E).,"['_gene_', 'mutations', 'were', 'identified', 'in', '_num_', 'of', '_num_', 'cases', 'of', 'high', 'grade', 'colorectal', 'neuroendocrine', 'tumors', '_num_', '_mutation_']"
2255,1.0,This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573).,"['this', 'study', 'provides', 'mechanistic', 'rationale', 'for', 'improved', 'efficacy', 'of', '_chemical_', 'in', '_gene_', 'mutant', 'models', 'compared', 'to', 'mek', 'inhibitors', 'acting', 'through', 'an', 'alternative', 'mechanism', '_chemical_', 'and', '_abbrev_']"
2256,1.0,"Rectal cancer patients with PIK3CA mutations showed a higher risk of local recurrence (HR:3.5; 95% CI:1.3-9.3, P=0.013, univariate analysis; HR:3.4, 95% CI:1.2-9.2, P=0.017, multivariate analysis) compared to wildtype PIK3CA patients.","['rectal', 'cancer', 'patients', 'with', '_gene_', 'mutations', 'showed', 'a', 'higher', 'risk', 'of', 'local', 'recurrence', 'hr:3', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'univariate', 'analysis', 'hr:3', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'multivariate', 'analysis', 'compared', 'to', 'wildtype', '_gene_', 'patients']"
2257,1.0,Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235.,"['preclinical', 'analysis', 'of', 'the', 'predicitive', 'value', 'of', '_gene_', 'mutations', 'for', '_gene_', '_gene_', 'inhibition', 'with', '_chemical_']"
2258,1.0,erlotinib).,['_chemical_']
2259,1.0,"Silencing of CCNE1 or CDK2 alone in MCF-7pR cells had no effect on cell-cycle arrest, but resulted in substantially increased cell-cycle arrest and reduction in cell growth in combination with palbociclib.","['silencing', 'of', '_gene_', 'or', '_gene_', 'alone', 'in', '_abbrev_', 'cells', 'had', 'no', 'effect', 'on', 'cell', 'cycle', 'arrest', 'but', 'resulted', 'in', 'substantially', 'increased', 'cell', 'cycle', 'arrest', 'and', 'reduction', 'in', 'cell', 'growth', 'in', 'combination', 'with', '_chemical_']"
2260,1.0,"It was found that treating these mice with afatinib and rapamycin had stronger effects than either treatment alone, including greater tumor regression and increased tumor necrosis.","['it', 'was', 'found', 'that', 'treating', 'these', 'mice', 'with', '_chemical_', 'and', '_gene_', 'had', 'stronger', 'effects', 'than', 'either', 'treatment', 'alone', 'including', 'greater', 'tumor', 'regression', 'and', 'increased', 'tumor', 'necrosis']"
2261,1.0,"Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response.","['of', '_num_', 'patients', 'with', 'measurable', 'cns', 'disease', '_num_', 'achieved', 'cns', 'complete', 'response', 'and', '_num_', 'showed', 'cns', 'partial', 'response']"
2262,1.0,94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.,"['_num_', 'endometrial', 'cancer', 'samples', 'of', 'women', 'who', 'had', 'been', 'treated', 'with', 'single', 'agent', '_gene_', 'inhibitors', '_chemical_', 'or', '_chemical_', 'were', 'retrospectively', 'analyzed']"
2263,1.0,Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.,"['addition', 'of', '_chemical_', 'to', 'mutant', '_gene_', 'cell', 'incubations', 'reduced', '_gene_', 'signal', 'and', 'induced', 'recompartmentalization', 'of', 'ectopic', '_gene_', 'protien', 'at', 'considerably', 'lower', 'conecntration', '_num_', '_unit_', '_chemical_']"
2264,1.0,"None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.","['none', 'of', 'the', 'xenografts', 'harboring', '_gene_', '_ineq_', 'nras', '_ineq_', 'or', '_gene_', '_ineq_', 'mutations', 'showed', 'resistance', 'whereas', '_num_', 'out', 'of', '_num_', 'xenografts', 'with', 'a', '_gene_', 'mutation', 'responded', 'to', '_chemical_']"
2265,1.0,Vemurafenib treatment of all of the BRAF mutant–expressing cells led to a decrease in phospho-MEK and ERK protein levels.,"['_chemical_', 'treatment', 'of', 'all', 'of', 'the', '_gene_', 'mutant–expressing', 'cells', 'led', 'to', 'a', 'decrease', 'in', '_chemical_', 'mek', 'and', '_gene_', 'protein', 'levels']"
2266,1.0,"Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with docetaxel.","['prostate', 'cancer', '_disease_', 'cell', 'lines', 'were', 'either', 'cultured', 'alone', 'co', 'cultured', 'with', 'osteoblasts', 'expressing', '_gene_', 'or', 'cultured', 'in', 'the', 'presence', 'of', 'media', 'with', '_gene_', 'to', 'examine', 'their', 'response', 'to', 'therapy', 'with', '_chemical_']"
2267,1.0,CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2.,"['_chemical_', 'and', 'to', 'a', 'lesser', 'extent', '_abbrev_', '_disease_', 'cell', 'lines', 'expressing', 'the', '_gene_', '_mutation_', 'mutation', 'had', 'increased', 'resistance', 'to', '_disease_', 'and', '_disease_', 'treatment', 'than', 'cells', 'expressing', 'wildtype', '_gene_']"
2268,1.0,Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage).,"['coexpression', 'of', 'egfrviii', 'and', '_gene_', 'was', 'associated', 'with', 'clinical', 'response', 'defined', 'as', '_num_', 'tumor', 'shrinkage']"
2269,1.0,Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review.,"['efficacy', 'of', '_chemical_', 'treatment', 'was', 'evaluated', 'by', '_disease_', 'analysis', 'of', 'results', 'from', '_num_', 'trials', 'and', 'literature', 'review']"
2270,1.0,FLT3 D835 mutations were shown to confer resistance to the tyrosine kinase inhibitor AC220 and ponatinib.,"['_gene_', '_abbrev_', 'mutations', 'were', 'shown', 'to', 'confer', 'resistance', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_abbrev_', 'and', '_chemical_']"
2271,1.0,Patients received either gefitinib only (N=136) or erlotinib only (N=5).,"['patients', 'received', 'either', '_chemical_', 'only', '_ineq_', 'or', '_chemical_', 'only', '_ineq_']"
2272,1.0,"Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine.","['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', '_num_', 'ci', '_range_', 'in', 'the', '_chemical_', 'group', 'and', '_num_', 'months', '_range_', 'in', 'the', '_chemical_', 'group', 'demonstrating', 'improved', 'progression', 'free', 'survival', 'of', '_chemical_', 'compared', 'with', '_chemical_']"
2273,1.0,"After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination.","['after', '_num_', 'month', 'a', 'ct', 'scan', 'showed', 'significant', 'size', 'reduction', 'in', 'lung', 'tumors', 'and', 'after', '_num_', 'months', 'the', 'patient', 'was', 'asymptomatic', 'with', 'an', 'entirely', 'negative', 'examination']"
2274,1.0,"95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal.","['_num_', 'trial', 'participants', 'with', 'archival', 'primary', 'tumor', 'were', 'reassessed', 'for', '_gene_', 'status', 'positivity', 'defined', 'by', 'fish', 'or', '_gene_', '3+', 'and', '_num_', 'patients', 'were', 'confirmed', 'for', '_gene_', 'positivity', 'and', '_num_', 'were', 'normal']"
2275,1.0,"Mutations are predominantly transversions, in keeping with a strong association with smoking.","['mutations', 'are', 'predominantly', 'transversions', 'in', 'keeping', 'with', 'a', 'strong', 'association', 'with', 'smoking']"
2276,1.0,we conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities.,"['we', 'conclude', 'that', 'high', '_gene_', 'expression', 'in', '_disease_', 'is', 'associated', 'with', 'poor', 'outcome', 'and', 'explains', 'observed', 'differences', 'in', 'outcome', 'between', 'ethnicities']"
2277,1.0,Tumor sample before crizotinib treatment was not available in this case.,"['tumor', 'sample', 'before', '_chemical_', 'treatment', 'was', 'not', 'available', 'in', 'this', 'case']"
2278,1.0,"Under increasing taselisib concentrations, reduction in phospho-Akt pro-survival signal was apparent, along with increased levels of pro-apoptotic marker cleaved PARP.","['under', 'increasing', 'taselisib', 'concentrations', 'reduction', 'in', '_chemical_', 'pro', 'survival', 'signal', 'was', 'apparent', 'along', 'with', 'increased', 'levels', 'of', 'pro', 'apoptotic', 'marker', 'cleaved', '_gene_']"
2279,1.0,"The PFS of patients with a concurrent PI3K/mTOR pathway alteration was significantly longer than those without when treated with AZD-5363 (median PFS, not reached v 4.3 months, respectively; HR, 0.21; P = 0.045).","['the', '_disease_', 'of', 'patients', 'with', 'a', 'concurrent', '_abbrev_', 'pathway', 'alteration', 'was', 'significantly', 'longer', 'than', 'those', 'without', 'when', 'treated', 'with', '_abbrev_', 'median', '_disease_', 'not', 'reached', 'v', '_num_', 'months', 'respectively', 'hr', '_num_', 'p', '_num_']"
2280,1.0,"Only one affected patient was identified with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts.","['only', '_num_', 'affected', 'patient', 'was', 'identified', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts']"
2281,1.0,This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6.,"['this', 'study', 'shows', 'a', 'reduction', 'in', 'the', 'risk', 'of', 'death', 'for', 'patients', 'with', '_gene_', 'copy', 'number', 'between', '_num_', 'and', '_num_']"
2282,1.0,PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.,"['_disease_', 'was', '_num_', 'months', 'in', '_disease_', 'group', 'vs', '_num_', 'months', 'in', '_chemical_', 'plus', '_chemical_']"
2283,1.0,Genetic characterization of the cell line with a SNP array identified a homozygous CDKN2A/B deletion.,"['genetic', 'characterization', 'of', 'the', 'cell', 'line', 'with', 'a', 'snp', 'array', 'identified', 'a', 'homozygous', '_gene_', 'deletion']"
2284,1.0,"EGFR G719 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.","['_gene_', '_abbrev_', 'mutations', 'have', 'been', 'associated', 'with', 'increased', 'sensitivity', 'to', '_num_', 'generation', '_gene_', 'tyrosine', 'kinase', 'inhibitors', 'including', '_chemical_', 'and', '_chemical_']"
2285,1.0,Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes.,"['responders', 'included', 'a', 'single', 'patient', 'with', 'a', 'somatic', 'missense', 'mutation', 'atm', '_abbrev_', 'and', 'no', 'other', 'alterations', 'in', 'atm', 'or', 'other', 'dna', 'repair', 'genes']"
2286,1.0,"In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity.","['in', 'other', 'cell', 'lines', 'activation', 'of', 'other', '_gene_', 'such', 'as', 'met', 'were', 'observed', 'upon', 'mek', 'inhibition', 'and', 'combination', 'of', 'rtki', 'and', 'meti', 'also', 'showed', 'synergistic', 'activity']"
2287,1.0,"Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations.","['unlike', 'other', 'studies', 'in', 'this', 'study', 'of', '_num_', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'there', 'was', 'no', 'significant', 'difference', 'in', 'the', 'overall', 'survival', 'of', 'patients', 'with', 'and', 'without', 'any', '_gene_', 'mutations']"
2288,1.0,"DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes.","['_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_abbrev_', 'were', 'associated', 'with', 'an', 'intermediate', 'risk', 'cytogenetic', 'profile', 'normal', 'cytogenetic', 'profile', 'and', '_gene_', 'and', '_gene_', 'fab', '_disease_']"
2289,1.0,"In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration between 3 and 14 months, while 13 patients with the more common HER2 p. A775_G776insYVMA showed no partial responses.","['in', 'this', 'phase', 'ii', 'study', '_abbrev_', 'of', '_chemical_', 'in', '_gene_', 'amplified', 'or', 'mutant', '_disease_', 'tumors', '_num_', 'of', '_num_', 'patients', 'with', '_gene_', 'p', '_abbrev_', 'or', 'p', '_abbrev_', 'showed', 'partial', 'responses', 'of', 'duration', 'between', '_num_', 'and', '_num_', 'months', 'while', '_num_', 'patients', 'with', 'the', 'more', 'common', '_gene_', 'p', '_abbrev_', 'showed', 'no', 'partial', 'responses']"
2290,1.0,These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer.,"['these', 'strong', 'results', 'make', 'a', 'case', 'for', 'dual', 'antibody', 'blockade', 'in', '_num_', 'line', 'treatments', 'of', '_gene_', 'metastatic', 'breast', 'cancer']"
2291,1.0,"Median age of onset was also not different between genotypes (GG: 49 years, GC: 50, CC: 50).","['median', 'age', 'of', 'onset', 'was', 'also', 'not', 'different', 'between', 'genotypes', '_disease_', '_num_', 'years', 'gc', '_num_', 'cc', '_num_']"
2292,1.0,Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor prognostic markers.,"['both', 'tumors', 'harbored', '_gene_', 'mutations', 'and', 'lack', 'of', '_gene_', 'promoter', 'hypermethylation', 'as', 'poor', 'prognostic', 'markers']"
2293,1.0,"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.","['in', 'an', 'evaluation', 'of', 'a', 'patient', 'with', '_chemical_', 'sensitive', 'lung', 'adenocarcinoma', 'an', '_abbrev_', '_gene_', 'rearrangement', 'was', 'identified', 'using', '_disease_']"
2294,1.0,The patient experienced stable disease and PFS of 10 months.,"['the', 'patient', 'experienced', 'stable', 'disease', 'and', '_disease_', 'of', '_num_', 'months']"
2295,1.0,"Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding.","['although', 'this', 'mutation', 'does', 'not', 'lie', 'at', 'the', 'gatekeeper', 'residue', 'it', 'confers', 'resistance', 'to', '_gene_', 'kinase', 'inhibition', 'through', 'steric', 'interference', 'with', 'drug', 'binding']"
2296,1.0,IDH1/2 mutations were significantly more common in cytogenetically normal AML (P=0.004).,"['_gene_', 'mutations', 'were', 'significantly', 'more', 'common', 'in', 'cytogenetically', 'normal', '_disease_', '_p_val_']"
2297,1.0,"The patient (F, 73, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.9 months, overall survival (OS) of 9.7 months and was not alive at study end.","['the', 'patient', 'f', '_num_', 'nonsmoker', 'progressive', 'disease', 'as', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
2298,1.0,This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.,"['this', 'phase', 'iii', 'trial', 'took', 'patients', 'with', 'locally', 'advanced', 'or', 'metastatic', '_gene_', '_gene_', 'positive', 'breast', 'cancer', 'that', 'had', 'progressed', 'on', 'prior', '_chemical_', 'treatment']"
2299,1.0,"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line expressing the L387F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', '_abbrev_', '_gene_', 'cell', 'line', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment']"
2300,0.0,we used a transfection based immunoblot assay to assess the impact of TSC1 (and TSC2) variants.,"['we', 'used', 'a', 'transfection', 'based', 'immunoblot', 'assay', 'to', 'assess', 'the', 'impact', 'of', '_gene_', 'and', '_gene_', 'variants']"
2301,1.0,"In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months.","['in', 'a', 'melanoma', 'patient', 'with', '_mutation_', 'mutation', 'treatment', 'with', '_chemical_', 'resulted', 'in', 'overall', 'survival', 'of', '_num_', 'months']"
2302,1.0,Fewer grade 3 or worse AE occurred with trastuzumab emtansine than with capecitabine plus lapatinib control treatment.,"['fewer', 'grade', '_num_', 'or', 'worse', '_gene_', 'occurred', 'with', '_chemical_', '_chemical_', 'than', 'with', '_chemical_', 'plus', '_chemical_', 'control', 'treatment']"
2303,1.0,The study did not compare to patients without rearrangement that were treated with Crizotinib.,"['the', 'study', 'did', 'not', 'compare', 'to', 'patients', 'without', 'rearrangement', 'that', 'were', 'treated', 'with', '_chemical_']"
2304,1.0,This is a frameshift mutation that results in a stop at codon 66.,"['this', 'is', 'a', 'frameshift', 'mutation', 'that', 'results', 'in', 'a', 'stop', 'at', 'codon', '_num_']"
2305,1.0,"In Ba/F3 cells, EML4-ALK variant 3 with C1156Y was introduced and tested for crizotinib sensitivity.","['in', 'ba', '_abbrev_', 'cells', '_chemical_', 'variant', '_num_', 'with', '_mutation_', 'was', 'introduced', 'and', 'tested', 'for', '_chemical_', 'sensitivity']"
2306,0.0,"A first-in-human phase 1/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients.","['a', '_disease_', 'phase', '_ratio_', 'trial', 'assessing', 'the', 'pharmacology', 'safety', 'and', 'activity', 'of', 'enasidenib', 'in', '_abbrev_', 'myeloid', 'hematoblastosis', 'patients']"
2307,1.0,"In the AML subgroup (n=176) of included patients (n=239) the overall response rate was 40.3%, with median response duration of 5.8 months.","['in', 'the', '_disease_', 'subgroup', '_ineq_', 'of', 'included', 'patients', '_ineq_', 'the', 'overall', 'response', 'rate', 'was', '_num_', 'with', 'median', 'response', 'duration', 'of', '_num_', 'months']"
2308,1.0,"However, in regimen A, the increase in survival for patients with low RRM1 expression as opposed to those with a high RRM1 expression was not as significant (P=0.366).","['however', 'in', 'regimen', 'a', 'the', 'increase', 'in', 'survival', 'for', 'patients', 'with', 'low', '_gene_', 'expression', 'as', 'opposed', 'to', 'those', 'with', 'a', 'high', '_gene_', 'expression', 'was', 'not', 'as', 'significant', '_p_val_']"
2309,1.0,"KRAS mutations in lung cancer patients are not associated with smoking history, age or gender.","['_gene_', 'mutations', 'in', 'lung', 'cancer', 'patients', 'are', 'not', 'associated', 'with', 'smoking', 'history', 'age', 'or', 'gender']"
2310,1.0,Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib.,"['mutational', 'profiling', 'was', 'performed', 'on', '_gene_', 'exons', '_range_', 'from', 'a', 'group', 'of', '_num_', 'retrospectively', 'chosen', 'patients', 'who', 'had', 'shown', 'partial', 'response', 'or', 'clinical', 'improvement', 'in', 'response', 'to', '_chemical_']"
2311,1.0,The median PFS for the 23 patients with uveal melanoma was 4.8 months.,"['the', 'median', '_disease_', 'for', 'the', '_num_', 'patients', 'with', 'uveal', 'melanoma', 'was', '_num_', 'months']"
2312,1.0,This deletion mutation was found in two VHL type 1 families of 15 individuals altogether (Family IDs 2693 and 2956 in publication).,"['this', 'deletion', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'of', '_num_', 'individuals', 'altogether', 'family', 'ids', '_num_', 'and', '_num_', 'in', 'publication']"
2313,1.0,"In longer term (15 day) palbociclib incubations of ER negative MDA-MB-231 cells and ER positive MCF-7 cells, significant resistance to palbociclib was seen in Rb knockdown conditions while wild type Rb cells maintained sensitivity.","['in', 'longer', 'term', '_num_', 'day', '_chemical_', 'incubations', 'of', 'er', 'negative', '_disease_', 'cells', 'and', 'er', 'positive', '_disease_', 'cells', 'significant', 'resistance', 'to', '_chemical_', 'was', 'seen', 'in', 'rb', 'knockdown', 'conditions', 'while', 'wild', 'type', 'rb', 'cells', 'maintained', 'sensitivity']"
2314,1.0,"Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other tumor types.","['cancers', 'predominantly', 'included', '_disease_', 'carcinoma', '_disease_', 'lymphoma', 'and', '_disease_', 'sarcoma', 'as', 'well', 'as', 'other', 'tumor', 'types']"
2315,1.0,"An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF.","['an', '_gene_', '_mutation_', 'was', 'detected', 'in', 'a', 'patient', 'with', 'metastatic', 'recurrent', 'refractory', '_disease_', 'allelic', 'fraction', '_num_', 'without', 'any', 'mutations', 'or', 'amplifications', 'in', 'other', '_gene_', 'signaling', 'members', 'such', 'as', '_gene_', 'and', '_gene_']"
2316,1.0,VHL mutations were evaluated in 78 tumors samples of patients with metastatic RCC treated with pazopanib as part of a clinical trial.,"['_gene_', 'mutations', 'were', 'evaluated', 'in', '_num_', 'tumors', 'samples', 'of', 'patients', 'with', 'metastatic', '_gene_', 'treated', 'with', '_chemical_', 'as', 'part', 'of', 'a', 'clinical', 'trial']"
2317,1.0,"In these assays, dasatinib was more efficacious than nilotinib or imatinib, showing results most similar to the known sensitive KIT mutation V559D.","['in', 'these', 'assays', '_chemical_', 'was', 'more', 'efficacious', 'than', '_chemical_', 'or', '_chemical_', 'showing', 'results', 'most', 'similar', 'to', 'the', 'known', 'sensitive', 'kit', 'mutation', '_mutation_']"
2318,1.0,"CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone.","['_chemical_', 'and', '_abbrev_', '_disease_', 'cell', 'lines', 'expressing', '_gene_', 'mutant', 'proteins', '_abbrev_', '_mutation_', 'or', '_mutation_', 'observed', 'in', 'relapsed', '_disease_', 'patients', 'showed', 'no', 'difference', 'in', 'sensitivity', 'to', '_chemical_', 'or', '_chemical_', 'treatment', 'when', 'compared', 'to', 'cells', 'expressing', 'wildtype', 'protein', 'or', 'vector', 'alone']"
2319,1.0,It was also highly resistant in isolation.,"['it', 'was', 'also', 'highly', 'resistant', 'in', 'isolation']"
2320,1.0,This nonsense mutation was found in a VHL type 1 family of 7 individuals (family ID 2753).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_']"
2321,1.0,Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6.,"['updates', 'were', 'sought', 'from', '_num_', 'further', 'patients', 'previously', 'described', 'in', 'the', 'literature', 'prompt', 'responses', 'were', 'described', 'in', '_num_', 'and', 'persist', 'in', '_num_']"
2322,1.0,The H3122 CHR-A1 cell line required approximately 10 fold increase in crizotinib concentration to induce similar levels of cell death to H3122.,"['the', '_abbrev_', '_abbrev_', 'cell', 'line', 'required', 'approximately', '_num_', 'fold', 'increase', 'in', '_chemical_', 'concentration', 'to', 'induce', 'similar', 'levels', 'of', 'cell', 'death', 'to', '_abbrev_']"
2323,1.0,75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression.,"['_num_', '_disease_', 'twice', 'daily', '_chemical_', 'caused', 'tumor', 'growth', 'inhibition', 'while', '_num_', '_disease_', 'twice', 'daily', 'induced', 'moderate', 'tumor', 'regression']"
2324,1.0,"(18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer).","['_num_', 'melanoma', '_num_', '_disease_', '_num_', 'colorectal', 'cancer', '_num_', 'renal', 'cell', 'cancer', '_num_', 'prostate', 'cancer']"
2325,1.0,we state that somatic mutations are specific to tumor location -- gain-of-function mutations in ACVR1 (such as G328V) occur in tumors of the pons in conjunction with H3.1 K27M (as compared to thalamic tumors with FGFR1 mutations).,"['we', 'state', 'that', 'somatic', 'mutations', 'are', 'specific', 'to', 'tumor', 'location', '_disease_', 'mutations', 'in', '_gene_', 'such', 'as', '_mutation_', 'occur', 'in', 'tumors', 'of', 'the', 'pons', 'in', 'conjunction', 'with', '_gene_', '_mutation_', 'as', 'compared', 'to', '_disease_', 'tumors', 'with', '_gene_', 'mutations']"
2326,1.0,"Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was associated with increased survival (17.7 months, P = 0.001).","['absent', 'expression', 'of', 'atm', 'as', 'assessed', 'by', '_gene_', 'in', '_num_', 'pancreatic', 'ductal', 'adenocarcinomas', 'was', 'found', 'to', 'be', 'associated', 'with', 'dismal', 'prognosis', 'median', 'survival', '_num_', 'months', 'whereas', 'expression', 'of', 'atm', 'was', 'associated', 'with', 'increased', 'survival', '_num_', 'months', 'p', '_num_']"
2327,1.0,Eight members of larger pedigree spanning four generations with inherited hematological cancers were sequenced with whole exome sequencing or sanger sequencing of DDX41 exons 5 and 6.,"['_num_', 'members', 'of', 'larger', 'pedigree', 'spanning', '_num_', 'generations', 'with', 'inherited', 'hematological', 'cancers', 'were', 'sequenced', 'with', 'whole', 'exome', 'sequencing', 'or', 'sanger', 'sequencing', 'of', '_gene_', 'exons', '_num_', 'and', '_num_']"
2328,1.0,"Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches.","['furthermore', 'patients', 'harboring', '_gene_', '_mutation_', 'mutations', 'are', 'at', 'particular', 'risk', 'for', 'recurrence', 'and', 'therefore', 'may', 'especially', 'benefit', 'from', 'adjuvant', 'therapeutic', 'approaches']"
2329,1.0,"HPO terms: hemangioblastoma, renal cell carcinoma, epididymal cysts, multiple pancreatic cysts.","['_disease_', 'terms', '_disease_', 'renal', 'cell', 'carcinoma', '_disease_', 'cysts', 'multiple', 'pancreatic', 'cysts']"
2330,1.0,Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model.,"['upregulation', 'of', '_gene_', 'due', 'to', 'epigenetic', 'reprogramming', 'may', 'confer', 'acquired', 'resistance', 'to', '_gene_', 'inhibitor', '_chemical_', 'in', 'breast', 'cancer', 'preclinical', 'model']"
2331,1.0,"In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo.","['in', 'the', 'bolero', 'trials', 'patients', 'with', '_abbrev_', 'advanced', 'breast', 'cancer', 'were', 'treated', 'with', '_chemical_', 'chemotherapy', 'and', 'randomized', 'to', 'receive', 'either', '_chemical_', 'or', 'placebo']"
2332,1.0,"This case did not have KRAS or BRAF mutations, indicating that ROS1 fusion may act in a small subset of colorectal cancer as a driver targetable by crizotinib or other inhibitors.","['this', 'case', 'did', 'not', 'have', '_gene_', 'or', '_gene_', 'mutations', 'indicating', 'that', '_gene_', 'fusion', 'may', 'act', 'in', 'a', 'small', 'subset', 'of', 'colorectal', 'cancer', 'as', 'a', 'driver', 'targetable', 'by', '_chemical_', 'or', 'other', 'inhibitors']"
2333,1.0,"121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21.","['_num_', 'patients', 'with', 'any', '_gene_', 'mutation', 'were', 'enrolled', '_num_', 'had', 'activating', 'mutations', 'in', 'exon', '_num_', 'or', '_num_']"
2334,1.0,This missense mutation was found in a VHL type 2A patient (patient no V233).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_abbrev_']"
2335,1.0,"When co-expressed with V560D (imatinib sensitive) in vitro T670I showed ""extreme"" imatinib resistance.","['when', 'co', 'expressed', 'with', '_mutation_', '_chemical_', 'sensitive', 'in', 'vitro', '_mutation_', 'showed', 'extreme', '_chemical_', 'resistance']"
2336,1.0,"R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report.","['_abbrev_', 'mutations', 'accounted', 'for', '_ratio_', 'reported', 'mutations', '_abbrev_', 'for', '_ratio_', 'mutations', 'and', 'the', 'remaining', 'had', 'not', 'been', 'previously', 'reported', 'at', 'the', 'time', 'of', 'this', 'report']"
2337,1.0,"In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).","['in', '_disease_', 'patients', 'with', '_disease_', 'age', '_range_', 'those', 'who', 'had', 'mutations', 'in', '_gene_', 'had', 'significantly', 'shorter', 'relapse', 'free', 'survival', 'following', 'conventional', 'post', 'remission', 'treatment', 'repetitive', 'cycles', 'of', '_disease_', '_chemical_', 'than', 'those', 'treated', 'with', 'an', 'allogeneic', 'hematopoietic', 'stem', 'cell', 'transplantation', '_ineq_', 'at', '_num_', 'remission', '_num_', 'year', 'rfs', '_num_', 'vs', '_num_', 'p', '_num_']"
2338,1.0,There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).,"['there', 'is', 'no', 'statistical', 'difference', 'in', 'progression', 'free', 'survival', 'between', 'lung', 'cancer', 'patients', 'treated', 'with', '_chemical_', 'or', '_chemical_', 'with', '_gene_', '_mutation_', 'mutations', '_ineq_', 'univariate', '_p_val_', 'multivariate', '_p_val_', 'compared', 'to', 'patients', 'with', 'exon', '_num_', 'mutations', '_ineq_']"
2339,1.0,Both of these fusions lead to constitutive kinase activity and were found to be oncogenic.,"['both', 'of', 'these', 'fusions', 'lead', 'to', 'constitutive', 'kinase', 'activity', 'and', 'were', 'found', 'to', 'be', '_disease_']"
2340,1.0,The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines.,"['the', 'presence', 'of', '_gene_', '_mutation_', 'snp', '_mutation_', 'was', 'associated', 'with', 'decreased', 'protein', 'expression', 'and', 'higher', '_chemical_', 'sensitivity', 'in', '_num_', '_disease_', 'and', '_gene_', 'cell', 'lines']"
2341,1.0,"Post surgery with extensive margins, she was given a dose of anti-CTLA-4 antibody and adjuvant radiation therapy for 2.5 weeks.","['post', 'surgery', 'with', 'extensive', 'margins', 'she', 'was', 'given', 'a', 'dose', 'of', 'anti', 'ctla', '_num_', 'antibody', 'and', 'adjuvant', 'radiation', 'therapy', 'for', '_num_', 'weeks']"
2342,1.0,"Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors.","['_num_', 'year', '_disease_', 'survival', 'was', 'significantly', 'poorer', 'in', '_abbrev_', '_disease_', '_num_', 'p', '_num_', 'vs', 'either', '_mutation_', '_num_', 'or', 'nonmutated', 'tumors']"
2343,1.0,FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel).,"['_gene_', 'expression', 'was', 'found', 'in', '_num_', 'tumor', 'samples', 'and', 'associated', 'with', 'improved', 'os', 'in', 'patients', 'treated', 'with', '_chemical_', 'based', 'adjuvant', 'chemotherapy', '_num_', 'cycles', 'of', ""'fec100"", 'aka', '_chemical_', '_chemical_', '_disease_', 'but', 'not', 'in', 'patients', 'treated', 'with', 'sequential', '_chemical_', '', '_chemical_', '_num_', 'cycles', 'of', '_abbrev_', 'followed', 'by', '_num_', 'cycles', 'of', '_chemical_']"
2344,0.0,This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs.,"['this', 'study', 'reports', 'that', 'the', '_gene_', '_gene_', 'pathway', 'contributes', 'to', 'acquired', 'resistance', 'to', '_num_', 'generation', '_gene_', '_disease_']"
2345,1.0,"19 were reported sensitive, and 9 resistant.","['_num_', 'were', 'reported', 'sensitive', 'and', '_num_', 'resistant']"
2346,1.0,"Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib.","['mice', 'were', 'then', 'treated', 'with', 'control', '_chemical_', '_chemical_', 'or', '_chemical_', '_chemical_']"
2347,1.0,3 of these 4 patients also had FGFR1 amplifications (≥6 copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH negative).,"['_num_', 'of', 'these', '_num_', 'patients', 'also', 'had', '_gene_', 'amplifications', '_ineq_', 'copies', 'by', 'qpcr', 'and', 'the', '_num_', 'presented', 'with', '_abbrev_', 'gain', '_num_', 'copies', 'of', '_gene_', 'by', 'qpcr', 'and', 'sish', 'negative']"
2348,1.0,A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer.,"['a', '_age_', 'non', 'ashkenazi', 'spanish', 'female', 'diagnosed', 'with', 'breast', 'cancer', 'at', '_num_', 'years', 'old', 'and', 'ovarian', 'cancer']"
2349,1.0,H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations.,"['_abbrev_', 'growth', 'inhibition', 'by', '_chemical_', 'was', 'more', 'similar', 'to', '_disease_', 'cell', 'lines', 'harboring', '_gene_', 'and', '_gene_', 'mutations']"
2350,1.0,"In contrast, the IC50 for brigatinib against the alectinib resistance variant EML4-ALK V1180L was 0.49, indicating increased sensitivity to brigatinib over non mutant EML4-ALK.","['in', 'contrast', 'the', '_abbrev_', 'for', 'brigatinib', 'against', 'the', '_chemical_', 'resistance', 'variant', '_chemical_', '_mutation_', 'was', '_num_', 'indicating', 'increased', 'sensitivity', 'to', 'brigatinib', 'over', 'non', 'mutant', '_chemical_']"
2351,1.0,This assertion is based on observed survival for 19 EIF1AX mutant UM cases compared to 69 EIF1AX wildtype cases.,"['this', 'assertion', 'is', 'based', 'on', 'observed', 'survival', 'for', '_num_', '_gene_', 'mutant', '_disease_', 'cases', 'compared', 'to', '_num_', '_gene_', 'wildtype', 'cases']"
2352,1.0,Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.,"['ba', '_abbrev_', 'cells', 'with', 'both', '_gene_', 'and', '_disease_', 'mutations', 'on', 'the', 'same', 'allele', 'have', 'more', 'resistance', 'to', 'the', 'protein', 'tyrosine', 'kinase', '_gene_', 'inhibitor', '_chemical_', 'than', 'cells', 'with', '_gene_', 'alone', 'or', '_gene_', '_gene_', 'and', '_disease_', 'mutations', 'on', 'opposing', 'alleles']"
2353,1.0,It was discovered that the E116K genotype was associated with a reduced median survival time of 4 and 7 months for E/K or K/K genotypes (P=2.61E-7) and an increased cancer death risk for heterozygous (HR=1.49) and homozygous (HR=1.94) genotypes for a pooled cohort.,"['it', 'was', 'discovered', 'that', 'the', '_mutation_', 'genotype', 'was', 'associated', 'with', 'a', 'reduced', 'median', 'survival', 'time', 'of', '_num_', 'and', '_num_', 'months', 'for', 'e', 'k', 'or', 'k', 'k', 'genotypes', '_p_val_', 'and', 'an', 'increased', 'cancer', 'death', 'risk', 'for', 'heterozygous', '_ineq_', 'and', 'homozygous', '_ineq_', 'genotypes', 'for', 'a', 'pooled', 'cohort']"
2354,1.0,"Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)","['study', 'found', 'that', 'mutations', 'in', '_gene_', 'are', 'enriched', 'in', 'patients', 'with', 'chronic', '_disease_', 'leukemia', '_disease_', 'or', 'atypical', 'chronic', 'myeloid', 'leukemia', '_ratio_', '_num_', 'when', 'compared', 'to', 'other', 'blood', 'disorders', '_ineq_', 't', 'cell', '_ineq_', '_disease_', '_ineq_']"
2355,1.0,"463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or BSC alone (n = 232).","['_num_', 'patients', 'with', '_num_', 'or', 'more', '_gene_', 'tumor', 'cell', 'membrane', 'staining', 'with', 'metastatic', '_gene_', 'progressive', 'after', 'standard', 'chemotherapy', 'were', 'randomized', 'to', 'panitumumab', 'plus', 'best', 'supportive', 'care', '_gene_', 'n', '_num_', 'or', '_gene_', 'alone', 'n', '_num_']"
2356,1.0,"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence.","['_disease_', '_disease_', 'is', 'a', 'rare', 'nonmetastatic', 'neoplasm', 'marked', 'by', 'local', '_disease_', 'and', 'relentless', 'recurrence']"
2357,1.0,Results were confirmed in an independent cohort of 33 patients.,"['results', 'were', 'confirmed', 'in', 'an', 'independent', 'cohort', 'of', '_num_', 'patients']"
2358,1.0,Only one permanent response occurred in a FLT3 mutant patient receiving the 100 mg dose.,"['only', '_num_', 'permanent', 'response', 'occurred', 'in', 'a', '_gene_', 'mutant', 'patient', 'receiving', 'the', '_num_', '_unit_', 'dose']"
2359,1.0,"This study used 58 cell lines, of which 14 exhibited ponatinib sensitivity.","['this', 'study', 'used', '_num_', 'cell', 'lines', 'of', 'which', '_num_', 'exhibited', '_chemical_', 'sensitivity']"
2360,1.0,GADD45A (1506T>C) association with ovarian cancer was investigated with 258 ovarian cancer patients and 332 age matched healthy women as controls using sequence analysis.,"['_gene_', '1506t', 'c', 'association', 'with', 'ovarian', 'cancer', 'was', 'investigated', 'with', '_num_', 'ovarian', 'cancer', 'patients', 'and', '_num_', 'age', 'matched', 'healthy', 'women', 'as', 'controls', 'using', 'sequence', 'analysis']"
2361,1.0,"In univariate and multivariate analysis, the expression of HEF1 was identified as an independent prognostic factor (Spearman's rank correlation, Kaplan-Meier plots and Cox regression model).","['in', 'univariate', 'and', 'multivariate', 'analysis', 'the', 'expression', 'of', '_gene_', 'was', 'identified', 'as', 'an', 'independent', 'prognostic', 'factor', 'spearman', ""'s"", 'rank', 'correlation', '_disease_', 'plots', 'and', 'cox', 'regression', 'model']"
2362,1.0,This mutation was found in a VHL type 1 patient (patient no V63).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
2363,1.0,Everolimus failed to meet its enpoint.,"['_chemical_', 'failed', 'to', 'meet', 'its', 'enpoint']"
2364,1.0,PP4 ACMG evidence criteria are met as PTEN hamartoma tumor syndrome is a disease with a single genetic etiology.,"['_gene_', 'acmg', 'evidence', 'criteria', 'are', 'met', 'as', '_gene_', 'hamartoma', 'tumor', 'syndrome', 'is', 'a', 'disease', 'with', 'a', 'single', 'genetic', 'etiology']"
2365,1.0,"The study also further showed that cytoplasmic Livin levels increased in four colon cancer cell lines (RKO, SW620, HCT116, and KM12C) after cisplatin treatment in a dose-dependent manner.","['the', 'study', 'also', 'further', 'showed', 'that', 'cytoplasmic', '_gene_', 'levels', 'increased', 'in', '_num_', 'colon', 'cancer', 'cell', 'lines', '_disease_', '_abbrev_', '_abbrev_', 'and', '_abbrev_', 'after', '_disease_', 'treatment', 'in', 'a', '_disease_', 'manner']"
2366,1.0,"In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance.","['in', 'contrast', '_abbrev_', '_abbrev_', 'and', '_abbrev_', 'caused', 'strong', '_chemical_', 'resistance']"
2367,1.0,"No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML.","['no', 'differences', 'in', 'relapse', 'free', 'or', 'overall', 'survival', 'were', 'identified', 'between', 'young', '_range_', 'patients', 'with', 'or', 'without', '_gene_', 'mutations', '_num_', 'exon', '_num_', '_num_', 'exon', '_num_', 'in', 'cytogenetically', 'normal', '_disease_']"
2368,1.0,"In a study of 16 patients with metastatic breast cancer (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16), including ESR1 D538G (n=2), detected at any time or at initial blood draw, were associated with reduced progression free survival (HR=0.31, 95% CI: 0.05-0.95, P=0.047), as compared with patients with wildtype ESR1 (n=11).","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'metastatic', 'breast', 'cancer', '_abbrev_', 'treated', 'with', '_chemical_', 'in', 'combination', 'with', '_chemical_', 'patients', 'with', '_gene_', 'mutations', '_ratio_', 'including', '_gene_', '_mutation_', '_gene_', 'detected', 'at', 'any', 'time', 'or', 'at', 'initial', 'blood', 'draw', 'were', 'associated', 'with', 'reduced', 'progression', 'free', 'survival', '_ineq_', '_num_', 'ci', '_range_', '_p_val_', 'as', 'compared', 'with', 'patients', 'with', 'wildtype', '_gene_', '_ineq_']"
2369,1.0,"Western blots of Ba/F3 with NPM-ALK wild type showed ablation of pALK levels above 100 nM alectinib, while pALK levels were essentially unchanged up to 1000 nM in NPM-ALK G1202R Ba/F3 cells.","['western', 'blots', 'of', 'ba', '_abbrev_', 'with', '_chemical_', 'wild', 'type', 'showed', 'ablation', 'of', 'palk', 'levels', 'above', '_num_', '_unit_', '_chemical_', 'while', 'palk', 'levels', 'were', 'essentially', 'unchanged', 'up', 'to', '_num_', '_unit_', 'in', '_chemical_', '_mutation_', 'ba', '_abbrev_', 'cells']"
2370,1.0,"A null, nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1).","['a', 'null', 'nonsense', 'mutation', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', '_abbrev_']"
2371,1.0,One also had renal cell carcinoma.,"['_num_', 'also', 'had', 'renal', 'cell', 'carcinoma']"
2372,1.0,This frameshift mutation was found in 3 family members with VHL type 1 phenotype (family ID 3312).,"['this', 'frameshift', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
2373,1.0,"Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781insGSP, c. 2339_2340ins GGCTCCCCA) and no amplification.","['_num_', 'patients', 'were', 'identified', 'with', 'identical', '_gene_', 'p', '_abbrev_', 'mutations', 'p', '_abbrev_', 'c', '2339_2340ins', 'ggctcccca', 'and', 'no', 'amplification']"
2374,1.0,"Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0).","['_disease_', 'analysis', 'of', '_num_', 'patients', 'with', 'localized', 'tumors', 'showed', 'that', 'the', '_num_', 'patients', 'with', '_abbrev_', 'had', 'significantly', 'better', 'metastasis', 'free', 'survival', 'than', 'the', '_num_', 'patients', 'with', '_abbrev_', '_p_val_', 'by', 'multivariate', 'analysis', 'relative', 'risk', '_num_']"
2375,1.0,"ATM point mutations were found in 8/57 patients with CLL and were associated with a shorter treatment-free interval, suggesting a more aggressive course.","['atm', 'point', 'mutations', 'were', 'found', 'in', '_ratio_', 'patients', 'with', '_disease_', 'and', 'were', 'associated', 'with', 'a', 'shorter', 'treatment', 'free', 'interval', 'suggesting', 'a', 'more', 'aggressive', 'course']"
2376,1.0,"VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab.","['_gene_', 'inhibition', 'included', '_chemical_', '_chemical_', '_chemical_', '_chemical_', '_chemical_']"
2377,1.0,"Experimental - Associated drug effects EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.","['experimental', 'associated', 'drug', 'effects', '_gene_', '_mutation_', 'mutation', 'has', 'been', 'associated', 'with', 'resistance', 'to', '_num_', 'generation', '_gene_', 'tyrosine', 'kinase', 'inhibitors', 'including', '_chemical_', 'and', '_chemical_']"
2378,1.0,"RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age.","['_gene_', 'mutations', 'were', 'associated', 'with', 'other', 'poor', 'risk', 'parameters', 'early', 'subtype', 'and', 'older', 'age']"
2379,1.0,In vitro models of HRAS G13D confirmed resistance mechanism in the same study.,"['in', 'vitro', 'models', 'of', '_gene_', '_mutation_', 'confirmed', 'resistance', 'mechanism', 'in', 'the', 'same', 'study']"
2380,1.0,"The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.","['the', 'emilia', 'study', '_abbrev_', 'was', 'a', 'phase', 'ii', 'trial', 'to', 'assess', 'the', 'efficacy', 'of', '_chemical_', '_chemical_', '_disease_', '_ineq_', 'in', 'comparison', 'to', '_chemical_', 'plus', '_chemical_', '_ineq_', 'in', 'treatment', 'of', 'advanced', '_gene_', 'positive', 'breast', 'cancer']"
2381,1.0,AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment.,"['_disease_', '_abbrev_', 'cells', 'were', 'cocultured', 'with', '_gene_', 'inhibitor', '_abbrev_', '_num_', '_unit_', 'and', 'selected', 'proteins', 'expressed', 'in', 'the', 'bone', 'marrow', 'microenvironment']"
2382,1.0,It was found that positive KIF23 V1 staining was correlated with longer overall survival over a period of 5 years (p=.0052).,"['it', 'was', 'found', 'that', 'positive', '_gene_', '_gene_', 'staining', 'was', 'correlated', 'with', 'longer', 'overall', 'survival', 'over', 'a', 'period', 'of', '_num_', 'years', 'p=', '_num_']"
2383,1.0,The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild type population.,"['the', 'difference', 'was', 'explained', 'by', 'potential', '_gene_', 'or', '_gene_', 'mutations', 'outside', 'of', 'exon', '_num_', 'in', 'the', '_disease_', 'wild', 'type', 'population']"
2384,1.0,"Pretreatment MET expression was frequent at the ≥1 + cutoff (BRIM3, 31%; BRIM2, 49%), but relatively infrequent at the ≥2 + cutoff (BRIM3, 9%; BRIM2, 19%).","['pretreatment', 'met', 'expression', 'was', 'frequent', 'at', 'the', '_ineq_', 'cutoff', '_abbrev_', '_num_', '_abbrev_', '_num_', 'but', 'relatively', 'infrequent', 'at', 'the', '_ineq_', 'cutoff', '_abbrev_', '_num_', '_abbrev_', '_num_']"
2385,1.0,Melanoma cells with low SOX10 and consequently high EGFR expression are enriched in the presence of vemurafenib.,"['melanoma', 'cells', 'with', 'low', '_gene_', 'and', 'consequently', 'high', '_gene_', 'expression', 'are', 'enriched', 'in', 'the', 'presence', 'of', '_chemical_']"
2386,1.0,NPM1 mutations were associated with normal karyotype in older (>60) patients.,"['_gene_', 'mutations', 'were', 'associated', 'with', 'normal', 'karyotype', 'in', 'older', '_num_', 'patients']"
2387,1.0,The patient was treated with single-agent lapatinib.,"['the', 'patient', 'was', 'treated', 'with', 'single', 'agent', '_chemical_']"
2388,1.0,"Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells.","['similarly', '_chemical_', 'ectopically', 'expression', '_abbrev_', 'showed', 'reduced', 'sensistivity', 'to', '_chemical_', 'compared', 'to', '_gene_', '_gene_', 'or', '_mutation_', 'mutant', 'cells']"
2389,1.0,Tumor xenografts in nude mice were established with 5 of the 6 cell lines.,"['tumor', 'xenografts', 'in', 'nude', 'mice', 'were', 'established', 'with', '_num_', 'of', 'the', '_num_', 'cell', 'lines']"
2390,1.0,Loss of heterozygosity of the wildtype allele was demonstrated resulting in higher mutated allele representation (80% variant allele frequency).,"['loss', 'of', 'heterozygosity', 'of', 'the', 'wildtype', 'allele', 'was', 'demonstrated', 'resulting', 'in', 'higher', 'mutated', 'allele', 'representation', '_num_', 'variant', 'allele', 'frequency']"
2391,1.0,"In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated  resistance to gefitinib and erlotinib (greater than 100-fold decreased sensitivity) compared to Ba/F3 expressing wild type EGFR.","['in', 'an', 'in', 'vitro', 'study', 'ba', '_abbrev_', 'cells', 'stably', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'resistance', 'to', '_chemical_', 'and', '_chemical_', 'greater', 'than', '_n_fold_', 'decreased', 'sensitivity', 'compared', 'to', 'ba', '_abbrev_', 'expressing', 'wild', 'type', '_gene_']"
2392,1.0,"A missense mutation, affecting a residue within the pVHL protein core, was found in 2 VHL family members.","['a', 'missense', 'mutation', 'affecting', 'a', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', '_num_', '_gene_', 'family', 'members']"
2393,1.0,The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib.,"['the', 'creation', 'of', 'a', 'cell', 'line', 'model', '_abbrev_', 'with', 'met', 'exon', '_num_', 'deletion', 'using', 'the', 'crispr', '_abbrev_', 'system', 'led', 'to', 'enhanced', 'cellular', 'growth', 'and', 'sensitivity', 'to', 'the', 'met', 'inhibitor', '_chemical_']"
2394,1.0,"One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylate–resistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors.","['_num_', 'patient', 'harboring', 'a', 'somatic', '_mutation_', 'mutation', 'at', 'roughly', '_num_', 'variant', 'allele', 'frequency', '_ratio_', 'with', 'wild', 'type', 'displayed', '_chemical_', 'mesylate–resistance', 'and', 'disease', 'progression', 'which', 'is', 'consistent', 'with', 'resistant', 'mechanisms', 'described', 'in', 'gastro', 'intestinal', 'stromal', 'tumors']"
2395,1.0,"In three cell lines H2405 (NSCLC with L485-P490>Y), BxPC-3 (pancreatic with V487-P492>A), and OV-90 (ovarian with N486-P490del), BRAF deletion–mediated MAPK activation was found to be sensitive to LY3009120 as evidenced by dose-dependent inhibition of phospho-MEK and ERK and cell growth inhibition with IC50 values of 0.04, 0.087, and 0.007 μmol/L in these three cell lines.","['in', '_num_', 'cell', 'lines', '_abbrev_', '_disease_', 'with', '_abbrev_', 'y', '_chemical_', 'pancreatic', 'with', '_abbrev_', 'a', 'and', '_abbrev_', 'ovarian', 'with', '_abbrev_', '_gene_', 'deletion–mediated', '_gene_', 'activation', 'was', 'found', 'to', 'be', 'sensitive', 'to', '_chemical_', 'as', 'evidenced', 'by', '_disease_', 'inhibition', 'of', '_chemical_', 'mek', 'and', '_gene_', 'and', 'cell', 'growth', 'inhibition', 'with', '_abbrev_', 'values', 'of', '_num_', '_num_', 'and', '_num_', 'μmol', '_unit_', 'in', 'these', '_num_', 'cell', 'lines']"
2396,1.0,"In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.","['in', '_disease_', 'containing', 'a', '_mutation_', 'mutation', '_chemical_', 'may', 'be', 'inhibitive', 'of', '_gene_', 'especially', 'when', 'an', '_mutation_', 'mutation', 'is', 'also', 'present']"
2397,1.0,"Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses.","['of', 'the', '_num_', 'evaluable', 'patients', 'with', '_gene_', 'mutations', 'total', 'there', 'were', '_num_', 'prs', '_num_', 'confirmed', '_num_', 'sd', 'and', '_num_', 'pd', 'as', 'best', 'radiological', 'responses']"
2398,1.0,Progression-free (250 days) and overall (435 days) survival suggested sensitivity in this patient.,"['_disease_', '_num_', 'days', 'and', 'overall', '_num_', 'days', 'survival', 'suggested', 'sensitivity', 'in', 'this', 'patient']"
2399,1.0,Each patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).,"['each', 'patient', ""'s"", 'phenotype', 'is', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'a', 'single', 'genetic', 'etiology', 'acmg', 'code', '_gene_']"
2400,1.0,In a multivariate analysis it was found that a loss of ARID1A expression was significant for shorter disease free survival (P=0.03) and shorter overall survival for patients whose ovarian clear cell carcinoma was treated with platinum-based chemotherapy (P=0.015).,"['in', 'a', 'multivariate', 'analysis', 'it', 'was', 'found', 'that', 'a', 'loss', 'of', '_gene_', 'expression', 'was', 'significant', 'for', 'shorter', 'disease', 'free', 'survival', '_p_val_', 'and', 'shorter', 'overall', 'survival', 'for', 'patients', 'whose', 'ovarian', 'clear', 'cell', 'carcinoma', 'was', 'treated', 'with', 'platinum', 'based', 'chemotherapy', '_p_val_']"
2401,1.0,"The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression.","['the', 'effects', 'of', '_gene_', 'inhibitors', '_chemical_', '_chemical_', 'and', '_chemical_', 'in', 'bladder', 'carcinoma', 'cell', 'lines', 'were', 'related', 'to', '_gene_', 'and', 'or', '_gene_', 'expression']"
2402,1.0,Multivariate analysis did not identify PRDM1 mutations as an independent prognostic factor.,"['multivariate', 'analysis', 'did', 'not', 'identify', '_gene_', 'mutations', 'as', 'an', 'independent', 'prognostic', 'factor']"
2403,1.0,"This mutation resulted in a nonsense mutation, and the mutation segregated with familial platelet disorder and acute myeloid leukemia in the pedigree.","['this', 'mutation', 'resulted', 'in', 'a', 'nonsense', 'mutation', 'and', 'the', 'mutation', 'segregated', 'with', 'familial', 'platelet', 'disorder', 'and', 'acute', 'myeloid', 'leukemia', 'in', 'the', 'pedigree']"
2404,1.0,"In nude mice with MGH045 xenografts, tumor response to crizotinib did not differ appreciably from vehicle, while ceritinib controlled tumor growth.","['in', 'nude', 'mice', 'with', '_abbrev_', 'xenografts', 'tumor', 'response', 'to', '_chemical_', 'did', 'not', 'differ', 'appreciably', 'from', 'vehicle', 'while', '_chemical_', 'controlled', 'tumor', 'growth']"
2405,1.0,Intrahepatic cholangiocarcinomas of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate.This study demonstrated a significant association of both disease-specific OS and recurrence-free survival with the homozygous TT genotype of the GNAS1 gene (hazard ratio = 2.47; 95% CI = 1.03–7.28).,"['_disease_', '_disease_', 'of', 'patients', 'with', 'homozygous', 'tt', 'genotypes', 'revealed', 'a', 'higher', 'proliferation', 'rate', 'and', 'a', 'lower', 'apoptotic', 'rate', 'this', 'study', 'demonstrated', 'a', 'significant', 'association', 'of', 'both', '_disease_', 'os', 'and', '_disease_', 'survival', 'with', 'the', 'homozygous', 'tt', 'genotype', 'of', 'the', '_gene_', 'gene', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_num_', '03–7', '_num_']"
2406,1.0,Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment.,"['marked', 'inhibition', 'of', 'soft', 'agar', 'colony', 'formation', 'of', '_abbrev_', 'cells', 'was', 'also', 'observed', 'with', 'drug', 'treatment']"
2407,1.0,84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays.,"['_num_', 'breast', 'cancer', 'samples', 'acquired', 'from', 'commercial', 'sources', 'were', 'assayed', 'on', 'affymetrix', 'human', 'exon', '_num_', 'arrays']"
2408,1.0,There was no difference between the two groups with regards to progression free survival.,"['there', 'was', 'no', 'difference', 'between', 'the', '_num_', 'groups', 'with', 'regards', 'to', 'progression', 'free', 'survival']"
2409,1.0,"Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P<0.001, P<0.001 and P=0.005).","['univariate', 'analysis', 'identified', 'gender', 'smoking', 'history', 'histology', 'and', '_gene_', '_mutation_', 'polymorphism', 'as', 'predictive', 'marker', 'of', '_disease_', '_p_val_', 'p', '_num_', 'p', '_num_', 'and', '_p_val_']"
2410,1.0,"Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds ratio 5.58 compared to WT, p=.038).","['multivariate', 'analysis', 'identified', '_gene_', 'as', 'a', 'factor', 'in', 'predicting', 'response', 'to', '_num_', 'line', 'chemotherapy', 'odds', 'ratio', '_num_', 'compared', 'to', '_gene_', 'p=', '_num_']"
2411,1.0,"PAX8–PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hürthle cell tumors.","['_abbrev_', 'gene', 'fusions', 'were', 'found', 'in', '_ratio_', 'follicular', 'thyroid', 'carcinoma', 'tumor', 'samples', 'but', 'were', 'rarely', 'found', 'in', 'thyroid', 'hürthle', 'cell', 'tumors']"
2412,1.0,"In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily.","['in', 'trial', '_abbrev_', '_chemical_', 'was', 'tested', 'in', 'various', 'solid', 'tumor', 'types', 'harboring', 'mutant', '_gene_', 'after', 'establishing', 'dosage', 'of', '_num_', '_unit_', 'twice', 'daily']"
2413,1.0,"EML4-ALK variant 2 was found, and the patient was started on crizotinib.","['_chemical_', 'variant', '_num_', 'was', 'found', 'and', 'the', 'patient', 'was', 'started', 'on', '_chemical_']"
2414,1.0,Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).,"['only', 'supporting', 'evidence', 'for', 'pathogenicity', 'because', 'patient', ""'s"", 'phenotype', 'is', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'a', 'single', 'genetic', 'etiology', 'acmg', 'code', '_gene_']"
2415,1.0,This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 103).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
2416,1.0,"FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification.","['fish', 'identified', 'a', 'deletion', 'of', ""5'ret"", 'fish', 'indicating', 'ret', 'gene', 'rearrangement', 'and', 'genomic', 'testing', 'confirmed', 'a', 'fusion', 'of', '_gene_', 'and', 'ret', 'as', 'well', 'as', 'an', '_gene_', 'gene', 'amplification']"
2417,1.0,"In-vitro studies linked PRL-3 (PP4A3) expression to hyperactivation and dependence on EGFR signaling (through downregulation of PTP1B, an inhibitory phosphatase of EGFR).","['in', 'vitro', 'studies', 'linked', '_gene_', '_abbrev_', 'expression', 'to', 'hyperactivation', 'and', 'dependence', 'on', '_gene_', 'signaling', 'through', 'downregulation', 'of', '_gene_', 'an', 'inhibitory', 'phosphatase', 'of', '_gene_']"
2418,1.0,44 cell lines and 145 patient samples were utilized in various aspects of this study.,"['_num_', 'cell', 'lines', 'and', '_num_', 'patient', 'samples', 'were', 'utilized', 'in', 'various', 'aspects', 'of', 'this', 'study']"
2419,1.0,Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks.,"['treatment', 'of', 'this', 'patient', 'with', '_abbrev_', 'yielded', 'disease', 'stabilization', 'lasting', '_num_', 'weeks']"
2420,1.0,"A lung adenocarcinoma patient responded to crizotinib treatment for 12 months, after which the cancer relapsed and sequencing of the ALK tyrosine kinase domain revealed a 1151insT mutation.","['a', 'lung', 'adenocarcinoma', 'patient', 'responded', 'to', '_chemical_', 'treatment', 'for', '_num_', 'months', 'after', 'which', 'the', 'cancer', 'relapsed', 'and', 'sequencing', 'of', 'the', '_gene_', 'tyrosine', 'kinase', 'domain', 'revealed', 'a', '1151inst', 'mutation']"
2421,1.0,Preclinical study in 293H cell line.,"['preclinical', 'study', 'in', '293h', 'cell', 'line']"
2422,1.0,The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).,"['the', 'hazard', 'ratio', 'for', '_disease_', 'survival', 'was', '_num_', 'times', 'greater', 'for', 'patients', 'with', '_gene_', 'deletion', 'as', 'compared', 'to', 'those', 'with', 'normal', '_gene_', 'diploidy', 'p', '_num_']"
2423,1.0,"NGS revealed a frameshift mutation in APC, a missense mutation in KRAS.","['ngs', 'revealed', 'a', 'frameshift', 'mutation', 'in', 'apc', 'a', 'missense', 'mutation', 'in', '_gene_']"
2424,1.0,This mutation combination was observed in a single patient with lung cancer and specifically in a metastatic brain lesion following gefitinib treatment.,"['this', 'mutation', 'combination', 'was', 'observed', 'in', 'a', 'single', 'patient', 'with', 'lung', 'cancer', 'and', 'specifically', 'in', 'a', 'metastatic', 'brain', 'lesion', 'following', '_chemical_', 'treatment']"
2425,1.0,"Thirteen tumors harbored identical 12 base pair exon 20 insertions [A775_G776insYVMA, alternative nomenclature p.Y772_A775dup(c.2313_2324dup)].","['thirteen', 'tumors', 'harbored', 'identical', '_num_', 'base', 'pair', 'exon', '_num_', 'insertions', '_abbrev_', 'alternative', 'nomenclature', 'p', '_abbrev_', 'c', '2313_2324dup']"
2426,1.0,"The patient (F, 46, nonsmoker) had progressive disease as response, progression free survival (PFS) of 3.3 months, overall survival (OS) of 13.9 months and was not alive at study end.","['the', 'patient', 'f', '_num_', 'nonsmoker', 'had', 'progressive', 'disease', 'as', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
2427,1.0,"TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers.","['_gene_', 'expression', 'was', 'associated', 'with', 'response', 'to', 'endocrine', 'therapy', 'tamoxifen', '_chemical_', 'or', 'oophorectomy', 'and', 'outperformed', 'er', 'pr', 'and', '_gene_', 'as', '_chemical_']"
2428,1.0,1 year adjuvant trastuzumab is currently the standard of care.,"['_num_', 'year', 'adjuvant', '_chemical_', 'is', 'currently', 'the', 'standard', 'of', 'care']"
2429,1.0,"This variant, identified in two cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in both patients with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', '_num_', 'cases', 'of', '_disease_', 'colorectal', 'cancer', 'was', 'confirmed', 'to', 'be', 'somatic', 'in', 'both', 'patients', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
2430,1.0,Estimated median PFS was 7.7 months.,"['estimated', 'median', '_disease_', 'was', '_num_', 'months']"
2431,1.0,The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R.,"['the', '_num_', 'inhibitory', 'concentration', '_abbrev_', 'of', '_chemical_', 'was', 'significantly', 'lower', 'in', 'cells', 'harboring', '_gene_', 'exon', '_num_', 'deletion', 'than', 'in', 'cells', 'harboring', '_gene_', '_mutation_']"
2432,1.0,No statistically significant improvement in PFS was seen with erlotinib in the KRAS mutant group over placebo.,"['no', 'statistically', 'significant', 'improvement', 'in', '_disease_', 'was', 'seen', 'with', '_chemical_', 'in', 'the', '_gene_', 'mutant', 'group', 'over', 'placebo']"
2433,1.0,ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).,"['acmg', 'codes', 'as', 'follows', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', '_gene_']"
2434,1.0,"Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.","['of', 'the', '_num_', 'patients', 'analyzed', '_num_', '_num_', 'had', 'the', '_mutation_', 'mutation', 'and', '_num_', '_num_', 'were', '_abbrev_']"
2435,1.0,"This mutation cause a frameshift, a premature stop codon, and was found in a 24 year old Korean female with hemangioblastomas of the central nervous system and retinal hemangioblastomas (patient no 4).","['this', 'mutation', 'cause', 'a', 'frameshift', 'a', 'premature', 'stop', 'codon', 'and', 'was', 'found', 'in', 'a', '_num_', 'year', 'old', 'korean', 'female', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', 'retinal', '_disease_', 'patient', 'no', '_num_']"
2436,1.0,PIK3CA amplification was significanly associated with BYL719 response.,"['_gene_', 'amplification', 'was', 'significanly', 'associated', 'with', '_chemical_', 'response']"
2437,1.0,"In cell lines overexpressing Sirt1, higher concentrations of nicotinamide were required to abrogate increased cell viability mediated by Sirt1 overexpression compared to controls.","['in', 'cell', 'lines', 'overexpressing', '_gene_', 'higher', 'concentrations', 'of', '_chemical_', 'were', 'required', 'to', 'abrogate', 'increased', 'cell', 'viability', 'mediated', 'by', '_gene_', 'overexpression', 'compared', 'to', 'controls']"
2438,1.0,"Mutation analysis was performed in 14 family members (7 affected, 7 unaffected).","['mutation', 'analysis', 'was', 'performed', 'in', '_num_', 'family', 'members', '_num_', 'affected', '_num_', 'unaffected']"
2439,1.0,Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate.,"['size', 'of', 'the', '_gene_', 'mutant', 'duplication', 'had', 'no', 'impact', 'on', 'overall', 'survival', 'or', 'relapse', 'rate']"
2440,1.0,Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.,"['patients', 'with', 'colorectal', 'cancer', 'harboring', 'nras', 'mutation', 'have', 'poorer', 'survival', 'outcome', 'and', 'worse', 'prognosis', 'than', 'patients', 'with', 'wildtype', 'nras']"
2441,1.0,A 40% reduction in size of contrast enhancing lesion was seen.,"['a', '_num_', 'reduction', 'in', 'size', 'of', 'contrast', 'enhancing', 'lesion', 'was', 'seen']"
2442,1.0,"Stereotactic radiation therapy, gamma knife radiosurgery, and ipilimumab did not lead to a relevant response (new pleural nodules, new intracranial metastases).","['stereotactic', 'radiation', 'therapy', 'gamma', 'knife', 'radiosurgery', 'and', 'ipilimumab', 'did', 'not', 'lead', 'to', 'a', 'relevant', 'response', 'new', 'pleural', 'nodules', 'new', 'intracranial', 'metastases']"
2443,1.0,"In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.","['in', 'the', 'subset', 'of', 'patients', 'showing', 'a', 'stronger', 'immunohistochemistry', 'result', 'for', '_gene_', '_abbrev_', 'progression', 'free', 'survival', 'was', 'significantly', 'different', 'at', '_num_', 'months', 'for', '_chemical_', 'pacitaxel', 'vs', '_num_', 'months', 'for', 'pacitaxel', 'alone']"
2444,1.0,"While trastuzumab has not shown clear benefit yet in wild type HER2 overexpressed NSCLC, we conclude that further prospective studies should be done with trastuzumab plus chemotherapy in advanced HER2 mutant NSCLC, and that trastuzumab plus chemotherapy should be considered in current treatment courses of this cancer type.","['while', '_chemical_', 'has', 'not', 'shown', 'clear', 'benefit', 'yet', 'in', 'wild', 'type', '_gene_', 'overexpressed', '_disease_', 'we', 'conclude', 'that', 'further', 'prospective', 'studies', 'should', 'be', 'done', 'with', '_chemical_', 'plus', 'chemotherapy', 'in', 'advanced', '_gene_', 'mutant', '_disease_', 'and', 'that', '_chemical_', 'plus', 'chemotherapy', 'should', 'be', 'considered', 'in', 'current', 'treatment', 'courses', 'of', 'this', 'cancer', 'type']"
2445,1.0,Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.,"['patients', 'with', 'advanced', '_disease_', 'and', 'acquired', 'resistance', 'to', '_gene_', '_disease_', '_chemical_', 'or', '_chemical_', 'were', 'analyzed', 'for', '_mutation_', 'mutations']"
2446,1.0,"Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation.","['saridegib', 'treatment', 'induced', 'tumor', 'reduction', 'and', 'significantly', 'prolonged', 'survival', 'in', 'a', '_gene_', 'driven', 'mouse', '_disease_', 'model', 'and', 'was', 'found', 'to', 'be', 'active', 'in', 'cells', 'with', 'the', '_mutation_', 'point', 'mutation']"
2447,1.0,Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector.,"['transfection', 'of', 'another', 'cell', 'line', 'with', 'this', 'mutation', 'led', 'to', 'lower', '_abbrev_', 'values', 'to', '_chemical_', 'and', '_chemical_', 'than', 'in', 'a', 'cell', 'line', 'transfected', 'with', 'a', 'control', 'vector']"
2448,1.0,"Phosphorylated EIF4EBP1 (T37/46, T70) levels were higher in cell lines and xenografts sensitive to everolimus.","['phosphorylated', '_gene_', '_gene_', '_abbrev_', 'levels', 'were', 'higher', 'in', 'cell', 'lines', 'and', 'xenografts', 'sensitive', 'to', '_chemical_']"
2449,1.0,"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC.","['_num_', '_disease_', 'patients', 'treated', 'with', '_chemical_', '_chemical_', 'were', 'retrospectively', 'analyzed', 'for', 'egfrviii', '_gene_', 'and', '_gene_', 'expression', 'by', '_gene_']"
2450,1.0,"FGFR1 amplification (24/454, assessed by FISH) and/or activated pFGFR1 protein (18/99, assessed by mRNA in situ hybridization) was identified in primary CRC tissue samples.","['_gene_', 'amplification', '_ratio_', 'assessed', 'by', 'fish', 'and', 'or', 'activated', '_abbrev_', 'protein', '_ratio_', 'assessed', 'by', 'mrna', 'in', '_disease_', 'hybridization', 'was', 'identified', 'in', 'primary', '_gene_', 'tissue', 'samples']"
2451,1.0,This paper reports functional studies of this variant.,"['this', 'paper', 'reports', 'functional', 'studies', 'of', 'this', 'variant']"
2452,1.0,"Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled.","['of', 'note', 'this', 'study', 'did', 'not', 'meet', 'its', 'primary', 'endpoint', 'of', '_num_', 'responses', 'cr', '_gene_', 'pr', 'or', 'mr', 'in', 'the', '_num_', '_num_', 'patients', 'enrolled']"
2453,1.0,"Large meta-analysis of 5,191 breast cancer patients and 3,834 controls did not find a conclusive link between codon 72 allele and breast cancer susceptibility.","['large', '_disease_', 'analysis', 'of', '_num_', 'breast', 'cancer', 'patients', 'and', '_num_', 'controls', 'did', 'not', 'find', 'a', 'conclusive', 'link', 'between', 'codon', '_num_', 'allele', 'and', 'breast', 'cancer', 'susceptibility']"
2454,1.0,AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome.,"['_gene_', 'protein', 'expression', 'as', 'assessed', 'by', '_gene_', 'was', 'not', 'significantly', 'associated', 'with', 'treatment', 'outcome']"
2455,1.0,This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild type patients (n = 22; p=0.005).,"['this', 'was', 'also', 'true', 'for', 'the', 'subset', 'of', 'patients', 'with', 'early', '_disease_', '_abbrev_', 'n', '_num_', 'compared', 'to', 'wild', 'type', 'patients', 'n', '_num_', '_p_val_']"
2456,1.0,"These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial.","['these', 'results', 'together', 'with', 'other', 'trials', 'such', 'as', '_abbrev_', 'indicate', 'promise', 'for', '_disease_', 'therapy', 'in', '_gene_', 'amplification', 'and', 'this', 'will', 'be', 'further', 'studied', 'in', 'an', 'arm', 'of', 'the', 'nci', 'match', 'trial']"
2457,1.0,"In western blotting, brigatinib at and above 100 nM ablated pALK signal (Y 1604), indicating sensitivity of this variant to brigatinib together with the other results.","['in', 'western', 'blotting', 'brigatinib', 'at', 'and', 'above', '_num_', '_unit_', 'ablated', 'palk', 'signal', 'y', '_num_', 'indicating', 'sensitivity', 'of', 'this', 'variant', 'to', 'brigatinib', 'together', 'with', 'the', 'other', 'results']"
2458,1.0,No partial responses were found in this subgroup even though some were on study treatment for >2 years and 3 patients with other HER2 mutations achieved PRs.,"['no', 'partial', 'responses', 'were', 'found', 'in', 'this', 'subgroup', 'even', 'though', 'some', 'were', 'on', 'study', 'treatment', 'for', '_num_', 'years', 'and', '_num_', 'patients', 'with', 'other', '_gene_', 'mutations', 'achieved', 'prs']"
2459,1.0,The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.,"['the', 'patient', 'was', 'treated', 'with', 'entrectinib', 'and', 'exhibited', 'a', 'partial', 'response', 'for', '_num_', 'months', 'followed', 'by', 'disease', 'progression']"
2460,1.0,This missense mutation was found in a VHL type 1 patient (patient no V374).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
2461,1.0,"Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker.","['increasing', 'taselisib', 'concentration', 'induced', 'reduction', 'of', '_chemical_', 'levels', 'in', '_abbrev_', 'cells', 'while', 'upregulating', 'the', 'cleaved', '_gene_', 'apoptotic', 'marker']"
2462,1.0,This missense mutation was found in a VHL type 1 patient (patient no V91).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
2463,1.0,"In a cohort of 120 patients with chronic lymphoytic leukemia, those with P2515 frameshift deletions in NOTCH1 at diagnosis had worse overall and treatment free survival.","['in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'chronic', 'lymphoytic', 'leukemia', 'those', 'with', '_abbrev_', 'frameshift', 'deletions', 'in', '_gene_', 'at', 'diagnosis', 'had', 'worse', 'overall', 'and', 'treatment', 'free', 'survival']"
2464,1.0,Loss of MRE11 was identified in 30.7% of endometrial tumors (N=521).,"['loss', 'of', '_gene_', 'was', 'identified', 'in', '_num_', 'of', 'endometrial', 'tumors', '_ineq_']"
2465,1.0,"This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant.","['this', 'fusion', 'was', 'associated', 'with', 'elevated', '_gene_', 'kinase', 'activity', 'similar', 'to', 'the', '_mutation_', 'variant']"
2466,1.0,BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro.,"['_gene_', 'fusion', 'agk', '_gene_', 'was', 'associated', 'with', 'decreased', 'sensitivity', 'to', '_chemical_', 'and', 'increased', 'sensitivity', 'to', '_chemical_', 'in', 'vitro']"
2467,1.0,the combination of salinomycin (downregulating ZEB1) and doxorubicin was syngergistic.,"['the', 'combination', 'of', '_chemical_', 'downregulating', '_gene_', 'and', 'doxorubicin', 'was', 'syngergistic']"
2468,1.0,"In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F.","['in', 'patients', 'with', '_gene_', '_mutation_', 'the', 'use', 'of', '_chemical_', '_chemical_', 'leads', 'to', 'reduction', 'in', 'the', 'percentage', 'of', 'cells', 'harboring', '_gene_', '_mutation_']"
2469,1.0,AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat.,"['_chemical_', 'is', 'effective', 'in', 'triggering', 'apoptosis', 'in', 'ba', '_abbrev_', 'and', 'primary', '_disease_', 'cells', 'with', '_gene_', 'internal', 'tandem', 'repeat']"
2470,1.0,R173C resides in the NH2-terminal phosphatase domain of PTEN.,"['_mutation_', 'resides', 'in', 'the', '_chemical_', 'phosphatase', 'domain', 'of', '_gene_']"
2471,1.0,Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib.,"['decreased', '_disease_', 'in', 'mutant', 'cells', 'was', 'noted', 'after', 'treatment', 'with', 'either', '_chemical_', 'or', '_chemical_']"
2472,1.0,"Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD).","['of', 'these', '_num_', 'somatic', '_mutation_', 'patients', '_num_', 'showed', 'progressive', 'disease', 'pd', 'and', '_num_', 'showed', 'stable', 'disease', 'sd']"
2473,0.0,These results were independent of DIPSS-plus risk but added prognostic information to this risk categorization.,"['these', 'results', 'were', 'independent', 'of', 'dipss', 'plus', 'risk', 'but', 'added', 'prognostic', 'information', 'to', 'this', 'risk', 'categorization']"
2474,1.0,"AG-221 suppressed oncometobolite 2HG production and induced cellular differentiation in primary human IDH2 mutated AML cells in vivo and in xenograft mouse models, providing a statistically significant benefit in an aggressive IDH2 R140Q-mutant AML xenograft mouse model.","['_abbrev_', 'suppressed', 'oncometobolite', '2hg', 'production', 'and', 'induced', 'cellular', 'differentiation', 'in', 'primary', 'human', '_gene_', 'mutated', '_disease_', 'cells', 'in', 'vivo', 'and', 'in', 'xenograft', 'mouse', 'models', 'providing', 'a', 'statistically', 'significant', 'benefit', 'in', 'an', 'aggressive', '_gene_', '_abbrev_', '_disease_', 'xenograft', 'mouse', 'model']"
2475,1.0,"Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53.","['phase', 'i', 'trial', 'of', '_chemical_', 'in', '_num_', 'heavily', 'pretreated', 'patients', 'with', '_disease_', 'all', '_gene_', '_disease_', 'scll', 'demonstrated', 'sustained', 'clinical', 'improvement', 'and', 'induction', 'of', '_gene_', 'target', 'genes', 'in', 'subset', 'of', 'patients', 'with', 'wild', 'type', '_gene_']"
2476,1.0,Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.,"['response', 'rates', 'are', 'higher', 'in', '_gene_', 'mutation', 'positive', 'women', 'with', 'high', 'grade', 'serous', 'or', 'undifferentiated', 'ovarian', 'cancer']"
2477,1.0,"In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate.","['in', 'a', 'retrospective', 'analysis', 'of', '_num_', 'patients', 'with', 'papillary', 'renal', 'cell', 'carcinoma', 'treated', 'with', '_chemical_', 'met', 'germline', 'mutation', 'was', 'associated', 'with', 'improved', 'response', 'rate']"
2478,1.0,c-MET was overexpressed in 21 of 48 (44%) resistant samples.,"['_gene_', 'was', 'overexpressed', 'in', '_num_', 'of', '_num_', '_num_', 'resistant', 'samples']"
2479,1.0,"This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', 'a', 'case', 'of', '_disease_', 'colorectal', 'cancer', 'was', 'confirmed', 'to', 'be', 'somatic', 'in', 'a', 'patient', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
2480,1.0,"For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib.","['for', 'cell', 'harboring', '_gene_', '_mutation_', 'mutation', 'osimertinib', 'and', '_chemical_', 'showed', 'potent', 'inhibition', 'compared', 'to', '_chemical_', 'or', '_chemical_']"
2481,1.0,"Overall, 63% of the patients in the T-allele group (TT + CT), i.e with the T393C genotype, were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%.","['overall', '_num_', 'of', 'the', 'patients', 'in', 'the', 't', 'allele', 'group', 'tt', 'ct', '_disease_', 'with', 'the', '_mutation_', 'genotype', 'were', 'minor', 'responders', 'with', 'more', 'than', '_num_', 'residual', 'vital', 'tumor', 'cells', 'in', 'resection', 'specimens', 'whereas', 't', 'genotypes', 'cc', 'showed', 'a', 'major', 'histopathological', 'response', 'with', 'less', 'than', '_num_', 'residual', 'vital', 'tumor', 'cells', 'in', '_num_']"
2482,1.0,Mutations in the Src homology 2 (SH2) domain (exon 21) of STAT3 were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia.,"['mutations', 'in', 'the', '_gene_', 'homology', '_num_', '_gene_', 'domain', 'exon', '_num_', 'of', '_gene_', 'were', 'found', 'in', '_num_', 'of', '_num_', 'patients', '_num_', 'with', 'large', 'granular', 'lymphocytic', 'leukemia']"
2483,1.0,54 patients with advanced gastric cancer were treated with everolimus.,"['_num_', 'patients', 'with', 'advanced', 'gastric', 'cancer', 'were', 'treated', 'with', '_chemical_']"
2484,1.0,ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status.,"['_disease_', 'treatment', 'did', 'not', 'effect', 'overall', 'survival', 'in', 'patients', '_num_', 'years', 'old', 'with', '_gene_', 'mutation', 'regardless', 'of', '_gene_', 'status']"
2485,1.0,Primary endpoints included independently assessed progression free survival (PFS) and safety.,"['primary', 'endpoints', 'included', 'independently', 'assessed', 'progression', 'free', 'survival', '_disease_', 'and', 'safety']"
2486,1.0,mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination.,"['_gene_', 'protein', 'levels', 'were', 'found', 'to', 'underly', 'a', 'circadian', '_num_', 'hour', 'rhythm', 'regulated', 'by', '_disease_', '_abbrev_', '_disease_']"
2487,1.0,66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations.,"['_num_', 'of', 'the', '_num_', 'patients', 'with', '_num_', 'common', 'activating', '_gene_', 'mutations', 'exon', '_num_', 'deletion', 'or', '_mutation_', 'had', 'an', 'objective', 'response', 'compared', 'to', '_num_', 'of', '_num_', 'patients', 'with', 'less', 'common', '_gene_', 'mutations']"
2488,1.0,"The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001).","['the', 'primary', 'endpoint', 'progression', 'free', 'survival', '_disease_', 'was', 'found', 'to', 'be', 'significantly', 'better', 'for', 'patients', 'treated', 'with', '_chemical_', 'median', '_num_', 'months', 'than', 'with', 'chemotherapy', 'median', '_num_', 'months', 'hazard', 'ratio', 'for', 'disease', 'progression', 'or', 'death', 'with', '_chemical_', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
2489,1.0,"Of these, 9 exhibited medullary thyroid cancers.","['of', 'these', '_num_', 'exhibited', 'medullary', 'thyroid', 'cancers']"
2490,1.0,"In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild type KRAS.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'colorectal', 'cancer', 'cell', 'line', 'endogenously', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'resistance', 'to', '_chemical_', 'treatment', 'compared', 'to', '_abbrev_', 'parental', 'cells', 'expressing', 'wild', 'type', '_gene_']"
2491,1.0,Microarray analysis showed a downregulation of MYC-dependent genes after treatment.,"['microarray', 'analysis', 'showed', 'a', 'downregulation', 'of', '_gene_', 'dependent', 'genes', 'after', 'treatment']"
2492,1.0,A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib).,"['a', 'set', 'of', '_num_', 'cell', 'lines', 'from', 'the', 'cancer', 'cell', 'line', 'encyclopedia', 'was', 'tested', 'for', 'responsiveness', 'to', 'the', '_gene_', 'specific', 'inhibitor', '_chemical_', 'alpelisib']"
2493,1.0,This nonsense mutation was found in 2 VHL families with 6 patients altogether.,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'families', 'with', '_num_', 'patients', 'altogether']"
2494,1.0,MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.,"['_chemical_', 'cell', 'lines', 'harboring', 'the', '_abbrev_', 'mutation', 'in', 'the', '_disease_', 'domain', 'of', '_gene_', 'have', 'shown', 'resistance', 'to', 'hormone', 'therapy']"
2495,1.0,PCa cells in the presence of GAS6 were found to be in G1 phase for a greater duration which may help explain the increased resistance to docetaxel.,"['_disease_', 'cells', 'in', 'the', 'presence', 'of', '_gene_', 'were', 'found', 'to', 'be', 'in', '_gene_', 'phase', 'for', 'a', 'greater', 'duration', 'which', 'may', 'help', 'explain', 'the', 'increased', 'resistance', 'to', '_chemical_']"
2496,1.0,"6 targets identified by this screen were evaluated in a second set of isogenic colorectal cancer cell lines (SW48) harboring wildtype (parental), G12S, G12D, G12V or G13D KRAS where only CDK1 knockdown more profoundly reduced survival in mutant cells compared to wildtype.","['_num_', 'targets', 'identified', 'by', 'this', 'screen', 'were', 'evaluated', 'in', 'a', '_num_', 'set', 'of', 'isogenic', 'colorectal', 'cancer', 'cell', 'lines', '_abbrev_', 'harboring', 'wildtype', 'parental', '_mutation_', '_mutation_', '_mutation_', 'or', '_mutation_', '_gene_', 'where', 'only', '_gene_', 'knockdown', 'more', 'profoundly', 'reduced', 'survival', 'in', 'mutant', 'cells', 'compared', 'to', 'wildtype']"
2497,1.0,32/40 tumors harbored KRAS mutations including 8 G12V mutations (3 with PIK3CA mutations) where progressive disease occurred in only 1 tumor upon doublet treatment but 6 tumors in monotherapy.,"['_ratio_', 'tumors', 'harbored', '_gene_', 'mutations', 'including', '_num_', '_mutation_', 'mutations', '_num_', 'with', '_gene_', 'mutations', 'where', 'progressive', 'disease', 'occurred', 'in', 'only', '_num_', 'tumor', 'upon', 'doublet', 'treatment', 'but', '_num_', 'tumors', 'in', 'monotherapy']"
2498,1.0,"In patients with acute myeloid leukemia, in a univariate analysis those with mutations in ASXL1 had worse overall survival than wild type.","['in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'in', 'a', 'univariate', 'analysis', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'worse', 'overall', 'survival', 'than', 'wild', 'type']"
2499,1.0,"77 patients (62% cutaneous, 30% uveal, 8% mucosal).","['_num_', 'patients', '_num_', 'cutaneous', '_num_', 'uveal', '_num_', 'mucosal']"
2500,1.0,This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years.,"['this', 'phase', 'i', 'study', 'of', '_chemical_', 'involved', 'a', 'cohort', 'of', 'pediatric', 'neuroblastoma', 'patients', 'between', 'ages', '_num_', 'months', 'and', '_num_', 'years']"
2501,1.0,Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond.,"['another', 'patient', 'with', 'non', '_gene_', 'rearranged', '_disease_', 'was', 'administered', '_chemical_', 'in', 'this', 'study', 'but', 'did', 'not', 'respond']"
2502,1.0,"In an absence of gene fusion products, patients with IDH2(R172) mutations showed higher survival rates when compared to mutations in NPM1, chromatin-spliceosome mutations and TP53–aneuploidy.","['in', 'an', 'absence', 'of', 'gene', 'fusion', 'products', 'patients', 'with', '_gene_', '_abbrev_', 'mutations', 'showed', 'higher', 'survival', 'rates', 'when', 'compared', 'to', 'mutations', 'in', '_gene_', 'chromatin', 'spliceosome', 'mutations', 'and', '_abbrev_']"
2503,1.0,This utation causes an early stop codon at position 158 and was found in a VHL type 1 family (lineage 64).,"['this', 'utation', 'causes', 'an', 'early', 'stop', 'codon', 'at', 'position', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
2504,1.0,"HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts, neuroendocrine neoplasm.","['_disease_', 'terms', 'retinal', '_disease_', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts', 'neuroendocrine', 'neoplasm']"
2505,1.0,This mutation was found in a VHL type 1 patient (patient no V67).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
2506,1.0,Three studies have found no significant survival impact for CCND1 in lung cancer.,"['_num_', 'studies', 'have', 'found', 'no', 'significant', 'survival', 'impact', 'for', '_gene_', 'in', 'lung', 'cancer']"
2507,1.0,"An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib.","['an', '_gene_', 'resistance', 'mutation', '_mutation_', 'was', 'discovered', 'by', 'deep', 'sequencing', 'of', 'cell', 'free', 'plasma', 'dna', 'cfdna', 'from', 'patients', 'with', 'advanced', 'lung', 'cancer', 'whose', 'tumors', 'had', 'developed', 'resistance', 'to', 'osimertinib']"
2508,1.0,Two patients did not have any clinical response to sorafenib upon initial treatment.,"['_num_', 'patients', 'did', 'not', 'have', 'any', 'clinical', 'response', 'to', '_chemical_', 'upon', 'initial', 'treatment']"
2509,1.0,The mRNA expression level of RRM2 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines  cultured in incrementally increased concentrations of gemcitabine.,"['the', 'mrna', 'expression', 'level', 'of', '_gene_', 'was', 'analyzed', 'by', '_disease_', 'in', '_num_', 'human', 'pancreatic', 'cancer', 'cell', 'lines', 'cultured', 'in', 'incrementally', 'increased', 'concentrations', 'of', '_chemical_']"
2510,1.0,"In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment.","['in', 'chronic', 'myeloid', 'leukemia', 'patients', 'with', 'the', '_gene_', '_mutation_', 'mutation', 'tumors', 'have', 'shown', 'to', 'be', 'resistant', 'to', '_chemical_', 'treatment']"
2511,1.0,This patient also harbored a MLH1 p.G606fs*2 mutation.,"['this', 'patient', 'also', 'harbored', 'a', '_gene_', 'p', '_abbrev_', 'mutation']"
2512,1.0,Expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region rescued tumor growth.,"['expression', 'of', 'a', '_gene_', 'resistant', '_gene_', 'cdna', 'lacking', 'the', '_num_', 'untranslated', 'region', 'rescued', 'tumor', 'growth']"
2513,1.0,This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'frameshift', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
2514,1.0,LOH of the WT allele was confirmed in the case of ovarian cancer.,"['_disease_', 'of', 'the', '_gene_', 'allele', 'was', 'confirmed', 'in', 'the', 'case', 'of', 'ovarian', 'cancer']"
2515,1.0,Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients.,"['brain', 'metastases', 'control', 'was', 'reported', 'in', '_num_', '_num_', 'ci', '_range_', 'of', '_num_', '_gene_', 'inhibitor', 'naive', 'patients', 'and', 'in', '_num_', '_range_', 'of', '_num_', '_gene_', 'inhibitor', 'pretreated', 'patients']"
2516,1.0,"PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation.","['_gene_', 'loss', 'of', 'function', 'due', 'to', 'loss', 'or', 'mutation', '_ineq_', 'was', 'found', 'to', 'be', 'significantly', 'correlated', 'with', '_chemical_', 'sensitivity', '_p_val_', 'and', 'correlation', 'improved', 'in', 'the', 'subpopulation', 'free', 'of', 'ras', 'mutation']"
2517,1.0,The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients.,"['the', '_gene_', '_num_', '3tpr', 'germline', 'variant', 'was', 'significantly', 'correlated', 'with', 'lower', 'response', 'to', '_chemical_', 'plus', '_disease_', 'treatment', 'in', 'colorectal', 'cancer', 'patients']"
2518,1.0,"One VHL type 1 family of 2 affected individuals had one patient with retinal angiomas, 2 with hemangioblastomas of the central nervous system, one with renal cell carcinoma, one with pancreatic cysts, and  one with cystadenomas of the epididymis (family VHL 32).","['_num_', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'affected', 'individuals', 'had', '_num_', 'patient', 'with', 'retinal', 'angiomas', '_num_', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'with', 'renal', 'cell', 'carcinoma', '_num_', 'with', 'pancreatic', 'cysts', 'and', '_num_', 'with', '_disease_', 'of', 'the', 'epididymis', 'family', '_gene_', '_num_']"
2519,1.0,The test development cohort consisted of 194 cases and an independent validation cohort consisted of 91 cases.,"['the', 'test', 'development', 'cohort', 'consisted', 'of', '_num_', 'cases', 'and', 'an', 'independent', 'validation', 'cohort', 'consisted', 'of', '_num_', 'cases']"
2520,1.0,"Case report of a patient with metastatic ALK-rearranged NSCLC after progression under sequential crizotinib, ceritinib, HSP90 inhibitor AUY922 and chemotherapy followed by crizotinib again.","['case', 'report', 'of', 'a', 'patient', 'with', 'metastatic', '_gene_', 'rearranged', '_disease_', 'after', 'progression', 'under', 'sequential', '_chemical_', '_chemical_', '_gene_', 'inhibitor', '_chemical_', 'and', 'chemotherapy', 'followed', 'by', '_chemical_', 'again']"
2521,1.0,Median OS in wild type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01).,"['median', 'os', 'in', 'wild', 'type', '_gene_', 'patients', 'compared', 'was', 'significantly', 'better', 'than', 'in', '_gene_', '_gene_', 'patients', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
2522,1.0,The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).,"['the', 'cell', 'line', '_abbrev_', 'with', 'the', '_gene_', 'mutation', '_mutation_', 'was', 'hypersensitive', 'to', '_gene_', 'treatment', '_abbrev_', 'of', '_num_', '_unit_', '_unit_']"
2523,1.0,There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000).,"['there', 'were', '_num_', '_num_', 'partial', 'responses', 'prs', 'in', 'the', '_chemical_', 'arm', 'and', '_num_', '_num_', 'prs', 'in', 'the', '_chemical_', 'arm', 'p', '_num_']"
2524,1.0,Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells.,"['nude', 'mouse', 'xenografts', 'were', 'established', 'with', '_abbrev_', '_gene_', '_mutation_', 'cells']"
2525,1.0,"These ATR mutations were observed in 12 of 248 patients (4.8%, 3 insertions, 9 deletions).","['these', '_gene_', 'mutations', 'were', 'observed', 'in', '_num_', 'of', '_num_', 'patients', '_num_', '_num_', 'insertions', '_num_', 'deletions']"
2526,1.0,"Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189).","['complete', 'remission', 'rates', 'were', 'higher', '_num_', 'vs', '_num_', 'p', '_num_', 'and', 'event', 'free', 'survival', 'was', 'longer', 'median', '_num_', 'vs', '_num_', 'days', 'p', '_num_', 'for', 'normal', 'karyotype', '_disease_', 'patients', 'median', 'age', '_num_', 'years', 'with', 'exon', '_num_', '_gene_', 'mutations', '_chemical_', 'compared', 'to', 'those', 'with', 'wildtype', '_gene_', '_ineq_']"
2527,1.0,COS7 cell lines transfected with BCR-ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity.,"['_abbrev_', 'cell', 'lines', 'transfected', 'with', '_gene_', 'constructs', 'harboring', '_mutation_', 'mutations', 'were', 'shown', 'to', 'be', 'resistant', 'to', '_chemical_', 'and', 'exhibited', 'increased', 'kinase', 'activity']"
2528,1.0,"In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation.","['in', 'younger', 'cytogenetically', 'normal', '_disease_', 'patients', '_num_', 'years', '_gene_', 'mutations', 'other', 'than', '_abbrev_', 'are', 'prognostic', 'for', 'shorter', 'disease', 'free', 'survival', 'and', 'overall', 'survival', 'compared', 'to', 'patients', 'without', 'the', 'mutation']"
2529,1.0,"In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild type patients.","['in', 'patients', 'with', 'anaplastic', '_disease_', 'those', 'with', 'mutations', 'at', '_abbrev_', 'of', '_gene_', 'had', 'better', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
2530,1.0,"Among 8 patients with NRAS mutated melanoma, 4 experienced SD or PR (1 Patient received study treatment for 323 days).","['among', '_num_', 'patients', 'with', 'nras', 'mutated', 'melanoma', '_num_', 'experienced', 'sd', 'or', 'pr', '_num_', 'patient', 'received', 'study', 'treatment', 'for', '_num_', 'days']"
2531,1.0,Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.,"['tumor', 'volume', 'grew', 'more', 'rapidly', 'in', 'mice', 'with', 'xenografts', 'of', '_abbrev_', '_gene_', 'mutant', '_chemical_', 'cells', 'treated', 'with', '_chemical_', 'than', '_gene_', 'or', '_abbrev_', 'treatment']"
2532,1.0,Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.,"['patients', 'with', '_abbrev_', 'mutated', 'cancers', 'were', 'identified', '_ineq_', 'and', 'clinical', 'response', 'to', '_chemical_', 'was', 'evaluated']"
2533,1.0,"Patients with BAP1 mutations treated with first line everolimus followed by sunitinib (N=87 wildtype, 22 mutant) were associated with shorter progression free survival (median [95% CI] 4.9 [2.9 - 8.1] vs 10.5 [7.3 - 12.9] mo; HR 1.84 [1.1-3.2]; P=0.02).","['patients', 'with', '_gene_', 'mutations', 'treated', 'with', '_num_', 'line', '_chemical_', 'followed', 'by', '_chemical_', '_ineq_', 'wildtype', '_num_', 'mutant', 'were', 'associated', 'with', 'shorter', 'progression', 'free', 'survival', 'median', '_num_', 'ci', '_num_', '_num_', '_num_', 'vs', '_num_', '_num_', '_num_', '_unit_', 'hr', '_num_', '_range_', '_p_val_']"
2534,1.0,"The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months.","['the', 'remaining', '_ratio_', 'mice', 'treated', 'at', '_num_', '_disease_', '_chemical_', 'and', 'all', 'mice', 'treated', 'at', '_num_', '_disease_', '_chemical_', 'maintained', 'complete', 'remission', 'for', '_num_', 'months']"
2535,1.0,There was no difference between the two groups with regards to overall response rate to pazopanib.,"['there', 'was', 'no', 'difference', 'between', 'the', '_num_', 'groups', 'with', 'regards', 'to', 'overall', 'response', 'rate', 'to', '_chemical_']"
2536,1.0,"Six had retinal angiomas, one had renal cell carcinoma, 6 had cerebellar hemangioblastomas, and 4 pheochromocytoma.","['_num_', 'had', 'retinal', 'angiomas', '_num_', 'had', 'renal', 'cell', 'carcinoma', '_num_', 'had', 'cerebellar', '_disease_', 'and', '_num_', 'pheochromocytoma']"
2537,1.0,"In chemotherapy-refractory patients with colorectal cancer, Exon 9 PIK3CA mutations (Exon 9) had no significant impact on response rate, disease control rate, progression free surivival or overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA.","['in', 'chemotherapy', 'refractory', 'patients', 'with', 'colorectal', 'cancer', 'exon', '_num_', '_gene_', 'mutations', 'exon', '_num_', 'had', 'no', 'significant', 'impact', 'on', 'response', 'rate', 'disease', 'control', 'rate', 'progression', 'free', 'surivival', 'or', 'overall', 'survival', 'following', '_chemical_', 'plus', 'chemotherapy', 'than', 'those', 'with', 'wildtype', '_gene_']"
2538,1.0,"Among patients with MGMT data available for analysis, radiotherapy was started and completed in 91% of patients with low MGMT expression.","['among', 'patients', 'with', '_gene_', 'data', 'available', 'for', 'analysis', 'radiotherapy', 'was', 'started', 'and', 'completed', 'in', '_num_', 'of', 'patients', 'with', 'low', '_gene_', 'expression']"
2539,1.0,This patient also harbored a p.K618del mutation.,"['this', 'patient', 'also', 'harbored', 'a', '_mutation_', 'mutation']"
2540,1.0,"Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression).","['_num_', 'of', '_num_', 'evaluable', 'patients', 'achieved', 'an', 'objective', 'response', '_num_', 'patients', 'total', 'had', 'either', 'stable', 'disease', 'or', 'radiographic', 'response', 'the', 'patient', 'with', '_disease_', 'cancer', 'had', 'disease', 'progression']"
2541,1.0,This missense mutation was found in 3 VHL type 1 family members (patient no V27).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'family', 'members', 'patient', 'no', '_gene_']"
2542,1.0,Mouse models with this variant show an increase in spontaneous tumor formation.,"['mouse', 'models', 'with', 'this', 'variant', 'show', 'an', 'increase', 'in', 'spontaneous', 'tumor', 'formation']"
2543,1.0,RICTOR amplification was confirmed via FISH and IHC.,"['_gene_', 'amplification', 'was', 'confirmed', 'via', 'fish', 'and', '_gene_']"
2544,1.0,"In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy.","['in', 'a', 'lung', 'adenocarcinoma', 'patient', 'harboring', 'an', '_gene_', '_mutation_', 'mutation', 'and', 'an', 'acquired', '_gene_', '_mutation_', 'co', 'mutation', '_gene_', '_mutation_', 'was', 'associated', 'with', 'sensitivity', 'to', 'osimertinib', 'monotherapy']"
2545,1.0,"In a study of patients treated with erlotinib or gefitinib, a subset of patients with EGFR mutation at codons G719 or L861 (n=30) was associated with improved response rate (47.5% vs 16.5%, P<0.001) median progression free survival (5.0 vs 2.0 months, P<0.001), and overall survival (15.0 vs. 10.4 months, P =0.030), compared to patients with wild type EGFR (n=272).","['in', 'a', 'study', 'of', 'patients', 'treated', 'with', '_chemical_', 'or', '_chemical_', 'a', 'subset', 'of', 'patients', 'with', '_gene_', 'mutation', 'at', 'codons', '_abbrev_', 'or', '_abbrev_', '_ineq_', 'was', 'associated', 'with', 'improved', 'response', 'rate', '_num_', 'vs', '_num_', 'p', '_num_', 'median', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'and', 'overall', 'survival', '_num_', 'vs', '_num_', 'months', 'p', '_ineq_', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', '_ineq_']"
2546,1.0,Afatinib monotherapy resulted in resolution of symptoms and 10 months before progressive disease.,"['_chemical_', 'monotherapy', 'resulted', 'in', 'resolution', 'of', 'symptoms', 'and', '_num_', 'months', 'before', 'progressive', 'disease']"
2547,1.0,"Treatment continued until disease progression, death, or withdrawal from the study.","['treatment', 'continued', 'until', 'disease', 'progression', 'death', 'or', 'withdrawal', 'from', 'the', 'study']"
2548,1.0,"Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38).","['sequencing', 'of', '_gene_', 'and', '_gene_', 'revealed', 'a', '_num_', 'base', 'frameshift', 'insertion', 'in', '_gene_', 'labeled', '3020insct', 'c', '2901insct', 'in', 'this', 'paper', 'with', 'the', 'data', 'shown', 'corresponding', 'to', 'a', 'ga', 'insertion', 'reading', 'left', 'to', 'right', 'in', 'the', 'reference', 'genome', 'between', '_abbrev_', 'in', '_abbrev_']"
2549,1.0,This mutation was also found in 3 family members with VHL type 1 phenotype (family ID 3616).,"['this', 'mutation', 'was', 'also', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
2550,1.0,No G12R was detected in the parental line despite high-resolution evaluation.,"['no', '_mutation_', 'was', 'detected', 'in', 'the', 'parental', 'line', 'despite', 'high', 'resolution', 'evaluation']"
2551,1.0,This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.,"['this', 'phase', 'iii', 'study', '_abbrev_', 'was', 'motivated', 'by', 'preclinical', 'and', 'other', 'data', 'demonstrating', 'synergistic', 'activity', 'between', '_chemical_', 'and', '_chemical_', 'against', '_gene_', 'positive', 'breast', 'cancer', 'bc', 'cells']"
2552,1.0,Treatment with chemotherapy produced no remarkable response.,"['treatment', 'with', 'chemotherapy', 'produced', 'no', 'remarkable', 'response']"
2553,1.0,"In a phase III clinical trial comparing different doses of imatinib in GIST patients, KIT exon 9 mutations were associated with significantly improved progression free survival (P=0.0013) and a 61% relative risk reduction in response to the higher dose regimen (N=31; 800mg/daily) when compared to the lower dose regimen (N=27; 400 mg/daily; HR 0.329; 95% CI 0.218–0.706).","['in', 'a', 'phase', 'iii', 'clinical', 'trial', 'comparing', 'different', 'doses', 'of', '_chemical_', 'in', 'gist', 'patients', 'kit', 'exon', '_num_', 'mutations', 'were', 'associated', 'with', 'significantly', 'improved', 'progression', 'free', 'survival', '_p_val_', 'and', 'a', '_num_', 'relative', 'risk', 'reduction', 'in', 'response', 'to', 'the', 'higher', 'dose', 'regimen', '_ineq_', '_unit_', 'daily', 'when', 'compared', 'to', 'the', 'lower', 'dose', 'regimen', '_ineq_', '_num_', '_unit_', 'daily', 'hr', '_num_', '_num_', 'ci', '_num_', '218–0', '_num_']"
2554,1.0,Case report of a 60-year old woman with lung adenocarcinoma.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'woman', 'with', 'lung', 'adenocarcinoma']"
2555,1.0,Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild type (N=6; not reached; p < 0.007).,"['significantly', 'shorter', 'median', 'progression', 'free', 'survival', 'was', 'observed', 'in', 'relapsed', '_disease_', 'peritonei', 'patients', 'with', '_gene_', 'mutations', '_chemical_', '_num_', 'months', 'as', 'compared', 'to', 'wild', 'type', '_ineq_', 'not', 'reached', 'p', '_num_']"
2556,1.0,PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs).,"['_gene_', 'is', 'not', 'only', 'expressed', 'in', 'tumor', 'cells', 'tcs', 'but', 'also', 'upregulated', 'in', '_disease_', 'immune', 'cells', 'tiics']"
2557,1.0,"The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11).","['the', 'subgroup', '_abbrev_', 'low', 'tumors', 'had', 'the', 'shortest', '_disease_', '_num_', 'months', 'p', '_num_', 'and', 'shortest', 'but', 'not', 'significantly', 'different', 'os', '_num_', 'months', 'p', '_num_']"
2558,1.0,"Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone.","['coocurrence', 'of', '_gene_', 'mutations', 'significantly', 'reduced', 'overall', '_ineq_', 'vs', '_num_', '_p_val_', 'and', '_disease_', 'survival', '_ineq_', 'vs', '_num_', '_p_val_', 'of', 'normal', 'karyotype', '_disease_', 'patients', '_num_', 'years', 'old', 'compared', 'to', 'patients', 'with', '_gene_', 'mutations', 'alone']"
2559,1.0,"Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.","['of', 'the', '_num_', 'patients', '_num_', '_ineq_', 'were', '_abbrev_', '_num_', 'were', '_gene_', '2+', '_ineq_', 'and', '_num_', '_ineq_', 'were', '_abbrev_', 'negative']"
2560,1.0,"The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide.","['the', '_gene_', '_mutation_', 'mutation', 'in', 'the', '_disease_', 'fusion', 'was', 'observed', 'in', 'a', 'patient', 'with', 'previously', 'atra', 'treated', 'relapsed', 'acute', 'promyelocytic', 'leukemia', 'refractory', 'to', 'arsenic', 'trioxide']"
2561,0.0,A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed.,"['a', '_disease_', 'analysis', 'of', '_gene_', 'gene', 'copy', 'number', 'as', 'a', 'predictive', '_chemical_', 'for', 'patients', 'receiving', 'tyrosine', 'kinase', 'inhibitor', 'treatment', 'was', 'performed']"
2562,0.0,HKI-272) are able to overcome this resistance via covalent bonding.,"['_chemical_', 'are', 'able', 'to', 'overcome', 'this', 'resistance', 'via', 'covalent', 'bonding']"
2563,0.0,"Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma.","['phase', '_num_', 'trial', 'in', 'metastatic', 'mucosal', 'acral', 'or', 'chronically', 'sun', 'damaged', 'melanoma']"
2564,1.0,"These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K.","['these', 'mutations', 'were', 'unrelated', 'to', 'tumor', 'differentiation', 'and', 'mostly', '_ratio_', '_num_', 'were', '_abbrev_']"
2565,1.0,"This mutation was found in 2 unrelated VHL type 1 patients (patient V3, V46).","['this', 'mutation', 'was', 'found', 'in', '_num_', 'unrelated', '_gene_', 'type', '_num_', 'patients', 'patient', '_gene_', '_gene_']"
2566,1.0,"In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3.","['in', 'ba', '_abbrev_', 'cells', '_chemical_', 'sensitivty', 'of', 'the', '_chemical_', 'variant', 'was', 'compared', 'to', '_chemical_', 'sensitivity', 'of', '_chemical_', 'variant', '_num_']"
2567,1.0,Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.,"['ba', '_abbrev_', 'cells', 'with', 'both', '_gene_', 'and', '_disease_', 'mutations', 'on', 'the', 'same', 'allele', 'have', 'more', 'resistance', 'to', '_chemical_', 'than', 'cells', 'with', '_gene_', 'alone']"
2568,1.0,Cell lines (n=5) with FBXW7 mutations or deletions were significantly sensitive to rapamycin and downregulation of FBXW7 (shRNA) increased the sensitivity to rapamycin.,"['cell', 'lines', '_gene_', 'with', '_gene_', 'mutations', 'or', 'deletions', 'were', 'significantly', 'sensitive', 'to', '_gene_', 'and', 'downregulation', 'of', '_gene_', 'shrna', 'increased', 'the', 'sensitivity', 'to', '_gene_']"
2569,1.0,The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs.,"['the', 'mutation', 'was', 'shown', 'to', 'occur', 'at', 'a', 'hotspot', '_abbrev_', 'of', 'previously', 'reported', 'secondary', 'kit', 'mutations', 'in', '_chemical_', 'resistant', 'gists']"
2570,1.0,Preclinical study of mouse melanoma in-vitro and in-vivo.,"['preclinical', 'study', 'of', 'mouse', 'melanoma', 'in', 'vitro', 'and', 'in', 'vivo']"
2571,1.0,"A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal angiomas and renal cell carcinoma.","['a', 'missense', 'mutation', 'affecting', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'with', 'retinal', 'angiomas', 'and', 'renal', 'cell', 'carcinoma']"
2572,1.0,"Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.","['variant', '3a', 'consisted', 'of', 'fusion', 'at', '_gene_', 'exon', '_num_', 'and', '_gene_', 'exon', '_num_', 'while', 'variant', '_chemical_', 'fused', 'a', '_num_', '_gene_', 'intronic', '_gene_', 'region', 'between', '_gene_', 'exon', '_num_', 'and', '_gene_', 'exon', '_num_']"
2573,1.0,"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed.","['_num_', '_gene_', 'patients', 'from', '_num_', 'families', 'who', 'had', 'undergone', 'a', 'partial', 'adrenalectomy', 'for', 'pheochromocytoma', 'were', 'retrospectively', 'analyzed']"
2574,1.0,"Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.","['experiments', 'include', 'flow', 'cytometry', 'binding', 'assay', 'kinase', '_disease_', 'cell', 'viability', 'downstream', 'signalling']"
2575,1.0,"In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9).","['in', '_num_', 'patients', 'with', 'advanced', 'gastric', 'cancer', 'retrospectively', 'analyzed', 'for', '_gene_', 'expression', 'using', '_gene_', '_gene_', 'loss', 'was', 'associated', 'with', 'a', 'shorter', 'duration', 'of', 'response', 'median', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'to', '_abbrev_', 'therapy', '_chemical_', '_ineq_', '_chemical_', '_chemical_']"
2576,1.0,Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.,"['young', '_disease_', 'patients', '_num_', 'patients', '_num_', 'years', 'old', 'with', '_gene_', '_abbrev_', 'mutations', '_ineq_', 'have', 'shorter', 'overall', 'and', 'relapse', 'free', 'survival', 'than', 'patients', 'with', 'wildtype', '_gene_']"
2577,1.0,Loss of heterozygosity leading to primarily the D667fs allele detected (90% VAF).,"['loss', 'of', 'heterozygosity', 'leading', 'to', 'primarily', 'the', '_abbrev_', 'allele', 'detected', '_num_', '_disease_']"
2578,1.0,"In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy.","['in', 'our', 'experience', '_mutation_', 'mutations', 'in', 'isolation', 'do', 'not', 'necessarily', 'confer', 'sensitivity', 'to', '_chemical_', 'but', 'in', 'conjunction', 'with', 'sensitizing', '_gene_', 'mutations', '_mutation_', 'mutations', 'do', 'not', 'restrict', 'efficacy']"
2579,1.0,"Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively.","['median', 'and', '_num_', 'year', 'overall', 'survivals', 'for', 'the', '_abbrev_', 'and', '_abbrev_', 'groups', 'were', '_num_', 'years', 'and', '_num_', 'and', '_num_', 'years', 'and', '_num_', 'respectively']"
2580,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L747_P753>S and EGFR L858R expressing cells were 5 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_abbrev_', 's', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
2581,0.0,POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis.,"['pole', 'proofreading', 'domain', 'mutations', 'identify', 'a', 'subset', 'of', 'immunogenic', 'colorectal', 'cancers', 'with', 'excellent', 'prognosis']"
2582,1.0,"After a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease.","['after', 'a', 'median', 'follow', 'up', 'of', '_num_', 'weeks', '_num_', '_num_', '_num_', 'ci', '_range_', 'of', '_num_', 'patients', 'had', 'achieved', 'an', 'objective', 'response', 'with', '_num_', 'patient', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'achieving', 'a', 'complete', 'response', 'and', '_num_', '_num_', '_num_', 'ci', '_range_', 'achieving', 'partial', 'responses', '_num_', '_num_', '_num_', 'ci', '_range_', 'patients', 'had', 'stable', 'disease']"
2583,1.0,"This missense mutation was detected in a type 1 VHL patient (family ID 4389) with angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.","['this', 'missense', 'mutation', 'was', 'detected', 'in', 'a', 'type', '_num_', '_gene_', 'patient', 'family', 'id', '_num_', 'with', 'angiomas', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
2584,1.0,This missense mutation was found in a VHL patient with retinal angiomas and cerebellar hemangioblastomas.,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'patient', 'with', 'retinal', 'angiomas', 'and', 'cerebellar', '_disease_']"
2585,1.0,"IHC staining was used to generate a Ki67 score, and cases were divided into 2 groups with Ki67 score greater or less than 10%.","['_gene_', 'staining', 'was', 'used', 'to', 'generate', 'a', '_gene_', 'score', 'and', 'cases', 'were', 'divided', 'into', '_num_', 'groups', 'with', '_gene_', 'score', 'greater', 'or', 'less', 'than', '_num_']"
2586,1.0,Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.,"['patients', 'with', '_disease_', 'harboring', '_gene_', '_mutation_', 'mutation', 'have', 'statistically', 'worse', 'overall', 'survival', 'compared', 'to', 'patients', 'with', '_mutation_', 'or', 'other', 'exon', '_num_', 'activating', 'mutations']"
2587,1.0,A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF).,"['a', '_abbrev_', 'fusion', 'was', 'identified', 'from', 'dna', 'from', 'a', 'brain', 'metastasis', 'inton', '_num_', 'of', '_gene_', 'fused', 'to', 'intron', '_num_', 'of', '_gene_']"
2588,1.0,Patient began therapy with cetuximab and sirolimus and continued for 9 months.,"['patient', 'began', 'therapy', 'with', '_chemical_', 'and', '_chemical_', 'and', 'continued', 'for', '_num_', 'months']"
2589,1.0,Objective response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel.,"['objective', 'response', 'rate', 'was', '_num_', 'with', '_chemical_', '_chemical_', 'and', '_num_', 'with', 'placebo', '_chemical_']"
2590,1.0,mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy.,"['mrna', 'expression', 'of', '_chemical_', '_gene_', '_gene_', 'in', '_num_', '_disease_', 'patients', 'correlated', 'with', 'response', 'rate', 'to', '_chemical_', 'mono', '', 'or', 'combination', 'therapy']"
2591,1.0,"At 20 wk, tumor multiplicity was also significantly decreased in the Ereg-/- mice.","['at', '_num_', '_disease_', 'tumor', 'multiplicity', 'was', 'also', 'significantly', 'decreased', 'in', 'the', 'ereg', '', '', '', 'mice']"
2592,1.0,Sensitivity to single-agent pertuzumab might also be increased through ERBB3 expression.,"['sensitivity', 'to', 'single', 'agent', 'pertuzumab', 'might', 'also', 'be', 'increased', 'through', '_gene_', 'expression']"
2593,1.0,Five year event free survival was 74 months in non-MYCN amplified cases and 39 months in amplified cases.,"['_num_', 'year', 'event', 'free', 'survival', 'was', '_num_', 'months', 'in', 'non', '_gene_', 'amplified', 'cases', 'and', '_num_', 'months', 'in', 'amplified', 'cases']"
2594,1.0,"Ten patients were treated with an mTOR inhibitor with 7 patients having stable disease as best responses and a median time to treatment failure of 2.8 months, two patients had prolonged stable disease of >16 weeks.","['_num_', 'patients', 'were', 'treated', 'with', 'an', '_gene_', 'inhibitor', 'with', '_num_', 'patients', 'having', 'stable', 'disease', 'as', 'best', 'responses', 'and', 'a', 'median', 'time', 'to', 'treatment', 'failure', 'of', '_num_', 'months', '_num_', 'patients', 'had', 'prolonged', 'stable', 'disease', 'of', '_num_', 'weeks']"
2595,1.0,ACMG evidence codes: 'PVS1' because the variant is an early frameshift and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology.,"['acmg', 'evidence', 'codes', ""'pvs1"", 'because', 'the', 'variant', 'is', 'an', 'early', 'frameshift', 'and', ""'pp4"", 'because', 'the', 'patients', 'phenotypes', 'and', 'family', 'history', 'are', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'single', 'genetic', 'etiology']"
2596,1.0,The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue.,"['the', 'fusion', 'was', 'confirmed', 'at', 'both', 'rna', 'and', 'dna', 'level', 'in', 'all', 'primary', 'and', 'metastatic', 'tumor', 'samples', 'but', 'not', 'in', 'adjacent', 'normal', 'tissue']"
2597,1.0,"The patient (F, 51, nonsmoker) had a partial response, progression free survival (PFS) of 6.9 months, overall survival (OS) of 29.7 months and was alive at study end.","['the', 'patient', 'f', '_num_', 'nonsmoker', 'had', 'a', 'partial', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'alive', 'at', 'study', 'end']"
2598,1.0,12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences.,"['_ratio_', 'patients', 'with', 'de', 'novo', '_disease_', 'syndrome', 'screened', 'for', '_gene_', 'mutations', 'bone', 'marrow', 'and', 'paired', 'normal', 'skin', 'had', 'heterozygous', 'mutations', 'with', 'predicted', 'translational', 'consequences']"
2599,1.0,Cell lines with the T/T genotype had lower expression of NQ01 and greater response to amrubicinol.,"['cell', 'lines', 'with', 'the', '_disease_', 'genotype', 'had', 'lower', 'expression', 'of', '_abbrev_', 'and', 'greater', 'response', 'to', '_chemical_']"
2600,1.0,"While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863).","['while', 'some', 'reports', 'indicate', '_gene_', 'loss', 'is', 'associated', 'with', 'resistance', 'to', '_chemical_', 'in', 'a', 'subgroup', 'of', '_gene_', 'breast', 'cancer', '_disease_', 'samples', 'from', 'patients', 'receiving', '_chemical_', 'as', 'later', 'line', 'therapy', '_num_', 'or', 'greater', 'line', 'therapy', 'with', '_num_', '_gene_', 'loss', 'and', 'and', '_num_', 'normal', 'samples', 'no', 'association', 'was', 'seen', 'between', '_chemical_', 'response', 'and', '_gene_', 'status', '_p_val_', 'or', 'overall', 'survival', 'and', '_gene_', 'status', '_p_val_']"
2601,1.0,101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy.,"['_num_', 'patients', 'with', 'metastatic', 'uveal', 'melanoma', 'were', 'randomized', '_ratio_', 'to', 'receive', '_chemical_', 'or', 'chemotherapy']"
2602,1.0,"31% of patients were diagnosed with cancer (n=2,595).","['_num_', 'of', 'patients', 'were', 'diagnosed', 'with', 'cancer', '_ineq_']"
2603,1.0,Case report of a patient with BRAF V600E mutant metastatic colorectal cancer.,"['case', 'report', 'of', 'a', 'patient', 'with', '_gene_', '_mutation_', 'mutant', 'metastatic', 'colorectal', 'cancer']"
2604,1.0,"This resulted in use of a cryptic donor splice site and a novel transcript with frameshift, 41 novel amino acids and termination at codon 177.","['this', 'resulted', 'in', 'use', 'of', 'a', 'cryptic', 'donor', 'splice', 'site', 'and', 'a', 'novel', 'transcript', 'with', 'frameshift', '_num_', 'novel', 'amino', 'acids', 'and', 'termination', 'at', 'codon', '_num_']"
2605,1.0,"In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild type patients.","['in', 'patients', 'with', 'a', 'glioblastoma', 'those', 'with', 'mutations', 'at', '_abbrev_', 'of', '_gene_', 'had', 'better', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
2606,1.0,"Mutations at 3 AL residues (D835 [n = 31], D839 [n = 3], and Y842 [n = 16]), with varying degrees of resistance to ponatinib were identified.","['mutations', 'at', '_num_', 'al', 'residues', '_abbrev_', 'n', '_num_', '_abbrev_', 'n', '_num_', 'and', '_abbrev_', 'n', '_num_', 'with', 'varying', 'degrees', 'of', 'resistance', 'to', '_chemical_', 'were', 'identified']"
2607,1.0,"Both tumors harbored driver mutations in POLE and were found to harbor 24,680 and 21,919 mutations per exome.","['both', 'tumors', 'harbored', 'driver', 'mutations', 'in', 'pole', 'and', 'were', 'found', 'to', 'harbor', '_num_', 'and', '_num_', 'mutations', 'per', 'exome']"
2608,1.0,Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient.,"['_chemical_', 'was', 'well', 'tolerated', 'in', 'this', '_num_', 'line', 'treatment', 'of', 'a', 'critically', 'ill', '_disease_', '_disease_', 'patient']"
2609,1.0,"The activation loop mutation D835Y was detected in three cases, D835V in two, and D835F was identified in a single patient.","['the', 'activation', 'loop', 'mutation', '_mutation_', 'was', 'detected', 'in', '_num_', 'cases', '_mutation_', 'in', '_num_', 'and', '_abbrev_', 'was', 'identified', 'in', 'a', 'single', 'patient']"
2610,1.0,"Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE.","['performed', 'a', 'systematic', 'molecular', 'analysis', 'of', '_num_', '_disease_', '_disease_', '_disease_', 'and', 'compared', 'to', '_num_', '_disease_', 'hemangiomas', '_num_', '_disease_', 'angiosarcomas', 'and', '_num_', '_disease_', 'sarcoma', 'like', '_disease_']"
2611,0.0,CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL).,"['_gene_', 'is', '_num_', 'of', 'the', 'most', 'common', '_gene_', 'fusions', 'found', 'in', 'diffuse', 'large', 'b', 'cell', 'lymphoma', '_disease_']"
2612,0.0,Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer.,"['_chemical_', 'demonstrated', 'clinical', 'activity', 'that', 'compared', 'favorably', 'to', '_chemical_', 'and', '_chemical_', 'for', 'neoadjuvant', 'treatment', 'of', '_gene_', 'breast', 'cancer']"
2613,1.0,"MAPK1 amplification was not observed in the pretreatment tumor, only the post-treatment resistant tumor which lacked other more common drug-resistance mechanisms EGFR T790M or MET amplification.","['_gene_', 'amplification', 'was', 'not', 'observed', 'in', 'the', 'pretreatment', 'tumor', 'only', 'the', 'post', 'treatment', 'resistant', 'tumor', 'which', 'lacked', 'other', 'more', 'common', 'drug', 'resistance', 'mechanisms', '_gene_', '_mutation_', 'or', 'met', 'amplification']"
2614,1.0,"Multivariate analysis identified ASXL1 mutations as an independent factor for adverse overall survival (P=0.032, relative risk: 1.70).","['multivariate', 'analysis', 'identified', '_gene_', 'mutations', 'as', 'an', 'independent', 'factor', 'for', 'adverse', 'overall', 'survival', '_p_val_', 'relative', 'risk', '_num_']"
2615,1.0,Liver metastasis was noted after 12 months with sequencing revealing a HIP1-ALK fusion with a I1171N variant.,"['liver', 'metastasis', 'was', 'noted', 'after', '_num_', 'months', 'with', 'sequencing', 'revealing', 'a', '_abbrev_', 'fusion', 'with', 'a', '_mutation_', 'variant']"
2616,0.0,Clinical trials are currently ongoing.,"['clinical', 'trials', 'are', 'currently', 'ongoing']"
2617,1.0,"This nonsense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, and pancreatic cysts (family VHL 30).","['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', 'pancreatic', 'cysts', 'family', '_gene_', '_num_']"
2618,1.0,85% of the synovial sarcomas were positive for this event.,"['_num_', 'of', 'the', 'synovial', 'sarcomas', 'were', 'positive', 'for', 'this', 'event']"
2619,1.0,All 25 patients with KRAS mutant colorectal cancer experienced PD.,"['all', '_num_', 'patients', 'with', '_gene_', 'mutant', 'colorectal', 'cancer', 'experienced', 'pd']"
2620,1.0,These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit.,"['these', 'results', 'are', 'an', 'interesting', 'contrast', 'to', 'results', 'of', 'long', 'term', 'adjuvant', 'therapy', 'with', '_chemical_', 'hera', 'which', 'did', 'not', 'show', 'significant', 'benefit']"
2621,1.0,"A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032).","['a', 'panel', 'of', '_num_', '_disease_', 'cell', 'lines', 'was', 'tested', 'for', 'efficacy', 'of', 'the', '_gene_', 'alpha', 'delta', 'and', 'gamma', '_chemical_', 'inhibitor', 'taselisib', '_chemical_']"
2622,1.0,Median progression free survival was 9.1 months and all patients had  been pretreated with 1 or more lines of chemotherapy.,"['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'and', 'all', 'patients', 'had', 'been', 'pretreated', 'with', '_num_', 'or', 'more', 'lines', 'of', 'chemotherapy']"
2623,1.0,"NPM1 mutation (N=724) was associated with higher complete remission rates (92% vs 82%; P < 0.0001), lower cumulative incidence of relapse (42% vs 58%; P < 0.0001) and higher overall survival (48% vs 27%; P < .0001) than NPM1 wildtype status (N=885) in intermediate risk, young adult AML patients (median age 46 years).","['_gene_', 'mutation', '_ineq_', 'was', 'associated', 'with', 'higher', 'complete', 'remission', 'rates', '_num_', 'vs', '_num_', 'p', '_num_', 'lower', 'cumulative', 'incidence', 'of', 'relapse', '_num_', 'vs', '_num_', 'p', '_num_', 'and', 'higher', 'overall', 'survival', '_num_', 'vs', '_num_', 'p', '_num_', 'than', '_gene_', 'wildtype', 'status', '_ineq_', 'in', 'intermediate', 'risk', 'young', 'adult', '_disease_', 'patients', 'median', 'age', '_num_', 'years']"
2624,1.0,"Human HER2 with YVMA insertion was put under a clara cell specific, rtTA promoter system inducible via doxycycline.","['human', '_gene_', 'with', '_gene_', 'insertion', 'was', 'put', 'under', 'a', 'clara', 'cell', 'specific', 'rtta', 'promoter', 'system', 'inducible', 'via', 'doxycycline']"
2625,1.0,Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine),"['significant', 'differences', 'were', 'seen', 'in', 'overall', 'survival', '_num_', 'months', 'with', '_chemical_', 'vs', '_num_', 'months', 'with', '_chemical_', 'and', 'median', 'progression', 'free', 'survival', '_num_', 'months', 'with', '_chemical_', 'vs', '_num_', 'months', 'with', '_chemical_']"
2626,1.0,Individuals with KILLIN-promoter methylation had a greater than 2-fold increase of kidney cancer (4/45 vs 6/155; p=0.004) over individuals with germline PTEN mutations.,"['individuals', 'with', '_gene_', 'promoter', 'methylation', 'had', 'a', 'greater', 'than', '_n_fold_', 'increase', 'of', 'kidney', 'cancer', '_ratio_', 'vs', '_ratio_', '_p_val_', 'over', 'individuals', 'with', 'germline', '_gene_', 'mutations']"
2627,1.0,"From 61 patients with uncommon EGFR mutations of unknown clinical significance, 47.5% were responders in contrast to the 74.1% responders in the exon 19 deletion/L858R group.","['from', '_num_', 'patients', 'with', 'uncommon', '_gene_', 'mutations', 'of', 'unknown', 'clinical', 'significance', '_num_', 'were', 'responders', 'in', 'contrast', 'to', 'the', '_num_', 'responders', 'in', 'the', 'exon', '_num_', 'deletion', '_abbrev_', 'group']"
2628,1.0,This mutation was found in 2 VHL type 1 family members with retinal angiomas and hemangioblastomas of the central nervous system.,"['this', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'family', 'members', 'with', 'retinal', 'angiomas', 'and', '_disease_', 'of', 'the', 'central', 'nervous', 'system']"
2629,1.0,"Two of 8 individuals were identified with angiomas, 3 with cerebellar hemangioblastomas and 3 with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
2630,1.0,Third generation ALK inhibitor lorlatinib led to a partial response that lasted for 8 months.,"['_num_', 'generation', '_gene_', 'inhibitor', 'lorlatinib', 'led', 'to', 'a', 'partial', 'response', 'that', 'lasted', 'for', '_num_', 'months']"
2631,1.0,At time of publication the patient continued to show persistent response at 6 months.,"['at', 'time', 'of', 'publication', 'the', 'patient', 'continued', 'to', 'show', 'persistent', 'response', 'at', '_num_', 'months']"
2632,1.0,"Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and we conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC.","['afatanib', 'plus', '_chemical_', 'was', 'less', 'well', 'tolerated', 'than', '_chemical_', 'plus', '_chemical_', 'and', 'we', 'conclude', 'that', '_chemical_', 'remains', 'the', 'best', 'choice', 'for', 'treatment', 'of', '_chemical_', 'progressed', '_gene_', 'positive', 'metastatic', 'bc']"
2633,1.0,"Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively).","['patients', 'with', 'increased', '_gene_', 'protein', 'had', 'significantly', 'shorter', 'median', '_disease_', '_num_', 'months', 'membranous', 'staining', 'and', '_num_', 'months', 'cytoplasmic', 'staining', 'vs', '_num_', 'months', 'negative', 'p', '_num_', 'and', 'p', '_num_', 'respectively']"
2634,1.0,"In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001).","['in', 'patients', 'with', 'stage', 'ii', 'disease', 'whose', 'tumors', 'expressed', '_gene_', 'the', '_num_', 'year', 'survival', 'rate', 'was', '_num_', 'percent', 'whereas', 'in', 'patients', 'with', '_gene_', 'negative', 'tumors', 'the', 'survival', 'rate', 'was', '_num_', 'percent', 'p', '_num_']"
2635,1.0,"In one cisplatin resistant cell line, DAC treatment and cisplatin had a synergistic effect.","['in', '_num_', '_disease_', 'resistant', 'cell', 'line', '_gene_', 'treatment', 'and', '_disease_', 'had', 'a', 'synergistic', 'effect']"
2636,1.0,"A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild type MAP2K1 or cells expressing a constitutively active form.","['_abbrev_', 'cells', 'expressing', '_gene_', '_mutation_', 'mutation', 'conferred', 'an', 'approximately', '_chemical_', 'increased', 'resistance', 'to', '_chemical_', '_chemical_', 'induced', 'growth', 'inhibition', 'when', 'compared', 'to', 'untransduced', 'cells', 'cells', 'expressing', 'wild', 'type', '_gene_', 'or', 'cells', 'expressing', 'a', '_disease_', 'active', 'form']"
2637,1.0,"Among the 26 patients with breast cancer and FGFR1/2 amplification (n=25,  n= 21 with FGFR1 amplification only) or FGFR3 mutation (n=1) four (15.4%) had a reduced tumor burden.","['among', 'the', '_num_', 'patients', 'with', 'breast', 'cancer', 'and', '_gene_', 'amplification', '_ineq_', 'n=', '_num_', 'with', '_gene_', 'amplification', 'only', 'or', '_gene_', 'mutation', '_ineq_', '_num_', '_num_', 'had', 'a', 'reduced', 'tumor', 'burden']"
2638,1.0,ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.,"['er', '+ve', 'patients', 'with', 'high', '_gene_', 'tumor', 'expression', 'did', 'not', 'show', 'any', 'difference', 'in', 'survival', 'between', 'tamoxifen', 'and', 'no', 'treatment']"
2639,1.0,364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment.,"['_num_', 'eligible', 'patients', 'with', '_gene_', 'mutations', 'were', 'assigned', 'to', '_chemical_', '_ineq_', 'or', '_chemical_', 'and', '_disease_', '_ineq_', 'treatment']"
2640,1.0,This mutation was found in a VHL type 1 patient (patient no V64).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
2641,1.0,"In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of 3.5 months, tumor regression in 41.9% of patients, and a 1-year overall survival rate of 51%.","['in', 'a', 'phase', 'ii', 'clinical', 'trial', 'of', '_num_', 'melanoma', 'patients', 'harboring', 'kit', 'mutations', 'or', 'amplifications', '_chemical_', 'treatment', 'exhibited', 'significant', 'anti', 'tumor', 'activity', 'with', 'a', 'median', 'progression', 'free', 'survival', 'of', '_num_', 'months', 'tumor', 'regression', 'in', '_num_', 'of', 'patients', 'and', 'a', '_num_', 'year', 'overall', 'survival', 'rate', 'of', '_num_']"
2642,1.0,Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells).,"['cells', 'were', 'derived', 'from', 'a', '_num_', 'year', 'old', 'patient', 'with', '_chemical_', 'resistant', '_gene_', 'mutated', '_mutation_', 'cutaneous', 'melanoma', 'designated', '_num_', '_num_', 'cells']"
2643,1.0,Preclinical models confirmed the result.,"['preclinical', 'models', 'confirmed', 'the', 'result']"
2644,1.0,The combination therapy arm had higher median duration of progression-free survival when compared to the letrozole only group (20.2 months vs. 10.2 months; p<0.0004).,"['the', 'combination', 'therapy', 'arm', 'had', 'higher', 'median', 'duration', 'of', 'progression', 'free', 'survival', 'when', 'compared', 'to', 'the', '_chemical_', 'only', 'group', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_']"
2645,1.0,Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine).,"['_num_', 'children', 'with', 'relapsed', 'or', 'refractory', '_abbrev_', '_disease_', 'received', 'initial', 'therapy', 'with', '_chemical_', 'alone', 'or', 'in', 'combination', 'with', '_chemical_', 'and', '_chemical_']"
2646,1.0,CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA.,"['_gene_', 'cells', 'expressing', 'this', 'variant', 'showed', 'similar', 'sensitivity', 'to', '_chemical_', 'as', 'cells', 'expressing', 'wildtype', '_gene_']"
2647,1.0,"Transfection of mLRP1B4, a fully functional minigene of LRP1B, in IGROV1 and OVCAR4 ovarian cell lines with low expression of LRP1B4 increased sensitivity to liposomal doxorubicin but not doxorubicin.","['transfection', 'of', '_abbrev_', 'a', 'fully', 'functional', 'minigene', 'of', '_gene_', 'in', '_abbrev_', 'and', '_abbrev_', 'ovarian', 'cell', 'lines', 'with', 'low', 'expression', 'of', '_abbrev_', 'increased', 'sensitivity', 'to', '_disease_', 'doxorubicin', 'but', 'not', 'doxorubicin']"
2648,1.0,Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease.,"['germline', 'mutations', 'were', 'found', 'in', 'all', '_num_', 'families', 'that', 'fulfilled', 'clinical', 'criteria', 'of', '_gene_', 'disease']"
2649,1.0,This patient was exome sequenced and two mutations co-occurring in MTOR were identified.,"['this', 'patient', 'was', 'exome', 'sequenced', 'and', '_num_', 'mutations', 'co', 'occurring', 'in', '_gene_', 'were', 'identified']"
2650,1.0,"Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719.","['sensitive', 'cells', '_abbrev_', '_unit_', 'showed', 'reduced', '_gene_', '_gene_', 'western', 'blot', 'levels', 'in', 'response', 'to', '_chemical_', 'treatment', 'while', 'resistant', 'cell', 'lines', '_abbrev_', '_unit_', 'showed', 'significantly', 'less', 'reduction', 'in', '_gene_', 'after', '_chemical_']"
2651,1.0,"In cohort 1, partial response was achieved in ten (38.5%) patients.","['in', 'cohort', '_num_', 'partial', 'response', 'was', 'achieved', 'in', '_num_', '_num_', 'patients']"
2652,1.0,This missense mutation was found in a VHL type 2 family (lineage 3).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
2653,1.0,"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'patients', 'with', 'multiple', 'myeloma', 'enrolled', 'in', 'a', 'clinical', 'trial', '_num_', 'had', 'mutaions', 'in', '_gene_']"
2654,1.0,Median PFS by Choi was 6 [interquartile (IQ) range 3-8] months.,"['median', '_disease_', 'by', 'choi', 'was', '_num_', 'interquartile', 'iq', 'range', '_range_', 'months']"
2655,1.0,This nonsense mutation was found in a suspect VHL mutation carrier by DHPLC (family VHL 110).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', 'suspect', '_gene_', 'mutation', 'carrier', 'by', '_disease_', 'family', '_gene_', '_num_']"
2656,1.0,"Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%).","['_num_', 'discrete', 'mutations', 'in', '_num_', 'codons', 'of', '_gene_', 'exon', '_num_', 'were', 'identified', '_mutation_', '_num_', '_mutation_', '_num_', 'and', '_mutation_', '_num_']"
2657,1.0,"In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response.","['in', 'a', 'phase', '_num_', 'trial', 'of', 'patients', 'with', 'metastatic', 'castration', 'resistant', 'prostate', 'cancer', 'treated', 'with', '_chemical_', 'tablets', 'at', 'a', 'dose', 'of', '_num_', '_unit_', 'twice', 'a', 'day', 'all', '_num_', 'patients', 'harbouring', '_gene_', 'loss', 'of', 'function', 'alleles', 'biallelic', 'somatic', 'loss', 'or', 'germline', 'mutations', 'in', 'combination', 'with', 'somatic', 'copy', 'loss', 'or', 'copy', 'neutral', '_disease_', 'demonstrated', 'a', 'clinical', 'response']"
2658,1.0,"All 6 individuals were identified with cerebellar hemangioblastomas, 4 with angiomas and 3 with renal cell carcinoma.","['all', '_num_', 'individuals', 'were', 'identified', 'with', 'cerebellar', '_disease_', '_num_', 'with', 'angiomas', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
2659,1.0,Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518.,"['murine', 'ba', '_abbrev_', 'cells', 'with', '_abbrev_', 'mutations', 'were', 'evaluated', 'as', 'non', 'responsive', 'to', '_chemical_']"
2660,1.0,"60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of types including: stop gain, splice site, frameshift, etc).","['_num_', 'cases', 'exhibited', '_gene_', 'mutations', 'most', 'of', 'which', 'were', 'likely', '_disease_', 'spread', 'across', 'the', 'gene', 'and', 'of', 'types', 'including', 'stop', 'gain', 'splice', 'site', 'frameshift', 'etc']"
2661,1.0,NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study.,"['_gene_', 'upregulation', 'or', '_gene_', 'amplification', 'were', 'the', 'main', 'causes', 'of', 'resistance', 'to', '_chemical_', 'in', 'vivo', 'and', 'in', 'vitro', 'in', 'this', 'study']"
2662,1.0,The ABCG2 Q141K variant was correlated with  higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.,"['the', '_gene_', '_mutation_', 'variant', 'was', 'correlated', 'with', 'higher', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'in', '_num_', 'ovarian', 'cancer', 'patients', 'treated', 'with', 'platinum', '_chemical_', 'based', 'chemotherapy']"
2663,1.0,Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.,"['colon', 'cancer', 'patient', 'derived', 'xenografts', 'with', '_gene_', 'mutations', 'are', 'sensitive', 'to', '_gene_', 'targeted', 'drugs', 'and', 'the', 'greatest', 'tumor', 'reduction', 'was', 'seen', 'with', 'the', 'combination', 'of', 'a', 'tyrosine', 'kinase', 'inhibitor', 'with', '_chemical_']"
2664,1.0,"Mutations (434; 36%) had no prognostic effect (OBS: HROS=0.99; [95%CI 0.77-1.28], p=0.95; HRDFS=0.99 [0.78-1.25], p=0.92) but were marginally predictive of benefit from ACT for OS (test for interaction: OS: p=0.06; DFS: p=0.11).","['mutations', '_num_', '_num_', 'had', 'no', 'prognostic', 'effect', 'obs', '_ineq_', '_num_', 'ci', '_range_', '_p_val_', '_ineq_', '_range_', '_p_val_', 'but', 'were', 'marginally', 'predictive', 'of', 'benefit', 'from', 'act', 'for', 'os', 'test', 'for', 'interaction', 'os', '_p_val_', '_disease_', '_p_val_']"
2665,1.0,"In the NCT00880321 trial using mutant BRAF inhibitor dabrafenib in solid tumors, 10 cases of melanoma brain metastases were assessed for dabrafenib response.","['in', 'the', '_abbrev_', 'trial', 'using', 'mutant', '_gene_', 'inhibitor', '_chemical_', 'in', 'solid', 'tumors', '_num_', 'cases', 'of', 'melanoma', 'brain', 'metastases', 'were', 'assessed', 'for', '_chemical_', 'response']"
2666,1.0,"In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization.","['in', 'a', 'panel', 'of', '_num_', '_gene_', 'mutant', 'and', '_num_', 'wild', 'type', 'cell', 'lines', 'synergistic', 'effects', 'between', '_gene_', 'inhibitor', '_chemical_', 'and', 'ribociclib', 'were', 'significantly', 'stronger', 'weighted', 'synergy', 'score', 'calculation', 'anova', '_p_val_', 'in', '_gene_', 'mutant', 'cells', 'indicating', 'variant', 'specific', 'sensitization']"
2667,1.0,"Ceritinib inhibited Ba/F3 cells expressing EML4-ALK L1196M slightly stronger than ALK wild type, but approximately double the potency as crizotinib, indicating ceritinib sensitivity in Ba/F3 EML4-ALK L1196M cells.","['_chemical_', 'inhibited', 'ba', '_abbrev_', 'cells', 'expressing', '_chemical_', '_mutation_', 'slightly', 'stronger', 'than', '_gene_', 'wild', 'type', 'but', 'approximately', 'double', 'the', 'potency', 'as', '_chemical_', 'indicating', '_chemical_', 'sensitivity', 'in', 'ba', '_abbrev_', '_chemical_', '_mutation_', 'cells']"
2668,1.0,PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts).,"['_disease_', 'and', 'os', 'was', 'shorter', 'for', 'the', '_gene_', 'high', 'expressing', 'group', '_num_', 'pts', 'than', 'for', 'the', 'low', 'to', 'moderate', 'expression', 'group', '_num_', 'pts']"
2669,1.0,"DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations.","['_gene_', 'mutations', 'associate', 'with', 'adverse', 'overall', 'survival', 'in', 'acute', 'myeloid', 'leukemia', 'patients', 'if', 'they', 'occur', 'in', 'the', 'context', 'of', 'mutated', '_gene_', 'and', '_gene_', '_abbrev_', 'phenotype', 'and', 'in', 'the', 'context', 'of', '_gene_', 'codon', '_chemical_', 'mutations']"
2670,1.0,16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to control ≤ 20%).,"['_num_', 'xenografts', 'showed', 'sensitivity', 'as', 'defined', 'by', '_disease_', 'tumor', 'growth', 'of', 'treated', 'compared', 'to', 'control', '≤', '_num_']"
2671,1.0,"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients.","['in', 'recurrent', 'lung', 'cancer', 'patients', 'treated', 'with', 'the', 'epidermal', 'growth', 'factor', 'receptor', 'tyrosine', 'kinase', 'inhibitor', '_chemical_', 'patients', 'with', '_gene_', 'mutations', 'had', 'a', 'lower', 'frequency', 'of', 'partial', 'response', 'pr', 'and', 'stable', 'disease', 'sd', 'and', 'a', 'higher', 'rate', 'of', 'progressive', 'disease', 'pd', 'pr:0', 'sd:1', 'pd:15', 'vs', 'pr:24', 'sd:8', 'pd:14', '_p_val_', 'compared', 'to', 'wildtype', '_gene_', 'patients']"
2672,1.0,"The degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients.","['the', 'degree', 'of', '_gene_', 'mrna', 'expression', 'was', 'highly', 'correlated', 'with', 'the', '_gene_', 'promoter', 'methylation', 'status', 'p', '_num_', 'however', 'discordant', 'findings', 'were', 'seen', 'in', '_num_', 'glioblastoma', 'patients']"
2673,1.0,"There were minimal lung, humerus and T9 spine metastases, and exhibited a very good response to the radioactive iodine treatment after he had underwent total thyroidectomy and bilateral neck dissection.","['there', 'were', 'minimal', 'lung', 'humerus', 'and', '_chemical_', 'spine', 'metastases', 'and', 'exhibited', 'a', 'very', 'good', 'response', 'to', 'the', 'radioactive', 'iodine', 'treatment', 'after', 'he', 'had', 'underwent', 'total', 'thyroidectomy', 'and', 'bilateral', 'neck', 'dissection']"
2674,1.0,Four wildtype patients had stable or progressive disease.,"['_num_', 'wildtype', 'patients', 'had', 'stable', 'or', 'progressive', 'disease']"
2675,1.0,82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients).,"['_num_', 'patients', 'treated', 'with', '_chemical_', 'were', 'retrospectively', 'analyzed', 'for', '_gene_', 'mrna', 'expression', 'rt', 'pcr', 'in', '_num_', 'patients']"
2676,1.0,Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.,"['oral', '_chemical_', 'showed', 'objective', 'response', 'rates', 'of', '_num_', 'and', '_num_', 'respectively', 'in', 'prior', '_chemical_', 'and', '_chemical_', 'naive', 'cohorts', 'in', 'a', 'phase', 'ii', 'trial', 'with', 'a', 'primary', 'endpoint', 'of', '_num_', 'week', 'progression', 'free', 'survival']"
2677,1.0,EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not significantly associated with patient survival.,"['_gene_', 'overexpression', 'was', 'found', 'in', '_num_', '_num_', 'cancers', 'by', 'immunohistochemistry', 'and', 'not', 'significantly', 'associated', 'with', 'patient', 'survival']"
2678,1.0,"KRAS wild type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib","['_gene_', 'wild', 'type', 'but', 'not', '_gene_', 'mutant', 'tumors', 'were', 'sensitive', 'to', 'proteasome', 'inhibitor', '_chemical_']"
2679,1.0,The patient has received 400mg Imatinib daily for 10 years.,"['the', 'patient', 'has', 'received', '_unit_', '_chemical_', 'daily', 'for', '_num_', 'years']"
2680,1.0,58 patients with advanced solid tumors were treated.,"['_num_', 'patients', 'with', 'advanced', 'solid', 'tumors', 'were', 'treated']"
2681,1.0,"In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild type patients.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'adenocarcinoma', 'of', 'the', 'pancreas', 'who', 'underwent', 'a', 'pancreaticoduodenectomy', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'shorter', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
2682,1.0,A NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the progressive tumor.,"['a', '_gene_', 'exon', '_num_', '_mutation_', 'c', '_unit_', 'a', 'mutation', 'was', 'identified', 'in', 'the', 'progressive', 'tumor']"
2683,1.0,In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines.,"['in', 'vivo', 'analysis', 'of', '_mutation_', 'and', '_mutation_', 'mutant', 'cell', 'lines', 'showed', 'regression', 'of', '_mutation_', 'and', 'tumor', 'growth', 'delay', 'of', '_mutation_', 'mutant', 'cell', 'lines']"
2684,1.0,Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.,"['_chemical_', 'resistance', 'is', 'associated', 'with', 'gain', 'of', '_abbrev_', 'mutation', 'in', 'nras']"
2685,1.0,"A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild type EGFR.","['a', 'variant', 'of', '_gene_', 'with', 'exon', '_num_', 'deletion', '_abbrev_', '_gene_', 'enhanced', 'the', '_disease_', 'and', '_disease_', 'resistance', 'of', 'epithelial', 'ovarian', 'cancer', 'cell', 'lines', '_abbrev_', '_abbrev_', '_gene_', 'in', 'vitro', 'when', 'compared', 'with', 'wild', 'type', '_gene_']"
2686,1.0,"In addition, these cell lines showed resistance to foretinib, a potent ROS1 inhibitor that is effective against ROS1 G2032R-mutant cells (16), and TAE684, a potent ALK inhibitor","['in', 'addition', 'these', 'cell', 'lines', 'showed', 'resistance', 'to', '_chemical_', 'a', 'potent', '_gene_', 'inhibitor', 'that', 'is', 'effective', 'against', '_gene_', '_abbrev_', 'cells', '_num_', 'and', '_chemical_', 'a', 'potent', '_gene_', 'inhibitor']"
2687,1.0,"Patients with EGFR mutations treated with gefitinib were associated with improved response rates (42.1% vs. 6.6%, P=0.04) compared to wildtype EGFR patients.","['patients', 'with', '_gene_', 'mutations', 'treated', 'with', '_chemical_', 'were', 'associated', 'with', 'improved', 'response', 'rates', '_num_', 'vs', '_num_', '_p_val_', 'compared', 'to', 'wildtype', '_gene_', 'patients']"
2688,1.0,Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1).,"['deep', 'sequencing', 'revealed', 'an', '_gene_', '_abbrev_', 'mutation', 'in', 'the', 'resistant', 'clone', '_gene_']"
2689,1.0,The F359V mutation was moderately resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
2690,1.0,Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.,"['_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'shorter', 'overall', 'survival', 'and', 'increased', 'metastasis', 'in', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma']"
2691,1.0,"72 patients had wild type KRAS, 147 had a codon-12 KRAS mutation (G12D, G12V, or G12R) and 73 had a G12D KRAS mutation, specifically.","['_num_', 'patients', 'had', 'wild', 'type', '_gene_', '_num_', 'had', 'a', '_abbrev_', '_gene_', 'mutation', '_mutation_', '_mutation_', 'or', '_mutation_', 'and', '_num_', 'had', 'a', '_mutation_', '_gene_', 'mutation', 'specifically']"
2692,1.0,Expression of the S463P mutant was found to induce modest activity in the absence of hormone.,"['expression', 'of', 'the', '_mutation_', 'mutant', 'was', 'found', 'to', 'induce', 'modest', 'activity', 'in', 'the', 'absence', 'of', 'hormone']"
2693,1.0,"A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 patient with retinal angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.","['a', 'missense', 'mutation', 'affecting', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
2694,1.0,"In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response.","['in', 'a', 'phase', '_num_', 'study', '_abbrev_', 'patients', 'with', 'lung', 'adenocarcinoma', 'stage', '_disease_', 'with', 'pleural', 'effusion', 'or', 'stage', 'iv', 'and', '_gene_', 'mutations', 'treated', 'with', '_chemical_', 'were', 'assessed', 'by', 'objective', 'response']"
2695,1.0,DDX43 Expression (qPCR) was higher in nonresponders (P = 0.045).,"['_gene_', 'expression', 'qpcr', 'was', 'higher', 'in', 'nonresponders', 'p', '_num_']"
2696,1.0,"Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions.","['radiation', 'and', 'taselisib', 'treatments', 'alone', 'showed', 'some', 'growth', 'inhibition', 'in', 'comparison', 'to', 'control', 'but', 'only', 'the', 'combined', 'treatment', 'led', 'durable', 'tumor', 'regressions']"
2697,1.0,"Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90.","['incubation', 'of', '_chemical_', 'variant', '_num_', 'transduced', 'ba', '_abbrev_', 'cells', 'with', '_gene_', 'inhibitor', '_chemical_', 'caused', 'cell', 'death', 'that', 'was', 'reversible', 'with', '_gene_', 'addition', 'suggesting', 'that', '_chemical_', 'was', 'effecting', 'the', '_chemical_', 'driver', 'of', '_abbrev_', 'proliferation', 'and', 'that', '_chemical_', 'variant', '_num_', 'is', 'a', 'client', 'protein', 'of', '_gene_']"
2698,1.0,"In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib.","['in', 'this', 'phase', '_num_', 'trial', '_num_', 'patients', 'with', 'advanced', 'solid', 'tumors', 'ovarian', 'breast', 'colorectal', 'melanoma', 'sarcoma', 'prostate', 'were', 'treated', 'with', '_gene_', 'inhibitor', '_chemical_']"
2699,1.0,Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.,"['_num_', 'patients', 'with', 'acquired', 'resistance', 'to', '_chemical_', 'showed', 'high', 'concentration', 'of', '_gene_', 'in', 'malignant', 'pleural', 'effusions']"
2700,1.0,ERBB4 protein expression was identified in breast cancer cell lines with acquired lapatinib resistance.,"['_gene_', 'protein', 'expression', 'was', 'identified', 'in', 'breast', 'cancer', 'cell', 'lines', 'with', 'acquired', '_chemical_', 'resistance']"
2701,1.0,Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC).,"['expression', 'of', '_gene_', 'and', '_gene_', 'were', 'evaluated', 'in', '_num_', 'biopsy', 'specimens', 'of', 'primary', '_disease_', '_gene_']"
2702,1.0,"The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor.","['the', 'resistant', 'tumor', 'had', 'a', 'somatic', 'mutation', 'in', '_gene_', '_abbrev_', 'that', 'was', 'not', 'detected', 'in', 'the', 'pretreatment', 'tumor']"
2703,1.0,PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines.,"['_chemical_', 'efficacy', 'proliferation', 'assay', 'was', 'assessed', 'in', 'a', 'panel', 'of', '_num_', 'melanoma', 'cell', 'lines']"
2704,1.0,Overall clinicopathological implications of BRAF V600E and D594G mutant tumors were similar but BRAF D594G mutations were more likely to be left-sided tumors (85.7% vs. 31.1%; p<0.0098) and they were more likely to present as metastatic tumors (71.4% vs. 28.9%; p<0.04) than BRAF V600E mutant tumors.,"['overall', 'clinicopathological', 'implications', 'of', '_gene_', '_mutation_', 'and', '_mutation_', 'mutant', 'tumors', 'were', 'similar', 'but', '_gene_', '_mutation_', 'mutations', 'were', 'more', 'likely', 'to', 'be', 'left', 'sided', 'tumors', '_num_', 'vs', '_num_', 'p', '_num_', 'and', 'they', 'were', 'more', 'likely', 'to', 'present', 'as', 'metastatic', 'tumors', '_num_', 'vs', '_num_', 'p', '_num_', 'than', '_gene_', '_mutation_', 'mutant', 'tumors']"
2705,0.0,Next-generation sequencing (NGS) often identifies mutations with unclear clinical or prognostic implications.,"['next', 'generation', 'sequencing', 'ngs', 'often', 'identifies', 'mutations', 'with', 'unclear', 'clinical', 'or', 'prognostic', 'implications']"
2706,1.0,Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.,"['response', 'rates', 'are', 'higher', 'in', '_gene_', 'mutation', 'positive', 'women', 'with', 'high', 'grade', 'serous', 'or', 'undifferentiated', 'ovarian', 'cancer']"
2707,1.0,"Ba/F3 cells expressing EML4-ALK variant 3 with ALK I1171T mutation were treated with ceritinib, and survival IC50 of 2.6 nM was observed, which compares favorably with highly ceritinib sensitive EML4-ALK wild type variant 1 survival IC50 of 1.7 nM reported from parallel experiments.","['ba', '_abbrev_', 'cells', 'expressing', '_chemical_', 'variant', '_num_', 'with', '_gene_', '_mutation_', 'mutation', 'were', 'treated', 'with', '_chemical_', 'and', 'survival', '_abbrev_', 'of', '_num_', '_unit_', 'was', 'observed', 'which', 'compares', 'favorably', 'with', 'highly', '_chemical_', 'sensitive', '_chemical_', 'wild', 'type', 'variant', '_num_', 'survival', '_abbrev_', 'of', '_num_', '_unit_', 'reported', 'from', 'parallel', 'experiments']"
2708,1.0,"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.","['in', 'part', '_num_', 'of', 'a', '_num_', 'part', 'dose', 'escalation', 'phase', 'i', 'trial', '_abbrev_', '_num_', 'patients', 'with', 'ewings', 'sarcoma', 'breast', 'ovarian', 'small', 'cell', 'lung', 'or', 'pancreatic', 'cancers', 'received', '_num_', '_disease_', '_chemical_', 'treatment']"
2709,1.0,This mutation was found in a VHL type 1 patient (patient V59).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', '_abbrev_']"
2710,1.0,These data suggest no difference in ORR or PFS with combination therapy of over monotherapy in KRAS mutant and KRAS wild type advanced NSCLC.,"['these', 'data', 'suggest', 'no', 'difference', 'in', 'orr', 'or', '_disease_', 'with', 'combination', 'therapy', 'of', 'over', 'monotherapy', 'in', '_gene_', 'mutant', 'and', '_gene_', 'wild', 'type', 'advanced', '_disease_']"
2711,1.0,ie the synergy score was low in cells having low basal levels of ERBB3 protein and high for cells having high basal ERBB3 expression.,"['ie', 'the', 'synergy', 'score', 'was', 'low', 'in', 'cells', 'having', 'low', 'basal', 'levels', 'of', '_gene_', 'protein', 'and', 'high', 'for', 'cells', 'having', 'high', 'basal', '_gene_', 'expression']"
2712,1.0,"In the intention-to-treat population, the median duration of progression-free survival was 4.8 months in the trametinib group as compared with 1.5 months in the chemotherapy group (hazard ratio for progression, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001).","['in', 'the', '_disease_', 'population', 'the', 'median', 'duration', 'of', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'in', 'the', '_chemical_', 'group', 'as', 'compared', 'with', '_num_', 'months', 'in', 'the', 'chemotherapy', 'group', 'hazard', 'ratio', 'for', 'progression', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
2713,1.0,Therapy was reinstated after worsening of disease.,"['therapy', 'was', 'reinstated', 'after', 'worsening', 'of', 'disease']"
2714,1.0,TERT promoter mutation C228T is significantly associated with BRAF V600E mutation in papillary thyroid cancer(PTC).,"['_gene_', 'promoter', 'mutation', '_mutation_', 'is', 'significantly', 'associated', 'with', '_gene_', '_mutation_', 'mutation', 'in', 'papillary', 'thyroid', 'cancer', '_gene_']"
2715,0.0,"Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT.","['fluorescence', 'in', '_disease_', 'hybridization', 'with', 'a', 'probe', 'flanking', 'the', '_gene_', 'gene', 'at', '2p23', 'and', 'immunohistochemistry', 'revealed', '_gene_', 'expression', 'suggesting', '_gene_', 'fusions', 'in', '_num_', 'cases', 'of', '_disease_']"
2716,1.0,CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations.,"['_chemical_', 'was', 'effective', 'in', 'reducing', 'blast', 'counts', 'of', '_ratio_', 'heavily', '_gene_', 'treated', '_disease_', 'patients', 'with', '_gene_', 'mutations']"
2717,1.0,"non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations","['_abbrev_', '_gene_', 'mutations', 'can', 'be', 'sensitive', 'to', 'clinically', 'relevant', 'doses', 'of', '_chemical_', 'and', '_chemical_', 'in', '_chemical_', 'cells', 'in', 'lung', 'epithelial', 'cellular', 'model', '_chemical_', 'and', 'in', 'human', 'cancer', 'cell', 'lines', 'harboring', '_abbrev_', '_gene_', 'mutations']"
2718,1.0,"In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab.","['in', 'this', 'retrospective', '_chemical_', 'analysis', 'of', 'the', 'expert', 'c', 'trial', 'patients', 'with', '_gene_', 'wild', 'type', 'status', 'had', 'a', 'statistically', 'significant', 'better', 'progression', 'free', 'survival', '_disease_', '_num_', 'vs', '_num_', 'at', '_num_', 'years', 'hazard', 'ratio', 'hr', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', '_num_', 'sided', 'p', '_num_', 'by', 'cox', 'regression', 'and', 'overall', 'survival', 'os', '_num_', 'vs', '_num_', 'at', '_num_', 'years', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_num_', 'sided', 'p', '_num_', 'by', 'cox', 'regression', 'when', 'treated', 'with', '_chemical_', 'capox', '_chemical_', '_chemical_', 'than', 'in', 'the', 'control', 'arm', 'without', '_chemical_']"
2719,1.0,"In 530 patients with colorectal cancer not using aspirin, the frequency of PIK3CA mutations was 17% (90/530).","['in', '_num_', 'patients', 'with', 'colorectal', 'cancer', 'not', 'using', 'aspirin', 'the', 'frequency', 'of', '_gene_', 'mutations', 'was', '_num_', '_ratio_']"
2720,1.0,"In S47/wild type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found.","['in', '_abbrev_', 'type', 'heterozygote', 'mice', 'an', 'increased', 'cancer', 'incidence', 'with', 'a', 'predisposition', 'for', '_disease_', 'carcinoma', 'was', 'also', 'found']"
2721,1.0,Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy.,"['cytoplasmic', 'localization', 'of', '_gene_', 'in', '_disease_', 'patients', 'was', 'associated', 'with', 'good', 'response', 'to', 'induction', 'therapy']"
2722,1.0,"Survival IC50 value of 177 nM was reported, which is 9.3 times the IC50 reported for crizotinib in EML4-ALK wild type Ba/F3 cells.","['survival', '_abbrev_', 'value', 'of', '_num_', '_unit_', 'was', 'reported', 'which', 'is', '_num_', 'times', 'the', '_abbrev_', 'reported', 'for', '_chemical_', 'in', '_chemical_', 'wild', 'type', 'ba', '_abbrev_', 'cells']"
2723,1.0,Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.,"['sensitivity', 'to', 'platinum', 'was', 'defined', 'by', 'maintenance', 'of', 'complete', 'response', 'greater', 'than', '_num_', 'months', 'post', 'platinum', 'based', 'therapy']"
2724,1.0,"Of the 42 patients treated with trametinib/pemetrexed, 14% (6/42) had a PR; the ORR was 17% (4/23) in KRAS-mutated NSCLC versus 11% (2/19) in KRAS wild type NSCLC.","['of', 'the', '_num_', 'patients', 'treated', 'with', '_chemical_', '_chemical_', '_num_', '_ratio_', 'had', 'a', 'pr', 'the', 'orr', 'was', '_num_', '_ratio_', 'in', '_gene_', 'mutated', '_disease_', 'vs', '_num_', '_ratio_', 'in', '_gene_', 'wild', 'type', '_disease_']"
2725,1.0,"In the subgroup of FGFR1-amplified NSCLC, 36 patients were treated at doses >100mg and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks.","['in', 'the', 'subgroup', 'of', '_abbrev_', '_disease_', '_num_', 'patients', 'were', 'treated', 'at', 'doses', '_unit_', 'and', 'disease', 'control', 'was', 'achieved', 'in', '_num_', 'of', 'patients', '_num_', 'pr', 'and', '_num_', 'sd', 'with', '_num_', 'patients', 'receiving', 'treatment', 'after', '_num_', 'weeks']"
2726,1.0,BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2).,"['_gene_', 'and', 'mek', 'inhibition', 'was', 'either', 'dabrafenib+trametinib', 'case', '_num_', 'or', 'vemurafenib+trametinib', 'case', '_num_']"
2727,1.0,"This variant, identified in two patients was confirmed to be a somatic mutation in both patients' microsatellite-unstable tumors (one endometrial cancer, one ovarian cancer) with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', '_num_', 'patients', 'was', 'confirmed', 'to', 'be', 'a', 'somatic', 'mutation', 'in', 'both', 'patients', '_disease_', 'tumors', '_num_', 'endometrial', 'cancer', '_num_', 'ovarian', 'cancer', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
2728,1.0,"This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen.","['this', 'finding', 'could', 'be', 'reproduced', 'in', 'colorectal', 'and', 'lung', 'cancer', 'cell', 'lines', 'in', 'a', '_num_', 'independent', 'screen']"
2729,1.0,The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs.,"['the', 'mutation', 'was', 'shown', 'to', 'occur', 'at', 'a', 'hotspot', '_abbrev_', 'of', 'previously', 'reported', 'secondary', 'kit', 'mutations', 'in', '_chemical_', 'resistant', 'gists']"
2730,1.0,V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).,"['_mutation_', 'is', 'correlated', 'with', 'disease', 'recurrence', 'in', 'both', 'age', 'cohorts', '_num_', 'and', '_num_', '_age_']"
2731,1.0,"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.","['in', '_disease_', 'patients', 'with', '_gene_', 'mutations', 'concurrent', '_gene_', 'mutations', 'were', 'associated', 'with', 'worse', 'overall', 'survival', 'compared', 'to', 'those', 'without', '_gene_', 'mutation']"
2732,1.0,"Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells.","['finally', '_chemical_', 'and', '_chemical_', 'showed', 'a', 'synergistic', 'effect', 'in', 'killing', '_chemical_', 'variant', '_num_', 'cells']"
2733,1.0,Recurrent splice site mutations that result in exon 14 skipping have been observed in ~3% of all lung cancers.,"['recurrent', 'splice', 'site', 'mutations', 'that', 'result', 'in', 'exon', '_num_', 'skipping', 'have', 'been', 'observed', 'in', '_num_', 'of', 'all', 'lung', 'cancers']"
2734,1.0,Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.,"['patients', 'in', 'the', 'pembrolizumab', 'group', 'exhibited', 'significantly', 'better', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'compared', 'to', 'patients', 'in', 'the', 'chemotherapy', 'group']"
2735,1.0,This mutation was found in 2 VHL type 1 family members with cerebellar hemangioblastomas.,"['this', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'family', 'members', 'with', 'cerebellar', '_disease_']"
2736,1.0,"In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype.","['in', 'leukemia', 'patients', '_gene_', '_abbrev_', 'mutation', 'is', 'associated', 'with', 'adults', 'and', 'normal', 'karyotype']"
2737,1.0,"Cancers with non-V600 BRAF mutations, compared with cancers with V600E mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively).","['cancers', 'with', '_abbrev_', '_gene_', 'mutations', 'compared', 'with', 'cancers', 'with', '_mutation_', 'mutations', 'were', 'found', 'in', 'patients', 'who', 'were', 'significantly', 'younger', '_num_', 'v', '_num_', 'years', 'respectively', 'fewer', 'female', 'patients', '_num_', 'v', '_num_', 'respectively', 'and', 'patients', 'who', 'had', 'fewer', 'high', 'grade', 'tumors', '_num_', 'v', '_num_', 'respectively', 'or', '_disease_', 'primary', 'tumors', '_num_', 'v', '_num_', 'respectively']"
2738,1.0,"In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 patients with uncommon mutations of unknown clinical significance (UMUCS) in EGFR exons 18-21 responded at a rate of 47.5% (primarily G719 and L861, N=30/61).","['in', 'a', 'cohort', 'of', '_disease_', 'patients', 'treated', 'with', 'tyrosine', 'kinase', 'inhibitors', '_chemical_', 'or', '_chemical_', '_num_', 'patients', 'with', 'uncommon', 'mutations', 'of', 'unknown', 'clinical', 'significance', 'umucs', 'in', '_gene_', 'exons', '_range_', 'responded', 'at', 'a', 'rate', 'of', '_num_', 'primarily', '_abbrev_', 'and', '_abbrev_', '_ineq_']"
2739,1.0,"While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, we state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans.","['while', '_num_', '_disease_', '_chemical_', 'in', 'mice', 'approximates', 'levels', '_range_', 'times', 'the', 'maximal', 'tolerated', 'dose', 'in', 'humans', 'we', 'state', '_num_', 'to', '_num_', '_disease_', '_chemical_', 'in', 'mice', 'is', 'predicted', 'to', 'approximate', 'tolerable', 'doses', 'in', 'humans']"
2740,1.0,Distant disease-free survival and time to distant recurrence were similar in both groups.,"['distant', '_disease_', 'survival', 'and', 'time', 'to', 'distant', 'recurrence', 'were', 'similar', 'in', 'both', 'groups']"
2741,0.0,"This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma.","['this', 'study', 'collected', 'data', 'on', '_gene_', 'ssx', 'fusion', 'type', 'pathology', 'and', 'clinical', 'course', 'in', 'a', 'retrospective', 'multi', 'institutional', 'study', 'of', '_num_', 'patients', 'age', 'range', '_range_', 'with', 'synovial', 'sarcoma']"
2742,1.0,A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib.,"['a', 'patient', 'with', 'met', 'c', '3028+1g', 't', 'mutation', '_abbrev_', 'had', 'partial', 'response', 'tumor', 'reduction', 'of', '_num_', 'after', '_num_', 'months', 'capmatinib']"
2743,1.0,The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment.,"['the', 'patient', 'had', 'multiple', 'lines', 'of', 'prior', 'treatment', 'and', 'showed', 'a', 'partial', 'response', 'to', '_num_', 'time', '_chemical_', 'treatment']"
2744,1.0,Rb positive and palbociclib responsive GBM cell line U87MG was treated with shRNA against Rb.,"['rb', 'positive', 'and', '_chemical_', 'responsive', '_disease_', 'cell', 'line', '_gene_', 'was', 'treated', 'with', 'shrna', 'against', 'rb']"
2745,1.0,51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study.,"['_num_', 'epithelial', 'and', '_num_', '_disease_', 'tube', 'frozen', 'tumors', 'were', 'analyzed', 'for', 'this', 'study']"
2746,1.0,The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.,"['the', 'mutation', '_mutation_', 'in', 'the', '_gene_', 'domain', 'of', '_gene_', 'in', 'the', '_disease_', 'fusion', 'was', 'seen', 'in', 'a', 'patient', 'with', 'atra', 'resistant', 'acute', 'promyelocytic', 'leukemia']"
2747,1.0,A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.,"['a', 'single', 'patient', 'with', '_gene_', '_abbrev_', 'bi', 'allelic', 'mutation', 'responded', 'to', 'the', '_mutation_', 'drug', '_chemical_']"
2748,1.0,"However, based on this study we can infer that the variant may predispose to LS in a germline setting.","['however', 'based', 'on', 'this', 'study', 'we', 'can', 'infer', 'that', 'the', 'variant', 'may', 'predispose', 'to', 'ls', 'in', 'a', 'germline', 'setting']"
2749,1.0,Meta-analysis of 2 studies of CHEK2 and prostate cancer showing that the IVS2+1G>A mutation is irrelevant as a predictor of prostate cancer.,"['_disease_', 'analysis', 'of', '_num_', 'studies', 'of', '_gene_', 'and', 'prostate', 'cancer', 'showing', 'that', 'the', '_abbrev_', 'a', 'mutation', 'is', 'irrelevant', 'as', 'a', 'predictor', 'of', 'prostate', 'cancer']"
2750,1.0,"In an in vitro study, Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.44-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib).","['in', 'an', 'in', 'vitro', 'study', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'gene', 'fusion', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein', 'reported', 'to', 'be', 'sensitizing', 'to', '_chemical_']"
2751,1.0,"In multivariate Cox proportional hazard analysis, the T393C polymorphism was an independent prognostic factor for clinical outcome.","['in', 'multivariate', 'cox', 'proportional', 'hazard', 'analysis', 'the', '_mutation_', 'polymorphism', 'was', 'an', 'independent', 'prognostic', 'factor', 'for', 'clinical', 'outcome']"
2752,1.0,ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.,"['acmg', 'evidence', 'codes', ""'pp2"", 'because', 'they', 'observe', 'a', 'missense', 'variant', 'in', 'a', 'gene', 'where', 'missense', 'variants', 'are', 'a', 'common', 'mechanism', 'of', 'disease']"
2753,1.0,Ectopic expression of EML4-ALK V1180L rendered Ba/F3 cells moderately less susceptible to crizotinib than ectopic EML4-ALK.,"['ectopic', 'expression', 'of', '_chemical_', '_mutation_', 'rendered', 'ba', '_abbrev_', 'cells', 'moderately', 'less', 'susceptible', 'to', '_chemical_', 'than', 'ectopic', '_chemical_']"
2754,1.0,This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (ACMG code: PS4).,"['this', 'study', 'contains', 'strong', 'evidence', 'of', 'pathogenicity', 'for', 'this', 'variant', 'because', 'the', 'prevalence', 'of', 'the', 'variant', 'in', 'affected', 'individuals', 'is', 'significantly', 'increased', 'compared', 'with', 'the', 'prevalence', 'in', 'controls', 'acmg', 'code', '_gene_']"
2755,1.0,"These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab.","['these', 'patients', 'did', 'not', 'show', 'a', 'difference', 'in', 'outcome', 'after', '_chemical_', '_chemical_', 'and', 'chemoradiotherapy', 'with', 'or', 'without', '_chemical_']"
2756,1.0,"This missense mutation was found in a Slovakian, VHL type 1 family of 13 affected individuals.","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'slovakian', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'affected', 'individuals']"
2757,1.0,"The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway.","['the', 'same', 'was', 'found', 'when', '_gene_', 'mutations', '_gene_', 'loss', 'and', '_gene_', '_mutation_', 'mutations', 'were', 'combinedly', 'analyzed', 'as', 'hyperactive', '_gene_', 'pathway']"
2758,1.0,"The study found that among an augmented cohort of breast cancer patients with the variant, there was a hazard ratio of 6.1 (p=.01).","['the', 'study', 'found', 'that', 'among', 'an', 'augmented', 'cohort', 'of', 'breast', 'cancer', 'patients', 'with', 'the', 'variant', 'there', 'was', 'a', 'hazard', 'ratio', 'of', '_num_', 'p=', '_num_']"
2759,1.0,Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels.,"['treatment', 'of', 'cells', 'obtained', 'from', 'mmtv', '_disease_', 'mouse', 'mammary', 'tumors', 'with', 'the', '_gene_', 'selective', 'inhibitor', '_chemical_', 'showed', 'significant', 'but', 'minimal', 'reductions', 'in', 'lipid', 'kinase', 'activity', 'and', 'negligible', 'reductions', 'in', '_chemical_', '_gene_', 'levels']"
2760,1.0,Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.,"['patients', 'had', '_num_', 'weeks', 'or', 'greater', 'previous', '_chemical_', 'treatment', 'with', 'time', 'since', 'end', 'of', 'last', 'cycle', 'less', 'than', '_num_', 'weeks']"
2761,1.0,Baseline biopsies were obtained before therapy initiation with pembrolizumab.,"['baseline', 'biopsies', 'were', 'obtained', 'before', 'therapy', 'initiation', 'with', 'pembrolizumab']"
2762,1.0,Docetaxel was discontinued after 22 cycles because of edema and fatigue.,"['_chemical_', 'was', 'discontinued', 'after', '_num_', 'cycles', 'because', 'of', 'edema', 'and', 'fatigue']"
2763,1.0,11 cases had the same mutation resulting in a predicted amino acid substitution of A149S.,"['_num_', 'cases', 'had', 'the', 'same', 'mutation', 'resulting', 'in', 'a', 'predicted', 'amino', 'acid', 'substitution', 'of', '_mutation_']"
2764,1.0,"Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed.","['other', 'clinical', 'manifestations', 'outside', 'of', 'a', 'pancreatic', 'neuroendocrine', 'tumor', 'are', 'possible', 'but', 'were', 'not', 'discussed']"
2765,1.0,Only moderate evidence for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'in', 'frame', 'deletion', 'in', 'a', 'nonrepeat', 'region', 'acmg', 'code', '_abbrev_']"
2766,1.0,Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and panitumumab).,"['_num_', 'patients', 'with', 'stage', 'iv', '_gene_', '_mutation_', 'mutations', 'received', 'anti', '_gene_', 'antibody', 'therapy', '_chemical_', 'and', 'panitumumab']"
2767,1.0,"Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed.","['event', 'free', 'survival', 'was', 'significantly', 'improved', 'in', 'patients', 'with', 'both', '_gene_', 'and', '_gene_', 'mutations', 'compared', 'to', 'patients', 'with', '_num_', '_gene_', 'mutations', 'alone', '_num_', 'either', '_gene_', 'or', '_gene_', 'when', '_gene_', 'patients', 'were', 'excluded', 'from', 'the', 'analysis', '_num_', 'neither', '_gene_', 'or', '_gene_', 'mutations', 'or', '_gene_', 'alone', 'when', 'only', 'de', 'novo', 'normal', 'karyotype', 'patients', 'were', 'analyzed']"
2768,1.0,"In patients with FGFR2 fusions, 1 patient with urothelial cancer had a PR harbored FGFR2-BICC1/FGFR2-CASP7 fusions, a patient with endometrial cancer and synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR, and tumor shrinkage was observed in a patient with adrenal carcinoma and FGFR3-TACC3/FGFR2-CCDC6 fusions.","['in', 'patients', 'with', '_gene_', 'fusions', '_num_', 'patient', 'with', 'urothelial', 'cancer', 'had', 'a', 'pr', 'harbored', '_abbrev_', 'fusions', 'a', 'patient', 'with', 'endometrial', 'cancer', 'and', 'synchronous', '_abbrev_', 'and', '_abbrev_', 'fusions', 'had', 'a', 'pr', 'and', 'tumor', 'shrinkage', 'was', 'observed', 'in', 'a', 'patient', 'with', 'adrenal', 'carcinoma', 'and', '_abbrev_', 'fusions']"
2769,1.0,Patients were stratified as having high or low ActA levels using the median expression level.,"['patients', 'were', 'stratified', 'as', 'having', 'high', 'or', 'low', '_gene_', 'levels', 'using', 'the', 'median', 'expression', 'level']"
2770,1.0,"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations and wildtype BRAF (n=10), including A146T (N=3), G15D (N=1), and V152M/NRAS V160A, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild type KRAS, NRAS and BRAF.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'treatment', 'naive', 'metastatic', 'colorectal', 'cancer', 'patients', 'patients', 'with', 'ras', 'mutations', 'and', 'wildtype', '_gene_', '_gene_', 'including', '_mutation_', '_ineq_', '_mutation_', '_ineq_', 'and', '_abbrev_', '_mutation_', 'treated', 'with', '_chemical_', 'plus', '_chemical_', 'were', 'associated', 'with', 'decreased', 'overall', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'and', 'decreased', 'progression', 'free', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', 'nras', 'and', '_gene_']"
2771,1.0,DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.,"['_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_abbrev_', 'were', 'associated', 'with', 'reduced', '_disease_', 'survival', 'in', 'patients', 'with', 'cytogenetically', 'normal', '_disease_']"
2772,1.0,In-vitro studies also did not show any effects.,"['in', 'vitro', 'studies', 'also', 'did', 'not', 'show', 'any', 'effects']"
2773,1.0,"An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).","['an', 'evaluation', 'of', 'alternative', 'strategies', 'for', 'detection', 'of', 'ews', '_gene_', 'fish', 'break', 'apart', 'fish', 'fusion', 'and', '_disease_']"
2774,1.0,Only supporting evidence for pathogenicity because patient's phenotyoe is highly specific for a disease with a single genetic etiology (ACMG code: PP4).,"['only', 'supporting', 'evidence', 'for', 'pathogenicity', 'because', 'patient', ""'s"", 'phenotyoe', 'is', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'a', 'single', 'genetic', 'etiology', 'acmg', 'code', '_gene_']"
2775,1.0,"Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1.","['addition', 'of', '_chemical_', 'to', '_chemical_', 'caused', 'synergistic', 'death', 'effects', 'suggesting', 'potential', 'clinical', 'benefit', 'for', 'this', 'inhibitor', 'combination', 'in', 'targeting', '_chemical_', 'variant', '_num_']"
2776,1.0,"While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.","['while', 'all', 'constructs', 'rendered', 'ba', '_abbrev_', 'cells', '_abbrev_', 'marked', 'differences', 'in', 'sensitivity', 'to', '_gene_', 'inhibitors', '_chemical_', 'and', '_chemical_', 'were', 'observed', 'where', '_abbrev_', 'was', 'most', 'sensitized', 'to', 'growth', 'inhibition', 'and', '_abbrev_', 'the', 'least', 'with', '_abbrev_', 'and', '_abbrev_', 'intermediate']"
2777,1.0,"In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation.","['in', 'the', 'phase', 'iii', 'study', 'of', '_chemical_', 'vs', '_chemical_', '_abbrev_', '_abbrev_', 'in', 'metastatic', 'melanoma', '_num_', 'patients', 'were', 'confirmed', 'to', 'have', '_mutation_', 'mutation']"
2778,1.0,"Two of 3 members carried angiomas, one carried cerebellar hemangioblastomas and one with renal cell carcinoma.","['_num_', 'of', '_num_', 'members', 'carried', 'angiomas', '_num_', 'carried', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
2779,1.0,"Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathway).","['melanoma', 'patients', 'treated', 'with', '_abbrev_', 'or', '_disease_', 'nivolumab', 'pembrolizumab', '_abbrev_', 'therapy', 'were', 'analyzed', 'for', 'expression', 'of', '_gene_', 'the', 'primary', 'antigen', 'presenting', 'molecule', 'of', 'the', '_gene_', 'pathway']"
2780,1.0,"In contrast, this SNP was detected in only seven of 31 (23%) patients without a response or disease stabilization (P = 0.027, Chi-squared test).","['in', 'contrast', 'this', 'snp', 'was', 'detected', 'in', 'only', '_num_', 'of', '_num_', '_num_', 'patients', 'without', 'a', 'response', 'or', 'disease', 'stabilization', 'p', '_num_', 'chi', 'squared', 'test']"
2781,1.0,Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719.,"['paired', 'biopsies', 'before', 'and', 'after', 'treatment', 'were', 'taken', 'from', 'a', 'set', 'of', '_num_', 'patients', 'classified', 'as', 'either', 'responder', 'or', 'non', 'responder', 'to', '_chemical_']"
2782,1.0,we state that SIFT (an in-silico missense functional prediction program) predicts the variant is tolerated.,"['we', 'state', 'that', 'sift', 'an', 'in', 'silico', 'missense', 'functional', 'prediction', 'program', 'predicts', 'the', 'variant', 'is', 'tolerated']"
2783,1.0,"In patients with glioblastoma multiforme, those with overespression of wild type EGFR had shorter overall survival.","['in', 'patients', 'with', 'glioblastoma', 'multiforme', 'those', 'with', 'overespression', 'of', 'wild', 'type', '_gene_', 'had', 'shorter', 'overall', 'survival']"
2784,1.0,Patient population was heavily pretreated.,"['patient', 'population', 'was', 'heavily', 'pretreated']"
2785,1.0,"In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free survival compared to wildtype KRAS (3.8mo vs. 5.1mo, HR:0.46, 95% CI:0.11-0.88, P=0.028).","['in', '_chemical_', 'resistant', 'metastatic', 'colorectal', 'cancer', 'patients', 'who', 'had', 'been', 'treated', 'with', '_chemical_', 'and', '_chemical_', '_gene_', 'mutations', 'in', 'codon', '_num_', 'or', '_num_', 'were', 'associated', 'with', 'shorter', 'progression', 'free', 'survival', 'compared', 'to', 'wildtype', '_gene_', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_']"
2786,1.0,"Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML.","['patients', 'with', '_gene_', '_num_', 'exon', '_num_', '_num_', 'exon', '_num_', 'and', '_gene_', 'mutations', 'had', 'significantly', 'lower', 'complete', 'remission', 'and', 'higher', 'refractory', 'disease', 'rates', 'than', 'those', 'with', 'wildtype', '_gene_', 'and', 'without', '_gene_', 'following', 'induction', 'therapy', 'in', 'young', '_range_', 'patients', 'with', 'cytogenetically', 'normal', '_disease_']"
2787,1.0,This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment.,"['this', 'was', 'a', 'retrospective', 'study', 'of', 'patients', 'with', 'advanced', '_abbrev_', '_disease_', 'who', 'had', 'undergone', 'varied', 'courses', 'of', 'treatment']"
2788,1.0,"Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK.","['multiplex', '_disease_', 'to', 'detect', 'in', 'frame', 'fusions', 'of', '_gene_', 'to', '_gene_', 'was', 'performed', 'on', 'total', 'rna', 'from', '_num_', 'lung', 'adenocarcinomas', 'and', '_num_', 'samples', 'were', 'found', 'to', 'contain', 'such', 'fusions', '_num_', 'of', 'which', 'was', 'a', 'novel', 'fusion', 'containing', '_gene_', 'exon', '_num_', 'and', 'exon', '_num_', 'of', '_gene_']"
2789,1.0,Biopsy was taken within half a month and total DNA was extracted from the sample.,"['biopsy', 'was', 'taken', 'within', 'half', 'a', 'month', 'and', 'total', 'dna', 'was', 'extracted', 'from', 'the', 'sample']"
2790,1.0,1 patient had a confirmed response among 8 patients treated with FGFR1-amplified breast cancer.,"['_num_', 'patient', 'had', 'a', 'confirmed', 'response', 'among', '_num_', 'patients', 'treated', 'with', '_abbrev_', 'breast', 'cancer']"
2791,1.0,"Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively).","['_num_', 'patients', 'were', 'treated', 'with', 'a', 'combination', 'of', '_gene_', 'and', 'mek', 'inhibition', 'and', 'exhibited', 'durable', 'response', 'beyond', '_num_', 'and', '_num_', 'months', 'respectively']"
2792,1.0,Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.,"['_chemical_', 'was', 'administered', 'when', 'disease', 'progression', 'was', 'noted', '_num_', 'months', 'later', 'and', 'the', 'patient', 'was', 'followed', 'up', 'without', 'signs', 'of', 'disease', 'progression', 'for', '_num_', 'days']"
2793,1.0,39% of resistant melanomas were not accounted for by any validated mutational mechanism.,"['_num_', 'of', 'resistant', 'melanomas', 'were', 'not', 'accounted', 'for', 'by', 'any', 'validated', 'mutational', 'mechanism']"
2794,1.0,Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication).,"['uncovering', 'this', 'mutation', 'prevented', 'an', 'unnecessary', 'allogeneic', 'transplant', 'and', 'the', 'patient', 'remained', 'in', 'remission', '_num_', 'months', 'post', 'treatment', 'date', 'of', 'publication']"
2795,1.0,Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines.,"['dual', '_gene_', '_gene_', 'inhibitors', '_chemical_', 'and', '_chemical_', 'and', 'mek', 'inhibition', 'was', 'synergistic', 'in', 'colorectal', 'and', 'lung', 'cancer', 'cell', 'lines']"
2796,1.0,"In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations.","['in', 'patients', 'with', 'sporatic', 'clear', 'cell', 'renal', 'cell', 'carcinoma', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'better', 'overall', 'survival', 'than', 'patients', 'with', '_gene_', 'mutations']"
2797,1.0,AREG was an independent prognosticator of OS in multivariate Cox analysis.,"['_gene_', 'was', 'an', 'independent', 'prognosticator', 'of', 'os', 'in', 'multivariate', 'cox', 'analysis']"
2798,1.0,PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines.,"['_gene_', 'mutant', 'cell', 'lines', 'were', 'significantly', 'more', 'sensitive', 'to', 'both', '_chemical_', 'and', '_chemical_', 'than', '_gene_', 'wild', 'type', 'cell', 'lines']"
2799,1.0,"The patient with G778_P780dup (Case 3 in the paper), had a rapid clinical and symptomatic response to Afatinib and stable disease which lasted for 3 months.","['the', 'patient', 'with', '_abbrev_', 'case', '_num_', 'in', 'the', 'paper', 'had', 'a', 'rapid', 'clinical', 'and', 'symptomatic', 'response', 'to', '_chemical_', 'and', 'stable', 'disease', 'which', 'lasted', 'for', '_num_', 'months']"
2800,1.0,This missense mutation was found in a VHL family of 6 individuals (proband no 7).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'family', 'of', '_num_', 'individuals', 'proband', 'no', '_num_']"
2801,1.0,In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.,"['in', 'vitro', 'experiments', 'showed', 'that', 'the', '_mutation_', 'mutation', 'increased', 'kinase', 'activity', 'and', 'conferred', 'resistance', 'to', '_chemical_']"
2802,1.0,It also showed resistance in isolation.,"['it', 'also', 'showed', 'resistance', 'in', 'isolation']"
2803,1.0,"Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses.","['of', '_num_', 'evaluable', 'patients', 'receiving', '_unit_', '_num_', 'patients', 'with', '_mutation_', '_gene_', 'mutation', '_num_', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'patient', 'and', 'a', 'patient', 'with', 'ovarian', 'cancer', 'had', 'unconfirmed', 'partial', 'responses']"
2804,1.0,"After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D.","['after', 'cultures', 'were', 'tested', 'for', 'reactivity', 'the', 'patient', 'was', 'infused', 'with', '_num_', 'x', '10^11', '_disease_', 'lymphocytes', '_num_', '_gene_', 't', 'cells', 'that', 'were', 'specifically', 'reactive', 'to', '_gene_', '_mutation_']"
2805,1.0,"Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.","['_chemical_', 'treatment', 'resulted', 'in', 'improvement', 'of', 'symptoms', 'and', 'considerable', 'reductions', 'in', 'tumor', 'mass', 'and', 'after', '_num_', 'months', 'the', 'patient', 'remained', 'on', 'therapy', 'with', 'well', 'controlled', 'disease']"
2806,1.0,"Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%).","['_num_', 'year', '_disease_', 'survival', 'was', 'significantly', 'poorer', 'in', '_abbrev_', '_disease_', '_num_', 'p', '_num_', 'vs', 'either', '_mutation_', '_num_', 'or', 'nonmutated', 'tumors', '_num_']"
2807,1.0,4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response.,"['_num_', 'patients', '_num_', 'of', '_num_', 'treated', '_num_', 'of', 'evaluable', 'patients', 'had', 'partial', 'response', 'and', '_num_', 'patients', '_num_', 'of', '_num_', 'had', 'stable', 'disease', 'as', 'best', 'response']"
2808,0.0,"Tissue HER2 levels were also predictive, but within this subgroup, serum HER2 still independently predicted lapatinib PFS benefit.","['tissue', '_gene_', 'levels', 'were', 'also', 'predictive', 'but', 'within', 'this', 'subgroup', 'serum', '_gene_', 'still', 'independently', 'predicted', '_chemical_', '_disease_', 'benefit']"
2809,1.0,"Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutations outside of this DNA binding domain.","['oral', '_disease_', 'cell', 'carcinoma', 'patients', 'with', '_gene_', 'mutations', 'in', 'the', 'dna', 'binding', 'domain', '_gene_', '_gene_', 'and', 'the', '_gene_', 'motif', 'have', 'significantly', 'reduced', 'cumulative', 'survival', 'when', 'compared', 'to', 'patients', 'with', '_gene_', 'mutations', 'outside', 'of', 'this', 'dna', 'binding', 'domain']"
2810,1.0,A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma.,"['a', '_num_', 'year', 'old', 'patient', 'with', 'prior', 'history', 'of', 'breast', 'cancer', 'presented', 'with', 'metastatic', 'papillary', 'thyroid', 'carcinoma']"
2811,1.0,The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC).,"['the', '_gene_', '_mutation_', 'variant', 'was', 'shown', 'to', 'be', 'correlated', 'with', 'increased', 'chance', 'of', 'response', 'to', 'platinum', 'based', 'chemotherapy', 'in', 'stage', 'iv', 'non', 'small', 'cell', 'lung', 'carcinoma', '_disease_']"
2812,1.0,"In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021).","['in', 'a', 'multivariate', 'analysis', 'of', '_num_', '_disease_', 'patients', '_gene_', 'aberrations', 'were', 'significantly', 'correlated', 'with', 'shorter', 'time', 'to', '_num_', 'treatment', '_ineq_', '_num_', '_ineq_']"
2813,1.0,"In nearly all (90%) pairwise comparisons of tumors and cell lines, differential c-MET mRNA expression could be accounted for by at least one differential CpG cluster methylation (Δβ ≥ 10% and FDR adjusted p ≤ 0.05).","['in', 'nearly', 'all', '_num_', 'pairwise', 'comparisons', 'of', 'tumors', 'and', 'cell', 'lines', 'differential', '_gene_', 'mrna', 'expression', 'could', 'be', 'accounted', 'for', 'by', 'at', 'least', '_num_', 'differential', '_chemical_', 'cluster', 'methylation', 'δβ', '≥', '_num_', 'and', 'fdr', 'adjusted', 'p', '≤', '_num_']"
2814,1.0,A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed.,"['a', 'panel', 'of', '_num_', 'endometrioid', 'endometrial', 'cancer', 'eec', 'cell', 'lines', 'was', 'characterized', 'for', 'a', 'set', 'of', 'mutations', 'and', 'sensitivity', 'to', 'pan', '_gene_', 'class', 'i', 'inhibitor', '_chemical_', 'pictilisib', 'was', 'assessed']"
2815,1.0,"Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).","['patients', 'with', '_gene_', 'mutations', 'also', 'had', 'a', 'shorter', 'overall', 'survival', 'compared', 'to', 'wildtype', '_gene_', 'patients', 'hr:2', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_']"
2816,1.0,This was significantly greater (p<0.001) than a response rate of 16.5% in EGFR wild type patients but significantly smaller (p<0.001) than a 74.1% response in EGFR mutant patients with canonical exon 19 deletion or L858R mutation.,"['this', 'was', 'significantly', 'greater', 'p', '_num_', 'than', 'a', 'response', 'rate', 'of', '_num_', 'in', '_gene_', 'wild', 'type', 'patients', 'but', 'significantly', 'smaller', 'p', '_num_', 'than', 'a', '_num_', 'response', 'in', '_gene_', 'mutant', 'patients', 'with', 'canonical', 'exon', '_num_', 'deletion', 'or', '_mutation_', 'mutation']"
2817,1.0,"In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML.","['in', 'a', 'large', 'cohort', 'of', 'young', '_disease_', 'patients', '_range_', 'years', 'old', '_gene_', '_abbrev_', 'mutations', 'were', 'associated', 'with', 'reduced', 'relapse', 'free', 'survival', 'in', 'the', 'entire', 'cohort', 'as', 'well', 'as', 'the', 'subset', 'of', 'patients', 'with', 'cytogenetically', 'normal', '_disease_']"
2818,1.0,Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient.,"['_disease_', '_num_', 'days', 'and', 'overall', '_num_', 'days', 'survival', 'suggested', 'sensitivity', 'in', 'this', 'patient']"
2819,1.0,Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel.,"['overexpression', 'and', 'high', 'p', '_gene_', '_gene_', 'ratio', 'were', 'associated', 'with', 'resistance', 'to', '_chemical_']"
2820,1.0,"In an in vitro study, Ba/F3 cell line stably expressing the E255K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 6.69-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib).","['in', 'an', 'in', 'vitro', 'study', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'as', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein', 'reported', 'to', 'be', 'sensitizing', 'to', '_chemical_']"
2821,1.0,"In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold), comparable to Ba/F3 cells expressing BCR-ABL fusion protein.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'fusion', 'protein']"
2822,1.0,"Belinostat AUC and half-life was significantly increased in UGT1A1*60 carriers, and they were at greater risk for thrombocytopenia.","['_chemical_', 'auc', 'and', 'half', 'life', 'was', 'significantly', 'increased', 'in', '_abbrev_', 'carriers', 'and', 'they', 'were', 'at', 'greater', 'risk', 'for', 'thrombocytopenia']"
2823,1.0,"After 3 months ceritinib, complete radiographic response was seen and the patient was without evidence of disease at 6 months.","['after', '_num_', 'months', '_chemical_', 'complete', 'radiographic', 'response', 'was', 'seen', 'and', 'the', 'patient', 'was', 'without', 'evidence', 'of', 'disease', 'at', '_num_', 'months']"
2824,1.0,"In patients with chronic lymphocytic leukemia, those with mutations in SF3B1 had shorter time to treatment, progression-free survival, and overall survival.","['in', 'patients', 'with', 'chronic', 'lymphocytic', 'leukemia', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'shorter', 'time', 'to', 'treatment', 'progression', 'free', 'survival', 'and', 'overall', 'survival']"
2825,1.0,"Heterozygous germline truncating (frameshift) and missense mutations confer highly penetrant predisposition to multiple cancer types including sarcoma, breast cancer, and brain tumors.","['heterozygous', 'germline', 'truncating', 'frameshift', 'and', 'missense', 'mutations', 'confer', 'highly', 'penetrant', 'predisposition', 'to', 'multiple', 'cancer', 'types', 'including', 'sarcoma', 'breast', 'cancer', 'and', 'brain', 'tumors']"
2826,1.0,"In multivariate analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively).","['in', 'multivariate', 'analysis', 'nuclear', 'expression', 'of', '_gene_', 'and', '_gene_', 'were', 'not', 'significant', 'predictors', 'of', 'overall', 'survival', 'p', '_num_', 'p', '_num_', 'respectively']"
2827,1.0,Subsequent chemotherapy (carboplatin–pemetrexed) was administered and the patient had a response for 6 months before progression.,"['subsequent', 'chemotherapy', 'carboplatin–pemetrexed', 'was', 'administered', 'and', 'the', 'patient', 'had', 'a', 'response', 'for', '_num_', 'months', 'before', 'progression']"
2828,1.0,"With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer.","['with', 'multiple', 'mechanisms', 'of', '_gene_', 'reprogramming', 'thought', 'to', 'be', 'behind', '_chemical_', 'resistance', 'including', 'increased', 'expression', 'of', '_gene_', 'members', '_chemical_', 'which', 'broadly', 'and', 'irreversibly', 'targets', '_gene_', 'receptors', 'was', 'tested', 'in', 'a', 'single', 'arm', 'phase', 'ii', 'trial', 'on', 'advanced', 'stage', '_gene_', 'positive', 'metastatic', 'breast', 'cancer']"
2829,1.0,"In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT).","['in', 'a', 'randomized', 'phase', 'ii', 'study', '_num_', 'line', 'treatment', 'of', '_gene_', 'metastatic', 'breast', 'cancer', 'with', '_chemical_', '_chemical_', '_disease_', 'resulted', 'in', 'improved', 'progression', 'free', 'survival', 'and', 'fewer', 'serious', 'adverse', 'effects', 'when', 'compared', 'to', 'treatment', 'with', 'combination', '_chemical_', 'plus', '_chemical_', '_disease_', 'median', 'follow', 'up', '_num_', 'months', 'median', '_disease_', 'with', '_disease_', '_num_', 'vs', '_num_', 'with', '_disease_']"
2830,1.0,Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.,"['_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'the', 'er', 'positive', 'subtype', 'of', 'breast', 'cancer']"
2831,1.0,Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations.,"['tumors', 'from', '_num_', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'were', 'analyzed', 'for', '_gene_', 'mutations']"
2832,0.0,we note larger cohorts will be required to confirm these results.,"['we', 'note', 'larger', 'cohorts', 'will', 'be', 'required', 'to', 'confirm', 'these', 'results']"
2833,1.0,"In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immunonegative glioblastomas.","['in', '_num_', 'glioblastomas', 'treated', 'with', '_chemical_', '_disease_', 'therapy', '_gene_', 'immunopositive', 'n', '_num_', 'negative', 'n', '_num_', 'both', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'were', 'significantly', 'better', 'in', '_gene_', 'immunonegative', 'glioblastomas']"
2834,1.0,"Study of a family with three generations of history indicating co-segregation of RET C609Y and multiple endocrine neoplasia type 2A, many of whom exhibited medullary thyroid cancers specifically.","['study', 'of', 'a', 'family', 'with', '_num_', 'generations', 'of', 'history', 'indicating', 'co', 'segregation', 'of', 'ret', '_mutation_', 'and', 'multiple', 'endocrine', 'neoplasia', 'type', '_gene_', 'many', 'of', 'whom', 'exhibited', 'medullary', 'thyroid', 'cancers', 'specifically']"
2835,1.0,"A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan.","['a', 'gene', 'fusion', 'between', 'exon', '_num_', 'of', '_gene_', 'and', 'exon', '_num_', 'of', 'the', '_gene_', 'genes', 'was', 'observed', 'in', 'a', 'patient', 'with', 'metastatic', 'colorectal', 'cancer', 'after', 'therapy', 'with', '_num_', 'line', '_chemical_', '_disease_', 'folfiri', '_chemical_', 'and', '_num_', 'line', '_chemical_']"
2836,1.0,"(HR, 0.33; 95% CI, 0.19 to 0.59; P<0.01)","['hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
2837,1.0,"A missense mutation, affecting residue on the surface of pVHL, was found in two VHL families of 4 patients altogether.","['a', 'missense', 'mutation', 'affecting', 'residue', 'on', 'the', 'surface', 'of', '_gene_', 'was', 'found', 'in', '_num_', '_gene_', 'families', 'of', '_num_', 'patients', 'altogether']"
2838,1.0,"In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate.","['in', 'the', 'single', 'arm', 'phase', 'ii', 'study', '_abbrev_', 'breast', 'cancer', 'patients', 'who', 'had', 'progressed', 'on', 'previous', '_disease_', 'therapy', 'were', 'given', 'transtuzumab', '_chemical_', '_disease_', 'a', '_gene_', 'monoclonal', 'antibody', 'and', 'antimicrotubule', 'drug', 'conjugate']"
2839,1.0,Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib.,"['expression', 'of', 'this', 'mutant', '_gene_', 'construct', 'in', 'a', 'cell', 'line', 'rendered', 'it', 'resistant', 'to', 'osimertinib']"
2840,1.0,"This is family V5 in the paper (VHL Type 1, no phechromocytoma).","['this', 'is', 'family', '_abbrev_', 'in', 'the', 'paper', '_gene_', 'type', '_num_', 'no', 'phechromocytoma']"
2841,1.0,"The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000).","['the', 'odds', 'ratio', 'or', 'was', '_num_', '_num_', 'ci', '_range_', '_ineq_', '_p_val_']"
2842,1.0,"In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.","['in', 'this', 'randomized', '_num_', 'arm', 'phase', 'ii', 'study', '_gene_', 'lob', 'patients', 'received', 'a', 'chemotherapy', 'plus', '_chemical_', 'b', 'chemotherapy', 'plus', '_chemical_', 'or', 'c', 'chemotherapy', 'plus', '_chemical_', 'and', '_chemical_', 'with', 'pathologic', 'complete', 'response', 'pcr', 'as', 'endpoint']"
2843,1.0,MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed.,"['_disease_', 'breast', 'cancer', 'cell', 'line', 'was', 'exposed', 'to', '_gene_', 'inhibitor', '_chemical_', 'until', 'resistance', 'developed']"
2844,1.0,The patient remained melanoma-free on 600mg imatinib until a follow up in Jan 2008.,"['the', 'patient', 'remained', 'melanoma', 'free', 'on', '_unit_', '_chemical_', 'until', 'a', 'follow', 'up', 'in', 'jan', '_year_']"
2845,1.0,Slight induction of the apoptotic marker cleaved PARP was only apparent at 4 micro-molar dose.,"['slight', 'induction', 'of', 'the', 'apoptotic', 'marker', 'cleaved', '_gene_', 'was', 'only', 'apparent', 'at', '_num_', 'micro', 'molar', 'dose']"
2846,1.0,"In the sunitinib-sensitive adenosquamous NSCLC cell line, PDGFRA expression was associated with focal PFGRA gene amplification, which was similarly detected in a small fraction of squamous cell NSCLC primary tumor specimens.","['in', 'the', '_chemical_', 'sensitive', '_disease_', '_disease_', 'cell', 'line', '_gene_', 'expression', 'was', 'associated', 'with', 'focal', 'pfgra', 'gene', 'amplification', 'which', 'was', 'similarly', 'detected', 'in', 'a', 'small', 'fraction', 'of', '_disease_', 'cell', '_disease_', 'primary', 'tumor', 'specimens']"
2847,1.0,"11/14 (79%) patients with positive HLA-DR staining, had complete (n=3) or partial (n=8) response.","['_ratio_', '_num_', 'patients', 'with', 'positive', '_chemical_', 'staining', 'had', 'complete', '_ineq_', 'or', 'partial', '_ineq_', 'response']"
2848,1.0,Overall response rate for patients with prior crizotinib treatment (83 out of 122) was 56% with median progression free survival of 6.9 months.,"['overall', 'response', 'rate', 'for', 'patients', 'with', 'prior', '_chemical_', 'treatment', '_num_', 'out', 'of', '_num_', 'was', '_num_', 'with', 'median', 'progression', 'free', 'survival', 'of', '_num_', 'months']"
2849,1.0,EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells.,"['_chemical_', 'with', '_gene_', '_mutation_', 'mutation', 'was', 'tested', 'for', 'sensitivity', 'to', '_chemical_', 'using', 'ba', '_abbrev_', 'cells']"
2850,1.0,"Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib.","['patients', 'with', '_gene_', '_abbrev_', '_disease_', '_ineq_', 'were', 'enrolled', 'into', 'a', 'phase', '_num_', 'multicentre', 'non', 'randomised', '_disease_', 'study', 'administering', '_chemical_', 'plus', '_chemical_']"
2851,1.0,Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance.,"['sequencing', 'in', 'this', 'and', 'other', 'patients', 'as', 'well', 'as', 'preclinical', 'models', 'showed', 'loss', 'of', '_gene_', 'as', 'the', 'probable', 'mechanism', 'of', 'resistance']"
2852,1.0,This missense mutation was found in 4 VHL type 1 family members (patient no V13).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'family', 'members', 'patient', 'no', '_gene_']"
2853,1.0,Combinatory treatment with gefitinib and nicotinamide showed a synergistic effect on cell viability.,"['combinatory', 'treatment', 'with', '_chemical_', 'and', '_chemical_', 'showed', 'a', 'synergistic', 'effect', 'on', 'cell', 'viability']"
2854,1.0,CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR.,"['_chemical_', '_chemical_', 'more', 'effectively', 'induced', 'apoptosis', 'in', '_gene_', 'mutated', '_mutation_', 'and', 'others', '_disease_', 'cell', 'lines', 'than', 'those', 'harboring', 'wildtype', '_gene_']"
2855,1.0,"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC.","['_num_', '_disease_', 'patients', 'treated', 'with', '_chemical_', '_chemical_', 'were', 'retrospectively', 'analyzed', 'for', 'egfrviii', '_gene_', 'and', '_gene_', 'expression', 'with', '_gene_']"
2856,1.0,One Q61K line was not sensitive to these inhibitors.,"['_num_', '_mutation_', 'line', 'was', 'not', 'sensitive', 'to', 'these', 'inhibitors']"
2857,1.0,The results were also confirmed in vitro by treating neuroblastoma and B-cell lines expressing the wild type or rs751402 polymorphism and finding that the rs751402 polymorphism was correlated with higher survival.,"['the', 'results', 'were', 'also', 'confirmed', 'in', 'vitro', 'by', 'treating', 'neuroblastoma', 'and', '_disease_', 'lines', 'expressing', 'the', 'wild', 'type', 'or', '_mutation_', 'polymorphism', 'and', 'finding', 'that', 'the', '_mutation_', 'polymorphism', 'was', 'correlated', 'with', 'higher', 'survival']"
2858,1.0,Ba/F3 cells expressing EML4-ALK L1196M or EML4-ALK C1156Y were more resistant to crizontinib treatment than those expressing EML4-ALK wildtype.,"['ba', '_abbrev_', 'cells', 'expressing', '_chemical_', '_mutation_', 'or', '_chemical_', '_mutation_', 'were', 'more', 'resistant', 'to', 'crizontinib', 'treatment', 'than', 'those', 'expressing', '_chemical_', 'wildtype']"
2859,1.0,Furthermore non-high-risk patients with IKZF1 deletions exhibited a ~12-fold higher relative relapse rate than those without IKZF1 deletions.,"['furthermore', '_disease_', 'patients', 'with', '_gene_', 'deletions', 'exhibited', 'a', '_n_fold_', 'higher', 'relative', 'relapse', 'rate', 'than', 'those', 'without', '_gene_', 'deletions']"
2860,1.0,"In 141 NSCLC patients with EGFR mutations, the presence of the polymorphism (N=26) was predictive of a significantly shorter PFS under treatment with EGFR-TKI (6.6 months vs. 11.9 months, p = 0.0027).","['in', '_num_', '_disease_', 'patients', 'with', '_gene_', 'mutations', 'the', 'presence', 'of', 'the', 'polymorphism', '_ineq_', 'was', 'predictive', 'of', 'a', 'significantly', 'shorter', '_disease_', 'under', 'treatment', 'with', '_gene_', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_']"
2861,1.0,"In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21.","['in', 'a', 'study', '_num_', 'participants', 'with', 'stage', 'iv', 'lung', 'adenocarcinoma', 'were', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_']"
2862,1.0,Further testing of this mutation in BaF3 cells revealed that cells expressing EML4-ALk with I1171T mutation required 10x higher concentration to induce cell death than BaF3 cells with wild type EML4-ALK.,"['further', 'testing', 'of', 'this', 'mutation', 'in', '_abbrev_', 'cells', 'revealed', 'that', 'cells', 'expressing', '_abbrev_', 'with', '_mutation_', 'mutation', 'required', '10x', 'higher', 'concentration', 'to', 'induce', 'cell', 'death', 'than', '_abbrev_', 'cells', 'with', 'wild', 'type', '_chemical_']"
2863,1.0,"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', 'iv', 'lung', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_abbrev_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
2864,1.0,"WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients.","['_gene_', 'mutations', 'were', 'associated', 'with', 'shorter', 'overall', 'and', 'disease', 'free', 'survival', 'in', 'a', 'cohort', 'of', 'cytogenetically', 'normal', 'young', '_num_', '_disease_', 'patients']"
2865,1.0,Trametinib was stopped and pembrolizumab introduced at this time.,"['_chemical_', 'was', 'stopped', 'and', 'pembrolizumab', 'introduced', 'at', 'this', 'time']"
2866,1.0,Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study.,"['tumor', 'samples', 'from', '_num_', 'patients', 'with', 'stage', '_disease_', 'or', '_gene_', 'bulky', 'greater', 'than', '_num_', '_unit_', 'in', 'size', 'cervical', 'carcinomas', 'were', 'used', 'in', 'this', 'study']"
2867,1.0,The cells showed a decrease in staining of NF-kappa-B p65 phosphorylation.,"['the', 'cells', 'showed', 'a', 'decrease', 'in', 'staining', 'of', '_gene_', '_gene_', '_disease_']"
2868,1.0,Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.,"['inhibition', 'of', '_abbrev_', 'signaling', 'restored', '_chemical_', 'sensitivity']"
2869,1.0,"Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (p = 0.003; HR 5.61; 95% CI 1.81, 17.35).","['pretreatment', '_gene_', '_gene_', 'expression', 'level', 'was', 'associated', 'with', 'poor', 'disease', 'free', 'survival', 'p', '_num_', 'hr', '_num_', '_num_', 'ci', '_num_', '_num_']"
2870,1.0,This was called variant 5.,"['this', 'was', 'called', 'variant', '_num_']"
2871,1.0,A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL).,"['a', 'cell', 'line', 'called', '_gene_', 'was', 'established', 'from', 'the', 'bone', 'marrow', 'of', 'a', '_num_', 'year', 'old', 'female', 'patient', 'with', 'relapsed', '_gene_', 'positive', 'diffuse', 'large', '_disease_', 'lymphoma', '_disease_']"
2872,1.0,In 134 patients with head and neck squamous cancer 32 had copy number variations.,"['in', '_num_', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cancer', '_num_', 'had', 'copy', 'number', 'variations']"
2873,1.0,FLT3 mutations were assessed before treatment and at the time of resistance.,"['_gene_', 'mutations', 'were', 'assessed', 'before', 'treatment', 'and', 'at', 'the', 'time', 'of', 'resistance']"
2874,1.0,"An imatinib-resistant cell line, DFSP105, was established from a dermatofibrosarcoma protuberans which had progressed to a high-grade fibrosarcomatous DFSP.","['an', '_chemical_', 'resistant', 'cell', 'line', '_abbrev_', 'was', 'established', 'from', 'a', '_disease_', 'protuberans', 'which', 'had', 'progressed', 'to', 'a', 'high', 'grade', '_disease_', '_disease_']"
2875,1.0,KRAS G12D mutation occurs in never smokers significantly more often than in smokers.,"['_gene_', '_mutation_', 'mutation', 'occurs', 'in', 'never', 'smokers', 'significantly', 'more', 'often', 'than', 'in', 'smokers']"
2876,1.0,Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vivo.,"['disruption', 'of', 'this', 'loop', 'led', 'to', 'decreased', 'cell', 'growth', 'in', 'vitro', 'and', 'prolonged', 'survival', 'in', 'vivo']"
2877,1.0,The MGH056-1 cell line was derived from a patient with ALK rearranged NSCLC who had progressed on crizotinib and then on lower dose alectinib (300 mg twice daily).,"['the', '_abbrev_', 'cell', 'line', 'was', 'derived', 'from', 'a', 'patient', 'with', '_gene_', 'rearranged', '_disease_', 'who', 'had', 'progressed', 'on', '_chemical_', 'and', 'then', 'on', 'lower', 'dose', '_chemical_', '_num_', '_unit_', 'twice', 'daily']"
2878,1.0,EPZ-6438 (Tazemetostat) induces apoptosis and differentiation specifically in SMARCB1-deleted malignant rhabdoid tumors (MRT) cells.,"['_chemical_', 'tazemetostat', 'induces', 'apoptosis', 'and', 'differentiation', 'specifically', 'in', '_abbrev_', 'malignant', '_disease_', 'tumors', '_disease_', 'cells']"
2879,1.0,This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 4327).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
2880,1.0,This patient also harbored MLH1 p.R226* and MSH6 p.I972F mutations at similar variant allele frequencies.,"['this', 'patient', 'also', 'harbored', '_gene_', 'p', '_abbrev_', 'and', '_gene_', 'p', '_abbrev_', 'mutations', 'at', 'similar', 'variant', 'allele', 'frequencies']"
2881,1.0,In vitro follow-up showed reduced crizotinib-induced ALK dephosphorylation (293T) and apoptosis (Ba/F3) when EML4-ALK G1269A overexpression was compared to EML4-ALK overexpression in these cell lines.,"['in', 'vitro', 'follow', 'up', 'showed', 'reduced', '_chemical_', 'induced', '_gene_', 'dephosphorylation', '_chemical_', 'and', 'apoptosis', 'ba', '_abbrev_', 'when', '_chemical_', '_mutation_', 'overexpression', 'was', 'compared', 'to', '_chemical_', 'overexpression', 'in', 'these', 'cell', 'lines']"
2882,0.0,"A multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic CRC.","['a', 'multicenter', 'retrospective', 'cohort', 'study', 'to', 'characterize', 'the', 'clinical', 'pathologic', 'and', 'survival', 'implications', 'of', '_abbrev_', '_gene_', 'mutations', 'in', 'metastatic', '_gene_']"
2883,1.0,MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.,"['_chemical_', 'cell', 'lines', 'harboring', 'the', '_abbrev_', 'mutation', 'in', 'the', '_disease_', 'domain', 'of', '_gene_', 'have', 'shown', 'resistance', 'to', 'hormone', 'therapy']"
2884,1.0,"Of the 66 patients, 25 were classified as responders and 41 were classified as non-responders.","['of', 'the', '_num_', 'patients', '_num_', 'were', 'classified', 'as', 'responders', 'and', '_num_', 'were', 'classified', 'as', 'non', 'responders']"
2885,1.0,The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months.,"['the', 'patient', 'was', 'treated', 'with', '_disease_', 'inhibitor', '_abbrev_', 'and', '_abbrev_', 'in', 'a', 'phase', '_num_', 'trial', 'and', 'had', 'a', 'complete', 'remission', 'within', '_num_', 'months', 'of', 'treatment', 'that', 'was', 'ongoing', 'after', '_num_', 'months']"
2886,1.0,HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients.,"['_gene_', '_gene_', 'expression', 'was', 'immunohistochemically', 'assessed', 'using', 'a', 'tissue', 'microarray', 'in', '_num_', 'gastric', 'cancer', 'patients']"
2887,1.0,Cell lines with PIK3CA mutation or amplification were the most sensitive.,"['cell', 'lines', 'with', '_gene_', 'mutation', 'or', 'amplification', 'were', 'the', 'most', 'sensitive']"
2888,1.0,SPHK1 protein expression was assessed in 287 cervical cancer and 5 normal cervical tissue samples using IHC.,"['_gene_', 'protein', 'expression', 'was', 'assessed', 'in', '_num_', 'cervical', 'cancer', 'and', '_num_', 'normal', 'cervical', 'tissue', 'samples', 'using', '_gene_']"
2889,1.0,RNA sequencing revealed FLT3 overexpression (also confirmed by IHC).,"['rna', 'sequencing', 'revealed', '_gene_', 'overexpression', 'also', 'confirmed', 'by', '_gene_']"
2890,1.0,Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure.,"['_num_', '_gene_', 'mutant', 'breast', 'cancer', 'cell', 'lines', 'were', 'rendered', 'resistant', 'to', '_gene_', 'inhibitors', '_chemical_', 'or', '_chemical_', 'by', 'chronic', 'exposure']"
2891,1.0,Study treatment was stopped early because of a higher number of deaths in the rilotumumab arm.,"['study', 'treatment', 'was', 'stopped', 'early', 'because', 'of', 'a', 'higher', 'number', 'of', 'deaths', 'in', 'the', 'rilotumumab', 'arm']"
2892,1.0,"The crizotinib resistant clones were produced from parental H3122 cells (CR1, CR2, CR3).","['the', '_chemical_', 'resistant', 'clones', 'were', 'produced', 'from', 'parental', '_abbrev_', 'cells', '_gene_', '_gene_', '_gene_']"
2893,1.0,This missense mutation was detected in a type 1 VHL patient with angiomas and cerebellar hemangioblastomas (family ID 3630).,"['this', 'missense', 'mutation', 'was', 'detected', 'in', 'a', 'type', '_num_', '_gene_', 'patient', 'with', 'angiomas', 'and', 'cerebellar', '_disease_', 'family', 'id', '_num_']"
2894,1.0,Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.,"['cells', 'with', 'an', '_gene_', '_abbrev_', 'mutation', 'demonstrated', 'an', 'improved', 'response', 'to', '_chemical_', '_abbrev_', '_num_', '185umol', '_unit_', 'vs', '10umol', '_unit_', 'compared', 'to', 'the', 'same', 'cells', 'treated', 'with', '_chemical_']"
2895,1.0,This frameshift mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 3669).,"['this', 'frameshift', 'mutation', 'was', 'detected', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'with', 'cerebellar', '_disease_', 'family', 'id', '_num_']"
2896,1.0,shRNA mediated ATM knockdown in a cell line increased sensitivity to olaparib.,"['shrna', 'mediated', 'atm', 'knockdown', 'in', 'a', 'cell', 'line', 'increased', 'sensitivity', 'to', '_chemical_']"
2897,1.0,NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).,"['_gene_', 'mutations', 'were', 'not', 'associated', 'with', 'the', '_abbrev_', 'acute', 'myeloid', 'leukemia', 'fab', 'subtype', '_ratio_']"
2898,1.0,Tumor showed HER2 positive SCLC cells with no amplification or mutation.,"['tumor', 'showed', '_gene_', 'positive', '_gene_', 'cells', 'with', 'no', 'amplification', 'or', 'mutation']"
2899,1.0,"Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]).","['most', 'patients', '_ratio_', 'evaluable', 'harbored', 'a', 'mutation', 'in', 'exon', '_num_', 'of', '_gene_', 'or', '_gene_', 'but', '_disease_', 'benefit', 'from', '_chemical_', 'compared', 'to', 'chemotherapy', 'was', 'greater', 'in', 'the', '_gene_', 'and', '_gene_', 'wild', 'type', 'population', '_num_', 'weeks', 'range', '_range_', 'weeks', 'vs', '_num_', 'weeks', 'range', '_range_', 'weeks']"
2900,1.0,The disease then progressed and the patient died 2 months after crizotinib initiation.,"['the', 'disease', 'then', 'progressed', 'and', 'the', 'patient', 'died', '_num_', 'months', 'after', '_chemical_', 'initiation']"
2901,1.0,"Grade 2 clear cell renal cess carcinoma is highly associated with VHL mutation, so PP4 label may be warranted.","['grade', '_num_', 'clear', 'cell', 'renal', 'cess', 'carcinoma', 'is', 'highly', 'associated', 'with', '_gene_', 'mutation', 'so', '_gene_', 'label', 'may', 'be', 'warranted']"
2902,1.0,"Carriers of the C-allele showed a significantly more severe tumor progression as estimated from the time period to develop metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017).","['carriers', 'of', 'the', 'c', 'allele', 'showed', 'a', 'significantly', 'more', 'severe', 'tumor', 'progression', 'as', 'estimated', 'from', 'the', 'time', 'period', 'to', 'develop', 'metastasis', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
2903,1.0,"The paper indicates however, that temporary BAP knockdown might not adequately reflect long-term BAP1 mutation.","['the', 'paper', 'indicates', 'however', 'that', 'temporary', 'bap', 'knockdown', 'might', 'not', 'adequately', 'reflect', 'long', 'term', '_gene_', 'mutation']"
2904,1.0,"The IC50 for brigatinib against EML4-ALK wild type was 0.95, which is about 3x higher than the IC50 that was observed for alectinib, but about 6x lower than that for crizotinib.","['the', '_abbrev_', 'for', 'brigatinib', 'against', '_chemical_', 'wild', 'type', 'was', '_num_', 'which', 'is', 'about', '3x', 'higher', 'than', 'the', '_abbrev_', 'that', 'was', 'observed', 'for', '_chemical_', 'but', 'about', '6x', 'lower', 'than', 'that', 'for', '_chemical_']"
2905,1.0,This cell line harbored the lowest IC50 values to both perifosine and temsirolimus and also showed increased apoptosis with perifosine in a xenograft model.,"['this', 'cell', 'line', 'harbored', 'the', 'lowest', '_abbrev_', 'values', 'to', 'both', '_chemical_', 'and', '_chemical_', 'and', 'also', 'showed', 'increased', 'apoptosis', 'with', '_chemical_', 'in', 'a', 'xenograft', 'model']"
2906,1.0,"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.","['data', 'from', 'deep', 'sequencing', 'of', 'a', 'ph', 'negative', 'clone', 'of', 'a', 'ph', 'positive', '_gene_', 'patient', 'has', 'found', 'a', 'driving', 'mutation', 'in', '_gene_', 'that', 'preceeded', 'the', '_gene_', 'fusion', 'and', 'may', 'imply', 'the', 'possibility', 'that', '_gene_', 'is', 'not', 'universally', 'the', 'initiating', 'event', 'in', '_gene_']"
2907,1.0,"Univariate analysis for OS showed SPHK1 expression (p = 0.033; Figure 1C), tumor size (p = 0.033), and lymph node metastasis (p = 0.008) as associated with OS.","['univariate', 'analysis', 'for', 'os', 'showed', '_gene_', 'expression', 'p', '_num_', 'figure', '1c', 'tumor', 'size', 'p', '_num_', 'and', 'lymph', 'node', 'metastasis', 'p', '_num_', 'as', 'associated', 'with', 'os']"
2908,1.0,Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.,"['treatment', 'of', 'metastatic', 'melanoma', 'with', '_chemical_', 'in', 'patients', 'with', 'tumors', 'that', 'carry', 'the', '_mutation_', '_gene_', 'mutation', 'resulted', 'in', 'complete', 'or', 'partial', 'tumor', 'regression', 'in', 'the', 'majority', 'of', 'patients']"
2909,1.0,"This mutation causes a frameshift, an early stop codon at amino acid 158, and was found in a VHL type 1 family with retinal angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.","['this', 'mutation', 'causes', 'a', 'frameshift', 'an', 'early', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'with', 'retinal', 'angiomas', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
2910,1.0,TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07.,"['_gene_', 'gain', 'was', 'nonsignificantly', 'associated', 'with', 'objective', 'response', 'to', '_chemical_', 'odds', 'ratio', 'or', '_num_', 'p', '_num_']"
2911,1.0,"Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants.","['cell', 'line', 'xenograft', 'and', 'transgenic', 'models', 'were', 'used', 'to', 'establish', 'osimertinib', 'as', 'an', 'inhibitor', 'of', 'both', '_gene_', 'mutation', 'sensitizing', '_mutation_', 'del', 'exon', '_num_', 'and', '_mutation_', 'resistance', 'mutants']"
2912,1.0,"A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone.","['a', 'randomized', 'clinical', 'trial', 'of', '_num_', 'patients', 'with', 'previously', 'untreated', '_gene_', 'metastatic', 'breast', 'cancer', 'demonstrated', 'improved', 'overall', 'survival', 'response', 'rate', 'response', 'duration', 'time', 'to', 'progression', 'and', 'time', 'to', 'treatment', 'failure', 'for', 'patients', 'who', 'received', '_chemical_', 'in', 'addition', 'to', 'chemotherapy', '_chemical_', 'compared', 'to', 'chemotherapy', 'alone']"
2913,1.0,we performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.,"['we', 'performed', 'a', 'tissue', 'microarray', 'analysis', 'of', '_num_', 'postmenopausal', 'breast', 'cancers', 'that', 'had', 'been', 'randomized', 'to', 'treatment', 'with', 'or', 'without', 'tamoxifen']"
2914,1.0,"However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P = 0.01).","['however', '_disease_', 'was', 'still', 'better', 'with', '_chemical_', 'than', 'chemotherapy', 'in', 'the', '_disease_', 'mutant', 'population', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
2915,1.0,No new metastases were identified.,"['no', 'new', 'metastases', 'were', 'identified']"
2916,1.0,"Over half of melanoma cell lines overexpressed MERTK compared with normal human melanocytes; however, overexpression did not correlate with mutations in BRAF or RAS.","['over', 'half', 'of', 'melanoma', 'cell', 'lines', 'overexpressed', '_gene_', 'compared', 'with', 'normal', 'human', 'melanocytes', 'however', 'overexpression', 'did', 'not', 'correlate', 'with', 'mutations', 'in', '_gene_', 'or', 'ras']"
2917,1.0,Mutation causes a stop codon at amino acid 158.,"['mutation', 'causes', 'a', 'stop', 'codon', 'at', 'amino', 'acid', '_num_']"
2918,1.0,AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild type IDH2.,"['_disease_', 'patients', 'with', '_gene_', 'mutations', 'such', 'as', '_mutation_', 'have', 'event', 'free', 'survival', 'and', 'overall', 'survival', 'similar', 'to', 'those', 'with', 'wild', 'type', '_gene_']"
2919,1.0,"Therefore, the association between 1p deletion and low MGMT protein expression was statistically significant when evaluated further and verified in the extended group of 31 patients with low-grade oligodendrogliomas.","['therefore', 'the', 'association', 'between', '1p', 'deletion', 'and', 'low', '_gene_', 'protein', 'expression', 'was', 'statistically', 'significant', 'when', 'evaluated', 'further', 'and', 'verified', 'in', 'the', 'extended', 'group', 'of', '_num_', 'patients', 'with', 'low', 'grade', '_disease_']"
2920,1.0,"12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study.","['_num_', 'patients', 'with', '_gene_', '_mutation_', 'mutant', 'metastatic', 'colorectal', 'cancer', 'were', 'treated', 'with', 'single', 'agent', '_chemical_', 'in', 'a', 'prospective', 'phase', 'ii', 'study']"
2921,1.0,"In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found.","['in', 'the', 'profile', '_num_', 'study', 'from', '_num_', '_disease_', 'tumors', 'positive', 'for', '_gene_', 'fusions', 'with', 'sufficient', 'material', 'for', '_disease_', 'aided', 'exon', 'breakpoint', 'identification', '_num_', 'case', 'of', '_chemical_', 'variant', '_num_', '_gene_', 'exon', '_num_', 'fused', 'to', '_gene_', 'exon', '_num_', 'was', 'found']"
2922,1.0,13/31 tested patients had the EML4-ALK variant 1.,"['_ratio_', 'tested', 'patients', 'had', 'the', '_chemical_', 'variant', '_num_']"
2923,1.0,The mother's parents did not carry the R173C mutation.,"['the', 'mother', ""'s"", 'parents', 'did', 'not', 'carry', 'the', '_mutation_', 'mutation']"
2924,1.0,This sensitivity was correlated with FGFR1 mRNA and protein expression.,"['this', 'sensitivity', 'was', 'correlated', 'with', '_gene_', 'mrna', 'and', 'protein', 'expression']"
2925,1.0,This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 83).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
2926,1.0,A375 melanoma cells containing an inducible shRNA for STAG3 were grown as xenograft tumors in nude mice.,"['_abbrev_', 'melanoma', 'cells', 'containing', 'an', 'inducible', 'shrna', 'for', '_gene_', 'were', 'grown', 'as', 'xenograft', 'tumors', 'in', 'nude', 'mice']"
2927,1.0,"6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.","['_ratio_', 'patients', 'were', 'treated', 'with', 'chop', 'chemotherapy', 'with', 'survival', 'of', '_num_', '_num_', '_num_', 'and', '_num_', 'months', 'and', '_num_', 'alive', 'at', 'end', 'of', 'study', 'and', '_num_', '_gene_', 'positive', 'patient', 'was', 'treated', 'with', 'chop', 'chemotherapy', 'supplemented', 'with', '_abbrev_', '_chemical_', 'with', 'survival', 'of', '_num_', 'months', 'resulting', 'in', 'median', 'survival', 'of', '_num_', 'months', 'for', 'this', 'group']"
2928,1.0,"In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival (3.23 months vs. 1.37 months, P=0.05), as compared to patients with wild type IDH1.","['in', 'a', 'clinical', 'study', 'of', '_num_', 'recurrent', 'glioma', 'patients', 'patients', 'treated', 'with', '_chemical_', 'monotherapy', '_ineq_', 'and', 'harboring', '_gene_', 'codon', '_num_', 'mutation', 'were', 'associated', 'with', 'improved', 'progression', 'free', 'survival', '_num_', 'months', 'vs', '_num_', 'months', '_p_val_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
2929,1.0,"While the variant is strongly suspected of being pathogenic for these tumors, this variant appears to result in later onset of cancer than some other variants and we recommend delaying prophylactic thyroidectomy until 10-15 years of age.","['while', 'the', 'variant', 'is', 'strongly', 'suspected', 'of', 'being', 'pathogenic', 'for', 'these', 'tumors', 'this', 'variant', 'appears', 'to', 'result', 'in', 'later', 'onset', 'of', 'cancer', 'than', 'some', 'other', 'variants', 'and', 'we', 'recommend', 'delaying', 'prophylactic', 'thyroidectomy', 'until', '_range_', 'years', 'of', 'age']"
2930,1.0,"Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64).","['gain', 'of', 'the', '_gene_', 'locus', 'qpcr', 'was', 'observed', 'in', '_num_', 'of', '_num_', 'patients', '_num_', 'and', 'ewing', 'sarcoma', 'cell', 'lines', '_abbrev_', '_chemical_', 'sk', 'nmc', 'sk', 'es', 'and', '_abbrev_']"
2931,1.0,Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib.,"['cells', 'with', 'an', '_gene_', '_abbrev_', 'mutation', 'demonstrated', 'an', 'improved', 'response', 'to', '_chemical_', '_abbrev_', '_unit_', 'vs', '_unit_', 'compared', 'to', 'the', 'same', 'cells', 'treated', 'with', '_chemical_']"
2932,1.0,This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.,"['this', 'phase', 'iii', 'trial', 'compared', 'the', 'activity', 'of', '_chemical_', 'vs', '_chemical_', 'vs', 'sequential', '_chemical_', 'followed', 'by', '_chemical_', 'vs', '_chemical_', 'plus', '_chemical_', 'in', 'an', 'adjuvant', 'treatment', 'setting']"
2933,0.0,Beta-Catenin deregulation has been commonly identified in sporadic desmoids.,"['_gene_', 'deregulation', 'has', 'been', 'commonly', 'identified', 'in', 'sporadic', '_disease_']"
2934,1.0,"Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensitive EML4-ALK wild type variant obtained in parallel experiments, as well as the GI50 value of 16 nM obtained for crizotinib treatment of EML4-ALK wild type.","['ba', '_abbrev_', 'cells', 'expressing', 'the', '_chemical_', '_mutation_', 'variant', 'were', 'treated', 'with', '_chemical_', 'and', 'survival', '_gene_', 'value', 'of', '_num_', '_unit_', 'was', 'obtained', 'which', 'compares', 'favorably', 'with', '_gene_', 'of', '_num_', 'for', 'the', 'highly', '_chemical_', 'sensitive', '_chemical_', 'wild', 'type', 'variant', 'obtained', 'in', 'parallel', 'experiments', 'as', 'well', 'as', 'the', '_gene_', 'value', 'of', '_num_', '_unit_', 'obtained', 'for', '_chemical_', 'treatment', 'of', '_chemical_', 'wild', 'type']"
2935,1.0,Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of VHL gene product (pVHL).,"['genotype', 'phenotype', 'correlations', 'of', '_num_', '_gene_', 'patients', 'were', 'analyzed', 'and', 'confirmed', 'that', 'higher', 'risk', 'of', 'pheochromocytoma', 'is', 'associated', 'with', 'missense', 'mutations', 'that', 'result', 'in', 'substitution', 'of', 'a', 'surface', 'amino', 'acid', 'or', 'that', 'disrupt', 'the', 'structural', 'integrity', 'of', '_gene_', 'gene', 'product', '_gene_']"
2936,1.0,Blood samples from 106 patients with mCRC before and after treatment were used for this study.,"['blood', 'samples', 'from', '_num_', 'patients', 'with', '_disease_', 'before', 'and', 'after', 'treatment', 'were', 'used', 'for', 'this', 'study']"
2937,1.0,Immunohistochemistry revealed loss of MHC1 outer-membrane localization.,"['immunohistochemistry', 'revealed', 'loss', 'of', '_gene_', 'outer', 'membrane', 'localization']"
2938,1.0,Proband's mother and two siblings (one 7 years and one 7 months) also carried the PTEN R173C mutation and were thus far asymptomatic.,"['proband', ""'s"", 'mother', 'and', '_num_', 'siblings', '_num_', '_num_', 'years', 'and', '_num_', '_num_', 'months', 'also', 'carried', 'the', '_gene_', '_mutation_', 'mutation', 'and', 'were', 'thus', 'far', 'asymptomatic']"
2939,1.0,"In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.","['in', 'non', 'small', 'cell', 'lung', 'cancer', 'the', 'appearance', 'of', '_mutation_', 'mutation', 'leads', 'to', 'resistance', 'to', '_chemical_']"
2940,1.0,"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74).","['in', 'young', 'patients', 'age', '_range_', 'with', 'previously', 'untreated', 'cytogenetically', 'normal', 'acute', 'myeloid', 'leukemia', '_gene_', 'mutation', 'was', 'significantly', 'associated', 'with', 'complete', 'remission', 'in', 'multivariate', 'analysis', 'odds', 'ratio', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_']"
2941,0.0,Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34).,"['results', 'were', 'validated', 'in', 'a', 'separate', 'retrospective', 'cohort', 'n', '_num_', 'and', 'also', 'tested', 'in', 'patients', 'treated', 'with', 'cytotoxic', 'agents', 'without', '_chemical_', 'n', '_num_']"
2942,1.0,Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.,"['_chemical_', 'treatment', 'inhibited', 'growth', 'of', 'ewing', 'sarcoma', 'cell', 'lines']"
2943,1.0,"Median overall survival was 8·8 months (95% CI 7·7-10·2) in the rilotumumab group compared with 10·7 months (9·6-12·4) in the placebo group (stratified hazard ratio 1·34, 95% CI 1·10-1·63; p=0·003).","['median', 'overall', 'survival', 'was', '_num_', 'months', '_num_', 'ci', '_range_', 'in', 'the', 'rilotumumab', 'group', 'compared', 'with', '_num_', 'months', '_range_', 'in', 'the', 'placebo', 'group', 'stratified', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_range_', '_p_val_']"
2944,1.0,"There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005).","['there', 'were', 'statistically', 'significant', 'improvements', 'between', 'the', 'personalized', 'therapy', 'group', 'vs', 'the', 'standard', 'therapy', 'group', 'in', 'disease', 'control', 'rate', '_num_', 'vs', '_num_', '_p_val_', 'and', 'progression', 'free', 'survival', 'median', '_num_', 'months', 'vs', '_num_', 'months', '_p_val_']"
2945,1.0,Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance.,"['silencing', 'of', '_gene_', 'by', 'small', 'molecule', 'jak', '_num_', '_num_', '_num_', 'inhibitor', 'led', 'to', 'resistance']"
2946,1.0,A pedigree of 48 individuals with multiple instances of bleeding and platelet disorders and 8 cases of leukemia showed an A>G substitution in RUNX1 exon 3 which segregated with Familial Platelet Disorder and Acute Myeloid Leukemia.,"['a', 'pedigree', 'of', '_num_', 'individuals', 'with', 'multiple', 'instances', 'of', 'bleeding', 'and', 'platelet', 'disorders', 'and', '_num_', 'cases', 'of', 'leukemia', 'showed', 'an', 'a', '_unit_', 'substitution', 'in', '_gene_', 'exon', '_num_', 'which', 'segregated', 'with', 'familial', 'platelet', 'disorder', 'and', 'acute', 'myeloid', 'leukemia']"
2947,1.0,The F317L mutation was  moderately resistant to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
2948,1.0,The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment.,"['the', 'patient', 'demonstrated', 'a', 'durable', 'response', '_num_', 'wks', 'while', 'on', 'therapy', 'which', 'was', 'reversed', 'when', 'the', 'patient', 'discontinued', 'treatment']"
2949,1.0,"Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012).","['moreover', 'multivariable', 'cox', 'regression', 'analysis', 'including', 'tumor', 'stage', 'and', 'melanoma', 'subtype', 'proved', 'the', '_mutation_', 'polymorphism', 'to', 'be', 'an', 'independent', 'factor', 'for', 'metastasis', 'p', '_num_']"
2950,1.0,"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.","['in', '_num_', 'patients', 'with', '_disease_', 'or', 'chemotherapy', 'refractory', 'metastatic', 'colorectal', 'cancer', 'who', 'were', 'treated', 'with', '_chemical_', 'and', 'chemotherapy', '_gene_', 'loss', 'was', 'associated', 'with', '_disease_']"
2951,1.0,Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V.,"['mutant', '_gene_', 'was', 'observed', 'in', '_num_', '_num_', 'cases', 'and', '_num_', 'of', 'these', 'were', '_mutation_']"
2952,1.0,TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response.,"['_chemical_', 'inhibited', '_gene_', 'and', '_gene_', '_disease_', 'in', '_abbrev_', 'cells', 'and', 'appeared', 'to', 'induce', 'a', '_chemical_', 'response']"
2953,1.0,Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild type cells (apoptosis and viability).,"['mouse', 'embryonic', 'fibroblasts', 'and', 'human', 'lymphoblastoid', 'cell', 'lines', 'with', '_abbrev_', 'mutations', 'were', 'significantly', 'less', 'sensitive', 'to', '_chemical_', 'treatment', 'compared', 'to', '_gene_', 'wild', 'type', 'cells', 'apoptosis', 'and', 'viability']"
2954,1.0,The cases with mutation that appeared unaffected were all very young (before the likely age of onset).,"['the', 'cases', 'with', 'mutation', 'that', 'appeared', 'unaffected', 'were', 'all', 'very', 'young', 'before', 'the', 'likely', 'age', 'of', 'onset']"
2955,1.0,Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance.,"['specimens', 'from', '_num_', 'pretreatment', 'and', 'or', '_chemical_', 'resistant', 'tumors', 'were', 'analyzed', 'to', 'identify', 'molecular', 'correlates', 'of', '_chemical_', 'resistance']"
2956,1.0,CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.,"['_chemical_', 'is', 'effective', 'in', 'inhibiting', 'the', 'activity', 'of', 'the', '_mutation_', '_gene_', 'mutant', 'in', 'a', 'kinase', 'activity', 'assay', 'and', 'proliferation', 'assay', 'using', 'neuroblastoma', 'kelly', 'cells']"
2957,0.0,The addition of crizotinib to this combination restored sensitivity in vitro.,"['the', 'addition', 'of', '_chemical_', 'to', 'this', 'combination', 'restored', 'sensitivity', 'in', 'vitro']"
2958,1.0,"In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient).","['in', 'a', 'retrospective', 'analysis', 'of', '_num_', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', '_gene_', 'mutations', 'were', 'more', 'common', 'among', 'patients', 'with', 'no', 'benefit', 'from', '_gene_', 'inhibition', '_chemical_', 'or', 'panitumumab', '_num_', 'patients', 'than', 'with', 'patients', 'with', 'response', 'to', '_gene_', 'directed', 'treatment', '_num_', 'patient']"
2959,1.0,149 metastatic CRC patients treated with irinotecan/5FU as first-line chemotherapy were followed in this study.,"['_num_', 'metastatic', '_gene_', 'patients', 'treated', 'with', '_chemical_', '5fu', 'as', '_num_', 'line', 'chemotherapy', 'were', 'followed', 'in', 'this', 'study']"
2960,1.0,"In-vitro, imatinib-induced apoptosis was reduced in cells harboring the BIM deletion polymorphism.","['in', 'vitro', '_chemical_', 'induced', 'apoptosis', 'was', 'reduced', 'in', 'cells', 'harboring', 'the', '_gene_', 'deletion', 'polymorphism']"
2961,1.0,The mechanism of this resistance was shown to be amplification of the BRAF V600E gene.,"['the', 'mechanism', 'of', 'this', 'resistance', 'was', 'shown', 'to', 'be', 'amplification', 'of', 'the', '_gene_', '_mutation_', 'gene']"
2962,1.0,The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.,"['the', 'group', 'of', '_num_', 'out', 'of', '_num_', 'tumor', 'samples', 'with', 'increased', 'copy', 'number', 'or', 'amplification', 'of', '_gene_', 'as', 'determined', 'by', 'fish', 'fish', 'positive', 'had', 'worse', 'progression', 'free', 'and', 'overall', 'survival', 'than', 'fish', 'negative', 'tumors']"
2963,1.0,It encompasses parts  of the FUS gene on l6pll at its 5’ end and the DDIT3 gene at 12q13 at its 3’ ends,"['it', 'encompasses', 'parts', 'of', 'the', '_gene_', 'gene', 'on', '_abbrev_', 'at', 'its', '_num_', '’', 'end', 'and', 'the', '_gene_', 'gene', 'at', '12q13', 'at', 'its', '_num_', '’', 'ends']"
2964,1.0,This translocation results primarily in two fusions.,"['this', 'translocation', 'results', 'primarily', 'in', '_num_', 'fusions']"
2965,1.0,"In this meta-analysis of nine studies querying the association between KRAS status and PD-L1expression, KRAS-mutant tumors were more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; OR 1.69; 95% CI 1.01-2.84; p = 0.045).","['in', 'this', '_disease_', 'analysis', 'of', '_num_', 'studies', 'querying', 'the', 'association', 'between', '_gene_', 'status', 'and', '_abbrev_', '_gene_', 'mutant', 'tumors', 'were', 'more', 'likely', 'to', 'be', '_gene_', 'positive', 'than', '_gene_', 'wild', 'type', 'tumors', '_num_', 'vs', '_num_', 'or', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
2966,1.0,RT-PCR indicated CLTC-ALK fusion.,"['_disease_', 'indicated', '_gene_', 'fusion']"
2967,1.0,"In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplications in exon 20 (n=25).","['in', 'a', 'study', 'of', '_num_', 'non', 'small', 'cell', 'lung', 'cancer', 'patients', '_num_', 'of', 'the', 'analyzed', 'tumors', 'had', '_gene_', 'mutations', 'including', 'deletions', 'in', 'exon', '_num_', '_ineq_', '_mutation_', '_ineq_', '_mutation_', '_ineq_', 'and', 'insertions', 'or', 'duplications', 'in', 'exon', '_num_', '_ineq_']"
2968,1.0,"In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor).","['in', 'an', 'evaluation', 'of', '_num_', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', '_disease_', 'cell', 'lines', '_num_', 'were', 'responsive', 'to', '_chemical_', '_gene_', 'inhibitor']"
2969,1.0,Individuals with KILLIN-promoter methylation had a 3-fold increased prevalence of breast cancer (35/42 vs 24/64; p<0.0001) over individuals with germline PTEN mutations.,"['individuals', 'with', '_gene_', 'promoter', 'methylation', 'had', 'a', '_n_fold_', 'increased', 'prevalence', 'of', 'breast', 'cancer', '_ratio_', 'vs', '_ratio_', 'p', '_num_', 'over', 'individuals', 'with', 'germline', '_gene_', 'mutations']"
2970,1.0,"A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991),  where IC50 below 150nM was sensitive, and above 1000nM resistant.","['a', 'panel', 'of', '_num_', 'breast', 'cancer', 'cell', 'lines', 'was', 'tested', 'for', 'sensitivty', 'resistance', 'to', '_gene_', 'inhibitor', '_chemical_', '_chemical_', 'where', '_abbrev_', 'below', '_unit_', 'was', 'sensitive', 'and', 'above', '_unit_', 'resistant']"
2971,1.0,MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed.,"['_disease_', 'breast', 'cancer', 'cell', 'line', 'was', 'exposed', 'to', '_gene_', 'inhibitors', '_chemical_', 'or', '_gene_', 'until', 'resistance', 'developed']"
2972,1.0,This mutation causes a premature stop codon at amino acid 201 and was found in a VHL type 2B patient (patient no V51).,"['this', 'mutation', 'causes', 'a', 'premature', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_gene_']"
2973,1.0,"In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively).","['in', 'a', 'randomized', 'open', 'label', 'phase', '_num_', 'study', '_abbrev_', 'women', 'with', '_gene_', 'positive', 'primary', 'breast', 'cancer', 'treated', 'with', '_chemical_', 'plus', 'trasuzumab', 'had', 'higher', 'rates', 'of', 'pathological', 'complete', 'responses', 'than', 'seen', 'in', 'control', 'groups', 'receiving', 'either', 'iv', '_chemical_', 'or', 'oral', '_chemical_', 'alone', 'combination', 'treatment', 'pcr', 'rate', 'of', '_num_', 'vs', '_num_', 'and', '_num_', 'for', '_chemical_', 'and', '_chemical_', 'alone', 'respectively']"
2974,0.0,we conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC.,"['we', 'conclude', 'that', 'their', 'findings', 'confirm', 'the', 'potential', 'for', '_gene_', 'targeting', 'therapy', 'in', 'select', 'cases', 'of', '_gene_']"
2975,1.0,CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or EML4-ALK with the L1196M mutation.,"['_chemical_', 'treatment', 'resulted', 'in', 'significant', 'tumor', 'regression', 'in', 'xenograft', 'models', 'produced', 'from', 'ba', '_abbrev_', 'cells', 'expressing', '_chemical_', 'or', '_chemical_', 'with', 'the', '_mutation_', 'mutation']"
2976,1.0,Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment.,"['_gene_', '_mutation_', 'and', '_gene_', 'knockout', 'mutant', 'mice', 'were', 'resistant', 'to', '_chemical_', 'monotherapy', 'but', 'sensitive', 'to', 'combined', 'treatment']"
2977,1.0,"Cells were subsequently cultured in 96 well plates at increasing concentrations of crizotinib (250, 500, 720, 1000, 1440 and 2000 nM).","['cells', 'were', 'subsequently', 'cultured', 'in', '_num_', 'well', 'plates', 'at', 'increasing', 'concentrations', 'of', '_chemical_', '_num_', '_num_', '_num_', '_num_', '_num_', 'and', '_year_', '_unit_']"
2978,1.0,"2,597 healthy individuals were screened and the deletion polymorphism was identified in 12.3% of East Asian Population but 0% in African or European Population.","['_num_', 'healthy', 'individuals', 'were', 'screened', 'and', 'the', 'deletion', 'polymorphism', 'was', 'identified', 'in', '_num_', 'of', 'east', 'asian', 'population', 'but', '_num_', 'in', 'african', 'or', 'european', 'population']"
2979,1.0,There is very strong evidence for pathogenicity in the form of  a frameshift variant in a gene where loss-of-function is  known mechanism of disease (ACMG code: PSV1).,"['there', 'is', 'very', 'strong', 'evidence', 'for', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'frameshift', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
2980,1.0,Double blind Phase II clinical trial found an objective response rate of 18.4% and 19% for two groups of patients treated with 250mg/d and 500mg/d respectively.,"['double', 'blind', 'phase', 'ii', 'clinical', 'trial', 'found', 'an', 'objective', 'response', 'rate', 'of', '_num_', 'and', '_num_', 'for', '_num_', 'groups', 'of', 'patients', 'treated', 'with', '_unit_', 'd', 'and', '_unit_', 'd', 'respectively']"
2981,1.0,One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13.,"['_num_', 'sample', 'showed', 'potential', 'rearrangement', 'and', '_disease_', 'demonstrated', 'an', '_chemical_', 'fusion', 'where', '_gene_', 'exon', '_num_', 'was', 'fused', 'to', '_gene_', 'exon', '_num_']"
2982,1.0,Study examined rare SNPs on MAP2K7 among a discovery and two validation cohorts.,"['study', 'examined', 'rare', 'snps', 'on', '_gene_', 'among', 'a', 'discovery', 'and', '_num_', 'validation', 'cohorts']"
2983,1.0,This silent mutation was found in two VHL type 2A family members (patient no V78).,"['this', 'silent', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_gene_', 'family', 'members', 'patient', 'no', '_abbrev_']"
2984,1.0,Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901.,"['_gene_', '_gene_', 'mutant', 'melanomas', 'were', 'less', 'sensitive', 'to', '_chemical_', 'than', 'the', 'mek', 'inhibitor', '_chemical_']"
2985,1.0,823 patients with GIST under therapy with imatinib were genotyped for this study.,"['_num_', 'patients', 'with', 'gist', 'under', 'therapy', 'with', '_chemical_', 'were', 'genotyped', 'for', 'this', 'study']"
2986,1.0,"Mutations in isocitrate dehydrogenase 1 and 2, which result in overproduction of 2-hydroxyglutarate (2HG).","['mutations', 'in', '_chemical_', '_gene_', '_num_', 'and', '_num_', 'which', 'result', 'in', 'overproduction', 'of', '_chemical_', '2hg']"
2987,1.0,"In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.","['in', 'patients', 'with', '_disease_', 'complete', 'remission', 'rates', 'are', 'not', 'different', 'between', 'patients', 'who', 'harbor', 'the', '_gene_', '_abbrev_', 'mutation', 'and', 'those', 'with', 'wild', 'type', '_gene_']"
2988,1.0,"In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11).","['in', 'this', 'phase', '_num_', 'trial', '_disease_', '_abbrev_', 'by', '_gene_', 'breast', 'cancer', 'patients', 'with', 'stage', '_disease_', 'b', 'c', 'or', 'inflammatory', 'disease', 'were', 'randomized', '1:1:1', 'to', '_chemical_', 'n', '_num_', '_chemical_', 'n', '_num_', 'or', '_chemical_', 'n', '_num_']"
2989,1.0,"Hopman et al presents a case study with an affected proband carrying PTEN R173C, and meeting the pediatric criteria for PTEN testing of Tan et al (2011).","['hopman', 'et', 'al', 'presents', 'a', 'case', 'study', 'with', 'an', 'affected', 'proband', 'carrying', '_gene_', '_mutation_', 'and', 'meeting', 'the', 'pediatric', 'criteria', 'for', '_gene_', 'testing', 'of', 'tan', 'et', 'al', '_year_']"
2990,1.0,But two of them had NRAS p.Q61K mutation.,"['but', '_num_', 'of', 'them', 'had', 'nras', '_mutation_', 'mutation']"
2991,1.0,"Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001).","['progression', 'free', 'survival', 'was', 'significantly', 'longer', 'with', '_chemical_', 'treatment', 'than', 'chemotherapy', '_num_', 'vs', '_num_', 'months', 'hazard', 'ratio', 'for', 'progression', 'or', 'death', 'with', '_chemical_', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_', 'and', 'objective', 'response', 'rate', 'was', 'higher', 'with', '_chemical_', 'treatment', 'than', 'chemotherapy', '_num_', 'vs', '_num_', 'p', '_num_']"
2992,1.0,"In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991).","['in', 'a', 'panel', 'of', '_num_', 'breast', 'cancer', 'cell', 'lines', '_gene_', 'overexpressing', 'cells', 'were', 'among', 'those', 'more', 'sensitive', 'to', '_gene_', 'inhibitor', '_chemical_', '_chemical_']"
2993,1.0,"Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors.","['_chemical_', 'was', 'growth', 'inhibitory', 'for', '_num_', 'pancreatic', 'cancer', 'cell', 'lines', 'but', 'cytotoxic', 'only', 'toward', '_abbrev_', '_gene_', '_gene_', 'and', '_abbrev_', '_gene_', '_gene_', 'cells', 'both', 'of', 'which', 'express', 'high', 'levels', 'of', '_gene_', '_gene_', 'and', '_gene_', 'receptors']"
2994,1.0,"the cell line was also resistant to crizotinib and alectinib, and sequencing of ALK from the cell line revealed the I1171T mutation.","['the', 'cell', 'line', 'was', 'also', 'resistant', 'to', '_chemical_', 'and', '_chemical_', 'and', 'sequencing', 'of', '_gene_', 'from', 'the', 'cell', 'line', 'revealed', 'the', '_mutation_', 'mutation']"
2995,1.0,87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo.,"['_num_', 'patients', 'with', '_gene_', 'mutant', 'stage', 'iib', 'iv', '_disease_', 'after', '_num_', 'line', 'therapy', 'were', 'randomly', 'assigned', '_ratio_', 'to', 'oral', 'selumetunib', 'and', '_chemical_', 'or', '_chemical_', 'and', 'placebo']"
2996,1.0,"One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations.","['_num_', 'ocular', 'melanoma', 'patient', 'with', 'prolonged', 'stable', 'disease', 'who', 'later', 'went', 'on', 'to', 'complete', '_num_', 'courses', 'was', 'positive', 'for', '_gene_', '_mutation_', 'and', '_gene_', '_mutation_', 'mutations']"
2997,1.0,Three studies have associated CCND1 expression with poorer survival.,"['_num_', 'studies', 'have', 'associated', '_gene_', 'expression', 'with', 'poorer', 'survival']"
2998,0.0,Expression levels of RRM1 progressively increased during the development of gemcitabine resistance.,"['expression', 'levels', 'of', '_gene_', 'progressively', 'increased', 'during', 'the', 'development', 'of', '_chemical_', 'resistance']"
2999,1.0,"Further, in an in vivo study, KPL-4 xenografts expressing PIK3CA H1047R were reportedly sensitive to ado-trastuzumab emtansine, as assessed by tumor growth.","['further', 'in', 'an', 'in', 'vivo', 'study', '_abbrev_', 'xenografts', 'expressing', '_gene_', '_mutation_', 'were', 'reportedly', 'sensitive', 'to', 'ado', '_chemical_', '_chemical_', 'as', 'assessed', 'by', 'tumor', 'growth']"
3000,1.0,KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT.,"['kit', 'mutation', 'is', 'associated', 'with', 'worse', 'overall', 'and', '_disease_', 'prognosis', 'in', 'patients', 'with', 'gist', 'compared', 'to', 'patients', 'with', 'wildtype', 'kit']"
3001,0.0,Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.,"['efficacy', 'of', '_chemical_', 'in', '_gene_', 'overexpressing', '_disease_', 'remains', 'unclear']"
3002,1.0,291 EOC patients without BRCA mutations were used in this study.,"['_num_', '_disease_', 'patients', 'without', '_gene_', 'mutations', 'were', 'used', 'in', 'this', 'study']"
3003,1.0,The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.,"['the', '_gene_', 'and', '_disease_', 'pathways', 'are', 'required', 'for', 'the', 'repair', 'of', '_chemical_', 'and', '_abbrev_', 'dna', 'damage', 'and', 'failure', 'to', 'do', 'so', 'leads', 'to', 'lethality']"
3004,1.0,474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib).,"['_num_', 'cancer', 'cell', 'lines', 'from', 'the', 'cancer', 'cell', 'line', 'encyclopedia', 'were', 'assessed', 'for', 'response', 'to', 'the', '_gene_', 'inhibitor', '_chemical_', 'alpelisib']"
3005,0.0,The study also tested the role of ERCC1 expression and its correlation to RRM1 expression.,"['the', 'study', 'also', 'tested', 'the', 'role', 'of', '_gene_', 'expression', 'and', 'its', 'correlation', 'to', '_gene_', 'expression']"
3006,1.0,siRNA knockdown of NQO1 (in two cell lines) increased amrubicinol cytotoxicity.,"['sirna', 'knockdown', 'of', '_gene_', 'in', '_num_', 'cell', 'lines', 'increased', '_chemical_', 'cytotoxicity']"
3007,1.0,"Next, patients with pancreatic cancer were recruited and 18 tissue samples were taken.","['next', 'patients', 'with', 'pancreatic', 'cancer', 'were', 'recruited', 'and', '_num_', 'tissue', 'samples', 'were', 'taken']"
3008,1.0,Cell lines with acquired resistance to palbociclib were developed.,"['cell', 'lines', 'with', 'acquired', 'resistance', 'to', '_chemical_', 'were', 'developed']"
3009,1.0,Case report of a phase 1 study in advanced melanoma patients.,"['case', 'report', 'of', 'a', 'phase', '_num_', 'study', 'in', 'advanced', 'melanoma', 'patients']"
3010,1.0,1 patient had a deletion of I843.,"['_num_', 'patient', 'had', 'a', 'deletion', 'of', '_abbrev_']"
3011,1.0,Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.,"['genomic', 'profiling', 'of', 'the', 'bone', 'biopsy', 'revealed', '_gene_', '_mutation_', 'activating', 'mutation', 'and', 'the', 'patient', 'was', 'treated', 'with', '_chemical_']"
3012,1.0,"One of 4 individuals were identified with angiomas, 2 with cerebellar hemangioblastomas and 2 with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
3013,1.0,Case shows clear-cell renal cell carcinoma.,"['case', 'shows', 'clear', 'cell', 'renal', 'cell', 'carcinoma']"
3014,1.0,The majority of patients were smokers (97%).,"['the', 'majority', 'of', 'patients', 'were', 'smokers', '_num_']"
3015,1.0,ERBB4 was the most commonly mutated protein tyrosine kinase in this study in melanoma (19% in 79 patients).,"['_gene_', 'was', 'the', 'most', 'commonly', 'mutated', 'protein', 'tyrosine', 'kinase', 'in', 'this', 'study', 'in', 'melanoma', '_num_', 'in', '_num_', 'patients']"
3016,1.0,ROC analysis showed that a cut-off of 1% for any mutated allele offered the best predictive value.,"['roc', 'analysis', 'showed', 'that', 'a', 'cut', 'off', 'of', '_num_', 'for', 'any', 'mutated', 'allele', 'offered', 'the', 'best', 'predictive', 'value']"
3017,1.0,Few differences were observed between groups when treated with docetaxel + placebo.,"['few', 'differences', 'were', 'observed', 'between', 'groups', 'when', 'treated', 'with', '_chemical_', 'placebo']"
3018,1.0,In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).,"['in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'stage', 'i', 'or', 'stage', 'ii', '_disease_', 'it', 'was', 'discovered', 'that', 'the', '_gene_', 'protein', '_abbrev_', 'retrospectively', 'evaluated', 'via', '_gene_', 'was', 'associated', 'with', 'adverse', 'outcomes', '_p_val_']"
3019,1.0,"In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those without mutations or with nondisruptive mutations.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'those', 'with', 'disruptive', 'mutations', 'in', '_gene_', 'had', 'shorter', 'overall', 'survival', 'and', 'a', 'higher', 'rate', 'of', 'locoregional', 'recurrence', 'than', 'those', 'without', 'mutations', 'or', 'with', 'nondisruptive', 'mutations']"
3020,1.0,"In luminal A cancers, FGFR1 expression was also significantly associated with higher pN (lymph node metastases; p = 0.023) and pT (unfavorable tumor characteristics; p = 0.003) stages and lymphovascular invasion (p = 0.010).","['in', 'luminal', 'a', 'cancers', '_gene_', 'expression', 'was', 'also', 'significantly', 'associated', 'with', 'higher', 'pn', 'lymph', 'node', 'metastases', 'p', '_num_', 'and', 'pt', 'unfavorable', 'tumor', 'characteristics', 'p', '_num_', 'stages', 'and', 'lymphovascular', 'invasion', 'p', '_num_']"
3021,1.0,381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo).,"['_num_', 'patients', 'without', 'amplification', 'did', 'show', 'a', 'benefit', 'compared', 'to', 'placebo', '_num_', 'treated', 'vs', '_num_', 'placebo']"
3022,1.0,Sensitivity was determined by assessing EGFR auto-phosphorylation.,"['sensitivity', 'was', 'determined', 'by', 'assessing', '_gene_', 'auto', '_disease_']"
3023,1.0,"NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia.","['_gene_', 'mutations', 'were', 'associated', 'with', '_gene_', '_abbrev_', 'and', '_abbrev_', 'fab', '_disease_', 'of', 'acute', 'myeloid', 'leukemia']"
3024,1.0,Midostaurin is FDA-approved for the treatment of newly-diagnosed acute myeloid leukemia patients harboring FLT3 mutations.,"['_chemical_', 'is', 'fda', 'approved', 'for', 'the', 'treatment', 'of', '_disease_', 'acute', 'myeloid', 'leukemia', 'patients', 'harboring', '_gene_', 'mutations']"
3025,1.0,A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks.,"['a', 'partial', 'radiographic', 'response', 'with', 'a', 'decrease', 'of', '_num_', 'in', 'the', 'sum', 'of', 'maximum', 'diameters', 'of', 'target', 'metastatic', 'lesions', 'in', 'the', 'liver', 'and', 'spleen', 'was', 'noted', 'after', '_num_', 'cycles', 'of', 'therapy', 'and', 'remained', 'progression', 'free', 'at', 'more', 'than', '_num_', 'weeks']"
3026,1.0,A variants resulting in A56G frameshift (with stop introduced at position 131) was observed in a single patient of a VHL family.,"['a', 'variants', 'resulting', 'in', '_mutation_', 'frameshift', 'with', 'stop', 'introduced', 'at', 'position', '_num_', 'was', 'observed', 'in', 'a', 'single', 'patient', 'of', 'a', '_gene_', 'family']"
3027,1.0,All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment.,"['all', '_num_', 'patients', 'demonstrated', 'improvement', 'in', 'clinical', 'symptoms', 'and', 'resolution', 'of', 'laboratory', 'abnormalities', 'and', 'bone', 'marrow', 'pathology', 'in', 'response', 'to', 'treatment']"
3028,1.0,The patient was treated with crizotinib with marked response at 1 week and resolution of the tumor confirmed at 8 and 12 weeks via CT-scans.,"['the', 'patient', 'was', 'treated', 'with', '_chemical_', 'with', 'marked', 'response', 'at', '_num_', 'week', 'and', 'resolution', 'of', 'the', 'tumor', 'confirmed', 'at', '_num_', 'and', '_num_', 'weeks', 'via', '_disease_']"
3029,1.0,"The observed efficacy of afatinib against M774insAYVM, and studies reporting afatinib activity against other variants in the HER2 kinase domain, are cited by we as motivation for the arm of NCI-MATCH focusing on afatinib and activating HER2 mutations.","['the', 'observed', 'efficacy', 'of', '_chemical_', 'against', '_abbrev_', 'and', 'studies', 'reporting', '_chemical_', 'activity', 'against', 'other', 'variants', 'in', 'the', '_gene_', 'kinase', 'domain', 'are', 'cited', 'by', 'we', 'as', 'motivation', 'for', 'the', 'arm', 'of', 'nci', 'match', 'focusing', 'on', '_chemical_', 'and', 'activating', '_gene_', 'mutations']"
3030,1.0,MLL2 was found to be the most frequently mutated gene in a sample of 31/35 follicular lymphoma patients and was not mutated in normal centroblast samples.,"['_gene_', 'was', 'found', 'to', 'be', 'the', 'most', 'frequently', 'mutated', 'gene', 'in', 'a', 'sample', 'of', '_ratio_', 'follicular', 'lymphoma', 'patients', 'and', 'was', 'not', 'mutated', 'in', 'normal', 'centroblast', 'samples']"
3031,1.0,"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated SF3B1 mutations (N=51) were significantly associated with reduced time to first treatment (HR: 1.73; 95%CI: 1.05-2.86; P = 0.031).","['in', 'a', 'study', 'of', '_num_', 'previously', 'untreated', '_disease_', 'cases', 'a', 'multivariate', 'analysis', 'indicated', '_gene_', 'mutations', '_ineq_', 'were', 'significantly', 'associated', 'with', 'reduced', 'time', 'to', '_num_', 'treatment', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
3032,1.0,"Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response.","['because', 'of', 'the', 'high', 'frequency', 'of', 'the', '_gene_', '_gene_', 'mutation', 'the', 'patient', 'was', 'considered', 'a', 'suitable', 'candidate', 'for', 'a', '_gene_', 'inhibitor', 'and', 'received', '_chemical_', 'monotherapy', 'which', 'is', 'approved', 'for', 'this', 'situation', 'at', '_unit_', 'daily', 'which', 'was', 'later', 'reduced', 'to', '_unit_', 'daily', 'and', 'had', '_gene_', 'normalization', 'as', 'well', 'as', 'partial', 'metabolic', 'and', 'radiologic', 'response']"
3033,1.0,"The patient also harbored PMS2 R315*, MSH2 p.E483G and MSH6 p.V352I mutations.","['the', 'patient', 'also', 'harbored', '_gene_', '_abbrev_', '_gene_', 'p', '_abbrev_', 'and', '_gene_', 'p', '_abbrev_', 'mutations']"
3034,1.0,Multivariate analysis identified NPM1 mutation in the absence of FLT3-ITD as a prognostic marker for the achievement of CR (P=0.004).,"['multivariate', 'analysis', 'identified', '_gene_', 'mutation', 'in', 'the', 'absence', 'of', '_gene_', 'as', 'a', 'prognostic', 'marker', 'for', 'the', 'achievement', 'of', 'cr', '_p_val_']"
3035,1.0,MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib.,"['_gene_', 'cell', 'lines', 'overexpressing', '_gene_', '_gene_', 'showed', 'growth', 'inhibition', 'with', '_chemical_']"
3036,1.0,"Overall, this work indicates that MEK inhibitors with this mechanism of action will be most effective in patients with both BRAF and KRAS mutations.","['overall', 'this', 'work', 'indicates', 'that', 'mek', 'inhibitors', 'with', 'this', 'mechanism', 'of', 'action', 'will', 'be', 'most', 'effective', 'in', 'patients', 'with', 'both', '_gene_', 'and', '_gene_', 'mutations']"
3037,1.0,Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin.,"['overexpression', 'of', '_gene_', 'in', '_num_', 'lung', 'cancer', 'cell', 'lines', 'was', 'associated', 'with', 'sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_']"
3038,1.0,"FCGR2A H131R carriers did not have a significantly different response rate, progression-free survival, or overall survival.","['_gene_', '_mutation_', 'carriers', 'did', 'not', 'have', 'a', 'significantly', 'different', 'response', 'rate', 'progression', 'free', 'survival', 'or', 'overall', 'survival']"
3039,1.0,This missense mutation was found in a suspected VHL mutation carrier by DHPLC (family VHL 106).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'suspected', '_gene_', 'mutation', 'carrier', 'by', '_disease_', 'family', '_gene_', '_num_']"
3040,1.0,Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'patient', 'with', 'metastatic', 'melanoma', 'treated', 'with', 'mek', 'inhibitor', '_chemical_', 'in', 'a', 'clinical', 'trial']"
3041,1.0,"While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned.","['while', 'afatanib', 'did', 'show', 'response', 'in', '_gene_', 'breast', 'cancer', 'patients', 'it', 'was', 'not', 'better', 'than', 'investigator', ""'s"", 'treatment', 'choice', 'and', 'the', 'investigators', 'state', 'that', 'no', 'further', 'development', 'of', '_chemical_', 'for', '_gene_', 'breast', 'cancer', 'will', 'be', 'planned']"
3042,1.0,"This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.","['this', 'report', 'covered', '_num_', 'african', 'american', 'patients', 'the', '_num_', 'of', 'which', 'presented', 'high', 'grade', 'endometrial', 'adenocarcinoma', 'with', '_abbrev_', '_disease_', 'as', 'well', 'as', 'positivity', 'by', 'fish']"
3043,1.0,"In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial).","['in', 'a', 'retrospective', 'study', '_gene_', 'expression', 'was', 'assessed', 'by', '_gene_', 'for', '_num_', 'breast', 'cancer', 'patients', 'from', 'tax', '_num_', 'trial']"
3044,1.0,"IDH1/2 mutations did also not confer an overall survival benefit in patients with an intermediate risk karyotype (N=68, P=0.484).","['_gene_', 'mutations', 'did', 'also', 'not', 'confer', 'an', 'overall', 'survival', 'benefit', 'in', 'patients', 'with', 'an', 'intermediate', 'risk', 'karyotype', '_ineq_', '_p_val_']"
3045,1.0,Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to the class I PI3K inhibitor GDC-0941(p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines).,"['cell', 'lines', 'with', 'either', '_gene_', 'and', 'or', '_gene_', 'mutations', 'did', 'not', 'show', 'a', 'significant', 'difference', 'in', 'response', 'to', 'the', 'class', 'i', '_gene_', 'inhibitor', '_chemical_', 'p', '_ineq_', 'for', 'combined', '_abbrev_', 'aberrations', 'with', 'a', 'trend', 'towards', 'lower', '_abbrev_', 'for', 'mutated', 'cell', 'lines']"
3046,1.0,This mutation was found in a VHL type 1 family of 5 individuals.,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals']"
3047,0.0,The combination showed superior antitumor efficacy that was sustained after treatment withdrawal.,"['the', 'combination', 'showed', 'superior', 'antitumor', 'efficacy', 'that', 'was', 'sustained', 'after', 'treatment', 'withdrawal']"
3048,1.0,A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy.,"['a', '_age_', 'female', 'was', 'diagnosed', 'with', 'an', 'adenocarcinoma', 'of', 'the', 'ascending', 'colon', 'and', 'received', '_num_', 'months', 'of', 'adjuvant', 'chemotherapy']"
3049,1.0,"The patient with Y772_A775dup (Case 1 in the paper), maintained a metabolic complete response for 3 months, ultimately received a total of 9 months of Afatinib, and survived one year from study entry.","['the', 'patient', 'with', '_abbrev_', 'case', '_num_', 'in', 'the', 'paper', 'maintained', 'a', 'metabolic', 'complete', 'response', 'for', '_num_', 'months', 'ultimately', 'received', 'a', 'total', 'of', '_num_', 'months', 'of', '_chemical_', 'and', 'survived', '_num_', 'year', 'from', 'study', 'entry']"
3050,1.0,The related clinical trial ID is NCT00079066.,"['the', 'related', 'clinical', 'trial', 'id', 'is', '_abbrev_']"
3051,1.0,Median progression-free survival was 3.9 months with selumetinib + docetaxel and 2.8 months with placebo + docetaxel.,"['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'with', '_chemical_', '_chemical_', 'and', '_num_', 'months', 'with', 'placebo', '_chemical_']"
3052,1.0,"However, no statistically significant association is seen on multivariate analysis.","['however', 'no', 'statistically', 'significant', 'association', 'is', 'seen', 'on', 'multivariate', 'analysis']"
3053,1.0,18 studies involving 3674 patients were included.,"['_num_', 'studies', 'involving', '_num_', 'patients', 'were', 'included']"
3054,1.0,"High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or ALDH1A2 high and CRABP2 low) was significantly associated with OS and PFS in multivariate Cox analysis (OS, HR: 0.303, 95%CI 0.14–0.63, p-value 0.002 PFS, HR: 0.395, 95%CI 0.20–0.77, p-value 0.007).","['high', 'expression', 'of', 'both', '_gene_', 'and', '_gene_', 'in', 'comparison', 'to', '_gene_', 'low', 'or', '_gene_', 'high', 'and', '_gene_', 'low', 'was', 'significantly', 'associated', 'with', 'os', 'and', '_disease_', 'in', 'multivariate', 'cox', 'analysis', 'os', 'hr', '_num_', '_num_', 'ci', '_num_', '14–0', '_num_', 'p', 'value', '_num_', '_disease_', 'hr', '_num_', '_num_', 'ci', '_num_', '20–0', '_num_', 'p', 'value', '_num_']"
3055,1.0,Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation.,"['case', 'report', 'of', 'an', '_num_', 'year', 'old', 'man', 'with', 'lung', 'adenocarcinoma', 'and', '_gene_', '_mutation_', 'mutation']"
3056,1.0,Phase 1 trial in 57 patients with advanced cancers treated with selumetinib.,"['phase', '_num_', 'trial', 'in', '_num_', 'patients', 'with', 'advanced', 'cancers', 'treated', 'with', '_chemical_']"
3057,1.0,Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX models bearing JAK1 S703I mutation and delays tumor progression.,"['_chemical_', 'causes', 'the', 'suppression', 'of', 'jak', '_gene_', 'signaling', 'pathway', 'in', '_gene_', 'models', 'bearing', '_gene_', '_abbrev_', 'mutation', 'and', 'delays', 'tumor', 'progression']"
3058,1.0,"Less than 4 weeks later, all nodules had disappeared.","['less', 'than', '_num_', 'weeks', 'later', 'all', 'nodules', 'had', 'disappeared']"
3059,1.0,48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients).,"['_num_', 'tumor', 'samples', 'from', '_num_', 'patients', 'with', '_gene_', 'mutant', 'lung', 'adenocarcinoma', 'that', 'were', 'resistant', 'to', 'tyrosine', 'kinase', 'inhibition', 'underwent', 'next', 'generation', 'sequencing', 'ngs', 'failed', 'in', '_num_', 'samples', 'leading', 'to', 'a', 'remaining', '_num_', 'specimens', 'from', '_num_', 'patients']"
3060,1.0,Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability.,"['inhibition', 'of', '_gene_', 'by', 'increasing', 'concentrations', 'of', '_chemical_', 'led', 'to', 'a', 'decrease', 'in', 'viability']"
3061,1.0,Median follow-up was 10.6 months.,"['median', 'follow', 'up', 'was', '_num_', 'months']"
3062,1.0,"CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts.","['_abbrev_', 'cells', 'sorted', 'were', 'xenografted', 'into', 'mice', 'producing', 'larger', 'more', '_gene_', 'inhibitor', 'responsive', 'tumors', 'than', '_abbrev_', 'xenografts']"
3063,1.0,This mutation causes stop codon at amino acid 133 and was found in VHL type 1 patient (kindred no 64).,"['this', 'mutation', 'causes', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', '_gene_', 'type', '_num_', 'patient', 'kindred', 'no', '_num_']"
3064,1.0,"Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466).","['samples', 'from', '_num_', 'patients', 'with', '_disease_', 'were', 'evaluated', 'for', '_num_', 'snps', 'in', '_gene_', '_mutation_', '_mutation_', 'and', '_mutation_']"
3065,1.0,"In 5 patients, C481S was the sole abnormality.","['in', '_num_', 'patients', '_mutation_', 'was', 'the', 'sole', 'abnormality']"
3066,1.0,Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage.,"['responders', 'included', 'a', 'single', 'patient', 'with', 'a', 'somatic', 'frameshift', 'mutation', 'atm', '_abbrev_', 'predicted', 'to', 'result', 'in', 'truncation', 'prior', 'to', 'the', '_gene_', 'catalytic', 'domain', 'and', 'other', 'domains', 'for', '_gene_', 'recognition', 'and', 'response', 'to', 'dna', 'damage']"
3067,1.0,HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts.,"['_gene_', 'overexpressing', 'breast', 'cancer', 'cell', 'lines', 'with', '_gene_', 'mutation', '_abbrev_', '_mutation_', 'and', '_abbrev_', '_mutation_', 'were', 'used', 'to', 'establish', 'mouse', 'tumor', 'xenografts']"
3068,1.0,"PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).","['_gene_', 'expression', 'was', 'also', 'related', 'to', 'better', 'progression', 'free', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', 'and', 'better', 'overall', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_']"
3069,1.0,"Twelve patients with BCR-ABL-negative chronic myeloproliferative disease and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months).","['_num_', 'patients', 'with', '_gene_', '_gene_', 'negative', 'chronic', '_disease_', 'disease', 'and', 'reciprocal', 'translocations', 'involving', '_gene_', 'received', '_chemical_', 'for', 'a', 'median', 'of', '_num_', 'months', 'range', '_range_', 'months']"
3070,1.0,Patient also had a BRAF p.D594G mutation.,"['patient', 'also', 'had', 'a', '_gene_', '_mutation_', 'mutation']"
3071,1.0,Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).,"['low', 'atm', 'protein', 'expression', 'led', 'to', 'sensitivity', 'to', '_gene_', 'inhibitors', 'in', '_gene_', '', 've', 'gastric', 'cancer', 'cell', 'lines', '_num_', 'lines', 'were', 'used', 'for', 'various', 'aspects', 'of', 'this', 'study']"
3072,1.0,"In 119 metastatic colorectal cancer patients treated with cetuximab-based first-line chemotherapy, KRAS G12D mutations (N=44) were associated with longer overall patient survival when compared to other KRAS G12 mutations (23.3 vs 14-18 months; G12V, A, C, S, R).","['in', '_num_', 'metastatic', 'colorectal', 'cancer', 'patients', 'treated', 'with', '_chemical_', 'based', '_num_', 'line', 'chemotherapy', '_gene_', '_mutation_', 'mutations', '_ineq_', 'were', 'associated', 'with', 'longer', 'overall', 'patient', 'survival', 'when', 'compared', 'to', 'other', '_gene_', '_gene_', 'mutations', '_num_', 'vs', '_range_', 'months', '_mutation_', 'a', 'c', 's', 'r']"
3073,1.0,"In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD.","['in', 'contrast', 'of', 'the', '_num_', 'characterized', 'patients', 'with', '_gene_', 'mutations', 'that', 'were', 'not', '_mutation_', '_num_', 'showed', 'pd', 'and', '_num_', 'sd']"
3074,1.0,"Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.","['significant', 'differences', 'between', 'the', 'treatment', 'arms', 'were', 'not', 'observed', 'but', 'in', 'a', 'small', 'subset', 'of', '_abbrev_', 'positive', 'patients', '_num_', 'of', '_num_', 'responded', 'to', '_chemical_', 'and', 'had', 'increased', '_disease_', 'of', '_num_', 'months', 'in', 'comparison', 'to', '_num_', 'months', 'in', 'the', '_abbrev_', 'group']"
3075,1.0,"A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control.","['a', 'patient', 'derived', 'gastric', 'cancer', 'xenograft', 'mouse', 'model', 'was', 'established', 'with', '_gene_', '_mutation_', 'mutant', 'cells', 'and', 'treatment', 'with', '_chemical_', 'induced', 'significant', 'tumor', 'growth', 'inhibition', 'in', 'comparison', 'to', 'vehicle', 'control']"
3076,1.0,"This variant, identified in three cases of microsatellite-unstable colorectal cancer was confirmed to be somatic in patients with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', '_num_', 'cases', 'of', '_disease_', 'colorectal', 'cancer', 'was', 'confirmed', 'to', 'be', 'somatic', 'in', 'patients', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
3077,1.0,The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).,"['the', 'objective', 'response', 'rate', 'to', 'anti', '_gene_', 'antibody', 'nimotuzumab', 'did', 'not', 'differ', 'significantly', 'between', '_gene_', 'high', '', '_num_', 'pts', 'and', '_gene_', 'low', 'to', 'moderate', 'groups', '_num_', 'pts']"
3078,1.0,"Progression-free survival was not significant (P = 0.21), however, overall survival remained significant (P = 0.03) under multivariate analysis.","['_disease_', 'survival', 'was', 'not', 'significant', 'p', '_num_', 'however', 'overall', 'survival', 'remained', 'significant', 'p', '_num_', 'under', 'multivariate', 'analysis']"
3079,1.0,"Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT amplifications, and five (21%) with both.","['_num_', 'patients', '_num_', 'had', 'tumors', 'with', 'kit', 'mutations', '_num_', '_num_', 'with', 'kit', 'amplifications', 'and', '_num_', '_num_', 'with', 'both']"
3080,1.0,Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation.,"['phase', '_num_', 'study', 'of', '_chemical_', 'in', 'patients', 'with', 'advanced', 'melanoma', 'and', 'nras', 'or', '_gene_', 'mutation']"
3081,1.0,This missense mutation was found in a VHL type 1 family (lineage 14).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
3082,1.0,This study contains very strong evidence of pathogenicity in the form of a canonical +2 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'canonical', '+2', 'splice', 'site', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
3083,1.0,"Patients with large HSP110 T(17) deletions (≥5 bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (≤4 bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.012–0.8; P = .03).","['patients', 'with', 'large', '_gene_', 't', '_num_', 'deletions', '_ineq_', '_gene_', '_num_', 'of', '_num_', 'patients', '_num_', 'had', 'longer', 'times', 'of', 'relapse', 'free', 'survival', 'than', 'patients', 'with', 'small', 'or', 'no', 'deletions', '_ineq_', '_gene_', '_num_', 'of', '_num_', 'patients', '_num_', 'in', 'multivariate', 'analysis', 'hazard', 'ratio', '_num_', '_num_', 'confidence', 'interval', '_num_', '012–0', '_num_', 'p', '_num_']"
3084,1.0,"However, both confidence intervals had minimums below one (0.9 and 0.6, respectively).","['however', 'both', 'confidence', 'intervals', 'had', 'minimums', 'below', '_num_', '_num_', 'and', '_num_', 'respectively']"
3085,1.0,Only moderate evidence for pathogenicity because protein length changes as a result of in-frame insertions in a nonrepeat region (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'in', 'frame', 'insertions', 'in', 'a', 'nonrepeat', 'region', 'acmg', 'code', '_abbrev_']"
3086,1.0,"The patient next received ceritinib on a “Signature Trial"" for tumors with aberrations in ALK or ROS1 that are treated with oral ceritinib (LDK378) at 750 mg daily (NCT02186821).","['the', 'patient', 'next', 'received', '_chemical_', 'on', 'a', '“', 'signature', 'trial', 'for', 'tumors', 'with', 'aberrations', 'in', '_gene_', 'or', '_gene_', 'that', 'are', 'treated', 'with', 'oral', '_chemical_', '_chemical_', 'at', '_num_', '_unit_', 'daily', '_abbrev_']"
3087,1.0,Patients with p53 alterations showed increase in poor tumor cell differentiation (p<0.001) and increase in tumor cellular S-phase fraction (p<0.001).,"['patients', 'with', '_gene_', 'alterations', 'showed', 'increase', 'in', 'poor', 'tumor', 'cell', 'differentiation', 'p', '_num_', 'and', 'increase', 'in', 'tumor', 'cellular', '_disease_', 'fraction', 'p', '_num_']"
3088,1.0,"Algorithms including Align-GVGD predicted pathogenicity, however PolyPhen predicted that this variant was benign.","['algorithms', 'including', 'align', 'gvgd', 'predicted', 'pathogenicity', 'however', '_chemical_', 'predicted', 'that', 'this', 'variant', 'was', 'benign']"
3089,1.0,"However, no mutations were identified in 15 testicular sex cord-stromal tumors (8 classical Sertoli cell tumors, 3 Sertoli cell tumors-large cell calcifying variant, 4 sex cord-stromal tumors not otherwise specified).","['however', 'no', 'mutations', 'were', 'identified', 'in', '_num_', 'testicular', 'sex', 'cord', 'stromal', 'tumors', '_num_', 'classical', '_disease_', 'cell', 'tumors', '_num_', '_disease_', 'cell', 'tumors', 'large', 'cell', 'calcifying', 'variant', '_num_', 'sex', 'cord', 'stromal', 'tumors', 'not', 'otherwise', 'specified']"
3090,1.0,WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type.,"['wbc', 'counts', 'were', 'higher', 'in', '_disease_', 'patients', 'with', 'internal', 'tandem', 'repeat', 'of', '_gene_', 'compared', 'to', 'wild', 'type']"
3091,1.0,3 patients from 3 families were confirmed to have the above mutation.,"['_num_', 'patients', 'from', '_num_', 'families', 'were', 'confirmed', 'to', 'have', 'the', 'above', 'mutation']"
3092,1.0,Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line.,"['_num_', '_chemical_', 'estrogen', 'receptor', 'degrader', 'resistant', 'cell', 'lines', 'were', 'derived', 'from', 'parent', '_chemical_', 'sensitive', 'er+', '_abbrev_', 'breast', 'cancer', 'cell', 'line']"
3093,1.0,EML4-ALK variant 3 with F1245C mutation was found with allele frequency of 2% and tumor purity 13%.,"['_chemical_', 'variant', '_num_', 'with', '_mutation_', 'mutation', 'was', 'found', 'with', 'allele', 'frequency', 'of', '_num_', 'and', 'tumor', 'purity', '_num_']"
3094,1.0,"In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarcinoma were randomized to chemotherapy (epirubicin, cisplatin, capecitabine) with placebo or MET inhibitor rilotumumab.","['in', 'this', 'randomised', 'double', 'blind', 'placebo', 'controlled', 'phase', '_num_', 'trial', '_num_', 'patients', 'with', 'met+', 'expression', 'of', 'at', 'least', '1+', 'intensity', 'on', '_num_', 'or', 'more', 'tumor', 'cells', 'gastric', 'cancer', 'or', 'gastroesophageal', 'adenocarcinoma', 'were', 'randomized', 'to', 'chemotherapy', '_chemical_', '_disease_', '_chemical_', 'with', 'placebo', 'or', 'met', 'inhibitor', 'rilotumumab']"
3095,1.0,KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or placebo.,"['_gene_', '_abbrev_', 'status', 'was', 'evaluated', 'in', 'cell', 'free', 'dna', 'cfdna', 'of', 'patients', 'with', 'untreated', 'metastatic', 'adenocarcinoma', 'of', 'the', 'pancreas', 'that', 'were', 'randomised', '_ratio_', 'to', 'receive', '_chemical_', 'plus', '_chemical_', 'or', 'placebo']"
3096,1.0,"Rasheed et al identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compared to low-grade and child gliomas (68 others, varied).","['rasheed', 'et', 'al', 'identified', 'that', '_gene_', 'mutations', 'occur', 'with', 'significantly', 'greater', 'frequency', 'in', 'adults', 'with', 'high', 'grade', 'gliomas', '_num_', 'adult', 'glioblastoma', 'multiforme', 'and', '_num_', 'adult', 'anaplastic', '_disease_', 'compared', 'to', 'low', 'grade', 'and', 'child', 'gliomas', '_num_', 'others', 'varied']"
3097,1.0,In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib.,"['in', 'a', 'phase', '_num_', 'clinical', 'trial', '_abbrev_', '_num_', 'patients', 'with', 'advanced', 'cancers', 'all', 'harboring', '_gene_', 'alterations', 'were', 'treated', 'with', '_chemical_']"
3098,1.0,A higher percentage of patients saw blast reductions in the FLT3 mutant group than in the FLT3 wild type group (71 vs 42%).,"['a', 'higher', 'percentage', 'of', 'patients', 'saw', 'blast', 'reductions', 'in', 'the', '_gene_', 'mutant', 'group', 'than', 'in', 'the', '_gene_', 'wild', 'type', 'group', '_num_', 'vs', '_num_']"
3099,1.0,"DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (ρ, −0.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines.","['_gene_', 'expression', 'mrna', 'expression', 'from', 'an', 'independent', 'study', 'correlated', 'with', 'sensitivity', 'to', '_chemical_', 'ρ', '−0', '_num_', 'pearson', 'regression', 'analysis', 'in', 'this', 'preclinical', 'study', 'of', '_num_', 'solid', 'tumor', 'cell', 'lines']"
3100,1.0,Combination of nimotuzumab and temozolomide further increased efficacy.,"['combination', 'of', 'nimotuzumab', 'and', '_chemical_', 'further', 'increased', 'efficacy']"
3101,1.0,All mutations were compared with non-mutated BCR-ABL protein and evaluated for anti-proliferative activity and substrate or auto-phosphorylation assays.,"['all', 'mutations', 'were', 'compared', 'with', 'non', 'mutated', '_gene_', 'protein', 'and', 'evaluated', 'for', 'anti', '_disease_', 'activity', 'and', 'substrate', 'or', 'auto', '_disease_', 'assays']"
3102,1.0,Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.,"['elevated', 'levels', 'of', '_gene_', 'mrna', 'has', 'been', 'shown', 'to', 'be', 'correlated', 'with', 'increased', 'depth', 'of', 'tumor', 'invasion', 'in', 'gastic', 'carcinoma']"
3103,1.0,"MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while those with p53 mutations demonstrated resistance.","['_gene_', 'inhibitor', 'screen', 'in', 'a', 'panel', 'of', '_num_', 'cancer', 'cell', 'lines', 'with', 'well', 'characterized', '_gene_', 'status', 'shows', 'that', 'only', 'cancer', 'cell', 'lines', 'with', 'unaltered', '_gene_', 'may', 'be', 'sensitive', 'to', '_gene_', 'inhibitor', '_abbrev_', 'while', 'those', 'with', '_gene_', 'mutations', 'demonstrated', 'resistance']"
3104,1.0,"In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy.","['in', 'a', 'stage', 'iv', 'lung', 'adenocarcinoma', 'patient', 'harboring', '_gene_', 'exon', '_num_', 'deletion', '_gene_', 'exon', '_num_', 'deletion', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'monotherapy']"
3105,1.0,"VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals.","['_gene_', 'mutations', 'were', 'detected', 'in', 'affected', 'family', 'members', 'but', 'not', 'in', 'unaffected', 'family', 'members', 'or', '_num_', 'normal', 'individuals']"
3106,1.0,Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion.,"['case', 'report', 'of', 'a', 'patient', 'with', 'mammary', 'analogue', 'secretory', 'carcinoma', '_disease_', 'harboring', 'an', '_abbrev_', 'fusion']"
3107,1.0,Alternative diagnostic assays for this event are also considered.,"['alternative', 'diagnostic', 'assays', 'for', 'this', 'event', 'are', 'also', 'considered']"
3108,1.0,A 62-year-old female carrying the mutation and a male with an unknown mutation had hemangioblastomas of the central nervous system (CNS).,"['a', '_age_', 'female', 'carrying', 'the', 'mutation', 'and', 'a', 'male', 'with', 'an', 'unknown', 'mutation', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'cns']"
3109,1.0,Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells.,"['decreased', '_disease_', 'on', '_gene_', 'tyrosine', '_num_', 'was', 'seen', 'with', '_chemical_', 'over', '_chemical_', 'at', '_num_', 'and', '_num_', '_unit_', 'concentrations', 'in', '_abbrev_', 'cells']"
3110,1.0,"In an in vitro study,  a SW48 cell line expressing KRAS G12V mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 241.90 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'decreased', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'p', '_num_', 'compared', 'to', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
3111,1.0,In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild type line.,"['in', 'vitro', 'studies', 'in', '_num_', '_disease_', 'cell', 'lines', 'showed', 'enhanced', '_gene_', '_disease_', 'and', '_chemical_', 'sensitivity', 'in', 'the', 'mutant', 'line', 'compared', 'with', 'the', 'wild', 'type', 'line']"
3112,1.0,"ACMG evidence codes: 'PP1' based on segregation results, 'PP4' the patients phenotypes are highly specific for a disease with single genetic etiology.","['acmg', 'evidence', 'codes', ""'pp1"", 'based', 'on', 'segregation', 'results', ""'pp4"", 'the', 'patients', 'phenotypes', 'are', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'single', 'genetic', 'etiology']"
3113,1.0,"Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutated CRC.","['_chemical_', 'treated', 'patients', 'with', '_gene_', 'low', '_gene_', 'wild', 'type', '_gene_', 'had', 'poor', 'survival', 'similar', 'to', '_gene_', 'mutated', '_gene_']"
3114,1.0,"However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC.","['however', '_abbrev_', 'oropharyngeal', '_disease_', 'still', 'had', 'better', '_disease_', 'and', 'os', 'than', '_abbrev_', 'non', 'oropharyngeal', '_disease_']"
3115,1.0,"MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab.","['_gene_', 'level', 'was', 'correlated', 'with', '_disease_', 'hazard', 'ratio', '_num_', '_num_', 'confidence', 'interval', 'ci', ':1', '_num_', '_num_', '_num_', 'p', '_num_', 'and', 'os', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'in', 'the', 'discovery', 'and', 'validation', 'cohorts', 'but', 'not', 'in', 'patients', 'treated', 'without', '_chemical_']"
3116,1.0,FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number.,"['_gene_', 'was', 'also', 'highly', 'expressed', 'in', 'ewing', 'sarcoma', 'mrna', 'and', '_gene_', 'and', 'correlated', 'with', 'copy', 'number']"
3117,1.0,"The fusion has clear diagnostic value, though we caution that it is not perfectly specific to synovial sarcomas, and suggest that demonstration of t(X;18) in a spindle cell neoplasm should be integrated with the morphology, immunoprofile, and clinical setting of the tumour.","['the', 'fusion', 'has', 'clear', 'diagnostic', 'value', 'though', 'we', 'caution', 'that', 'it', 'is', 'not', 'perfectly', 'specific', 'to', 'synovial', 'sarcomas', 'and', 'suggest', 'that', 'demonstration', 'of', 't', 'x', '_num_', 'in', 'a', 'spindle', 'cell', 'neoplasm', 'should', 'be', 'integrated', 'with', 'the', 'morphology', 'immunoprofile', 'and', 'clinical', 'setting', 'of', 'the', 'tumour']"
3118,1.0,Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector,"['transfection', 'of', 'another', 'cell', 'line', 'with', 'this', 'mutation', 'led', 'to', 'lower', '_abbrev_', 'values', 'to', '_chemical_', 'and', '_chemical_', 'than', 'in', 'a', 'cell', 'line', 'transfected', 'with', 'a', 'control', 'vector']"
3119,1.0,This worse prognosis did not appear to be correlated with bone invasion (p=0.98).,"['this', 'worse', 'prognosis', 'did', 'not', 'appear', 'to', 'be', 'correlated', 'with', 'bone', 'invasion', '_p_val_']"
3120,1.0,"In older patients (>59 years) with cytogenetically normal acute myeloid leukemia classified as ELN favorable, multivariate analysis identified ASXL1 mutations (12/99 patients) were associated with lower complete remission rates (P = 0.03), disease-free survival (P < 0.001), overall survival (P < 0.001), and event-free survival (P < 0.001).","['in', 'older', 'patients', '_num_', 'years', 'with', 'cytogenetically', 'normal', 'acute', 'myeloid', 'leukemia', 'classified', 'as', 'eln', 'favorable', 'multivariate', 'analysis', 'identified', '_gene_', 'mutations', '_ratio_', 'patients', 'were', 'associated', 'with', 'lower', 'complete', 'remission', 'rates', 'p', '_num_', '_disease_', 'survival', 'p', '_num_', 'overall', 'survival', 'p', '_num_', 'and', 'event', 'free', 'survival', 'p', '_num_']"
3121,1.0,"Exon-2 KRAS mutation status was analyzed in 219 patients with pancreatic ductal carcinoma, excluding those who had previously undergone chemotherapy, first-line pancreatic resection, or neoadjuvant treatment with chemotherapy or radiotherapy.","['_abbrev_', '_gene_', 'mutation', 'status', 'was', 'analyzed', 'in', '_num_', 'patients', 'with', 'pancreatic', 'ductal', 'carcinoma', 'excluding', 'those', 'who', 'had', 'previously', 'undergone', 'chemotherapy', '_num_', 'line', 'pancreatic', 'resection', 'or', 'neoadjuvant', 'treatment', 'with', 'chemotherapy', 'or', 'radiotherapy']"
3122,1.0,CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.,"['ct', 'scans', 'after', '_num_', 'cycles', 'of', '_chemical_', 'treatment', 'showed', 'a', 'reduction', 'of', 'the', 'tumor', 'mass', 'which', 'continued', 'to', 'decrease', 'at', 'the', 'time', 'of', 'publication', 'after', '_num_', 'months', 'of', 'crizonitib', 'treatment']"
3123,1.0,Among them one 46-year old woman with spitzoid melanoma that  harbored  a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib.,"['among', 'them', '_num_', '_num_', 'year', 'old', 'woman', 'with', 'spitzoid', 'melanoma', 'that', 'harbored', 'a', '_abbrev_', 'fusion', 'responded', 'to', 'treatment', 'with', 'the', 'mek', 'inhibitor', '_chemical_']"
3124,1.0,None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor.,"['none', 'of', '_num_', 'cancer', 'cell', 'lines', 'with', '_gene_', 'mutation', 'and', 'absence', 'of', '_gene_', 'allele', 'are', 'sensitive', 'to', '_gene_', 'inhibitor']"
3125,1.0,"15 of these cell lines were genotyped for C609T (only 3 were T/T, and the rest were C/C or C/T).","['_num_', 'of', 'these', 'cell', 'lines', 'were', 'genotyped', 'for', '_mutation_', 'only', '_num_', 'were', '_disease_', 'and', 'the', 'rest', 'were', 'c', 'c', 'or', '_mutation_']"
3126,1.0,"Anti-tumor effects of nimotuzumab were greater in EGFRvIII in comparison to EGFRwt (as measured by antitumor effects, growth suppression, survival elongation and EGFR and Akt phosphorylation).","['anti', 'tumor', 'effects', 'of', 'nimotuzumab', 'were', 'greater', 'in', 'egfrviii', 'in', 'comparison', 'to', 'egfrwt', 'as', 'measured', 'by', 'antitumor', 'effects', 'growth', 'suppression', 'survival', 'elongation', 'and', '_gene_', 'and', '_gene_', '_disease_']"
3127,1.0,HPO terms: retinal hemangioblastomas.,"['_disease_', 'terms', 'retinal', '_disease_']"
3128,1.0,Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'patient', 'with', 'disease', 'progression', 'after', 'radiotherapy', 'and', '_num_', '_chemical_', 'cycles']"
3129,1.0,"This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR.","['this', 'patient', 'with', 'metastatic', 'disease', 'after', 'treatment', 'with', '_chemical_', 'and', '_chemical_', 'was', 'enrolled', 'onto', 'a', 'study', 'of', '_chemical_', 'in', 'combination', 'with', 'an', 'oral', 'mek', 'inhibitor', 'and', 'achieved', 'a', 'cr']"
3130,1.0,A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.,"['a', 'melanoma', 'cell', 'line', 'with', 'agk', '_gene_', 'in', 'frame', 'fusion', 'showed', 'decreased', 'sensitivity', 'towards', '_chemical_', 'in', 'comparison', 'with', '_gene_', 'mutated', '_mutation_', 'cell', 'lines']"
3131,1.0,Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.,"['cells', 'lines', 'expressing', '_gene_', 'harboring', 'the', '_mutation_', 'mutation', 'are', 'less', 'sensitive', 'to', 'growth', 'inhibition', 'by', '_chemical_', 'than', 'cells', 'expressing', 'the', '_mutation_', 'mutation']"
3132,1.0,"Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier.","['cerebrospinal', 'fluid', 'levels', 'of', '_chemical_', 'increased', 'linearly', 'with', 'blood', '_chemical_', 'levels', 'indicating', 'it', 'effectively', 'crossed', 'the', '_disease_', 'barrier']"
3133,1.0,There was no statistically significant difference in disease-free survival between trastuzumab-treated patients who had the FCGR3A 158 V/V high-affinity genotype and patients without that genotype (V/F and F/F).,"['there', 'was', 'no', 'statistically', 'significant', 'difference', 'in', '_disease_', 'survival', 'between', '_chemical_', 'treated', 'patients', 'who', 'had', 'the', '_gene_', '_num_', '_mutation_', '_disease_', 'genotype', 'and', 'patients', 'without', 'that', 'genotype', 'v', 'f', 'and', 'f', 'f']"
3134,1.0,"In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-associated genes.","['in', 'patients', 'with', '_disease_', 'bladder', 'chancer', 'a', 'cohort', 'of', 'complete', 'responders', 'to', 'platinum', 'chemotherapy', '_ineq_', 'and', 'non', 'responders', 'to', 'platinum', 'chemotherapy', '_gene_', 'were', 'evaluated', 'for', '_num_', 'cancer', 'associated', 'genes']"
3135,1.0,Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.,"['targeting', 'overactive', '_abbrev_', 'pathways', 'with', 'inhibitors', '_chemical_', 'and', '_chemical_', 'led', 'to', 'dramatic', 'tumor', 'regression']"
3136,1.0,Partial response was observed in 4 of 17 patients with BRAF V600 mutated melanoma.,"['partial', 'response', 'was', 'observed', 'in', '_num_', 'of', '_num_', 'patients', 'with', '_gene_', '_abbrev_', 'mutated', 'melanoma']"
3137,1.0,The rs17084733 variant in the 3' UTR of KIT was correlated with susceptibility to melanoma when comparing 70 melanoma patients to 94 healthy individuals from the same community.,"['the', '_mutation_', 'variant', 'in', 'the', '_num_', '_gene_', 'of', 'kit', 'was', 'correlated', 'with', 'susceptibility', 'to', 'melanoma', 'when', 'comparing', '_num_', 'melanoma', 'patients', 'to', '_num_', 'healthy', 'individuals', 'from', 'the', 'same', 'community']"
3138,1.0,This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).,"['this', 'study', 'contains', 'supporting', 'evidence', 'of', 'pathogenicity', 'due', 'to', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']"
3139,1.0,This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations.,"['this', 'study', 'performed', 'drug', 'response', 'assays', 'using', '_num_', 'human', '_disease_', 'cell', 'lines', 'with', 'various', 'combinations', 'of', '_gene_', 'mutations']"
3140,1.0,"we conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment.","['we', 'conclude', 'that', 'in', 'the', 'context', 'of', 'metastatic', '_chemical_', 'progressed', '_gene_', 'positive', 'bc', '_chemical_', 'with', '_chemical_', '_disease_', 'addition', 'is', 'a', 'favorable', 'treatment']"
3141,1.0,"This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging.","['this', '_year_', 'study', 'remains', 'cited', 'in', '_year_', 'literature', 'in', 'discussing', 'the', 'unclear', 'efficacy', 'of', '_chemical_', 'in', 'wild', 'type', '_gene_', 'overexpressing', '_disease_', 'but', 'mutant', '_gene_', 'in', '_disease_', 'has', 'been', 'further', 'studied', 'and', 'a', 'picture', 'of', 'different', '_gene_', 'mutations', 'being', 'potentially', 'responsive', 'to', 'specific', 'targeted', 'therapies', 'is', 'emerging']"
3142,1.0,In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases.,"['in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'primary', 'invasive', 'melanoma', 'hemizygous', 'or', 'homozygous', 'loss', 'of', '_gene_', 'was', 'observed', 'fish', 'in', '_num_', 'of', 'cases']"
3143,1.0,"172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patients, GSE35452).","['_num_', 'patients', 'treated', 'with', 'neoadjuvant', 'concurrent', 'chemoradiotherapy', 'ccrt', 'were', 'retrospectively', 'analyzed', 'for', 'expression', 'of', '_gene_', '_num_', '_gene_', 'using', '_gene_', 'discovery', 'set', 'with', '_num_', 'rectal', 'cancer', 'patients', '_abbrev_']"
3144,1.0,These findings were statistically independent of 17p deletions.,"['these', 'findings', 'were', 'statistically', 'independent', 'of', '17p', 'deletions']"
3145,1.0,A JAK1 Q503* mutation was observed at the time of relapse in patient 1.,"['a', '_gene_', '_abbrev_', 'mutation', 'was', 'observed', 'at', 'the', 'time', 'of', 'relapse', 'in', 'patient', '_num_']"
3146,1.0,Loss of heterozygosity (wildtype allele loss) was also demonstrated.,"['loss', 'of', 'heterozygosity', 'wildtype', 'allele', 'loss', 'was', 'also', 'demonstrated']"
3147,1.0,A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib plus an aromatase inhbitor (NCT01870505).,"['a', 'group', 'of', '_num_', 'breast', 'cancer', 'patients', 'were', 'treated', 'with', '_gene_', 'inhibitor', 'alpelisib', 'plus', 'an', '_gene_', 'inhbitor', '_abbrev_']"
3148,1.0,Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells.,"['_chemical_', 'increased', 'the', 'radiosensitivity', 'of', '_abbrev_', 'and', '_abbrev_', 'cells']"
3149,1.0,A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding.,"['a', 'panel', 'of', '_num_', 'mutations', 'representing', '_num_', 'of', 'known', 'mutations', 'seen', 'in', '_chemical_', '_gene_', 'patents', 'were', 'used', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'drug', 'binding']"
3150,0.0,"Further preclinical analyses suggested, that FGFR2 amplification mainly signals via the PI3K pathway.","['further', 'preclinical', 'analyses', 'suggested', 'that', '_gene_', 'amplification', 'mainly', 'signals', 'via', 'the', '_gene_', 'pathway']"
3151,1.0,"In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression.","['in', 'patients', 'with', 'breast', 'cancer', 'those', 'with', 'low', 'expression', 'of', '_gene_', 'had', 'worse', '_disease_', 'survival', 'than', 'those', 'with', 'high', 'expression']"
3152,1.0,"The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment.","['the', 'study', 'consisted', 'of', '_num_', 'patients', 'with', 'advanced', 'or', 'metastatic', '_disease_', 'that', 'tested', 'positive', 'for', '_gene_', 'rearrangement', 'via', 'break', 'apart', 'fish', 'assay', 'and', 'had', 'no', 'prior', 'systemic', 'treatment']"
3153,1.0,"46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).","['_num_', 'samples', 'showed', '_gene_', 'loss', 'while', '_num_', 'did', 'not', 'and', '_gene_', 'loss', 'alone', 'was', 'found', 'to', 'be', 'significantly', 'associated', 'with', 'resistance', 'to', '_chemical_', '_p_val_', 'and', 'shorter', 'overall', 'survival', '_p_val_']"
3154,1.0,IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening.,"['_abbrev_', 'values', 'with', '_gene_', 'inhibitor', '_chemical_', 'were', 'significantly', 'lower', 'in', '_gene_', 'and', 'or', '_gene_', 'mutated', 'cell', 'lines', 'in', 'the', 'sanger', 'cell', 'line', 'screening', 'but', 'these', 'results', 'could', 'not', 'be', 'reproduced', 'in', 'the', 'cancer', 'cell', 'line', 'encyclopedia', 'screening']"
3155,1.0,"High vIII expression was associated with reduced disease control rate (DCR) and shortened progression free survival (PFS) (HR: 3.3, P = 0.005) but not with OS.","['high', 'viii', 'expression', 'was', 'associated', 'with', 'reduced', 'disease', 'control', 'rate', '_gene_', 'and', 'shortened', 'progression', 'free', 'survival', '_disease_', 'hr', '_num_', 'p', '_num_', 'but', 'not', 'with', 'os']"
3156,1.0,Functional activity of ALK ATI was shown in-vitro.,"['functional', 'activity', 'of', '_gene_', '_gene_', 'was', 'shown', 'in', 'vitro']"
3157,1.0,"In contrast, the hazard ratio for KRAS wild type (WT) tumours was 0.85 (95% CI; 0.76, 0.95).","['in', 'contrast', 'the', 'hazard', 'ratio', 'for', '_gene_', 'wild', 'type', '_gene_', 'tumours', 'was', '_num_', '_num_', 'ci', '_num_', '_num_']"
3158,1.0,All 31 patients exhibited a hematologic response at the time of followup (European LeukemiaNet criteria).,"['all', '_num_', 'patients', 'exhibited', 'a', 'hematologic', 'response', 'at', 'the', 'time', 'of', 'followup', 'european', 'leukemianet', 'criteria']"
3159,1.0,130 patients had NPM1 mutations without FLT3-ITD.,"['_num_', 'patients', 'had', '_gene_', 'mutations', 'without', '_gene_']"
3160,1.0,"PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients.","['_gene_', 'nonsense', 'mutations', 'including', '_abbrev_', 'have', 'been', 'shown', 'to', 'be', 'inactivating', 'and', '_disease_', 'but', 'do', 'not', 'have', 'prognostic', 'value', 'in', 'glioblastoma', 'multiforme', 'patients']"
3161,1.0,A frameshift mutation in NF2 at position Y177 was found in a patient who did not respond to the standard platinum doublet chemotherapy regimen.,"['a', 'frameshift', 'mutation', 'in', '_gene_', 'at', 'position', '_abbrev_', 'was', 'found', 'in', 'a', 'patient', 'who', 'did', 'not', 'respond', 'to', 'the', 'standard', 'platinum', 'doublet', 'chemotherapy', 'regimen']"
3162,1.0,ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA).,"['_gene_', 'level', 'was', 'measured', 'in', 'serum', 'and', 'plasma', 'samples', 'of', '_ratio_', 'lung', 'adenocarcinoma', 'patients', 'and', '_ratio_', 'age', '', 'and', 'gender', 'matched', 'controls', 'elisa']"
3163,1.0,Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation.,"['analysis', 'of', 'original', 'tumor', 'samples', 'from', '_year_', 'and', '_year_', 'were', 'found', 'to', 'also', 'harbor', 'the', '_mutation_', 'but', 'not', '_mutation_', 'mutation']"
3164,1.0,Gene expression measures (qRT-PCR) were available for 103 patients.,"['gene', 'expression', 'measures', 'qrt', 'pcr', 'were', 'available', 'for', '_num_', 'patients']"
3165,1.0,This phenomenon was observed in patients treated in the pre-TKI era as well as those treated with imatinib when compared to wild type patients undergoing similar treatment.,"['this', 'phenomenon', 'was', 'observed', 'in', 'patients', 'treated', 'in', 'the', '_gene_', 'tki', 'era', 'as', 'well', 'as', 'those', 'treated', 'with', '_chemical_', 'when', 'compared', 'to', 'wild', 'type', 'patients', 'undergoing', 'similar', 'treatment']"
3166,1.0,"While they were observed in a somatic context in an RCC, we can infer that they could be predisposing for VHL in a germline context.","['while', 'they', 'were', 'observed', 'in', 'a', 'somatic', 'context', 'in', 'an', '_gene_', 'we', 'can', 'infer', 'that', 'they', 'could', 'be', 'predisposing', 'for', '_gene_', 'in', 'a', 'germline', 'context']"
3167,1.0,The other VHL family had 2 individuals with hemangioblastomas of the central nervous system (proband no 11).,"['the', 'other', '_gene_', 'family', 'had', '_num_', 'individuals', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'proband', 'no', '_num_']"
3168,0.0,"Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M).","['meningiomas', 'were', 'categorized', 'into', 'non', 'recurrent', '_gene_', 'recurrent', 'r', 'and', 'tumors', 'undergoing', 'malignant', 'progression', '_unit_']"
3169,1.0,"In a retrospective study of 151 patients with sporadic colorectal cancer, 5-year survival rate was significantly higher in patients with International Union Against Cancer (UICC) stages I to II (mean follow-up, 43 months) and the GNAS1 T393C polymorphism-associated TT genotypes (87.8%) compared with TC (71.0%) and CC genotypes (50.0%; P = 0.009).","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'patients', 'with', 'sporadic', 'colorectal', 'cancer', '_num_', 'year', 'survival', 'rate', 'was', 'significantly', 'higher', 'in', 'patients', 'with', 'international', 'union', 'against', 'cancer', '_disease_', 'stages', 'i', 'to', 'ii', 'mean', 'follow', 'up', '_num_', 'months', 'and', 'the', '_gene_', '_mutation_', 'polymorphism', 'associated', 'tt', 'genotypes', '_num_', 'compared', 'with', 'tc', '_num_', 'and', 'cc', 'genotypes', '_num_', 'p', '_num_']"
3170,1.0,"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.","['in', 'the', 'setting', 'of', '_gene_', '_mutation_', '_gene_', 'loss', 'resulted', 'in', 'elevated', 'activation', 'of', 'ras', '_chemical_', 'and', 'resistance', 'to', 'raf', 'inhibitors']"
3171,1.0,Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild type PIK3CA gene.,"['breast', 'cancer', 'cell', 'lines', 'with', '_mutation_', 'mutation', 'showed', 'increased', 'sensitivity', 'to', '_chemical_', 'than', 'cells', 'with', 'wild', 'type', '_gene_', 'gene']"
3172,1.0,"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13).","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'patients', 'with', 'multiple', 'myeloma', 'enrolled', 'in', 'a', 'clinical', 'trial', '_num_', 'had', 'mutations', 'in', '_gene_', '_ratio_', 'in', '_abbrev_']"
3173,1.0,Primary endpoint was time to progression.,"['primary', 'endpoint', 'was', 'time', 'to', 'progression']"
3174,1.0,"Similarly, mouse xenografts of PL11 cells (empty vector) were more sensitive to MMC or gemcitabine than PL11 cells expressing a wildtype FANCC.","['similarly', 'mouse', 'xenografts', 'of', '_abbrev_', 'cells', 'empty', 'vector', 'were', 'more', 'sensitive', 'to', '_disease_', 'or', '_chemical_', 'than', '_abbrev_', 'cells', 'expressing', 'a', 'wildtype', '_gene_']"
3175,1.0,Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance to rapamycin but maintained sensistivity to AZD8055.,"['downstream', 'signalling', 'was', 'independent', 'of', 'inhibitor', 'presence', 'in', 'these', 'clones', 'and', 'expression', 'of', 'the', 'mutation', 'in', '_disease_', 'cells', 'led', 'to', 'resistance', 'to', '_gene_', 'but', 'maintained', 'sensistivity', 'to', '_chemical_']"
3176,1.0,"In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild type alleles (n=2,194).","['in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'those', 'with', '_gene_', 'mutations', '_ineq_', 'had', 'significantly', 'worse', 'outcomes', 'when', 'compared', 'to', 'those', 'with', '_gene_', 'wild', 'type', 'alleles', '_ineq_']"
3177,1.0,"One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.","['_num_', 'patient', 'was', 'a', 'male', 'former', 'smoker', 'who', 'demonstrated', 'response', 'for', '_num_', 'months', 'with', 'overall', 'survival', 'of', '_num_', 'months', 'and', 'the', 'other', 'patient', 'was', 'a', 'female', 'never', 'smoker', 'who', 'had', 'response', 'for', '_num_', 'months', 'and', 'overall', 'survival', 'of', '17+', 'months', 'as', 'the', 'patient', 'was', 'alive', 'at', 'study', 'end']"
3178,1.0,"Evidence was found for the expression of FGFR1 in cancer-associated fibroblasts, other results were conflicting.","['evidence', 'was', 'found', 'for', 'the', 'expression', 'of', '_gene_', 'in', 'cancer', 'associated', 'fibroblasts', 'other', 'results', 'were', 'conflicting']"
3179,1.0,"In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'the', 'in', 'frame', 'insertion', 'of', 'a', 'single', 'amino', 'acid', 'at', 'position', '_num_', 'was', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
3180,0.0,"In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanomas.","['in', 'this', 'preclinical', 'study', 'gene', 'set', 'enrichment', 'analysis', 'revealed', '_gene_', 'inhibitors', 'as', 'potential', 'drugs', 'in', '_gene_', 'mutant', 'uveal', 'melanomas']"
3181,1.0,Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed.,"['metastases', 'were', 'seen', 'in', 'lymph', 'node', 'biopsy', 'and', 'subsequently', 'in', 'ct', '_gene_', 'inhibitor', '_chemical_', 'was', 'then', 'administered', 'at', '_num_', '_unit_', 'twice', 'daily', 'and', 'later', 'at', '_num_', '_unit_', 'twice', 'daily', 'and', 'reduction', 'in', 'metastases', 'was', 'observed']"
3182,1.0,Non-transformed human mammary epithelial MCF10A cells were compared to an isogenic line with PTEN knockout.,"['non', 'transformed', 'human', 'mammary', 'epithelial', '_abbrev_', 'cells', 'were', 'compared', 'to', 'an', 'isogenic', 'line', 'with', '_gene_', 'knockout']"
3183,1.0,"In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission (70% vs 87.5%), and lower 3-year Leukemia-Free Survival (44.4% vs. 84.4%).","['in', 'a', 'study', 'of', '_num_', '_gene_', 'patients', 'treated', 'with', 'combination', 'atra', '_chemical_', 'chemotherapy', 'patients', 'with', 'the', '_gene_', '_gene_', 'mutation', '_gene_', 'had', 'higher', 'rates', 'of', 'relapse', '_num_', 'vs', '_num_', 'lower', 'rates', 'of', 'remission', '_num_', 'vs', '_num_', 'and', 'lower', '_num_', 'year', 'leukemia', 'free', 'survival', '_num_', 'vs', '_num_']"
3184,1.0,qRT-PCR showed that MYCL1 but not c-MYC and MYCN was expressed in U266 cells and I-BET151 induced downregulation of MYCL1.,"['qrt', 'pcr', 'showed', 'that', '_gene_', 'but', 'not', '_gene_', 'and', '_gene_', 'was', 'expressed', 'in', '_chemical_', 'cells', 'and', '_chemical_', 'induced', 'downregulation', 'of', '_gene_']"
3185,1.0,"Six patients had a partial response, including four out of eight patients with NRAS mutations.","['_num_', 'patients', 'had', 'a', 'partial', 'response', 'including', '_num_', 'out', 'of', '_num_', 'patients', 'with', 'nras', 'mutations']"
3186,1.0,A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases.,"['a', 'mutation', 'in', 'exon', '_num_', 'of', 'the', '_gene_', 'gene', 'was', 'identified', 'in', '_num_', '_num_', 'of', 'the', '_num_', 'cases']"
3187,1.0,"The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047).","['the', 'patients', 'that', 'were', 'positive', 'for', '_gene_', 'expression', 'had', 'a', 'better', 'response', 'to', '_chemical_', 'or', '_chemical_', 'treatment', 'than', '_chemical_', '_p_val_', 'and', '_p_val_']"
3188,1.0,A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain.,"['a', 'biopsy', 'of', 'a', 'resistant', 'tumor', 'showed', 'an', 'acquired', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'kinase', 'domain']"
3189,1.0,"Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations.","['mutations', 'were', 'found', 'in', '_num_', 'of', '_num_', 'analyzed', 'tumors', '_num_', 'of', 'which', 'were', '_gene_', 'mutations']"
3190,1.0,"In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.","['in', '_disease_', 'patients', 'with', '_mutation_', 'and', 'another', 'activating', 'mutations', 'their', 'progression', 'free', 'survival', 'is', 'shorter', 'compared', 'to', 'those', 'who', 'do', 'not', 'possess', '_mutation_', 'mutation']"
3191,1.0,"In gastric cancer cell lines (MKN7, MKN45), siRNA mediated HSP110 knockdown led to a higher sensitivity to 5-FU and cisplatin compared with the parent and control cells (p < 0.05).","['in', 'gastric', 'cancer', 'cell', 'lines', '_chemical_', '_abbrev_', 'sirna', 'mediated', '_gene_', 'knockdown', 'led', 'to', 'a', 'higher', 'sensitivity', 'to', '_chemical_', 'and', '_disease_', 'compared', 'with', 'the', 'parent', 'and', 'control', 'cells', 'p', '_num_']"
3192,1.0,"In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease.","['in', 'response', 'to', '_chemical_', '_num_', 'patients', 'with', 'ret', '_mutation_', 'mutations', 'had', 'stable', 'disease', '_num_', 'ret', '_mutation_', 'mutant', 'had', 'partial', 'response', 'and', '_num_', 'patient', 'with', 'a', 'ret', '_mutation_', 'mutation', 'had', 'stable', 'disease']"
3193,1.0,This patient also harbored a heterozygous p.V49A variant.,"['this', 'patient', 'also', 'harbored', 'a', 'heterozygous', 'p', '_abbrev_', 'variant']"
3194,1.0,A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib.,"['a', 'single', 'patient', 'with', 'a', 'met', 'c', '_unit_', 'a', 'splice', 'donor', 'site', 'of', 'exon', '_num_', 'mutation', 'exhibited', 'clinical', 'sensitivity', 'to', 'the', '_gene_', 'inhibitor', '_chemical_']"
3195,1.0,"Similar experiments using NPM-ALK instead of EML4-ALK yielded survival IC50 of 549 nM of NPM-ALK G1202R to alectinib, which was 27.9 times higher than IC50 for NPM-ALK wild type.","['similar', 'experiments', 'using', '_chemical_', 'instead', 'of', '_chemical_', 'yielded', 'survival', '_abbrev_', 'of', '_num_', '_unit_', 'of', '_chemical_', '_mutation_', 'to', '_chemical_', 'which', 'was', '_num_', 'times', 'higher', 'than', '_abbrev_', 'for', '_chemical_', 'wild', 'type']"
3196,1.0,"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'ovarian', 'cancer', '_num_', 'patients', 'had', '_gene_', 'or', '_gene_', 'mutations', 'and', '_num_', 'patients', 'had', 'no', '_gene_', 'mutations']"
3197,1.0,"A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology).","['a', 'retrospective', '_chemical_', 'analysis', 'was', 'performed', 'in', '_num_', 'patients', 'for', '_gene_', 'nras', 'and', '_gene_', 'mutations', 'beam', 'technology']"
3198,1.0,422 mutations representing 16 different sites were identified.,"['_num_', 'mutations', 'representing', '_num_', 'different', 'sites', 'were', 'identified']"
3199,1.0,"It was found that in the patient subgroup with BRAF mutation (V600E in the majority of cases), there were no benefits to overall survival, progression free survival, or overall response rate with addition of cetuximab or panitumumab to treatment.","['it', 'was', 'found', 'that', 'in', 'the', 'patient', 'subgroup', 'with', '_gene_', 'mutation', '_mutation_', 'in', 'the', 'majority', 'of', 'cases', 'there', 'were', 'no', 'benefits', 'to', 'overall', 'survival', 'progression', 'free', 'survival', 'or', 'overall', 'response', 'rate', 'with', 'addition', 'of', '_chemical_', 'or', 'panitumumab', 'to', 'treatment']"
3200,1.0,"46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations and MLH1 expression (immunohistochemistry).","['_num_', 'patients', 'with', 'poorly', 'cohesive', 'signet', 'cell', 'ring', 'gastric', 'carcinoma', 'were', 'evaluated', 'for', 'genetic', 'mutations', 'and', '_gene_', 'expression', 'immunohistochemistry']"
3201,1.0,"In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated  with poor survival.","['in', 'this', 'retrospective', 'analysis', 'of', '_num_', 'breast', 'cancer', 'tissues', '_gene_', 'overexpression', 'was', 'correlated', 'with', 'poor', 'survival']"
3202,1.0,"DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs.","['_gene_', '_abbrev_', 'mutation', 'was', 'associated', 'with', 'reduced', 'relapse', 'free', 'and', 'overall', 'survival', 'in', 'eln', 'unfavorable', 'cytogenetically', 'normal', '_disease_']"
3203,1.0,"The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.","['the', 'clinical', 'pharmacogenomics', 'implementation', 'consortium', 'guidelines', 'for', '_gene_', 'genotype', 'and', '_chemical_', 'dosing', 'does', 'not', 'recommend', 'the', 'use', 'of', '_chemical_', 'or', '_chemical_', 'in', 'patients', 'with', 'homozygous', 'dpyd*2a', '_num_', 'or', '_mutation_', 'and', 'the', 'fda', 'drug', 'labels', 'warn', 'to', 'use', 'precautions', 'in', 'this', 'patient', 'population']"
3204,1.0,"This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK.","['this', 'fusion', 'generated', 'a', 'protein', 'with', '_chemical_', 'consisting', 'of', '_gene_', 'exons', '_range_', 'and', '_disease_', 'consisting', 'of', '_gene_', 'exons', '_range_', 'which', 'comprise', 'the', 'intracellular', 'kinase', 'domain', 'of', '_gene_']"
3205,1.0,The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments.,"['the', '_chemical_', '_disease_', 'cell', 'line', 'was', 'used', 'as', 'control', 'to', 'verify', '_gene_', '_gene_', 'overexpression', 'but', 'was', 'not', 'used', 'as', 'a', 'control', 'in', '_chemical_', 'inhibitor', 'experiments']"
3206,1.0,"Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.","['median', '_disease_', 'was', '_num_', 'months', 'in', 'the', '_chemical_', 'group', 'compared', 'with', '_num_', 'months', 'in', 'the', 'standard', 'chemotherapy', 'group']"
3207,1.0,RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus.,"['_disease_', 'and', 'fish', 'assays', 'were', 'developed', 'for', 'the', 'detection', 'of', 'rearrangements', 'of', 'the', '_gene_', 'locus']"
3208,1.0,Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort.,"['patients', 'with', '_gene_', '_mutation_', 'exhibited', 'worse', 'os', 'and', '_gene_', 'compared', 'with', 'the', 'entire', 'cohort']"
3209,1.0,Case 2 involved a 68 year old never-smoker with relapsed SCLC.,"['case', '_num_', 'involved', 'a', '_num_', 'year', 'old', 'never', 'smoker', 'with', 'relapsed', '_gene_']"
3210,1.0,Preclinical study in KRAS mutant lung and colon cancer models.,"['preclinical', 'study', 'in', '_gene_', 'mutant', 'lung', 'and', 'colon', 'cancer', 'models']"
3211,1.0,Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy.,"['analysis', 'was', 'performed', 'on', 'the', 'placebo', 'group', '_ineq_', 'of', 'the', 'phase', 'iii', 'study', 'saturn', 'using', '_chemical_', 'maintenance', 'therapy', 'for', 'patients', 'with', 'advanced', '_disease_', 'who', 'were', 'selected', 'for', 'response', 'or', 'stable', 'disease', 'after', '_num_', 'line', 'chemotherapy']"
3212,1.0,"In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment.","['in', 'a', 'colorectal', 'cancer', 'patient', 'with', 'a', '_gene_', '_mutation_', 'mutation', '_gene_', '_mutation_', 'was', 'reported', 'to', 'be', 'refractory', 'to', '_chemical_', 'treatment']"
3213,1.0,EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.,"['_gene_', 'amplification', 'was', 'not', 'a', 'predictor', 'of', 'response', 'to', '_chemical_', '_num_', '_gene_', 'platinum', 'in', 'patients', 'with', 'recurrent', 'or', 'metastatic', '_disease_', 'from', 'the', 'extreme', 'study']"
3214,1.0,"DUX4 fusions clustered into groups distinct from the other fusions, and these fusions as a whole clustered with Ph- ALL cases.","['_gene_', 'fusions', 'clustered', 'into', 'groups', 'distinct', 'from', 'the', 'other', 'fusions', 'and', 'these', 'fusions', 'as', 'a', 'whole', 'clustered', 'with', 'ph', '', 'all', 'cases']"
3215,1.0,Exon 19 deletion has been shown to be correlated with gefitinib response.,"['exon', '_num_', 'deletion', 'has', 'been', 'shown', 'to', 'be', 'correlated', 'with', '_chemical_', 'response']"
3216,1.0,There was no significant difference between responders and non-responders with regards to overall response rate to pazopanib (44% vs 33%; P=0.36).,"['there', 'was', 'no', 'significant', 'difference', 'between', 'responders', 'and', 'non', 'responders', 'with', 'regards', 'to', 'overall', 'response', 'rate', 'to', '_chemical_', '_num_', 'vs', '_num_', '_p_val_']"
3217,1.0,"In this study, Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015).","['in', 'this', 'study', '_disease_', 'curves', 'for', 'tumor', 'progression', 'development', 'of', 'metastasis', 'and', 'tumor', 'related', 'death', 'showed', 'a', 'significant', 'association', 'of', 'the', '_mutation_', 'polymorphism', 'with', 'outcome', '_num_', 'year', '_disease_', 'survival', 'rates', 'tt', '_num_', 'tc', '_num_', 'cc', '_num_', 'p', '_num_']"
3218,1.0,One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years.,"['_num_', 'patient', 'with', 'a', '_gene_', '_mutation_', 'had', 'a', 'confirmed', 'partial', 'response', 'with', '_num_', 'tumour', 'reduction', 'and', 'received', 'study', 'treatment', 'for', 'more', 'than', '_num_', 'years']"
3219,1.0,"In multivariate analysis, low expression served as negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002).","['in', 'multivariate', 'analysis', 'low', 'expression', 'served', 'as', 'negative', 'prognostic', 'factor', 'for', '_disease_', 'survival', 'hazard', '_ineq_', '_p_val_']"
3220,1.0,This led to concentration dependent decrease in the survival fraction in both cell lines with higher efficacy in Cal27 (ED50 ≈ 1 μM) as compared to FaDu cells (ED ≈ 44 μM).,"['this', 'led', 'to', 'concentration', 'dependent', 'decrease', 'in', 'the', 'survival', 'fraction', 'in', 'both', 'cell', 'lines', 'with', 'higher', 'efficacy', 'in', '_abbrev_', '_abbrev_', '≈', '_num_', 'μm', 'as', 'compared', 'to', '_chemical_', 'cells', 'ed', '≈', '_num_', 'μm']"
3221,1.0,"A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in all three resistant samples.","['a', 'structural', 'variation', 'in', '_abbrev_', '_gene_', 'with', 'an', 'identical', '_num_', '_num_', '_gene_', 'genomic', 'deletion', 'was', 'identified', 'in', 'all', '_num_', 'resistant', 'samples']"
3222,1.0,This missense mutation was found in a VHL type 2 family (lineage 73).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
3223,1.0,Significant decreased time to progression (p=0.037) was seen in the subset of  patients with p53 alteration (n=54) in comparison to the group with normatl p53 (n=20),"['significant', 'decreased', 'time', 'to', 'progression', '_p_val_', 'was', 'seen', 'in', 'the', 'subset', 'of', 'patients', 'with', '_gene_', 'alteration', '_ineq_', 'in', 'comparison', 'to', 'the', 'group', 'with', 'normatl', '_gene_', '_ineq_']"
3224,1.0,"The frequency of mutation in exon 19 deletion and L858R was 53.6% (140/261) and 42.5% (111/261), respectively.","['the', 'frequency', 'of', 'mutation', 'in', 'exon', '_num_', 'deletion', 'and', '_mutation_', 'was', '_num_', '_ratio_', 'and', '_num_', '_ratio_', 'respectively']"
3225,0.0,A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC.,"['a', '_disease_', 'analysis', 'to', 'evaluate', 'the', 'association', 'between', 'the', '_gene_', 'alteration', 'and', 'clinical', 'outcomes', 'in', 'patients', 'with', '_gene_']"
3226,1.0,SYT-SSX1 (aka SS18-SSX1) and SYT-SSX2 (aka SS18-SSX2).,"['_abbrev_', 'aka', '_abbrev_', 'and', '_abbrev_', 'aka', '_abbrev_']"
3227,1.0,"A 51-year old female never smoker with stage IV lung adenocarcinoma carrying a HER2 insertion in exon 20 (p.A775_G776insYVMA) by sequencing archived material, HER2 overexpression by IHC (2+) and HER2 amplification by in situ hybridization was treated with T-DM1 (trastuzumab emtansine).","['a', '_num_', 'year', 'old', 'female', 'never', 'smoker', 'with', 'stage', 'iv', 'lung', 'adenocarcinoma', 'carrying', 'a', '_gene_', 'insertion', 'in', 'exon', '_num_', '_mutation_', 'by', 'sequencing', 'archived', 'material', '_gene_', 'overexpression', 'by', '_gene_', '2+', 'and', '_gene_', 'amplification', 'by', 'in', '_disease_', 'hybridization', 'was', 'treated', 'with', '_disease_', '_chemical_', '_chemical_']"
3228,1.0,"MERTK inhibition via shRNA reduced MERTK-mediated downstream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft model.","['_gene_', 'inhibition', 'via', 'shrna', 'reduced', '_gene_', 'mediated', 'downstream', 'signaling', 'reduced', 'colony', 'formation', 'by', 'up', 'to', '_num_', 'and', 'diminished', 'tumor', 'volume', 'by', '_num_', 'in', 'a', 'human', 'melanoma', 'murine', 'xenograft', 'model']"
3229,1.0,"This mutation causes a premature stop codon at amino acid 142 and was found in a VHL type 1 patient and a VHL type 2B patient (patient no V73, V80).","['this', 'mutation', 'causes', 'a', 'premature', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'and', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_gene_', '_abbrev_']"
3230,1.0,"In a  clinical study of 63 recurrent glioma patients, de novo glioblastoma patients treated with cetuximab monotherapy (n=27) and harboring IDH1 codon 132 mutation were associated with improved overall survival (5.13 months vs. 0.90 months, 95% CI: 1.8, P=0.035), as compared to patients with wild type IDH1.","['in', 'a', 'clinical', 'study', 'of', '_num_', 'recurrent', 'glioma', 'patients', 'de', 'novo', 'glioblastoma', 'patients', 'treated', 'with', '_chemical_', 'monotherapy', '_ineq_', 'and', 'harboring', '_gene_', 'codon', '_num_', 'mutation', 'were', 'associated', 'with', 'improved', 'overall', 'survival', '_num_', 'months', 'vs', '_num_', 'months', '_num_', 'ci', '_num_', '_p_val_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
3231,1.0,Multivariate analysis adjusting for age and type of surgery also supported LRP1B deletion being associated with a higher hazard ratio.,"['multivariate', 'analysis', 'adjusting', 'for', 'age', 'and', 'type', 'of', 'surgery', 'also', 'supported', '_gene_', 'deletion', 'being', 'associated', 'with', 'a', 'higher', 'hazard', 'ratio']"
3232,1.0,45% of cases expressed high level of AREG.,"['_num_', 'of', 'cases', 'expressed', 'high', 'level', 'of', '_gene_']"
3233,1.0,TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098).,"['_gene_', 'mutation', 'was', 'shown', 'to', 'be', 'associated', 'with', 'shorter', 'overall', 'survival', 'in', 'patients', 'with', 'adrenocortical', 'tumors', 'log', 'rank', 'test', '_p_val_']"
3234,0.0,Efficacy of MEK inhibitors (GDC-0623 and G-573) in KRAS-driven tumours is mediated by a hydrogen-bond interaction with S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild type RAF.,"['efficacy', 'of', 'mek', 'inhibitors', '_chemical_', 'and', '_abbrev_', 'in', '_gene_', 'driven', 'tumours', 'is', 'mediated', 'by', 'a', 'hydrogen', 'bond', 'interaction', 'with', '_gene_', 'in', 'mek', 'that', 'is', 'critical', 'for', 'blocking', 'mek', 'feedback', '_disease_', 'by', 'wild', 'type', 'raf']"
3235,1.0,"Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with topotecan, cyclophosphamide and carboplatin followed by an autologous hematopoietic stem cell transplant.","['shorter', 'progression', 'free', 'survival', 'was', 'observed', 'in', 'patients', 'with', 'low', 'expression', '_gene_', 'of', 'topoisomerase', '_num_', 'in', '_num_', 'patients', 'with', 'relapsed', 'or', 'persistent', 'ovarian', 'or', 'peritoneal', 'carcinoma', 'after', 'treatment', 'with', '_chemical_', '_chemical_', 'and', '_chemical_', 'followed', 'by', 'an', 'autologous', 'hematopoietic', 'stem', 'cell', 'transplant']"
3236,1.0,The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans.,"['the', '_mutation_', '_mutation_', 'variant', 'of', '_gene_', 'is', 'observed', 'in', '_num_', 'in', 'african', 'americans', 'and', 'between', '_num_', 'and', '_num_', 'in', 'certain', 'african', 'populations', 'but', 'has', 'not', 'been', 'detected', 'in', 'caucasian', 'americans']"
3237,1.0,"Differences were not statistically significant, and afatanib patients experienced more adverse effects.","['differences', 'were', 'not', 'statistically', 'significant', 'and', 'afatanib', 'patients', 'experienced', 'more', 'adverse', 'effects']"
3238,1.0,No responses were seen in patients without BRCA mutation.,"['no', 'responses', 'were', 'seen', 'in', 'patients', 'without', '_gene_', 'mutation']"
3239,1.0,"Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by we as failing to control tumor growth.","['doxorubicin', 'was', 'part', 'of', 'the', 'patient', ""'s"", 'treatment', 'neoadjuvant', 'chemotherapy', 'with', '_chemical_', 'vincristine', 'and', '_chemical_', 'and', 'was', 'noted', 'by', 'we', 'as', 'failing', 'to', 'control', 'tumor', 'growth']"
3240,1.0,3 patients achieved PR and 4 achieved SD.,"['_num_', 'patients', 'achieved', 'pr', 'and', '_num_', 'achieved', 'sd']"
3241,1.0,One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment.,"['_num_', 'patient', 'enrolled', 'in', 'a', 'clinical', 'study', 'to', 'evaluate', '_chemical_', 'treatment', 'of', '_gene_', '_mutation_', 'mutant', 'hairy', 'cell', 'leukemia', 'developed', 'resistance', 'to', '_chemical_', 'retreatment']"
3242,1.0,Five patients tested positive for the 3a/3b EML4-ALK variant.,"['_num_', 'patients', 'tested', 'positive', 'for', 'the', '3a', '_chemical_', '_chemical_', 'variant']"
3243,1.0,"In RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic (9/10 cell lines) response rather than a cytotoxic response (1/10 cell lines).","['in', 'raf', 'ras', 'mutant', 'colon', 'cancer', 'cell', 'lines', 'co', 'occurring', '_abbrev_', 'mutations', 'led', 'to', 'a', '_chemical_', '_ratio_', 'cell', 'lines', 'response', 'rather', 'than', 'a', 'cytotoxic', 'response', '_ratio_', 'cell', 'lines']"
3244,1.0,"A t(X;18) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype.","['a', 't', 'x', '_num_', 'is', 'detected', 'cytogenetically', 'in', 'over', '_num_', 'of', 'synovial', 'sarcomas', 'regardless', 'of', 'histologic', 'subtype']"
3245,1.0,"Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene mutations.","['tumors', 'from', '_num_', 'patients', '_num_', 'with', 'partial', 'response', 'or', 'stable', 'disease', 'with', 'advanced', 'endometrial', 'carcinoma', 'were', 'assessed', 'for', '_gene_', 'mutational', 'status', 'revealing', '_num_', 'tumors', 'with', 'non', 'identical', '_gene_', 'gene', 'mutations']"
3246,1.0,"One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification.","['_num_', 'patient', 'had', 'small', 'cell', 'transformation', 'and', 'met', 'amplification', '_num_', 'patients', 'had', '_gene_', '_mutation_', 'mutation', 'and', 'met', 'amplification']"
3247,1.0,"At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells.","['at', 'values', 'of', '_num_', 'and', '_num_', '_unit_', '_chemical_', 'showed', 'increased', 'ability', 'to', 'inhibit', '_gene_', '_num_', 'tyrosine', '_disease_', 'in', '_abbrev_', 'cells']"
3248,1.0,"They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome.","['they', 'are', 'strongly', 'linked', 'to', 'non', 'mutated', '_gene_', 'genes', '_ratio_', 'p', '_num_', 'a', 'widely', 'recognized', 'prognostic', 'signature', 'for', 'poor', 'outcome']"
3249,1.0,"The discovery cohort consisted of 6 patients, results were validated in 10 patients.","['the', 'discovery', 'cohort', 'consisted', 'of', '_num_', 'patients', 'results', 'were', 'validated', 'in', '_num_', 'patients']"
3250,1.0,"In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK.","['in', 'a', 'phase', 'i', 'trial', '_abbrev_', 'of', 'the', 'drug', '_chemical_', 'in', 'pediatric', 'patients', 'a', 'subset', 'of', '_num_', 'neuroblastoma', 'patients', 'were', 'characterized', 'for', 'mutations', 'in', '_gene_']"
3251,0.0,After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well.,"['after', '_num_', 'cycles', 'of', 'therapy', 'a', 'repeat', 'mri', 'brain', 'showed', 'a', 'decrease', 'in', 'the', 'intracranial', 'disease', 'burden', 'and', '_gene_', 'showed', 'systemic', 'response', 'as', 'well']"
3252,1.0,"Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%).","['variants', 'of', 'uncertain', 'significance', 'were', 'a', 'missense', 'variant', 'in', '_gene_', 'and', 'a', 'missense', 'variant', 'in', '_gene_', 'at', 'amino', 'acid', '_num_', 'converting', 'the', 'wild', 'type', 'residue', 'arginine', 'to', 'tryptophan', 'frequency', '_num_']"
3253,1.0,She was treated with crizotinib at 250 mg twice daily but discontinued due to adverse response.,"['she', 'was', 'treated', 'with', '_chemical_', 'at', '_num_', '_unit_', 'twice', 'daily', 'but', 'discontinued', 'due', 'to', 'adverse', 'response']"
3254,1.0,Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1.,"['_chemical_', 'was', 'assessed', 'in', 'the', '_abbrev_', 'ba', '_abbrev_', 'cells', 'and', '_chemical_', 'resistant', '_disease_', 'cancer', 'cells', '_abbrev_', 'harboring', '_abbrev_', '_abbrev_']"
3255,1.0,He was initially treated with chemotherapy and he received an autologous stem cell transplant.,"['he', 'was', 'initially', 'treated', 'with', 'chemotherapy', 'and', 'he', 'received', 'an', 'autologous', 'stem', 'cell', 'transplant']"
3256,1.0,"None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.","['none', 'of', 'the', 'xenografts', 'harboring', '_gene_', '_ineq_', 'nras', '_ineq_', 'or', '_gene_', '_ineq_', 'mutations', 'showed', 'a', 'response', 'to', '_chemical_', 'and', 'only', '_num_', 'out', 'of', '_num_', 'xenografts', 'with', 'a', '_gene_', 'mutation', 'responded', 'to', '_chemical_']"
3257,1.0,The mRNA expression level of RRM1 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines cultured in incrementally increased concentrations of gemcitabine.,"['the', 'mrna', 'expression', 'level', 'of', '_gene_', 'was', 'analyzed', 'by', '_disease_', 'in', '_num_', 'human', 'pancreatic', 'cancer', 'cell', 'lines', 'cultured', 'in', 'incrementally', 'increased', 'concentrations', 'of', '_chemical_']"
3258,1.0,"Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response.","['overall', '_ratio_', 'patients', '_ratio_', 'with', 'no', 'other', 'identified', 'aberrations', 'in', 'dna', 'repair', 'genes', 'with', 'several', 'germline', 'and', 'somatic', 'aberrations', 'of', 'atm', 'had', 'a', 'response']"
3259,1.0,"Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition.","['chemical', 'library', 'screen', 'in', '_num_', 'cell', 'lines', 'also', 'identified', '_gene_', '_gene_', 'family', 'inhibitors', '_chemical_', '_chemical_', 'to', 'act', 'synergistically', 'with', '_gene_', 'inhibition']"
3260,1.0,NOTCH1 amplifications (as determined by FISH) were significantly (log-rank p = 0.025) associated with worse survival in a cohort of 116 patients with colorectal cancer.,"['_gene_', 'amplifications', 'as', 'determined', 'by', 'fish', 'were', 'significantly', 'log', 'rank', 'p', '_num_', 'associated', 'with', 'worse', 'survival', 'in', 'a', 'cohort', 'of', '_num_', 'patients', 'with', 'colorectal', 'cancer']"
3261,1.0,This loss of response was also modeled in another cell line.,"['this', 'loss', 'of', 'response', 'was', 'also', 'modeled', 'in', 'another', 'cell', 'line']"
3262,1.0,This patient also had loss of heterozygosity.,"['this', 'patient', 'also', 'had', 'loss', 'of', 'heterozygosity']"
3263,1.0,"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding.","['in', '_num_', 'cell', 'based', 'studies', 'a', 'panel', 'of', 'either', '_num_', 'or', '_num_', 'mutations', 'representing', '_num_', 'of', 'known', 'mutations', 'seen', 'in', '_chemical_', '_gene_', 'patents', 'were', 'used', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'drug', 'binding']"
3264,1.0,Knockdown of LKB1 in one additional cell line did not lead to an increase in sensitivity to mTOR inhibitors.,"['knockdown', 'of', '_gene_', 'in', '_num_', 'additional', 'cell', 'line', 'did', 'not', 'lead', 'to', 'an', 'increase', 'in', 'sensitivity', 'to', '_gene_', 'inhibitors']"
3265,1.0,This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.,"['this', 'mutation', 'should', 'be', 'tested', 'for', 'in', 'clinical', 'trials', 'and', 'is', 'recommended', 'for', 'testing', 'in', 'patients', 'with', 'cytogentically', 'normal', '_disease_']"
3266,1.0,"In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents.","['in', 'patients', 'lacking', '_gene_', 'promoter', 'methylation', 'the', 'use', 'of', 'an', '_gene_', 'inhibitor', 'such', 'as', 'o', '_num_', '', '_chemical_', 'in', 'combination', 'with', '_chemical_', 'agents', '_chemical_', 'may', 'be', 'useful', 'in', 'treating', 'patients', 'with', 'initial', 'resistance', 'to', '_chemical_', 'agents']"
3267,1.0,38 KRAS wild type patients were randomized to erlotinib or combination of selumetinib with erlotinib.,"['_num_', '_gene_', 'wild', 'type', 'patients', 'were', 'randomized', 'to', '_chemical_', 'or', 'combination', 'of', '_chemical_', 'with', '_chemical_']"
3268,1.0,A total of 60 patients with advanced solid tumors were enrolled in this study.,"['a', 'total', 'of', '_num_', 'patients', 'with', 'advanced', 'solid', 'tumors', 'were', 'enrolled', 'in', 'this', 'study']"
3269,1.0,"In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease.","['in', 'patients', 'with', 'non', 'small', 'cell', 'lung', 'cancer', 'harboring', 'the', '_chemical_', 'fusion', 'treatment', 'with', '_chemical_', 'has', 'shown', 'to', 'be', 'effective', 'in', 'acheiving', 'stable', 'disease']"
3270,1.0,The H3122 CR2 cell line survival IC50 value for alectinib treatment was approximately 20x higher than that for H3122 cells.,"['the', '_abbrev_', '_gene_', 'cell', 'line', 'survival', '_abbrev_', 'value', 'for', '_chemical_', 'treatment', 'was', 'approximately', '20x', 'higher', 'than', 'that', 'for', '_abbrev_', 'cells']"
3271,1.0,"In metastatic colorectal cancer, the objective tumor response rate to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab was lower in patients with PIK3CA mutations (23% vs. 0%, P=0.038, univariate analysis; odds ratio:0.1153, 95% CI:0.000-0.865, P=0.0337, multivariate analysis) compared to wildtype patients.","['in', 'metastatic', 'colorectal', 'cancer', 'the', 'objective', 'tumor', 'response', 'rate', 'to', 'the', 'anti', 'epidermal', 'growth', 'factor', 'receptor', '_gene_', 'monoclonal', 'antibodies', '_chemical_', 'or', 'panitumumab', 'was', 'lower', 'in', 'patients', 'with', '_gene_', 'mutations', '_num_', 'vs', '_num_', '_p_val_', 'univariate', 'analysis', 'odds', 'ratio:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'multivariate', 'analysis', 'compared', 'to', 'wildtype', 'patients']"
3272,1.0,The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases.,"['the', 'patient', 'initially', 'achieved', 'a', 'complete', 'response', 'on', 'met', 'inhibitor', '_chemical_', 'onartuzumab', 'for', '_num_', 'years', 'and', 'mixed', 'response', 'after', 'recurrence', 'with', 'resistance', 'in', 'some', 'of', 'the', 'newly', 'developing', 'metastases']"
3273,1.0,"Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029).","['absent', 'low', 'expression', 'of', '_gene_', '_gene_', 'was', 'associated', 'with', 'improved', 'response', 'to', 'chemotherapy', 'in', '_num_', 'patients', 'with', 'sporadic', 'ovarian', 'cancer', 'compared', 'to', 'patients', 'with', 'high', 'expression', 'odds', 'ratio', '_num_', '_num_', 'ci', '_range_', '_p_val_']"
3274,1.0,"Conversely, the BRAF V600E mutation is significantly more common in PTC cases with the TERT C228T mutation than in cases with the wild type allele of TERT.","['conversely', 'the', '_gene_', '_mutation_', 'mutation', 'is', 'significantly', 'more', 'common', 'in', '_gene_', 'cases', 'with', 'the', '_gene_', '_mutation_', 'mutation', 'than', 'in', 'cases', 'with', 'the', 'wild', 'type', 'allele', 'of', '_gene_']"
3275,0.0,HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy.,"['_gene_', 'status', 'was', 'determined', 'using', 'immunohistochemistry', 'and', 'silver', 'in', '_disease_', 'hybridization', 'and', 'correlated', 'with', '_chemical_', 'efficacy']"
3276,1.0,"Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively).","['regardless', 'of', '_gene_', 'status', 'patients', 'with', '_gene_', 'mutations', 'had', 'reduced', 'progression', 'free', 'and', 'overall', 'survival', '_p_val_', 'and', 'p', '_num_', 'respectively']"
3277,1.0,"More specifically, this mutation causes the following protein change: C162AfsX8.","['more', 'specifically', 'this', 'mutation', 'causes', 'the', 'following', 'protein', 'change', '_abbrev_']"
3278,1.0,"Hybrid capture next generation sequencing was performed and an I1171N mutation was found in rearranged ALK, and estimated to be in 33% of the tumor cells.","['hybrid', 'capture', 'next', 'generation', 'sequencing', 'was', 'performed', 'and', 'an', '_mutation_', 'mutation', 'was', 'found', 'in', 'rearranged', '_gene_', 'and', 'estimated', 'to', 'be', 'in', '_num_', 'of', 'the', 'tumor', 'cells']"
3279,1.0,Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001).,"['patients', 'with', '_gene_', 'mutations', 'were', 'found', 'to', 'have', 'significantly', 'shorter', 'progression', 'free', 'hr', '_num_', 'p', '_num_', 'and', 'overall', 'survival', 'hr', '_num_', 'p', '_num_']"
3280,1.0,Patient with c-kit-positive mesenchymal tumor in descending part of the duodenum.,"['patient', 'with', '_gene_', '_disease_', 'tumor', 'in', 'descending', 'part', 'of', 'the', 'duodenum']"
3281,1.0,Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region  (AMCG code: PM4).,"['only', 'moderate', 'evidence', 'of', 'pathogenicity', 'since', 'the', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'an', 'in', 'frame', 'deletion', 'in', 'a', 'nonrepeat', 'region', 'amcg', 'code', '_abbrev_']"
3282,1.0,MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed.,"['_disease_', 'breast', 'cancer', 'cell', 'line', 'was', 'exposed', 'to', '_gene_', 'inhibitor', '_gene_', 'until', 'resistance', 'developed']"
3283,1.0,These results were further confirmed in a Ba/F3 cell line model,"['these', 'results', 'were', 'further', 'confirmed', 'in', 'a', 'ba', '_abbrev_', 'cell', 'line', 'model']"
3284,1.0,"HPO terms: hemangioblastomas, retinal hemangioblastomas, renal cell carcinoma, multiple pancreatic cysts, papillary cystadenomas of the broad ligament.","['_disease_', 'terms', '_disease_', 'retinal', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts', 'papillary', '_disease_', 'of', 'the', 'broad', 'ligament']"
3285,1.0,"Only one patient was identified with retinal angiomas, hemangioblastomas of the central nervous system, pheochromocytoma, and renal cell carcinoma.","['only', '_num_', 'patient', 'was', 'identified', 'with', 'retinal', 'angiomas', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'pheochromocytoma', 'and', 'renal', 'cell', 'carcinoma']"
3286,1.0,The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasis.,"['the', 'patient', 'was', 'treated', 'with', 'pembrolizumab', 'and', 'lymphocyte', 'infiltration', 'was', 'noted', 'after', 'resection', 'of', 'a', 'spinal', 'metastasis']"
3287,1.0,"In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M.","['in', 'response', 'tumors', 'may', 'accumulate', 'an', 'additional', ""'gatekeeper"", 'mutation', 'in', '_gene_', '_mutation_']"
3288,1.0,"A minimum common region of deletion of 0.19Mb, encompassing exons 12–22 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance.","['a', 'minimum', 'common', 'region', 'of', 'deletion', 'of', '_num_', '19mb', 'encompassing', 'exons', '12–22', 'of', '_abbrev_', 'was', 'observed', 'in', '_num_', 'patients', 'exhibiting', 'acquired', 'treatment', 'resistance']"
3289,1.0,MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with standard of care therapy (cisplatin and pemetrexed).,"['_gene_', 'mrna', 'and', 'protein', 'expression', 'correlated', 'with', 'poor', 'os', 'and', '_disease_', 'for', 'patients', 'treated', 'with', 'standard', 'of', 'care', 'therapy', '_disease_', 'and', '_chemical_']"
3290,1.0,"Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0·49 [0·22-1·07; p=0·068], TC2/3 or IC2/3 HR 0·54 [0·33-0·89; p=0·014], TC1/2/3 or IC1/2/3 HR 0·59 [0·40-0·85; p=0·005], TC0 and IC0 HR 1·04 [0·62-1·75; p=0·871]) but not progression free survival or overall response rate.","['increasing', '_gene_', 'expression', 'was', 'associated', 'with', 'improved', 'overall', 'survival', '_chemical_', 'or', '_gene_', 'hr', '_num_', '_range_', '_p_val_', '_gene_', 'or', '_gene_', 'hr', '_num_', '_range_', '_p_val_', '_gene_', 'or', '_gene_', 'hr', '_num_', '_range_', '_p_val_', '_abbrev_', 'and', '_abbrev_', 'hr', '_num_', '_range_', '_p_val_', 'but', 'not', 'progression', 'free', 'survival', 'or', 'overall', 'response', 'rate']"
3291,1.0,"In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer.","['in', 'this', 'preclinical', 'study', 'of', 'the', 'effects', 'of', '_chemical_', 'panitumumab', 'or', '_abbrev_', 'on', 'various', '_gene_', 'mutations', 'in', 'colorectal', 'cancer']"
3292,1.0,Numerous variants were tested independently across 4 replicates and the mean and s.e.m.,"['numerous', 'variants', 'were', 'tested', 'independently', 'across', '_num_', 'replicates', 'and', 'the', 'mean', 'and', 's', 'e', '_unit_']"
3293,1.0,"SU11248 + Cytarabin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation (Combination Index = 0.59 for ED50, Combination Index = 0.71 for ED75, Combination Index = 0.82 for ED90)","['_chemical_', 'cytarabin', 'has', 'a', 'synergic', 'effect', 'on', 'murine', 'ba', '_abbrev_', 'cells', 'with', '_gene_', '_mutation_', 'mutation', 'combination', 'index', '_num_', 'for', '_abbrev_', 'combination', 'index', '_num_', 'for', '_abbrev_', 'combination', 'index', '_num_', 'for', '_abbrev_']"
3294,1.0,"The VHL type 1 family of 4 affected individuals had 2 patients with retinal angiomas, 5 with hemangioblastomas of the central nervous system, and one with renal cell carcinoma (family VHL 53).","['the', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'affected', 'individuals', 'had', '_num_', 'patients', 'with', 'retinal', 'angiomas', '_num_', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma', 'family', '_gene_', '_num_']"
3295,1.0,Her 10 month CEA was 1.4.,"['her', '_num_', 'month', '_gene_', 'was', '_num_']"
3296,1.0,BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.,"['_gene_', '_mutation_', 'is', 'shown', 'to', 'be', 'associated', 'with', 'the', 'tall', 'cell', 'variant', 'of', 'papillary', 'thyroid', 'cancer']"
3297,1.0,"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene.","['in', 'patients', 'with', 'papillary', 'thyroid', 'cancer', 'harboring', 'both', '_gene_', '_mutation_', 'and', 'the', '_gene_', 'promotor', 'mutation', '_mutation_', '_disease_', 'survival', 'is', 'worse', 'than', 'in', 'patients', 'harboring', '_num_', 'of', 'these', 'mutations', 'or', 'no', 'mutations', 'in', 'either', 'gene']"
3298,1.0,HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines.,"['_gene_', 'nuclear', 'translocation', 'was', 'identified', 'as', 'a', 'mediator', 'of', '_chemical_', 'resistance', 'in', '_gene_', 'positive', 'breast', 'cancer', 'cell', 'lines']"
3299,1.0,65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab).,"['_num_', 'patients', 'were', 'retrospectively', 'analyzed', 'for', 'mutational', 'profiles', 'predictive', 'of', 'response', 'to', '_gene_', 'inhibitors', '_chemical_', 'or', 'panitumumab']"
3300,1.0,"Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild type.","['regarding', '_disease_', 'benefit', 'with', 'anti', '_gene_', '_gene_', 'the', 'hazard', 'ratio', 'was', '_num_', '_num_', 'ci', '_num_', '_num_', 'for', 'other', '_gene_', 'mt', '_num_', '_num_', 'ci', '_num_', '_num_', 'for', '_gene_', '_mutation_', 'and', '_num_', '_num_', 'ci', '_num_', '_num_', 'for', '_gene_', 'wild', 'type']"
3301,1.0,"12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days.","['_num_', 'patients', 'responded', 'but', '_chemical_', 'response', 'was', 'lost', 'in', 'most', 'patients', 'after', '_num_', 'range', '_range_', 'days']"
3302,1.0,"Autophosphorylation was observed on tyrosine of mutant cells, but not wild type cells, which were starved from serum for 6 hours without rhVEGF stimulation.","['autophosphorylation', 'was', 'observed', 'on', 'tyrosine', 'of', 'mutant', 'cells', 'but', 'not', 'wild', 'type', 'cells', 'which', 'were', 'starved', 'from', 'serum', 'for', '_num_', 'hours', 'without', 'rhvegf', 'stimulation']"
3303,1.0,"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.","['the', 'presence', 'of', '_gene_', 'fusion', 'is', 'considered', 'the', 'characterizing', 'feature', 'of', 'chronic', 'myeloid', 'leukemia', 'and', 'has', 'been', 'widely', 'thought', 'of', 'as', 'the', 'initiating', 'event', 'in', 'the', 'disease']"
3304,1.0,The study's primary endpoint was progression free survival.,"['the', 'study', ""'s"", 'primary', 'endpoint', 'was', 'progression', 'free', 'survival']"
3305,1.0,Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.,"['breast', 'tumors', 'with', '_mutation_', 'or', '_abbrev_', 'mutations', 'are', 'more', 'responsive', 'to', 'doxorubicin', 'than', 'breast', 'tumors', 'with', 'wild', 'type', '_gene_']"
3306,1.0,"(HR, 1.50; 95% CI, 1.06 to 2.12; P=0.20)","['hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_']"
3307,1.0,This nonsense mutation was found in a VHL type 1 family (lineage 78).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
3308,1.0,The patient had a progression-free survival (PFS) of about 10 weeks.,"['the', 'patient', 'had', 'a', 'progression', 'free', 'survival', '_disease_', 'of', 'about', '_num_', 'weeks']"
3309,1.0,One patient with FGFR1 amplified bladder/urothelial carcinoma was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment.,"['_num_', 'patient', 'with', '_gene_', 'amplified', 'bladder', 'urothelial', 'carcinoma', 'was', 'treated', 'with', '_num_', '_unit_', 'and', 'progressed', 'rapidly', 'in', 'cycle', '_num_', 'after', '_num_', 'days', 'of', 'treatment']"
3310,1.0,Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested.,"['cell', 'proliferation', 'analysis', 'showed', 'that', 'the', '_abbrev_', 'mutant', 'had', 'the', 'highest', 'sensitivity', 'against', '_chemical_', 'among', 'all', 'mutations', 'tested']"
3311,1.0,"Five year overall survival was 83 months and non-MYCN amplified cases and 46  months in amplified cases, with p < 0.0001, indicating poorer prognosis for MYCN-amplified cases.","['_num_', 'year', 'overall', 'survival', 'was', '_num_', 'months', 'and', 'non', '_gene_', 'amplified', 'cases', 'and', '_num_', 'months', 'in', 'amplified', 'cases', 'with', 'p', '_num_', 'indicating', 'poorer', 'prognosis', 'for', '_gene_', 'amplified', 'cases']"
3312,1.0,DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.,"['_gene_', '_abbrev_', 'mutations', 'were', 'associated', 'with', 'cytogenetically', 'normal', '_disease_', 'in', 'a', 'large', 'cohort', 'of', 'younger', '_range_', '_disease_', 'patients']"
3313,1.0,This mutation was found in a VHL type 1 patient (patient no V287).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
3314,1.0,Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations.,"['changes', 'in', 'tumor', 'size', 'were', 'similar', 'between', 'groups', 'with', 'the', 'best', 'responses', 'in', 'tumors', 'with', '_mutation_', 'mutations']"
3315,1.0,Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2).,"['large', 'deletions', 'or', 'intragenic', 'mutations', 'predicted', 'to', 'cause', 'a', 'truncated', 'protein', 'were', 'found', 'in', '_num_', 'of', '_num_', 'families', 'without', 'pheochromocytoma', '_gene_', 'type', '_num_', 'and', '_num_', 'of', '_num_', 'families', 'with', 'pheochromocytoma', '_gene_', 'type', '_num_']"
3316,1.0,Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib.,"['cell', 'lines', 'with', 'a', '_abbrev_', 'fusion', 'were', 'resistant', 'to', 'treatment', 'with', '_chemical_', 'but', 'sensitive', 'to', 'treatment', 'with', '_chemical_']"
3317,1.0,"In patients with breast cancer, those with low expression of PgR treated with tamoxifen had the same disease-free survial as those with high expression of PgR.","['in', 'patients', 'with', 'breast', 'cancer', 'those', 'with', 'low', 'expression', 'of', '_gene_', 'treated', 'with', 'tamoxifen', 'had', 'the', 'same', '_disease_', 'survial', 'as', 'those', 'with', 'high', 'expression', 'of', '_gene_']"
3318,1.0,"In a study of 448 metastatic colorectal cancer patients treated with EGFR-TKIs and tested for EGFR and KRAS mutations, 69 tested positive for KRAS mutations.","['in', 'a', 'study', 'of', '_num_', 'metastatic', 'colorectal', 'cancer', 'patients', 'treated', 'with', '_gene_', 'and', 'tested', 'for', '_gene_', 'and', '_gene_', 'mutations', '_num_', 'tested', 'positive', 'for', '_gene_', 'mutations']"
3319,1.0,"Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls.","['athymic', 'mice', 'recieved', 'mmtv', '_disease_', 'tumor', 'cell', 'transplants', 'and', 'were', 'treated', 'with', '_chemical_', 'which', 'resulted', 'in', 'significant', 'but', 'minimal', 'reduction', 'in', 'tumor', 'growth', 'compared', 'to', 'controls']"
3320,1.0,"BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK.","['ba', '_abbrev_', 'cells', 'expressing', '_chemical_', 'were', 'able', 'to', 'grow', 'independently', 'of', '_gene_', 'addition', 'but', 'addition', 'of', '_gene_', 'inhibitor', '_chemical_', 'induced', 'cell', 'death', 'and', 'inhibited', 'tyrosine', '_disease_', 'of', '_chemical_']"
3321,1.0,"Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib.","['comparison', 'of', '_chemical_', 'and', '_chemical_', 'growth', 'inhibition', 'in', '_mutation_', 'cells', '_abbrev_', '_disease_', '_num_', 'imdm', 'and', 'kelly', 'showed', 'increased', 'sensitivity', 'to', '_chemical_', 'as', 'compared', 'to', '_chemical_']"
3322,1.0,"In contrast, crizotinib treatment of Ba/F3 with EML4-ALK G1269A had survival GI50 of 130nM.","['in', 'contrast', '_chemical_', 'treatment', 'of', 'ba', '_abbrev_', 'with', '_chemical_', '_mutation_', 'had', 'survival', '_gene_', 'of', '_unit_']"
3323,1.0,The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib.,"['the', '_disease_', 'cell', 'line', '_abbrev_', 'with', '_gene_', 'amplification', 'was', 'shown', 'to', 'have', 'low', 'antiproliferative', '_abbrev_', 'for', 'the', '_abbrev_', '_gene_', 'inhibitor', 'taselisib']"
3324,1.0,"In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression).","['in', '_num_', 'cohorts', '_ineq_', 'and', '_ineq_', 'of', 'er+', 'breast', 'cancer', 'patients', 'who', 'had', 'received', '_chemical_', '_gene_', 'overexpression', 'correlated', 'with', 'shorter', 'median', 'time', 'to', 'progression', 'in', 'both', 'cohorts', '_num_', 'vs', '_num_', 'months', 'and', '_num_', 'vs', '_num_', 'months', 'for', '_gene_', 'overexpression', 'vs', 'normal', 'expression']"
3325,1.0,"Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling.","['introduction', 'of', 'this', 'mutation', 'in', 'an', '_chemical_', 'sensitive', 'lymphoma', 'cell', 'line', 'showed', 'resistance', 'comparable', 'to', 'the', 'known', '_abbrev_', 'resistance', 'mutations', 'which', 'was', 'also', 'confirmed', 'by', 'absence', 'of', 'downstream', 'signaling']"
3326,1.0,Extension and reduction of the ATR exon 10 A10 repeat (alters codon I774) was associated with poorer overall and disease-free survival in patients with endometrioid endometrial cancer when compared to patients with wildtype ATR and with or without microsatellite instability.,"['extension', 'and', 'reduction', 'of', 'the', '_gene_', 'exon', '_num_', '_gene_', 'repeat', 'alters', 'codon', '_abbrev_', 'was', 'associated', 'with', 'poorer', 'overall', 'and', '_disease_', 'survival', 'in', 'patients', 'with', 'endometrioid', 'endometrial', 'cancer', 'when', 'compared', 'to', 'patients', 'with', 'wildtype', '_gene_', 'and', 'with', 'or', 'without', '_disease_', 'instability']"
3327,1.0,"HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts.","['_disease_', 'terms', '_disease_', 'retinal', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts']"
3328,1.0,"NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively.","['_abbrev_', 'groups', 'demonstrated', 'clinical', 'benefit', 'from', 'additional', 'patritumab', 'with', 'hazard', 'ratios', 'of', '_num_', 'p', '_num_', 'and', '_num_', 'p', '_num_', 'in', 'the', 'high', '', 'and', '_disease_', 'patritumab', 'arms', 'respectively']"
3329,1.0,Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks.,"['imaging', 'revealed', 'a', '_num_', 'decrease', 'in', 'extracranial', 'and', '_num_', 'decrease', 'in', 'intracranial', 'metastases', 'with', 'no', 'new', 'metastases', 'and', 'no', 'progressing', 'sites', 'at', '_num_', 'weeks']"
3330,1.0,"In patients with angioimmunoblastic T-cell lymphoma (a subtype of peripheral T-cell lymphoma), IDH2 R172 mutations (N=16) had no impact on overall survival when compared to patients with wildtype IDH2 (N=24).","['in', 'patients', 'with', '_disease_', '_disease_', 'lymphoma', 'a', 'subtype', 'of', 'peripheral', '_disease_', 'lymphoma', '_gene_', '_abbrev_', 'mutations', '_ineq_', 'had', 'no', 'impact', 'on', 'overall', 'survival', 'when', 'compared', 'to', 'patients', 'with', 'wildtype', '_gene_', '_ineq_']"
3331,1.0,The untreated PDX grew by over 100 percent while the BYL719 tumor was reduced by 86 percent.,"['the', 'untreated', '_gene_', 'grew', 'by', 'over', '_num_', 'percent', 'while', 'the', '_chemical_', 'tumor', 'was', 'reduced', 'by', '_num_', 'percent']"
3332,1.0,"In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study.","['in', 'a', '_disease_', 'analysis', 'of', '_num_', 'clinical', 'trials', 'evaluating', 'the', 'efficacy', 'of', '_chemical_', '_num_', 'patient', 'was', 'described', 'with', 'the', 'exon', '_num_', 'mutation', '_mutation_', 'from', 'the', 'merit', 'study']"
3333,1.0,"A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal angiomas and cerebellar hemangioblastomas.","['a', 'missense', 'mutation', 'affecting', 'residue', 'on', 'the', 'surface', 'of', '_gene_', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', 'and', 'cerebellar', '_disease_']"
3334,1.0,"One family of 3 had a asymptomatic 27-year-old female, a 27-year-old male with epididymal cystadenoma, and a 55-year old with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no 10).","['_num_', 'family', 'of', '_num_', 'had', 'a', 'asymptomatic', '_age_', 'female', 'a', '_age_', 'male', 'with', '_disease_', '_disease_', 'and', 'a', '_num_', 'year', 'old', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'proband', 'no', '_num_']"
3335,1.0,"NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML.","['nras', 'mutation', 'status', 'does', 'not', 'impact', 'overall', 'event', 'free', 'or', '_disease_', 'survival', 'in', 'patients', 'with', '_disease_']"
3336,1.0,"Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild type RET.","['medullary', 'thyroid', 'cancer', 'cells', 'with', 'ret', '_mutation_', 'mutation', 'are', 'insensitive', 'to', '_chemical_', 'compared', 'to', 'wild', 'type', 'ret']"
3337,1.0,"A pleural nodule was biopsied and profiled using hybrid-capture next generation sequencing, and revealed EML4-ALK variant 3 with F1245C mutation at mutant allele frequency of 2% and tumor purity of 13%.","['a', 'pleural', 'nodule', 'was', 'biopsied', 'and', 'profiled', 'using', 'hybrid', 'capture', 'next', 'generation', 'sequencing', 'and', 'revealed', '_chemical_', 'variant', '_num_', 'with', '_mutation_', 'mutation', 'at', 'mutant', 'allele', 'frequency', 'of', '_num_', 'and', 'tumor', 'purity', 'of', '_num_']"
3338,1.0,IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the Sanger cell line screening but these results could not be reproduced in the Broad cancer cell line encyclopedia screening.,"['_abbrev_', 'values', 'with', '_gene_', 'inhibitor', '_chemical_', 'were', 'significantly', 'lower', 'in', '_gene_', 'and', 'or', '_gene_', 'mutated', 'cell', 'lines', 'in', 'the', 'sanger', 'cell', 'line', 'screening', 'but', 'these', 'results', 'could', 'not', 'be', 'reproduced', 'in', 'the', 'broad', 'cancer', 'cell', 'line', 'encyclopedia', 'screening']"
3339,1.0,HGF signalling was among the top pathways identified.,"['_gene_', 'signalling', 'was', 'among', 'the', 'top', 'pathways', 'identified']"
3340,1.0,Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (HR 1.14; p = 0.5197).,"['median', '_disease_', 'was', '_num_', 'weeks', 'in', 'the', '_chemical_', 'arm', 'and', '_num_', 'weeks', 'in', 'the', '_chemical_', 'arm', 'hr', '_num_', 'p', '_num_']"
3341,1.0,"This silent mutation was found in a 34-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no 15).","['this', 'silent', 'mutation', 'was', 'found', 'in', 'a', '_age_', '_gene_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'proband', 'no', '_num_']"
3342,1.0,The patient's maternal grandparents were haematologicaly  normal.,"['the', 'patient', ""'s"", 'maternal', 'grandparents', 'were', 'haematologicaly', 'normal']"
3343,1.0,The 6-month overall survival rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group.,"['the', '_num_', 'month', 'overall', 'survival', 'rate', 'in', 'the', '_disease_', 'population', 'was', '_num_', 'in', 'the', '_chemical_', 'group', 'and', '_num_', 'in', 'the', 'chemotherapy', 'group']"
3344,1.0,The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response.,"['the', 'presence', 'of', 'a', '_gene_', 'mutation', 'in', 'exon', '_num_', 'such', 'as', '_mutation_', 'or', 'exon', '_num_', 'were', 'associated', 'with', 'lack', 'of', 'panitumumab', 'or', '_chemical_', 'response']"
3345,1.0,DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.,"['_gene_', 'mutations', 'were', 'associated', 'with', 'achievement', 'of', 'complete', 'remission', 'in', 'a', 'large', 'cohort', 'of', 'younger', '_range_', '_disease_', 'patients']"
3346,1.0,"Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel.","['stable', '_gene_', 'knockdown', 'in', 'ovarian', 'carcinoma', '_abbrev_', 'cell', 'lines', 'showed', 'increased', 'sensitivity', 'to', 'platinum', 'based', 'chemotherapy', 'drugs', '_chemical_', '_chemical_', '_chemical_', 'and', '_chemical_']"
3347,1.0,"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the L536Q ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.","['using', 'an', 'estrogen', 'response', 'element', '_disease_', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_abbrev_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_chemical_', 'cell', 'lines']"
3348,1.0,"In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).","['in', 'this', 'study', '_gene_', 'expression', 'measured', 'by', '_gene_', 'was', 'associated', 'with', 'better', 'overall', 'survival', 'in', 'the', 'subgroup', 'of', 'lung', '_disease_', 'cell', 'carcinomas', '_num_', 'of', '_num_', 'patients', 'in', 'the', 'study']"
3349,1.0,Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy.,"['patients', 'were', 'randomly', 'allocated', '_ratio_', 'to', 'receive', 'either', '_chemical_', 'or', 'standard', 'chemotherapy']"
3350,1.0,"EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02).","['_gene_', 'amplification', 'was', 'associated', 'with', 'increased', 'os', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', '_disease_', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'and', '_gene_', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
3351,1.0,"In a discovery cohort, 30 patients underwent IHC for HLA-DRA.","['in', 'a', 'discovery', 'cohort', '_num_', 'patients', 'underwent', '_gene_', 'for', '_gene_']"
3352,1.0,"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.","['among', '_num_', 'patients', 'treated', 'with', 'pan', '_gene_', 'inhibitor', '_chemical_', 'in', 'this', 'phase', '_num_', 'study', '_num_', 'patient', 'with', 'pancreatic', 'adenocarcinoma', 'and', '_gene_', 'loss', 'and', 'a', '_gene_', '_mutation_', 'mutation', 'experienced', 'a', 'decrease', 'of', 'approximately', '_num_', 'in', 'cancer', 'antigen', '_range_', 'levels', 'and', '_num_', 'shrinkage', 'in', 'tumor', 'measurements']"
3353,1.0,"In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK.","['in', 'a', 'cohort', 'of', '_num_', '_disease_', 'patients', 'that', 'had', 'tested', 'positive', 'for', '_num_', '_chemical_', 'rearrangements', '_num_', 'individuals', 'were', 'identified', 'via', '_disease_', 'with', 'a', 'novel', '_chemical_', 'translocation', 'involving', 'the', '_num_', '_num_', 'exons', 'of', '_gene_', 'fused', 'to', 'the', 'kinase', 'domain', 'of', '_gene_']"
3354,1.0,The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.,"['the', 'overall', 'response', 'rate', 'was', '_num_', 'with', '_ratio_', 'having', 'a', 'complete', 'response', 'and', '_ratio_', 'having', 'a', 'partial', 'response']"
3355,1.0,There was also no correlation to overall survival.,"['there', 'was', 'also', 'no', 'correlation', 'to', 'overall', 'survival']"
3356,1.0,Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations.,"['study', 'explored', 'the', 'hematologic', 'and', 'molecular', 'responses', 'in', 'a', 'cohort', 'of', '_num_', 'patients', 'presenting', 'with', '_disease_', 'and', '_gene_', 'exon', '_num_', 'frameshift', 'mutations']"
3357,1.0,Sequencing of this liver metastasis revealed an EML4-ALK fusion with an I1171S variant at a variant frequency of 36% (tumor purity estimated as 70%).,"['sequencing', 'of', 'this', 'liver', 'metastasis', 'revealed', 'an', '_chemical_', 'fusion', 'with', 'an', '_mutation_', 'variant', 'at', 'a', 'variant', 'frequency', 'of', '_num_', 'tumor', 'purity', 'estimated', 'as', '_num_']"
3358,1.0,"In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, a cohort of 12 cases with the AYVM insertion did not show any partial responses to dacomitinib, in contrast to a 50% PR rate in P780_Y781insGSP patients in this same study.","['in', 'this', 'phase', 'ii', 'study', '_abbrev_', 'of', '_chemical_', 'in', '_gene_', 'amplified', 'or', 'mutant', '_disease_', 'tumors', 'a', 'cohort', 'of', '_num_', 'cases', 'with', 'the', 'ayvm', 'insertion', 'did', 'not', 'show', 'any', 'partial', 'responses', 'to', '_chemical_', 'in', 'contrast', 'to', 'a', '_num_', 'pr', 'rate', 'in', '_abbrev_', 'patients', 'in', 'this', 'same', 'study']"
3359,1.0,"One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors  (SU5402, TKI258 or PD173074).","['_num_', 'urothelial', 'cell', 'line', '_abbrev_', 'with', 'high', 'expression', 'of', '_gene_', 'was', 'sensitive', 'to', 'treatment', 'with', '_gene_', 'inhibitors', '_chemical_', '_chemical_', 'or', '_chemical_']"
3360,1.0,"Of 40 cell lines (25 responsive, 15 non-responsive) that were exome sequenced, 6 cell lines had NOTCH1 loss-of-function mutations (N-terminal frameshift/nonsense) and 5/6 cell lines that had NOTCH1 mutations were susceptible to LGK974 (PORCN inhibitor).","['of', '_num_', 'cell', 'lines', '_num_', 'responsive', '_num_', 'non', 'responsive', 'that', 'were', 'exome', 'sequenced', '_num_', 'cell', 'lines', 'had', '_gene_', '_disease_', 'mutations', '_chemical_', 'frameshift', 'nonsense', 'and', '_ratio_', 'cell', 'lines', 'that', 'had', '_gene_', 'mutations', 'were', 'susceptible', 'to', '_chemical_', '_gene_', 'inhibitor']"
3361,1.0,HPO terms: retinal hemangioblastoma.,"['_disease_', 'terms', 'retinal', '_disease_']"
3362,1.0,"In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib.","['in', 'contrast', 'in', 'the', 'remaining', '_num_', 'patients', 'with', 'mutations', 'different', 'than', '_mutation_', '_num_', 'had', 'pd', '_num_', 'had', 'sd', 'and', '_num_', 'had', 'complete', 'response', 'as', 'best', 'response', 'after', 'initiation', 'of', '_chemical_']"
3363,1.0,Case shows renal cell carcinoma.,"['case', 'shows', 'renal', 'cell', 'carcinoma']"
3364,1.0,Basal ERBB3 expression was associated with higher synergy scores.,"['basal', '_gene_', 'expression', 'was', 'associated', 'with', 'higher', 'synergy', 'scores']"
3365,1.0,Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay.,"['stable', '_abbrev_', 'cell', 'lines', 'expressing', 'mutant', '_gene_', 'cdnas', 'were', 'created', 'using', 'a', 'pqclin', 'retroviral', 'vector', 'and', 'their', 'drug', 'sensitivities', 'to', '_chemical_', 'were', 'examined', 'by', '_gene_', 'assay']"
3366,1.0,This mutation was found in a patient with retinal angiomas.,"['this', 'mutation', 'was', 'found', 'in', 'a', 'patient', 'with', 'retinal', 'angiomas']"
3367,1.0,ERBB4 inhibition with shRNA or lapatinib led to reduced cell growth.,"['_gene_', 'inhibition', 'with', 'shrna', 'or', '_chemical_', 'led', 'to', 'reduced', 'cell', 'growth']"
3368,1.0,In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.,"['in', '3t3', 'fibroblasts', 'expressing', 'the', '_mutation_', 'mutation', 'have', 'to', 'be', 'sensitive', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_chemical_']"
3369,1.0,COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild type or D717V-mutant KDR.,"['_abbrev_', 'cells', 'were', 'transiently', 'transfected', 'with', 'expression', 'constructs', 'encoding', 'cdnas', 'for', 'wild', 'type', 'or', '_abbrev_', '_gene_']"
3370,1.0,A prospective study of ibrutinib in 63 symptomatic patients with Waldenström's macroglobulinemia who had received at least one previous treatment.,"['a', 'prospective', 'study', 'of', '_chemical_', 'in', '_num_', 'symptomatic', 'patients', 'with', 'waldenström', ""'s"", '_disease_', 'who', 'had', 'received', 'at', 'least', '_num_', 'previous', 'treatment']"
3371,1.0,"Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.","['patient', 'derived', 'xenografts', 'of', 'neuroblastoma', 'felix', 'cells', 'with', '_mutation_', '_gene_', 'mutation', 'in', '_abbrev_', 'scid', 'mice', 'showed', 'growth', 'inhibition', 'with', '_chemical_', 'treatment', 'over', 'control', 'and', 'mice', 'had', 'improved', 'duration', 'of', 'event', 'free', 'survival', '_gene_', 'with', '_chemical_', 'treatment', 'over', 'vehicle', 'but', '_gene_', 'with', '_chemical_', 'went', 'down', 'to', '_num_', 'by', '_num_', 'weeks']"
3372,1.0,"Based on this paper, the following ACMG evidence codes seem potentially valid: 'PS1', 'PS3',  'PM5', 'PP1', 'PP4', and 'PP5'.","['based', 'on', 'this', 'paper', 'the', 'following', 'acmg', 'evidence', 'codes', 'seem', 'potentially', 'valid', ""'ps1"", ""'ps3"", ""'pm5"", ""'pp1"", ""'pp4"", 'and', ""'pp5""]"
3373,1.0,"A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone.","['a', 'randomized', 'clinical', 'trial', 'of', '_num_', 'patients', 'with', 'previously', 'untreated', '_gene_', 'metastatic', 'breast', 'cancer', 'demonstrated', 'improved', 'time', 'to', 'disease', 'progression', 'objective', 'response', 'rate', 'and', 'duration', 'of', 'response', 'for', 'patients', 'who', 'received', '_chemical_', 'in', 'addition', 'to', 'chemotherapy', 'compared', 'to', 'chemotherapy', 'alone']"
3374,1.0,"This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment.","['this', 'corresponded', 'to', '_num_', 'event', 'free', 'survival', '_gene_', 'in', 'these', 'mice', 'by', '_num_', 'weeks', 'with', '_chemical_', 'treatment', 'but', '_num_', '_gene_', 'with', '_chemical_', 'treatment']"
3375,1.0,"Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangement.","['study', 'describes', 'a', '_num_', 'year', 'old', 'male', 'never', 'smoker', 'patient', 'with', 'advanced', '_disease_', 'with', 'a', '_gene_', 'rearrangement']"
3376,1.0,No clear difference was shown between PIK3CA-mutant and wild type cell lines and there was a trend towards increased resistance.,"['no', 'clear', 'difference', 'was', 'shown', 'between', '_abbrev_', 'and', 'wild', 'type', 'cell', 'lines', 'and', 'there', 'was', 'a', 'trend', 'towards', 'increased', 'resistance']"
3377,1.0,56% of patients achieved stable disease.,"['_num_', 'of', 'patients', 'achieved', 'stable', 'disease']"
3378,1.0,"NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.","['nras', '_mutation_', 'in', 'addition', 'to', 'the', '_gene_', '_mutation_', 'mutation', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'but', 'sensitivity', 'to', '_chemical_', '_chemical_', 'in', 'vitro', 'in', 'the', 'acquired', 'resistant', 'cell', 'line', '_abbrev_', 'and', 'in', 'the', '_disease_', 'acquired', 'resistant', 'cell', 'line', '_abbrev_']"
3379,0.0,G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity.,"['_chemical_', 'inhibits', 'in', 'vivo', 'tumor', 'growth', 'in', 'a', 'subset', 'of', 'apc', 'mutant', 'colorectal', 'cancers', 'xenograft', 'models', 'but', 'may', 'be', 'limited', 'by', 'intestinal', 'toxicity']"
3380,1.0,"Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations.","['uveal', 'melanoma', 'cohort', 'included', '_num_', 'patients', '_num_', 'with', '_gene_', '_gene_', 'and', '_gene_', '_gene_', 'mutations']"
3381,1.0,"Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.","['only', '_num_', 'showed', 'cytoplasmic', 'nuclear', 'and', '_chemical_', 'staining', 'associated', 'with', '_chemical_', 'while', 'the', 'others', 'showed', 'granular', 'cytoplasmic', '_gene_', 'stain', 'characteristic', 'for', '_gene_']"
3382,1.0,"In a glioblastoma mouse model induced by NRAS and p53 knockdown, ATRX loss was associated with a decreased median survival (69 days vs. 84 days; P = .0032).","['in', 'a', 'glioblastoma', 'mouse', 'model', 'induced', 'by', 'nras', 'and', '_gene_', 'knockdown', '_gene_', 'loss', 'was', 'associated', 'with', 'a', 'decreased', 'median', 'survival', '_num_', 'days', 'vs', '_num_', 'days', 'p', '_num_']"
3383,1.0,"In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform.","['in', 'simmilar', 'cells', 'subjected', 'to', '_gene_', '_chemical_', 'knockout', '_chemical_', 'treatment', 'fully', 'blocked', '_gene_', 'activation', 'indicating', 'that', '_chemical_', 'was', 'fully', 'inhibiting', 'the', '_gene_', '_chemical_']"
3384,1.0,"Out of 40 BRCA mutant patients, 10 had somatic BRCA1 mutation.","['out', 'of', '_num_', '_gene_', 'mutant', 'patients', '_num_', 'had', 'somatic', '_gene_', 'mutation']"
3385,1.0,"When co-expressed with V560D (imatinib sensitive) in vitro D816H showed ""extreme"" imatinib resistance.","['when', 'co', 'expressed', 'with', '_mutation_', '_chemical_', 'sensitive', 'in', 'vitro', '_mutation_', 'showed', 'extreme', '_chemical_', 'resistance']"
3386,1.0,"In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab.","['in', 'this', 'study', 'of', '_gene_', 'positive', 'metastatic', 'bc', 'which', 'had', 'progressed', 'on', '_chemical_', '_num_', 'arms', 'were', 'compared', '_chemical_', 'vs', '_chemical_', '_chemical_']"
3387,1.0,"In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', '_gene_', 'lung', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_mutation_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
3388,1.0,ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 non–HPV-driven; n = 26 HPV-driven).,"['_gene_', 'protein', 'levels', 'were', 'determined', '_gene_', 'in', '_num_', 'patients', 'with', 'oropharyngeal', '_disease_', 'cell', 'carcinoma', 'with', 'known', '_disease_', 'status', 'n', '_num_', 'non–hpv', 'driven', 'n', '_num_', 'hpv', 'driven']"
3389,1.0,498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC).,"['_num_', 'patients', 'were', 'retrospectively', 'analyzed', 'for', 'topoisomerase', '_num_', 'expression', '_gene_']"
3390,0.0,EML4-ALK fusions occur in 2-7% of lung adenocarcinomas.,"['_chemical_', 'fusions', 'occur', 'in', '_range_', 'of', 'lung', 'adenocarcinomas']"
3391,1.0,Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.,"['xenografts', 'of', 'these', 'cells', 'were', 'more', 'resistant', 'to', '_gene_', 'than', '_chemical_', 'or', '_abbrev_', 'treatment']"
3392,1.0,The SLCO1B1 rs4149056 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.,"['the', '_gene_', '_mutation_', 'variant', 'was', 'significantly', 'associated', 'with', '_gene_', '_abbrev_', 'and', 'as', 'such', 'associated', 'with', 'increased', 'toxicity']"
3393,1.0,"Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment.","['mutant', 'cell', 'lines', 'that', 'exhibited', 'a', 'greater', 'than', '_n_fold_', 'increase', 'in', '_abbrev_', 'value', 'were', 'considered', 'resistant', 'to', 'drug', '_chemical_', 'fold', 'increase', 'in', '_abbrev_', 'were', 'moderately', 'resistant', 'and', 'less', 'than', '_n_fold_', 'change', 'in', '_abbrev_', 'was', 'sensitive', 'to', 'drug', 'treatment']"
3394,1.0,"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF.","['age', 'sex', 'fab', 'subtype', 'and', 'karyotypes', 'were', 'not', 'statistically', 'significant', 'between', '_disease_', 'patients', 'with', '_gene_', '_abbrev_', 'mutations', 'and', 'those', 'who', 'harbor', 'wild', 'type', '_gene_']"
3395,1.0,The same was found in 17 cell lines.,"['the', 'same', 'was', 'found', 'in', '_num_', 'cell', 'lines']"
3396,1.0,No standard of care currently exists for HER2-mutant NSCLC.,"['no', 'standard', 'of', 'care', 'currently', 'exists', 'for', '_abbrev_', '_disease_']"
3397,1.0,"The median progression free survival (PFS) was 3.5 months, longer than the median PFS (2.5 months) reported for metastatic CRC treated with standard chemotherapy.","['the', 'median', 'progression', 'free', 'survival', '_disease_', 'was', '_num_', 'months', 'longer', 'than', 'the', 'median', '_disease_', '_num_', 'months', 'reported', 'for', 'metastatic', '_gene_', 'treated', 'with', 'standard', 'chemotherapy']"
3398,1.0,"A T674I mutation in the PDGFRA split kinase domain was hypothesized to confer resistance, due to the strong evidence of this fusion in driving myeloproliferative hypereosinophilic syndrome and the contextual similarity to T315I mutations in BCR-ABL.","['a', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'split', 'kinase', 'domain', 'was', 'hypothesized', 'to', 'confer', 'resistance', 'due', 'to', 'the', 'strong', 'evidence', 'of', 'this', 'fusion', 'in', 'driving', '_disease_', '_disease_', 'syndrome', 'and', 'the', 'contextual', 'similarity', 'to', '_mutation_', 'mutations', 'in', '_gene_']"
3399,1.0,"Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).","['objective', 'response', 'rate', 'was', 'significantly', 'better', 'with', 'osimertinib', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'than', 'with', 'chemotherapy', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'odds', 'ratio', 'for', 'objective', 'response', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
3400,1.0,There is very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).,"['there', 'is', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'frameshift', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
3401,1.0,"The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts.","['the', '_gene_', 'breast', 'cancer', 'cell', 'line', '_abbrev_', 'with', '_gene_', '_mutation_', 'shows', 'sub', 'optimal', 'responses', 'to', '_chemical_', 'and', '_chemical_', 'and', 'was', 'used', 'to', 'establish', 'mouse', 'xenografts']"
3402,1.0,"In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild type IDH2.","['in', '_disease_', 'patients', 'with', '_gene_', '_chemical_', 'mutation', 'have', 'improved', 'overall', 'survival', 'compared', 'to', 'those', 'with', 'wild', 'type', '_gene_']"
3403,1.0,"In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%.","['in', 'the', 'italian', 'study', '_ineq_', 'the', 'median', 'relapse', 'free', 'survival', 'was', '_num_', 'months', 'and', 'in', 'the', 'u', 's', 'study', '_chemical_', 'rate', 'of', 'progression', 'free', 'survival', 'was', '_num_', 'with', 'overall', 'survival', 'rate', 'of', '_num_']"
3404,1.0,The median survival from the time of first observation of a TP53 mutation was much more pronounced (P = <0.001).,"['the', 'median', 'survival', 'from', 'the', 'time', 'of', '_num_', 'observation', 'of', 'a', '_gene_', 'mutation', 'was', 'much', 'more', 'pronounced', 'p', '_num_']"
3405,1.0,"The patient received a sustained response to everolimus for 18 months, after which time resistance developed.","['the', 'patient', 'received', 'a', 'sustained', 'response', 'to', '_chemical_', 'for', '_num_', 'months', 'after', 'which', 'time', 'resistance', 'developed']"
3406,1.0,"Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays.","['cell', 'lines', '_num_', '_num_', 'assay', 'with', 'nras', 'mutation', 'were', 'more', 'sensitive', 'to', '_chemical_', 'inhibitor', 'targets', 'multiple', 'tyrosine', 'kinases', 'than', '_gene_', 'mutant', 'cell', 'lines', 'in', 'growth', 'inhibition', 'tyrosine', '_disease_', 'inhibition', 'cell', 'cycle', 'and', 'apoptotic', '_gene_', 'v', 'assays']"
3407,0.0,Researchers examined the prognostic role of miR-218 expression in CRC tumor samples when receiving 5-FU based treatment.,"['researchers', 'examined', 'the', 'prognostic', 'role', 'of', '_gene_', 'expression', 'in', '_gene_', 'tumor', 'samples', 'when', 'receiving', '_chemical_', 'based', 'treatment']"
3408,1.0,"In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification.","['in', 'a', 'panel', 'of', '_num_', 'breast', 'cancer', 'cell', 'lines', 'with', 'varied', 'mutation', 'backgrounds', '_num_', 'cell', 'lines', 'harbored', '_gene_', '_gene_', 'amplification']"
3409,1.0,Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines).,"['cell', 'lines', 'with', 'either', '_gene_', 'and', 'or', '_gene_', 'mutations', 'did', 'not', 'show', 'a', 'significant', 'difference', 'in', 'response', 'to', 'class', 'i', '_gene_', 'inhibitor', '_chemical_', 'p', '_ineq_', 'for', 'combined', '_abbrev_', 'aberrations', 'with', 'a', 'trend', 'towards', 'lower', '_abbrev_', 'for', 'mutated', 'cell', 'lines']"
3410,1.0,"In western blots,  Y1604 pALK levels for wild type NPM-ALK were ablated at 100 nM, while at 100 nM residual pALK levels were seen in G1269A blotting, with ablation of signal at and above 300 nM, which differed somewhat from the equivalent IC50 values reported for mutant and wild type in the NPM-ALK background, but still agrees with sensitivity to ceritinib for this mutation.","['in', 'western', 'blots', '_gene_', 'palk', 'levels', 'for', 'wild', 'type', '_chemical_', 'were', 'ablated', 'at', '_num_', '_unit_', 'while', 'at', '_num_', '_unit_', 'residual', 'palk', 'levels', 'were', 'seen', 'in', '_mutation_', 'blotting', 'with', 'ablation', 'of', 'signal', 'at', 'and', 'above', '_num_', '_unit_', 'which', 'differed', 'somewhat', 'from', 'the', 'equivalent', '_abbrev_', 'values', 'reported', 'for', 'mutant', 'and', 'wild', 'type', 'in', 'the', '_chemical_', 'background', 'but', 'still', 'agrees', 'with', 'sensitivity', 'to', '_chemical_', 'for', 'this', 'mutation']"
3411,1.0,"Following, 60 of those samples, the patients withe clear cell ovarian cancer, were analyzed for ARID1A expression using immunohistochemistry.","['following', '_num_', 'of', 'those', 'samples', 'the', 'patients', 'withe', 'clear', 'cell', 'ovarian', 'cancer', 'were', 'analyzed', 'for', '_gene_', 'expression', 'using', 'immunohistochemistry']"
3412,1.0,"Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).","['among', '_num_', 'patients', 'with', '_gene_', '_mutation_', 'who', 'could', 'be', 'evaluated', 'for', 'response', 'the', 'response', 'rate', 'was', '_num_', '_num_', 'ci', '_num_', 'to', '_num_']"
3413,1.0,"In the control group (n = 936), higher serum HER2 (sHER2) was associated with worse prognosis in multivariable analyses (progression free survival hazard ratio per 10 ng/mL: PFS, 1.024; P < .001; and OS, 1.018; P < .001).","['in', 'the', 'control', 'group', 'n', '_num_', 'higher', 'serum', '_gene_', '_abbrev_', 'was', 'associated', 'with', 'worse', 'prognosis', 'in', 'multivariable', 'analyses', 'progression', 'free', 'survival', 'hazard', 'ratio', 'per', '_num_', '_unit_', '_unit_', '_disease_', '_num_', 'p', '_num_', 'and', 'os', '_num_', 'p', '_num_']"
3414,1.0,"An acquired G2032R mutation in the ROS1 kinase domain was observed in the resistant tumor, and was found to confer resistance to ROS1 kinase inhibition through steric interference with drug binding.","['an', 'acquired', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'kinase', 'domain', 'was', 'observed', 'in', 'the', 'resistant', 'tumor', 'and', 'was', 'found', 'to', 'confer', 'resistance', 'to', '_gene_', 'kinase', 'inhibition', 'through', 'steric', 'interference', 'with', 'drug', 'binding']"
3415,1.0,"ALK wild type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors.","['_gene_', 'wild', 'type', 'neuroblastoma', 'cell', 'lines', 'did', 'not', 'show', 'differential', 'sensitivity', 'to', 'the', 'treatments', 'within', 'the', 'sensitivity', 'range', 'of', '_mutation_', 'cells', 'and', 'had', '_abbrev_', 'values', 'above', '_num_', '_unit_', 'to', 'the', 'inhibitors']"
3416,1.0,"Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants.","['normal', 'karyotype', 'patients', 'with', '_gene_', 'mutation', 'and', 'without', '_gene_', 'had', 'improved', 'overall', 'and', 'relapse', 'free', 'survival', 'complete', 'remission', 'rates', 'and', 'remission', 'duration', 'compared', 'to', 'all', 'other', 'combinations', 'of', 'mutants']"
3417,1.0,Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-ι/λ/GLI inhibitor) or arsenic trioxide.,"['basal', 'cell', 'carcinomas', 'with', '_disease_', 'pocket', 'or', '_disease_', 'active', 'mutations', 'in', 'the', '_gene_', 'gene', 'were', 'sensitive', 'to', 'inhibition', 'of', 'downstream', 'hedgehog', 'signaling', 'with', 'psi', '_gene_', 'ι', 'λ', '_gene_', 'inhibitor', 'or', 'arsenic', 'trioxide']"
3418,1.0,"In contrast, ceritinib caused loss of viability in EML4-ALK wild type and I1171T BaF3 cells at comparable concentrations.","['in', 'contrast', '_chemical_', 'caused', 'loss', 'of', 'viability', 'in', '_chemical_', 'wild', 'type', 'and', '_mutation_', '_abbrev_', 'cells', 'at', 'comparable', 'concentrations']"
3419,1.0,"In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival.","['in', 'patients', 'with', 'renal', 'clear', 'cell', 'carcinoma', 'patients', 'with', 'loss', 'of', 'function', '_gene_', 'mutations', 'had', 'shorter', 'tumor', 'specific', 'survival']"
3420,1.0,"Of all 220 patients, 19% of had BAP1 mutations.","['of', 'all', '_num_', 'patients', '_num_', 'of', 'had', '_gene_', 'mutations']"
3421,1.0,"TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671 ± 0.844 versus 5.978 ± 1.895, p=0.0142).","['_gene_', 'mrna', 'levels', 'were', 'lower', 'in', 'responders', 'compared', 'to', 'non', 'responders', 'to', '_chemical_', '_num_', '±', '_num_', 'vs', '_num_', '±', '_num_', '_p_val_']"
3422,1.0,"mTOR inhibition with rapamycin had a more pronounced effect than GDC-0941 on mouse melanoma, but synergized with PD0325901(but not vemurafenib) to promote tumor regression.","['_gene_', 'inhibition', 'with', '_gene_', 'had', 'a', 'more', 'pronounced', 'effect', 'than', '_chemical_', 'on', 'mouse', 'melanoma', 'but', 'synergized', 'with', '_chemical_', 'but', 'not', '_chemical_', 'to', 'promote', 'tumor', 'regression']"
3423,1.0,Imatinib mesylate led to complete metabolic response (PET-CT).,"['_chemical_', '_chemical_', 'led', 'to', 'complete', 'metabolic', 'response', 'pet', 'ct']"
3424,1.0,"Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001).","['primary', 'end', 'point', 'was', '_disease_', 'which', 'was', 'significantly', 'longer', 'with', 'osimertinib', 'than', 'with', 'chemotherapy', '_num_', 'months', 'vs', '_num_', 'months', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
3425,1.0,"In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03).","['in', 'patients', 'with', 'stage', 'iii', 'disease', 'the', 'respective', 'survival', 'rates', 'were', '_num_', 'percent', 'and', '_num_', 'percent', '_p_val_']"
3426,1.0,"In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death.","['in', 'a', 'cohort', 'of', '_num_', 'young', 'adult', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'those', 'with', '_gene_', 'mutations', 'did', 'not', 'have', 'significantly', 'different', 'rates', 'of', 'complete', 'recovery', 'refractory', 'disease', 'or', '_disease_', 'death']"
3427,1.0,"From the 46 patients, 41 showed partial response, and 2 showed complete response.","['from', 'the', '_num_', 'patients', '_num_', 'showed', 'partial', 'response', 'and', '_num_', 'showed', 'complete', 'response']"
3428,1.0,Perifosine treatment also increased apoptosis of a thyroid tumor xenograft with PIK3CA H1047R mutation.,"['_chemical_', 'treatment', 'also', 'increased', 'apoptosis', 'of', 'a', 'thyroid', 'tumor', 'xenograft', 'with', '_gene_', '_mutation_', 'mutation']"
3429,1.0,"In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival.","['in', 'patients', 'with', 'cytogenetically', 'normal', 'acute', 'myeloid', 'leukemia', 'those', 'in', 'the', 'eln', 'favorable', 'risk', 'group', 'with', '_gene_', 'mutations', 'had', 'shorter', 'event', 'free', 'survival', 'lower', 'rates', 'of', 'complete', 'remission', 'and', 'shorter', '_disease_', 'survival']"
3430,1.0,"Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified.","['among', '_num_', 'quadruple', 'negative', 'samples', 'with', 'resistance', 'to', '_chemical_', '_gene_', 'overexpression', 'and', 'amplification', '_ineq_', 'and', 'amplification', '_ineq_', 'were', 'identified']"
3431,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
3432,0.0,Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766.,"['phase', 'i', 'trial', 'of', 'the', 'mitogen', 'activated', 'protein', 'kinase', '_ratio_', 'inhibitor', 'bay', '_range_']"
3433,1.0,One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation.,"['_num_', 'patient', 'had', 'an', 'acquired', '_gene_', '_abbrev_', 'mutation', 'that', 'was', 'not', 'identified', 'before', 'treatment', 'initiation']"
3434,1.0,"In these studies, mutant BRAF specifically meant the V600E mutation.","['in', 'these', 'studies', 'mutant', '_gene_', 'specifically', 'meant', 'the', '_mutation_', 'mutation']"
3435,1.0,Growth arrest caused by CCI-779 correlated with a block in translation of HIF1A mRNA.,"['growth', 'arrest', 'caused', 'by', '_chemical_', 'correlated', 'with', 'a', 'block', 'in', 'translation', 'of', '_gene_', 'mrna']"
3436,1.0,Chemotherapy-refractory patients with colorectal cancer harboring Exon 20 PIK3CA mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA.,"['chemotherapy', 'refractory', 'patients', 'with', 'colorectal', 'cancer', 'harboring', 'exon', '_num_', '_gene_', 'mutations', 'had', 'lower', 'response', 'and', 'disease', 'control', 'rates', 'as', 'well', 'as', 'shorter', 'progression', 'free', 'and', 'overall', 'survival', 'following', '_chemical_', 'plus', 'chemotherapy', 'than', 'those', 'with', 'wildtype', '_gene_']"
3437,1.0,siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.,"['sirna', 'knockdown', 'of', '_gene_', 'or', 'inhibition', 'with', '_chemical_', 'enhanced', '_chemical_', 'response', 'in', 'breast', 'cancer', 'cell', 'lines']"
3438,0.0,"Inhibition of CDK4 and 6, regulators of the G1/S cell cycle checkpoint, arrests the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell growth.","['inhibition', 'of', '_gene_', 'and', '_num_', 'regulators', 'of', 'the', '_abbrev_', 'cell', 'cycle', 'checkpoint', 'arrests', 'the', 'cell', 'cycle', 'in', 'the', '_gene_', 'phase', 'suppresses', 'dna', 'synthesis', 'and', 'inhibits', 'cancer', 'cell', 'growth']"
3439,1.0,"The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples.","['the', 'expression', 'of', '_gene_', '_gene_', 'and', '_gene_', 'was', 'tested', '_gene_', 'in', '_num_', '_disease_', 'archival', 'tumor', 'samples']"
3440,1.0,"Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro.","['_num_', 'human', 'glioma', 'cell', 'lines', '_gene_', 'or', '_chemical_', 'overexpressing', 'either', 'wild', 'type', '_gene_', '_gene_', 'or', 'egfrviii', 'were', 'treated', 'with', 'nimotuzumab', '_chemical_', 'or', 'both', 'in', 'vitro']"
3441,1.0,"The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death).","['the', 'presence', 'of', 'nras', 'mutation', 'in', '_disease_', 'patients', 'does', 'not', 'impact', 'diease', 'prognosis', 'resistant', 'disease', '_disease_', 'survival', 'complete', 'remission', 'rate', 'relapse', 'rate', 'induction', 'death']"
3442,1.0,Those with promoter methylation had better progression-free and overall survival.,"['those', 'with', 'promoter', 'methylation', 'had', 'better', 'progression', 'free', 'and', 'overall', 'survival']"
3443,1.0,Response rates were 82.9% (Alectinib) and 75.5% (crizotinib).,"['response', 'rates', 'were', '_num_', '_chemical_', 'and', '_num_', '_chemical_']"
3444,1.0,CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors.,"['_gene_', 'was', 'identified', 'in', 'a', 'preclinical', 'sirna', 'screen', 'to', 'identify', 'targets', 'in', '_gene_', 'mutant', 'tumors']"
3445,1.0,Crizotinib was shown to confer significantly more potency than ceritinib (43-fold decrease in IC50).,"['_chemical_', 'was', 'shown', 'to', 'confer', 'significantly', 'more', 'potency', 'than', '_chemical_', '_n_fold_', 'decrease', 'in', '_abbrev_']"
3446,1.0,This missense mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 4401).,"['this', 'missense', 'mutation', 'was', 'detected', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'with', 'cerebellar', '_disease_', 'family', 'id', '_num_']"
3447,0.0,This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in different types of cancers.,"['this', '_disease_', 'analysis', 'evaluated', 'the', 'prognostic', 'value', 'of', '_gene_', 'expression', 'in', 'tiics', 'in', 'different', 'types', 'of', 'cancers']"
3448,1.0,The study showed that MLH1 methylation was associated with resistance to treatment with oxaliplatin.,"['the', 'study', 'showed', 'that', '_gene_', 'methylation', 'was', 'associated', 'with', 'resistance', 'to', 'treatment', 'with', '_chemical_']"
3449,1.0,The G250E mutation was  resistant to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
3450,1.0,There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.,"['there', 'was', 'no', 'statistical', 'difference', 'in', '_disease_', 'survival', 'between', '_chemical_', 'treated', 'patients', 'who', 'had', 'the', '_gene_', '_num_', '_disease_', '_disease_', 'genotype', 'and', 'patients', 'without', 'that', 'genotype']"
3451,1.0,"They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better outcome in CLL.","['they', 'were', 'exclusively', 'seen', 'in', 'instances', 'of', 'mutated', '_gene_', 'genes', '_ratio_', 'p', '_num_', 'a', 'widely', 'recognized', 'prognostic', 'signature', 'for', 'better', 'outcome', 'in', '_disease_']"
3452,1.0,Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks.,"['subsequent', 'treatment', 'of', 'this', 'patient', 'with', '_abbrev_', 'yielded', 'disease', 'stabilization', 'lasting', '_num_', 'weeks']"
3453,1.0,KRAS mutations were found in 72% of samples and KRAS mutations were independently associated with PFS (p=0.012) after multivariate analysis.,"['_gene_', 'mutations', 'were', 'found', 'in', '_num_', 'of', 'samples', 'and', '_gene_', 'mutations', 'were', 'independently', 'associated', 'with', '_disease_', '_p_val_', 'after', 'multivariate', 'analysis']"
3454,1.0,"Median PFS by RECIST was 8 (IQ range 4-12) months, with a 22% CBR.","['median', '_disease_', 'by', '_disease_', 'was', '_num_', 'iq', 'range', '_range_', 'months', 'with', 'a', '_num_', 'cbr']"
3455,1.0,"Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006).","['patients', 'with', 'high', '_gene_', 'mrna', 'expression', '_num_', 'had', '_num_', 'response', 'probability', 'whereas', 'patients', 'with', 'low', '_gene_', 'mrna', 'expression', 'had', '_num_', 'response', 'probability', 'p', '_num_']"
3456,1.0,"16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, BrdU flow cytometry) and growth arrest characteristic of senescence, while the 5 cell lines that did not show a palbociclib response had homozygous deletion of Rb.","['_num_', 'of', 'the', 'cell', 'lines', 'with', 'intact', 'rb', 'showed', 'decreased', 'proliferation', '_chemical_', 'incorporation', '_disease_', 'flow', 'cytometry', 'and', 'growth', 'arrest', 'characteristic', 'of', 'senescence', 'while', 'the', '_num_', 'cell', 'lines', 'that', 'did', 'not', 'show', 'a', '_chemical_', 'response', 'had', 'homozygous', 'deletion', 'of', 'rb']"
3457,1.0,STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.,"['_abbrev_', 'cells', 'were', 'sensitive', 'to', 'treatment', 'with', '_gene_', 'inhibitor', '_chemical_']"
3458,1.0,"Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005).","['patients', 'with', '_gene_', 'wildtype', 'had', 'an', 'improved', 'os', 'hr', '_num_', 'p', '_num_']"
3459,1.0,The Y253F mutation was  moderately resistant to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
3460,1.0,SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.,"['_abbrev_', 'and', 'kelly', 'cells', 'with', 'mutant', '_gene_', '_mutation_', 'and', 'ba', '_abbrev_', 'cells', 'overexpressing', '_gene_', 'harboring', 'the', '_mutation_', 'mutation', 'are', 'sensitive', 'to', '_abbrev_', 'growth', 'inhibition']"
3461,1.0,Median PFS and OS were 1.9 (95% CI 1.7–3.8) and 7.2 months (95% CI 5.7–9.7).,"['median', '_disease_', 'and', 'os', 'were', '_num_', '_num_', 'ci', '_num_', '7–3', '_num_', 'and', '_num_', 'months', '_num_', 'ci', '_num_', '7–9', '_num_']"
3462,1.0,Both H3122 and H3122 CHR-A1 cells were highly and equally sensitive to ceritinib induced death.,"['both', '_abbrev_', 'and', '_abbrev_', '_abbrev_', 'cells', 'were', 'highly', 'and', 'equally', 'sensitive', 'to', '_chemical_', 'induced', 'death']"
3463,1.0,KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.,"['_gene_', 'mutation', 'status', 'was', 'not', 'predictive', 'of', 'response', 'to', '_chemical_', 'treatment', 'in', 'patients', 'that', 'had', 'received', 'standard', 'therapy', 'and', 'progressed', 'within', '_num_', 'months', 'of', 'their', 'last', 'treatment']"
3464,1.0,Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.,"['_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'the', 'presence', 'pf', 'lymph', 'node', 'metastasis', 'in', 'gastric', 'cancers']"
3465,1.0,A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy.,"['a', 'total', 'of', '_num_', 'women', 'with', '_gene_', 'metastatic', 'breast', 'cancer', 'were', 'analyzed', 'after', '_chemical_', 'plus', '_chemical_', 'chemotherapy']"
3466,1.0,Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months.,"['median', '_disease_', 'was', '_num_', 'months', 'and', 'median', 'os', 'not', 'reached', 'after', 'a', 'median', 'follow', 'up', 'pf', '_num_', 'months']"
3467,1.0,"However, the adjusted p-value for multiple testing is 0.11.","['however', 'the', 'adjusted', 'p', 'value', 'for', 'multiple', 'testing', 'is', '_num_']"
3468,1.0,This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4).,"['this', 'study', 'contains', 'strong', 'evidence', 'of', 'pathogenicity', 'for', 'this', 'variant', 'because', 'the', 'prevalence', 'of', 'the', 'variant', 'in', 'affected', 'individuals', 'is', 'significantly', 'increased', 'compared', 'with', 'the', 'prevalence', 'in', 'controls', 'acmg', 'code', '_gene_']"
3469,1.0,Combined MEK inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.,"['combined', 'mek', 'inhibitor', '_chemical_', 'and', '_gene_', 'inhibitor', '_chemical_', 'administration', 'to', '_gene_', 'mice', 'subcutanousely', 'injected', 'with', 'colorectal', 'cell', 'lines', 'with', 'a', '_gene_', '_mutation_', 'mutation', 'effectively', 'inhibited', 'tumor', 'growth', 'and', 'reduced', 'cellular', 'proliferation']"
3470,1.0,"Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).","['study', 'endpoint', 'was', 'overall', 'survival', 'which', 'was', 'significantly', 'different', 'in', 'the', '_num_', 'populations', '_num_', 'months', 'with', 'chemotherapy', '_chemical_', 'and', '_num_', 'months', 'for', 'chemotherapy', 'alone']"
3471,1.0,Median progression-free survival was 6.6 months (range=6.2-10.5).,"['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', '_ineq_']"
3472,1.0,"HCC78CR1, 2, and 3 cells and Ba/F3 cells transfected with CD74–ROS1 L2155S, showed resistance to crizotinib compared with parental HCC78 and Ba/F3 cells.","['_abbrev_', '_num_', 'and', '_num_', 'cells', 'and', 'ba', '_abbrev_', 'cells', 'transfected', 'with', '_abbrev_', '_mutation_', 'showed', 'resistance', 'to', '_chemical_', 'compared', 'with', 'parental', '_abbrev_', 'and', 'ba', '_abbrev_', 'cells']"
3473,1.0,Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months.,"['_chemical_', 'was', 'initiated', 'on', 'the', 'basis', 'of', 'these', 'findings', 'and', 'a', 'partial', 'response', 'was', 'achieved', 'for', '_num_', 'months']"
3474,1.0,Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease.,"['study', 'evaluated', 'a', 'total', 'of', '_num_', 'small', 'cell', 'lung', 'cancer', 'patients', 'with', 'extensive', 'stage', 'disease']"
3475,1.0,"EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048).","['_gene_', 'expression', 'as', 'assessed', 'by', 'quantitative', '_disease_', 'in', '_num_', 'colorectal', 'cancer', 'patients', 'treated', 'with', '_chemical_', 'was', 'higher', 'in', 'non', 'responders', 'p', '_num_']"
3476,1.0,The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib.,"['the', 'patient', 'was', 'enrolled', 'in', 'a', 'clinical', 'trial', 'with', '_chemical_', 'and', '_chemical_', '_abbrev_', 'with', '_chemical_', 'used', 'to', 'enhance', 'brain', 'accumulation', 'of', '_chemical_']"
3477,1.0,"Thus, the combination of everolimus and fulvestrant was administered.","['thus', 'the', 'combination', 'of', '_chemical_', 'and', '_chemical_', 'was', 'administered']"
3478,1.0,"Inhibition of MEK1/2 (BEZ235) and PI3K/mTOR (AZD6244 [selumetinib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition).","['inhibition', 'of', '_gene_', '_chemical_', 'and', '_abbrev_', '_chemical_', '_chemical_', 'was', 'the', 'most', 'effective', 'approach', 'to', 'counteract', 'resistance', 'in', 'comparison', 'to', 'inhibition', 'with', 'the', '_abbrev_', 'where', 'response', 'was', 'assessed', 'by', 'apoptosis', 'viability', '_gene_', '_gene_', 'inhibition']"
3479,1.0,Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition.,"['addition', 'of', '_gene_', 'inhibitor', '_chemical_', 'to', 'the', '_chemical_', 'variant', '_num_', 'cells', 'induced', 'cell', 'death', 'which', 'was', 'rescued', 'at', 'lower', '_chemical_', 'concentrations', 'by', '_gene_', 'addition']"
3480,1.0,Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months).,"['median', 'overall', 'survival', 'was', 'significantly', 'longer', 'in', 'patients', 'with', '_abbrev_', '_gene_', 'mutant', 'metastatic', '_gene_', 'compared', 'with', 'those', 'with', 'both', '_mutation_', '_gene_', 'mutant', 'and', 'wild', 'type', '_gene_', 'metastatic', '_gene_', '_num_', 'v', '_num_', 'v', '_num_', 'months']"
3481,1.0,Somatic and germline BAP1 mutations are associated with uveal melanoma.,"['somatic', 'and', 'germline', '_gene_', 'mutations', 'are', 'associated', 'with', 'uveal', 'melanoma']"
3482,1.0,This mutation was found in 5/8 individuals with FPD/AML but not in 3/8 unaffected individuals as well as 10 unrelated control samples.,"['this', 'mutation', 'was', 'found', 'in', '_ratio_', 'individuals', 'with', '_disease_', 'but', 'not', 'in', '_ratio_', 'unaffected', 'individuals', 'as', 'well', 'as', '_num_', 'unrelated', 'control', 'samples']"
3483,1.0,"The D816V+ advanced systemic mastocytosis patients with additional mutations in SRSF2 (N=30), ASLX1 (N=20), or RUNX1 (N=16) exhibited lower overall survival over 14 years as compared to D816V+ patients with wildtype SRSF2 (N=40), ASXL1(N=50), or RUNX1 (N=54).","['the', '_abbrev_', 'advanced', 'systemic', '_disease_', 'patients', 'with', 'additional', 'mutations', 'in', '_gene_', '_ineq_', '_abbrev_', '_ineq_', 'or', '_gene_', '_ineq_', 'exhibited', 'lower', 'overall', 'survival', 'over', '_num_', 'years', 'as', 'compared', 'to', '_abbrev_', 'patients', 'with', 'wildtype', '_gene_', '_ineq_', '_gene_', '_ineq_', 'or', '_gene_', '_ineq_']"
3484,1.0,"Conversely, patients with a concomitant NPM1/DNMT3A co-mutation, in the absence of an NRAS (G12/13) mutation, showed a clinically unfavorable 10-year survival rate of 30%.","['conversely', 'patients', 'with', 'a', 'concomitant', '_abbrev_', 'co', 'mutation', 'in', 'the', 'absence', 'of', 'an', 'nras', '_abbrev_', 'mutation', 'showed', 'a', 'clinically', 'unfavorable', '_num_', 'year', 'survival', 'rate', 'of', '_num_']"
3485,1.0,Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases after primary radiochemotherapy.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'patient', 'with', '_gene_', 'positive', 'tumor', 'of', 'the', 'tonsil', 'with', 'lung', 'metastases', 'after', 'primary', 'radiochemotherapy']"
3486,1.0,IC50 values of canertinib were comparable to afatinib.,"['_abbrev_', 'values', 'of', '_chemical_', 'were', 'comparable', 'to', '_chemical_']"
3487,1.0,"Unlike those treated with radiotherapy, those treated with surgery did not show a significant difference in rates of loco-regional control between those with and without mutations in TP53.","['unlike', 'those', 'treated', 'with', 'radiotherapy', 'those', 'treated', 'with', 'surgery', 'did', 'not', 'show', 'a', 'significant', 'difference', 'in', 'rates', 'of', 'loco', 'regional', 'control', 'between', 'those', 'with', 'and', 'without', 'mutations', 'in', '_gene_']"
3488,1.0,Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM).,"['cells', 'with', 'single', '_gene_', '_mutation_', 'mutants', 'were', 'resistant', 'to', '_chemical_', '_abbrev_', '_unit_', 'whereas', 'cells', 'with', '_gene_', '_gene_', 'mutants', 'were', 'not', 'resistant', 'to', '_chemical_', '_abbrev_', '_num_', '_unit_']"
3489,1.0,"The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end.","['the', 'patient', '_unit_', '_num_', 'smoker', 'had', 'progressive', 'disease', 'as', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
3490,1.0,Neither the VHL phenotype details or segregation data were provided by this publication.,"['neither', 'the', '_gene_', 'phenotype', 'details', 'or', 'segregation', 'data', 'were', 'provided', 'by', 'this', 'publication']"
3491,1.0,EGF downregulation suppressed proliferation of cell lines.,"['_gene_', 'downregulation', 'suppressed', 'proliferation', 'of', 'cell', 'lines']"
3492,1.0,"PL11 cells (empty vector transduced) were more sensitive to mitomycin C (MMC), cisplatin, chlorambucil, and melphalan than PL11 cells transduced with a vector wildtype FANCC.","['_abbrev_', 'cells', 'empty', 'vector', 'transduced', 'were', 'more', 'sensitive', 'to', 'mitomycin', 'c', '_disease_', '_disease_', 'chlorambucil', 'and', 'melphalan', 'than', '_abbrev_', 'cells', 'transduced', 'with', 'a', 'vector', 'wildtype', '_gene_']"
3493,1.0,Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed.,"['tumor', 'sequencing', 'in', '_gene_', '', 'and', 'post', 'therapy', 'specimens', 'from', '_num_', 'individuals', 'with', '_disease_', 'who', 'experienced', 'disease', 'progression', 'after', 'a', 'prior', 'response', 'to', '_chemical_', 'with', 'chemotherapy', 'was', 'performed']"
3494,1.0,"This missense mutation was found in a German, VHL type 2B family.","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_gene_', 'family']"
3495,1.0,"This missense mutation was found in a German, VHL type 1 family of 6.","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'family', 'of', '_num_']"
3496,1.0,This missense mutation was found in a VHL type 1 family (lineage 128).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
3497,1.0,"Ceritinib was also effective at killing MGH056-1 cells that were resistant to alectinib, and reduced Akt and ERK phosphorylation in these cells.","['_chemical_', 'was', 'also', 'effective', 'at', 'killing', '_abbrev_', 'cells', 'that', 'were', 'resistant', 'to', '_chemical_', 'and', 'reduced', '_gene_', 'and', '_gene_', '_disease_', 'in', 'these', 'cells']"
3498,1.0,Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly.,"['preclinial', 'data', 'from', '_gene_', 'mutant', 'colorectal', 'cancer', 'cell', 'lines', 'show', 'syngergistic', 'effect', 'on', 'cell', 'viability', 'and', 'apoptosis', 'in', 'vitro', 'and', 'in', 'vivo', 'when', 'mek', 'and', '_gene_', 'are', 'inhibited', 'concomitantly']"
3499,1.0,The mutation was found in the mother and son.,"['the', 'mutation', 'was', 'found', 'in', 'the', 'mother', 'and', 'son']"
3500,1.0,"Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood.","['because', 'of', 'this', 'mutation', ""'s"", 'rarity', 'and', 'the', 'variability', 'of', 'responses', 'of', 'treated', 'cases', 'its', 'exact', 'prognostic', 'and', 'predictive', 'role', 'is', 'not', 'fully', 'understood']"
3501,1.0,"Phosphorylation of Y1068 (assessed by IHC) was associated with improved progression free survival (PFS) in 205 patients with stage IIb and IV NSCLC treated with EGFR tyrosine kinase inhibitors (gefitinib or erlotinib) compared to phospho-Y1068 negative patients (median PFS 7.0 months vs. 1.2 months, P < 0.001).","['_disease_', 'of', '_gene_', 'assessed', 'by', '_gene_', 'was', 'associated', 'with', 'improved', 'progression', 'free', 'survival', '_disease_', 'in', '_num_', 'patients', 'with', 'stage', '_gene_', 'and', 'iv', '_disease_', 'treated', 'with', '_gene_', 'tyrosine', 'kinase', 'inhibitors', '_chemical_', 'or', '_chemical_', 'compared', 'to', '_abbrev_', 'negative', 'patients', 'median', '_disease_', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_']"
3502,1.0,"Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4/5 individuals harbouring DNMT3A alteration.","['consecutive', 'stage', 'iv', 'cancer', 'patients', 'who', 'received', 'immunotherapies', '_gene_', '_gene_', 'inhibitors', 'or', 'other', 'investigational', 'agents', 'and', 'had', 'their', 'tumor', 'evaluated', 'by', 'next', 'generation', 'sequencing', 'amongst', '_num_', 'patients', '_gene_', 'time', 'to', 'treatment', 'failure', '_num_', 'months', 'was', 'seen', 'in', '_ratio_', 'individuals', 'harbouring', '_gene_', 'alteration']"
3503,1.0,2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy.,"['_num_', 'of', '_num_', 'patients', 'studied', 'also', 'harbored', '_gene_', '_mutation_', 'and', 'were', 'resistant', 'to', '_chemical_', 'therapy']"
3504,1.0,"In colorectal cancer, PIK3CA mutations were associated with reduced relapse-free survival in stage II/III patients (HR:2.587, 95% CI:1.108-6.039, P=0.0280, univariate analysis; HR:2.478, 95% CI:1.028-5.973, P=0.0433, multivariate analysis) and reduced disease-specific survival in patients of any stage (n=18 vs. n=140, P=0.0357) compared to wildtype PIK3CA.","['in', 'colorectal', 'cancer', '_gene_', 'mutations', 'were', 'associated', 'with', 'reduced', 'relapse', 'free', 'survival', 'in', 'stage', 'ii', 'iii', 'patients', 'hr:2', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'univariate', 'analysis', 'hr:2', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_', 'multivariate', 'analysis', 'and', 'reduced', '_disease_', 'survival', 'in', 'patients', 'of', 'any', 'stage', '_ineq_', 'vs', '_ineq_', '_p_val_', 'compared', 'to', 'wildtype', '_gene_']"
3505,1.0,"In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.","['in', 'a', 'patient', 'with', '_abbrev_', '_disease_', '_gene_', '_mutation_', 'seemed', 'to', 'confer', 'resistance', 'to', '_chemical_']"
3506,1.0,Trastuzumab did not show notable effects on cell growth in any tested cells.,"['_chemical_', 'did', 'not', 'show', 'notable', 'effects', 'on', 'cell', 'growth', 'in', 'any', 'tested', 'cells']"
3507,1.0,"A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway.","['a', 'phase', 'i', 'clinical', 'trial', 'of', 'the', '_abbrev_', '_gene_', 'inhibitor', 'in', '_gene_', 'mutant', 'positive', 'solid', 'tumors', 'including', 'glioma', 'is', 'currently', 'underway']"
3508,1.0,74 tumors (37 Mullerian/37 non-Mullerian) were examined for PAX8 expression via IHC.,"['_num_', 'tumors', '_num_', 'mullerian', '_num_', 'non', 'mullerian', 'were', 'examined', 'for', '_gene_', 'expression', 'via', '_gene_']"
3509,1.0,The primary endpoint of the study was time to progression.,"['the', 'primary', 'endpoint', 'of', 'the', 'study', 'was', 'time', 'to', 'progression']"
3510,1.0,"In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively.","['in', 'this', 'study', '_gene_', 'ssx', 'fusion', 'transcripts', '_abbrev_', 'and', '_abbrev_', 'were', 'detected', 'in', '_num_', '_num_', 'and', '_num_', '_num_', 'of', 'the', 'tumors', 'respectively']"
3511,1.0,285 patients were assessed for p16 Status (IHC).,"['_num_', 'patients', 'were', 'assessed', 'for', '_gene_', 'status', '_gene_']"
3512,1.0,"Ba/F3 cells transduced with EML4-ALK 1151 insT were treated with 17-AAG producing an IC50 value of 44.5 nM, which was 0.4 times that reported for EML4-ALK wildtype in Ba/F3, indicating possible increased dependence of EML4-ALK 1151 insT on HSP90.","['ba', '_abbrev_', 'cells', 'transduced', 'with', '_chemical_', '_num_', 'inst', 'were', 'treated', 'with', '_chemical_', 'producing', 'an', '_abbrev_', 'value', 'of', '_num_', '_unit_', 'which', 'was', '_num_', 'times', 'that', 'reported', 'for', '_chemical_', 'wildtype', 'in', 'ba', '_abbrev_', 'indicating', 'possible', 'increased', 'dependence', 'of', '_chemical_', '_num_', 'inst', 'on', '_gene_']"
3513,1.0,"Amplification of wild type EML4-ALK in the non-small cell lung carcinoma cell line, H3122, caused resistance to crizotinib.","['amplification', 'of', 'wild', 'type', '_chemical_', 'in', 'the', 'non', 'small', 'cell', 'lung', 'carcinoma', 'cell', 'line', '_abbrev_', 'caused', 'resistance', 'to', '_chemical_']"
3514,1.0,"Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild type HER2 overexpressing NSCLC.","['although', 'from', '_year_', 'this', 'study', 'remains', 'cited', 'in', '_year_', 'literature', 'when', 'discussing', 'the', 'unclear', 'efficacy', 'of', '_chemical_', 'in', 'wild', 'type', '_gene_', 'overexpressing', '_disease_']"
3515,1.0,Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma).,"['phase', '_num_', 'study', 'of', '_chemical_', 'in', '_num_', 'patients', 'with', 'melanoma', '_num_', 'with', 'uveal', 'melanoma']"
3516,1.0,NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.,"['_chemical_', 'in', 'anaplastic', 'large', 'cell', 'lymphoma', '_disease_', 'was', 'the', '_num_', '_gene_', 'fusion', 'to', 'be', 'discovered', 'and', 'characterized']"
3517,1.0,"Median progression free survival was 11.0 months (10.6-12.9) with afatinib and 10.9 months (9.1-11.5) with gefitinib, HR 0.73 [0.57-0.95] p=0.017.","['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', '_range_', 'with', '_chemical_', 'and', '_num_', 'months', '_range_', 'with', '_chemical_', 'hr', '_num_', '_range_', '_p_val_']"
3518,1.0,Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.,"['young', '_disease_', 'patients', '_num_', 'patients', '_num_', 'years', 'old', 'with', 'any', '_gene_', 'mutation', '_ineq_', 'have', 'shorter', 'overall', 'survival', 'and', 'relapse', 'free', 'survival', 'than', 'patients', 'with', 'wildtype', '_gene_']"
3519,1.0,"In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903).","['in', 'a', 'study', 'of', '_num_', 'colorectal', 'cancer', 'samples', '_num_', 'patients', 'had', '_disease_', 'instability', 'and', 'there', 'was', 'a', 'statistically', 'significantly', 'better', 'prognosis', 'for', '_gene_', '_gene_', 'patients', 'relative', 'to', '_gene_', '_mutation_', '', 'mutated', 'patients', 'log', 'rank', '_p_val_']"
3520,1.0,82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study.,"['_num_', 'patients', 'with', 'stage', 'iv', '_disease_', 'who', 'had', 'not', 'previously', 'been', 'treated', 'with', 'chemotherapy', 'were', 'used', 'in', 'this', 'study']"
3521,1.0,"For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients).","['for', 'the', '_chemical_', 'treated', '_disease_', 'patient', 'group', '_num_', 'year', 'survival', 'was', '_num_', 'and', '_num_', 'year', 'overall', 'survival', 'was', '_num_', 'compared', 'with', '_num_', 'and', '_num_', 'for', 'the', 'control', 'group', '_disease_', '_chemical_', 'naive', 'patients']"
3522,1.0,Study was a phase-1 with 60 patients enrolled.,"['study', 'was', 'a', '_abbrev_', 'with', '_num_', 'patients', 'enrolled']"
3523,1.0,"Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement.","['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'male', 'patient', 'with', 'lung', 'adenocarcinoma', '_abbrev_', 'stage', '_gene_', 'without', '_gene_', '_gene_', 'or', '_gene_', 'mutations', 'and', 'no', '_gene_', 'gene', 'rearrangement']"
3524,1.0,Patient was treated with crizotinib (partial response) and alectinib (complete response).,"['patient', 'was', 'treated', 'with', '_chemical_', 'partial', 'response', 'and', '_chemical_', 'complete', 'response']"
3525,1.0,Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib.,"['case', 'report', 'of', 'a', 'patient', 'with', '_disease_', 'harboring', 'a', 'met', 'exon', '_num_', 'skipping', 'mutation', 'and', 'initial', 'response', 'to', '_chemical_']"
3526,1.0,"In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival.","['in', 'patients', 'with', 'uveal', 'melanoma', 'those', 'with', '_gene_', 'expression', 'determined', 'by', 'immunohistochemical', 'staining', 'had', 'better', 'survival']"
3527,1.0,BCR-ABL F317L has been shown to confer resistance to dasatinib in patients with CML.,"['_gene_', '_mutation_', 'has', 'been', 'shown', 'to', 'confer', 'resistance', 'to', '_chemical_', 'in', 'patients', 'with', '_gene_']"
3528,1.0,"Overall odds ratio for resistant disease among subjects with the deletion polymorphism compared to those without it was 2.94 (P = 0.02, 95% CI 1.17–7.43).","['overall', 'odds', 'ratio', 'for', 'resistant', 'disease', 'among', 'subjects', 'with', 'the', 'deletion', 'polymorphism', 'compared', 'to', 'those', 'without', 'it', 'was', '_num_', 'p', '_num_', '_num_', 'ci', '_num_', '17–7', '_num_']"
3529,1.0,"In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'the', '_mutation_', 'mutation', 'was', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
3530,1.0,"In contrast, among patients with high MGMT expression, only 64% started radiotherapy, and 43% completed it.","['in', 'contrast', 'among', 'patients', 'with', 'high', '_gene_', 'expression', 'only', '_num_', 'started', 'radiotherapy', 'and', '_num_', 'completed', 'it']"
3531,1.0,"This missense mutation was found in a 43-year-old VHL patient with renal cell carcinoma, pancreatic cysts, an endolymphatic sac tumor, and an epididymal /ovarian cystadenoma (proband no 5).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_age_', '_gene_', 'patient', 'with', 'renal', 'cell', 'carcinoma', 'pancreatic', 'cysts', 'an', 'endolymphatic', 'sac', 'tumor', 'and', 'an', '_disease_', '', 'ovarian', '_disease_', 'proband', 'no', '_num_']"
3532,1.0,This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 104).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
3533,1.0,Results for amphiregulin and epiregulin were inconclusive.,"['results', 'for', '_gene_', 'and', '_gene_', 'were', 'inconclusive']"
3534,1.0,"FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET.","['fish', 'identified', 'a', 'deletion', 'of', ""5'ret"", 'fish', 'indicating', 'ret', 'gene', 'rearrangement', 'and', 'genomic', 'testing', 'confirmed', 'a', 'fusion', 'of', '_gene_', 'and', 'ret']"
3535,1.0,A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease.,"['a', 'randomized', 'phase', '_num_', 'trial', '_abbrev_', 'involving', '_num_', '_disease_', 'patients', 'with', '_gene_', 'mutations', 'exon', '_num_', 'deletion', 'or', '_mutation_', 'mutation', 'in', 'exon', '_num_', 'with', 'no', 'history', 'of', 'chemotherapy', 'for', 'metastatic', 'disease']"
3536,1.0,"Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P < 0.001).","['median', '_disease_', 'among', 'patients', 'randomized', 'to', 'chemotherapy', 'was', '_num_', 'weeks', '_num_', 'ci', '_range_', 'weeks', 'median', 'treatment', 'duration', '_num_', 'weeks', 'interquartile', 'range', 'iqr', '_range_', 'weeks', 'vs', '_num_', 'weeks', 'with', '_chemical_', '_num_', 'ci', '_range_', 'weeks', 'median', 'treatment', 'duration', '_num_', 'weeks', 'iqr', '_range_', 'weeks', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
3537,1.0,In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.,"['in', 'this', 'cohort', 'no', '_gene_', 'overexpression', 'or', 'amplification', 'was', 'identified', 'in', '_num_', '_gene_', '_gene_', 'patients', 'with', 'response', 'to', '_chemical_']"
3538,1.0,CT scans showed a partial response and complete resolution of brain metastases.,"['ct', 'scans', 'showed', 'a', 'partial', 'response', 'and', 'complete', 'resolution', 'of', 'brain', 'metastases']"
3539,1.0,A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice.,"['_abbrev_', 'melanoma', 'cells', 'containing', 'an', 'inducible', 'shrna', 'for', '_gene_', 'were', 'grown', 'as', 'xenograft', 'tumors', 'in', 'nude', 'mice']"
3540,1.0,"After establishing that the CD74-ROS1 L2026M mutation confers crizotinib resistance in kinase activity and cell viability assays (in transduced BaF3 cells), response to PF-06463922 was tested.","['after', 'establishing', 'that', 'the', '_abbrev_', '_mutation_', 'mutation', 'confers', '_chemical_', 'resistance', 'in', 'kinase', 'activity', 'and', 'cell', 'viability', 'assays', 'in', 'transduced', '_abbrev_', 'cells', 'response', 'to', '_chemical_', 'was', 'tested']"
3541,1.0,Loss of heterozygosity resulting in overrepresentation of the M1L allele was observed.,"['loss', 'of', 'heterozygosity', 'resulting', 'in', 'overrepresentation', 'of', 'the', '_mutation_', 'allele', 'was', 'observed']"
3542,1.0,"In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients.","['in', 'relapsed', '_disease_', 'patients', '_gene_', 'mutations', 'were', 'associated', 'with', 'morphologic', 'nonresponse', 'to', 'therapy', '_num_', 'blasts', 'in', 'the', 'bone', 'marrow', 'after', '_num_', 'weeks', 'of', 'treatment', 'as', 'well', 'as', 'reduced', 'event', 'free', 'and', 'overall', 'survival', 'when', 'compared', 'to', '_gene_', 'wildtype', 'patients']"
3543,1.0,Knockdown of Rb in 3 of the tested Rb positive cell lines led to moderate palbociclib resistance in short term incubation experiments.,"['knockdown', 'of', 'rb', 'in', '_num_', 'of', 'the', 'tested', 'rb', 'positive', 'cell', 'lines', 'led', 'to', 'moderate', '_chemical_', 'resistance', 'in', 'short', 'term', 'incubation', 'experiments']"
3544,1.0,A germline STK11 D194E mutation was identified with LOH in the tumor sample.,"['a', 'germline', '_gene_', '_mutation_', 'mutation', 'was', 'identified', 'with', '_disease_', 'in', 'the', 'tumor', 'sample']"
3545,1.0,Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefitinib or erlotinib.,"['both', 'patients', 'were', 'found', 'to', 'have', '_mutation_', 'mutation', 'and', 'were', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_', 'or', '_chemical_']"
3546,1.0,Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment.,"['administration', 'of', '_num_', '_disease_', '_chemical_', 'to', 'athymic', 'mice', 'with', 'transplantation', 'of', 'tumor', 'cells', 'caused', 'marked', 'reduction', 'of', 'tumor', 'cell', 'volume', 'in', 'comparison', 'to', 'control', 'treatment']"
3547,1.0,"On sequential monitoring of minimal residual disease, relapse was reliably predicted by a rising level of NPM1-mutated transcripts.","['on', 'sequential', 'monitoring', 'of', 'minimal', 'residual', 'disease', 'relapse', 'was', 'reliably', 'predicted', 'by', 'a', 'rising', 'level', 'of', '_abbrev_', 'transcripts']"
3548,1.0,"Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib.","['engineered', 'cells', 'compared', 'to', 'the', 'parental', 'cell', 'line', 'showed', 'decreased', 'sensitivity', 'to', '_chemical_', '_chemical_', 'or', '_chemical_']"
3549,1.0,"A 51 year old female never smoker was diagnosed with stage IV NSCLC with liver metastases, and had adverse response to crizotinib treatment, after which she responded to alectinib until disease progressed after 5 months with new liver metastases.","['a', '_num_', 'year', 'old', 'female', 'never', 'smoker', 'was', 'diagnosed', 'with', 'stage', 'iv', '_disease_', 'with', 'liver', 'metastases', 'and', 'had', 'adverse', 'response', 'to', '_chemical_', 'treatment', 'after', 'which', 'she', 'responded', 'to', '_chemical_', 'until', 'disease', 'progressed', 'after', '_num_', 'months', 'with', 'new', 'liver', 'metastases']"
3550,1.0,TYMS expression was lower in ALK-positive cells.,"['_gene_', 'expression', 'was', 'lower', 'in', '_disease_', 'cells']"
3551,1.0,The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum.,"['the', '_gene_', '_mutation_', 'variant', 'was', 'significantly', 'correlated', 'with', 'higher', 'overall', 'survival', 'in', 'non', 'small', 'cell', 'lung', 'carcinoma', '_disease_', 'patients', 'treated', 'with', '_chemical_', 'and', 'platinum']"
3552,1.0,A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.,"['a', '_gene_', '_mutation_', 'mutation', 'was', 'identified', 'as', 'unanimously', 'present', 'in', 'all', '_num_', 'tumors']"
3553,1.0,In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR).,"['in', 'vitro', 'and', 'xenograft', 'studies', 'of', 'response', 'of', 'breast', 'cancer', 'cell', 'lines', 'to', '_abbrev_', 'inhibitor', '_chemical_', 'showed', 'that', 'sensitivity', 'correlated', 'with', 'expression', 'of', 'the', 'androgen', 'receptor', 'ar']"
3554,1.0,"Of these 11 patients, 4 had the F1174L mutation.","['of', 'these', '_num_', 'patients', '_num_', 'had', 'the', '_mutation_', 'mutation']"
3555,1.0,"In an in vitro study, a Ba/F3  cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 39.41-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'as', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein', 'reported', 'to', 'be', 'sensitizing', 'to', '_chemical_']"
3556,1.0,"Single agent MEK inhibition (AZD6244/selumetinib, MEK162 or PD0325901) and single agent mTOR inhibition (Everolimus or AZD8055) also blocked cell growth in NRAS mutant cell lines, whereas single agent PI3K inhibitors or MEK Inhibitors in combination with PIK3CA/AKT inhibitors did not show synergistic effects.","['single', 'agent', 'mek', 'inhibition', '_abbrev_', '_chemical_', 'or', '_chemical_', 'and', 'single', 'agent', '_gene_', 'inhibition', '_chemical_', 'or', '_chemical_', 'also', 'blocked', 'cell', 'growth', 'in', 'nras', 'mutant', 'cell', 'lines', 'whereas', 'single', 'agent', '_gene_', 'inhibitors', 'or', 'mek', 'inhibitors', 'in', 'combination', 'with', '_abbrev_', 'inhibitors', 'did', 'not', 'show', 'synergistic', 'effects']"
3557,1.0,A V1180L missense mutation was found in the kinase domain of ALK in H3122 CHR-A1 cells.,"['a', '_mutation_', 'missense', 'mutation', 'was', 'found', 'in', 'the', 'kinase', 'domain', 'of', '_gene_', 'in', '_abbrev_', '_abbrev_', 'cells']"
3558,1.0,"Four of the 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter, and 3 of 4 died of disease within 12 months of surgical resection.","['_num_', 'of', 'the', '_num_', 'patients', 'with', 'a', '_gene_', 'mutation', 'had', 'metastases', 'at', 'diagnosis', 'or', 'detected', 'soon', 'thereafter', 'and', '_num_', 'of', '_num_', 'died', 'of', 'disease', 'within', '_num_', 'months', 'of', 'surgical', 'resection']"
3559,1.0,"5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.","['5a', 'and', '_chemical_', 'transformed', '3t3', 'cells', 'formed', 'tumors', 'when', 'injected', 'in', '_ratio_', 'nude', 'mice', 'but', '3t3', 'transformed', 'with', '_gene_', 'alone', 'did', 'not']"
3560,1.0,"This persistence was associated with a greater risk of relapse after 3 years of follow-up than was an absence of such transcripts (82% vs. 30%; hazard ratio, 4.80; 95% confidence interval [CI], 2.95 to 7.80; P<0.001) and a lower rate of survival (24% vs. 75%; hazard ratio for death, 4.38; 95% CI, 2.57 to 7.47; P<0.001).","['this', 'persistence', 'was', 'associated', 'with', 'a', 'greater', 'risk', 'of', 'relapse', 'after', '_num_', 'years', 'of', 'follow', 'up', 'than', 'was', 'an', 'absence', 'of', 'such', 'transcripts', '_num_', 'vs', '_num_', 'hazard', 'ratio', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', 'p', '_num_', 'and', 'a', 'lower', 'rate', 'of', 'survival', '_num_', 'vs', '_num_', 'hazard', 'ratio', 'for', 'death', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
3561,1.0,"Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well.","['of', 'note', 'sequencing', 'of', '_num_', '_disease_', 'genes', 'identified', '_gene_', '_mutation_', '_gene_', '_abbrev_', '_gene_', '_abbrev_', 'and', 'homozygous', 'deletion', 'of', '_gene_', 'as', 'well']"
3562,1.0,"In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy.","['in', 'a', 'stage', 'iv', 'lung', 'adenocarcinoma', 'patient', 'harboring', 'an', '_gene_', '_mutation_', 'mutation', 'and', 'an', 'acquired', '_gene_', '_mutation_', 'co', 'mutation', '_gene_', '_mutation_', 'was', 'associated', 'with', 'sensitivity', 'to', 'osimertinib', 'monotherapy']"
3563,1.0,The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes.,"['the', 'fda', 'approved', 'package', 'insert', 'for', '_chemical_', 'recommends', 'dose', 'adjustment', 'for', '_gene_', 'allele', 'homozygotes']"
3564,1.0,"ICI improved overall survival over that with docetaxel in KRAS mutant, previously-treated advanced NSCLC (hazard ratio=0.64 [95% confidence interval, 0.43-0.96], P = 0.03) but not in those with KRAS wild type tumor (HR = 0.88 [95% CI, 0.68-1.13], P = 0.30).","['_disease_', 'improved', 'overall', 'survival', 'over', 'that', 'with', '_chemical_', 'in', '_gene_', 'mutant', 'previously', 'treated', 'advanced', '_disease_', 'hazard', '_ineq_', '_num_', 'confidence', 'interval', '_range_', 'p', '_num_', 'but', 'not', 'in', 'those', 'with', '_gene_', 'wild', 'type', 'tumor', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
3565,1.0,"Although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy.","['although', '_gene_', 'exon', '_num_', 'insertions', 'may', 'confer', 'reduced', 'sensitivity', 'to', '_chemical_', 'patients', 'with', 'this', 'particular', 'mutation', 'appeared', 'to', 'benefit', 'from', 'therapy']"
3566,1.0,"A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.","['a', 'retroviral', 'cdna', 'expression', 'library', 'was', 'constructed', 'using', 'a', 'lung', 'adenocarcinoma', 'specimen', 'from', 'a', '_num_', 'year', 'old', '_disease_', 'patient', 'and', 'transfected', 'into', 'mouse', '3t3', 'fibroblasts', 'which', 'were', 'assessed', 'for', 'transformed', 'foci']"
3567,1.0,A pre-clinical study in 10 solid cancer cell lines.,"['a', '_gene_', 'clinical', 'study', 'in', '_num_', 'solid', 'cancer', 'cell', 'lines']"
3568,1.0,"This missense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 42).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'family', '_gene_', '_num_']"
3569,1.0,"HPO terms: retinal hemangioblastoma, renal cell carcinoma.","['_disease_', 'terms', 'retinal', '_disease_', 'renal', 'cell', 'carcinoma']"
3570,1.0,Three cell lines did not have CDKN2A (p16) mutations and showed expression of the protein on western blot analysis.,"['_num_', 'cell', 'lines', 'did', 'not', 'have', '_gene_', '_gene_', 'mutations', 'and', 'showed', 'expression', 'of', 'the', 'protein', 'on', 'western', 'blot', 'analysis']"
3571,1.0,However this mutation did not affect the ability of PTEN to bind lipid membranes in-vivo.,"['however', 'this', 'mutation', 'did', 'not', 'affect', 'the', 'ability', 'of', '_gene_', 'to', 'bind', 'lipid', 'membranes', 'in', 'vivo']"
3572,1.0,Treatment with nivolumab was begun and both patients had radiologic response.,"['treatment', 'with', 'nivolumab', 'was', 'begun', 'and', 'both', 'patients', 'had', 'radiologic', 'response']"
3573,1.0,"Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20).","['of', 'these', '_abbrev_', 'harbored', '_chemical_', 'variant', '3a', 'b', '_gene_', 'exon', '_num_', 'and', '_gene_', 'exon', '_num_']"
3574,1.0,"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.","['in', 'in', 'vitro', 'experiments', 'myeloma', 'cell', 'lines', 'expressing', 'activating', 'nras', 'and', '_gene_', 'mutations', 'are', 'less', 'sensitive', 'to', 'the', 'apoptosis', 'inducing', 'effects', 'of', 'dexamethasone', 'doxorubicin', 'and', 'melphalan', 'in', 'comparison', 'to', 'cells', 'with', 'wildtype', 'ras']"
3575,1.0,"The TYMS rs34743033 tandem repeat polymorphism was the only significant predictor of stomatitis in a multiple regression model considering sex, age, MRD class, WBC, MTX AUC0-48h, and genotypes as independent variables (B = −0.48; 95% CI, −0.84, −0.12; R2 = 0.018; P = .009)","['the', '_gene_', '_mutation_', 'tandem', 'repeat', 'polymorphism', 'was', 'the', 'only', 'significant', 'predictor', 'of', 'stomatitis', 'in', 'a', 'multiple', 'regression', 'model', 'considering', 'sex', 'age', 'mrd', 'class', 'wbc', '_gene_', '_abbrev_', 'and', 'genotypes', 'as', 'independent', 'variables', 'b', '−0', '_num_', '_num_', 'ci', '−0', '_num_', '−0', '_num_', '_gene_', '_num_', 'p', '_num_']"
3576,1.0,Sequencing of MGH056-1 cells revealed the I1171T mutation in ALK.,"['sequencing', 'of', '_abbrev_', 'cells', 'revealed', 'the', '_mutation_', 'mutation', 'in', '_gene_']"
3577,1.0,Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line.,"['mitomycin', 'c', 'specifically', 'led', 'to', 'regression', 'in', '_ratio_', 'xenografts', 'of', 'the', '_abbrev_', 'cell', 'line', 'compared', 'to', '_ratio_', 'in', 'the', 'cfpac', '_gene_', 'wildtype', 'cell', 'line']"
3578,1.0,"G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively).","['_mutation_', '_mutation_', 'and', '_mutation_', 'were', 'the', 'most', 'common', 'mutations', '_num_', '_num_', '_num_', 'respectively']"
3579,1.0,13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery.,"['_num_', '_gene_', 'breast', 'cancer', 'patients', 'were', 'treated', 'with', '_chemical_', 'and', 'then', '_chemical_', '_chemical_', 'prior', 'to', 'surgery']"
3580,1.0,Longitudinal analysis of ctDNA in plasma samples revealed a p.G595R- and p.G667C mutation in NTRK1 that were absent before treatment initiation but  emerged 4 weeks upon initiation of treatment with entrectinib.,"['longitudinal', 'analysis', 'of', 'ctdna', 'in', 'plasma', 'samples', 'revealed', 'a', 'p', '_abbrev_', '', 'and', '_mutation_', 'mutation', 'in', '_gene_', 'that', 'were', 'absent', 'before', 'treatment', 'initiation', 'but', 'emerged', '_num_', 'weeks', 'upon', 'initiation', 'of', 'treatment', 'with', 'entrectinib']"
3581,1.0,Difference in response to gefitinib between the two EGFR mutation types was not observed.,"['difference', 'in', 'response', 'to', '_chemical_', 'between', 'the', '_num_', '_gene_', 'mutation', 'types', 'was', 'not', 'observed']"
3582,1.0,This missense mutation was found in a VHL type 2A patient (patient no V240).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_abbrev_']"
3583,1.0,This synergism was not apparent in 4 tested HNSCC cell lines with wild type PIK3CA or PTEN mutation.,"['this', 'synergism', 'was', 'not', 'apparent', 'in', '_num_', 'tested', '_disease_', 'cell', 'lines', 'with', 'wild', 'type', '_gene_', 'or', '_gene_', 'mutation']"
3584,1.0,"In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'long', 'term', 'follow', 'up', '_gene_', 'mutations', 'were', 'significantly', 'associated', 'with', 'shorter', 'median', 'survival', 'in', 'patients', 'p', '_num_', 'from', 'time', 'of', 'diagnosis']"
3585,1.0,32/40 tumors harbored KRAS mutations including 2 tumors with A146V mutations which achieved stable disease with combined therapy but progressive disease in either monotherapy.,"['_ratio_', 'tumors', 'harbored', '_gene_', 'mutations', 'including', '_num_', 'tumors', 'with', '_mutation_', 'mutations', 'which', 'achieved', 'stable', 'disease', 'with', 'combined', 'therapy', 'but', 'progressive', 'disease', 'in', 'either', 'monotherapy']"
3586,1.0,Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model.,"['_chemical_', 'inhibited', 'tumor', 'growth', 'and', 'caused', 'regression', 'in', 'both', 'a', '_abbrev_', 'and', '_abbrev_', 'xenograft', 'model']"
3587,1.0,This missense mutation was found in a VHL type 2B patient (patient no V345).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_abbrev_']"
3588,1.0,This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'for', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'nonsense', 'mutation', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
3589,1.0,c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro.,"['_gene_', 'and', 'ligand', '_gene_', 'were', 'expressed', 'by', '_num_', 'uveal', 'melanoma', 'cell', 'lines', 'in', 'vitro']"
3590,1.0,ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cell lines.,"['_gene_', 'silencing', 'increased', 'sensitivity', 'to', '_gene_', 'in', '_ratio_', 'of', 'ovarian', 'cancer', 'cell', 'lines']"
3591,1.0,2 patients from 2 families were confirmed to have the above mutation.,"['_num_', 'patients', 'from', '_num_', 'families', 'were', 'confirmed', 'to', 'have', 'the', 'above', 'mutation']"
3592,1.0,"This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation.","['this', 'study', 'compared', 'drug', 'responses', 'in', 'ba', '_abbrev_', 'cells', 'expressing', 'either', '_chemical_', 'or', '_chemical_', 'fusions', 'with', 'or', 'without', '_mutation_', '_gene_', 'mutation']"
3593,1.0,This missense mutation was found in a VHL type 1 family of 4 individuals (family ID 3315).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_']"
3594,1.0,664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.,"['_num_', 'patients', 'with', 'non', 'bulky', '_disease_', 'stage', 'ii', 'iv', 'ovarian', 'cancer', 'were', 'evaluated', 'for', '_disease_', 'when', 'treated', 'with', '_chemical_', 'vs', 'placebo']"
3595,1.0,Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.,"['patients', 'with', 'nuclear', '_gene_', '_gene_', 'expression', 'had', 'significantly', 'better', 'responses', 'to', '_chemical_', 'platinum', 'chemotherapy', 'than', 'those', 'with', 'low', 'tumor', 'n', '_gene_', 'expression', 'p', '_num_', 'in', 'a', 'retrospective', 'analysis', 'of', '_num_', 'patients', 'with', 'non', 'small', 'cell', 'lung', 'cancer']"
3596,1.0,The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs.,"['the', 'mutation', 'was', 'shown', 'to', 'occur', 'at', 'a', 'hotspot', '_abbrev_', 'of', 'previously', 'reported', 'secondary', 'kit', 'mutations', 'in', '_chemical_', 'resistant', 'gists']"
3597,1.0,"In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels.","['in', 'the', '_mutation_', 'mutant', 'cell', 'lines', 'and', 'the', 'wildtype', 'cell', 'line', 'tested', '_chemical_', 'and', '_gene_', 'levels', 'were', 'diminished', 'with', 'increasing', '_chemical_', 'levels']"
3598,1.0,"In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival.","['in', 'patients', 'with', 'diffuse', 'large', 'b', 'cell', 'lymphoma', 'those', 'with', 'increased', 'levels', 'of', '_gene_', 'were', 'shown', 'to', 'have', 'decreased', 'overall', '_disease_', 'and', 'relapse', 'free', 'survival']"
3599,1.0,"A pivotal, randomized Phase III trial is currently underway.","['a', 'pivotal', 'randomized', 'phase', 'iii', 'trial', 'is', 'currently', 'underway']"
3600,1.0,PDX were treated with cetuximab and mechanisms of resistance investigated.,"['_gene_', 'were', 'treated', 'with', '_chemical_', 'and', 'mechanisms', 'of', 'resistance', 'investigated']"
3601,1.0,Only 2 patients had objective responses.,"['only', '_num_', 'patients', 'had', 'objective', 'responses']"
3602,1.0,This missense mutation was found in a VHL type 2 patient (patient no V209).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
3603,1.0,"In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs.","['in', 'an', 'in', 'vitro', 'study', 'using', 'purified', '_gene_', 'protein', 'kinase', 'activity', 'was', 'assayed', 'and', 'compared', 'for', 'wildtype', '_gene_', '_disease_', 'and', '_abbrev_', 'using', 'both', 'reversible', 'and', 'irreversible', '_disease_', 'drugs']"
3604,1.0,"In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone).","['in', 'metastatic', 'colorectal', 'cancer', 'patients', 'with', 'wildtype', '_gene_', '_gene_', 'mutations', 'were', 'associated', 'with', 'poor', 'progression', 'free', 'survival', 'regardless', 'of', 'treatment', 'panitumumab', 'with', 'best', 'supportive', 'care', 'or', 'best', 'supportive', 'care', 'alone']"
3605,1.0,"The other NF1 mutations were silent events (patient 15, c.135T>C, patient 45 c.4023G>A, and patient 50 c3018C>T) located within candidate splicing motifs.","['the', 'other', '_gene_', 'mutations', 'were', 'silent', 'events', 'patient', '_num_', 'c', '135t', 'c', 'patient', '_num_', 'c', '_unit_', 'a', 'and', 'patient', '_num_', '_abbrev_', 't', 'located', 'within', 'candidate', 'splicing', 'motifs']"
3606,1.0,"The studies included ER positive and negative cases, and the MIB-1 antibody was used in the large majority of studies.","['the', 'studies', 'included', 'er', 'positive', 'and', 'negative', 'cases', 'and', 'the', '_gene_', 'antibody', 'was', 'used', 'in', 'the', 'large', 'majority', 'of', 'studies']"
3607,1.0,"In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild type IDH2.","['in', '_disease_', 'patients', 'with', 'an', '_gene_', '_mutation_', 'mutation', 'have', 'worse', 'overall', 'survival', 'compared', 'to', 'those', 'with', 'wild', 'type', '_gene_']"
3608,1.0,"Further, amplification of the MET gene was observed.","['further', 'amplification', 'of', 'the', 'met', 'gene', 'was', 'observed']"
3609,1.0,Afatinib and temozolomide led to disease regression.,"['_chemical_', 'and', '_chemical_', 'led', 'to', 'disease', 'regression']"
3610,1.0,"Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild type (n=3) cell line.","['cell', 'lines', '_gene_', 'with', '_gene_', '_num_', '_abbrev_', '_abbrev_', '_abbrev_', 'or', '_gene_', '_abbrev_', 'mutation', 'were', 'more', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_abbrev_', 'than', '_gene_', '_num_', 'wild', 'type', '_ineq_', 'cell', 'line']"
3611,1.0,"In a study of 1,540 patients with Acute Myeloid Leukemia, 18 patients had a mutation in IDH2(R172).","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '_num_', 'patients', 'had', 'a', 'mutation', 'in', '_gene_', '_abbrev_']"
3612,1.0,Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines.,"['expression', 'of', '_gene_', 'was', 'associated', 'with', 'sensitivity', 'to', 'mek', 'inhibitor', '_chemical_', 'sensitivity', '_num_', 'specificity', '_num_', 'p', '_num_', 'in', '_num_', 'solid', 'cancer', 'cell', 'lines']"
3613,1.0,The effectiveness of cetuximab was significantly associated with K-ras mutation status (P=0.01 for overall survival and P<0.001 for progression-free survival).,"['the', 'effectiveness', 'of', '_chemical_', 'was', 'significantly', 'associated', 'with', '_gene_', 'mutation', 'status', '_p_val_', 'for', 'overall', 'survival', 'and', 'p', '_num_', 'for', 'progression', 'free', 'survival']"
3614,1.0,Earlier deaths were seen with heavier HER2 expression.,"['earlier', 'deaths', 'were', 'seen', 'with', 'heavier', '_gene_', 'expression']"
3615,1.0,"EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.","['_chemical_', 'variants', '_abbrev_', '_gene_', '_gene_', '_abbrev_', '_chemical_', '_gene_', '_abbrev_', '_gene_', '_gene_', 'and', '_abbrev_', '_abbrev_', '_gene_', 'were', 'expressed', 'in', 'ba', '_abbrev_', 'cells', 'using', 'retrovirus']"
3616,1.0,Patient also harbored a BRAF V600E mutation.,"['patient', 'also', 'harbored', 'a', '_gene_', '_mutation_', 'mutation']"
3617,1.0,"Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild type K-ras did benefit from cetuximab.","['patients', 'with', 'a', 'colorectal', 'tumor', 'bearing', 'mutated', '_gene_', 'did', 'not', 'benefit', 'from', '_chemical_', 'whereas', 'patients', 'with', 'a', 'tumor', 'bearing', 'wild', 'type', '_gene_', 'did', 'benefit', 'from', '_chemical_']"
3618,0.0,LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors.,"['_abbrev_', 'is', 'an', 'orally', 'administered', 'inhibitor', 'of', 'the', '_gene_', 'kinase', 'and', 'is', 'highly', 'selective', 'only', 'for', 'the', '_gene_', 'family', 'of', 'receptors']"
3619,1.0,Only 3/30 patients on this trial had a partial response (no complete responses).,"['only', '_ratio_', 'patients', 'on', 'this', 'trial', 'had', 'a', 'partial', 'response', 'no', 'complete', 'responses']"
3620,1.0,"Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%).","['genomic', 'profiling', 'of', 'the', 'cystectomy', 'specimen', 'identified', '_gene_', '_gene_', 'and', '_gene_', 'amplification', 'as', 'well', 'as', 'an', '_gene_', '_mutation_', 'mutation', 'allele', 'frequency', '_num_']"
3621,1.0,"Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines.","['mutations', '_mutation_', 'in', 'the', 'ligand', 'binding', 'domain', 'of', 'the', 'androgen', 'receptor', 'confered', 'resistance', 'to', '_chemical_', 'and', '_chemical_', 'causing', 'these', 'compounds', 'to', 'function', 'as', 'partial', 'agonists', 'in', '_num_', 'prostate', 'cancer', 'cell', 'lines']"
3622,1.0,Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab.,"['case', 'report', 'of', 'a', 'patient', 'with', 'metastatic', 'colorectal', 'carcinoma', 'and', 'a', 'novel', '_gene_', '_mutation_', 'mutation', 'showed', 'resistance', 'to', 'treatment', 'with', 'panitumumab']"
3623,1.0,KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines.,"['_gene_', 'mutation', 'or', 'amplification', 'predicted', 'sensitivity', 'to', '_chemical_', 'in', 'ovarian', 'cancer', 'cell', 'lines']"
3624,1.0,All three family members had hemangioblastomas of the central nervous system (proband no 13).,"['all', '_num_', 'family', 'members', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'proband', 'no', '_num_']"
3625,1.0,During lead-in phase 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma).,"['during', 'lead', 'in', 'phase', '_num_', 'of', 'evaluable', 'patients', 'showed', 'reduction', 'in', 'target', 'lesion', 'size', '_num_', 'uveal', 'melanoma']"
3626,1.0,"After 5 years of completion of adjuvant chemotherapy, the disease relapsed.","['after', '_num_', 'years', 'of', 'completion', 'of', 'adjuvant', 'chemotherapy', 'the', 'disease', 'relapsed']"
3627,1.0,"Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1.","['_num_', 'patients', 'were', 'found', 'to', 'harbor', 'gene', 'fusions', 'maintaining', 'the', 'kinase', 'domain', 'of', '_gene_', '_num_', 'partner', 'specifically', '_abbrev_', 'and', '_abbrev_']"
3628,1.0,"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild type EGFR (median 8.9 versus 2.1).","['_num_', '_disease_', 'patients', 'with', 'stage', 'iiib', 'iv', 'chemotherapy', 'resistant', 'tumors', 'were', 'treated', 'with', '_chemical_', 'and', 'exon', '_num_', 'deletion', 'of', '_gene_', 'was', 'associated', 'with', 'longer', 'time', 'to', 'treatment', 'failure', 'than', 'those', 'with', 'wild', 'type', '_gene_', 'median', '_num_', 'vs', '_num_']"
3629,1.0,"Of the 275 patients assessable for KRAS mutation status, 49 (18%) were positive for KRAS mutation.","['of', 'the', '_num_', 'patients', 'assessable', 'for', '_gene_', 'mutation', 'status', '_num_', '_num_', 'were', 'positive', 'for', '_gene_', 'mutation']"
3630,1.0,This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 85).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
3631,1.0,Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance.,"['leukemia', 'initiating', 'cells', 'bearing', 'the', '_abbrev_', 'mutation', 'expanded', 'during', '_chemical_', 'treatment', 'and', 'dominated', 'during', 'the', 'subsequent', 'clinical', 'resistance']"
3632,1.0,Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 amplification (median sHER2 levels were 25.1 ng/mL in patients with HER2-positive tumors).,"['serum', '_gene_', '_abbrev_', 'levels', 'measured', 'by', 'elisa', 'were', 'higher', 'in', 'patients', 'with', '_gene_', 'amplification', 'median', '_abbrev_', 'levels', 'were', '_num_', '_unit_', '_unit_', 'in', 'patients', 'with', '_gene_', 'tumors']"
3633,1.0,"Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.","['patients', 'were', '_gene_', 'by', '_abbrev_', 'or', 'fish', 'and', 'patients', 'who', 'had', 'received', 'prior', 'hormonal', 'treatment', 'or', 'adjuvant', 'neo', 'adjuvant', 'therapy', 'with', 'or', 'without', '_chemical_', 'for', 'longer', 'than', '_num_', 'months', 'before', 'randomization', 'were', 'also', 'eligible']"
3634,1.0,"The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.","['the', 'degree', 'of', '_gene_', 'dependence', 'and', 'targetability', 'of', '_chemical_', 'for', '_gene_', 'inhibition', 'may', 'vary', 'among', '_gene_', 'fusion', 'variants']"
3635,1.0,The tumor was not sequenced prior to alectinib resistance.,"['the', 'tumor', 'was', 'not', 'sequenced', 'prior', 'to', '_chemical_', 'resistance']"
3636,1.0,"2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had IC50 100 fold lower than the non MET amplified cell lines.","['_num_', 'met', 'amplified', '_disease_', 'cell', 'lines', '_abbrev_', 'and', '_abbrev_', 'as', 'well', 'as', '_num_', '_gene_', 'mutant', 'and', '_num_', 'met', 'and', '_gene_', 'wild', 'type', 'cell', 'lines', 'were', 'treated', 'with', '_gene_', 'and', 'met', 'inhibitor', '_chemical_', 'and', 'the', 'met', 'amplified', 'cells', 'had', '_abbrev_', '_num_', 'fold', 'lower', 'than', 'the', 'non', 'met', 'amplified', 'cell', 'lines']"
3637,1.0,Activity of the FGFR-selective inhibitor AZD4547 in FGFR1-amplified breast cancer and FGFR2-amplified gastroesophageal cancer was analyzed in this study.,"['activity', 'of', 'the', 'fgfr', 'selective', 'inhibitor', '_chemical_', 'in', '_abbrev_', 'breast', 'cancer', 'and', '_abbrev_', 'gastroesophageal', 'cancer', 'was', 'analyzed', 'in', 'this', 'study']"
3638,1.0,Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.,"['cell', 'lines', 'with', '_abbrev_', 'fusion', 'show', 'sensitivity', 'to', 'the', 'tyrosine', 'kinase', 'inhibitors', '_chemical_', 'and', '_abbrev_']"
3639,1.0,2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis).,"['_num_', 'of', '_num_', 'patients', 'tested', 'were', 'found', 'to', 'have', '_gene_', 'amplification', 'but', 'no', 'baseline', 'samples', 'available', 'for', 'analysis']"
3640,1.0,AZD8055 also retained efficacy in these clones in xenograft.,"['_chemical_', 'also', 'retained', 'efficacy', 'in', 'these', 'clones', 'in', 'xenograft']"
3641,1.0,Knockdown of WRD5 in 32D cells (mouse hematopoietic cell line) or transplanted primary mouse bone marrow expressing the p30 isoform restored myeloid differentiation in these cells.,"['knockdown', 'of', '_abbrev_', 'in', '32d', 'cells', 'mouse', 'hematopoietic', 'cell', 'line', 'or', 'transplanted', 'primary', 'mouse', 'bone', 'marrow', 'expressing', 'the', '_gene_', '_chemical_', 'restored', 'myeloid', 'differentiation', 'in', 'these', 'cells']"
3642,1.0,Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations.,"['age', 'related', 'risks', 'of', 'retinal', 'angiomas', 'and', 'renal', 'cell', 'carcinoma', 'were', 'higher', 'in', 'patients', 'with', 'nonsense', 'or', 'frameshift', 'mutations']"
3643,1.0,This study evaluated the effects of everolimus and sunitinib on patients with metastatic renal cell carcinoma.,"['this', 'study', 'evaluated', 'the', 'effects', 'of', '_chemical_', 'and', '_chemical_', 'on', 'patients', 'with', 'metastatic', 'renal', 'cell', 'carcinoma']"
3644,1.0,"Open-label, randomized phase 3 trial with 704 patients with metastatic melanoma with a BRAF V600 mutation.","['open', 'label', 'randomized', 'phase', '_num_', 'trial', 'with', '_num_', 'patients', 'with', 'metastatic', 'melanoma', 'with', 'a', '_gene_', '_abbrev_', 'mutation']"
3645,1.0,EML4-ALK variant 3 containing NSCLC cell line H2228 xenografts in SCID beige mice were treated with increasing doses of crizotinib up to 100 mg/kg per day by oral gavage.,"['_chemical_', 'variant', '_num_', 'containing', '_disease_', 'cell', 'line', '_abbrev_', 'xenografts', 'in', 'scid', 'beige', 'mice', 'were', 'treated', 'with', 'increasing', 'doses', 'of', '_chemical_', 'up', 'to', '_num_', '_disease_', 'per', 'day', 'by', 'oral', 'gavage']"
3646,1.0,"In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol.","['in', 'the', 'cervial', 'andenocarcinoma', 'cell', 'line', 'hela', 'when', 'aurk', 'a', 'was', 'overexpressed', 'the', 'cells', 'were', 'resistant', 'to', 'the', 'apoptotic', 'effects', 'of', '_chemical_']"
3647,1.0,"PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5 ± 1.5 months, P = 0.03.","['_disease_', '_num_', '±', '_num_', 'vs', '_num_', '±', '_num_', 'months', 'p', '_num_', 'os', '_num_', '±', '_num_', 'vs', '_num_', '±', '_num_', 'months', 'p', '_num_']"
3648,1.0,Patients with this mutation had a 22 month median survival compared to 77 months in aCML patients without the mutation (P=.01).,"['patients', 'with', 'this', 'mutation', 'had', 'a', '_num_', 'month', 'median', 'survival', 'compared', 'to', '_num_', 'months', 'in', '_disease_', 'patients', 'without', 'the', 'mutation', 'p=', '_num_']"
3649,1.0,Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression.,"['treatment', 'of', '_abbrev_', 'cells', 'implanted', 'into', 'left', 'kidneys', 'of', 'nude', 'mice', 'resulted', 'in', 'almost', 'complete', 'tumor', 'regression']"
3650,1.0,ACMG codes as follows: A frameshift variant in a gene where loss-of-function is known mechanism of disease (PSV1).,"['acmg', 'codes', 'as', 'follows', 'a', 'frameshift', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'known', 'mechanism', 'of', 'disease', '_abbrev_']"
3651,1.0,"For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99].","['for', 'other', '_gene_', 'mt', 'the', 'hazard', 'ratio', 'for', 'os', 'benefit', 'with', 'addition', 'of', 'anti', '_gene_', 'mab', 'therapy', 'was', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', '_num_', 'compared', 'to', '_num_', '_num_', 'ci', '_num_', '_num_', 'for', '_gene_', '_mutation_', 'test', 'for', 'interaction', '_p_val_']"
3652,1.0,"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', 'iv', 'lung', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_abbrev_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
3653,1.0,Results were recapitulated in-vivo.,"['results', 'were', 'recapitulated', 'in', 'vivo']"
3654,1.0,"Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition.","['since', '_chemical_', 'inhibits', 'met', '_num_', 'patients', 'with', 'available', 'tissue', 'were', 'screened', 'for', 'met', 'amplification', 'and', 'were', 'found', 'negative', 'further', 'indicating', 'that', 'patient', 'response', 'was', 'due', 'to', '_gene_', 'inhibition']"
3655,0.0,These results suggest that KRAS mutation status may be a potential biomarker for survival benefits to ICIs.,"['these', 'results', 'suggest', 'that', '_gene_', 'mutation', 'status', 'may', 'be', 'a', 'potential', '_chemical_', 'for', 'survival', 'benefits', 'to', '_disease_']"
3656,1.0,Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification.,"['_disease_', 'analysis', 'on', 'prognostic', 'value', 'of', '_gene_', 'amplification', 'in', 'different', 'types', 'of', 'cancer', 'shows', 'significantly', 'worse', 'overall', 'survival', 'for', 'patients', 'with', '_gene_', 'and', '_gene_', 'amplification']"
3657,1.0,"we conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.","['we', 'conclude', 'that', 'their', 'findings', 'in', 'this', 'heavily', 'pretreated', 'population', 'along', 'with', 'findings', 'in', 'the', 'emilia', 'trial', 'indicate', 'promise', 'for', 'antibody', 'drug', 'conjugates']"
3658,1.0,"In patients (n=57) that had been treated with trastuzumab plus chemotherapy, an overall response rate of 75% and progression free survival of 5.1 months were observed.","['in', 'patients', '_ineq_', 'that', 'had', 'been', 'treated', 'with', '_chemical_', 'plus', 'chemotherapy', 'an', 'overall', 'response', 'rate', 'of', '_num_', 'and', 'progression', 'free', 'survival', 'of', '_num_', 'months', 'were', 'observed']"
3659,1.0,It was found that patients with a combined high RRM1 and ERCC1 expression had good prognosis with the highest survival rate (P=0.0127).,"['it', 'was', 'found', 'that', 'patients', 'with', 'a', 'combined', 'high', '_gene_', 'and', '_gene_', 'expression', 'had', 'good', 'prognosis', 'with', 'the', 'highest', 'survival', 'rate', '_p_val_']"
3660,1.0,"NPM-ALK G1269A was also tested for brigatinib sensitivity, and IC50 values of 11 nM were reported for both NPM-ALK G1269A and NPM-ALK wild type.","['_chemical_', '_mutation_', 'was', 'also', 'tested', 'for', 'brigatinib', 'sensitivity', 'and', '_abbrev_', 'values', 'of', '_num_', '_unit_', 'were', 'reported', 'for', 'both', '_chemical_', '_mutation_', 'and', '_chemical_', 'wild', 'type']"
3661,1.0,A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684.,"['a', 'cell', 'line', '_abbrev_', 'with', '_abbrev_', 'fusion', 'and', 'resistance', 'mutation', '_mutation_', 'showed', 'no', 'response', 'to', '_gene_', 'inhibition', 'with', '_chemical_', 'or', '_chemical_']"
3662,1.0,"The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001).","['the', 'median', 'survival', 'after', 'start', 'of', 'therapy', 'was', 'shorter', 'in', 'patients', 'with', 'mutations', 'in', '_gene_', 'than', 'for', 'patients', 'with', 'wild', 'type', '_gene_', '_unit_', 'vs', '_unit_', 'hr:1', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', 'p', '_num_']"
3663,1.0,"More specifically, genetic testing demonstrated the above mutation (X214WextX15) in 1 individual in a single family.","['more', 'specifically', 'genetic', 'testing', 'demonstrated', 'the', 'above', 'mutation', '_abbrev_', 'in', '_num_', 'individual', 'in', 'a', 'single', 'family']"
3664,1.0,Inhibition of SYK with R406 resensitized cell lines to paclitaxel.,"['inhibition', 'of', '_gene_', 'with', '_chemical_', 'resensitized', 'cell', 'lines', 'to', '_chemical_']"
3665,1.0,"144 cases (discovery set: N=62 discovery; independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing, or WHO grade III).","['_num_', 'cases', 'discovery', 'set', '_ineq_', 'discovery', 'independent', 'validation', 'set', 'n', '_num_', 'of', 'meningiomas', 'were', 'analyzed', 'for', 'transcriptional', 'features', 'defining', 'aggressive', 'clinical', 'course', 'recurrent', 'malignantly', 'progressing', 'or', 'who', 'grade', 'iii']"
3666,1.0,"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib).","['_num_', 'patients', 'with', 'lung', 'adenocarcinomas', 'underwent', 'rebiopsy', 'and', 'genotyping', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', '_gene_', 'nras', '_gene_', 'and', 'fish', 'for', 'met', 'and', '_gene_', 'after', 'the', 'development', 'of', 'acquired', 'resistance', 'to', '_gene_', 'inhibitors', '_chemical_', 'or', '_chemical_']"
3667,1.0,Passaging of the alectinib sensitive EML4-ALK containing H3122 NSCLC cell line with increasing levels of alectinib resulted in an alectinib resistant derivative of this cell line named H3122 CHR-A1.,"['passaging', 'of', 'the', '_chemical_', 'sensitive', '_chemical_', 'containing', '_abbrev_', '_disease_', 'cell', 'line', 'with', 'increasing', 'levels', 'of', '_chemical_', 'resulted', 'in', 'an', '_chemical_', 'resistant', 'derivative', 'of', 'this', 'cell', 'line', 'named', '_abbrev_', '_abbrev_']"
3668,1.0,Especially the combination of two DNA-damaging agents was associated with efficacy.,"['especially', 'the', 'combination', 'of', '_num_', 'dna', 'damaging', 'agents', 'was', 'associated', 'with', 'efficacy']"
3669,1.0,"Retrospective subset analyses showed that, irrespective of the cutoff used or the treatment arm, MET expression did not show prognostic significance, in terms of objective response rate, progression-free survival, or overall survival.","['retrospective', 'subset', 'analyses', 'showed', 'that', 'irrespective', 'of', 'the', 'cutoff', 'used', 'or', 'the', 'treatment', 'arm', 'met', 'expression', 'did', 'not', 'show', 'prognostic', 'significance', 'in', 'terms', 'of', 'objective', 'response', 'rate', 'progression', 'free', 'survival', 'or', 'overall', 'survival']"
3670,1.0,A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease.,"['a', 'randomized', 'phase', '_num_', 'trial', 'involving', '_num_', '_disease_', 'patients', 'with', '_gene_', 'mutations', 'exon', '_num_', 'deletion', 'or', '_mutation_', 'mutation', 'in', 'exon', '_num_', 'with', 'no', 'history', 'of', 'chemotherapy', 'for', 'metastatic', 'disease']"
3671,1.0,"HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma.","['_disease_', 'terms', '_disease_', 'retinal', '_disease_', 'renal', 'cell', 'carcinoma']"
3672,1.0,This sensitivity was confirmed in a mouse xenograft.,"['this', 'sensitivity', 'was', 'confirmed', 'in', 'a', 'mouse', 'xenograft']"
3673,1.0,"The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.33–5.75, P = 0.006, Pc = 0.030) and decreased disease-free survival (DFS) (HR = 2.45, 95% CI: 1.30–4.61, P = 0.005) compared to patients without this mutation.","['the', 'tc', 'cc', 'genotype', 'of', '_gene_', 'at', '_mutation_', 'had', 'decreased', 'overall', 'survival', 'hr', '_num_', '_num_', 'ci', '_num_', '33–5', '_num_', 'p', '_num_', 'pc', '_num_', 'and', 'decreased', '_disease_', 'survival', '_disease_', 'hr', '_num_', '_num_', 'ci', '_num_', '30–4', '_num_', 'p', '_num_', 'compared', 'to', 'patients', 'without', 'this', 'mutation']"
3674,1.0,The S1206Y mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.,"['the', '_mutation_', 'mutation', 'in', 'the', '_chemical_', 'fusion', 'was', 'found', 'to', 'confer', 'resistance', 'to', '_chemical_', 'in', 'ba', '_abbrev_', 'cells']"
3675,1.0,The overall objective tumor response rate was 51%.,"['the', 'overall', 'objective', 'tumor', 'response', 'rate', 'was', '_num_']"
3676,1.0,"In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement.","['in', 'a', 'retrospective', 'study', '_num_', 'patients', 'were', 'evaluated', 'after', '_chemical_', 'treatment', 'for', 'stage', 'iv', '_disease_', 'confirmed', 'for', '_gene_', 'rearrangement']"
3677,1.0,"The patients had EGFR mutations (exon 19 deletions or L858R), and improved progression-free survival was reported in the erlotinib treated cohort as compared to the cohort that was treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).","['the', 'patients', 'had', '_gene_', 'mutations', 'exon', '_num_', 'deletions', 'or', '_mutation_', 'and', 'improved', 'progression', 'free', 'survival', 'was', 'reported', 'in', 'the', '_chemical_', 'treated', 'cohort', 'as', 'compared', 'to', 'the', 'cohort', 'that', 'was', 'treated', 'with', 'standard', 'chemotherapy', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'univariate', 'analysis', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'multivariate', 'analysis']"
3678,1.0,"For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR wildtype, ASXL1 mutant patients (2.3 years; HR, 5.9; 95% CI, 3.5–10.0, N=62); and either CALR/ASXL1wildtype or CALR/ASXL1 mutant patients (5.8 years; HR, 2.5; 95% CI, 1.5–4.0, N=169).","['for', '_num_', 'patients', '_gene_', 'mutated', '_gene_', 'wildtype', 'patients', 'median', 'survival', '_num_', 'years', '_ineq_', '_gene_', 'wildtype', '_gene_', 'mutant', 'patients', '_num_', 'years', 'hr', '_num_', '_num_', 'ci', '_num_', '5–10', '_num_', '_ineq_', 'and', 'either', '_gene_', '_abbrev_', 'or', '_gene_', '_abbrev_', 'mutant', 'patients', '_num_', 'years', 'hr', '_num_', '_num_', 'ci', '_num_', '5–4', '_num_', '_ineq_']"
3679,1.0,GDC-0941 and AZD-6244 (selumetinib) impaired colony formation in-vitro.,"['_chemical_', 'and', '_chemical_', '_chemical_', 'impaired', 'colony', 'formation', 'in', 'vitro']"
3680,1.0,The E255K mutation was resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
3681,1.0,"In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median, 5.5 v 1.9 months, respectively; P = .009) and OS (median, 16 v 5 months, respectively; P = .003).","['in', 'this', 'study', 'patients', 'with', 'low', '_gene_', 'expression', 'compared', 'with', 'patients', 'with', 'high', '_gene_', 'expression', 'had', 'a', 'significantly', 'higher', 'response', 'rate', '_num_', 'v', '_num_', 'respectively', 'p', '_num_', 'and', 'improved', '_disease_', 'median', '_num_', 'v', '_num_', 'months', 'respectively', 'p', '_num_', 'and', 'os', 'median', '_num_', 'v', '_num_', 'months', 'respectively', 'p', '_num_']"
3682,1.0,There was a significant association between high cytoplasmic FGF13 staining and a risk of biochemical recurrence (BCR) after radical prostatectomy.,"['there', 'was', 'a', 'significant', 'association', 'between', 'high', 'cytoplasmic', '_gene_', 'staining', 'and', 'a', 'risk', 'of', 'biochemical', 'recurrence', '_gene_', 'after', 'radical', 'prostatectomy']"
3683,1.0,These agents also increased the lifespan of mice transfused with ATM-deficient lymphoma cells when compared with etoposide or control.,"['these', 'agents', 'also', 'increased', 'the', 'lifespan', 'of', 'mice', 'transfused', 'with', '_disease_', 'lymphoma', 'cells', 'when', 'compared', 'with', '_chemical_', 'or', 'control']"
3684,1.0,"On the other hand, the often used tool ALK inhibitor TAE684 was highly effective in killing H3122 CHR-A1, where H3122 cells were only slightly more sensitized to TAE684-induced cell death.","['on', 'the', 'other', 'hand', 'the', 'often', 'used', 'tool', '_gene_', 'inhibitor', '_chemical_', 'was', 'highly', 'effective', 'in', 'killing', '_abbrev_', '_abbrev_', 'where', '_abbrev_', 'cells', 'were', 'only', 'slightly', 'more', 'sensitized', 'to', '_abbrev_', 'cell', 'death']"
3685,1.0,"DUX4, ZNF384 and MEF2D fusions were the most frequent found.","['_gene_', '_gene_', 'and', '_gene_', 'fusions', 'were', 'the', 'most', 'frequent', 'found']"
3686,1.0,"Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt).","['_disease_', 'analysis', 'of', '_num_', 'studies', 'with', '_num_', 'patients', '_num_', 'were', '_gene_', '_gene_']"
3687,1.0,"Among the alterations, One cell line harbored a PIK3CA E542K mutation.","['among', 'the', 'alterations', '_num_', 'cell', 'line', 'harbored', 'a', '_gene_', '_mutation_', 'mutation']"
3688,1.0,"Western blots of UD-SCC-3 cells with increasing taselisib concentration showed reduction of phospho-Akt only at micro-molar doses, in contrast to nano-molar range for sensitized cells.","['western', 'blots', 'of', 'ud', '_gene_', '_num_', 'cells', 'with', 'increasing', 'taselisib', 'concentration', 'showed', 'reduction', 'of', '_chemical_', 'only', 'at', 'micro', 'molar', 'doses', 'in', 'contrast', 'to', '_gene_', 'molar', 'range', 'for', 'sensitized', 'cells']"
3689,1.0,Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA.,"['responses', 'were', 'not', 'restricted', 'to', 'patients', 'with', 'detectable', '_gene_', '_mutation_', 'in', 'pretreatment', 'cfdna']"
3690,1.0,"For patients treated with sunitinib followed by everolimus (N=91 wildtype, 20 mutant) were associated with a trend towards shorter progression free survival (median [95% CI] 8.1 [3.1-11.3] vs 11.0 [8.3-13.8] mo; HR 1.69 [0.9-3.2]; P=0.06).","['for', 'patients', 'treated', 'with', '_chemical_', 'followed', 'by', '_chemical_', '_ineq_', 'wildtype', '_num_', 'mutant', 'were', 'associated', 'with', 'a', 'trend', 'towards', 'shorter', 'progression', 'free', 'survival', 'median', '_num_', 'ci', '_num_', '_range_', 'vs', '_num_', '_range_', '_unit_', 'hr', '_num_', '_range_', '_p_val_']"
3691,1.0,PFS but not OS was also longer in patients with high EGFR mRNA expression.,"['_disease_', 'but', 'not', 'os', 'was', 'also', 'longer', 'in', 'patients', 'with', 'high', '_gene_', 'mrna', 'expression']"
3692,1.0,308 patients had either exon 19 or L858 mutations.,"['_num_', 'patients', 'had', 'either', 'exon', '_num_', 'or', '_abbrev_', 'mutations']"
3693,1.0,Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations.,"['expression', 'of', 'egfrviii', 'and', '_gene_', 'was', 'evaluated', 'in', '_num_', 'patients', 'with', 'glioblastomas', 'treated', 'with', '_chemical_', 'or', '_chemical_', 'and', 'no', '_gene_', 'or', '_gene_', 'kinase', 'domain', 'mutations']"
3694,1.0,"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.","['among', '_num_', 'patients', 'treated', 'with', 'pan', '_gene_', 'inhibitor', '_chemical_', 'in', 'this', 'phase', '_num_', 'study', '_num_', 'patient', 'with', 'pancreatic', 'adenocarcinoma', 'and', '_gene_', 'loss', '_gene_', '_mutation_', 'mutation', 'experienced', 'a', 'decrease', 'of', 'approximately', '_num_', 'in', 'cancer', 'antigen', '_range_', 'levels', 'and', '_num_', 'shrinkage', 'in', 'tumor', 'measurements']"
3695,1.0,11 of these mutations were predicted to be truncating.,"['_num_', 'of', 'these', 'mutations', 'were', 'predicted', 'to', 'be', 'truncating']"
3696,1.0,"In this phase II trial, trametinib or docetaxel was given to patients with advanced KRAS-mutant NSCLC.","['in', 'this', 'phase', 'ii', 'trial', '_chemical_', 'or', '_chemical_', 'was', 'given', 'to', 'patients', 'with', 'advanced', '_gene_', 'mutant', '_disease_']"
3697,1.0,"Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity.","['some', 'of', 'the', '_gene_', 'mutant', 'cells', 'contained', '_gene_', 'and', '_gene_', 'mutations', 'but', 'in', 'these', 'cells', 'these', 'mutations', 'did', 'not', 'effect', 'sensitivity']"
3698,1.0,98 patients were found to have developed EGFR T790M mutations.,"['_num_', 'patients', 'were', 'found', 'to', 'have', 'developed', '_gene_', '_mutation_', 'mutations']"
3699,1.0,"Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, identified 3 patients with CD44s isoform.","['retrospective', 'evaluation', 'of', '_num_', 'patients', 'from', 'a', 'phase', '_num_', 'study', 'treated', 'with', '_abbrev_', 'identified', '_num_', 'patients', 'with', '_gene_', '_chemical_']"
3700,1.0,Case study describes a female (age 58) never-smoker presenting with stage IV NSCLC with an ALK rearrangement (confirmed by fish).,"['case', 'study', 'describes', 'a', 'female', 'age', '_num_', 'never', 'smoker', 'presenting', 'with', 'stage', 'iv', '_disease_', 'with', 'an', '_gene_', 'rearrangement', 'confirmed', 'by', 'fish']"
3701,1.0,Another 13 patients had stable disease (63% disease control rate).,"['another', '_num_', 'patients', 'had', 'stable', 'disease', '_num_', 'disease', 'control', 'rate']"
3702,1.0,"Six of 7 individuals were identified with angiomas, 3 with cerebellar hemangioblastomas and one with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
3703,1.0,"Olaparib was found to inhibit cancer cell growth in ATM mutant cell lines of several blood cancers including Lymphoblastoid Leukemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and in a murine xenograft model of Mantle Cell Lymphoma.","['_chemical_', 'was', 'found', 'to', 'inhibit', 'cancer', 'cell', 'growth', 'in', 'atm', 'mutant', 'cell', 'lines', 'of', 'several', 'blood', 'cancers', 'including', 'lymphoblastoid', 'leukemia', 'mantle', 'cell', 'lymphoma', 'chronic', 'lymphocytic', 'leukemia', 'and', 'in', 'a', 'murine', 'xenograft', 'model', 'of', 'mantle', 'cell', 'lymphoma']"
3704,1.0,"Treatment of these mouse xenograft models with ceritinib reduced tumor volume to zero, while in contrast tumor size increased with crizotinib treatment.","['treatment', 'of', 'these', 'mouse', 'xenograft', 'models', 'with', '_chemical_', 'reduced', 'tumor', 'volume', 'to', '_num_', 'while', 'in', 'contrast', 'tumor', 'size', 'increased', 'with', '_chemical_', 'treatment']"
3705,1.0,Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'stop', 'loss', 'variant', 'acmg', 'code', '_abbrev_']"
3706,1.0,Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib.,"['case', 'report', 'of', 'a', 'patient', 'with', 'lung', 'adenocarcinoma', 'harboring', 'a', 'met', 'exon', '_num_', 'skipping', 'mutation', 'and', 'major', 'response', 'to', '_chemical_']"
3707,1.0,Each patient had hemangioblastomas of the central nervous system and 4 had cystadenomas of the epididymis (family VHL 51).,"['each', 'patient', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', '_num_', 'had', '_disease_', 'of', 'the', 'epididymis', 'family', '_gene_', '_num_']"
3708,1.0,Case report of a patient with glioblastoma multiforme and POLE germline mutation.,"['case', 'report', 'of', 'a', 'patient', 'with', 'glioblastoma', 'multiforme', 'and', 'pole', 'germline', 'mutation']"
3709,1.0,"This missense mutation was found in a German, VHL type 1 family of 11.","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'family', 'of', '_num_']"
3710,1.0,Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.,"['median', 'os', 'in', 'the', 'control', 'arm', 'was', '_num_', 'months', 'and', '_num_', 'months', 'with', 'pertuzumab']"
3711,1.0,"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'advanced', 'gastric', 'cancer', 'mutations', 'in', '_gene_', 'were', 'identified', 'in', '_num_', 'of', 'primary', 'tumors']"
3712,1.0,"With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.","['with', 'induction', 'of', '_chemical_', 'and', '_chemical_', 'treatment', 'tumor', 'regression', 'was', 'observed', 'with', 'progression', 'free', 'survival', 'of', '_num_', 'months']"
3713,1.0,Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs.,"['melanoma', 'cell', 'lines', 'harboring', 'the', '_gene_', '_mutation_', 'hotspot', 'mutation', 'were', 'shown', 'to', 'be', 'resistant', 'to', '_gene_', 'inhibition', 'with', '_chemical_', 'or', '_chemical_', 'and', 'knock', 'in', 'or', 'knock', 'out', 'of', 'this', 'mutation', 'decreased', 'and', 'increased', 'sensitivity', 'to', 'these', 'drugs']"
3714,1.0,High B4GALT1 expression was associated with poor overall survival (P<0.001 and P<0.001 in training and validation cohort) and identified as an independent adverse prognostic factor for survival (P=0.007 and P=0.002).,"['high', '_gene_', 'expression', 'was', 'associated', 'with', 'poor', 'overall', 'survival', 'p', '_num_', 'and', 'p', '_num_', 'in', 'training', 'and', 'validation', 'cohort', 'and', 'identified', 'as', 'an', 'independent', 'adverse', 'prognostic', 'factor', 'for', 'survival', '_p_val_', 'and', '_p_val_']"
3715,1.0,Chemical inhibition of CDK1 by AZD5438 in KRAS mutant vs WT pancreatic and colorectal cancer cell lines showed increased efficacy in mutant cell lines.,"['chemical', 'inhibition', 'of', '_gene_', 'by', '_chemical_', 'in', '_gene_', 'mutant', 'vs', '_gene_', 'pancreatic', 'and', 'colorectal', 'cancer', 'cell', 'lines', 'showed', 'increased', 'efficacy', 'in', 'mutant', 'cell', 'lines']"
3716,1.0,One patient with evaluable disease had stable disease with treatment ongoing at the time of publication.,"['_num_', 'patient', 'with', 'evaluable', 'disease', 'had', 'stable', 'disease', 'with', 'treatment', 'ongoing', 'at', 'the', 'time', 'of', 'publication']"
3717,1.0,"Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45.","['subcutaneous', 'tumor', 'nodules', 'exhibited', 'clinical', 'responses', 'within', '_num_', 'days', 'of', 'therapy', 'and', 'her', 'dominant', 'bulky', 'right', 'lung', 'metastases', 'showed', 'significant', 'response', 'by', 'day', '_num_']"
3718,1.0,This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1),"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'for', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'frameshift', 'mutation', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
3719,1.0,Phorphorylation of EGFR was assayed by Western blot.,"['phorphorylation', 'of', '_gene_', 'was', 'assayed', 'by', 'western', 'blot']"
3720,1.0,128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum.,"['_num_', 'patients', 'with', 'oral', '_disease_', 'cell', 'carcinoma', '_disease_', 'and', '_num_', 'normal', 'control', 'subjects', 'were', 'evaluated', 'for', 'the', 'concentration', 'of', '_gene_', 'in', 'their', 'plasma', 'serum']"
3721,1.0,"In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib).","['in', '_num_', 'patients', 'with', 'advanced', '_disease_', '_num_', 'of', 'which', 'were', 'treated', 'with', '_gene_', '_disease_', '_chemical_', 'or', '_chemical_']"
3722,1.0,"In vitro and in PDX models, FGFR2-amplified cell lines were sensitive to FGFR inhibition.","['in', 'vitro', 'and', 'in', '_gene_', 'models', '_abbrev_', 'cell', 'lines', 'were', 'sensitive', 'to', '_gene_', 'inhibition']"
3723,1.0,These mutations occurred in 10/13 patients with familial PJS and 7/20 patients with sporadic PJS.,"['these', 'mutations', 'occurred', 'in', '_ratio_', 'patients', 'with', 'familial', '_gene_', 'and', '_ratio_', 'patients', 'with', 'sporadic', '_gene_']"
3724,1.0,"From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  we conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC.","['from', '_num_', 'patients', 'pcr', 'rates', 'were', '_num_', 'in', 'arm', 'a', '_num_', 'in', 'arm', 'b', 'and', '_num_', 'in', 'arm', 'c', 'we', 'conclude', 'these', 'results', 'support', 'the', 'superiority', 'of', '_abbrev_', 'inhibition', 'in', 'the', 'neoadjuvant', 'context', 'of', '_gene_', 'positive', 'bc']"
3725,1.0,p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome.,"['_gene_', 'expression', 'in', 'non', 'oropharyngeal', '_disease_', 'was', 'also', 'prognostic', 'and', 'associated', 'with', 'a', 'better', 'outcome']"
3726,1.0,"This missense mutation was found in a 40 year old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no 1).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_num_', 'year', 'old', '_gene_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'proband', 'no', '_num_']"
3727,1.0,"Biopsies were optional, and therefore not fully randomized.","['biopsies', 'were', 'optional', 'and', 'therefore', 'not', 'fully', 'randomized']"
3728,0.0,There is an ongoing phase 1/2 trial of binimetinib with the CDK4/6 inhibitor ribociclib (LEE011) in mutant NRAS melanoma patients (NCT01781572).,"['there', 'is', 'an', 'ongoing', 'phase', '_ratio_', 'trial', 'of', '_chemical_', 'with', 'the', '_gene_', 'inhibitor', 'ribociclib', '_chemical_', 'in', 'mutant', 'nras', 'melanoma', 'patients', '_abbrev_']"
3729,1.0,"Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation.","['only', '_num_', 'patients', 'in', 'the', 'study', 'were', 'evaluated', 'for', '_gene_', '_num_', 'of', 'which', 'had', 'a', 'mutation']"
3730,1.0,A study of sporadic renal cell carcinoma identified this frameshift confirmed somatic variant along with LOH of the VHL gene in a case with clear cell renal carcinoma (case #152 in the study).,"['a', 'study', 'of', 'sporadic', 'renal', 'cell', 'carcinoma', 'identified', 'this', 'frameshift', 'confirmed', 'somatic', 'variant', 'along', 'with', '_disease_', 'of', 'the', '_gene_', 'gene', 'in', 'a', 'case', 'with', 'clear', 'cell', 'renal', 'carcinoma', 'case', '_num_', 'in', 'the', 'study']"
3731,1.0,"10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835).","['_ratio_', 'patients', 'with', '_gene_', 'mutations', 'also', 'had', '_gene_', 'mutations', '_num_', '_gene_', '_num_', '_abbrev_']"
3732,1.0,"Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286).","['besides', 'the', 'overall', 'survival', 'had', 'a', 'tendency', 'to', 'become', 'more', 'prolonged', 'median', '_num_', 'months', 'vs', '_num_', 'months', '_p_val_']"
3733,1.0,"293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation.","['_num_', 'cases', 'of', 'clinically', 'localized', 'prostate', 'cancer', 'were', 'analyzed', 'on', 'needle', 'biopsy', '_disease_', 'tissue', 'microarray', 'using', 'the', '_gene_', 'antibody', 'against', 'the', '_gene_', 'marker', 'of', 'proliferation']"
3734,1.0,"In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations.","['in', 'patients', 'with', 'lung', 'adenocarcinoma', 'those', 'with', '_disease_', 'mutations', 'in', '_gene_', 'had', 'worse', 'overall', 'survival', 'than', 'those', 'with', 'only', 'missense', 'or', 'no', 'mutations']"
3735,1.0,4 patients with KRAS +/- PIK3CA mutant colorectal cancer.,"['_num_', 'patients', 'with', '_gene_', '_gene_', 'mutant', 'colorectal', 'cancer']"
3736,1.0,"Four of 5 individuals were identified with angiomas, 2 with cerebellar hemangioblastomas, and one with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
3737,1.0,This case also harbored a second somatic variant in VHL: 209-210delAG (Stop130).,"['this', 'case', 'also', 'harbored', 'a', '_num_', 'somatic', 'variant', 'in', '_gene_', '_num_', '210delag', '_abbrev_']"
3738,1.0,No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53.,"['no', 'sustained', 'clinical', 'improvement', 'or', 'induction', 'of', '_gene_', 'target', 'genes', 'was', 'observed', 'in', 'patients', 'with', 'mutant', '_gene_']"
3739,1.0,"High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15 months, p=0.0005).","['high', '_gene_', 'mrna', 'expression', 'in', '_gene_', 'wild', 'type', 'tumours', 'was', 'a', 'favorable', 'predictor', 'in', 'a', 'multivariate', 'analysis', 'median', 'survival', '_num_', 'vs', '_num_', 'months', '_p_val_']"
3740,1.0,"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation.","['in', '_disease_', 'patients', 'with', '_gene_', 'mutations', 'concurrent', '_gene_', 'mutations', 'including', '_abbrev_', 'were', 'associated', 'with', 'worse', 'overall', 'survival', 'compared', 'to', 'those', 'without', '_gene_', 'mutation']"
3741,1.0,2/3 patients with a mutation determined to be sensitive in vitro (del I843 included) achieved partial response on imatinib treatment.,"['_ratio_', 'patients', 'with', 'a', 'mutation', 'determined', 'to', 'be', 'sensitive', 'in', 'vitro', 'del', '_abbrev_', 'included', 'achieved', 'partial', 'response', 'on', '_chemical_', 'treatment']"
3742,1.0,A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment.,"['a', 'patient', 'with', 'metastatic', 'lung', 'adenocarcinoma', 'was', 'found', 'to', 'harbor', '_gene_', '_mutation_', 'and', '_mutation_', 'mutations', 'when', 'acquired', 'resistance', 'developed', 'after', '_num_', 'years', 'of', '_chemical_', 'treatment']"
3743,1.0,"A phase 2 study of 120 stage IIIB-IV lung adenocarcinoma patients reported improved progression free survival in patients with EGFR mutation (defined as exon 19 deletion or exon 21 mutation) when treated (n=13) with gefitinib and pemetrexed/platinum combination therapy (HR: 0.20, 95% CI: 0.05-0.75, P=0.017) as compared to treatment (n=18) with pemtrexed/platinum alone.","['a', 'phase', '_num_', 'study', 'of', '_num_', 'stage', 'iiib', 'iv', 'lung', 'adenocarcinoma', 'patients', 'reported', 'improved', 'progression', 'free', 'survival', 'in', 'patients', 'with', '_gene_', 'mutation', 'defined', 'as', 'exon', '_num_', 'deletion', 'or', 'exon', '_num_', 'mutation', 'when', 'treated', '_ineq_', 'with', '_chemical_', 'and', '_chemical_', 'platinum', 'combination', 'therapy', 'hr', '_num_', '_num_', 'ci', '_range_', '_p_val_', 'as', 'compared', 'to', 'treatment', '_ineq_', 'with', 'pemtrexed', 'platinum', 'alone']"
3744,1.0,"In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'ovarian', 'carcinomas', '_num_', 'had', 'amplification', 'of', '_gene_']"
3745,1.0,"Overexpression of HIF1A was associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007, adjusted for clinical and tumoral features: microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation).","['overexpression', 'of', '_gene_', 'was', 'associated', 'with', 'higher', 'colorectal', '_disease_', 'mortality', 'in', '_disease_', 'analysis', 'log', 'rank', 'test', 'p', '_num_', 'univariate', 'cox', 'regression', 'hazard', 'ratio', '_num_', '_num_', 'confidence', 'interval', '_num_', 'to', '_num_', 'p', '_num_', 'and', 'multivariate', 'analysis', 'adjusted', 'hazard', 'ratio', '_num_', '_num_', 'confidence', 'interval', '_num_', 'to', '_num_', 'p', '_num_', 'adjusted', 'for', 'clinical', 'and', '_disease_', 'features', '_disease_', 'instability', '_gene_', '_gene_', '_gene_', '_abbrev_', '_chemical_', 'island', 'methylator', 'phenotype', 'and', '_gene_', '_gene_', '_gene_', 'and', '_abbrev_', 'methylation']"
3746,1.0,"In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters.","['in', 'patients', 'with', 'glioblastoma', 'those', 'with', 'methylated', '_gene_', 'promoters', 'have', 'better', 'overall', 'survival', 'than', 'those', 'with', 'unmethylated', 'promoters']"
3747,1.0,Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome.,"['case', 'report', 'of', 'a', '_age_', 'white', 'female', 'patient', '_num_', 'pack', 'years', 'with', 'a', '_disease_']"
3748,1.0,Mutation was detected in three unaffected members of Polish VHL families.,"['mutation', 'was', 'detected', 'in', '_num_', 'unaffected', 'members', 'of', 'polish', '_gene_', 'families']"
3749,1.0,"Imatinib, BMS-354825, PD-180970, MLN-518, and SU-11248 bind variant V559D with high affinity (Kd =< 20 nM), and inhibit KIT autophosphorylation.","['_chemical_', '_chemical_', '_chemical_', '_chemical_', 'and', '_chemical_', 'bind', 'variant', '_mutation_', 'with', 'high', 'affinity', '_disease_', '_num_', '_unit_', 'and', 'inhibit', 'kit', 'autophosphorylation']"
3750,1.0,4 ovarian lines with KRAS mutation were among the most sensitive to decitabine.,"['_num_', 'ovarian', 'lines', 'with', '_gene_', 'mutation', 'were', 'among', 'the', 'most', 'sensitive', 'to', '_chemical_']"
3751,1.0,"Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reported for alectinib on Ba/F3 with EML4-ALK wild type.","['ba', '_abbrev_', 'cell', 'line', 'expressing', '_chemical_', 'variant', '_num_', 'with', '_mutation_', '_gene_', 'mutation', 'was', 'assessed', 'for', '_chemical_', 'sensitivity', 'and', '_abbrev_', 'for', 'survival', 'of', '_num_', '_unit_', 'was', 'reported', 'which', 'was', '_num_', '4x', 'higher', 'than', 'the', '_abbrev_', 'reported', 'for', '_chemical_', 'on', 'ba', '_abbrev_', 'with', '_chemical_', 'wild', 'type']"
3752,1.0,The patient progressed following salvage chemotherapy and autologous stem cell transplant.,"['the', 'patient', 'progressed', 'following', 'salvage', 'chemotherapy', 'and', 'autologous', 'stem', 'cell', 'transplant']"
3753,1.0,"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.","['in', 'breast', 'cancer', 'patients', 'harboring', '_gene_', 'mutation', 'mutations', 'in', 'dna', 'contact', 'regions', 'such', 'as', '_abbrev_', 'are', 'prognostic', 'for', 'a', 'worse', 'relapse', 'free', 'survival', 'compared', 'to', 'other', 'non', 'silent', 'mutations', 'in', '_gene_']"
3754,1.0,"Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed).","['patients', 'were', 'randomized', 'in', 'a', '_ratio_', 'ratio', 'to', 'oral', 'osimertinib', 'or', 'chemotherapy', '_chemical_', 'plus', 'either', '_chemical_', 'or', '_disease_', 'every', '_num_', 'weeks', 'for', 'up', 'to', '_num_', 'cycles', 'maintenance', '_chemical_', 'was', 'allowed']"
3755,1.0,This mutation also attenuated pERK inhibition by selumetinib in these cells.,"['this', 'mutation', 'also', 'attenuated', 'perk', 'inhibition', 'by', '_chemical_', 'in', 'these', 'cells']"
3756,1.0,Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin.,"['both', '_chemical_', 'and', '_chemical_', 'cohorts', 'were', 'significantly', 'more', 'effective', 'than', 'control', 'and', 'doxorubicin']"
3757,1.0,"Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells.","['genomic', '_disease_', 'resolved', 'a', 'single', 'breakpoint', 'but', '_num_', 'variants', 'of', 'the', 'fusion', 'were', 'observed', 'in', 'cells']"
3758,1.0,"In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34).","['in', 'contrast', 'among', '_num_', 'patients', 'without', '_gene_', '_mutation_', 'the', 'response', 'rate', 'was', '_num_', '_num_', 'ci', '_num_', 'to', '_num_']"
3759,1.0,"Two out of 11 patients with an acquired crizotinib resistance showed new ALK copy-number gain (defined as more than 2-fold increase in the mean of the rearranged gene per cell in the posttreatment specimen compared with the pretreatment specimen), both with >4 fold increase.","['_num_', 'out', 'of', '_num_', 'patients', 'with', 'an', 'acquired', '_chemical_', 'resistance', 'showed', 'new', '_gene_', 'copy', 'number', 'gain', 'defined', 'as', 'more', 'than', '_n_fold_', 'increase', 'in', 'the', 'mean', 'of', 'the', 'rearranged', 'gene', 'per', 'cell', 'in', 'the', 'posttreatment', 'specimen', 'compared', 'with', 'the', 'pretreatment', 'specimen', 'both', 'with', '_num_', 'fold', 'increase']"
3760,1.0,we conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL.,"['we', 'conclude', 'these', '_num_', 'cases', 'indicate', 'sensitivity', 'to', '_chemical_', 'of', 'relapsed', '_gene_', 'rearranged', '_disease_']"
3761,1.0,Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients.,"['urinary', '_gene_', '_mutation_', 'tumor', 'dna', 'correlated', 'with', 'disease', 'response', 'in', '_num_', 'of', 'the', 'patients']"
3762,1.0,"The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06/16) without significant toxicity.","['the', 'patient', 'was', 'started', 'on', 'combined', '_chemical_', 'and', '_chemical_', 'in', 'january', '_year_', 'and', 'had', 'a', 'metabolic', 'clinical', 'and', 'tumor', 'marker', 'response', 'that', 'was', 'ongoing', 'at', 'the', 'time', 'of', 'publication', '_ratio_', 'without', 'significant', 'toxicity']"
3763,1.0,An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines.,"['an', 'shdna', 'screen', 'identified', 'synergy', 'betwenn', '_gene_', 'inhibition', 'and', 'mek', 'inhibition', 'in', '_gene_', 'mutated', 'cell', 'lines']"
3764,1.0,Mutation detected in one case.,"['mutation', 'detected', 'in', '_num_', 'case']"
3765,1.0,"In a preclinical model, FGFR1 amplification in breast cancer cell lines was less pronounced than FGFR2-amplifications in gastroesophageal cancers, which also had a higher response rate in the trial, indicating that high level amplification is associated with response and less common in FGFR1-amplified breast cancer.","['in', 'a', 'preclinical', 'model', '_gene_', 'amplification', 'in', 'breast', 'cancer', 'cell', 'lines', 'was', 'less', 'pronounced', 'than', '_abbrev_', 'in', 'gastroesophageal', 'cancers', 'which', 'also', 'had', 'a', 'higher', 'response', 'rate', 'in', 'the', 'trial', 'indicating', 'that', 'high', 'level', 'amplification', 'is', 'associated', 'with', 'response', 'and', 'less', 'common', 'in', '_abbrev_', 'breast', 'cancer']"
3766,1.0,MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.,"['_abbrev_', 'cells', 'transduced', 'with', '_gene_', 'harboring', 'an', '_mutation_', 'mutation', 'were', 'sensitive', 'to', '_chemical_', 'and', 'the', 'irreversible', 'kinase', 'inhibitor', '_chemical_', 'in', 'an', 'matrigel', 'colony', 'forming', 'assay']"
3767,1.0,Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab.,"['case', 'report', 'of', 'a', '_age_', 'woman', 'with', 'stage', 'ivb', '_gene_', 'after', 'progression', 'under', '_disease_', 'and', '_chemical_']"
3768,1.0,The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment.,"['the', 'patient', 'was', 'resistant', 'to', 'classical', 'chemotherapeutic', 'agents', 'and', '_disease_', 'treatment']"
3769,1.0,Multigene panel testing with an 18-gene panel revealed a germline truncating pathogenic mutation in RAD51D (p.R186X; c. 556C>T).,"['multigene', 'panel', 'testing', 'with', 'an', '_num_', 'gene', 'panel', 'revealed', 'a', 'germline', 'truncating', 'pathogenic', 'mutation', 'in', '_gene_', '_mutation_', 'c', '556c', 't']"
3770,1.0,Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations.,"['phase', '_num_', 'study', 'of', 'fgfr', 'inhibitor', '_chemical_', 'in', 'advanced', 'cancer', 'with', 'fgfr', 'aberrations']"
3771,1.0,"Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients.","['objective', 'response', 'was', 'seen', 'in', '_num_', '_chemical_', '', '_num_', '_chemical_', '', 'and', '_num_', '_chemical_', 'treated', 'patients']"
3772,1.0,49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression.,"['_num_', 'patients', 'gastric', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'chemotherapy', 'were', 'immunohistochemically', 'assessed', 'for', 'nuclear', '_gene_', '_gene_', 'expression']"
3773,1.0,In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs we also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.,"['in', 'order', 'to', 'directly', 'compare', 'the', 'sensitivity', 'of', 'multiple', '_gene_', 'mutations', 'to', '_gene_', 'we', 'also', 'generated', 'multiple', '_gene_', 'transduced', 'ba', '_abbrev_', 'stable', 'cell', 'lines', 'and', 'evaluated', 'sensitivity', 'to', '_gene_', 'by', 'mts', 'assay']"
3774,1.0,"Of these tumors, 67% had moderate or strong COX2 expression and 33% had weak or absent COX-2 expression.","['of', 'these', 'tumors', '_num_', 'had', 'moderate', 'or', 'strong', '_gene_', 'expression', 'and', '_num_', 'had', 'weak', 'or', 'absent', '_abbrev_', 'expression']"
3775,1.0,"IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation.","['_gene_', '_abbrev_', 'mutation', 'is', 'associated', 'with', 'patients', 'of', 'older', 'age', 'high', 'platelet', 'count', 'during', 'diagnosis', 'cytogenic', 'normalcy', 'and', '_gene_', 'mutation']"
3776,1.0,"After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission.","['after', 'further', 'surgery', '_chemical_', 'was', 'restarted', 'at', '_unit_', 'twice', 'daily', 'and', 'almost', '_num_', 'years', 'later', 'the', 'patient', 'was', 'in', 'complete', 'radiographic', 'remission']"
3777,1.0,"Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were analyzed.","['whole', 'exome', 'sequencing', 'transcriptome', 'and', 'methylome', 'alterations', 'in', '_num_', 'melanoma', 'samples', 'with', 'acquired', 'resistance', 'to', 'brafi', '_disease_', 'therapy', 'compared', 'to', 'patient', 'matched', 'baseline', 'melanoma', 'tissues', 'were', 'analyzed']"
3778,1.0,"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', 'iv', 'lung', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_mutation_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
3779,1.0,An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement.,"['an', 'expansion', 'cohort', 'of', 'a', '_abbrev_', '_chemical_', 'study', 'found', 'a', '_num_', 'objective', 'response', 'rate', 'among', '_num_', 'patients', 'with', '_gene_', 'rearrangement']"
3780,1.0,"A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with retinal angiomas and cerebellar hemangioblastomas.","['a', 'missense', 'mutation', 'affecting', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', 'a', '_gene_', 'patient', 'with', 'retinal', 'angiomas', 'and', 'cerebellar', '_disease_']"
3781,1.0,Overall survival rate of MLH1 negative cases were significantly better than MLH1 positive cases (p=0.020).,"['overall', 'survival', 'rate', 'of', '_gene_', 'negative', 'cases', 'were', 'significantly', 'better', 'than', '_gene_', 'positive', 'cases', '_p_val_']"
3782,0.0,This may be linked to the mutation abrogating a ubiquitination site.,"['this', 'may', 'be', 'linked', 'to', 'the', 'mutation', 'abrogating', 'a', '_disease_', 'site']"
3783,1.0,"Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.","['patients', 'were', 'given', 'a', 'chemotherapy', 'regime', 'containing', '_chemical_', 'flourouracil', 'and', '_disease_', 'with', '_ineq_', 'or', 'without', '_ineq_', '_chemical_', 'and', 'had', 'not', 'been', 'previously', 'treated', 'for', 'metastatic', 'cancer']"
3784,1.0,Patients without the V600E mutation had evidence of tumor regression.,"['patients', 'without', 'the', '_mutation_', 'mutation', 'had', 'evidence', 'of', 'tumor', 'regression']"
3785,1.0,Upregulation of proteasome subunit beta type 8 (PSMB8) and PDZ binding kinase (PBK) was confirmed by real-time reverse transcription-PCR Analysis.,"['upregulation', 'of', 'proteasome', 'subunit', 'beta', 'type', '_num_', '_gene_', 'and', '_gene_', 'binding', 'kinase', '_gene_', 'was', 'confirmed', 'by', 'real', 'time', 'reverse', 'transcription', 'pcr', 'analysis']"
3786,1.0,Two ATM deficient mantle cell lymphoma (MCL) cell lines were more sensitive to PARP-1 inhibition with olaparib or PJ-34 than 4 other MCL cell lines.,"['_num_', 'atm', 'deficient', 'mantle', 'cell', 'lymphoma', '_gene_', 'cell', 'lines', 'were', 'more', 'sensitive', 'to', '_gene_', 'inhibition', 'with', '_chemical_', 'or', '_chemical_', 'than', '_num_', 'other', '_gene_', 'cell', 'lines']"
3787,1.0,"In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression.","['in', 'biopsies', 'taken', 'from', 'a', 'group', 'of', '_num_', 'responders', 'who', 'progressed', '_gene_', 'levels', 'were', 'increased', 'after', 'progression']"
3788,1.0,"These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin.","['these', 'tumors', 'were', 'studied', 'for', 'a', 'relationship', 'between', '_gene_', 'expression', 'and', 'chemotherapy', 'regimens', '_chemical_', '_chemical_', 'and', '_chemical_', 'and', '_chemical_', 'and', '_chemical_']"
3789,1.0,"Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years.","['patients', 'with', 'acute', 'myeloid', 'leukemia', 'showed', 'an', 'synergistic', 'mortality', 'rate', 'with', '_gene_', 'and', '_gene_', 'co', 'mutations', 'such', 'that', 'individual', 'mutations', 'of', 'either', '_gene_', 'or', '_gene_', 'resulted', 'in', '_num_', 'probability', 'of', 'survival', 'after', '_num_', 'years', 'whereas', 'co', 'mutations', 'resulted', 'in', 'a', '_num_', 'mortality', 'rate', 'after', '_num_', 'years']"
3790,1.0,This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 99).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
3791,1.0,BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.,"['_gene_', 'mutation', 'correlated', 'with', 'poor', 'prognosis', 'in', 'papillary', 'thyroid', 'cancer', 'in', 'both', 'older', '_num_', '_age_', 'and', 'younger', '_num_', '_age_', 'cohorts']"
3792,1.0,Methylome analysis revealed three CpG clusters (C1–3) with differential methylation to be negatively correlated with differential c-MET mRNA expression.,"['methylome', 'analysis', 'revealed', '_num_', '_chemical_', 'clusters', '_abbrev_', 'with', 'differential', 'methylation', 'to', 'be', 'negatively', 'correlated', 'with', 'differential', '_gene_', 'mrna', 'expression']"
3793,1.0,"Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively.","['median', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'for', 'patients', 'receiving', 'combination', 'therapy', 'were', '_num_', 'months', '_num_', 'ci', '_num_', 'to', '_num_', 'and', '_num_', 'months', '_num_', 'ci', '_num_', 'to', 'not', 'reached', 'respectively']"
3794,0.0,The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer.,"['the', 'results', 'indicated', 'that', '_chemical_', 'may', 'be', 'useful', 'in', 'addressing', 'the', 'problem', 'of', '_chemical_', 'progression', 'in', '_gene_', 'breast', 'cancer']"
3795,1.0,"we showed that rs3910384 is closely linked with the putative functional WEE1 promoter at SNPs rs6486433, rs3763869 and rs3763868.","['we', 'showed', 'that', '_mutation_', 'is', 'closely', 'linked', 'with', 'the', 'putative', 'functional', '_gene_', 'promoter', 'at', 'snps', '_mutation_', '_mutation_', 'and', '_mutation_']"
3796,1.0,The prevalence of various mutations post-treatment was analyzed.,"['the', 'prevalence', 'of', 'various', 'mutations', 'post', 'treatment', 'was', 'analyzed']"
3797,1.0,"we state that in the case of afatinib vs. trastuzumab, intracellular HER2 signaling may be blocked by afatanib but remain unaltered by trastuzumab.","['we', 'state', 'that', 'in', 'the', 'case', 'of', '_chemical_', 'vs', '_chemical_', 'intracellular', '_gene_', 'signaling', 'may', 'be', 'blocked', 'by', 'afatanib', 'but', 'remain', 'unaltered', 'by', '_chemical_']"
3798,1.0,"Biomarkers for Response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2).","['_chemical_', 'for', 'response', 'to', 'antiangiogenic', 'treatment', 'were', 'screened', 'for', 'in', '_disease_', 'cancer', 'n', '_num_', 'renal', 'cell', 'cancer', 'n', '_num_', 'and', 'non', 'small', 'cell', 'lung', 'cancer', 'n', '_num_']"
3799,0.0,Clinical trials are ongoing.,"['clinical', 'trials', 'are', 'ongoing']"
3800,1.0,In contrast pALK signal was ablated at and above 100 nM in NPM-ALK wild type.,"['in', 'contrast', 'palk', 'signal', 'was', 'ablated', 'at', 'and', 'above', '_num_', '_unit_', 'in', '_chemical_', 'wild', 'type']"
3801,1.0,Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018).,"['patients', 'with', '_gene_', 'positive', 'tumor', 'cells', 'had', 'a', 'significant', 'better', 'overall', '_p_val_', 'and', 'tumor', 'specific', 'survival', '_p_val_']"
3802,1.0,"In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA.","['in', 'a', 'set', 'of', '_num_', 'pediatric', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '_num_', 'had', 'mutations', 'in', '_gene_']"
3803,1.0,"88 patients were treated with EGFR inhibitor gefitinib, while 89 were treated with cisplatin/docetaxel.","['_num_', 'patients', 'were', 'treated', 'with', '_gene_', 'inhibitor', '_chemical_', 'while', '_num_', 'were', 'treated', 'with', '_disease_', '_chemical_']"
3804,1.0,Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib.,"['cells', 'with', 'an', '_gene_', '_abbrev_', 'mutation', 'demonstrated', 'an', 'improved', 'response', 'to', '_chemical_', '_abbrev_', '_unit_', 'vs', '_unit_', 'compared', 'to', 'the', 'same', 'cells', 'treated', 'with', '_chemical_']"
3805,1.0,"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.","['_gene_', 'loss', 'is', 'associated', 'with', 'loss', 'of', 'sensitivity', 'to', 'the', '_abbrev_', '_chemical_', 'in', 'breast', 'cancer', 'in', 'smaller', 'trials', 'a', 'phase', 'iii', 'trial', 'ncctg', '_abbrev_', 'did', 'not', 'show', 'an', 'effect', 'of', '_gene_', 'on', '_disease_', 'survival']"
3806,1.0,"Western blot analyses were performed for HR23b (RAD23B) expression sarcoma cell lines after treatment with vorinostat, belinostat, mocetinostat and entinostat.","['western', 'blot', 'analyses', 'were', 'performed', 'for', '_gene_', '_gene_', 'expression', 'sarcoma', 'cell', 'lines', 'after', 'treatment', 'with', '_chemical_', '_chemical_', '_chemical_', 'and', '_chemical_']"
3807,1.0,EIF1AX was identified as a uveal melanoma (UM) driver gene by whole-exome sequencing.,"['_gene_', 'was', 'identified', 'as', 'a', 'uveal', 'melanoma', '_disease_', 'driver', 'gene', 'by', 'whole', 'exome', 'sequencing']"
3808,1.0,This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 1255).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
3809,1.0,"A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with cerebellar hemangioblastomas.","['a', 'missense', 'mutation', 'affecting', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', 'a', '_gene_', 'patient', 'with', 'cerebellar', '_disease_']"
3810,1.0,This study contains very strong evidence of pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'nonsense', 'mutation', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
3811,1.0,"Radiographic studies performed 3 months after initiation of therapy revealed marked improvement of her cervical, mediastinal, and retroperitoneal lymphadenopathy, and marked regression of splenomegaly to normal size.","['radiographic', 'studies', 'performed', '_num_', 'months', 'after', 'initiation', 'of', 'therapy', 'revealed', 'marked', 'improvement', 'of', 'her', 'cervical', '_disease_', 'and', '_disease_', 'lymphadenopathy', 'and', 'marked', 'regression', 'of', 'splenomegaly', 'to', 'normal', 'size']"
3812,1.0,"A total of 9,643 patients with metastatic CRC underwent NGS testing.","['a', 'total', 'of', '_num_', 'patients', 'with', 'metastatic', '_gene_', 'underwent', 'ngs', 'testing']"
3813,1.0,Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab.,"['overexpression', 'of', 'met', 'in', 'a', '_gene_', 'mutant', '_gene_', 'cell', 'line', 'widr', 'confered', 'resistance', 'to', 'combined', '_chemical_', 'and', 'panitumumab']"
3814,1.0,The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification.,"['the', 'nci', 'match', 'trial', 'with', 'further', 'study', '_disease_', 'in', 'the', 'context', 'of', '_gene_', 'amplification']"
3815,1.0,The patient achieved a partial response but progressed after 5 months of treatment.,"['the', 'patient', 'achieved', 'a', 'partial', 'response', 'but', 'progressed', 'after', '_num_', 'months', 'of', 'treatment']"
3816,1.0,"In this meta-analysis of 16 Trials, TERT mutations were more common in glioblastomas (69%), oligodendrogliomas (72%) in comparison to astrocytomas (24%) and oligoastrocytomas (38%).","['in', 'this', '_disease_', 'analysis', 'of', '_num_', 'trials', '_gene_', 'mutations', 'were', 'more', 'common', 'in', 'glioblastomas', '_num_', '_disease_', '_num_', 'in', 'comparison', 'to', '_disease_', '_num_', 'and', '_disease_', '_num_']"
3817,1.0,The most common mutation was C228T (73% of mutants) followed by C250T (27% of mutants).,"['the', 'most', 'common', 'mutation', 'was', '_mutation_', '_num_', 'of', 'mutants', 'followed', 'by', '_mutation_', '_num_', 'of', 'mutants']"
3818,1.0,Ectopic expression of EML4-ALK I1171T in Ba/F3 cells made these cells moderately resistant to crizotinib and resistant to alectinib.,"['ectopic', 'expression', 'of', '_chemical_', '_mutation_', 'in', 'ba', '_abbrev_', 'cells', 'made', 'these', 'cells', 'moderately', 'resistant', 'to', '_chemical_', 'and', 'resistant', 'to', '_chemical_']"
3819,1.0,The ratio of SYT-SSX1 to SYT-SSX2 cases is close to 2:1.,"['the', 'ratio', 'of', '_abbrev_', 'to', '_abbrev_', 'cases', 'is', 'close', 'to', '_ratio_']"
3820,1.0,"In contrast, PF-06463922 was effectively inhibited the fusion harboring this mutation in these assays.","['in', 'contrast', '_chemical_', 'was', 'effectively', 'inhibited', 'the', 'fusion', 'harboring', 'this', 'mutation', 'in', 'these', 'assays']"
3821,1.0,This conclusion held in the first line treatment as well as general treatment setting.,"['this', 'conclusion', 'held', 'in', 'the', '_num_', 'line', 'treatment', 'as', 'well', 'as', 'general', 'treatment', 'setting']"
3822,1.0,"The metastases were analyzed using a commercial molecular analysis and overexpression of HER2 was identified (IHC, 95% of cells, with high intensity 3+ staining) which was confirmed on RNA-level.","['the', 'metastases', 'were', 'analyzed', 'using', 'a', 'commercial', 'molecular', 'analysis', 'and', 'overexpression', 'of', '_gene_', 'was', 'identified', '_gene_', '_num_', 'of', 'cells', 'with', 'high', 'intensity', '3+', 'staining', 'which', 'was', 'confirmed', 'on', 'rna', 'level']"
3823,1.0,"In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'colorectal', 'cancer', '_num_', 'patients', 'had', '_gene_', '_mutation_', 'mutations', 'and', '_num_', 'patients', 'were', '_gene_', 'wild', 'type']"
3824,1.0,"This mutation was found in a 42-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no 12).","['this', 'mutation', 'was', 'found', 'in', 'a', '_age_', '_gene_', 'patient', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'proband', 'no', '_num_']"
3825,1.0,One patient with unknown FLT3 status also had no response.,"['_num_', 'patient', 'with', 'unknown', '_gene_', 'status', 'also', 'had', 'no', 'response']"
3826,1.0,ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition).,"['_gene_', '_mutation_', 'variants', 'were', 'observed', 'after', 'extensive', 'treatment', 'with', 'hormonal', 'therapy', '_gene_', 'inhibition']"
3827,1.0,"All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure.","['all', 'patients', 'received', '_chemical_', 'after', '_chemical_', '_chemical_', 'and', 'fluoropyrimidine', 'failure']"
3828,1.0,IC50 for the pan-Akt inhibitor ipatasertib (GDC-0068) was determined over a panel of 100 cancer cell lines.,"['_abbrev_', 'for', 'the', 'pan', '_gene_', 'inhibitor', 'ipatasertib', '_chemical_', 'was', 'determined', 'over', 'a', 'panel', 'of', '_num_', 'cancer', 'cell', 'lines']"
3829,1.0,Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01).,"['patients', 'with', 'methylated', 'tumors', 'with', 'high', '_gene_', 'mrna', 'expression', 'n', '_num_', 'did', 'significantly', 'worse', 'than', 'those', 'with', 'low', 'transcriptional', 'activity', 'p', '_num_']"
3830,1.0,The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4).,"['the', 'prevalence', 'of', 'the', 'variant', 'in', 'affected', 'individuals', 'is', 'significantly', 'increased', 'compared', 'with', 'the', 'prevalence', 'in', 'controls', '_gene_']"
3831,1.0,This missense mutation was found in 3 VHL type 2B family members (patient no V11).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_gene_', 'family', 'members', 'patient', 'no', '_abbrev_']"
3832,1.0,"IDH2(R172) mutations rarely showed co-mutation with NPM1 (odds ratio= 0.06; P=4x10-5), whereas IDH2(R140) mutations showed strong co-mutation with NPM1 (odds ratio= 3.6; P=5x10-10).","['_gene_', '_abbrev_', 'mutations', 'rarely', 'showed', 'co', 'mutation', 'with', '_gene_', 'odds', 'ratio=', '_num_', '_p_val_', 'whereas', '_gene_', '_chemical_', 'mutations', 'showed', 'strong', 'co', 'mutation', 'with', '_gene_', 'odds', 'ratio=', '_num_', '_p_val_']"
3833,1.0,"A somatic mutation detected in one case, a 79ya patient with renal cell carcinoma (case '1VT').","['a', 'somatic', 'mutation', 'detected', 'in', '_num_', 'case', 'a', '79ya', 'patient', 'with', 'renal', 'cell', 'carcinoma', 'case', ""'1vt""]"
3834,1.0,"Two cases show CNS hemangioblastoma, pancreatic/hepatic/renal cysts, and renal cell carcinoma.","['_num_', 'cases', 'show', 'cns', '_disease_', 'pancreatic', 'hepatic', 'renal', 'cysts', 'and', 'renal', 'cell', 'carcinoma']"
3835,1.0,One patient with NRAS mutation had 70% tumor shrinkage after three cycles of selumetinib (AZD6244) but developed symptomatic brain metastases before confirmatory scans could be performed.,"['_num_', 'patient', 'with', 'nras', 'mutation', 'had', '_num_', 'tumor', 'shrinkage', 'after', '_num_', 'cycles', 'of', '_chemical_', '_chemical_', 'but', 'developed', 'symptomatic', 'brain', 'metastases', 'before', 'confirmatory', 'scans', 'could', 'be', 'performed']"
3836,1.0,"In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01).","['in', 'the', 'patients', 'receiving', '_chemical_', 'treatment', 'the', 'progression', 'free', 'survival', 'of', '_abbrev_', 'patients', 'was', 'significantly', 'higher', 'than', 'that', 'of', '_abbrev_', 'patients', '_num_', 'months', 'vs', '_num_', 'months', 'p', '_num_']"
3837,1.0,21 exhibited primary resistance to BRAF inhibition using PLX4720.,"['_num_', 'exhibited', 'primary', 'resistance', 'to', '_gene_', 'inhibition', 'using', '_chemical_']"
3838,1.0,"These fusions were mutually exclusive with other oncogenic drivers and showed in-vitro sensitivity to TrkA Inhibitor ARRY470 (one cell line with fusion (KM12), one control cell line).","['these', 'fusions', 'were', 'mutually', 'exclusive', 'with', 'other', '_disease_', 'drivers', 'and', 'showed', 'in', 'vitro', 'sensitivity', 'to', '_gene_', 'inhibitor', '_abbrev_', '_num_', 'cell', 'line', 'with', 'fusion', '_abbrev_', '_num_', 'control', 'cell', 'line']"
3839,1.0,"In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab.","['in', 'this', '_abbrev_', 'study', '_num_', 'patients', 'were', 'randomized', 'to', 'either', '_chemical_', 'and', 'placebo', 'or', '_chemical_', 'and', '_gene_', 'monoclonal', 'antibody', 'patritumab']"
3840,1.0,In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.,"['in', '3t3', 'fibroblasts', 'expressing', 'the', '_mutation_', 'mutation', 'have', 'to', 'be', 'sensitive', 'to', 'the', 'tyrosine', 'kinase', 'inhibitor', '_chemical_']"
3841,1.0,Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.,"['_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'shorter', 'overall', 'survival', 'and', 'increased', 'metastasis', 'in', 'mantle', 'cell', 'lymphoma']"
3842,1.0,One of them also harbored a resistance mutation (G1269A).,"['_num_', 'of', 'them', 'also', 'harbored', 'a', 'resistance', 'mutation', '_mutation_']"
3843,1.0,ARS-853 targets the inactive state and inhibited proliferation in a subset  (3/11) of KRAS G12C mutant cell lines in 2-D growth assays and 11/11 cell lines in soft-agar colony formation and 3-D assays.,"['_abbrev_', 'targets', 'the', 'inactive', 'state', 'and', 'inhibited', 'proliferation', 'in', 'a', 'subset', '_ratio_', 'of', '_gene_', '_mutation_', 'mutant', 'cell', 'lines', 'in', '_chemical_', 'growth', 'assays', 'and', '_ratio_', 'cell', 'lines', 'in', 'soft', 'agar', 'colony', 'formation', 'and', '_num_', 'd', 'assays']"
3844,1.0,3 tongue cancer cell lines were used for this study.,"['_num_', 'tongue', 'cancer', 'cell', 'lines', 'were', 'used', 'for', 'this', 'study']"
3845,1.0,"In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants.","['in', 'vitro', 'analysis', 'in', 'colorectal', 'cancer', 'cell', 'line', '_chemical_', 'with', '_gene_', 'mutations', '_mutation_', '_mutation_', '_mutation_', 'and', '_mutation_', 'showed', 'that', 'antibody', 'mixture', '_abbrev_', 'effectively', 'bound', 'to', 'all', 'mutants', 'whereas', '_chemical_', 'and', 'panitumumab', 'did', 'not', 'effectively', 'bind', 'to', 'all', 'mutants']"
3846,1.0,"In HCT116 xenograft tumors, tumor growth IR with FRB was 25 % in mock cells, 24 % in clones with reference alleles (G alleles) of PPP1R15A rs557806, and 17 % in clones with substitution alleles (C alleles) of PPP1R15A rs557806 (P = 0.004, day 13).","['in', '_abbrev_', 'xenograft', 'tumors', 'tumor', 'growth', 'ir', 'with', '_gene_', 'was', '_num_', 'in', 'mock', 'cells', '_num_', 'in', 'clones', 'with', 'reference', 'alleles', '_unit_', 'alleles', 'of', '_gene_', '_mutation_', 'and', '_num_', 'in', 'clones', 'with', 'substitution', 'alleles', 'c', 'alleles', 'of', '_gene_', '_mutation_', 'p', '_num_', 'day', '_num_']"
3847,1.0,"EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory concentration of 9 nM was seen, which was 1.5 times the IC50 of EML4-ALK wild type to brigatinib.","['_chemical_', 'with', '_gene_', '_mutation_', 'has', 'been', 'seen', 'in', '_chemical_', 'resistant', '_disease_', 'and', 'this', 'mutation', 'was', 'tested', 'for', 'brigatinib', 'sensitivity', 'via', 'ectopic', 'expression', 'in', 'ba', '_abbrev_', 'cells', 'where', 'half', 'maximal', 'inhibitory', 'concentration', 'of', '_num_', '_unit_', 'was', 'seen', 'which', 'was', '_num_', 'times', 'the', '_abbrev_', 'of', '_chemical_', 'wild', 'type', 'to', 'brigatinib']"
3848,1.0,A response to crizotinib was observed in both cases suggesting that MET amplification may predict response to this drug even in the absence of MET exon 14 mutations.,"['a', 'response', 'to', '_chemical_', 'was', 'observed', 'in', 'both', 'cases', 'suggesting', 'that', 'met', 'amplification', 'may', 'predict', 'response', 'to', 'this', 'drug', 'even', 'in', 'the', 'absence', 'of', 'met', 'exon', '_num_', 'mutations']"
3849,1.0,"Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed.","['prior', 'to', 'study', 'entry', 'all', 'patients', 'with', 'ret', '_mutation_', 'mutations', 'had', 'progressive', 'disease', 'or', 'were', 'newly', 'diagnosed']"
3850,1.0,"EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21).","['_gene_', 'was', 'also', 'shorter', 'for', 'the', 'cytogenetically', 'normal', '_gene_', 'subgroup', 'with', '_gene_', 'mutations', '_ineq_', '_num_', 'vs', '_num_', 'p', '_num_', 'compared', 'to', 'wild', 'type', '_ineq_', 'but', 'only', 'trending', 'for', 'relapse', 'free', 'survival', '_num_', 'vs', '_num_', '_p_val_']"
3851,1.0,Next-generation sequencing discovered an ALK I1171N mutation.,"['next', 'generation', 'sequencing', 'discovered', 'an', '_gene_', '_mutation_', 'mutation']"
3852,0.0,we indicate that the mutation may not be pathogenic.,"['we', 'indicate', 'that', 'the', 'mutation', 'may', 'not', 'be', 'pathogenic']"
3853,1.0,Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age.,"['mutated', '_gene_', 'associated', 'with', 'shorter', 'rfs', 'hr', '_num_', 'p=', '_num_', 'irrespective', 'of', 'patient', 'age']"
3854,1.0,A synthetic lethal screen identified ERBB3 blockade to confer sensitivity to MEK inhibitors.,"['a', 'synthetic', 'lethal', 'screen', 'identified', '_gene_', 'blockade', 'to', 'confer', 'sensitivity', 'to', 'mek', 'inhibitors']"
3855,1.0,"HPO terms: papillary cystadenomas of the broad ligament, retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, pheochromocytoma, multiple pancreatic cysts.","['_disease_', 'terms', 'papillary', '_disease_', 'of', 'the', 'broad', 'ligament', 'retinal', '_disease_', '_disease_', 'renal', 'cell', 'carcinoma', 'pheochromocytoma', 'multiple', 'pancreatic', 'cysts']"
3856,1.0,"In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.","['in', 'the', 'profile', '_num_', 'study', 'of', '_chemical_', 'in', '_num_', 'patients', 'with', '_gene_', 'rearranged', '_disease_', '_num_', 'patients', 'with', 'sufficient', 'tumor', 'material', 'were', 'tested', 'using', '_disease_', 'for', 'the', 'presence', 'of', 'certain', '_chemical_', 'variants']"
3857,1.0,"In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed.","['in', '_abbrev_', 'cell', 'lines', 'engineered', 'to', 'reduce', '_gene_', 'expression', 'by', 'transfection', 'with', '_gene_', 'resensitization', 'to', '_disease_', 'apoptosis', 'was', 'observed']"
3858,1.0,"Patient family history indicated a history of prostate cancer with a first degree relative was more common when compared to non-carriers (36.2% vs. 16.0%, P = 0.0003).","['patient', 'family', 'history', 'indicated', 'a', 'history', 'of', 'prostate', 'cancer', 'with', 'a', '_num_', 'degree', 'relative', 'was', 'more', 'common', 'when', 'compared', 'to', '_disease_', '_num_', 'vs', '_num_', 'p', '_num_']"
3859,1.0,Introduction of this polymorphism in a previously EGFR-inhibitor sensitive cell line led to TKI-resistance.,"['introduction', 'of', 'this', 'polymorphism', 'in', 'a', 'previously', '_gene_', 'inhibitor', 'sensitive', 'cell', 'line', 'led', 'to', 'tki', 'resistance']"
3860,1.0,"Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR.","['starting', 'with', '_num_', 'cases', 'intact', 'rna', 'could', 'be', 'isolated', 'from', '_num_', 'and', 'of', 'these', 'the', 'ews', '_gene_', 'event', 'was', 'detected', 'in', '_num_', 'by', 'nested', '_disease_']"
3861,1.0,Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.,"['_chemical_', 'increases', 'the', 'overall', 'survival', 'and', 'disease', 'free', 'survival', 'in', 'de', 'novo', '_disease_', 'patients', 'with', '_gene_', '_abbrev_', 'mutation', 'compared', 'to', 'those', 'who', 'do', 'not', 'harbor', 'this', 'mutation']"
3862,1.0,"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002).","['in', 'a', 'study', 'of', 'ovarian', 'carcinomas', '_num_', 'of', 'tumors', 'with', 'somatic', '_gene_', 'mutations', 'were', 'platinum', 'sensitive', 'whereas', 'only', '_num_', 'of', 'tumors', 'with', '_abbrev_', 'mutations', 'were', 'platinum', 'sensitive', '_ineq_', '_ineq_', '_p_val_']"
3863,1.0,"Treatment with 3 μM ATRA sensitized Cal27 cells to irradiation at a dose of 2 Gy, but had no or only a minor effect on ALDH1A2-postitive cells.","['treatment', 'with', '_num_', 'μm', '_disease_', 'sensitized', '_abbrev_', 'cells', 'to', 'irradiation', 'at', 'a', 'dose', 'of', '_num_', 'gy', 'but', 'had', 'no', 'or', 'only', 'a', 'minor', 'effect', 'on', '_abbrev_', 'cells']"
3864,1.0,17% of cases expressed high levels of EGFRvIII.,"['_num_', 'of', 'cases', 'expressed', 'high', 'levels', 'of', 'egfrviii']"
3865,1.0,This missense mutation was found in a VHL type 1 family of 10 individuals (family ID 1239).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_']"
3866,0.0,"AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways.","['_abbrev_', 'inhibited', '_gene_', 'signaling', 'in', 'these', 'cells', 'within', '_num_', 'hours', 'of', 'treatment', 'and', 'activated', 'apoptosis', 'and', '_gene_', 'pathways']"
3867,0.0,An ERBB3 directed antibody (MM-121) inhibited tumor-growth in-vivo.,"['an', '_gene_', 'directed', 'antibody', '_abbrev_', 'inhibited', '_disease_', 'in', 'vivo']"
3868,1.0,Further nude mice harboring this variant showed increased xenograft growth and metastasis.,"['further', 'nude', 'mice', 'harboring', 'this', 'variant', 'showed', 'increased', 'xenograft', 'growth', 'and', 'metastasis']"
3869,1.0,Combined PI3K/MEK inhibition was more effective than single agent treatment in-vitro.,"['combined', '_gene_', 'inhibition', 'was', 'more', 'effective', 'than', 'single', 'agent', 'treatment', 'in', 'vitro']"
3870,1.0,Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy.,"['patients', 'were', 'randomized', 'to', 'receive', 'either', 'a', 'combination', 'of', '_chemical_', 'and', '_chemical_', 'or', '_chemical_', 'orally', 'as', '_num_', 'line', 'therapy']"
3871,1.0,"In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.","['in', '_gene_', 'cells', 'with', '_gene_', '_abbrev_', 'mutation', 'that', 'have', 'shown', '_chemical_', 'resistance', '_chemical_', 'was', 'significantly', 'more', 'potent', 'at', 'inhibiting', 'kinase', 'activity', 'than', '_chemical_']"
3872,0.0,Crizotinib was well tolerated in these children.,"['_chemical_', 'was', 'well', 'tolerated', 'in', 'these', 'children']"
3873,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
3874,1.0,Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.,"['gefinitib', 'has', 'been', 'shown', 'to', 'be', 'effective', 'in', 'treating', 'cell', 'lines', 'with', '_mutation_', 'missense', 'mutations']"
3875,1.0,The Y253F mutation was moderately resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
3876,1.0,"HPO terms: retinal hemangioblastoma, hemangioblastoma.","['_disease_', 'terms', 'retinal', '_disease_', '_disease_']"
3877,1.0,Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes.,"['unconfirmed', 'response', 'or', 'stable', 'disease', '_num_', 'months', 'was', 'observed', 'in', '_num_', 'of', '_abbrev_', 'vs', '_num_', '_abbrev_', 'breast', 'cancer', 'patientes']"
3878,1.0,32/40 tumors studied had KRAS mutations with 9 G12D (2 with PIK3CA H1047R) and 13 other G12 mutations.,"['_ratio_', 'tumors', 'studied', 'had', '_gene_', 'mutations', 'with', '_num_', '_mutation_', '_num_', 'with', '_gene_', '_mutation_', 'and', '_num_', 'other', '_gene_', 'mutations']"
3879,1.0,"The mutation was also tested for ceritinib sensitivity in the context of NPM-ALK, where IC50 values were reported of 19 nM and 20 nM for mutant and wild type versions, respectively, also indicating sensitivity.","['the', 'mutation', 'was', 'also', 'tested', 'for', '_chemical_', 'sensitivity', 'in', 'the', 'context', 'of', '_chemical_', 'where', '_abbrev_', 'values', 'were', 'reported', 'of', '_num_', '_unit_', 'and', '_num_', '_unit_', 'for', 'mutant', 'and', 'wild', 'type', 'versions', 'respectively', 'also', 'indicating', 'sensitivity']"
3880,1.0,Sensitivity was determined by assessing PDGFRA auto-phosphorylation.,"['sensitivity', 'was', 'determined', 'by', 'assessing', '_gene_', 'auto', '_disease_']"
3881,1.0,18 advanced progressing chordoma patients entered this study (median age: 61 years; disease extent: metastatic 72% and locally advanced 28%).,"['_num_', 'advanced', 'progressing', '_gene_', 'patients', 'entered', 'this', 'study', 'median', 'age', '_num_', 'years', 'disease', 'extent', 'metastatic', '_num_', 'and', 'locally', 'advanced', '_num_']"
3882,1.0,BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.,"['_gene_', '_mutation_', 'is', 'correlated', 'with', 'shorter', '_disease_', 'and', 'overall', 'survival', 'in', 'a', 'spanish', 'cohort', 'of', 'melanoma', 'patients']"
3883,1.0,Exon 19 and L858R mutations were mutually exclusive in this cohort.,"['exon', '_num_', 'and', '_mutation_', 'mutations', 'were', 'mutually', 'exclusive', 'in', 'this', 'cohort']"
3884,1.0,"A hazard ratio for high Ki67 values of 3.42 was seen in univariate analysis, and  Ki67 score also added significant predictive value in multivariate analysis, with a hazard ratio of 2.78.","['a', 'hazard', 'ratio', 'for', 'high', '_gene_', 'values', 'of', '_num_', 'was', 'seen', 'in', 'univariate', 'analysis', 'and', '_gene_', 'score', 'also', 'added', 'significant', 'predictive', 'value', 'in', 'multivariate', 'analysis', 'with', 'a', 'hazard', 'ratio', 'of', '_num_']"
3885,1.0,96 patients were tested for TP53 mutation and 19 cases of mutation were detected.,"['_num_', 'patients', 'were', 'tested', 'for', '_gene_', 'mutation', 'and', '_num_', 'cases', 'of', 'mutation', 'were', 'detected']"
3886,1.0,ACMG codes as follows: Protein length changes as a result of insertion in a nonrepeat region and stop-loss variant (PM4).,"['acmg', 'codes', 'as', 'follows', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'insertion', 'in', 'a', 'nonrepeat', 'region', 'and', 'stop', 'loss', 'variant', '_abbrev_']"
3887,1.0,"Furthermore, patients harboring CTNNB1 (45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches.","['furthermore', 'patients', 'harboring', '_gene_', '45f', 'mutations', 'are', 'at', 'particular', 'risk', 'for', 'recurrence', 'and', 'therefore', 'may', 'especially', 'benefit', 'from', 'adjuvant', 'therapeutic', 'approaches']"
3888,1.0,"IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006).","['ic', 'dcr', 'was', 'significantly', 'improved', 'in', 'the', 'tbm', 'group', 'given', '_chemical_', '_ineq_', 'over', 'chemotherapy', '_chemical_', '_disease_', 'or', '_chemical_', '_ineq_', 'at', '_num_', 'weeks', '_num_', 'vs', '_num_', 'p', '_num_', 'and', 'at', '_num_', 'weeks', '_num_', 'vs', '_num_', '_p_val_']"
3889,1.0,Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis.,"['combined', 'inhibition', 'of', 'mek', 'and', '_gene_', 'with', '_chemical_', 'and', '_abbrev_', 'to', 'sustained', '_gene_', 'signalling', 'blockade', 'and', 'induced', 'apoptosis']"
3890,1.0,This patient's phenotype is highly specific for a disease with a single etiology (ACMG code: PP4).,"['this', 'patient', ""'s"", 'phenotype', 'is', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'a', 'single', 'etiology', 'acmg', 'code', '_gene_']"
3891,1.0,Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression.,"['subsequent', 'ice', 'chemotherapy', 'regiment', 'relieved', 'some', 'symptoms', 'prompting', 'the', 'patient', 'to', 'refuse', 'further', 'treatment', 'despite', 'other', 'indications', 'of', 'disease', 'progression']"
3892,0.0,"Clinical evidence suggested an additional 1 family member was affected with VHL, but genetic testing was not conducted on this individual.","['clinical', 'evidence', 'suggested', 'an', 'additional', '_num_', 'family', 'member', 'was', 'affected', 'with', '_gene_', 'but', 'genetic', 'testing', 'was', 'not', 'conducted', 'on', 'this', 'individual']"
3893,1.0,"In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen.","['in', 'a', 'patient', 'subgroup', 'with', 'mutations', 'in', '_gene_', 'amino', 'acids', 'that', 'directly', 'interact', 'with', 'dna', '_num_', 'of', '_num_', '_num_', 'of', 'patients', 'responded', 'to', 'tamoxifen']"
3894,1.0,"This nonsense mutation was found in an Iranian, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and pancreatic islet cell tumors (family VHL 65).","['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'an', 'iranian', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'pancreatic', 'cysts', 'and', 'pancreatic', 'islet', 'cell', 'tumors', 'family', '_gene_', '_num_']"
3895,1.0,TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.,"['_gene_', 'overexpression', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'in', 'breast', 'cancer', 'cell', 'lines']"
3896,1.0,"Among the patterns of failure ""metastatic and locally destructive"", It was discovered that DPC4 loss was significantly associated with metastatic disease (p=.007).","['among', 'the', 'patterns', 'of', 'failure', 'metastatic', 'and', 'locally', 'destructive', 'it', 'was', 'discovered', 'that', '_gene_', 'loss', 'was', 'significantly', 'associated', 'with', 'metastatic', 'disease', 'p=', '_num_']"
3897,1.0,Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).,"['complete', 'remission', 'rate', 'was', 'not', 'different', 'between', 'young', '_disease_', 'patients', '_num_', 'years', 'old', 'with', 'or', 'without', '_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_abbrev_']"
3898,0.0,we note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner.,"['we', 'note', 'that', 'the', 'break', 'apart', 'fish', 'assay', 'used', 'to', 'determine', '_gene_', 'rearrangement', 'status', 'does', 'not', 'determine', 'the', 'identity', 'of', 'the', '_gene_', 'fusion', 'partner', 'and', 'the', 'promising', 'results', 'shown', 'here', 'may', 'be', 'dependent', 'on', 'the', 'nature', 'of', 'the', '_gene_', 'fusion', 'partner']"
3899,1.0,"The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment.","['the', 'patient', 'attained', 'a', 'reduction', 'in', 'the', 'target', 'lesions', 'by', '_num_', 'and', 'the', 'patient', 'maintained', 'response', 'for', 'at', 'least', '_num_', 'months', 'post', 'treatment']"
3900,1.0,"Expression of mutant, but not wild type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells.","['expression', 'of', 'mutant', 'but', 'not', 'wild', 'type', '_gene_', 'leads', 'to', 'constitutive', 'activity', 'of', 'extracellular', 'signal', 'regulated', 'kinase', '_gene_', '', '_num_', '_num_', 'in', 'human', '_chemical_', 'cells', 'and', 'to', 'growth', 'factor', 'independent', 'proliferation', 'of', 'murine', 'ba', '_abbrev_', 'cells']"
3901,1.0,Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC.,"['primary', 'tumors', 'of', '_num_', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'were', 'analyzed', 'for', 'expression', 'of', '_gene_', 'and', '_gene_', 'using', '_gene_']"
3902,1.0,"After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291.","['after', 'further', 'progression', 'rebiopsy', 'additionally', 'identified', 'the', '_gene_', '_mutation_', 'mutation', 'and', 'the', 'patient', 'received', 'several', 'cycles', 'of', 'chemotherapy', 'and', 'targeted', 'therapy', 'including', '_chemical_', '_chemical_', '_chemical_', '_chemical_']"
3903,1.0,"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens.","['_gene_', 'inhibitors', 'such', 'as', '_chemical_', 'have', 'lead', 'to', 'significantly', 'improved', 'prognosis', 'response', 'rate', 'overall', 'survival', 'and', 'patient', 'outcome', 'in', '_gene_', 'patients', 'compared', 'to', 'previous', 'therapeutic', 'regimens']"
3904,1.0,"For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid.","['for', 'patients', 'with', '_gene_', 'mutation', 'that', 'achieved', 'cr', 'following', 'induction', 'therapy', 'relapse', 'free', 'survival', 'was', 'improved', 'following', 'treatment', 'with', 'valproic', 'acid']"
3905,1.0,HIF1A overexpression was assessed by IHC in 731 colorectal cancers from two prospective cohort studies.,"['_gene_', 'overexpression', 'was', 'assessed', 'by', '_gene_', 'in', '_num_', 'colorectal', 'cancers', 'from', '_num_', 'prospective', 'cohort', 'studies']"
3906,1.0,"Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.","['_num_', 'patients', 'with', 'detectable', '_chemical_', 'transcript', 'levels', 'responded', 'with', 'partial', 'response', '_num_', 'with', 'complete', 'response', 'and', '_num_', 'with', 'stable', 'disease']"
3907,1.0,"Additionally, KRAS mutations combined with CDKN2A alterations (N=26) showed an even worse OS than those wild type for both (N=17; HR: 95%CI 1.33-7.10).","['additionally', '_gene_', 'mutations', 'combined', 'with', '_gene_', 'alterations', '_ineq_', 'showed', 'an', 'even', 'worse', 'os', 'than', 'those', 'wild', 'type', 'for', 'both', '_ineq_', 'hr', '_num_', 'ci', '_range_']"
3908,0.0,"322 eligible patients (281 with the V600E mutation, 40 with the V600K mutation, and 1 with both mutations) in a 2:1 ratio to receive oral trametinib (2 mg once daily) or intravenous chemotherapy consisting of either dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter), at the discretion of the investigator, every 3 weeks.","['_num_', 'eligible', 'patients', '_num_', 'with', 'the', '_mutation_', 'mutation', '_num_', 'with', 'the', '_mutation_', 'mutation', 'and', '_num_', 'with', 'both', 'mutations', 'in', 'a', '_ratio_', 'ratio', 'to', 'receive', 'oral', '_chemical_', '_num_', '_unit_', 'once', 'daily', 'or', 'intravenous', 'chemotherapy', 'consisting', 'of', 'either', '_chemical_', '_num_', '_unit_', 'per', 'square', 'meter', 'of', 'body', 'surface', 'area', 'or', '_chemical_', '_num_', '_unit_', 'per', 'square', 'meter', 'at', 'the', 'discretion', 'of', 'the', 'investigator', 'every', '_num_', 'weeks']"
3909,1.0,"In western blots, pALK levels in H3122 CR2 cells remained apparent under 1000 nM crizotinib, whereas pALK signal was ablated under these conditions in parental H3122 cells.","['in', 'western', 'blots', 'palk', 'levels', 'in', '_abbrev_', '_gene_', 'cells', 'remained', 'apparent', 'under', '_num_', '_unit_', '_chemical_', 'whereas', 'palk', 'signal', 'was', 'ablated', 'under', 'these', 'conditions', 'in', 'parental', '_abbrev_', 'cells']"
3910,1.0,"Based on all of this analysis, we conclude that C609Y causes medullary thyroid cancers but a milder form than some other variants.","['based', 'on', 'all', 'of', 'this', 'analysis', 'we', 'conclude', 'that', '_mutation_', 'causes', 'medullary', 'thyroid', 'cancers', 'but', 'a', 'milder', 'form', 'than', 'some', 'other', 'variants']"
3911,1.0,"Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001).","['overall', 'in', 'the', 'intent', 'to', 'treat', 'population', '_chemical_', 'significantly', 'improved', '_disease_', 'over', 'placebo', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
3912,1.0,19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma/heme panel.,"['_num_', 'advanced', 'sarcoma', 'patients', 'treated', 'with', '_chemical_', 'were', 'retrospectively', 'assessed', 'for', 'mutations', 'associated', 'with', 'response', 'using', 'the', 'foundation', '_num_', 'sarcoma', 'heme', 'panel']"
3913,1.0,PTPRT promoter hypermethylation was associated with increased sensitivity to STAT3 inhibition in this preclinical study in HNSCC.,"['_gene_', 'promoter', 'hypermethylation', 'was', 'associated', 'with', 'increased', 'sensitivity', 'to', '_gene_', 'inhibition', 'in', 'this', 'preclinical', 'study', 'in', '_disease_']"
3914,1.0,The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779).,"['the', '_gene_', '_gene_', 'deletion', 'polymorphism', 'was', 'identified', 'in', 'an', '_gene_', 'mutant', '_disease_', 'cell', 'line', 'with', 'resistance', 'to', '_gene_', '_abbrev_']"
3915,1.0,PF-06463922 was 125x more potent at reducing cell viability than crizotinib.,"['_chemical_', 'was', '125x', 'more', 'potent', 'at', 'reducing', 'cell', 'viability', 'than', '_chemical_']"
3916,1.0,"ACMG evidence codes: 'PP1' based on segregation results, 'PM5' because we describe a prior report of a similar mutation at the same site (A149T), 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology.","['acmg', 'evidence', 'codes', ""'pp1"", 'based', 'on', 'segregation', 'results', ""'pm5"", 'because', 'we', 'describe', 'a', 'prior', 'report', 'of', 'a', 'similar', 'mutation', 'at', 'the', 'same', 'site', '_mutation_', ""'pp2"", 'because', 'they', 'observe', 'a', 'missense', 'variant', 'in', 'gene', 'where', 'missense', 'variants', 'are', 'common', 'mechanism', 'of', 'disease', 'and', ""'pp4"", 'because', 'the', 'patients', 'phenotypes', 'and', 'family', 'history', 'are', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'single', 'genetic', 'etiology']"
3917,1.0,MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53  status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor.,"['_gene_', 'inhibitor', 'screen', 'in', 'a', 'panel', 'of', '_num_', 'cancer', 'cell', 'lines', 'with', 'well', 'characterized', '_gene_', 'status', 'shows', 'that', 'only', 'cancer', 'cell', 'lines', 'with', 'unaltered', '_gene_', 'may', 'be', 'sensitive', 'to', '_gene_', 'inhibitor']"
3918,1.0,An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines.,"['an', '_abbrev_', '_chemical_', 'signal', 'transducing', 'loop', 'was', 'identified', 'in', 'a', 'subset', 'of', 'ovarian', 'cancers', 'and', 'cell', 'lines']"
3919,1.0,The biomarker displayed 100% diagnostic specificity and 7% sensitivity.,"['the', '_chemical_', 'displayed', '_num_', 'diagnostic', 'specificity', 'and', '_num_', 'sensitivity']"
3920,1.0,"The patient attained a decrease in RESIST target lesions by 26.8% (stable disease); however, the patient relapsed 4 months later.","['the', 'patient', 'attained', 'a', 'decrease', 'in', 'resist', 'target', 'lesions', 'by', '_num_', 'stable', 'disease', 'however', 'the', 'patient', 'relapsed', '_num_', 'months', 'later']"
3921,1.0,The patient was subsequently treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.,"['the', 'patient', 'was', 'subsequently', 'treated', 'with', 'entrectinib', 'and', 'exhibited', 'a', 'partial', 'response', 'for', '_num_', 'months', 'followed', 'by', 'disease', 'progression']"
3922,1.0,A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined.,"['a', '_disease_', 'in', 'frame', 'fusion', 'between', '_abbrev_', 'of', '_gene_', 'and', '_abbrev_', 'of', '_gene_', 'resulting', 'from', 'a', '~400kb', 'deletion', 'was', 'observed', 'in', '_num_', '_ratio_', 'fibrolamellar', '_disease_', 'carcinomas', 'examined']"
3923,1.0,MET exon 14 deletion results in an in-frame deletion in the MET protein.,"['met', 'exon', '_num_', 'deletion', 'results', 'in', 'an', 'in', 'frame', 'deletion', 'in', 'the', 'met', 'protein']"
3924,1.0,"In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.","['in', '_chemical_', 'cells', 'expressing', '_gene_', 'with', 'a', '_mutation_', 'mutation', '_abbrev_', 'and', 'panitumumab', 'bound', 'the', 'mutated', 'receptor', 'and', 'inhibited', '_gene_', '_disease_', 'in', 'the', 'presence', 'of', 'ligand', 'while', '_chemical_', 'neither', 'bound', 'to', 'nor', 'inhibited', '_gene_', '_disease_', 'of', 'the', 'mutated', 'receptor']"
3925,1.0,"6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941.","['_num_', 'head', 'and', 'neck', 'cancer', 'cell', 'lines', 'were', 'tested', 'for', 'response', 'to', '_chemical_', '_chemical_']"
3926,1.0,"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer).","['phase', '1b', 'study', 'of', '_chemical_', '_chemical_', 'and', '_chemical_', 'in', '_num_', 'patients', 'with', 'colorectal', 'cancer', '_num_', 'with', '_disease_', 'cancer']"
3927,1.0,Morphology and immunohistochemistry were unable to establish the primary tumor site.,"['morphology', 'and', 'immunohistochemistry', 'were', 'unable', 'to', 'establish', 'the', 'primary', 'tumor', 'site']"
3928,1.0,The most commonly occurring UMUCS were G719 and L861 mutations.,"['the', 'most', 'commonly', 'occurring', 'umucs', 'were', '_abbrev_', 'and', '_abbrev_', 'mutations']"
3929,1.0,"One family had a 32-year-old with hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma, and their 8-year-old asymptomatic son (proband no 8).","['_num_', 'family', 'had', 'a', '_age_', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'pancreatic', 'cysts', 'and', '_disease_', '_disease_', 'and', 'their', '_age_', 'asymptomatic', 'son', 'proband', 'no', '_num_']"
3930,0.0,"This preclinical study establishes that the p30 isoform of CEBPA expressed as a result of N-terminal truncating mutations preferentially interacts with WRD5, a component of the SET/MLL complex.","['this', 'preclinical', 'study', 'establishes', 'that', 'the', '_gene_', '_chemical_', 'of', '_gene_', 'expressed', 'as', 'a', 'result', 'of', '_chemical_', 'truncating', 'mutations', 'preferentially', 'interacts', 'with', '_abbrev_', 'a', 'component', 'of', 'the', 'set', '_gene_', 'complex']"
3931,1.0,"In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation.","['in', 'older', 'cytogenetically', 'normal', '_disease_', 'patients', '_num_', 'years', '_gene_', '_abbrev_', 'mutation', 'is', 'prognostic', 'for', 'shorter', 'disease', 'free', 'survival', 'and', 'overall', 'survival', 'compared', 'to', 'patients', 'without', 'the', 'mutation']"
3932,1.0,"In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild type, there was not a significant difference in overall survival in a multivariate analysis.","['in', 'patients', 'with', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'when', 'comparing', 'patients', 'with', 'any', 'mutation', 'in', '_gene_', 'to', 'wild', 'type', 'there', 'was', 'not', 'a', 'significant', 'difference', 'in', 'overall', 'survival', 'in', 'a', 'multivariate', 'analysis']"
3933,1.0,Case report of a 67 year old woman with high-grade papillary urothelial carcinoma.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'woman', 'with', 'high', 'grade', 'papillary', 'urothelial', 'carcinoma']"
3934,1.0,"Seven of the identified mutations in ERBB4 (E317K, E452K, E542K, R544W, E563K, E836K and E872K) were transforming and activating in-vitro.","['_num_', 'of', 'the', 'identified', 'mutations', 'in', '_gene_', '_mutation_', '_mutation_', '_mutation_', '_abbrev_', '_mutation_', '_abbrev_', 'and', '_mutation_', 'were', 'transforming', 'and', 'activating', 'in', 'vitro']"
3935,1.0,An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.,"['an', '_gene_', 'screen', 'in', 'the', 'widr', 'cell', 'line', 'a', '_mutation_', '_gene_', 'line', 'identified', '_gene_', 'as', 'an', 'enhancer', 'for', 'survival', 'when', 'exposed', 'to', '_chemical_']"
3936,1.0,Study of a large kindred with von Hippel-Lindau disease (VHLD) and pheochromocytoma (spread over four generations).,"['study', 'of', 'a', 'large', 'kindred', 'with', '_disease_', 'hippel', 'lindau', 'disease', '_disease_', 'and', 'pheochromocytoma', 'spread', 'over', '_num_', 'generations']"
3937,1.0,"Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average.","['median', '_disease_', 'was', '_num_', 'months', 'median', 'os', 'was', '_num_', 'months', 'this', 'trend', 'was', 'worse', 'with', 'increases', 'in', '_gene_', 'amplification', 'above', 'average']"
3938,1.0,"Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses.","['of', 'those', '_num_', 'patients', 'with', 'mutant', '_gene_', '_num_', 'saw', 'reductions', 'in', 'tumor', 'size', 'ranging', 'from', '_range_', 'including', '_num_', 'partial', 'responses']"
3939,1.0,A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro.,"['a', 'novel', '_gene_', 'inhibitor', '_abbrev_', 'was', 'designed', 'and', 'showed', 'efficacy', 'in', '_abbrev_', '_gene_', 'mutant', 'cell', 'lines', 'in', 'vivo', 'and', 'in', 'vitro']"
3940,1.0,In an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth.,"['in', 'an', 'in', 'vitro', 'study', 'ba', '_abbrev_', 'cells', 'transfected', 'with', 'either', '_abbrev_', 'or', '_abbrev_', 'were', 'used', 'to', 'assay', 'cell', 'growth']"
3941,1.0,Only moderate support for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region and stop-loss variant (ACMG code: PM4).,"['only', 'moderate', 'support', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'in', 'frame', 'deletion', 'in', 'a', 'nonrepeat', 'region', 'and', 'stop', 'loss', 'variant', 'acmg', 'code', '_abbrev_']"
3942,1.0,Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment.,"['administration', 'of', 'dual', 'inhibitors', 'induced', 'tumor', 'regression', 'apparent', 'in', 'a', 'decrease', 'of', 'colonic', 'area', 'covered', 'by', 'tumors', 'over', 'the', 'course', 'of', 'treatment']"
3943,1.0,"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line expressing the E292V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', '_abbrev_', '_gene_', 'cell', 'line', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment']"
3944,1.0,"In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2).","['in', 'pancreatic', 'cell', 'lines', '_abbrev_', '_disease_', 'and', '_abbrev_', '_abbrev_', 'sensitivity', 'to', 'dna', 'cross', 'linking', 'agents', 'was', 'observed', 'compared', 'to', '_gene_', '_gene_', 'wildtype', 'cell', 'lines', '_abbrev_', 'cfpac', '_abbrev_', 'and', '_abbrev_']"
3945,1.0,Control neuroblastoma cell lines with wild type ALK did not show inhibition below 3800 nM with either drug.,"['control', 'neuroblastoma', 'cell', 'lines', 'with', 'wild', 'type', '_gene_', 'did', 'not', 'show', 'inhibition', 'below', '_num_', '_unit_', 'with', 'either', 'drug']"
3946,0.0,So the overall conclusion remains mixed on the significance of this polymorphism in the prognosis for cervical cancer.,"['so', 'the', 'overall', 'conclusion', 'remains', 'mixed', 'on', 'the', 'significance', 'of', 'this', 'polymorphism', 'in', 'the', 'prognosis', 'for', 'cervical', 'cancer']"
3947,1.0,Deep sequencing revealed an MTOR A2034V mutation in the resistant clone.,"['deep', 'sequencing', 'revealed', 'an', '_gene_', '_abbrev_', 'mutation', 'in', 'the', 'resistant', 'clone']"
3948,1.0,"t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples.","['t', '_num_', '_num_', 'rearrangements', 'of', '_abbrev_', 'are', 'diagnostic', 'of', 'ewing', 'sarcoma', 'and', 'are', 'observed', 'in', '_num_', 'of', 'cytogenetic', 'samples']"
3949,1.0,A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse.,"['a', 'patient', 'with', '_gene_', 'rearranged', 'lung', 'adenocarcinoma', 'responded', 'to', '_chemical_', 'treatment', 'and', 'then', 'had', 'relapse']"
3950,1.0,"In a study of 37 patients with AKT1 (E13K) mutations, 5 patients harbored a concurrent PI3K/mTOR pathway alteration.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', '_gene_', '_mutation_', 'mutations', '_num_', 'patients', 'harbored', 'a', 'concurrent', '_abbrev_', 'pathway', 'alteration']"
3951,1.0,"Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective.","['selective', '_gene_', 'inhibitors', 'retained', 'activity', 'against', 'the', '_mutation_', 'mutation', 'cabozatinib', '_chemical_', 'whereas', 'dual', '_gene_', 'ros', 'inhibitors', '_chemical_', 'brigatinib', '_chemical_', '_abbrev_', 'or', '_gene_', 'selective', 'inhibitors', '_chemical_', 'were', 'ineffective']"
3952,1.0,V559D is a positive predictor of imatinib response with long term usage.,"['_mutation_', 'is', 'a', 'positive', 'predictor', 'of', '_chemical_', 'response', 'with', 'long', 'term', 'usage']"
3953,1.0,"In the uveal melanoma cohort, 61% of patients (14/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%.","['in', 'the', 'uveal', 'melanoma', 'cohort', '_num_', 'of', 'patients', '_ratio_', 'had', 'sd', 'at', 'week', '_num_', 'and', 'no', 'patient', 'had', 'a', 'pr', 'resulting', 'in', 'an', 'overall', 'disease', 'control', 'rate', 'of', '_num_']"
3954,1.0,"Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild type EGFR lines.","['preclinically', 'the', 'drug', 'inhibits', 'signaling', 'pathways', 'and', 'cellular', 'growth', 'in', 'both', 'egfrm', 'and', 'egfrm', '', '_abbrev_', 'mutant', 'cell', 'lines', 'in', 'vitro', 'with', 'lower', 'activity', 'against', 'wild', 'type', '_gene_', 'lines']"
3955,1.0,"N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance.","['_mutation_', 'was', 'observed', 'as', 'a', 'secondary', 'kit', 'mutation', 'in', '_num_', 'patients', 'with', 'secondary', '_chemical_', 'resistance', 'and', '_num_', 'patient', 'with', 'primary', 'resistance', 'and', 'also', 'as', 'a', 'primary', 'mutation', 'in', 'a', 'patient', 'with', 'primary', 'resistance']"
3956,1.0,A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation.,"['a', 'case', 'report', 'described', 'a', 'responder', 'to', '_gene_', 'inhibitor', '_chemical_', 'for', 'a', 'tumor', 'with', '_gene_', '_mutation_', 'mutation']"
3957,1.0,The primary endpoint was progression-free survival (PFS).,"['the', 'primary', 'endpoint', 'was', 'progression', 'free', 'survival', '_disease_']"
3958,1.0,"Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity.","['expression', 'of', '_gene_', 'in', '_disease_', 'cell', 'lines', '_ineq_', 'was', 'associated', 'with', 'resistance', 'to', '_gene_', 'inhibitor', '_chemical_', 'however', 'knock', 'in', 'or', 'knock', 'out', 'of', '_gene_', 'did', 'not', 'affect', '_chemical_', 'sensitivity']"
3959,1.0,"TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion.","['_gene_', 'depletion', 'sirna', 'inhibited', 'migration', 'and', 'invasion', 'whereas', 'its', 'constitutive', 'overexpression', 'led', 'to', 'an', 'increase', 'in', 'invasion']"
3960,1.0,"The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib.","['the', 'melanoma', 'cell', 'line', '_abbrev_', 'which', 'harbors', 'the', '_mutation_', 'mutation', 'is', 'not', 'sensitive', 'to', '_chemical_', '_chemical_', 'and', '_chemical_']"
3961,1.0,"Wild type cell lines used here were ""SCC-9"" and ""PE/CA-PJ34(clone C12)"".","['wild', 'type', 'cell', 'lines', 'used', 'here', 'were', '_gene_', 'and', 'pe', 'ca', '_abbrev_', 'clone', '_gene_']"
3962,1.0,Heterozygous Lkb1 (STK11) knockout mice were generated and treated with rapamycin after the onset of polyposis at 9 months of age.,"['heterozygous', '_gene_', '_gene_', 'knockout', 'mice', 'were', 'generated', 'and', 'treated', 'with', '_gene_', 'after', 'the', 'onset', 'of', '_disease_', 'at', '_num_', 'months', 'of', 'age']"
3963,1.0,"Three had retinal angiomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma.","['_num_', 'had', 'retinal', 'angiomas', '_num_', 'had', 'cerebellar', '_disease_', 'and', '_num_', 'had', 'renal', 'cell', 'carcinoma']"
3964,1.0,"194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD.","['_num_', 'patients', 'who', 'had', 'developed', 'pd', 'by', 'data', 'cutoff', 'were', 'studied', 'where', '_num_', 'received', '_chemical_', 'for', 'a', 'median', 'duration', 'of', '_num_', 'weeks', 'and', '_num_', 'discontinued', '_chemical_', 'after', 'pd']"
3965,1.0,"This splice mutation was found in a German, VHL type 1 family.","['this', 'splice', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'family']"
3966,1.0,"In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.","['in', 'young', '_disease_', 'patients', '_num_', 'years', 'old', '_gene_', 'mutation', 'status', 'was', 'not', 'predictive', 'of', 'overall', 'and', 'relapse', 'free', 'survival', 'in', 'patients', 'with', '_gene_', 'mutations', 'and', 'wildtype', '_gene_', 'or', 'wildtype', '_gene_', 'and', '_gene_']"
3967,1.0,Patients had HER2 positive non-metastatic operable BC.,"['patients', 'had', '_gene_', 'positive', '_disease_', 'operable', 'bc']"
3968,1.0,A 44 year old man was diagnosed with IMT.,"['a', '_num_', 'year', 'old', 'man', 'was', 'diagnosed', 'with', '_disease_']"
3969,1.0,40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC).,"['_num_', 'patients', 'with', '_disease_', 'peritonei', 'underwent', 'panel', 'sequencing', 'after', 'cytoreductive', 'surgery', 'and', 'hypertermic', 'intraperitoneal', 'chemotherapy', '_disease_']"
3970,1.0,"STK11 mutations were detected in 86% of those tested (18 of 21 probands) and included eight nonsense mutations, five frameshift mutations, two splice site mutations, two large genomic rearrangements, and one missense mutation.","['_gene_', 'mutations', 'were', 'detected', 'in', '_num_', 'of', 'those', 'tested', '_num_', 'of', '_num_', 'probands', 'and', 'included', '_num_', 'nonsense', 'mutations', '_num_', 'frameshift', 'mutations', '_num_', 'splice', 'site', 'mutations', '_num_', 'large', 'genomic', 'rearrangements', 'and', '_num_', 'missense', 'mutation']"
3971,1.0,The presence of exon 20 (such as H1047R) or exon 9 mutation may result in poorer survival compared to those with wild type PIK3CA mutation.,"['the', 'presence', 'of', 'exon', '_num_', 'such', 'as', '_mutation_', 'or', 'exon', '_num_', 'mutation', 'may', 'result', 'in', 'poorer', 'survival', 'compared', 'to', 'those', 'with', 'wild', 'type', '_gene_', 'mutation']"
3972,1.0,"The second case of ROS1 fusion was of undetermined fusion partner, where known ROS1 fusion parters SLC34A2, CD74 and SDC4 were tested.","['the', '_num_', 'case', 'of', '_gene_', 'fusion', 'was', 'of', 'undetermined', 'fusion', 'partner', 'where', 'known', '_gene_', 'fusion', 'parters', '_gene_', '_gene_', 'and', '_gene_', 'were', 'tested']"
3973,1.0,They also screened other 23 fatal cases and revealed that none of them had GNAS p.R201H mutation.,"['they', 'also', 'screened', 'other', '_num_', 'fatal', 'cases', 'and', 'revealed', 'that', 'none', 'of', 'them', 'had', '_gene_', '_mutation_', 'mutation']"
3974,1.0,"In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.","['in', 'this', 'phase', 'ii', 'trial', 'a', 'small', 'group', 'of', 'patients', 'with', '_abbrev_', 'or', '_abbrev_', '_gene_', '_disease_', 'in', 'which', 'primary', 'platinum', 'based', 'therapy', 'had', 'failed', 'were', 'given', 'either', '_chemical_', 'or', '_chemical_', 'after', 'which', 'both', 'groups', 'were', 'given', '_chemical_', 'and', '_chemical_', 'together']"
3975,1.0,"At publication, sustained CR had lasted > 18 months.","['at', 'publication', 'sustained', 'cr', 'had', 'lasted', '_num_', 'months']"
3976,1.0,"In an in vitro study, MCF7 cell lines expressing PIK3CA E545K mutation was associated with increased sensitivity to ado-trastuzumab emtansine treatment compared to trastuzumab treated MCF7 cells.","['in', 'an', 'in', 'vitro', 'study', '_chemical_', 'cell', 'lines', 'expressing', '_gene_', '_mutation_', 'mutation', 'was', 'associated', 'with', 'increased', 'sensitivity', 'to', 'ado', '_chemical_', '_chemical_', 'treatment', 'compared', 'to', '_chemical_', 'treated', '_chemical_', 'cells']"
3977,1.0,Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162.,"['phase', 'ii', 'study', 'in', '_num_', 'patients', 'with', 'nras', 'or', '_gene_', '_abbrev_', 'mutant', 'melanoma', 'treated', 'with', '_chemical_']"
3978,1.0,G465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro.,"['_mutation_', 'mutant', 'cell', 'lines', 'were', 'resistant', 'to', 'treatment', 'with', 'panitumumab', 'or', '_chemical_', 'in', 'vitro']"
3979,1.0,"In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.","['in', 'a', 'patient', 'expressing', 'a', '_gene_', '_mutation_', 'mutation', 'treatment', 'with', '_chemical_', 'plus', '_chemical_', 'acheived', 'a', 'partial', 'response']"
3980,1.0,Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples.,"['further', '_gene_', 'fusions', '_abbrev_', 'were', 'identified', 'in', '_disease_', 'and', 'additional', 'samples']"
3981,1.0,Immunohistochemistry revealed a significant difference in expression between tumor and adjacent normal samples.,"['immunohistochemistry', 'revealed', 'a', 'significant', 'difference', 'in', 'expression', 'between', 'tumor', 'and', 'adjacent', 'normal', 'samples']"
3982,1.0,"we profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine.","['we', 'profiled', 'the', 'response', 'of', '_num_', 'ovarian', 'melanoma', 'and', 'breast', 'cancer', 'cell', 'lines', 'over', '_num_', 'days', 'of', 'treatment', 'with', '_chemical_']"
3983,1.0,"we demonstrate this in (A) isogenic lines derived from C643 cells (HRASG13R, NF2-WT) modified to stably express shNF2, (B) in set of 7 RAS-mutant thyroid cancer cell lines that differ in their NF2 expression levels, and (C) in a Hras-G12V/Nf2-null mouse model.","['we', 'demonstrate', 'this', 'in', 'a', 'isogenic', 'lines', 'derived', 'from', '_abbrev_', 'cells', '_abbrev_', '_abbrev_', 'modified', 'to', 'stably', 'express', '_abbrev_', 'b', 'in', 'set', 'of', '_num_', 'ras', 'mutant', 'thyroid', 'cancer', 'cell', 'lines', 'that', 'differ', 'in', 'their', '_gene_', 'expression', 'levels', 'and', 'c', 'in', 'a', '_abbrev_', 'mouse', 'model']"
3984,1.0,Only moderate evidence for pathogenicity because protein length changes as a result of deletion in a nonrepeat region and stop-loss variant (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'deletion', 'in', 'a', 'nonrepeat', 'region', 'and', 'stop', 'loss', 'variant', 'acmg', 'code', '_abbrev_']"
3985,1.0,Only moderate evidence of pathogenicity since the protein length changes as a result of in-frame deletions in a nonrepeat region (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'of', 'pathogenicity', 'since', 'the', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'in', 'frame', 'deletions', 'in', 'a', 'nonrepeat', 'region', 'acmg', 'code', '_abbrev_']"
3986,1.0,Only supporting evidence for pathogenicity because of cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).,"['only', 'supporting', 'evidence', 'for', 'pathogenicity', 'because', 'of', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']"
3987,1.0,Improvements in quality of life were also reported.,"['improvements', 'in', 'quality', 'of', 'life', 'were', 'also', 'reported']"
3988,1.0,"2 patients were reported to harbor FGFR2 amplifications and both had a reduction in tumor size of 18.5 and 28.2%, respectively.","['_num_', 'patients', 'were', 'reported', 'to', 'harbor', '_gene_', 'amplifications', 'and', 'both', 'had', 'a', 'reduction', 'in', 'tumor', 'size', 'of', '_num_', 'and', '_num_', 'respectively']"
3989,1.0,"In this study, 229 tumors were analyzed for RRM1 expression.","['in', 'this', 'study', '_num_', 'tumors', 'were', 'analyzed', 'for', '_gene_', 'expression']"
3990,1.0,PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.,"['_gene_', 'loss', 'is', 'associated', 'with', 'reduced', 'response', 'to', '_gene_', 'inhibitors', 'in', 'patients', 'with', 'bladder', 'cancer']"
3991,1.0,2/3 additional patients with TSC1 mutations also had mild responses to everolimus.,"['_ratio_', 'additional', 'patients', 'with', '_gene_', 'mutations', 'also', 'had', 'mild', 'responses', 'to', '_chemical_']"
3992,1.0,Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1).,"['supporting', 'evidence', 'of', 'pathogenicity', 'because', 'of', 'the', 'introduction', 'of', 'an', 'early', 'stop', 'codon', 'in', 'a', 'gene', 'where', 'loss', 'of', 'function', 'is', 'an', 'established', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
3993,0.0,"An in-vitro cell-based screening approach generated FLT3-ITD-expressing cell lines resistant to the FLT3 inhibitors SU5614, PKC412, and sorafenib.","['an', 'in', 'vitro', 'cell', 'based', 'screening', 'approach', 'generated', '_abbrev_', 'cell', 'lines', 'resistant', 'to', 'the', '_gene_', 'inhibitors', '_chemical_', '_gene_', 'and', '_chemical_']"
3994,1.0,"Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved.","['patients', 'with', '_gene_', 'mutations', 'were', 'associated', 'with', 'improved', 'complete', 'remission', 'rates', 'as', 'well', 'as', 'overall', 'and', 'disease', 'free', 'survival', 'when', 'all', 'ages', 'and', 'karyotype', 'were', 'analyzed', 'however', 'when', 'only', 'normal', 'karyotype', 'patients', 'were', 'analyzed', 'only', 'complete', 'remission', 'rates', 'were', 'improved']"
3995,1.0,Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study.,"['forty', '_num_', 'patients', 'with', 'relapsed', 'refractory', '_disease_', 'or', '60+', 'years', 'old', 'with', 'untreated', '_disease_', 'were', 'enrolled', 'on', 'a', 'phase', 'ii', 'study']"
3996,1.0,Response to the therapy was demonstrated by comparing CAT scans obtained before treatment to those obtained during treatment (at 2 months of crizotinib therapy).,"['response', 'to', 'the', 'therapy', 'was', 'demonstrated', 'by', 'comparing', 'cat', 'scans', 'obtained', 'before', 'treatment', 'to', 'those', 'obtained', 'during', 'treatment', 'at', '_num_', 'months', 'of', '_chemical_', 'therapy']"
3997,0.0,TERT promoter mutations are prevalent in aggressive sub-types of thyroid cancers.,"['_gene_', 'promoter', 'mutations', 'are', 'prevalent', 'in', 'aggressive', 'sub', 'types', 'of', 'thyroid', 'cancers']"
3998,1.0,Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild type CD74–ROS1.,"['ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', '_mutation_', 'mutation', 'showed', 'similar', 'sensitivity', 'to', '_chemical_', 'compared', 'with', 'those', 'expressing', 'wild', 'type', '_abbrev_']"
3999,1.0,339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.,"['_num_', 'patients', 'were', 'assigned', 'to', 'afatanib', '_chemical_', 'and', '_num_', 'to', '_chemical_', '_chemical_']"
4000,1.0,"In the 600 mg cohort (N=13), there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease.","['in', 'the', '_num_', '_unit_', 'cohort', '_ineq_', 'there', 'were', '_num_', 'confirmed', 'partial', 'responses', '_num_', 'unconfirmed', 'partial', 'responses', 'and', '_num_', 'instances', 'of', 'stable', 'disease']"
4001,1.0,40 cell lines harbored a KRAS mutation.,"['_num_', 'cell', 'lines', 'harbored', 'a', '_gene_', 'mutation']"
4002,1.0,"The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001).","['the', 'complete', 'remission', 'rate', 'for', 'patients', 'with', '_gene_', 'mutations', 'was', 'significantly', 'lower', '_num_', 'vs', '_num_', 'p', '_num_', 'the', 'refractory', 'disease', 'rate', 'was', 'significantly', 'higher', '_num_', '_num_', '_p_val_', 'the', '_num_', 'year', 'event', 'free', 'survival', 'rate', 'was', 'significantly', 'lower', '_num_', '_num_', 'p', '_num_', 'the', '_num_', 'year', 'relapse', 'free', 'survival', 'rate', 'was', 'significantly', 'lower', '_num_', '_num_', '_p_val_', 'and', 'the', '_num_', 'year', 'overall', 'survival', 'rate', 'was', 'significantly', 'lower', '_num_', '_num_', '_p_val_']"
4003,1.0,"In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA.","['in', 'a', 'group', 'of', 'young', '_num_', 'years', 'old', 'acute', 'myeloid', 'leukemia', 'exclude', 'acute', 'promyelocytic', 'leukemia', 'and', 'high', 'risk', 'mds', 'patients', 'those', 'with', '_gene_', 'mutations', '_ratio_', 'showed', 'marginally', 'improved', 'overall', 'survival', '_num_', 'vs', '_num_', 'p', '_num_', 'than', 'those', 'with', 'wildtype', '_gene_']"
4004,1.0,ATM-deficient H1395 and HT144 cancer cell lines showed growth inhibition when treated with DNA PKcs inhibitors KU-0060648 and NU7441.,"['_disease_', '_abbrev_', 'and', '_abbrev_', 'cancer', 'cell', 'lines', 'showed', 'growth', 'inhibition', 'when', 'treated', 'with', 'dna', 'pkcs', 'inhibitors', '_chemical_', 'and', '_chemical_']"
4005,1.0,This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM).,"['this', 'prospective', 'phase', 'iii', 'study', 'named', 'profile', '_num_', 'on', '_disease_', '_gene_', 'rearranged', 'patients', 'assessed', 'intracranial', 'disease', 'control', 'rate', 'ic', 'dcr', 'in', 'the', 'subset', 'of', 'patients', 'entering', 'the', 'study', 'with', 'preexisting', 'treated', 'brain', 'metastasis', 'tbm']"
4006,1.0,Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.,"['sequencing', 'of', 'the', 'recurrent', 'tumor', 'harbored', '_gene_', '_mutation_', 'mutation', 'and', 'he', 'was', 'treated', 'with', '_chemical_']"
4007,1.0,"In addition, amplification of EGFR wild type alleles but not mutant alleles was sufficient to confer acquired resistance.","['in', 'addition', 'amplification', 'of', '_gene_', 'wild', 'type', 'alleles', 'but', 'not', 'mutant', 'alleles', 'was', 'sufficient', 'to', 'confer', 'acquired', 'resistance']"
4008,1.0,"The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib.","['the', '_gene_', 'was', 'treated', 'in', '_num_', 'cohorts', 'each', '_ineq_', 'with', 'control', 'doxorubicin', '_gene_', 'inhibitor', '_chemical_', 'or', '_gene_', 'inhibitor', '_chemical_']"
4009,1.0,"Both before and after adjustment for age, karyotype and sex.","['both', 'before', 'and', 'after', 'adjustment', 'for', 'age', 'karyotype', 'and', 'sex']"
4010,1.0,"This missense mutation was detected in a VHL type 2B patient with angioma, renal cell carcinoma, and pheochromocytoma (family ID 4422).","['this', 'missense', 'mutation', 'was', 'detected', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'with', 'angioma', 'renal', 'cell', 'carcinoma', 'and', 'pheochromocytoma', 'family', 'id', '_num_']"
4011,1.0,The alectinib resistant cell line H3122 CHR-A1 was generated by culturing of the EML4-ALK (variant 1) containing cell line H3122 with increasing levels of alectinib.,"['the', '_chemical_', 'resistant', 'cell', 'line', '_abbrev_', '_abbrev_', 'was', 'generated', 'by', 'culturing', 'of', 'the', '_chemical_', 'variant', '_num_', 'containing', 'cell', 'line', '_abbrev_', 'with', 'increasing', 'levels', 'of', '_chemical_']"
4012,1.0,"In an in vitro study, a SW48 cell line expressing KRAS G12S mutation demonstrated decreased sensitivity  to regorafenib treatment (IC50: 264.23 nmol vs. 114.28 nmol, P<0.01) compared to SW48 cells expressing KRAS wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'mutation', 'demonstrated', 'decreased', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'p', '_num_', 'compared', 'to', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
4013,1.0,All 3 individuals carried cerebellar hemangioblastomas and one also carried renal cell carcinoma.,"['all', '_num_', 'individuals', 'carried', 'cerebellar', '_disease_', 'and', '_num_', 'also', 'carried', 'renal', 'cell', 'carcinoma']"
4014,1.0,"Overall response rate was 57%, with 46 partial responses and one complete response.","['overall', 'response', 'rate', 'was', '_num_', 'with', '_num_', 'partial', 'responses', 'and', '_num_', 'complete', 'response']"
4015,1.0,"A statistically significant difference in the GADD454A (1506T>C) variant between the controls groups was found in correlation with an increased risk of ovarian cancer (P<0.001, OR = 1.71, 95% CI 1.28–2.29).","['a', 'statistically', 'significant', 'difference', 'in', 'the', '_abbrev_', '1506t', 'c', 'variant', 'between', 'the', 'controls', 'groups', 'was', 'found', 'in', 'correlation', 'with', 'an', 'increased', 'risk', 'of', 'ovarian', 'cancer', 'p', '_num_', 'or', '_num_', '_num_', 'ci', '_num_', '28–2', '_num_']"
4016,1.0,A high neoantigen load was identified.,"['a', 'high', 'neoantigen', 'load', 'was', 'identified']"
4017,1.0,Genomic testing revealed a CCDC6-RET fusion but no other actionable mutations (confirmed by FISH).,"['genomic', 'testing', 'revealed', 'a', '_abbrev_', 'fusion', 'but', 'no', 'other', 'actionable', 'mutations', 'confirmed', 'by', 'fish']"
4018,1.0,"In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001).","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'lung', 'adenocarcinomas', 'patients', 'with', '_gene_', 'mutations', '_ineq_', 'showed', 'better', 'prognosis', 'os', '_num_', 'months', 'vs', '_num_', 'months', '_ineq_', 'p', '_num_']"
4019,1.0,Amplification of FOXP1 is shown to be associated with ABC DLBCL.,"['amplification', 'of', '_gene_', 'is', 'shown', 'to', 'be', 'associated', 'with', 'abc', '_disease_']"
4020,1.0,"In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition.","['in', '_gene_', 'cells', 'with', 'the', '_gene_', 'deletion', '_abbrev_', 'mutation', 'that', 'have', 'shown', '_chemical_', 'sensitivity', '_chemical_', 'showed', 'no', 'significant', 'difference', 'from', '_chemical_', 'in', 'kinase', 'activity', 'inhibition']"
4021,1.0,"Three family members had retinal angiomas, 2 had hemangioblastomas of the central nervous system, 2 had renal cell carcinoma, and one had pheochromocytoma.","['_num_', 'family', 'members', 'had', 'retinal', 'angiomas', '_num_', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'had', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'had', 'pheochromocytoma']"
4022,1.0,"Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.","['patients', 'were', '_gene_', 'positive', 'with', 'completely', 'excised', 'invasive', 'bc', 'node', 'positive', 'or', 'negative', 'and', 'having', 'undergone', 'prior', 'adjuvant', 'or', 'neo', 'adjuvant', 'chemotherapy']"
4023,1.0,This mutation was found in a VHL type 1 patient (patient no V77).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
4024,1.0,This missense mutation was found in a VHL type 1 family (lineage 103).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
4025,1.0,A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone.,"['a', 'cell', 'line', 'derived', 'from', 'a', 'separate', 'patient', 'with', 'the', 'same', 'primary', '_mutation_', 'and', 'secondary', '_mutation_', 'mutations', 'showed', 'moderately', 'increased', 'resistance', 'to', '_chemical_', 'compared', 'to', 'reports', 'for', 'gist', 'lines', 'with', 'primary', 'exon', '_num_', 'kit', 'mutations', 'alone']"
4026,1.0,This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations.,"['this', 'is', 'a', 'retrospective', 'analysis', 'of', '_num_', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', 'and', '_gene_', 'mutations']"
4027,1.0,"Patients with NPM1 mutations and low (<25%, N=63), intermediate (25-50%, N=156) or high (>50%, N=66) levels of FLT3-ITD have worse overall survival (P<0.0001 for trend) and cumulative incidence of relapse (P<0.001) than those with NPM1 mutations alone (N=387) in young adult, intermediate risk AML patients.","['patients', 'with', '_gene_', 'mutations', 'and', 'low', '_num_', '_ineq_', 'intermediate', '_range_', '_ineq_', 'or', 'high', '_num_', '_ineq_', 'levels', 'of', '_gene_', 'have', 'worse', 'overall', 'survival', 'p', '_num_', 'for', 'trend', 'and', 'cumulative', 'incidence', 'of', 'relapse', 'p', '_num_', 'than', 'those', 'with', '_gene_', 'mutations', 'alone', '_ineq_', 'in', 'young', 'adult', 'intermediate', 'risk', '_disease_', 'patients']"
4028,1.0,"FGFR1 expression, was assessed by IHC in 1,086 invasive breast cancers.","['_gene_', 'expression', 'was', 'assessed', 'by', '_gene_', 'in', '_num_', 'invasive', 'breast', 'cancers']"
4029,1.0,A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas.,"['a', 'characteristic', '_gene_', 'ssx', 'fusion', 'gene', 'resulting', 'from', 'the', 'chromosomal', 'translocation', 't', 'x', '_num_', '_gene_', '_gene_', 'is', 'detectable', 'in', 'almost', 'all', 'synovial', 'sarcomas']"
4030,1.0,The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines.,"['the', 'combination', 'of', '_gene_', 'and', 'mek', 'inhibitors', 'synergistically', 'blocked', 'cell', 'growth', 'in', 'nras', 'mutant', 'but', 'not', 'wild', 'type', 'cell', 'lines']"
4031,1.0,In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma.,"['in', 'a', '_num_', 'year', 'old', 'female', 'patient', 'with', 'this', 'fusion', 'in', '_disease_', '_disease_']"
4032,1.0,"However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).","['however', 'subsequent', 'treatment', 'with', '_chemical_', 'showed', 'partial', 'response', 'in', '_num_', 'patients', 'where', '_ratio_', '_num_', 'were', 'in', 'the', '_abbrev_', 'group', 'and', '_ratio_', '_num_', 'were', 'in', 'the', '_abbrev_', 'group', '_p_val_']"
4033,1.0,Three of 4 individuals were identified with angiomas and one with cerebellar hemangioblastomas.,"['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', 'and', '_num_', 'with', 'cerebellar', '_disease_']"
4034,1.0,This mutation was found in 3 VHL type 1 families of 7 individuals total.,"['this', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'of', '_num_', 'individuals', 'total']"
4035,1.0,HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding.,"['_gene_', '_gene_', 'expression', 'was', 'retrospectively', 'defined', 'as', 'predictive', '_chemical_', 'but', 'prospectively', 'assessed', 'in', '_num_', 'patients', 'before', 'unblinding']"
4036,1.0,"Of these, 12/13 had a partial response, and 1 had stable disease.","['of', 'these', '_ratio_', 'had', 'a', 'partial', 'response', 'and', '_num_', 'had', 'stable', 'disease']"
4037,1.0,There was no statistically significant difference in OS between BRAF D594G and BRAF wt but BRAF V600E mutant patients had significantly worse survival when only stage IV patients (BRAF D594G N=5) were analyzed.,"['there', 'was', 'no', 'statistically', 'significant', 'difference', 'in', 'os', 'between', '_gene_', '_mutation_', 'and', '_gene_', '_gene_', 'but', '_gene_', '_mutation_', 'mutant', 'patients', 'had', 'significantly', 'worse', 'survival', 'when', 'only', 'stage', 'iv', 'patients', '_gene_', '_mutation_', '_ineq_', 'were', 'analyzed']"
4038,1.0,"Whole-exome analysis revealed copy-neutral loss of heterozygosity at chromosome 6, encoding the HLA locus and resulting in loss of the targeted HLA-C*08:02 allele.","['whole', 'exome', 'analysis', 'revealed', 'copy', 'neutral', 'loss', 'of', 'heterozygosity', 'at', 'chromosome', '_num_', 'encoding', 'the', '_gene_', 'locus', 'and', 'resulting', 'in', 'loss', 'of', 'the', 'targeted', 'hla', 'c*08:02', 'allele']"
4039,1.0,Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'patient', 'with', 'high', 'grade', 'stromal', 'endometrial', 'sarcoma', 'and', 'a', 'large', 'abdominal', 'and', '_disease_', 'mass', 'progressing', 'after', 'chemotherapy']"
4040,1.0,"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 patients who had not shown gefitinib response.","['mutational', 'profiling', 'was', 'performed', 'on', '_gene_', 'exons', '_range_', 'from', 'a', 'group', 'of', '_num_', 'retrospectively', 'chosen', 'patients', 'who', 'had', 'shown', 'partial', 'response', 'or', 'clinical', 'imporvement', 'in', 'response', 'to', '_chemical_', 'and', 'in', '_num_', 'patients', 'who', 'had', 'not', 'shown', '_chemical_', 'response']"
4041,1.0,"CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy).","['_gene_', 'expression', 'did', 'not', 'correlate', 'with', 'other', 'lines', 'of', 'treatment', '_ineq_', 'tamoxifen', 'or', 'endocrine', 'therapy']"
4042,1.0,Three metastatic glioblastoma cell lines were compared with their parental cell lines with regard to differential gene expression.,"['_num_', 'metastatic', 'glioblastoma', 'cell', 'lines', 'were', 'compared', 'with', 'their', 'parental', 'cell', 'lines', 'with', 'regard', 'to', 'differential', 'gene', 'expression']"
4043,1.0,"In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild type.","['in', 'patients', 'with', 'multiple', 'myeloma', 'those', 'with', '_gene_', '_mutation_', 'had', 'shorter', 'overall', 'survival', 'than', 'wild', 'type']"
4044,1.0,"In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).","['in', 'the', '_chemical_', 'arm', 'the', 'response', 'rate', 'was', 'significantly', 'higher', '_num_', 'vs', '_num_', 'p', '_num_', 'the', 'progression', 'free', 'survival', 'was', 'increased', '_num_', 'months', 'vs', '_num_', 'months', '_ineq_', '_num_', 'ci:14', '_abbrev_', 'months', 'p', '_num_', 'however', 'there', 'was', 'no', 'significant', 'improvement', 'in', 'overall', 'survival', '_ineq_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_']"
4045,1.0,"This mutation was found in 2 German, VHL type 1 family members with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 44).","['this', 'mutation', 'was', 'found', 'in', '_num_', 'german', '_gene_', 'type', '_num_', 'family', 'members', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'family', '_gene_', '_num_']"
4046,1.0,"In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide.","['in', 'a', 'randomized', 'clinical', 'trial', 'patients', 'with', '_gene_', 'promoter', 'methyaltion', 'benefitted', 'from', '_chemical_']"
4047,1.0,"In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild type KRAS (5.8 vs 8.0 months; P = 0.001; multivariate analysis).","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'pancreatic', 'cancer', 'patients', 'point', 'mutations', 'in', '_gene_', 'exon', '_num_', 'were', 'associated', 'with', 'worse', 'overall', 'survival', 'compared', 'to', 'that', 'of', 'wild', 'type', '_gene_', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'multivariate', 'analysis']"
4048,1.0,"Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased.","['using', '_gene_', '_mutation_', 'sirna', 'in', '_num_', '_num_', 'cells', '_gene_', 'activity', 'was', 'suppressed', 'and', 'cell', 'sensitivity', 'to', '_chemical_', 'was', 'increased']"
4049,1.0,Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts.,"['preclinical', 'study', 'analyzing', 'the', 'differential', 'response', 'to', 'mek', 'inhibitors', 'in', '_gene_', 'and', '_gene_', 'mutant', 'cancer', 'cell', 'lines', 'and', 'mouse', 'xenografts']"
4050,1.0,Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy.,"['cancer', 'and', 'normal', 'tissue', 'samples', 'were', 'taken', 'from', '_num_', 'gastric', 'cancer', 'patients', 'undergoing', 'surgery', 'without', 'prior', 'chemotherapy']"
4051,1.0,"Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells.","['inactivity', 'of', '_gene_', 'as', 'mediated', 'by', 'specific', 'mutation', '_mutation_', '_mutation_', 'or', '_abbrev_', 'or', 'selective', 'pharmacological', 'inhibition', 'leads', 'to', 'mek', 'hyperactivation', 'through', '_gene_', 'binding', 'in', 'nras', 'mutant', '_abbrev_', 'cells']"
4052,1.0,"High expression of HEF1 correlated with higher advanced tumor, node, metastasis (TNM) stage and vascular invasion (P<0.05).","['high', 'expression', 'of', '_gene_', 'correlated', 'with', 'higher', 'advanced', 'tumor', 'node', 'metastasis', '_gene_', 'stage', 'and', 'vascular', 'invasion', 'p', '_num_']"
4053,1.0,"35 patients had a G719X mutation but the majority of these were G719S (20 with G719S, 9 with G719A, 3 with G719C).","['_num_', 'patients', 'had', 'a', '_mutation_', 'mutation', 'but', 'the', 'majority', 'of', 'these', 'were', '_mutation_', '_num_', 'with', '_mutation_', '_num_', 'with', '_mutation_', '_num_', 'with', '_mutation_']"
4054,1.0,25 proven cases of VHLD and 17 cases with pheochromocytoma were identified.,"['_num_', 'proven', 'cases', 'of', '_disease_', 'and', '_num_', 'cases', 'with', 'pheochromocytoma', 'were', 'identified']"
4055,1.0,"Since this was a case of sporadic RCC, with a somatic variant observed in the tumor, we can only infer that the variant is functional and would be predisposing if it occurred in a germline context.","['since', 'this', 'was', 'a', 'case', 'of', 'sporadic', '_gene_', 'with', 'a', 'somatic', 'variant', 'observed', 'in', 'the', 'tumor', 'we', 'can', 'only', 'infer', 'that', 'the', 'variant', 'is', 'functional', 'and', 'would', 'be', 'predisposing', 'if', 'it', 'occurred', 'in', 'a', 'germline', 'context']"
4056,1.0,we conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects.,"['we', 'conclude', 'that', 'future', 'studies', 'of', '_chemical_', 'in', '_gene_', 'positive', '_disease_', 'should', 'focus', 'on', 'high', 'expressing', 'subjects']"
4057,1.0,"Five patients had retinal angiomas, 3 had hemangioblastomas of the central nervous system, and 6 had renal cell carcinoma.","['_num_', 'patients', 'had', 'retinal', 'angiomas', '_num_', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'and', '_num_', 'had', 'renal', 'cell', 'carcinoma']"
4058,1.0,"This missense mutation was found in a German, VHL type 1 patient with retinal angiomas (family VHL 59).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', 'family', '_gene_', '_num_']"
4059,1.0,Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.,"['ba', '_abbrev_', 'cells', 'expressing', 'the', '_abbrev_', 'fusion', 'containing', 'an', '_mutation_', 'mutation', 'were', 'more', 'resistant', 'to', '_chemical_', 'treatment', 'than', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'without', 'this', 'mutation']"
4060,1.0,"Participants had stage III, IV or recurrent HER2 positive endometrial cancer.","['participants', 'had', 'stage', 'iii', 'iv', 'or', 'recurrent', '_gene_', 'positive', 'endometrial', 'cancer']"
4061,1.0,D473 mutations were identified in 5/30 resistant basal cell carcinomas.,"['_abbrev_', 'mutations', 'were', 'identified', 'in', '_ratio_', 'resistant', 'basal', 'cell', 'carcinomas']"
4062,1.0,"CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy.","['_gene_', 'expression', 'was', 'significantly', 'increased', 'in', 'patients', 'with', '_gene_', 'mutation', 'with', 'or', 'without', '_gene_', 'indicating', 'these', 'patients', 'may', 'respond', 'to', '_abbrev_', 'therapy']"
4063,1.0,Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy.,"['immunhistochemistry', 'of', '_gene_', 'expression', 'in', '_num_', 'patients', 'revealed', 'no', 'correlation', 'to', 'response', 'to', '_disease_', 'based', 'chemotherapy']"
4064,1.0,"Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).","['median', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'in', 'the', 'combination', 'therapy', 'group', 'and', '_num_', 'months', 'in', 'the', '_chemical_', 'group', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
4065,1.0,"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01).","['in', 'a', 'study', 'of', 'ovarian', 'carcinomas', '_num_', 'of', 'tumors', 'with', 'germline', '_gene_', 'mutations', 'were', 'platinum', 'sensitive', 'whereas', 'only', '_num_', 'of', 'tumors', 'with', '_abbrev_', 'mutations', 'were', 'platinum', 'sensitive', '_ineq_', '_ineq_', '_p_val_']"
4066,1.0,There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).,"['there', 'is', 'very', 'strong', 'evidence', 'for', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'nonsense', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
4067,1.0,we conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types.,"['we', 'conducted', 'an', 'in', 'vivo', 'efficacy', 'study', 'of', '_abbrev_', '_gene_', 'inhibitory', 'antibody', 'using', 'a', 'panel', 'of', '_num_', 'xenograft', 'models', 'representing', '_num_', 'human', 'cancer', 'types']"
4068,1.0,All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions.,"['all', 'tumors', 'were', 'adenocarcinoma', 'with', 'in', 'frame', '_gene_', 'exon', '_num_', 'insertions']"
4069,1.0,This included 1 large family pedigree with strong co-segregation of the mutation with cancer development.,"['this', 'included', '_num_', 'large', 'family', 'pedigree', 'with', 'strong', 'co', 'segregation', 'of', 'the', 'mutation', 'with', 'cancer', 'development']"
4070,1.0,"Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA.","['favorable', 'predictors', 'in', 'a', 'multivariate', 'analysis', 'were', 'high', '_gene_', 'mrna', 'in', '_gene_', 'wild', 'type', 'tumours', 'high', '_gene_', 'mrna', 'and', 'low', '_gene_', '_gene_', 'receptor', 'mrna']"
4071,1.0,"This missense mutation was found in six VHL type 2 families (lineages 100, 42, 44, 88, 105, 135).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'lineages', '_num_', '_num_', '_num_', '_num_', '_num_', '_num_']"
4072,1.0,Loss of heterozygosity leading to  p.I68S at 77% variant allele frequency was demonstrated.,"['loss', 'of', 'heterozygosity', 'leading', 'to', 'p', '_abbrev_', 'at', '_num_', 'variant', 'allele', 'frequency', 'was', 'demonstrated']"
4073,1.0,2 of the 43 patients were found to have the above mutation.,"['_num_', 'of', 'the', '_num_', 'patients', 'were', 'found', 'to', 'have', 'the', 'above', 'mutation']"
4074,1.0,TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD.,"['_gene_', 'mutation', 'reduces', 'overall', 'survival', 'of', 'normal', 'karyotype', 'patients', 'with', 'either', 'an', '_gene_', 'mutation', 'or', '_gene_', 'mutation', 'without', '_gene_']"
4075,1.0,The rs751402 polymorphism in the 5' UTR of ERCC5 was correlated with reduced progression free-survival in children with ependymoma that had been treated with platinum-based therapies.,"['the', '_mutation_', 'polymorphism', 'in', 'the', '_num_', '_gene_', 'of', '_gene_', 'was', 'correlated', 'with', 'reduced', 'progression', 'free', 'survival', 'in', 'children', 'with', '_disease_', 'that', 'had', 'been', 'treated', 'with', 'platinum', 'based', 'therapies']"
4076,1.0,"In a large study of patients with primary myelofibrosis evaluating mutations associated with anemia, 457 patients were evaluated for U2AF1 mutations.","['in', 'a', 'large', 'study', 'of', 'patients', 'with', 'primary', 'myelofibrosis', 'evaluating', 'mutations', 'associated', 'with', 'anemia', '_num_', 'patients', 'were', 'evaluated', 'for', '_gene_', 'mutations']"
4077,1.0,"Presence of the GADD45A (1506T>C) variant was also found to have higher GADD45A mRNA expression, longer ovarian cancer relapse free survival and overall survival.","['presence', 'of', 'the', '_gene_', '1506t', 'c', 'variant', 'was', 'also', 'found', 'to', 'have', 'higher', '_gene_', 'mrna', 'expression', 'longer', 'ovarian', 'cancer', 'relapse', 'free', 'survival', 'and', 'overall', 'survival']"
4078,1.0,"Family 3682 in this publication, variant segregates with disease.","['family', '_num_', 'in', 'this', 'publication', 'variant', 'segregates', 'with', 'disease']"
4079,1.0,PTEN and PIK3CA mutations were heavily represented in the panel.,"['_gene_', 'and', '_gene_', 'mutations', 'were', 'heavily', 'represented', 'in', 'the', 'panel']"
4080,1.0,"Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)].","['nuclear', 'expression', 'of', '_gene_', 'was', 'identified', 'in', '_num_', 'of', '_num_', 'patients', 'with', 'colorectal', 'cancer', 'and', 'was', 'associated', 'with', 'decreased', 'progression', 'free', 'survival', '_disease_', 'and', 'overall', 'survival', 'os', 'after', 'chemotherapy', '_chemical_', 'folfiri', 'or', '_chemical_', 'adjusted', 'hr', '_num_', '_num_', 'confidence', 'interval', 'ci', '_range_', 'p', '_num_']"
4081,1.0,The patient had been heavily treated with chemotherapy before establishment of the cell line.,"['the', 'patient', 'had', 'been', 'heavily', 'treated', 'with', 'chemotherapy', 'before', 'establishment', 'of', 'the', 'cell', 'line']"
4082,1.0,"PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.","['_chemical_', 'inhibited', 'viability', 'in', 'felix', 'cells', 'at', '37x', 'efficacy', 'over', '_chemical_', 'with', '_abbrev_', 'values', 'of', '_num_', '_num_', 'and', '_num_', '_num_', 'respectively']"
4083,1.0,"Multivariate analysis was performed on all patients that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study.","['multivariate', 'analysis', 'was', 'performed', 'on', 'all', 'patients', 'that', 'were', 'evaluated', 'for', 'a', 'mutation', 'in', 'at', 'least', '_num_', 'gene', '_gene_', '_gene_', 'or', '_gene_', 'totaling', '_ratio_', 'patients', 'in', 'the', 'study']"
4084,1.0,Confirmed partial response (PR) was observed in 21% (10/47) patients receiving trametinib/docetaxel.,"['confirmed', 'partial', 'response', 'pr', 'was', 'observed', 'in', '_num_', '_ratio_', 'patients', 'receiving', '_chemical_', '_chemical_']"
4085,0.0,"we discovered that 2HG overproduction impairs homologous recombination used in DNA repair and sensitizes cancer cells to treatment with PARP inhibitors, another class of cancer drugs that are already in clinical use.","['we', 'discovered', 'that', '2hg', 'overproduction', 'impairs', 'homologous', 'recombination', 'used', 'in', 'dna', 'repair', 'and', 'sensitizes', 'cancer', 'cells', 'to', 'treatment', 'with', '_gene_', 'inhibitors', 'another', 'class', 'of', 'cancer', 'drugs', 'that', 'are', 'already', 'in', 'clinical', 'use']"
4086,1.0,"The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001).","['the', '_num_', 'year', 'survival', 'rate', 'was', 'significantly', 'poorer', 'in', 'the', '_mutation_', 'group', 'when', 'compared', 'to', 'the', 'wild', 'type', 'group', '_num_', '_num_', 'p', '_num_']"
4087,1.0,The other copy of PTEN was lost with a chromosome-wide loss of chr 10.,"['the', 'other', 'copy', 'of', '_gene_', 'was', 'lost', 'with', 'a', 'chromosome', 'wide', 'loss', 'of', '_gene_', '_num_']"
4088,1.0,Mutation was detected in one patient.,"['mutation', 'was', 'detected', 'in', '_num_', 'patient']"
4089,1.0,"When co-expressed with V560D (imatinib sensitive) in vitro D820G showed ""extreme"" imatinib resistance.","['when', 'co', 'expressed', 'with', '_mutation_', '_chemical_', 'sensitive', 'in', 'vitro', '_mutation_', 'showed', 'extreme', '_chemical_', 'resistance']"
4090,1.0,The ORR was 18% (4 PR in 22 patients) in KRAS wild type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC.,"['the', 'orr', 'was', '_num_', '_num_', 'pr', 'in', '_num_', 'patients', 'in', '_gene_', 'wild', 'type', 'vs', '_num_', '_num_', 'pr', 'in', '_num_', 'patients', 'in', '_gene_', 'mutant', '_disease_']"
4091,1.0,"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations.","['mutational', 'analysis', 'for', '_num_', 'patients', 'with', 'clinically', 'diagnosed', '_gene_', 'disease', 'revealed', '_num_', 'germline', 'mutations']"
4092,1.0,The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement.,"['the', 'patient', 'underwent', 'chemotherapy', 'and', 'palliative', 'cystectomy', 'followed', 'by', 'tumor', 'progression', 'and', 'pulmonary', 'lesion', 'enlargement']"
4093,1.0,"While clonal mutations (VAF >= 12%) were associated with reduced time to first treatment by univariate analysis (N=28, P<0.0001), subclonal mutations were not (N=21, P=0.22).","['while', 'clonal', 'mutations', '_disease_', '_num_', 'were', 'associated', 'with', 'reduced', 'time', 'to', '_num_', 'treatment', 'by', 'univariate', 'analysis', '_ineq_', 'p', '_num_', 'subclonal', 'mutations', 'were', 'not', '_chemical_', '_p_val_']"
4094,1.0,"CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.","['cleopatra', '_abbrev_', 'was', 'a', 'phase', 'iii', 'randomized', 'and', 'double', 'blind', 'placebo', 'controlled', 'study', 'of', '_num_', 'patients', 'with', '_gene_', 'metastatic', 'breast', 'cancer']"
4095,1.0,"Analysis of only KRAS exon 2 hotspot mutations showed that patients with more than 1% mutant allele fraction (n = 19/83) had a hazard ratio of 3.43 for PFS (95% CI, 1.67–7.02; P=0.002) and 2.72 for OS (95% CI, 1.52–4.88; P=0.002) compared to wild type patients or patients with less than 1% mutant allele fraction.","['analysis', 'of', 'only', '_gene_', 'exon', '_num_', 'hotspot', 'mutations', 'showed', 'that', 'patients', 'with', 'more', 'than', '_num_', 'mutant', 'allele', 'fraction', 'n', '_ratio_', 'had', 'a', 'hazard', 'ratio', 'of', '_num_', 'for', '_disease_', '_num_', 'ci', '_num_', '67–7', '_num_', '_p_val_', 'and', '_num_', 'for', 'os', '_num_', 'ci', '_num_', '52–4', '_num_', '_p_val_', 'compared', 'to', 'wild', 'type', 'patients', 'or', 'patients', 'with', 'less', 'than', '_num_', 'mutant', 'allele', 'fraction']"
4096,1.0,"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'breast', 'cancer', '_num_', 'patients', 'were', '_gene_', 'positive', 'and', '_num_', 'patients', 'were', '_gene_', 'negative']"
4097,1.0,"Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer.","['compared', 'to', 'those', 'who', 'harbor', 'a', 'wild', 'type', 'ret', 'patients', 'with', 'ret', '_mutation_', 'mutation', 'develop', 'larger', 'and', 'more', 'aggressive', 'medullary', 'thyroid', 'cancer']"
4098,1.0,"In retrospective study, 413 patients were assessed for RSF1 amplification.","['in', 'retrospective', 'study', '_num_', 'patients', 'were', 'assessed', 'for', '_gene_', 'amplification']"
4099,1.0,"Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701 and, to a lesser extent, crizotinib) inhibited autophosphorylation of TRKA and cell growth.","['treatment', 'of', 'cells', 'expressing', '_gene_', 'fusions', 'with', 'inhibitors', 'of', '_gene_', 'kinase', 'activity', '_abbrev_', '_chemical_', 'and', 'to', 'a', 'lesser', 'extent', '_chemical_', 'inhibited', 'autophosphorylation', 'of', '_gene_', 'and', 'cell', 'growth']"
4100,1.0,CLB-BAR xenografts in BalbC/NUDE mice responded to brigatinib with reduced tumor volume and weight (N=8/group) as well as reduced ALK phosphorylation and MYCN levels compared to untreated controls.,"['_gene_', 'bar', 'xenografts', 'in', 'balbc', 'nude', 'mice', 'responded', 'to', 'brigatinib', 'with', 'reduced', 'tumor', 'volume', 'and', 'weight', '_ineq_', 'as', 'well', 'as', 'reduced', '_gene_', '_disease_', 'and', '_gene_', 'levels', 'compared', 'to', 'untreated', 'controls']"
4101,1.0,The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months.,"['the', '_num_', 'patient', 'was', 'on', '_chemical_', 'plus', '_chemical_', 'and', 'showed', 'no', 'signs', 'of', 'progression', 'for', '_num_', 'months']"
4102,1.0,"Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL.","['instead', 'the', 'investigators', 'report', 'that', 'other', 'publications', 'report', 'cell', 'lines', 'without', '_gene_', '_gene_', 'overexpression', 'had', 'higher', '_abbrev_', 'values', 'for', '_chemical_', 'suggesting', 'overexpresssed', '_gene_', '_gene_', 'targetability', 'in', '_gene_']"
4103,0.0,"Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advanced NSCLC patients using a sequenom mass spectrometry-based genotype assay.","['eighty', 'snps', 'in', 'mirna', 'binding', 'sites', 'of', 'cancer', 'related', 'genes', 'selected', 'from', '_num_', 'mirna', 'target', 'bindings', 'in', 'crosslinking', 'ligation', 'and', 'sequencing', 'of', 'hybrids', 'clash', 'data', 'were', 'investigated', 'in', '_num_', 'advanced', '_disease_', 'patients', 'using', 'a', 'sequenom', 'mass', 'spectrometry', 'based', 'genotype', 'assay']"
4104,1.0,"However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*).","['however', 'there', 'was', 'a', 'rapid', 'clinical', 'worsening', 'which', 'may', 'possibly', 'be', 'attributed', 'to', 'a', 'somatic', 'mutation', 'in', '_gene_', '_chemical_']"
4105,1.0,"While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation.","['while', 'incubation', 'of', 'ba', '_abbrev_', 'cells', 'transduced', 'with', '_chemical_', 'variants', '_num_', 'and', '_num_', 'with', '_gene_', 'inhibitor', '_chemical_', 'caused', 'cell', 'death', 'that', 'was', 'reversible', 'with', '_gene_', 'addition', 'ba', '_abbrev_', 'cells', 'with', 'variant', '3a', 'were', 'not', 'sensitized', 'to', '_chemical_', 'induced', 'death', 'suggesting', 'that', '_chemical_', 'was', 'effecting', 'the', '_chemical_', 'driver', 'of', '_abbrev_', 'proliferation']"
4106,1.0,Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.,"['children', 'with', 'early', 'age', 'leukaemia', 'who', 'had', '_num_', 'hand', 'smoke', 'exposure', 'are', 'more', 'likely', 'to', 'harbor', '_gene_', 'mutation']"
4107,1.0,"No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.","['no', 'predictive', '_chemical_', 'were', 'identified', 'including', '_gene_', 'mutations', '_gene_', 'mutations', 'or', '_gene_', 'loss']"
4108,1.0,Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.,"['expression', 'of', '_gene_', 'in', '_num_', 'mesothelioma', 'cell', 'lines', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'in', 'functional', 'studies']"
4109,1.0,"In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67).","['in', '_num_', 'patients', 'with', 'tumors', 'of', 'the', 'exocrine', 'pancreas', 'a', '_gene_', '_mutation_', 'mutation', '_ineq_', 'was', 'associated', 'with', 'shorter', 'overall', 'survival', 'than', 'being', 'wild', 'type', 'for', '_gene_', '_chemical_', 'hazard', 'ratio', '_num_', 'ci', 'between', '_num_', 'and', '_num_']"
4110,1.0,32/40 tumors harbored KRAS mutations including 2 A146T tumors (1 also harboring PIK3CA E545K) which both showed disease stabilization during doublet therapy but progression on either single agent.,"['_ratio_', 'tumors', 'harbored', '_gene_', 'mutations', 'including', '_num_', '_mutation_', 'tumors', '_num_', 'also', 'harboring', '_gene_', '_mutation_', 'which', 'both', 'showed', 'disease', 'stabilization', 'during', 'doublet', 'therapy', 'but', 'progression', 'on', 'either', 'single', 'agent']"
4111,1.0,"Six patients had retinal angiomas, 10 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma.","['_num_', 'patients', 'had', 'retinal', 'angiomas', '_num_', 'had', 'cerebellar', '_disease_', 'and', '_num_', 'had', 'renal', 'cell', 'carcinoma']"
4112,1.0,"In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild type patients.","['in', 'patients', 'with', 'anaplastic', '_disease_', 'those', 'with', 'mutations', 'at', '_abbrev_', 'of', '_gene_', 'had', 'better', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
4113,1.0,One of the partial responses harbored a PIK3CA E542K mutation.,"['_num_', 'of', 'the', 'partial', 'responses', 'harbored', 'a', '_gene_', '_mutation_', 'mutation']"
4114,1.0,"Patients with more than one line of therapy, MEK or B-RAF inhibitor treatment or prior irinotecan treatment were excluded.","['patients', 'with', 'more', 'than', '_num_', 'line', 'of', 'therapy', 'mek', 'or', '_gene_', 'inhibitor', 'treatment', 'or', 'prior', '_chemical_', 'treatment', 'were', 'excluded']"
4115,1.0,"In resistant xenografts, western blot analysis showed a decrease of pRb protein levels in 4 of 7 CDK4/6-acquired resistant tumors and a sustained expression of the E2F target cyclin E2, in contrast to CDK4/6 inhibitor-sensitive PDX244.","['in', 'resistant', 'xenografts', 'western', 'blot', 'analysis', 'showed', 'a', 'decrease', 'of', '_gene_', 'protein', 'levels', 'in', '_num_', 'of', '_num_', '_abbrev_', 'resistant', 'tumors', 'and', 'a', 'sustained', 'expression', 'of', 'the', '_gene_', 'target', '_gene_', '_gene_', 'in', 'contrast', 'to', '_gene_', 'inhibitor', 'sensitive', '_abbrev_']"
4116,1.0,Results from a mass spectrometry-based assay to evaluate KRAS activity suggests that G12C mutant KRAS is in a “hyperexcitable” rather than a “statically active” state.,"['results', 'from', 'a', 'mass', 'spectrometry', 'based', 'assay', 'to', 'evaluate', '_gene_', 'activity', 'suggests', 'that', '_mutation_', 'mutant', '_gene_', 'is', 'in', 'a', '“', 'hyperexcitable', '”', 'rather', 'than', 'a', '“', 'statically', 'active', '”', 'state']"
4117,1.0,High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients.,"['high', 'expression', 'of', '_gene_', 'was', 'associated', 'with', 'poorer', 'outcome', 'in', 'a', '_disease_', 'analysis', 'encompassing', '_num_', 'studies', 'and', '_num_', 'patients']"
4118,1.0,"In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'the', '_mutation_', 'mutation', 'was', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
4119,1.0,Median duration of response was 17·0 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients.,"['median', 'duration', 'of', 'response', 'was', '_num_', 'months', '_num_', 'ci', '_num_', '_num_', 'non', 'estimable', 'ne', 'in', '_gene_', 'inhibitor', 'naive', 'patients', 'and', '_num_', 'months', '_range_', 'in', '_gene_', 'inhibitor', 'pretreated', 'patients']"
4120,1.0,"However, incomplete inhibition in 3a/3b containing H2228 cells was observed.","['however', 'incomplete', 'inhibition', 'in', '3a', '_chemical_', 'containing', '_abbrev_', 'cells', 'was', 'observed']"
4121,1.0,"Patients 15 and 50 exhibited response rates of relatively short duration (10 and 12 weeks, respectively) and the mutations were observed in both the pretreatment and postrelapse biopsies.","['patients', '_num_', 'and', '_num_', 'exhibited', 'response', 'rates', 'of', 'relatively', 'short', 'duration', '_num_', 'and', '_num_', 'weeks', 'respectively', 'and', 'the', 'mutations', 'were', 'observed', 'in', 'both', 'the', 'pretreatment', 'and', 'postrelapse', 'biopsies']"
4122,1.0,Rapamycin treatment abolished FDG-PET signal on imaging.,"['_gene_', 'treatment', 'abolished', '_chemical_', 'signal', 'on', 'imaging']"
4123,1.0,"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor Rucaparib on 3 genetically defined subsets of patients.","['a', 'phase', '_num_', 'trial', 'on', 'patients', 'with', 'relapsed', 'platinum', 'sensitive', 'high', 'grade', 'ovarian', 'carcinoma', '_abbrev_', '_abbrev_', '_abbrev_', 'was', 'held', 'to', 'assess', '_gene_', 'inhibitor', '_chemical_', 'on', '_num_', 'genetically', 'defined', 'subsets', 'of', 'patients']"
4124,1.0,"In BRAF wildtype patients, KRAS mutations in codon 61 or 146 were associated with reduced response rate (0% vs. 37%, P=0.047) and reduced progression-free survival compared to wildtype KRAS patients (3.8mo vs. 5.3mo, HR:0.45, 95% CI:0.10-0.85, P=0.023).","['in', '_gene_', 'wildtype', 'patients', '_gene_', 'mutations', 'in', 'codon', '_num_', 'or', '_num_', 'were', 'associated', 'with', 'reduced', 'response', 'rate', '_num_', 'vs', '_num_', '_p_val_', 'and', 'reduced', 'progression', 'free', 'survival', 'compared', 'to', 'wildtype', '_gene_', 'patients', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_']"
4125,1.0,This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants.,"['this', 'in', 'turn', 'suggests', 'that', 'variant', '3a', 'may', 'not', 'rely', 'on', '_gene_', 'for', 'stability', 'in', 'cancer', 'cells', 'to', 'the', 'extent', 'of', 'other', 'variants']"
4126,1.0,The F317L mutation was moderately resistant to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'moderately', 'resistant', 'to', '_chemical_']"
4127,1.0,All 3 patients had retinal angioma.,"['all', '_num_', 'patients', 'had', 'retinal', 'angioma']"
4128,1.0,"Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and disease-free survival.","['tumors', 'with', 'variation', 'either', 'increase', 'or', 'decrease', 'in', 'copy', 'number', 'of', '_gene_', 'had', 'worse', 'overall', '_disease_', 'and', '_disease_', 'survival']"
4129,0.0,"These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment.","['these', 'results', 'indicated', 'that', '_chemical_', 'may', 'be', 'a', 'driver', 'mutation', 'in', '_disease_', 'and', 'a', 'target', 'for', '_gene_', 'inhibitor', 'treatment']"
4130,1.0,"26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed.","['_num_', '_gene_', 'patients', 'from', '_num_', 'families', 'who', 'had', 'undergone', 'a', 'partial', 'adrenalectomy', 'for', 'pheochromocytoma', 'were', 'retrospectively', 'analyzed']"
4131,1.0,Both individuals were identified with cerebellar hemangioblastomas and one with angiomas.,"['both', 'individuals', 'were', 'identified', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'angiomas']"
4132,1.0,A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.,"['a', '_abbrev_', 'clinical', 'trial', 'evaluated', '_num_', 'patients', 'with', '_disease_', 'lung', 'cancer']"
4133,1.0,bMMP2 was associated with relapse (p=0.002) and death (p=0.049).,"['_abbrev_', 'was', 'associated', 'with', 'relapse', '_p_val_', 'and', 'death', '_p_val_']"
4134,1.0,There was no statistical difference in overall survival between patients with and without gene amplification.,"['there', 'was', 'no', 'statistical', 'difference', 'in', 'overall', 'survival', 'between', 'patients', 'with', 'and', 'without', 'gene', 'amplification']"
4135,1.0,55 post-operative frozen samples were used in this study.,"['_num_', 'post', 'operative', 'frozen', 'samples', 'were', 'used', 'in', 'this', 'study']"
4136,1.0,"Five patients (9%; 95% CI, 3% to 19%) achieved a partial response.","['_num_', 'patients', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'achieved', 'a', 'partial', 'response']"
4137,1.0,HCT116 and SW480 cell lines became resistant through UGT1A overexpression.,"['_abbrev_', 'and', '_abbrev_', 'cell', 'lines', 'became', 'resistant', 'through', '_mutation_', 'overexpression']"
4138,1.0,BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.,"['_gene_', '_mutation_', 'is', 'correlated', 'with', 'poor', 'prognosis', 'in', 'papillary', 'thyroid', 'cancer', 'in', 'a', 'study', 'of', '_num_', 'patients', 'with', '_gene_', 'and', 'other', 'thyroid', 'diseases']"
4139,1.0,"NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old.","['_gene_', 'mutations', 'were', 'associated', 'with', 'increased', 'complete', 'remission', 'rates', 'as', 'well', 'as', 'longer', 'overall', 'disease', 'free', 'survival', 'in', 'normal', 'karyotype', '_disease_', 'patients', '_num_', 'years', 'old', 'particularly', 'in', 'those', '_num_', 'years', 'old']"
4140,1.0,"Mail-in surveys conducted every two years since 1980 evaluated 82,911 woman and 47,363 men for regular aspirin use.","['mail', 'in', 'surveys', 'conducted', 'every', '_num_', 'years', 'since', '_year_', 'evaluated', '_num_', 'woman', 'and', '_num_', 'men', 'for', 'regular', 'aspirin', 'use']"
4141,1.0,Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variant (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'of', 'pathogenicity', 'since', 'the', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'a', 'stop', 'loss', 'variant', 'acmg', 'code', '_abbrev_']"
4142,1.0,In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild type MEK1 as well as increased colony formation and tumor growth in-vivo.,"['in', 'silico', 'modelling', 'suggested', 'loss', 'of', 'negative', 'feedback', 'on', 'kinase', 'activity', 'from', 'this', 'deletion', 'in', 'vitro', 'expression', 'of', 'the', '_gene_', '_abbrev_', 'deletion', 'as', 'well', 'as', 'the', 'previously', 'characterized', '_gene_', '_mutation_', 'mutation', 'in', '293h', 'cells', 'resulted', 'in', 'elevated', 'levels', 'of', 'phosphorylated', '_gene_', 'and', 'phosphorylated', 'ribosomal', 'protein', '_gene_', 'kinase', 'as', 'compared', 'with', 'wild', 'type', '_gene_', 'as', 'well', 'as', 'increased', 'colony', 'formation', 'and', 'tumor', 'growth', 'in', 'vivo']"
4143,1.0,"This missense mutation was found in five VHL type 2 families of 18 individuals altogether (family IDs 4421, 3718, 3767, 3493, 3731).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'of', '_num_', 'individuals', 'altogether', 'family', 'ids', '_num_', '_num_', '_num_', '_num_', '_num_']"
4144,1.0,"The presence of minimal residual disease was the only independent prognostic factor for death in multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; P<0.001).","['the', 'presence', 'of', 'minimal', 'residual', 'disease', 'was', 'the', 'only', 'independent', 'prognostic', 'factor', 'for', 'death', 'in', 'multivariate', 'analysis', 'hazard', 'ratio', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
4145,1.0,This patient was therefore negative for LS.,"['this', 'patient', 'was', 'therefore', 'negative', 'for', 'ls']"
4146,1.0,ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.,"['_disease_', 'treatment', 'improved', 'overall', 'and', 'relapse', 'free', 'survival', 'in', 'older', '_num_', 'patients', 'with', 'mutant', '_gene_', 'and', 'without', '_gene_']"
4147,1.0,Results were validated in-vivo.,"['results', 'were', 'validated', 'in', 'vivo']"
4148,1.0,Thus the status of both TP53 alleles should be assessed because even one copy of wild type TP53 may contribute to poor response to chemotherapy.,"['thus', 'the', 'status', 'of', 'both', '_gene_', 'alleles', 'should', 'be', 'assessed', 'because', 'even', '_num_', 'copy', 'of', 'wild', 'type', '_gene_', 'may', 'contribute', 'to', 'poor', 'response', 'to', 'chemotherapy']"
4149,1.0,"6/16 (38%) HLA-DR non-expressing melanomas responded to therapy (overall response rate 79 versus 38%, Fisher’s exact test P=0.033).","['_ratio_', '_num_', '_chemical_', 'non', 'expressing', 'melanomas', 'responded', 'to', 'therapy', 'overall', 'response', 'rate', '_num_', 'vs', '_num_', 'fisher', '’', 's', 'exact', 'test', '_p_val_']"
4150,1.0,Pooled data from 13 studies of patients with lung cancer found little effect of codon 72 allele on the overall survival of patients with lung cancer.,"['pooled', 'data', 'from', '_num_', 'studies', 'of', 'patients', 'with', 'lung', 'cancer', 'found', 'little', 'effect', 'of', 'codon', '_num_', 'allele', 'on', 'the', 'overall', 'survival', 'of', 'patients', 'with', 'lung', 'cancer']"
4151,1.0,"CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy.","['_gene_', 'and', '_gene_', 'expression', 'was', 'significantly', 'increased', 'in', 'patients', 'with', '_gene_', 'mutation', 'with', '_gene_', 'indicating', 'these', 'patients', 'may', 'respond', 'to', 'combined', '_abbrev_', 'and', '_abbrev_', 'therapy']"
4152,1.0,Tumor samples from 125 patients with bladder cancer were assessed by IHC for STAG2 expression.,"['tumor', 'samples', 'from', '_num_', 'patients', 'with', 'bladder', 'cancer', 'were', 'assessed', 'by', '_gene_', 'for', '_gene_', 'expression']"
4153,1.0,"This missense mutation was found in two VHL type 1 families and six VHL type 2 families (lineages 202, 47, 102, 106, 153, 109).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'and', '_num_', '_gene_', 'type', '_num_', 'families', 'lineages', '_num_', '_num_', '_num_', '_num_', '_num_', '_num_']"
4154,1.0,Loss of heterozygosity analysis was non-informative.,"['loss', 'of', 'heterozygosity', 'analysis', 'was', 'non', 'informative']"
4155,1.0,"In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only","['in', 'addition', '_gene_', '_abbrev_', 'and', '_gene_', '_mutation_', 'mutations', 'were', 'present', 'in', 'all', '_num_', 'samples', 'and', 'a', '_gene_', '_abbrev_', 'was', 'seen', 'in', 'the', '_num_', 'biopsy', 'sample', 'only']"
4156,1.0,CPS therapy was associated with improved overall survival compared with CP in patients with tumors positive for KRAS gene copy gains (HR = 0.25; P = 0.035).,"['cps', 'therapy', 'was', 'associated', 'with', 'improved', 'overall', 'survival', 'compared', 'with', '_gene_', 'in', 'patients', 'with', 'tumors', 'positive', 'for', '_gene_', 'gene', 'copy', 'gains', 'hr', '_num_', 'p', '_num_']"
4157,1.0,"For RAS wild type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P < .001.","['for', 'ras', 'wild', 'type', 'patients', 'with', 'high', 'ligand', 'expression', 'median', '_disease_', 'was', '_num_', '_range_', 'months', '_chemical_', 'with', 'panitumumab', 'vs', '_num_', '_range_', 'months', '_chemical_', 'alone', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
4158,1.0,"Low expression was associated with advanced pretreatment tumor, nodal status, post-treatment tumor, vascular invasion and inferior regression grade.","['low', 'expression', 'was', 'associated', 'with', 'advanced', 'pretreatment', 'tumor', '_gene_', 'status', 'post', 'treatment', 'tumor', 'vascular', 'invasion', 'and', 'inferior', 'regression', 'grade']"
4159,1.0,Results were less clear for response rate (interaction P = .17) and OS (interaction P = .11).,"['results', 'were', 'less', 'clear', 'for', 'response', 'rate', 'interaction', 'p', '_num_', 'and', 'os', 'interaction', 'p', '_num_']"
4160,1.0,A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma.,"['a', '_num_', 'year', 'old', 'patient', 'presented', 'with', '_chemical_', 'resistant', '_gene_', 'mutated', '_mutation_', 'cutaneous', 'melanoma']"
4161,1.0,"Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.","['results', 'showed', 'progression', 'free', 'survival', 'was', '_num_', 'months', 'in', '_disease_', 'treatment', 'vs', '_num_', 'months', 'under', 'physician', ""'s"", 'choice', 'along', 'with', 'lower', 'incidence', 'of', 'grade', '_num_', 'or', 'worse', 'events', 'with', '_disease_']"
4162,0.0,A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome.,"['a', 'high', 'level', 'of', 'expression', 'of', 'the', '_gene_', 'proto', 'oncogene', 'in', 'a', 'neuroblastoma', 'is', 'strongly', 'predictive', 'of', 'a', 'favorable', 'outcome']"
4163,1.0,"Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.","['active', 'drugs', 'were', 'nivolumab', 'and', 'pembrolizumab', '_gene_', 'receptor', 'targeting', 'antibodies']"
4164,1.0,Median overall survival was 8.7 months with selumetinib + docetaxel and 7.9 months with placebo + docetaxel.,"['median', 'overall', 'survival', 'was', '_num_', 'months', 'with', '_chemical_', '_chemical_', 'and', '_num_', 'months', 'with', 'placebo', '_chemical_']"
4165,1.0,"Expression of 294 and 116 genes was enriched in good and poor prognosis subtypes, respectively.","['expression', 'of', '_num_', 'and', '_num_', 'genes', 'was', 'enriched', 'in', 'good', 'and', 'poor', 'prognosis', '_disease_', 'respectively']"
4166,1.0,"In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I744KIPVAI), on mutation in exon 20 (S768I), and 16 point mutations in exon 21 (L858R and E709H).","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'recurrent', 'lung', 'cancer', '_num_', 'individuals', 'had', '_gene_', 'mutation', 'including', '_num_', 'point', 'mutations', 'in', 'exon', '_num_', '_mutation_', 'and', '_abbrev_', '_num_', 'deletions', 'in', 'exon', '_num_', '_num_', 'insertions', 'in', 'exon', '_num_', '_abbrev_', 'on', 'mutation', 'in', 'exon', '_num_', '_mutation_', 'and', '_num_', 'point', 'mutations', 'in', 'exon', '_num_', '_mutation_', 'and', '_abbrev_']"
4167,1.0,No mutation of VHL was detected in other patients who did not meet clinical criteria.,"['no', 'mutation', 'of', '_gene_', 'was', 'detected', 'in', 'other', 'patients', 'who', 'did', 'not', 'meet', 'clinical', 'criteria']"
4168,1.0,"CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019).","['_gene_', 'expression', 'as', 'assessed', 'by', 'microarray', 'analysis', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'in', '_num_', 'cancer', 'cell', 'lines', '_gene_', '_num_', 'p', '_num_']"
4169,1.0,Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman.,"['adenocarcinoma', 'cells', 'were', 'detected', 'via', 'urinary', 'cytology', 'in', 'a', '_num_', 'year', 'old', 'woman']"
4170,1.0,This missense mutation was found in 2 family members with VHL type 1 phenotype (family ID 4480).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
4171,1.0,"OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate cancer cell lines.","['_chemical_', 'an', '_abbrev_', 'inhibitor', 'sensitizes', 'cell', 'lines', 'to', '_chemical_', 'and', '_chemical_', 'resulting', 'in', 'better', 'overall', 'survival', 'in', 'mouse', 'xenografts', 'of', 'patient', 'derived', 'chemotherapy', 'resistant', 'castration', 'resistant', 'prostate', 'cancer', 'cell', 'lines']"
4172,1.0,Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab.,"['patients', 'with', 'colorectal', 'cancer', 'who', 'harbor', '_gene_', 'mutation', 'have', 'low', 'response', 'rate', 'to', '_chemical_']"
4173,1.0,"Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation.","['of', 'these', '_num_', 'patients', 'had', 'variants', 'in', 'kit', 'and', '_num_', 'of', 'these', 'were', 'treated', 'with', '_chemical_', '_chemical_', 'at', '_num_', '_unit_', 'orally', 'twice', 'daily', 'with', '_num_', 'patients', 'eligible', 'for', 'response', 'evaluation']"
4174,0.0,Targeting ERBB3 and cMET could overcome resistance to trametinib.,"['targeting', '_gene_', 'and', '_gene_', 'could', 'overcome', 'resistance', 'to', '_chemical_']"
4175,1.0,The patients were therefore negative for LS.,"['the', 'patients', 'were', 'therefore', 'negative', 'for', 'ls']"
4176,1.0,"After 7 weeks of treatment, the patient relapsed and died.","['after', '_num_', 'weeks', 'of', 'treatment', 'the', 'patient', 'relapsed', 'and', 'died']"
4177,1.0,A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121).,"['a', 'patient', 'with', 'metastatic', 'colorectal', 'cancer', 'was', 'enrolled', 'in', 'a', 'phase', '_num_', 'clinical', 'trial', '_abbrev_']"
4178,1.0,The L1196M mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.,"['the', '_mutation_', 'mutation', 'in', 'the', '_chemical_', 'fusion', 'was', 'found', 'to', 'confer', 'resistance', 'to', '_chemical_', 'in', 'ba', '_abbrev_', 'cells']"
4179,1.0,NOTCH1 mutations were also found to be an independent poor predictor of survival regardless of TP53 and IGHV status.,"['_gene_', 'mutations', 'were', 'also', 'found', 'to', 'be', 'an', 'independent', 'poor', 'predictor', 'of', 'survival', 'regardless', 'of', '_gene_', 'and', '_gene_', 'status']"
4180,1.0,465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression.,"['_num_', 'gastric', 'cancer', 'samples', 'and', '_num_', 'corresponding', 'liver', 'metastases', 'underwent', '_gene_', 'for', '_abbrev_', 'protein', 'expression']"
4181,0.0,Ceritinib was given at 750 mg once daily but dose reduction to 600 mg once daily was required due to persistent nausea.,"['_chemical_', 'was', 'given', 'at', '_num_', '_unit_', 'once', 'daily', 'but', 'dose', 'reduction', 'to', '_num_', '_unit_', 'once', 'daily', 'was', 'required', 'due', 'to', 'persistent', 'nausea']"
4182,1.0,The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform.,"['the', '_gene_', 'mammary', 'tumor', 'mouse', 'model', 'mmtv', '_disease_', 'was', 'employed', 'to', 'demonstrate', 'dependence', 'of', '_gene_', 'tumor', 'formation', 'on', '_gene_', '_gene_', '_chemical_']"
4183,1.0,"EIF1AX mutations are associated with a good prognosis, and are inversely associated with metastasis.","['_gene_', 'mutations', 'are', 'associated', 'with', 'a', 'good', 'prognosis', 'and', 'are', 'inversely', 'associated', 'with', 'metastasis']"
4184,1.0,"From 14 prosatate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one had a biallelic inactivation of PALB2 (frameshift mutation and deletion).","['from', '_num_', 'prosatate', 'cancer', 'patients', '_num_', 'who', 'had', 'a', 'response', 'to', '_chemical_', '_num_', 'patients', 'had', '_gene_', 'loss', '_num_', 'with', 'biallelic', 'somatic', 'loss', 'and', '_num_', 'with', 'germline', 'mutations', '_num_', 'of', '_num_', 'with', 'had', 'atm', 'aberrations', 'and', '_num_', 'had', 'a', 'biallelic', 'inactivation', 'of', '_gene_', 'frameshift', 'mutation', 'and', 'deletion']"
4185,1.0,"Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas.","['adding', '_chemical_', 'to', '_chemical_', 'does', 'not', 'improve', 'overall', 'survival', 'os', 'progression', 'free', 'survival', '_disease_', 'overall', 'response', 'rate', 'orr', 'or', 'duration', 'of', 'response', '_gene_', 'in', 'patients', 'with', 'untreated', 'metastatic', 'adenocarcinoma', 'of', 'the', 'pancreas']"
4186,1.0,32/40 tumors harbored KRAS mutations including 4 G12C mutations where disease stabilization occurred in 3/4 treated with BEZ235 or doublet therapy and 2/4 treated with AZD6244 only.,"['_ratio_', 'tumors', 'harbored', '_gene_', 'mutations', 'including', '_num_', '_mutation_', 'mutations', 'where', 'disease', 'stabilization', 'occurred', 'in', '_ratio_', 'treated', 'with', '_chemical_', 'or', 'doublet', 'therapy', 'and', '_ratio_', 'treated', 'with', '_chemical_', 'only']"
4187,1.0,Treatment of the patient-derived 797 NMC cell line for 48 hours with JQ1 (500 nM)  provoked terminal differentiation which was accompanied by growth arrest and sustained inhibition of proliferation.,"['treatment', 'of', 'the', '_disease_', '_num_', '_disease_', 'cell', 'line', 'for', '_num_', 'hours', 'with', '_abbrev_', '_num_', '_unit_', 'provoked', 'terminal', 'differentiation', 'which', 'was', 'accompanied', 'by', 'growth', 'arrest', 'and', 'sustained', 'inhibition', 'of', 'proliferation']"
4188,1.0,More than 90% of well-differentiated or dedifferentiated liposarcomas (WD/DDLS) have CDK4 amplification.,"['more', 'than', '_num_', 'of', '_disease_', 'or', 'dedifferentiated', 'liposarcomas', 'wd', 'ddls', 'have', '_gene_', 'amplification']"
4189,1.0,"This missense mutation was found in 2 family members with VHL disease type 2A, who both had angiomas and cerebellar hemangioblastomas (family ID 3786).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'disease', 'type', '_gene_', 'who', 'both', 'had', 'angiomas', 'and', 'cerebellar', '_disease_', 'family', 'id', '_num_']"
4190,1.0,"Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup).","['_num_', 'patients', 'with', 'metastatic', 'lung', 'adenocarcinomas', 'bearing', 'mutations', 'in', 'the', 'kinase', 'domain', 'of', '_gene_', 'gene', 'were', 'identified', '_abbrev_', '_mutation_', 'and', '_abbrev_']"
4191,1.0,FL and FGF2 were the only proteins that increased viability >2 standard deviations.,"['fl', 'and', '_gene_', 'were', 'the', 'only', 'proteins', 'that', 'increased', 'viability', '_num_', 'standard', 'deviations']"
4192,1.0,Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift mutation at V317) was identified as unanimously present in all five tumors and a pre-treatment biopsy.,"['_num_', 'metastases', 'were', 'evaluated', 'using', 'whole', 'genome', 'sequencing', 'and', 'a', '_num_', '_gene_', 'deletion', 'in', '_gene_', 'frameshift', 'mutation', 'at', '_abbrev_', 'was', 'identified', 'as', 'unanimously', 'present', 'in', 'all', '_num_', 'tumors', 'and', 'a', '_gene_', 'treatment', 'biopsy']"
4193,1.0,"This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate.","['this', 'response', 'rate', 'of', '_num_', 'is', 'in', 'contrast', 'to', 'the', '_num_', 'response', 'rate', 'in', 'the', 'overall', 'patient', 'population', 'but', 'the', 'numbers', 'of', 'patients', 'with', 'specific', '_chemical_', 'breakpoints', 'were', 'insufficient', 'to', 'correlate', 'with', 'patient', 'response', 'rate']"
4194,1.0,"The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later.","['the', 'patient', 'attained', 'a', 'reduction', 'in', 'the', 'target', 'lesions', 'by', '_num_', 'however', 'the', 'patient', 'relapsed', '_num_', 'months', 'later']"
4195,1.0,All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.,"['all', '_num_', 'patients', 'with', '_gene_', 'loss', 'had', 'benefit', 'from', 'adding', '_chemical_', 'to', 'carboplatin+paclitaxel', 'therapy', 'in', 'a', 'phase', 'i', 'study', 'in', 'advanced', 'solid', 'cancers']"
4196,1.0,"DUX4 fusions were discovered in a subset of Ph- ALL tumors through RNA-seq, and their mutation profile was found to cluster with non-Ph like ALL.","['_gene_', 'fusions', 'were', 'discovered', 'in', 'a', 'subset', 'of', 'ph', '', 'all', 'tumors', 'through', 'rna', 'seq', 'and', 'their', 'mutation', 'profile', 'was', 'found', 'to', 'cluster', 'with', 'non', 'ph', 'like', 'all']"
4197,1.0,"In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.","['in', 'this', 'study', 'a', '_chemical_', 'sensitive', 'cell', 'line', '_chemical_', 'acquired', '_chemical_', 'resistance', '_chemical_', '_gene_', 'by', 'a', 'focal', 'amplification', 'of', 'met']"
4198,1.0,The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas.,"['the', 't', '_num_', '_num_', 'transloaction', 'of', '_gene_', 'is', 'shown', 'to', 'be', 'associated', 'with', 'germinal', 'center', 'b', 'cell–like', 'diffuse', 'large', 'b', 'cell', 'lymphomas']"
4199,1.0,ABCC3 amplification (and expression) in ERBB2 (HER2) amplified breast cancer cell lines was associated with resistance to paclitaxel and  MMAE.,"['_gene_', 'amplification', 'and', 'expression', 'in', '_gene_', '_gene_', 'amplified', 'breast', 'cancer', 'cell', 'lines', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'and', 'mmae']"
4200,1.0,"After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days.","['after', 'initiation', 'of', '_chemical_', 'pet', 'ct', 'and', 'bone', 'marrow', 'aspirates', 'showed', 'complete', 'remission', 'of', 'previous', 'lesions', 'at', '_num_', 'days']"
4201,1.0,"Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).","['additionally', 'patients', 'with', '_gene_', 'mutations', 'showed', 'no', 'significant', 'improvement', 'between', 'treatment', 'with', 'panitumumab', 'and', 'best', 'supportive', 'care', 'alone', '_disease_', '_num_', '_disease_', 'vs', '_num_', '_disease_']"
4202,1.0,The Q252H mutation was sensitive to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'sensitive', 'to', '_chemical_']"
4203,1.0,ACMG codes as follows: Protein length changes as a result of in-frame deletions in a nonrepeat region and stop-loss variant (PM4).,"['acmg', 'codes', 'as', 'follows', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'in', 'frame', 'deletions', 'in', 'a', 'nonrepeat', 'region', 'and', 'stop', 'loss', 'variant', '_abbrev_']"
4204,1.0,The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.,"['the', '_mutation_', 'mutation', 'in', 'the', '_chemical_', 'fusion', 'was', 'found', 'to', 'confer', 'resistance', 'to', '_chemical_', 'in', 'ba', '_abbrev_', 'cells']"
4205,1.0,Chemotherapy-refractory patients with colorectal cancer harboring NRAS mutation (primarily Q61) have a significantly lower response rate to cetuximab than patients wildtype for NRAS.,"['chemotherapy', 'refractory', 'patients', 'with', 'colorectal', 'cancer', 'harboring', 'nras', 'mutation', 'primarily', '_abbrev_', 'have', 'a', 'significantly', 'lower', 'response', 'rate', 'to', '_chemical_', 'than', 'patients', 'wildtype', 'for', 'nras']"
4206,1.0,Both were more highly expressed in patients not responding to sorafenib.,"['both', 'were', 'more', 'highly', 'expressed', 'in', 'patients', 'not', 'responding', 'to', '_chemical_']"
4207,1.0,42% of the tumors evaluated had at least one mutation in exon 2.,"['_num_', 'of', 'the', 'tumors', 'evaluated', 'had', 'at', 'least', '_num_', 'mutation', 'in', 'exon', '_num_']"
4208,1.0,All patients had L861Q mutation and were treated with the 1st generation TKI gefitinib.,"['all', 'patients', 'had', '_mutation_', 'mutation', 'and', 'were', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
4209,1.0,Analysis of TCGA RNA-seq data revealed an association between POLE mutations and high immune marker expression.,"['analysis', 'of', '_disease_', 'rna', 'seq', 'data', 'revealed', 'an', 'association', 'between', 'pole', 'mutations', 'and', 'high', 'immune', 'marker', 'expression']"
4210,1.0,Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of Follicular non-Hodgkin Lymphoma in 18 / 251 patient samples.,"['heterozygous', 'mutations', 'in', '_gene_', 'at', '_abbrev_', 'were', 'the', '_num_', 'most', 'frequent', 'genetic', 'event', 'after', '_gene_', 't', '_num_', '_num_', 'associated', 'with', 'a', 'diagnosis', 'of', 'follicular', '_disease_', 'lymphoma', 'in', '_num_', '_num_', 'patient', 'samples']"
4211,1.0,Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.,"['breast', 'and', 'prostate', 'cancer', 'cell', 'lines', 'responsive', 'to', '_chemical_', 'were', 'enriched', 'for', '_gene_', 'deficiency']"
4212,1.0,"6 patients with partial response or stable disease for ≥16 weeks, were defined as “responders” (R), 8 patients who had disease progression before 16 weeks were defined as “nonresponders” (NR).","['_num_', 'patients', 'with', 'partial', 'response', 'or', 'stable', 'disease', 'for', '_ineq_', 'weeks', 'were', 'defined', 'as', '“', 'responders', '”', 'r', '_num_', 'patients', 'who', 'had', 'disease', 'progression', 'before', '_num_', 'weeks', 'were', 'defined', 'as', '“', 'nonresponders', '”', '_gene_']"
4213,1.0,"Ten-year survival rates were 63% for CC, 40% for TC and 23% for TT genotypes, respectively.","['_num_', 'year', 'survival', 'rates', 'were', '_num_', 'for', 'cc', '_num_', 'for', 'tc', 'and', '_num_', 'for', 'tt', 'genotypes', 'respectively']"
4214,1.0,"In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib.","['in', '_abbrev_', 'cell', 'lines', 'retrovirally', 'transduced', 'with', 'wildtype', 'or', 'mutant', '_gene_', 'cells', 'expressing', 'the', 'in', 'frame', 'deletion', 'of', 'amino', 'acids', '_range_', 'were', 'shown', 'to', 'be', 'sensitive', 'to', '_chemical_']"
4215,1.0,"This finding was reproduced two NSCLC cell lines in a second, independent shRNA screen.","['this', 'finding', 'was', 'reproduced', '_num_', '_disease_', 'cell', 'lines', 'in', 'a', '_num_', 'independent', 'shrna', 'screen']"
4216,1.0,"Tumors caused by MET amplified EBC-1 cells injected into mice were significantly inhibited with crizotinib treatment, while tumors from non-MET amplified cells showed no substantial effect.","['tumors', 'caused', 'by', 'met', 'amplified', '_abbrev_', 'cells', 'injected', 'into', 'mice', 'were', 'significantly', 'inhibited', 'with', '_chemical_', 'treatment', 'while', 'tumors', 'from', 'non', 'met', 'amplified', 'cells', 'showed', 'no', 'substantial', 'effect']"
4217,1.0,Patients were a mix of those having undergone gastrectomy and not.,"['patients', 'were', 'a', 'mix', 'of', 'those', 'having', 'undergone', 'gastrectomy', 'and', 'not']"
4218,1.0,"Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy.","['randomized', 'international', '_disease_', 'phase', '_num_', 'trial', '_abbrev_', 'in', '_num_', 'patients', 'with', '_abbrev_', 'advanced', '_disease_', 'and', 'disease', 'progression', 'after', '_num_', 'line', '_gene_', 'therapy']"
4219,1.0,Further improvements after a couple of months suggested a rapid complete response.,"['further', 'improvements', 'after', 'a', 'couple', 'of', 'months', 'suggested', 'a', 'rapid', 'complete', 'response']"
4220,1.0,"Immunohistochemistry (IHC) showed that FGF13 was detectable in the majority of human PCa samples, and FGF13 IHC scores were higher in high-grade prostatic intraepithelial neoplasia, in primary PCa, and in metastatic PCa than in benign prostatic tissue.","['immunohistochemistry', '_gene_', 'showed', 'that', '_gene_', 'was', 'detectable', 'in', 'the', 'majority', 'of', 'human', '_disease_', 'samples', 'and', '_gene_', '_gene_', 'scores', 'were', 'higher', 'in', 'high', 'grade', 'prostatic', 'intraepithelial', 'neoplasia', 'in', 'primary', '_disease_', 'and', 'in', 'metastatic', '_disease_', 'than', 'in', 'benign', 'prostatic', 'tissue']"
4221,1.0,Mutation also found in 3 family members with VHL type 1 phenotype (family ID 3575).,"['mutation', 'also', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
4222,1.0,KRAS G12 mutations were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma.,"['_gene_', '_gene_', 'mutations', 'were', 'the', 'primary', 'predictor', 'of', '_gene_', '_disease_', 'resistance', 'in', 'patients', 'with', 'lung', 'adenocarcinoma']"
4223,1.0,CNS disease) were randomized to reiceive either Alectinib or Crizotinib.,"['cns', 'disease', 'were', 'randomized', 'to', 'reiceive', 'either', '_chemical_', 'or', '_chemical_']"
4224,1.0,"In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS.","['in', 'this', 'prospective', 'study', 'in', '_num_', 'patients', 'of', 'whom', '_num_', 'were', 'treated', 'with', 'different', '_gene_', 'inhibitors', '_chemical_', '_chemical_', '_chemical_', '_gene_', 'mutations', 'and', 'a', 'higher', 'relative', 'expression', 'of', '_gene_', 'in', 'comparison', 'to', 'met', 'expression', 'were', 'correlated', 'with', 'longer', '_disease_']"
4225,1.0,No further testing was done.,"['no', 'further', 'testing', 'was', 'done']"
4226,1.0,"Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08).","['increased', 'expression', 'of', 'tumor', 'endothelial', 'markers', '_gene_', 'and', '_gene_', 'nonsignificantly', 'correlated', 'with', 'prolonged', 'antiangiogenic', 'time', 'to', 'progression', '_gene_', 'high', '_num_', 'days', 'vs', '_gene_', 'low', '_num_', 'days', 'p', '_num_', 'and', 'for', '_gene_', 'high', '_num_', 'days', 'vs', '_gene_', 'low', '_num_', 'days', 'p', '_num_']"
4227,1.0,"In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56).","['in', 'normal', 'karyotype', 'patients', 'with', '_disease_', '_range_', 'years', 'old', 'complete', 'remission', 'rates', 'and', 'overall', 'event', 'free', 'and', 'relapse', 'free', 'survival', 'were', 'not', 'different', 'for', 'patients', 'harboring', '_gene_', 'exon', '_num_', 'mutations', '_ineq_', 'than', 'those', 'wildtype', 'for', '_gene_', '_ineq_']"
4228,1.0,Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib or erlotinib.,"['both', 'patients', 'were', 'found', 'to', 'have', '_mutation_', 'mutation', 'and', 'were', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_', 'or', '_chemical_']"
4229,1.0,"When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed ""extreme"" imatinib resistance.","['when', 'co', 'expressed', 'with', '_mutation_', '_chemical_', 'sensitive', 'in', 'vitro', '_mutation_', 'showed', 'extreme', '_chemical_', 'resistance']"
4230,1.0,Only the patients with low RRM1 expression received a significant benefit from gemcitabine (p=0.0010) whereas the benefit for those with a high RRM1 expression was not significantly better (p=0.3309).,"['only', 'the', 'patients', 'with', 'low', '_gene_', 'expression', 'received', 'a', 'significant', 'benefit', 'from', '_chemical_', '_p_val_', 'whereas', 'the', 'benefit', 'for', 'those', 'with', 'a', 'high', '_gene_', 'expression', 'was', 'not', 'significantly', 'better', '_p_val_']"
4231,1.0,COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild type or A1065T-mutant KDR.,"['_abbrev_', 'cells', 'were', 'transiently', 'transfected', 'with', 'expression', 'constructs', 'encoding', 'cdnas', 'for', 'wild', 'type', 'or', '_abbrev_', '_gene_']"
4232,1.0,A panel of 16 mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding.,"['a', 'panel', 'of', '_num_', 'mutations', 'seen', 'in', '_chemical_', '_gene_', 'patents', 'were', 'used', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'drug', 'binding']"
4233,1.0,Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655.,"['phase', 'i', 'expansion', 'and', 'pharmacodynamic', 'study', 'of', 'the', 'oral', 'mek', 'inhibitor', '_abbrev_']"
4234,1.0,"Among patients that had UMUCS but not G719 or L861, the response rate to tyrosine kinase inhibitors erlotinib or gefitinib, progression free survival, and overall survival were 20%, 1.6 month and 11.1 months, which was similar for wild type EGFR (16.5%, 2.0 months and 10.4 months), which contrasted to higher response for more commonly occurring G719 and L861 mutations (53.3% and 60.0%, respectively).","['among', 'patients', 'that', 'had', 'umucs', 'but', 'not', '_abbrev_', 'or', '_abbrev_', 'the', 'response', 'rate', 'to', 'tyrosine', 'kinase', 'inhibitors', '_chemical_', 'or', '_chemical_', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'were', '_num_', '_num_', 'month', 'and', '_num_', 'months', 'which', 'was', 'similar', 'for', 'wild', 'type', '_gene_', '_num_', '_num_', 'months', 'and', '_num_', 'months', 'which', 'contrasted', 'to', 'higher', 'response', 'for', 'more', 'commonly', 'occurring', '_abbrev_', 'and', '_abbrev_', 'mutations', '_num_', 'and', '_num_', 'respectively']"
4235,1.0,Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.,"['cells', 'with', '_gene_', 'deficiency', 'have', 'been', 'shown', 'to', 'exhibit', 'slowed', 'growth', 'in', 'reponse', 'to', '_abbrev_', 'inhibitors']"
4236,1.0,"This frameshift mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family of 5 patients.","['this', 'frameshift', 'mutation', 'affecting', 'residue', 'within', 'the', '_gene_', 'protein', 'core', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'patients']"
4237,1.0,"The primary tumor was HR positive; however, the metastatic tumor was HR negative.","['the', 'primary', 'tumor', 'was', 'hr', 'positive', 'however', 'the', 'metastatic', 'tumor', 'was', 'hr', 'negative']"
4238,1.0,A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels.,"['a', '_disease_', 'resistant', 'derivative', 'of', 'ovarian', 'cancer', 'cell', 'line', '_abbrev_', 'was', 'generated', 'by', 'long', 'term', 'passage', 'with', 'increasing', '_disease_', 'levels']"
4239,1.0,"Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients).","['overall', 'survival', 'and', 'remission', 'duration', 'were', 'significantly', 'longer', '_p_val_', 'and', '_p_val_', 'respectively', 'in', 'younger', '_range_', 'cytogenetically', 'normal', 'acute', 'myeloid', 'leukemia', 'patients', 'with', '_gene_', 'mutations', '_ratio_', 'patients']"
4240,1.0,Chemical inhibition (MEK inhibition with either CI-1040 or GSK1120212) or shRNA knockdown of MAPK1 resensitized cells to EGFR inhibition with WZ4002 in-vitro.,"['chemical', 'inhibition', 'mek', 'inhibition', 'with', 'either', '_chemical_', 'or', '_chemical_', 'or', 'shrna', 'knockdown', 'of', '_gene_', 'resensitized', 'cells', 'to', '_gene_', 'inhibition', 'with', '_chemical_', 'in', 'vitro']"
4241,1.0,"In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia.","['in', '_num_', 'patients', 'with', 'mostly', 'renal', 'cell', 'carcinoma', 'and', 'some', 'gastrointestinal', 'stromal', 'tumors', 'given', '_chemical_', 'treatment', '_gene_', '_abbrev_', '_mutation_', 'was', 'associated', 'with', 'the', 'development', 'of', 'leukopenia']"
4242,1.0,"This missense mutation was found in four VHL type 2 families of 51 individuals altogether (family IDs 2338, 3490, 4477, 4405).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'of', '_num_', 'individuals', 'altogether', 'family', 'ids', '_num_', '_num_', '_num_', '_num_']"
4243,0.0,"To identify biomarkers that can predict response to AV-203, the relationship between tumor growth inhibition (TGI) by AV-203 and the expression levels of ERBB3 and NRG1 were evaluated in these tumor models.","['_gene_', 'identify', '_chemical_', 'that', 'can', 'predict', 'response', 'to', '_abbrev_', 'the', 'relationship', 'between', 'tumor', 'growth', 'inhibition', '_disease_', 'by', '_abbrev_', 'and', 'the', 'expression', 'levels', 'of', '_gene_', 'and', '_gene_', 'were', 'evaluated', 'in', 'these', 'tumor', 'models']"
4244,0.0,we conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.,"['we', 'conclude', 'that', '_chemical_', 'should', 'be', 'a', 'standard', 'option', 'for', '_gene_', 'positive', 'advanced', 'gastric', 'cancer']"
4245,1.0,Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers.,"['mutations', 'in', '_gene_', 'were', 'identified', 'in', '_ratio_', 'er', 'positive', 'vs', '_ratio_', 'er', 'negative', 'breast', 'cancers']"
4246,1.0,Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors.,"['phase', '_num_', 'study', 'of', 'pan', 'fgfr', 'inhibitor', '_abbrev_', 'in', 'patients', 'with', 'solid', 'tumors']"
4247,1.0,This cell line showed overexpression of AKT and no expression of PTEN.,"['this', 'cell', 'line', 'showed', 'overexpression', 'of', '_gene_', 'and', 'no', 'expression', 'of', '_gene_']"
4248,1.0,Restaging scans after two cycles showed a partial response confirmed after four cycles (56% decrease) per RECIST1.1.,"['restaging', 'scans', 'after', '_num_', 'cycles', 'showed', 'a', 'partial', 'response', 'confirmed', 'after', '_num_', 'cycles', '_num_', 'decrease', 'per', '_abbrev_']"
4249,1.0,"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'metastatic', 'colorectal', 'patients', '_gene_', 'mutations', 'were', 'observed', 'in', '_num_', 'of', 'the', 'tumor', 'samples']"
4250,1.0,"Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-609G > C) GG genotype (HRPFS 6.2, 95%CI = 2.01, 19.41, P = 0.002; HROS 9.6, 95%CI = 1.89, 48.54, P = 0.006).","['resistance', 'to', '_chemical_', 'containing', 'treatment', 'was', 'limited', 'to', 'patients', 'with', 'a', '_gene_', '_mutation_', 'c', '', '_unit_', 'c', '_disease_', 'genotype', 'hrpfs', '_num_', '_num_', 'ci', '_num_', '_num_', 'p', '_num_', '_disease_', '_num_', '_num_', 'ci', '_num_', '_num_', 'p', '_num_']"
4251,1.0,One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673.,"['_num_', 'endometrial', 'cell', 'line', 'with', 'decreased', '_gene_', 'expression', 'caused', 'by', 'a', 'homozygous', '_chemical_', 't', 'mutation', 'exhibited', 'increased', 'sensitivity', 'to', 'the', '_gene_', 'inhibitor', '_chemical_']"
4252,0.0,we investigated whether phosphorylated EGFR could be a potential predictive biomarker in patients with wild type EGFR.,"['we', 'investigated', 'whether', 'phosphorylated', '_gene_', 'could', 'be', 'a', 'potential', 'predictive', '_chemical_', 'in', 'patients', 'with', 'wild', 'type', '_gene_']"
4253,1.0,The I1171T ALK kinase domain mutation was found in this cell line (established after alectinib resistance).,"['the', '_mutation_', '_gene_', 'kinase', 'domain', 'mutation', 'was', 'found', 'in', 'this', 'cell', 'line', 'established', 'after', '_chemical_', 'resistance']"
4254,1.0,"Trastuzumab emtansine has its indication for patients with HER2-positive metastatic breast cancer after therapy with Trastuzumab and Taxane, approval based on PFS and preliminary OS data.","['_chemical_', '_chemical_', 'has', 'its', 'indication', 'for', 'patients', 'with', '_gene_', 'metastatic', 'breast', 'cancer', 'after', 'therapy', 'with', '_chemical_', 'and', '_chemical_', 'approval', 'based', 'on', '_disease_', 'and', 'preliminary', 'os', 'data']"
4255,1.0,"Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.","['except', 'for', 'the', '_chemical_', 'resistant', '_mutation_', 'mutation', 'all', 'the', 'other', 'mutations', 'were', 'sensitive', 'to', 'both', '_chemical_', 'and', '_chemical_']"
4256,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'reduced', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
4257,1.0,KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR.,"['_gene_', 'variant', '_num_', 'was', 'found', 'to', 'be', 'expressed', 'in', 'the', 'cdna', 'of', 'tumor', 'tissues', 'from', 'a', 'large', 'cohort', 'of', '_gene_', 'patients', 'of', 'chinese', 'descent', 'via', '_disease_']"
4258,1.0,This mutation causes a premature stop codon at amino acid 131 and was found in a VHL type 2A patient (patient no V69).,"['this', 'mutation', 'causes', 'a', 'premature', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_abbrev_']"
4259,1.0,All lung metastases decreased in size within 3 months of lapatinib mono therapy initiation.,"['all', 'lung', 'metastases', 'decreased', 'in', 'size', 'within', '_num_', 'months', 'of', '_chemical_', 'mono', 'therapy', 'initiation']"
4260,1.0,"WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML.","['_gene_', 'mutations', 'were', 'associated', 'with', 'an', 'inferior', 'response', 'to', 'induction', 'chemotherapy', 'with', 'a', 'higher', 'rate', 'of', 'resistant', 'disease', 'in', 'young', '_num_', '60+', 'median', '_num_', 'patients', 'with', 'cytogenetically', 'normal', '_disease_']"
4261,1.0,"PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells.","['_gene_', 'positivity', 'in', 'tumor', 'cells', 'was', 'defined', 'by', 'at', 'least', '_num_', 'tumor', 'cells', 'with', 'membranous', 'positivity', '_gene_', 'positivity', 'in', 'immune', 'cells', 'by', 'at', 'least', '_num_', '_gene_', 'positive', 'immune', 'cells']"
4262,1.0,Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1).,"['baseline', 'biopsies', 'were', 'obtained', 'before', 'therapy', 'initiation', 'with', 'pembrolizumab', 'before', 'prior', '_chemical_', 'treatment', 'in', 'patient', '_num_']"
4263,1.0,"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring mutations in KRAS, NRAS, BRAF, or PIK3CA and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization.","['in', '_num_', 'out', 'of', '_num_', '_num_', 'metastatic', 'colorectal', 'cancer', 'tumors', 'harboring', 'mutations', 'in', '_gene_', 'nras', '_gene_', 'or', '_gene_', 'and', 'implanted', 'into', 'mice', 'the', 'therapeutic', 'combination', 'of', 'the', 'mek', 'inhibitor', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'disease', 'stabilization']"
4264,0.0,"Mutations in IDH1 or IDH2 are identified in approximately 20% of patients with AML.This study report the discovery and characterization of AG-221, orally available, selective, potent inhibitor of the mutant IDH2 enzyme.","['mutations', 'in', '_gene_', 'or', '_gene_', 'are', 'identified', 'in', 'approximately', '_num_', 'of', 'patients', 'with', '_disease_', 'this', 'study', 'report', 'the', 'discovery', 'and', 'characterization', 'of', '_abbrev_', 'orally', 'available', 'selective', 'potent', 'inhibitor', 'of', 'the', 'mutant', '_gene_', 'enzyme']"
4265,1.0,A prior phase 2 study demonstrated that treatment with palbociclib (200 mg/d for 14 days every 21 days) resulted in clinical benefit in WD/DDLS but moderate hematologic toxic effects.,"['a', 'prior', 'phase', '_num_', 'study', 'demonstrated', 'that', 'treatment', 'with', '_chemical_', '_num_', '_chemical_', 'for', '_num_', 'days', 'every', '_num_', 'days', 'resulted', 'in', 'clinical', 'benefit', 'in', 'wd', 'ddls', 'but', 'moderate', 'hematologic', 'toxic', 'effects']"
4266,1.0,"In the background of the NPM-ALK fusion, IC50 for G1269A mutation was 104 nM, which was 5.3 fold that reported for NPM-ALK wild type.","['in', 'the', 'background', 'of', 'the', '_chemical_', 'fusion', '_abbrev_', 'for', '_mutation_', 'mutation', 'was', '_num_', '_unit_', 'which', 'was', '_num_', 'fold', 'that', 'reported', 'for', '_chemical_', 'wild', 'type']"
4267,1.0,"Objective response rates favored panitumumab over BSC; after a 12-month minimum follow-up, response rates were 10% for panitumumab and 0% for BSC (P < .0001).","['objective', 'response', 'rates', 'favored', 'panitumumab', 'over', '_gene_', 'after', 'a', '_num_', 'month', 'minimum', 'follow', 'up', 'response', 'rates', 'were', '_num_', 'for', 'panitumumab', 'and', '_num_', 'for', '_gene_', 'p', '_num_']"
4268,1.0,The patient was therefore negative for LS.,"['the', 'patient', 'was', 'therefore', 'negative', 'for', 'ls']"
4269,1.0,Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC.,"['minimal', 'anti', 'tumor', 'activity', 'was', 'observed', 'in', '_gene_', 'mutant', 'refractory', 'metastatic', '_gene_']"
4270,1.0,EGFR expression had no impact on PFS or OS.,"['_gene_', 'expression', 'had', 'no', 'impact', 'on', '_disease_', 'or', 'os']"
4271,1.0,Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector.,"['transfection', 'of', 'the', 'colorectal', 'cancer', 'cell', 'line', '_chemical_', 'with', 'a', '_gene_', '_mutation_', 'expression', 'vector', 'conferred', 'decreased', 'sensitivity', 'to', '_chemical_', 'and', 'panitumumab', 'in', 'comparison', 'to', 'cells', 'transfected', 'with', 'empty', 'vector']"
4272,1.0,Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease.,"['_chemical_', 'treatment', 'resulted', 'in', 'necrosis', 'and', 'shrinkage', 'of', 'the', 'primary', 'and', 'metastatic', 'sites', 'and', 'overall', 'stable', 'disease']"
4273,1.0,In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).,"['in', 'a', 'randomized', 'trial', 'of', 'previously', 'untreated', 'younger', '_num_', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'excluding', 'acute', 'promyelocytic', 'leukemia', 'and', 'high', 'risk', '_disease_', 'syndrome', '_gene_', 'mutation', 'status', 'had', 'no', 'significant', 'impact', 'on', 'patient', 'response', 'to', '_disease_', '_ineq_', 'compared', 'to', 'randomized', 'control', '_ineq_']"
4274,1.0,"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537N ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.","['using', 'an', 'estrogen', 'response', 'element', '_disease_', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_mutation_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_chemical_', 'cell', 'lines']"
4275,1.0,"In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival.","['in', '_disease_', 'patients', 'younger', 'than', '_num_', 'years', 'at', 'age', 'of', 'diagnosis', '_gene_', '_gene_', 'promoter', 'hypermethylation', 'is', 'associated', 'with', 'shorter', 'time', 'to', 'recurrence', 'and', 'shorter', 'overall', 'survival']"
4276,1.0,"Meta-analysis of 25 studies involving 13,629 women with tamoxifen treated breast cancer.","['_disease_', 'analysis', 'of', '_num_', 'studies', 'involving', '_num_', 'women', 'with', 'tamoxifen', 'treated', 'breast', 'cancer']"
4277,1.0,"The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039).","['the', 'disease', 'control', 'rate', 'of', 'patients', 'with', '_gene_', '_mutation_', 'cc', 'genotype', 'was', 'lower', 'than', 'that', 'of', 'patients', 'with', 'variant', 'genotype', 'tt', 'or', 'ct', '_num_', 'vs', '_num_', '_p_val_']"
4278,1.0,"Two of 19 melanomas examined harbored KIT mutations, with one subject harboring mutation at D820Y.","['_num_', 'of', '_num_', 'melanomas', 'examined', 'harbored', 'kit', 'mutations', 'with', '_num_', 'subject', 'harboring', 'mutation', 'at', '_mutation_']"
4279,1.0,"Of the complete responders, 24% had an ERBB2 missense mutations and no non-responders had ERBB2 mutations (p=0.003).","['of', 'the', 'complete', 'responders', '_num_', 'had', 'an', '_gene_', 'missense', 'mutations', 'and', 'no', 'non', 'responders', 'had', '_gene_', 'mutations', '_p_val_']"
4280,1.0,Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition.,"['preclinical', 'evidence', 'in', 'vitro', 'for', 'predictive', 'value', 'of', '_gene_', 'mrna', 'and', 'protein', 'expression', 'as', 'well', 'as', 'mrna', 'expression', 'of', '_gene_', 'and', '_gene_', 'for', 'sensitivity', 'to', '_gene_', 'inhibition']"
4281,1.0,Non-BRD4-dependent cell lines including a squamous carcinoma cell line (TE10) failed to exhibit differentiation effects when treated with JQ1.,"['_abbrev_', 'cell', 'lines', 'including', 'a', '_disease_', 'carcinoma', 'cell', 'line', '_abbrev_', 'failed', 'to', 'exhibit', 'differentiation', 'effects', 'when', 'treated', 'with', '_abbrev_']"
4282,1.0,This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF.,"['this', '_disease_', 'analysis', 'of', '_num_', 'randomized', 'control', 'trials', 'evaluating', 'overall', 'survival', 'os', '_num_', 'for', 'progression', 'free', 'survival', 'could', 'not', 'definitely', 'state', 'that', 'survival', 'benefit', 'of', 'anti', '_gene_', 'monoclonal', 'antibodies', 'is', 'limited', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
4283,1.0,66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.,"['_num_', 'of', 'the', '_num_', 'patients', 'with', '_num_', 'common', 'activating', '_gene_', 'mutations', 'deletion', '_num_', 'or', '_mutation_', 'had', 'an', 'objective', 'response', 'compared', 'to', '_num_', 'of', '_num_', 'patients', 'with', 'less', 'common', 'mutations']"
4284,1.0,"In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds ratios above one (3.5 and 2.2, respectively) after adjusting for age and HPV infection.","['in', 'a', 'relatively', 'small', '_disease_', 'analysis', 'of', '_num_', 'women', 'with', 'cervical', 'cancer', 'and', '_num_', 'controls', 'associations', 'with', 'homozygosity', 'for', 'arginine', 'and', 'heterozygosity', 'at', 'this', 'locus', 'were', 'both', 'associated', 'with', 'odds', 'ratios', 'above', '_num_', '_num_', 'and', '_num_', 'respectively', 'after', 'adjusting', 'for', 'age', 'and', '_disease_', 'infection']"
4285,1.0,Differences were significant with p < 0.0001.,"['differences', 'were', 'significant', 'with', 'p', '_num_']"
4286,1.0,"Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after.","['_chemical_', 'was', 'then', 'administered', 'at', '_num_', '_unit_', 'twice', 'daily', 'and', '_gene_', 'levels', 'rapidly', 'dropped', 'along', 'with', 'disappearance', 'of', 'palpable', 'lymphadenopathy', 'but', 'progression', 'ensued', 'after', '_num_', 'days', 'and', 'the', 'patient', 'died', 'soon', 'after']"
4287,1.0,"At 12 months, no patients had reduction in tumor volume >20%, however, five patients had stable disease with a reduction in annual growth rate from 67% growth/year to 0.5% growth/year.","['at', '_num_', 'months', 'no', 'patients', 'had', 'reduction', 'in', 'tumor', 'volume', '_num_', 'however', '_num_', 'patients', 'had', 'stable', 'disease', 'with', 'a', 'reduction', 'in', 'annual', 'growth', 'rate', 'from', '_num_', 'growth', 'year', 'to', '_num_', 'growth', 'year']"
4288,1.0,The site of mutation is reported to potentially be important for DDX41 helicase activity.,"['the', 'site', 'of', 'mutation', 'is', 'reported', 'to', 'potentially', 'be', 'important', 'for', '_gene_', '_gene_', 'activity']"
4289,1.0,In autochthonous mouse melanoma models active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy.,"['in', 'autochthonous', 'mouse', 'melanoma', 'models', 'active', '_gene_', 'signalling', 'results', 'in', '_disease_', 'exclusion', 'and', 'resistance', 'to', 'anti', 'pd', '_gene_', 'anti', 'ctla', '_num_', 'monoclonal', 'antibody', 'therapy']"
4290,1.0,"ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis.","['_gene_', 'expression', 'as', 'evaluated', 'by', '_gene_', 'in', '_num_', 'patients', 'was', 'associated', 'with', 'better', '_disease_', 'survival', 'hr', '_num_', 'p', '_num_', 'and', 'cancer', 'specific', 'survival', 'hr', '_num_', 'p', '_num_', 'on', 'multivariable', 'analysis']"
4291,0.0,"In summary, this evidence suggests that FBXW7 may be a biomarker for cancers sensitivity to inhibitors of the mTOR pathway.","['in', 'summary', 'this', 'evidence', 'suggests', 'that', '_gene_', 'may', 'be', 'a', '_chemical_', 'for', 'cancers', 'sensitivity', 'to', 'inhibitors', 'of', 'the', '_gene_', 'pathway']"
4292,1.0,"In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'prostate', 'cancer', '_num_', 'had', 'germline', '_gene_', 'mutations', '_num_', 'had', 'germline', '_gene_', 'mutations', 'and', '_num_', 'were', '_disease_']"
4293,1.0,This may have been driven by patients with exon1-2 mutations (N=15; P=0.021 for OS; P=0.024 for PFS) versus those with exon 3-7 mutations (N=31; P=0.16 for OS; P=0.24 for PFS) when compared to wildtype patients.,"['this', 'may', 'have', 'been', 'driven', 'by', 'patients', 'with', '_abbrev_', 'mutations', '_ineq_', '_p_val_', 'for', 'os', '_p_val_', 'for', '_disease_', 'vs', 'those', 'with', 'exon', '_chemical_', 'mutations', '_ineq_', '_p_val_', 'for', 'os', '_p_val_', 'for', '_disease_', 'when', 'compared', 'to', 'wildtype', 'patients']"
4294,1.0,Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation.,"['phase', '_num_', 'trial', 'in', '_num_', 'patients', 'with', 'previously', 'treated', 'metastatic', 'melanoma', 'with', '_gene_', '_mutation_', 'mutation']"
4295,1.0,The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day).,"['the', 'patient', 'with', '_mutation_', 'case', '_num_', 'in', 'the', 'paper', 'achieved', 'a', 'partial', 'response', 'after', '_num_', 'months', 'of', '_chemical_', '_num_', '_disease_']"
4296,1.0,"The proband died at 2 years due to a fatal chylothorax, having been seen at 1 year with progressive dyspnoea and displaying extensive lymphatic and venus malformations that displaced the right lung, as well as osteolytic lesions of the bones.","['the', 'proband', 'died', 'at', '_num_', 'years', 'due', 'to', 'a', 'fatal', '_disease_', 'having', 'been', 'seen', 'at', '_num_', 'year', 'with', 'progressive', 'dyspnoea', 'and', 'displaying', 'extensive', 'lymphatic', 'and', 'venus', 'malformations', 'that', 'displaced', 'the', 'right', 'lung', 'as', 'well', 'as', '_disease_', 'lesions', 'of', 'the', 'bones']"
4297,1.0,Two weeks post radiation she developed nodules in the same region and testing indicated they were malignant melanoma with high KIT expression.,"['_num_', 'weeks', 'post', 'radiation', 'she', 'developed', 'nodules', 'in', 'the', 'same', 'region', 'and', 'testing', 'indicated', 'they', 'were', 'malignant', 'melanoma', 'with', 'high', 'kit', 'expression']"
4298,1.0,"Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions.","['of', 'the', '_num_', 'patients', 'with', 'lung', 'cancers', '_num_', 'showed', 'nras', 'mutations', 'which', 'corresponded', 'to', '_num_', 'different', 'amino', 'acid', 'substitutions']"
4299,1.0,"Knockdown of MTAP in one cell line increased sensitivity to inhibitors of de novo adenine synthesis (5-FU, AZA and MTX), mainly 5-FU.","['knockdown', 'of', '_gene_', 'in', '_num_', 'cell', 'line', 'increased', 'sensitivity', 'to', 'inhibitors', 'of', 'de', 'novo', 'adenine', 'synthesis', '_chemical_', '_gene_', 'and', '_gene_', 'mainly', '_chemical_']"
4300,1.0,AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence.,"['_gene_', '_mutation_', 'mutations', 'are', '_disease_', 'and', 'occur', 'in', 'many', 'cancers', 'at', 'a', 'low', 'prevalence']"
4301,1.0,"In this study, KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib.","['in', 'this', 'study', '_gene_', 'was', 'neither', 'prognostic', 'nor', 'predictive', 'of', 'benefit', 'for', 'either', '_chemical_', 'or', '_chemical_']"
4302,1.0,"IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.","['_chemical_', 'treatment', 'caused', 'regression', 'of', '_abbrev_', 'tumors', 'in', 'nude', 'mice', 'whereas', '_gene_', 'inhibitors', 'usually', 'only', 'cause', 'growth', 'inhibition', 'in', 'these', 'models']"
4303,1.0,we examine a prevailing hypothesis that individuals carrying a reduced function CYP2D6 allele have poorer outcomes due to less metabolism of tamoxifen to active metabolites.,"['we', 'examine', 'a', 'prevailing', 'hypothesis', 'that', 'individuals', 'carrying', 'a', 'reduced', 'function', '_gene_', 'allele', 'have', 'poorer', 'outcomes', 'due', 'to', 'less', 'metabolism', 'of', 'tamoxifen', 'to', 'active', 'metabolites']"
4304,1.0,This missense mutation was found in a VHL type 1 family of four individuals (family ID 4917).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_']"
4305,1.0,The FLT3 D835 mutation positive patients were treated with sunitinib after failure of standard chemotherapy.,"['the', '_gene_', '_abbrev_', 'mutation', 'positive', 'patients', 'were', 'treated', 'with', '_chemical_', 'after', 'failure', 'of', 'standard', 'chemotherapy']"
4306,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
4307,1.0,All AR mutations were exclusive to mCRPC neoplasms and were not found in primary prostate cancer.,"['all', 'ar', 'mutations', 'were', 'exclusive', 'to', '_disease_', 'neoplasms', 'and', 'were', 'not', 'found', 'in', 'primary', 'prostate', 'cancer']"
4308,1.0,"Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.","['longer', 'progression', 'free', 'survival', 'was', 'observed', 'in', '_gene_', 'positive', 'carriers', 'vs', '_gene_', 'negative', 'carriers', 'in', 'both', 'the', '_chemical_', 'arm', 'and', 'the', 'placebo', 'arm', 'however', 'due', 'to', 'small', 'sample', 'size', 'the', '_disease_', 'increase', 'in', 'the', '_chemical_', 'arm', 'was', 'not', 'statistically', 'significant']"
4309,1.0,"In contrast, two ER negative cell lines lacking detectable Rb were fully resistant to palbociclib.","['in', 'contrast', '_num_', 'er', 'negative', 'cell', 'lines', 'lacking', 'detectable', 'rb', 'were', 'fully', 'resistant', 'to', '_chemical_']"
4310,1.0,"These findings are not statistically significant, but we suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions.","['these', 'findings', 'are', 'not', 'statistically', 'significant', 'but', 'we', 'suggest', 'that', 'alemtuzumab', 'is', 'an', 'effective', 'therapy', 'for', 'patients', 'with', '_gene_', 'mutations', 'or', 'deletions']"
4311,1.0,347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed.,"['_num_', 'patients', 'with', 'disease', 'progression', 'after', '_num_', 'round', 'of', 'platinum', 'based', 'chemotherapy', 'were', 'randomized', 'to', 'receive', '_chemical_', '_ineq_', 'or', 'chemotherapy', '_ineq_', 'consisting', 'of', '_chemical_', 'in', '_chemical_', 'naive', 'patients', 'and', '_chemical_', 'for', 'patients', 'previously', 'treated', 'with', '_chemical_']"
4312,1.0,The study did not indicate the specific fusion detected but from related studies we know that the majority of these fusions are SYT-SSX1 (aka SS18-SSX1).,"['the', 'study', 'did', 'not', 'indicate', 'the', 'specific', 'fusion', 'detected', 'but', 'from', 'related', 'studies', 'we', 'know', 'that', 'the', 'majority', 'of', 'these', 'fusions', 'are', '_abbrev_', 'aka', '_abbrev_']"
4313,1.0,53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry.,"['_num_', 'patients', 'with', 'a', '_chemical_', 'confirmed', '_gene_', 'mutation', 'and', 'a', 'pancreatic', 'neuroendocrine', 'tumor', 'were', 'collected', 'from', 'the', 'german', 'net', 'registry', 'and', 'the', 'german', '_gene_', 'registry']"
4314,1.0,"One patient had progressive disease as response, with PFS of 2.8 months, OS of 10.7 months, and was not alive at study end.","['_num_', 'patient', 'had', 'progressive', 'disease', 'as', 'response', 'with', '_disease_', 'of', '_num_', 'months', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
4315,1.0,"LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.","['lncap', 'fgc', 'cells', 'with', 'mutations', 'at', 'codon', '_num_', '_abbrev_', '_mutation_', 'were', 'able', 'to', 'use', '_chemical_', 'as', 'an', 'ar', 'agonist', 'promoting', 'cell', 'growth', 'and', 'increased', '_disease_', 'antigen', 'secretion']"
4316,1.0,"Missense mutation detected in a VHL type 1 patient (Family ID 3509 in publication) with angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.","['missense', 'mutation', 'detected', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'family', 'id', '_num_', 'in', 'publication', 'with', 'angiomas', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
4317,1.0,Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.,"['_gene_', '_gene_', 'overexpression', 'is', 'associated', 'with', 'the', 'increased', 'depth', 'of', 'cancer', 'invasion', 'in', 'gastric', 'cancers']"
4318,1.0,Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3.,"['patients', 'with', '_gene_', 'mutation', 'and', '_gene_', 'had', 'reduced', 'event', 'free', 'survival', 'compared', 'to', 'patients', 'with', 'wildtype', '_gene_']"
4319,1.0,"3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.","['3a', 'and', '_chemical_', 'showed', 'strong', 'in', 'vitro', 'kinase', 'activity', 'transformed', 'mouse', '3t3', 'cells', 'and', '_chemical_', 'transformed', '3t3', 'cells', 'formed', 'tumors', 'in', '_ratio_', 'nude', 'mice']"
4320,1.0,"In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162.","['in', 'a', 'panel', 'of', '_num_', 'nras', 'mutant', 'melanoma', 'cell', 'lines', 'all', '_num_', 'were', 'found', 'to', 'be', 'sensitive', 'to', 'the', 'mek', 'inhibitor', '_chemical_', 'whereas', '_num_', 'of', '_num_', 'melanoma', 'cell', 'lines', 'that', 'were', 'wild', 'type', 'for', '_gene_', 'and', 'nras', 'were', 'not', 'sensitive', 'to', '_chemical_']"
4321,0.0,Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.,"['expression', 'of', 'the', '_abbrev_', 'fusion', 'kinase', 'in', '_chemical_', 'cells', 'demonstrated', 'transforming', 'ability', 'that', 'was', 'effectively', 'suppressed', 'with', 'the', 'fibroblast', 'growth', 'factor', 'receptor', '_gene_', 'kinase', 'inhibitors', '_chemical_', 'and', '_chemical_']"
4322,1.0,Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).,"['lentiviral', 'transduction', 'of', '_gene_', '_mutation_', 'mutation', 'into', 'head', 'and', 'neck', 'cancer', 'cell', 'line', '_gene_', 'led', 'to', 'increased', 'sensitivity', 'to', '_abbrev_', 'inhibition', 'with', '_chemical_', 'compared', 'to', 'unmanipulated', 'cells', '_abbrev_', 'values', '_num_', '_unit_', 'and', '_num_', '_unit_']"
4323,1.0,One identified with angiomas.,"['_num_', 'identified', 'with', 'angiomas']"
4324,1.0,"Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK.","['patients', 'had', 'received', '_num_', 'or', 'more', 'rounds', 'of', 'previous', 'chemotherapy', 'but', 'no', 'prior', 'targeted', 'therapy', 'towards', '_gene_']"
4325,1.0,"One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing.","['_num_', 'patient', 'with', 'low', 'grade', 'serous', 'ovarian', 'cancer', 'had', 'an', 'in', 'frame', 'fusion', 'between', 'the', '_gene_', 'kinase', 'domain', 'and', '_gene_', 'identified', 'by', 'panel', 'sequencing', '_gene_', 'impact', 'with', 'expression', 'confirmed', 'by', '_disease_', 'sequencing']"
4326,1.0,"Also of note, in RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic response rather than a cytotoxic response.","['also', 'of', 'note', 'in', 'raf', 'ras', 'mutant', 'colon', 'cancer', 'cell', 'lines', 'co', 'occurring', '_abbrev_', 'mutations', 'led', 'to', 'a', '_chemical_', 'response', 'rather', 'than', 'a', 'cytotoxic', 'response']"
4327,1.0,Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T  which had a significantly lower risk of developing pancreatic cancer compared with the wild type CC genotype.,"['results', 'indicated', 'a', 'lower', 'risk', 'for', 'the', 'heterozygous', 'ct', 'genotype', 'and', 'homozygous', 'tt', 'genotype', 'carriers', 'of', '_gene_', 'c', '677c', 't', 'which', 'had', 'a', 'significantly', 'lower', 'risk', 'of', 'developing', 'pancreatic', 'cancer', 'compared', 'with', 'the', 'wild', 'type', 'cc', 'genotype']"
4328,1.0,NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.,"['_gene_', 'mutations', 'were', 'associated', 'with', '_abbrev_', 'and', '_abbrev_', 'fab', '_disease_', 'of', 'acute', 'myeloid', 'leukemia']"
4329,1.0,Four family members had retinal angiomas and 3 had hemangioblastomas of the central nervous system.,"['_num_', 'family', 'members', 'had', 'retinal', 'angiomas', 'and', '_num_', 'had', '_disease_', 'of', 'the', 'central', 'nervous', 'system']"
4330,1.0,This missense mutation was found in 14 VHL type 1 family members (patient no V8).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'family', 'members', 'patient', 'no', '_abbrev_']"
4331,1.0,Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib.,"['case', 'report', 'of', 'a', 'patient', 'with', 'stage', 'iva', '_disease_', 'with', 'near', 'complete', 'histologic', 'response', 'after', '_num_', 'days', 'of', 'neoadjuvant', '_chemical_']"
4332,1.0,"Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice.","['study', 'reporting', 'an', 'in', 'vivo', '_disease_', '_disease_', 'model', 'testing', 'the', 'hypothesis', 'that', '_gene_', 'deficiency', 'would', 'reduce', 'lung', 'tumor', 'promotion', 'in', 'mice']"
4333,1.0,An overall of 4 (6 by modified RECIST) patients achieved PR.,"['an', 'overall', 'of', '_num_', '_num_', 'by', 'modified', '_disease_', 'patients', 'achieved', 'pr']"
4334,0.0,HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.,"['_gene_', 'expression', 'in', 'uterine', 'serous', 'papillary', 'carcinoma', '_disease_', 'is', 'thought', 'to', 'be', 'associated', 'with', 'poor', 'prognosis', 'and', 'may', 'act', 'as', 'a', 'targetable', 'driver', 'mutation', 'in', 'this', 'cancer']"
4335,1.0,High-level FGFR2-amplified (arbitrarily defined as FISH-ratio > 5) cancers had a higher likelihood of response and were associated with a substantially higher expression of both FGFR2 mRNA and FGFR2 protein (IHC).,"['high', 'level', '_abbrev_', 'arbitrarily', 'defined', 'as', 'fish', 'ratio', '_num_', 'cancers', 'had', 'a', 'higher', 'likelihood', 'of', 'response', 'and', 'were', 'associated', 'with', 'a', 'substantially', 'higher', 'expression', 'of', 'both', '_gene_', 'mrna', 'and', '_gene_', 'protein', '_gene_']"
4336,1.0,"In MEK-resistant NRAS mutant melanoma cell lines, TBK1 depletion or inhibition (AZ909) in combination with MEK inhibitors (selumetinib) promoted apoptosis in 3D culture.","['in', 'mek', 'resistant', 'nras', 'mutant', 'melanoma', 'cell', 'lines', '_gene_', 'depletion', 'or', 'inhibition', '_abbrev_', 'in', 'combination', 'with', 'mek', 'inhibitors', '_chemical_', 'promoted', 'apoptosis', 'in', '3d', 'culture']"
4337,1.0,Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547.,"['_num_', 'patients', 'with', '_abbrev_', 'gastroesophageal', 'cancer', 'were', 'treated', 'with', '_chemical_']"
4338,1.0,Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies.,"['expression', 'of', '_gene_', '_gene_', 'was', 'assessed', 'in', '_num_', 'colorectal', 'cancers', 'from', '_num_', 'prospective', 'cohort', 'studies']"
4339,1.0,"In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'metastatic', 'castration', 'resistant', 'prostate', 'cancer', '_disease_', '_num_', 'of', 'cases', '_ineq_', 'harbored', 'androgen', 'receptor', 'ar', 'pathway', 'aberrations']"
4340,1.0,A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.,"['a', 'participant', 'in', 'children', ""'s"", 'oncology', 'group', 'cog', 'study', '_abbrev_', 'with', 'measurable', 'neuroblastoma', 'mutated', 'at', '_gene_', '_mutation_', 'was', 'administered', '_chemical_', 'at', '_unit_', 'twice', 'daily']"
4341,1.0,"At 25 nmol/L of crizotinib, only the migration of G-protein mutant cells lines and not G-protein wild type cell lines was decreased.","['at', '_num_', '_unit_', '_unit_', 'of', '_chemical_', 'only', 'the', 'migration', 'of', '_gene_', 'mutant', 'cells', 'lines', 'and', 'not', '_gene_', 'wild', 'type', 'cell', 'lines', 'was', 'decreased']"
4342,1.0,"Ph- ALL (Philadelphia chromosome negative acute lymphoblastic leukemia) gene expression profiles cluster into two main groups, Ph like and non-Ph like ALL.","['ph', '', 'all', 'philadelphia', 'chromosome', 'negative', 'acute', '_disease_', 'leukemia', 'gene', 'expression', 'profiles', 'cluster', 'into', '_num_', 'main', 'groups', 'ph', 'like', 'and', 'non', 'ph', 'like', 'all']"
4343,1.0,This finding was confirmed in a second independent data set of 23 melanoma patients with 6/8 (75%) of HLA-DR(+) tumours in comparison to 4/15 (27%) HLA-DR(−) responding (Fisher’s exact test P=0.025).,"['this', 'finding', 'was', 'confirmed', 'in', 'a', '_num_', 'independent', 'data', 'set', 'of', '_num_', 'melanoma', 'patients', 'with', '_ratio_', '_num_', 'of', '_chemical_', 'tumours', 'in', 'comparison', 'to', '_ratio_', '_num_', '_chemical_', '−', 'responding', 'fisher', '’', 's', 'exact', 'test', '_p_val_']"
4344,1.0,Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia.,"['mutations', 'in', 'the', '_gene_', 'domain', 'of', '_gene_', 'in', 'the', '_disease_', 'fusion', 'have', 'been', 'shown', 'to', 'be', 'associated', 'with', 'resistance', 'to', 'standard', '_disease_', 'treatment', 'in', 'patients', 'with', 'acute', 'promyelocytic', 'leukemia']"
4345,1.0,IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck.,"['_gene_', 'for', 'expression', 'of', '_gene_', 'and', '_gene_', 'was', 'performed', 'in', '_num_', 'patients', 'with', '_disease_', 'cell', 'carcinoma', 'of', 'the', 'head', 'and', 'neck']"
4346,1.0,81 patients were enrolled in the trial and treated with dovitinib.,"['_num_', 'patients', 'were', 'enrolled', 'in', 'the', 'trial', 'and', 'treated', 'with', '_chemical_']"
4347,1.0,Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline).,"['sequencing', '_gene_', 'impact', 'panel', 'was', 'performed', 'on', 'the', 'patients', 'tumor', 'and', 'germline', 'and', 'identified', 'a', '_num_', '_gene_', 'in', 'frame', 'deletion', 'of', '_gene_', '_num_', 'of', 'tumor', 'reads', 'but', '_num_', 'in', 'germline']"
4348,1.0,"In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone.","['in', 'a', 'mouse', 'model', 'of', '_gene_', '_mutation_', 'colorectal', 'cancer', 'western', 'blots', 'from', 'tumors', 'in', 'mice', 'treated', 'with', '_gene_', 'inhibitor', '_chemical_', 'and', '_abbrev_', 'inhibitor', '_chemical_', 'showed', 'stronger', 'reduction', 'in', '_chemical_', 'and', '_gene_', 'than', '_abbrev_', 'inhibitor', 'alone', 'and', 'combination', 'inhibition', 'also', 'resulted', 'in', 'stronger', '_gene_', 'inhibition', 'in', 'tumors', 'than', 'did', '_gene_', 'inhibition', 'alone']"
4349,1.0,This was not found for cytoplasmic expression.,"['this', 'was', 'not', 'found', 'for', 'cytoplasmic', 'expression']"
4350,0.0,A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used).,"['a', 'lung', 'lesion', 'sample', 'with', 'sufficient', 'material', 'for', 'molecular', 'profiling', 'was', 'not', 'attainable', 'but', 'sufficient', 'material', 'was', 'present', 'from', 'the', 'rue', 'for', 'hybrid', 'capture', 'genomic', 'profiling', 'foundationone', 'kit', 'was', 'used']"
4351,1.0,"In patients with myeloma, those with mutations in TP53 had worse overall survival than those without.","['in', 'patients', 'with', 'myeloma', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'worse', 'overall', 'survival', 'than', 'those', 'without']"
4352,1.0,Inceased copy number of CCND1 is associated with poorer overall survival.,"['inceased', 'copy', 'number', 'of', '_gene_', 'is', 'associated', 'with', 'poorer', 'overall', 'survival']"
4353,1.0,"The researchers transfected 293T cells with SETBP1 G870S, a variant found to be associated with poor prognosis in aCML, and found those cells had higher proliferation and higher expression of SET and SETBP1 proteins.","['the', 'researchers', 'transfected', '_chemical_', 'cells', 'with', '_gene_', '_mutation_', 'a', 'variant', 'found', 'to', 'be', 'associated', 'with', 'poor', 'prognosis', 'in', '_disease_', 'and', 'found', 'those', 'cells', 'had', 'higher', 'proliferation', 'and', 'higher', 'expression', 'of', 'set', 'and', '_gene_', 'proteins']"
4354,1.0,This mutation causes an early stop codon at amino acid 133 and was found in a VHL patient with cerebellar hemangioblastomas.,"['this', 'mutation', 'causes', 'an', 'early', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'patient', 'with', 'cerebellar', '_disease_']"
4355,1.0,33 patients were retrospectively analyzed for Stathmin expression by IHC.,"['_num_', 'patients', 'were', 'retrospectively', 'analyzed', 'for', '_gene_', 'expression', 'by', '_gene_']"
4356,1.0,In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines.,"['in', 'vitro', 'study', 'with', '_disease_', 'and', '_gene_', 'pancreatic', 'cancer', 'cell', 'lines']"
4357,1.0,"In nine patients a decrease in size of metastases was seen, and in four cases a complete resolution of brain lesions was observed.","['in', '_num_', 'patients', 'a', 'decrease', 'in', 'size', 'of', 'metastases', 'was', 'seen', 'and', 'in', '_num_', 'cases', 'a', 'complete', 'resolution', 'of', 'brain', 'lesions', 'was', 'observed']"
4358,0.0,"Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF).","['neither', 'of', 'these', '_num_', 'tumors', 'harbored', 'known', 'mutations', 'in', 'other', 'genes', 'encoding', 'components', 'of', 'the', '_gene_', 'signaling', 'pathway', '_disease_', '_gene_', '_gene_', '_gene_', '_gene_', 'and', '_gene_']"
4359,1.0,991 patients were enrolled.,"['_num_', 'patients', 'were', 'enrolled']"
4360,1.0,None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.,"['none', 'of', 'the', '_num_', 'lesions', 'mimicking', '_disease_', 'tumors', 'analyzed', 'harbored', 'any', '_gene_', 'mutations']"
4361,1.0,The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs.,"['the', 'mutation', 'was', 'shown', 'to', 'occur', 'at', 'a', 'hotspot', '_abbrev_', 'of', 'previously', 'reported', 'secondary', 'kit', 'mutations', 'in', '_chemical_', 'resistant', 'gists']"
4362,1.0,Two of the mutations were at ALK C1156Y.,"['_num_', 'of', 'the', 'mutations', 'were', 'at', '_gene_', '_mutation_']"
4363,1.0,This was true when restricted to patients with an adenocarcinoma subtype only (n=18 vs 12; 4.1 vs 9 weeks; P = 0.007; HR=3.1).,"['this', 'was', 'true', 'when', 'restricted', 'to', 'patients', 'with', 'an', 'adenocarcinoma', 'subtype', 'only', '_ineq_', 'vs', '_num_', '_num_', 'vs', '_num_', 'weeks', 'p', '_num_', '_ineq_']"
4364,1.0,Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models.,"['sustained', 'tumor', 'regression', 'was', 'observed', 'in', '_gene_', 'mutant', 'tumor', 'xenograft', 'and', 'transgenic', 'models']"
4365,1.0,28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo).,"['_num_', 'patients', 'with', '_gene_', 'amplification', 'did', 'not', 'show', 'a', 'benefit', 'from', 'adjuvant', 'tamoxifen', 'compared', 'to', 'placebo', '_num_', 'treated', 'vs', '_num_', 'placebo']"
4366,1.0,"This effect was specific for KRAS G12C as 12/12 cell lines with other KRAS mutations (including other G12 mutations V, D and A) were not inhibited in either soft-agar assay.","['this', 'effect', 'was', 'specific', 'for', '_gene_', '_mutation_', 'as', '_ratio_', 'cell', 'lines', 'with', 'other', '_gene_', 'mutations', 'including', 'other', '_gene_', 'mutations', 'v', 'd', 'and', 'a', 'were', 'not', 'inhibited', 'in', 'either', 'soft', 'agar', 'assay']"
4367,1.0,There were no cell lines with only CDKN2B deletion.,"['there', 'were', 'no', 'cell', 'lines', 'with', 'only', '_gene_', 'deletion']"
4368,1.0,"The first patient (M, 62, nonsmoker) was treated with gefitinib and had progressive disease, progression free survival (PFS) of 1.0 months, overall survival (OS) of 7.7 months and was not alive at study end.","['the', '_num_', 'patient', '_unit_', '_num_', 'nonsmoker', 'was', 'treated', 'with', '_chemical_', 'and', 'had', 'progressive', 'disease', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
4369,1.0,This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 3101).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
4370,1.0,CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib.,"['cns', 'metastases', 'in', '_num_', 'patients', 'which', 'had', 'not', 'received', 'prior', 'brain', 'irradiation', 'showed', 'response', 'to', '_chemical_']"
4371,1.0,ATRX loss was also associated with greater microsatellite instability.,"['_gene_', 'loss', 'was', 'also', 'associated', 'with', 'greater', '_disease_', 'instability']"
4372,1.0,"Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib.","['among', 'these', '_num_', 'patients', 'stable', 'disease', 'sd', 'was', 'observed', 'in', '_num_', 'and', 'progressive', 'disease', 'pd', 'was', 'observed', 'in', '_num_', 'others', 'after', 'administration', 'of', '_chemical_']"
4373,1.0,Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.,"['elevated', 'levels', 'of', '_gene_', 'mrna', 'has', 'been', 'shown', 'to', 'be', 'correlated', 'with', 'advanced', 'stage', 'gastric', 'carcinoma']"
4374,1.0,Three independently derived EVSA-T cell lines overexpressing ABCC3 were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values.,"['_num_', 'independently', 'derived', '_disease_', 'cell', 'lines', 'overexpressing', '_gene_', 'were', 'at', 'least', '_n_fold_', 'less', 'sensitive', 'to', '_chemical_', 'and', 'mmae', 'based', 'on', '_abbrev_', 'values']"
4375,1.0,Proportions of 5-year metastasis-free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers.,"['proportions', 'of', '_num_', 'year', 'metastasis', 'free', 'intervals', 'were', '_num_', 'for', 'tt', 'genotypes', 'and', '_num_', 'for', 'c', 'allele', 'carriers']"
4376,1.0,Six studies (total of 633 patients) were included.,"['_num_', 'studies', 'total', 'of', '_num_', 'patients', 'were', 'included']"
4377,1.0,7 patients responded to treatment while 19 progressed rapidly.,"['_num_', 'patients', 'responded', 'to', 'treatment', 'while', '_num_', 'progressed', 'rapidly']"
4378,1.0,"These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28–0.65), P<0.0001 for OS.","['these', 'results', 'were', 'confirmed', 'using', 'multivariate', 'analyses', '_abbrev_', 'status', 'hazard', 'ratio', 'hr', '_num_', 'confidence', 'interval', '_num_', '28–0', '_num_', 'p', '_num_', 'for', 'os']"
4379,0.0,Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.,"['expression', 'of', 'the', '_abbrev_', 'fusion', 'kinase', 'in', '_chemical_', 'cells', 'demonstrated', 'transforming', 'ability', 'that', 'was', 'effectively', 'suppressed', 'with', 'the', 'fibroblast', 'growth', 'factor', 'receptor', '_gene_', 'kinase', 'inhibitors', '_chemical_', 'and', '_chemical_']"
4380,1.0,"In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative).","['in', 'the', 'concurrent', 'regimen', 'cohort', '_num_', 'of', 'patients', 'showed', 'clinical', 'activity', 'with', 'no', 'correlation', 'between', '_gene_', 'expression', 'and', 'response', '_num_', 'of', '_num_', 'patients', 'were', '_gene_', 'positive', 'vs', '_num_', 'of', '_num_', 'patients', 'were', '_gene_', 'negative']"
4381,1.0,"Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more).","['durable', 'antitumor', 'activity', 'was', 'only', 'observed', 'in', '_gene_', 'mutation', 'carriers', '_num_', '_gene_', 'carriers', 'had', 'ovarian', 'breast', 'or', 'prostate', 'cancers', '_num_', 'of', 'these', '_num_', 'had', 'a', 'clinical', 'benefit', 'from', 'treatment', 'with', '_chemical_', 'radiologic', 'or', 'tumor', 'marker', 'responses', 'or', 'meaningful', 'disease', 'stabilization', 'stable', 'disease', 'for', 'a', 'period', 'of', '_num_', 'months', 'or', 'more']"
4382,1.0,"In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival.","['in', 'patients', 'with', '_gene_', '_chemical_', 'and', '_abbrev_', 'mutation', 'the', 'presence', 'of', 'mutation', 'does', 'not', 'impact', 'overall', 'survival', 'or', 'disease', 'free', 'survival']"
4383,1.0,"In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'progressive', 'non', 'small', 'cell', 'lung', 'cancer', 'during', '_chemical_', 'or', '_chemical_', 'therapy', 'comparison', 'of', 'dna', 'sequences', 'from', 'the', 'original', 'diagnostic', 'biopsy', 'specimen', 'and', 'the', '_num_', 'biopsy', 'specimen', 'demonstrated', 'that', '_num_', 'patients', 'acquired', 'a', 'new', '_disease_', 'mutation']"
4384,1.0,Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%).,"['sequencing', 'of', 'sequential', 'samples', 'of', 'this', 'patient', 'revealed', 'a', 'novel', '_gene_', '_abbrev_', 'mutation', 'at', 'relapse', 'allele', 'frequency', 'of', '_num_']"
4385,1.0,De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.,"['de', 'novo', '_disease_', 'patients', 'with', '_gene_', '_abbrev_', 'mutation', 'showed', 'worse', 'survival', 'event', 'free', 'and', 'overall', 'outcome', 'than', 'those', 'without', '_gene_', 'mutation']"
4386,1.0,"Patients with the GSTP1 I105V variant had greater response to FOLFOX-4 treatment, longer progression-free survival, and longer overall survival.","['patients', 'with', 'the', '_gene_', '_mutation_', 'variant', 'had', 'greater', 'response', 'to', '_chemical_', 'treatment', 'longer', 'progression', 'free', 'survival', 'and', 'longer', 'overall', 'survival']"
4387,1.0,There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.,"['there', 'is', 'no', 'difference', 'in', 'the', 'complete', 'remission', 'rate', 'of', 'de', 'novo', '_disease_', 'patients', 'with', '_gene_', 'mutation', 'compared', 'to', 'those', 'who', 'are', 'wild', 'type', 'for', '_gene_']"
4388,1.0,"In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.335–1.024], two-sided log-rank, P = 0.058) but did not reach significance.","['in', 'exon', '_num_', 'mutated', 'patients', '_ineq_', 'and', '_num_', '_disease_', 'was', 'better', 'for', '_chemical_', 'treated', 'patients', 'hr', 'of', '_num_', '_num_', 'ci', '_num_', '335–1', '_num_', '_num_', 'sided', 'log', 'rank', 'p', '_num_', 'but', 'did', 'not', 'reach', 'significance']"
4389,1.0,"In a Phase II trial for the treatment of GIST patients with imatinib, patients with Exon 11 Kit mutations (N=85) had significantly better event-free and overall survival than patients with Exon 9 Kit mutations (N=23) or no Kit mutations (N=9).","['in', 'a', 'phase', 'ii', 'trial', 'for', 'the', 'treatment', 'of', 'gist', 'patients', 'with', '_chemical_', 'patients', 'with', 'exon', '_num_', 'kit', 'mutations', '_ineq_', 'had', 'significantly', 'better', 'event', 'free', 'and', 'overall', 'survival', 'than', 'patients', 'with', 'exon', '_num_', 'kit', 'mutations', '_ineq_', 'or', 'no', 'kit', 'mutations', '_chemical_']"
4390,1.0,NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma.,"['_gene_', 'was', 'identified', 'in', 'an', 'unbiased', '_gene_', 'screen', 'as', 'mediator', 'of', 'resistance', 'to', '_gene_', 'inhibition', 'in', '_gene_', 'mutant', 'melanoma']"
4391,1.0,"Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition.","['_num_', '_gene_', 'mutant', 'breast', 'cancer', 'cell', 'lines', 'were', 'rendered', 'resistant', 'to', '_gene_', 'inhibitors', '_chemical_', 'or', '_chemical_', 'and', 'a', 'panel', 'of', '_num_', 'inhibitor', 'compounds', 'was', 'tested', 'on', 'the', 'cells', 'for', 'ability', 'to', 'resensitize', 'the', 'cells', 'to', '_gene_', 'inhibition']"
4392,1.0,"However, only 54% of the study group had evaluation of 1p/19q status, and MGMT protein expression was studied in only 33%.","['however', 'only', '_num_', 'of', 'the', 'study', 'group', 'had', 'evaluation', 'of', '1p', '19q', 'status', 'and', '_gene_', 'protein', 'expression', 'was', 'studied', 'in', 'only', '_num_']"
4393,1.0,"we attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL.","['we', 'attribute', 'the', 'short', 'response', 'to', '_chemical_', 'to', 'the', 'possibility', 'of', 'this', 'tumor', 'having', 'an', '_gene_', 'fusion', 'variant', 'less', 'responsive', 'to', '_gene_', 'inhibition', 'and', 'to', 'a', 'high', '_gene_', 'index', 'in', 'the', 'patient', 'and', 'deem', 'that', 'despite', 'the', 'brief', 'response', '_chemical_', 'shows', 'promise', 'in', '_gene_', 'rearranged', '_disease_']"
4394,1.0,Livin (BIRC7) overexpression in two colon cancer cell lines (RKO and SW620) increased resistance of these cells to cisplatin.,"['_gene_', '_gene_', 'overexpression', 'in', '_num_', 'colon', 'cancer', 'cell', 'lines', '_disease_', 'and', '_abbrev_', 'increased', 'resistance', 'of', 'these', 'cells', 'to', '_disease_']"
4395,1.0,The same mechanism could be reproduced in a cell line (H3122) without EML1-ALK mutation and resistance to crizotinib that was acquired in-vitro.,"['the', 'same', 'mechanism', 'could', 'be', 'reproduced', 'in', 'a', 'cell', 'line', '_abbrev_', 'without', '_abbrev_', 'mutation', 'and', 'resistance', 'to', '_chemical_', 'that', 'was', 'acquired', 'in', 'vitro']"
4396,1.0,"HR of 1.84 (P=0.02) and 1.44 (P=0.01), respectively.","['hr', 'of', '_num_', '_p_val_', 'and', '_num_', '_p_val_', 'respectively']"
4397,1.0,One of 3 members carried angiomas and 2 carried cerebellar hemangioblastomas.,"['_num_', 'of', '_num_', 'members', 'carried', 'angiomas', 'and', '_num_', 'carried', 'cerebellar', '_disease_']"
4398,1.0,Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation.,"['_chemical_', 'treatment', 'of', '_abbrev_', 'cells', 'confirmed', 'retained', 'sensitivity', 'to', 'mek', 'inhibition', 'and', 'inhibition', 'of', 'colony', 'formation']"
4399,1.0,Progression then occurred and biopsy of a pleural nodule was performed with hybrid-capture NGS.,"['progression', 'then', 'occurred', 'and', 'biopsy', 'of', 'a', 'pleural', 'nodule', 'was', 'performed', 'with', 'hybrid', 'capture', 'ngs']"
4400,1.0,Protein length changes as a result of in-frame insertion in a nonrepeat region (ACMG code: PM4).,"['protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'in', 'frame', 'insertion', 'in', 'a', 'nonrepeat', 'region', 'acmg', 'code', '_abbrev_']"
4401,1.0,This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus.,"['this', 'pattern', 'of', '_gene_', 'positive', 'cell', 'sensitivity', 'was', 'not', 'reported', 'with', 'the', '_gene_', 'analog', '_gene_', 'inhibitor', '_chemical_']"
4402,1.0,"Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival (N=74, P = .001), relapse-free survival (N=86, P < .001) and response to induction chemotherapy.","['younger', '_range_', 'normal', 'karyotype', '_disease_', 'patients', 'with', 'exon', '_num_', '_gene_', 'mutation', 'and', 'without', '_gene_', 'have', 'increased', 'overall', 'survival', '_ineq_', 'p', '_num_', 'relapse', 'free', 'survival', '_ineq_', 'p', '_num_', 'and', 'response', 'to', 'induction', 'chemotherapy']"
4403,1.0,"PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells.","['_gene_', 'mutant', '_mutation_', 'was', 'overexpressed', 'in', 'the', '_chemical_', 'sensitive', '_gene_', '_abbrev_', 'breast', 'cancer', 'cell', 'line', 'and', 'significant', 'resistance', 'to', '_chemical_', 'was', 'induced', 'in', 'comparison', 'to', 'control', 'cells']"
4404,1.0,Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed.,"['paired', '_gene_', 'treatment', 'and', 'post', 'progression', 'tumor', 'biopsies', 'from', '_gene_', 'mutant', '_gene_', 'patients', 'treated', 'with', 'raf', 'inhibitor', 'combinations', 'were', 'analyzed']"
4405,1.0,"A total of 18 patients (12%) in the alectinib group had an event of CNS progression, compared to 68 patients (45%) in the crizotinib group.","['a', 'total', 'of', '_num_', 'patients', '_num_', 'in', 'the', '_chemical_', 'group', 'had', 'an', 'event', 'of', 'cns', 'progression', 'compared', 'to', '_num_', 'patients', '_num_', 'in', 'the', '_chemical_', 'group']"
4406,1.0,This mutation causes stop codon at amino acid 131 and was found in a VHL type 1 family (lineage 13).,"['this', 'mutation', 'causes', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
4407,1.0,3 patients achieved PRs and 3 patients had SD.,"['_num_', 'patients', 'achieved', 'prs', 'and', '_num_', 'patients', 'had', 'sd']"
4408,1.0,A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation.,"['a', 'ratio', 'of', '_num_', '_gene_', 'wildtype', 'level', 'was', 'associated', 'with', 'reduced', 'event', 'free', 'and', 'overall', 'survival', 'in', 'old', '_num_', 'and', 'younger', 'patients', '_num_', 'with', 'an', '_gene_', 'mutation']"
4409,1.0,"In the randomized UK LRF CCL4 phase 3 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, univariate analysis of patients with NOTCH1 mutations (within amino acids 2405-2525, a 399bp region of the PEST domain) demonstrated poorer overall survival (54.8 vs 74.6 months, P=0.02) and progression free survival (22 vs 26.4 months, P=0.02) compared to patients with wild type NOTCH1.","['in', 'the', 'randomized', 'uk', '_gene_', '_gene_', 'phase', '_num_', 'trial', 'comparing', '_num_', 'line', 'treatment', 'with', 'chlorambucil', '_chemical_', 'or', '_chemical_', 'plus', '_chemical_', 'univariate', 'analysis', 'of', 'patients', 'with', '_gene_', 'mutations', 'within', 'amino', 'acids', '_range_', 'a', '399bp', 'region', 'of', 'the', 'pest', 'domain', 'demonstrated', 'poorer', 'overall', 'survival', '_num_', 'vs', '_num_', 'months', '_p_val_', 'and', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', '_p_val_', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']"
4410,1.0,Described as being in the non-conserved portion of the VHL coding region where mutations are not typically seen according to these we.,"['described', 'as', 'being', 'in', 'the', 'non', 'conserved', 'portion', 'of', 'the', '_gene_', 'coding', 'region', 'where', 'mutations', 'are', 'not', 'typically', 'seen', 'according', 'to', 'these', 'we']"
4411,1.0,"After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019).","['after', 'a', 'median', 'follow', 'up', 'of', '_num_', 'months', 'range', '_range_', 'months', 'median', 'progression', 'free', 'survival', '_disease_', 'was', 'significantly', 'different', 'according', 'to', '_gene_', 'status', '_num_', 'months', 'in', 'patients', 'with', '_gene_', 'amplification', 'compared', 'with', '_num_', 'months', 'in', 'those', 'with', 'non', 'amplified', '_gene_', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
4412,1.0,"An ASXL1 mutation, especially in conjunction with DNMT3A and EZH2 mutations, results in a fourfold increase in resistance to treatment with ruxolitinib and a reduced time to treatment discontinuation (TTD) for patients with myelofibrosis.","['an', '_gene_', 'mutation', 'especially', 'in', 'conjunction', 'with', '_gene_', 'and', '_gene_', 'mutations', 'results', 'in', 'a', 'fourfold', 'increase', 'in', 'resistance', 'to', 'treatment', 'with', '_chemical_', 'and', 'a', 'reduced', 'time', 'to', 'treatment', 'discontinuation', '_gene_', 'for', 'patients', 'with', 'myelofibrosis']"
4413,1.0,"Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment.","['of', '_num_', 'patients', 'prospectively', 'accrued', 'with', '_disease_', 'syndrome', '_num_', 'had', 'favorable', 'responses', 'to', '_chemical_', 'that', 'lasted', '_num_', 'months', 'post', 'treatment']"
4414,1.0,"NRAS mutations were in 4/40 tumors (three Q61K, one G12D).","['nras', 'mutations', 'were', 'in', '_ratio_', 'tumors', '_num_', '_mutation_', '_num_', '_mutation_']"
4415,1.0,Only supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4).,"['only', 'supporting', 'evidence', 'for', 'pathogenicity', 'because', 'the', 'patient', ""'s"", 'phenotype', 'is', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'a', 'single', 'genetic', 'etiology', 'acmg', 'code', '_gene_']"
4416,1.0,Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus or rapamycin) than two wild type cell lines.,"['_num_', '_gene_', '_gene_', 'mutant', 'cell', 'lines', 'had', 'higher', 'basal', 'levels', 'of', '_gene_', 'activity', '_gene_', 'and', '_abbrev_', 'levels', 'but', 'were', 'not', 'more', 'sensitive', 'to', '_gene_', 'inhibitors', '_chemical_', 'or', '_gene_', 'than', '_num_', 'wild', 'type', 'cell', 'lines']"
4417,1.0,"At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively.","['at', '_num_', 'year', 'follow', 'up', '_num_', 'vs', '_num_', '_disease_', 'survival', 'events', 'had', 'occurred', 'and', '_disease_', 'survival', 'rates', 'were', '_num_', 'vs', '_num_', 'significant', 'in', '_chemical_', 'vs', 'placebo', 'groups', 'respectively']"
4418,1.0,"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated clonal NOTCH1 mutations (N=55) were significantly associated with reduced overall survival (HR: 1.5; 95%CI: 1.13-1.99; P = 0.0049).","['in', 'a', 'study', 'of', '_num_', 'previously', 'untreated', '_disease_', 'cases', 'a', 'multivariate', 'analysis', 'indicated', 'clonal', '_gene_', 'mutations', '_ineq_', 'were', 'significantly', 'associated', 'with', 'reduced', 'overall', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
4419,1.0,8 were T790M-positive prior to treatment with osimertinib.,"['_num_', 'were', '_abbrev_', 'prior', 'to', 'treatment', 'with', 'osimertinib']"
4420,1.0,"Exclusive nuclear immunostaining was associated with better progression free survival and overall survival after therapy with IGF1R antibodies (R1507, IMC-A12, SCH 717454 and CP-751.871).","['exclusive', 'nuclear', 'immunostaining', 'was', 'associated', 'with', 'better', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'after', 'therapy', 'with', '_gene_', 'antibodies', '_abbrev_', '_abbrev_', '_disease_', '_num_', 'and', '_abbrev_']"
4421,1.0,"In a study of 1,540 patients with Acute Myeloid Leukemia, 66 patients (4%) had a CEBPA (biallelic) mutation.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '_num_', 'patients', '_num_', 'had', 'a', '_gene_', 'biallelic', 'mutation']"
4422,1.0,"FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe.","['_disease_', 'tumor', 'samples', 'from', '_num_', 'patients', 'with', 'colorectal', 'cancer', 'who', 'had', 'received', '_chemical_', 'monotherapy', 'were', 'analyzed', 'with', 'a', 'fish', 'dual', 'probe']"
4423,1.0,"Five patients had readily observable mutations in these genes, one of which was a previously unidentified TSC1 missense change R1062W.","['_num_', 'patients', 'had', 'readily', 'observable', 'mutations', 'in', 'these', 'genes', '_num_', 'of', 'which', 'was', 'a', 'previously', 'unidentified', '_gene_', 'missense', 'change', '_abbrev_']"
4424,1.0,In a random effect model the pooled OR (3.38 (95% CI: 2.45–4.66)) of the studies supported the link between HOXB13 G84E variant and a susceptibility to prostate cancer.,"['in', 'a', 'random', 'effect', 'model', 'the', 'pooled', 'or', '_num_', '_num_', 'ci', '_num_', '45–4', '_num_', 'of', 'the', 'studies', 'supported', 'the', 'link', 'between', '_gene_', '_mutation_', 'variant', 'and', 'a', 'susceptibility', 'to', 'prostate', 'cancer']"
4425,1.0,"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line expressing the L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', '_abbrev_', '_gene_', 'cell', 'line', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment']"
4426,1.0,"In a retrospective study of 144 patients with B-cell chronic lymphocytic leukemia, the median progression-free survival was significantly different between GNAS T393C genotypes (TT 130 months; TC 100 months; CC 31 months; P = 0.0066) and an independent prognostic factor for progression-free survival by multivariable analysis [hazard ratio (HR) CC versus TT 2.7; P = 0.010].","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'patients', 'with', '_disease_', 'chronic', 'lymphocytic', 'leukemia', 'the', 'median', 'progression', 'free', 'survival', 'was', 'significantly', 'different', 'between', '_gene_', '_mutation_', 'genotypes', 'tt', '_num_', 'months', 'tc', '_num_', 'months', 'cc', '_num_', 'months', 'p', '_num_', 'and', 'an', 'independent', 'prognostic', 'factor', 'for', 'progression', 'free', 'survival', 'by', 'multivariable', 'analysis', 'hazard', 'ratio', 'hr', 'cc', 'vs', 'tt', '_num_', 'p', '_num_']"
4427,1.0,This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed.,"['this', 'study', 'included', '_num_', 'patients', 'with', 'clear', 'cell', 'renal', 'cell', 'carcinoma', 'whose', 'tumor', 'tissues', 'were', 'sampled', 'and', 'then', 'analyzed']"
4428,1.0,"Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1).","['re', 'biopsy', 'at', 'the', 'time', 'of', 'progression', 'showed', 'a', 'met', 'amplification', 'and', 'overexpression', '_gene_', '_disease_', 'but', 'no', 'secondary', 'mutations', 'in', 'candidate', 'resistance', 'genes', '_gene_', '_gene_', 'nras', '_gene_']"
4429,1.0,"In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses.","['in', '_disease_', 'patients', 'aged', '60years', 'presence', 'of', 'a', '_gene_', 'mutation', 'associated', 'with', 'inferior', 'cr', 'rate', 'hr', '_num_', '_gene_', 'and', 'shorter', 'os', 'hr', '_num_', 'p', '_num_', 'in', 'multivariate', 'analyses']"
4430,1.0,"In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.","['in', 'this', 'phase', 'ii', 'trial', 'with', '_num_', 'arms', '_num_', 'patients', 'with', 'untreated', 'stage', 'iiib', 'iv', '_gene_', 'positive', '_disease_', 'were', 'given', '_chemical_', 'with', 'or', 'without', '_chemical_']"
4431,1.0,"This variant, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a patient with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', 'a', 'case', 'of', '_disease_', 'colorectal', 'cancer', 'was', 'confirmed', 'to', 'be', 'a', 'somatic', 'mutation', 'in', 'a', 'patient', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
4432,1.0,Surgery was performed and the patient was free of disease two years later.,"['surgery', 'was', 'performed', 'and', 'the', 'patient', 'was', 'free', 'of', 'disease', '_num_', 'years', 'later']"
4433,1.0,Two East Asian CML cohorts (n=203) treated with imatinib were analzed for the polymorphism.,"['_num_', 'east', 'asian', '_gene_', 'cohorts', '_ineq_', 'treated', 'with', '_chemical_', 'were', 'analzed', 'for', 'the', 'polymorphism']"
4434,1.0,Five of his metastases were evaluated using whole genome sequencing.,"['_num_', 'of', 'his', 'metastases', 'were', 'evaluated', 'using', 'whole', 'genome', 'sequencing']"
4435,1.0,Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherpy.,"['analysis', 'was', 'performed', 'on', 'the', 'placebo', 'group', '_ineq_', 'of', 'the', 'phase', 'iii', 'study', 'saturn', 'using', '_chemical_', 'maintenance', 'therapy', 'for', 'patients', 'with', 'advanced', '_disease_', 'who', 'were', 'selected', 'for', 'response', 'or', 'stable', 'disease', 'after', '_num_', 'line', 'chemotherpy']"
4436,1.0,Retrospective analysis of 68 patients showed improved clinical response to the EGFR inhibitor cetuximab in tumors expressing PRL-3.,"['retrospective', 'analysis', 'of', '_num_', 'patients', 'showed', 'improved', 'clinical', 'response', 'to', 'the', '_gene_', 'inhibitor', '_chemical_', 'in', 'tumors', 'expressing', '_gene_']"
4437,1.0,12 CRC cell lines were evaluated.,"['_num_', '_gene_', 'cell', 'lines', 'were', 'evaluated']"
4438,1.0,This nonsense mutation was found in a VHL type 1 family (lineage 179).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
4439,1.0,Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.,"['median', '_disease_', 'was', '_num_', 'months', 'in', 'the', '_chemical_', 'group', 'and', '_num_', 'months', 'in', 'the', '_chemical_', 'group']"
4440,1.0,An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy.,"['an', 'arab', 'basal', 'cell', 'carcinoma', 'patient', 'harboring', '_gene_', '_mutation_', 'mutation', 'was', 'associated', 'with', 'response', 'to', '_chemical_', 'monotherapy']"
4441,1.0,"PD-L1 overexpression had no significant impact on metastasis-free survival (HR 0.924, 95% CI = 0.747-1.141, p = 0.462), disease-free survival (HR 1.122, 95% CI = 0.878-1.434, p = 0.357) and overall specific survival (HR 0.837, 95% CI = 0.640-1.093, p = 0.191), but significantly correlated with shortened overall survival (HR 1.573, 95% CI = 1.010-2.451, p = 0.045).","['_gene_', 'overexpression', 'had', 'no', 'significant', 'impact', 'on', 'metastasis', 'free', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', '_disease_', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'and', 'overall', 'specific', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'but', 'significantly', 'correlated', 'with', 'shortened', 'overall', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_']"
4442,1.0,TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells.,"['_chemical_', '_num_', '_unit_', 'appreciably', 'inhibited', 'growth', 'as', 'well', 'as', '_gene_', 'and', '_gene_', '_disease_', 'in', 'variant', '_num_', 'containing', '_abbrev_', 'cells']"
4443,1.0,Three HGF autocrine cell lines were grown in mice and showed significantly increased sensitivity to SGX523 than three non-HGF autocrine cell lines (P<0.05).,"['_num_', '_gene_', '_chemical_', 'cell', 'lines', 'were', 'grown', 'in', 'mice', 'and', 'showed', 'significantly', 'increased', 'sensitivity', 'to', '_chemical_', 'than', '_num_', 'non', '_gene_', '_chemical_', 'cell', 'lines', 'p', '_num_']"
4444,1.0,KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.,"['_gene_', '_mutation_', 'mutation', 'is', 'associated', 'with', 'better', 'response', 'to', '_chemical_', 'with', 'longer', 'progression', 'free', 'and', 'overall', 'survival', 'in', 'colorectal', 'patients', 'compared', 'to', 'other', '_gene_']"
4445,1.0,"A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days.","['a', '_gene_', '_mutation_', 'point', 'mutation', 'was', 'observed', 'the', 'patient', 'was', 'therefore', 'treated', 'with', '_chemical_', 'but', 'the', 'disease', 'progressed', 'after', '_num_', 'days']"
4446,1.0,"2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance.","['_num_', 'out', 'of', 'the', '_num_', 'patients', 'had', 'the', '_mutation_', '_gene_', 'mutation', 'in', 'the', 'absence', 'of', '_gene_', '_mutation_', 'indicating', 'that', '_mutation_', 'may', 'be', 'an', 'alternative', 'mutation', 'contributing', 'to', 'resistance']"
4447,1.0,"In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively.","['in', 'patients', 'with', '_gene_', '_abbrev_', 'tumors', 'n', '_num_', 'and', 'a', 'median', 'of', '_num_', 'lines', 'of', 'prior', 'therapy', 'the', 'median', '_disease_', 'was', '_num_', 'months', '_num_', 'months', 'and', '_num_', 'months', 'in', 'patients', 'with', 'er+', 'breast', 'gynecologic', 'and', 'other', 'solid', 'tumors', 'respectively']"
4448,1.0,"Patients with EGFR deletions in exon 19 or L858R mutations were associated with an improved response to erlotinib or gefitinib with partial or complete response (74.1% vs. 16.5%, P<0.001) when compared to wildtype EGFR patients.","['patients', 'with', '_gene_', 'deletions', 'in', 'exon', '_num_', 'or', '_mutation_', 'mutations', 'were', 'associated', 'with', 'an', 'improved', 'response', 'to', '_chemical_', 'or', '_chemical_', 'with', 'partial', 'or', 'complete', 'response', '_num_', 'vs', '_num_', 'p', '_num_', 'when', 'compared', 'to', 'wildtype', '_gene_', 'patients']"
4449,1.0,"In patients with myelodysplastic syndrome, the presence of IDH2 R140Q (N=3) or IDH1 R132 (N=2) mutations did not confer prognostic value (overall survival) compared to wild type IDH1/2 patients (N=61; P=0.794).","['in', 'patients', 'with', '_disease_', 'syndrome', 'the', 'presence', 'of', '_gene_', '_mutation_', '_ineq_', 'or', '_gene_', '_abbrev_', '_ineq_', 'mutations', 'did', 'not', 'confer', 'prognostic', 'value', 'overall', 'survival', 'compared', 'to', 'wild', 'type', '_gene_', 'patients', '_ineq_', '_p_val_']"
4450,1.0,Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months).,"['case', 'report', 'of', 'a', 'patient', 'with', '_disease_', 'and', 'richter', 'transformed', 'relapse', 'under', '_chemical_', 'after', 'an', 'initial', 'partial', 'response', 'for', '_num_', 'months']"
4451,1.0,Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor.,"['remaining', 'mutations', 'showed', 'a', 'shift', 'towards', 'significant', 'higher', 'cellular', '_abbrev_', 'values', 'compared', 'to', 'the', 'wild', 'type', 'receptor']"
4452,1.0,"Docetaxel efficiently induced apoptosis in the cells cultured without any GAS6, but it was not able to do so in the cells that were in media with GAS6 present or that were co-cultured with osteoblasts expressing GAS6.","['_chemical_', 'efficiently', 'induced', 'apoptosis', 'in', 'the', 'cells', 'cultured', 'without', 'any', '_gene_', 'but', 'it', 'was', 'not', 'able', 'to', 'do', 'so', 'in', 'the', 'cells', 'that', 'were', 'in', 'media', 'with', '_gene_', 'present', 'or', 'that', 'were', 'co', 'cultured', 'with', 'osteoblasts', 'expressing', '_gene_']"
4453,1.0,Significantly higher ALDH1A2 protein levels were identified in HPV-driven than non-HPV-driven tumors.,"['significantly', 'higher', '_gene_', 'protein', 'levels', 'were', 'identified', 'in', 'hpv', 'driven', 'than', 'non', 'hpv', 'driven', 'tumors']"
4454,1.0,"Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts.","['combined', 'treatment', 'with', '_chemical_', 'and', '_chemical_', 'but', 'not', 'either', 'agent', 'in', 'monotherapy', 'had', 'an', 'antitumor', 'efficacy', 'in', 'vitro', 'and', 'in', 'xenografts']"
4455,1.0,PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.,"['_gene_', 'mutation', 'status', 'was', 'not', 'predictive', 'of', 'response', 'to', '_chemical_', 'treatment', 'in', 'patients', 'that', 'had', 'received', 'standard', 'therapy', 'and', 'progressed', 'within', '_num_', 'months', 'of', 'their', 'last', 'treatment']"
4456,1.0,"In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT.","['in', 'acute', 'myloid', 'leukemia', 'patients', '_abbrev_', 'mutation', 'is', 'associated', 'with', 'earlier', 'relapse', 'and', 'poorer', 'prognosis', 'than', 'wildtype', 'kit']"
4457,1.0,"GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline.","['_chemical_', 'chemotherapy', 'was', 'administered', 'with', 'dexamethasone', 'and', '_unit_', '_chemical_', 'twice', 'daily', 'resulting', 'in', 'symptom', 'relief', 'decreased', 'lymphadenopathy', 'and', '_gene_', 'decline']"
4458,1.0,"Finally, OICR-9429 reduced viability of primary human AML blasts harboring N-terminal domain CEBPA mutations in culture but not AML blasts with other mutations.","['finally', '_abbrev_', 'reduced', 'viability', 'of', 'primary', 'human', '_disease_', 'blasts', 'harboring', '_chemical_', 'domain', '_gene_', 'mutations', 'in', 'culture', 'but', 'not', '_disease_', 'blasts', 'with', 'other', 'mutations']"
4459,1.0,"In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild type patients.","['in', 'patients', 'with', 'a', 'glioblastoma', 'those', 'with', 'mutations', 'at', '_abbrev_', 'of', '_gene_', 'had', 'better', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
4460,1.0,"mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively).","['mrna', 'expression', 'of', '_gene_', 'in', '_num_', 'patients', 'with', 'tamoxifen', 'treated', 'postmenopausal', 'breast', 'cancer', 'was', 'determined', 'by', 'qrt', 'pcr', 'and', 'was', 'inversely', 'associated', 'with', 'treatment', 'response', 'and', 'progression', 'free', 'survival', 'p=', '_num_', 'p', '_num_', 'respectively']"
4461,1.0,A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma.,"['a', '_gene_', '_gene_', 'fusion', 'transcript', 'was', 'detected', 'at', 'very', 'high', 'expression', 'levels', 'by', 'rna', 'seq', 'in', 'a', 'case', 'of', 'mixed', 'fibrolamellar', '_disease_', 'carcinoma']"
4462,1.0,"EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab.","['_gene_', 'was', 'assessed', 'by', 'immunohistochemistry', 'and', 'the', 'patient', 'was', 'subsequently', 'treated', 'with', 'the', 'anti', '_gene_', 'monoclonal', 'antibody', 'panitumumab']"
4463,1.0,No responses were seen 36 patients without FGFR pathway aberrations.,"['no', 'responses', 'were', 'seen', '_num_', 'patients', 'without', '_gene_', 'pathway', 'aberrations']"
4464,1.0,Cells lacking functional TP53 were completely insensitive to the drug.,"['cells', 'lacking', 'functional', '_gene_', 'were', 'completely', 'insensitive', 'to', 'the', 'drug']"
4465,1.0,This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 105).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', 'previously', 'diagnosed', '_gene_', 'patient', 'by', '_disease_', 'family', '_gene_', '_num_']"
4466,1.0,Twenty-five patients were enrolled (24 evaluable).,"['twenty', '_num_', 'patients', 'were', 'enrolled', '_num_', 'evaluable']"
4467,1.0,RRM1-speciﬁc RNAi transfection significantly reduced the gemcitabine chemoresistance of MiaPaCa2-RG to the same level as that of gemcitabine sensitive MiaPaCa2.,"['_abbrev_', '_gene_', 'transfection', 'significantly', 'reduced', 'the', '_chemical_', 'chemoresistance', 'of', '_abbrev_', 'to', 'the', 'same', 'level', 'as', 'that', 'of', '_chemical_', 'sensitive', '_abbrev_']"
4468,1.0,"In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response.","['in', 'this', 'phase', 'ii', 'pilot', 'study', '_abbrev_', 'of', '_gene_', '_abbrev_', 'inhibitor', '_chemical_', 'in', '_num_', 'metastatic', 'colorectal', 'cancer', '_gene_', 'patients', 'with', '_gene_', '_mutation_', '_num_', 'patient', 'had', 'a', 'durable', '_num_', 'week', 'partial', 'response', 'and', '_num_', 'patients', 'had', '_num_', 'week', 'stable', 'disease', 'as', 'best', 'response']"
4469,1.0,"The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus.","['the', 'pretreatment', 'tumor', 'contained', 'a', 'somatic', 'nonsense', 'mutation', '_abbrev_', 'in', 'the', '_gene_', 'gene', '_gene_', 'that', 'inactivates', 'the', 'gene', 'allowing', 'for', 'activation', 'of', 'the', '_gene_', 'pathway', 'and', 'resulting', 'in', 'sensitivity', 'to', '_gene_', 'inhibition', 'by', '_chemical_']"
4470,1.0,Preclinical study in uveal melanoma cell lines.,"['preclinical', 'study', 'in', 'uveal', 'melanoma', 'cell', 'lines']"
4471,1.0,"The survival rate of CRC patients at 3 years was significantly poorer in the BRAF D595G mutations when compared to the wild type group (50%, 87.9%; p<0.00152).","['the', 'survival', 'rate', 'of', '_gene_', 'patients', 'at', '_num_', 'years', 'was', 'significantly', 'poorer', 'in', 'the', '_gene_', '_abbrev_', 'mutations', 'when', 'compared', 'to', 'the', 'wild', 'type', 'group', '_num_', '_num_', 'p', '_num_']"
4472,1.0,"Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild type patients (P=.008)","['among', '_num_', '_disease_', 'patients', 'treated', 'with', '_chemical_', 'the', 'response', 'rate', 'was', '_num_', '_ratio_', 'among', '_gene_', 'mutated', 'and', '_num_', '_ratio_', 'among', '_gene_', 'wild', 'type', 'patients', 'p=', '_num_']"
4473,0.0,75% of the malignant peripheral nerve sheath tumors (MPNSTs) were positive for this event.,"['_num_', 'of', 'the', 'malignant', 'peripheral', 'nerve', 'sheath', 'tumors', '_disease_', 'were', 'positive', 'for', 'this', 'event']"
4474,1.0,Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM).,"['parallel', '_chemical_', 'incubations', 'of', 'cells', 'with', 'wildtype', '_gene_', 'induced', 'recompartmentalization', 'of', 'ectopic', '_gene_', 'protien', 'only', 'at', 'high', 'concentration', '_unit_']"
4475,1.0,5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib.,"['_num_', 'of', '_num_', 'colorectal', 'cancer', '_gene_', 'cell', 'lines', 'with', '_gene_', '_mutation_', 'mutation', 'were', 'resistant', 'to', 'treatment', 'with', 'the', '_gene_', 'inhibitor', '_chemical_']"
4476,1.0,Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies.,"['responder', 'samples', 'showed', 'significantly', 'reduced', '_gene_', 'staining', 'after', 'treatment', 'in', 'comparison', 'to', 'non', 'responder', 'biopsies']"
4477,1.0,"In this phase 2, nonrandomized, open-label clinical trial conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 years and older with advanced WD/DDLS and measurable disease by RECIST 1.1 were enrolled from December 2011 to January 2014 and followed to March 2015.","['in', 'this', 'phase', '_num_', 'nonrandomized', '_disease_', 'clinical', 'trial', 'conducted', 'at', 'the', 'memorial', 'sloan', 'kettering', 'cancer', 'center', '_num_', 'patients', '_num_', 'years', 'and', 'older', 'with', 'advanced', 'wd', 'ddls', 'and', 'measurable', 'disease', 'by', '_disease_', '_num_', 'were', 'enrolled', 'from', 'december', '_year_', 'to', 'january', '_year_', 'and', 'followed', 'to', 'march', '_year_']"
4478,1.0,76 patients were analyzed for this study.,"['_num_', 'patients', 'were', 'analyzed', 'for', 'this', 'study']"
4479,1.0,"Using IHC and custom generated antibody, the overall survival with respect to KIF23 V1 expression was evaluated using the kaplan-meier method with a log rank test.","['using', '_gene_', 'and', 'custom', 'generated', 'antibody', 'the', 'overall', 'survival', 'with', 'respect', 'to', '_gene_', '_gene_', 'expression', 'was', 'evaluated', 'using', 'the', 'kaplan', 'meier', 'method', 'with', 'a', 'log', 'rank', 'test']"
4480,1.0,"In 177 patients with activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), PRDM1 mutations (N=46) were associated with worse overall (P=0.016) and progression-free (P=0.023) survival compared to wildtype patients.","['in', '_num_', 'patients', 'with', 'activated', '_disease_', 'diffuse', 'large', '_disease_', 'lymphoma', '_disease_', '_gene_', 'mutations', '_ineq_', 'were', 'associated', 'with', 'worse', 'overall', '_p_val_', 'and', 'progression', 'free', '_p_val_', 'survival', 'compared', 'to', 'wildtype', 'patients']"
4481,1.0,The M351T mutation was sensitive to imatinib.,"['the', '_mutation_', 'mutation', 'was', 'sensitive', 'to', '_chemical_']"
4482,1.0,Phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655.,"['phase', 'i', 'expansion', 'and', 'pharmacodynamic', 'study', 'of', 'oral', 'mek', 'inhibitor', '_abbrev_']"
4483,1.0,"In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monotherapy, respectively; both patients were previously treated with standard chemotherapy.","['in', 'stage', 'iv', 'lung', 'adenocarcinoma', 'patients', '_gene_', 'harboring', '_gene_', 'inframe', 'exon', '_num_', 'insertion', 'mutation', '_gene_', 'exon', '_num_', 'insertion', 'was', 'associated', 'with', 'progressive', 'disease', 'after', '_num_', 'and', '_num_', 'months', 'of', '_chemical_', 'monotherapy', 'respectively', 'both', 'patients', 'were', 'previously', 'treated', 'with', 'standard', 'chemotherapy']"
4484,1.0,"Alterations in MAPK pathway genes were found in resistant tumors not present in matched pre-treatment tumors, including KRAS amplification, BRAF amplification, and a MEK1 mutation.","['alterations', 'in', '_gene_', 'pathway', 'genes', 'were', 'found', 'in', 'resistant', 'tumors', 'not', 'present', 'in', 'matched', '_gene_', 'treatment', 'tumors', 'including', '_gene_', 'amplification', '_gene_', 'amplification', 'and', 'a', '_gene_', 'mutation']"
4485,1.0,This study contains very strong evidence of pathogenicity in the form of a canonical +1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).,"['this', 'study', 'contains', 'very', 'strong', 'evidence', 'of', 'pathogenicity', 'in', 'the', 'form', 'of', 'a', 'canonical', '+1', 'splice', 'site', 'variant', 'in', 'a', 'gene', 'where', '_disease_', 'is', 'a', 'known', 'mechanism', 'of', 'disease', 'acmg', 'code', '_abbrev_']"
4486,1.0,"In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS/DDLS) were treated with a selective CDK 4/6 inhibitor, PD0332991.","['in', 'a', 'phase', '_num_', 'clinical', 'trial', '_abbrev_', '_num_', 'patients', 'with', '_abbrev_', 'and', 'rb', 'expressing', 'well', 'differentiated', 'and', 'dedifferentiated', 'liposarcomas', 'wdls', 'ddls', 'were', 'treated', 'with', 'a', 'selective', '_gene_', '_ratio_', 'inhibitor', '_chemical_']"
4487,1.0,"In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation.","['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'progressive', 'non', 'small', 'cell', 'lung', 'cancer', 'during', '_chemical_', 'comparison', 'of', 'dna', 'sequences', 'from', 'the', 'original', 'diagnostic', 'biopsy', 'specimen', 'and', 'the', '_num_', 'biopsy', 'specimen', 'demonstrated', 'that', '_num_', 'patients', 'acquired', 'a', 'new', '_disease_', 'mutation']"
4488,1.0,The RET inhibitor Vandetanib led to remission in the patient.,"['the', 'ret', 'inhibitor', '_chemical_', 'led', 'to', 'remission', 'in', 'the', 'patient']"
4489,1.0,Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.,"['decreased', 'peri', '', 'and', 'post', 'therapeutic', 'expression', 'of', '_gene_', 'were', 'significantly', 'associated', 'with', 'response', 'to', 'folfiri', 'plus', '_chemical_', 'in', '_num_', 'patients', 'with', 'metastatic', '_gene_']"
4490,1.0,Two additional patients had a response in day 15 using FDG-PET but were not considered complete responders by RECIST criteria.,"['_num_', 'additional', 'patients', 'had', 'a', 'response', 'in', 'day', '_num_', 'using', '_chemical_', 'but', 'were', 'not', 'considered', 'complete', 'responders', 'by', '_disease_', 'criteria']"
4491,1.0,Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation.,"['sequencing', 'revealed', 'a', '_abbrev_', 'fusion', 'protein', 'such', 'that', 'the', 'inhibitory', '_gene_', 'receptor', 'activated', 'a', 'stimulatory', '_gene_', 'intracellular', 'domain', 'that', 'promoted', 'proliferation']"
4492,1.0,The variant PPP1R15A (rs557806) showed the most significant association (P = 0.000401) with FOLFIRI-bevacizumab-driven tumor inhibition rate in exome sequencing data and the highest correlation (r = 0.74) with the drug responses in RNA sequencing data.,"['the', 'variant', '_gene_', '_mutation_', 'showed', 'the', 'most', 'significant', 'association', 'p', '_num_', 'with', 'folfiri', '_chemical_', 'driven', 'tumor', 'inhibition', 'rate', 'in', 'exome', 'sequencing', 'data', 'and', 'the', 'highest', 'correlation', 'r', '_num_', 'with', 'the', 'drug', 'responses', 'in', 'rna', 'sequencing', 'data']"
4493,1.0,"Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response.","['prior', 'to', 'the', 'identification', 'of', 'the', 'mutation', 'the', 'patient', 'was', 'treated', 'with', '_chemical_', 'but', 'did', 'not', 'achieve', 'any', 'response']"
4494,0.0,"we show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie.","['we', 'show', 'that', '_mutation_', 'retain', 'low', 'affinity', 'for', '_chemical_', 'and', 'that', 'introduction', 'of', '_mutation_', 'in', 'the', 'presence', 'of', '_mutation_', 'mutant', 'increases', 'the', 'atp', 'affinity', 'of', '_mutation_', 'and', 'activates', 'wild', 'type', '_gene_', 'thus', 'showing', 'that', 'increased', 'atp', 'affinity', 'is', 'the', 'primary', 'mode', 'of', 'resistance', 'in', 'tumors', 'with', '_mutation_', 'though', 'irreversible', 'atp', 'inhibitors', 'ie']"
4495,1.0,One of 2 individuals carried pheochromocytomas as well.,"['_num_', 'of', '_num_', 'individuals', 'carried', 'pheochromocytomas', 'as', 'well']"
4496,1.0,"The results are in contrast to the principle of change of treatment on disease progression, and we suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression.","['the', 'results', 'are', 'in', 'contrast', 'to', 'the', 'principle', 'of', 'change', 'of', 'treatment', 'on', 'disease', 'progression', 'and', 'we', 'suggest', 'that', 'chemotherapy', 'sensitizing', 'mechanisms', 'of', '_chemical_', 'remain', 'intact', 'in', '_gene_', 'breast', 'cancer', 'cells', 'with', '_chemical_', 'progression']"
4497,1.0,"A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL).","['a', '_num_', 'year', 'old', 'female', 'patient', 'with', '_disease_', 'iv', '_gene_', 'negative', 'diffuse', 'large', 'b', 'cell', 'lymphoma', '_disease_']"
4498,0.0,Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma.,"['evidence', 'of', 'the', '_abbrev_', 'fusion', 'was', 'found', 'in', 'all', 'fibrolamellar', 'cases', 'but', 'not', 'in', 'other', 'tumor', 'types', 'for', 'both', 'methods', 'indicating', 'that', 'detection', 'of', '_abbrev_', 'is', 'a', 'very', 'sensitive', 'and', 'specific', 'finding', 'in', 'support', 'of', 'the', 'diagnosis', 'of', 'fibrolamellar', 'carcinoma']"
4499,1.0,Patients with low TS (≤150) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=0.01).,"['patients', 'with', 'low', 'ts', '_ineq_', 'expression', 'had', 'a', 'longer', 'median', 'progression', 'free', 'survival', '_disease_', 'than', 'those', 'with', 'high', 'ts', '_num_', 'expression', '_num_', 'vs', '_num_', 'months', '_p_val_']"
4500,1.0,The mutation was not found in 108 control subjects.,"['the', 'mutation', 'was', 'not', 'found', 'in', '_num_', 'control', 'subjects']"
4501,1.0,"In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53.","['in', 'a', 'study', '_num_', 'breast', 'cancer', 'patients', 'undergoing', '_num_', 'line', 'tamoxifen', 'treatment', '_num_', 'patients', 'had', 'mutations', 'in', '_gene_']"
4502,1.0,"For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup.","['for', 'multivariate', 'analysis', '_gene_', 'was', 'a', 'significant', 'marker', 'of', 'inferior', '_gene_', 'in', 'the', 'entire', 'cohort', '_p_val_', 'and', 'the', 'intermediate', 'risk', '_p_val_', 'subgroup', 'but', 'not', 'the', '_gene_', 'subgroup']"
4503,1.0,In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein.,"['in', 'vitro', 'studies', 'showed', 'efficacy', 'of', '_gene_', 'inhibitor', '_chemical_', 'in', 'cell', 'lines', 'exhibiting', 'high', '_gene_', 'protein']"
4504,1.0,"After partial response for 9.5 months, resistance developed.","['after', 'partial', 'response', 'for', '_num_', 'months', 'resistance', 'developed']"
4505,1.0,"Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable disease with a reduced tumor burden.","['among', '_num_', 'patients', 'with', '_disease_', 'and', '_gene_', 'aberrations', '_num_', 'fusions', '_num_', 'mutation', 'all', '_num_', 'had', 'stable', 'disease', 'with', 'a', 'reduced', 'tumor', 'burden']"
4506,1.0,"Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay.","['patients', 'with', '_gene_', '_disease_', 'were', 'significantly', 'more', 'likely', 'to', 'have', 'elevated', '_gene_', '_p_val_', 'and', 'high', '_gene_', 'samples', 'were', 'significantly', 'less', 'sensitive', 'to', 'chemotherapy', 'agents', '_chemical_', '_chemical_', 'mitomycin', 'and', '_chemical_', 'in', '_gene_', 'assay']"
4507,1.0,"Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation.","['following', 'identification', 'of', 'this', 'fusion', 'in', 'a', 'patient', 'this', 'fusion', 'was', 'expressed', 'in', '_gene_', '_chemical_', 'cells', 'leading', 'to', 'oligomerization', 'in', 'the', 'absence', 'of', 'ligand', 'induced', 'morphologic', 'changes', 'in', 'the', 'cell', 'and', 'increased', 'cellular', 'proliferation', 'consistent', 'with', '_gene_', 'activation']"
4508,1.0,ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.,"['ddpcr', 'on', 'serial', 'cfdna', 'specimens', 'collected', 'from', '_num_', 'osimertinib', 'treated', 'subjects', 'all', 'positive', 'for', '_mutation_', 'before', 'treatment', 'revealed', '_num_', 'cases', 'with', 'acquired', '_mutation_', 'mutation']"
4509,1.0,Preclinical study in 9 melanoma cell lines.,"['preclinical', 'study', 'in', '_num_', 'melanoma', 'cell', 'lines']"
4510,1.0,The disease control rate for the KRAS-mutant population was 55% (16/29) compared to 39% (13/33)  in KRAS wildtype cohort.,"['the', 'disease', 'control', 'rate', 'for', 'the', '_gene_', 'mutant', 'population', 'was', '_num_', '_ratio_', 'compared', 'to', '_num_', '_ratio_', 'in', '_gene_', 'wildtype', 'cohort']"
4511,1.0,"In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.","['in', '_gene_', 'cells', 'with', '_gene_', '_mutation_', 'mutation', 'that', 'have', 'shown', '_chemical_', 'resistance', '_chemical_', 'was', 'significantly', 'more', 'potent', 'at', 'inhibiting', 'kinase', 'activity', 'than', '_chemical_']"
4512,1.0,"In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mitomycin C, and the patient was shown to be asymptomatic after 3 years of follow-up.","['in', 'a', 'patient', 'with', '_chemical_', 'refractory', 'pancreatic', 'cancer', 'a', '_disease_', 'xenograft', 'was', 'found', 'to', 'be', 'responsive', 'to', 'mitomycin', 'c', 'after', 'disease', 'progression', 'the', 'patient', 'was', 'started', 'on', 'a', 'regimen', 'of', 'mitomycin', 'c', 'and', 'the', 'patient', 'was', 'shown', 'to', 'be', 'asymptomatic', 'after', '_num_', 'years', 'of', 'follow', 'up']"
4513,1.0,Treatment of Ba/F3 cells expressing EML4-ALK 1151 insT with TAE684 produced an IC50 value (28.3 nM) 20x higher cells expressing EML4-ALK wildtype variant 1.,"['treatment', 'of', 'ba', '_abbrev_', 'cells', 'expressing', '_chemical_', '_num_', 'inst', 'with', '_chemical_', 'produced', 'an', '_abbrev_', 'value', '_num_', '_unit_', '20x', 'higher', 'cells', 'expressing', '_chemical_', 'wildtype', 'variant', '_num_']"
4514,1.0,Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival.,"['patients', 'with', '_gene_', 'mutations', 'had', 'a', 'statistically', 'significant', 'longer', 'overall', 'survival', 'as', 'well', 'as', 'event', 'free', 'survival']"
4515,1.0,"In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild type counterparts.","['in', '_disease_', 'syndrome', 'patients', 'with', 'point', 'mutations', 'in', '_gene_', 'have', 'worse', 'overall', 'survival', 'that', 'their', 'wild', 'type', 'counterparts']"
4516,1.0,NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43).,"['_gene_', 'mutation', 'without', '_gene_', 'was', 'associated', 'with', 'reduced', 'relapse', 'risk', 'and', 'increased', 'overall', 'survival', 'in', 'young', 'adult', 'acute', 'myeloid', 'leukemia', 'patients', 'median', 'age', '_num_']"
4517,1.0,we found that PTPRT promoter methylation and sensitivity to Stattic (a STAT3 SH2 domain inhibitor) or JSI-124 (a JAK/STAT3 pathway inhibitor) are significantly correlated (P<0.05).,"['we', 'found', 'that', '_gene_', 'promoter', 'methylation', 'and', 'sensitivity', 'to', '_chemical_', 'a', '_gene_', '_gene_', 'domain', 'inhibitor', 'or', '_chemical_', 'a', 'jak', '_gene_', 'pathway', 'inhibitor', 'are', 'significantly', 'correlated', 'p', '_num_']"
4518,1.0,"HPO terms: renal cell carcinoma, multiple pancreatic cysts, epididymal cysts, endolymphatic sac tumors.","['_disease_', 'terms', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts', '_disease_', 'cysts', 'endolymphatic', 'sac', 'tumors']"
4519,1.0,Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.,"['_chemical_', 'treatment', 'resulted', 'in', 'similar', 'overall', 'survival', 'and', 'disease', 'free', 'survival', 'in', 'de', 'novo', '_disease_', 'patients', 'with', '_gene_', '_abbrev_', 'mutation', 'compared', 'to', 'those', 'who', 'do', 'not', 'harbor', 'this', 'mutation']"
4520,1.0,"In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 wild type patients.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'acute', 'myeloid', 'leukemia', 'patients', 'the', 'patients', 'with', '_gene_', '_abbrev_', 'mutation', '_gene_', 'were', 'associated', 'with', 'improved', 'response', 'to', '_chemical_', 'treatment', '_ratio_', 'vs', '_ratio_', 'compared', 'to', '_gene_', 'wild', 'type', 'patients']"
4521,1.0,"Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b.","['_chemical_', 'was', '28x', 'more', 'potent', '_gene_', '_num_', '_unit_', 'than', '_chemical_', '_gene_', '_unit_', 'at', 'inhibiting', 'growth', 'of', '_abbrev_', 'an', '_disease_', 'cell', 'line', 'which', 'harbors', 'the', '_chemical_', 'variant', '3a', '_chemical_']"
4522,1.0,Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study.,"['positive', '_gene_', 'expression', '2+', 'by', '_gene_', 'was', 'associated', 'with', 'adverse', 'outcomes', 'in', 'a', 'cohort', 'of', '_num_', 'cases', 'with', 'stage', 'i', 'and', 'ii', '_disease_', 'p', '_num_', 'in', 'this', 'retrospective', 'study']"
4523,1.0,This aberration was mainly identified in head and neck cancer cell lines.,"['this', 'aberration', 'was', 'mainly', 'identified', 'in', 'head', 'and', 'neck', 'cancer', 'cell', 'lines']"
4524,1.0,This missense mutation causes a premature stop codon at amino acid 66 and was found in a VHL type 1 patient (patient no V9).,"['this', 'missense', 'mutation', 'causes', 'a', 'premature', 'stop', 'codon', 'at', 'amino', 'acid', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
4525,1.0,"In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 patients who did not.","['in', 'a', 'phase', 'ii', 'trial', 'for', '_disease_', 'carcinoma', '_disease_', 'or', 'in', '_disease_', 'pulmonary', 'adenocarcinoma', '_gene_', 'exons', '_range_', 'were', 'analyzed', 'in', '_num_', 'patients', 'who', 'had', 'shown', 'a', 'partial', 'response', 'to', '_chemical_', 'and', '_num_', 'patients', 'who', 'did', 'not']"
4526,1.0,"In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR:0.48, 95% CI:0.36-0.64, P<0.001), compared to carboplatin plus paclitaxel treatment.","['in', 'a', 'phase', '_num_', 'clinical', 'trial', 'of', 'east', 'asian', 'advanced', 'pulmonary', 'adenocarcinoma', 'patients', 'a', 'subset', 'of', 'patients', 'with', '_gene_', 'mutations', '_ineq_', 'treated', 'with', '_chemical_', 'were', 'associated', 'with', 'improved', 'response', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'compared', 'to', '_chemical_', 'plus', '_chemical_', 'treatment']"
4527,1.0,A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib.,"['a', 'case', 'study', 'of', 'an', '_disease_', 'patient', 'with', 'met', 'amplification', 'met', '_abbrev_', 'ratio', '_num_', 'who', 'achieved', 'a', 'durable', 'partial', 'response', 'to', 'met', '_gene_', 'inhibitor', '_chemical_']"
4528,1.0,Sym004 is a 1:1 mixture of two non-overlapping anti-EGFR monoclonal antibodies.,"['_abbrev_', 'is', 'a', '_ratio_', 'mixture', 'of', '_num_', '_disease_', 'anti', '_gene_', 'monoclonal', 'antibodies']"
4529,1.0,we propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.,"['we', 'propose', '_disease_', 'as', 'a', 'diagnostic', 'test', 'for', 'ewing', 'sarcoma', 'using', '_disease_', 'materials']"
4530,1.0,"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild type KRAS and NRAS.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'treatment', 'naive', 'metastatic', 'colorectal', 'cancer', 'patients', 'patients', 'with', 'ras', 'mutations', '_gene_', 'including', '_gene_', '_mutation_', '_gene_', '_mutation_', 'nras', '_mutation_', 'and', 'nras', '_abbrev_', 'treated', 'with', '_chemical_', 'plus', '_chemical_', 'were', 'associated', 'with', 'decreased', 'overall', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'and', 'decreased', 'progression', 'free', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', 'and', 'nras']"
4531,1.0,"The patient (M, 77, smoker) progressive disease as response, progression free survival (PFS) of 1.1 months, overall survival (OS) of 1.1 months and was not alive at study end.","['the', 'patient', '_unit_', '_num_', 'smoker', 'progressive', 'disease', 'as', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'not', 'alive', 'at', 'study', 'end']"
4532,1.0,"Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]).","['panitumumab', 'significantly', 'prolonged', '_disease_', 'hazard', 'ratio', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
4533,1.0,"The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance.","['the', 'same', 'resistance', 'mutation', 'was', 'observed', 'at', 'all', 'the', 'metastatic', 'sites', 'that', 'were', 'examined', 'at', 'autopsy', 'suggesting', 'that', 'this', 'mutation', 'was', 'an', 'early', 'event', 'in', 'the', 'clonal', 'evolution', 'of', 'resistance']"
4534,1.0,"Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker.","['treatment', 'with', '_chemical_', 'and', '_gene_', 'inhibitor', '_chemical_', 'or', '_chemical_', 'in', '_mutation_', '_gene_', 'cells', 'widr', '_abbrev_', 'and', '_abbrev_', 'showed', 'inhibited', 'growth', 'as', 'well', 'as', 'induction', 'of', 'the', 'cleaved', '_gene_', 'apoptotic', 'marker']"
4535,1.0,Preclinical study of mouse melanoma both in-vitro and in-vivo.,"['preclinical', 'study', 'of', 'mouse', 'melanoma', 'both', 'in', 'vitro', 'and', 'in', 'vivo']"
4536,1.0,"Five of 7 individuals were identified with angiomas, 8 with cerebellar hemangioblastomas, and 7 with renal cell carcinoma.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
4537,1.0,Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease.,"['germline', '_gene_', 'mutations', 'were', 'found', 'in', 'all', 'korean', 'patients', 'who', 'fulfilled', 'clinical', 'criteria', 'for', '_gene_', 'disease']"
4538,1.0,All three had retinal angiomas and hemangioblastomas of the central nervous system.,"['all', '_num_', 'had', 'retinal', 'angiomas', 'and', '_disease_', 'of', 'the', 'central', 'nervous', 'system']"
4539,1.0,"Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.","['genomic', '_disease_', 'showed', 'that', '_chemical_', 'variant', '_num_', 'tumor', 'cells', 'contained', 'a', 'single', '_chemical_', 'fusion', 'suggesting', '5a', 'and', '_chemical_', 'arise', 'from', 'alternate', 'splicing']"
4540,1.0,"In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated.","['in', 'mice', '_gene_', 'but', 'not', '_abbrev_', 'xenografts', 'regressed', 'with', '_chemical_', 'administration', 'and', 'complete', 'remission', 'for', '_num_', 'weeks', 'was', 'observed', 'before', 'experiment', 'was', 'terminated']"
4541,0.0,FGFR1 amplification also correlates with cigarette smoking.,"['_gene_', 'amplification', 'also', 'correlates', 'with', 'cigarette', 'smoking']"
4542,1.0,"In tumors with COX-2 overexpression, regular aspirin use conferred significant risk reduction of colorectal cancer (RR=0.64; 95%CI 0.52-0.78) however, in tumors with reduced COX2 expression, aspirin use had no influence on colorectal cancer incidence (RR=0.96, 95%CI 0.73-1.26).","['in', 'tumors', 'with', '_abbrev_', 'overexpression', 'regular', 'aspirin', 'use', 'conferred', 'significant', 'risk', 'reduction', 'of', 'colorectal', 'cancer', '_ineq_', '_num_', 'ci', '_range_', 'however', 'in', 'tumors', 'with', 'reduced', '_gene_', 'expression', 'aspirin', 'use', 'had', 'no', 'influence', 'on', 'colorectal', 'cancer', 'incidence', '_ineq_', '_num_', 'ci', '_range_']"
4543,1.0,"Rapamycin treatment significantly suppressed polyposis (p=0.017) and pS6 staining (IHC, p=0.011).","['_gene_', 'treatment', 'significantly', 'suppressed', '_disease_', '_p_val_', 'and', '_gene_', 'staining', '_gene_', '_p_val_']"
4544,1.0,All 12 chronic-phase CML patients with a T315I mutation showed a complete hematologic response.,"['all', '_num_', '_disease_', '_gene_', 'patients', 'with', 'a', '_mutation_', 'mutation', 'showed', 'a', 'complete', 'hematologic', 'response']"
4545,1.0,"Overall, 87% had one VHL mutation, 12% showed promoter hypermethylation, and 6 patients had both.","['overall', '_num_', 'had', '_num_', '_gene_', 'mutation', '_num_', 'showed', 'promoter', 'hypermethylation', 'and', '_num_', 'patients', 'had', 'both']"
4546,1.0,"This was especially found for D835Y and D835V mutations, whereas D835H mutations were found to confer moderate resistance to ponatinib but relatively minimal resistance to AC220.","['this', 'was', 'especially', 'found', 'for', '_mutation_', 'and', '_mutation_', 'mutations', 'whereas', '_mutation_', 'mutations', 'were', 'found', 'to', 'confer', 'moderate', 'resistance', 'to', '_chemical_', 'but', 'relatively', 'minimal', 'resistance', 'to', '_abbrev_']"
4547,1.0,"This missense mutation was found in 3 unrelated VHL type 2A patients (patients V32, V60, V97).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'unrelated', '_gene_', 'type', '_gene_', 'patients', 'patients', '_gene_', '_abbrev_', '_abbrev_']"
4548,1.0,"83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation.","['_num_', 'patients', 'from', 'a', 'phase', 'ii', 'trial', '_chemical_', 'placebo', 'or', '_gene_', 'inhibitor', '_chemical_', 'with', '_gene_', 'mutant', 'tumors', 'were', 'retrospectively', 'assessed', 'for', 'differences', 'in', 'os', '_disease_', 'orr', 'and', 'change', 'in', 'tumor', 'size', 'at', 'week', '_num_', 'according', 'to', 'type', 'of', '_gene_', 'mutation']"
4549,1.0,"MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines.","['mek', 'inhibitor', 'resistant', '_chemical_', '_chemical_', '_abbrev_', 'uveal', 'melanoma', 'cell', 'lines', 'were', 'created', 'from', '_num_', '_gene_', '_mutation_', 'mutant', 'cell', 'lines']"
4550,1.0,Patients with IDH2(R172) mutations showed worse prognosis when compared to CEBPA(biallelic) mutations.,"['patients', 'with', '_gene_', '_abbrev_', 'mutations', 'showed', 'worse', 'prognosis', 'when', 'compared', 'to', '_gene_', 'biallelic', 'mutations']"
4551,1.0,"The overall survival rate was significantly lower in patients with high nuclear expression (N=121, 2+ moderate/3+ strong staining) than patients with low nuclear staining (N=89, 0 no/1+ weak staining)(P = 0.0169).","['the', 'overall', 'survival', 'rate', 'was', 'significantly', 'lower', 'in', 'patients', 'with', 'high', 'nuclear', 'expression', '_ineq_', '2+', 'moderate', '3+', 'strong', 'staining', 'than', 'patients', 'with', 'low', 'nuclear', 'staining', '_ineq_', '_num_', 'no', '1+', 'weak', 'staining', 'p', '_num_']"
4552,1.0,The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.,"['the', 'researchers', 'utilized', 'data', 'from', '_num_', 'previous', 'clinical', 'trials', 'in', 'japan', 'and', 'the', 'united', 'states', 'with', 'a', 'total', 'of', '_num_', '_disease_', 'patients']"
4553,1.0,"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.","['in', 'breast', 'cancer', 'patients', 'harboring', '_gene_', 'mutation', 'mutations', 'in', 'dna', 'contact', 'regions', 'such', 'as', '_abbrev_', 'are', 'prognostic', 'for', 'a', 'worse', 'relapse', 'free', 'survival', 'compared', 'to', 'other', 'non', 'silent', 'mutations', 'in', '_gene_']"
4554,1.0,"In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild type.","['in', 'patients', 'with', 'clear', 'cell', 'renal', 'cell', 'carcinoma', 'those', 'with', 'nonsilent', 'mutations', 'of', '_gene_', 'had', 'worse', 'overall', 'survival', 'than', 'wild', 'type']"
4555,1.0,4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal.,"['_ratio_', 'mice', 'treated', 'with', '_num_', '_disease_', '_chemical_', 'showed', 'regrowth', 'after', '_num_', 'month', 'treatment', 'withdrawal']"
4556,1.0,"In a clinical validation cohort, MAGEH protein expression was found in 4/4 ""non-effective"" cases and 2/5 effective cases based on RECIST criteria after gemcitabine treatment.","['in', 'a', 'clinical', 'validation', 'cohort', 'mageh', 'protein', 'expression', 'was', 'found', 'in', '_ratio_', 'non', 'effective', 'cases', 'and', '_ratio_', 'effective', 'cases', 'based', 'on', '_disease_', 'criteria', 'after', '_chemical_', 'treatment']"
4557,0.0,The meta-analysis investigated the association between CYP2D6 genotypes and response to tamoxifen treatment (loss/reduced function vs. unchanged/increased function).,"['the', '_disease_', 'analysis', 'investigated', 'the', 'association', 'between', '_gene_', 'genotypes', 'and', 'response', 'to', 'tamoxifen', 'treatment', 'loss', 'reduced', 'function', 'vs', 'unchanged', 'increased', 'function']"
4558,1.0,"In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21.","['in', 'a', 'study', 'a', 'group', 'of', '_num_', 'participants', '_num_', 'with', 'stage', 'iv', 'and', '_num_', 'with', 'stage', '_gene_', 'lung', 'adenocarcinoma', 'were', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_']"
4559,1.0,"BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).","['_gene_', '_mutation_', 'mutations', 'were', 'more', 'likely', 'to', 'be', 'proximal', 'tumors', '_num_', '_num_', 'p', '_num_', 'they', 'were', 'more', 'likely', 'to', 'be', 'poorly', 'differentiated', '_num_', '_num_', 'p', '_num_', 'they', 'were', 'more', 'likely', 'to', 'be', 'mucinous', 'carcinoma', 'type', '_num_', '_num_', '_p_val_', 'they', 'were', 'more', 'likely', 'to', 'have', 'lymphatic', 'invasion', '_num_', '_num_', '_p_val_', 'and', 'they', 'had', 'a', 'shorter', 'survival', 'time', '_num_', '_unit_', '_num_', '_unit_', '_p_val_']"
4560,1.0,"Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941.","['next', 'mmtv', '_disease_', 'tumors', 'were', 'dissociated', 'and', 'treated', 'with', '_abbrev_', 'inhibitor', '_chemical_']"
4561,1.0,"Except for the  imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.","['except', 'for', 'the', '_chemical_', 'resistant', '_mutation_', 'mutation', 'all', 'the', 'other', 'mutations', 'were', 'sensitive', 'to', 'both', '_chemical_', 'and', '_chemical_']"
4562,1.0,The S492R mutation was identified in two persons.,"['the', '_mutation_', 'mutation', 'was', 'identified', 'in', '_num_', 'persons']"
4563,1.0,"In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_abbrev_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'gene', 'fusion', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein', 'reported', 'to', 'be', 'sensitizing', 'to', '_chemical_']"
4564,0.0,"The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions.","['the', 'majority', 'of', 'synovial', 'sarcomas', 'are', 'characterized', 'by', '_abbrev_', 'or', '_abbrev_', 'but', 'other', 'rare', 'events', 'such', 'as', 'this', '_abbrev_', 'may', 'explain', 'some', 'or', 'all', 'of', 'the', 'synovial', 'sarcomas', 'that', 'are', 'negative', 'for', 'the', 'most', 'common', 'fusions']"
4565,1.0,"In an in vitro study, a Ba/F3  cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs. IC50: 1.83nM), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_abbrev_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'vs', '_abbrev_', '_num_', '_unit_', 'comparable', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein']"
4566,1.0,"Out of 178 patients, p53 alteration (n=132) was associated with decreased overall survival in comparison to normal p53 (n=46), p=0.007.","['out', 'of', '_num_', 'patients', '_gene_', 'alteration', '_ineq_', 'was', 'associated', 'with', 'decreased', 'overall', 'survival', 'in', 'comparison', 'to', 'normal', '_gene_', '_ineq_', '_p_val_']"
4567,1.0,91 osteosarcoma patients with a median age of 15 years were followed in this study.,"['_num_', 'osteosarcoma', 'patients', 'with', 'a', 'median', 'age', 'of', '_num_', 'years', 'were', 'followed', 'in', 'this', 'study']"
4568,1.0,"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs.","['in', 'an', 'in', 'vitro', 'study', 'using', '_abbrev_', 'cells', 'wildtype', '_gene_', 'and', '_abbrev_', 'cells', '_abbrev_', 'inhibition', 'of', 'cell', 'growth', 'was', 'used', 'as', 'an', 'assay', 'to', 'determine', 'sensitivity', 'to', 'irreversible', 'tyrosine', 'kinase', 'inhibitor', '_disease_', 'drugs']"
4569,1.0,"51 patients were enrolled (26 cohort 1, 25 cohort 2).","['_num_', 'patients', 'were', 'enrolled', '_num_', 'cohort', '_num_', '_num_', 'cohort', '_num_']"
4570,1.0,This resulted in 146 that were negative for RRM1 expression and 83 that were positive.,"['this', 'resulted', 'in', '_num_', 'that', 'were', 'negative', 'for', '_gene_', 'expression', 'and', '_num_', 'that', 'were', 'positive']"
4571,1.0,"In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).","['in', 'wild', 'type', '_gene_', 'patients', 'the', 'pooled', 'or', 'was', '_num_', '_num_', 'ci', '_range_', '_ineq_', '_p_val_']"
4572,1.0,"The ALK kinase domain mutation V1180L was found in these cells, and Ba/F3 cells expressing EML4 ALK  V1180L were highly resistant to alectinib.","['the', '_gene_', 'kinase', 'domain', 'mutation', '_mutation_', 'was', 'found', 'in', 'these', 'cells', 'and', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', '_gene_', '_mutation_', 'were', 'highly', 'resistant', 'to', '_chemical_']"
4573,1.0,There was co-dependancy on AKT and EGFR-signaling and inhibition of both pathways led to decreased cell-growth.,"['there', 'was', 'co', 'dependancy', 'on', '_gene_', 'and', '_gene_', 'signaling', 'and', 'inhibition', 'of', 'both', 'pathways', 'led', 'to', 'decreased', 'cell', 'growth']"
4574,1.0,This nonsense mutation was found in a VHL type 1 family of 6 individuals (family ID 3720).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_']"
4575,1.0,"FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts.","['_gene_', 'mrna', 'expression', 'rather', 'than', 'copy', 'number', 'alterations', 'were', 'predictive', 'of', 'response', 'to', '_gene_', 'inhibitor', '_chemical_', 'in', 'cell', 'lines', 'and', 'patient', 'derived', 'xenografts']"
4576,1.0,"IGF-1R nuclear immunostaining (IHC) was observed in 9 out of 16 samples of patients with different sarcomas (osteosarcoma, ewing sarcoma, liposarcoma, synovialsarcoma, desmoplastic tumor, rhabdomyosarcoma).","['_gene_', 'nuclear', 'immunostaining', '_gene_', 'was', 'observed', 'in', '_num_', 'out', 'of', '_num_', 'samples', 'of', 'patients', 'with', 'different', 'sarcomas', 'osteosarcoma', 'ewing', 'sarcoma', 'liposarcoma', 'synovialsarcoma', '_disease_', 'tumor', 'rhabdomyosarcoma']"
4577,1.0,Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib.,"['colorectal', 'cancer', 'cell', 'lines', 'were', 'evaluated', 'for', 'response', 'to', 'the', '_gene_', 'inhibitor', '_chemical_']"
4578,1.0,No patient with FLT3-ITD (n = 10) responded.,"['no', 'patient', 'with', '_gene_', 'n', '_num_', 'responded']"
4579,1.0,95% confidence interval of hazard ratio of between .17 and .77.,"['_num_', 'confidence', 'interval', 'of', 'hazard', 'ratio', 'of', 'between', '_num_', 'and', '_num_']"
4580,1.0,97 patients with melanoma were enrolled and treated with trametinib.,"['_num_', 'patients', 'with', 'melanoma', 'were', 'enrolled', 'and', 'treated', 'with', '_chemical_']"
4581,1.0,"In clones that emerged at 1,500 nmol/L SU5614 after ENU (mutagen) treatment, 127 of 179 clones (71%) displayed mutations, generating 9 different exchanges affecting 6 positions in the activation loop of FLT3.","['in', 'clones', 'that', 'emerged', 'at', '_num_', '_unit_', '_unit_', '_chemical_', 'after', '_gene_', 'mutagen', 'treatment', '_num_', 'of', '_num_', 'clones', '_num_', 'displayed', 'mutations', 'generating', '_num_', 'different', 'exchanges', 'affecting', '_num_', 'positions', 'in', 'the', 'activation', 'loop', 'of', '_gene_']"
4582,1.0,Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.,"['combined', '_gene_', 'and', '_gene_', 'inhibition', 'panitumumab', 'and', '_chemical_', 'showed', 'an', 'initial', 'partial', 'response', 'for', '_num_', 'months', 'with', 'subsequent', 'disease', 'progression']"
4583,1.0,"The second patient had USPC, and was treated with surgery and radiation.","['the', '_num_', 'patient', 'had', '_disease_', 'and', 'was', 'treated', 'with', 'surgery', 'and', 'radiation']"
4584,1.0,This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female).,"['this', 'study', 'analyses', '_num_', 'new', 'acute', 'promyelocytic', 'leukemia', 'patients', '_num_', 'male', 'and', '_num_', 'female']"
4585,1.0,"This variant, identified in a case of microsatellite-unstable villous adenomas was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', 'a', 'case', 'of', '_disease_', '_disease_', 'adenomas', 'was', 'confirmed', 'to', 'be', 'somatic', 'in', 'a', 'patient', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
4586,1.0,"In previously untreated patients with chronic lymphocytic leukemia, POT1 mutations (N=13) were associated with shorter overall survival than wildtype POT1 (N=148) in univariate and multivariate analysis (HR, 4.0; 95% CI, 1.6-10.1; P = .003) independent of IGHV mutation status, Binet stage, and serum beta-2-microglobulin.","['in', 'previously', 'untreated', 'patients', 'with', 'chronic', 'lymphocytic', 'leukemia', '_gene_', 'mutations', '_ineq_', 'were', 'associated', 'with', 'shorter', 'overall', 'survival', 'than', 'wildtype', '_gene_', '_ineq_', 'in', 'univariate', 'and', 'multivariate', 'analysis', 'hr', '_num_', '_num_', 'ci', '_range_', 'p', '_num_', 'independent', 'of', '_gene_', 'mutation', 'status', 'binet', 'stage', 'and', 'serum', '_gene_']"
4587,1.0,HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma.,"['_gene_', 'status', 'was', 'shown', 'to', 'be', 'a', 'strong', 'and', 'independent', 'risk', 'factor', 'in', 'oropharyngeal', 'carcinoma']"
4588,1.0,The methylation status of MLH1 was analyzed in a study of 53 paraffin-embedded gastric cancer samples.,"['the', 'methylation', 'status', 'of', '_gene_', 'was', 'analyzed', 'in', 'a', 'study', 'of', '_num_', 'paraffin', 'embedded', 'gastric', 'cancer', 'samples']"
4589,1.0,Case report of a 44-year-old patient with recurrent HER2-positive breast cancer.,"['case', 'report', 'of', 'a', '_age_', 'patient', 'with', 'recurrent', '_gene_', 'breast', 'cancer']"
4590,1.0,The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.,"['the', '_num_', 'arms', 'of', 'the', 'study', 'were', '_chemical_', 'and', '_chemical_', 'with', 'either', 'placebo', 'or', 'pertuzumab']"
4591,1.0,(family #146 in the publication).,"['family', '_num_', 'in', 'the', 'publication']"
4592,1.0,Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature.,"['molecular', 'analysis', 'of', 'human', 'metastatic', 'melanoma', 'samples', 'revealed', 'a', 'correlation', 'between', 'activation', 'of', 'the', '_gene_', 'β', '_gene_', 'signalling', 'pathway', 'and', 'absence', 'of', 'a', '_disease_', 'gene', 'expression', 'signature']"
4593,1.0,"In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study.","['in', '_num_', 'colorectal', 'cancer', 'patients', 'with', 'established', '_mutation_', 'mutation', '_num_', 'confirmed', 'response', '_num_', 'instances', 'of', 'stable', 'disease', 'and', '_num_', 'case', 'of', 'progressive', 'disease', 'was', 'seen', 'which', 'contrasted', 'strongly', 'with', 'a', '_num_', 'confirmed', 'response', 'rate', 'seen', 'in', 'metastatic', '_mutation_', 'melanoma', 'patients', 'similarly', 'treated', 'in', 'the', 'same', 'study']"
4594,1.0,In all patients with multiple affected family members the missense mutation segregated with the disease.,"['in', 'all', 'patients', 'with', 'multiple', 'affected', 'family', 'members', 'the', 'missense', 'mutation', 'segregated', 'with', 'the', 'disease']"
4595,1.0,Median progression-free survival was 15.1 weeks.,"['median', 'progression', 'free', 'survival', 'was', '_num_', 'weeks']"
4596,1.0,"In an in vitro study, a Ba/F3  cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 10.31-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'as', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein']"
4597,1.0,"EGFR mutations were seen in 5/7 responders but not in any of the non-responders, which was a significant result (p=0.003).","['_gene_', 'mutations', 'were', 'seen', 'in', '_ratio_', 'responders', 'but', 'not', 'in', 'any', 'of', 'the', 'non', 'responders', 'which', 'was', 'a', 'significant', 'result', '_p_val_']"
4598,1.0,"Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation.","['_chemical_', 'is', 'effective', 'in', 'patients', 'with', '_gene_', 'internal', 'tandem', 'repeat', 'mutations', 'but', 'not', 'in', 'patients', 'with', 'wild', 'type', 'or', '_abbrev_', 'mutation']"
4599,1.0,"In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer.","['in', 'this', 'preclinical', 'study', 'on', 'the', 'effects', 'of', '_chemical_', 'panitumumab', 'or', '_abbrev_', 'on', 'various', '_gene_', 'mutations', 'in', 'colorectal', 'cancer']"
4600,1.0,"Of these 9 patients, 3 showed confirmed responses to AZD4547.","['of', 'these', '_num_', 'patients', '_num_', 'showed', 'confirmed', 'responses', 'to', '_chemical_']"
4601,1.0,"In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy.","['in', 'chemotherapy', 'refractory', 'patients', 'with', 'colorectal', 'cancer', 'nras', 'mutation', 'status', 'primarily', '_abbrev_', 'was', 'not', 'informative', 'for', 'disease', 'control', 'rate', 'progression', 'free', 'survival', 'or', 'overall', 'survival', 'following', '_chemical_', 'plus', 'chemotherapy']"
4602,1.0,"Both patients harbored a second MLH1 mutation (c.790+1G > A and p.M1L, respectively).","['both', 'patients', 'harbored', 'a', '_num_', '_gene_', 'mutation', 'c', '790+1g', 'a', 'and', '_mutation_', 'respectively']"
4603,1.0,"All 3 individuals carried angiomas, 2 of 3 carried cerebellar hemangioblastomas and one carried renal cell carcinoma.","['all', '_num_', 'individuals', 'carried', 'angiomas', '_num_', 'of', '_num_', 'carried', 'cerebellar', '_disease_', 'and', '_num_', 'carried', 'renal', 'cell', 'carcinoma']"
4604,1.0,PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.,"['_gene_', 'expression', 'was', 'associated', 'with', 'response', 'to', '_chemical_', 'in', 'a', 'retrospective', 'analysis', 'of', '_num_', 'patients', 'after', 'preclinical', 'validation', 'and', 'mechanistic', 'analysis', 'of', 'the', '_chemical_']"
4605,1.0,"80 progressed tumors were tested for ALK mutations, and 6 mutant ALK variants were found.","['_num_', 'progressed', 'tumors', 'were', 'tested', 'for', '_gene_', 'mutations', 'and', '_num_', 'mutant', '_gene_', 'variants', 'were', 'found']"
4606,1.0,This missense mutation was found in 2 family members with VHL type 1 phenotype (Family ID 3736 in publication).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_', 'in', 'publication']"
4607,1.0,NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype).,"['_gene_', 'mutations', 'were', 'associated', 'with', 'intermediate', 'risk', 'cytogenetics', 'including', 'normal', 'karyotype']"
4608,1.0,"A healthy, 36-year-old woman presented with a palpable right breast mass upon biopsy determined to be high-grade, triple negative invasive ductal carcinoma.","['a', 'healthy', '_age_', 'woman', 'presented', 'with', 'a', 'palpable', 'right', 'breast', 'mass', 'upon', 'biopsy', 'determined', 'to', 'be', 'high', 'grade', 'triple', 'negative', 'invasive', 'ductal', 'carcinoma']"
4609,1.0,Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity.,"['knockdown', 'of', '_gene_', 'in', 'these', 'derivative', 'cells', 'resulted', 'in', '_chemical_', 'sensitivity']"
4610,1.0,"With low or high EGF culture conditions, a 4x or 3.5x decrease in IC50 for ipatasertib was seen in PTEN knockout cells, respectively.","['with', 'low', 'or', 'high', '_gene_', 'culture', 'conditions', 'a', '4x', 'or', '_num_', '5x', 'decrease', 'in', '_abbrev_', 'for', 'ipatasertib', 'was', 'seen', 'in', '_gene_', 'knockout', 'cells', 'respectively']"
4611,1.0,Two of 3 also carried renal cell carcinoma.,"['_num_', 'of', '_num_', 'also', 'carried', 'renal', 'cell', 'carcinoma']"
4612,1.0,Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy.,"['paired', 'tumor', 'samples', 'were', 'analyzed', 'from', '_num_', 'patients', 'with', 'metastatic', 'melanoma', 'and', 'initial', 'response', 'with', 'a', 'subsequent', 'relapse', 'under', 'pembrolizumab', '_gene_', 'checkpoint', 'inhibitor', 'therapy']"
4613,1.0,"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.","['in', 'patients', 'with', 'invasive', 'epithelial', 'ovarian', 'cancer', 'those', 'with', 'mutations', 'in', '_gene_', 'had', 'better', '_num_', 'year', 'overall', 'survival']"
4614,1.0,IKZF1 deletions in patients with BCR-ABL–positive adult acute lymphoblastic leukemia were associated with reduced disease-free survival compared to wild type patients.,"['_gene_', 'deletions', 'in', 'patients', 'with', '_gene_', 'abl–positive', 'adult', 'acute', '_disease_', 'leukemia', 'were', 'associated', 'with', 'reduced', '_disease_', 'survival', 'compared', 'to', 'wild', 'type', 'patients']"
4615,1.0,"we observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased.","['we', 'observed', 'that', 'while', 'valproic', 'acid', 'has', 'no', 'intrinsic', 'cytotoxic', 'effect', 'on', 'tumor', 'cells', 'it', 'enhanced', 'the', 'cytotoxic', 'effect', 'of', '_chemical_', 'specifically', 'in', 'cell', 'lines', 'where', '_gene_', 'expression', 'was', 'increased']"
4616,1.0,Genomic characterization of PDX244LR1 showed the acquisition of an RB1 frameshift mutation (RB1 p.M695fs*26).,"['genomic', 'characterization', 'of', '_abbrev_', 'showed', 'the', 'acquisition', 'of', 'an', '_gene_', 'frameshift', 'mutation', '_gene_', 'p', '_abbrev_']"
4617,1.0,At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.,"['at', '_num_', 'months', 'post', 'treatment', 'time', 'of', 'case', 'study', 'report', 'the', 'patient', 'maintains', 'near', 'resolution', 'of', '_disease_', 'lesions']"
4618,1.0,"These mutations were also validated using xenograft, in vitro and 3D-modeling.","['these', 'mutations', 'were', 'also', 'validated', 'using', 'xenograft', 'in', 'vitro', 'and', '3d', 'modeling']"
4619,1.0,"In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', 'iv', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_abbrev_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
4620,1.0,Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.,"['melanoma', 'associated', 'with', 'nras', '_abbrev_', 'mutation', 'was', 'more', 'often', 'associated', 'with', 'those', 'at', 'the', 'extremity', 'than', 'those', 'at', 'the', 'trunk']"
4621,1.0,Mutations E2014K and E2419K were shown to be activating in-vitro.,"['mutations', '_abbrev_', 'and', '_mutation_', 'were', 'shown', 'to', 'be', 'activating', 'in', 'vitro']"
4622,1.0,"In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations.","['in', 'a', 'phase', '_num_', 'clinical', 'trial', 'for', 'the', 'use', 'of', '_chemical_', 'for', 'various', 'advanced', 'solid', 'tumors', '_num_', 'out', 'of', '_num_', '_disease_', 'patients', 'harbored', '_gene_', 'mutations']"
4623,1.0,"Cells harboring in-frame deletions in BRAF in the L485-P490 amino acid region were found to be sensitive to the RAF dimer inhibitor LY3009120, but not sensitive to the BRAF-selective inhibitors vemurafenib or dabrafenib.","['cells', 'harboring', 'in', 'frame', 'deletions', 'in', '_gene_', 'in', 'the', '_abbrev_', 'amino', 'acid', 'region', 'were', 'found', 'to', 'be', 'sensitive', 'to', 'the', 'raf', 'dimer', 'inhibitor', '_chemical_', 'but', 'not', 'sensitive', 'to', 'the', '_gene_', 'selective', 'inhibitors', '_chemical_', 'or', '_chemical_']"
4624,1.0,7 patients showed stable disease.,"['_num_', 'patients', 'showed', 'stable', 'disease']"
4625,1.0,"Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma.","['radiographic', 'responses', 'were', 'achieved', 'in', 'previously', 'treated', 'patients', 'with', 'breast', 'cancer', '_disease_', 'and', 'melanoma']"
4626,1.0,MET amplification was seen in 4 of 75 patients tested (no baseline samples available).,"['met', 'amplification', 'was', 'seen', 'in', '_num_', 'of', '_num_', 'patients', 'tested', 'no', 'baseline', 'samples', 'available']"
4627,1.0,"VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals .This nonsense mutation was found in a VHL type 1 family of 6 individuals (Family ID 3770 in publication).","['_gene_', 'mutations', 'were', 'detected', 'in', 'affected', 'family', 'members', 'but', 'not', 'in', 'unaffected', 'family', 'members', 'or', '_num_', 'normal', 'individuals', 'this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_', 'in', 'publication']"
4628,1.0,"Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation.","['finally', 'transduction', 'of', 'ba', '_abbrev_', 'cells', 'with', '_gene_', '_abbrev_', '_gene_', 'independent', 'proliferation']"
4629,1.0,"This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup.","['this', 'effect', 'was', 'observed', 'in', 'the', '_gene_', 'exon', '_num_', 'deletion', 'subgroup', 'but', 'not', 'in', 'the', '_mutation_', 'mutant', 'subgroup']"
4630,1.0,Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma.,"['phase', 'iii', 'trial', 'to', 'compare', '_chemical_', 'or', 'metothrexate', 'in', 'recurrent', 'or', 'metastatic', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma']"
4631,1.0,"Report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in 2/3 Ewing Sarcoma patients with germline PTPRD mutations (V253I and W775*, R995C).","['report', 'of', 'complete', 'response', 'to', '_gene_', 'antibody', 'with', 'or', 'without', '_gene_', 'inhibitor', 'tensirolimus', 'in', '_ratio_', 'ewing', 'sarcoma', 'patients', 'with', 'germline', '_gene_', 'mutations', '_mutation_', 'and', '_abbrev_', '_abbrev_']"
4632,1.0,"This splice mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 45).","['this', 'splice', 'mutation', 'was', 'found', 'in', 'a', 'german', '_gene_', 'type', '_num_', 'patient', 'with', 'retinal', 'angiomas', '_disease_', 'of', 'the', 'central', 'nervous', 'system', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts', 'family', '_gene_', '_num_']"
4633,1.0,Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.,"['combined', '_chemical_', 'and', '_chemical_', 'administration', 'to', 'athymic', 'nude', 'mice', 'subcutanousely', 'injected', 'with', 'the', '_abbrev_', 'colorectal', 'cell', 'line', 'with', 'a', '_gene_', '_mutation_', 'mutation', 'effectively', 'inhibited', 'tumor', 'growth', 'significantly', 'more', 'than', 'single', 'agent', 'therapy']"
4634,1.0,"Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume.","['administration', 'of', '_abbrev_', '_chemical_', 'and', '_gene_', 'inhibitor', '_chemical_', 'to', '_mutation_', 'mice', 'with', 'established', 'tumors', 'resulted', 'in', 'reduced', 'tumor', '_chemical_', 'and', '_abbrev_', 'levels', 'and', 'significant', 'regression', 'of', 'tumor', 'volume']"
4635,0.0,"Confidence in this variant being pathogenic for VHL disease is not high enough to warrant classification of Likely Pathogenic, and is therefore classified as Uncertain Significance.","['confidence', 'in', 'this', 'variant', 'being', 'pathogenic', 'for', '_gene_', 'disease', 'is', 'not', 'high', 'enough', 'to', 'warrant', 'classification', 'of', 'likely', 'pathogenic', 'and', 'is', 'therefore', 'classified', 'as', 'uncertain', 'significance']"
4636,1.0,"The MLL-MLLT3 translocation, along with other MLL translocations, are so common in acute myeloid leukemia that the World Health Organization has developed a sub-type of ""AML with t(9;11)(p22;q23); MLLT3-MLL"" under the AML with recurrent genetic abnormalities diagnosis.","['the', '_abbrev_', 'translocation', 'along', 'with', 'other', '_gene_', 'translocations', 'are', 'so', 'common', 'in', 'acute', 'myeloid', 'leukemia', 'that', 'the', 'world', 'health', 'organization', 'has', 'developed', 'a', 'sub', 'type', 'of', '_disease_', 'with', 't', '_num_', '_num_', '_gene_', '_abbrev_', '_abbrev_', 'under', 'the', '_disease_', 'with', 'recurrent', 'genetic', 'abnormalities', 'diagnosis']"
4637,1.0,No mutations found in PTEN were effective in predicting tumor response to everolimus treatment.,"['no', 'mutations', 'found', 'in', '_gene_', 'were', 'effective', 'in', 'predicting', 'tumor', 'response', 'to', '_chemical_', 'treatment']"
4638,1.0,"In the absence of gene fusion products, patients with biallelic CEBPA mutations showed the highest rate of survival (~78%) when compared to IDH2 (R172) mutations, NPM1(W288fs) mutations, chromatin-spliceosome mutations and TP53–aneuploidy.","['in', 'the', 'absence', 'of', 'gene', 'fusion', 'products', 'patients', 'with', 'biallelic', '_gene_', 'mutations', 'showed', 'the', 'highest', 'rate', 'of', 'survival', '_num_', 'when', 'compared', 'to', '_gene_', '_abbrev_', 'mutations', '_gene_', '_abbrev_', 'mutations', 'chromatin', 'spliceosome', 'mutations', 'and', '_abbrev_']"
4639,1.0,This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC.,"['this', 'phase', 'iii', 'clinical', 'trial', 'lux', 'lung', '_num_', '_abbrev_', 'was', 'performed', 'in', 'asian', 'patients', 'with', '_gene_', 'mutant', 'advanced', '_disease_']"
4640,1.0,"High AREG expression in tumor cells was associated with reduced overall survival  (hazard ratio: 2.2, P = 0.002) and progression free survival (hazard ratio: 2.2, P = 0.016) compared to patients with low AREG expression score.","['high', '_gene_', 'expression', 'in', 'tumor', 'cells', 'was', 'associated', 'with', 'reduced', 'overall', 'survival', 'hazard', 'ratio', '_num_', 'p', '_num_', 'and', 'progression', 'free', 'survival', 'hazard', 'ratio', '_num_', 'p', '_num_', 'compared', 'to', 'patients', 'with', 'low', '_gene_', 'expression', 'score']"
4641,0.0,V600E is associated with adverse pathological features of colorectal cancer.,"['_mutation_', 'is', 'associated', 'with', 'adverse', 'pathological', 'features', 'of', 'colorectal', 'cancer']"
4642,1.0,MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.,"['_chemical_', 'cell', 'lines', 'harboring', 'the', '_mutation_', 'mutation', 'in', 'the', '_disease_', 'domain', 'of', '_gene_', 'have', 'shown', 'resistance', 'to', 'hormone', 'therapy']"
4643,1.0,"In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).","['in', 'analysis', 'of', 'lux', 'lung', '_num_', 'and', 'lux', 'lung', '_num_', 'trials', '_abbrev_', 'and', '_abbrev_', 'of', '_gene_', 'mutant', '_disease_', 'median', 'overall', 'survival', 'with', '_chemical_', 'treatment', 'was', 'seen', 'to', 'be', 'significantly', 'improved', 'over', 'chemotherapy', '_num_', 'vs', '_num_', 'and', '_num_', 'vs', '_num_', 'months', 'in', 'lux', 'lung', '_num_', 'and', 'lux', 'lung', '_num_', 'respectively']"
4644,1.0,"Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.","['unlike', 'other', 'studies', 'that', 'suggest', 'a', 'poorer', 'outcome', '_gene_', 'mutation', 'in', 'this', 'study', 'was', 'not', 'correlated', 'with', 'poorer', 'prognosis', 'in', 'papillary', 'thyroid', 'cancer']"
4645,1.0,This nonsense mutation was found in a VHL type 1 patient and familiy of 4 individuals (family IDs 3759 and 3760).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'and', 'familiy', 'of', '_num_', 'individuals', 'family', 'ids', '_num_', 'and', '_num_']"
4646,1.0,A significant interaction between chemotherapy and T17 deletion was found (P =.009).,"['a', 'significant', 'interaction', 'between', 'chemotherapy', 'and', '_gene_', 'deletion', 'was', 'found', 'p', '=', '_num_']"
4647,1.0,6/18 (33%) of the resistant lines and in only 1/22 (5%) of the sensitive lines (P = 0.017) had CCND1 copy number gain.,"['_ratio_', '_num_', 'of', 'the', 'resistant', 'lines', 'and', 'in', 'only', '_ratio_', '_num_', 'of', 'the', 'sensitive', 'lines', 'p', '_num_', 'had', '_gene_', 'copy', 'number', 'gain']"
4648,1.0,The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants.,"['the', 'results', 'indicate', 'that', '3a', 'b', 'is', 'a', 'targetable', 'driver', 'mutation', 'as', 'other', '_chemical_', 'variants']"
4649,1.0,A second case of mFL-HCC confirmed that the fusion was detectable in conventional components.,"['a', '_num_', 'case', 'of', 'mfl', '_gene_', 'confirmed', 'that', 'the', 'fusion', 'was', 'detectable', 'in', 'conventional', 'components']"
4650,1.0,"Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%.","['overall', 'in', 'the', '_num_', '_gene_', 'positive', 'patients', 'treated', 'in', 'the', 'study', '_num_', 'had', 'partial', 'responses', 'including', 'this', 'patient', 'and', '_num_', 'had', 'a', 'complete', 'response', 'for', 'an', 'overall', 'response', 'rate', 'of', '_num_']"
4651,1.0,"In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis.","['in', '_gene_', 'positive', '_chemical_', 'resistant', 'breast', 'cancer', 'cell', 'lines', 'knockdown', 'of', '_gene_', 'with', '_gene_', 'or', 'with', '_chemical_', 'induced', 'growth', 'inhibition', 'and', 'apoptosis']"
4652,1.0,"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data.","['_gene_', 'fusion', 'in', 'pan', 'negative', 'melanomas', 'were', 'identified', 'in', '_disease_', 'data']"
4653,1.0,Significant difference was seen in objective response with 70%  of cases with afatinib vs. 56% of cases with gefitinib.,"['significant', 'difference', 'was', 'seen', 'in', 'objective', 'response', 'with', '_num_', 'of', 'cases', 'with', '_chemical_', 'vs', '_num_', 'of', 'cases', 'with', '_chemical_']"
4654,1.0,Ba/F3 cells with unaltered EML4-ALK had crizotinib IC50 values for viability of 132 +/- 45 nM.,"['ba', '_abbrev_', 'cells', 'with', 'unaltered', '_chemical_', 'had', '_chemical_', '_abbrev_', 'values', 'for', 'viability', 'of', '_num_', '_num_', '_unit_']"
4655,1.0,Response to olaparib was observed in 4 of 5 with prostate cancer patients with ATM aberrations (2 germline).,"['response', 'to', '_chemical_', 'was', 'observed', 'in', '_num_', 'of', '_num_', 'with', 'prostate', 'cancer', 'patients', 'with', 'atm', 'aberrations', '_num_', 'germline']"
4656,1.0,129 patients were treated with afatinib.,"['_num_', 'patients', 'were', 'treated', 'with', '_chemical_']"
4657,1.0,141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC.,"['_num_', 'patients', 'were', 'analyzed', 'for', '_gene_', '_gene_', 'positivity', 'by', 'fish', 'and', 'or', '_gene_']"
4658,1.0,This patient also harbored MLH1 p.Q149* and MSH6 p.I972F mutations as similar variant allele frequencies.,"['this', 'patient', 'also', 'harbored', '_gene_', 'p', '_abbrev_', 'and', '_gene_', 'p', '_abbrev_', 'mutations', 'as', 'similar', 'variant', 'allele', 'frequencies']"
4659,1.0,C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance.,"['_mutation_', 'was', 'observed', 'as', 'a', 'secondary', 'kit', 'mutation', 'in', '_num_', 'patient', 'with', 'secondary', '_chemical_', 'resistance']"
4660,1.0,"In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival.","['in', 'renal', 'clear', 'cell', 'carcinoma', 'patients', 'with', '_gene_', 'mutations', 'did', 'not', 'have', 'a', 'significant', 'impact', 'on', 'cancer', 'specific', 'survival']"
4661,1.0,Gefitinib treatment with concentrations of 50 μM showed similar effects as observed for the application of 25 mM nicotinamide.,"['_chemical_', 'treatment', 'with', 'concentrations', 'of', '_num_', 'μm', 'showed', 'similar', 'effects', 'as', 'observed', 'for', 'the', 'application', 'of', '_num_', '_unit_', '_chemical_']"
4662,1.0,"ACMG evidence codes: 'PVS1' based on deletion of all exons, 'PP1' based on segregation results, 'PP4' because the patients phenotypes are highly specific for a disease with single genetic etiology.","['acmg', 'evidence', 'codes', ""'pvs1"", 'based', 'on', 'deletion', 'of', 'all', 'exons', ""'pp1"", 'based', 'on', 'segregation', 'results', ""'pp4"", 'because', 'the', 'patients', 'phenotypes', 'are', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'single', 'genetic', 'etiology']"
4663,1.0,"In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', 'iv', '_disease_', 'cell', 'lung', 'carcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_mutation_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
4664,1.0,"This insertion mutation was detected in a VHL type 1 patient (family ID 4410 in publication) with angiomas, cerebellar hemangioblastomas, and renal cell carcinoma.","['this', 'insertion', 'mutation', 'was', 'detected', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'family', 'id', '_num_', 'in', 'publication', 'with', 'angiomas', 'cerebellar', '_disease_', 'and', 'renal', 'cell', 'carcinoma']"
4665,1.0,Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.,"['case', 'report', 'of', 'a', 'patient', 'with', 'metastatic', 'prostate', 'cancer', 'and', 'underexpression', 'of', '_gene_', 'who', 'showed', 'a', 'nonspecified', 'response', 'to', '_chemical_', 'for', 'at', 'least', '_num_', 'months']"
4666,1.0,Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).,"['_chemical_', 'was', 'more', 'effective', 'in', 'cell', 'lines', '_abbrev_', 'vs', '_disease_', '_abbrev_', 'and', '_num_', 'patient', 'samples', 'that', 'exhibit', 'elevated', '_gene_', 'expression', 'by', '_gene_']"
4667,1.0,"Ectopic expression of EML4-ALK V1180L in Ba/F3 cells caused IL3 independent growth as well as marked sensitization to TAE684, to a level greater than that seen in EML4-ALK I1171T (alectinib resistance mutation) or EML4-ALK wt, and over 1000x greater sensitivity than unaltered Ba/F3 + IL3.","['ectopic', 'expression', 'of', '_chemical_', '_mutation_', 'in', 'ba', '_abbrev_', 'cells', 'caused', '_gene_', 'independent', 'growth', 'as', 'well', 'as', 'marked', 'sensitization', 'to', '_chemical_', 'to', 'a', 'level', 'greater', 'than', 'that', 'seen', 'in', '_chemical_', '_mutation_', '_chemical_', 'resistance', 'mutation', 'or', '_chemical_', '_gene_', 'and', 'over', '1000x', 'greater', 'sensitivity', 'than', 'unaltered', 'ba', '_abbrev_', '_gene_']"
4668,1.0,"we conclude that DUX4 fusions may be a target driver resulting in AYA-ALL, and that AYA-ALL may be a distinct clinical entity.","['we', 'conclude', 'that', '_gene_', 'fusions', 'may', 'be', 'a', 'target', 'driver', 'resulting', 'in', 'aya', 'all', 'and', 'that', 'aya', 'all', 'may', 'be', 'a', 'distinct', 'clinical', 'entity']"
4669,1.0,"Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts.","['among', 'the', 'genes', 'tested', 'for', 'mutations', '_gene_', '_gene_', '_gene_', 'met', '_gene_', 'ret', 'and', '_gene_', '_gene_', 'mutations', '_num_', '_disease_', 'showed', 'a', 'significant', 'enrichment', 'in', 'sensitive', 'xenografts']"
4670,1.0,Survival rates of tumor-bearing mice with everolimus showed time-dependency consistent with mTOR protein levels.,"['survival', 'rates', 'of', '_disease_', 'mice', 'with', '_chemical_', 'showed', 'time', 'dependency', 'consistent', 'with', '_gene_', 'protein', 'levels']"
4671,1.0,GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT.,"['gist', 'patients', 'with', 'exon', '_num_', 'kit', 'mutations', 'had', 'reduced', 'overall', 'survival', 'compared', 'to', 'patients', 'wiltype', 'for', 'kit']"
4672,1.0,"In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed.","['in', 'this', 'study', 'the', 'investigators', 'followed', '_num_', 'patients', 'treated', 'with', '_chemical_', 'and', 'then', 'they', 'collected', 'biopsies', 'of', 'lesions', 'that', 'progressed']"
4673,1.0,"Additionally, controlling for cases with TP53 deletions/mutations, SF3B1 mutations were associated with reduced progression free survival for patients in the fludarabine plus cyclophosphamide treatment arm when compared to wildtype SF3B1 (29.4 vs 46 months, P=0.002).","['additionally', 'controlling', 'for', 'cases', 'with', '_gene_', 'deletions', 'mutations', '_gene_', 'mutations', 'were', 'associated', 'with', 'reduced', 'progression', 'free', 'survival', 'for', 'patients', 'in', 'the', '_chemical_', 'plus', '_chemical_', 'treatment', 'arm', 'when', 'compared', 'to', 'wildtype', '_gene_', '_num_', 'vs', '_num_', 'months', '_p_val_']"
4674,1.0,"The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life.","['the', 'patient', 'was', 'treated', 'with', 'iplimumab', 'a', '_gene_', 'receptor', 'inhibitor', 'and', 'after', '_num_', 'days', 'there', 'was', 'a', 'reduction', 'in', 'erythema', 'and', 'ulceration', 'by', '_num_', 'a', 'reduction', 'in', 'tumor', 'size', 'by', '_num_', 'and', 'overall', 'improved', 'quality', 'of', 'life']"
4675,1.0,Study explored the expression of the PTPN11 protein (SHP2) and found that expression was increased in a cohort of 112 laryngeal cancer samples.,"['study', 'explored', 'the', 'expression', 'of', 'the', '_gene_', 'protein', '_gene_', 'and', 'found', 'that', 'expression', 'was', 'increased', 'in', 'a', 'cohort', 'of', '_num_', 'laryngeal', 'cancer', 'samples']"
4676,1.0,"Several different ROS1 fusion partners were identified, but no clinical differences in outcome were associated with the identity of the 5' partner.","['several', 'different', '_gene_', 'fusion', 'partners', 'were', 'identified', 'but', 'no', 'clinical', 'differences', 'in', 'outcome', 'were', 'associated', 'with', 'the', 'identity', 'of', 'the', '_num_', 'partner']"
4677,1.0,"The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells.","['the', '_abbrev_', 'for', 'parental', 'ba', '_abbrev_', 'supplemented', 'with', '_gene_', 'was', '_num_', '_unit_', 'resulting', 'in', 'a', 'fold', 'difference', 'of', '_num_', 'for', '_chemical_', 'and', '_num_', 'for', '_chemical_', 'indicating', 'some', 'reduced', 'sensitivity', 'for', '_chemical_', 'in', 'direct', 'comparison', 'to', '_chemical_', 'but', 'substantial', 'sensitization', 'to', '_chemical_', 'for', '_chemical_', 'in', 'ba', '_abbrev_', 'cells']"
4678,1.0,Two harbored the G1269A mutation that also led to crizotinib-resistance in-vitro.,"['_num_', 'harbored', 'the', '_mutation_', 'mutation', 'that', 'also', 'led', 'to', '_chemical_', 'resistance', 'in', 'vitro']"
4679,1.0,"Those with mutations had worse overall survival than wild type (median OS, 1.43 years vs. 3.86 years).","['those', 'with', 'mutations', 'had', 'worse', 'overall', 'survival', 'than', 'wild', 'type', 'median', 'os', '_num_', 'years', 'vs', '_num_', 'years']"
4680,1.0,43 Italian patients were molecularly analyzed for Von Hippel-Lindau disease based on clinical suspicion.,"['_num_', 'italian', 'patients', 'were', '_chemical_', 'analyzed', 'for', '_disease_', 'hippel', 'lindau', 'disease', 'based', 'on', 'clinical', 'suspicion']"
4681,1.0,EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.,"['egfrviii', 'and', '_gene_', 'coexpression', 'were', 'associated', 'with', 'responsiveness', 'to', '_gene_', '_disease_']"
4682,1.0,RNAi mediated BAP1 knockdown increased sensitivity to HDAC inhibition (VPA).,"['_gene_', 'mediated', '_gene_', 'knockdown', 'increased', 'sensitivity', 'to', '_gene_', 'inhibition', '_disease_']"
4683,1.0,"A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild type MAP2K1, or cells expressing a constitutively active form.","['_abbrev_', 'cells', 'expressing', '_gene_', '_mutation_', 'mutation', 'conferred', 'an', 'approximately', '_n_fold_', 'increased', 'resistance', 'to', '_chemical_', '_chemical_', 'induced', 'growth', 'inhibition', 'when', 'compared', 'to', 'untransduced', 'cells', 'cells', 'expressing', 'wild', 'type', '_gene_', 'or', 'cells', 'expressing', 'a', '_disease_', 'active', 'form']"
4684,1.0,Two palbociclib-resistant cell lines were derived through chronic exposure to 1 μmol/L palbociclib during 3 to 4 months.,"['_num_', '_chemical_', 'resistant', 'cell', 'lines', 'were', 'derived', 'through', 'chronic', 'exposure', 'to', '_num_', 'μmol', '_unit_', '_chemical_', 'during', '_num_', 'to', '_num_', 'months']"
4685,1.0,The M351T mutation was  sensitive to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'sensitive', 'to', '_chemical_']"
4686,1.0,"A total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors.","['a', 'total', 'of', '_num_', 'patients', 'with', '_gene_', '_gene_', 'were', 'screened', 'for', 'this', 'study', '_num_', 'patients', '_num_', 'were', 'identified', 'to', 'have', '_gene_', 'tumors']"
4687,1.0,There was no correlation between VHL status and overall response rate or progression free survival under pazopanib therapy.,"['there', 'was', 'no', 'correlation', 'between', '_gene_', 'status', 'and', 'overall', 'response', 'rate', 'or', 'progression', 'free', 'survival', 'under', '_chemical_', 'therapy']"
4688,1.0,NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients).,"['_gene_', 'fusions', '_num_', '_abbrev_', 'and', '_num_', '_abbrev_', 'were', 'identified', 'in', '_num_', 'of', 'korean', 'colorectal', 'cancer', 'patients', '_num_', 'patients']"
4689,1.0,In cell culture studies Ba/F3 cells with EML4-ALK I1171T required more that 10x the concentration of alectinib to significantly reduce viability that was required for EML4-ALK wild type expressing cells.,"['in', 'cell', 'culture', 'studies', 'ba', '_abbrev_', 'cells', 'with', '_chemical_', '_mutation_', 'required', 'more', 'that', '10x', 'the', 'concentration', 'of', '_chemical_', 'to', 'significantly', 'reduce', 'viability', 'that', 'was', 'required', 'for', '_chemical_', 'wild', 'type', 'expressing', 'cells']"
4690,1.0,ALK rearrangement was verified via FISH.,"['_gene_', 'rearrangement', 'was', 'verified', 'via', 'fish']"
4691,1.0,"The patient progressed on lorlatinib after 8 months, at which point whole exome sequencing revealed an EML4-ALK C1156Y–L1198F double mutation.","['the', 'patient', 'progressed', 'on', 'lorlatinib', 'after', '_num_', 'months', 'at', 'which', 'point', 'whole', 'exome', 'sequencing', 'revealed', 'an', '_chemical_', '_abbrev_', 'double', 'mutation']"
4692,1.0,"Three patients had a PR, 16 patients had SD >= 4 weeks.","['_num_', 'patients', 'had', 'a', 'pr', '_num_', 'patients', 'had', 'sd', '_num_', 'weeks']"
4693,1.0,A 21 year old male presented with lymphadenopathy and a low density mass in pancreas.,"['a', '_num_', 'year', 'old', 'male', 'presented', 'with', 'lymphadenopathy', 'and', 'a', 'low', 'density', 'mass', 'in', 'pancreas']"
4694,1.0,Preclinical study in a mouse model of Peutz-Jeghers syndrome.,"['preclinical', 'study', 'in', 'a', 'mouse', 'model', 'of', '_disease_', 'syndrome']"
4695,1.0,"This variant, identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS).","['this', 'variant', 'identified', 'in', 'a', 'case', 'of', '_disease_', 'endometrial', 'cancer', 'was', 'confirmed', 'to', 'be', 'somatic', 'in', 'a', 'patient', 'with', 'suspected', 'lynch', 'syndrome', 'ls']"
4696,1.0,This nonsense mutation was found in a VHL type 1 family (lineage 81).,"['this', 'nonsense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
4697,1.0,"All 6 individuals were identified with cerebellar hemangioblastomas, 4 with angiomas, and 5 with renal cell carcinoma.","['all', '_num_', 'individuals', 'were', 'identified', 'with', 'cerebellar', '_disease_', '_num_', 'with', 'angiomas', 'and', '_num_', 'with', 'renal', 'cell', 'carcinoma']"
4698,1.0,"In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).","['in', 'this', 'study', 'using', 'a', 'panel', 'of', '_disease_', '_gene_', 'overexpressing', 'cell', 'lines', 'antiproliferative', 'effects', 'of', '_chemical_', '_chemical_', '_disease_', 'were', 'observed', 'in', 'a', '_abbrev_', 'dependant', 'manner', 'with', 'strongest', 'effects', 'in', '_abbrev_', 'high', 'expressing', 'and', 'no', 'effects', 'in', '_abbrev_', 'low', 'expressing']"
4699,1.0,Promoter methylation at SGK1 was increased in sensitive cells compared to alpelisib resistant cell lines.,"['promoter', 'methylation', 'at', '_gene_', 'was', 'increased', 'in', 'sensitive', 'cells', 'compared', 'to', 'alpelisib', 'resistant', 'cell', 'lines']"
4700,1.0,"The first patient (M, 81, smoker) was treated with gefitinib and had a partial response, progression free survival (PFS) of 21.7 months, overall survival (OS) of 22.5 months and was alive at study end.","['the', '_num_', 'patient', '_unit_', '_num_', 'smoker', 'was', 'treated', 'with', '_chemical_', 'and', 'had', 'a', 'partial', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'alive', 'at', 'study', 'end']"
4701,1.0,499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes.,"['_num_', 'children', 'from', 'all', 'trials', 'treated', 'with', 'methotrexate', 'were', 'genotyped', 'for', '_num_', 'snps', 'in', '_num_', 'genes']"
4702,1.0,Functional assay suggested the mutant RUNX1 transcription factor had impaired DNA binding.,"['functional', 'assay', 'suggested', 'the', 'mutant', '_gene_', 'transcription', 'factor', 'had', 'impaired', 'dna', 'binding']"
4703,1.0,"Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival.","['only', 'when', 'both', '_gene_', 'density', 'and', '_gene_', 'expression', 'were', 'both', 'considered', 'was', '_gene_', 'expression', 'associated', 'with', 'survival']"
4704,1.0,Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months).,"['case', 'report', 'of', 'a', 'patient', 'with', 'endometrial', 'cancer', 'and', 'exceptional', 'response', 'to', 'pembrolizumab', 'maintained', 'at', '_num_', 'months']"
4705,1.0,"Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8).","['breast', 'cancer', 'patients', 'who', 'harbor', 'a', '_mutation_', 'mutation', '_ineq_', 'have', 'worse', 'overall', 'survival', 'than', 'those', 'with', 'wild', 'type', '_gene_', '_ineq_', 'but', 'have', 'better', 'prognosis', 'than', 'those', 'with', 'a', '_mutation_', 'mutation', '_ineq_']"
4706,1.0,"As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib.","['as', 'part', 'of', 'a', 'phase', '_num_', 'dose', 'escalation', 'trial', '_abbrev_', '_num_', 'patients', 'between', 'ages', '_num_', 'months', 'and', '_num_', 'years', 'with', 'relapsed', 'or', 'refractory', 'inflammatory', 'myofibroblastic', 'tumors', 'with', '_gene_', 'rearrangement', 'were', 'given', '_chemical_']"
4707,1.0,"Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive).","['_chemical_', 'was', 'started', 'and', 'fatigue', 'and', 'ecog', 'status', 'improved', 'but', 'imaging', 'revealed', 'slight', 'disease', 'progression', 'after', '_num_', 'weeks', '_num_', 'sites', 'measurable', '_num_', 'stable', '_num_', 'progressive']"
4708,1.0,"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib.","['in', 'a', 'study', '_num_', 'participant', 'with', 'stage', 'iv', 'lung', 'adenocarcinoma', 'was', 'sequenced', 'at', '_gene_', 'exons', '_num_', 'to', '_num_', 'and', 'was', 'found', 'to', 'have', '_mutation_', 'mutation', 'and', 'was', 'treated', 'with', 'the', '_num_', 'generation', '_disease_', '_chemical_']"
4709,1.0,Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy.,"['patients', 'with', '_abbrev_', 'mutated', 'cancers', 'were', 'identified', '_ineq_', 'and', 'subsequently', 'underwent', 'targeted', 'therapy']"
4710,1.0,In a single patient with this fusion in intrahepatic cholangiocarcinoma.,"['in', 'a', 'single', 'patient', 'with', 'this', 'fusion', 'in', '_disease_', '_disease_']"
4711,1.0,"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).","['in', 'a', 'study', 'of', 'patients', 'receiving', 'melphalan', 'based', 'therapy', 'those', 'with', '_gene_', 'codon', '_num_', 'mutations', 'were', 'less', 'likely', 'to', 'have', 'a', 'positive', 'response', 'than', 'those', 'with', 'wildtype', '_gene_', '_num_', 'vs', '_num_', '_p_val_']"
4712,1.0,"NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients.","['_gene_', 'mutation', 'was', 'associated', 'with', 'increased', 'overall', 'event', 'free', 'and', 'relapse', 'free', 'survival', 'and', 'remission', 'after', 'induction', 'therapy', 'in', 'the', 'entire', 'cohort', 'and', 'in', 'the', 'cytogenetically', 'normal', 'subset', 'of', 'patients']"
4713,1.0,Seven molecularly characterized cases were positive for CLTC-ALK.,"['_num_', '_chemical_', 'characterized', 'cases', 'were', 'positive', 'for', '_gene_']"
4714,1.0,"In Ba/F3 cells, ectopic expression of EML4-ALK V1180L rendered cells significantly more sensitive to ceritinib than Ba/F3 containing EML4-ALK I1171T mutant (alectinib and crizotinib resistant) or EML4-ALK wt.","['in', 'ba', '_abbrev_', 'cells', 'ectopic', 'expression', 'of', '_chemical_', '_mutation_', 'rendered', 'cells', 'significantly', 'more', 'sensitive', 'to', '_chemical_', 'than', 'ba', '_abbrev_', 'containing', '_chemical_', '_mutation_', 'mutant', '_chemical_', 'and', '_chemical_', 'resistant', 'or', '_chemical_', '_gene_']"
4715,1.0,"In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines.","['in', '_num_', 'nras', 'mutant', 'melanoma', 'cell', 'lines', 'concomitant', 'use', 'of', 'mek', 'inhibitor', 'and', '_abbrev_', 'inhibitor', 'resulted', 'in', 'greater', 'decrease', 'in', 'cell', 'viability', 'than', 'either', 'alone', 'with', 'the', 'synergistic', 'effect', 'being', 'marked', 'in', '_ratio_', 'cell', 'lines']"
4716,1.0,NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab.,"['_disease_', 'guidelines', 'indicate', 'colorectal', 'cancer', 'patients', 'with', '_gene_', 'mutations', 'should', 'not', 'be', 'treated', 'with', 'the', 'anti', '_gene_', 'therapies', '_chemical_', 'or', 'panitumumab']"
4717,1.0,Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification.,"['phase', '_num_', 'trial', 'of', '_gene_', 'inhibitor', '_chemical_', 'in', 'stage', 'iiib', 'iv', 'lung', 'cancers', 'with', '_gene_', 'mutations', 'or', 'amplification']"
4718,1.0,"In the randomized phase 3 UK LRF CCL4 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, SF3B1 mutations (73/437 patients) were associated with poorer overall survival (median 54.3 vs 79 months, P <0.001), independent of treatment.","['in', 'the', 'randomized', 'phase', '_num_', 'uk', '_gene_', '_gene_', 'trial', 'comparing', '_num_', 'line', 'treatment', 'with', 'chlorambucil', '_chemical_', 'or', '_chemical_', 'plus', '_chemical_', '_gene_', 'mutations', '_ratio_', 'patients', 'were', 'associated', 'with', 'poorer', 'overall', 'survival', 'median', '_num_', 'vs', '_num_', 'months', 'p', '_num_', 'independent', 'of', 'treatment']"
4719,1.0,"In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.","['in', 'the', '_num_', 'arm', 'study', 'patients', 'were', 'given', '_chemical_', 'courses', 'of', '_num_', 'year', '_num_', 'years', 'or', 'untreated']"
4720,1.0,No additional functional testing or clinical description was given.,"['no', 'additional', 'functional', 'testing', 'or', 'clinical', 'description', 'was', 'given']"
4721,1.0,"RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001).","['_gene_', 'mutations', 'are', 'associated', 'with', 'diffuse', 'type', 'mucinous', 'gastric', 'carcinoma', 'which', 'indicate', 'worse', 'prognosis', 'when', 'compared', 'to', 'intestinal', 'type', 'p', '_num_']"
4722,1.0,22 individuals in this family were carriers of C609Y.,"['_num_', 'individuals', 'in', 'this', 'family', 'were', 'carriers', 'of', '_mutation_']"
4723,1.0,"In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy.","['in', 'the', 'personalized', 'therapy', 'group', 'of', 'this', 'study', 'patients', 'received', 'chemotherapy', 'based', 'on', '_gene_', '_gene_', 'expression', 'levels', 'whereas', 'the', 'standard', 'therapy', 'group', 'received', 'non', 'customized', 'chemotherapy']"
4724,1.0,6 transitioned directly from rociletinib to osimertinib.,"['_num_', 'transitioned', 'directly', 'from', '_chemical_', 'to', 'osimertinib']"
4725,1.0,Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance.,"['_mutation_', 'was', 'observed', 'as', 'a', 'secondary', 'kit', 'mutation', 'in', '_num_', 'patients', 'with', 'secondary', '_chemical_', 'resistance']"
4726,1.0,Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients.,"['overall', 'response', 'rate', 'was', '_num_', '_num_', 'ci', '_range_', 'of', '_num_', '_gene_', 'inhibitor', 'naive', 'patients', 'and', '_num_', '_range_', 'of', '_num_', '_gene_', 'inhibitor', 'pretreated', 'patients']"
4727,1.0,Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH.,"['complete', 'remission', 'was', 'achieved', 'with', 'bone', 'marrow', 'mrd', 'of', '_num_', 'by', 'flow', 'cytometry', 'and', 'normal', '_gene_', 'by', 'fish']"
4728,1.0,Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).,"['genetic', 'testing', 'of', 'pleural', 'effusion', 'after', 'disease', 'progression', 'revealed', 'a', '_gene_', '_mutation_', 'gene', 'mutation', 'but', 'was', 'positive', 'for', '_gene_', 'expression', '_gene_']"
4729,1.0,This missense mutation was found in a VHL type 1 patient (patient no V285).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
4730,1.0,"In 219 patients with metastatic pancreatic ductal adenocarcinoma, a multivariate analysis identified KRAS G12D mutations as an independent predictor of poorer prognosis both in patients that have received chemotherapy (N=49/162), and the entire series (N=73/219).","['in', '_num_', 'patients', 'with', 'metastatic', 'pancreatic', 'ductal', 'adenocarcinoma', 'a', 'multivariate', 'analysis', 'identified', '_gene_', '_mutation_', 'mutations', 'as', 'an', 'independent', 'predictor', 'of', 'poorer', 'prognosis', 'both', 'in', 'patients', 'that', 'have', 'received', 'chemotherapy', '_ineq_', 'and', 'the', 'entire', 'series', '_ineq_']"
4731,1.0,MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy.,"['_gene_', 'serum', 'levels', 'were', 'assessed', 'elisa', 'at', 'baseline', 'b', 'and', 'before', 'surgery', 'in', '_num_', 'available', 'samples', 'from', 'patients', 'with', 'inflammatory', 'breast', 'cancer', 'treated', 'with', '_chemical_', 'based', 'neoadjuvant', 'therapy']"
4732,1.0,The 32-year-old sister and 27-year-old proband had renal cell carcinoma and pancreatic cysts.,"['the', '_age_', 'sister', 'and', '_age_', 'proband', 'had', 'renal', 'cell', 'carcinoma', 'and', 'pancreatic', 'cysts']"
4733,1.0,A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4.,"['a', '_num_', 'year', 'old', 'female', 'was', 'diagnosed', 'with', 'glioblastoma', '_disease_', 'who', 'grade', '_num_']"
4734,1.0,FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.,"['_gene_', 'inhibitor', '_chemical_', 'was', 'most', 'effective', 'in', 'a', 'gastric', 'cancer', 'cell', 'line', 'model', 'with', 'high', 'expression', 'of', '_gene_', 'and', '_gene_']"
4735,1.0,A total of 48 treatment cycles (26 cycles of nintedanib alone) was administered over 33 months before documentation of disease progression in March 2013.,"['a', 'total', 'of', '_num_', 'treatment', 'cycles', '_num_', 'cycles', 'of', '_chemical_', 'alone', 'was', 'administered', 'over', '_num_', 'months', 'before', 'documentation', 'of', 'disease', 'progression', 'in', 'march', '_year_']"
4736,1.0,"SIRT1 expression was associated with poor survival in univariate (p = 0.002) and multivariate (HR 1.65, p = 0.045) analyses.","['_gene_', 'expression', 'was', 'associated', 'with', 'poor', 'survival', 'in', 'univariate', 'p', '_num_', 'and', 'multivariate', 'hr', '_num_', 'p', '_num_', 'analyses']"
4737,1.0,A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib.,"['a', 'cell', 'line', '293h', 'ectopically', 'expressing', 'the', '_abbrev_', 'fusion', 'was', 'found', 'to', 'be', 'sensitive', 'to', 'the', 'mek', 'inhibitor', '_chemical_']"
4738,1.0,The dual EGFR-ERBB2 inhibitors afatinib and dacomitinib each showed synergy with MEK Inhibition via selumetinib in 4 KRAS mutant cell lines.,"['the', 'dual', '_abbrev_', 'inhibitors', '_chemical_', 'and', '_chemical_', 'each', 'showed', 'synergy', 'with', 'mek', 'inhibition', 'via', '_chemical_', 'in', '_num_', '_gene_', 'mutant', 'cell', 'lines']"
4739,1.0,WiDr and VACO432 cells were injected into immunodeficient mice.,"['widr', 'and', '_abbrev_', 'cells', 'were', 'injected', 'into', 'immunodeficient', 'mice']"
4740,1.0,"Patients with KRAS mutations also had a longer overall survival compared to wildtype EGFR patients (HR:2.526, 95% CI:1.314-4.858, P=0.0055).","['patients', 'with', '_gene_', 'mutations', 'also', 'had', 'a', 'longer', 'overall', 'survival', 'compared', 'to', 'wildtype', '_gene_', 'patients', 'hr:2', '_num_', '_num_', 'ci:1', '_num_', '_num_', '_num_', '_p_val_']"
4741,1.0,"Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months.","['of', '_num_', 'patients', 'with', 'measurable', 'disease', '_num_', 'achieved', 'objective', 'response', 'with', 'median', 'duration', 'of', 'response', '_num_', 'months']"
4742,1.0,SMARCA4 expression was determined with gene expression microarray in 133 patients.,"['_gene_', 'expression', 'was', 'determined', 'with', 'gene', 'expression', 'microarray', 'in', '_num_', 'patients']"
4743,1.0,Ceritinib dosed at 400 mg or higher had similar results in patients who had or had not received prior crizotinib treatment.,"['_chemical_', 'dosed', 'at', '_num_', '_unit_', 'or', 'higher', 'had', 'similar', 'results', 'in', 'patients', 'who', 'had', 'or', 'had', 'not', 'received', 'prior', '_chemical_', 'treatment']"
4744,1.0,IHC was focally positive for CD117.,"['_gene_', 'was', 'focally', 'positive', 'for', '_gene_']"
4745,1.0,Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.,"['simultaneous', 'tandem', 'repeat', 'of', '_gene_', 'with', 'loss', 'of', 'wild', 'type', '_gene_', 'leads', 'to', 'poor', 'survival', 'and', 'inferior', 'disease', 'free', 'survival', 'in', 'patients', 'with', '_disease_']"
4746,1.0,"After preliminary studies in cell lines, GEO datasets and fresh frozen tissues, RIT1 expression was determined in 257 tumors and 31 normal tissues.","['after', 'preliminary', 'studies', 'in', 'cell', 'lines', '_disease_', 'datasets', 'and', 'fresh', 'frozen', 'tissues', '_gene_', 'expression', 'was', 'determined', 'in', '_num_', 'tumors', 'and', '_num_', 'normal', 'tissues']"
4747,1.0,bMMP9 was associated with death (p=0.035).,"['_abbrev_', 'was', 'associated', 'with', 'death', '_p_val_']"
4748,1.0,"In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%), shorter progression free survival (5 year PFS 5% vs 17%), and overall survival (20% vs 59%) compared to patients without TP53 mutations.","['in', 'the', '_abbrev_', 'trial', 'assessing', '_num_', 'line', 'treatment', 'with', 'chlorambucil', 'or', '_chemical_', 'with', 'or', 'without', '_chemical_', 'patients', 'with', '_gene_', 'mutations', 'experienced', 'poorer', 'overall', 'response', 'rates', '_num_', 'vs', '_num_', 'shorter', 'progression', 'free', 'survival', '_num_', 'year', '_disease_', '_num_', 'vs', '_num_', 'and', 'overall', 'survival', '_num_', 'vs', '_num_', 'compared', 'to', 'patients', 'without', '_gene_', 'mutations']"
4749,1.0,It effectively inhibited the survival of CD74-ROS1 wild type (WT) and resistant mutants harboring Ba/F3 and MGH047 cells.,"['it', 'effectively', 'inhibited', 'the', 'survival', 'of', '_abbrev_', 'wild', 'type', '_gene_', 'and', 'resistant', 'mutants', 'harboring', 'ba', '_abbrev_', 'and', '_abbrev_', 'cells']"
4750,1.0,PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies.,"['_gene_', 'expression', 'was', 'tested', 'in', '_num_', 'patients', 'by', '_disease_', 'from', 'tumor', '_disease_', 'biopsies']"
4751,1.0,About 50 fold higher concentration of crizotinib was required to inhibit Ba/F3 cells expressing EML4 ALK I1171T than was required for EML4 ALK wild type.,"['about', '_num_', 'fold', 'higher', 'concentration', 'of', '_chemical_', 'was', 'required', 'to', 'inhibit', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', '_gene_', '_mutation_', 'than', 'was', 'required', 'for', '_gene_', '_gene_', 'wild', 'type']"
4752,1.0,PTPRD mutated cell-lines were more sensitive to STAT3 inhibition (JSI-124) than wild type cells.,"['_gene_', 'mutated', 'cell', 'lines', 'were', 'more', 'sensitive', 'to', '_gene_', 'inhibition', '_chemical_', 'than', 'wild', 'type', 'cells']"
4753,1.0,"In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.","['in', 'patients', 'with', 'cervical', '_disease_', 'cell', 'carcinoma', 'those', 'with', 'gene', 'amplification', 'of', '_gene_', 'had', 'worse', 'overall', 'survival']"
4754,1.0,MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with cisplatin and pemetrexed (standard of care therapy).,"['_gene_', 'mrna', 'and', 'protein', 'expression', 'correlated', 'with', 'poor', 'os', 'and', '_disease_', 'for', 'patients', 'treated', 'with', '_disease_', 'and', '_chemical_', 'standard', 'of', 'care', 'therapy']"
4755,1.0,55 tumor samples were analyzed for EGFR expression using IHC.,"['_num_', 'tumor', 'samples', 'were', 'analyzed', 'for', '_gene_', 'expression', 'using', '_gene_']"
4756,1.0,"In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine,  and standard adjuvant temozolomide chemotherapy.","['in', 'a', 'phase', 'ii', 'clinical', 'trial', 'patients', 'with', 'glioblastoma', 'multiforme', '_disease_', 'positive', 'for', '_gene_', 'viii', 'deletion', 'mutation', '_ineq_', 'were', 'treated', 'with', 'the', '_chemical_', 'cancer', 'vaccine', 'and', 'standard', 'adjuvant', '_chemical_', 'chemotherapy']"
4757,1.0,"341 patients with advanced cancer were screened by FISH, identifying FGFR1 amplification in 18% of advanced HER2-negative breast cancers and FGFR2 amplification in 9% of advanced gastroesophageal cancer.","['_num_', 'patients', 'with', 'advanced', 'cancer', 'were', 'screened', 'by', 'fish', 'identifying', '_gene_', 'amplification', 'in', '_num_', 'of', 'advanced', '_gene_', 'breast', 'cancers', 'and', '_gene_', 'amplification', 'in', '_num_', 'of', 'advanced', 'gastroesophageal', 'cancer']"
4758,1.0,"For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056).","['for', 'overall', 'survival', 'the', 'hazard', 'ratio', 'was', '_num_', 'times', 'greater', 'for', '_gene_', 'deletion', 'p', '_num_']"
4759,1.0,89 of these cases had C609Y specifically.,"['_num_', 'of', 'these', 'cases', 'had', '_mutation_', 'specifically']"
4760,1.0,The H396R mutation was  resistant to imatinib .,"['the', '_mutation_', 'mutation', 'was', 'resistant', 'to', '_chemical_']"
4761,1.0,"Additionally, MAPK1 amplification was identified in 1/21 erlotinib-resistant NSCLC patients.","['additionally', '_gene_', 'amplification', 'was', 'identified', 'in', '_ratio_', '_chemical_', 'resistant', '_disease_', 'patients']"
4762,1.0,"During treatment, significant increase in MMP2 was observed in 100% of patients.","['during', 'treatment', 'significant', 'increase', 'in', '_gene_', 'was', 'observed', 'in', '_num_', 'of', 'patients']"
4763,1.0,This mechanism was distinct from GDC-0973 which is less potent in KRAS mutant tumors.,"['this', 'mechanism', 'was', 'distinct', 'from', '_chemical_', 'which', 'is', 'less', 'potent', 'in', '_gene_', 'mutant', 'tumors']"
4764,1.0,TP53 mutant cells lacking functional TP53 were completely insensitive to the drug.,"['_gene_', 'mutant', 'cells', 'lacking', 'functional', '_gene_', 'were', 'completely', 'insensitive', 'to', 'the', 'drug']"
4765,1.0,"Median OS, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; P = 0.934).","['median', 'os', 'while', 'the', 'data', 'are', 'immature', 'was', '_num_', 'months', 'in', 'the', '_chemical_', 'arm', 'and', 'was', 'not', 'reached', 'in', 'the', '_chemical_', 'arm', 'hr', '_num_', 'p', '_num_']"
4766,1.0,"While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.","['while', '_chemical_', '_gene_', 'western', 'blots', 'indicated', 'that', 'the', '_gene_', 'inhibitors', 'acted', 'similarly', 'on', 'both', '_abbrev_', 'and', '_abbrev_', '_chemical_', 'variants', 'blots', 'of', '_chemical_', 'treated', 'cells', 'showed', 'that', '_abbrev_', 'had', 'a', 'shorter', 'half', 'life', 'than', '3a', 'in', 'the', 'transduced', 'cells', 'potentially', 'explaining', 'increased', '_abbrev_', 'sensitivity']"
4767,1.0,"Administration of afatinib had a stronger effect than erlotinib or trastuzumab, as measured by histology and tumor volume regression.","['administration', 'of', '_chemical_', 'had', 'a', 'stronger', 'effect', 'than', '_chemical_', 'or', '_chemical_', 'as', 'measured', 'by', 'histology', 'and', 'tumor', 'volume', 'regression']"
4768,1.0,Objective response was observed in all three of these patients.,"['objective', 'response', 'was', 'observed', 'in', 'all', '_num_', 'of', 'these', 'patients']"
4769,1.0,"ETS2 rs461155A>G was significantly associated with decreased ETS2 mRNA expression in both tumor and paired normal lung tissues (Ptrend = 4 × 10-7, and 3 × 10-4, respectively).","['_gene_', '_abbrev_', '_unit_', 'was', 'significantly', 'associated', 'with', 'decreased', '_gene_', 'mrna', 'expression', 'in', 'both', 'tumor', 'and', 'paired', 'normal', 'lung', 'tissues', 'ptrend', '_num_', '×', '_range_', 'and', '_num_', '×', '_range_', 'respectively']"
4770,1.0,In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-lines with high MYD88 expression.,"['in', 'vitro', 'experiments', 'showed', 'a', 'decrease', 'in', 'sensitivity', 'towards', '_chemical_', 'in', 'cell', 'lines', 'with', 'high', '_gene_', 'expression']"
4771,1.0,Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.,"['patients', 'were', 'required', 'to', 'have', 'prior', 'exposure', 'to', '_chemical_', 'and', '_chemical_', 'as', 'well', 'as', 'a', '_chemical_']"
4772,1.0,"9 were unidentified, suggesting other fusion partners in these instances.","['_num_', 'were', 'unidentified', 'suggesting', 'other', 'fusion', 'partners', 'in', 'these', 'instances']"
4773,1.0,Case report of a patient with metastatic ALK-rearranged NSCLC.,"['case', 'report', 'of', 'a', 'patient', 'with', 'metastatic', '_gene_', 'rearranged', '_disease_']"
4774,1.0,"In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild type patients (n=59; p=0.011).","['in', 'adult', 'patients', 'with', 'early', 'n', '_num_', 'cortical', 'n', '_num_', 'mature', 'n', '_num_', 'or', 'unknown', 'n', '_num_', '_disease_', 'acute', '_disease_', 'leukemia', 'those', 'with', 'mutations', 'in', '_gene_', '_ineq_', 'had', 'shorter', 'overall', 'survival', 'than', 'wild', 'type', 'patients', '_ineq_', '_p_val_']"
4775,1.0,"Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins.","['consistent', 'with', 'this', 'isolated', 'mutant', 'proteins', 'also', 'showed', 'increased', 'enzyme', 'activity', 'compared', 'to', 'wildtype', 'proteins']"
4776,1.0,One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.,"['_num_', 'patient', 'of', 'which', 'had', 'a', 'metastasis', 'sample', 'which', 'was', 'reported', 'to', 'have', 'only', '_gene_', 'amplification', 'whereas', 'another', 'autopsy', 'specimen', 'from', 'the', 'same', 'patient', 'was', '_gene_', 'negative', 'but', '_gene_', '_mutation_', 'positive']"
4777,1.0,"In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201).","['in', '_num_', 'patients', 'with', '_disease_', 'exon', '_num_', '_gene_', 'mutations', 'were', 'associated', 'with', 'resistance', 'to', 'the', '_gene_', 'kinase', 'inhibitors', '_chemical_', 'or', '_chemical_', '_ratio_', 'refractory', 'vs', '_ratio_', 'sensitive', 'patients', '_p_val_']"
4778,1.0,285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.,"['_num_', '_disease_', 'tumors', 'and', '_num_', 'diffuse', 'type', 'tumors', 'were', 'evaluated', 'for', 'mutational', 'profiles']"
4779,1.0,Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma.,"['case', 'report', 'of', 'a', '_num_', 'year', 'old', 'woman', 'of', 'japanese', 'descent', 'with', 'recurrent', 'urothelial', 'carcinoma']"
4780,1.0,"In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission.","['in', 'a', 'clinical', 'study', 'of', '_num_', 'relapsed', 'or', 'refractory', '_disease_', 'patients', 'harboring', '_gene_', 'mutations', 'these', 'patients', 'were', 'associated', 'with', 'response', 'to', '_abbrev_', 'monotherapy', '_ratio_', 'patients', 'who', 'achieved', 'a', 'response', 'experienced', 'complete', 'remission']"
4781,1.0,"In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.","['in', 'gist', 'tumor', 'cells', 'and', 'patients', 'harboring', 'kit', '_mutation_', 'mutation', '_chemical_', 'is', 'effective', 'for', 'those', 'that', 'are', 'refractory', 'to', '_chemical_']"
4782,1.0,Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.,"['fusion', 'protein', 'degradation', 'is', 'accelerated', 'upon', '_disease_', 'treatment', 'of', 'acute', 'promyelocytic', 'cells', 'at', 'pharmalogical', 'concentrations']"
4783,1.0,FISH analysis revealed a KIF5B-RET fusion.,"['fish', 'analysis', 'revealed', 'a', '_abbrev_', 'fusion']"
4784,1.0,Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment).,"['_num_', 'patients', 'were', 'found', 'to', 'harbor', 'an', 'nras', 'mutation', 'and', '_num_', 'of', 'them', 'experienced', 'stable', 'disease', '_num_', '_num_', 'weeks', 'on', 'treatment']"
4785,1.0,Expression of AURKA was measured using immunohistochemical techniques on tumor samples.,"['expression', 'of', '_gene_', 'was', 'measured', 'using', 'immunohistochemical', 'techniques', 'on', 'tumor', 'samples']"
4786,1.0,"The VHL type 2 family of 3 affected individuals had one patient with retinal angioma, 3 with hemangioblastomas of the central nervous system, one with pheochromocytoma, one with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 9).","['the', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'affected', 'individuals', 'had', '_num_', 'patient', 'with', 'retinal', 'angioma', '_num_', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'with', 'pheochromocytoma', '_num_', 'with', 'renal', 'cell', 'carcinoma', '_num_', 'with', 'pancreatic', 'cysts', 'and', '_num_', 'with', '_disease_', 'of', 'the', 'epididymis', 'family', '_gene_', '_num_']"
4787,1.0,Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.,"['molecular', 'modeling', 'indicated', 'the', '_mutation_', 'mutation', 'alters', 'the', 'conformation', 'of', 'kit', 'but', 'did', 'not', 'alter', 'the', 'binding', 'affinity', 'of', '_chemical_']"
4788,1.0,The tumor harbored a high mutational load as assessed by panel sequencing.,"['the', 'tumor', 'harbored', 'a', 'high', 'mutational', 'load', 'as', 'assessed', 'by', 'panel', 'sequencing']"
4789,1.0,"293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor.","['_chemical_', 'cells', 'stably', 'transduced', 'with', '_gene_', '_mutation_', 'showed', 'constitutive', 'tyrosine', '_disease_', 'in', 'the', 'absense', 'of', 'ligand', 'however', 'when', 'treated', 'with', '_chemical_', 'this', '_disease_', 'was', 'inhibited', 'similarly', 'to', 'that', 'of', 'wildtype', '_gene_', 'consistent', 'with', 'sensitivity', 'to', 'this', 'inhibitor']"
4790,1.0,"Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab and erlotinib.","['overexpression', 'of', '_gene_', 'exon', '_num_', 'affymetrix', 'human', 'exon', '_num_', '_gene_', 'in', 'tumor', 'or', 'blood', 'samples', 'was', 'associated', 'with', 'tumor', 'shrinkage', 'independently', 'of', '_gene_', 'mutational', 'status', 'in', '_disease_', 'treated', 'with', '_chemical_', 'and', '_chemical_']"
4791,0.0,Pericytoma with t(7;12) is a soft tissue tumor characterized by fusion of the ACTB and GLI genes through the translocation t(7;12)(p22;q13).,"['pericytoma', 'with', 't', '_num_', '_num_', 'is', 'a', 'soft', 'tissue', 'tumor', 'characterized', 'by', 'fusion', 'of', 'the', '_gene_', 'and', '_gene_', 'genes', 'through', 'the', 'translocation', 't', '_num_', '_num_', '_gene_', '_abbrev_']"
4792,1.0,GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation.,"['gna', 'mutant', 'cell', 'lines', '_ineq_', 'showed', 'stronger', 'expression', 'of', 'ligand', 'and', 'receptor', 'as', 'well', 'as', 'more', 'receptor', '_disease_']"
4793,1.0,A patient with metastatic melanoma and ALK ATI expression but no MET or ALK aberrations identified with FISH and a 341-gene panel sequencing  was treated with crizotinib and had symptomatic improvement and tumor shrinkage within 6 weeks of therapy,"['a', 'patient', 'with', 'metastatic', 'melanoma', 'and', '_gene_', '_gene_', 'expression', 'but', 'no', 'met', 'or', '_gene_', 'aberrations', 'identified', 'with', 'fish', 'and', 'a', '_num_', 'gene', 'panel', 'sequencing', 'was', 'treated', 'with', '_chemical_', 'and', 'had', 'symptomatic', 'improvement', 'and', 'tumor', 'shrinkage', 'within', '_num_', 'weeks', 'of', 'therapy']"
4794,1.0,"In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28).","['in', '_num_', 'patients', 'with', 'unresectable', 'pancreatic', 'cancer', 'the', 'presence', 'of', '_gene_', '_mutation_', '_ineq_', 'or', '_mutation_', '_ineq_', 'was', 'associated', 'with', 'poorer', 'prognosis', 'overall', 'survival', 'hr', '_num_', '_num_', 'confidence', 'interval', '_range_']"
4795,1.0,"In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel.","['in', 'a', 'phase', '_num_', 'clinical', 'trial', 'of', 'non', 'small', 'cell', 'lung', 'cancer', '_disease_', 'patients', 'a', 'subset', 'of', 'patients', 'with', '_gene_', 'mutations', '_ineq_', 'treated', 'with', '_chemical_', 'were', 'associated', 'with', 'improved', 'progression', 'free', 'survival', 'hr', '_num_', '_num_', 'ci', '_range_', '_p_val_', 'and', 'a', 'higher', 'objective', 'response', 'rate', 'orr', '_num_', 'vs', '_num_', '_p_val_', 'compared', 'to', 'patients', 'treated', 'with', '_chemical_']"
4796,1.0,Amplification of MAPK1 or downregulation of ERK-pathway inhibitors led to resistance to EGFR inhibition with WZ4002.,"['amplification', 'of', '_gene_', 'or', 'downregulation', 'of', '_gene_', 'pathway', 'inhibitors', 'led', 'to', 'resistance', 'to', '_gene_', 'inhibition', 'with', '_chemical_']"
4797,1.0,"Similar results were reported with the PTEN mutant HNSCC cell line UPCI-SCC-90, and 4 of the 6 most taselisib resistant cell lines had PTEN mutation.","['similar', 'results', 'were', 'reported', 'with', 'the', '_gene_', 'mutant', '_disease_', 'cell', 'line', 'upci', '_gene_', '_num_', 'and', '_num_', 'of', 'the', '_num_', 'most', 'taselisib', 'resistant', 'cell', 'lines', 'had', '_gene_', 'mutation']"
4798,1.0,It was found that patients with DUX4 fusions (N=9) had improved disease free survival over Ph like ALL patients (N=6) in the study.,"['it', 'was', 'found', 'that', 'patients', 'with', '_gene_', 'fusions', '_chemical_', 'had', 'improved', 'disease', 'free', 'survival', 'over', 'ph', 'like', 'all', 'patients', '_ineq_', 'in', 'the', 'study']"
4799,1.0,"In contrast, in the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD.","['in', 'contrast', 'in', 'the', '_num_', 'characterized', 'patients', 'with', '_gene_', 'mutations', 'that', 'were', 'not', '_mutation_', '_num_', 'showed', 'pd', 'and', '_num_', 'sd']"
4800,1.0,The mice in which STAG3 was silenced had tumors that were more sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).,"['the', 'mice', 'in', 'which', '_gene_', 'was', 'silenced', 'had', 'tumors', 'that', 'were', 'more', 'sensitive', 'to', '_chemical_', 'induced', 'tumor', 'shrinkage', 'than', 'the', 'tumors', 'of', 'the', 'control', 'mice', 'p', '_num_']"
4801,1.0,The patient also harbored a heterozygous MLH1 p.T117M mutation (38% VAF).,"['the', 'patient', 'also', 'harbored', 'a', 'heterozygous', '_gene_', 'p', '_abbrev_', 'mutation', '_num_', '_disease_']"
4802,1.0,"In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody.","['in', 'a', 'preclinical', 'study', 'in', 'an', 'immunocompetent', 'mouse', 'model', 'of', 'lung', 'adenocarcinoma', 'upregulation', 'of', 'alternative', 'immune', 'checkpoints', 'notably', '_disease_', 'immunoglobulin', '_gene_', '_gene_', 'aka', '_gene_', 'was', 'observed', 'after', 'progression', 'under', '_gene_', 'antibody']"
4803,1.0,The patient remains free of local or distant disease 5 years after starting lapatinib.,"['the', 'patient', 'remains', 'free', 'of', 'local', 'or', 'distant', 'disease', '_num_', 'years', 'after', 'starting', '_chemical_']"
4804,1.0,"In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild type patients.","['in', '_num_', 'patients', 'with', 'glioblastoma', 'those', 'with', '_gene_', 'promoter', 'mutations', 'had', 'worse', 'cummulative', 'survival', 'than', 'wild', 'type', 'patients']"
4805,1.0,"In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls.","['in', 'contrast', 'mutations', 'in', '_gene_', '_abbrev_', 'are', 'not', 'observed', 'in', 'centroblast', 'samples', 'from', 'healthy', 'controls']"
4806,1.0,Preclinical study in colorectal cancer xenografts.,"['preclinical', 'study', 'in', 'colorectal', 'cancer', 'xenografts']"
4807,1.0,Nuclear Sirt1 expression was identified by IHC in 36 (27.9%) of 129 pancreatic ductal adenocarcinoma cases.,"['nuclear', '_gene_', 'expression', 'was', 'identified', 'by', '_gene_', 'in', '_num_', '_num_', 'of', '_num_', 'pancreatic', 'ductal', 'adenocarcinoma', 'cases']"
4808,1.0,Overall survival rate of BCOR positive cases were significantly better than BCOR negative cases cases (p=0.038).,"['overall', 'survival', 'rate', 'of', '_gene_', 'positive', 'cases', 'were', 'significantly', 'better', 'than', '_gene_', 'negative', 'cases', 'cases', '_p_val_']"
4809,0.0,"Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib).","['multicenter', 'phase', '_num_', 'dose', 'escalation', 'trial', 'of', '_chemical_', '_chemical_']"
4810,1.0,"Since this variant is found in renal cell carcinoma, we can make an inference that it might be relevant to VHL disease in a germline context.","['since', 'this', 'variant', 'is', 'found', 'in', 'renal', 'cell', 'carcinoma', 'we', 'can', 'make', 'an', 'inference', 'that', 'it', 'might', 'be', 'relevant', 'to', '_gene_', 'disease', 'in', 'a', 'germline', 'context']"
4811,1.0,This missense mutation was found in 2 family members with VHL type 1 phenotype (family ID 3708).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'type', '_num_', 'phenotype', 'family', 'id', '_num_']"
4812,1.0,"Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA.","['_num_', '_gene_', 'mutations', '_mutation_', '_mutation_', '_mutation_', '_mutation_', 'and', '_mutation_', 'resulted', 'in', 'strong', 'autophosphorylation', 'of', '_gene_']"
4813,1.0,"MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines.","['_gene_', 'inhibitor', '_chemical_', 'induced', 'senescence', 'in', 'presence', 'of', 'functional', '_gene_', 'in', 'murine', 'primary', 'fibroblasts', 'oncogenically', 'transformed', 'fibroblasts', 'and', '_disease_', 'cell', 'lines']"
4814,1.0,Cells with double mutants (ITD-D835H/Y or ITD F691L) were highly resistant to sorafenib (IC50 460-3300 nM).,"['cells', 'with', 'double', 'mutants', '_abbrev_', 'or', '_gene_', '_mutation_', 'were', 'highly', 'resistant', 'to', '_chemical_', '_abbrev_', '_range_', '_unit_']"
4815,1.0,"In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer treated at doses ≥ 100 mg, the disease control rate (SD + PR) was 75%.","['in', 'the', 'subgroup', 'of', '_num_', 'patients', 'with', '_abbrev_', 'bladder', 'urothelial', 'cancer', 'treated', 'at', 'doses', '≥', '_num_', '_unit_', 'the', 'disease', 'control', 'rate', 'sd', 'pr', 'was', '_num_']"
4816,1.0,Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells.,"['increased', 'apoptosis', 'in', 'tumors', 'was', 'seen', 'in', 'dual', 'treatment', 'conditions', 'with', 'increased', 'tunel', 'positive', 'cells']"
4817,1.0,"The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib.","['the', '_abbrev_', '_disease_', 'cell', 'line', 'with', '_mutation_', 'mutation', 'was', 'found', 'to', 'have', 'a', 'low', 'antiproliferative', '_abbrev_', 'value', 'for', 'the', 'alpha', 'gamma', 'and', 'delta', '_chemical_', 'specific', '_gene_', 'inhibitor', 'taselisib']"
4818,1.0,GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.,"['gist', 'tumors', 'harboring', '_gene_', '_mutation_', 'mutation', 'are', 'more', 'likely', 'to', 'be', 'benign', 'than', 'malignant']"
4819,1.0,"Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors.","['preclinical', 'in', 'vitro', 'in', 'vivo', 'evidence', 'suggests', 'predictive', 'value', 'of', '_gene_', 'amplification', 'for', 'treatment', 'with', '_abbrev_']"
4820,1.0,A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression.,"['a', 'panel', 'of', '_num_', 'endometroid', 'endometrial', 'cancer', 'eec', 'cell', 'lines', 'was', 'characterized', 'for', 'mutations', 'and', '_num_', 'cell', 'lines', 'were', 'found', 'to', 'have', 'mutations', 'in', '_gene_', 'or', 'absence', 'of', 'expression']"
4821,1.0,"5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders.","['_num_', 'of', '_num_', 'patients', 'responded', 'to', 'treatment', 'and', 'pretreatment', 'biopsies', 'from', 'non', 'responders', 'showed', 'significantly', 'higher', '_gene_', '_gene_', 'mrna', '_p_val_', 'levels', 'than', 'responders']"
4822,1.0,"CC genotypes were at highest risk for death compared with T-alleles (median overall survival 197 vs 310 months, respectively) in both univariate (HR, 4.8; P < 0.0001) and multivariable analysis (HR, 5.6; P = 0.002).","['cc', 'genotypes', 'were', 'at', 'highest', 'risk', 'for', 'death', 'compared', 'with', 't', 'alleles', 'median', 'overall', 'survival', '_num_', 'vs', '_num_', 'months', 'respectively', 'in', 'both', 'univariate', 'hr', '_num_', 'p', '_num_', 'and', 'multivariable', 'analysis', 'hr', '_num_', 'p', '_num_']"
4823,1.0,"In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild type IDH1.","['in', 'an', 'experimental', 'in', 'vitro', 'study', 'glioma', 'cells', 'expressing', '_gene_', '_mutation_', 'were', 'associated', 'with', 'sensitivity', 'to', '_chemical_', '_abbrev_', '_num_', '_unit_', 'vs', '_abbrev_', '_num_', '_unit_', 'as', 'compared', 'to', 'cells', 'expressing', 'wild', 'type', '_gene_']"
4824,1.0,"Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo).","['_num_', 'cell', 'lines', 'with', '_gene_', 'mutation', '_mutation_', 'were', 'more', 'sensitive', 'to', '_chemical_', 'than', '_num_', 'cell', 'lines', 'with', 'wild', 'type', '_gene_', 'in', 'vitro', 'results', 'from', '_num_', 'cell', 'line', 'also', 'confirmed', 'in', 'vivo']"
4825,1.0,MRI showed that his brain metastases decreased as well.,"['mri', 'showed', 'that', 'his', 'brain', 'metastases', 'decreased', 'as', 'well']"
4826,1.0,cfDNA panel sequencing was performed in 10 patients after disease progression.,"['cfdna', 'panel', 'sequencing', 'was', 'performed', 'in', '_num_', 'patients', 'after', 'disease', 'progression']"
4827,1.0,"One carried pheochromocytoma, while both carried angiomas.","['_num_', 'carried', 'pheochromocytoma', 'while', 'both', 'carried', 'angiomas']"
4828,1.0,"WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML.","['_gene_', 'mutations', 'were', 'associated', 'with', 'a', 'higher', 'cumulative', 'incidence', 'of', 'relapse', 'and', 'shorter', 'relapse', 'free', 'survival', 'in', 'young', '_num_', '60+', 'median', '_num_', 'patients', 'with', 'cytogenetically', 'normal', '_disease_']"
4829,1.0,Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.,"['therapy', 'related', '_disease_', 'was', 'less', 'common', 'in', 'patients', 'with', '_gene_', 'mutations', '_num_', 'of', 'which', 'were', '_abbrev_', 'than', 'patients', 'wildtype', 'for', '_gene_', 'in', 'a', 'large', 'cohort', 'of', 'younger', '_range_', '_disease_', 'patients']"
4830,1.0,Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of GCB-DLBCL in 35 / 320 patient samples.,"['heterozygous', 'mutations', 'in', '_gene_', 'at', '_abbrev_', 'were', 'the', '_num_', 'most', 'frequent', 'genetic', 'event', 'after', '_gene_', 't', '_num_', '_num_', 'associated', 'with', 'a', 'diagnosis', 'of', '_disease_', 'in', '_num_', '_num_', 'patient', 'samples']"
4831,1.0,"This patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers.","['this', 'patient', ""'s"", 'tumors', 'underwent', 'rapid', 'and', 'substantial', 'tumor', 'regression', 'with', 'an', 'accompanying', 'improvement', 'in', 'pulmonary', 'dyspnea', 'oxygen', 'saturation', 'and', 'plasma', 'tumor', 'markers']"
4832,1.0,"Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels.","['patients', 'with', 'high', 'expression', 'of', 'total', '_gene_', 'e', 'and', 'low', 'molecular', 'weight', '_gene_', 'e', 'is', 'strongly', 'associated', 'with', 'poor', 'prognosis', 'in', 'breast', 'cancer', 'and', 'the', 'hazard', 'ratio', 'for', 'these', 'patients', 'in', '_num_', 'times', 'higher', 'than', 'those', 'with', 'normal', '_gene_', 'e', 'levels']"
4833,1.0,The study did not reach the targeted endpoint of 20% ORR.,"['the', 'study', 'did', 'not', 'reach', 'the', 'targeted', 'endpoint', 'of', '_num_', 'orr']"
4834,1.0,NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.,"['_chemical_', 'combined', 'with', '_disease_', 'treatment', 'induces', 'apoptosis', 'in', 'primary', '_disease_', 'cells', 'harboring', 'mutant', '_gene_', 'but', 'not', 'in', 'cells', 'with', 'wildtype', '_gene_', 'or', 'both', 'mutant', '_gene_', 'and', '_gene_']"
4835,1.0,"In patients with Philadelphia Chromosome negative B-cell precursor acute lymphoblastic leukemia, focal deletion involving 3-5 exons of IKZF1 was associated with higher cumulative incidence of relapse (CIR) than wildtype IKZF1.","['in', 'patients', 'with', 'philadelphia', 'chromosome', 'negative', '_disease_', 'precursor', 'acute', '_disease_', 'leukemia', 'focal', 'deletion', 'involving', '_range_', 'exons', 'of', '_gene_', 'was', 'associated', 'with', 'higher', 'cumulative', 'incidence', 'of', 'relapse', '_gene_', 'than', 'wildtype', '_gene_']"
4836,1.0,"Biomarkers for response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2).","['_chemical_', 'for', 'response', 'to', 'antiangiogenic', 'treatment', 'were', 'screened', 'for', 'in', '_disease_', 'cancer', 'n', '_num_', 'renal', 'cell', 'cancer', 'n', '_num_', 'and', 'non', 'small', 'cell', 'lung', 'cancer', 'n', '_num_']"
4837,1.0,"Patient shows CNS hemangioblastoma and pancreatic neuroendocrine tumors, renal and pancreatic cysts, or central nervous system tumors.","['patient', 'shows', 'cns', '_disease_', 'and', 'pancreatic', 'neuroendocrine', 'tumors', 'renal', 'and', 'pancreatic', 'cysts', 'or', 'central', 'nervous', 'system', 'tumors']"
4838,1.0,"This missense mutation was found in 2 VHL type 1 families (lineage 83 and 146).Discovered the presence of the same missense mutation in another VHL type 1 family, so I changed evidence statement to include findings from both VHL families.","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'lineage', '_num_', 'and', '_num_', 'discovered', 'the', 'presence', 'of', 'the', 'same', 'missense', 'mutation', 'in', 'another', '_gene_', 'type', '_num_', 'family', 'so', 'i', 'changed', 'evidence', 'statement', 'to', 'include', 'findings', 'from', 'both', '_gene_', 'families']"
4839,1.0,"Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis.","['effect', 'of', '_gene_', 'amplification', 'on', 'survival', 'unclear', 'no', 'significant', 'correlation', 'with', '_disease_', 'and', 'os', 'seen', 'in', 'this', '_disease_', 'analysis']"
4840,1.0,"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC.","['based', 'on', 'a', '_disease_', 'analysis', 'of', '_num_', 'trials', '_num_', 'patients', '_gene_', 'expression', 'was', 'associated', 'with', 'a', 'higher', 'orr', 'rate', 'in', 'patients', 'with', '_disease_']"
4841,1.0,we conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy.,"['we', 'conclude', 'that', 'the', 'clinical', 'activity', 'observed', 'in', 'this', 'trial', 'warrants', 'further', 'work', 'with', '_chemical_', 'and', '_chemical_', 'combination', 'therapy']"
4842,1.0,"In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions.","['in', 'patients', 'with', 'ewing', ""'s"", 'sarcoma', 'those', 'with', 'type', '_num_', '_gene_', 'fusions', 'had', 'longer', 'overall', 'survival', 'than', 'those', 'with', 'other', 'types', 'of', '_gene_', 'fusions']"
4843,1.0,"In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response.","['in', 'a', 'phase', '_num_', 'study', 'of', 'patients', 'with', 'lung', 'adenocarcinoma', 'stage', '_disease_', 'with', 'pleural', 'effusion', 'or', 'stage', 'iv', 'and', '_gene_', 'mutations', 'treated', 'with', '_chemical_', 'were', 'assessed', 'by', 'objective', 'response']"
4844,1.0,The HIF1A rs2057482 SNP was genotyped in 410 pancreatic ductal adenocarcinoma cases and 490 healthy controls.,"['the', '_gene_', '_mutation_', 'snp', 'was', 'genotyped', 'in', '_num_', 'pancreatic', 'ductal', 'adenocarcinoma', 'cases', 'and', '_num_', 'healthy', 'controls']"
4845,1.0,"In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone.","['in', '_num_', '_chemical_', 'resistant', '_gene_', 'overexpressing', 'breast', 'cancer', 'cell', 'lines', 'combination', 'of', 'the', '_abbrev_', 'inhibitor', '_chemical_', 'and', '_chemical_', 'treatment', 'induced', 'cell', 'death', 'to', 'similar', 'or', 'greater', 'levels', 'than', '_chemical_', 'alone']"
4846,1.0,MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.,"['_abbrev_', 'cells', 'transduced', 'with', '_gene_', 'harboring', 'an', '_abbrev_', 'mutation', 'were', 'sensitive', 'to', 'the', 'irreversible', 'kinase', 'inhibitor', '_chemical_', 'in', 'an', 'matrigel', 'colony', 'forming', 'assay']"
4847,1.0,These mutations were not significantly associated with overall survival.,"['these', 'mutations', 'were', 'not', 'significantly', 'associated', 'with', 'overall', 'survival']"
4848,1.0,The 5-year DFS was 9.6% in methylated and 62.5% in unmethylated samples.,"['the', '_num_', 'year', '_disease_', 'was', '_num_', 'in', 'methylated', 'and', '_num_', 'in', 'unmethylated', 'samples']"
4849,1.0,"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.","['toga', 'a', 'phase', 'iii', 'study', '_abbrev_', 'addressed', 'use', 'of', '_chemical_', 'in', '_gene_', 'positive', 'advanced', 'gastric', 'cancer', 'where', 'chemotherapy', 'using', 'fluoropyrimidine', 'based', 'and', 'platinum', 'based', 'combinations', 'had', 'been', 'common', 'practice']"
4850,1.0,"The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab.","['the', '_gene_', 'overexpressing', 'breast', 'cancer', 'cell', 'line', '_chemical_', 'transduced', 'with', 'mutant', '_gene_', '_mutation_', 'demonstrated', 'essentially', 'normal', 'proliferation', 'under', '_chemical_', 'while', 'control', 'cells', 'showed', 'negligible', 'proliferation', 'with', '_chemical_']"
4851,1.0,"EMILIA was a randomised open-label, phase III study for patients with HER2-positive, unresectable, locally advanced, or metastatic breast cancer previously treated with Trastuzumab and a Taxane, randomized 1:1 to Trastuzumab-emtansine or Capecitabine plus Lapatinib.","['emilia', 'was', 'a', 'randomised', '_disease_', 'phase', 'iii', 'study', 'for', 'patients', 'with', '_gene_', 'unresectable', 'locally', 'advanced', 'or', 'metastatic', 'breast', 'cancer', 'previously', 'treated', 'with', '_chemical_', 'and', 'a', '_chemical_', 'randomized', '_ratio_', 'to', '_chemical_', '_chemical_', 'or', '_chemical_', 'plus', '_chemical_']"
4852,1.0,A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991).,"['a', 'pharmacodynamic', 'study', '_abbrev_', 'of', '_num_', 'mantle', 'cell', 'lymphoma', '_gene_', 'patients', 'was', 'performed', 'using', 'the', '_gene_', 'inhibitor', '_chemical_', '_chemical_']"
4853,1.0,SiRNA mediated MET-knockdown reduced cell migration but not cell growth.,"['sirna', 'mediated', 'met', 'knockdown', 'reduced', 'cell', 'migration', 'but', 'not', 'cell', 'growth']"
4854,1.0,Two of 3 members carried angiomas and renal cell carcinoma.,"['_num_', 'of', '_num_', 'members', 'carried', 'angiomas', 'and', 'renal', 'cell', 'carcinoma']"
4855,1.0,High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020).,"['high', '_gene_', 'levels', 'were', 'associated', 'with', 'worse', '_num_', 'year', 'disease', 'free', 'survival', '_num_', 'than', 'low', 'levels', '_num_', 'p', '_num_']"
4856,1.0,"we analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations.","['we', 'analyzed', '_num_', 'patients', 'with', '_disease_', 'of', 'which', '_num_', 'were', 'identified', 'to', 'have', '_gene_', 'mutations']"
4857,1.0,Univariate analysis did not show any differences between these groups.,"['univariate', 'analysis', 'did', 'not', 'show', 'any', 'differences', 'between', 'these', 'groups']"
4858,1.0,"In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandetanib slowed tumor growth.","['in', 'xenografts', 'with', 'high', 'expression', 'of', '_gene_', 'or', 'ret', '_chemical_', 'led', 'to', 'tumor', 'regression', 'in', 'those', 'without', 'high', 'expression', '_chemical_', 'slowed', 'tumor', 'growth']"
4859,1.0,ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines.,"['_gene_', 'amplification', 'and', 'expression', 'was', 'associated', 'with', 'resistance', 'to', '_gene_', 'in', 'ovarian', 'cancer', 'and', 'leukemia', 'cell', 'lines']"
4860,1.0,Those with mutations had better overall survival than wild type patients.,"['those', 'with', 'mutations', 'had', 'better', 'overall', 'survival', 'than', 'wild', 'type', 'patients']"
4861,1.0,"In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.","['in', 'a', '_abbrev_', 'study', 'patients', 'with', 'the', '_mutation_', 'mutation', 'were', 'more', 'sensitive', 'to', 'rocelitinib', 'in', 'comparison', 'to', 'patients', 'with', '_abbrev_', '_disease_']"
4862,1.0,28% of the cancers were of the serous type that had shown trastuzumab response in case studies.,"['_num_', 'of', 'the', 'cancers', 'were', 'of', 'the', 'serous', 'type', 'that', 'had', 'shown', '_chemical_', 'response', 'in', 'case', 'studies']"
4863,1.0,"The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.","['the', 'phase', 'iii', 'trial', '_abbrev_', '_abbrev_', 'was', 'performed', 'in', 'patients', 'with', 'advanced', '_gene_', 'breast', 'cancer', 'that', 'was', 'heavily', 'pretreated']"
4864,1.0,"Patients with a triple mutation of NPM1, DNMT3A, and NRAS (G12/13) (three-way interaction p=0.04) showed a relatively benign prognosis with an 8-year survival rate of 75% and a 10-year survival rate of 55%.","['patients', 'with', 'a', 'triple', 'mutation', 'of', '_gene_', '_gene_', 'and', 'nras', '_abbrev_', '_num_', 'way', 'interaction', '_p_val_', 'showed', 'a', 'relatively', 'benign', 'prognosis', 'with', 'an', '_num_', 'year', 'survival', 'rate', 'of', '_num_', 'and', 'a', '_num_', 'year', 'survival', 'rate', 'of', '_num_']"
4865,1.0,Release of brigatinib administration at day 15 resulted in tumor growth (N=2).,"['release', 'of', 'brigatinib', 'administration', 'at', 'day', '_num_', 'resulted', 'in', 'tumor', 'growth', '_ineq_']"
4866,1.0,"While methylation also associated with young age, a multivariate analysis found CDKN2B methylation to be the only independent marker with significance (P=0.008) for DFS.","['while', 'methylation', 'also', 'associated', 'with', 'young', 'age', 'a', 'multivariate', 'analysis', 'found', '_gene_', 'methylation', 'to', 'be', 'the', 'only', 'independent', 'marker', 'with', 'significance', '_p_val_', 'for', '_disease_']"
4867,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_abbrev_', 'demonstrated', 'reduced', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', 'a', 'known', 'sensitizing', 'mutation', '_gene_', '_mutation_']"
4868,1.0,Two of the cell lines did not carry PIK3CA mutations.,"['_num_', 'of', 'the', 'cell', 'lines', 'did', 'not', 'carry', '_gene_', 'mutations']"
4869,1.0,"In a retrospective study of four relapsed, malignant melanoma patients, JAK2 (c.1641+2T>G) F547 splice site mutation was associated with acquired resistance to pembrolizumab monotherapy in one patient.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'relapsed', 'malignant', 'melanoma', 'patients', '_gene_', 'c', '1641+2t', '_unit_', '_abbrev_', 'splice', 'site', 'mutation', 'was', 'associated', 'with', 'acquired', 'resistance', 'to', 'pembrolizumab', 'monotherapy', 'in', '_num_', 'patient']"
4870,1.0,PPP1R15A rs557806 nonsignificantly correlated with DCR in multivariate analysis (P = 0.054).,"['_gene_', '_mutation_', 'nonsignificantly', 'correlated', 'with', '_gene_', 'in', 'multivariate', 'analysis', 'p', '_num_']"
4871,1.0,6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway.,"['_num_', 'cell', 'lines', 'with', 'alterations', 'of', 'the', '_gene_', 'pathway', 'were', 'more', 'sensitive', 'to', '_gene_', 'inhibitor', '_chemical_', 'or', '_gene_', 'inhibitor', '_chemical_', 'than', '_num_', 'cell', 'lines', 'without', 'genetic', 'alterations', 'in', 'the', '_gene_', 'pathway']"
4872,1.0,"Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48).","['median', 'progression', 'free', 'survival', 'and', 'median', 'survival', 'were', 'better', 'following', '_chemical_', 'treatment', '_num_', 'and', '_num_', 'months', '_ineq_', 'than', '_chemical_', '_num_', 'and', '_num_', 'p', '_num_', 'and', 'p', '_num_', '_ineq_']"
4873,1.0,"SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling.","['sirna', 'screening', 'in', '_num_', '_gene_', 'mutant', 'colorectal', 'cancer', 'cell', 'lines', 'identified', '_gene_', 'and', 'mek', 'inhibition', 'as', 'synergistic', 'whereas', 'mek', 'inhibition', 'alone', 'led', 'to', 'quick', 'resistance', 'via', 'upregulation', 'of', 'raf', 'signalling']"
4874,1.0,"Of 80 tumors, 6 had ALK mutation and 3 of these were G1202R.","['of', '_num_', 'tumors', '_num_', 'had', '_gene_', 'mutation', 'and', '_num_', 'of', 'these', 'were', '_mutation_']"
4875,1.0,Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample.,"['foundation', '_num_', 'ngs', 'assay', 'and', 'targeted', 'rnaseq', 'identified', '_abbrev_', 'fusion', 'in', 'a', 'melanoma', 'sample']"
4876,1.0,"In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.","['in', 'contrast', '_chemical_', 'treatment', 'induced', 'complete', 'tumor', 'regression', 'and', '_gene_', 'rate', 'of', '_num_', 'at', '_num_', 'weeks']"
4877,1.0,This study contains supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).,"['this', 'study', 'contains', 'supporting', 'evidence', 'for', 'pathogenicity', 'due', 'to', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']"
4878,1.0,"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'treatment', 'naive', 'metastatic', 'colorectal', 'cancer', 'patients', 'patients', 'with', '_gene_', '_mutation_', '_gene_', 'mutation', 'treated', 'with', '_chemical_', 'plus', '_chemical_', 'were', 'associated', 'with', 'a', 'decreased', 'progression', 'free', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'and', 'decreased', 'overall', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'as', 'compared', 'to', 'patients', 'with', 'wildtype', '_gene_']"
4879,1.0,"This patient had two somatic pathogenic mutations in MSH2 (E28fs, K172*).","['this', 'patient', 'had', '_num_', 'somatic', 'pathogenic', 'mutations', 'in', '_gene_', '_abbrev_', '_chemical_']"
4880,1.0,"In an in vitro study, a Ba/F3  cell line stably expressing the F359V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 5.16-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib).","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'stably', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_num_', 'fold', 'as', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', 'fusion', 'protein', 'reported', 'to', 'be', 'sensitizing', 'to', '_chemical_']"
4881,1.0,"Furthermore, within the OSCC patients, increased GAS6 serum concentration was associated with higher stage tumors ( P < .01) , poorly differentiated tumors ( P < .01 ), and increased lymph node metastasis ( OR = 2.79 ; CI = 1.72-4.48 ).","['furthermore', 'within', 'the', '_disease_', 'patients', 'increased', '_gene_', 'serum', 'concentration', 'was', 'associated', 'with', 'higher', 'stage', 'tumors', 'p', '_num_', 'poorly', 'differentiated', 'tumors', 'p', '_num_', 'and', 'increased', 'lymph', 'node', 'metastasis', 'or', '_num_', 'ci', '_range_']"
4882,1.0,Both had retinal angiomas and cerebellar hemangioblastomas.,"['both', 'had', 'retinal', 'angiomas', 'and', 'cerebellar', '_disease_']"
4883,1.0,A 39-year-old man presented was observed to have lung acinar adenocarcinoma.,"['a', '_age_', 'man', 'presented', 'was', 'observed', 'to', 'have', 'lung', 'acinar', 'adenocarcinoma']"
4884,1.0,"NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression.","['_abbrev_', 'cells', 'induced', 'tumors', 'in', '_abbrev_', 'scid', 'mice', 'and', '_chemical_', 'treatment', 'inhibited', 'tumor', 'growth', 'over', 'vehicle', 'treatment', 'but', '_chemical_', 'induced', 'complete', 'tumor', 'regression']"
4885,1.0,"Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C).","['inhibition', 'effects', 'were', 'not', 'seen', 'on', 'neuroblastoma', 'cells', 'with', 'wild', 'type', '_gene_', '_abbrev_', '_chemical_', '_num_', 'c']"
4886,1.0,H3122 CR2 was found to contain an 1151 insT ALK mutation and increased EML4-ALK levels.,"['_abbrev_', '_gene_', 'was', 'found', 'to', 'contain', 'an', '_num_', 'inst', '_gene_', 'mutation', 'and', 'increased', '_chemical_', 'levels']"
4887,1.0,Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations.,"['repeat', 'biopsy', 'detected', '_abbrev_', 'mutation', 'additionally', 'to', 'both', 'aforementioned', '_gene_', 'aberrations']"
4888,1.0,41 KRAS mutant patients were randomized to selumetinib or the combination.,"['_num_', '_gene_', 'mutant', 'patients', 'were', 'randomized', 'to', '_chemical_', 'or', 'the', 'combination']"
4889,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_abbrev_', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
4890,1.0,"Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.","['mouse', 'xenografts', 'using', '_abbrev_', 'cells', 'harboring', 'the', '_gene_', '_mutation_', 'mutation', 'treated', 'with', 'combination', 'therapy', '_chemical_', '_chemical_', '_chemical_', 'showed', 'increased', 'survival', 'and', 'reduced', 'tumor', 'burden', 'compared', 'to', 'single', 'and', 'double', 'agent', 'therapies']"
4891,1.0,TP53 R248Q loss of function mutation is present in 5 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.,"['_gene_', '_mutation_', 'loss', 'of', 'function', 'mutation', 'is', 'present', 'in', '_num_', 'cell', 'lines', 'and', 'all', 'are', 'insensitive', 'to', '_gene_', 'inhibitor', '_abbrev_']"
4892,1.0,"In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer.","['in', 'this', '_disease_', 'analysis', '_num_', 'studies', 'totalling', '_num_', 'cases', 'were', 'combined', 'to', 'assess', 'the', 'prognostic', 'association', 'of', '_gene_', 'expression', 'in', 'breast', 'cancer']"
4893,1.0,18 patients (2%) with PDGFRA mutations were identified.,"['_num_', 'patients', '_num_', 'with', '_gene_', 'mutations', 'were', 'identified']"
4894,1.0,Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression.,"['combined', 'treatment', 'of', 'these', 'mice', 'with', '_chemical_', 'and', '_chemical_', 'caused', 'an', 'even', 'stronger', 'tumor', 'regression']"
4895,1.0,A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.,"['a', 'cohort', 'of', 'pediatric', 'neuroblastoma', 'patients', 'ages', '_num_', 'months', 'to', '_num_', 'years', 'were', 'assessed', 'for', 'response', 'to', '_chemical_', 'in', 'a', 'phase', 'i', 'study']"
4896,1.0,An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<0·0001).,"['an', 'objective', 'response', 'was', 'observed', 'in', '_num_', '_num_', 'patients', 'in', 'the', '_chemical_', 'group', 'and', 'none', 'in', 'the', 'placebo', 'group', 'p', '_num_']"
4897,1.0,"Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types.","['analysis', 'of', '_gene_', 'fusions', 'in', '_num_', 'tumors', 'across', '_num_', 'distinct', 'tumor', 'types']"
4898,1.0,The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer.,"['the', '_gene_', '_mutation_', 'variant', 'was', 'correlated', 'with', 'increased', 'response', 'to', 'platinum', 'based', 'neoadjuvant', 'chemotherapy', 'in', 'patients', 'with', 'cervical', 'cancer']"
4899,1.0,PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.,"['_gene_', '_mutation_', 'mutation', 'increased', 'sensitivity', 'to', '_gene_', 'inhibitor', '_chemical_', 'and', '_gene_', 'inhibitor', '_chemical_', 'in', 'a', 'breast', 'cancer', 'cell', 'line', 'model']"
4900,1.0,23 patients were treated with temsirolimus containing regimens.,"['_num_', 'patients', 'were', 'treated', 'with', '_chemical_', 'containing', 'regimens']"
4901,1.0,"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP.","['in', 'an', 'evaluation', 'of', 'a', 'patient', 'with', '_chemical_', 'sensitive', 'lung', 'adenocarcinoma', 'an', 'met', 'amplification', 'was', 'identified', 'using', '_disease_']"
4902,1.0,An objective radiographic response was noted in the intracranial lesion.,"['an', 'objective', 'radiographic', 'response', 'was', 'noted', 'in', 'the', 'intracranial', 'lesion']"
4903,1.0,"The NSCLC cell line MGH021-4, harboring SQSTM1-ALK G1269A, was 6 times more sensitive to ceritinib (80nM GI50) than crizotinib (500 nM) in proliferation assays and caused notable reductions in phospho-ALK and phospho-AKT (detected by Western blot) at concentrations 10 fold lower than crizotinib.","['the', '_disease_', 'cell', 'line', '_abbrev_', 'harboring', '_abbrev_', '_mutation_', 'was', '_num_', 'times', 'more', 'sensitive', 'to', '_chemical_', '_unit_', '_gene_', 'than', '_chemical_', '_num_', '_unit_', 'in', 'proliferation', 'assays', 'and', 'caused', 'notable', 'reductions', 'in', '_chemical_', '_gene_', 'and', '_gene_', 'detected', 'by', 'western', 'blot', 'at', 'concentrations', '_num_', 'fold', 'lower', 'than', '_chemical_']"
4904,1.0,From 500 through 1440 nM there were progressively fewer resistant clones present.,"['from', '_num_', 'through', '_num_', '_unit_', 'there', 'were', 'progressively', 'fewer', 'resistant', 'clones', 'present']"
4905,1.0,IHC for c-Kit was positive and treatment with imatinib led to an objective Response.,"['_gene_', 'for', '_gene_', 'was', 'positive', 'and', 'treatment', 'with', '_chemical_', 'led', 'to', 'an', 'objective', 'response']"
4906,1.0,"Of 3 eligible studies using either nivolumab or atezolizumab, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild type were included.","['of', '_num_', 'eligible', 'studies', 'using', 'either', 'nivolumab', 'or', 'atezolizumab', '_num_', 'patients', 'with', '_gene_', 'mutant', '_disease_', 'and', '_num_', 'with', '_gene_', 'wild', 'type', 'were', 'included']"
4907,1.0,Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.,"['treatment', 'of', '_num_', 'patients', 'with', 'advanced', 'egfrm', '_mutation_', '_disease_', 'was', 'reported', 'as', 'proof', 'of', 'principle']"
4908,1.0,ACMG codes as follows.,"['acmg', 'codes', 'as', 'follows']"
4909,1.0,"226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG).","['_num_', '_chemical_', 'treated', 'patients', 'with', 'colorectal', 'cancer', '_gene_', 'were', 'analyzed', 'for', 'mrna', 'expression', 'by', 'qpcr', 'of', '_gene_', 'and', 'its', 'ligands', '_gene_', '_gene_', '_gene_', 'and', '_gene_']"
4910,1.0,Either pan-RAF  eg sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors could instead block ERK pathway hyperactivation in RAS mutated cancers.,"['either', 'pan', 'raf', 'eg', '_chemical_', 'in', 'the', 'abscence', 'of', '_gene_', '_abbrev_', 'gatekeeper', 'mutation', 'or', 'mek', 'inhibitors', 'could', 'instead', 'block', '_gene_', 'pathway', 'hyperactivation', 'in', 'ras', 'mutated', 'cancers']"
4911,1.0,"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.","['in', '_num_', 'patient', 'with', '_mutation_', 'mutation', 'the', 'use', 'of', '_chemical_', 'has', 'led', 'to', 'more', 'than', '_num_', 'years', 'of', 'survival', 'and', 'near', 'remission']"
4912,1.0,NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.,"['_gene_', 'mutations', 'were', 'associated', 'with', 'de', 'novo', '_disease_', 'as', 'well', 'as', '_gene_', 'and', '_gene_', 'fab', '_disease_']"
4913,1.0,"Proline homozygous patients were correlated with slightly poorer outcome, odds ratio 1.18 with a 95% confidence interval of 0.99-1.41.","['proline', 'homozygous', 'patients', 'were', 'correlated', 'with', 'slightly', 'poorer', 'outcome', 'odds', 'ratio', '_num_', 'with', 'a', '_num_', 'confidence', 'interval', 'of', '_range_']"
4914,1.0,"At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.","['at', '_num_', 'months', 'overall', 'survival', 'was', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', 'in', 'the', '_chemical_', 'group', 'and', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'in', 'the', '_chemical_', 'group']"
4915,1.0,"At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005).","['at', 'preplanned', 'interim', 'analysis', 'the', 'overall', 'survival', 'rate', 'at', '_num_', 'months', 'was', '_num_', '_num_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', 'in', 'the', 'combination', 'therapy', 'group', 'and', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'in', 'the', '_chemical_', 'group', 'hazard', 'ratio', 'for', 'death', 'in', 'the', 'combination', 'therapy', 'group', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', '_p_val_']"
4916,1.0,High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).,"['high', 'expression', 'of', '_gene_', 'and', '_gene_', 'were', 'associated', 'with', 'a', 'favorable', 'prognosis', 'in', 'patients', 'with', 'high', 'grade', 'serous', 'ovarian', 'carcinoma', 'n', '_num_', 'cases']"
4917,1.0,This mutation was found in a VHL type 1 patient (patient no V96).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
4918,1.0,ACMG evidence codes: 'PVS1' because they observe a multiexon deletion variant in a gene where loss of function is a known mechanism of disease.,"['acmg', 'evidence', 'codes', ""'pvs1"", 'because', 'they', 'observe', 'a', 'multiexon', 'deletion', 'variant', 'in', 'a', 'gene', 'where', 'loss', 'of', 'function', 'is', 'a', 'known', 'mechanism', 'of', 'disease']"
4919,1.0,A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration.,"['a', 'genomic', 'profiling', 'assay', 'foundationone', 'revealed', 'a', '_num_', 'copy', 'amplification', 'of', '_gene_', 'as', 'the', 'only', 'somatic', 'alteration']"
4920,1.0,"In 3 ER positive and 2 ER negative breast cancer cell lines with intact Rb, significant growth inhibition, as measured by BrdU incorporation, was seen with incubation in CDK4/6 inhibitor palbociclib (PD-0332991).","['in', '_num_', 'er', 'positive', 'and', '_num_', 'er', 'negative', 'breast', 'cancer', 'cell', 'lines', 'with', 'intact', 'rb', 'significant', 'growth', 'inhibition', 'as', 'measured', 'by', '_disease_', 'incorporation', 'was', 'seen', 'with', 'incubation', 'in', '_gene_', 'inhibitor', '_chemical_', '_disease_']"
4921,1.0,"Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.","['of', 'the', '_gene_', 'positive', 'patients', '_ratio_', '_num_', '_num_', 'ci', '_range_', 'showed', 'objective', 'response', 'to', '_chemical_', 'whereas', 'only', '_ratio_', '_gene_', 'negative', 'patients', '_num_', '_num_', 'ci', '_range_', 'showed', 'objective', 'response', 'to', '_chemical_']"
4922,1.0,This missense mutation was found in a VHL type 1 family (lineage 69).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
4923,1.0,FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).,"['_gene_', 'mutation', 'was', 'found', 'to', 'be', 'more', 'prevalent', 'in', 'non', 'responders', '_num_', 'mutations', 'than', 'responders', '_num_', 'mutation']"
4924,1.0,Results were recapitulated in cell lines and public databases.,"['results', 'were', 'recapitulated', 'in', 'cell', 'lines', 'and', 'public', 'databases']"
4925,1.0,These results suggest possible variant resistance to the TAE684-derived compound ceritinib.,"['these', 'results', 'suggest', 'possible', 'variant', 'resistance', 'to', 'the', '_abbrev_', 'compound', '_chemical_']"
4926,1.0,"The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro.","['the', '_gene_', '_gene_', 'ligase', '_gene_', 'was', 'identified', 'as', 'a', 'candidate', '_chemical_', 'for', '_chemical_', 'sensitivity', 'in', 'a', 'sirna', 'screen', 'and', 'further', 'validated', 'in', 'vitro']"
4927,1.0,"Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice.","['diassacociated', 'tumors', 'cells', 'from', 'these', 'mice', 'were', 'treated', 'with', '_gene_', 'adenovirus', 'to', 'delete', '_gene_', 'or', '_gene_', 'adenovirus', 'and', 'cells', 'were', 'transplanted', 'into', 'athymic', 'mice']"
4928,1.0,Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma.,"['study', 'describes', 'an', '_num_', 'year', 'old', 'never', 'smoker', 'patient', 'presenting', 'with', 'lung', 'adenocarcinoma']"
4929,1.0,"High EGFRvIII and AREG expression levels identified SCCHN (squamous cell carcinoma, head and neck) patients that were less likely to benefit from combination treatment with cetuximab and docetaxel.","['high', 'egfrviii', 'and', '_gene_', 'expression', 'levels', 'identified', '_disease_', '_disease_', 'cell', 'carcinoma', 'head', 'and', 'neck', 'patients', 'that', 'were', 'less', 'likely', 'to', 'benefit', 'from', 'combination', 'treatment', 'with', '_chemical_', 'and', '_chemical_']"
4930,1.0,"Despite similar binding affinities, the cellular activity of BMS-354825 was >10-fold greater than that of SU-11248 or PD-180970, and we hypothesize that additional pharmaceutical properties may contribute to the greater cellular potency.","['despite', 'similar', 'binding', 'affinities', 'the', 'cellular', 'activity', 'of', '_chemical_', 'was', '_n_fold_', 'greater', 'than', 'that', 'of', '_chemical_', 'or', '_chemical_', 'and', 'we', 'hypothesize', 'that', 'additional', 'pharmaceutical', 'properties', 'may', 'contribute', 'to', 'the', 'greater', 'cellular', 'potency']"
4931,1.0,"In patients with EGFR mutation, erlotinib maintenance reduced progression and death significantly with median progression free survival (PFS) of 44.6 vs. 13 weeks over placebo.","['in', 'patients', 'with', '_gene_', 'mutation', '_chemical_', 'maintenance', 'reduced', 'progression', 'and', 'death', 'significantly', 'with', 'median', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'vs', '_num_', 'weeks', 'over', 'placebo']"
4932,1.0,PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.,"['_gene_', 'loss', 'by', 'fish', 'is', 'associated', 'with', 'poorer', 'prognosis', 'in', 'patients', 'with', 'prostate', 'cancer']"
4933,1.0,"EML4-ALK variant 1 expressing H3122 NSCLC cell line was cultured in increasing levels of crizotinib to produce crizotinib resistant cell lines CR1, CR2 and CR3.","['_chemical_', 'variant', '_num_', 'expressing', '_abbrev_', '_disease_', 'cell', 'line', 'was', 'cultured', 'in', 'increasing', 'levels', 'of', '_chemical_', 'to', 'produce', '_chemical_', 'resistant', 'cell', 'lines', '_gene_', '_gene_', 'and', '_gene_']"
4934,1.0,"R173C was one of four mutations (out of 42 tested) that displayed no significant phosphatase activity against either substrate, indicating, by this assay, that the mutation negatively impacts the function of PTEN.","['_mutation_', 'was', '_num_', 'of', '_num_', 'mutations', 'out', 'of', '_num_', 'tested', 'that', 'displayed', 'no', 'significant', 'phosphatase', 'activity', 'against', 'either', 'substrate', 'indicating', 'by', 'this', 'assay', 'that', 'the', 'mutation', 'negatively', 'impacts', 'the', 'function', 'of', '_gene_']"
4935,1.0,"In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L858R mutation was associated with resistance to erlotinib treatment; the patient survived 3.9 months, as compared to the overall 24 months median overall survival of the other patients who were not resistant to erlotinib treatment.","['in', 'a', 'retrospective', 'study', 'of', '_num_', 'caucasian', 'advanced', 'lung', 'adenocarcinoma', 'patients', 'a', 'patient', 'harboring', '_gene_', '_mutation_', 'mutation', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment', 'the', 'patient', 'survived', '_num_', 'months', 'as', 'compared', 'to', 'the', 'overall', '_num_', 'months', 'median', 'overall', 'survival', 'of', 'the', 'other', 'patients', 'who', 'were', 'not', 'resistant', 'to', '_chemical_', 'treatment']"
4936,1.0,"Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively.","['sensitivity', 'was', 'determined', 'by', 'assessing', 'cell', 'proliferation', 'the', '_abbrev_', 'of', '_chemical_', 'for', '_gene_', '_mutation_', 'and', '_gene_', '_mutation_', 'expressing', 'cells', 'were', '_num_', '_unit_', '_unit_', 'and', '_num_', '_unit_', '_unit_', 'respectively']"
4937,1.0,"One case shows CNS hemangioblastoma, pancreatic cysts, and Grawitz.","['_num_', 'case', 'shows', 'cns', '_disease_', 'pancreatic', 'cysts', 'and', 'grawitz']"
4938,1.0,Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.,"['_chemical_', 'can', 'inhibit', '_gene_', 'mediated', 'mek', '_disease_', 'and', 'soft', 'agar', 'colony', 'formation', 'of', 'aale', 'cells', 'expressing', '_gene_', '_mutation_', 'in', 'vitro']"
4939,1.0,"In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients.","['in', '_num_', 'patients', 'with', 'hairy', 'cell', 'leukemia', 'sequencing', 'discovered', 'a', '_mutation_', 'mutation', 'in', 'all', '_num_', 'of', 'the', 'sequenced', 'patients']"
4940,1.0,This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.,"['this', '_disease_', 'analysis', 'did', 'not', 'find', 'a', 'significant', 'connection', 'between', 'expression', 'of', '_gene_', 'and', 'overall', 'survival', 'in', 'patients', 'with', '_disease_']"
4941,1.0,FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation.,"['_disease_', 'tumor', 'specimens', 'from', '_num_', 'melanoma', 'patients', 'were', 'screened', 'for', 'kit', 'amplification', 'and', 'mutation']"
4942,1.0,The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD.,"['the', '_num_', 'patient', 'with', 'a', 'ras', 'mutation', 'discontinued', 'study', 'treatment', 'after', '_num_', 'days', 'on', 'therapy', 'due', 'to', 'pd']"
4943,0.0,Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible relationship to UGT1A expression.,"['correlating', 'cell', 'line', 'specific', '_abbrev_', 'with', 'the', 'corresponding', 'gene', 'expression', 'patterns', 'revealed', 'a', 'possible', 'relationship', 'to', '_mutation_', 'expression']"
4944,1.0,"Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients.","['median', '_disease_', 'was', '_num_', 'months', '_num_', 'ci', '_num_', 'months', 'to', 'not', 'estimable', 'in', 'patients', 'with', 'confirmed', '_gene_', 'tumors', 'and', '_num_', 'months', '_num_', 'ci', '_num_', 'to', '_num_', 'months', 'in', '_gene_', 'normal', 'patients']"
4945,1.0,The presence of a PIK3CA mutation in exon 9 or exon 20 (such as H1047R) were associated with lack of panitumumab or cetuximab response.,"['the', 'presence', 'of', 'a', '_gene_', 'mutation', 'in', 'exon', '_num_', 'or', 'exon', '_num_', 'such', 'as', '_mutation_', 'were', 'associated', 'with', 'lack', 'of', 'panitumumab', 'or', '_chemical_', 'response']"
4946,1.0,The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.,"['the', '_gene_', '_mutation_', 'mutation', 'has', 'been', 'shown', 'to', 'confer', 'resistance', 'to', '_gene_', 'inhibitors', '_chemical_', 'in', 'melanoma', 'cell', 'line', '_abbrev_']"
4947,1.0,The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.,"['the', '_abbrev_', 'fusion', 'has', 'been', 'shown', 'to', 'be', 'associated', 'with', 'favorable', 'prognosis', 'in', 'acute', 'myeloid', 'leukemia']"
4948,1.0,"All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 μmol/L for all three cell lines).","['all', '_num_', 'cell', 'lines', 'were', 'resistant', 'to', '_chemical_', 'in', 'vitro', 'but', 'sensitive', 'to', '_chemical_', '_abbrev_', '_num_', 'μmol', '_unit_', 'for', 'all', '_num_', 'cell', 'lines']"
4949,1.0,Cells harboring L858R were sensitive to afatinib.,"['cells', 'harboring', '_mutation_', 'were', 'sensitive', 'to', '_chemical_']"
4950,1.0,4 patients were identified to harbor RAS mutations.,"['_num_', 'patients', 'were', 'identified', 'to', 'harbor', 'ras', 'mutations']"
4951,1.0,The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.,"['the', '_mutation_', 'mutation', 'showed', 'mild', 'response', 'to', '_chemical_', 'in', '_abbrev_', 'cell', 'lines', 'retrovirally', 'transduced', 'with', 'wildtype', 'or', 'mutant', '_gene_']"
4952,1.0,Crizotinib led to a partial response.,"['_chemical_', 'led', 'to', 'a', 'partial', 'response']"
4953,1.0,"In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification.","['in', 'an', 'independent', '_num_', 'retrospective', 'cohort', '_num_', 'out', 'of', '_num_', 'patients', 'with', '_gene_', '_gene_', '_chemical_', 'resitant', '_gene_', 'were', 'found', 'to', 'harbor', '_gene_', 'overexpression', 'and', 'amplification']"
4954,1.0,High UGT1A expression was correlated with ganetespib resistance.,"['high', '_mutation_', 'expression', 'was', 'correlated', 'with', '_chemical_', 'resistance']"
4955,1.0,"In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations.","['in', 'a', 'phase', 'i', 'study', 'of', '_chemical_', 'partial', 'response', 'was', 'observed', 'in', '_num_', 'patients', 'with', 'breast', 'and', 'ovarian', 'carcinoma', 'respectively', 'and', '_gene_', '_mutation_', 'mutations']"
4956,1.0,"In this review, the author summarize the role of this fusion in diagnosis of synovial sarcomas.","['in', 'this', 'review', 'the', 'author', 'summarize', 'the', 'role', 'of', 'this', 'fusion', 'in', 'diagnosis', 'of', 'synovial', 'sarcomas']"
4957,1.0,"An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment.","['an', '_gene_', '_mutation_', 'mutation', '_num_', 'of', 'mutant', 'alleles', 'was', 'detected', 'in', 'a', 'biopsy', 'from', '_num_', 'patient', 'which', 'had', 'been', 'previously', 'treated', 'with', '_chemical_', 'in', 'the', 'analysis', 'of', '_num_', 'patients', 'with', 'refractory', 'metastatic', '_gene_', 'after', '_chemical_', 'panitumumab', 'prior', 'to', '_abbrev_', 'treatment']"
4958,1.0,"The pooled response rates (RR) for KRAS wild type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02).","['the', 'pooled', 'response', 'rates', '_gene_', 'for', '_gene_', 'wild', 'type', '_gene_', 'vs', 'mutated', '_gene_', 'patients', 'were', '_num_', 'and', '_num_', 'respectively', 'or', '_num_', 'p', '_num_']"
4959,1.0,EML4-ALK with G1269A mutation was tested for sensitivity to ceritinib via transduction into Ba/F3 cells and generation of survival curves varying ceritinib concentration.,"['_chemical_', 'with', '_mutation_', 'mutation', 'was', 'tested', 'for', 'sensitivity', 'to', '_chemical_', 'via', 'transduction', 'into', 'ba', '_abbrev_', 'cells', 'and', 'generation', 'of', 'survival', 'curves', 'varying', '_chemical_', 'concentration']"
4960,1.0,"DFS/PFS was poor in patients with hepatocellular carcinoma (HR = 1.72,  P = 0.003), melanoma (HR = 3.39,  P <0.001), and renal carcinoma, (HR = 5.04,  P <0.001).","['dfs', 'pfs', 'was', 'poor', 'in', 'patients', 'with', '_disease_', 'carcinoma', 'hr', '_num_', 'p', '_num_', 'melanoma', 'hr', '_num_', 'p', '_num_', 'and', 'renal', 'carcinoma', 'hr', '_num_', 'p', '_num_']"
4961,1.0,Exome and RNA sequencing was performed in tumor and matched normal tissue of 19 patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab.,"['exome', 'and', 'rna', 'sequencing', 'was', 'performed', 'in', 'tumor', 'and', 'matched', 'normal', 'tissue', 'of', '_num_', 'patients', 'with', 'metastatic', 'colorectal', 'cancer', 'treated', 'with', 'chemotherapy', 'and', '_chemical_']"
4962,1.0,KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer.,"['_gene_', 'mutations', 'were', 'significantly', 'associated', 'with', 'reduced', 'progression', 'free', 'and', 'overall', 'survival', 'in', 'patients', 'with', 'advanced', 'colorectal', 'cancer']"
4963,1.0,Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance.,"['downstream', 'signalling', 'was', 'independent', 'of', 'inhibitor', 'presence', 'in', 'these', 'clones', 'and', 'expression', 'of', 'the', 'mutation', 'in', '_disease_', 'cells', 'led', 'to', 'resistance']"
4964,1.0,Only supporting evidence of pathogenicity because of cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).,"['only', 'supporting', 'evidence', 'of', 'pathogenicity', 'because', 'of', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']"
4965,1.0,KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer.,"['kit', 'mutations', 'detected', 'in', '_ratio_', 'patients', 'showed', 'no', 'prognostic', 'significance', 'in', 'patients', 'with', 'small', 'cell', 'lung', 'cancer']"
4966,1.0,"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).","['a', 'phase', 'iii', 'clinical', 'trial', '_abbrev_', 'found', 'that', 'median', 'progression', 'free', 'survival', 'among', 'patients', 'with', 'exon', '_num_', 'deletions', 'or', '_mutation_', '_gene_', 'mutations', 'n', '_num_', 'was', '_num_', 'months', 'for', '_chemical_', 'and', '_num_', 'months', 'for', 'chemotherapy', 'hr', '_num_', '_num_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']"
4967,1.0,The sensitivity and specificity of using this as a biomarker to differentiate between the two tumor types was 78.4% and 97.3% respectively.,"['the', 'sensitivity', 'and', 'specificity', 'of', 'using', 'this', 'as', 'a', '_chemical_', 'to', 'differentiate', 'between', 'the', '_num_', 'tumor', 'types', 'was', '_num_', 'and', '_num_', 'respectively']"
4968,1.0,Persistence of NPM1-mutated transcripts in blood was present in 15% of the patients after the second chemotherapy cycle.,"['persistence', 'of', '_abbrev_', 'transcripts', 'in', 'blood', 'was', 'present', 'in', '_num_', 'of', 'the', 'patients', 'after', 'the', '_num_', 'chemotherapy', 'cycle']"
4969,1.0,Patient received two cycles off-label at 3.6mg/kg and was found to have morphologic response of lung and bone lesions by PET and CT. TDM-1 therapy was ongoing as of publication April 2015.,"['patient', 'received', '_num_', 'cycles', 'off', 'label', 'at', '_num_', '_unit_', '_unit_', 'and', 'was', 'found', 'to', 'have', 'morphologic', 'response', 'of', 'lung', 'and', 'bone', 'lesions', 'by', 'pet', 'and', 'ct', '_abbrev_', 'therapy', 'was', 'ongoing', 'as', 'of', 'publication', 'april', '_year_']"
4970,1.0,An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib.,"['an', 'in', 'vitro', 'saturation', 'mutagenesis', 'screen', 'of', '_num_', 'independently', 'derived', '_gene_', 'clones', 'was', 'performed', 'to', 'identify', 'mutations', 'that', 'confer', 'resistance', 'to', '_chemical_']"
4971,1.0,Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.,"['_num_', 'patients', 'who', 'developed', 'adaptive', 'resistance', 'to', '_disease_', 'treatment', 'also', 'showed', '_gene_', 'upregulation', 'in', 'blocking', 'antibody', 'bound', 't', 'cells', 'at', 'treatment', 'failure']"
4972,1.0,"50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK.","['_num_', 'of', 'maximal', 'inhibitory', 'concentration', 'for', '_chemical_', 'was', '_num_', '_unit_', 'which', 'was', 'approximately', '4x', 'greater', 'than', '_abbrev_', 'of', '_num_', '_unit_', 'obtained', 'for', '_chemical_']"
4973,1.0,"HPO terms: hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts, epididymal cysts.","['_disease_', 'terms', '_disease_', 'renal', 'cell', 'carcinoma', 'multiple', 'pancreatic', 'cysts', '_disease_', 'cysts']"
4974,1.0,"Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)","['patients', 'with', 'amplification', 'in', 'all', 'neoplastic', 'cells', '_num_', 'had', 'worse', 'outcome', 'compared', 'to', 'patients', 'without', 'amplification', '_num_', 'intermediate', 'outcome', 'or', 'amplification', 'in', 'minor', 'clones', '_num_', 'highest', 'survival', 'probability']"
4975,1.0,Expression of p16 was assayed in 69 HNSCC patients by IHC.,"['expression', 'of', '_gene_', 'was', 'assayed', 'in', '_num_', '_disease_', 'patients', 'by', '_gene_']"
4976,1.0,D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance.,"['_mutation_', 'was', 'observed', 'as', 'a', 'secondary', 'kit', 'mutation', 'in', '_num_', 'patients', 'with', 'secondary', '_chemical_', 'resistance']"
4977,1.0,Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.,"['_chemical_', 'with', '_chemical_', 'provides', 'higher', 'response', 'rate', 'and', 'lower', 'toxicity', 'as', 'compared', 'to', 'chemotherapy', 'in', 'patients', 'with', 'melanoma']"
4978,1.0,Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19.,"['case', 'report', 'of', 'a', 'patient', 'with', 'stage', 'iv', 'lung', 'adenocarcinoma', 'and', 'a', '15–base', 'pair', 'deletion', 'in', '_gene_', 'exon', '_num_']"
4979,1.0,"These deletions were observed in KRAS wildtype pancreatic, ovarian, NSCLC, and thyroid cancers.","['these', 'deletions', 'were', 'observed', 'in', '_gene_', 'wildtype', 'pancreatic', 'ovarian', '_disease_', 'and', 'thyroid', 'cancers']"
4980,1.0,"NOTCH1 mutations were mostly represented (26/34, 76.5%) by a recurrent 2-bp frameshift deletion (c.7544_7545delCT), with the remaining being other frameshift deletions or insertions.","['_gene_', 'mutations', 'were', 'mostly', 'represented', '_ratio_', '_num_', 'by', 'a', 'recurrent', '_num_', '_gene_', 'frameshift', 'deletion', '_mutation_', 'with', 'the', 'remaining', 'being', 'other', 'frameshift', 'deletions', 'or', 'insertions']"
4981,1.0,Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin.,"['antitumour', 'effect', 'of', '_chemical_', 'treatment', 'in', 'esophageal', 'adenocarcinomas', 'can', 'be', 'intensified', 'in', 'combination', 'with', '_disease_']"
4982,1.0,"Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30).","['improved', '_num_', 'year', '_disease_', 'survival', 'dss', 'was', 'noted', 'only', 'in', 'patients', 'with', 'low', '_gene_', 'expression', 'when', 'treated', 'with', 'adjuvant', '_disease_', '_chemical_', '_ineq_', '_ineq_', '_num_', 'ci', '_range_', '_p_val_', 'low', 'hr', '_num_', '_num_', 'ci', '_range_', '_p_val_', 'high', 'compared', 'to', 'patients', 'in', 'the', 'observation', 'arm', '_ineq_']"
4983,1.0,Phase 1 study of MAPK1/2 inhibitor BAY 86-9766.,"['phase', '_num_', 'study', 'of', '_gene_', 'inhibitor', 'bay', '_range_']"
4984,1.0,SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg).,"['scid', 'mice', 'xenografted', 'with', '_abbrev_', 'were', 'treated', 'for', '_num_', 'days', 'with', '_chemical_', '_num_', '_disease_', 'or', '_chemical_', '_num_', 'or', '_num_', '_disease_']"
4985,1.0,Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation.,"['tumor', 'xenografts', 'in', 'mice', 'were', 'established', 'with', 'the', '_abbrev_', '_gene_', 'positive', 'breast', 'cancer', 'cell', 'line', 'with', '_gene_', '_mutation_', 'mutation']"
4986,1.0,"In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II.","['in', 'this', 'initial', 'report', 'of', 'a', 'single', 'arm', 'phase', 'i', 'and', 'ii', 'study', '_abbrev_', 'of', '_chemical_', '_chemical_', '_num_', 'patients', 'with', 'advanced', 'or', 'metastatic', '_gene_', 'rearranged', 'non', 'small', 'cell', 'lung', 'cancer', '_disease_', 'were', 'assessed', 'for', 'objective', 'response', 'during', 'phase', 'ii']"
4987,1.0,"In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function.","['in', 'a', 'panel', 'of', '_num_', 'breast', 'cancer', 'cell', 'lines', '_num_', 'had', 'loss', 'of', '_gene_', 'function']"
4988,1.0,High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer.,"['high', 'expression', 'of', '_gene_', '_gene_', 'was', 'associated', 'with', 'shorter', 'overall', 'survival', 'os', 'from', '_chemical_', 'treatment', 'in', 'patients', 'with', 'metastatic', 'colorectal', 'cancer']"
4989,1.0,"Patients with wild type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005).","['patients', 'with', 'wild', 'type', '_gene_', 'had', 'better', 'outcomes', 'with', 'act', 'than', 'obs', '_ineq_', '_range_', '_p_val_', '_ineq_', '_range_', '_p_val_']"
4990,0.0,"we generated several representative HNSCC-derived PTPRD mutants by site-directed mutagenesis (S384R, K1502M, T1100M and L1147F).","['we', 'generated', 'several', 'representative', 'hnscc', 'derived', '_gene_', 'mutants', 'by', 'site', 'directed', 'mutagenesis', '_abbrev_', '_abbrev_', '_abbrev_', 'and', '_abbrev_']"
4991,1.0,"Either pan-RAF  eg sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers.","['either', 'pan', 'raf', 'eg', '_chemical_', 'in', 'the', 'abscence', 'of', '_gene_', '_abbrev_', 'gatekeeper', 'mutation', 'or', 'mek', 'inhibitors', 'eg', '_chemical_', 'could', 'instead', 'block', '_gene_', 'pathway', 'hyperactivation', 'in', 'ras', 'mutated', 'cancers']"
4992,1.0,"During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression/death occurred in 41% (62/152  pt) in the alectinib group and 68% (102/151 patients) in the crizotinib group.","['during', 'a', 'median', 'follow', 'up', 'of', '_num_', 'months', '_chemical_', 'and', '_num_', 'months', '_chemical_', 'an', 'event', 'of', 'disease', 'progression', 'death', 'occurred', 'in', '_num_', '_ratio_', 'pt', 'in', 'the', '_chemical_', 'group', 'and', '_num_', '_ratio_', 'patients', 'in', 'the', '_chemical_', 'group']"
4993,0.0,These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors.,"['these', 'data', 'demonstrate', 'the', 'dependency', 'of', '_gene_', 'mutant', '_disease_', 'on', '_gene_', 'enzymatic', 'activity', 'and', 'suggest', 'treatment', 'of', 'these', 'genetically', 'defined', 'cancers', 'with', '_gene_', 'inhibitors']"
4994,1.0,"For patients who had no prior crizotinib treatment, median progression free survival was 10.4 months.","['for', 'patients', 'who', 'had', 'no', 'prior', '_chemical_', 'treatment', 'median', 'progression', 'free', 'survival', 'was', '_num_', 'months']"
4995,1.0,"These same experiments performed with the NPM-ALK fusion resulted in IC50 of 149 nM for G1202R and 11nM for wild type, consistent with resistance.","['these', 'same', 'experiments', 'performed', 'with', 'the', '_chemical_', 'fusion', 'resulted', 'in', '_abbrev_', 'of', '_num_', '_unit_', 'for', '_mutation_', 'and', '_unit_', 'for', 'wild', 'type', 'consistent', 'with', 'resistance']"
4996,1.0,"In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.","['in', 'breast', 'cancer', 'patients', 'harboring', '_gene_', 'mutation', 'mutations', 'in', 'dna', 'contact', 'regions', 'such', 'as', '_abbrev_', 'are', 'prognostic', 'for', 'a', 'worse', 'relapse', 'free', 'survival', 'compared', 'to', 'other', 'non', 'silent', 'mutations', 'in', '_gene_']"
4997,1.0,"20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild type A375P cells.","['_num_', '_num_', 'cells', 'were', 'insensitive', 'to', '_gene_', 'inhibition', '_chemical_', 'in', 'both', 'proliferation', 'assays', 'and', 'evaluation', 'of', 'perk', 'compared', 'to', '_gene_', '_mutation_', 'mutated', '_gene_', 'wild', 'type', '_abbrev_', 'cells']"
4998,1.0,"For each drug, 3 biological replicates were performed for this study, and effectiveness was evaluated using an MTT assay.","['for', 'each', 'drug', '_num_', 'biological', 'replicates', 'were', 'performed', 'for', 'this', 'study', 'and', 'effectiveness', 'was', 'evaluated', 'using', 'an', '_gene_', 'assay']"
4999,0.0,The study concludes that there is insufficient evidence to support use of CYP2D6 genotyping as a guide for tamoxifen use in breast cancer.,"['the', 'study', 'concludes', 'that', 'there', 'is', 'insufficient', 'evidence', 'to', 'support', 'use', 'of', '_gene_', 'genotyping', 'as', 'a', 'guide', 'for', 'tamoxifen', 'use', 'in', 'breast', 'cancer']"
5000,1.0,This patient also harbored a MLH1 p.E13fs*3 mutation.,"['this', 'patient', 'also', 'harbored', 'a', '_gene_', 'p', '_abbrev_', 'mutation']"
5001,1.0,Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3.,"['subset', 'of', '_num_', 'cancer', 'cell', 'lines', 'with', 'unaltered', '_gene_', 'is', 'sensitive', 'to', '_gene_', 'inhibitor', '_abbrev_']"
5002,1.0,This missense mutation was found in 2 family members with VHL (Family ID 3969 in publication).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'family', 'members', 'with', '_gene_', 'family', 'id', '_num_', 'in', 'publication']"
5003,1.0,"Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild type CD74–ROS1, and were sensitive to foretinib.","['ba', '_abbrev_', 'cells', 'expressing', '_abbrev_', '_abbrev_', 'showed', 'resistance', 'to', '_chemical_', 'compared', 'with', 'those', 'expressing', 'wild', 'type', '_abbrev_', 'and', 'were', 'sensitive', 'to', '_chemical_']"
5004,1.0,(family VHL 57).,"['family', '_gene_', '_num_']"
5005,1.0,166 Chinese patients with metastatic colorectal carcinoma who had been treated with FOLFOX-4 were used in this study.,"['_num_', 'chinese', 'patients', 'with', 'metastatic', 'colorectal', 'carcinoma', 'who', 'had', 'been', 'treated', 'with', '_chemical_', 'were', 'used', 'in', 'this', 'study']"
5006,1.0,A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed.,"['a', '_disease_', 'analysis', 'of', '_num_', 'metastatic', 'colorectal', 'cancer', 'studies', '_num_', 'patients', 'was', 'performed']"
5007,1.0,A t(8;13)(p11;q12) patient with ZNF198-FGFR1-induced progressive myeloproliferative disorder was treated with PKC412.,"['a', 't', '_num_', '_num_', '_gene_', '_gene_', 'patient', 'with', '_abbrev_', 'progressive', '_disease_', 'disorder', 'was', 'treated', 'with', '_gene_']"
5008,1.0,"Using selumetinib in patient-derived CRC xenografts or trametinib in NSCLC xenografts, MEK inhibition by selumetinib or trametinib in combination with afatinib more effectively inhibited increases in tumor volume than either monotherapy.","['using', '_chemical_', 'in', '_disease_', '_gene_', 'xenografts', 'or', '_chemical_', 'in', '_disease_', 'xenografts', 'mek', 'inhibition', 'by', '_chemical_', 'or', '_chemical_', 'in', 'combination', 'with', '_chemical_', 'more', 'effectively', 'inhibited', 'increases', 'in', 'tumor', 'volume', 'than', 'either', 'monotherapy']"
5009,1.0,"In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations.","['in', 'a', 'phase', '_num_', 'clinical', 'trial', 'of', '_chemical_', 'in', 'patients', 'with', 'hereditary', 'or', 'sporadic', 'advanced', 'medullary', 'thyroid', 'cancer', '_num_', 'out', 'of', '_num_', 'patients', 'genotyped', 'in', 'arm', 'b', 'sporadic', '_gene_', 'tested', 'positive', 'for', 'ret', 'mutations']"
5010,1.0,Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines.,"['increased', '_gene_', 'activity', 'was', 'found', 'in', 'uveal', 'melanoma', 'cell', 'lines', 'with', '_gene_', 'or', '_gene_', 'mutations', '_ineq_', 'compared', 'to', '_disease_', '_gene_', 'cell', 'lines', '_gene_', 'and', 'could', 'be', 'induced', 'by', 'introducing', 'these', 'mutations', 'into', '_gene_', 'cell', 'lines']"
5011,1.0,"Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.","['prior', 'to', 'identification', 'of', 'the', '_gene_', 'exon', '_num_', 'deletion', 'the', 'patient', 'was', 'underwent', 'complex', 'treatments', 'with', 'standard', 'chemotherapy', 'and', 'experienced', 'disease', 'progression', 'upon', 'identification', 'of', '_gene_', 'exon', '_num_', 'deletion', 'and', 'treatment', 'with', '_chemical_', 'the', 'patient', 'achieved', 'a', 'clinical', 'response']"
5012,1.0,Loss of heterozygosity of the wildtype allele was demonstrated.,"['loss', 'of', 'heterozygosity', 'of', 'the', 'wildtype', 'allele', 'was', 'demonstrated']"
5013,1.0,Only moderate evidence for pathogenicity because protein length changes as a result of a deletion in a nonrepeat region and stop-loss variant (ACMG code: PM4).,"['only', 'moderate', 'evidence', 'for', 'pathogenicity', 'because', 'protein', 'length', 'changes', 'as', 'a', 'result', 'of', 'a', 'deletion', 'in', 'a', 'nonrepeat', 'region', 'and', 'stop', 'loss', 'variant', 'acmg', 'code', '_abbrev_']"
5014,1.0,"After 4wk of sunitinib therapy, one patient showed morphological response and the other patient showed partial response to sunitinib therapy.","['after', '4wk', 'of', '_chemical_', 'therapy', '_num_', 'patient', 'showed', 'morphological', 'response', 'and', 'the', 'other', 'patient', 'showed', 'partial', 'response', 'to', '_chemical_', 'therapy']"
5015,1.0,The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria.,"['the', 'trial', 'ended', 'early', 'due', 'to', 'poor', 'accrual', 'with', '_num_', 'of', '_num_', 'screened', 'meeting', 'the', 'phase', 'b', 'criteria']"
5016,1.0,"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization.","['in', '_num_', 'out', 'of', '_num_', '_num_', 'metastatic', 'colorectal', 'cancer', 'tumors', 'harboring', '_gene_', 'nras', '_gene_', 'or', '_gene_', 'mutations', 'and', 'implanted', 'into', 'mice', 'the', 'therapeutic', 'combination', 'of', 'the', 'mek', 'inhibitor', '_chemical_', 'and', 'the', '_gene_', 'inhibitor', '_chemical_', 'resulted', 'in', 'disease', 'stabilization']"
5017,1.0,"Clinical manifestations associated with this mutation include: pheochromocytoma, retinal hemangioblastoma, and pancreatic neuroendocrine tumor.","['clinical', 'manifestations', 'associated', 'with', 'this', 'mutation', 'include', 'pheochromocytoma', 'retinal', '_disease_', 'and', 'pancreatic', 'neuroendocrine', 'tumor']"
5018,1.0,"By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27).","['by', 'contrast', 'in', '_gene_', 'mutation', 'negative', 'cases', 'the', 'response', 'rate', 'was', 'much', 'lower', '_num_', '_ratio_']"
5019,1.0,The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor.,"['the', '_gene_', '_mutation_', 'mutation', 'was', 'identified', 'as', 'a', 'relapse', 'specific', 'variant', 'and', 'was', 'undetectable', 'in', 'the', '_gene_', 'treatment', 'tumor']"
5020,1.0,"26 of 55 individuals were identified with angiomas, 5 with cerebellar hemangioblastomas, and 30 with pheochromocytomas.","['_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'angiomas', '_num_', 'with', 'cerebellar', '_disease_', 'and', '_num_', 'with', 'pheochromocytomas']"
5021,1.0,All three family members had retinal angiomas.,"['all', '_num_', 'family', 'members', 'had', 'retinal', 'angiomas']"
5022,1.0,This was true for cytogenetically normal AML and the entire cohort.,"['this', 'was', 'true', 'for', 'cytogenetically', 'normal', '_disease_', 'and', 'the', 'entire', 'cohort']"
5023,1.0,This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and L858R).,"['this', 'open', 'label', 'phase', '_num_', 'trial', 'performed', 'across', '_num_', 'centers', 'in', 'japan', '_abbrev_', 'assessed', 'patients', 'with', 'postoperative', 'recurrent', 'or', 'stage', 'iiib', 'iv', '_disease_', 'and', 'activating', '_gene_', 'mutations', 'exon', '_num_', 'deletion', 'and', '_mutation_']"
5024,1.0,In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1.,"['in', 'this', 'study', 'a', 'collection', 'of', '_num_', 'sporadic', '_disease_', 'tumors', 'were', 'analysed', 'for', 'presence', 'of', 'mutations', 'in', '_gene_']"
5025,1.0,Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group.,"['recruitment', 'was', 'stopped', 'prematurely', 'when', 'it', 'was', 'deemed', 'unlikely', 'that', 'the', 'increased', '_disease_', 'would', 'be', 'seen', 'in', 'the', '_chemical_', 'group']"
5026,1.0,"The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.","['the', 'patient', 'was', 'treated', 'with', '_chemical_', 'and', 'after', '_num_', 'weeks', 'of', 'therapy', 'the', '_gene_', 'value', 'decreased', 'from', '_num_', 'to', '_num_', 'and', 'there', 'was', 'radiological', 'resolution', 'of', 'the', 'disease']"
5027,1.0,"A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression.","['a', '_num_', 'yr', 'old', 'male', 'patient', 'with', 'metastatic', 'acral', 'lentiginous', 'melanoma', '_gene_', 'nras', 'kit', 'negative', 'was', 'found', 'to', 'harbor', 'a', '_chemical_', 'intron', '_num_', 'intron', '_num_', 'fusion', 'in', 'a', 'subcutaneous', 'metastasis', 'sample', 'after', 'disease', 'progression']"
5028,1.0,"Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53.","['phase', 'i', 'trial', 'of', '_gene_', 'inhibitor', '_chemical_', 'in', '_num_', 'patients', 'with', '_disease_', 'all', '_gene_', '_disease_', 'scll', 'demonstrated', 'sustained', 'clinical', 'improvement', 'and', 'induction', 'of', '_gene_', 'target', 'genes', 'in', 'subset', 'of', 'patients', 'with', 'wild', 'type', '_gene_']"
5029,1.0,"The patient (M, 77, nonsmoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 28.1 months and was alive at study end.","['the', 'patient', '_unit_', '_num_', 'nonsmoker', 'had', 'progressive', 'disease', 'as', 'response', 'progression', 'free', 'survival', '_disease_', 'of', '_num_', 'months', 'overall', 'survival', 'os', 'of', '_num_', 'months', 'and', 'was', 'alive', 'at', 'study', 'end']"
5030,1.0,FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).,"['_gene_', 'mutation', 'without', '_gene_', 'was', 'associated', 'with', 'increased', 'relapse', 'risk', 'and', 'reduced', 'overall', 'survival', 'in', 'young', 'adult', '_disease_', 'patients', 'median', 'age', '_num_']"
5031,1.0,Primary endpoint was intention-to-treat group PFS.,"['primary', 'endpoint', 'was', '_disease_', 'group', '_disease_']"
5032,1.0,"Odds ratios were 0.98 (95% CI, 0.91–1.05) for heterozygotes and 0.97 (95% CI, 0.86–1.11) in homozygotes (per-allele OR, 0.98; 95% CI, 0.91–1.04).","['odds', 'ratios', 'were', '_num_', '_num_', 'ci', '_num_', '91–1', '_num_', 'for', 'heterozygotes', 'and', '_num_', '_num_', 'ci', '_num_', '86–1', '_num_', 'in', 'homozygotes', 'per', 'allele', 'or', '_num_', '_num_', 'ci', '_num_', '91–1', '_num_']"
5033,1.0,This data justifies PS3 level evidence for pathogenicity according to ACMG guidelines.,"['this', 'data', 'justifies', '_gene_', 'level', 'evidence', 'for', 'pathogenicity', 'according', 'to', 'acmg', 'guidelines']"
5034,1.0,A pedigree (Pedigree number 3) with 24 members with multiple instances of bleeding disorder and three cases of familial leukemia showed a C>A substitution in exon 7B of the transcription factor RUNX1.,"['a', 'pedigree', 'pedigree', 'number', '_num_', 'with', '_num_', 'members', 'with', 'multiple', 'instances', 'of', 'bleeding', 'disorder', 'and', '_num_', 'cases', 'of', 'familial', 'leukemia', 'showed', 'a', 'c', 'a', 'substitution', 'in', 'exon', '7b', 'of', 'the', 'transcription', 'factor', '_gene_']"
5035,1.0,This missense mutation was found in a VHL type 1 family (lineage 7).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
5036,1.0,This mutation was found in VHL type 1 family (lineage 11).,"['this', 'mutation', 'was', 'found', 'in', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
5037,1.0,"In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for TTF (HR = 0.1030; P = .0004).","['in', 'multivariate', 'analysis', '_mutation_', 'mutations', 'plus', 'adenocarcinoma', 'was', 'a', 'significant', 'predictive', 'factor', 'for', '_gene_', 'hr', '_num_', 'p', '_num_']"
5038,1.0,In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors.,"['in', 'vivo', 'studies', 'confirmed', 'the', 'activity', 'of', '_chemical_', '_gene_', 'inhibitor', 'on', '_gene_', '_mutation_', 'mutant', 'tumors']"
5039,1.0,Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype.,"['improved', 'cr', 'rates', 'were', 'also', 'higher', 'for', 'those', 'with', '_gene_', 'exon', '_num_', 'mutations', 'and', 'normal', 'karyotype']"
5040,1.0,"In patients with acute myeloid leukemia, the presence of IDH2 R140Q (n = 7), IDH2 R172K (n = 3) or IDH1 R132 (N=4) mutations did not confer prognostic value (overall survival) compared to wild type IDH1/2 patients overall (N=102; P=0.177).","['in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'the', 'presence', 'of', '_gene_', '_mutation_', 'n', '_num_', '_gene_', '_mutation_', 'n', '_num_', 'or', '_gene_', '_abbrev_', '_ineq_', 'mutations', 'did', 'not', 'confer', 'prognostic', 'value', 'overall', 'survival', 'compared', 'to', 'wild', 'type', '_gene_', 'patients', 'overall', '_ineq_', '_p_val_']"
5041,1.0,Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA.,"['_chemical_', 'showed', 'higher', 'potency', 'than', '_chemical_', 'in', 'inhibiting', 'the', 'kinase', 'activity', 'of', '_gene_']"
5042,1.0,BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cell viability and ROS1 phosphorylation.,"['_abbrev_', 'cells', 'expressing', '_abbrev_', '_mutation_', 'were', 'more', 'resistant', 'to', '_chemical_', 'treatment', 'than', 'wildtype', '_abbrev_', 'in', 'both', 'cell', 'viability', 'and', '_gene_', '_disease_']"
5043,1.0,CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids.,"['_gene_', 'mutations', 'were', 'observed', 'in', '_num_', 'of', '_num_', '_num_', 'of', '_disease_']"
5044,1.0,This can be concluded as a marker of poor prognosis.,"['this', 'can', 'be', 'concluded', 'as', 'a', 'marker', 'of', 'poor', 'prognosis']"
5045,1.0,"HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055).","['_gene_', 'mutations', '_mutation_', '_mutation_', 'and', '_mutation_', 'sensitized', 'cell', 'lines', 'toward', 'mek', 'inhibitors', '_abbrev_', '_chemical_', 'and', '_chemical_', 'and', '_gene_', 'inhibitors', '_chemical_', 'and', '_chemical_']"
5046,1.0,Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.,"['expression', 'of', '_gene_', 'or', '_gene_', 'were', 'associated', 'with', 'reduced', '_disease_', 'and', '_disease_', 'survival']"
5047,1.0,"Detection of AR-V7 in circulating tumor cells of 62 patients treated with either enzalitamide (n=31) or arbiraterone (n=31), was correlated with lower PSA response rates and PSA PFS in men receiving enzalutamide or abiraterone.","['detection', 'of', '_disease_', 'in', 'circulating', 'tumor', 'cells', 'of', '_num_', 'patients', 'treated', 'with', 'either', 'enzalitamide', '_ineq_', 'or', 'arbiraterone', '_ineq_', 'was', 'correlated', 'with', 'lower', 'psa', 'response', 'rates', 'and', 'psa', '_disease_', 'in', 'men', 'receiving', '_chemical_', 'or', '_chemical_']"
5048,1.0,"In vitro, GRP78 inhibition reduced response to 5-FU.","['in', 'vitro', '_gene_', 'inhibition', 'reduced', 'response', 'to', '_chemical_']"
5049,1.0,This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells.,"['this', 'result', 'suggests', 'that', '_chemical_', 'specifically', 'targeted', 'the', '_chemical_', 'driver', 'in', 'these', 'cells']"
5050,1.0,Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL).,"['_chemical_', 'at', '_unit_', 'daily', 'was', 'given', 'to', '_num_', 'patients', 'with', 'relapsed', '_gene_', 'rearranged', 'anaplastic', 'large', 'cell', 'lymphoma', '_disease_']"
5051,1.0,A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases.,"['a', 'tissue', 'microarray', 'of', '_num_', 'patients', 'with', 'histologically', 'confirmed', 'colorectal', 'adenocarcinoma', 'was', 'performed', 'to', 'search', 'for', '_gene_', 'gene', 'fusion', 'events', 'to', 'guide', 'potential', 'targeted', 'therapy', 'in', 'future', 'cases']"
5052,1.0,"In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification.","['in', 'an', 'independent', '_num_', 'retrospective', 'patient', 'cohort', '_num_', 'out', 'of', '_num_', 'patients', 'with', '_gene_', '_gene_', '_chemical_', 'resitant', '_gene_', 'were', 'found', 'to', 'harbor', '_gene_', 'overexpression', 'and', 'amplification']"
5053,1.0,Clinical response lasted 4 months.,"['clinical', 'response', 'lasted', '_num_', 'months']"
5054,1.0,This missense mutation was found in a VHL type 1 patient (patient no V48).,"['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'patient', 'no', '_abbrev_']"
5055,1.0,"However, a PTEN and PIK3CA wild type cell line 'HS578T' was found to harbor a mutation in the PI3K regulatory protein PIK3R1.","['however', 'a', '_gene_', 'and', '_gene_', 'wild', 'type', 'cell', 'line', ""'hs578t"", 'was', 'found', 'to', 'harbor', 'a', 'mutation', 'in', 'the', '_gene_', 'regulatory', 'protein', '_gene_']"
5056,1.0,OCT4B1 (POU5F1 splice variant) expression reduced sensitivity to oxaliplatin (via P-gp and ABCG2 differential expression) in vitro.,"['_abbrev_', '_gene_', 'splice', 'variant', 'expression', 'reduced', 'sensitivity', 'to', '_chemical_', 'via', '_gene_', 'and', '_gene_', 'differential', 'expression', 'in', 'vitro']"
5057,1.0,"In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild type.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', 'cell', 'line', 'expressing', '_gene_', '_mutation_', 'demonstrated', 'increased', 'sensitivity', 'to', '_chemical_', 'treatment', 'compared', 'to', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', 'wild', 'type']"
5058,1.0,Both had a confirmed partial response lasting 11 and 14 months.,"['both', 'had', 'a', 'confirmed', 'partial', 'response', 'lasting', '_num_', 'and', '_num_', 'months']"
5059,1.0,Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons.,"['_num_', 'versions', 'of', 'this', 'variant', 'were', 'seen', '5a', 'consisted', 'of', '_gene_', 'exon', '_num_', 'fused', 'to', '_gene_', 'exon', '_num_', 'while', '_chemical_', 'contained', 'a', '117bp', 'intronic', '_gene_', 'region', 'between', 'the', '_num_', 'exons']"
5060,1.0,Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer.,"['currently', 'a', 'clinical', 'trial', '_abbrev_', 'is', 'evaluating', '_chemical_', '_chemical_', 'with', 'or', 'without', '_chemical_', 'in', 'uterine', 'serous', 'cancer']"
5061,1.0,"Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001).","['of', 'the', 'patients', 'on', '_chemical_', 'treatment', 'global', 'quality', 'of', 'life', 'was', 'improved', 'relative', 'to', 'baseline', 'when', 'compared', 'to', 'chemotherapy', 'patients', '+5', 'mean', 'change', '_num_', 'mean', 'change', 'p', '_num_']"
5062,1.0,This mutation causes an early stop codon at position 158 and was found in a VHL type 1 family (lineage 119).,"['this', 'mutation', 'causes', 'an', 'early', 'stop', 'codon', 'at', 'position', '_num_', 'and', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'lineage', '_num_']"
5063,0.0,"KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST.","['kit', 'mutations', 'were', 'identified', 'in', 'morphologically', 'benign', 'incidentally', 'discovered', 'gists', 'at', 'a', 'rate', 'similar', 'to', 'that', 'seen', 'in', 'advanced', 'metastatic', 'gist', 'patients', 'indicating', 'is', 'not', 'a', 'prognostic', 'marker', 'for', 'gist']"
5064,1.0,Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.,"['ba', '_abbrev_', 'cells', 'expressing', 'the', '_chemical_', 'fusion', 'containing', 'an', '_mutation_', 'mutation', 'were', 'more', 'resistant', 'to', '_chemical_', 'treatment', 'than', 'ba', '_abbrev_', 'cells', 'expressing', '_chemical_', 'without', 'this', 'mutation']"
5065,1.0,"This missense mutation was found in two unrelated VHL type 1 patients (patient no V53, V94).","['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', 'unrelated', '_gene_', 'type', '_num_', 'patients', 'patient', 'no', '_abbrev_', '_abbrev_']"
5066,0.0,we suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy.,"['we', 'suggest', 'that', 'the', 'type', 'structure', 'of', '_gene_', 'fusion', 'may', 'have', 'some', 'impact', 'on', 'patient', 'outcome', 'in', 'targeted', 'therapy']"
5067,1.0,"He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement.","['he', 'was', 'treated', 'with', 'surgery', 'and', 'catheter', 'placement', 'for', 'administration', 'of', '_disease_', 'doxyrubicin', 'and', 'mitomycin', 'c', 'break', 'apart', 'fish', 'showed', '_gene_', 'rearrangement', 'and', 'immunohistochemical', 'staining', 'was', 'characteristic', 'of', '_gene_', 'rearrangement']"
5068,1.0,ActA Levels were higher in patients than in controls and were significantly correlated with disease stage and metastasis.,"['_gene_', 'levels', 'were', 'higher', 'in', 'patients', 'than', 'in', 'controls', 'and', 'were', 'significantly', 'correlated', 'with', 'disease', 'stage', 'and', 'metastasis']"
5069,1.0,"When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control.","['when', 'used', 'in', 'combination', '_chemical_', 'and', '_chemical_', 'induced', 'significant', 'tumor', 'growth', 'inhibition', 'in', 'comparison', 'to', 'monotherapy', 'and', 'vehicle', 'control']"
5070,1.0,"Initially a significantly reduced amount of inflammation (macrophages, PMNs) was observed in the Ereg-/- mice.","['initially', 'a', 'significantly', 'reduced', 'amount', 'of', 'inflammation', 'macrophages', '_disease_', 'was', 'observed', 'in', 'the', 'ereg', '', '', '', 'mice']"
5071,0.0,We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping.,"['we', 'now', 'report', 'responses', 'to', 'the', 'met', 'inhibitors', '_chemical_', 'and', '_chemical_', 'in', '_num_', 'patients', 'with', 'stage', 'iv', 'lung', 'adenocarcinomas', 'harboring', 'mutations', 'leading', 'to', 'met', 'exon', '_num_', 'skipping']"
5072,1.0,"Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway.","['immunohistochemical', 'and', 'genetic', 'workup', 'showed', 'overexpression', 'of', '_gene_', 'and', 'fos', 'which', 'presumably', 'signals', 'through', 'the', '_disease_', 'pathway']"
5073,1.0,"In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779).","['in', 'prostate', 'cancer', 'xenographs', '_gene_', 'null', 'tumors', 'had', 'a', 'significant', 'decrease', 'in', 'cell', 'size', 'and', 'proliferation', 'when', 'treated', 'with', '_chemical_', '_chemical_']"
5074,1.0,"Low levels of baseline p-AMPK (PRKAA2, measured at Thr172) were predictive of efficacy of ACLY inhibition by siRNA in cell lines of various cancer histologies.","['low', 'levels', 'of', 'baseline', '_gene_', '_gene_', 'measured', 'at', '_abbrev_', 'were', 'predictive', 'of', 'efficacy', 'of', '_gene_', 'inhibition', 'by', 'sirna', 'in', 'cell', 'lines', 'of', 'various', 'cancer', 'histologies']"
5075,1.0,"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line expressing the L384M mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment.","['in', 'an', 'in', 'vitro', 'study', 'a', 'ba', '_abbrev_', '_abbrev_', '_gene_', 'cell', 'line', 'expressing', 'the', '_mutation_', 'mutation', 'in', 'the', '_gene_', 'portion', 'of', 'the', '_abbrev_', 'fusion', 'protein', 'was', 'associated', 'with', 'resistance', 'to', '_chemical_', 'treatment']"
5076,1.0,"In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months).","['in', '_abbrev_', 'gists', '_disease_', 'median', '_num_', 'months', 'and', 'os', 'median', '_num_', 'months', 'were', 'significantly', 'poorer', 'than', '_abbrev_', 'mutated', '_disease_', 'median', '_num_', 'months', 'os', 'median', '_num_', 'months']"
5077,1.0,"Exons 20-28, which correspond to the tyrosine kinase domain of ALK, were sequenced, and ALK G1202A was found.","['exons', '_range_', 'which', 'correspond', 'to', 'the', 'tyrosine', 'kinase', 'domain', 'of', '_gene_', 'were', 'sequenced', 'and', '_gene_', '_abbrev_', 'was', 'found']"
5078,1.0,"We identified 208 patients with non-V600 BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified.","['we', 'identified', '_num_', 'patients', 'with', '_abbrev_', '_gene_', 'mutations', 'which', 'occurred', 'in', '_num_', 'of', 'all', 'patients', 'tested', 'and', 'accounted', 'for', '_num_', 'of', 'all', '_gene_', 'mutations', 'identified']"
5079,1.0,"In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis).","['in', 'a', 'study', '_num_', 'breast', 'cancer', 'patients', 'undergoing', 'tamoxifen', 'treatment', 'a', 'higher', 'frequency', 'of', 'wildtype', '_gene_', 'patients', 'responded', 'to', 'treatment', 'compared', 'to', 'those', 'with', 'mutations', 'in', '_gene_', '_num_', 'wild', 'type', 'vs', '_num_', 'odds', 'ratio', 'or', ':0', '_num_', '95ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'univariate', 'analysis', 'or:0', '_num_', '_num_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'multivariate', 'analysis']"
5080,1.0,"In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan).","['in', 'this', 'study', '_gene_', 'expression', 'was', 'associated', 'with', 'sensitivity', 'to', '_chemical_', 'an', 'active', 'metabolite', 'of', 'topoisomerase', 'inhibitor', '_chemical_']"
5081,1.0,"First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.","['_num_', 'results', 'report', 'that', 'after', 'median', '_num_', 'year', 'follow', 'up', 'a', 'non', 'significant', '_num_', 'improvement', 'in', '_disease_', 'was', 'seen', 'in', '_chemical_', '_chemical_', 'vs', '_chemical_', 'alone']"
5082,1.0,A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion.,"['a', 'patient', 'with', 'a', 'malignant', 'spindle', 'cell', 'tumor', 'of', 'the', 'chest', 'wall', 'treated', 'as', 'a', 'soft', 'tissue', 'sarcoma', 'was', 'identified', 'to', 'harbor', 'a', '_chemical_', 'fusion']"
5083,1.0,"One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months.","['_num_', 'patient', 'with', '_gene_', '_mutation_', 'mutated', 'melanoma', 'with', 'no', 'detected', '_gene_', 'pathway', 'deregulation', 'had', 'a', 'partial', 'response', 'on', 'treatment', 'with', 'pictilisib', 'a', '_gene_', 'inhibitor', 'for', '_num_', 'months']"
5084,1.0,This missense mutation was found in two VHL type 1 families of 12 individuals altogether (family IDs 2612 and 3568).,"['this', 'missense', 'mutation', 'was', 'found', 'in', '_num_', '_gene_', 'type', '_num_', 'families', 'of', '_num_', 'individuals', 'altogether', 'family', 'ids', '_num_', 'and', '_num_']"
5085,1.0,"Moreover, PFS and OS strongly correlated with the ALDH1A2 protein expression level (OS, P < 0.001; PFS, P = 0.001; log-rank/Mantel-Cox test.","['moreover', '_disease_', 'and', 'os', 'strongly', 'correlated', 'with', 'the', '_gene_', 'protein', 'expression', 'level', 'os', 'p', '_num_', '_disease_', 'p', '_num_', 'log', 'rank', 'mantel', 'cox', 'test']"
5086,1.0,This mutation was found in a VHL type 1 family of 3.,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_']"
5087,1.0,Phase 2 study in Asian patients with unresectable hepatocellular carcinoma.,"['phase', '_num_', 'study', 'in', 'asian', 'patients', 'with', 'unresectable', '_disease_', 'carcinoma']"
5088,1.0,"However, patients with the G12D mutation exhibited significantly lower overall survival compared to wild type patients in univariate and multivariate analyses.","['however', 'patients', 'with', 'the', '_mutation_', 'mutation', 'exhibited', 'significantly', 'lower', 'overall', 'survival', 'compared', 'to', 'wild', 'type', 'patients', 'in', 'univariate', 'and', 'multivariate', 'analyses']"
5089,1.0,"EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment.","['_gene_', 'proteins', 'with', '_mutation_', 'or', '_abbrev_', 'mutations', 'were', 'more', 'sensitive', 'to', '_chemical_', 'treatment', '_abbrev_', '_num_', '_unit_', 'and', '_unit_', 'respectively', 'vs', '_abbrev_', '_unit_', 'and', '_unit_', 'respectively', 'compared', 'to', 'treatment', 'with', '_chemical_', 'or', '_chemical_', 'treatment']"
5090,1.0,"Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks.","['_num_', 'patients', 'achieved', 'a', 'durable', 'complete', 'response', '_num_', 'achieved', 'a', 'durable', 'partial', 'response', 'and', '_num_', 'achieved', 'stable', 'disease', '_num_', 'weeks', 'with', 'a', 'median', 'survival', 'of', '_num_', 'weeks']"
5091,1.0,Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.,"['_chemical_', 'or', 'panitumumab', 'may', 'be', 'ineffective', 'in', 'patients', 'with', '_gene_', 'mutation', 'unless', '_gene_', 'inhibitor', 'such', 'as', '_chemical_', 'is', 'introduced']"
5092,1.0,Cross-resistance to sorafenib was identified in-vitro.,"['_disease_', 'to', '_chemical_', 'was', 'identified', 'in', 'vitro']"
5093,1.0,This mutation was also detected in a VHL type 1 patient with angiomas (family ID 3699).,"['this', 'mutation', 'was', 'also', 'detected', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'with', 'angiomas', 'family', 'id', '_num_']"
5094,1.0,DNMT1 protein expression was also evaluated in two KRAS-mutant ovarian cancer cell lines pre and post-decitabine treatment showing downregulation following treatment.,"['_gene_', 'protein', 'expression', 'was', 'also', 'evaluated', 'in', '_num_', '_gene_', 'mutant', 'ovarian', 'cancer', 'cell', 'lines', '_gene_', 'and', 'post', '_chemical_', 'treatment', 'showing', 'downregulation', 'following', 'treatment']"
5095,1.0,"Patient 45 experienced a PFS of 5 months, and the NF1 mutation was only present in the postrelapse biopsy indicative of acquired resistance.","['patient', '_num_', 'experienced', 'a', '_disease_', 'of', '_num_', 'months', 'and', 'the', '_gene_', 'mutation', 'was', 'only', 'present', 'in', 'the', 'postrelapse', 'biopsy', 'indicative', 'of', 'acquired', 'resistance']"
5096,1.0,This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease.,"['this', 'phase', '_num_', 'trial', 'named', 'profile', '_num_', '_abbrev_', 'compared', '_chemical_', 'to', 'established', 'chemotherapy', 'in', '_num_', 'line', 'treatment', 'for', 'this', 'disease']"
5097,1.0,NRG1 inhibition (YW538.24.71 antibody) led to decreased tumor growth and enhanced magnitude and response to chemotherapy.,"['_gene_', 'inhibition', '_abbrev_', 'antibody', 'led', 'to', 'decreased', 'tumor', 'growth', 'and', 'enhanced', 'magnitude', 'and', 'response', 'to', 'chemotherapy']"
5098,1.0,Non-Ph like ALL have favorable outcomes when compared with Ph like ALL.,"['non', 'ph', 'like', 'all', 'have', 'favorable', 'outcomes', 'when', 'compared', 'with', 'ph', 'like', 'all']"
5099,1.0,Case report of two patients with MET amplification (MET:CEP7 ratio ≥5) and no concomitant MET exon 14 deletion.,"['case', 'report', 'of', '_num_', 'patients', 'with', 'met', 'amplification', 'met', '_chemical_', 'ratio', '_ineq_', 'and', 'no', 'concomitant', 'met', 'exon', '_num_', 'deletion']"
5100,1.0,"This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib.","['this', 'retrospective', 'study', 'of', 'patients', 'from', 'the', 'profile', '_num_', 'and', '_num_', 'studies', 'of', '_chemical_', 'in', 'advanced', '_gene_', 'rearranged', '_disease_', 'assessed', 'the', 'potential', 'benefit', 'of', '_chemical_', 'beyond', 'progressive', 'disease', '_disease_', 'defined', 'as', 'continuation', 'of', '_chemical_', 'for', '_num_', 'or', 'more', 'weeks', 'after', 'disease', 'progression', 'on', '_chemical_']"
5101,1.0,"In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was added to their platinum-based regimen (log-rank P = 0.04).","['in', 'the', 'retrospective', 'analysis', 'of', '_num_', '_disease_', 'the', '_mutation_', '_mutation_', 'variant', 'was', 'associated', 'with', 'poor', 'response', 'to', '_disease_', 'log', 'rank', 'p', '_num_', 'there', 'seemed', 'to', 'be', 'some', 'improvement', 'when', '_chemical_', 'was', 'added', 'to', 'their', 'platinum', 'based', 'regimen', 'log', 'rank', 'p', '_num_']"
5102,1.0,49-year old woman diagnosed with breast cancer was assessed for BRCA2 mutations.,"['_num_', 'year', 'old', 'woman', 'diagnosed', 'with', 'breast', 'cancer', 'was', 'assessed', 'for', '_gene_', 'mutations']"
5103,0.0,In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.,"['in', 'a', 'small', 'number', 'of', 'human', '_disease_', 'patients', 'with', 'these', 'genotypes', '_chemical_', 'signal', 'intensity', 'changes', 'and', 'perk', '_gene_', 'staining', 'correlated', 'with', 'mouse', 'data']"
5104,1.0,"The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.","['the', 'irreversible', '_disease_', '_chemical_', 'blocks', '_gene_', '_gene_', '_gene_', 'and', '_gene_']"
5105,1.0,It could be hypothesized that FBXW7 loss leads to an increase in mTOR protein levels independent of circadian regulation and higher sensitivity to mTOR inhibitors.,"['it', 'could', 'be', 'hypothesized', 'that', '_gene_', 'loss', 'leads', 'to', 'an', 'increase', 'in', '_gene_', 'protein', 'levels', 'independent', 'of', 'circadian', 'regulation', 'and', 'higher', 'sensitivity', 'to', '_gene_', 'inhibitors']"
5106,1.0,"This missense mutation was found in a VHL type 1 patient and two VHL type 2B patients (patient no V322, V36, V262).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'patient', 'and', '_num_', '_gene_', 'type', '_gene_', 'patients', 'patient', 'no', '_abbrev_', '_abbrev_', '_abbrev_']"
5107,0.0,"Patients received oral palbociclib at new dose scheme, 125 mg/d for 21 days in 28-day cycles.","['patients', 'received', 'oral', '_chemical_', 'at', 'new', 'dose', 'scheme', '_num_', '_chemical_', 'for', '_num_', 'days', 'in', '_num_', 'day', 'cycles']"
5108,1.0,"This missense mutation was found in a VHL type 2A patient and 5 VHL type 2B patients (patient no V30, V1).","['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'and', '_num_', '_gene_', 'type', '_gene_', 'patients', 'patient', 'no', '_abbrev_', '_gene_']"
5109,1.0,103 Chinese patients with NSCLC were evaluated in this study.,"['_num_', 'chinese', 'patients', 'with', '_disease_', 'were', 'evaluated', 'in', 'this', 'study']"
5110,1.0,"In multivariate Analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively).","['in', 'multivariate', 'analysis', 'nuclear', 'expression', 'of', '_gene_', 'and', '_gene_', 'were', 'not', 'significant', 'predictors', 'of', 'overall', 'survival', 'p', '_num_', 'p', '_num_', 'respectively']"
5111,0.0,"The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval.","['the', 'use', 'of', '_chemical_', 'and', '_chemical_', '_num_', 'generation', '_gene_', 'targeted', 'therapies', 'has', 'been', 'effective', 'in', 'patients', 'resistant', 'to', '_chemical_', 'leading', 'to', 'their', 'fda', 'approval']"
5112,1.0,"Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years.","['here', 'we', 'summarize', 'the', 'overall', 'safety', 'and', 'report', 'the', 'antitumor', 'activity', 'of', 'entrectinib', 'in', 'a', 'cohort', 'of', 'patients', 'with', 'tumors', 'harboring', '_gene_', '_gene_', 'or', '_gene_', 'gene', 'fusions', 'responses', 'were', 'observed', 'in', 'non', 'small', 'cell', 'lung', 'cancer', 'colorectal', 'cancer', 'mammary', 'analogue', 'secretory', 'carcinoma', 'melanoma', 'and', 'renal', 'cell', 'carcinoma', 'as', 'early', 'as', '_num_', 'weeks', 'after', 'starting', 'treatment', 'and', 'lasting', 'as', 'long', 'as', '_num_', 'years']"
5113,1.0,This mutation was found in a VHL type 2B patient (patient no V89).,"['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_gene_', 'patient', 'patient', 'no', '_abbrev_']"
5114,1.0,"PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild type, G2032R and L2026M mutations in ROS1.","['_chemical_', 'showed', 'inhibition', 'of', 'kinase', 'activity', 'cell', 'viability', 'and', 'tumor', 'growth', 'in', 'wild', 'type', '_mutation_', 'and', '_mutation_', 'mutations', 'in', '_gene_']"
5115,1.0,At 6 years old he was diagnosed with AML.,"['at', '_num_', 'years', 'old', 'he', 'was', 'diagnosed', 'with', '_disease_']"
